cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
THYM	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	19.27	2.03e-34	2.71e-27	0.93	0.89	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
THYM	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	18.54	3.64e-33	3.21e-26	1.12	0.89	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	18.43	5.75e-33	3.21e-26	0.91	0.88	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	18.4	6.42e-33	3.21e-26	0.91	0.88	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	17.42	3.44e-31	8.88e-25	0.9	0.87	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
THYM	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-17.39	4e-31	8.88e-25	-1.16	-0.87	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
THYM	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-17.02	1.86e-30	3.09e-24	-1.14	-0.87	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
THYM	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-17.02	1.86e-30	3.09e-24	-1.14	-0.87	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
THYM	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-17.02	1.86e-30	3.09e-24	-1.14	-0.87	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
THYM	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	16.95	2.42e-30	3.87e-24	1.14	0.87	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-16.69	7.25e-30	1.07e-23	-1.13	-0.86	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-16.49	1.74e-29	2.49e-23	-1.13	-0.86	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-16.38	2.72e-29	3.37e-23	-1.13	-0.86	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-16.38	2.72e-29	3.37e-23	-1.13	-0.86	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
THYM	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-16.38	2.72e-29	3.37e-23	-1.13	-0.86	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	16.37	2.87e-29	3.37e-23	1.13	0.86	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	16.37	2.87e-29	3.37e-23	1.13	0.86	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	16.29	4.04e-29	4.49e-23	1.11	0.86	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
THYM	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-16.24	4.97e-29	5.37e-23	-1.13	-0.86	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
THYM	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-16.19	6.24e-29	6.56e-23	-1.13	-0.86	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
THYM	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	16.03	1.24e-28	1.27e-22	1.12	0.86	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	15.92	1.96e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	15.88	2.32e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
THYM	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
THYM	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
THYM	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
THYM	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
THYM	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
THYM	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	15.86	2.57e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	15.86	2.58e-28	1.72e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	15.83	2.88e-28	1.86e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	15.83	2.88e-28	1.86e-22	1.11	0.85	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
THYM	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-15.75	4.2e-28	2.62e-22	-1.11	-0.85	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	15.71	4.98e-28	3.06e-22	0.99	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	15.69	5.36e-28	3.25e-22	0.95	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	15.51	1.17e-27	6.22e-22	0.95	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
THYM	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	15.35	2.4e-27	1.26e-21	1.08	0.85	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	15.33	2.63e-27	1.34e-21	1.08	0.85	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	15.33	2.63e-27	1.34e-21	1.08	0.85	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	15.32	2.76e-27	1.35e-21	0.99	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
THYM	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-15.3	3e-27	1.45e-21	-1.12	-0.84	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
THYM	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	15.29	3.1e-27	1.46e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	15.29	3.1e-27	1.46e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	15.21	4.38e-27	1.99e-21	1.1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	15.15	5.66e-27	2.54e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
THYM	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	15.14	5.88e-27	2.58e-21	1.11	0.84	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	15.12	6.41e-27	2.58e-21	1	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
THYM	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	15.12	6.43e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	15.11	6.72e-27	2.58e-21	1.1	0.84	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-15.09	7.36e-27	2.58e-21	-1.09	-0.84	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-15.09	7.36e-27	2.58e-21	-1.09	-0.84	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
THYM	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	15.09	7.36e-27	2.58e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	15.08	7.67e-27	2.67e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	15.08	7.73e-27	2.67e-21	0.96	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
THYM	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	15.04	9.53e-27	3.23e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	15.03	9.6e-27	3.23e-21	0.89	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
THYM	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-14.99	1.18e-26	3.39e-21	-1.06	-0.84	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	14.99	1.19e-26	3.4e-21	0.95	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
THYM	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-14.93	1.49e-26	3.72e-21	-1.12	-0.84	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
THYM	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
THYM	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	14.93	1.53e-26	3.72e-21	1.18	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
THYM	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
THYM	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
THYM	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
THYM	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
THYM	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	14.9	1.77e-26	3.72e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	14.86	2.08e-26	4.27e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	14.86	2.08e-26	4.27e-21	1.11	0.84	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	14.73	3.74e-26	7.52e-21	1.09	0.84	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	14.56	8.04e-26	1.5e-20	1.07	0.83	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	14.53	8.98e-26	1.67e-20	0.86	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	14.53	9.19e-26	1.69e-20	0.98	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
THYM	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	14.53	9.26e-26	1.69e-20	1.17	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	14.53	9.26e-26	1.69e-20	1.17	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	14.53	9.26e-26	1.69e-20	1.17	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
THYM	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	14.47	1.19e-25	2.11e-20	0.97	0.83	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
THYM	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-14.42	1.48e-25	2.57e-20	-1.1	-0.83	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	14.38	1.75e-25	2.99e-20	0.87	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	14.37	1.86e-25	3.11e-20	0.88	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-14.37	1.86e-25	3.11e-20	-0.88	-0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-14.37	1.86e-25	3.11e-20	-0.88	-0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
THYM	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	14.32	2.31e-25	3.72e-20	1.17	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
THYM	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	14.32	2.36e-25	3.72e-20	0.87	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	14.32	2.36e-25	3.72e-20	0.87	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
THYM	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
THYM	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
THYM	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-14.31	2.4e-25	3.72e-20	-1.15	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
THYM	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	14.26	3.08e-25	4.39e-20	1.07	0.83	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	14.25	3.16e-25	4.39e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
THYM	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-14.25	3.16e-25	4.39e-20	-1.06	-0.83	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-14.25	3.16e-25	4.39e-20	-1.06	-0.83	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	14.24	3.31e-25	4.56e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	14.24	3.31e-25	4.56e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
THYM	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-14.17	4.63e-25	5.7e-20	-1.05	-0.83	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
THYM	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	14.16	4.81e-25	5.87e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	14.16	4.81e-25	5.87e-20	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
THYM	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	14.13	5.57e-25	6.77e-20	1.09	0.82	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
THYM	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-14.09	6.76e-25	8.16e-20	-1.05	-0.82	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
THYM	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-14.08	7.04e-25	8.48e-20	-1.1	-0.82	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
THYM	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-13.96	1.18e-24	1.38e-19	-1.1	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
THYM	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	13.91	1.53e-24	1.72e-19	0.92	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
THYM	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-13.89	1.62e-24	1.8e-19	-1.03	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	13.86	1.92e-24	1.82e-19	0.95	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
THYM	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	13.86	1.94e-24	1.83e-19	1.08	0.82	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
THYM	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	13.84	2.06e-24	1.94e-19	1.18	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
THYM	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-13.82	2.25e-24	2.11e-19	-1.18	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
THYM	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	13.82	2.34e-24	2.18e-19	1.07	0.82	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	13.8	2.46e-24	2.29e-19	0.86	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	13.8	2.46e-24	2.29e-19	0.86	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	13.79	2.56e-24	2.38e-19	0.93	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
THYM	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-13.78	2.77e-24	2.57e-19	-1.08	-0.82	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
THYM	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	13.77	2.83e-24	2.61e-19	1.04	0.82	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	13.77	2.88e-24	2.66e-19	0.86	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
THYM	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	13.76	2.96e-24	2.72e-19	1.03	0.82	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
THYM	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
THYM	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
THYM	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-13.72	3.6e-24	3.19e-19	-1.03	-0.82	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-13.71	3.83e-24	3.38e-19	-0.86	-0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	13.71	3.83e-24	3.38e-19	0.86	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	13.67	4.64e-24	3.75e-19	0.94	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
THYM	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	13.66	4.72e-24	3.8e-19	1.06	0.82	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
THYM	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	13.64	5.34e-24	4.26e-19	1.05	0.81	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	13.6	6.31e-24	5e-19	1.06	0.81	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-13.6	6.31e-24	5e-19	-1.06	-0.81	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
THYM	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	13.59	6.63e-24	5.24e-19	0.92	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
THYM	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	13.57	7.29e-24	5.71e-19	0.94	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	13.57	7.29e-24	5.71e-19	0.94	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
THYM	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	13.57	7.33e-24	5.71e-19	1.15	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	13.57	7.33e-24	5.71e-19	1.15	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
THYM	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	13.57	7.33e-24	5.71e-19	1.15	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
THYM	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-13.51	9.7e-24	7.4e-19	-1.01	-0.81	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
THYM	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-13.51	9.7e-24	7.4e-19	-1.01	-0.81	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-13.51	9.7e-24	7.4e-19	-1.01	-0.81	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	13.47	1.14e-23	8.6e-19	1.04	0.81	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	13.47	1.14e-23	8.6e-19	1.04	0.81	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	13.47	1.14e-23	8.6e-19	1.04	0.81	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	13.47	1.15e-23	8.6e-19	1.04	0.81	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	13.47	1.15e-23	8.6e-19	1.04	0.81	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	13.47	1.15e-23	8.6e-19	1.04	0.81	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-13.46	1.2e-23	8.94e-19	-1.04	-0.81	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
THYM	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-13.45	1.25e-23	9.3e-19	-1.05	-0.81	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	13.43	1.37e-23	9.95e-19	0.87	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	13.43	1.37e-23	9.95e-19	0.87	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
THYM	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	13.4	1.61e-23	1.15e-18	1.15	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
THYM	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
THYM	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
THYM	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
THYM	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
THYM	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	13.35	2e-23	1.39e-18	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
THYM	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	13.34	2.08e-23	1.43e-18	1.04	0.81	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	13.34	2.08e-23	1.43e-18	1.04	0.81	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	13.28	2.81e-23	1.91e-18	0.87	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	13.28	2.81e-23	1.91e-18	0.87	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	13.26	2.96e-23	2.01e-18	0.87	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
THYM	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-13.26	3.09e-23	2.08e-18	-1.02	-0.81	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-13.26	3.09e-23	2.08e-18	-1.02	-0.81	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
THYM	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-13.24	3.24e-23	2.18e-18	-1.03	-0.81	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-13.24	3.24e-23	2.18e-18	-1.03	-0.81	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	13.22	3.58e-23	2.3e-18	1.04	0.81	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	13.22	3.58e-23	2.3e-18	1.04	0.81	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	13.22	3.58e-23	2.3e-18	1.04	0.81	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
THYM	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	13.22	3.58e-23	2.3e-18	1.04	0.81	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	13.22	3.58e-23	2.3e-18	1.04	0.81	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	13.22	3.58e-23	2.3e-18	1.04	0.81	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
THYM	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
THYM	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
THYM	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-13.22	3.58e-23	2.3e-18	-1.04	-0.81	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
THYM	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	13.2	4.07e-23	2.55e-18	1.17	0.81	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
THYM	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	13.19	4.14e-23	2.59e-18	1.07	0.81	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
THYM	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	13.18	4.31e-23	2.65e-18	1.07	0.81	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
THYM	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-13.18	4.43e-23	2.65e-18	-0.92	-0.81	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
THYM	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
THYM	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
THYM	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
THYM	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
THYM	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	13.17	4.69e-23	2.65e-18	1.02	0.81	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-13.17	4.69e-23	2.65e-18	-1.02	-0.81	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
THYM	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-13.17	4.69e-23	2.65e-18	-1.02	-0.81	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-13.17	4.69e-23	2.65e-18	-1.02	-0.81	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
THYM	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-13.17	4.69e-23	2.65e-18	-1.02	-0.81	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-13.17	4.69e-23	2.65e-18	-1.02	-0.81	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-13.17	4.69e-23	2.65e-18	-1.02	-0.81	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
THYM	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	13.15	5.1e-23	2.87e-18	1.03	0.8	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
THYM	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	13.09	6.79e-23	3.78e-18	0.9	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	13.09	6.79e-23	3.78e-18	0.9	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	13.09	6.79e-23	3.78e-18	0.9	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
THYM	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	13.07	7.49e-23	4.17e-18	1.04	0.8	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
THYM	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	13.06	7.55e-23	4.2e-18	0.93	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
THYM	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	13.06	7.63e-23	4.22e-18	1.03	0.8	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	13.06	7.63e-23	4.22e-18	1.03	0.8	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	13.06	7.63e-23	4.22e-18	1.03	0.8	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
THYM	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	13.04	8.26e-23	4.57e-18	1.04	0.8	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	13.04	8.46e-23	4.67e-18	1.01	0.8	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-13.03	8.81e-23	4.86e-18	-1.03	-0.8	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
THYM	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	13.03	8.96e-23	4.94e-18	0.81	0.8	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
THYM	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	12.99	1.05e-22	5.75e-18	1.03	0.8	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
THYM	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	12.95	1.26e-22	6.93e-18	1.11	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
THYM	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	12.92	1.47e-22	8.01e-18	1.04	0.8	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
THYM	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-12.91	1.52e-22	8.29e-18	-1.01	-0.8	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
THYM	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	12.91	1.57e-22	8.5e-18	0.91	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	12.91	1.57e-22	8.5e-18	0.91	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
THYM	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	12.91	1.57e-22	8.5e-18	0.91	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
THYM	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-12.88	1.8e-22	9.7e-18	-1.01	-0.8	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-12.88	1.8e-22	9.7e-18	-1.01	-0.8	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
THYM	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-12.88	1.8e-22	9.7e-18	-1.01	-0.8	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
THYM	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	12.87	1.89e-22	1.01e-17	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
THYM	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	12.87	1.89e-22	1.01e-17	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
THYM	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	12.81	2.48e-22	1.32e-17	1.05	0.8	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
THYM	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-12.81	2.49e-22	1.32e-17	-0.98	-0.8	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
THYM	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	12.81	2.53e-22	1.34e-17	1.17	0.8	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
THYM	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
THYM	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
THYM	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
THYM	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-12.79	2.73e-22	1.43e-17	-0.89	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
THYM	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	12.77	2.93e-22	1.53e-17	1.04	0.8	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	12.77	2.96e-22	1.54e-17	0.93	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-12.77	2.96e-22	1.54e-17	-0.93	-0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-12.77	2.96e-22	1.54e-17	-0.93	-0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
THYM	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-12.76	3.13e-22	1.62e-17	-0.96	-0.8	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
THYM	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-12.72	3.74e-22	1.91e-17	-0.86	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
THYM	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	12.72	3.77e-22	1.92e-17	1.01	0.8	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
THYM	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	12.72	3.77e-22	1.92e-17	1.01	0.8	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	12.67	4.69e-22	2.32e-17	0.96	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
THYM	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-12.66	4.97e-22	2.46e-17	-0.92	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
THYM	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	12.65	5.25e-22	2.58e-17	0.92	0.79	Shingles;	chr7:38346957	chr7:38343894~38350022:-
THYM	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	12.64	5.41e-22	2.65e-17	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	12.64	5.41e-22	2.65e-17	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	12.64	5.41e-22	2.65e-17	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	12.63	5.66e-22	2.76e-17	0.91	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	12.63	5.66e-22	2.76e-17	0.91	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
THYM	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	12.62	5.92e-22	2.88e-17	1.01	0.79	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
THYM	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-12.59	6.91e-22	3.34e-17	-1.02	-0.79	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
THYM	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-12.59	6.95e-22	3.36e-17	-0.98	-0.79	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
THYM	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	12.59	6.96e-22	3.36e-17	0.99	0.79	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	12.57	7.69e-22	3.66e-17	0.92	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
THYM	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-12.57	7.7e-22	3.66e-17	-0.92	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
THYM	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-12.56	8.02e-22	3.8e-17	-1	-0.79	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
THYM	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	12.56	8.15e-22	3.86e-17	1.13	0.79	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
THYM	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	12.55	8.32e-22	3.92e-17	0.93	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	12.55	8.32e-22	3.92e-17	0.93	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
THYM	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	12.55	8.36e-22	3.93e-17	0.9	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
THYM	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	12.54	8.88e-22	4.17e-17	1.17	0.79	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
THYM	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	12.54	8.88e-22	4.17e-17	1.17	0.79	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
THYM	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-12.53	9.08e-22	4.26e-17	-1.02	-0.79	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
THYM	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-12.51	1.01e-21	4.72e-17	-1	-0.79	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-12.51	1.01e-21	4.74e-17	-0.92	-0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	12.51	1.01e-21	4.74e-17	0.92	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	12.49	1.09e-21	5.08e-17	0.93	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
THYM	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	12.47	1.25e-21	5.76e-17	0.98	0.79	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
THYM	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	12.42	1.59e-21	7.2e-17	1.02	0.79	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	12.39	1.79e-21	8.09e-17	0.94	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
THYM	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-12.33	2.36e-21	1.05e-16	-0.98	-0.79	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
THYM	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	12.31	2.58e-21	1.15e-16	0.83	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
THYM	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	12.31	2.64e-21	1.17e-16	1.15	0.79	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
THYM	cis	rs10256972	0.552	rs6953538	ENSG00000229043.2	AC091729.9	-12.29	2.87e-21	1.26e-16	-1.13	-0.79	Endometriosis;Longevity;	chr7:1157338	chr7:1160374~1165267:+
THYM	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-12.28	3.01e-21	1.31e-16	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-12.28	3.01e-21	1.31e-16	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-12.28	3.01e-21	1.31e-16	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-12.28	3.01e-21	1.31e-16	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
THYM	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	12.14	5.93e-21	2.54e-16	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
THYM	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	12.14	5.93e-21	2.54e-16	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
THYM	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	12.14	5.93e-21	2.54e-16	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
THYM	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	12.14	5.93e-21	2.54e-16	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	12.14	5.93e-21	2.54e-16	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
THYM	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	12.14	5.93e-21	2.54e-16	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
THYM	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	12.14	5.93e-21	2.54e-16	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
THYM	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	12.12	6.33e-21	2.69e-16	0.91	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
THYM	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-12.12	6.59e-21	2.79e-16	-1.12	-0.78	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-12.12	6.59e-21	2.79e-16	-1.12	-0.78	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-12.12	6.59e-21	2.79e-16	-1.12	-0.78	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
THYM	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	12.1	7.18e-21	3.01e-16	0.94	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	12.1	7.18e-21	3.01e-16	0.94	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
THYM	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	12.09	7.32e-21	3.04e-16	0.9	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	12.09	7.32e-21	3.04e-16	0.9	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-12.09	7.32e-21	3.04e-16	-0.9	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-12.09	7.32e-21	3.04e-16	-0.9	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
THYM	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-12.06	8.65e-21	3.56e-16	-0.95	-0.78	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
THYM	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	12.06	8.7e-21	3.58e-16	0.91	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	12.03	9.93e-21	4.02e-16	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	12.03	9.93e-21	4.02e-16	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	12.03	9.93e-21	4.02e-16	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	12.03	9.93e-21	4.02e-16	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	12.03	9.93e-21	4.02e-16	0.89	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-12.03	9.93e-21	4.02e-16	-0.89	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-12.03	9.93e-21	4.02e-16	-0.89	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-12.03	9.93e-21	4.02e-16	-0.89	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-12.03	9.93e-21	4.02e-16	-0.89	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	12.03	9.98e-21	4.03e-16	0.92	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	12.03	9.98e-21	4.03e-16	0.92	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	12	1.12e-20	4.5e-16	0.92	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	11.99	1.18e-20	4.71e-16	0.82	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
THYM	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-11.99	1.18e-20	4.71e-16	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	11.99	1.21e-20	4.8e-16	0.91	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
THYM	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	11.96	1.4e-20	5.5e-16	1.11	0.78	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
THYM	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	11.96	1.4e-20	5.5e-16	1.11	0.78	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
THYM	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	11.96	1.4e-20	5.5e-16	1.11	0.78	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
THYM	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	11.95	1.46e-20	5.72e-16	0.91	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
THYM	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-11.91	1.72e-20	6.67e-16	-1	-0.78	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-11.91	1.77e-20	6.83e-16	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-11.91	1.77e-20	6.83e-16	-0.91	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-11.88	2.07e-20	7.85e-16	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-11.88	2.07e-20	7.85e-16	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-11.88	2.07e-20	7.85e-16	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-11.87	2.13e-20	8.06e-16	-0.9	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
THYM	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-11.84	2.48e-20	9.32e-16	-1.12	-0.77	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
THYM	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	11.83	2.57e-20	9.63e-16	1.01	0.77	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	11.82	2.65e-20	9.93e-16	0.91	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
THYM	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-11.78	3.29e-20	1.22e-15	-1.1	-0.77	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-11.78	3.29e-20	1.22e-15	-1.1	-0.77	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
THYM	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-11.77	3.43e-20	1.27e-15	-0.8	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
THYM	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	11.77	3.44e-20	1.28e-15	1.03	0.77	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
THYM	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-11.77	3.45e-20	1.28e-15	-1.12	-0.77	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
THYM	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	11.77	3.46e-20	1.28e-15	0.8	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
THYM	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	11.74	3.93e-20	1.45e-15	0.86	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
THYM	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	11.73	4.14e-20	1.52e-15	0.82	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
THYM	cis	rs4853012	0.887	rs2122290	ENSG00000217702.2	RP11-287D1.4	11.7	4.69e-20	1.72e-15	1.19	0.77	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74130583~74135395:+
THYM	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	11.69	5.01e-20	1.83e-15	0.93	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-11.69	5.01e-20	1.83e-15	-0.93	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-11.69	5.01e-20	1.83e-15	-0.93	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
THYM	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-11.68	5.4e-20	1.96e-15	-0.95	-0.77	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
THYM	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-11.65	6.08e-20	2.2e-15	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-11.65	6.08e-20	2.2e-15	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-11.65	6.08e-20	2.2e-15	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-11.65	6.08e-20	2.2e-15	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
THYM	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-11.64	6.36e-20	2.29e-15	-1.12	-0.77	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
THYM	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-11.61	7.36e-20	2.64e-15	-0.9	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-11.61	7.47e-20	2.68e-15	-0.91	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
THYM	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-11.6	7.9e-20	2.82e-15	-0.99	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
THYM	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	11.59	8.26e-20	2.95e-15	0.92	0.77	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
THYM	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	11.59	8.29e-20	2.95e-15	1.1	0.77	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
THYM	cis	rs4691139	0.524	rs28548593	ENSG00000250227.1	TRIM60P14	11.59	8.32e-20	2.96e-15	0.92	0.77	Ovarian cancer in BRCA1 mutation carriers;	chr4:164965160	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.588	rs6827270	ENSG00000250227.1	TRIM60P14	11.59	8.32e-20	2.96e-15	0.92	0.77	Ovarian cancer in BRCA1 mutation carriers;	chr4:164967275	chr4:164915565~164916983:+
THYM	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-11.57	8.94e-20	3.17e-15	-1	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
THYM	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	11.57	9.14e-20	3.24e-15	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
THYM	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	11.54	1.03e-19	3.65e-15	1.1	0.77	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
THYM	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	11.54	1.03e-19	3.65e-15	1.1	0.77	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
THYM	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	11.54	1.03e-19	3.65e-15	1.1	0.77	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
THYM	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-11.52	1.16e-19	4.04e-15	-0.89	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
THYM	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	11.51	1.2e-19	4.19e-15	0.99	0.76	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
THYM	cis	rs4691139	0.588	rs28475532	ENSG00000250227.1	TRIM60P14	11.48	1.36e-19	4.72e-15	0.92	0.76	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974076	chr4:164915565~164916983:+
THYM	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-11.48	1.41e-19	4.88e-15	-0.99	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
THYM	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	11.47	1.44e-19	4.99e-15	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	11.47	1.47e-19	5.05e-15	0.92	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	11.47	1.47e-19	5.05e-15	0.92	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	11.47	1.48e-19	5.1e-15	0.93	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	11.47	1.48e-19	5.1e-15	0.93	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
THYM	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-11.45	1.57e-19	5.34e-15	-0.89	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-11.45	1.57e-19	5.34e-15	-0.89	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-11.45	1.57e-19	5.34e-15	-0.89	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-11.45	1.57e-19	5.34e-15	-0.89	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	11.45	1.57e-19	5.34e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
THYM	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	11.45	1.61e-19	5.44e-15	1.07	0.76	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
THYM	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-11.45	1.63e-19	5.53e-15	-1.08	-0.76	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
THYM	cis	rs4691139	0.549	rs10001548	ENSG00000250227.1	TRIM60P14	11.44	1.65e-19	5.57e-15	0.92	0.76	Ovarian cancer in BRCA1 mutation carriers;	chr4:164958229	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.588	rs6814756	ENSG00000250227.1	TRIM60P14	11.44	1.65e-19	5.57e-15	0.92	0.76	Ovarian cancer in BRCA1 mutation carriers;	chr4:164965772	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.524	rs4349559	ENSG00000250227.1	TRIM60P14	11.44	1.65e-19	5.57e-15	0.92	0.76	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968795	chr4:164915565~164916983:+
THYM	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-11.43	1.76e-19	5.92e-15	-0.91	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
THYM	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	11.42	1.86e-19	6.24e-15	1.11	0.76	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
THYM	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	11.42	1.86e-19	6.24e-15	1.11	0.76	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
THYM	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-11.4	2.06e-19	6.88e-15	-0.85	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
THYM	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	11.39	2.09e-19	6.96e-15	1.01	0.76	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
THYM	cis	rs4691139	0.588	rs6848637	ENSG00000250227.1	TRIM60P14	11.39	2.12e-19	7.08e-15	0.92	0.76	Ovarian cancer in BRCA1 mutation carriers;	chr4:164956811	chr4:164915565~164916983:+
THYM	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	11.38	2.22e-19	7.36e-15	0.88	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-11.38	2.23e-19	7.36e-15	-0.87	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	11.35	2.59e-19	8.5e-15	0.8	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
THYM	cis	rs4691139	0.549	rs28633542	ENSG00000250227.1	TRIM60P14	11.34	2.66e-19	8.69e-15	0.91	0.76	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974792	chr4:164915565~164916983:+
THYM	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	11.34	2.67e-19	8.71e-15	0.89	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-11.34	2.74e-19	8.71e-15	-0.89	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-11.34	2.74e-19	8.71e-15	-0.89	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-11.34	2.74e-19	8.71e-15	-0.89	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
THYM	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-11.33	2.82e-19	8.75e-15	-0.92	-0.76	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
THYM	cis	rs4691139	0.588	rs7680569	ENSG00000250227.1	TRIM60P14	11.31	3.2e-19	9.83e-15	0.91	0.76	Ovarian cancer in BRCA1 mutation carriers;	chr4:164978073	chr4:164915565~164916983:+
THYM	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	11.29	3.45e-19	1.06e-14	0.88	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
THYM	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-11.28	3.63e-19	1.09e-14	-1.02	-0.76	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
THYM	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	11.26	3.92e-19	1.17e-14	0.97	0.76	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
THYM	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	11.26	3.92e-19	1.17e-14	0.97	0.76	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	11.23	4.59e-19	1.34e-14	0.91	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
THYM	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	11.21	5.21e-19	1.52e-14	0.99	0.76	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-11.19	5.59e-19	1.62e-14	-0.86	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
THYM	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-11.19	5.6e-19	1.63e-14	-1	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
THYM	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	11.19	5.65e-19	1.64e-14	0.9	0.76	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
THYM	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-11.17	6.29e-19	1.81e-14	-1	-0.76	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	11.14	7e-19	1.99e-14	0.91	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-11.14	7e-19	1.99e-14	-0.91	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	11.14	7.16e-19	2.03e-14	0.76	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-11.14	7.16e-19	2.03e-14	-0.76	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
THYM	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	11.13	7.33e-19	2.07e-14	0.76	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
THYM	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	11.13	7.52e-19	2.09e-14	0.93	0.75	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
THYM	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	11.13	7.55e-19	2.09e-14	0.76	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
THYM	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-11.11	8.16e-19	2.25e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
THYM	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-11.11	8.38e-19	2.29e-14	-0.94	-0.75	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
THYM	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	11.07	9.91e-19	2.67e-14	0.92	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	11.06	1.04e-18	2.76e-14	0.92	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	11.06	1.04e-18	2.76e-14	0.92	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
THYM	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-11.05	1.08e-18	2.85e-14	-0.89	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
THYM	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	11.04	1.14e-18	3.01e-14	0.91	0.75	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
THYM	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	11.04	1.14e-18	3.01e-14	0.91	0.75	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
THYM	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-11.04	1.16e-18	3.06e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-11.03	1.24e-18	3.25e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-11.03	1.24e-18	3.25e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-11.03	1.24e-18	3.25e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-11.03	1.24e-18	3.25e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-11.03	1.24e-18	3.25e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-11.02	1.25e-18	3.26e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
THYM	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	11.02	1.26e-18	3.29e-14	0.97	0.75	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
THYM	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-11.01	1.31e-18	3.36e-14	-1.04	-0.75	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-11.01	1.36e-18	3.36e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-11.01	1.36e-18	3.36e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-11.01	1.36e-18	3.36e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-11.01	1.36e-18	3.36e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-11.01	1.36e-18	3.36e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-11.01	1.36e-18	3.36e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
THYM	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	11	1.44e-18	3.43e-14	0.97	0.75	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-10.99	1.47e-18	3.46e-14	-0.88	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
THYM	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-10.99	1.47e-18	3.46e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
THYM	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	10.97	1.62e-18	3.62e-14	1.05	0.75	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
THYM	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-10.96	1.67e-18	3.74e-14	-1.06	-0.75	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
THYM	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-10.96	1.69e-18	3.77e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-10.96	1.69e-18	3.77e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
THYM	cis	rs4691139	0.524	rs3196673	ENSG00000250227.1	TRIM60P14	10.96	1.73e-18	3.86e-14	0.94	0.75	Ovarian cancer in BRCA1 mutation carriers;	chr4:164957457	chr4:164915565~164916983:+
THYM	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-10.93	2.01e-18	4.42e-14	-0.91	-0.75	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
THYM	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-10.92	2.03e-18	4.44e-14	-1.02	-0.75	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-10.92	2.03e-18	4.44e-14	-1.02	-0.75	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
THYM	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-10.92	2.06e-18	4.5e-14	-1.04	-0.75	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-10.92	2.06e-18	4.5e-14	-1.04	-0.75	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-10.92	2.06e-18	4.5e-14	-1.04	-0.75	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
THYM	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-10.91	2.17e-18	4.71e-14	-0.72	-0.75	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
THYM	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-10.91	2.21e-18	4.76e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
THYM	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-10.91	2.21e-18	4.77e-14	-1.06	-0.75	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-10.91	2.21e-18	4.77e-14	-1.06	-0.75	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-10.91	2.21e-18	4.77e-14	-1.06	-0.75	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
THYM	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-10.91	2.23e-18	4.79e-14	-1.02	-0.75	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
THYM	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	10.89	2.38e-18	5.09e-14	0.87	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	10.89	2.38e-18	5.09e-14	0.87	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-10.89	2.38e-18	5.09e-14	-0.87	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-10.89	2.4e-18	5.13e-14	-0.8	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
THYM	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-10.89	2.4e-18	5.13e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-10.89	2.43e-18	5.17e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-10.89	2.43e-18	5.17e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-10.89	2.43e-18	5.17e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-10.89	2.43e-18	5.17e-14	-1.02	-0.75	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-10.88	2.5e-18	5.31e-14	-0.86	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
THYM	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-10.88	2.5e-18	5.31e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-10.88	2.5e-18	5.31e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-10.88	2.5e-18	5.31e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-10.88	2.5e-18	5.31e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-10.88	2.55e-18	5.41e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-10.87	2.59e-18	5.47e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-10.87	2.59e-18	5.47e-14	-0.88	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
THYM	cis	rs4691139	0.588	rs72697954	ENSG00000250227.1	TRIM60P14	10.86	2.74e-18	5.78e-14	0.91	0.75	Ovarian cancer in BRCA1 mutation carriers;	chr4:164982890	chr4:164915565~164916983:+
THYM	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-10.84	3.02e-18	6.25e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-10.84	3.02e-18	6.25e-14	-1.03	-0.75	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	10.84	3.02e-18	6.25e-14	1.03	0.75	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	10.82	3.37e-18	6.92e-14	0.87	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
THYM	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	10.82	3.45e-18	6.97e-14	1.03	0.74	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-10.82	3.45e-18	6.97e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-10.8	3.66e-18	7.31e-14	-1.04	-0.74	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
THYM	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	10.78	4e-18	7.94e-14	0.86	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
THYM	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-10.78	4.04e-18	8.03e-14	-1.01	-0.74	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-10.78	4.06e-18	8.06e-14	-1.03	-0.74	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
THYM	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	10.78	4.07e-18	8.08e-14	0.99	0.74	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
THYM	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-10.77	4.22e-18	8.36e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-10.77	4.22e-18	8.36e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
THYM	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-10.74	4.85e-18	9.5e-14	-1.07	-0.74	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-10.74	4.91e-18	9.6e-14	-1.06	-0.74	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
THYM	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-10.74	4.98e-18	9.66e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-10.74	4.98e-18	9.66e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-10.74	4.98e-18	9.66e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-10.74	4.98e-18	9.66e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-10.74	4.98e-18	9.66e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-10.74	4.98e-18	9.66e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-10.74	4.98e-18	9.66e-14	-0.85	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	10.74	4.98e-18	9.66e-14	0.85	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
THYM	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-10.74	5.07e-18	9.66e-14	-1.02	-0.74	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
THYM	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	10.73	5.33e-18	1.01e-13	0.97	0.74	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
THYM	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-10.72	5.42e-18	1.02e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-10.72	5.42e-18	1.02e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-10.72	5.47e-18	1.02e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
THYM	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-10.72	5.58e-18	1.04e-13	-0.9	-0.74	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
THYM	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-10.71	5.68e-18	1.06e-13	-0.95	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
THYM	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	10.71	5.74e-18	1.07e-13	1.18	0.74	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
THYM	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-10.7	5.92e-18	1.1e-13	-1.05	-0.74	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-10.7	6.08e-18	1.13e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-10.7	6.18e-18	1.14e-13	-0.87	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	10.68	6.67e-18	1.23e-13	0.75	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
THYM	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-10.68	6.72e-18	1.23e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-10.68	6.72e-18	1.23e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
THYM	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	10.67	7.03e-18	1.29e-13	0.9	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
THYM	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-10.67	7.1e-18	1.29e-13	-1.05	-0.74	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-10.67	7.1e-18	1.29e-13	-1.05	-0.74	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-10.67	7.1e-18	1.29e-13	-1.05	-0.74	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-10.67	7.1e-18	1.29e-13	-1.05	-0.74	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-10.67	7.1e-18	1.29e-13	-1.05	-0.74	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-10.67	7.1e-18	1.29e-13	-1.05	-0.74	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-10.67	7.1e-18	1.29e-13	-1.05	-0.74	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
THYM	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-10.67	7.11e-18	1.29e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-10.67	7.11e-18	1.29e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-10.67	7.11e-18	1.29e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-10.67	7.11e-18	1.29e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
THYM	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	10.66	7.22e-18	1.31e-13	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
THYM	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	10.66	7.22e-18	1.31e-13	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
THYM	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	10.66	7.22e-18	1.31e-13	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
THYM	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	10.66	7.22e-18	1.31e-13	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
THYM	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	10.66	7.22e-18	1.31e-13	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
THYM	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	10.66	7.22e-18	1.31e-13	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
THYM	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-10.66	7.4e-18	1.34e-13	-0.86	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-10.66	7.4e-18	1.34e-13	-0.86	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
THYM	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	10.66	7.44e-18	1.34e-13	0.97	0.74	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
THYM	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-10.62	8.88e-18	1.59e-13	-1.04	-0.74	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-10.62	8.88e-18	1.59e-13	-1.04	-0.74	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
THYM	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-10.61	9.39e-18	1.67e-13	-0.91	-0.74	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
THYM	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-10.6	9.74e-18	1.72e-13	-1.02	-0.74	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-10.6	9.77e-18	1.73e-13	-1.04	-0.74	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-10.6	1e-17	1.76e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-10.6	1e-17	1.76e-13	-1.03	-0.74	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
THYM	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	10.59	1.05e-17	1.82e-13	0.91	0.74	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-10.59	1.05e-17	1.82e-13	-0.91	-0.74	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-10.59	1.05e-17	1.82e-13	-0.91	-0.74	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-10.59	1.05e-17	1.82e-13	-0.91	-0.74	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-10.59	1.05e-17	1.82e-13	-0.91	-0.74	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
THYM	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	10.58	1.06e-17	1.83e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	10.58	1.06e-17	1.83e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	10.58	1.06e-17	1.83e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-10.58	1.06e-17	1.83e-13	-0.73	-0.74	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-10.58	1.06e-17	1.83e-13	-0.73	-0.74	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-10.58	1.06e-17	1.83e-13	-0.73	-0.74	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-10.58	1.06e-17	1.83e-13	-0.73	-0.74	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	10.58	1.06e-17	1.83e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	10.58	1.06e-17	1.83e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	10.58	1.06e-17	1.83e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
THYM	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-10.57	1.12e-17	1.91e-13	-0.9	-0.74	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
THYM	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-10.55	1.26e-17	2.13e-13	-1.01	-0.74	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-10.55	1.26e-17	2.13e-13	-1.01	-0.74	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-10.55	1.26e-17	2.13e-13	-1.01	-0.74	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-10.55	1.26e-17	2.13e-13	-1.01	-0.74	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-10.54	1.34e-17	2.26e-13	-1	-0.74	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-10.54	1.34e-17	2.26e-13	-1	-0.74	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
THYM	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	10.52	1.48e-17	2.47e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	10.52	1.48e-17	2.47e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	10.52	1.48e-17	2.47e-13	0.73	0.74	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
THYM	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	10.5	1.59e-17	2.65e-13	0.95	0.73	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-10.49	1.64e-17	2.72e-13	-0.86	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	10.49	1.69e-17	2.79e-13	0.85	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
THYM	cis	rs1799949	0.832	rs2070835	ENSG00000198496.9	NBR2	-10.46	1.91e-17	3.13e-13	-1.04	-0.73	Menopause (age at onset);	chr17:43022008	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-10.46	1.93e-17	3.15e-13	-0.85	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
THYM	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-10.46	1.93e-17	3.15e-13	-1.01	-0.73	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
THYM	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	10.46	1.98e-17	3.24e-13	0.7	0.73	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	10.46	1.98e-17	3.24e-13	0.7	0.73	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	10.46	1.98e-17	3.24e-13	0.7	0.73	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-10.45	1.99e-17	3.25e-13	-0.7	-0.73	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
THYM	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-10.45	2.05e-17	3.33e-13	-0.85	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-10.45	2.05e-17	3.33e-13	-0.85	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-10.43	2.2e-17	3.54e-13	-0.86	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
THYM	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-10.43	2.28e-17	3.67e-13	-0.91	-0.73	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
THYM	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-10.39	2.73e-17	4.37e-13	-0.7	-0.73	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
THYM	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	10.39	2.77e-17	4.42e-13	0.91	0.73	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
THYM	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-10.39	2.77e-17	4.42e-13	-1.01	-0.73	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-10.39	2.77e-17	4.42e-13	-1.01	-0.73	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
THYM	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	10.38	2.86e-17	4.56e-13	0.69	0.73	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	10.38	2.86e-17	4.56e-13	0.69	0.73	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-10.38	2.86e-17	4.56e-13	-0.69	-0.73	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
THYM	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	10.37	3.06e-17	4.87e-13	0.74	0.73	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
THYM	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-10.36	3.1e-17	4.89e-13	-0.85	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	10.36	3.1e-17	4.89e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	10.36	3.1e-17	4.89e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	10.36	3.1e-17	4.89e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	10.36	3.1e-17	4.89e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	10.36	3.13e-17	4.9e-13	0.86	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-10.36	3.16e-17	4.95e-13	-0.86	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	10.36	3.24e-17	5.05e-13	0.86	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	10.36	3.24e-17	5.05e-13	0.86	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	10.36	3.24e-17	5.05e-13	0.86	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	10.35	3.29e-17	5.12e-13	0.84	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
THYM	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	10.35	3.3e-17	5.13e-13	0.71	0.73	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	10.35	3.3e-17	5.13e-13	0.71	0.73	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-10.35	3.3e-17	5.13e-13	-0.71	-0.73	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-10.35	3.3e-17	5.13e-13	-0.71	-0.73	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-10.35	3.3e-17	5.13e-13	-0.71	-0.73	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	10.35	3.33e-17	5.17e-13	0.73	0.73	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
THYM	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	10.35	3.4e-17	5.28e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	10.34	3.43e-17	5.31e-13	0.87	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
THYM	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-10.34	3.48e-17	5.38e-13	-1.01	-0.73	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
THYM	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-10.34	3.57e-17	5.46e-13	-0.85	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-10.34	3.57e-17	5.46e-13	-0.85	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-10.34	3.57e-17	5.46e-13	-0.85	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	10.34	3.57e-17	5.46e-13	0.85	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	10.33	3.58e-17	5.47e-13	0.86	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	10.32	3.8e-17	5.79e-13	0.84	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	10.32	3.8e-17	5.79e-13	0.84	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	10.32	3.8e-17	5.79e-13	0.84	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	10.32	3.8e-17	5.79e-13	0.84	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
THYM	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	10.32	3.8e-17	5.79e-13	0.86	0.73	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
THYM	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	10.32	3.8e-17	5.79e-13	0.86	0.73	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
THYM	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	10.32	3.8e-17	5.79e-13	0.86	0.73	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
THYM	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-10.32	3.82e-17	5.82e-13	-0.75	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
THYM	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-10.32	3.84e-17	5.83e-13	-0.84	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
THYM	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	10.3	4.15e-17	6.28e-13	1.11	0.73	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
THYM	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-10.29	4.36e-17	6.56e-13	-0.84	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	10.29	4.36e-17	6.56e-13	0.84	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
THYM	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-10.29	4.45e-17	6.7e-13	-0.9	-0.73	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
THYM	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	10.29	4.49e-17	6.75e-13	0.88	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
THYM	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-10.28	4.67e-17	7e-13	-1.05	-0.73	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
THYM	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-10.27	4.81e-17	7.18e-13	-1.01	-0.73	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
THYM	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-10.27	4.85e-17	7.23e-13	-0.7	-0.73	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
THYM	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-10.27	5e-17	7.44e-13	-1	-0.73	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
THYM	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-10.26	5.27e-17	7.84e-13	-0.7	-0.73	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
THYM	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	10.24	5.71e-17	8.47e-13	0.72	0.73	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
THYM	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-10.23	5.85e-17	8.66e-13	-1	-0.73	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
THYM	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-10.23	5.96e-17	8.81e-13	-1.04	-0.73	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-10.23	5.96e-17	8.81e-13	-1.04	-0.73	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-10.23	5.96e-17	8.81e-13	-0.8	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	10.23	5.96e-17	8.81e-13	0.8	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
THYM	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	10.23	6.05e-17	8.93e-13	0.87	0.73	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
THYM	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	10.22	6.36e-17	9.35e-13	0.8	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
THYM	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	10.21	6.59e-17	9.67e-13	0.8	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
THYM	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	10.2	6.77e-17	9.94e-13	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
THYM	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-10.19	7.3e-17	1.06e-12	-1.01	-0.72	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-10.19	7.3e-17	1.06e-12	-1.01	-0.72	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-10.19	7.3e-17	1.06e-12	-1.01	-0.72	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-10.19	7.3e-17	1.06e-12	-1.01	-0.72	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-10.19	7.3e-17	1.06e-12	-1.01	-0.72	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-10.19	7.3e-17	1.06e-12	-1.01	-0.72	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
THYM	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	10.18	7.75e-17	1.13e-12	0.69	0.72	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
THYM	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-10.17	7.92e-17	1.15e-12	-0.89	-0.72	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-10.17	7.92e-17	1.15e-12	-0.89	-0.72	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
THYM	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	10.17	7.97e-17	1.16e-12	0.96	0.72	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
THYM	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	10.17	8.09e-17	1.17e-12	0.83	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
THYM	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	10.17	8.13e-17	1.18e-12	0.72	0.72	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
THYM	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	10.17	8.13e-17	1.18e-12	0.82	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
THYM	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-10.16	8.25e-17	1.19e-12	-0.72	-0.72	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
THYM	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-10.16	8.58e-17	1.23e-12	-0.82	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
THYM	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	10.15	9.01e-17	1.29e-12	0.95	0.72	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
THYM	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-10.14	9.47e-17	1.35e-12	-0.89	-0.72	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
THYM	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	10.13	9.67e-17	1.37e-12	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	10.13	9.96e-17	1.41e-12	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	10.13	9.96e-17	1.41e-12	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	10.13	9.96e-17	1.41e-12	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	10.11	1.05e-16	1.48e-12	0.84	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	10.1	1.1e-16	1.55e-12	0.86	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
THYM	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	10.1	1.13e-16	1.58e-12	1.05	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
THYM	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-10.1	1.15e-16	1.61e-12	-1.06	-0.72	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
THYM	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	10.09	1.18e-16	1.65e-12	0.85	0.72	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
THYM	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	10.08	1.23e-16	1.71e-12	0.74	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
THYM	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	10.06	1.35e-16	1.88e-12	0.85	0.72	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
THYM	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	10.06	1.38e-16	1.91e-12	0.85	0.72	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
THYM	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-10.06	1.39e-16	1.93e-12	-1	-0.72	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
THYM	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	10.06	1.4e-16	1.94e-12	0.86	0.72	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
THYM	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-10.05	1.46e-16	2.02e-12	-0.7	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
THYM	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-10.05	1.46e-16	2.02e-12	-0.7	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
THYM	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	10.02	1.63e-16	2.24e-12	0.7	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
THYM	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	10.02	1.63e-16	2.24e-12	0.7	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
THYM	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-10.02	1.63e-16	2.24e-12	-0.7	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
THYM	cis	rs858239	0.669	rs56400441	ENSG00000230658.1	KLHL7-AS1	10.01	1.72e-16	2.35e-12	0.95	0.72	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23101228~23105703:-
THYM	cis	rs4691139	0.545	rs6828659	ENSG00000250227.1	TRIM60P14	10.01	1.72e-16	2.35e-12	0.91	0.72	Ovarian cancer in BRCA1 mutation carriers;	chr4:164960882	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.545	rs28631315	ENSG00000250227.1	TRIM60P14	10.01	1.72e-16	2.35e-12	0.91	0.72	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971104	chr4:164915565~164916983:+
THYM	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	10.01	1.77e-16	2.42e-12	0.93	0.72	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
THYM	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-10	1.82e-16	2.48e-12	-0.93	-0.72	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
THYM	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	10	1.83e-16	2.49e-12	0.86	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
THYM	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-9.99	1.92e-16	2.61e-12	-0.92	-0.72	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-9.99	1.92e-16	2.61e-12	-0.92	-0.72	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
THYM	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-9.98	2.04e-16	2.77e-12	-0.89	-0.72	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-9.98	2.04e-16	2.77e-12	-0.89	-0.72	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
THYM	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-9.98	2.06e-16	2.79e-12	-0.99	-0.72	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
THYM	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-9.98	2.06e-16	2.79e-12	-0.99	-0.72	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
THYM	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	9.97	2.09e-16	2.84e-12	1.1	0.72	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
THYM	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	9.97	2.18e-16	2.95e-12	0.87	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
THYM	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	9.96	2.22e-16	3e-12	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	9.96	2.22e-16	3e-12	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
THYM	cis	rs995834	0.872	rs10425754	ENSG00000267320.4	AC005780.1	-9.96	2.26e-16	3.05e-12	-0.77	-0.72	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387708	chr19:28316705~28386204:-
THYM	cis	rs995834	0.869	rs10853719	ENSG00000267320.4	AC005780.1	-9.96	2.26e-16	3.05e-12	-0.77	-0.72	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392287	chr19:28316705~28386204:-
THYM	cis	rs995834	0.869	rs10405674	ENSG00000267320.4	AC005780.1	-9.96	2.26e-16	3.05e-12	-0.77	-0.72	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393703	chr19:28316705~28386204:-
THYM	cis	rs995834	0.869	rs9304581	ENSG00000267320.4	AC005780.1	-9.96	2.26e-16	3.05e-12	-0.77	-0.72	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394084	chr19:28316705~28386204:-
THYM	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	9.95	2.34e-16	3.16e-12	0.79	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
THYM	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-9.95	2.4e-16	3.23e-12	-0.9	-0.72	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
THYM	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	9.95	2.4e-16	3.23e-12	0.85	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	9.94	2.44e-16	3.29e-12	0.84	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
THYM	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-9.94	2.47e-16	3.31e-12	-0.9	-0.72	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	9.93	2.53e-16	3.39e-12	0.89	0.72	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
THYM	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-9.92	2.71e-16	3.63e-12	-0.83	-0.72	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
THYM	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	9.92	2.72e-16	3.64e-12	0.7	0.72	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
THYM	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	9.92	2.78e-16	3.71e-12	0.69	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
THYM	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	9.92	2.78e-16	3.71e-12	0.69	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
THYM	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	9.92	2.78e-16	3.71e-12	0.69	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
THYM	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-9.89	3.18e-16	4.23e-12	-1.03	-0.71	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
THYM	cis	rs4691139	0.545	rs11100586	ENSG00000250227.1	TRIM60P14	-9.88	3.23e-16	4.29e-12	-0.91	-0.71	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974607	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.545	rs28581275	ENSG00000250227.1	TRIM60P14	9.88	3.23e-16	4.29e-12	0.91	0.71	Ovarian cancer in BRCA1 mutation carriers;	chr4:164974454	chr4:164915565~164916983:+
THYM	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-9.88	3.35e-16	4.43e-12	-0.7	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
THYM	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-9.87	3.41e-16	4.51e-12	-0.84	-0.71	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
THYM	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-9.87	3.54e-16	4.66e-12	-0.84	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
THYM	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-9.87	3.56e-16	4.68e-12	-0.98	-0.71	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
THYM	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-9.86	3.71e-16	4.87e-12	-1	-0.71	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
THYM	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-9.86	3.71e-16	4.87e-12	-1	-0.71	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
THYM	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-9.85	3.81e-16	4.98e-12	-0.91	-0.71	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	9.85	3.81e-16	4.99e-12	0.91	0.71	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-9.85	3.81e-16	4.99e-12	-0.91	-0.71	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
THYM	cis	rs995834	0.912	rs12150882	ENSG00000267320.4	AC005780.1	-9.85	3.92e-16	5.12e-12	-0.72	-0.71	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362126	chr19:28316705~28386204:-
THYM	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	9.85	3.92e-16	5.12e-12	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	9.85	3.92e-16	5.12e-12	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	9.85	3.92e-16	5.12e-12	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	9.85	3.92e-16	5.12e-12	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
THYM	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-9.84	3.95e-16	5.16e-12	-0.87	-0.71	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
THYM	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-9.84	3.98e-16	5.19e-12	-0.91	-0.71	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-9.84	3.98e-16	5.19e-12	-0.91	-0.71	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
THYM	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-9.84	4e-16	5.22e-12	-0.7	-0.71	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
THYM	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-9.82	4.38e-16	5.67e-12	-0.93	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
THYM	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-9.81	4.59e-16	5.93e-12	-0.9	-0.71	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
THYM	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	9.81	4.65e-16	5.98e-12	0.89	0.71	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
THYM	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	9.81	4.65e-16	5.98e-12	0.89	0.71	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
THYM	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	9.81	4.65e-16	5.98e-12	0.89	0.71	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
THYM	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	9.81	4.65e-16	5.98e-12	0.89	0.71	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
THYM	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	9.81	4.65e-16	5.98e-12	0.89	0.71	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
THYM	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	9.8	4.87e-16	6.22e-12	0.7	0.71	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
THYM	cis	rs995834	0.869	rs1476763	ENSG00000267320.4	AC005780.1	-9.8	4.99e-16	6.36e-12	-0.76	-0.71	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394591	chr19:28316705~28386204:-
THYM	cis	rs995834	0.828	rs10460161	ENSG00000267320.4	AC005780.1	-9.8	4.99e-16	6.36e-12	-0.76	-0.71	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394686	chr19:28316705~28386204:-
THYM	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	9.79	5.02e-16	6.4e-12	0.85	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
THYM	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-9.78	5.29e-16	6.74e-12	-0.7	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
THYM	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-9.78	5.39e-16	6.86e-12	-0.96	-0.71	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
THYM	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-9.78	5.39e-16	6.86e-12	-0.96	-0.71	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
THYM	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-9.78	5.39e-16	6.86e-12	-0.96	-0.71	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
THYM	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-9.78	5.39e-16	6.86e-12	-0.96	-0.71	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
THYM	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-9.78	5.39e-16	6.86e-12	-0.96	-0.71	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
THYM	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	9.77	5.74e-16	7.28e-12	0.9	0.71	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-9.77	5.77e-16	7.31e-12	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-9.77	5.77e-16	7.31e-12	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
THYM	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-9.77	5.79e-16	7.33e-12	-0.98	-0.71	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
THYM	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	9.76	5.85e-16	7.38e-12	0.8	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
THYM	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-9.76	5.91e-16	7.45e-12	-0.86	-0.71	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
THYM	cis	rs10256972	0.527	rs2949170	ENSG00000229043.2	AC091729.9	-9.75	6.14e-16	7.73e-12	-0.99	-0.71	Endometriosis;Longevity;	chr7:1176802	chr7:1160374~1165267:+
THYM	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-9.75	6.21e-16	7.81e-12	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-9.75	6.21e-16	7.81e-12	-0.82	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
THYM	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	9.74	6.62e-16	8.29e-12	0.9	0.71	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
THYM	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	9.74	6.62e-16	8.29e-12	0.9	0.71	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
THYM	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	9.74	6.62e-16	8.29e-12	0.9	0.71	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
THYM	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	9.74	6.62e-16	8.29e-12	0.9	0.71	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
THYM	cis	rs995834	1	rs7250520	ENSG00000267320.4	AC005780.1	-9.74	6.63e-16	8.29e-12	-0.72	-0.71	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376844	chr19:28316705~28386204:-
THYM	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-9.74	6.63e-16	8.3e-12	-0.88	-0.71	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-9.74	6.63e-16	8.3e-12	-0.88	-0.71	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
THYM	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	9.74	6.64e-16	8.3e-12	0.94	0.71	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
THYM	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-9.73	6.75e-16	8.44e-12	-0.99	-0.71	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
THYM	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-9.73	7.01e-16	8.75e-12	-1.09	-0.71	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
THYM	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-9.73	7.04e-16	8.77e-12	-0.89	-0.71	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-9.73	7.04e-16	8.77e-12	-0.89	-0.71	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-9.73	7.04e-16	8.77e-12	-0.89	-0.71	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
THYM	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-9.73	7.04e-16	8.77e-12	-0.89	-0.71	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
THYM	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-9.72	7.27e-16	9.05e-12	-0.97	-0.71	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
THYM	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-9.71	7.74e-16	9.59e-12	-0.9	-0.71	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-9.71	7.74e-16	9.59e-12	-0.9	-0.71	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	9.71	7.75e-16	9.6e-12	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
THYM	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-9.7	7.81e-16	9.67e-12	-0.93	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
THYM	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	9.69	8.39e-16	1.03e-11	0.79	0.71	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
THYM	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	9.69	8.43e-16	1.03e-11	0.69	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
THYM	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-9.68	8.61e-16	1.05e-11	-1.01	-0.71	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
THYM	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-9.68	8.88e-16	1.08e-11	-0.69	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
THYM	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	9.68	8.94e-16	1.09e-11	0.88	0.71	Depression;	chr6:28327262	chr6:28176188~28176674:+
THYM	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-9.68	9e-16	1.09e-11	-0.87	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
THYM	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-9.67	9.2e-16	1.12e-11	-0.89	-0.71	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
THYM	cis	rs995834	0.912	rs12608446	ENSG00000267320.4	AC005780.1	-9.67	9.36e-16	1.14e-11	-0.76	-0.71	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384329	chr19:28316705~28386204:-
THYM	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	9.67	9.38e-16	1.14e-11	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
THYM	cis	rs4691139	0.504	rs56231925	ENSG00000250227.1	TRIM60P14	9.67	9.4e-16	1.14e-11	0.9	0.71	Ovarian cancer in BRCA1 mutation carriers;	chr4:164977350	chr4:164915565~164916983:+
THYM	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	9.66	9.49e-16	1.15e-11	1	0.71	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
THYM	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-9.66	9.61e-16	1.16e-11	-0.95	-0.71	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
THYM	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	9.66	9.65e-16	1.17e-11	1.1	0.71	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
THYM	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-9.66	9.71e-16	1.17e-11	-0.8	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
THYM	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	9.66	9.9e-16	1.2e-11	0.86	0.71	Depression;	chr6:28301886	chr6:28176188~28176674:+
THYM	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	9.66	9.9e-16	1.2e-11	0.86	0.71	Depression;	chr6:28303421	chr6:28176188~28176674:+
THYM	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	9.66	9.9e-16	1.2e-11	0.86	0.71	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
THYM	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	9.66	9.9e-16	1.2e-11	0.86	0.71	Depression;	chr6:28317705	chr6:28176188~28176674:+
THYM	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	9.66	9.9e-16	1.2e-11	0.86	0.71	Depression;	chr6:28323463	chr6:28176188~28176674:+
THYM	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-9.65	1e-15	1.21e-11	-0.87	-0.71	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
THYM	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-9.65	1.01e-15	1.22e-11	-0.85	-0.71	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
THYM	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-9.65	1.02e-15	1.23e-11	-0.88	-0.71	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
THYM	cis	rs995834	0.912	rs4806341	ENSG00000267320.4	AC005780.1	-9.65	1.02e-15	1.23e-11	-0.76	-0.71	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384371	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs4806343	ENSG00000267320.4	AC005780.1	-9.65	1.02e-15	1.23e-11	-0.76	-0.71	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384874	chr19:28316705~28386204:-
THYM	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-9.64	1.06e-15	1.27e-11	-0.98	-0.71	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
THYM	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-9.64	1.08e-15	1.29e-11	-0.8	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-9.64	1.08e-15	1.29e-11	-0.8	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-9.64	1.08e-15	1.29e-11	-0.8	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
THYM	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-9.64	1.08e-15	1.3e-11	-0.89	-0.7	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
THYM	cis	rs995834	0.912	rs12151340	ENSG00000267320.4	AC005780.1	9.64	1.09e-15	1.3e-11	0.71	0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362360	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs2058192	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346236	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs4806319	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346419	chr19:28316705~28386204:-
THYM	cis	rs995834	0.872	rs10408276	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346667	chr19:28316705~28386204:-
THYM	cis	rs995834	0.872	rs28612438	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348957	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs7256199	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350657	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs7252509	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350710	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs7258117	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353475	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs10402976	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353776	chr19:28316705~28386204:-
THYM	cis	rs995834	0.912	rs10403247	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354139	chr19:28316705~28386204:-
THYM	cis	rs995834	0.797	rs10401181	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354223	chr19:28316705~28386204:-
THYM	cis	rs995834	0.872	rs7253391	ENSG00000267320.4	AC005780.1	-9.64	1.09e-15	1.3e-11	-0.71	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28367736	chr19:28316705~28386204:-
THYM	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-9.64	1.09e-15	1.3e-11	-0.8	-0.7	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
THYM	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	9.63	1.12e-15	1.33e-11	0.87	0.7	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
THYM	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	9.63	1.12e-15	1.33e-11	0.87	0.7	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
THYM	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	9.63	1.12e-15	1.33e-11	0.87	0.7	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
THYM	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	9.63	1.12e-15	1.33e-11	0.87	0.7	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
THYM	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	9.63	1.12e-15	1.33e-11	0.87	0.7	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
THYM	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-9.63	1.12e-15	1.33e-11	-0.89	-0.7	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-9.62	1.15e-15	1.37e-11	-0.89	-0.7	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
THYM	cis	rs995834	0.833	rs1034885	ENSG00000267320.4	AC005780.1	-9.62	1.16e-15	1.38e-11	-0.76	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28381527	chr19:28316705~28386204:-
THYM	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-9.62	1.17e-15	1.39e-11	-0.92	-0.7	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
THYM	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-9.61	1.27e-15	1.5e-11	-0.9	-0.7	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
THYM	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-9.6	1.33e-15	1.56e-11	-0.85	-0.7	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
THYM	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-9.6	1.33e-15	1.56e-11	-0.85	-0.7	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
THYM	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-9.6	1.33e-15	1.56e-11	-0.85	-0.7	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
THYM	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	9.57	1.53e-15	1.79e-11	1.07	0.7	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
THYM	cis	rs995834	0.869	rs6508821	ENSG00000267320.4	AC005780.1	-9.55	1.69e-15	1.96e-11	-0.78	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396506	chr19:28316705~28386204:-
THYM	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-9.55	1.69e-15	1.96e-11	-1.01	-0.7	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	9.54	1.75e-15	2.01e-11	0.78	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
THYM	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-9.54	1.78e-15	2.04e-11	-1.01	-0.7	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
THYM	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-9.54	1.78e-15	2.04e-11	-1.01	-0.7	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
THYM	cis	rs995834	0.789	rs758124	ENSG00000267320.4	AC005780.1	-9.53	1.8e-15	2.07e-11	-0.77	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402966	chr19:28316705~28386204:-
THYM	cis	rs858239	0.614	rs2014816	ENSG00000230658.1	KLHL7-AS1	9.52	1.9e-15	2.17e-11	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23101228~23105703:-
THYM	cis	rs995834	0.957	rs11667725	ENSG00000267320.4	AC005780.1	-9.52	1.97e-15	2.24e-11	-0.7	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28361557	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs758127	ENSG00000267320.4	AC005780.1	9.51	2.05e-15	2.33e-11	0.8	0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403344	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs758124	ENSG00000266928.1	CTB-70G10.1	-9.5	2.12e-15	2.41e-11	-0.83	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402966	chr19:28294093~28313500:-
THYM	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	9.49	2.28e-15	2.58e-11	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
THYM	cis	rs995834	0.869	rs10417250	ENSG00000267320.4	AC005780.1	-9.48	2.34e-15	2.65e-11	-0.76	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395342	chr19:28316705~28386204:-
THYM	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	9.47	2.42e-15	2.73e-11	0.68	0.7	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
THYM	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-9.47	2.44e-15	2.75e-11	-0.83	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	9.47	2.45e-15	2.76e-11	0.82	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
THYM	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-9.47	2.51e-15	2.82e-11	-0.85	-0.7	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
THYM	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-9.46	2.52e-15	2.83e-11	-0.69	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
THYM	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-9.46	2.52e-15	2.83e-11	-0.69	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
THYM	cis	rs904251	0.861	rs1757180	ENSG00000279942.1	RP1-153P14.7	-9.46	2.56e-15	2.85e-11	-0.97	-0.7	Cognitive performance;	chr6:37518369	chr6:37567716~37571460:+
THYM	cis	rs995834	0.826	rs10419909	ENSG00000267320.4	AC005780.1	-9.46	2.64e-15	2.93e-11	-0.76	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395848	chr19:28316705~28386204:-
THYM	cis	rs995834	0.826	rs8112121	ENSG00000267320.4	AC005780.1	-9.46	2.64e-15	2.93e-11	-0.76	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396047	chr19:28316705~28386204:-
THYM	cis	rs995834	0.826	rs6508819	ENSG00000267320.4	AC005780.1	-9.46	2.64e-15	2.93e-11	-0.76	-0.7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396068	chr19:28316705~28386204:-
THYM	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-9.45	2.78e-15	3.08e-11	-0.95	-0.7	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
THYM	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	9.42	3.08e-15	3.4e-11	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
THYM	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-9.41	3.32e-15	3.65e-11	-1.01	-0.7	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
THYM	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-9.41	3.32e-15	3.65e-11	-1.01	-0.7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
THYM	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	9.39	3.63e-15	3.98e-11	1.16	0.7	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
THYM	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-9.37	3.98e-15	4.34e-11	-0.96	-0.7	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
THYM	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	9.37	4.04e-15	4.4e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	9.36	4.29e-15	4.58e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	9.36	4.29e-15	4.58e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	9.36	4.29e-15	4.58e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	9.36	4.29e-15	4.58e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
THYM	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-9.35	4.34e-15	4.63e-11	-0.89	-0.69	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
THYM	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	9.35	4.34e-15	4.63e-11	0.89	0.69	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
THYM	cis	rs995834	0.789	rs4806362	ENSG00000267320.4	AC005780.1	9.34	4.57e-15	4.84e-11	0.76	0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398414	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs10425833	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401807	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs10402916	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402001	chr19:28316705~28386204:-
THYM	cis	rs995834	0.753	rs10405354	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402005	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs7248138	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402207	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs7246817	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402219	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs10411886	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402396	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs758123	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402872	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs758125	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403001	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs758126	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403236	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs10421214	ENSG00000267320.4	AC005780.1	-9.34	4.57e-15	4.84e-11	-0.76	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404538	chr19:28316705~28386204:-
THYM	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-9.34	4.74e-15	5.02e-11	-0.85	-0.69	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
THYM	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-9.33	4.85e-15	5.13e-11	-0.8	-0.69	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
THYM	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	9.33	4.89e-15	5.16e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	9.33	4.89e-15	5.16e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
THYM	cis	rs4691139	0.505	rs10034083	ENSG00000250227.1	TRIM60P14	9.32	5.17e-15	5.46e-11	0.89	0.69	Ovarian cancer in BRCA1 mutation carriers;	chr4:164957855	chr4:164915565~164916983:+
THYM	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-9.31	5.51e-15	5.8e-11	-0.85	-0.69	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
THYM	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	9.3	5.57e-15	5.86e-11	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
THYM	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-9.3	5.71e-15	6e-11	-0.93	-0.69	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
THYM	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-9.29	5.85e-15	6.14e-11	-0.9	-0.69	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
THYM	cis	rs916888	0.558	rs199521	ENSG00000214401.4	KANSL1-AS1	-9.28	6.27e-15	6.55e-11	-0.69	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776090	chr17:46193576~46196723:+
THYM	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-9.27	6.41e-15	6.68e-11	-0.87	-0.69	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-9.27	6.41e-15	6.68e-11	-0.87	-0.69	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-9.27	6.48e-15	6.75e-11	-0.91	-0.69	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-9.27	6.51e-15	6.77e-11	-0.89	-0.69	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	9.27	6.53e-15	6.78e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	9.27	6.53e-15	6.78e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	9.27	6.53e-15	6.78e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	9.27	6.53e-15	6.78e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
THYM	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	9.26	6.76e-15	7.01e-11	1.05	0.69	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
THYM	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-9.25	7.25e-15	7.49e-11	-0.9	-0.69	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
THYM	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	9.25	7.29e-15	7.53e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	9.25	7.29e-15	7.53e-11	0.81	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
THYM	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-9.24	7.74e-15	7.98e-11	-0.84	-0.69	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
THYM	cis	rs995834	0.789	rs758127	ENSG00000266928.1	CTB-70G10.1	9.23	7.8e-15	8.04e-11	0.84	0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403344	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs4806372	ENSG00000267320.4	AC005780.1	9.23	7.82e-15	8.05e-11	0.73	0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403612	chr19:28316705~28386204:-
THYM	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	9.23	7.82e-15	8.05e-11	0.88	0.69	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
THYM	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-9.23	8.16e-15	8.39e-11	-0.74	-0.69	Breast cancer;	chr11:743813	chr11:779617~780755:+
THYM	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-9.23	8.16e-15	8.39e-11	-0.85	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
THYM	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-9.23	8.16e-15	8.39e-11	-0.85	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
THYM	cis	rs904251	0.766	rs1757175	ENSG00000279942.1	RP1-153P14.7	-9.21	8.9e-15	9.1e-11	-0.93	-0.69	Cognitive performance;	chr6:37518918	chr6:37567716~37571460:+
THYM	cis	rs904251	0.828	rs1757174	ENSG00000279942.1	RP1-153P14.7	-9.21	8.9e-15	9.1e-11	-0.93	-0.69	Cognitive performance;	chr6:37518919	chr6:37567716~37571460:+
THYM	cis	rs904251	0.861	rs1757173	ENSG00000279942.1	RP1-153P14.7	-9.21	8.9e-15	9.1e-11	-0.93	-0.69	Cognitive performance;	chr6:37519176	chr6:37567716~37571460:+
THYM	cis	rs904251	0.861	rs1757169	ENSG00000279942.1	RP1-153P14.7	-9.21	8.9e-15	9.1e-11	-0.93	-0.69	Cognitive performance;	chr6:37519300	chr6:37567716~37571460:+
THYM	cis	rs904251	0.861	rs2776877	ENSG00000279942.1	RP1-153P14.7	-9.21	8.9e-15	9.1e-11	-0.93	-0.69	Cognitive performance;	chr6:37519359	chr6:37567716~37571460:+
THYM	cis	rs4691139	0.524	rs4350966	ENSG00000250227.1	TRIM60P14	9.2	9.2e-15	9.39e-11	0.87	0.69	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981127	chr4:164915565~164916983:+
THYM	cis	rs7829975	0.511	rs2980512	ENSG00000253893.2	FAM85B	-9.19	9.81e-15	9.99e-11	-0.85	-0.69	Mood instability;	chr8:8283379	chr8:8167819~8226614:-
THYM	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-9.19	9.83e-15	1e-10	-0.84	-0.69	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
THYM	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-9.19	9.87e-15	1e-10	-0.92	-0.69	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-9.19	9.87e-15	1e-10	-0.92	-0.69	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
THYM	cis	rs904251	0.861	rs1776456	ENSG00000279942.1	RP1-153P14.7	-9.18	1.02e-14	1.04e-10	-1	-0.69	Cognitive performance;	chr6:37516922	chr6:37567716~37571460:+
THYM	cis	rs904251	0.828	rs1757178	ENSG00000279942.1	RP1-153P14.7	9.18	1.02e-14	1.04e-10	0.91	0.69	Cognitive performance;	chr6:37518534	chr6:37567716~37571460:+
THYM	cis	rs995834	0.872	rs10425754	ENSG00000266928.1	CTB-70G10.1	-9.17	1.06e-14	1.07e-10	-0.79	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387708	chr19:28294093~28313500:-
THYM	cis	rs995834	0.869	rs10853719	ENSG00000266928.1	CTB-70G10.1	-9.17	1.06e-14	1.07e-10	-0.79	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392287	chr19:28294093~28313500:-
THYM	cis	rs995834	0.869	rs10405674	ENSG00000266928.1	CTB-70G10.1	-9.17	1.06e-14	1.07e-10	-0.79	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393703	chr19:28294093~28313500:-
THYM	cis	rs995834	0.869	rs9304581	ENSG00000266928.1	CTB-70G10.1	-9.17	1.06e-14	1.07e-10	-0.79	-0.69	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394084	chr19:28294093~28313500:-
THYM	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-9.17	1.07e-14	1.07e-10	-0.87	-0.69	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
THYM	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-9.17	1.08e-14	1.08e-10	-0.84	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
THYM	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-9.17	1.08e-14	1.08e-10	-0.84	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
THYM	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	9.17	1.09e-14	1.09e-10	0.87	0.69	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-9.17	1.09e-14	1.09e-10	-0.87	-0.69	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
THYM	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-9.17	1.09e-14	1.09e-10	-0.87	-0.69	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-9.17	1.09e-14	1.09e-10	-0.87	-0.69	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-9.17	1.09e-14	1.09e-10	-0.87	-0.69	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-9.17	1.09e-14	1.09e-10	-0.87	-0.69	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
THYM	cis	rs904251	0.861	rs1757171	ENSG00000279942.1	RP1-153P14.7	-9.16	1.15e-14	1.14e-10	-0.94	-0.69	Cognitive performance;	chr6:37519268	chr6:37567716~37571460:+
THYM	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-9.15	1.18e-14	1.18e-10	-0.92	-0.69	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
THYM	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	9.13	1.28e-14	1.27e-10	0.86	0.69	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	9.13	1.28e-14	1.27e-10	0.86	0.69	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
THYM	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	9.12	1.38e-14	1.35e-10	0.95	0.69	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
THYM	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-9.12	1.39e-14	1.35e-10	-0.83	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
THYM	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	9.12	1.39e-14	1.35e-10	0.83	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
THYM	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	9.12	1.39e-14	1.35e-10	0.83	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
THYM	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-9.1	1.54e-14	1.5e-10	-0.87	-0.68	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-9.1	1.54e-14	1.5e-10	-0.87	-0.68	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
THYM	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-9.1	1.54e-14	1.5e-10	-0.88	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
THYM	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-9.09	1.57e-14	1.52e-10	-0.83	-0.68	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
THYM	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	9.09	1.58e-14	1.53e-10	0.8	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
THYM	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	9.09	1.59e-14	1.53e-10	0.87	0.68	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
THYM	cis	rs995834	0.869	rs10417250	ENSG00000266928.1	CTB-70G10.1	-9.09	1.59e-14	1.53e-10	-0.79	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395342	chr19:28294093~28313500:-
THYM	cis	rs904251	0.737	rs914347	ENSG00000279942.1	RP1-153P14.7	-9.09	1.61e-14	1.56e-10	-0.95	-0.68	Cognitive performance;	chr6:37517194	chr6:37567716~37571460:+
THYM	cis	rs904251	0.797	rs1776460	ENSG00000279942.1	RP1-153P14.7	-9.09	1.61e-14	1.56e-10	-0.95	-0.68	Cognitive performance;	chr6:37517708	chr6:37567716~37571460:+
THYM	cis	rs904251	0.861	rs1757183	ENSG00000279942.1	RP1-153P14.7	9.08	1.65e-14	1.59e-10	0.91	0.68	Cognitive performance;	chr6:37517014	chr6:37567716~37571460:+
THYM	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-9.07	1.73e-14	1.67e-10	-0.91	-0.68	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
THYM	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-9.07	1.78e-14	1.71e-10	-1.12	-0.68	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
THYM	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	9.06	1.79e-14	1.71e-10	0.79	0.68	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
THYM	cis	rs995834	0.869	rs6508821	ENSG00000266928.1	CTB-70G10.1	-9.06	1.83e-14	1.75e-10	-0.81	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396506	chr19:28294093~28313500:-
THYM	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-9.06	1.87e-14	1.78e-10	-1.12	-0.68	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
THYM	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-9.05	1.89e-14	1.8e-10	-0.92	-0.68	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-9.05	1.89e-14	1.8e-10	-0.92	-0.68	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-9.05	1.89e-14	1.8e-10	-0.92	-0.68	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-9.05	1.89e-14	1.8e-10	-0.92	-0.68	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-9.05	1.89e-14	1.8e-10	-0.92	-0.68	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
THYM	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	9.05	1.92e-14	1.83e-10	0.6	0.68	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
THYM	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	9.05	1.95e-14	1.86e-10	0.86	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
THYM	cis	rs7224296	0.709	rs199518	ENSG00000214401.4	KANSL1-AS1	-9.05	1.96e-14	1.86e-10	-0.68	-0.68	Intelligence (multi-trait analysis);	chr17:46777214	chr17:46193576~46196723:+
THYM	cis	rs916888	0.647	rs199517	ENSG00000214401.4	KANSL1-AS1	-9.05	1.96e-14	1.86e-10	-0.68	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46777221	chr17:46193576~46196723:+
THYM	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-9.05	1.96e-14	1.86e-10	-1.08	-0.68	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-9.05	1.96e-14	1.86e-10	-1.08	-0.68	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-9.05	1.96e-14	1.86e-10	-1.08	-0.68	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
THYM	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-9.05	1.96e-14	1.86e-10	-1.08	-0.68	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-9.05	1.96e-14	1.86e-10	-1.08	-0.68	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-9.05	1.96e-14	1.86e-10	-1.08	-0.68	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
THYM	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-9.05	1.97e-14	1.86e-10	-0.82	-0.68	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
THYM	cis	rs904251	0.861	rs2776875	ENSG00000279942.1	RP1-153P14.7	-9.04	1.98e-14	1.87e-10	-0.92	-0.68	Cognitive performance;	chr6:37519020	chr6:37567716~37571460:+
THYM	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	9.04	2.06e-14	1.93e-10	0.97	0.68	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
THYM	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	9.03	2.13e-14	1.98e-10	0.87	0.68	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
THYM	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	9.03	2.15e-14	2e-10	0.9	0.68	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
THYM	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-9.03	2.17e-14	2.01e-10	-1.06	-0.68	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
THYM	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	9.02	2.24e-14	2.07e-10	0.85	0.68	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
THYM	cis	rs904251	0.797	rs1757181	ENSG00000279942.1	RP1-153P14.7	9.01	2.35e-14	2.17e-10	0.9	0.68	Cognitive performance;	chr6:37517952	chr6:37567716~37571460:+
THYM	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	9.01	2.36e-14	2.18e-10	0.8	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
THYM	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-9.01	2.37e-14	2.19e-10	-0.81	-0.68	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
THYM	cis	rs995834	0.789	rs10425833	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401807	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs10402916	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402001	chr19:28294093~28313500:-
THYM	cis	rs995834	0.753	rs10405354	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402005	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs7248138	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402207	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs7246817	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402219	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs10411886	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402396	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs758123	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402872	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs758125	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403001	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs758126	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403236	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs10421214	ENSG00000266928.1	CTB-70G10.1	-9.01	2.39e-14	2.2e-10	-0.8	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404538	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs4806362	ENSG00000266928.1	CTB-70G10.1	9.01	2.39e-14	2.2e-10	0.8	0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398414	chr19:28294093~28313500:-
THYM	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	9	2.43e-14	2.23e-10	0.82	0.68	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
THYM	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	9	2.43e-14	2.23e-10	0.82	0.68	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
THYM	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	9	2.43e-14	2.23e-10	0.82	0.68	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
THYM	cis	rs904251	0.861	rs914349	ENSG00000279942.1	RP1-153P14.7	-9	2.44e-14	2.24e-10	-0.99	-0.68	Cognitive performance;	chr6:37516939	chr6:37567716~37571460:+
THYM	cis	rs995834	0.912	rs12150882	ENSG00000266928.1	CTB-70G10.1	-9	2.44e-14	2.24e-10	-0.73	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362126	chr19:28294093~28313500:-
THYM	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	9	2.52e-14	2.31e-10	0.82	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
THYM	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	9	2.52e-14	2.31e-10	0.82	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
THYM	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	9	2.52e-14	2.31e-10	0.82	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
THYM	cis	rs904251	0.797	rs1757177	ENSG00000279942.1	RP1-153P14.7	-8.99	2.62e-14	2.4e-10	-0.88	-0.68	Cognitive performance;	chr6:37518594	chr6:37567716~37571460:+
THYM	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-8.99	2.63e-14	2.4e-10	-0.75	-0.68	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
THYM	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	8.98	2.68e-14	2.44e-10	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
THYM	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	8.98	2.68e-14	2.44e-10	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
THYM	cis	rs995834	1	rs7250520	ENSG00000266928.1	CTB-70G10.1	-8.98	2.74e-14	2.5e-10	-0.74	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376844	chr19:28294093~28313500:-
THYM	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	8.98	2.77e-14	2.53e-10	0.97	0.68	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
THYM	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	8.98	2.77e-14	2.53e-10	0.97	0.68	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
THYM	cis	rs904251	0.861	rs914349	ENSG00000227920.2	RP1-153P14.5	-8.97	2.79e-14	2.54e-10	-1.03	-0.68	Cognitive performance;	chr6:37516939	chr6:37545145~37550860:+
THYM	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	8.96	2.94e-14	2.67e-10	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
THYM	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	8.96	3e-14	2.72e-10	0.83	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
THYM	cis	rs995834	0.869	rs1476763	ENSG00000266928.1	CTB-70G10.1	-8.96	3.05e-14	2.76e-10	-0.78	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394591	chr19:28294093~28313500:-
THYM	cis	rs995834	0.828	rs10460161	ENSG00000266928.1	CTB-70G10.1	-8.96	3.05e-14	2.76e-10	-0.78	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394686	chr19:28294093~28313500:-
THYM	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	8.95	3.07e-14	2.78e-10	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
THYM	cis	rs995834	0.912	rs4806341	ENSG00000266928.1	CTB-70G10.1	-8.95	3.11e-14	2.82e-10	-0.78	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384371	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs4806343	ENSG00000266928.1	CTB-70G10.1	-8.95	3.11e-14	2.82e-10	-0.78	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384874	chr19:28294093~28313500:-
THYM	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	8.95	3.13e-14	2.83e-10	0.86	0.68	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
THYM	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	8.95	3.13e-14	2.83e-10	0.86	0.68	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
THYM	cis	rs995834	0.833	rs1034885	ENSG00000266928.1	CTB-70G10.1	-8.95	3.15e-14	2.84e-10	-0.78	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28381527	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs12608446	ENSG00000266928.1	CTB-70G10.1	-8.95	3.2e-14	2.89e-10	-0.78	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384329	chr19:28294093~28313500:-
THYM	cis	rs916888	0.647	rs199520	ENSG00000214401.4	KANSL1-AS1	-8.94	3.36e-14	3.01e-10	-0.67	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776506	chr17:46193576~46196723:+
THYM	cis	rs916888	0.647	rs199519	ENSG00000214401.4	KANSL1-AS1	-8.94	3.36e-14	3.01e-10	-0.67	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776558	chr17:46193576~46196723:+
THYM	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	8.94	3.37e-14	3.01e-10	1.09	0.68	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	8.94	3.37e-14	3.01e-10	1.09	0.68	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	8.94	3.37e-14	3.01e-10	1.09	0.68	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
THYM	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
THYM	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-8.94	3.37e-14	3.01e-10	-1.09	-0.68	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
THYM	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-8.93	3.4e-14	3.04e-10	-0.78	-0.68	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
THYM	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	8.93	3.44e-14	3.06e-10	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
THYM	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-8.93	3.45e-14	3.07e-10	-0.94	-0.68	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
THYM	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	8.93	3.49e-14	3.11e-10	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
THYM	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-8.93	3.51e-14	3.12e-10	-0.86	-0.68	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
THYM	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	8.93	3.52e-14	3.13e-10	0.86	0.68	Depression;	chr6:28314871	chr6:28176188~28176674:+
THYM	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-8.92	3.56e-14	3.16e-10	-1.1	-0.68	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-8.92	3.56e-14	3.16e-10	-1.1	-0.68	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
THYM	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	8.92	3.56e-14	3.16e-10	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
THYM	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	8.92	3.64e-14	3.23e-10	0.89	0.68	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
THYM	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	8.92	3.64e-14	3.23e-10	0.89	0.68	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
THYM	cis	rs995834	0.826	rs10419909	ENSG00000266928.1	CTB-70G10.1	-8.92	3.65e-14	3.24e-10	-0.79	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395848	chr19:28294093~28313500:-
THYM	cis	rs995834	0.826	rs8112121	ENSG00000266928.1	CTB-70G10.1	-8.92	3.65e-14	3.24e-10	-0.79	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396047	chr19:28294093~28313500:-
THYM	cis	rs995834	0.826	rs6508819	ENSG00000266928.1	CTB-70G10.1	-8.92	3.65e-14	3.24e-10	-0.79	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396068	chr19:28294093~28313500:-
THYM	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-8.91	3.77e-14	3.34e-10	-0.83	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
THYM	cis	rs995834	0.622	rs4806395	ENSG00000266928.1	CTB-70G10.1	-8.91	3.83e-14	3.38e-10	-0.85	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28416529	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs8102434	ENSG00000266928.1	CTB-70G10.1	-8.91	3.83e-14	3.38e-10	-0.85	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28418061	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs10413972	ENSG00000266928.1	CTB-70G10.1	-8.91	3.83e-14	3.38e-10	-0.85	-0.68	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419219	chr19:28294093~28313500:-
THYM	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-8.9	3.95e-14	3.49e-10	-0.78	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	8.9	3.95e-14	3.49e-10	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
THYM	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	8.9	4.05e-14	3.56e-10	0.66	0.68	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
THYM	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	8.9	4.08e-14	3.59e-10	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	8.89	4.11e-14	3.62e-10	0.78	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
THYM	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-8.87	4.53e-14	3.98e-10	-0.88	-0.68	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-8.87	4.53e-14	3.98e-10	-0.88	-0.68	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	8.87	4.53e-14	3.98e-10	0.88	0.68	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
THYM	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	8.87	4.54e-14	3.98e-10	0.82	0.68	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
THYM	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-8.86	4.77e-14	4.17e-10	-0.84	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
THYM	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-8.85	5.04e-14	4.4e-10	-1.07	-0.67	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
THYM	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	8.85	5.17e-14	4.5e-10	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
THYM	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-8.85	5.19e-14	4.51e-10	-0.9	-0.67	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
THYM	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	8.83	5.55e-14	4.81e-10	0.68	0.67	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-8.83	5.6e-14	4.85e-10	-0.82	-0.67	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
THYM	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	8.83	5.66e-14	4.89e-10	0.7	0.67	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	8.83	5.72e-14	4.95e-10	0.7	0.67	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
THYM	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	8.82	5.79e-14	5.01e-10	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
THYM	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	8.82	5.83e-14	5.03e-10	0.82	0.67	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
THYM	cis	rs995834	0.622	rs2159078	ENSG00000266928.1	CTB-70G10.1	-8.82	5.89e-14	5.08e-10	-0.83	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404431	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs2869481	ENSG00000266928.1	CTB-70G10.1	-8.82	5.89e-14	5.08e-10	-0.83	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404927	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs2869482	ENSG00000266928.1	CTB-70G10.1	-8.82	5.89e-14	5.08e-10	-0.83	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405261	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs10407917	ENSG00000266928.1	CTB-70G10.1	-8.82	5.89e-14	5.08e-10	-0.83	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405441	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs10408833	ENSG00000266928.1	CTB-70G10.1	-8.82	5.89e-14	5.08e-10	-0.83	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405825	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs2159077	ENSG00000266928.1	CTB-70G10.1	8.82	5.89e-14	5.08e-10	0.83	0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404348	chr19:28294093~28313500:-
THYM	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	8.82	5.93e-14	5.11e-10	0.69	0.67	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
THYM	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	8.81	6.19e-14	5.33e-10	0.79	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
THYM	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	8.81	6.2e-14	5.33e-10	0.78	0.67	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
THYM	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	8.81	6.2e-14	5.33e-10	0.78	0.67	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
THYM	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-8.81	6.23e-14	5.36e-10	-0.88	-0.67	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
THYM	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	8.81	6.34e-14	5.45e-10	0.89	0.67	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
THYM	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-8.8	6.51e-14	5.59e-10	-0.64	-0.67	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
THYM	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-8.8	6.61e-14	5.68e-10	-0.86	-0.67	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
THYM	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-8.8	6.63e-14	5.69e-10	-0.8	-0.67	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
THYM	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	8.78	7.09e-14	6.06e-10	0.89	0.67	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
THYM	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-8.78	7.09e-14	6.06e-10	-0.82	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
THYM	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	8.78	7.33e-14	6.26e-10	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
THYM	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	8.77	7.43e-14	6.34e-10	0.9	0.67	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
THYM	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-8.77	7.54e-14	6.43e-10	-0.85	-0.67	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
THYM	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-8.77	7.54e-14	6.43e-10	-0.85	-0.67	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
THYM	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-8.77	7.54e-14	6.43e-10	-0.85	-0.67	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
THYM	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-8.77	7.54e-14	6.43e-10	-0.85	-0.67	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
THYM	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	8.76	7.78e-14	6.63e-10	0.87	0.67	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
THYM	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-8.76	7.89e-14	6.71e-10	-0.84	-0.67	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
THYM	cis	rs995834	0.585	rs10404961	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28417370	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs10419520	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419267	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs4806402	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420314	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs10419336	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420386	chr19:28294093~28313500:-
THYM	cis	rs995834	0.551	rs1558124	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420672	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs10403634	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28422714	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs10409773	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423090	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs8101242	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423341	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs720924	ENSG00000266928.1	CTB-70G10.1	-8.76	8.11e-14	6.87e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424180	chr19:28294093~28313500:-
THYM	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	8.76	8.12e-14	6.88e-10	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
THYM	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	8.76	8.12e-14	6.88e-10	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
THYM	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-8.76	8.14e-14	6.88e-10	-0.67	-0.67	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
THYM	cis	rs995834	0.912	rs2058192	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346236	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs4806319	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346419	chr19:28294093~28313500:-
THYM	cis	rs995834	0.872	rs10408276	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346667	chr19:28294093~28313500:-
THYM	cis	rs995834	0.872	rs28612438	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348957	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs7256199	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350657	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs7252509	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350710	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs7258117	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353475	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs10402976	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353776	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs10403247	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354139	chr19:28294093~28313500:-
THYM	cis	rs995834	0.797	rs10401181	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354223	chr19:28294093~28313500:-
THYM	cis	rs995834	0.912	rs12151340	ENSG00000266928.1	CTB-70G10.1	8.75	8.15e-14	6.88e-10	0.72	0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362360	chr19:28294093~28313500:-
THYM	cis	rs995834	0.872	rs7253391	ENSG00000266928.1	CTB-70G10.1	-8.75	8.15e-14	6.88e-10	-0.72	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28367736	chr19:28294093~28313500:-
THYM	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-8.75	8.2e-14	6.93e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
THYM	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	8.75	8.21e-14	6.93e-10	0.58	0.67	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
THYM	cis	rs7044106	0.791	rs4836831	ENSG00000226752.6	PSMD5-AS1	-8.75	8.43e-14	7.11e-10	-0.8	-0.67	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120824828~120854385:+
THYM	cis	rs995834	0.743	rs1860211	ENSG00000266928.1	CTB-70G10.1	-8.75	8.47e-14	7.14e-10	-0.8	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28386236	chr19:28294093~28313500:-
THYM	cis	rs904251	0.864	rs2797801	ENSG00000279942.1	RP1-153P14.7	-8.75	8.52e-14	7.18e-10	-0.93	-0.67	Cognitive performance;	chr6:37519385	chr6:37567716~37571460:+
THYM	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
THYM	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-8.74	8.66e-14	7.27e-10	-1.08	-0.67	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
THYM	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	8.74	8.68e-14	7.29e-10	0.69	0.67	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	8.74	8.68e-14	7.29e-10	0.69	0.67	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	8.74	8.68e-14	7.29e-10	0.69	0.67	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
THYM	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	8.74	8.89e-14	7.45e-10	0.85	0.67	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
THYM	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	8.74	8.89e-14	7.45e-10	0.85	0.67	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
THYM	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-8.74	8.89e-14	7.45e-10	-0.85	-0.67	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
THYM	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-8.74	8.9e-14	7.46e-10	-0.84	-0.67	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
THYM	cis	rs2739330	0.892	rs4822455	ENSG00000272787.1	KB-226F1.2	-8.73	8.99e-14	7.53e-10	-0.74	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23969211~23969873:+
THYM	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	8.73	9.04e-14	7.58e-10	0.92	0.67	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
THYM	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-8.73	9.05e-14	7.58e-10	-0.84	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
THYM	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	8.73	9.08e-14	7.6e-10	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
THYM	cis	rs904251	0.797	rs2776878	ENSG00000279942.1	RP1-153P14.7	-8.73	9.29e-14	7.75e-10	-0.95	-0.67	Cognitive performance;	chr6:37519497	chr6:37567716~37571460:+
THYM	cis	rs904251	0.828	rs2797803	ENSG00000279942.1	RP1-153P14.7	-8.73	9.29e-14	7.75e-10	-0.95	-0.67	Cognitive performance;	chr6:37519564	chr6:37567716~37571460:+
THYM	cis	rs7224296	0.709	rs199518	ENSG00000262539.1	RP11-259G18.3	-8.71	9.9e-14	8.23e-10	-0.83	-0.67	Intelligence (multi-trait analysis);	chr17:46777214	chr17:46259551~46260606:-
THYM	cis	rs916888	0.647	rs199517	ENSG00000262539.1	RP11-259G18.3	-8.71	9.9e-14	8.23e-10	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46777221	chr17:46259551~46260606:-
THYM	cis	rs916888	0.558	rs199521	ENSG00000262539.1	RP11-259G18.3	-8.71	9.99e-14	8.29e-10	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776090	chr17:46259551~46260606:-
THYM	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	8.71	1e-13	8.33e-10	0.9	0.67	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
THYM	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	8.71	1e-13	8.33e-10	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
THYM	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	8.71	1.04e-13	8.59e-10	0.57	0.67	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
THYM	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	8.7	1.05e-13	8.65e-10	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
THYM	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.7	1.07e-13	8.87e-10	0.57	0.67	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
THYM	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-8.7	1.09e-13	8.94e-10	-0.88	-0.67	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-8.7	1.09e-13	8.94e-10	-0.88	-0.67	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-8.7	1.09e-13	8.94e-10	-0.88	-0.67	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
THYM	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.57	0.67	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.57	0.67	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.57	0.67	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	8.7	1.09e-13	8.94e-10	0.59	0.67	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
THYM	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-8.7	1.09e-13	8.95e-10	-1.03	-0.67	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
THYM	cis	rs995834	0.664	rs8110139	ENSG00000266928.1	CTB-70G10.1	-8.69	1.12e-13	9.17e-10	-0.83	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395640	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs1029661	ENSG00000266928.1	CTB-70G10.1	-8.69	1.12e-13	9.2e-10	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406394	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs7249889	ENSG00000266928.1	CTB-70G10.1	-8.69	1.12e-13	9.2e-10	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406402	chr19:28294093~28313500:-
THYM	cis	rs995834	0.703	rs4806354	ENSG00000266928.1	CTB-70G10.1	-8.69	1.14e-13	9.39e-10	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396974	chr19:28294093~28313500:-
THYM	cis	rs995834	0.703	rs4806355	ENSG00000266928.1	CTB-70G10.1	-8.69	1.14e-13	9.39e-10	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396997	chr19:28294093~28313500:-
THYM	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	8.68	1.16e-13	9.49e-10	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
THYM	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	8.68	1.17e-13	9.56e-10	0.59	0.67	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
THYM	cis	rs995834	0.743	rs1860211	ENSG00000267320.4	AC005780.1	-8.68	1.19e-13	9.71e-10	-0.74	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28386236	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs720923	ENSG00000266928.1	CTB-70G10.1	-8.68	1.2e-13	9.79e-10	-0.85	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423935	chr19:28294093~28313500:-
THYM	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-8.68	1.2e-13	9.81e-10	-1.03	-0.67	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
THYM	cis	rs916888	0.647	rs199520	ENSG00000262539.1	RP11-259G18.3	-8.67	1.25e-13	1.02e-09	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776506	chr17:46259551~46260606:-
THYM	cis	rs916888	0.647	rs199519	ENSG00000262539.1	RP11-259G18.3	-8.67	1.25e-13	1.02e-09	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776558	chr17:46259551~46260606:-
THYM	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	8.67	1.25e-13	1.02e-09	0.6	0.67	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
THYM	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-8.66	1.3e-13	1.05e-09	-0.87	-0.67	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
THYM	cis	rs995834	0.622	rs10408649	ENSG00000266928.1	CTB-70G10.1	-8.66	1.3e-13	1.05e-09	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405965	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs6508824	ENSG00000266928.1	CTB-70G10.1	-8.66	1.3e-13	1.05e-09	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406925	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs8111081	ENSG00000266928.1	CTB-70G10.1	-8.66	1.3e-13	1.05e-09	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407156	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs10407317	ENSG00000266928.1	CTB-70G10.1	-8.66	1.3e-13	1.05e-09	-0.84	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28411352	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs2159074	ENSG00000266928.1	CTB-70G10.1	8.66	1.3e-13	1.05e-09	0.84	0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407490	chr19:28294093~28313500:-
THYM	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	8.66	1.31e-13	1.06e-09	0.59	0.67	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
THYM	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-8.65	1.37e-13	1.11e-09	-0.81	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
THYM	cis	rs995834	0.784	rs12983816	ENSG00000266928.1	CTB-70G10.1	-8.64	1.4e-13	1.13e-09	-0.79	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387019	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs2190992	ENSG00000266928.1	CTB-70G10.1	-8.64	1.4e-13	1.13e-09	-0.79	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28389894	chr19:28294093~28313500:-
THYM	cis	rs995834	0.661	rs8100368	ENSG00000266928.1	CTB-70G10.1	-8.64	1.4e-13	1.13e-09	-0.79	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28390727	chr19:28294093~28313500:-
THYM	cis	rs995834	0.703	rs10853718	ENSG00000266928.1	CTB-70G10.1	-8.64	1.4e-13	1.13e-09	-0.79	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392058	chr19:28294093~28313500:-
THYM	cis	rs995834	0.664	rs10411350	ENSG00000266928.1	CTB-70G10.1	-8.64	1.4e-13	1.13e-09	-0.79	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393737	chr19:28294093~28313500:-
THYM	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-8.64	1.4e-13	1.13e-09	-0.76	-0.67	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
THYM	cis	rs995834	0.784	rs12983816	ENSG00000267320.4	AC005780.1	-8.64	1.41e-13	1.14e-09	-0.74	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387019	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs2190992	ENSG00000267320.4	AC005780.1	-8.64	1.41e-13	1.14e-09	-0.74	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28389894	chr19:28316705~28386204:-
THYM	cis	rs995834	0.661	rs8100368	ENSG00000267320.4	AC005780.1	-8.64	1.41e-13	1.14e-09	-0.74	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28390727	chr19:28316705~28386204:-
THYM	cis	rs995834	0.703	rs10853718	ENSG00000267320.4	AC005780.1	-8.64	1.41e-13	1.14e-09	-0.74	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392058	chr19:28316705~28386204:-
THYM	cis	rs995834	0.664	rs10411350	ENSG00000267320.4	AC005780.1	-8.64	1.41e-13	1.14e-09	-0.74	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393737	chr19:28316705~28386204:-
THYM	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	8.64	1.43e-13	1.15e-09	0.5	0.67	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
THYM	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-8.64	1.44e-13	1.16e-09	-1.08	-0.67	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-8.64	1.44e-13	1.16e-09	-1.08	-0.67	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
THYM	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	8.64	1.45e-13	1.16e-09	0.77	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
THYM	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-8.63	1.48e-13	1.18e-09	-0.77	-0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
THYM	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	8.63	1.49e-13	1.2e-09	0.86	0.66	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
THYM	cis	rs995834	0.622	rs4806395	ENSG00000267320.4	AC005780.1	-8.63	1.52e-13	1.21e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28416529	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs8102434	ENSG00000267320.4	AC005780.1	-8.63	1.52e-13	1.21e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28418061	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs10413972	ENSG00000267320.4	AC005780.1	-8.63	1.52e-13	1.21e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419219	chr19:28316705~28386204:-
THYM	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-8.63	1.53e-13	1.22e-09	-0.79	-0.66	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
THYM	cis	rs995834	0.585	rs10404961	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28417370	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs10419520	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419267	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs4806402	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420314	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs10419336	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420386	chr19:28316705~28386204:-
THYM	cis	rs995834	0.551	rs1558124	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420672	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs10403634	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28422714	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs10409773	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423090	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs8101242	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423341	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs720924	ENSG00000267320.4	AC005780.1	-8.62	1.54e-13	1.23e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424180	chr19:28316705~28386204:-
THYM	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-8.62	1.57e-13	1.25e-09	-0.88	-0.66	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
THYM	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	8.62	1.58e-13	1.25e-09	0.83	0.66	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
THYM	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-8.62	1.6e-13	1.27e-09	-0.59	-0.66	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
THYM	cis	rs995834	0.957	rs11667725	ENSG00000266928.1	CTB-70G10.1	-8.61	1.68e-13	1.33e-09	-0.71	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28361557	chr19:28294093~28313500:-
THYM	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-8.61	1.68e-13	1.33e-09	-0.81	-0.66	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
THYM	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	8.61	1.68e-13	1.33e-09	0.75	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
THYM	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-8.6	1.72e-13	1.36e-09	-0.83	-0.66	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-8.6	1.72e-13	1.36e-09	-0.83	-0.66	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
THYM	cis	rs5760092	0.755	rs5760096	ENSG00000273295.1	AP000350.5	8.6	1.72e-13	1.36e-09	0.81	0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905123	chr22:23901432~23907068:-
THYM	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-8.6	1.73e-13	1.36e-09	-0.79	-0.66	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	8.58	1.88e-13	1.48e-09	0.76	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
THYM	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-8.57	1.97e-13	1.54e-09	-0.88	-0.66	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
THYM	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	8.57	1.97e-13	1.54e-09	0.79	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
THYM	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	8.57	1.98e-13	1.54e-09	0.65	0.66	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
THYM	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	8.57	2.03e-13	1.58e-09	0.57	0.66	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.57	2.03e-13	1.58e-09	0.57	0.66	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.57	2.03e-13	1.58e-09	0.57	0.66	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
THYM	cis	rs995834	0.622	rs2159076	ENSG00000266928.1	CTB-70G10.1	-8.57	2.05e-13	1.59e-09	-0.8	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403929	chr19:28294093~28313500:-
THYM	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	8.57	2.06e-13	1.6e-09	0.67	0.66	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
THYM	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	8.56	2.09e-13	1.62e-09	0.81	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
THYM	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	8.56	2.12e-13	1.64e-09	0.59	0.66	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
THYM	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-8.56	2.13e-13	1.64e-09	-0.56	-0.66	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-8.56	2.13e-13	1.64e-09	-0.56	-0.66	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-8.56	2.13e-13	1.64e-09	-0.56	-0.66	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
THYM	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-8.56	2.13e-13	1.64e-09	-0.56	-0.66	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-8.56	2.13e-13	1.64e-09	-0.56	-0.66	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-8.56	2.13e-13	1.64e-09	-0.56	-0.66	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-8.56	2.13e-13	1.64e-09	-0.56	-0.66	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
THYM	cis	rs904251	0.828	rs1757178	ENSG00000227920.2	RP1-153P14.5	8.55	2.17e-13	1.67e-09	0.91	0.66	Cognitive performance;	chr6:37518534	chr6:37545145~37550860:+
THYM	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-8.55	2.23e-13	1.71e-09	-0.85	-0.66	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
THYM	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-8.55	2.24e-13	1.72e-09	-0.89	-0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
THYM	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	8.54	2.29e-13	1.76e-09	0.76	0.66	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
THYM	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-8.54	2.3e-13	1.77e-09	-0.71	-0.66	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
THYM	cis	rs995834	0.664	rs8109361	ENSG00000266928.1	CTB-70G10.1	-8.54	2.31e-13	1.78e-09	-0.8	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395343	chr19:28294093~28313500:-
THYM	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	8.54	2.35e-13	1.8e-09	0.85	0.66	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
THYM	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	8.54	2.35e-13	1.8e-09	0.55	0.66	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
THYM	cis	rs995834	1	rs995834	ENSG00000267320.4	AC005780.1	-8.54	2.36e-13	1.81e-09	-0.69	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375689	chr19:28316705~28386204:-
THYM	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-8.54	2.38e-13	1.82e-09	-0.79	-0.66	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
THYM	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	8.53	2.4e-13	1.83e-09	0.56	0.66	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	8.53	2.4e-13	1.83e-09	0.56	0.66	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
THYM	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	8.53	2.41e-13	1.84e-09	0.84	0.66	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
THYM	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	8.53	2.43e-13	1.85e-09	0.68	0.66	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	8.53	2.43e-13	1.85e-09	0.68	0.66	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	8.53	2.43e-13	1.85e-09	0.68	0.66	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
THYM	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-8.53	2.46e-13	1.87e-09	-0.75	-0.66	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-8.53	2.46e-13	1.87e-09	-0.75	-0.66	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-8.53	2.46e-13	1.87e-09	-0.75	-0.66	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
THYM	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	8.53	2.47e-13	1.87e-09	0.73	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
THYM	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	8.53	2.47e-13	1.87e-09	0.86	0.66	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
THYM	cis	rs995834	0.703	rs4806356	ENSG00000266928.1	CTB-70G10.1	-8.53	2.48e-13	1.88e-09	-0.82	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397536	chr19:28294093~28313500:-
THYM	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-8.52	2.55e-13	1.92e-09	-1.01	-0.66	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
THYM	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	8.52	2.58e-13	1.92e-09	0.59	0.66	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-8.52	2.58e-13	1.92e-09	-0.59	-0.66	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-8.52	2.58e-13	1.92e-09	-0.59	-0.66	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-8.52	2.58e-13	1.92e-09	-0.59	-0.66	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
THYM	cis	rs995834	0.585	rs720923	ENSG00000267320.4	AC005780.1	-8.52	2.58e-13	1.92e-09	-0.79	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423935	chr19:28316705~28386204:-
THYM	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	8.51	2.68e-13	1.98e-09	0.59	0.66	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
THYM	cis	rs5760092	0.717	rs5760101	ENSG00000273295.1	AP000350.5	8.5	2.77e-13	2.04e-09	0.81	0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906525	chr22:23901432~23907068:-
THYM	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-8.5	2.84e-13	2.09e-09	-0.74	-0.66	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
THYM	cis	rs7829975	0.777	rs486781	ENSG00000253893.2	FAM85B	8.5	2.89e-13	2.13e-09	0.8	0.66	Mood instability;	chr8:8782230	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-8.49	2.93e-13	2.15e-09	-0.8	-0.66	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
THYM	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	8.49	2.96e-13	2.17e-09	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
THYM	cis	rs995834	0.622	rs10408649	ENSG00000267320.4	AC005780.1	-8.49	3e-13	2.2e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405965	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs6508824	ENSG00000267320.4	AC005780.1	-8.49	3e-13	2.2e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406925	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs8111081	ENSG00000267320.4	AC005780.1	-8.49	3e-13	2.2e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407156	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs10407317	ENSG00000267320.4	AC005780.1	-8.49	3e-13	2.2e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28411352	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs2159074	ENSG00000267320.4	AC005780.1	8.49	3e-13	2.2e-09	0.77	0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407490	chr19:28316705~28386204:-
THYM	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-8.48	3.05e-13	2.23e-09	-0.78	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
THYM	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-8.48	3.05e-13	2.23e-09	-0.74	-0.66	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-8.48	3.05e-13	2.23e-09	-0.74	-0.66	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
THYM	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-8.48	3.12e-13	2.28e-09	-0.85	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
THYM	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	8.48	3.15e-13	2.3e-09	0.89	0.66	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
THYM	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	8.48	3.18e-13	2.32e-09	0.64	0.66	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
THYM	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-8.48	3.18e-13	2.32e-09	-0.76	-0.66	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
THYM	cis	rs995834	0.789	rs4806372	ENSG00000266928.1	CTB-70G10.1	8.47	3.2e-13	2.33e-09	0.75	0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403612	chr19:28294093~28313500:-
THYM	cis	rs995834	0.552	rs7251838	ENSG00000266928.1	CTB-70G10.1	-8.47	3.21e-13	2.33e-09	-0.84	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424805	chr19:28294093~28313500:-
THYM	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-8.47	3.21e-13	2.34e-09	-0.83	-0.66	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
THYM	cis	rs995834	0.664	rs1476762	ENSG00000267320.4	AC005780.1	-8.47	3.23e-13	2.34e-09	-0.73	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394427	chr19:28316705~28386204:-
THYM	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-8.47	3.25e-13	2.35e-09	-0.63	-0.66	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-8.47	3.25e-13	2.35e-09	-0.63	-0.66	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-8.47	3.25e-13	2.35e-09	-0.63	-0.66	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-8.47	3.25e-13	2.35e-09	-0.63	-0.66	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-8.47	3.25e-13	2.35e-09	-0.63	-0.66	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-8.47	3.25e-13	2.35e-09	-0.63	-0.66	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-8.47	3.25e-13	2.35e-09	-0.63	-0.66	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	8.47	3.25e-13	2.35e-09	0.63	0.66	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
THYM	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	8.47	3.28e-13	2.37e-09	0.56	0.66	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	8.47	3.28e-13	2.37e-09	0.56	0.66	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
THYM	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	8.46	3.36e-13	2.43e-09	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	8.46	3.36e-13	2.43e-09	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	8.46	3.36e-13	2.43e-09	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	8.46	3.36e-13	2.43e-09	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	8.46	3.36e-13	2.43e-09	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
THYM	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	8.46	3.39e-13	2.45e-09	0.96	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
THYM	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-8.46	3.41e-13	2.46e-09	-0.88	-0.66	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-8.46	3.41e-13	2.46e-09	-0.88	-0.66	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
THYM	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	8.46	3.44e-13	2.48e-09	0.84	0.66	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
THYM	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-8.46	3.45e-13	2.48e-09	-0.56	-0.66	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-8.46	3.45e-13	2.48e-09	-0.56	-0.66	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
THYM	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-8.46	3.48e-13	2.5e-09	-0.88	-0.66	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
THYM	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.48e-13	2.5e-09	-0.76	-0.66	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	8.46	3.48e-13	2.5e-09	0.76	0.66	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
THYM	cis	rs995834	0.664	rs8110139	ENSG00000267320.4	AC005780.1	-8.45	3.53e-13	2.53e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395640	chr19:28316705~28386204:-
THYM	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-8.45	3.54e-13	2.53e-09	-0.89	-0.66	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
THYM	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	8.45	3.66e-13	2.61e-09	0.59	0.66	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	8.45	3.66e-13	2.61e-09	0.59	0.66	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	8.45	3.66e-13	2.61e-09	0.59	0.66	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	8.45	3.66e-13	2.61e-09	0.59	0.66	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
THYM	cis	rs995834	0.957	rs8105942	ENSG00000267320.4	AC005780.1	-8.44	3.73e-13	2.66e-09	-0.68	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28359455	chr19:28316705~28386204:-
THYM	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	8.44	3.77e-13	2.68e-09	0.67	0.66	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
THYM	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-8.44	3.78e-13	2.68e-09	-0.86	-0.66	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
THYM	cis	rs2739330	0.892	rs5751776	ENSG00000272787.1	KB-226F1.2	-8.44	3.78e-13	2.68e-09	-0.72	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23969211~23969873:+
THYM	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-8.44	3.81e-13	2.7e-09	-0.83	-0.66	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
THYM	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-8.44	3.81e-13	2.7e-09	-0.83	-0.66	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
THYM	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-8.43	3.88e-13	2.75e-09	-0.57	-0.66	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
THYM	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	8.43	3.91e-13	2.77e-09	0.67	0.66	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-8.43	3.92e-13	2.77e-09	-0.67	-0.66	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
THYM	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-8.43	3.94e-13	2.78e-09	-0.88	-0.66	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
THYM	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-8.43	3.99e-13	2.82e-09	-0.87	-0.66	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-8.43	3.99e-13	2.82e-09	-0.87	-0.66	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-8.43	3.99e-13	2.82e-09	-0.87	-0.66	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-8.43	3.99e-13	2.82e-09	-0.87	-0.66	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
THYM	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	8.42	4.11e-13	2.9e-09	0.78	0.66	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
THYM	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-8.42	4.13e-13	2.91e-09	-0.86	-0.66	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
THYM	cis	rs995834	0.703	rs4806354	ENSG00000267320.4	AC005780.1	-8.42	4.14e-13	2.92e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396974	chr19:28316705~28386204:-
THYM	cis	rs995834	0.703	rs4806355	ENSG00000267320.4	AC005780.1	-8.42	4.14e-13	2.92e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396997	chr19:28316705~28386204:-
THYM	cis	rs995834	0.742	rs4806342	ENSG00000266928.1	CTB-70G10.1	-8.42	4.2e-13	2.96e-09	-0.78	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384461	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs11083471	ENSG00000266928.1	CTB-70G10.1	-8.42	4.2e-13	2.96e-09	-0.78	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28385094	chr19:28294093~28313500:-
THYM	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	8.42	4.27e-13	3.01e-09	0.74	0.66	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
THYM	cis	rs995834	0.552	rs7251838	ENSG00000267320.4	AC005780.1	-8.41	4.27e-13	3.01e-09	-0.78	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424805	chr19:28316705~28386204:-
THYM	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-8.41	4.35e-13	3.06e-09	-0.71	-0.66	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
THYM	cis	rs995834	0.622	rs1029661	ENSG00000267320.4	AC005780.1	-8.41	4.39e-13	3.08e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406394	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs7249889	ENSG00000267320.4	AC005780.1	-8.41	4.39e-13	3.08e-09	-0.77	-0.66	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406402	chr19:28316705~28386204:-
THYM	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-8.41	4.4e-13	3.08e-09	-1.03	-0.66	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
THYM	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-8.41	4.45e-13	3.12e-09	-0.88	-0.66	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
THYM	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	8.41	4.47e-13	3.13e-09	0.85	0.66	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	8.41	4.47e-13	3.13e-09	0.85	0.66	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
THYM	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-8.41	4.47e-13	3.13e-09	-1.06	-0.66	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
THYM	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-8.41	4.48e-13	3.13e-09	-0.87	-0.66	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-8.41	4.48e-13	3.13e-09	-0.87	-0.66	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
THYM	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	8.4	4.62e-13	3.22e-09	0.63	0.65	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	8.4	4.62e-13	3.22e-09	0.63	0.65	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
THYM	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	8.4	4.67e-13	3.25e-09	0.58	0.65	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
THYM	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
THYM	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
THYM	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
THYM	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
THYM	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-8.39	4.78e-13	3.29e-09	-0.55	-0.65	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
THYM	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	8.39	4.78e-13	3.29e-09	0.55	0.65	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
THYM	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	8.39	4.9e-13	3.32e-09	0.69	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
THYM	cis	rs995834	0.664	rs1476762	ENSG00000266928.1	CTB-70G10.1	-8.38	5.04e-13	3.41e-09	-0.78	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394427	chr19:28294093~28313500:-
THYM	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-8.38	5.13e-13	3.46e-09	-0.57	-0.65	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
THYM	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-8.38	5.13e-13	3.46e-09	-0.57	-0.65	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
THYM	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	8.38	5.18e-13	3.5e-09	0.88	0.65	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
THYM	cis	rs995834	0.742	rs4806342	ENSG00000267320.4	AC005780.1	-8.37	5.3e-13	3.57e-09	-0.73	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384461	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs11083471	ENSG00000267320.4	AC005780.1	-8.37	5.3e-13	3.57e-09	-0.73	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28385094	chr19:28316705~28386204:-
THYM	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	8.37	5.35e-13	3.6e-09	0.86	0.65	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
THYM	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	8.37	5.35e-13	3.6e-09	0.86	0.65	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
THYM	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	8.37	5.35e-13	3.6e-09	0.75	0.65	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
THYM	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-8.36	5.48e-13	3.69e-09	-0.81	-0.65	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
THYM	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-8.36	5.61e-13	3.77e-09	-0.81	-0.65	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
THYM	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	8.36	5.67e-13	3.81e-09	0.76	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-8.36	5.71e-13	3.84e-09	-0.69	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
THYM	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	8.35	5.78e-13	3.88e-09	0.89	0.65	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
THYM	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	8.35	5.78e-13	3.88e-09	0.64	0.65	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
THYM	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-8.35	5.84e-13	3.92e-09	-0.75	-0.65	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
THYM	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	8.35	5.84e-13	3.92e-09	0.86	0.65	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
THYM	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-8.35	5.94e-13	3.98e-09	-0.74	-0.65	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
THYM	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-8.35	5.94e-13	3.98e-09	-0.74	-0.65	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
THYM	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-8.35	5.95e-13	3.98e-09	-0.9	-0.65	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-8.35	5.95e-13	3.98e-09	-0.9	-0.65	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-8.35	5.95e-13	3.98e-09	-0.9	-0.65	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-8.35	5.95e-13	3.98e-09	-0.9	-0.65	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-8.35	5.95e-13	3.98e-09	-0.9	-0.65	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
THYM	cis	rs995834	0.912	rs2868970	ENSG00000267320.4	AC005780.1	-8.35	5.97e-13	3.99e-09	-0.7	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393432	chr19:28316705~28386204:-
THYM	cis	rs995834	0.828	rs10403516	ENSG00000267320.4	AC005780.1	-8.35	5.97e-13	3.99e-09	-0.7	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393842	chr19:28316705~28386204:-
THYM	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	8.34	6.01e-13	4.01e-09	0.7	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
THYM	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-8.34	6.07e-13	4.04e-09	-0.87	-0.65	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-8.34	6.07e-13	4.04e-09	-0.87	-0.65	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-8.34	6.07e-13	4.04e-09	-0.87	-0.65	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-8.34	6.07e-13	4.04e-09	-0.87	-0.65	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-8.34	6.07e-13	4.04e-09	-0.87	-0.65	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-8.34	6.07e-13	4.04e-09	-0.87	-0.65	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
THYM	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	8.34	6.07e-13	4.04e-09	0.87	0.65	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	8.34	6.07e-13	4.04e-09	0.87	0.65	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	8.34	6.07e-13	4.04e-09	0.87	0.65	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
THYM	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	8.34	6.12e-13	4.07e-09	0.63	0.65	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
THYM	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	8.34	6.14e-13	4.08e-09	0.76	0.65	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
THYM	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-8.34	6.15e-13	4.09e-09	-0.75	-0.65	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
THYM	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-8.34	6.23e-13	4.14e-09	-0.75	-0.65	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-8.34	6.23e-13	4.14e-09	-0.75	-0.65	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-8.34	6.23e-13	4.14e-09	-0.75	-0.65	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
THYM	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
THYM	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-8.33	6.36e-13	4.19e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
THYM	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
THYM	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
THYM	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
THYM	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
THYM	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
THYM	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
THYM	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-8.33	6.41e-13	4.21e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
THYM	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-8.33	6.43e-13	4.22e-09	-0.72	-0.65	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
THYM	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	8.33	6.52e-13	4.28e-09	0.87	0.65	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
THYM	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	8.33	6.52e-13	4.28e-09	0.87	0.65	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
THYM	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	-8.33	6.54e-13	4.28e-09	-0.71	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
THYM	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-8.33	6.59e-13	4.32e-09	-0.58	-0.65	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
THYM	cis	rs995834	0.743	rs7256207	ENSG00000267320.4	AC005780.1	8.32	6.69e-13	4.38e-09	0.71	0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356775	chr19:28316705~28386204:-
THYM	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	8.32	6.7e-13	4.38e-09	1.08	0.65	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-8.32	6.7e-13	4.38e-09	-1.08	-0.65	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
THYM	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-8.32	6.7e-13	4.38e-09	-1.08	-0.65	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-8.32	6.7e-13	4.38e-09	-1.08	-0.65	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-8.32	6.7e-13	4.38e-09	-1.08	-0.65	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
THYM	cis	rs7044106	0.791	rs2900177	ENSG00000226752.6	PSMD5-AS1	-8.32	6.88e-13	4.49e-09	-0.78	-0.65	Hip circumference adjusted for BMI;	chr9:120735367	chr9:120824828~120854385:+
THYM	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-8.32	6.93e-13	4.52e-09	-0.56	-0.65	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
THYM	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	8.31	6.95e-13	4.53e-09	0.77	0.65	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
THYM	cis	rs995834	0.622	rs10424022	ENSG00000266928.1	CTB-70G10.1	-8.31	6.95e-13	4.53e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401351	chr19:28294093~28313500:-
THYM	cis	rs904251	0.861	rs1757183	ENSG00000227920.2	RP1-153P14.5	8.31	6.97e-13	4.54e-09	0.9	0.65	Cognitive performance;	chr6:37517014	chr6:37545145~37550860:+
THYM	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-8.31	6.99e-13	4.55e-09	-0.69	-0.65	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
THYM	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	8.31	7.16e-13	4.64e-09	0.88	0.65	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
THYM	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	8.3	7.36e-13	4.76e-09	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
THYM	cis	rs904251	0.737	rs914347	ENSG00000227920.2	RP1-153P14.5	-8.3	7.37e-13	4.77e-09	-0.93	-0.65	Cognitive performance;	chr6:37517194	chr6:37545145~37550860:+
THYM	cis	rs904251	0.797	rs1776460	ENSG00000227920.2	RP1-153P14.5	-8.3	7.37e-13	4.77e-09	-0.93	-0.65	Cognitive performance;	chr6:37517708	chr6:37545145~37550860:+
THYM	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-8.3	7.44e-13	4.8e-09	-0.9	-0.65	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
THYM	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	8.3	7.58e-13	4.9e-09	0.84	0.65	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
THYM	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	8.29	7.72e-13	4.97e-09	0.78	0.65	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
THYM	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	8.29	7.73e-13	4.98e-09	0.74	0.65	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
THYM	cis	rs2739330	0.929	rs5751775	ENSG00000272787.1	KB-226F1.2	-8.29	7.88e-13	5.07e-09	-0.72	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23969211~23969873:+
THYM	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-8.29	7.96e-13	5.11e-09	-0.91	-0.65	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
THYM	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	8.29	7.97e-13	5.12e-09	0.56	0.65	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
THYM	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	8.29	8.02e-13	5.15e-09	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
THYM	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-8.28	8.1e-13	5.21e-09	-0.83	-0.65	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
THYM	cis	rs904251	0.861	rs1776456	ENSG00000227920.2	RP1-153P14.5	-8.28	8.3e-13	5.33e-09	-0.98	-0.65	Cognitive performance;	chr6:37516922	chr6:37545145~37550860:+
THYM	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	8.28	8.39e-13	5.39e-09	0.74	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
THYM	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	8.28	8.42e-13	5.41e-09	0.66	0.65	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	8.28	8.42e-13	5.41e-09	0.66	0.65	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
THYM	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	8.27	8.43e-13	5.41e-09	0.56	0.65	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	8.27	8.43e-13	5.41e-09	0.56	0.65	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	8.27	8.43e-13	5.41e-09	0.56	0.65	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
THYM	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-8.27	8.45e-13	5.42e-09	-0.87	-0.65	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
THYM	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-8.27	8.46e-13	5.43e-09	-0.86	-0.65	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-8.27	8.5e-13	5.45e-09	-0.87	-0.65	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
THYM	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-8.27	8.52e-13	5.46e-09	-0.75	-0.65	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
THYM	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-8.27	8.56e-13	5.49e-09	-0.86	-0.65	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-8.27	8.56e-13	5.49e-09	-0.86	-0.65	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	8.27	8.56e-13	5.49e-09	0.86	0.65	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
THYM	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	8.27	8.72e-13	5.57e-09	0.85	0.65	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
THYM	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	8.27	8.75e-13	5.59e-09	0.5	0.65	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
THYM	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-8.26	8.88e-13	5.67e-09	-0.75	-0.65	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
THYM	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-8.26	8.98e-13	5.73e-09	-0.62	-0.65	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
THYM	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	8.26	9e-13	5.74e-09	0.59	0.65	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
THYM	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-8.26	9.1e-13	5.8e-09	-0.85	-0.65	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
THYM	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-8.26	9.11e-13	5.81e-09	-0.84	-0.65	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
THYM	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-8.26	9.21e-13	5.86e-09	-0.82	-0.65	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
THYM	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	8.26	9.21e-13	5.87e-09	0.85	0.65	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
THYM	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-8.26	9.28e-13	5.9e-09	-0.75	-0.65	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-8.26	9.28e-13	5.9e-09	-0.75	-0.65	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-8.26	9.28e-13	5.9e-09	-0.75	-0.65	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-8.26	9.28e-13	5.9e-09	-0.75	-0.65	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
THYM	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	8.25	9.32e-13	5.92e-09	0.56	0.65	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	8.25	9.32e-13	5.92e-09	0.56	0.65	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	8.25	9.32e-13	5.92e-09	0.56	0.65	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
THYM	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	8.25	9.4e-13	5.97e-09	0.67	0.65	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-8.25	9.61e-13	6.1e-09	-0.82	-0.65	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
THYM	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-8.25	9.64e-13	6.12e-09	-0.85	-0.65	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-8.25	9.67e-13	6.13e-09	-0.86	-0.65	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
THYM	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
THYM	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
THYM	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
THYM	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
THYM	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
THYM	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
THYM	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-8.24	9.77e-13	6.17e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
THYM	cis	rs673078	0.562	rs61944672	ENSG00000275759.1	RP11-131L12.3	-8.24	9.94e-13	6.28e-09	-1.05	-0.65	Glucose homeostasis traits;	chr12:118450123	chr12:118428281~118428870:+
THYM	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
THYM	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
THYM	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-8.24	1.01e-12	6.34e-09	-0.85	-0.65	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
THYM	cis	rs995834	0.622	rs8102417	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397409	chr19:28294093~28313500:-
THYM	cis	rs995834	0.704	rs4806358	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397907	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs4806359	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398042	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs7252140	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398110	chr19:28294093~28313500:-
THYM	cis	rs995834	0.663	rs7252145	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398119	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs4806360	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398277	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs1558121	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398522	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs2159075	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398551	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs2079593	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398973	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs1558122	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399320	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs1558123	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399355	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs7257975	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399556	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs7246622	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399578	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs7258662	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400902	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs7246754	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400913	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs4806368	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402133	chr19:28294093~28313500:-
THYM	cis	rs995834	0.622	rs4806369	ENSG00000266928.1	CTB-70G10.1	-8.24	1.02e-12	6.38e-09	-0.81	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402569	chr19:28294093~28313500:-
THYM	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-8.23	1.04e-12	6.5e-09	-0.76	-0.65	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
THYM	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	8.23	1.05e-12	6.55e-09	0.77	0.65	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
THYM	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	8.23	1.05e-12	6.55e-09	0.94	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
THYM	cis	rs995834	0.661	rs11882204	ENSG00000267320.4	AC005780.1	-8.23	1.05e-12	6.57e-09	-0.71	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347263	chr19:28316705~28386204:-
THYM	cis	rs995834	0.661	rs8101988	ENSG00000267320.4	AC005780.1	-8.23	1.05e-12	6.57e-09	-0.71	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348975	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs758507	ENSG00000267320.4	AC005780.1	-8.23	1.05e-12	6.57e-09	-0.71	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350158	chr19:28316705~28386204:-
THYM	cis	rs995834	0.701	rs2903968	ENSG00000267320.4	AC005780.1	-8.23	1.05e-12	6.57e-09	-0.71	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350613	chr19:28316705~28386204:-
THYM	cis	rs995834	0.701	rs8103281	ENSG00000267320.4	AC005780.1	-8.23	1.05e-12	6.57e-09	-0.71	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358547	chr19:28316705~28386204:-
THYM	cis	rs995834	0.509	rs11666682	ENSG00000267320.4	AC005780.1	-8.23	1.05e-12	6.57e-09	-0.71	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358650	chr19:28316705~28386204:-
THYM	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	8.23	1.05e-12	6.58e-09	0.83	0.65	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	8.23	1.05e-12	6.58e-09	0.83	0.65	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
THYM	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-8.23	1.07e-12	6.66e-09	-1.04	-0.65	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
THYM	cis	rs995834	0.664	rs8109361	ENSG00000267320.4	AC005780.1	-8.23	1.07e-12	6.67e-09	-0.73	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395343	chr19:28316705~28386204:-
THYM	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
THYM	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-8.22	1.08e-12	6.7e-09	-0.83	-0.65	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
THYM	cis	rs995834	0.622	rs2159077	ENSG00000267320.4	AC005780.1	8.22	1.1e-12	6.81e-09	0.75	0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404348	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs2159078	ENSG00000267320.4	AC005780.1	-8.22	1.1e-12	6.81e-09	-0.75	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404431	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs2869481	ENSG00000267320.4	AC005780.1	-8.22	1.1e-12	6.81e-09	-0.75	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404927	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs2869482	ENSG00000267320.4	AC005780.1	-8.22	1.1e-12	6.81e-09	-0.75	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405261	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs10407917	ENSG00000267320.4	AC005780.1	-8.22	1.1e-12	6.81e-09	-0.75	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405441	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs10408833	ENSG00000267320.4	AC005780.1	-8.22	1.1e-12	6.81e-09	-0.75	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405825	chr19:28316705~28386204:-
THYM	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	8.22	1.1e-12	6.82e-09	0.48	0.65	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
THYM	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-8.22	1.11e-12	6.88e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-8.22	1.11e-12	6.88e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-8.22	1.11e-12	6.88e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-8.22	1.11e-12	6.88e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
THYM	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	8.21	1.13e-12	7.01e-09	0.56	0.65	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
THYM	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	8.21	1.14e-12	7.04e-09	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
THYM	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-8.21	1.14e-12	7.05e-09	-0.93	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
THYM	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-8.21	1.14e-12	7.06e-09	-0.84	-0.65	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
THYM	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-8.2	1.21e-12	7.49e-09	-0.56	-0.65	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
THYM	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	8.2	1.23e-12	7.56e-09	0.9	0.65	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
THYM	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	8.2	1.24e-12	7.61e-09	0.68	0.65	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
THYM	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	8.2	1.24e-12	7.62e-09	0.82	0.65	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
THYM	cis	rs904251	1	rs10947673	ENSG00000279942.1	RP1-153P14.7	-8.19	1.25e-12	7.66e-09	-0.87	-0.65	Cognitive performance;	chr6:37477303	chr6:37567716~37571460:+
THYM	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-8.19	1.25e-12	7.67e-09	-0.82	-0.65	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
THYM	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-8.19	1.26e-12	7.74e-09	-0.55	-0.65	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
THYM	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-8.19	1.26e-12	7.74e-09	-0.76	-0.65	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
THYM	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-8.19	1.27e-12	7.79e-09	-0.84	-0.65	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
THYM	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-8.19	1.27e-12	7.79e-09	-0.84	-0.65	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
THYM	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-8.19	1.27e-12	7.79e-09	-0.84	-0.65	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
THYM	cis	rs995834	0.789	rs10410807	ENSG00000267320.4	AC005780.1	-8.19	1.28e-12	7.81e-09	-0.73	-0.65	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28410408	chr19:28316705~28386204:-
THYM	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	8.19	1.28e-12	7.82e-09	0.9	0.65	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
THYM	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-8.19	1.28e-12	7.84e-09	-0.84	-0.65	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-8.19	1.28e-12	7.84e-09	-0.84	-0.65	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
THYM	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-8.19	1.29e-12	7.85e-09	-0.78	-0.65	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
THYM	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	8.19	1.29e-12	7.85e-09	0.85	0.65	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	8.19	1.29e-12	7.85e-09	0.85	0.65	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	8.19	1.29e-12	7.85e-09	0.85	0.65	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
THYM	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	8.19	1.3e-12	7.89e-09	0.71	0.65	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
THYM	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	8.18	1.32e-12	8e-09	0.76	0.65	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
THYM	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-8.18	1.32e-12	8.01e-09	-0.81	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
THYM	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-8.18	1.32e-12	8.02e-09	-0.76	-0.64	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
THYM	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-8.18	1.32e-12	8.02e-09	-0.76	-0.64	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
THYM	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-8.18	1.33e-12	8.07e-09	-0.8	-0.64	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
THYM	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	8.18	1.34e-12	8.14e-09	0.72	0.64	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
THYM	cis	rs995834	0.743	rs7256207	ENSG00000266928.1	CTB-70G10.1	8.18	1.35e-12	8.17e-09	0.76	0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356775	chr19:28294093~28313500:-
THYM	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-8.18	1.36e-12	8.25e-09	-0.75	-0.64	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
THYM	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	8.18	1.37e-12	8.28e-09	0.68	0.64	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
THYM	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	8.17	1.38e-12	8.35e-09	0.65	0.64	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
THYM	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	8.17	1.39e-12	8.43e-09	0.51	0.64	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
THYM	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	8.17	1.41e-12	8.5e-09	0.84	0.64	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	8.17	1.41e-12	8.5e-09	0.84	0.64	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	8.17	1.41e-12	8.5e-09	0.84	0.64	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
THYM	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-8.17	1.41e-12	8.5e-09	-0.68	-0.64	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
THYM	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	8.17	1.41e-12	8.5e-09	0.71	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	8.17	1.41e-12	8.5e-09	0.71	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
THYM	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-8.17	1.42e-12	8.55e-09	-0.88	-0.64	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
THYM	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	8.16	1.44e-12	8.68e-09	0.83	0.64	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
THYM	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-8.16	1.45e-12	8.69e-09	-0.92	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
THYM	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-8.16	1.45e-12	8.69e-09	-0.75	-0.64	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
THYM	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	8.16	1.45e-12	8.71e-09	0.67	0.64	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	8.16	1.45e-12	8.71e-09	0.67	0.64	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
THYM	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-8.16	1.47e-12	8.83e-09	-0.82	-0.64	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
THYM	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	8.16	1.5e-12	9e-09	0.58	0.64	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
THYM	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-8.16	1.5e-12	9e-09	-0.83	-0.64	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
THYM	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	8.15	1.52e-12	9.12e-09	0.84	0.64	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
THYM	cis	rs7829975	0.774	rs11249893	ENSG00000253893.2	FAM85B	-8.15	1.52e-12	9.12e-09	-0.83	-0.64	Mood instability;	chr8:8843341	chr8:8167819~8226614:-
THYM	cis	rs995834	0.661	rs11882204	ENSG00000266928.1	CTB-70G10.1	-8.15	1.53e-12	9.12e-09	-0.75	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347263	chr19:28294093~28313500:-
THYM	cis	rs995834	0.661	rs8101988	ENSG00000266928.1	CTB-70G10.1	-8.15	1.53e-12	9.12e-09	-0.75	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348975	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs758507	ENSG00000266928.1	CTB-70G10.1	-8.15	1.53e-12	9.12e-09	-0.75	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350158	chr19:28294093~28313500:-
THYM	cis	rs995834	0.701	rs2903968	ENSG00000266928.1	CTB-70G10.1	-8.15	1.53e-12	9.12e-09	-0.75	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350613	chr19:28294093~28313500:-
THYM	cis	rs995834	0.701	rs8103281	ENSG00000266928.1	CTB-70G10.1	-8.15	1.53e-12	9.12e-09	-0.75	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358547	chr19:28294093~28313500:-
THYM	cis	rs995834	0.509	rs11666682	ENSG00000266928.1	CTB-70G10.1	-8.15	1.53e-12	9.12e-09	-0.75	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358650	chr19:28294093~28313500:-
THYM	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-8.15	1.54e-12	9.21e-09	-0.78	-0.64	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
THYM	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-8.15	1.54e-12	9.21e-09	-0.78	-0.64	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
THYM	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-8.15	1.54e-12	9.21e-09	-0.78	-0.64	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
THYM	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-8.15	1.54e-12	9.21e-09	-0.82	-0.64	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
THYM	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	8.15	1.56e-12	9.32e-09	0.84	0.64	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
THYM	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-8.15	1.57e-12	9.35e-09	-1.08	-0.64	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
THYM	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	8.14	1.6e-12	9.49e-09	0.65	0.64	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
THYM	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-8.14	1.6e-12	9.53e-09	-1.06	-0.64	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
THYM	cis	rs995834	0.703	rs4806356	ENSG00000267320.4	AC005780.1	-8.14	1.6e-12	9.54e-09	-0.75	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397536	chr19:28316705~28386204:-
THYM	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-8.14	1.62e-12	9.62e-09	-0.82	-0.64	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-8.14	1.62e-12	9.62e-09	-0.82	-0.64	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
THYM	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-8.13	1.67e-12	9.92e-09	-0.57	-0.64	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	8.13	1.67e-12	9.92e-09	0.57	0.64	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	8.13	1.67e-12	9.92e-09	0.57	0.64	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	8.13	1.67e-12	9.92e-09	0.57	0.64	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	8.13	1.67e-12	9.92e-09	0.57	0.64	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	8.13	1.69e-12	1e-08	0.58	0.64	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
THYM	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	8.13	1.69e-12	1e-08	0.85	0.64	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	8.13	1.69e-12	1e-08	0.85	0.64	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-8.13	1.69e-12	1e-08	-0.85	-0.64	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
THYM	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	8.13	1.69e-12	1e-08	0.85	0.64	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
THYM	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-8.13	1.69e-12	1e-08	-0.85	-0.64	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
THYM	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	8.13	1.69e-12	1e-08	0.85	0.64	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
THYM	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-8.13	1.69e-12	1e-08	-0.85	-0.64	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
THYM	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-8.13	1.69e-12	1e-08	-0.85	-0.64	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
THYM	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-8.13	1.7e-12	1.01e-08	-0.77	-0.64	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
THYM	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-8.12	1.78e-12	1.05e-08	-0.82	-0.64	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
THYM	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-8.12	1.78e-12	1.05e-08	-0.85	-0.64	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-8.12	1.78e-12	1.05e-08	-0.85	-0.64	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-8.12	1.78e-12	1.05e-08	-0.85	-0.64	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-8.12	1.78e-12	1.05e-08	-0.85	-0.64	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-8.12	1.78e-12	1.05e-08	-0.85	-0.64	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
THYM	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	8.12	1.78e-12	1.05e-08	0.76	0.64	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
THYM	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-8.12	1.79e-12	1.05e-08	-0.52	-0.64	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
THYM	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-8.12	1.79e-12	1.06e-08	-0.82	-0.64	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-8.12	1.79e-12	1.06e-08	-0.82	-0.64	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-8.12	1.79e-12	1.06e-08	-0.82	-0.64	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
THYM	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-8.12	1.82e-12	1.07e-08	-0.79	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
THYM	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-8.12	1.82e-12	1.07e-08	-0.73	-0.64	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-8.12	1.82e-12	1.07e-08	-0.73	-0.64	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
THYM	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	8.12	1.83e-12	1.08e-08	0.76	0.64	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
THYM	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	8.11	1.86e-12	1.09e-08	0.84	0.64	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	8.11	1.86e-12	1.09e-08	0.84	0.64	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
THYM	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	8.11	1.86e-12	1.09e-08	0.84	0.64	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	8.11	1.86e-12	1.09e-08	0.84	0.64	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
THYM	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-8.11	1.88e-12	1.1e-08	-0.93	-0.64	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
THYM	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-8.11	1.88e-12	1.1e-08	-0.55	-0.64	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
THYM	cis	rs995834	0.622	rs4805188	ENSG00000266928.1	CTB-70G10.1	-8.11	1.89e-12	1.11e-08	-0.8	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400780	chr19:28294093~28313500:-
THYM	cis	rs995834	0.585	rs4806363	ENSG00000266928.1	CTB-70G10.1	-8.11	1.89e-12	1.11e-08	-0.8	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400810	chr19:28294093~28313500:-
THYM	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-8.11	1.89e-12	1.11e-08	-0.58	-0.64	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-8.11	1.89e-12	1.11e-08	-0.58	-0.64	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
THYM	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-8.11	1.9e-12	1.11e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-8.11	1.9e-12	1.11e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
THYM	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-8.11	1.9e-12	1.11e-08	-0.82	-0.64	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-8.11	1.9e-12	1.11e-08	-0.82	-0.64	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-8.11	1.9e-12	1.11e-08	-0.82	-0.64	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
THYM	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	8.11	1.91e-12	1.12e-08	0.75	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
THYM	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-8.1	1.92e-12	1.13e-08	-0.84	-0.64	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
THYM	cis	rs904251	0.797	rs1757181	ENSG00000227920.2	RP1-153P14.5	8.1	1.93e-12	1.13e-08	0.88	0.64	Cognitive performance;	chr6:37517952	chr6:37545145~37550860:+
THYM	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
THYM	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-8.1	1.95e-12	1.13e-08	-0.82	-0.64	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
THYM	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-8.1	1.97e-12	1.15e-08	-0.74	-0.64	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-8.1	1.97e-12	1.15e-08	-0.74	-0.64	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-8.1	1.97e-12	1.15e-08	-0.74	-0.64	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
THYM	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	8.1	1.99e-12	1.15e-08	0.72	0.64	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-8.1	1.99e-12	1.15e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
THYM	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-8.1	1.99e-12	1.16e-08	-0.55	-0.64	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
THYM	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-8.1	2e-12	1.16e-08	-0.84	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
THYM	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	8.1	2.01e-12	1.17e-08	0.66	0.64	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
THYM	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-8.09	2.03e-12	1.18e-08	-0.85	-0.64	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
THYM	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	8.09	2.03e-12	1.18e-08	0.58	0.64	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
THYM	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-8.09	2.06e-12	1.19e-08	-0.76	-0.64	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
THYM	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-8.09	2.07e-12	1.19e-08	-0.74	-0.64	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
THYM	cis	rs904251	0.797	rs1757177	ENSG00000227920.2	RP1-153P14.5	-8.09	2.08e-12	1.2e-08	-0.86	-0.64	Cognitive performance;	chr6:37518594	chr6:37545145~37550860:+
THYM	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	8.09	2.09e-12	1.2e-08	0.74	0.64	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
THYM	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	8.09	2.1e-12	1.21e-08	0.74	0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
THYM	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	8.09	2.11e-12	1.21e-08	0.65	0.64	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	8.09	2.11e-12	1.21e-08	0.65	0.64	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
THYM	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-8.08	2.13e-12	1.23e-08	-0.9	-0.64	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
THYM	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	8.08	2.15e-12	1.24e-08	0.89	0.64	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
THYM	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	8.08	2.18e-12	1.25e-08	0.93	0.64	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
THYM	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-8.08	2.2e-12	1.26e-08	-0.57	-0.64	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
THYM	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	8.08	2.2e-12	1.26e-08	0.78	0.64	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	8.08	2.2e-12	1.26e-08	0.78	0.64	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
THYM	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	8.08	2.21e-12	1.27e-08	0.58	0.64	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
THYM	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	8.08	2.21e-12	1.27e-08	0.76	0.64	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
THYM	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	8.07	2.28e-12	1.31e-08	0.81	0.64	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
THYM	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-8.07	2.28e-12	1.31e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	8.07	2.28e-12	1.31e-08	0.72	0.64	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
THYM	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-8.07	2.29e-12	1.31e-08	-0.91	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-8.07	2.29e-12	1.31e-08	-0.91	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-8.07	2.29e-12	1.31e-08	-0.91	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-8.07	2.29e-12	1.31e-08	-0.91	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-8.07	2.29e-12	1.31e-08	-0.91	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
THYM	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-8.07	2.31e-12	1.32e-08	-0.82	-0.64	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
THYM	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-8.07	2.32e-12	1.33e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
THYM	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	8.07	2.32e-12	1.33e-08	0.47	0.64	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
THYM	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-8.07	2.32e-12	1.33e-08	-0.47	-0.64	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
THYM	cis	rs995834	0.743	rs4555267	ENSG00000267320.4	AC005780.1	-8.07	2.32e-12	1.33e-08	-0.7	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28374933	chr19:28316705~28386204:-
THYM	cis	rs995834	0.784	rs4141219	ENSG00000267320.4	AC005780.1	-8.07	2.32e-12	1.33e-08	-0.7	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375247	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs2041195	ENSG00000267320.4	AC005780.1	-8.07	2.32e-12	1.33e-08	-0.7	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376305	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs11083486	ENSG00000267320.4	AC005780.1	-8.07	2.33e-12	1.33e-08	-0.72	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407449	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs10421826	ENSG00000267320.4	AC005780.1	-8.07	2.33e-12	1.33e-08	-0.72	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28408275	chr19:28316705~28386204:-
THYM	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-8.06	2.33e-12	1.33e-08	-0.77	-0.64	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
THYM	cis	rs1150668	0.805	rs2859348	ENSG00000216901.1	AL022393.7	8.06	2.34e-12	1.33e-08	0.72	0.64	Pubertal anthropometrics;	chr6:28391393	chr6:28176188~28176674:+
THYM	cis	rs995834	0.701	rs6508799	ENSG00000267320.4	AC005780.1	-8.06	2.34e-12	1.33e-08	-0.7	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28360493	chr19:28316705~28386204:-
THYM	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-8.06	2.34e-12	1.34e-08	-0.72	-0.64	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
THYM	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-8.06	2.36e-12	1.34e-08	-0.85	-0.64	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
THYM	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-8.06	2.36e-12	1.34e-08	-0.85	-0.64	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
THYM	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	8.06	2.36e-12	1.35e-08	0.67	0.64	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	8.06	2.36e-12	1.35e-08	0.67	0.64	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
THYM	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-8.06	2.38e-12	1.35e-08	-0.97	-0.64	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
THYM	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-8.06	2.42e-12	1.37e-08	-0.75	-0.64	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-8.06	2.42e-12	1.37e-08	-0.75	-0.64	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
THYM	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-8.06	2.43e-12	1.37e-08	-0.71	-0.64	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
THYM	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-8.06	2.44e-12	1.37e-08	-0.83	-0.64	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-8.06	2.44e-12	1.37e-08	-0.83	-0.64	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-8.06	2.44e-12	1.37e-08	-0.83	-0.64	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-8.06	2.44e-12	1.37e-08	-0.83	-0.64	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
THYM	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	8.05	2.49e-12	1.39e-08	0.81	0.64	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
THYM	cis	rs995834	0.622	rs2159076	ENSG00000267320.4	AC005780.1	-8.05	2.49e-12	1.39e-08	-0.72	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403929	chr19:28316705~28386204:-
THYM	cis	rs995834	0.957	rs2109066	ENSG00000267320.4	AC005780.1	-8.05	2.53e-12	1.41e-08	-0.66	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344420	chr19:28316705~28386204:-
THYM	cis	rs995834	0.957	rs2159327	ENSG00000267320.4	AC005780.1	-8.05	2.53e-12	1.41e-08	-0.66	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344664	chr19:28316705~28386204:-
THYM	cis	rs995834	0.957	rs7248916	ENSG00000267320.4	AC005780.1	-8.05	2.53e-12	1.41e-08	-0.66	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344916	chr19:28316705~28386204:-
THYM	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-8.05	2.53e-12	1.41e-08	-0.83	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
THYM	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-8.05	2.53e-12	1.41e-08	-0.8	-0.64	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
THYM	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	8.04	2.57e-12	1.43e-08	0.58	0.64	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
THYM	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
THYM	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
THYM	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
THYM	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-8.04	2.59e-12	1.44e-08	-0.83	-0.64	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
THYM	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	8.04	2.59e-12	1.44e-08	0.78	0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
THYM	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	8.04	2.6e-12	1.44e-08	0.65	0.64	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
THYM	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-8.04	2.63e-12	1.46e-08	-0.52	-0.64	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
THYM	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-8.04	2.68e-12	1.48e-08	-0.83	-0.64	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
THYM	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-8.04	2.68e-12	1.48e-08	-0.83	-0.64	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
THYM	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-8.04	2.68e-12	1.48e-08	-0.83	-0.64	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
THYM	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-8.04	2.68e-12	1.48e-08	-0.83	-0.64	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
THYM	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-8.03	2.71e-12	1.5e-08	-0.7	-0.64	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	8.03	2.71e-12	1.5e-08	0.7	0.64	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
THYM	cis	rs995834	0.743	rs4806332	ENSG00000266928.1	CTB-70G10.1	-8.02	2.85e-12	1.57e-08	-0.72	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28366100	chr19:28294093~28313500:-
THYM	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	8.02	2.86e-12	1.58e-08	0.83	0.64	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
THYM	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	8.02	2.89e-12	1.59e-08	0.76	0.64	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	8.02	2.89e-12	1.59e-08	0.76	0.64	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
THYM	cis	rs2739330	0.753	rs4822452	ENSG00000272787.1	KB-226F1.2	-8.02	2.91e-12	1.6e-08	-0.72	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23969211~23969873:+
THYM	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-8.02	2.92e-12	1.61e-08	-0.83	-0.64	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
THYM	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-8.02	2.92e-12	1.61e-08	-0.83	-0.64	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-8.02	2.92e-12	1.61e-08	-0.83	-0.64	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
THYM	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-8.02	2.92e-12	1.61e-08	-0.83	-0.64	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-8.02	2.92e-12	1.61e-08	-0.83	-0.64	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-8.02	2.92e-12	1.61e-08	-0.83	-0.64	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-8.02	2.92e-12	1.61e-08	-0.83	-0.64	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
THYM	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-8.02	2.95e-12	1.62e-08	-0.8	-0.64	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
THYM	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	8.02	2.95e-12	1.62e-08	0.76	0.64	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	8.02	2.95e-12	1.62e-08	0.76	0.64	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
THYM	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	8.02	2.95e-12	1.62e-08	0.88	0.64	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-8.02	2.95e-12	1.62e-08	-0.88	-0.64	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-8.02	2.95e-12	1.62e-08	-0.88	-0.64	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-8.02	2.95e-12	1.62e-08	-0.88	-0.64	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
THYM	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	8.02	2.96e-12	1.62e-08	0.83	0.64	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
THYM	cis	rs995834	0.743	rs6508794	ENSG00000267320.4	AC005780.1	8.01	2.98e-12	1.63e-08	0.68	0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356703	chr19:28316705~28386204:-
THYM	cis	rs995834	0.661	rs4407171	ENSG00000267320.4	AC005780.1	8.01	2.98e-12	1.63e-08	0.68	0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372452	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs2015841	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28345899	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs10415623	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346878	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs10416153	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347155	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs8108726	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347425	chr19:28316705~28386204:-
THYM	cis	rs995834	0.701	rs6508784	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347560	chr19:28316705~28386204:-
THYM	cis	rs995834	0.701	rs8111880	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348171	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs8112315	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348498	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs8111630	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348642	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs11670286	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348909	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs758314	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363165	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs726845	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363761	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs2868967	ENSG00000267320.4	AC005780.1	-8.01	2.98e-12	1.63e-08	-0.68	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372690	chr19:28316705~28386204:-
THYM	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-8.01	3.01e-12	1.64e-08	-0.85	-0.64	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
THYM	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	8.01	3.03e-12	1.66e-08	0.62	0.64	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	8.01	3.04e-12	1.66e-08	0.62	0.64	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
THYM	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-8.01	3.06e-12	1.67e-08	-0.83	-0.64	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
THYM	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-8	3.18e-12	1.73e-08	-0.84	-0.64	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
THYM	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-8	3.19e-12	1.73e-08	-0.6	-0.64	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-8	3.19e-12	1.73e-08	-0.6	-0.64	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
THYM	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-8	3.19e-12	1.73e-08	-0.6	-0.64	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
THYM	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-7.99	3.3e-12	1.79e-08	-0.88	-0.64	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-7.99	3.3e-12	1.79e-08	-0.88	-0.64	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-7.99	3.3e-12	1.79e-08	-0.88	-0.64	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
THYM	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	7.99	3.42e-12	1.85e-08	0.52	0.64	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
THYM	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	7.99	3.42e-12	1.85e-08	0.57	0.64	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
THYM	cis	rs995834	0.743	rs2015841	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28345899	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs10415623	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346878	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs10416153	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347155	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs8108726	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347425	chr19:28294093~28313500:-
THYM	cis	rs995834	0.701	rs6508784	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347560	chr19:28294093~28313500:-
THYM	cis	rs995834	0.701	rs8111880	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348171	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs8112315	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348498	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs8111630	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348642	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs11670286	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348909	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs758314	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363165	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs726845	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363761	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs2868967	ENSG00000266928.1	CTB-70G10.1	-7.99	3.43e-12	1.85e-08	-0.73	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372690	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs6508794	ENSG00000266928.1	CTB-70G10.1	7.99	3.43e-12	1.85e-08	0.73	0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356703	chr19:28294093~28313500:-
THYM	cis	rs995834	0.661	rs4407171	ENSG00000266928.1	CTB-70G10.1	7.99	3.43e-12	1.85e-08	0.73	0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372452	chr19:28294093~28313500:-
THYM	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	7.98	3.43e-12	1.86e-08	0.64	0.64	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	7.98	3.44e-12	1.86e-08	0.64	0.64	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
THYM	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	7.98	3.46e-12	1.87e-08	0.83	0.64	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
THYM	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-7.98	3.5e-12	1.89e-08	-0.64	-0.64	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
THYM	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	7.98	3.54e-12	1.9e-08	0.53	0.64	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
THYM	cis	rs1757171	0.542	rs3818986	ENSG00000204110.6	RP1-153P14.8	-7.98	3.55e-12	1.91e-08	-0.78	-0.64	Cognitive performance;	chr6:37516573	chr6:37507348~37535616:+
THYM	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	7.97	3.61e-12	1.94e-08	0.58	0.64	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	7.97	3.61e-12	1.94e-08	0.58	0.64	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	7.97	3.61e-12	1.94e-08	0.58	0.64	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
THYM	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-7.97	3.63e-12	1.95e-08	-0.71	-0.64	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
THYM	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	7.97	3.64e-12	1.95e-08	0.64	0.64	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	7.97	3.64e-12	1.95e-08	0.64	0.64	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
THYM	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	7.97	3.69e-12	1.97e-08	0.81	0.64	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
THYM	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	7.97	3.7e-12	1.98e-08	0.63	0.64	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
THYM	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-7.97	3.7e-12	1.98e-08	-0.74	-0.63	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
THYM	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	7.96	3.79e-12	2.02e-08	0.69	0.63	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
THYM	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-7.96	3.83e-12	2.04e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-7.96	3.83e-12	2.04e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
THYM	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-7.96	3.88e-12	2.06e-08	-0.74	-0.63	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
THYM	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-7.96	3.88e-12	2.06e-08	-0.74	-0.63	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
THYM	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-7.96	3.88e-12	2.06e-08	-0.74	-0.63	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
THYM	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	7.96	3.95e-12	2.1e-08	0.49	0.63	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
THYM	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-7.96	3.95e-12	2.1e-08	-0.82	-0.63	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
THYM	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	7.95	3.99e-12	2.11e-08	0.82	0.63	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	7.95	3.99e-12	2.11e-08	0.82	0.63	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	7.95	3.99e-12	2.11e-08	0.82	0.63	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
THYM	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-7.95	4e-12	2.12e-08	-0.83	-0.63	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
THYM	cis	rs1150668	0.543	rs2531805	ENSG00000216901.1	AL022393.7	7.95	4.02e-12	2.13e-08	0.77	0.63	Pubertal anthropometrics;	chr6:28444549	chr6:28176188~28176674:+
THYM	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-7.95	4.14e-12	2.19e-08	-0.74	-0.63	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
THYM	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-7.95	4.14e-12	2.19e-08	-0.74	-0.63	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
THYM	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-7.95	4.14e-12	2.19e-08	-0.74	-0.63	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
THYM	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	7.94	4.24e-12	2.23e-08	0.81	0.63	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	7.94	4.24e-12	2.23e-08	0.81	0.63	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	7.94	4.24e-12	2.23e-08	0.81	0.63	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
THYM	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
THYM	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-7.94	4.24e-12	2.23e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
THYM	cis	rs995834	0.622	rs10424022	ENSG00000267320.4	AC005780.1	-7.94	4.25e-12	2.23e-08	-0.74	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401351	chr19:28316705~28386204:-
THYM	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-7.94	4.28e-12	2.25e-08	-0.77	-0.63	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-7.94	4.28e-12	2.25e-08	-1.08	-0.63	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
THYM	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-7.94	4.3e-12	2.25e-08	-1.06	-0.63	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
THYM	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-7.94	4.31e-12	2.26e-08	-0.77	-0.63	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
THYM	cis	rs904251	1	rs12212090	ENSG00000279942.1	RP1-153P14.7	-7.94	4.37e-12	2.28e-08	-0.84	-0.63	Cognitive performance;	chr6:37464032	chr6:37567716~37571460:+
THYM	cis	rs904251	0.965	rs62406516	ENSG00000279942.1	RP1-153P14.7	-7.94	4.37e-12	2.28e-08	-0.84	-0.63	Cognitive performance;	chr6:37471588	chr6:37567716~37571460:+
THYM	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-7.93	4.37e-12	2.28e-08	-0.81	-0.63	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
THYM	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-7.93	4.37e-12	2.28e-08	-0.82	-0.63	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
THYM	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-7.93	4.37e-12	2.28e-08	-0.82	-0.63	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
THYM	cis	rs995834	0.701	rs6508799	ENSG00000266928.1	CTB-70G10.1	-7.93	4.4e-12	2.3e-08	-0.74	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28360493	chr19:28294093~28313500:-
THYM	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
THYM	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-7.93	4.57e-12	2.38e-08	-0.82	-0.63	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
THYM	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-7.92	4.59e-12	2.39e-08	-0.73	-0.63	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
THYM	cis	rs995834	0.743	rs28579409	ENSG00000266928.1	CTB-70G10.1	-7.92	4.61e-12	2.4e-08	-0.72	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347315	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs8108624	ENSG00000266928.1	CTB-70G10.1	-7.92	4.61e-12	2.4e-08	-0.72	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347359	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs8108711	ENSG00000266928.1	CTB-70G10.1	-7.92	4.61e-12	2.4e-08	-0.72	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347390	chr19:28294093~28313500:-
THYM	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-7.92	4.65e-12	2.42e-08	-0.85	-0.63	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
THYM	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-7.92	4.71e-12	2.45e-08	-0.77	-0.63	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
THYM	cis	rs995834	0.622	rs4805188	ENSG00000267320.4	AC005780.1	-7.92	4.72e-12	2.45e-08	-0.74	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400780	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs4806363	ENSG00000267320.4	AC005780.1	-7.92	4.72e-12	2.45e-08	-0.74	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400810	chr19:28316705~28386204:-
THYM	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-7.92	4.78e-12	2.48e-08	-1.01	-0.63	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
THYM	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-7.91	4.84e-12	2.51e-08	-0.78	-0.63	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
THYM	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-7.91	4.84e-12	2.51e-08	-0.78	-0.63	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
THYM	cis	rs995834	0.743	rs4555267	ENSG00000266928.1	CTB-70G10.1	-7.91	4.97e-12	2.57e-08	-0.74	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28374933	chr19:28294093~28313500:-
THYM	cis	rs995834	0.784	rs4141219	ENSG00000266928.1	CTB-70G10.1	-7.91	4.97e-12	2.57e-08	-0.74	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375247	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs2041195	ENSG00000266928.1	CTB-70G10.1	-7.91	4.97e-12	2.57e-08	-0.74	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376305	chr19:28294093~28313500:-
THYM	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	7.91	5.05e-12	2.61e-08	1.21	0.63	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	7.91	5.05e-12	2.61e-08	1.21	0.63	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	7.91	5.05e-12	2.61e-08	1.21	0.63	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
THYM	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-7.9	5.06e-12	2.61e-08	-0.87	-0.63	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
THYM	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	7.9	5.15e-12	2.65e-08	0.61	0.63	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
THYM	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	7.9	5.2e-12	2.67e-08	0.75	0.63	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
THYM	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	7.89	5.31e-12	2.73e-08	0.64	0.63	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
THYM	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	7.89	5.32e-12	2.73e-08	0.7	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
THYM	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	7.89	5.42e-12	2.78e-08	0.64	0.63	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	7.89	5.42e-12	2.78e-08	0.64	0.63	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
THYM	cis	rs995834	0.622	rs8102417	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397409	chr19:28316705~28386204:-
THYM	cis	rs995834	0.704	rs4806358	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397907	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs4806359	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398042	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs7252140	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398110	chr19:28316705~28386204:-
THYM	cis	rs995834	0.663	rs7252145	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398119	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs4806360	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398277	chr19:28316705~28386204:-
THYM	cis	rs995834	0.585	rs1558121	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398522	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs2159075	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398551	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs2079593	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398973	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs1558122	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399320	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs1558123	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399355	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs7257975	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399556	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs7246622	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399578	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs7258662	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400902	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs7246754	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400913	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs4806368	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402133	chr19:28316705~28386204:-
THYM	cis	rs995834	0.622	rs4806369	ENSG00000267320.4	AC005780.1	-7.89	5.46e-12	2.79e-08	-0.73	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402569	chr19:28316705~28386204:-
THYM	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-7.89	5.52e-12	2.82e-08	-0.8	-0.63	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
THYM	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-7.89	5.52e-12	2.82e-08	-0.8	-0.63	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
THYM	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	7.89	5.54e-12	2.82e-08	0.74	0.63	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	7.89	5.54e-12	2.82e-08	0.74	0.63	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	7.89	5.54e-12	2.82e-08	0.74	0.63	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
THYM	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	7.88	5.58e-12	2.85e-08	0.81	0.63	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
THYM	cis	rs995834	0.589	rs6508802	ENSG00000267320.4	AC005780.1	-7.88	5.58e-12	2.85e-08	-0.69	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362304	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs758313	ENSG00000267320.4	AC005780.1	-7.88	5.58e-12	2.85e-08	-0.69	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363094	chr19:28316705~28386204:-
THYM	cis	rs995834	0.742	rs1155575	ENSG00000267320.4	AC005780.1	-7.88	5.58e-12	2.85e-08	-0.69	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28369526	chr19:28316705~28386204:-
THYM	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-7.88	5.62e-12	2.86e-08	-0.77	-0.63	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
THYM	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	7.88	5.65e-12	2.88e-08	0.64	0.63	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
THYM	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	7.88	5.71e-12	2.91e-08	0.74	0.63	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	7.88	5.71e-12	2.91e-08	0.74	0.63	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
THYM	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	7.88	5.78e-12	2.94e-08	0.62	0.63	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
THYM	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-7.88	5.82e-12	2.96e-08	-0.82	-0.63	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
THYM	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-7.87	5.85e-12	2.97e-08	-0.8	-0.63	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
THYM	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-7.87	5.85e-12	2.97e-08	-0.82	-0.63	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
THYM	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-7.87	5.87e-12	2.98e-08	-0.71	-0.63	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-7.87	5.87e-12	2.98e-08	-0.71	-0.63	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
THYM	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	7.87	5.96e-12	3.02e-08	0.9	0.63	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
THYM	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-7.87	5.99e-12	3.04e-08	-0.74	-0.63	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-7.87	5.99e-12	3.04e-08	-0.74	-0.63	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
THYM	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-7.87	6.03e-12	3.05e-08	-0.65	-0.63	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
THYM	cis	rs904251	1	rs904251	ENSG00000279942.1	RP1-153P14.7	-7.87	6.05e-12	3.06e-08	-0.84	-0.63	Cognitive performance;	chr6:37483920	chr6:37567716~37571460:+
THYM	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-7.87	6.1e-12	3.09e-08	-0.77	-0.63	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
THYM	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-7.86	6.15e-12	3.11e-08	-0.71	-0.63	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-7.86	6.15e-12	3.11e-08	-0.71	-0.63	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
THYM	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	7.86	6.15e-12	3.11e-08	0.64	0.63	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	7.86	6.15e-12	3.11e-08	0.64	0.63	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	7.86	6.15e-12	3.11e-08	0.64	0.63	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
THYM	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	7.86	6.2e-12	3.13e-08	0.68	0.63	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
THYM	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-7.86	6.22e-12	3.14e-08	-0.73	-0.63	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
THYM	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	7.86	6.27e-12	3.17e-08	0.73	0.63	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
THYM	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	7.86	6.3e-12	3.18e-08	0.49	0.63	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
THYM	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-7.86	6.31e-12	3.19e-08	-0.8	-0.63	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
THYM	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	7.86	6.38e-12	3.22e-08	0.75	0.63	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
THYM	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	7.86	6.4e-12	3.23e-08	1.1	0.63	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
THYM	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-7.85	6.53e-12	3.29e-08	-0.59	-0.63	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
THYM	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-7.85	6.53e-12	3.29e-08	-0.59	-0.63	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
THYM	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-7.85	6.53e-12	3.29e-08	-0.59	-0.63	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
THYM	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-7.85	6.53e-12	3.29e-08	-0.59	-0.63	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-7.85	6.53e-12	3.29e-08	-0.59	-0.63	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
THYM	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-7.85	6.64e-12	3.34e-08	-0.89	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
THYM	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	7.85	6.69e-12	3.36e-08	0.84	0.63	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
THYM	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-7.84	6.81e-12	3.42e-08	-0.74	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
THYM	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-7.84	6.89e-12	3.45e-08	-0.88	-0.63	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
THYM	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	7.84	6.99e-12	3.5e-08	0.8	0.63	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
THYM	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	7.84	7.02e-12	3.51e-08	1.21	0.63	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
THYM	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	7.83	7.11e-12	3.56e-08	0.69	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.828	rs5751770	ENSG00000272787.1	KB-226F1.2	-7.83	7.16e-12	3.58e-08	-0.69	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23969211~23969873:+
THYM	cis	rs995834	0.743	rs28579409	ENSG00000267320.4	AC005780.1	-7.83	7.19e-12	3.6e-08	-0.67	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347315	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs8108624	ENSG00000267320.4	AC005780.1	-7.83	7.19e-12	3.6e-08	-0.67	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347359	chr19:28316705~28386204:-
THYM	cis	rs995834	0.743	rs8108711	ENSG00000267320.4	AC005780.1	-7.83	7.19e-12	3.6e-08	-0.67	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347390	chr19:28316705~28386204:-
THYM	cis	rs673078	0.562	rs61944672	ENSG00000275409.1	RP11-131L12.4	-7.83	7.19e-12	3.6e-08	-0.81	-0.63	Glucose homeostasis traits;	chr12:118450123	chr12:118430147~118430699:+
THYM	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-7.83	7.21e-12	3.6e-08	-0.89	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
THYM	cis	rs7829975	0.748	rs693109	ENSG00000253893.2	FAM85B	7.83	7.25e-12	3.62e-08	0.75	0.63	Mood instability;	chr8:8782662	chr8:8167819~8226614:-
THYM	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-7.82	7.46e-12	3.73e-08	-0.82	-0.63	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
THYM	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	7.82	7.49e-12	3.74e-08	0.65	0.63	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	7.82	7.49e-12	3.74e-08	0.65	0.63	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
THYM	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	7.82	7.57e-12	3.78e-08	0.65	0.63	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
THYM	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	7.82	7.6e-12	3.79e-08	0.85	0.63	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
THYM	cis	rs2739330	0.828	rs5760108	ENSG00000272787.1	KB-226F1.2	-7.82	7.64e-12	3.81e-08	-0.7	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23969211~23969873:+
THYM	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	7.82	7.77e-12	3.87e-08	0.68	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
THYM	cis	rs995834	0.789	rs10410807	ENSG00000266928.1	CTB-70G10.1	-7.81	7.79e-12	3.88e-08	-0.76	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28410408	chr19:28294093~28313500:-
THYM	cis	rs2739330	0.828	rs2877178	ENSG00000272787.1	KB-226F1.2	-7.81	7.9e-12	3.94e-08	-0.71	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.828	rs2154593	ENSG00000272787.1	KB-226F1.2	-7.81	7.9e-12	3.94e-08	-0.71	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23969211~23969873:+
THYM	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-7.81	7.96e-12	3.97e-08	-1.07	-0.63	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
THYM	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	7.81	7.96e-12	3.97e-08	1.09	0.63	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	7.81	7.96e-12	3.97e-08	1.09	0.63	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
THYM	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	7.81	8.12e-12	4.04e-08	0.63	0.63	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
THYM	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	7.81	8.15e-12	4.05e-08	1.09	0.63	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
THYM	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-7.8	8.23e-12	4.09e-08	-0.72	-0.63	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
THYM	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-7.8	8.29e-12	4.11e-08	-1.05	-0.63	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
THYM	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-7.79	8.58e-12	4.25e-08	-0.66	-0.63	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
THYM	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-7.79	8.63e-12	4.27e-08	-0.71	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
THYM	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-7.79	8.64e-12	4.28e-08	-0.61	-0.63	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
THYM	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-7.79	8.81e-12	4.35e-08	-0.78	-0.63	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-7.79	8.81e-12	4.35e-08	-0.78	-0.63	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-7.79	8.81e-12	4.35e-08	-0.78	-0.63	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
THYM	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-7.79	8.81e-12	4.35e-08	-0.78	-0.63	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-7.79	8.81e-12	4.35e-08	-0.78	-0.63	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-7.79	8.81e-12	4.35e-08	-0.78	-0.63	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	7.79	8.84e-12	4.36e-08	1.04	0.63	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	7.79	8.84e-12	4.36e-08	1.04	0.63	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-7.79	8.84e-12	4.36e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-7.79	8.84e-12	4.36e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-7.79	8.84e-12	4.36e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-7.79	8.84e-12	4.36e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-7.79	8.84e-12	4.36e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-7.79	8.84e-12	4.36e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
THYM	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-7.79	8.94e-12	4.41e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
THYM	cis	rs995834	0.872	rs10425754	ENSG00000260725.1	AC005307.1	-7.79	8.96e-12	4.41e-08	-0.61	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387708	chr19:28418483~28429490:-
THYM	cis	rs995834	0.869	rs10853719	ENSG00000260725.1	AC005307.1	-7.79	8.96e-12	4.41e-08	-0.61	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392287	chr19:28418483~28429490:-
THYM	cis	rs995834	0.869	rs10405674	ENSG00000260725.1	AC005307.1	-7.79	8.96e-12	4.41e-08	-0.61	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393703	chr19:28418483~28429490:-
THYM	cis	rs995834	0.869	rs9304581	ENSG00000260725.1	AC005307.1	-7.79	8.96e-12	4.41e-08	-0.61	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394084	chr19:28418483~28429490:-
THYM	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-7.78	9.01e-12	4.44e-08	-0.81	-0.63	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-7.78	9.01e-12	4.44e-08	-0.81	-0.63	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	7.78	9.02e-12	4.44e-08	0.76	0.63	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
THYM	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-7.78	9.04e-12	4.45e-08	-0.84	-0.63	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
THYM	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-7.78	9.1e-12	4.48e-08	-1.04	-0.63	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
THYM	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-7.78	9.2e-12	4.52e-08	-0.87	-0.63	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
THYM	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	7.78	9.24e-12	4.54e-08	0.64	0.63	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	7.78	9.24e-12	4.54e-08	0.64	0.63	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	7.78	9.24e-12	4.54e-08	0.64	0.63	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
THYM	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-7.78	9.26e-12	4.55e-08	-0.59	-0.63	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
THYM	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-7.78	9.26e-12	4.55e-08	-0.59	-0.63	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
THYM	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-7.78	9.26e-12	4.55e-08	-0.59	-0.63	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
THYM	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	7.78	9.27e-12	4.55e-08	0.82	0.63	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
THYM	cis	rs995834	0.869	rs10417250	ENSG00000260725.1	AC005307.1	-7.78	9.33e-12	4.58e-08	-0.62	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395342	chr19:28418483~28429490:-
THYM	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	7.77	9.45e-12	4.64e-08	0.68	0.63	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
THYM	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-7.77	9.48e-12	4.65e-08	-0.74	-0.63	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
THYM	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-7.77	9.49e-12	4.65e-08	-0.76	-0.63	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-7.77	9.57e-12	4.69e-08	-0.8	-0.63	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
THYM	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	7.77	9.64e-12	4.71e-08	0.72	0.63	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
THYM	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-7.77	9.7e-12	4.75e-08	-0.79	-0.63	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-7.77	9.7e-12	4.75e-08	-0.79	-0.63	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
THYM	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	7.77	9.73e-12	4.76e-08	0.66	0.63	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	7.77	9.73e-12	4.76e-08	0.66	0.63	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
THYM	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	7.76	9.97e-12	4.87e-08	0.88	0.63	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
THYM	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	7.76	1.03e-11	5.01e-08	0.63	0.62	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
THYM	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-7.76	1.03e-11	5.01e-08	-0.86	-0.62	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
THYM	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
THYM	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-7.76	1.03e-11	5.01e-08	-1.05	-0.62	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
THYM	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	7.76	1.04e-11	5.03e-08	0.63	0.62	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	7.76	1.04e-11	5.03e-08	0.63	0.62	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	7.76	1.04e-11	5.03e-08	0.63	0.62	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
THYM	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-7.75	1.04e-11	5.05e-08	-0.7	-0.62	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-7.75	1.04e-11	5.05e-08	-0.7	-0.62	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-7.75	1.04e-11	5.05e-08	-0.7	-0.62	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
THYM	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	7.75	1.04e-11	5.05e-08	0.62	0.62	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
THYM	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-7.75	1.05e-11	5.07e-08	-0.59	-0.62	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
THYM	cis	rs995834	0.833	rs1034885	ENSG00000260725.1	AC005307.1	-7.75	1.05e-11	5.09e-08	-0.61	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28381527	chr19:28418483~28429490:-
THYM	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-7.75	1.05e-11	5.1e-08	-0.81	-0.62	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-7.75	1.05e-11	5.1e-08	-0.81	-0.62	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
THYM	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	7.75	1.07e-11	5.17e-08	0.59	0.62	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
THYM	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	7.75	1.08e-11	5.2e-08	0.63	0.62	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	7.75	1.08e-11	5.2e-08	0.63	0.62	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
THYM	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	7.74	1.1e-11	5.32e-08	0.86	0.62	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
THYM	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	7.74	1.12e-11	5.4e-08	0.74	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
THYM	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	7.74	1.12e-11	5.4e-08	0.74	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
THYM	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	7.74	1.12e-11	5.4e-08	0.63	0.62	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	7.74	1.12e-11	5.4e-08	0.63	0.62	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	7.74	1.12e-11	5.4e-08	0.63	0.62	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
THYM	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	7.74	1.13e-11	5.45e-08	0.88	0.62	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
THYM	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	7.74	1.13e-11	5.45e-08	0.69	0.62	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
THYM	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-7.74	1.14e-11	5.5e-08	-0.89	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
THYM	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	7.74	1.14e-11	5.51e-08	0.67	0.62	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
THYM	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	7.74	1.14e-11	5.51e-08	0.67	0.62	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
THYM	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
THYM	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
THYM	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
THYM	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-7.73	1.15e-11	5.52e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
THYM	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-7.73	1.15e-11	5.53e-08	-0.85	-0.62	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
THYM	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	7.73	1.15e-11	5.53e-08	0.77	0.62	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
THYM	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-7.73	1.16e-11	5.57e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
THYM	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-7.73	1.16e-11	5.57e-08	-0.73	-0.62	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
THYM	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	7.73	1.16e-11	5.59e-08	0.83	0.62	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	7.73	1.16e-11	5.59e-08	0.83	0.62	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	7.73	1.16e-11	5.59e-08	0.83	0.62	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
THYM	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	7.73	1.16e-11	5.59e-08	0.56	0.62	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	7.73	1.16e-11	5.59e-08	0.56	0.62	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
THYM	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-7.73	1.17e-11	5.61e-08	-0.77	-0.62	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
THYM	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-7.73	1.18e-11	5.65e-08	-0.92	-0.62	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
THYM	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	7.73	1.19e-11	5.72e-08	0.74	0.62	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
THYM	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-7.72	1.2e-11	5.77e-08	-0.89	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-7.72	1.2e-11	5.77e-08	-0.89	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
THYM	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-7.72	1.23e-11	5.88e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-7.72	1.23e-11	5.88e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-7.72	1.23e-11	5.88e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
THYM	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-7.72	1.23e-11	5.88e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
THYM	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-7.72	1.23e-11	5.88e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
THYM	cis	rs995834	0.742	rs4805164	ENSG00000266928.1	CTB-70G10.1	-7.72	1.23e-11	5.91e-08	-0.74	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28340111	chr19:28294093~28313500:-
THYM	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-7.72	1.24e-11	5.94e-08	-0.82	-0.62	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
THYM	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-7.72	1.25e-11	6e-08	-0.79	-0.62	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
THYM	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	7.71	1.26e-11	6.05e-08	0.8	0.62	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
THYM	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	7.71	1.27e-11	6.06e-08	0.67	0.62	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
THYM	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	7.71	1.27e-11	6.07e-08	1.03	0.62	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
THYM	cis	rs995834	0.742	rs4805164	ENSG00000267320.4	AC005780.1	-7.71	1.27e-11	6.09e-08	-0.69	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28340111	chr19:28316705~28386204:-
THYM	cis	rs995834	0.789	rs758124	ENSG00000260725.1	AC005307.1	-7.71	1.29e-11	6.14e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402966	chr19:28418483~28429490:-
THYM	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	7.71	1.3e-11	6.18e-08	0.57	0.62	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
THYM	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-7.71	1.3e-11	6.19e-08	-0.79	-0.62	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
THYM	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-7.71	1.32e-11	6.29e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
THYM	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	7.7	1.32e-11	6.3e-08	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
THYM	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-7.7	1.33e-11	6.34e-08	-0.75	-0.62	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
THYM	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	7.7	1.35e-11	6.41e-08	0.64	0.62	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	7.7	1.35e-11	6.41e-08	0.64	0.62	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-7.7	1.35e-11	6.41e-08	-0.64	-0.62	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
THYM	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-7.7	1.35e-11	6.42e-08	-0.82	-0.62	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
THYM	cis	rs995834	0.742	rs1971674	ENSG00000266928.1	CTB-70G10.1	-7.7	1.37e-11	6.5e-08	-0.74	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28343033	chr19:28294093~28313500:-
THYM	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-7.7	1.38e-11	6.57e-08	-0.75	-0.62	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
THYM	cis	rs995834	0.589	rs6508802	ENSG00000266928.1	CTB-70G10.1	-7.69	1.4e-11	6.62e-08	-0.72	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362304	chr19:28294093~28313500:-
THYM	cis	rs995834	0.743	rs758313	ENSG00000266928.1	CTB-70G10.1	-7.69	1.4e-11	6.62e-08	-0.72	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363094	chr19:28294093~28313500:-
THYM	cis	rs995834	0.742	rs1155575	ENSG00000266928.1	CTB-70G10.1	-7.69	1.4e-11	6.62e-08	-0.72	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28369526	chr19:28294093~28313500:-
THYM	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	7.69	1.4e-11	6.65e-08	0.64	0.62	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	7.69	1.4e-11	6.65e-08	0.64	0.62	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	7.69	1.4e-11	6.65e-08	0.64	0.62	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	7.69	1.4e-11	6.65e-08	0.64	0.62	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	7.69	1.4e-11	6.65e-08	0.64	0.62	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	7.69	1.4e-11	6.65e-08	0.64	0.62	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	7.69	1.4e-11	6.65e-08	0.64	0.62	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	7.69	1.41e-11	6.7e-08	0.64	0.62	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	7.69	1.41e-11	6.7e-08	0.64	0.62	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	7.69	1.43e-11	6.76e-08	0.64	0.62	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
THYM	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	7.69	1.44e-11	6.81e-08	0.74	0.62	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	7.69	1.44e-11	6.81e-08	0.74	0.62	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	7.69	1.44e-11	6.82e-08	0.74	0.62	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	7.69	1.44e-11	6.82e-08	0.74	0.62	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
THYM	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	7.69	1.45e-11	6.86e-08	0.89	0.62	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
THYM	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	7.68	1.46e-11	6.89e-08	0.72	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
THYM	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-7.68	1.49e-11	7.05e-08	-0.81	-0.62	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
THYM	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-7.68	1.5e-11	7.07e-08	-0.74	-0.62	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-7.68	1.5e-11	7.07e-08	-0.74	-0.62	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-7.68	1.5e-11	7.07e-08	-0.74	-0.62	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-7.68	1.5e-11	7.07e-08	-0.74	-0.62	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
THYM	cis	rs995834	0.742	rs1971674	ENSG00000267320.4	AC005780.1	-7.68	1.51e-11	7.12e-08	-0.69	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28343033	chr19:28316705~28386204:-
THYM	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	7.68	1.51e-11	7.13e-08	0.74	0.62	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
THYM	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-7.67	1.53e-11	7.23e-08	-0.77	-0.62	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
THYM	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-7.67	1.54e-11	7.25e-08	-0.83	-0.62	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
THYM	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	7.67	1.54e-11	7.26e-08	0.57	0.62	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
THYM	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-7.67	1.55e-11	7.3e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
THYM	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	7.67	1.56e-11	7.33e-08	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
THYM	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	7.67	1.57e-11	7.36e-08	0.55	0.62	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
THYM	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	7.67	1.58e-11	7.43e-08	0.8	0.62	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
THYM	cis	rs995834	0.869	rs6508821	ENSG00000260725.1	AC005307.1	-7.67	1.58e-11	7.43e-08	-0.63	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396506	chr19:28418483~28429490:-
THYM	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	7.66	1.6e-11	7.52e-08	0.74	0.62	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	7.66	1.6e-11	7.52e-08	0.74	0.62	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
THYM	cis	rs673078	0.66	rs61943524	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118151530	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17440315	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118158819	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs73220119	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118159864	chr12:118430147~118430699:+
THYM	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-7.66	1.61e-11	7.52e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
THYM	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-7.66	1.61e-11	7.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
THYM	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	7.66	1.62e-11	7.56e-08	0.64	0.62	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
THYM	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	7.66	1.62e-11	7.58e-08	0.95	0.62	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
THYM	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	7.66	1.64e-11	7.66e-08	0.71	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
THYM	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	7.66	1.65e-11	7.72e-08	0.74	0.62	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	7.66	1.65e-11	7.72e-08	0.74	0.62	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
THYM	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	7.66	1.65e-11	7.74e-08	0.74	0.62	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
THYM	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	7.66	1.66e-11	7.75e-08	0.59	0.62	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
THYM	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-7.66	1.66e-11	7.78e-08	-0.7	-0.62	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
THYM	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	7.66	1.67e-11	7.8e-08	0.54	0.62	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	7.66	1.67e-11	7.8e-08	0.54	0.62	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
THYM	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-7.66	1.67e-11	7.81e-08	-0.86	-0.62	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
THYM	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	7.66	1.68e-11	7.83e-08	0.74	0.62	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
THYM	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	7.65	1.72e-11	7.99e-08	0.66	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
THYM	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-7.65	1.73e-11	8.02e-08	-0.7	-0.62	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
THYM	cis	rs995834	0.789	rs4806362	ENSG00000260725.1	AC005307.1	7.65	1.73e-11	8.03e-08	0.62	0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398414	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs10425833	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401807	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs10402916	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402001	chr19:28418483~28429490:-
THYM	cis	rs995834	0.753	rs10405354	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402005	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs7248138	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402207	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs7246817	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402219	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs10411886	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402396	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs758123	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402872	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs758125	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403001	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs758126	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403236	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs10421214	ENSG00000260725.1	AC005307.1	-7.65	1.73e-11	8.03e-08	-0.62	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404538	chr19:28418483~28429490:-
THYM	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-7.65	1.73e-11	8.03e-08	-0.75	-0.62	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-7.65	1.73e-11	8.03e-08	-0.75	-0.62	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-7.65	1.73e-11	8.03e-08	-0.75	-0.62	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-7.65	1.73e-11	8.03e-08	-0.75	-0.62	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
THYM	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-7.65	1.75e-11	8.09e-08	-0.7	-0.62	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
THYM	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	7.65	1.76e-11	8.13e-08	0.91	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
THYM	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	7.64	1.76e-11	8.16e-08	0.74	0.62	Depression;	chr6:28363475	chr6:28176188~28176674:+
THYM	cis	rs995834	0.912	rs2868970	ENSG00000266928.1	CTB-70G10.1	-7.64	1.79e-11	8.27e-08	-0.71	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393432	chr19:28294093~28313500:-
THYM	cis	rs995834	0.828	rs10403516	ENSG00000266928.1	CTB-70G10.1	-7.64	1.79e-11	8.27e-08	-0.71	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393842	chr19:28294093~28313500:-
THYM	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	7.64	1.79e-11	8.3e-08	0.69	0.62	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
THYM	cis	rs1426063	0.8	rs28861517	ENSG00000248165.1	RP11-44F21.2	7.64	1.81e-11	8.36e-08	1.15	0.62	QT interval;	chr4:75092995	chr4:74993877~75034824:-
THYM	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-7.64	1.83e-11	8.46e-08	-0.82	-0.62	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
THYM	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
THYM	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
THYM	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-7.64	1.84e-11	8.46e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
THYM	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	7.64	1.84e-11	8.47e-08	0.75	0.62	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
THYM	cis	rs995834	0.912	rs12608446	ENSG00000260725.1	AC005307.1	-7.63	1.85e-11	8.52e-08	-0.6	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384329	chr19:28418483~28429490:-
THYM	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-7.63	1.86e-11	8.54e-08	-0.73	-0.62	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
THYM	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-7.63	1.87e-11	8.58e-08	-0.87	-0.62	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
THYM	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	7.63	1.89e-11	8.66e-08	0.56	0.62	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
THYM	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-7.63	1.89e-11	8.69e-08	-1.06	-0.62	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
THYM	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-7.63	1.89e-11	8.69e-08	-1.06	-0.62	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
THYM	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	7.63	1.9e-11	8.72e-08	0.56	0.62	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	7.63	1.9e-11	8.72e-08	0.56	0.62	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
THYM	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	7.62	1.94e-11	8.9e-08	0.91	0.62	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
THYM	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-7.62	1.94e-11	8.91e-08	-0.57	-0.62	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
THYM	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-7.62	1.96e-11	8.97e-08	-0.7	-0.62	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
THYM	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	7.62	1.96e-11	8.97e-08	0.62	0.62	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
THYM	cis	rs2739330	0.828	rs4822451	ENSG00000272787.1	KB-226F1.2	-7.62	1.97e-11	9.01e-08	-0.7	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.828	rs5760099	ENSG00000272787.1	KB-226F1.2	-7.62	1.97e-11	9.01e-08	-0.7	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23969211~23969873:+
THYM	cis	rs995834	0.742	rs2868965	ENSG00000266928.1	CTB-70G10.1	7.62	1.99e-11	9.09e-08	0.71	0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362886	chr19:28294093~28313500:-
THYM	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	7.62	1.99e-11	9.1e-08	0.64	0.62	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
THYM	cis	rs904251	0.861	rs1757180	ENSG00000227920.2	RP1-153P14.5	-7.62	2e-11	9.12e-08	-0.89	-0.62	Cognitive performance;	chr6:37518369	chr6:37545145~37550860:+
THYM	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	7.61	2.06e-11	9.38e-08	0.46	0.62	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
THYM	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-7.61	2.1e-11	9.55e-08	-0.72	-0.62	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
THYM	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-7.6	2.23e-11	1.01e-07	-0.85	-0.62	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-7.6	2.23e-11	1.01e-07	-0.85	-0.62	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-7.6	2.23e-11	1.01e-07	-0.85	-0.62	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-7.6	2.23e-11	1.01e-07	-0.85	-0.62	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
THYM	cis	rs2739330	0.796	rs1006771	ENSG00000272787.1	KB-226F1.2	-7.59	2.25e-11	1.02e-07	-0.7	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23969211~23969873:+
THYM	cis	rs995834	0.742	rs2868965	ENSG00000267320.4	AC005780.1	7.59	2.31e-11	1.04e-07	0.66	0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362886	chr19:28316705~28386204:-
THYM	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	7.59	2.33e-11	1.05e-07	0.56	0.62	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
THYM	cis	rs995834	0.869	rs1476763	ENSG00000260725.1	AC005307.1	-7.59	2.33e-11	1.05e-07	-0.6	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394591	chr19:28418483~28429490:-
THYM	cis	rs995834	0.828	rs10460161	ENSG00000260725.1	AC005307.1	-7.59	2.33e-11	1.05e-07	-0.6	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394686	chr19:28418483~28429490:-
THYM	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-7.59	2.33e-11	1.05e-07	-0.69	-0.62	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
THYM	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	7.59	2.34e-11	1.06e-07	0.77	0.62	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
THYM	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-7.58	2.37e-11	1.07e-07	-0.7	-0.62	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-7.58	2.37e-11	1.07e-07	-0.7	-0.62	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	7.58	2.37e-11	1.07e-07	0.7	0.62	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
THYM	cis	rs673078	0.562	rs61944668	ENSG00000275409.1	RP11-131L12.4	-7.58	2.38e-11	1.07e-07	-0.81	-0.62	Glucose homeostasis traits;	chr12:118448446	chr12:118430147~118430699:+
THYM	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	7.58	2.38e-11	1.07e-07	0.64	0.62	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	7.58	2.38e-11	1.07e-07	0.64	0.62	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-7.58	2.4e-11	1.08e-07	-0.77	-0.62	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
THYM	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
THYM	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	7.58	2.44e-11	1.1e-07	0.83	0.62	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
THYM	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-7.57	2.47e-11	1.1e-07	-0.8	-0.62	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
THYM	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	7.57	2.49e-11	1.11e-07	0.81	0.62	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
THYM	cis	rs995834	1	rs995834	ENSG00000266928.1	CTB-70G10.1	-7.57	2.5e-11	1.12e-07	-0.68	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375689	chr19:28294093~28313500:-
THYM	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	7.57	2.52e-11	1.13e-07	0.63	0.62	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	7.57	2.52e-11	1.13e-07	0.63	0.62	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	7.57	2.52e-11	1.13e-07	0.63	0.62	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
THYM	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	7.57	2.54e-11	1.14e-07	0.85	0.62	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
THYM	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	7.57	2.56e-11	1.14e-07	0.63	0.62	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
THYM	cis	rs995834	0.912	rs4806341	ENSG00000260725.1	AC005307.1	-7.57	2.56e-11	1.15e-07	-0.6	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384371	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs4806343	ENSG00000260725.1	AC005307.1	-7.57	2.56e-11	1.15e-07	-0.6	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384874	chr19:28418483~28429490:-
THYM	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	7.57	2.57e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	7.57	2.58e-11	1.15e-07	0.64	0.62	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
THYM	cis	rs673078	0.607	rs7974375	ENSG00000275759.1	RP11-131L12.3	-7.56	2.59e-11	1.15e-07	-1.01	-0.62	Glucose homeostasis traits;	chr12:118147893	chr12:118428281~118428870:+
THYM	cis	rs904251	0.523	rs9349039	ENSG00000204110.6	RP1-153P14.8	-7.56	2.61e-11	1.16e-07	-0.82	-0.62	Cognitive performance;	chr6:37512616	chr6:37507348~37535616:+
THYM	cis	rs904251	0.523	rs9366935	ENSG00000204110.6	RP1-153P14.8	-7.56	2.61e-11	1.16e-07	-0.82	-0.62	Cognitive performance;	chr6:37512628	chr6:37507348~37535616:+
THYM	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	7.56	2.63e-11	1.17e-07	0.64	0.61	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
THYM	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	7.56	2.64e-11	1.17e-07	0.67	0.61	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
THYM	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-7.56	2.66e-11	1.18e-07	-1.02	-0.61	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
THYM	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-7.56	2.66e-11	1.18e-07	-0.89	-0.61	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
THYM	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	7.56	2.66e-11	1.18e-07	0.76	0.61	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
THYM	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	7.56	2.66e-11	1.18e-07	0.76	0.61	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
THYM	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	7.55	2.72e-11	1.2e-07	0.83	0.61	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	7.55	2.72e-11	1.2e-07	0.83	0.61	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	7.55	2.72e-11	1.2e-07	0.83	0.61	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	7.55	2.72e-11	1.2e-07	0.83	0.61	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	7.55	2.72e-11	1.2e-07	0.83	0.61	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	7.55	2.72e-11	1.2e-07	0.83	0.61	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
THYM	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-7.55	2.74e-11	1.21e-07	-0.86	-0.61	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
THYM	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	7.55	2.78e-11	1.22e-07	0.67	0.61	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
THYM	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	7.55	2.79e-11	1.23e-07	0.94	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
THYM	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-7.55	2.8e-11	1.23e-07	-0.89	-0.61	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
THYM	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-7.55	2.83e-11	1.25e-07	-0.72	-0.61	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
THYM	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-7.55	2.84e-11	1.25e-07	-0.75	-0.61	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
THYM	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-7.54	2.86e-11	1.26e-07	-0.77	-0.61	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
THYM	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-7.54	2.89e-11	1.27e-07	-0.96	-0.61	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
THYM	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-7.54	2.91e-11	1.28e-07	-0.73	-0.61	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
THYM	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-7.54	2.91e-11	1.28e-07	-0.73	-0.61	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
THYM	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	7.54	2.95e-11	1.3e-07	0.92	0.61	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
THYM	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-7.54	2.96e-11	1.3e-07	-0.76	-0.61	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
THYM	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-7.53	3e-11	1.32e-07	-0.64	-0.61	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
THYM	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-7.53	3.01e-11	1.32e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-7.53	3.01e-11	1.32e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-7.53	3.01e-11	1.32e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
THYM	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	7.53	3.02e-11	1.33e-07	0.64	0.61	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
THYM	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-7.53	3.03e-11	1.33e-07	-0.75	-0.61	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
THYM	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-7.53	3.05e-11	1.34e-07	-0.67	-0.61	Breast cancer;	chr11:825777	chr11:779617~780755:+
THYM	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
THYM	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-7.53	3.05e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-7.53	3.06e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-7.53	3.06e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-7.53	3.06e-11	1.34e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
THYM	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-7.53	3.08e-11	1.35e-07	-0.74	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-7.53	3.08e-11	1.35e-07	-0.74	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
THYM	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-7.53	3.09e-11	1.35e-07	-0.7	-0.61	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
THYM	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	7.53	3.1e-11	1.35e-07	0.7	0.61	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	7.53	3.1e-11	1.35e-07	0.7	0.61	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	7.53	3.1e-11	1.35e-07	0.7	0.61	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	7.53	3.1e-11	1.35e-07	0.7	0.61	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
THYM	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-7.52	3.13e-11	1.37e-07	-0.76	-0.61	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-7.52	3.13e-11	1.37e-07	-0.76	-0.61	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-7.52	3.13e-11	1.37e-07	-0.76	-0.61	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
THYM	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	7.52	3.15e-11	1.37e-07	0.85	0.61	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
THYM	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	7.52	3.15e-11	1.37e-07	0.71	0.61	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
THYM	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-7.52	3.21e-11	1.4e-07	-0.73	-0.61	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-7.52	3.21e-11	1.4e-07	-0.73	-0.61	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
THYM	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-7.51	3.33e-11	1.45e-07	-0.64	-0.61	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	7.51	3.43e-11	1.49e-07	0.61	0.61	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
THYM	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	7.51	3.44e-11	1.49e-07	0.55	0.61	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	7.51	3.44e-11	1.49e-07	0.55	0.61	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
THYM	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-7.5	3.45e-11	1.5e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
THYM	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-7.5	3.46e-11	1.5e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
THYM	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-7.5	3.46e-11	1.5e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-7.5	3.46e-11	1.5e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
THYM	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-7.5	3.46e-11	1.5e-07	-0.93	-0.61	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
THYM	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-7.5	3.48e-11	1.51e-07	-0.81	-0.61	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
THYM	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-7.5	3.48e-11	1.51e-07	-0.81	-0.61	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
THYM	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-7.5	3.5e-11	1.52e-07	-0.74	-0.61	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
THYM	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-7.5	3.52e-11	1.53e-07	-0.62	-0.61	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
THYM	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	7.5	3.53e-11	1.53e-07	1.18	0.61	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
THYM	cis	rs1426063	0.858	rs11931653	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75080856	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs55775471	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75081074	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs9990627	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75081244	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs10026994	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75081551	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs6830936	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75083952	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs11936768	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75084506	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs72662426	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75084828	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs6823982	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75084961	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs6837969	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75085005	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs6843217	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75085201	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.858	rs7666182	ENSG00000248165.1	RP11-44F21.2	7.5	3.54e-11	1.53e-07	1.27	0.61	QT interval;	chr4:75090989	chr4:74993877~75034824:-
THYM	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	7.5	3.55e-11	1.54e-07	0.83	0.61	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
THYM	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-7.49	3.61e-11	1.56e-07	-0.75	-0.61	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
THYM	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-7.49	3.62e-11	1.57e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
THYM	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-7.49	3.64e-11	1.57e-07	-0.97	-0.61	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
THYM	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	7.49	3.7e-11	1.6e-07	0.48	0.61	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
THYM	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	7.48	3.79e-11	1.63e-07	0.82	0.61	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
THYM	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-7.48	3.88e-11	1.66e-07	-0.9	-0.61	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
THYM	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-7.47	3.97e-11	1.7e-07	-0.57	-0.61	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-7.47	3.97e-11	1.7e-07	-0.57	-0.61	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-7.47	3.97e-11	1.7e-07	-0.57	-0.61	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
THYM	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-7.47	3.97e-11	1.7e-07	-0.57	-0.61	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
THYM	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-7.47	3.99e-11	1.71e-07	-0.69	-0.61	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
THYM	cis	rs995834	0.826	rs10419909	ENSG00000260725.1	AC005307.1	-7.47	4e-11	1.71e-07	-0.6	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395848	chr19:28418483~28429490:-
THYM	cis	rs995834	0.826	rs8112121	ENSG00000260725.1	AC005307.1	-7.47	4e-11	1.71e-07	-0.6	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396047	chr19:28418483~28429490:-
THYM	cis	rs995834	0.826	rs6508819	ENSG00000260725.1	AC005307.1	-7.47	4e-11	1.71e-07	-0.6	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396068	chr19:28418483~28429490:-
THYM	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	7.47	4.03e-11	1.72e-07	0.82	0.61	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
THYM	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	7.47	4.04e-11	1.73e-07	0.53	0.61	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	7.47	4.04e-11	1.73e-07	0.53	0.61	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
THYM	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-7.47	4.06e-11	1.73e-07	-0.86	-0.61	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-7.47	4.06e-11	1.73e-07	-0.86	-0.61	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
THYM	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	7.47	4.06e-11	1.73e-07	0.6	0.61	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
THYM	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	7.47	4.13e-11	1.76e-07	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
THYM	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-7.47	4.13e-11	1.76e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-7.47	4.13e-11	1.76e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
THYM	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	7.47	4.15e-11	1.77e-07	0.81	0.61	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	7.47	4.15e-11	1.77e-07	0.81	0.61	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	7.47	4.15e-11	1.77e-07	0.81	0.61	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
THYM	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	7.47	4.16e-11	1.77e-07	0.55	0.61	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
THYM	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-7.46	4.17e-11	1.77e-07	-0.81	-0.61	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
THYM	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-7.46	4.19e-11	1.78e-07	-0.77	-0.61	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
THYM	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-7.46	4.19e-11	1.78e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-7.46	4.19e-11	1.78e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-7.46	4.19e-11	1.78e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
THYM	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-7.46	4.22e-11	1.79e-07	-0.74	-0.61	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-7.46	4.22e-11	1.79e-07	-0.74	-0.61	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
THYM	cis	rs995834	0.957	rs8105942	ENSG00000266928.1	CTB-70G10.1	-7.46	4.25e-11	1.8e-07	-0.68	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28359455	chr19:28294093~28313500:-
THYM	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-7.46	4.28e-11	1.81e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-7.46	4.28e-11	1.81e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-7.46	4.28e-11	1.81e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-7.46	4.28e-11	1.81e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
THYM	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	7.46	4.3e-11	1.82e-07	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	7.46	4.3e-11	1.82e-07	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	7.46	4.3e-11	1.82e-07	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
THYM	cis	rs5760092	0.755	rs5760096	ENSG00000225282.1	AP000350.6	7.46	4.36e-11	1.84e-07	0.82	0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905123	chr22:23926900~23929574:+
THYM	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-7.45	4.37e-11	1.85e-07	-0.91	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-7.45	4.37e-11	1.85e-07	-0.91	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
THYM	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	7.45	4.38e-11	1.85e-07	0.67	0.61	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
THYM	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	7.45	4.4e-11	1.86e-07	0.56	0.61	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
THYM	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-7.45	4.42e-11	1.87e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
THYM	cis	rs995834	0.789	rs11083486	ENSG00000266928.1	CTB-70G10.1	-7.45	4.42e-11	1.87e-07	-0.74	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407449	chr19:28294093~28313500:-
THYM	cis	rs995834	0.789	rs10421826	ENSG00000266928.1	CTB-70G10.1	-7.45	4.42e-11	1.87e-07	-0.74	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28408275	chr19:28294093~28313500:-
THYM	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	7.45	4.44e-11	1.87e-07	0.83	0.61	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
THYM	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-7.45	4.45e-11	1.88e-07	-0.72	-0.61	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
THYM	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	7.45	4.47e-11	1.89e-07	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
THYM	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-7.45	4.5e-11	1.9e-07	-0.71	-0.61	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
THYM	cis	rs2739330	0.734	rs2000467	ENSG00000272787.1	KB-226F1.2	7.45	4.51e-11	1.9e-07	0.7	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23969211~23969873:+
THYM	cis	rs9326248	0.608	rs1076485	ENSG00000254851.1	RP11-109L13.1	7.45	4.56e-11	1.92e-07	0.91	0.61	Blood protein levels;	chr11:116901725	chr11:117135528~117138582:+
THYM	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	7.45	4.58e-11	1.92e-07	0.79	0.61	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	7.45	4.58e-11	1.92e-07	0.79	0.61	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-7.45	4.58e-11	1.92e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-7.45	4.58e-11	1.92e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-7.45	4.58e-11	1.92e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-7.45	4.58e-11	1.92e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-7.45	4.58e-11	1.92e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-7.45	4.58e-11	1.92e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-7.44	4.59e-11	1.93e-07	-0.85	-0.61	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-7.44	4.59e-11	1.93e-07	-0.85	-0.61	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-7.44	4.59e-11	1.93e-07	-0.85	-0.61	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-7.44	4.59e-11	1.93e-07	-0.85	-0.61	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-7.44	4.59e-11	1.93e-07	-0.85	-0.61	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-7.44	4.59e-11	1.93e-07	-0.85	-0.61	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-7.44	4.59e-11	1.93e-07	-0.85	-0.61	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
THYM	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	7.44	4.66e-11	1.95e-07	0.55	0.61	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
THYM	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-7.44	4.69e-11	1.96e-07	-0.52	-0.61	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
THYM	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-7.44	4.74e-11	1.98e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
THYM	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	7.44	4.74e-11	1.98e-07	0.67	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
THYM	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	7.44	4.77e-11	1.99e-07	0.83	0.61	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	7.44	4.77e-11	1.99e-07	0.83	0.61	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
THYM	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-7.44	4.8e-11	2e-07	-0.61	-0.61	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
THYM	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-7.43	4.89e-11	2.03e-07	-0.72	-0.61	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
THYM	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-7.43	4.95e-11	2.06e-07	-0.74	-0.61	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-7.43	4.95e-11	2.06e-07	-0.74	-0.61	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
THYM	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
THYM	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-7.42	5.07e-11	2.1e-07	-0.8	-0.61	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
THYM	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	7.42	5.09e-11	2.11e-07	0.88	0.61	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
THYM	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	7.42	5.11e-11	2.11e-07	0.7	0.61	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	7.42	5.11e-11	2.11e-07	0.7	0.61	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
THYM	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-7.42	5.11e-11	2.12e-07	-0.8	-0.61	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
THYM	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	7.42	5.13e-11	2.12e-07	0.67	0.61	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
THYM	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	7.42	5.16e-11	2.14e-07	0.5	0.61	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
THYM	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	7.42	5.17e-11	2.14e-07	0.69	0.61	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
THYM	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
THYM	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	7.42	5.18e-11	2.14e-07	0.52	0.61	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
THYM	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-7.42	5.19e-11	2.14e-07	-0.74	-0.61	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
THYM	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-7.42	5.26e-11	2.17e-07	-0.92	-0.61	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-7.42	5.26e-11	2.17e-07	-0.92	-0.61	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
THYM	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	7.41	5.33e-11	2.2e-07	0.6	0.61	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	7.41	5.33e-11	2.2e-07	0.6	0.61	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
THYM	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	7.41	5.36e-11	2.21e-07	0.74	0.61	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
THYM	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-7.41	5.37e-11	2.22e-07	-0.82	-0.61	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
THYM	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-7.41	5.38e-11	2.22e-07	-0.74	-0.61	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
THYM	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-7.41	5.39e-11	2.22e-07	-0.7	-0.61	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
THYM	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	7.41	5.41e-11	2.23e-07	0.7	0.61	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
THYM	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-7.41	5.41e-11	2.23e-07	-0.74	-0.61	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
THYM	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	7.41	5.5e-11	2.26e-07	0.77	0.61	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
THYM	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-7.41	5.5e-11	2.26e-07	-0.77	-0.61	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
THYM	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-7.41	5.5e-11	2.26e-07	-0.77	-0.61	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
THYM	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	7.41	5.52e-11	2.26e-07	0.59	0.61	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	7.41	5.52e-11	2.26e-07	0.59	0.61	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	7.41	5.52e-11	2.26e-07	0.59	0.61	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	7.41	5.52e-11	2.26e-07	0.59	0.61	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	7.41	5.52e-11	2.26e-07	0.59	0.61	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-7.41	5.52e-11	2.26e-07	-0.59	-0.61	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
THYM	cis	rs995834	0.743	rs4806332	ENSG00000267320.4	AC005780.1	-7.41	5.54e-11	2.27e-07	-0.64	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28366100	chr19:28316705~28386204:-
THYM	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	7.4	5.55e-11	2.27e-07	0.52	0.61	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
THYM	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-7.4	5.56e-11	2.28e-07	-0.74	-0.61	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-7.4	5.56e-11	2.28e-07	-0.74	-0.61	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-7.4	5.56e-11	2.28e-07	-0.74	-0.61	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-7.4	5.56e-11	2.28e-07	-0.74	-0.61	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-7.4	5.56e-11	2.28e-07	-0.74	-0.61	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
THYM	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	7.4	5.57e-11	2.28e-07	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
THYM	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-7.4	5.6e-11	2.29e-07	-0.69	-0.61	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
THYM	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-7.4	5.63e-11	2.31e-07	-0.74	-0.61	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-7.4	5.63e-11	2.31e-07	-0.74	-0.61	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-7.4	5.63e-11	2.31e-07	-0.74	-0.61	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
THYM	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-7.4	5.65e-11	2.31e-07	-0.8	-0.61	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
THYM	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-7.4	5.69e-11	2.33e-07	-0.66	-0.61	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
THYM	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-7.4	5.75e-11	2.34e-07	-0.74	-0.61	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-7.4	5.77e-11	2.35e-07	-0.74	-0.61	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-7.4	5.77e-11	2.35e-07	-0.74	-0.61	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
THYM	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-7.4	5.78e-11	2.36e-07	-0.86	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
THYM	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	7.39	5.83e-11	2.38e-07	0.66	0.61	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
THYM	cis	rs2739330	0.828	rs4822454	ENSG00000272787.1	KB-226F1.2	-7.39	5.86e-11	2.39e-07	-0.69	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.796	rs2154594	ENSG00000272787.1	KB-226F1.2	7.39	5.86e-11	2.39e-07	0.69	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.828	rs2186366	ENSG00000272787.1	KB-226F1.2	7.39	5.86e-11	2.39e-07	0.69	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23969211~23969873:+
THYM	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-7.39	5.89e-11	2.4e-07	-0.81	-0.61	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-7.39	5.89e-11	2.4e-07	-0.81	-0.61	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
THYM	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	7.39	5.9e-11	2.4e-07	0.78	0.61	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
THYM	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	7.39	5.91e-11	2.4e-07	0.85	0.61	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
THYM	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-7.39	6.09e-11	2.47e-07	-0.73	-0.61	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
THYM	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	7.38	6.15e-11	2.5e-07	0.48	0.61	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
THYM	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	7.38	6.17e-11	2.51e-07	0.79	0.61	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-7.38	6.17e-11	2.51e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
THYM	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-7.38	6.17e-11	2.51e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-7.38	6.17e-11	2.51e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-7.38	6.17e-11	2.51e-07	-0.79	-0.61	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
THYM	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	7.38	6.3e-11	2.56e-07	0.6	0.61	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
THYM	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	7.38	6.34e-11	2.57e-07	0.59	0.61	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	7.38	6.34e-11	2.57e-07	0.59	0.61	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	7.38	6.34e-11	2.57e-07	0.59	0.61	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
THYM	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-7.38	6.36e-11	2.58e-07	-0.75	-0.61	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
THYM	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	7.38	6.36e-11	2.58e-07	0.59	0.61	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
THYM	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	7.38	6.37e-11	2.58e-07	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
THYM	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-7.37	6.4e-11	2.59e-07	-0.73	-0.61	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-7.37	6.4e-11	2.59e-07	-0.73	-0.61	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
THYM	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-7.37	6.4e-11	2.59e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-7.37	6.46e-11	2.61e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-7.37	6.46e-11	2.61e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-7.37	6.46e-11	2.61e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
THYM	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-7.37	6.48e-11	2.62e-07	-0.71	-0.61	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
THYM	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-7.37	6.51e-11	2.63e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-7.37	6.51e-11	2.63e-07	-0.7	-0.61	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
THYM	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-7.37	6.54e-11	2.64e-07	-0.74	-0.61	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
THYM	cis	rs1426063	0.858	rs10004802	ENSG00000248165.1	RP11-44F21.2	7.37	6.55e-11	2.65e-07	1.26	0.61	QT interval;	chr4:75084413	chr4:74993877~75034824:-
THYM	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	7.37	6.58e-11	2.66e-07	0.78	0.61	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
THYM	cis	rs5760092	0.755	rs5760096	ENSG00000218537.1	MIF-AS1	7.37	6.67e-11	2.69e-07	0.84	0.6	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905123	chr22:23894426~23898930:-
THYM	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	7.37	6.68e-11	2.69e-07	0.54	0.6	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
THYM	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	7.36	6.73e-11	2.71e-07	0.73	0.6	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
THYM	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-7.36	6.74e-11	2.72e-07	-0.7	-0.6	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	7.36	6.74e-11	2.72e-07	0.7	0.6	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
THYM	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	7.36	6.76e-11	2.72e-07	0.54	0.6	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	7.36	6.76e-11	2.72e-07	0.54	0.6	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
THYM	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-7.36	6.81e-11	2.74e-07	-0.87	-0.6	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
THYM	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	7.36	6.85e-11	2.75e-07	0.87	0.6	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	7.36	6.85e-11	2.75e-07	0.87	0.6	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
THYM	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	7.36	6.88e-11	2.75e-07	0.54	0.6	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
THYM	cis	rs995834	0.742	rs2159326	ENSG00000267320.4	AC005780.1	-7.36	6.94e-11	2.77e-07	-0.7	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28338023	chr19:28316705~28386204:-
THYM	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-7.36	6.94e-11	2.78e-07	-0.51	-0.6	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
THYM	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-7.36	6.96e-11	2.78e-07	-0.55	-0.6	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
THYM	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-7.36	6.98e-11	2.79e-07	-0.71	-0.6	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
THYM	cis	rs5760092	0.717	rs5760101	ENSG00000225282.1	AP000350.6	7.35	7.2e-11	2.88e-07	0.81	0.6	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906525	chr22:23926900~23929574:+
THYM	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-7.35	7.21e-11	2.88e-07	-0.69	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-7.35	7.21e-11	2.88e-07	-0.69	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
THYM	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-7.35	7.21e-11	2.88e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
THYM	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-7.35	7.27e-11	2.9e-07	-0.84	-0.6	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-7.35	7.27e-11	2.9e-07	-0.84	-0.6	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-7.35	7.27e-11	2.9e-07	-0.84	-0.6	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
THYM	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-7.34	7.42e-11	2.96e-07	-0.8	-0.6	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
THYM	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-7.34	7.48e-11	2.98e-07	-0.73	-0.6	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
THYM	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	7.34	7.53e-11	3e-07	0.62	0.6	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
THYM	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	7.34	7.53e-11	3e-07	0.52	0.6	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
THYM	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	7.34	7.56e-11	3.01e-07	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
THYM	cis	rs673078	0.66	rs61943525	ENSG00000275409.1	RP11-131L12.4	-7.34	7.58e-11	3.02e-07	-0.83	-0.6	Glucose homeostasis traits;	chr12:118152927	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-7.34	7.58e-11	3.02e-07	-0.83	-0.6	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-7.34	7.58e-11	3.02e-07	-0.83	-0.6	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-7.34	7.58e-11	3.02e-07	-0.83	-0.6	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-7.34	7.58e-11	3.02e-07	-0.83	-0.6	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-7.34	7.58e-11	3.02e-07	-0.83	-0.6	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-7.34	7.58e-11	3.02e-07	-0.83	-0.6	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
THYM	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	7.34	7.68e-11	3.05e-07	0.63	0.6	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
THYM	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	7.34	7.7e-11	3.06e-07	0.74	0.6	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-7.34	7.7e-11	3.06e-07	-0.74	-0.6	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-7.34	7.7e-11	3.06e-07	-0.74	-0.6	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-7.34	7.7e-11	3.06e-07	-0.74	-0.6	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-7.34	7.7e-11	3.06e-07	-0.74	-0.6	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
THYM	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-7.34	7.7e-11	3.06e-07	-0.74	-0.6	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-7.34	7.7e-11	3.06e-07	-0.74	-0.6	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
THYM	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	7.34	7.71e-11	3.06e-07	0.83	0.6	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-7.34	7.71e-11	3.06e-07	-0.83	-0.6	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-7.34	7.71e-11	3.06e-07	-0.83	-0.6	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
THYM	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	7.34	7.71e-11	3.06e-07	0.87	0.6	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
THYM	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	7.33	7.81e-11	3.09e-07	0.83	0.6	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	7.33	7.81e-11	3.09e-07	0.83	0.6	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
THYM	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	7.33	7.81e-11	3.09e-07	0.83	0.6	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
THYM	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-7.33	8.02e-11	3.17e-07	-0.6	-0.6	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-7.33	8.02e-11	3.17e-07	-0.6	-0.6	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-7.33	8.02e-11	3.17e-07	-0.6	-0.6	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
THYM	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	7.33	8.1e-11	3.2e-07	0.55	0.6	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
THYM	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	7.32	8.44e-11	3.32e-07	0.59	0.6	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
THYM	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-7.32	8.45e-11	3.32e-07	-0.81	-0.6	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
THYM	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-7.31	8.5e-11	3.34e-07	-0.8	-0.6	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
THYM	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-7.31	8.61e-11	3.38e-07	-0.77	-0.6	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
THYM	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	7.31	8.63e-11	3.39e-07	0.66	0.6	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
THYM	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-7.31	8.67e-11	3.4e-07	-0.87	-0.6	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
THYM	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	7.31	8.7e-11	3.41e-07	0.77	0.6	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
THYM	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-7.31	8.78e-11	3.44e-07	-0.73	-0.6	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
THYM	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-7.31	8.78e-11	3.44e-07	-0.87	-0.6	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
THYM	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-7.31	8.78e-11	3.44e-07	-0.87	-0.6	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
THYM	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	7.31	8.84e-11	3.46e-07	0.81	0.6	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
THYM	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
THYM	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
THYM	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
THYM	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	7.31	8.87e-11	3.46e-07	0.8	0.6	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-7.31	8.87e-11	3.46e-07	-0.8	-0.6	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
THYM	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	7.3	8.97e-11	3.49e-07	0.62	0.6	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	7.3	8.97e-11	3.49e-07	0.62	0.6	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	7.3	8.97e-11	3.49e-07	0.62	0.6	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	7.3	8.97e-11	3.49e-07	0.62	0.6	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	7.3	8.97e-11	3.49e-07	0.62	0.6	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	7.3	8.97e-11	3.49e-07	0.62	0.6	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-7.3	8.99e-11	3.5e-07	-0.78	-0.6	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
THYM	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-7.3	9.03e-11	3.51e-07	-0.92	-0.6	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-7.3	9.03e-11	3.51e-07	-0.92	-0.6	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-7.3	9.03e-11	3.51e-07	-0.92	-0.6	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-7.3	9.03e-11	3.51e-07	-0.92	-0.6	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
THYM	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-7.3	9.07e-11	3.53e-07	-0.65	-0.6	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
THYM	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	7.3	9.11e-11	3.54e-07	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	7.3	9.11e-11	3.54e-07	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
THYM	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-7.3	9.15e-11	3.56e-07	-0.53	-0.6	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
THYM	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-7.3	9.23e-11	3.58e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
THYM	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	7.29	9.41e-11	3.65e-07	0.49	0.6	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
THYM	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-7.29	9.42e-11	3.65e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
THYM	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	7.29	9.47e-11	3.67e-07	0.64	0.6	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
THYM	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-7.29	9.49e-11	3.68e-07	-0.77	-0.6	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
THYM	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	7.29	9.53e-11	3.69e-07	0.59	0.6	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
THYM	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	7.29	9.55e-11	3.7e-07	0.73	0.6	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
THYM	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	7.29	9.6e-11	3.71e-07	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
THYM	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	7.29	9.6e-11	3.71e-07	0.71	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
THYM	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-7.29	9.64e-11	3.73e-07	-0.9	-0.6	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
THYM	cis	rs904251	0.523	rs12202055	ENSG00000279942.1	RP1-153P14.7	-7.29	9.65e-11	3.73e-07	-0.75	-0.6	Cognitive performance;	chr6:37518304	chr6:37567716~37571460:+
THYM	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	7.29	9.73e-11	3.76e-07	0.54	0.6	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-7.28	9.84e-11	3.8e-07	-0.6	-0.6	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
THYM	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	7.28	9.85e-11	3.8e-07	0.67	0.6	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
THYM	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-7.28	9.91e-11	3.82e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-7.28	9.94e-11	3.83e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
THYM	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	7.28	9.98e-11	3.85e-07	0.58	0.6	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
THYM	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-7.28	9.99e-11	3.85e-07	-0.86	-0.6	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
THYM	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-7.28	1e-10	3.86e-07	-0.69	-0.6	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-7.28	1e-10	3.86e-07	-0.69	-0.6	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-7.28	1e-10	3.86e-07	-0.69	-0.6	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
THYM	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	7.28	1.03e-10	3.94e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
THYM	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-7.27	1.05e-10	4.02e-07	-0.86	-0.6	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
THYM	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-7.27	1.06e-10	4.06e-07	-0.62	-0.6	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
THYM	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
THYM	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
THYM	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-7.27	1.07e-10	4.1e-07	-0.62	-0.6	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-7.27	1.07e-10	4.1e-07	-0.62	-0.6	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
THYM	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
THYM	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
THYM	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
THYM	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.1e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.11e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-7.27	1.07e-10	4.11e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
THYM	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	7.26	1.09e-10	4.15e-07	0.58	0.6	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	7.26	1.09e-10	4.15e-07	0.58	0.6	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
THYM	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-7.26	1.09e-10	4.15e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-7.26	1.09e-10	4.15e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-7.26	1.09e-10	4.15e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
THYM	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	7.26	1.09e-10	4.16e-07	0.72	0.6	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
THYM	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-7.26	1.09e-10	4.17e-07	-0.72	-0.6	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
THYM	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	7.26	1.09e-10	4.18e-07	0.66	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
THYM	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-7.26	1.1e-10	4.19e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
THYM	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	7.26	1.1e-10	4.19e-07	0.66	0.6	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
THYM	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	7.26	1.1e-10	4.21e-07	0.74	0.6	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
THYM	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	7.26	1.11e-10	4.22e-07	0.81	0.6	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	7.26	1.11e-10	4.22e-07	0.81	0.6	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
THYM	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	7.26	1.11e-10	4.22e-07	0.81	0.6	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	7.26	1.11e-10	4.22e-07	0.81	0.6	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	7.26	1.11e-10	4.22e-07	0.81	0.6	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
THYM	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-7.26	1.12e-10	4.26e-07	-0.73	-0.6	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
THYM	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-7.26	1.12e-10	4.27e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
THYM	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-7.26	1.12e-10	4.27e-07	-0.68	-0.6	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
THYM	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	7.26	1.13e-10	4.29e-07	0.72	0.6	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
THYM	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-7.25	1.13e-10	4.32e-07	-0.8	-0.6	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
THYM	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	7.25	1.14e-10	4.34e-07	0.64	0.6	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
THYM	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-7.25	1.14e-10	4.34e-07	-0.76	-0.6	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
THYM	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-7.25	1.15e-10	4.35e-07	-0.72	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
THYM	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	7.25	1.15e-10	4.35e-07	0.72	0.6	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
THYM	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	7.25	1.15e-10	4.35e-07	0.72	0.6	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
THYM	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	7.25	1.15e-10	4.35e-07	0.72	0.6	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
THYM	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-7.25	1.15e-10	4.36e-07	-0.89	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
THYM	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-7.25	1.15e-10	4.36e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
THYM	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-7.25	1.15e-10	4.36e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
THYM	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	7.25	1.15e-10	4.36e-07	0.67	0.6	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
THYM	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	7.25	1.15e-10	4.38e-07	0.5	0.6	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
THYM	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-7.25	1.16e-10	4.39e-07	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
THYM	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	7.25	1.17e-10	4.42e-07	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
THYM	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-7.25	1.17e-10	4.45e-07	-0.9	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-7.25	1.17e-10	4.45e-07	-0.9	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-7.25	1.17e-10	4.45e-07	-0.9	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
THYM	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	7.25	1.18e-10	4.45e-07	0.62	0.6	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
THYM	cis	rs995834	0.912	rs12150882	ENSG00000260725.1	AC005307.1	-7.24	1.19e-10	4.49e-07	-0.55	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362126	chr19:28418483~28429490:-
THYM	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-7.24	1.21e-10	4.57e-07	-0.69	-0.6	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-7.24	1.21e-10	4.57e-07	-0.69	-0.6	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
THYM	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.24	1.21e-10	4.58e-07	-0.72	-0.6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
THYM	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	7.24	1.22e-10	4.6e-07	0.6	0.6	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
THYM	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	7.24	1.23e-10	4.63e-07	0.52	0.6	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
THYM	cis	rs995834	0.742	rs2159326	ENSG00000266928.1	CTB-70G10.1	-7.24	1.24e-10	4.67e-07	-0.74	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28338023	chr19:28294093~28313500:-
THYM	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-7.23	1.25e-10	4.71e-07	-0.8	-0.6	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
THYM	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-7.23	1.25e-10	4.71e-07	-0.67	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
THYM	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	7.23	1.25e-10	4.72e-07	0.8	0.6	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
THYM	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	7.23	1.26e-10	4.74e-07	0.7	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
THYM	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	7.23	1.28e-10	4.83e-07	0.81	0.6	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
THYM	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	7.23	1.28e-10	4.83e-07	0.73	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
THYM	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-7.23	1.3e-10	4.88e-07	-0.69	-0.6	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
THYM	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	7.22	1.31e-10	4.92e-07	0.64	0.6	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
THYM	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-7.22	1.31e-10	4.92e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-7.22	1.31e-10	4.92e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-7.22	1.31e-10	4.92e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-7.22	1.31e-10	4.92e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-7.22	1.31e-10	4.92e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-7.22	1.31e-10	4.92e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-7.22	1.31e-10	4.92e-07	-1.06	-0.6	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
THYM	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	7.22	1.31e-10	4.92e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	7.22	1.31e-10	4.92e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	7.22	1.31e-10	4.92e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	7.22	1.31e-10	4.92e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	7.22	1.31e-10	4.92e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	7.22	1.31e-10	4.92e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	7.22	1.31e-10	4.92e-07	0.83	0.6	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
THYM	cis	rs2739330	0.828	rs5760107	ENSG00000272787.1	KB-226F1.2	-7.22	1.32e-10	4.94e-07	-0.67	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.789	rs5760109	ENSG00000272787.1	KB-226F1.2	-7.22	1.32e-10	4.94e-07	-0.67	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23969211~23969873:+
THYM	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	7.22	1.32e-10	4.94e-07	0.8	0.6	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
THYM	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	7.22	1.32e-10	4.95e-07	0.53	0.6	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
THYM	cis	rs2739330	0.828	rs2330635	ENSG00000272787.1	KB-226F1.2	-7.22	1.33e-10	4.98e-07	-0.67	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.828	rs5760098	ENSG00000272787.1	KB-226F1.2	-7.22	1.34e-10	4.99e-07	-0.68	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.796	rs5760097	ENSG00000272787.1	KB-226F1.2	-7.22	1.35e-10	5.04e-07	-0.69	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.828	rs5760102	ENSG00000272787.1	KB-226F1.2	-7.22	1.35e-10	5.04e-07	-0.69	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23969211~23969873:+
THYM	cis	rs995834	1	rs7250520	ENSG00000260725.1	AC005307.1	-7.22	1.35e-10	5.05e-07	-0.55	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376844	chr19:28418483~28429490:-
THYM	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	7.22	1.36e-10	5.08e-07	0.71	0.6	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
THYM	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	7.21	1.37e-10	5.1e-07	0.8	0.6	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
THYM	cis	rs904251	0.766	rs1757175	ENSG00000227920.2	RP1-153P14.5	-7.21	1.39e-10	5.17e-07	-0.84	-0.6	Cognitive performance;	chr6:37518918	chr6:37545145~37550860:+
THYM	cis	rs904251	0.828	rs1757174	ENSG00000227920.2	RP1-153P14.5	-7.21	1.39e-10	5.17e-07	-0.84	-0.6	Cognitive performance;	chr6:37518919	chr6:37545145~37550860:+
THYM	cis	rs904251	0.861	rs1757173	ENSG00000227920.2	RP1-153P14.5	-7.21	1.39e-10	5.17e-07	-0.84	-0.6	Cognitive performance;	chr6:37519176	chr6:37545145~37550860:+
THYM	cis	rs904251	0.861	rs1757169	ENSG00000227920.2	RP1-153P14.5	-7.21	1.39e-10	5.17e-07	-0.84	-0.6	Cognitive performance;	chr6:37519300	chr6:37545145~37550860:+
THYM	cis	rs904251	0.861	rs2776877	ENSG00000227920.2	RP1-153P14.5	-7.21	1.39e-10	5.17e-07	-0.84	-0.6	Cognitive performance;	chr6:37519359	chr6:37545145~37550860:+
THYM	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	7.21	1.4e-10	5.22e-07	0.6	0.6	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
THYM	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	7.21	1.41e-10	5.26e-07	0.82	0.6	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
THYM	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-7.21	1.42e-10	5.28e-07	-0.71	-0.6	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
THYM	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-7.21	1.42e-10	5.28e-07	-0.71	-0.6	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
THYM	cis	rs2739330	0.828	rs4820572	ENSG00000272787.1	KB-226F1.2	-7.21	1.43e-10	5.31e-07	-0.67	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.796	rs5760106	ENSG00000272787.1	KB-226F1.2	7.21	1.43e-10	5.31e-07	0.67	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23969211~23969873:+
THYM	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-7.2	1.45e-10	5.4e-07	-0.75	-0.6	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
THYM	cis	rs995834	0.789	rs4806372	ENSG00000260725.1	AC005307.1	7.2	1.46e-10	5.42e-07	0.57	0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403612	chr19:28418483~28429490:-
THYM	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	7.2	1.46e-10	5.42e-07	0.53	0.6	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
THYM	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	7.2	1.46e-10	5.43e-07	1.11	0.6	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
THYM	cis	rs904251	0.523	rs914348	ENSG00000279942.1	RP1-153P14.7	-7.2	1.48e-10	5.49e-07	-0.78	-0.6	Cognitive performance;	chr6:37516953	chr6:37567716~37571460:+
THYM	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	7.19	1.5e-10	5.57e-07	0.72	0.6	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
THYM	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	7.19	1.5e-10	5.57e-07	0.48	0.6	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	7.19	1.5e-10	5.57e-07	0.48	0.6	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
THYM	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	7.19	1.55e-10	5.73e-07	0.66	0.6	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
THYM	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	7.19	1.55e-10	5.73e-07	1.11	0.6	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	7.19	1.55e-10	5.73e-07	1.11	0.6	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
THYM	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-7.19	1.56e-10	5.76e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-7.19	1.56e-10	5.76e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-7.19	1.56e-10	5.76e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-7.19	1.56e-10	5.76e-07	-0.69	-0.6	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-7.19	1.56e-10	5.76e-07	-0.69	-0.6	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
THYM	cis	rs694739	0.861	rs479552	ENSG00000236935.1	AP003774.1	7.19	1.56e-10	5.78e-07	0.45	0.6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343211	chr11:64325050~64329504:-
THYM	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	7.19	1.57e-10	5.79e-07	0.51	0.6	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	7.19	1.57e-10	5.79e-07	0.51	0.6	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	7.19	1.57e-10	5.79e-07	0.51	0.6	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
THYM	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-7.19	1.57e-10	5.79e-07	-0.76	-0.6	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
THYM	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-7.18	1.58e-10	5.84e-07	-0.65	-0.6	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-7.18	1.58e-10	5.84e-07	-0.65	-0.6	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
THYM	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	7.18	1.59e-10	5.86e-07	0.67	0.6	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
THYM	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-7.18	1.6e-10	5.89e-07	-0.69	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
THYM	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-7.18	1.6e-10	5.89e-07	-0.71	-0.6	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	7.18	1.6e-10	5.89e-07	0.71	0.6	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
THYM	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	7.18	1.61e-10	5.91e-07	0.63	0.6	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	7.18	1.61e-10	5.92e-07	0.64	0.6	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
THYM	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	7.18	1.61e-10	5.94e-07	0.54	0.6	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
THYM	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-7.18	1.63e-10	5.97e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-7.18	1.63e-10	5.97e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-7.18	1.63e-10	5.97e-07	-0.67	-0.6	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
THYM	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	7.18	1.63e-10	5.98e-07	0.63	0.6	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
THYM	cis	rs995834	0.957	rs2109066	ENSG00000266928.1	CTB-70G10.1	-7.18	1.63e-10	5.98e-07	-0.66	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344420	chr19:28294093~28313500:-
THYM	cis	rs995834	0.957	rs2159327	ENSG00000266928.1	CTB-70G10.1	-7.18	1.63e-10	5.98e-07	-0.66	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344664	chr19:28294093~28313500:-
THYM	cis	rs995834	0.957	rs7248916	ENSG00000266928.1	CTB-70G10.1	-7.18	1.63e-10	5.98e-07	-0.66	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344916	chr19:28294093~28313500:-
THYM	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-7.18	1.63e-10	5.99e-07	-0.73	-0.59	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-7.18	1.63e-10	5.99e-07	-0.73	-0.59	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
THYM	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
THYM	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	7.18	1.63e-10	5.99e-07	0.64	0.59	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
THYM	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	7.18	1.65e-10	6.04e-07	0.71	0.59	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	7.18	1.65e-10	6.04e-07	0.71	0.59	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	7.18	1.65e-10	6.04e-07	0.71	0.59	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
THYM	cis	rs673078	0.607	rs7974375	ENSG00000275409.1	RP11-131L12.4	-7.17	1.66e-10	6.08e-07	-0.77	-0.59	Glucose homeostasis traits;	chr12:118147893	chr12:118430147~118430699:+
THYM	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-7.17	1.68e-10	6.14e-07	-0.76	-0.59	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
THYM	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	7.17	1.68e-10	6.15e-07	0.64	0.59	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
THYM	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-7.17	1.68e-10	6.16e-07	-0.76	-0.59	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
THYM	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-7.17	1.69e-10	6.16e-07	-0.78	-0.59	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
THYM	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	7.17	1.7e-10	6.21e-07	0.68	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	7.17	1.7e-10	6.21e-07	0.68	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
THYM	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	7.17	1.71e-10	6.22e-07	1.11	0.59	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
THYM	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	7.17	1.71e-10	6.22e-07	0.72	0.59	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
THYM	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	7.17	1.71e-10	6.22e-07	0.66	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
THYM	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	7.17	1.72e-10	6.25e-07	0.66	0.59	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
THYM	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	7.17	1.72e-10	6.27e-07	0.63	0.59	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	7.17	1.72e-10	6.27e-07	0.63	0.59	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
THYM	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	7.16	1.75e-10	6.36e-07	0.71	0.59	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
THYM	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	7.16	1.75e-10	6.36e-07	1.08	0.59	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
THYM	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-7.16	1.76e-10	6.38e-07	-0.49	-0.59	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
THYM	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	7.16	1.77e-10	6.4e-07	0.51	0.59	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	7.16	1.77e-10	6.4e-07	0.51	0.59	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
THYM	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-7.16	1.77e-10	6.42e-07	-0.83	-0.59	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
THYM	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	7.16	1.78e-10	6.44e-07	0.71	0.59	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	7.16	1.79e-10	6.47e-07	0.69	0.59	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
THYM	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-7.16	1.79e-10	6.48e-07	-0.92	-0.59	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
THYM	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-7.16	1.79e-10	6.48e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
THYM	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-7.16	1.8e-10	6.51e-07	-0.58	-0.59	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
THYM	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	7.15	1.83e-10	6.61e-07	0.66	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
THYM	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-7.15	1.83e-10	6.62e-07	-0.8	-0.59	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
THYM	cis	rs904251	0.864	rs2797801	ENSG00000227920.2	RP1-153P14.5	-7.15	1.89e-10	6.82e-07	-0.85	-0.59	Cognitive performance;	chr6:37519385	chr6:37545145~37550860:+
THYM	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	7.14	1.93e-10	6.94e-07	1.08	0.59	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
THYM	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	7.14	1.94e-10	6.99e-07	0.79	0.59	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	7.14	1.95e-10	7.02e-07	0.8	0.59	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
THYM	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	7.14	1.95e-10	7.02e-07	0.8	0.59	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
THYM	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-7.14	1.97e-10	7.07e-07	-0.72	-0.59	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
THYM	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	7.14	1.97e-10	7.09e-07	0.64	0.59	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
THYM	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	7.13	2e-10	7.17e-07	0.51	0.59	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	7.13	2e-10	7.17e-07	0.51	0.59	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	7.13	2e-10	7.17e-07	0.51	0.59	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
THYM	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	7.13	2e-10	7.19e-07	0.61	0.59	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	7.13	2e-10	7.19e-07	0.61	0.59	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	7.13	2e-10	7.19e-07	0.61	0.59	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	7.13	2e-10	7.19e-07	0.61	0.59	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	7.13	2e-10	7.19e-07	0.61	0.59	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
THYM	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-7.13	2.02e-10	7.22e-07	-0.66	-0.59	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-7.13	2.02e-10	7.22e-07	-0.66	-0.59	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
THYM	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-7.13	2.02e-10	7.22e-07	-0.66	-0.59	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
THYM	cis	rs904251	0.861	rs2776875	ENSG00000227920.2	RP1-153P14.5	-7.13	2.02e-10	7.23e-07	-0.83	-0.59	Cognitive performance;	chr6:37519020	chr6:37545145~37550860:+
THYM	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	7.13	2.02e-10	7.24e-07	0.71	0.59	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
THYM	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	7.13	2.03e-10	7.26e-07	0.76	0.59	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
THYM	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-7.13	2.04e-10	7.28e-07	-0.81	-0.59	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
THYM	cis	rs5760092	0.717	rs5760101	ENSG00000218537.1	MIF-AS1	7.13	2.05e-10	7.34e-07	0.83	0.59	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906525	chr22:23894426~23898930:-
THYM	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-7.13	2.06e-10	7.35e-07	-0.65	-0.59	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-7.13	2.06e-10	7.35e-07	-0.65	-0.59	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
THYM	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-7.13	2.06e-10	7.35e-07	-0.7	-0.59	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
THYM	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-7.13	2.06e-10	7.35e-07	-0.7	-0.59	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
THYM	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-7.13	2.07e-10	7.38e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-7.13	2.07e-10	7.38e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-7.13	2.07e-10	7.38e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-7.13	2.07e-10	7.38e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-7.13	2.07e-10	7.38e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-7.13	2.07e-10	7.38e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
THYM	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-7.13	2.08e-10	7.4e-07	-0.66	-0.59	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
THYM	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-7.13	2.09e-10	7.43e-07	-0.68	-0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
THYM	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-7.12	2.09e-10	7.46e-07	-0.66	-0.59	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
THYM	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-7.12	2.09e-10	7.46e-07	-0.66	-0.59	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
THYM	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-7.12	2.14e-10	7.62e-07	-0.65	-0.59	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
THYM	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-7.12	2.14e-10	7.62e-07	-0.77	-0.59	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
THYM	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	7.12	2.14e-10	7.62e-07	0.72	0.59	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
THYM	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	7.12	2.16e-10	7.67e-07	0.68	0.59	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	7.12	2.16e-10	7.67e-07	0.68	0.59	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	7.12	2.16e-10	7.67e-07	0.68	0.59	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-7.12	2.16e-10	7.67e-07	-0.68	-0.59	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
THYM	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	7.12	2.19e-10	7.75e-07	0.61	0.59	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
THYM	cis	rs904251	0.797	rs2776878	ENSG00000227920.2	RP1-153P14.5	-7.11	2.2e-10	7.8e-07	-0.87	-0.59	Cognitive performance;	chr6:37519497	chr6:37545145~37550860:+
THYM	cis	rs904251	0.828	rs2797803	ENSG00000227920.2	RP1-153P14.5	-7.11	2.2e-10	7.8e-07	-0.87	-0.59	Cognitive performance;	chr6:37519564	chr6:37545145~37550860:+
THYM	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	7.11	2.2e-10	7.8e-07	0.75	0.59	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
THYM	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	7.11	2.21e-10	7.81e-07	0.68	0.59	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
THYM	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	7.11	2.21e-10	7.81e-07	0.68	0.59	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
THYM	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-7.11	2.21e-10	7.83e-07	-0.8	-0.59	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
THYM	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	7.11	2.23e-10	7.9e-07	0.6	0.59	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
THYM	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-7.11	2.24e-10	7.91e-07	-0.67	-0.59	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
THYM	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	7.11	2.29e-10	8.08e-07	0.58	0.59	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
THYM	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-7.11	2.29e-10	8.09e-07	-0.64	-0.59	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-7.11	2.29e-10	8.09e-07	-0.64	-0.59	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
THYM	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	7.1	2.3e-10	8.11e-07	0.61	0.59	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	7.1	2.3e-10	8.11e-07	0.61	0.59	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	7.1	2.3e-10	8.11e-07	0.61	0.59	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	7.1	2.3e-10	8.11e-07	0.61	0.59	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	7.1	2.3e-10	8.11e-07	0.61	0.59	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-7.1	2.31e-10	8.13e-07	-0.74	-0.59	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
THYM	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	7.1	2.31e-10	8.15e-07	0.62	0.59	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
THYM	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	7.1	2.34e-10	8.23e-07	0.72	0.59	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
THYM	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
THYM	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
THYM	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
THYM	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
THYM	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
THYM	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
THYM	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
THYM	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
THYM	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
THYM	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
THYM	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
THYM	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
THYM	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-7.1	2.35e-10	8.24e-07	-0.79	-0.59	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
THYM	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-7.1	2.37e-10	8.29e-07	-0.72	-0.59	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
THYM	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	7.1	2.37e-10	8.3e-07	0.56	0.59	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
THYM	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	7.1	2.38e-10	8.32e-07	0.59	0.59	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
THYM	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-7.09	2.41e-10	8.42e-07	-0.67	-0.59	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
THYM	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	7.09	2.43e-10	8.48e-07	0.67	0.59	Height;	chr6:109391084	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	7.09	2.43e-10	8.48e-07	0.67	0.59	Height;	chr6:109407238	chr6:109382795~109383666:+
THYM	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-7.09	2.45e-10	8.55e-07	-1.03	-0.59	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-7.09	2.45e-10	8.55e-07	-1.03	-0.59	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-7.09	2.45e-10	8.55e-07	-1.03	-0.59	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-7.09	2.45e-10	8.55e-07	-1.03	-0.59	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-7.09	2.45e-10	8.55e-07	-1.03	-0.59	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-7.09	2.45e-10	8.55e-07	-1.03	-0.59	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-7.09	2.45e-10	8.55e-07	-1.03	-0.59	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
THYM	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	7.09	2.45e-10	8.56e-07	0.68	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	7.09	2.45e-10	8.56e-07	0.68	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	7.09	2.45e-10	8.56e-07	0.68	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
THYM	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-7.09	2.46e-10	8.59e-07	-0.63	-0.59	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
THYM	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-7.09	2.49e-10	8.68e-07	-0.85	-0.59	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
THYM	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-7.09	2.49e-10	8.68e-07	-0.8	-0.59	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-7.09	2.49e-10	8.68e-07	-0.8	-0.59	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
THYM	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	7.09	2.51e-10	8.73e-07	0.6	0.59	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
THYM	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	7.09	2.52e-10	8.76e-07	0.52	0.59	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
THYM	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	7.08	2.53e-10	8.79e-07	0.78	0.59	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
THYM	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-7.08	2.55e-10	8.85e-07	-0.77	-0.59	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
THYM	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.08	2.55e-10	8.86e-07	0.71	0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
THYM	cis	rs4691139	1	rs13134489	ENSG00000250227.1	TRIM60P14	7.08	2.56e-10	8.9e-07	0.68	0.59	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968285	chr4:164915565~164916983:+
THYM	cis	rs995834	0.585	rs8106726	ENSG00000266928.1	CTB-70G10.1	-7.08	2.59e-10	8.98e-07	-0.75	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397316	chr19:28294093~28313500:-
THYM	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-7.08	2.6e-10	9e-07	-0.76	-0.59	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
THYM	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	7.08	2.61e-10	9.03e-07	0.59	0.59	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
THYM	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	7.08	2.61e-10	9.03e-07	0.72	0.59	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
THYM	cis	rs904251	0.523	rs2776872	ENSG00000279942.1	RP1-153P14.7	-7.07	2.67e-10	9.24e-07	-0.75	-0.59	Cognitive performance;	chr6:37515011	chr6:37567716~37571460:+
THYM	cis	rs904251	0.523	rs1757191	ENSG00000279942.1	RP1-153P14.7	-7.07	2.67e-10	9.24e-07	-0.75	-0.59	Cognitive performance;	chr6:37515095	chr6:37567716~37571460:+
THYM	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	7.07	2.68e-10	9.26e-07	0.59	0.59	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
THYM	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-7.07	2.68e-10	9.27e-07	-0.78	-0.59	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-7.07	2.68e-10	9.27e-07	-0.78	-0.59	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-7.07	2.68e-10	9.27e-07	-0.78	-0.59	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
THYM	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	7.07	2.69e-10	9.28e-07	0.8	0.59	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
THYM	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	7.07	2.7e-10	9.33e-07	0.77	0.59	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	7.07	2.7e-10	9.33e-07	0.77	0.59	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	7.07	2.7e-10	9.33e-07	0.77	0.59	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
THYM	cis	rs904251	0.504	rs9380677	ENSG00000279942.1	RP1-153P14.7	-7.07	2.71e-10	9.35e-07	-0.76	-0.59	Cognitive performance;	chr6:37512590	chr6:37567716~37571460:+
THYM	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	7.07	2.72e-10	9.38e-07	1.09	0.59	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	7.07	2.72e-10	9.38e-07	1.09	0.59	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	7.07	2.72e-10	9.39e-07	1.03	0.59	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	7.07	2.72e-10	9.39e-07	1.03	0.59	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
THYM	cis	rs995834	0.789	rs758127	ENSG00000260725.1	AC005307.1	7.07	2.73e-10	9.41e-07	0.61	0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403344	chr19:28418483~28429490:-
THYM	cis	rs904251	0.523	rs2776874	ENSG00000279942.1	RP1-153P14.7	-7.07	2.74e-10	9.45e-07	-0.71	-0.59	Cognitive performance;	chr6:37515421	chr6:37567716~37571460:+
THYM	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	7.07	2.75e-10	9.46e-07	0.5	0.59	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
THYM	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-7.07	2.76e-10	9.51e-07	-0.69	-0.59	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
THYM	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-7.06	2.77e-10	9.54e-07	-0.7	-0.59	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
THYM	cis	rs904251	0.523	rs9369005	ENSG00000279942.1	RP1-153P14.7	-7.06	2.77e-10	9.54e-07	-0.72	-0.59	Cognitive performance;	chr6:37515333	chr6:37567716~37571460:+
THYM	cis	rs995834	0.912	rs2058192	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346236	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs4806319	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346419	chr19:28418483~28429490:-
THYM	cis	rs995834	0.872	rs10408276	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346667	chr19:28418483~28429490:-
THYM	cis	rs995834	0.872	rs28612438	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348957	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs7256199	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350657	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs7252509	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350710	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs7258117	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353475	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs10402976	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353776	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs10403247	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354139	chr19:28418483~28429490:-
THYM	cis	rs995834	0.797	rs10401181	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354223	chr19:28418483~28429490:-
THYM	cis	rs995834	0.912	rs12151340	ENSG00000260725.1	AC005307.1	7.06	2.78e-10	9.58e-07	0.54	0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362360	chr19:28418483~28429490:-
THYM	cis	rs995834	0.872	rs7253391	ENSG00000260725.1	AC005307.1	-7.06	2.78e-10	9.58e-07	-0.54	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28367736	chr19:28418483~28429490:-
THYM	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-7.06	2.79e-10	9.61e-07	-0.86	-0.59	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
THYM	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	7.06	2.81e-10	9.65e-07	0.58	0.59	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	7.06	2.81e-10	9.65e-07	0.58	0.59	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	7.06	2.81e-10	9.65e-07	0.58	0.59	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
THYM	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-7.06	2.82e-10	9.69e-07	-0.87	-0.59	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
THYM	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-7.06	2.83e-10	9.73e-07	-0.77	-0.59	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-7.06	2.83e-10	9.73e-07	-0.77	-0.59	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
THYM	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-7.06	2.83e-10	9.73e-07	-0.5	-0.59	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
THYM	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	7.06	2.83e-10	9.73e-07	0.5	0.59	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
THYM	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	7.06	2.86e-10	9.82e-07	0.58	0.59	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	7.06	2.88e-10	9.88e-07	0.58	0.59	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	7.06	2.88e-10	9.88e-07	0.58	0.59	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
THYM	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	7.06	2.88e-10	9.88e-07	0.64	0.59	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
THYM	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	7.05	2.9e-10	9.95e-07	0.73	0.59	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
THYM	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-7.05	2.91e-10	9.97e-07	-0.64	-0.59	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
THYM	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.05	2.95e-10	1.01e-06	-0.7	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
THYM	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	7.05	2.95e-10	1.01e-06	0.61	0.59	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
THYM	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-7.05	2.95e-10	1.01e-06	-0.6	-0.59	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
THYM	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-7.05	2.97e-10	1.01e-06	-0.78	-0.59	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-7.05	2.97e-10	1.01e-06	-0.78	-0.59	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-7.05	2.97e-10	1.01e-06	-0.78	-0.59	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
THYM	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-7.05	2.97e-10	1.01e-06	-0.78	-0.59	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-7.05	2.97e-10	1.01e-06	-0.78	-0.59	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-7.05	2.97e-10	1.01e-06	-0.78	-0.59	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
THYM	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-7.05	2.97e-10	1.01e-06	-0.78	-0.59	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
THYM	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	7.05	3e-10	1.03e-06	0.65	0.59	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
THYM	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	7.05	3.02e-10	1.03e-06	0.66	0.59	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
THYM	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	7.05	3.03e-10	1.03e-06	0.84	0.59	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
THYM	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	7.05	3.03e-10	1.03e-06	0.84	0.59	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
THYM	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	7.05	3.04e-10	1.04e-06	1.01	0.59	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
THYM	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-7.04	3.05e-10	1.04e-06	-1.11	-0.59	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
THYM	cis	rs1757171	0.542	rs3818986	ENSG00000279942.1	RP1-153P14.7	-7.04	3.08e-10	1.05e-06	-0.72	-0.59	Cognitive performance;	chr6:37516573	chr6:37567716~37571460:+
THYM	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	7.04	3.08e-10	1.05e-06	1.09	0.59	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
THYM	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	7.04	3.09e-10	1.05e-06	0.59	0.59	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
THYM	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	7.04	3.09e-10	1.05e-06	0.58	0.59	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
THYM	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	7.04	3.11e-10	1.06e-06	0.52	0.59	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	7.04	3.11e-10	1.06e-06	0.52	0.59	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	7.04	3.11e-10	1.06e-06	0.52	0.59	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	7.04	3.11e-10	1.06e-06	0.52	0.59	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	7.04	3.11e-10	1.06e-06	0.52	0.59	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
THYM	cis	rs904251	0.523	rs1776455	ENSG00000279942.1	RP1-153P14.7	-7.04	3.12e-10	1.06e-06	-0.77	-0.59	Cognitive performance;	chr6:37515147	chr6:37567716~37571460:+
THYM	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-7.04	3.13e-10	1.06e-06	-0.65	-0.59	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
THYM	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-7.04	3.14e-10	1.06e-06	-0.72	-0.59	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
THYM	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	7.04	3.15e-10	1.07e-06	0.72	0.59	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
THYM	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-7.04	3.15e-10	1.07e-06	-1.06	-0.59	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-7.04	3.15e-10	1.07e-06	-1.06	-0.59	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-7.04	3.15e-10	1.07e-06	-1.06	-0.59	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-7.04	3.15e-10	1.07e-06	-1.06	-0.59	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-7.04	3.15e-10	1.07e-06	-1.06	-0.59	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-7.04	3.15e-10	1.07e-06	-1.06	-0.59	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-7.04	3.15e-10	1.07e-06	-1.06	-0.59	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
THYM	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	7.04	3.16e-10	1.07e-06	0.59	0.59	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
THYM	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	7.04	3.18e-10	1.08e-06	0.67	0.59	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
THYM	cis	rs904251	0.861	rs1757171	ENSG00000227920.2	RP1-153P14.5	-7.03	3.22e-10	1.09e-06	-0.83	-0.59	Cognitive performance;	chr6:37519268	chr6:37545145~37550860:+
THYM	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	7.03	3.22e-10	1.09e-06	0.5	0.59	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
THYM	cis	rs4691139	0.901	rs9762579	ENSG00000250227.1	TRIM60P14	7.03	3.23e-10	1.09e-06	0.69	0.59	Ovarian cancer in BRCA1 mutation carriers;	chr4:164956838	chr4:164915565~164916983:+
THYM	cis	rs2739330	0.652	rs2000469	ENSG00000272787.1	KB-226F1.2	-7.03	3.26e-10	1.1e-06	-0.69	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23969211~23969873:+
THYM	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-7.03	3.29e-10	1.11e-06	-0.81	-0.59	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-7.03	3.29e-10	1.11e-06	-0.81	-0.59	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
THYM	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	7.03	3.32e-10	1.12e-06	0.53	0.59	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
THYM	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-7.02	3.36e-10	1.13e-06	-0.8	-0.59	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
THYM	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-7.02	3.36e-10	1.13e-06	-0.8	-0.59	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
THYM	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-7.02	3.38e-10	1.14e-06	-0.81	-0.59	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
THYM	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-7.02	3.38e-10	1.14e-06	-0.81	-0.59	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
THYM	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	7.02	3.44e-10	1.16e-06	1.09	0.59	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
THYM	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-7.02	3.44e-10	1.16e-06	-0.68	-0.59	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
THYM	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	7.02	3.45e-10	1.16e-06	0.51	0.59	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
THYM	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	7.02	3.49e-10	1.17e-06	0.78	0.59	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
THYM	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-7.02	3.49e-10	1.17e-06	-0.7	-0.59	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
THYM	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-7.01	3.52e-10	1.18e-06	-0.69	-0.59	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
THYM	cis	rs995834	0.957	rs11667725	ENSG00000260725.1	AC005307.1	-7.01	3.65e-10	1.22e-06	-0.53	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28361557	chr19:28418483~28429490:-
THYM	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	7.01	3.66e-10	1.23e-06	0.67	0.59	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
THYM	cis	rs1757171	0.504	rs11969056	ENSG00000279942.1	RP1-153P14.7	-7	3.67e-10	1.23e-06	-0.76	-0.59	Cognitive performance;	chr6:37516509	chr6:37567716~37571460:+
THYM	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	7	3.7e-10	1.24e-06	0.56	0.59	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
THYM	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	7	3.72e-10	1.25e-06	0.53	0.59	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	7	3.72e-10	1.25e-06	0.53	0.59	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	7	3.72e-10	1.25e-06	0.53	0.59	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
THYM	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7	3.72e-10	1.25e-06	-0.69	-0.59	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
THYM	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-7	3.79e-10	1.27e-06	-0.79	-0.59	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
THYM	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-7	3.79e-10	1.27e-06	-0.79	-0.59	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
THYM	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-7	3.79e-10	1.27e-06	-0.79	-0.59	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
THYM	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	7	3.81e-10	1.27e-06	0.58	0.59	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
THYM	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-7	3.81e-10	1.27e-06	-0.66	-0.59	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
THYM	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-7	3.81e-10	1.27e-06	-0.66	-0.59	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
THYM	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
THYM	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
THYM	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
THYM	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-7	3.82e-10	1.28e-06	-0.67	-0.59	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
THYM	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	6.99	3.85e-10	1.28e-06	0.66	0.59	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
THYM	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-6.99	3.86e-10	1.29e-06	-0.65	-0.59	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-6.99	3.86e-10	1.29e-06	-0.65	-0.59	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-6.99	3.86e-10	1.29e-06	-0.65	-0.59	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
THYM	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-6.99	3.86e-10	1.29e-06	-0.65	-0.59	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-6.99	3.86e-10	1.29e-06	-0.65	-0.59	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
THYM	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-6.99	3.86e-10	1.29e-06	-0.61	-0.59	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
THYM	cis	rs7829975	0.653	rs13259070	ENSG00000253893.2	FAM85B	-6.99	3.87e-10	1.29e-06	-0.78	-0.59	Mood instability;	chr8:8833277	chr8:8167819~8226614:-
THYM	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	6.99	3.89e-10	1.3e-06	0.53	0.58	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
THYM	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	6.99	3.89e-10	1.3e-06	0.75	0.58	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	6.99	3.89e-10	1.3e-06	0.75	0.58	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
THYM	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	6.99	3.93e-10	1.31e-06	0.83	0.58	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
THYM	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
THYM	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
THYM	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-6.99	3.94e-10	1.31e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
THYM	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	6.99	4.01e-10	1.33e-06	0.42	0.58	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
THYM	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-6.99	4.01e-10	1.33e-06	-0.42	-0.58	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-6.99	4.01e-10	1.33e-06	-0.42	-0.58	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-6.99	4.01e-10	1.33e-06	-0.42	-0.58	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-6.99	4.01e-10	1.33e-06	-0.42	-0.58	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
THYM	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	6.98	4.08e-10	1.36e-06	0.69	0.58	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
THYM	cis	rs11722228	0.508	rs9732	ENSG00000261490.1	RP11-448G15.3	6.98	4.09e-10	1.36e-06	0.59	0.58	Urate levels;Serum uric acid levels;Gout;	chr4:10075034	chr4:10068089~10073019:-
THYM	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	6.98	4.1e-10	1.36e-06	1.01	0.58	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
THYM	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	6.98	4.13e-10	1.37e-06	0.67	0.58	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
THYM	cis	rs11722228	0.508	rs3756227	ENSG00000261490.1	RP11-448G15.3	6.98	4.14e-10	1.37e-06	0.59	0.58	Urate levels;Serum uric acid levels;Gout;	chr4:10086371	chr4:10068089~10073019:-
THYM	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	6.98	4.14e-10	1.37e-06	0.59	0.58	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
THYM	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-6.98	4.21e-10	1.39e-06	-0.7	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-6.98	4.21e-10	1.39e-06	-0.7	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-6.98	4.21e-10	1.39e-06	-0.7	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
THYM	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	6.97	4.27e-10	1.41e-06	0.74	0.58	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
THYM	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-6.97	4.35e-10	1.44e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
THYM	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	6.97	4.42e-10	1.46e-06	0.65	0.58	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
THYM	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	6.97	4.42e-10	1.46e-06	0.59	0.58	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
THYM	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-6.97	4.42e-10	1.46e-06	-0.75	-0.58	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
THYM	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-6.96	4.48e-10	1.48e-06	-0.64	-0.58	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
THYM	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-6.96	4.5e-10	1.49e-06	-0.7	-0.58	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
THYM	cis	rs904251	0.523	rs10947675	ENSG00000279942.1	RP1-153P14.7	-6.96	4.5e-10	1.49e-06	-0.74	-0.58	Cognitive performance;	chr6:37512196	chr6:37567716~37571460:+
THYM	cis	rs904251	0.523	rs9349039	ENSG00000279942.1	RP1-153P14.7	-6.96	4.52e-10	1.49e-06	-0.78	-0.58	Cognitive performance;	chr6:37512616	chr6:37567716~37571460:+
THYM	cis	rs904251	0.523	rs9366935	ENSG00000279942.1	RP1-153P14.7	-6.96	4.52e-10	1.49e-06	-0.78	-0.58	Cognitive performance;	chr6:37512628	chr6:37567716~37571460:+
THYM	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-6.96	4.54e-10	1.5e-06	-0.62	-0.58	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
THYM	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	6.96	4.55e-10	1.5e-06	0.78	0.58	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
THYM	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-6.96	4.56e-10	1.5e-06	-0.71	-0.58	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
THYM	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-6.96	4.56e-10	1.5e-06	-1.07	-0.58	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
THYM	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-6.96	4.58e-10	1.51e-06	-0.65	-0.58	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
THYM	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	6.96	4.62e-10	1.52e-06	0.67	0.58	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
THYM	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	6.96	4.62e-10	1.52e-06	0.58	0.58	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
THYM	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-6.96	4.62e-10	1.52e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
THYM	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	6.95	4.66e-10	1.54e-06	0.6	0.58	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
THYM	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-6.95	4.72e-10	1.55e-06	-0.73	-0.58	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
THYM	cis	rs13256369	0.774	rs13260303	ENSG00000253893.2	FAM85B	-6.95	4.72e-10	1.55e-06	-0.77	-0.58	Obesity-related traits;	chr8:8729832	chr8:8167819~8226614:-
THYM	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-6.95	4.73e-10	1.55e-06	-0.5	-0.58	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
THYM	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	6.95	4.74e-10	1.56e-06	0.6	0.58	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	6.95	4.74e-10	1.56e-06	0.6	0.58	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
THYM	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-6.95	4.75e-10	1.56e-06	-0.78	-0.58	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
THYM	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	6.95	4.78e-10	1.57e-06	0.61	0.58	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	6.95	4.78e-10	1.57e-06	0.61	0.58	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
THYM	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-6.95	4.79e-10	1.57e-06	-0.64	-0.58	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
THYM	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	6.95	4.81e-10	1.58e-06	0.78	0.58	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
THYM	cis	rs7829975	0.777	rs6989926	ENSG00000253893.2	FAM85B	6.95	4.83e-10	1.59e-06	0.75	0.58	Mood instability;	chr8:8689803	chr8:8167819~8226614:-
THYM	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-6.95	4.84e-10	1.59e-06	-0.68	-0.58	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
THYM	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
THYM	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
THYM	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
THYM	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
THYM	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
THYM	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
THYM	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
THYM	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-6.94	4.86e-10	1.59e-06	-0.79	-0.58	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
THYM	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-6.94	4.87e-10	1.59e-06	-0.52	-0.58	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
THYM	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	6.94	4.91e-10	1.61e-06	0.66	0.58	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-6.94	4.91e-10	1.61e-06	-0.66	-0.58	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
THYM	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-6.94	4.92e-10	1.61e-06	-0.61	-0.58	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
THYM	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	6.94	4.98e-10	1.63e-06	0.52	0.58	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
THYM	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	6.94	5e-10	1.63e-06	0.57	0.58	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
THYM	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-6.94	5.02e-10	1.64e-06	-0.74	-0.58	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
THYM	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-6.93	5.1e-10	1.66e-06	-0.82	-0.58	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-6.93	5.1e-10	1.66e-06	-0.82	-0.58	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-6.93	5.1e-10	1.66e-06	-0.82	-0.58	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
THYM	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	6.93	5.12e-10	1.67e-06	0.71	0.58	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
THYM	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-6.93	5.14e-10	1.68e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
THYM	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	6.93	5.17e-10	1.69e-06	0.74	0.58	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
THYM	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	6.93	5.2e-10	1.69e-06	0.64	0.58	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
THYM	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	6.93	5.28e-10	1.72e-06	0.61	0.58	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
THYM	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	6.93	5.29e-10	1.72e-06	0.54	0.58	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	6.93	5.29e-10	1.72e-06	0.54	0.58	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
THYM	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-6.93	5.3e-10	1.72e-06	-0.73	-0.58	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
THYM	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	6.93	5.3e-10	1.73e-06	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
THYM	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-6.93	5.31e-10	1.73e-06	-0.8	-0.58	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
THYM	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-6.93	5.32e-10	1.73e-06	-1.09	-0.58	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
THYM	cis	rs6061231	0.675	rs755726	ENSG00000273619.1	RP5-908M14.9	-6.92	5.4e-10	1.75e-06	-0.45	-0.58	Colorectal cancer;	chr20:62387568	chr20:62386303~62386970:-
THYM	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-6.92	5.4e-10	1.75e-06	-0.65	-0.58	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-6.92	5.4e-10	1.75e-06	-0.65	-0.58	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-6.92	5.4e-10	1.75e-06	-0.65	-0.58	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-6.92	5.4e-10	1.75e-06	-0.65	-0.58	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
THYM	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	6.92	5.42e-10	1.76e-06	0.66	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	6.92	5.42e-10	1.76e-06	0.66	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
THYM	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	6.92	5.43e-10	1.76e-06	0.6	0.58	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	6.92	5.47e-10	1.77e-06	0.6	0.58	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	6.92	5.47e-10	1.77e-06	0.6	0.58	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
THYM	cis	rs904251	0.523	rs2797799	ENSG00000279942.1	RP1-153P14.7	-6.92	5.48e-10	1.77e-06	-0.74	-0.58	Cognitive performance;	chr6:37515844	chr6:37567716~37571460:+
THYM	cis	rs904251	0.504	rs1757188	ENSG00000279942.1	RP1-153P14.7	-6.92	5.48e-10	1.77e-06	-0.74	-0.58	Cognitive performance;	chr6:37516032	chr6:37567716~37571460:+
THYM	cis	rs904251	0.522	rs882322	ENSG00000279942.1	RP1-153P14.7	-6.92	5.48e-10	1.77e-06	-0.74	-0.58	Cognitive performance;	chr6:37516327	chr6:37567716~37571460:+
THYM	cis	rs1757171	0.542	rs1757186	ENSG00000279942.1	RP1-153P14.7	-6.92	5.48e-10	1.77e-06	-0.74	-0.58	Cognitive performance;	chr6:37516335	chr6:37567716~37571460:+
THYM	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-6.92	5.5e-10	1.78e-06	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
THYM	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	6.92	5.51e-10	1.78e-06	0.67	0.58	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
THYM	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	6.92	5.57e-10	1.8e-06	0.61	0.58	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
THYM	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-6.92	5.59e-10	1.81e-06	-0.64	-0.58	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
THYM	cis	rs995834	0.585	rs8106726	ENSG00000267320.4	AC005780.1	-6.91	5.6e-10	1.81e-06	-0.69	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397316	chr19:28316705~28386204:-
THYM	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-6.91	5.64e-10	1.82e-06	-1.06	-0.58	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
THYM	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-6.91	5.67e-10	1.83e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-6.91	5.67e-10	1.83e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-6.91	5.67e-10	1.83e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-6.91	5.67e-10	1.83e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-6.91	5.67e-10	1.83e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
THYM	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	6.91	5.7e-10	1.84e-06	0.74	0.58	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-6.91	5.7e-10	1.84e-06	-0.74	-0.58	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-6.91	5.7e-10	1.84e-06	-0.74	-0.58	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
THYM	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	6.91	5.79e-10	1.87e-06	0.6	0.58	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	6.91	5.79e-10	1.87e-06	0.6	0.58	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
THYM	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	6.91	5.8e-10	1.87e-06	1.07	0.58	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	6.91	5.8e-10	1.87e-06	1.07	0.58	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	6.91	5.8e-10	1.87e-06	1.07	0.58	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
THYM	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-6.9	5.9e-10	1.9e-06	-0.7	-0.58	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
THYM	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-6.9	5.96e-10	1.92e-06	-0.78	-0.58	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
THYM	cis	rs9532669	0.89	rs2149570	ENSG00000176268.5	CYCSP34	6.9	6.07e-10	1.95e-06	0.51	0.58	Cervical cancer;	chr13:40858533	chr13:40863599~40863902:-
THYM	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	6.9	6.11e-10	1.96e-06	0.69	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
THYM	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-6.89	6.15e-10	1.98e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-6.89	6.15e-10	1.98e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
THYM	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-6.89	6.17e-10	1.98e-06	-0.71	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
THYM	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-6.89	6.21e-10	2e-06	-0.69	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-6.89	6.21e-10	2e-06	-0.69	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
THYM	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	6.89	6.24e-10	2e-06	0.78	0.58	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
THYM	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	6.89	6.28e-10	2.02e-06	0.59	0.58	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
THYM	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-6.89	6.29e-10	2.02e-06	-0.64	-0.58	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
THYM	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	6.89	6.29e-10	2.02e-06	0.5	0.58	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	6.89	6.29e-10	2.02e-06	0.5	0.58	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	6.89	6.3e-10	2.02e-06	0.49	0.58	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	6.89	6.3e-10	2.02e-06	0.49	0.58	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	6.89	6.3e-10	2.02e-06	0.49	0.58	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
THYM	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	6.89	6.3e-10	2.02e-06	0.49	0.58	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
THYM	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	6.89	6.38e-10	2.03e-06	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
THYM	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-6.88	6.44e-10	2.05e-06	-0.82	-0.58	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
THYM	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	6.88	6.55e-10	2.08e-06	0.59	0.58	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
THYM	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-6.88	6.58e-10	2.09e-06	-0.62	-0.58	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
THYM	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	6.88	6.59e-10	2.1e-06	0.62	0.58	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
THYM	cis	rs11722228	0.508	rs2241473	ENSG00000261490.1	RP11-448G15.3	6.88	6.62e-10	2.1e-06	0.59	0.58	Urate levels;Serum uric acid levels;Gout;	chr4:10084325	chr4:10068089~10073019:-
THYM	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-6.88	6.66e-10	2.11e-06	-0.49	-0.58	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
THYM	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	6.88	6.67e-10	2.12e-06	0.75	0.58	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
THYM	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-6.88	6.71e-10	2.13e-06	-0.64	-0.58	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
THYM	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	6.88	6.72e-10	2.13e-06	0.59	0.58	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
THYM	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	6.88	6.72e-10	2.13e-06	0.49	0.58	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
THYM	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-6.87	6.76e-10	2.14e-06	-0.62	-0.58	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.87	6.81e-10	2.16e-06	-0.64	-0.58	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
THYM	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.87	6.81e-10	2.16e-06	-0.64	-0.58	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
THYM	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	6.87	6.84e-10	2.17e-06	0.81	0.58	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
THYM	cis	rs904251	0.523	rs10807184	ENSG00000279942.1	RP1-153P14.7	-6.87	6.84e-10	2.17e-06	-0.7	-0.58	Cognitive performance;	chr6:37515937	chr6:37567716~37571460:+
THYM	cis	rs904251	0.561	rs1757189	ENSG00000279942.1	RP1-153P14.7	-6.87	6.84e-10	2.17e-06	-0.7	-0.58	Cognitive performance;	chr6:37515951	chr6:37567716~37571460:+
THYM	cis	rs1757171	0.542	rs3818985	ENSG00000279942.1	RP1-153P14.7	-6.87	6.84e-10	2.17e-06	-0.7	-0.58	Cognitive performance;	chr6:37516438	chr6:37567716~37571460:+
THYM	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	6.87	6.87e-10	2.17e-06	0.46	0.58	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
THYM	cis	rs5760092	0.842	rs5751763	ENSG00000273295.1	AP000350.5	6.87	6.9e-10	2.18e-06	0.76	0.58	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23901432~23907068:-
THYM	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-6.87	6.99e-10	2.21e-06	-0.58	-0.58	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
THYM	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	6.86	7.07e-10	2.23e-06	0.58	0.58	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
THYM	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	6.86	7.11e-10	2.25e-06	0.65	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
THYM	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-6.86	7.12e-10	2.25e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-6.86	7.12e-10	2.25e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-6.86	7.12e-10	2.25e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-6.86	7.12e-10	2.25e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-6.86	7.12e-10	2.25e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	6.86	7.12e-10	2.25e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	6.86	7.12e-10	2.25e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	6.86	7.12e-10	2.25e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
THYM	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-6.86	7.12e-10	2.25e-06	-0.43	-0.58	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-6.86	7.12e-10	2.25e-06	-0.43	-0.58	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
THYM	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-6.86	7.12e-10	2.25e-06	-0.43	-0.58	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-6.86	7.12e-10	2.25e-06	-0.43	-0.58	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-6.86	7.12e-10	2.25e-06	-0.43	-0.58	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
THYM	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	6.86	7.29e-10	2.3e-06	0.59	0.58	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
THYM	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-6.86	7.34e-10	2.31e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-6.86	7.34e-10	2.31e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
THYM	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-6.86	7.34e-10	2.31e-06	-0.67	-0.58	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
THYM	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-6.85	7.42e-10	2.33e-06	-0.51	-0.58	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
THYM	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	6.85	7.42e-10	2.33e-06	0.59	0.58	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	6.85	7.42e-10	2.33e-06	0.59	0.58	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	6.85	7.42e-10	2.33e-06	0.59	0.58	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	6.85	7.42e-10	2.33e-06	0.59	0.58	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	6.85	7.42e-10	2.33e-06	0.59	0.58	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	6.85	7.42e-10	2.33e-06	0.59	0.58	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	6.85	7.42e-10	2.33e-06	0.59	0.58	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
THYM	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	6.85	7.43e-10	2.33e-06	0.7	0.58	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
THYM	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-6.85	7.44e-10	2.33e-06	-0.49	-0.58	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
THYM	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	6.85	7.44e-10	2.34e-06	0.77	0.58	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
THYM	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-6.85	7.44e-10	2.34e-06	-0.77	-0.58	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-6.85	7.51e-10	2.35e-06	-0.41	-0.58	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
THYM	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
THYM	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
THYM	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-6.85	7.51e-10	2.35e-06	-0.78	-0.58	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
THYM	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	6.85	7.52e-10	2.36e-06	0.59	0.58	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	6.85	7.52e-10	2.36e-06	0.59	0.58	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	6.85	7.52e-10	2.36e-06	0.59	0.58	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
THYM	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	6.85	7.6e-10	2.38e-06	0.75	0.58	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
THYM	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	6.85	7.61e-10	2.38e-06	0.59	0.58	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
THYM	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-6.85	7.66e-10	2.4e-06	-0.72	-0.58	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
THYM	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	6.85	7.69e-10	2.41e-06	0.67	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
THYM	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-6.85	7.71e-10	2.41e-06	-0.63	-0.58	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
THYM	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-6.85	7.72e-10	2.41e-06	-0.84	-0.58	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
THYM	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-6.85	7.74e-10	2.42e-06	-0.56	-0.58	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
THYM	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-6.84	7.81e-10	2.44e-06	-0.84	-0.58	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
THYM	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-6.84	7.81e-10	2.44e-06	-0.84	-0.58	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
THYM	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	6.84	7.84e-10	2.45e-06	0.68	0.58	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
THYM	cis	rs4908760	0.783	rs301799	ENSG00000232912.4	RP5-1115A15.1	6.84	7.91e-10	2.47e-06	0.54	0.58	Vitiligo;	chr1:8429242	chr1:8424645~8434838:+
THYM	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	6.84	7.97e-10	2.48e-06	0.61	0.58	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-6.84	7.97e-10	2.48e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
THYM	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-6.84	8e-10	2.49e-06	-0.62	-0.58	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
THYM	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	6.84	8.06e-10	2.51e-06	0.77	0.58	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
THYM	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-6.83	8.2e-10	2.55e-06	-0.89	-0.58	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
THYM	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-6.83	8.23e-10	2.56e-06	-0.72	-0.58	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
THYM	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	6.83	8.34e-10	2.59e-06	0.65	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	6.83	8.34e-10	2.59e-06	0.65	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
THYM	cis	rs904251	0.561	rs4714070	ENSG00000204110.6	RP1-153P14.8	-6.83	8.35e-10	2.59e-06	-0.76	-0.58	Cognitive performance;	chr6:37505422	chr6:37507348~37535616:+
THYM	cis	rs904251	0.561	rs4714071	ENSG00000204110.6	RP1-153P14.8	-6.83	8.35e-10	2.59e-06	-0.76	-0.58	Cognitive performance;	chr6:37506617	chr6:37507348~37535616:+
THYM	cis	rs673078	0.66	rs61943362	ENSG00000275409.1	RP11-131L12.4	-6.83	8.42e-10	2.61e-06	-0.85	-0.58	Glucose homeostasis traits;	chr12:118322042	chr12:118430147~118430699:+
THYM	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	6.83	8.43e-10	2.61e-06	0.59	0.58	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
THYM	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-6.83	8.44e-10	2.61e-06	-0.64	-0.58	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-6.83	8.44e-10	2.61e-06	-0.64	-0.58	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
THYM	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
THYM	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
THYM	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
THYM	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
THYM	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-6.83	8.46e-10	2.62e-06	-0.76	-0.58	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
THYM	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-6.83	8.5e-10	2.63e-06	-0.43	-0.58	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
THYM	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
THYM	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Depression;	chr6:28399886	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	6.82	8.59e-10	2.65e-06	0.71	0.58	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
THYM	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	6.82	8.65e-10	2.67e-06	0.57	0.58	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
THYM	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-6.82	8.66e-10	2.67e-06	-0.56	-0.58	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
THYM	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-6.82	8.69e-10	2.68e-06	-0.68	-0.58	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
THYM	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-6.82	8.85e-10	2.73e-06	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
THYM	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	6.82	8.85e-10	2.73e-06	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
THYM	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	6.81	8.96e-10	2.76e-06	0.67	0.57	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
THYM	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-6.81	9.06e-10	2.79e-06	-0.57	-0.57	Temperament;	chr17:14075460	chr17:14024514~14025488:+
THYM	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-6.81	9.09e-10	2.8e-06	-0.79	-0.57	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
THYM	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	6.81	9.11e-10	2.8e-06	0.92	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
THYM	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	6.81	9.2e-10	2.83e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	6.81	9.2e-10	2.83e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
THYM	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	6.81	9.23e-10	2.83e-06	0.72	0.57	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
THYM	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-6.81	9.26e-10	2.84e-06	-0.64	-0.57	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
THYM	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-6.81	9.3e-10	2.85e-06	-0.74	-0.57	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
THYM	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-6.81	9.33e-10	2.86e-06	-0.78	-0.57	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
THYM	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-6.81	9.34e-10	2.86e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-6.81	9.34e-10	2.86e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
THYM	cis	rs904251	0.504	rs12202664	ENSG00000279942.1	RP1-153P14.7	-6.8	9.37e-10	2.87e-06	-0.7	-0.57	Cognitive performance;	chr6:37513422	chr6:37567716~37571460:+
THYM	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	6.8	9.47e-10	2.9e-06	0.71	0.57	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
THYM	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-6.8	9.5e-10	2.91e-06	-0.61	-0.57	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
THYM	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-6.8	9.56e-10	2.93e-06	-0.77	-0.57	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	6.8	9.64e-10	2.95e-06	0.43	0.57	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-6.8	9.64e-10	2.95e-06	-0.43	-0.57	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-6.8	9.64e-10	2.95e-06	-0.43	-0.57	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-6.8	9.64e-10	2.95e-06	-0.43	-0.57	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-6.8	9.64e-10	2.95e-06	-0.43	-0.57	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-6.8	9.64e-10	2.95e-06	-0.43	-0.57	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
THYM	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	6.8	9.72e-10	2.97e-06	0.62	0.57	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
THYM	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	6.8	9.74e-10	2.98e-06	0.81	0.57	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	6.8	9.74e-10	2.98e-06	0.81	0.57	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
THYM	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-6.8	9.76e-10	2.99e-06	-0.78	-0.57	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
THYM	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	6.79	9.8e-10	3e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	6.79	9.8e-10	3e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
THYM	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-6.79	9.84e-10	3.01e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
THYM	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-6.79	9.85e-10	3.01e-06	-0.51	-0.57	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
THYM	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	6.79	9.93e-10	3.03e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	6.79	9.93e-10	3.03e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
THYM	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-6.79	9.95e-10	3.04e-06	-0.85	-0.57	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
THYM	cis	rs8396	1	rs11737481	ENSG00000271817.2	U3	-6.79	9.95e-10	3.04e-06	-0.41	-0.57	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700098	chr4:158700691~158700909:+
THYM	cis	rs904251	0.523	rs1776454	ENSG00000279942.1	RP1-153P14.7	-6.79	9.97e-10	3.04e-06	-0.74	-0.57	Cognitive performance;	chr6:37514323	chr6:37567716~37571460:+
THYM	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-6.79	1.01e-09	3.07e-06	-0.66	-0.57	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-6.79	1.01e-09	3.07e-06	-0.66	-0.57	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-6.79	1.01e-09	3.07e-06	-0.66	-0.57	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
THYM	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	6.79	1.01e-09	3.08e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	6.79	1.01e-09	3.08e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
THYM	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	6.79	1.02e-09	3.1e-06	0.75	0.57	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	6.79	1.02e-09	3.1e-06	0.75	0.57	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	6.79	1.02e-09	3.1e-06	0.75	0.57	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	6.79	1.02e-09	3.1e-06	0.75	0.57	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-6.79	1.02e-09	3.1e-06	-0.75	-0.57	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
THYM	cis	rs5760092	0.842	rs5751763	ENSG00000225282.1	AP000350.6	6.79	1.02e-09	3.1e-06	0.83	0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23926900~23929574:+
THYM	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	6.79	1.02e-09	3.12e-06	0.69	0.57	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
THYM	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	6.79	1.02e-09	3.12e-06	0.89	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	6.79	1.02e-09	3.12e-06	0.89	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	6.79	1.02e-09	3.12e-06	0.89	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	6.79	1.02e-09	3.12e-06	0.89	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	6.79	1.02e-09	3.12e-06	0.89	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	6.79	1.02e-09	3.12e-06	0.89	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
THYM	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-6.78	1.03e-09	3.14e-06	-0.76	-0.57	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
THYM	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	6.78	1.03e-09	3.14e-06	0.74	0.57	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
THYM	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	6.78	1.05e-09	3.19e-06	0.65	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
THYM	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	6.78	1.05e-09	3.2e-06	0.76	0.57	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
THYM	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-6.78	1.05e-09	3.2e-06	-0.66	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
THYM	cis	rs4691139	0.873	rs12509081	ENSG00000250227.1	TRIM60P14	6.78	1.06e-09	3.21e-06	0.65	0.57	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971812	chr4:164915565~164916983:+
THYM	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-6.78	1.06e-09	3.22e-06	-0.56	-0.57	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	6.78	1.06e-09	3.22e-06	0.56	0.57	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
THYM	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-6.78	1.06e-09	3.23e-06	-0.75	-0.57	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
THYM	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-6.78	1.06e-09	3.23e-06	-0.74	-0.57	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
THYM	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-6.78	1.07e-09	3.25e-06	-0.63	-0.57	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
THYM	cis	rs17772222	0.682	rs1152377	ENSG00000258983.2	RP11-507K2.2	-6.78	1.07e-09	3.25e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88496243	chr14:88499334~88515502:+
THYM	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	6.77	1.08e-09	3.27e-06	0.65	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	6.77	1.08e-09	3.27e-06	0.65	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	6.77	1.08e-09	3.27e-06	0.65	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
THYM	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-6.77	1.08e-09	3.27e-06	-0.66	-0.57	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
THYM	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	6.77	1.08e-09	3.27e-06	0.56	0.57	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
THYM	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	6.77	1.08e-09	3.28e-06	0.56	0.57	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
THYM	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-6.77	1.09e-09	3.31e-06	-0.66	-0.57	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
THYM	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-6.77	1.1e-09	3.33e-06	-1.06	-0.57	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
THYM	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-6.77	1.1e-09	3.33e-06	-1.06	-0.57	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
THYM	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-6.77	1.1e-09	3.33e-06	-0.78	-0.57	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
THYM	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-6.77	1.1e-09	3.33e-06	-0.78	-0.57	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
THYM	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-6.77	1.1e-09	3.33e-06	-0.78	-0.57	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	6.77	1.12e-09	3.36e-06	0.65	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
THYM	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-6.77	1.12e-09	3.36e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-6.77	1.12e-09	3.36e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-6.77	1.12e-09	3.36e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-6.77	1.12e-09	3.36e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-6.77	1.12e-09	3.36e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-6.77	1.12e-09	3.36e-06	-0.79	-0.57	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
THYM	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	6.77	1.12e-09	3.36e-06	0.61	0.57	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
THYM	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-6.77	1.12e-09	3.37e-06	-0.72	-0.57	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
THYM	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	6.77	1.12e-09	3.37e-06	0.59	0.57	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	6.77	1.12e-09	3.37e-06	0.59	0.57	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	6.77	1.12e-09	3.37e-06	0.59	0.57	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	6.77	1.12e-09	3.37e-06	0.59	0.57	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	6.77	1.12e-09	3.38e-06	0.59	0.57	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
THYM	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	6.76	1.13e-09	3.39e-06	0.78	0.57	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
THYM	cis	rs5760092	0.755	rs3884794	ENSG00000225282.1	AP000350.6	6.76	1.13e-09	3.41e-06	0.81	0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23926900~23929574:+
THYM	cis	rs11722228	0.549	rs73212828	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10077132	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs73212830	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10077135	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs56146302	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10079428	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs55848383	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10079493	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.508	rs2241472	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10084278	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.508	rs3796826	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10091104	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.508	rs3796825	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10091255	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.508	rs3822246	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10093074	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs73212853	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10094606	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs3796818	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10096352	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs41268389	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10097653	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.521	rs62288520	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10098050	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs62288521	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10098148	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs2241488	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10099507	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.549	rs73212863	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10102549	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.508	rs73212864	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10102567	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.521	rs56403947	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10110905	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.522	rs2241468	ENSG00000261490.1	RP11-448G15.3	6.76	1.14e-09	3.43e-06	0.59	0.57	Urate levels;Serum uric acid levels;Gout;	chr4:10112281	chr4:10068089~10073019:-
THYM	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	6.76	1.15e-09	3.46e-06	1.09	0.57	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
THYM	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-6.76	1.15e-09	3.46e-06	-0.56	-0.57	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
THYM	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-6.76	1.16e-09	3.46e-06	-0.44	-0.57	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-6.76	1.17e-09	3.51e-06	-0.76	-0.57	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
THYM	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	6.75	1.18e-09	3.53e-06	0.73	0.57	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	6.75	1.18e-09	3.53e-06	0.73	0.57	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
THYM	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	6.75	1.18e-09	3.53e-06	0.73	0.57	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
THYM	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	6.75	1.18e-09	3.54e-06	0.57	0.57	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
THYM	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	6.75	1.19e-09	3.55e-06	0.44	0.57	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
THYM	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-6.75	1.19e-09	3.57e-06	-0.52	-0.57	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
THYM	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	6.75	1.2e-09	3.58e-06	0.44	0.57	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
THYM	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-6.75	1.2e-09	3.59e-06	-0.73	-0.57	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-6.75	1.2e-09	3.59e-06	-0.73	-0.57	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-6.75	1.2e-09	3.59e-06	-0.73	-0.57	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
THYM	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-6.75	1.2e-09	3.59e-06	-0.65	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	6.75	1.21e-09	3.6e-06	0.65	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-6.75	1.21e-09	3.61e-06	-0.67	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
THYM	cis	rs5760092	0.755	rs3884794	ENSG00000273295.1	AP000350.5	6.75	1.22e-09	3.62e-06	0.73	0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23901432~23907068:-
THYM	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-6.75	1.22e-09	3.62e-06	-1.03	-0.57	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	6.75	1.22e-09	3.62e-06	1.03	0.57	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
THYM	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-6.75	1.23e-09	3.66e-06	-0.78	-0.57	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
THYM	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-6.74	1.24e-09	3.68e-06	-0.62	-0.57	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
THYM	cis	rs7182621	0.546	rs11632596	ENSG00000182397.13	DNM1P46	6.74	1.25e-09	3.72e-06	0.65	0.57	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99790156~99806927:-
THYM	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-6.74	1.26e-09	3.73e-06	-0.65	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	6.74	1.26e-09	3.73e-06	0.65	0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
THYM	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	6.74	1.27e-09	3.75e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
THYM	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-6.74	1.27e-09	3.76e-06	-0.68	-0.57	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
THYM	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	6.74	1.28e-09	3.78e-06	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	6.74	1.28e-09	3.78e-06	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	6.74	1.28e-09	3.78e-06	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
THYM	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	6.74	1.28e-09	3.78e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
THYM	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-6.74	1.28e-09	3.79e-06	-0.78	-0.57	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
THYM	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-6.74	1.28e-09	3.8e-06	-0.64	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
THYM	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	6.73	1.31e-09	3.88e-06	0.43	0.57	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	6.73	1.32e-09	3.89e-06	0.76	0.57	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	6.73	1.32e-09	3.89e-06	0.76	0.57	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
THYM	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	6.73	1.32e-09	3.89e-06	0.76	0.57	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	6.73	1.32e-09	3.89e-06	0.76	0.57	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	6.73	1.32e-09	3.89e-06	0.76	0.57	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
THYM	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-6.73	1.32e-09	3.89e-06	-0.42	-0.57	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
THYM	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	6.73	1.32e-09	3.9e-06	0.75	0.57	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
THYM	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-6.73	1.34e-09	3.94e-06	-0.54	-0.57	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
THYM	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	6.73	1.34e-09	3.95e-06	0.65	0.57	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
THYM	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-6.73	1.35e-09	3.95e-06	-0.72	-0.57	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-6.73	1.35e-09	3.95e-06	-0.72	-0.57	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
THYM	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-6.73	1.35e-09	3.97e-06	-0.68	-0.57	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
THYM	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-6.73	1.35e-09	3.97e-06	-0.76	-0.57	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	6.73	1.35e-09	3.97e-06	0.76	0.57	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	6.73	1.35e-09	3.97e-06	0.76	0.57	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	6.73	1.35e-09	3.97e-06	0.76	0.57	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	6.73	1.35e-09	3.97e-06	0.76	0.57	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	6.73	1.35e-09	3.97e-06	0.76	0.57	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
THYM	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-6.72	1.36e-09	3.98e-06	-0.57	-0.57	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
THYM	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	6.72	1.37e-09	4e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
THYM	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-6.72	1.37e-09	4.02e-06	-0.68	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-6.72	1.37e-09	4.02e-06	-0.68	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-6.72	1.37e-09	4.02e-06	-0.68	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-6.72	1.37e-09	4.02e-06	-0.68	-0.57	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
THYM	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-6.72	1.37e-09	4.02e-06	-0.68	-0.57	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
THYM	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	6.72	1.38e-09	4.06e-06	0.81	0.57	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
THYM	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-6.72	1.39e-09	4.07e-06	-0.73	-0.57	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
THYM	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-6.72	1.4e-09	4.09e-06	-0.67	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
THYM	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	6.72	1.41e-09	4.12e-06	0.6	0.57	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
THYM	cis	rs4691139	1	rs9917978	ENSG00000250227.1	TRIM60P14	6.72	1.41e-09	4.12e-06	0.66	0.57	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963991	chr4:164915565~164916983:+
THYM	cis	rs4691139	1	rs10007789	ENSG00000250227.1	TRIM60P14	6.72	1.41e-09	4.12e-06	0.66	0.57	Ovarian cancer in BRCA1 mutation carriers;	chr4:164969225	chr4:164915565~164916983:+
THYM	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-6.72	1.42e-09	4.14e-06	-0.75	-0.57	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
THYM	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-6.71	1.43e-09	4.17e-06	-0.61	-0.57	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
THYM	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	6.71	1.43e-09	4.17e-06	0.55	0.57	Temperament;	chr17:14068990	chr17:14024514~14025488:+
THYM	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-6.71	1.43e-09	4.17e-06	-0.66	-0.57	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
THYM	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-6.71	1.44e-09	4.19e-06	-0.57	-0.57	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
THYM	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-6.71	1.44e-09	4.2e-06	-0.65	-0.57	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
THYM	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-6.71	1.45e-09	4.21e-06	-0.51	-0.57	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
THYM	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-6.71	1.45e-09	4.21e-06	-0.51	-0.57	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
THYM	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-6.71	1.45e-09	4.21e-06	-0.51	-0.57	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
THYM	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-6.71	1.45e-09	4.21e-06	-0.52	-0.57	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
THYM	cis	rs8396	1	rs4690909	ENSG00000271817.2	U3	-6.71	1.45e-09	4.22e-06	-0.41	-0.57	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158707999	chr4:158700691~158700909:+
THYM	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-6.71	1.46e-09	4.25e-06	-0.76	-0.57	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
THYM	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-6.71	1.46e-09	4.25e-06	-0.65	-0.57	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-6.71	1.46e-09	4.25e-06	-0.65	-0.57	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-6.71	1.46e-09	4.25e-06	-0.65	-0.57	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-6.71	1.46e-09	4.25e-06	-0.65	-0.57	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-6.71	1.46e-09	4.25e-06	-0.65	-0.57	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-6.71	1.46e-09	4.25e-06	-0.65	-0.57	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-6.71	1.46e-09	4.25e-06	-0.65	-0.57	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
THYM	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-6.71	1.47e-09	4.26e-06	-0.56	-0.57	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-6.71	1.47e-09	4.26e-06	-0.56	-0.57	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-6.71	1.47e-09	4.26e-06	-0.56	-0.57	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-6.71	1.47e-09	4.26e-06	-0.56	-0.57	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-6.71	1.47e-09	4.26e-06	-0.56	-0.57	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-6.71	1.47e-09	4.26e-06	-0.56	-0.57	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-6.71	1.47e-09	4.26e-06	-0.56	-0.57	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
THYM	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	6.71	1.48e-09	4.29e-06	0.59	0.57	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
THYM	cis	rs7927592	0.513	rs901823	ENSG00000212093.1	AP000807.1	6.7	1.49e-09	4.32e-06	0.49	0.57	Total body bone mineral density;	chr11:68438110	chr11:68506083~68506166:-
THYM	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-6.7	1.49e-09	4.32e-06	-0.53	-0.57	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
THYM	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-6.7	1.51e-09	4.38e-06	-0.68	-0.57	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
THYM	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	6.7	1.53e-09	4.42e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	6.7	1.53e-09	4.42e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
THYM	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	6.7	1.55e-09	4.47e-06	0.69	0.57	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	6.7	1.55e-09	4.47e-06	0.69	0.57	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	6.7	1.55e-09	4.47e-06	0.69	0.57	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	6.7	1.55e-09	4.47e-06	0.69	0.57	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	6.7	1.55e-09	4.47e-06	0.69	0.57	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
THYM	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	6.7	1.55e-09	4.48e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	6.7	1.55e-09	4.48e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
THYM	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-6.69	1.56e-09	4.51e-06	-0.78	-0.57	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
THYM	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	6.69	1.57e-09	4.52e-06	0.75	0.57	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
THYM	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	6.69	1.57e-09	4.53e-06	0.75	0.57	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
THYM	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-6.69	1.57e-09	4.53e-06	-0.72	-0.57	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
THYM	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	6.69	1.58e-09	4.56e-06	0.58	0.57	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	6.69	1.58e-09	4.56e-06	0.58	0.57	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	6.69	1.58e-09	4.56e-06	0.58	0.57	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	6.69	1.58e-09	4.56e-06	0.58	0.57	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	6.69	1.58e-09	4.56e-06	0.58	0.57	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
THYM	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-6.69	1.58e-09	4.57e-06	-0.65	-0.57	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
THYM	cis	rs17772222	0.701	rs376698	ENSG00000258983.2	RP11-507K2.2	-6.69	1.59e-09	4.58e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88391886	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.701	rs453112	ENSG00000258983.2	RP11-507K2.2	-6.69	1.59e-09	4.58e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88392657	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.701	rs1627444	ENSG00000258983.2	RP11-507K2.2	-6.69	1.59e-09	4.58e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88413784	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.565	rs845759	ENSG00000258983.2	RP11-507K2.2	-6.69	1.59e-09	4.58e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88415538	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.545	rs1758846	ENSG00000258983.2	RP11-507K2.2	-6.69	1.59e-09	4.58e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88449288	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.701	rs845757	ENSG00000258983.2	RP11-507K2.2	-6.69	1.59e-09	4.58e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88455372	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.675	rs845769	ENSG00000258983.2	RP11-507K2.2	-6.69	1.59e-09	4.58e-06	-0.63	-0.57	Coronary artery calcification;	chr14:88461455	chr14:88499334~88515502:+
THYM	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	6.69	1.59e-09	4.58e-06	1.02	0.57	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
THYM	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-6.69	1.6e-09	4.61e-06	-0.65	-0.57	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
THYM	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	6.69	1.6e-09	4.61e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	6.69	1.6e-09	4.61e-06	0.41	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
THYM	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-6.69	1.61e-09	4.62e-06	-0.64	-0.57	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
THYM	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	6.69	1.61e-09	4.62e-06	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
THYM	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	6.69	1.62e-09	4.65e-06	0.8	0.57	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
THYM	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	6.68	1.64e-09	4.71e-06	1.04	0.57	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
THYM	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-6.68	1.64e-09	4.72e-06	-0.62	-0.57	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
THYM	cis	rs17772222	0.582	rs1288122	ENSG00000258983.2	RP11-507K2.2	-6.68	1.66e-09	4.78e-06	-0.62	-0.57	Coronary artery calcification;	chr14:88472736	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.655	rs816072	ENSG00000258983.2	RP11-507K2.2	-6.68	1.66e-09	4.78e-06	-0.62	-0.57	Coronary artery calcification;	chr14:88484335	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.655	rs1152376	ENSG00000258983.2	RP11-507K2.2	-6.68	1.66e-09	4.78e-06	-0.62	-0.57	Coronary artery calcification;	chr14:88495121	chr14:88499334~88515502:+
THYM	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	6.68	1.67e-09	4.8e-06	0.57	0.57	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	6.68	1.67e-09	4.8e-06	0.57	0.57	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
THYM	cis	rs5760092	0.842	rs5760103	ENSG00000273295.1	AP000350.5	6.68	1.68e-09	4.82e-06	0.75	0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23901432~23907068:-
THYM	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-6.68	1.69e-09	4.86e-06	-0.63	-0.57	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
THYM	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-6.67	1.71e-09	4.9e-06	-0.78	-0.57	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
THYM	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	6.67	1.72e-09	4.92e-06	0.69	0.57	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
THYM	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-6.67	1.72e-09	4.93e-06	-0.65	-0.57	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-6.67	1.72e-09	4.93e-06	-0.65	-0.57	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
THYM	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	6.67	1.72e-09	4.93e-06	0.56	0.57	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
THYM	cis	rs904251	0.523	rs2797794	ENSG00000279942.1	RP1-153P14.7	-6.67	1.75e-09	5e-06	-0.76	-0.57	Cognitive performance;	chr6:37512828	chr6:37567716~37571460:+
THYM	cis	rs904251	0.504	rs2797795	ENSG00000279942.1	RP1-153P14.7	-6.67	1.75e-09	5e-06	-0.76	-0.57	Cognitive performance;	chr6:37512907	chr6:37567716~37571460:+
THYM	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-6.67	1.75e-09	5.01e-06	-0.74	-0.57	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
THYM	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	6.67	1.77e-09	5.06e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
THYM	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
THYM	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
THYM	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
THYM	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
THYM	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	6.67	1.78e-09	5.06e-06	0.77	0.57	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-6.67	1.78e-09	5.06e-06	-0.77	-0.57	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-6.67	1.78e-09	5.06e-06	-0.77	-0.57	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
THYM	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-6.67	1.78e-09	5.06e-06	-0.77	-0.57	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-6.67	1.78e-09	5.06e-06	-0.77	-0.57	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
THYM	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	6.67	1.78e-09	5.06e-06	0.58	0.57	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
THYM	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-6.67	1.79e-09	5.07e-06	-0.68	-0.57	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
THYM	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-6.66	1.8e-09	5.08e-06	-0.88	-0.57	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
THYM	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-6.66	1.8e-09	5.08e-06	-0.73	-0.57	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
THYM	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	6.66	1.8e-09	5.08e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-6.66	1.8e-09	5.08e-06	-0.73	-0.57	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
THYM	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	6.66	1.8e-09	5.08e-06	0.75	0.57	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
THYM	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	6.66	1.81e-09	5.1e-06	0.65	0.57	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
THYM	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	6.66	1.81e-09	5.11e-06	0.56	0.57	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
THYM	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	6.66	1.84e-09	5.17e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	6.66	1.84e-09	5.17e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	6.66	1.84e-09	5.17e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	6.66	1.84e-09	5.17e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	6.66	1.84e-09	5.17e-06	0.74	0.57	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
THYM	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	6.66	1.84e-09	5.18e-06	0.7	0.57	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	6.66	1.84e-09	5.18e-06	0.7	0.57	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	6.66	1.84e-09	5.18e-06	0.7	0.57	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	6.66	1.84e-09	5.18e-06	0.7	0.57	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	6.66	1.84e-09	5.18e-06	0.7	0.57	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
THYM	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	6.66	1.86e-09	5.24e-06	0.58	0.57	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
THYM	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-6.65	1.87e-09	5.27e-06	-0.75	-0.57	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-6.65	1.87e-09	5.27e-06	-0.75	-0.57	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-6.65	1.87e-09	5.27e-06	-0.75	-0.57	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-6.65	1.87e-09	5.27e-06	-0.75	-0.57	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-6.65	1.87e-09	5.27e-06	-0.75	-0.57	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
THYM	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-6.65	1.88e-09	5.29e-06	-0.76	-0.57	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
THYM	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-6.65	1.88e-09	5.29e-06	-0.76	-0.57	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
THYM	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	6.65	1.9e-09	5.34e-06	1	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
THYM	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-6.65	1.91e-09	5.36e-06	-0.75	-0.57	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
THYM	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-6.65	1.92e-09	5.38e-06	-0.68	-0.57	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
THYM	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	6.65	1.92e-09	5.38e-06	0.73	0.57	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
THYM	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-6.65	1.92e-09	5.38e-06	-0.78	-0.57	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
THYM	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-6.65	1.92e-09	5.38e-06	-0.78	-0.57	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
THYM	cis	rs17772222	0.727	rs3179969	ENSG00000258983.2	RP11-507K2.2	6.65	1.92e-09	5.39e-06	0.65	0.57	Coronary artery calcification;	chr14:88396185	chr14:88499334~88515502:+
THYM	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	6.65	1.94e-09	5.43e-06	0.73	0.57	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
THYM	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	6.65	1.94e-09	5.43e-06	0.73	0.57	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
THYM	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-6.65	1.95e-09	5.47e-06	-0.73	-0.57	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-6.65	1.95e-09	5.47e-06	-0.73	-0.57	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
THYM	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-6.65	1.95e-09	5.47e-06	-0.74	-0.57	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
THYM	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	6.65	1.95e-09	5.47e-06	0.77	0.57	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-6.65	1.95e-09	5.47e-06	-0.77	-0.57	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
THYM	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	6.65	1.96e-09	5.48e-06	0.76	0.57	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
THYM	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-6.65	1.96e-09	5.48e-06	-0.88	-0.57	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
THYM	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-6.65	1.96e-09	5.48e-06	-0.88	-0.57	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
THYM	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	6.64	1.98e-09	5.54e-06	0.69	0.57	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
THYM	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-6.64	1.99e-09	5.56e-06	-0.67	-0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
THYM	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-6.64	1.99e-09	5.57e-06	-0.76	-0.57	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-6.64	1.99e-09	5.57e-06	-0.76	-0.57	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
THYM	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-6.64	2e-09	5.59e-06	-0.64	-0.57	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
THYM	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-6.64	2.01e-09	5.61e-06	-0.74	-0.57	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
THYM	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-6.64	2.02e-09	5.63e-06	-0.89	-0.56	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
THYM	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-6.64	2.03e-09	5.67e-06	-0.5	-0.56	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-6.64	2.03e-09	5.67e-06	-0.5	-0.56	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
THYM	cis	rs5769707	0.749	rs7286706	ENSG00000188511.11	C22orf34	6.64	2.03e-09	5.68e-06	0.4	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49414524~49657542:-
THYM	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-6.64	2.04e-09	5.69e-06	-0.49	-0.56	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-6.64	2.04e-09	5.69e-06	-0.49	-0.56	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
THYM	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-6.64	2.05e-09	5.71e-06	-0.91	-0.56	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
THYM	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	6.63	2.07e-09	5.75e-06	0.72	0.56	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
THYM	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-6.63	2.07e-09	5.77e-06	-0.76	-0.56	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
THYM	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-6.63	2.07e-09	5.77e-06	-0.76	-0.56	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
THYM	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-6.63	2.07e-09	5.77e-06	-0.76	-0.56	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
THYM	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-6.63	2.1e-09	5.84e-06	-0.5	-0.56	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	6.63	2.1e-09	5.84e-06	0.5	0.56	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
THYM	cis	rs5760092	0.842	rs5760103	ENSG00000225282.1	AP000350.6	6.63	2.11e-09	5.86e-06	0.82	0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23926900~23929574:+
THYM	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-6.63	2.11e-09	5.86e-06	-0.51	-0.56	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
THYM	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-6.63	2.11e-09	5.86e-06	-0.51	-0.56	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
THYM	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	6.63	2.12e-09	5.91e-06	0.63	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
THYM	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	6.63	2.14e-09	5.95e-06	0.78	0.56	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
THYM	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	6.63	2.14e-09	5.95e-06	0.78	0.56	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
THYM	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	6.63	2.14e-09	5.95e-06	0.77	0.56	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
THYM	cis	rs28475163	1	rs28475163	ENSG00000255328.1	RP11-326C3.12	6.62	2.16e-09	6e-06	0.44	0.56	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:327143	chr11:327171~330122:+
THYM	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-6.62	2.17e-09	6.01e-06	-0.68	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
THYM	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	6.62	2.17e-09	6.01e-06	0.71	0.56	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
THYM	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-6.62	2.17e-09	6.01e-06	-0.76	-0.56	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-6.62	2.17e-09	6.01e-06	-0.76	-0.56	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-6.62	2.17e-09	6.01e-06	-0.76	-0.56	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-6.62	2.17e-09	6.01e-06	-0.76	-0.56	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-6.62	2.17e-09	6.01e-06	-0.76	-0.56	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
THYM	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-6.62	2.17e-09	6.01e-06	-0.76	-0.56	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-6.62	2.17e-09	6.01e-06	-0.76	-0.56	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	6.62	2.17e-09	6.01e-06	0.76	0.56	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
THYM	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	6.62	2.18e-09	6.03e-06	0.74	0.56	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
THYM	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-6.61	2.26e-09	6.24e-06	-0.75	-0.56	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
THYM	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-6.61	2.26e-09	6.26e-06	-0.77	-0.56	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
THYM	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	6.61	2.28e-09	6.29e-06	0.63	0.56	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-6.61	2.28e-09	6.29e-06	-0.63	-0.56	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
THYM	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-6.61	2.29e-09	6.32e-06	-1.04	-0.56	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
THYM	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	6.61	2.3e-09	6.33e-06	0.76	0.56	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-6.61	2.3e-09	6.33e-06	-0.76	-0.56	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
THYM	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	6.61	2.31e-09	6.36e-06	0.74	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-6.61	2.31e-09	6.36e-06	-0.74	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
THYM	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
THYM	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	6.61	2.32e-09	6.37e-06	1.04	0.56	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
THYM	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-6.61	2.32e-09	6.38e-06	-0.64	-0.56	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-6.61	2.32e-09	6.38e-06	-0.64	-0.56	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
THYM	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	6.61	2.32e-09	6.38e-06	0.64	0.56	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
THYM	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	6.61	2.32e-09	6.38e-06	0.69	0.56	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
THYM	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-6.61	2.33e-09	6.4e-06	-0.65	-0.56	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
THYM	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-6.61	2.33e-09	6.4e-06	-0.77	-0.56	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-6.61	2.33e-09	6.4e-06	-0.77	-0.56	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
THYM	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-6.61	2.33e-09	6.4e-06	-0.77	-0.56	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-6.61	2.33e-09	6.4e-06	-0.77	-0.56	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
THYM	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-6.61	2.33e-09	6.4e-06	-0.77	-0.56	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-6.61	2.33e-09	6.4e-06	-0.77	-0.56	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
THYM	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	6.61	2.33e-09	6.4e-06	0.76	0.56	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
THYM	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-6.61	2.34e-09	6.43e-06	-0.75	-0.56	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-6.61	2.34e-09	6.43e-06	-0.75	-0.56	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	6.61	2.34e-09	6.43e-06	0.42	0.56	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
THYM	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	6.61	2.34e-09	6.43e-06	0.69	0.56	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	6.61	2.34e-09	6.43e-06	0.69	0.56	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	6.61	2.34e-09	6.43e-06	0.69	0.56	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	6.61	2.34e-09	6.43e-06	0.69	0.56	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	6.61	2.34e-09	6.43e-06	0.69	0.56	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	6.61	2.34e-09	6.43e-06	0.69	0.56	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	6.61	2.34e-09	6.43e-06	0.69	0.56	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
THYM	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	6.61	2.34e-09	6.43e-06	0.55	0.56	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
THYM	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	6.61	2.35e-09	6.44e-06	0.76	0.56	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
THYM	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	6.6	2.36e-09	6.46e-06	0.74	0.56	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
THYM	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-6.6	2.36e-09	6.46e-06	-0.75	-0.56	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
THYM	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-6.6	2.36e-09	6.46e-06	-0.75	-0.56	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
THYM	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-6.6	2.36e-09	6.46e-06	-0.75	-0.56	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
THYM	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-6.6	2.36e-09	6.47e-06	-0.73	-0.56	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
THYM	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	6.6	2.36e-09	6.47e-06	0.62	0.56	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
THYM	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	6.6	2.37e-09	6.49e-06	0.75	0.56	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-6.6	2.38e-09	6.5e-06	-0.75	-0.56	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
THYM	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-6.6	2.42e-09	6.61e-06	-0.75	-0.56	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
THYM	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	6.6	2.42e-09	6.61e-06	0.86	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
THYM	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	6.6	2.43e-09	6.64e-06	0.74	0.56	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
THYM	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	6.6	2.43e-09	6.64e-06	0.63	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	6.6	2.43e-09	6.64e-06	0.63	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
THYM	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-6.6	2.44e-09	6.65e-06	-0.62	-0.56	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-6.6	2.44e-09	6.65e-06	-0.62	-0.56	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
THYM	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-6.6	2.44e-09	6.66e-06	-0.48	-0.56	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
THYM	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-6.6	2.44e-09	6.66e-06	-0.48	-0.56	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
THYM	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-6.6	2.46e-09	6.72e-06	-0.76	-0.56	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
THYM	cis	rs11722228	0.522	rs73212880	ENSG00000261490.1	RP11-448G15.3	6.6	2.46e-09	6.72e-06	0.59	0.56	Urate levels;Serum uric acid levels;Gout;	chr4:10114068	chr4:10068089~10073019:-
THYM	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	6.6	2.47e-09	6.72e-06	0.72	0.56	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
THYM	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	6.59	2.49e-09	6.77e-06	0.68	0.56	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
THYM	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	6.59	2.51e-09	6.83e-06	0.42	0.56	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
THYM	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	6.59	2.53e-09	6.87e-06	0.97	0.56	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
THYM	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-6.59	2.54e-09	6.89e-06	-0.63	-0.56	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
THYM	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-6.59	2.54e-09	6.89e-06	-0.63	-0.56	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
THYM	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-6.59	2.54e-09	6.89e-06	-0.63	-0.56	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
THYM	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	6.59	2.54e-09	6.91e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	6.59	2.54e-09	6.91e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	6.59	2.54e-09	6.91e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	6.59	2.54e-09	6.91e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	6.59	2.54e-09	6.91e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
THYM	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	6.59	2.55e-09	6.92e-06	0.65	0.56	Height;	chr6:109424139	chr6:109382795~109383666:+
THYM	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-6.59	2.55e-09	6.92e-06	-0.63	-0.56	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-6.59	2.55e-09	6.92e-06	-0.63	-0.56	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
THYM	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-6.59	2.55e-09	6.92e-06	-0.63	-0.56	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
THYM	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-6.59	2.56e-09	6.94e-06	-0.73	-0.56	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-6.59	2.56e-09	6.94e-06	-0.73	-0.56	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-6.59	2.56e-09	6.94e-06	-0.73	-0.56	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-6.59	2.56e-09	6.94e-06	-0.73	-0.56	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
THYM	cis	rs2739330	0.627	rs9608219	ENSG00000272787.1	KB-226F1.2	-6.58	2.6e-09	7.03e-06	-0.63	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23969211~23969873:+
THYM	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	6.58	2.6e-09	7.04e-06	0.64	0.56	Height;	chr6:109634847	chr6:109382795~109383666:+
THYM	cis	rs995834	0.789	rs10410807	ENSG00000260725.1	AC005307.1	-6.58	2.61e-09	7.07e-06	-0.58	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28410408	chr19:28418483~28429490:-
THYM	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-6.58	2.63e-09	7.11e-06	-0.76	-0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-6.58	2.63e-09	7.11e-06	-0.76	-0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
THYM	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-6.58	2.64e-09	7.13e-06	-0.71	-0.56	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
THYM	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-6.58	2.65e-09	7.15e-06	-0.76	-0.56	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
THYM	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-6.58	2.65e-09	7.15e-06	-0.76	-0.56	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-6.58	2.65e-09	7.15e-06	-0.76	-0.56	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-6.58	2.65e-09	7.15e-06	-0.76	-0.56	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-6.58	2.65e-09	7.15e-06	-0.76	-0.56	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-6.58	2.65e-09	7.15e-06	-0.76	-0.56	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
THYM	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-6.58	2.65e-09	7.16e-06	-0.73	-0.56	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-6.58	2.65e-09	7.16e-06	-0.73	-0.56	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-6.58	2.65e-09	7.16e-06	-0.73	-0.56	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
THYM	cis	rs904251	0.6	rs4714068	ENSG00000279942.1	RP1-153P14.7	-6.58	2.66e-09	7.17e-06	-0.72	-0.56	Cognitive performance;	chr6:37487866	chr6:37567716~37571460:+
THYM	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	6.58	2.69e-09	7.25e-06	0.69	0.56	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
THYM	cis	rs995834	0.912	rs2868970	ENSG00000260725.1	AC005307.1	-6.58	2.7e-09	7.29e-06	-0.55	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393432	chr19:28418483~28429490:-
THYM	cis	rs995834	0.828	rs10403516	ENSG00000260725.1	AC005307.1	-6.58	2.7e-09	7.29e-06	-0.55	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393842	chr19:28418483~28429490:-
THYM	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-6.58	2.71e-09	7.3e-06	-0.62	-0.56	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
THYM	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	6.57	2.71e-09	7.31e-06	0.78	0.56	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
THYM	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-6.57	2.71e-09	7.31e-06	-0.76	-0.56	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	6.57	2.71e-09	7.31e-06	0.76	0.56	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
THYM	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	6.57	2.71e-09	7.31e-06	0.56	0.56	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
THYM	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	6.57	2.72e-09	7.31e-06	0.73	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	6.57	2.72e-09	7.31e-06	0.73	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
THYM	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	6.57	2.72e-09	7.32e-06	0.63	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
THYM	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	6.57	2.72e-09	7.33e-06	0.51	0.56	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	6.57	2.72e-09	7.33e-06	0.51	0.56	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	6.57	2.72e-09	7.33e-06	0.51	0.56	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	6.57	2.72e-09	7.33e-06	0.51	0.56	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	6.57	2.72e-09	7.33e-06	0.51	0.56	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	6.57	2.72e-09	7.33e-06	0.51	0.56	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
THYM	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-6.57	2.73e-09	7.35e-06	-0.63	-0.56	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
THYM	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-6.57	2.74e-09	7.37e-06	-0.63	-0.56	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
THYM	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-6.57	2.76e-09	7.42e-06	-0.63	-0.56	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
THYM	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-6.57	2.76e-09	7.42e-06	-0.63	-0.56	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
THYM	cis	rs904251	0.523	rs2797796	ENSG00000279942.1	RP1-153P14.7	-6.57	2.78e-09	7.46e-06	-0.73	-0.56	Cognitive performance;	chr6:37513110	chr6:37567716~37571460:+
THYM	cis	rs904251	0.523	rs2776870	ENSG00000279942.1	RP1-153P14.7	-6.57	2.78e-09	7.46e-06	-0.73	-0.56	Cognitive performance;	chr6:37513588	chr6:37567716~37571460:+
THYM	cis	rs904251	0.523	rs2797798	ENSG00000279942.1	RP1-153P14.7	-6.57	2.78e-09	7.46e-06	-0.73	-0.56	Cognitive performance;	chr6:37513661	chr6:37567716~37571460:+
THYM	cis	rs904251	0.523	rs2776871	ENSG00000279942.1	RP1-153P14.7	-6.57	2.78e-09	7.46e-06	-0.73	-0.56	Cognitive performance;	chr6:37513983	chr6:37567716~37571460:+
THYM	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-6.57	2.78e-09	7.48e-06	-0.74	-0.56	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
THYM	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
THYM	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-6.57	2.79e-09	7.5e-06	-0.61	-0.56	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
THYM	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	6.57	2.8e-09	7.5e-06	0.9	0.56	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
THYM	cis	rs9532669	0.926	rs4356344	ENSG00000176268.5	CYCSP34	6.56	2.84e-09	7.6e-06	0.51	0.56	Cervical cancer;	chr13:40874086	chr13:40863599~40863902:-
THYM	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	6.56	2.84e-09	7.61e-06	0.7	0.56	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
THYM	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-6.56	2.85e-09	7.64e-06	-0.76	-0.56	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
THYM	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-6.56	2.89e-09	7.74e-06	-0.87	-0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	6.56	2.89e-09	7.74e-06	0.87	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	6.56	2.89e-09	7.74e-06	0.87	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
THYM	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	6.56	2.91e-09	7.78e-06	0.45	0.56	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
THYM	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	6.56	2.91e-09	7.79e-06	0.79	0.56	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	6.56	2.91e-09	7.79e-06	0.79	0.56	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
THYM	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-6.56	2.93e-09	7.83e-06	-0.77	-0.56	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
THYM	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-6.56	2.93e-09	7.84e-06	-0.63	-0.56	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
THYM	cis	rs995834	0.789	rs11083486	ENSG00000260725.1	AC005307.1	-6.56	2.97e-09	7.92e-06	-0.58	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407449	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs10421826	ENSG00000260725.1	AC005307.1	-6.56	2.97e-09	7.92e-06	-0.58	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28408275	chr19:28418483~28429490:-
THYM	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-6.55	2.98e-09	7.95e-06	-0.71	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
THYM	cis	rs904251	0.6	rs12211110	ENSG00000279942.1	RP1-153P14.7	-6.55	2.98e-09	7.96e-06	-0.72	-0.56	Cognitive performance;	chr6:37498456	chr6:37567716~37571460:+
THYM	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	6.55	2.99e-09	7.97e-06	1.03	0.56	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
THYM	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	6.55	2.99e-09	7.97e-06	1.03	0.56	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
THYM	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-6.55	2.99e-09	7.98e-06	-0.71	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
THYM	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-6.55	3e-09	7.99e-06	-0.72	-0.56	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
THYM	cis	rs904251	0.965	rs1317563	ENSG00000279942.1	RP1-153P14.7	-6.55	3.02e-09	8.06e-06	-0.75	-0.56	Cognitive performance;	chr6:37484078	chr6:37567716~37571460:+
THYM	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-6.55	3.03e-09	8.08e-06	-0.72	-0.56	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
THYM	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	6.55	3.06e-09	8.14e-06	0.72	0.56	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	6.55	3.06e-09	8.14e-06	0.77	0.56	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
THYM	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-6.55	3.1e-09	8.23e-06	-0.51	-0.56	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
THYM	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-6.54	3.11e-09	8.27e-06	-0.73	-0.56	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
THYM	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	6.54	3.14e-09	8.33e-06	0.73	0.56	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
THYM	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	6.54	3.16e-09	8.37e-06	0.71	0.56	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
THYM	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	6.54	3.17e-09	8.41e-06	0.76	0.56	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
THYM	cis	rs4691139	1	rs10517825	ENSG00000250227.1	TRIM60P14	-6.54	3.18e-09	8.42e-06	-0.66	-0.56	Ovarian cancer in BRCA1 mutation carriers;	chr4:164972334	chr4:164915565~164916983:+
THYM	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-6.54	3.21e-09	8.5e-06	-0.5	-0.56	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
THYM	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	6.54	3.22e-09	8.51e-06	0.78	0.56	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	6.54	3.22e-09	8.51e-06	0.78	0.56	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	6.54	3.22e-09	8.51e-06	0.78	0.56	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	6.54	3.22e-09	8.51e-06	0.78	0.56	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	6.54	3.22e-09	8.51e-06	0.78	0.56	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	6.54	3.22e-09	8.51e-06	0.78	0.56	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
THYM	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	6.54	3.22e-09	8.51e-06	0.78	0.56	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
THYM	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-6.54	3.22e-09	8.51e-06	-0.5	-0.56	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
THYM	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
THYM	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
THYM	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
THYM	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	6.54	3.22e-09	8.51e-06	0.75	0.56	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
THYM	cis	rs28475163	0.958	rs7395116	ENSG00000255328.1	RP11-326C3.12	-6.54	3.24e-09	8.54e-06	-0.44	-0.56	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:327171~330122:+
THYM	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-6.54	3.24e-09	8.55e-06	-0.75	-0.56	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
THYM	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-6.53	3.26e-09	8.59e-06	-1	-0.56	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
THYM	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-6.53	3.28e-09	8.65e-06	-0.71	-0.56	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
THYM	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	6.53	3.29e-09	8.68e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
THYM	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-6.53	3.3e-09	8.7e-06	-0.75	-0.56	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-6.53	3.3e-09	8.7e-06	-0.75	-0.56	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-6.53	3.3e-09	8.7e-06	-0.75	-0.56	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-6.53	3.3e-09	8.7e-06	-0.75	-0.56	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
THYM	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-6.53	3.3e-09	8.7e-06	-0.75	-0.56	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
THYM	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	6.53	3.3e-09	8.71e-06	0.73	0.56	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
THYM	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	6.53	3.3e-09	8.71e-06	0.71	0.56	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
THYM	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-6.53	3.32e-09	8.76e-06	-1.29	-0.56	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
THYM	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	6.53	3.34e-09	8.81e-06	0.54	0.56	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
THYM	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-6.53	3.35e-09	8.83e-06	-0.77	-0.56	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
THYM	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	6.53	3.35e-09	8.83e-06	0.63	0.56	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
THYM	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	6.53	3.39e-09	8.91e-06	0.52	0.56	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
THYM	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	6.52	3.42e-09	9e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	6.52	3.42e-09	9e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	6.52	3.42e-09	9e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
THYM	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	6.52	3.44e-09	9.04e-06	0.7	0.56	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-6.52	3.44e-09	9.04e-06	-0.7	-0.56	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
THYM	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-6.52	3.45e-09	9.07e-06	-0.64	-0.56	Height;	chr6:109432968	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	6.52	3.45e-09	9.07e-06	0.64	0.56	Height;	chr6:109440234	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	6.52	3.45e-09	9.07e-06	0.64	0.56	Height;	chr6:109443332	chr6:109382795~109383666:+
THYM	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
THYM	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
THYM	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
THYM	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
THYM	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-6.52	3.46e-09	9.07e-06	-0.42	-0.56	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	6.52	3.46e-09	9.07e-06	0.42	0.56	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	6.52	3.46e-09	9.07e-06	0.42	0.56	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
THYM	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	6.52	3.46e-09	9.07e-06	0.42	0.56	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	6.52	3.46e-09	9.07e-06	0.42	0.56	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
THYM	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	6.52	3.46e-09	9.07e-06	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
THYM	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	6.52	3.47e-09	9.09e-06	0.7	0.56	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	6.52	3.47e-09	9.09e-06	0.7	0.56	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	6.52	3.47e-09	9.09e-06	0.7	0.56	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	6.52	3.47e-09	9.09e-06	0.7	0.56	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
THYM	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	6.52	3.47e-09	9.1e-06	0.66	0.56	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
THYM	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	6.52	3.48e-09	9.11e-06	0.51	0.56	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
THYM	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-6.52	3.48e-09	9.11e-06	-0.51	-0.56	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
THYM	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-6.52	3.48e-09	9.11e-06	-0.51	-0.56	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
THYM	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-6.52	3.48e-09	9.11e-06	-0.51	-0.56	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
THYM	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	6.52	3.49e-09	9.13e-06	1.02	0.56	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
THYM	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	6.52	3.52e-09	9.2e-06	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	6.52	3.52e-09	9.2e-06	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	6.52	3.52e-09	9.2e-06	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	6.52	3.52e-09	9.2e-06	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	6.52	3.52e-09	9.2e-06	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
THYM	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	6.52	3.52e-09	9.21e-06	0.42	0.56	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	6.52	3.52e-09	9.21e-06	0.42	0.56	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	6.52	3.54e-09	9.25e-06	0.41	0.56	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
THYM	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	6.51	3.57e-09	9.33e-06	0.66	0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
THYM	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	6.51	3.58e-09	9.36e-06	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
THYM	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-6.51	3.59e-09	9.37e-06	-0.69	-0.56	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-6.51	3.59e-09	9.37e-06	-0.69	-0.56	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-6.51	3.59e-09	9.37e-06	-0.69	-0.56	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-6.51	3.6e-09	9.38e-06	-0.72	-0.56	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
THYM	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-6.51	3.6e-09	9.39e-06	-0.76	-0.56	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-6.51	3.6e-09	9.39e-06	-0.76	-0.56	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
THYM	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-6.51	3.62e-09	9.44e-06	-0.74	-0.56	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
THYM	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	6.51	3.63e-09	9.47e-06	0.57	0.56	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
THYM	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	6.51	3.64e-09	9.49e-06	0.73	0.56	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
THYM	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-6.51	3.64e-09	9.5e-06	-0.7	-0.56	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-6.51	3.66e-09	9.52e-06	-0.68	-0.56	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-6.51	3.66e-09	9.52e-06	-0.68	-0.56	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
THYM	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	6.51	3.68e-09	9.59e-06	0.71	0.56	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.708	rs10903310	ENSG00000253893.2	FAM85B	6.51	3.7e-09	9.64e-06	0.76	0.56	Obesity-related traits;	chr8:8732177	chr8:8167819~8226614:-
THYM	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	6.51	3.71e-09	9.64e-06	0.61	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	6.51	3.71e-09	9.64e-06	0.61	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	6.51	3.71e-09	9.64e-06	0.61	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	6.51	3.71e-09	9.64e-06	0.61	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	6.51	3.71e-09	9.64e-06	0.61	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	6.51	3.71e-09	9.64e-06	0.61	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	6.51	3.71e-09	9.64e-06	0.61	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
THYM	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	6.51	3.72e-09	9.66e-06	0.61	0.56	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
THYM	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	6.51	3.72e-09	9.66e-06	0.61	0.56	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
THYM	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	6.51	3.73e-09	9.7e-06	1	0.56	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
THYM	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	6.51	3.73e-09	9.7e-06	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	6.51	3.73e-09	9.7e-06	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	6.51	3.73e-09	9.7e-06	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	6.51	3.73e-09	9.7e-06	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
THYM	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-6.5	3.75e-09	9.74e-06	-0.65	-0.56	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
THYM	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-6.5	3.78e-09	9.81e-06	-0.54	-0.56	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-6.5	3.78e-09	9.81e-06	-0.54	-0.56	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-6.5	3.78e-09	9.81e-06	-0.54	-0.56	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	6.5	3.78e-09	9.81e-06	0.54	0.56	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
THYM	cis	rs17772222	0.71	rs1028455	ENSG00000258983.2	RP11-507K2.2	6.5	3.78e-09	9.82e-06	0.63	0.56	Coronary artery calcification;	chr14:88363631	chr14:88499334~88515502:+
THYM	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	6.5	3.8e-09	9.86e-06	0.62	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
THYM	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-6.5	3.8e-09	9.87e-06	-0.85	-0.56	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
THYM	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	6.5	3.82e-09	9.92e-06	0.64	0.56	Height;	chr6:109447092	chr6:109382795~109383666:+
THYM	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-6.5	3.82e-09	9.92e-06	-0.48	-0.56	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
THYM	cis	rs4691139	1	rs6536882	ENSG00000250227.1	TRIM60P14	6.5	3.87e-09	1e-05	0.65	0.56	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979528	chr4:164915565~164916983:+
THYM	cis	rs4691139	1	rs6536883	ENSG00000250227.1	TRIM60P14	6.5	3.87e-09	1e-05	0.65	0.56	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979552	chr4:164915565~164916983:+
THYM	cis	rs4691139	1	rs6821283	ENSG00000250227.1	TRIM60P14	6.5	3.87e-09	1e-05	0.65	0.56	Ovarian cancer in BRCA1 mutation carriers;	chr4:164980493	chr4:164915565~164916983:+
THYM	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	6.49	3.92e-09	1.02e-05	0.42	0.56	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
THYM	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-6.49	3.93e-09	1.02e-05	-0.65	-0.56	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
THYM	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	6.49	3.94e-09	1.02e-05	0.76	0.56	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
THYM	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	6.49	3.94e-09	1.02e-05	0.7	0.56	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.49	3.94e-09	1.02e-05	-0.68	-0.56	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
THYM	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	6.49	3.95e-09	1.02e-05	0.55	0.56	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
THYM	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-6.49	3.95e-09	1.02e-05	-0.74	-0.56	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
THYM	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	6.49	3.97e-09	1.03e-05	0.73	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
THYM	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	6.49	3.97e-09	1.03e-05	0.45	0.56	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
THYM	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	6.49	3.98e-09	1.03e-05	0.74	0.56	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
THYM	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-6.49	3.98e-09	1.03e-05	-0.7	-0.56	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
THYM	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	6.49	4.03e-09	1.04e-05	0.42	0.56	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	6.49	4.03e-09	1.04e-05	0.42	0.56	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
THYM	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	6.49	4.03e-09	1.04e-05	0.42	0.56	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	6.49	4.03e-09	1.04e-05	0.42	0.56	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
THYM	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	6.49	4.03e-09	1.04e-05	0.42	0.56	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	6.49	4.03e-09	1.04e-05	0.42	0.56	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
THYM	cis	rs5769707	0.777	rs739243	ENSG00000188511.11	C22orf34	6.49	4.06e-09	1.05e-05	0.4	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49414524~49657542:-
THYM	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-6.48	4.1e-09	1.06e-05	-0.73	-0.56	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
THYM	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	6.48	4.1e-09	1.06e-05	0.66	0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
THYM	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-6.48	4.1e-09	1.06e-05	-0.61	-0.56	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
THYM	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-6.48	4.12e-09	1.06e-05	-0.69	-0.56	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
THYM	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	6.48	4.13e-09	1.06e-05	0.42	0.56	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
THYM	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-6.48	4.2e-09	1.08e-05	-1.03	-0.56	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
THYM	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	6.48	4.21e-09	1.08e-05	0.79	0.56	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
THYM	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	6.48	4.21e-09	1.08e-05	0.79	0.56	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
THYM	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	6.48	4.21e-09	1.08e-05	0.79	0.56	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
THYM	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	6.48	4.22e-09	1.08e-05	0.47	0.56	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
THYM	cis	rs4908760	0.811	rs301802	ENSG00000232912.4	RP5-1115A15.1	6.48	4.26e-09	1.09e-05	0.54	0.56	Vitiligo;	chr1:8437247	chr1:8424645~8434838:+
THYM	cis	rs34976449	1	rs34976449	ENSG00000232912.4	RP5-1115A15.1	6.48	4.26e-09	1.09e-05	0.54	0.56	Lymphocyte counts;	chr1:8438266	chr1:8424645~8434838:+
THYM	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-6.48	4.26e-09	1.09e-05	-0.62	-0.56	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
THYM	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	6.48	4.28e-09	1.1e-05	0.5	0.56	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
THYM	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	6.47	4.3e-09	1.1e-05	0.65	0.56	Height;	chr6:109446727	chr6:109382795~109383666:+
THYM	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-6.47	4.3e-09	1.1e-05	-0.74	-0.56	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
THYM	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-6.47	4.31e-09	1.1e-05	-0.52	-0.56	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
THYM	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	6.47	4.34e-09	1.11e-05	0.55	0.56	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
THYM	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-6.47	4.36e-09	1.11e-05	-0.67	-0.56	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
THYM	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-6.47	4.36e-09	1.12e-05	-0.53	-0.56	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
THYM	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-6.47	4.37e-09	1.12e-05	-0.49	-0.56	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-6.47	4.37e-09	1.12e-05	-0.49	-0.56	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
THYM	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-6.47	4.38e-09	1.12e-05	-0.63	-0.56	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
THYM	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-6.47	4.38e-09	1.12e-05	-0.67	-0.56	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
THYM	cis	rs6061231	0.701	rs6061505	ENSG00000273619.1	RP5-908M14.9	-6.47	4.39e-09	1.12e-05	-0.44	-0.56	Colorectal cancer;	chr20:62385155	chr20:62386303~62386970:-
THYM	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-6.47	4.42e-09	1.13e-05	-0.67	-0.55	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
THYM	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-6.47	4.43e-09	1.13e-05	-0.49	-0.55	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-6.47	4.43e-09	1.13e-05	-0.49	-0.55	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-6.47	4.43e-09	1.13e-05	-0.49	-0.55	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
THYM	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-6.47	4.43e-09	1.13e-05	-0.86	-0.55	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
THYM	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-6.46	4.49e-09	1.14e-05	-0.77	-0.55	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
THYM	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	6.46	4.5e-09	1.15e-05	0.63	0.55	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
THYM	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-6.46	4.54e-09	1.15e-05	-0.75	-0.55	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
THYM	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-6.46	4.58e-09	1.16e-05	-0.55	-0.55	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
THYM	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	6.46	4.59e-09	1.17e-05	0.73	0.55	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
THYM	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-6.46	4.6e-09	1.17e-05	-0.48	-0.55	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
THYM	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	6.46	4.64e-09	1.18e-05	0.65	0.55	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	6.46	4.64e-09	1.18e-05	0.65	0.55	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
THYM	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-6.46	4.65e-09	1.18e-05	-0.75	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-6.46	4.65e-09	1.18e-05	-0.75	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-6.46	4.65e-09	1.18e-05	-0.75	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-6.46	4.65e-09	1.18e-05	-0.75	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-6.46	4.65e-09	1.18e-05	-0.75	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-6.46	4.65e-09	1.18e-05	-0.75	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-6.46	4.65e-09	1.18e-05	-0.75	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
THYM	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	6.45	4.75e-09	1.2e-05	0.75	0.55	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
THYM	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-6.45	4.78e-09	1.21e-05	-0.76	-0.55	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
THYM	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	6.45	4.79e-09	1.21e-05	0.5	0.55	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
THYM	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	6.45	4.8e-09	1.21e-05	0.54	0.55	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
THYM	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	6.45	4.81e-09	1.22e-05	0.98	0.55	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
THYM	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	6.45	4.82e-09	1.22e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
THYM	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	6.45	4.84e-09	1.22e-05	0.55	0.55	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
THYM	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-6.45	4.86e-09	1.23e-05	-0.49	-0.55	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
THYM	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	6.45	4.89e-09	1.23e-05	0.65	0.55	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
THYM	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	6.45	4.89e-09	1.23e-05	0.52	0.55	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
THYM	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-6.45	4.9e-09	1.24e-05	-0.54	-0.55	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	6.45	4.9e-09	1.24e-05	0.54	0.55	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
THYM	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-6.45	4.9e-09	1.24e-05	-0.48	-0.55	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
THYM	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-6.45	4.91e-09	1.24e-05	-0.77	-0.55	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-6.45	4.91e-09	1.24e-05	-0.77	-0.55	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	6.45	4.91e-09	1.24e-05	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
THYM	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	6.44	4.95e-09	1.25e-05	0.59	0.55	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
THYM	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-6.44	4.95e-09	1.25e-05	-0.49	-0.55	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-6.44	4.95e-09	1.25e-05	-0.49	-0.55	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.44	5e-09	1.26e-05	-0.49	-0.55	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-6.44	5e-09	1.26e-05	-0.49	-0.55	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
THYM	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-6.44	5.03e-09	1.27e-05	-0.65	-0.55	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
THYM	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-6.44	5.08e-09	1.28e-05	-0.52	-0.55	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
THYM	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-6.44	5.11e-09	1.28e-05	-0.73	-0.55	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
THYM	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-6.44	5.11e-09	1.28e-05	-0.73	-0.55	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
THYM	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	6.43	5.16e-09	1.29e-05	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
THYM	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	6.43	5.18e-09	1.29e-05	0.71	0.55	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
THYM	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	6.43	5.18e-09	1.29e-05	0.55	0.55	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
THYM	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	6.43	5.18e-09	1.29e-05	0.71	0.55	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
THYM	cis	rs7182621	0.639	rs12906068	ENSG00000182397.13	DNM1P46	6.43	5.26e-09	1.31e-05	0.7	0.55	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99790156~99806927:-
THYM	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-6.43	5.28e-09	1.31e-05	-0.52	-0.55	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
THYM	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	6.43	5.28e-09	1.31e-05	0.92	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	6.43	5.28e-09	1.31e-05	0.92	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
THYM	cis	rs995834	0.912	rs12150882	ENSG00000267243.4	AC005307.3	-6.43	5.36e-09	1.33e-05	-0.46	-0.55	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362126	chr19:28435388~28727777:-
THYM	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	6.42	5.39e-09	1.34e-05	1.02	0.55	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
THYM	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-6.42	5.4e-09	1.34e-05	-0.71	-0.55	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
THYM	cis	rs1426063	0.8	rs28861517	ENSG00000249717.1	RP11-44F21.3	6.42	5.4e-09	1.34e-05	1.04	0.55	QT interval;	chr4:75092995	chr4:74955974~74970362:-
THYM	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	6.42	5.4e-09	1.34e-05	0.95	0.55	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
THYM	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	6.42	5.41e-09	1.34e-05	0.61	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
THYM	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-6.42	5.42e-09	1.34e-05	-0.65	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-6.42	5.42e-09	1.34e-05	-0.65	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
THYM	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	6.42	5.43e-09	1.35e-05	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
THYM	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-6.42	5.43e-09	1.35e-05	-0.67	-0.55	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-6.42	5.43e-09	1.35e-05	-0.67	-0.55	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
THYM	cis	rs4691139	1	rs7693977	ENSG00000250227.1	TRIM60P14	6.42	5.48e-09	1.36e-05	0.62	0.55	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981898	chr4:164915565~164916983:+
THYM	cis	rs2739330	0.703	rs5760112	ENSG00000272787.1	KB-226F1.2	-6.42	5.49e-09	1.36e-05	-0.61	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23969211~23969873:+
THYM	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-6.42	5.49e-09	1.36e-05	-0.76	-0.55	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
THYM	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-6.42	5.5e-09	1.36e-05	-0.62	-0.55	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
THYM	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-6.42	5.52e-09	1.37e-05	-0.42	-0.55	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	6.42	5.52e-09	1.37e-05	0.42	0.55	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
THYM	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	6.42	5.52e-09	1.37e-05	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
THYM	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	6.42	5.53e-09	1.37e-05	0.52	0.55	Depression;	chr6:28142370	chr6:28115628~28116551:+
THYM	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	6.42	5.56e-09	1.38e-05	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
THYM	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-6.42	5.58e-09	1.38e-05	-0.82	-0.55	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
THYM	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-6.42	5.58e-09	1.38e-05	-0.82	-0.55	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
THYM	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	6.42	5.59e-09	1.38e-05	0.64	0.55	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
THYM	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-6.42	5.6e-09	1.39e-05	-0.71	-0.55	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
THYM	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	6.41	5.66e-09	1.4e-05	0.59	0.55	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
THYM	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-6.41	5.66e-09	1.4e-05	-0.74	-0.55	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
THYM	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	6.41	5.69e-09	1.4e-05	0.69	0.55	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
THYM	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-6.41	5.7e-09	1.41e-05	-0.65	-0.55	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
THYM	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	6.41	5.71e-09	1.41e-05	0.72	0.55	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
THYM	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-6.41	5.73e-09	1.41e-05	-0.73	-0.55	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	6.41	5.73e-09	1.41e-05	0.73	0.55	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
THYM	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-6.41	5.73e-09	1.41e-05	-0.7	-0.55	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
THYM	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	6.41	5.76e-09	1.42e-05	0.42	0.55	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	6.41	5.76e-09	1.42e-05	0.42	0.55	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
THYM	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	6.41	5.76e-09	1.42e-05	0.64	0.55	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
THYM	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	6.41	5.76e-09	1.42e-05	0.64	0.55	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
THYM	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	6.41	5.77e-09	1.42e-05	0.55	0.55	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
THYM	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	6.41	5.82e-09	1.43e-05	0.41	0.55	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	6.41	5.82e-09	1.43e-05	0.41	0.55	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	6.41	5.82e-09	1.43e-05	0.41	0.55	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	6.41	5.82e-09	1.43e-05	0.41	0.55	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	6.41	5.82e-09	1.43e-05	0.41	0.55	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
THYM	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	6.41	5.82e-09	1.43e-05	0.41	0.55	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	6.41	5.82e-09	1.43e-05	0.41	0.55	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-6.41	5.82e-09	1.43e-05	-0.41	-0.55	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
THYM	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	6.41	5.86e-09	1.44e-05	0.72	0.55	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
THYM	cis	rs694739	0.595	rs11542299	ENSG00000236935.1	AP003774.1	6.41	5.89e-09	1.45e-05	0.4	0.55	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371333	chr11:64325050~64329504:-
THYM	cis	rs694739	0.726	rs17857342	ENSG00000236935.1	AP003774.1	6.41	5.89e-09	1.45e-05	0.4	0.55	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371433	chr11:64325050~64329504:-
THYM	cis	rs694739	0.657	rs11231770	ENSG00000236935.1	AP003774.1	6.41	5.89e-09	1.45e-05	0.4	0.55	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373153	chr11:64325050~64329504:-
THYM	cis	rs694739	0.687	rs11231771	ENSG00000236935.1	AP003774.1	6.41	5.89e-09	1.45e-05	0.4	0.55	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373170	chr11:64325050~64329504:-
THYM	cis	rs694739	0.628	rs10897487	ENSG00000236935.1	AP003774.1	6.41	5.89e-09	1.45e-05	0.4	0.55	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373232	chr11:64325050~64329504:-
THYM	cis	rs694739	0.654	rs10897488	ENSG00000236935.1	AP003774.1	6.41	5.89e-09	1.45e-05	0.4	0.55	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373334	chr11:64325050~64329504:-
THYM	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	6.4	5.92e-09	1.45e-05	0.56	0.55	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
THYM	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-6.4	5.95e-09	1.46e-05	-0.73	-0.55	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
THYM	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-6.4	5.97e-09	1.46e-05	-0.56	-0.55	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
THYM	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	6.4	5.99e-09	1.47e-05	0.74	0.55	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
THYM	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	6.4	6e-09	1.47e-05	0.64	0.55	Height;	chr6:109374782	chr6:109382795~109383666:+
THYM	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-6.4	6.01e-09	1.47e-05	-0.69	-0.55	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-6.4	6.01e-09	1.47e-05	-0.69	-0.55	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
THYM	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	6.4	6.02e-09	1.47e-05	1.01	0.55	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
THYM	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-6.4	6.05e-09	1.48e-05	-0.72	-0.55	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
THYM	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	6.4	6.05e-09	1.48e-05	0.69	0.55	Myopia;	chr6:28302807	chr6:28176188~28176674:+
THYM	cis	rs4691139	1	rs12498808	ENSG00000250227.1	TRIM60P14	6.4	6.05e-09	1.48e-05	0.63	0.55	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985753	chr4:164915565~164916983:+
THYM	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	6.4	6.06e-09	1.48e-05	0.6	0.55	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
THYM	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	6.4	6.06e-09	1.48e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	6.4	6.06e-09	1.48e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	6.4	6.06e-09	1.48e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	6.4	6.06e-09	1.48e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	6.4	6.06e-09	1.48e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	6.4	6.06e-09	1.48e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	6.4	6.06e-09	1.48e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
THYM	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	6.4	6.07e-09	1.48e-05	0.98	0.55	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
THYM	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	6.4	6.09e-09	1.49e-05	0.72	0.55	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
THYM	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-6.4	6.16e-09	1.5e-05	-0.69	-0.55	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
THYM	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-6.4	6.17e-09	1.51e-05	-0.78	-0.55	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-6.39	6.22e-09	1.51e-05	-0.74	-0.55	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-6.39	6.22e-09	1.51e-05	-0.74	-0.55	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-6.39	6.22e-09	1.51e-05	-0.74	-0.55	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-6.39	6.22e-09	1.51e-05	-0.74	-0.55	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-6.39	6.22e-09	1.51e-05	-0.74	-0.55	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-6.39	6.22e-09	1.51e-05	-0.74	-0.55	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
THYM	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-6.39	6.24e-09	1.52e-05	-0.76	-0.55	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
THYM	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	6.39	6.31e-09	1.53e-05	0.61	0.55	Height;	chr6:109405536	chr6:109382795~109383666:+
THYM	cis	rs2739330	0.791	rs9612520	ENSG00000272787.1	KB-226F1.2	-6.39	6.32e-09	1.54e-05	-0.62	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23969211~23969873:+
THYM	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-6.39	6.32e-09	1.54e-05	-0.67	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
THYM	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	6.39	6.33e-09	1.54e-05	0.62	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
THYM	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-6.39	6.33e-09	1.54e-05	-0.85	-0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
THYM	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	6.39	6.34e-09	1.54e-05	0.7	0.55	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
THYM	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	6.39	6.37e-09	1.55e-05	1.01	0.55	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
THYM	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-6.39	6.4e-09	1.55e-05	-0.85	-0.55	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-6.39	6.4e-09	1.55e-05	-0.85	-0.55	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
THYM	cis	rs4691139	0.967	rs4588418	ENSG00000250227.1	TRIM60P14	6.39	6.4e-09	1.55e-05	0.63	0.55	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981136	chr4:164915565~164916983:+
THYM	cis	rs4691139	1	rs7692919	ENSG00000250227.1	TRIM60P14	6.39	6.4e-09	1.55e-05	0.63	0.55	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981629	chr4:164915565~164916983:+
THYM	cis	rs4691139	1	rs1914859	ENSG00000250227.1	TRIM60P14	6.39	6.4e-09	1.55e-05	0.63	0.55	Ovarian cancer in BRCA1 mutation carriers;	chr4:164984989	chr4:164915565~164916983:+
THYM	cis	rs4691139	1	rs6855591	ENSG00000250227.1	TRIM60P14	6.39	6.4e-09	1.55e-05	0.63	0.55	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985571	chr4:164915565~164916983:+
THYM	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	6.38	6.47e-09	1.57e-05	0.41	0.55	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
THYM	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	6.38	6.47e-09	1.57e-05	0.41	0.55	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	6.38	6.47e-09	1.57e-05	0.41	0.55	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	6.38	6.47e-09	1.57e-05	0.41	0.55	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	6.38	6.47e-09	1.57e-05	0.41	0.55	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	6.38	6.47e-09	1.57e-05	0.41	0.55	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
THYM	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	6.38	6.47e-09	1.57e-05	0.63	0.55	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
THYM	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-6.38	6.47e-09	1.57e-05	-0.54	-0.55	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
THYM	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.38	6.53e-09	1.58e-05	0.53	0.55	Depression;	chr6:28200948	chr6:28115628~28116551:+
THYM	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	6.38	6.54e-09	1.59e-05	0.52	0.55	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-6.38	6.56e-09	1.59e-05	-0.73	-0.55	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
THYM	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-6.38	6.58e-09	1.59e-05	-0.44	-0.55	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
THYM	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-6.38	6.61e-09	1.6e-05	-0.98	-0.55	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-6.38	6.61e-09	1.6e-05	-0.98	-0.55	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
THYM	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-6.38	6.62e-09	1.6e-05	-0.77	-0.55	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
THYM	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	6.38	6.63e-09	1.6e-05	0.95	0.55	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
THYM	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.38	6.65e-09	1.61e-05	-0.6	-0.55	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-6.38	6.65e-09	1.61e-05	-0.6	-0.55	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
THYM	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-6.38	6.7e-09	1.62e-05	-0.62	-0.55	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-6.38	6.7e-09	1.62e-05	-0.62	-0.55	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-6.38	6.7e-09	1.62e-05	-0.62	-0.55	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-6.38	6.7e-09	1.62e-05	-0.62	-0.55	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
THYM	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-6.38	6.7e-09	1.62e-05	-0.51	-0.55	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
THYM	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	6.38	6.74e-09	1.62e-05	0.55	0.55	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
THYM	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	6.38	6.76e-09	1.63e-05	0.82	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
THYM	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	6.37	6.8e-09	1.64e-05	0.63	0.55	Height;	chr6:109462738	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	6.37	6.8e-09	1.64e-05	0.63	0.55	Height;	chr6:109464011	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	6.37	6.8e-09	1.64e-05	0.63	0.55	Height;	chr6:109465777	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	6.37	6.8e-09	1.64e-05	0.63	0.55	Height;	chr6:109470427	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	6.37	6.8e-09	1.64e-05	0.63	0.55	Height;	chr6:109470900	chr6:109382795~109383666:+
THYM	cis	rs5760092	0.618	rs4461358	ENSG00000272787.1	KB-226F1.2	6.37	6.8e-09	1.64e-05	0.67	0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23969211~23969873:+
THYM	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	6.37	6.83e-09	1.64e-05	0.64	0.55	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
THYM	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	6.37	6.83e-09	1.64e-05	0.78	0.55	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
THYM	cis	rs4908760	0.757	rs301807	ENSG00000232912.4	RP5-1115A15.1	6.37	6.87e-09	1.65e-05	0.53	0.55	Vitiligo;	chr1:8424763	chr1:8424645~8434838:+
THYM	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	6.37	6.88e-09	1.65e-05	0.65	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
THYM	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	6.37	6.91e-09	1.66e-05	1.02	0.55	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
THYM	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	6.37	6.92e-09	1.66e-05	0.72	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
THYM	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-6.37	6.93e-09	1.67e-05	-0.66	-0.55	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
THYM	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-6.37	7.02e-09	1.69e-05	-0.41	-0.55	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
THYM	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-6.37	7.02e-09	1.69e-05	-0.62	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-6.37	7.02e-09	1.69e-05	-0.62	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-6.37	7.02e-09	1.69e-05	-0.62	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-6.37	7.02e-09	1.69e-05	-0.62	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
THYM	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-6.37	7.06e-09	1.7e-05	-0.62	-0.55	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
THYM	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-6.37	7.07e-09	1.7e-05	-0.52	-0.55	Depression;	chr6:28126588	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-6.37	7.07e-09	1.7e-05	-0.52	-0.55	Depression;	chr6:28126953	chr6:28115628~28116551:+
THYM	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	6.36	7.08e-09	1.7e-05	0.59	0.55	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	6.36	7.08e-09	1.7e-05	0.59	0.55	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
THYM	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	6.36	7.11e-09	1.71e-05	0.63	0.55	Height;	chr6:109454233	chr6:109382795~109383666:+
THYM	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-6.36	7.19e-09	1.72e-05	-0.62	-0.55	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
THYM	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-6.36	7.2e-09	1.73e-05	-0.49	-0.55	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
THYM	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-6.36	7.22e-09	1.73e-05	-0.8	-0.55	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
THYM	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	6.36	7.23e-09	1.73e-05	0.55	0.55	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
THYM	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	6.36	7.24e-09	1.74e-05	1	0.55	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
THYM	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	6.36	7.3e-09	1.75e-05	0.56	0.55	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
THYM	cis	rs11722228	0.539	rs62287552	ENSG00000261490.1	RP11-448G15.3	6.36	7.31e-09	1.75e-05	0.58	0.55	Urate levels;Serum uric acid levels;Gout;	chr4:10151573	chr4:10068089~10073019:-
THYM	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-6.36	7.36e-09	1.76e-05	-0.69	-0.55	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-6.36	7.36e-09	1.76e-05	-0.69	-0.55	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-6.36	7.36e-09	1.76e-05	-0.69	-0.55	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-6.36	7.36e-09	1.76e-05	-0.69	-0.55	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-6.36	7.36e-09	1.76e-05	-0.69	-0.55	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-6.36	7.36e-09	1.76e-05	-0.69	-0.55	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-6.36	7.36e-09	1.76e-05	-0.69	-0.55	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
THYM	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.36	7.39e-09	1.77e-05	-0.6	-0.55	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-6.36	7.39e-09	1.77e-05	-0.6	-0.55	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
THYM	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-6.36	7.39e-09	1.77e-05	-0.73	-0.55	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
THYM	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	6.35	7.42e-09	1.77e-05	1.01	0.55	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
THYM	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	6.35	7.43e-09	1.78e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	6.35	7.43e-09	1.78e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	6.35	7.43e-09	1.78e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	6.35	7.43e-09	1.78e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	6.35	7.43e-09	1.78e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	6.35	7.43e-09	1.78e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
THYM	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	6.35	7.46e-09	1.78e-05	0.54	0.55	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
THYM	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-6.35	7.48e-09	1.79e-05	-0.64	-0.55	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
THYM	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-6.35	7.48e-09	1.79e-05	-0.64	-0.55	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
THYM	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	6.35	7.55e-09	1.8e-05	0.53	0.55	Depression;	chr6:28109824	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-6.35	7.55e-09	1.8e-05	-0.53	-0.55	Depression;	chr6:28079011	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-6.35	7.55e-09	1.8e-05	-0.53	-0.55	Depression;	chr6:28091242	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-6.35	7.55e-09	1.8e-05	-0.53	-0.55	Depression;	chr6:28096845	chr6:28115628~28116551:+
THYM	cis	rs7829975	0.577	rs7816329	ENSG00000253893.2	FAM85B	6.35	7.56e-09	1.8e-05	0.66	0.55	Mood instability;	chr8:8686333	chr8:8167819~8226614:-
THYM	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-6.35	7.57e-09	1.8e-05	-0.74	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-6.35	7.57e-09	1.8e-05	-0.74	-0.55	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
THYM	cis	rs673078	1	rs673078	ENSG00000275409.1	RP11-131L12.4	6.35	7.57e-09	1.81e-05	0.61	0.55	Glucose homeostasis traits;	chr12:118353636	chr12:118430147~118430699:+
THYM	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	6.35	7.6e-09	1.81e-05	0.75	0.55	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
THYM	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	6.35	7.71e-09	1.84e-05	0.59	0.55	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	6.35	7.71e-09	1.84e-05	0.59	0.55	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
THYM	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	6.35	7.71e-09	1.84e-05	0.63	0.55	Height;	chr6:109476101	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	6.35	7.71e-09	1.84e-05	0.63	0.55	Height;	chr6:109477209	chr6:109382795~109383666:+
THYM	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-6.35	7.75e-09	1.84e-05	-0.68	-0.55	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
THYM	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-6.34	7.76e-09	1.85e-05	-0.49	-0.55	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-6.34	7.76e-09	1.85e-05	-0.49	-0.55	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-6.34	7.79e-09	1.85e-05	-0.49	-0.55	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
THYM	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-6.34	7.79e-09	1.85e-05	-0.49	-0.55	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
THYM	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-6.34	7.82e-09	1.86e-05	-0.99	-0.55	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
THYM	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-6.34	7.84e-09	1.86e-05	-0.61	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
THYM	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-6.34	7.86e-09	1.86e-05	-0.73	-0.55	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-6.34	7.86e-09	1.86e-05	-0.73	-0.55	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	6.34	7.86e-09	1.86e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
THYM	cis	rs4908760	0.811	rs301806	ENSG00000232912.4	RP5-1115A15.1	6.34	7.87e-09	1.86e-05	0.53	0.55	Vitiligo;	chr1:8422018	chr1:8424645~8434838:+
THYM	cis	rs7829975	0.539	rs71537846	ENSG00000253893.2	FAM85B	6.34	7.9e-09	1.87e-05	0.66	0.55	Mood instability;	chr8:8684610	chr8:8167819~8226614:-
THYM	cis	rs11157436	0.958	rs17255510	ENSG00000211813.2	TRAV34	-6.34	7.93e-09	1.87e-05	-0.41	-0.55	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22207522~22208129:+
THYM	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	6.34	8.02e-09	1.89e-05	0.65	0.55	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	6.34	8.02e-09	1.89e-05	0.65	0.55	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	6.34	8.02e-09	1.89e-05	0.65	0.55	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	6.34	8.02e-09	1.89e-05	0.65	0.55	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
THYM	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	6.34	8.02e-09	1.89e-05	0.65	0.55	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
THYM	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	6.34	8.03e-09	1.89e-05	0.47	0.55	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
THYM	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-6.34	8.06e-09	1.9e-05	-0.65	-0.55	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
THYM	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-6.34	8.08e-09	1.9e-05	-0.75	-0.55	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
THYM	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-6.34	8.08e-09	1.9e-05	-0.75	-0.55	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
THYM	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
THYM	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
THYM	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	6.34	8.08e-09	1.9e-05	0.75	0.55	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
THYM	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-6.34	8.09e-09	1.9e-05	-0.75	-0.55	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
THYM	cis	rs4908760	0.773	rs301805	ENSG00000232912.4	RP5-1115A15.1	6.33	8.13e-09	1.91e-05	0.53	0.55	Vitiligo;	chr1:8420956	chr1:8424645~8434838:+
THYM	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-6.33	8.15e-09	1.92e-05	-0.79	-0.55	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-6.33	8.15e-09	1.92e-05	-0.79	-0.55	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
THYM	cis	rs11722228	0.522	rs73212817	ENSG00000261490.1	RP11-448G15.3	6.33	8.18e-09	1.92e-05	0.61	0.55	Urate levels;Serum uric acid levels;Gout;	chr4:10062387	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.522	rs12504600	ENSG00000261490.1	RP11-448G15.3	6.33	8.18e-09	1.92e-05	0.61	0.55	Urate levels;Serum uric acid levels;Gout;	chr4:10065514	chr4:10068089~10073019:-
THYM	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	6.33	8.21e-09	1.93e-05	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
THYM	cis	rs11157436	0.958	rs61972231	ENSG00000211813.2	TRAV34	6.33	8.22e-09	1.93e-05	0.42	0.55	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22207522~22208129:+
THYM	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-6.33	8.32e-09	1.95e-05	-0.86	-0.55	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
THYM	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-6.33	8.4e-09	1.97e-05	-0.67	-0.55	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
THYM	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	6.33	8.44e-09	1.98e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	6.33	8.44e-09	1.98e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	6.33	8.44e-09	1.98e-05	0.73	0.55	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
THYM	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-6.33	8.44e-09	1.98e-05	-0.42	-0.55	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
THYM	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	6.33	8.46e-09	1.98e-05	0.75	0.55	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
THYM	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-6.32	8.5e-09	1.99e-05	-0.52	-0.55	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
THYM	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-6.32	8.51e-09	1.99e-05	-0.64	-0.55	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-6.32	8.51e-09	1.99e-05	-0.64	-0.55	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-6.32	8.51e-09	1.99e-05	-0.64	-0.55	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-6.32	8.51e-09	1.99e-05	-0.64	-0.55	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-6.32	8.51e-09	1.99e-05	-0.64	-0.55	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
THYM	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	6.32	8.52e-09	2e-05	0.75	0.55	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	6.32	8.53e-09	2e-05	0.61	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
THYM	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-6.32	8.55e-09	2e-05	-0.42	-0.55	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
THYM	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-6.32	8.59e-09	2.01e-05	-0.67	-0.55	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
THYM	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-6.32	8.63e-09	2.02e-05	-0.54	-0.55	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
THYM	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	6.32	8.65e-09	2.02e-05	0.75	0.55	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
THYM	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	6.32	8.69e-09	2.03e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
THYM	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	6.32	8.69e-09	2.03e-05	0.63	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
THYM	cis	rs2729354	0.817	rs2848626	ENSG00000265566.2	RN7SL605P	-6.32	8.7e-09	2.03e-05	-0.81	-0.55	Blood protein levels;	chr11:57516515	chr11:57528085~57528365:-
THYM	cis	rs11722228	0.508	rs61335146	ENSG00000261490.1	RP11-448G15.3	6.32	8.72e-09	2.04e-05	0.55	0.55	Urate levels;Serum uric acid levels;Gout;	chr4:10129169	chr4:10068089~10073019:-
THYM	cis	rs1426063	1	rs11941556	ENSG00000248165.1	RP11-44F21.2	6.32	8.75e-09	2.04e-05	1.19	0.55	QT interval;	chr4:75093825	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs10022814	ENSG00000248165.1	RP11-44F21.2	6.32	8.75e-09	2.04e-05	1.19	0.55	QT interval;	chr4:75094704	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs10029141	ENSG00000248165.1	RP11-44F21.2	6.32	8.75e-09	2.04e-05	1.19	0.55	QT interval;	chr4:75097437	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs10030850	ENSG00000248165.1	RP11-44F21.2	6.32	8.75e-09	2.04e-05	1.19	0.55	QT interval;	chr4:75099199	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs9993589	ENSG00000248165.1	RP11-44F21.2	6.32	8.75e-09	2.04e-05	1.19	0.55	QT interval;	chr4:75099556	chr4:74993877~75034824:-
THYM	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	6.32	8.77e-09	2.05e-05	0.72	0.55	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
THYM	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	6.32	8.81e-09	2.05e-05	0.72	0.55	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
THYM	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	6.32	8.87e-09	2.07e-05	0.56	0.55	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
THYM	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-6.32	8.88e-09	2.07e-05	-0.63	-0.55	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-6.32	8.88e-09	2.07e-05	-0.63	-0.55	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-6.32	8.88e-09	2.07e-05	-0.63	-0.55	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
THYM	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-6.31	8.92e-09	2.08e-05	-0.65	-0.55	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
THYM	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	6.31	8.93e-09	2.08e-05	0.69	0.55	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
THYM	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	6.31	8.93e-09	2.08e-05	0.69	0.55	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
THYM	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	6.31	8.93e-09	2.08e-05	1	0.55	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
THYM	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	6.31	9.01e-09	2.1e-05	0.57	0.55	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
THYM	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	6.31	9.02e-09	2.1e-05	0.71	0.55	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
THYM	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-6.31	9.05e-09	2.1e-05	-0.67	-0.55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
THYM	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-6.31	9.07e-09	2.11e-05	-0.84	-0.55	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
THYM	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-6.31	9.07e-09	2.11e-05	-0.84	-0.55	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
THYM	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	6.31	9.2e-09	2.13e-05	0.67	0.55	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
THYM	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	6.31	9.2e-09	2.13e-05	0.67	0.55	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
THYM	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	6.31	9.2e-09	2.13e-05	0.67	0.55	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
THYM	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	6.3	9.3e-09	2.15e-05	0.42	0.55	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
THYM	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
THYM	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
THYM	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-6.3	9.3e-09	2.15e-05	-0.42	-0.55	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
THYM	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	6.3	9.3e-09	2.15e-05	0.42	0.55	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
THYM	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-6.3	9.32e-09	2.16e-05	-0.45	-0.55	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
THYM	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	6.3	9.34e-09	2.16e-05	0.54	0.55	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	6.3	9.34e-09	2.16e-05	0.54	0.55	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	6.3	9.34e-09	2.16e-05	0.54	0.55	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
THYM	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	6.3	9.35e-09	2.16e-05	0.56	0.55	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.577	rs79495969	ENSG00000253893.2	FAM85B	6.3	9.51e-09	2.2e-05	0.65	0.54	Mood instability;	chr8:8687740	chr8:8167819~8226614:-
THYM	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	6.3	9.61e-09	2.22e-05	0.72	0.54	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	6.3	9.61e-09	2.22e-05	0.72	0.54	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
THYM	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	6.3	9.67e-09	2.23e-05	0.74	0.54	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
THYM	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	6.3	9.71e-09	2.24e-05	0.49	0.54	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	6.3	9.71e-09	2.24e-05	0.49	0.54	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	6.3	9.71e-09	2.24e-05	0.49	0.54	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
THYM	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-6.3	9.71e-09	2.24e-05	-0.49	-0.54	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
THYM	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	6.29	9.74e-09	2.24e-05	0.75	0.54	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	6.29	9.74e-09	2.24e-05	0.75	0.54	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	6.29	9.74e-09	2.24e-05	0.75	0.54	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	6.29	9.74e-09	2.24e-05	0.75	0.54	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
THYM	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	6.29	9.74e-09	2.24e-05	0.75	0.54	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	6.29	9.74e-09	2.24e-05	0.75	0.54	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
THYM	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
THYM	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-6.29	9.74e-09	2.24e-05	-0.75	-0.54	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
THYM	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-6.29	9.78e-09	2.25e-05	-0.67	-0.54	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
THYM	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	6.29	9.79e-09	2.25e-05	0.51	0.54	Depression;	chr6:28110525	chr6:28115628~28116551:+
THYM	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	6.29	9.81e-09	2.25e-05	0.62	0.54	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
THYM	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	6.29	9.81e-09	2.25e-05	0.76	0.54	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
THYM	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-6.29	9.83e-09	2.26e-05	-0.75	-0.54	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-6.29	9.83e-09	2.26e-05	-0.75	-0.54	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-6.29	9.83e-09	2.26e-05	-0.75	-0.54	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
THYM	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	6.29	9.84e-09	2.26e-05	0.67	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
THYM	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-6.29	9.86e-09	2.26e-05	-0.66	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
THYM	cis	rs995834	1	rs7250520	ENSG00000267243.4	AC005307.3	-6.29	9.88e-09	2.27e-05	-0.46	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376844	chr19:28435388~28727777:-
THYM	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-6.29	9.89e-09	2.27e-05	-0.67	-0.54	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-6.29	9.89e-09	2.27e-05	-0.67	-0.54	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	6.29	9.89e-09	2.27e-05	0.76	0.54	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	6.29	9.89e-09	2.27e-05	0.76	0.54	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
THYM	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	6.29	9.89e-09	2.27e-05	0.76	0.54	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
THYM	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-6.29	9.9e-09	2.27e-05	-0.64	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
THYM	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	6.29	9.94e-09	2.28e-05	0.71	0.54	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
THYM	cis	rs995758	0.512	rs13142776	ENSG00000236296.6	GUSBP5	-6.29	9.95e-09	2.28e-05	-0.62	-0.54	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144512139	chr4:143559472~143649305:+
THYM	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-6.29	1e-08	2.3e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
THYM	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-6.29	1.01e-08	2.31e-05	-0.63	-0.54	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
THYM	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	6.28	1.02e-08	2.33e-05	0.66	0.54	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	6.28	1.02e-08	2.33e-05	0.66	0.54	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	6.28	1.02e-08	2.33e-05	0.66	0.54	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
THYM	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	6.28	1.03e-08	2.35e-05	0.71	0.54	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	6.28	1.03e-08	2.36e-05	0.39	0.54	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
THYM	cis	rs995834	0.912	rs2058192	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346236	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs4806319	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346419	chr19:28435388~28727777:-
THYM	cis	rs995834	0.872	rs10408276	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346667	chr19:28435388~28727777:-
THYM	cis	rs995834	0.872	rs28612438	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348957	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs7256199	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350657	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs7252509	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350710	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs7258117	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353475	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs10402976	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28353776	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs10403247	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354139	chr19:28435388~28727777:-
THYM	cis	rs995834	0.797	rs10401181	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28354223	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs12151340	ENSG00000267243.4	AC005307.3	6.28	1.03e-08	2.36e-05	0.45	0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362360	chr19:28435388~28727777:-
THYM	cis	rs995834	0.872	rs7253391	ENSG00000267243.4	AC005307.3	-6.28	1.03e-08	2.36e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28367736	chr19:28435388~28727777:-
THYM	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-6.28	1.04e-08	2.39e-05	-0.41	-0.54	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
THYM	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-6.28	1.05e-08	2.39e-05	-0.63	-0.54	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
THYM	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	6.28	1.05e-08	2.39e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
THYM	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	6.28	1.05e-08	2.4e-05	0.51	0.54	Depression;	chr6:28205232	chr6:28115628~28116551:+
THYM	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-6.28	1.05e-08	2.4e-05	-0.52	-0.54	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-6.28	1.05e-08	2.4e-05	-0.52	-0.54	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
THYM	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-6.28	1.05e-08	2.4e-05	-0.45	-0.54	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
THYM	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	6.28	1.06e-08	2.41e-05	0.71	0.54	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	6.28	1.06e-08	2.41e-05	0.71	0.54	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	6.28	1.06e-08	2.41e-05	0.71	0.54	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
THYM	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-6.28	1.06e-08	2.41e-05	-0.6	-0.54	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
THYM	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-6.28	1.06e-08	2.41e-05	-0.67	-0.54	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
THYM	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	6.28	1.06e-08	2.41e-05	0.73	0.54	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
THYM	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	6.28	1.06e-08	2.41e-05	0.73	0.54	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
THYM	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	6.28	1.06e-08	2.41e-05	0.73	0.54	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
THYM	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	6.28	1.06e-08	2.42e-05	0.76	0.54	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	6.28	1.06e-08	2.42e-05	0.76	0.54	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	6.28	1.06e-08	2.42e-05	0.76	0.54	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	6.28	1.06e-08	2.42e-05	0.76	0.54	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	6.28	1.06e-08	2.42e-05	0.76	0.54	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	6.28	1.06e-08	2.42e-05	0.76	0.54	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	6.28	1.06e-08	2.42e-05	0.76	0.54	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
THYM	cis	rs904251	0.523	rs2776874	ENSG00000227920.2	RP1-153P14.5	-6.27	1.07e-08	2.43e-05	-0.68	-0.54	Cognitive performance;	chr6:37515421	chr6:37545145~37550860:+
THYM	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-6.27	1.08e-08	2.45e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
THYM	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	6.27	1.08e-08	2.45e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	6.27	1.08e-08	2.45e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
THYM	cis	rs4691139	1	rs12512283	ENSG00000250227.1	TRIM60P14	6.27	1.08e-08	2.46e-05	0.63	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987775	chr4:164915565~164916983:+
THYM	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-6.27	1.08e-08	2.46e-05	-0.51	-0.54	Depression;	chr6:28201380	chr6:28115628~28116551:+
THYM	cis	rs11722228	0.521	rs12501336	ENSG00000261490.1	RP11-448G15.3	6.27	1.1e-08	2.49e-05	0.57	0.54	Urate levels;Serum uric acid levels;Gout;	chr4:10135727	chr4:10068089~10073019:-
THYM	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	6.27	1.11e-08	2.51e-05	0.66	0.54	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	6.27	1.11e-08	2.51e-05	0.66	0.54	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	6.27	1.11e-08	2.51e-05	0.66	0.54	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	6.27	1.11e-08	2.51e-05	0.66	0.54	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	6.27	1.11e-08	2.51e-05	0.66	0.54	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
THYM	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-6.27	1.11e-08	2.51e-05	-0.63	-0.54	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
THYM	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-6.27	1.11e-08	2.51e-05	-0.63	-0.54	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
THYM	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	6.27	1.11e-08	2.51e-05	0.54	0.54	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
THYM	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	6.26	1.12e-08	2.52e-05	0.54	0.54	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	6.26	1.12e-08	2.52e-05	0.54	0.54	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
THYM	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-6.26	1.12e-08	2.52e-05	-0.54	-0.54	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	6.26	1.12e-08	2.52e-05	0.54	0.54	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
THYM	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	6.26	1.12e-08	2.53e-05	0.66	0.54	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
THYM	cis	rs4927850	1	rs6799572	ENSG00000231464.1	AC024937.4	6.26	1.12e-08	2.53e-05	0.7	0.54	Pancreatic cancer;	chr3:196013537	chr3:195996738~195998233:+
THYM	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-6.26	1.12e-08	2.53e-05	-0.7	-0.54	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
THYM	cis	rs904251	0.525	rs12200378	ENSG00000279942.1	RP1-153P14.7	-6.26	1.13e-08	2.54e-05	-0.7	-0.54	Cognitive performance;	chr6:37457528	chr6:37567716~37571460:+
THYM	cis	rs904251	0.6	rs1874736	ENSG00000279942.1	RP1-153P14.7	-6.26	1.14e-08	2.56e-05	-0.7	-0.54	Cognitive performance;	chr6:37480218	chr6:37567716~37571460:+
THYM	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-6.26	1.15e-08	2.59e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
THYM	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-6.26	1.15e-08	2.59e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
THYM	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-6.26	1.15e-08	2.59e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-6.26	1.15e-08	2.59e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
THYM	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	6.26	1.15e-08	2.59e-05	0.85	0.54	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
THYM	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	6.26	1.15e-08	2.6e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	6.26	1.15e-08	2.6e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	6.26	1.15e-08	2.6e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
THYM	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-6.26	1.16e-08	2.6e-05	-0.63	-0.54	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
THYM	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	6.26	1.16e-08	2.61e-05	0.71	0.54	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
THYM	cis	rs4691139	1	rs4691139	ENSG00000250227.1	TRIM60P14	6.26	1.17e-08	2.62e-05	0.63	0.54	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987569	chr4:164915565~164916983:+
THYM	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-6.26	1.17e-08	2.62e-05	-0.77	-0.54	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-6.26	1.17e-08	2.62e-05	-0.77	-0.54	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-6.26	1.17e-08	2.62e-05	-0.77	-0.54	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
THYM	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-6.25	1.17e-08	2.63e-05	-0.96	-0.54	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-6.25	1.17e-08	2.63e-05	-0.96	-0.54	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-6.25	1.17e-08	2.63e-05	-0.96	-0.54	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
THYM	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	6.25	1.17e-08	2.64e-05	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
THYM	cis	rs995834	1	rs995834	ENSG00000260725.1	AC005307.1	-6.25	1.18e-08	2.66e-05	-0.51	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375689	chr19:28418483~28429490:-
THYM	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	6.25	1.19e-08	2.67e-05	0.71	0.54	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	6.25	1.19e-08	2.67e-05	0.71	0.54	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
THYM	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-6.25	1.19e-08	2.67e-05	-0.66	-0.54	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
THYM	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-6.25	1.19e-08	2.67e-05	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
THYM	cis	rs904251	0.6	rs11756241	ENSG00000279942.1	RP1-153P14.7	-6.25	1.19e-08	2.67e-05	-0.69	-0.54	Cognitive performance;	chr6:37477325	chr6:37567716~37571460:+
THYM	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-6.25	1.2e-08	2.69e-05	-0.99	-0.54	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
THYM	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-6.25	1.2e-08	2.69e-05	-0.78	-0.54	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
THYM	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-6.25	1.2e-08	2.69e-05	-0.77	-0.54	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-6.25	1.2e-08	2.69e-05	-0.77	-0.54	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-6.25	1.2e-08	2.69e-05	-0.77	-0.54	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-6.25	1.2e-08	2.69e-05	-0.77	-0.54	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
THYM	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-6.25	1.21e-08	2.7e-05	-0.74	-0.54	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
THYM	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-6.25	1.21e-08	2.71e-05	-0.66	-0.54	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
THYM	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	6.25	1.22e-08	2.71e-05	0.67	0.54	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
THYM	cis	rs7182621	0.639	rs35248328	ENSG00000182397.13	DNM1P46	6.25	1.22e-08	2.71e-05	0.67	0.54	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99790156~99806927:-
THYM	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	6.25	1.22e-08	2.71e-05	0.39	0.54	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
THYM	cis	rs11157436	0.958	rs17183308	ENSG00000211813.2	TRAV34	6.25	1.22e-08	2.72e-05	0.42	0.54	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs2075494	ENSG00000211813.2	TRAV34	6.25	1.22e-08	2.72e-05	0.42	0.54	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs2242542	ENSG00000211813.2	TRAV34	6.25	1.22e-08	2.72e-05	0.42	0.54	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs17255537	ENSG00000211813.2	TRAV34	6.25	1.22e-08	2.72e-05	0.42	0.54	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.871	rs8003190	ENSG00000211813.2	TRAV34	6.25	1.22e-08	2.72e-05	0.42	0.54	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs17183356	ENSG00000211813.2	TRAV34	6.25	1.22e-08	2.72e-05	0.42	0.54	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22207522~22208129:+
THYM	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-6.25	1.22e-08	2.72e-05	-0.66	-0.54	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
THYM	cis	rs995834	0.833	rs1034885	ENSG00000267243.4	AC005307.3	-6.24	1.22e-08	2.73e-05	-0.49	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28381527	chr19:28435388~28727777:-
THYM	cis	rs7195287	0.591	rs63744561	ENSG00000276791.1	CTD-2270P14.5	6.24	1.24e-08	2.76e-05	0.71	0.54	Eosinophil counts;	chr16:2778171	chr16:2777319~2780568:+
THYM	cis	rs2335455	1	rs2335455	ENSG00000276791.1	CTD-2270P14.5	6.24	1.24e-08	2.76e-05	0.71	0.54	Sum eosinophil basophil counts;	chr16:2778172	chr16:2777319~2780568:+
THYM	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-6.24	1.24e-08	2.76e-05	-0.61	-0.54	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	6.24	1.24e-08	2.76e-05	0.61	0.54	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	6.24	1.24e-08	2.76e-05	0.61	0.54	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	6.24	1.24e-08	2.76e-05	0.61	0.54	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
THYM	cis	rs995834	0.789	rs758124	ENSG00000267243.4	AC005307.3	-6.24	1.25e-08	2.77e-05	-0.5	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402966	chr19:28435388~28727777:-
THYM	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	6.24	1.25e-08	2.77e-05	0.79	0.54	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
THYM	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-6.24	1.25e-08	2.78e-05	-0.41	-0.54	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
THYM	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-6.24	1.26e-08	2.79e-05	-0.66	-0.54	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
THYM	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-6.24	1.26e-08	2.79e-05	-0.66	-0.54	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
THYM	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	6.24	1.26e-08	2.79e-05	0.4	0.54	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
THYM	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	6.24	1.27e-08	2.81e-05	0.52	0.54	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
THYM	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-6.24	1.28e-08	2.82e-05	-0.51	-0.54	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
THYM	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-6.23	1.28e-08	2.83e-05	-0.58	-0.54	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-6.23	1.28e-08	2.83e-05	-0.58	-0.54	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
THYM	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-6.23	1.29e-08	2.85e-05	-0.61	-0.54	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
THYM	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	6.23	1.29e-08	2.85e-05	0.76	0.54	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	6.23	1.29e-08	2.85e-05	0.76	0.54	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
THYM	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	6.23	1.29e-08	2.86e-05	0.61	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
THYM	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	6.23	1.3e-08	2.86e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
THYM	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	6.23	1.3e-08	2.87e-05	0.64	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
THYM	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	6.23	1.3e-08	2.87e-05	0.64	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
THYM	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-6.23	1.3e-08	2.88e-05	-0.72	-0.54	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-6.23	1.3e-08	2.88e-05	-0.72	-0.54	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
THYM	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-6.23	1.3e-08	2.88e-05	-0.92	-0.54	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-6.23	1.3e-08	2.88e-05	-0.92	-0.54	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
THYM	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	6.23	1.3e-08	2.88e-05	0.53	0.54	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
THYM	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-6.23	1.31e-08	2.88e-05	-0.72	-0.54	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
THYM	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-6.23	1.31e-08	2.89e-05	-0.76	-0.54	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
THYM	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	6.23	1.31e-08	2.9e-05	0.72	0.54	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
THYM	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	6.23	1.32e-08	2.9e-05	0.72	0.54	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
THYM	cis	rs4273100	0.85	rs11204306	ENSG00000228157.4	AC007952.5	6.23	1.33e-08	2.92e-05	0.85	0.54	Schizophrenia;	chr17:19364058	chr17:19092974~19096837:+
THYM	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	6.23	1.33e-08	2.92e-05	0.4	0.54	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
THYM	cis	rs17772222	0.675	rs1099698	ENSG00000258983.2	RP11-507K2.2	-6.23	1.33e-08	2.93e-05	-0.6	-0.54	Coronary artery calcification;	chr14:88414904	chr14:88499334~88515502:+
THYM	cis	rs904251	0.523	rs914348	ENSG00000227920.2	RP1-153P14.5	-6.23	1.33e-08	2.94e-05	-0.73	-0.54	Cognitive performance;	chr6:37516953	chr6:37545145~37550860:+
THYM	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-6.22	1.34e-08	2.94e-05	-0.58	-0.54	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-6.22	1.34e-08	2.94e-05	-0.58	-0.54	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
THYM	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	6.22	1.34e-08	2.95e-05	0.63	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
THYM	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	6.22	1.35e-08	2.96e-05	0.53	0.54	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	6.22	1.35e-08	2.96e-05	0.53	0.54	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
THYM	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.22	1.35e-08	2.96e-05	-0.75	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
THYM	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-6.22	1.36e-08	2.97e-05	-0.7	-0.54	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
THYM	cis	rs17772222	0.582	rs11625009	ENSG00000258983.2	RP11-507K2.2	-6.22	1.38e-08	3.01e-05	-0.62	-0.54	Coronary artery calcification;	chr14:88521018	chr14:88499334~88515502:+
THYM	cis	rs2739330	0.731	rs4822450	ENSG00000272787.1	KB-226F1.2	-6.22	1.38e-08	3.01e-05	-0.58	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23969211~23969873:+
THYM	cis	rs2739330	0.76	rs5751761	ENSG00000272787.1	KB-226F1.2	6.22	1.38e-08	3.01e-05	0.58	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23969211~23969873:+
THYM	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	6.22	1.39e-08	3.02e-05	0.72	0.54	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
THYM	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	6.22	1.39e-08	3.02e-05	0.72	0.54	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
THYM	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	6.22	1.39e-08	3.02e-05	0.72	0.54	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
THYM	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	6.22	1.39e-08	3.02e-05	0.72	0.54	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
THYM	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	6.22	1.39e-08	3.02e-05	0.95	0.54	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
THYM	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	6.22	1.39e-08	3.02e-05	0.85	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
THYM	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	6.21	1.4e-08	3.03e-05	0.69	0.54	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
THYM	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	6.21	1.4e-08	3.04e-05	0.72	0.54	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
THYM	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-6.21	1.4e-08	3.04e-05	-0.65	-0.54	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
THYM	cis	rs2739330	0.76	rs1007888	ENSG00000272787.1	KB-226F1.2	-6.21	1.41e-08	3.06e-05	-0.58	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23969211~23969873:+
THYM	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-6.21	1.41e-08	3.06e-05	-0.7	-0.54	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
THYM	cis	rs2739330	0.76	rs5751760	ENSG00000272787.1	KB-226F1.2	-6.21	1.41e-08	3.07e-05	-0.58	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23969211~23969873:+
THYM	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	6.21	1.41e-08	3.07e-05	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	6.21	1.41e-08	3.07e-05	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs6004657	ENSG00000100058.11	CRYBB2P1	6.21	1.41e-08	3.07e-05	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	6.21	1.41e-08	3.07e-05	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
THYM	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	6.21	1.42e-08	3.07e-05	0.71	0.54	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	6.21	1.42e-08	3.07e-05	0.71	0.54	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	6.21	1.42e-08	3.08e-05	0.71	0.54	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-6.21	1.43e-08	3.1e-05	-0.42	-0.54	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-6.21	1.43e-08	3.1e-05	-0.42	-0.54	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
THYM	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-6.21	1.43e-08	3.1e-05	-0.42	-0.54	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
THYM	cis	rs7242404	0.811	rs12970808	ENSG00000260302.1	RP11-973H7.1	6.21	1.43e-08	3.1e-05	0.39	0.54	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12749850	chr18:12774651~12775923:-
THYM	cis	rs904251	1	rs12212090	ENSG00000227920.2	RP1-153P14.5	-6.21	1.43e-08	3.1e-05	-0.75	-0.54	Cognitive performance;	chr6:37464032	chr6:37545145~37550860:+
THYM	cis	rs904251	0.965	rs62406516	ENSG00000227920.2	RP1-153P14.5	-6.21	1.43e-08	3.1e-05	-0.75	-0.54	Cognitive performance;	chr6:37471588	chr6:37545145~37550860:+
THYM	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-6.21	1.44e-08	3.11e-05	-0.39	-0.54	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-6.21	1.44e-08	3.11e-05	-0.39	-0.54	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
THYM	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-6.21	1.44e-08	3.11e-05	-0.65	-0.54	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
THYM	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	6.21	1.44e-08	3.11e-05	0.7	0.54	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
THYM	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	6.21	1.44e-08	3.12e-05	0.71	0.54	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
THYM	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-6.21	1.45e-08	3.14e-05	-0.67	-0.54	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
THYM	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-6.21	1.45e-08	3.14e-05	-0.67	-0.54	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
THYM	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-6.21	1.45e-08	3.14e-05	-0.67	-0.54	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
THYM	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-6.21	1.45e-08	3.14e-05	-0.73	-0.54	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-6.21	1.45e-08	3.14e-05	-0.73	-0.54	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
THYM	cis	rs950169	0.763	rs35372971	ENSG00000235370.6	DNM1P51	6.2	1.46e-08	3.16e-05	0.69	0.54	Schizophrenia;	chr15:84387097	chr15:84398316~84411701:-
THYM	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	6.2	1.46e-08	3.16e-05	0.69	0.54	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
THYM	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	6.2	1.47e-08	3.16e-05	0.64	0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
THYM	cis	rs995834	0.957	rs8105942	ENSG00000260725.1	AC005307.1	-6.2	1.47e-08	3.16e-05	-0.51	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28359455	chr19:28418483~28429490:-
THYM	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	6.2	1.47e-08	3.16e-05	0.6	0.54	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
THYM	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-6.2	1.47e-08	3.17e-05	-0.65	-0.54	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
THYM	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-6.2	1.47e-08	3.17e-05	-0.72	-0.54	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
THYM	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	6.2	1.48e-08	3.17e-05	0.42	0.54	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
THYM	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	6.2	1.48e-08	3.18e-05	0.48	0.54	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
THYM	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	6.2	1.5e-08	3.23e-05	0.65	0.54	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
THYM	cis	rs453301	0.538	rs7830804	ENSG00000253893.2	FAM85B	6.2	1.51e-08	3.24e-05	0.64	0.54	Joint mobility (Beighton score);	chr8:9113252	chr8:8167819~8226614:-
THYM	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	6.2	1.51e-08	3.25e-05	0.41	0.54	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
THYM	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	6.2	1.51e-08	3.25e-05	0.41	0.54	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
THYM	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	6.2	1.51e-08	3.25e-05	0.41	0.54	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
THYM	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	6.2	1.52e-08	3.26e-05	0.68	0.54	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
THYM	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	6.2	1.52e-08	3.27e-05	0.44	0.54	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	6.2	1.52e-08	3.27e-05	0.44	0.54	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
THYM	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	6.2	1.53e-08	3.27e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
THYM	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	6.19	1.54e-08	3.29e-05	0.61	0.54	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-6.19	1.54e-08	3.29e-05	-0.61	-0.54	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
THYM	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-6.19	1.55e-08	3.31e-05	-0.78	-0.54	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
THYM	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	6.19	1.55e-08	3.31e-05	0.53	0.54	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	6.19	1.55e-08	3.31e-05	0.53	0.54	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	6.19	1.55e-08	3.31e-05	0.53	0.54	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	6.19	1.55e-08	3.31e-05	0.53	0.54	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
THYM	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-6.19	1.55e-08	3.31e-05	-0.68	-0.54	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
THYM	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-6.19	1.55e-08	3.32e-05	-0.75	-0.54	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
THYM	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-6.19	1.55e-08	3.32e-05	-0.54	-0.54	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
THYM	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	6.19	1.56e-08	3.33e-05	0.48	0.54	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
THYM	cis	rs694739	0.79	rs1199047	ENSG00000236935.1	AP003774.1	6.19	1.57e-08	3.35e-05	0.42	0.54	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64350711	chr11:64325050~64329504:-
THYM	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	6.19	1.57e-08	3.35e-05	0.66	0.54	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	6.19	1.57e-08	3.35e-05	0.66	0.54	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	6.19	1.57e-08	3.35e-05	0.66	0.54	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	6.19	1.57e-08	3.35e-05	0.66	0.54	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	6.19	1.57e-08	3.35e-05	0.66	0.54	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	6.19	1.57e-08	3.35e-05	0.66	0.54	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
THYM	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-6.19	1.57e-08	3.36e-05	-0.69	-0.54	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
THYM	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	6.18	1.6e-08	3.42e-05	0.49	0.54	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
THYM	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-6.18	1.6e-08	3.42e-05	-0.49	-0.54	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
THYM	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-6.18	1.6e-08	3.42e-05	-0.49	-0.54	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
THYM	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-6.18	1.6e-08	3.42e-05	-0.63	-0.54	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
THYM	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	6.18	1.61e-08	3.43e-05	0.59	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
THYM	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	6.18	1.61e-08	3.43e-05	0.76	0.54	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
THYM	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	6.18	1.61e-08	3.44e-05	0.5	0.54	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
THYM	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-6.18	1.61e-08	3.44e-05	-0.57	-0.54	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
THYM	cis	rs995834	0.957	rs11667725	ENSG00000267243.4	AC005307.3	-6.18	1.61e-08	3.44e-05	-0.45	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28361557	chr19:28435388~28727777:-
THYM	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-6.18	1.62e-08	3.45e-05	-0.47	-0.54	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
THYM	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-6.18	1.62e-08	3.46e-05	-0.53	-0.54	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	6.18	1.62e-08	3.46e-05	0.53	0.54	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
THYM	cis	rs7242404	0.811	rs12959287	ENSG00000260302.1	RP11-973H7.1	6.18	1.64e-08	3.49e-05	0.39	0.54	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12761499	chr18:12774651~12775923:-
THYM	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-6.18	1.64e-08	3.5e-05	-0.61	-0.54	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
THYM	cis	rs11722228	0.522	rs62286604	ENSG00000261490.1	RP11-448G15.3	6.18	1.66e-08	3.52e-05	0.57	0.54	Urate levels;Serum uric acid levels;Gout;	chr4:10129537	chr4:10068089~10073019:-
THYM	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-6.18	1.66e-08	3.52e-05	-0.64	-0.54	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
THYM	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	6.18	1.66e-08	3.52e-05	0.63	0.54	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
THYM	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	6.18	1.67e-08	3.54e-05	0.52	0.54	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
THYM	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-6.18	1.67e-08	3.54e-05	-0.62	-0.54	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
THYM	cis	rs5760092	0.618	rs5996631	ENSG00000272787.1	KB-226F1.2	6.18	1.67e-08	3.54e-05	0.67	0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23969211~23969873:+
THYM	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	6.18	1.67e-08	3.54e-05	0.68	0.54	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
THYM	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-6.18	1.67e-08	3.55e-05	-0.49	-0.54	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
THYM	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	6.18	1.67e-08	3.55e-05	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
THYM	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	6.17	1.68e-08	3.57e-05	0.65	0.54	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
THYM	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	6.17	1.68e-08	3.57e-05	0.62	0.54	Height;	chr6:109424122	chr6:109382795~109383666:+
THYM	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-6.17	1.69e-08	3.58e-05	-1.04	-0.54	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
THYM	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-6.17	1.69e-08	3.58e-05	-1.04	-0.54	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-6.17	1.69e-08	3.58e-05	-1.04	-0.54	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
THYM	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	6.17	1.69e-08	3.58e-05	1.04	0.54	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
THYM	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-6.17	1.69e-08	3.58e-05	-1.04	-0.54	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
THYM	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-6.17	1.69e-08	3.58e-05	-1.04	-0.54	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
THYM	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-6.17	1.69e-08	3.58e-05	-1.04	-0.54	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
THYM	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-6.17	1.69e-08	3.58e-05	-1.04	-0.54	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
THYM	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	6.17	1.69e-08	3.59e-05	0.95	0.54	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
THYM	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-6.17	1.7e-08	3.6e-05	-0.84	-0.54	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
THYM	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-6.17	1.7e-08	3.61e-05	-0.66	-0.54	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-6.17	1.7e-08	3.61e-05	-0.66	-0.54	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-6.17	1.7e-08	3.61e-05	-0.66	-0.54	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-6.17	1.7e-08	3.61e-05	-0.66	-0.54	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
THYM	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-6.17	1.71e-08	3.61e-05	-0.62	-0.54	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
THYM	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-6.17	1.71e-08	3.61e-05	-0.62	-0.54	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
THYM	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-6.17	1.71e-08	3.61e-05	-0.62	-0.54	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
THYM	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-6.17	1.72e-08	3.64e-05	-0.85	-0.54	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-6.17	1.72e-08	3.64e-05	-0.85	-0.54	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
THYM	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	6.17	1.72e-08	3.65e-05	0.55	0.54	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-6.17	1.72e-08	3.65e-05	-0.51	-0.54	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
THYM	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-6.17	1.73e-08	3.66e-05	-0.62	-0.54	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
THYM	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	6.17	1.73e-08	3.67e-05	0.83	0.54	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-6.17	1.73e-08	3.67e-05	-0.83	-0.54	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-6.17	1.73e-08	3.67e-05	-0.83	-0.54	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-6.17	1.73e-08	3.67e-05	-0.83	-0.54	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-6.17	1.73e-08	3.67e-05	-0.83	-0.54	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
THYM	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-6.17	1.73e-08	3.67e-05	-0.83	-0.54	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
THYM	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-6.17	1.73e-08	3.67e-05	-0.83	-0.54	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
THYM	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-6.17	1.73e-08	3.67e-05	-0.4	-0.54	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	6.17	1.73e-08	3.67e-05	0.4	0.54	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	6.17	1.73e-08	3.67e-05	0.4	0.54	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
THYM	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-6.17	1.74e-08	3.68e-05	-0.52	-0.54	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
THYM	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-6.17	1.74e-08	3.68e-05	-0.73	-0.54	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
THYM	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	6.17	1.75e-08	3.69e-05	0.65	0.54	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
THYM	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-6.16	1.75e-08	3.7e-05	-0.49	-0.54	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
THYM	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-6.16	1.75e-08	3.7e-05	-0.49	-0.54	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
THYM	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	6.16	1.75e-08	3.71e-05	0.48	0.54	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
THYM	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
THYM	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
THYM	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
THYM	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
THYM	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
THYM	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
THYM	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
THYM	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-6.16	1.76e-08	3.73e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
THYM	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	6.16	1.77e-08	3.73e-05	0.53	0.54	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
THYM	cis	rs950169	0.922	rs11631096	ENSG00000235370.6	DNM1P51	6.16	1.77e-08	3.73e-05	0.65	0.54	Schizophrenia;	chr15:84557698	chr15:84398316~84411701:-
THYM	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-6.16	1.78e-08	3.75e-05	-0.55	-0.54	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-6.16	1.78e-08	3.75e-05	-0.55	-0.54	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-6.16	1.78e-08	3.75e-05	-0.55	-0.54	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
THYM	cis	rs4273100	0.79	rs2048230	ENSG00000228157.4	AC007952.5	6.16	1.78e-08	3.75e-05	0.84	0.54	Schizophrenia;	chr17:19372886	chr17:19092974~19096837:+
THYM	cis	rs4273100	0.79	rs60606605	ENSG00000228157.4	AC007952.5	6.16	1.78e-08	3.75e-05	0.84	0.54	Schizophrenia;	chr17:19373831	chr17:19092974~19096837:+
THYM	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-6.16	1.79e-08	3.77e-05	-0.65	-0.54	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
THYM	cis	rs7772486	0.654	rs4896829	ENSG00000235652.6	RP11-545I5.3	6.16	1.79e-08	3.78e-05	0.39	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145799409~145886585:+
THYM	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-6.16	1.8e-08	3.8e-05	-0.66	-0.54	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
THYM	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-6.16	1.82e-08	3.83e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-6.16	1.82e-08	3.83e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
THYM	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	6.16	1.83e-08	3.84e-05	0.4	0.54	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
THYM	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-6.16	1.83e-08	3.85e-05	-0.67	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
THYM	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-6.16	1.83e-08	3.85e-05	-0.67	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
THYM	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	6.16	1.83e-08	3.85e-05	0.97	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
THYM	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-6.15	1.84e-08	3.86e-05	-0.63	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
THYM	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-6.15	1.84e-08	3.87e-05	-0.67	-0.54	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
THYM	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	6.15	1.84e-08	3.87e-05	0.69	0.54	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	6.15	1.84e-08	3.87e-05	0.69	0.54	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	6.15	1.84e-08	3.87e-05	0.69	0.54	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	6.15	1.84e-08	3.87e-05	0.69	0.54	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
THYM	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-6.15	1.86e-08	3.9e-05	-0.67	-0.54	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
THYM	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	6.15	1.86e-08	3.91e-05	0.68	0.54	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
THYM	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	6.15	1.87e-08	3.92e-05	0.85	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
THYM	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	6.15	1.87e-08	3.92e-05	0.85	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	6.15	1.87e-08	3.92e-05	0.85	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
THYM	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	6.15	1.87e-08	3.92e-05	0.85	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
THYM	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-6.15	1.87e-08	3.92e-05	-0.76	-0.54	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
THYM	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-6.15	1.88e-08	3.93e-05	-0.68	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	6.15	1.88e-08	3.94e-05	0.68	0.54	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-6.15	1.88e-08	3.94e-05	-0.68	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	6.15	1.88e-08	3.94e-05	0.68	0.54	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-6.15	1.88e-08	3.94e-05	-0.68	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-6.15	1.88e-08	3.94e-05	-0.68	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-6.15	1.88e-08	3.94e-05	-0.68	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-6.15	1.88e-08	3.94e-05	-0.73	-0.54	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
THYM	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-6.15	1.88e-08	3.94e-05	-0.59	-0.54	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
THYM	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	6.15	1.9e-08	3.97e-05	0.62	0.54	Height;	chr6:109383848	chr6:109382795~109383666:+
THYM	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-6.15	1.9e-08	3.98e-05	-0.42	-0.54	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
THYM	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	6.15	1.91e-08	3.99e-05	0.5	0.54	Depression;	chr6:28086929	chr6:28115628~28116551:+
THYM	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-6.15	1.91e-08	4e-05	-0.7	-0.54	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
THYM	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	6.14	1.92e-08	4.02e-05	0.41	0.54	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
THYM	cis	rs995834	0.872	rs10425754	ENSG00000267243.4	AC005307.3	-6.14	1.92e-08	4.02e-05	-0.48	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387708	chr19:28435388~28727777:-
THYM	cis	rs995834	0.869	rs10853719	ENSG00000267243.4	AC005307.3	-6.14	1.92e-08	4.02e-05	-0.48	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392287	chr19:28435388~28727777:-
THYM	cis	rs995834	0.869	rs10405674	ENSG00000267243.4	AC005307.3	-6.14	1.92e-08	4.02e-05	-0.48	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393703	chr19:28435388~28727777:-
THYM	cis	rs995834	0.869	rs9304581	ENSG00000267243.4	AC005307.3	-6.14	1.92e-08	4.02e-05	-0.48	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394084	chr19:28435388~28727777:-
THYM	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-6.14	1.93e-08	4.04e-05	-0.67	-0.54	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-6.14	1.93e-08	4.04e-05	-0.67	-0.54	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-6.14	1.93e-08	4.04e-05	-0.67	-0.54	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
THYM	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-6.14	1.94e-08	4.05e-05	-0.78	-0.54	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
THYM	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-6.14	1.95e-08	4.07e-05	-0.6	-0.54	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
THYM	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	6.14	1.95e-08	4.07e-05	0.77	0.54	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
THYM	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	6.14	1.96e-08	4.07e-05	0.7	0.54	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	6.14	1.96e-08	4.07e-05	0.7	0.54	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	6.14	1.96e-08	4.07e-05	0.7	0.54	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	6.14	1.96e-08	4.07e-05	0.7	0.54	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
THYM	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	6.14	1.96e-08	4.08e-05	0.52	0.54	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
THYM	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-6.14	1.96e-08	4.08e-05	-0.77	-0.54	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
THYM	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	6.14	1.98e-08	4.11e-05	0.7	0.53	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
THYM	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	6.14	1.98e-08	4.11e-05	0.53	0.53	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
THYM	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-6.14	1.98e-08	4.11e-05	-0.68	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
THYM	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	6.14	1.99e-08	4.12e-05	0.53	0.53	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	6.14	1.99e-08	4.12e-05	0.53	0.53	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	6.14	1.99e-08	4.12e-05	0.53	0.53	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	6.14	1.99e-08	4.12e-05	0.53	0.53	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
THYM	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-6.14	1.99e-08	4.13e-05	-0.76	-0.53	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
THYM	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	6.14	1.99e-08	4.13e-05	0.52	0.53	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
THYM	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-6.13	2.01e-08	4.16e-05	-0.7	-0.53	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
THYM	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	6.13	2.03e-08	4.21e-05	0.59	0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-6.13	2.03e-08	4.21e-05	-0.59	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
THYM	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	6.13	2.04e-08	4.23e-05	0.53	0.53	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
THYM	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	6.13	2.06e-08	4.26e-05	0.66	0.53	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
THYM	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	6.13	2.07e-08	4.27e-05	0.6	0.53	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
THYM	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	6.13	2.08e-08	4.28e-05	0.87	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
THYM	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-6.12	2.1e-08	4.32e-05	-0.67	-0.53	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
THYM	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	6.12	2.11e-08	4.34e-05	0.63	0.53	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
THYM	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	6.12	2.12e-08	4.35e-05	0.75	0.53	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
THYM	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-6.12	2.12e-08	4.35e-05	-0.72	-0.53	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
THYM	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-6.12	2.12e-08	4.35e-05	-0.72	-0.53	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
THYM	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-6.12	2.13e-08	4.36e-05	-0.42	-0.53	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-6.12	2.13e-08	4.36e-05	-0.42	-0.53	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-6.12	2.13e-08	4.36e-05	-0.42	-0.53	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-6.12	2.13e-08	4.36e-05	-0.42	-0.53	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-6.12	2.13e-08	4.36e-05	-0.42	-0.53	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-6.12	2.13e-08	4.36e-05	-0.42	-0.53	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-6.12	2.13e-08	4.36e-05	-0.42	-0.53	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
THYM	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-6.12	2.15e-08	4.4e-05	-0.67	-0.53	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-6.12	2.15e-08	4.4e-05	-0.67	-0.53	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
THYM	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-6.12	2.15e-08	4.4e-05	-0.6	-0.53	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	6.12	2.15e-08	4.4e-05	0.6	0.53	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	6.12	2.15e-08	4.4e-05	0.6	0.53	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
THYM	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	6.12	2.17e-08	4.44e-05	0.65	0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
THYM	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-6.12	2.17e-08	4.44e-05	-0.67	-0.53	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-6.12	2.17e-08	4.44e-05	-0.67	-0.53	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	6.12	2.17e-08	4.44e-05	0.67	0.53	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	6.12	2.18e-08	4.46e-05	0.75	0.53	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
THYM	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	6.12	2.18e-08	4.47e-05	0.53	0.53	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
THYM	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	6.12	2.18e-08	4.47e-05	0.41	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
THYM	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	6.12	2.19e-08	4.48e-05	0.63	0.53	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
THYM	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	6.11	2.19e-08	4.48e-05	0.77	0.53	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
THYM	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-6.11	2.19e-08	4.49e-05	-0.66	-0.53	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
THYM	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	6.11	2.21e-08	4.51e-05	0.53	0.53	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
THYM	cis	rs7242404	0.811	rs17655374	ENSG00000260302.1	RP11-973H7.1	-6.11	2.22e-08	4.52e-05	-0.39	-0.53	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12750759	chr18:12774651~12775923:-
THYM	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	6.11	2.23e-08	4.55e-05	0.43	0.53	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
THYM	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	6.11	2.24e-08	4.55e-05	0.71	0.53	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
THYM	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-6.11	2.24e-08	4.56e-05	-0.68	-0.53	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
THYM	cis	rs904251	1	rs10947673	ENSG00000227920.2	RP1-153P14.5	-6.11	2.24e-08	4.56e-05	-0.75	-0.53	Cognitive performance;	chr6:37477303	chr6:37545145~37550860:+
THYM	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	6.11	2.24e-08	4.56e-05	0.97	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
THYM	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-6.11	2.26e-08	4.6e-05	-0.85	-0.53	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
THYM	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	6.11	2.27e-08	4.6e-05	0.39	0.53	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	6.11	2.27e-08	4.6e-05	0.39	0.53	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	6.11	2.27e-08	4.6e-05	0.39	0.53	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	6.11	2.27e-08	4.6e-05	0.39	0.53	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
THYM	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-6.11	2.27e-08	4.61e-05	-0.64	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
THYM	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-6.1	2.3e-08	4.67e-05	-0.76	-0.53	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-6.1	2.3e-08	4.67e-05	-0.76	-0.53	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-6.1	2.3e-08	4.67e-05	-0.76	-0.53	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-6.1	2.3e-08	4.67e-05	-0.76	-0.53	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
THYM	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-6.1	2.3e-08	4.67e-05	-0.76	-0.53	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	6.1	2.3e-08	4.67e-05	0.68	0.53	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
THYM	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	6.1	2.31e-08	4.68e-05	0.75	0.53	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	6.1	2.31e-08	4.68e-05	0.75	0.53	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	6.1	2.31e-08	4.68e-05	0.75	0.53	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
THYM	cis	rs950169	0.922	rs4842939	ENSG00000235370.6	DNM1P51	-6.1	2.31e-08	4.68e-05	-0.68	-0.53	Schizophrenia;	chr15:84159214	chr15:84398316~84411701:-
THYM	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	6.1	2.32e-08	4.71e-05	0.71	0.53	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
THYM	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	6.1	2.33e-08	4.72e-05	0.68	0.53	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
THYM	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-6.1	2.33e-08	4.72e-05	-0.66	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
THYM	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	6.1	2.33e-08	4.72e-05	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	6.1	2.33e-08	4.72e-05	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	6.1	2.33e-08	4.72e-05	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	6.1	2.33e-08	4.72e-05	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	6.1	2.33e-08	4.72e-05	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	6.1	2.33e-08	4.72e-05	0.61	0.53	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
THYM	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	6.1	2.33e-08	4.72e-05	0.52	0.53	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
THYM	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	6.1	2.34e-08	4.74e-05	0.39	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
THYM	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-6.1	2.35e-08	4.75e-05	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-6.1	2.35e-08	4.75e-05	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-6.1	2.35e-08	4.75e-05	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
THYM	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-6.1	2.37e-08	4.78e-05	-0.6	-0.53	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
THYM	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-6.1	2.38e-08	4.8e-05	-0.48	-0.53	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
THYM	cis	rs11722228	0.522	rs73212808	ENSG00000261490.1	RP11-448G15.3	6.1	2.38e-08	4.81e-05	0.59	0.53	Urate levels;Serum uric acid levels;Gout;	chr4:10053815	chr4:10068089~10073019:-
THYM	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-6.1	2.38e-08	4.81e-05	-0.61	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
THYM	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-6.1	2.38e-08	4.81e-05	-0.94	-0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
THYM	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	6.1	2.38e-08	4.82e-05	0.68	0.53	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
THYM	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	6.1	2.38e-08	4.82e-05	0.68	0.53	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
THYM	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	6.1	2.38e-08	4.82e-05	0.68	0.53	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
THYM	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	6.1	2.38e-08	4.82e-05	0.68	0.53	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
THYM	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	6.1	2.38e-08	4.82e-05	0.68	0.53	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
THYM	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	6.1	2.39e-08	4.84e-05	0.64	0.53	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
THYM	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-6.09	2.4e-08	4.84e-05	-0.59	-0.53	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
THYM	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	6.09	2.4e-08	4.84e-05	0.55	0.53	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
THYM	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	6.09	2.41e-08	4.86e-05	0.68	0.53	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
THYM	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	6.09	2.41e-08	4.86e-05	0.65	0.53	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
THYM	cis	rs950169	0.845	rs4106951	ENSG00000235370.6	DNM1P51	6.09	2.41e-08	4.86e-05	0.68	0.53	Schizophrenia;	chr15:84164642	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs4586394	ENSG00000235370.6	DNM1P51	-6.09	2.41e-08	4.86e-05	-0.68	-0.53	Schizophrenia;	chr15:84153633	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs6603022	ENSG00000235370.6	DNM1P51	-6.09	2.41e-08	4.86e-05	-0.68	-0.53	Schizophrenia;	chr15:84161418	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs4842940	ENSG00000235370.6	DNM1P51	-6.09	2.41e-08	4.86e-05	-0.68	-0.53	Schizophrenia;	chr15:84162473	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs4842941	ENSG00000235370.6	DNM1P51	-6.09	2.41e-08	4.86e-05	-0.68	-0.53	Schizophrenia;	chr15:84162560	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs12911223	ENSG00000235370.6	DNM1P51	-6.09	2.41e-08	4.86e-05	-0.68	-0.53	Schizophrenia;	chr15:84162919	chr15:84398316~84411701:-
THYM	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-6.09	2.43e-08	4.89e-05	-0.68	-0.53	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
THYM	cis	rs11722228	0.522	rs881641	ENSG00000261490.1	RP11-448G15.3	6.09	2.43e-08	4.89e-05	0.55	0.53	Urate levels;Serum uric acid levels;Gout;	chr4:10132123	chr4:10068089~10073019:-
THYM	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-6.09	2.44e-08	4.92e-05	-0.61	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
THYM	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	6.09	2.44e-08	4.92e-05	0.69	0.53	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
THYM	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-6.09	2.45e-08	4.94e-05	-0.64	-0.53	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-6.09	2.45e-08	4.94e-05	-0.64	-0.53	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
THYM	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-6.09	2.46e-08	4.95e-05	-0.55	-0.53	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
THYM	cis	rs950169	0.881	rs150965	ENSG00000235370.6	DNM1P51	6.09	2.47e-08	4.98e-05	0.67	0.53	Schizophrenia;	chr15:84537296	chr15:84398316~84411701:-
THYM	cis	rs11722228	0.522	rs7681250	ENSG00000261490.1	RP11-448G15.3	6.09	2.47e-08	4.98e-05	0.55	0.53	Urate levels;Serum uric acid levels;Gout;	chr4:10131389	chr4:10068089~10073019:-
THYM	cis	rs11722228	0.522	rs7662229	ENSG00000261490.1	RP11-448G15.3	6.09	2.47e-08	4.98e-05	0.55	0.53	Urate levels;Serum uric acid levels;Gout;	chr4:10131390	chr4:10068089~10073019:-
THYM	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	6.09	2.49e-08	5.01e-05	0.49	0.53	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
THYM	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	6.09	2.49e-08	5.01e-05	0.69	0.53	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
THYM	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	6.08	2.51e-08	5.04e-05	0.68	0.53	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
THYM	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	6.08	2.52e-08	5.05e-05	0.71	0.53	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
THYM	cis	rs995834	0.912	rs4806341	ENSG00000267243.4	AC005307.3	-6.08	2.52e-08	5.06e-05	-0.47	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384371	chr19:28435388~28727777:-
THYM	cis	rs995834	0.912	rs4806343	ENSG00000267243.4	AC005307.3	-6.08	2.52e-08	5.06e-05	-0.47	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384874	chr19:28435388~28727777:-
THYM	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	6.08	2.53e-08	5.08e-05	0.53	0.53	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
THYM	cis	rs995834	0.912	rs12608446	ENSG00000267243.4	AC005307.3	-6.08	2.55e-08	5.11e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384329	chr19:28435388~28727777:-
THYM	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	6.08	2.56e-08	5.12e-05	0.59	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
THYM	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-6.08	2.56e-08	5.12e-05	-0.59	-0.53	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
THYM	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	6.08	2.56e-08	5.13e-05	0.41	0.53	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
THYM	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-6.08	2.57e-08	5.14e-05	-0.52	-0.53	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
THYM	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	6.08	2.57e-08	5.14e-05	0.63	0.53	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
THYM	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	6.08	2.57e-08	5.14e-05	0.7	0.53	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
THYM	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	6.08	2.57e-08	5.14e-05	0.7	0.53	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
THYM	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	6.08	2.57e-08	5.14e-05	0.7	0.53	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
THYM	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	6.08	2.57e-08	5.14e-05	0.7	0.53	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
THYM	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-6.08	2.57e-08	5.14e-05	-0.59	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
THYM	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-6.08	2.58e-08	5.15e-05	-0.45	-0.53	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
THYM	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-6.08	2.58e-08	5.15e-05	-0.9	-0.53	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
THYM	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-6.08	2.58e-08	5.16e-05	-0.57	-0.53	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-6.08	2.58e-08	5.16e-05	-0.57	-0.53	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.08	2.58e-08	5.16e-05	-0.57	-0.53	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.08	2.58e-08	5.16e-05	-0.57	-0.53	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
THYM	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	6.08	2.61e-08	5.21e-05	0.7	0.53	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
THYM	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-6.08	2.62e-08	5.23e-05	-0.96	-0.53	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
THYM	cis	rs7829975	0.632	rs28663303	ENSG00000253893.2	FAM85B	6.07	2.63e-08	5.24e-05	0.65	0.53	Mood instability;	chr8:8698768	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.632	rs68168815	ENSG00000253893.2	FAM85B	6.07	2.63e-08	5.24e-05	0.65	0.53	Mood instability;	chr8:8699355	chr8:8167819~8226614:-
THYM	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	6.07	2.63e-08	5.24e-05	0.71	0.53	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
THYM	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-6.07	2.63e-08	5.24e-05	-0.72	-0.53	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
THYM	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-6.07	2.66e-08	5.29e-05	-0.59	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
THYM	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	6.07	2.66e-08	5.3e-05	0.56	0.53	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
THYM	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	6.07	2.67e-08	5.32e-05	0.38	0.53	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	6.07	2.67e-08	5.32e-05	0.38	0.53	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	6.07	2.67e-08	5.32e-05	0.38	0.53	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
THYM	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-6.07	2.68e-08	5.32e-05	-0.59	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
THYM	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	6.07	2.68e-08	5.34e-05	0.74	0.53	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
THYM	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	6.07	2.69e-08	5.35e-05	0.53	0.53	Depression;	chr6:28167882	chr6:28115628~28116551:+
THYM	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-6.07	2.69e-08	5.36e-05	-0.53	-0.53	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-6.07	2.69e-08	5.36e-05	-0.53	-0.53	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
THYM	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-6.07	2.71e-08	5.37e-05	-0.65	-0.53	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
THYM	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	6.07	2.71e-08	5.39e-05	0.58	0.53	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
THYM	cis	rs950169	0.887	rs220333	ENSG00000235370.6	DNM1P51	6.07	2.72e-08	5.4e-05	0.65	0.53	Schizophrenia;	chr15:84547902	chr15:84398316~84411701:-
THYM	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	6.06	2.75e-08	5.44e-05	0.68	0.53	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
THYM	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	6.06	2.75e-08	5.45e-05	0.43	0.53	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
THYM	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	6.06	2.78e-08	5.5e-05	0.49	0.53	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
THYM	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	6.06	2.8e-08	5.53e-05	0.39	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
THYM	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	6.06	2.8e-08	5.53e-05	0.39	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
THYM	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	6.06	2.8e-08	5.53e-05	0.39	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
THYM	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	6.06	2.8e-08	5.53e-05	0.39	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
THYM	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	6.06	2.8e-08	5.53e-05	0.39	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
THYM	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	6.06	2.8e-08	5.53e-05	0.39	0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
THYM	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	6.06	2.8e-08	5.54e-05	0.69	0.53	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	6.06	2.8e-08	5.54e-05	0.69	0.53	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	6.06	2.8e-08	5.54e-05	0.69	0.53	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	6.06	2.8e-08	5.54e-05	0.69	0.53	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
THYM	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-6.06	2.81e-08	5.55e-05	-0.38	-0.53	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-6.06	2.81e-08	5.55e-05	-0.38	-0.53	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
THYM	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-6.06	2.81e-08	5.55e-05	-0.59	-0.53	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-6.06	2.81e-08	5.55e-05	-0.59	-0.53	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
THYM	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-6.06	2.81e-08	5.55e-05	-0.59	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
THYM	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-6.06	2.81e-08	5.55e-05	-0.59	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
THYM	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-6.06	2.81e-08	5.55e-05	-0.59	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
THYM	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-6.06	2.82e-08	5.56e-05	-0.53	-0.53	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-6.06	2.82e-08	5.56e-05	-0.53	-0.53	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-6.06	2.82e-08	5.56e-05	-0.53	-0.53	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
THYM	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
THYM	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
THYM	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
THYM	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	6.06	2.82e-08	5.56e-05	0.38	0.53	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
THYM	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	6.06	2.85e-08	5.61e-05	0.6	0.53	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
THYM	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	6.06	2.86e-08	5.62e-05	0.4	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
THYM	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	6.06	2.86e-08	5.62e-05	0.38	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	6.06	2.86e-08	5.62e-05	0.38	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-6.06	2.86e-08	5.62e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
THYM	cis	rs995834	0.869	rs10417250	ENSG00000267243.4	AC005307.3	-6.06	2.86e-08	5.63e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395342	chr19:28435388~28727777:-
THYM	cis	rs17772222	0.638	rs11159859	ENSG00000258983.2	RP11-507K2.2	6.05	2.88e-08	5.66e-05	0.64	0.53	Coronary artery calcification;	chr14:88561547	chr14:88499334~88515502:+
THYM	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	6.05	2.88e-08	5.66e-05	0.69	0.53	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
THYM	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-6.05	2.89e-08	5.66e-05	-0.6	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
THYM	cis	rs11722228	0.522	rs77691548	ENSG00000261490.1	RP11-448G15.3	6.05	2.89e-08	5.66e-05	0.55	0.53	Urate levels;Serum uric acid levels;Gout;	chr4:10134491	chr4:10068089~10073019:-
THYM	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	6.05	2.89e-08	5.67e-05	0.4	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	6.05	2.89e-08	5.67e-05	0.4	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
THYM	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-6.05	2.89e-08	5.67e-05	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
THYM	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-6.05	2.89e-08	5.67e-05	-0.47	-0.53	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
THYM	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	6.05	2.89e-08	5.67e-05	0.52	0.53	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
THYM	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-6.05	2.89e-08	5.67e-05	-0.55	-0.53	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
THYM	cis	rs950169	0.922	rs8037078	ENSG00000235370.6	DNM1P51	-6.05	2.9e-08	5.69e-05	-0.66	-0.53	Schizophrenia;	chr15:84150119	chr15:84398316~84411701:-
THYM	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-6.05	2.91e-08	5.7e-05	-0.64	-0.53	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
THYM	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-6.05	2.92e-08	5.72e-05	-0.62	-0.53	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
THYM	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-6.05	2.93e-08	5.74e-05	-0.41	-0.53	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-6.05	2.93e-08	5.74e-05	-0.41	-0.53	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
THYM	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	6.05	2.93e-08	5.74e-05	0.84	0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
THYM	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	6.05	2.94e-08	5.76e-05	0.56	0.53	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
THYM	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-6.05	2.94e-08	5.76e-05	-0.71	-0.53	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-6.05	2.94e-08	5.76e-05	-0.71	-0.53	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	6.05	2.94e-08	5.76e-05	0.71	0.53	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
THYM	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-6.05	2.95e-08	5.76e-05	-0.59	-0.53	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-6.05	2.95e-08	5.76e-05	-0.59	-0.53	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-6.05	2.95e-08	5.76e-05	-0.59	-0.53	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
THYM	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	6.05	2.97e-08	5.81e-05	0.38	0.53	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
THYM	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	6.05	2.97e-08	5.81e-05	0.38	0.53	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	6.05	2.97e-08	5.81e-05	0.38	0.53	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
THYM	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	6.05	2.97e-08	5.81e-05	0.38	0.53	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	6.05	2.97e-08	5.81e-05	0.38	0.53	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	6.05	2.97e-08	5.81e-05	0.38	0.53	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	6.05	2.97e-08	5.81e-05	0.38	0.53	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	6.04	3.02e-08	5.89e-05	0.43	0.53	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
THYM	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	6.04	3.03e-08	5.9e-05	0.67	0.53	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
THYM	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	6.04	3.03e-08	5.9e-05	0.67	0.53	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
THYM	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	6.04	3.03e-08	5.91e-05	0.58	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
THYM	cis	rs904251	0.6	rs2270687	ENSG00000279942.1	RP1-153P14.7	-6.04	3.04e-08	5.92e-05	-0.69	-0.53	Cognitive performance;	chr6:37450487	chr6:37567716~37571460:+
THYM	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	6.04	3.05e-08	5.93e-05	0.67	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
THYM	cis	rs995758	0.512	rs973796	ENSG00000236296.6	GUSBP5	6.04	3.05e-08	5.94e-05	0.6	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144502816	chr4:143559472~143649305:+
THYM	cis	rs1960493	1	rs1960493	ENSG00000236296.6	GUSBP5	6.04	3.05e-08	5.94e-05	0.6	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:144504600	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs35937742	ENSG00000236296.6	GUSBP5	6.04	3.05e-08	5.94e-05	0.6	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144504697	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs34265962	ENSG00000236296.6	GUSBP5	6.04	3.05e-08	5.94e-05	0.6	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144504784	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs1512283	ENSG00000236296.6	GUSBP5	6.04	3.05e-08	5.94e-05	0.6	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144509941	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs1512282	ENSG00000236296.6	GUSBP5	6.04	3.05e-08	5.94e-05	0.6	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144510345	chr4:143559472~143649305:+
THYM	cis	rs7829975	0.577	rs17684466	ENSG00000253893.2	FAM85B	6.04	3.07e-08	5.98e-05	0.64	0.53	Mood instability;	chr8:8687723	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.557	rs7816427	ENSG00000253893.2	FAM85B	6.04	3.07e-08	5.98e-05	0.64	0.53	Mood instability;	chr8:8688374	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	6.04	3.07e-08	5.98e-05	0.64	0.53	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
THYM	cis	rs995834	0.622	rs4806395	ENSG00000260725.1	AC005307.1	-6.04	3.07e-08	5.98e-05	-0.57	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28416529	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs8102434	ENSG00000260725.1	AC005307.1	-6.04	3.07e-08	5.98e-05	-0.57	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28418061	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs10413972	ENSG00000260725.1	AC005307.1	-6.04	3.07e-08	5.98e-05	-0.57	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419219	chr19:28418483~28429490:-
THYM	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-6.04	3.07e-08	5.98e-05	-0.59	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
THYM	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	6.04	3.08e-08	5.98e-05	0.59	0.53	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
THYM	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	6.04	3.08e-08	5.98e-05	0.59	0.53	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
THYM	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-6.04	3.08e-08	5.99e-05	-0.62	-0.53	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
THYM	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	6.04	3.1e-08	6.02e-05	0.38	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
THYM	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	6.04	3.11e-08	6.03e-05	0.61	0.53	Height;	chr6:109392096	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	6.04	3.11e-08	6.04e-05	0.6	0.53	Height;	chr6:109382188	chr6:109382795~109383666:+
THYM	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
THYM	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.11e-08	6.04e-05	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
THYM	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	6.04	3.12e-08	6.05e-05	0.5	0.53	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
THYM	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	6.04	3.13e-08	6.07e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	6.04	3.13e-08	6.07e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	6.04	3.13e-08	6.07e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	6.04	3.13e-08	6.07e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	6.04	3.13e-08	6.07e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
THYM	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.13e-08	6.07e-05	-0.65	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.13e-08	6.07e-05	-0.65	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.13e-08	6.07e-05	-0.65	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
THYM	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-6.04	3.13e-08	6.07e-05	-0.65	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
THYM	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	6.04	3.13e-08	6.07e-05	0.38	0.53	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
THYM	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	6.04	3.13e-08	6.07e-05	0.38	0.53	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
THYM	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-6.03	3.16e-08	6.13e-05	-0.55	-0.53	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
THYM	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-6.03	3.19e-08	6.18e-05	-0.47	-0.53	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
THYM	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	6.03	3.2e-08	6.18e-05	0.69	0.53	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
THYM	cis	rs2739330	0.731	rs2000468	ENSG00000272787.1	KB-226F1.2	-6.03	3.2e-08	6.19e-05	-0.57	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23969211~23969873:+
THYM	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-6.03	3.21e-08	6.2e-05	-0.62	-0.53	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
THYM	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-6.03	3.22e-08	6.23e-05	-0.58	-0.53	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
THYM	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-6.03	3.23e-08	6.23e-05	-0.39	-0.53	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
THYM	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-6.03	3.23e-08	6.23e-05	-0.39	-0.53	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
THYM	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	6.03	3.23e-08	6.24e-05	0.59	0.53	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
THYM	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	6.03	3.25e-08	6.28e-05	0.48	0.53	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	6.03	3.25e-08	6.28e-05	0.48	0.53	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
THYM	cis	rs9535495	0.965	rs750176	ENSG00000200711.1	RNA5SP28	-6.03	3.27e-08	6.3e-05	-0.6	-0.53	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50809917	chr13:50812988~50813106:-
THYM	cis	rs13256369	0.774	rs13248423	ENSG00000253893.2	FAM85B	-6.03	3.27e-08	6.31e-05	-0.74	-0.53	Obesity-related traits;	chr8:8720092	chr8:8167819~8226614:-
THYM	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-6.02	3.29e-08	6.33e-05	-0.53	-0.53	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
THYM	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-6.02	3.3e-08	6.36e-05	-0.42	-0.53	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-6.02	3.3e-08	6.36e-05	-0.42	-0.53	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-6.02	3.3e-08	6.36e-05	-0.42	-0.53	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
THYM	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-6.02	3.32e-08	6.39e-05	-0.63	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
THYM	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	6.02	3.33e-08	6.4e-05	0.61	0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
THYM	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-6.02	3.33e-08	6.4e-05	-0.47	-0.53	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-6.02	3.33e-08	6.4e-05	-0.47	-0.53	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
THYM	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-6.02	3.34e-08	6.41e-05	-0.64	-0.53	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
THYM	cis	rs995758	0.512	rs7678427	ENSG00000236296.6	GUSBP5	6.02	3.36e-08	6.45e-05	0.6	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144512423	chr4:143559472~143649305:+
THYM	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	6.02	3.36e-08	6.45e-05	0.71	0.53	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
THYM	cis	rs5760092	0.842	rs5751763	ENSG00000218537.1	MIF-AS1	6.02	3.37e-08	6.46e-05	0.79	0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23894426~23898930:-
THYM	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-6.02	3.37e-08	6.46e-05	-0.51	-0.53	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	6.02	3.37e-08	6.46e-05	0.51	0.53	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
THYM	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-6.02	3.38e-08	6.47e-05	-0.81	-0.53	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
THYM	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	6.02	3.38e-08	6.47e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	6.02	3.38e-08	6.47e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	6.02	3.38e-08	6.47e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	6.02	3.38e-08	6.47e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
THYM	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	6.02	3.39e-08	6.49e-05	0.69	0.53	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	6.02	3.39e-08	6.49e-05	0.69	0.53	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	6.02	3.39e-08	6.49e-05	0.69	0.53	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
THYM	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-6.02	3.4e-08	6.51e-05	-0.67	-0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
THYM	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-6.02	3.4e-08	6.51e-05	-0.6	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
THYM	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-6.02	3.4e-08	6.51e-05	-0.6	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
THYM	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-6.02	3.4e-08	6.51e-05	-0.6	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
THYM	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-6.02	3.4e-08	6.51e-05	-0.6	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
THYM	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	6.02	3.4e-08	6.51e-05	0.67	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
THYM	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-6.02	3.41e-08	6.53e-05	-0.58	-0.53	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-6.02	3.41e-08	6.53e-05	-0.58	-0.53	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-6.02	3.41e-08	6.53e-05	-0.58	-0.53	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-6.02	3.41e-08	6.53e-05	-0.58	-0.53	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	6.02	3.41e-08	6.53e-05	0.58	0.53	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
THYM	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	6.01	3.43e-08	6.55e-05	0.43	0.53	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
THYM	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	6.01	3.44e-08	6.57e-05	0.7	0.53	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
THYM	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-6.01	3.44e-08	6.58e-05	-0.58	-0.53	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
THYM	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-6.01	3.45e-08	6.59e-05	-0.63	-0.53	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
THYM	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-6.01	3.45e-08	6.59e-05	-0.58	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
THYM	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109383239	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109383248	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109384807	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109390116	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109390638	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109391534	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109393881	chr6:109382795~109383666:+
THYM	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109397362	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109402736	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109403734	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109409679	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109424305	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109425054	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109426518	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109427644	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	6.01	3.46e-08	6.6e-05	0.6	0.53	Height;	chr6:109430292	chr6:109382795~109383666:+
THYM	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	6.01	3.46e-08	6.61e-05	0.6	0.53	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
THYM	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	6.01	3.48e-08	6.63e-05	0.38	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-6.01	3.53e-08	6.73e-05	-0.38	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
THYM	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	6.01	3.54e-08	6.74e-05	0.69	0.53	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	6.01	3.54e-08	6.74e-05	0.69	0.53	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
THYM	cis	rs950169	0.922	rs11630507	ENSG00000235370.6	DNM1P51	6.01	3.54e-08	6.74e-05	0.64	0.53	Schizophrenia;	chr15:84552494	chr15:84398316~84411701:-
THYM	cis	rs7560272	0.501	rs17350188	ENSG00000273245.1	RP11-434P11.2	6.01	3.54e-08	6.75e-05	0.6	0.53	Schizophrenia;	chr2:73737715	chr2:73750256~73750786:-
THYM	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	6.01	3.55e-08	6.76e-05	0.74	0.53	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
THYM	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	6.01	3.55e-08	6.76e-05	0.64	0.53	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
THYM	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	6.01	3.55e-08	6.76e-05	0.63	0.53	Height;	chr6:109471826	chr6:109382795~109383666:+
THYM	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	6.01	3.56e-08	6.78e-05	0.51	0.53	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
THYM	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	6	3.59e-08	6.83e-05	0.65	0.53	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
THYM	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	6	3.59e-08	6.83e-05	1	0.53	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
THYM	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	6	3.6e-08	6.85e-05	0.61	0.53	Height;	chr6:109357369	chr6:109382795~109383666:+
THYM	cis	rs995758	0.512	rs56304346	ENSG00000236296.6	GUSBP5	6	3.6e-08	6.85e-05	0.61	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144476714	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs35440220	ENSG00000236296.6	GUSBP5	6	3.6e-08	6.85e-05	0.61	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144478680	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs7666298	ENSG00000236296.6	GUSBP5	6	3.6e-08	6.85e-05	0.61	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144480798	chr4:143559472~143649305:+
THYM	cis	rs1961266	1	rs1961266	ENSG00000236296.6	GUSBP5	6	3.6e-08	6.85e-05	0.61	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:144483361	chr4:143559472~143649305:+
THYM	cis	rs1813337	1	rs1813337	ENSG00000236296.6	GUSBP5	6	3.6e-08	6.85e-05	0.61	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:144486570	chr4:143559472~143649305:+
THYM	cis	rs973796	0.966	rs13142879	ENSG00000236296.6	GUSBP5	6	3.6e-08	6.85e-05	0.61	0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:144489325	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs7656246	ENSG00000236296.6	GUSBP5	6	3.6e-08	6.85e-05	0.61	0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144491359	chr4:143559472~143649305:+
THYM	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-6	3.61e-08	6.87e-05	-0.39	-0.53	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
THYM	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-6	3.62e-08	6.88e-05	-0.7	-0.53	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
THYM	cis	rs11157436	1	rs61972228	ENSG00000211813.2	TRAV34	6	3.63e-08	6.89e-05	0.41	0.53	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22207522~22208129:+
THYM	cis	rs11157436	1	rs12587157	ENSG00000211813.2	TRAV34	6	3.63e-08	6.89e-05	0.41	0.53	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22207522~22208129:+
THYM	cis	rs11157436	1	rs11157440	ENSG00000211813.2	TRAV34	6	3.63e-08	6.89e-05	0.41	0.53	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.915	rs11622938	ENSG00000211813.2	TRAV34	6	3.63e-08	6.89e-05	0.41	0.53	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22207522~22208129:+
THYM	cis	rs11157436	1	rs75648426	ENSG00000211813.2	TRAV34	6	3.63e-08	6.89e-05	0.41	0.53	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs61972229	ENSG00000211813.2	TRAV34	6	3.63e-08	6.89e-05	0.41	0.53	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs17183301	ENSG00000211813.2	TRAV34	6	3.63e-08	6.89e-05	0.41	0.53	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22207522~22208129:+
THYM	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	6	3.64e-08	6.91e-05	0.4	0.53	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
THYM	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-6	3.64e-08	6.92e-05	-0.59	-0.53	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
THYM	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	6	3.66e-08	6.95e-05	0.58	0.53	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
THYM	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	6	3.67e-08	6.96e-05	0.68	0.53	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
THYM	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	6	3.69e-08	7e-05	0.68	0.53	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
THYM	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-6	3.69e-08	7e-05	-0.6	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
THYM	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-6	3.7e-08	7.01e-05	-0.37	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
THYM	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	6	3.7e-08	7.01e-05	0.48	0.53	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
THYM	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-6	3.7e-08	7.02e-05	-0.58	-0.53	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
THYM	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	6	3.71e-08	7.05e-05	0.69	0.53	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
THYM	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-6	3.72e-08	7.06e-05	-0.92	-0.53	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
THYM	cis	rs694739	0.628	rs475032	ENSG00000236935.1	AP003774.1	-6	3.73e-08	7.07e-05	-0.38	-0.53	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373265	chr11:64325050~64329504:-
THYM	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	6	3.73e-08	7.07e-05	0.57	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
THYM	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	6	3.74e-08	7.09e-05	0.61	0.53	Height;	chr6:109358652	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	6	3.74e-08	7.09e-05	0.61	0.53	Height;	chr6:109367528	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	6	3.74e-08	7.09e-05	0.61	0.53	Height;	chr6:109368704	chr6:109382795~109383666:+
THYM	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	6	3.74e-08	7.09e-05	0.39	0.53	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
THYM	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	5.99	3.75e-08	7.1e-05	0.5	0.53	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	5.99	3.75e-08	7.1e-05	0.5	0.53	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
THYM	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	5.99	3.77e-08	7.13e-05	0.63	0.53	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	5.99	3.77e-08	7.13e-05	0.63	0.53	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
THYM	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
THYM	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	5.99	3.79e-08	7.18e-05	0.38	0.53	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
THYM	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-5.99	3.8e-08	7.18e-05	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
THYM	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-5.99	3.8e-08	7.18e-05	-0.67	-0.53	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
THYM	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	5.99	3.8e-08	7.18e-05	0.48	0.53	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	5.99	3.8e-08	7.18e-05	0.48	0.53	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-5.99	3.8e-08	7.18e-05	-0.48	-0.53	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
THYM	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	5.99	3.82e-08	7.23e-05	0.59	0.53	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
THYM	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	5.99	3.82e-08	7.23e-05	0.69	0.53	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	5.99	3.82e-08	7.23e-05	0.69	0.53	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	5.99	3.82e-08	7.23e-05	0.69	0.53	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	5.99	3.82e-08	7.23e-05	0.69	0.53	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	5.99	3.82e-08	7.23e-05	0.69	0.53	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	5.99	3.82e-08	7.23e-05	0.69	0.53	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	5.99	3.82e-08	7.23e-05	0.69	0.53	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
THYM	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	5.99	3.83e-08	7.23e-05	0.43	0.53	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	5.99	3.83e-08	7.23e-05	0.43	0.53	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	5.99	3.83e-08	7.23e-05	0.43	0.53	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	5.99	3.83e-08	7.23e-05	0.43	0.53	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	5.99	3.83e-08	7.23e-05	0.43	0.53	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	5.99	3.83e-08	7.23e-05	0.43	0.53	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	5.99	3.83e-08	7.23e-05	0.43	0.53	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-5.99	3.83e-08	7.23e-05	-0.43	-0.53	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
THYM	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	5.99	3.83e-08	7.24e-05	0.64	0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
THYM	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	5.99	3.83e-08	7.24e-05	0.64	0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
THYM	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	5.99	3.85e-08	7.26e-05	0.61	0.53	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
THYM	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-5.99	3.85e-08	7.27e-05	-0.58	-0.53	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
THYM	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-5.99	3.87e-08	7.3e-05	-0.66	-0.53	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
THYM	cis	rs950169	0.922	rs67804993	ENSG00000235370.6	DNM1P51	5.99	3.87e-08	7.3e-05	0.64	0.53	Schizophrenia;	chr15:84560799	chr15:84398316~84411701:-
THYM	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	5.99	3.87e-08	7.3e-05	0.4	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
THYM	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-5.99	3.88e-08	7.32e-05	-0.63	-0.53	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
THYM	cis	rs7560272	0.501	rs7210	ENSG00000273245.1	RP11-434P11.2	-5.98	3.93e-08	7.35e-05	-0.6	-0.53	Schizophrenia;	chr2:73729997	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs2272178	ENSG00000273245.1	RP11-434P11.2	-5.98	3.93e-08	7.35e-05	-0.6	-0.53	Schizophrenia;	chr2:73750482	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs12713798	ENSG00000273245.1	RP11-434P11.2	-5.98	3.93e-08	7.35e-05	-0.6	-0.53	Schizophrenia;	chr2:73759294	chr2:73750256~73750786:-
THYM	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	5.98	3.93e-08	7.35e-05	0.89	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-5.98	3.93e-08	7.35e-05	-0.89	-0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
THYM	cis	rs4273100	1	rs16960158	ENSG00000228157.4	AC007952.5	5.98	3.94e-08	7.35e-05	0.82	0.53	Schizophrenia;	chr17:19259739	chr17:19092974~19096837:+
THYM	cis	rs995834	0.789	rs4806362	ENSG00000267243.4	AC005307.3	5.98	3.94e-08	7.35e-05	0.48	0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398414	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs10425833	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401807	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs10402916	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402001	chr19:28435388~28727777:-
THYM	cis	rs995834	0.753	rs10405354	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402005	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs7248138	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402207	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs7246817	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402219	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs10411886	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402396	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs758123	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402872	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs758125	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403001	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs758126	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403236	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs10421214	ENSG00000267243.4	AC005307.3	-5.98	3.94e-08	7.35e-05	-0.48	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404538	chr19:28435388~28727777:-
THYM	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	5.98	3.98e-08	7.35e-05	0.39	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	5.98	3.98e-08	7.35e-05	0.39	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
THYM	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-5.98	3.99e-08	7.37e-05	-0.47	-0.52	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-5.98	3.99e-08	7.37e-05	-0.47	-0.52	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
THYM	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	5.98	4.01e-08	7.4e-05	0.51	0.52	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	5.98	4.01e-08	7.4e-05	0.51	0.52	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
THYM	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	5.98	4.02e-08	7.42e-05	0.68	0.52	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.63	rs816069	ENSG00000258983.2	RP11-507K2.2	-5.98	4.04e-08	7.44e-05	-0.6	-0.52	Coronary artery calcification;	chr14:88500992	chr14:88499334~88515502:+
THYM	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-5.98	4.05e-08	7.46e-05	-0.64	-0.52	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
THYM	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-5.98	4.05e-08	7.46e-05	-0.64	-0.52	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
THYM	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-5.98	4.05e-08	7.46e-05	-0.64	-0.52	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
THYM	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-5.98	4.05e-08	7.46e-05	-0.58	-0.52	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-5.98	4.05e-08	7.46e-05	-0.61	-0.52	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-5.98	4.05e-08	7.46e-05	-0.61	-0.52	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-5.98	4.06e-08	7.47e-05	-0.63	-0.52	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
THYM	cis	rs2739330	0.791	rs4822458	ENSG00000272787.1	KB-226F1.2	-5.98	4.07e-08	7.5e-05	-0.59	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23969211~23969873:+
THYM	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-5.98	4.09e-08	7.52e-05	-0.4	-0.52	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
THYM	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-5.98	4.09e-08	7.52e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
THYM	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-5.97	4.09e-08	7.52e-05	-0.69	-0.52	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
THYM	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-5.97	4.11e-08	7.55e-05	-0.66	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
THYM	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	5.97	4.13e-08	7.58e-05	0.39	0.52	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
THYM	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-5.97	4.13e-08	7.58e-05	-0.45	-0.52	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
THYM	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-5.97	4.14e-08	7.59e-05	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-5.97	4.14e-08	7.59e-05	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-5.97	4.14e-08	7.59e-05	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
THYM	cis	rs950169	0.922	rs11635505	ENSG00000235370.6	DNM1P51	-5.97	4.14e-08	7.59e-05	-0.65	-0.52	Schizophrenia;	chr15:84553803	chr15:84398316~84411701:-
THYM	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-5.97	4.14e-08	7.59e-05	-0.64	-0.52	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
THYM	cis	rs13256369	0.774	rs11777719	ENSG00000253893.2	FAM85B	-5.97	4.15e-08	7.6e-05	-0.72	-0.52	Obesity-related traits;	chr8:8723528	chr8:8167819~8226614:-
THYM	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
THYM	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
THYM	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-5.97	4.15e-08	7.6e-05	-0.64	-0.52	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
THYM	cis	rs995834	0.789	rs4806372	ENSG00000267243.4	AC005307.3	5.97	4.15e-08	7.61e-05	0.46	0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403612	chr19:28435388~28727777:-
THYM	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-5.97	4.17e-08	7.61e-05	-0.77	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
THYM	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	5.97	4.2e-08	7.66e-05	0.44	0.52	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
THYM	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	5.97	4.21e-08	7.68e-05	0.68	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	5.97	4.21e-08	7.68e-05	0.68	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	5.97	4.21e-08	7.68e-05	0.68	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
THYM	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-5.97	4.23e-08	7.71e-05	-0.69	-0.52	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
THYM	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-5.97	4.23e-08	7.71e-05	-0.38	-0.52	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
THYM	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	5.97	4.27e-08	7.78e-05	0.52	0.52	Depression;	chr6:28187640	chr6:28115628~28116551:+
THYM	cis	rs904251	0.561	rs4714070	ENSG00000279942.1	RP1-153P14.7	-5.96	4.28e-08	7.79e-05	-0.7	-0.52	Cognitive performance;	chr6:37505422	chr6:37567716~37571460:+
THYM	cis	rs904251	0.561	rs4714071	ENSG00000279942.1	RP1-153P14.7	-5.96	4.28e-08	7.79e-05	-0.7	-0.52	Cognitive performance;	chr6:37506617	chr6:37567716~37571460:+
THYM	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	5.96	4.28e-08	7.79e-05	0.47	0.52	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
THYM	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	5.96	4.3e-08	7.82e-05	0.75	0.52	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
THYM	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	5.96	4.3e-08	7.82e-05	0.75	0.52	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
THYM	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	5.96	4.3e-08	7.82e-05	0.75	0.52	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
THYM	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-5.96	4.3e-08	7.82e-05	-0.51	-0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
THYM	cis	rs950169	0.545	rs4842841	ENSG00000235370.6	DNM1P51	5.96	4.32e-08	7.86e-05	0.74	0.52	Schizophrenia;	chr15:83972373	chr15:84398316~84411701:-
THYM	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-5.96	4.33e-08	7.88e-05	-0.65	-0.52	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
THYM	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-5.96	4.41e-08	7.99e-05	-0.93	-0.52	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-5.96	4.41e-08	7.99e-05	-0.93	-0.52	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-5.96	4.41e-08	7.99e-05	-0.93	-0.52	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-5.96	4.41e-08	7.99e-05	-0.93	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-5.96	4.41e-08	7.99e-05	-0.93	-0.52	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-5.96	4.41e-08	7.99e-05	-0.93	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
THYM	cis	rs950169	0.922	rs62029585	ENSG00000235370.6	DNM1P51	5.96	4.43e-08	8.03e-05	0.73	0.52	Schizophrenia;	chr15:84397176	chr15:84398316~84411701:-
THYM	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	5.96	4.43e-08	8.04e-05	0.65	0.52	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
THYM	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	5.96	4.45e-08	8.07e-05	0.62	0.52	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
THYM	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-5.96	4.46e-08	8.09e-05	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-5.96	4.46e-08	8.09e-05	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-5.96	4.46e-08	8.09e-05	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-5.96	4.46e-08	8.09e-05	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-5.96	4.46e-08	8.09e-05	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-5.96	4.46e-08	8.09e-05	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
THYM	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-5.95	4.47e-08	8.11e-05	-0.76	-0.52	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
THYM	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	5.95	4.49e-08	8.12e-05	0.67	0.52	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
THYM	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	5.95	4.49e-08	8.12e-05	0.67	0.52	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
THYM	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	5.95	4.49e-08	8.12e-05	0.67	0.52	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
THYM	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	5.95	4.49e-08	8.12e-05	0.67	0.52	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
THYM	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	5.95	4.49e-08	8.12e-05	0.67	0.52	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
THYM	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	5.95	4.49e-08	8.13e-05	0.53	0.52	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
THYM	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-5.95	4.5e-08	8.14e-05	-0.68	-0.52	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
THYM	cis	rs950169	0.845	rs4502182	ENSG00000235370.6	DNM1P51	5.95	4.5e-08	8.14e-05	0.68	0.52	Schizophrenia;	chr15:84254768	chr15:84398316~84411701:-
THYM	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-5.95	4.54e-08	8.21e-05	-0.66	-0.52	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
THYM	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-5.95	4.57e-08	8.26e-05	-0.93	-0.52	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-5.95	4.57e-08	8.26e-05	-0.93	-0.52	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
THYM	cis	rs2834288	0.5	rs7280837	ENSG00000237945.6	LINC00649	5.95	4.58e-08	8.26e-05	0.43	0.52	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.5	rs4817602	ENSG00000237945.6	LINC00649	5.95	4.58e-08	8.26e-05	0.43	0.52	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33915534~33977691:+
THYM	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	5.95	4.59e-08	8.29e-05	0.52	0.52	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	5.95	4.59e-08	8.29e-05	0.52	0.52	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	5.95	4.59e-08	8.29e-05	0.52	0.52	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
THYM	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-5.95	4.6e-08	8.3e-05	-0.61	-0.52	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
THYM	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-5.95	4.66e-08	8.41e-05	-0.48	-0.52	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
THYM	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-5.95	4.67e-08	8.42e-05	-0.61	-0.52	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
THYM	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-5.94	4.68e-08	8.43e-05	-0.38	-0.52	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-5.94	4.68e-08	8.43e-05	-0.38	-0.52	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-5.94	4.68e-08	8.43e-05	-0.38	-0.52	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
THYM	cis	rs13256369	0.826	rs12678414	ENSG00000253893.2	FAM85B	-5.94	4.69e-08	8.45e-05	-0.7	-0.52	Obesity-related traits;	chr8:8728506	chr8:8167819~8226614:-
THYM	cis	rs2283792	0.812	rs94194	ENSG00000228050.1	TOP3BP1	5.94	4.7e-08	8.46e-05	0.59	0.52	Multiple sclerosis;	chr22:21933937	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.812	rs5995269	ENSG00000228050.1	TOP3BP1	5.94	4.7e-08	8.46e-05	0.59	0.52	Multiple sclerosis;	chr22:21935025	chr22:22223187~22224566:-
THYM	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-5.94	4.71e-08	8.48e-05	-0.54	-0.52	Depression;	chr6:28135913	chr6:28115628~28116551:+
THYM	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	5.94	4.72e-08	8.5e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	5.94	4.74e-08	8.52e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
THYM	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-5.94	4.75e-08	8.52e-05	-0.61	-0.52	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
THYM	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	5.94	4.75e-08	8.53e-05	0.98	0.52	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
THYM	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	5.94	4.76e-08	8.54e-05	0.56	0.52	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
THYM	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-5.94	4.78e-08	8.57e-05	-0.62	-0.52	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
THYM	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	5.94	4.78e-08	8.58e-05	0.72	0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
THYM	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-5.94	4.8e-08	8.61e-05	-0.54	-0.52	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
THYM	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	5.94	4.81e-08	8.62e-05	0.52	0.52	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
THYM	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-5.94	4.82e-08	8.62e-05	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
THYM	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-5.94	4.82e-08	8.62e-05	-0.76	-0.52	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
THYM	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-5.94	4.82e-08	8.62e-05	-0.76	-0.52	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
THYM	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-5.94	4.82e-08	8.63e-05	-0.6	-0.52	Height;	chr6:109531713	chr6:109382795~109383666:+
THYM	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	5.94	4.82e-08	8.64e-05	0.57	0.52	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
THYM	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	5.94	4.83e-08	8.65e-05	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	5.94	4.83e-08	8.65e-05	0.88	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
THYM	cis	rs950169	0.881	rs34117475	ENSG00000235370.6	DNM1P51	5.94	4.84e-08	8.67e-05	0.64	0.52	Schizophrenia;	chr15:84565212	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs12915832	ENSG00000235370.6	DNM1P51	5.94	4.84e-08	8.67e-05	0.64	0.52	Schizophrenia;	chr15:84568226	chr15:84398316~84411701:-
THYM	cis	rs2834288	0.5	rs7277248	ENSG00000237945.6	LINC00649	5.94	4.85e-08	8.67e-05	0.42	0.52	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33915534~33977691:+
THYM	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-5.94	4.87e-08	8.71e-05	-0.62	-0.52	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
THYM	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-5.93	4.93e-08	8.81e-05	-0.92	-0.52	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-5.93	4.93e-08	8.81e-05	-0.92	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
THYM	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	5.93	4.94e-08	8.81e-05	0.63	0.52	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
THYM	cis	rs11157436	0.918	rs1076546	ENSG00000211813.2	TRAV34	5.93	4.94e-08	8.82e-05	0.38	0.52	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22159015	chr14:22207522~22208129:+
THYM	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-5.93	4.96e-08	8.85e-05	-0.43	-0.52	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
THYM	cis	rs2834288	0.5	rs766425	ENSG00000237945.6	LINC00649	5.93	4.97e-08	8.87e-05	0.42	0.52	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33915534~33977691:+
THYM	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-5.93	4.98e-08	8.88e-05	-0.54	-0.52	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
THYM	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	5.93	4.98e-08	8.89e-05	0.62	0.52	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
THYM	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	5.93	4.99e-08	8.9e-05	0.66	0.52	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
THYM	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	5.93	4.99e-08	8.9e-05	0.66	0.52	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
THYM	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	5.93	4.99e-08	8.9e-05	0.66	0.52	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
THYM	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	5.93	5e-08	8.91e-05	0.46	0.52	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
THYM	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	5.93	5.05e-08	9e-05	0.51	0.52	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	5.93	5.05e-08	9e-05	0.51	0.52	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
THYM	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	5.93	5.06e-08	9.02e-05	0.65	0.52	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	5.93	5.06e-08	9.02e-05	0.65	0.52	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
THYM	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	5.93	5.09e-08	9.06e-05	0.67	0.52	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
THYM	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	5.92	5.13e-08	9.12e-05	0.6	0.52	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
THYM	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	5.92	5.14e-08	9.14e-05	0.38	0.52	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
THYM	cis	rs7560272	0.501	rs2421675	ENSG00000273245.1	RP11-434P11.2	-5.92	5.17e-08	9.16e-05	-0.61	-0.52	Schizophrenia;	chr2:73728174	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.529	rs2421672	ENSG00000273245.1	RP11-434P11.2	-5.92	5.17e-08	9.16e-05	-0.61	-0.52	Schizophrenia;	chr2:73728413	chr2:73750256~73750786:-
THYM	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-5.92	5.18e-08	9.17e-05	-0.38	-0.52	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
THYM	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	5.92	5.18e-08	9.18e-05	0.49	0.52	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
THYM	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	5.92	5.24e-08	9.26e-05	0.67	0.52	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
THYM	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
THYM	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
THYM	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
THYM	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-5.92	5.24e-08	9.26e-05	-0.39	-0.52	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
THYM	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-5.92	5.27e-08	9.32e-05	-0.56	-0.52	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
THYM	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	5.92	5.29e-08	9.34e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	5.92	5.29e-08	9.34e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	5.92	5.29e-08	9.34e-05	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
THYM	cis	rs950169	0.922	rs12910334	ENSG00000235370.6	DNM1P51	5.92	5.3e-08	9.36e-05	0.68	0.52	Schizophrenia;	chr15:84403620	chr15:84398316~84411701:-
THYM	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-5.92	5.31e-08	9.37e-05	-0.66	-0.52	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-5.92	5.31e-08	9.37e-05	-0.66	-0.52	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-5.92	5.31e-08	9.37e-05	-0.66	-0.52	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
THYM	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-5.92	5.31e-08	9.37e-05	-0.66	-0.52	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
THYM	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	5.92	5.32e-08	9.38e-05	0.53	0.52	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	5.92	5.32e-08	9.38e-05	0.53	0.52	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	5.92	5.32e-08	9.38e-05	0.53	0.52	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	5.92	5.32e-08	9.38e-05	0.53	0.52	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	5.92	5.32e-08	9.38e-05	0.53	0.52	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
THYM	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-5.92	5.32e-08	9.38e-05	-0.5	-0.52	Temperament;	chr17:14046511	chr17:14024514~14025488:+
THYM	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-5.92	5.32e-08	9.38e-05	-0.5	-0.52	Temperament;	chr17:14048649	chr17:14024514~14025488:+
THYM	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-5.91	5.37e-08	9.46e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-5.91	5.37e-08	9.46e-05	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
THYM	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	5.91	5.37e-08	9.47e-05	0.81	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
THYM	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	5.91	5.38e-08	9.48e-05	0.63	0.52	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
THYM	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	5.91	5.39e-08	9.5e-05	0.6	0.52	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
THYM	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	5.91	5.39e-08	9.5e-05	0.6	0.52	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
THYM	cis	rs995834	0.869	rs6508821	ENSG00000267243.4	AC005307.3	-5.91	5.39e-08	9.5e-05	-0.48	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396506	chr19:28435388~28727777:-
THYM	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	5.91	5.4e-08	9.51e-05	0.5	0.52	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	5.91	5.4e-08	9.51e-05	0.5	0.52	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	5.91	5.4e-08	9.51e-05	0.5	0.52	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
THYM	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-5.91	5.45e-08	9.59e-05	-0.63	-0.52	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
THYM	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-5.91	5.45e-08	9.59e-05	-0.43	-0.52	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
THYM	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	5.91	5.47e-08	9.62e-05	0.86	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
THYM	cis	rs2739330	0.685	rs4822453	ENSG00000272787.1	KB-226F1.2	-5.91	5.47e-08	9.62e-05	-0.57	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23969211~23969873:+
THYM	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-5.91	5.48e-08	9.63e-05	-0.45	-0.52	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
THYM	cis	rs995834	0.789	rs758127	ENSG00000267243.4	AC005307.3	5.91	5.49e-08	9.65e-05	0.49	0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403344	chr19:28435388~28727777:-
THYM	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	5.91	5.5e-08	9.66e-05	0.48	0.52	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
THYM	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	5.91	5.5e-08	9.68e-05	0.74	0.52	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
THYM	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-5.91	5.52e-08	9.7e-05	-0.74	-0.52	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
THYM	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-5.91	5.56e-08	9.76e-05	-0.97	-0.52	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
THYM	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-5.9	5.59e-08	9.8e-05	-0.46	-0.52	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
THYM	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-5.9	5.62e-08	9.86e-05	-0.37	-0.52	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
THYM	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	5.9	5.63e-08	9.87e-05	0.41	0.52	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
THYM	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-5.9	5.65e-08	9.91e-05	-0.64	-0.52	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
THYM	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	5.9	5.69e-08	9.96e-05	0.67	0.52	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
THYM	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-5.9	5.71e-08	1e-04	-0.53	-0.52	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
THYM	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-5.9	5.74e-08	1e-04	-0.49	-0.52	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-5.9	5.74e-08	1e-04	-0.49	-0.52	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	5.9	5.74e-08	1e-04	0.49	0.52	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	5.9	5.74e-08	1e-04	0.49	0.52	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	5.9	5.74e-08	1e-04	0.49	0.52	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	5.9	5.75e-08	0.000101	0.52	0.52	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
THYM	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	5.9	5.76e-08	0.000101	0.7	0.52	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
THYM	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-5.9	5.78e-08	0.000101	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-5.9	5.78e-08	0.000101	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	5.9	5.78e-08	0.000101	0.83	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
THYM	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	5.9	5.79e-08	0.000101	0.75	0.52	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
THYM	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	5.9	5.8e-08	0.000101	0.52	0.52	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	5.9	5.8e-08	0.000101	0.52	0.52	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
THYM	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	5.9	5.81e-08	0.000102	0.51	0.52	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
THYM	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-5.9	5.82e-08	0.000102	-0.67	-0.52	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
THYM	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	5.89	5.87e-08	0.000103	0.55	0.52	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
THYM	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	5.89	5.87e-08	0.000103	0.55	0.52	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
THYM	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	5.89	5.87e-08	0.000103	0.55	0.52	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
THYM	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	5.89	5.9e-08	0.000103	0.42	0.52	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	5.89	5.9e-08	0.000103	0.42	0.52	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	5.89	5.9e-08	0.000103	0.42	0.52	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	5.89	5.9e-08	0.000103	0.42	0.52	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	5.89	5.9e-08	0.000103	0.42	0.52	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	5.89	5.9e-08	0.000103	0.42	0.52	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
THYM	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-5.89	5.9e-08	0.000103	-0.42	-0.52	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-5.89	5.9e-08	0.000103	-0.42	-0.52	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
THYM	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-5.89	5.9e-08	0.000103	-0.42	-0.52	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
THYM	cis	rs995834	0.869	rs1476763	ENSG00000267243.4	AC005307.3	-5.89	5.92e-08	0.000103	-0.46	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394591	chr19:28435388~28727777:-
THYM	cis	rs995834	0.828	rs10460161	ENSG00000267243.4	AC005307.3	-5.89	5.92e-08	0.000103	-0.46	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394686	chr19:28435388~28727777:-
THYM	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	5.89	5.92e-08	0.000103	0.69	0.52	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
THYM	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	5.89	5.92e-08	0.000103	0.69	0.52	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
THYM	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-5.89	5.98e-08	0.000104	-0.54	-0.52	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
THYM	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	5.89	5.98e-08	0.000104	0.53	0.52	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
THYM	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-5.89	5.99e-08	0.000104	-0.66	-0.52	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
THYM	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	5.89	5.99e-08	0.000104	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	5.89	5.99e-08	0.000104	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
THYM	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	5.89	6e-08	0.000104	0.52	0.52	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
THYM	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	5.89	6e-08	0.000104	0.66	0.52	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
THYM	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	5.89	6.01e-08	0.000105	0.38	0.52	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
THYM	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-5.89	6.06e-08	0.000105	-0.41	-0.52	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
THYM	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	5.89	6.07e-08	0.000105	0.49	0.52	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	5.89	6.07e-08	0.000105	0.49	0.52	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	5.89	6.07e-08	0.000105	0.49	0.52	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	5.89	6.07e-08	0.000105	0.49	0.52	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
THYM	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
THYM	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
THYM	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	5.88	6.1e-08	0.000106	0.38	0.52	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
THYM	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	5.88	6.1e-08	0.000106	0.79	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
THYM	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	5.88	6.11e-08	0.000106	0.8	0.52	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
THYM	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	5.88	6.11e-08	0.000106	0.8	0.52	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
THYM	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	5.88	6.11e-08	0.000106	0.8	0.52	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
THYM	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	5.88	6.11e-08	0.000106	0.8	0.52	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
THYM	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	5.88	6.11e-08	0.000106	0.8	0.52	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
THYM	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	5.88	6.11e-08	0.000106	0.8	0.52	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
THYM	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-5.88	6.11e-08	0.000106	-0.57	-0.52	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
THYM	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	5.88	6.11e-08	0.000106	0.64	0.52	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	5.88	6.11e-08	0.000106	0.64	0.52	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	5.88	6.11e-08	0.000106	0.64	0.52	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	5.88	6.11e-08	0.000106	0.64	0.52	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	5.88	6.11e-08	0.000106	0.64	0.52	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
THYM	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	5.88	6.12e-08	0.000106	0.48	0.52	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
THYM	cis	rs904251	0.772	rs2776906	ENSG00000279942.1	RP1-153P14.7	-5.88	6.15e-08	0.000107	-0.76	-0.52	Cognitive performance;	chr6:37463981	chr6:37567716~37571460:+
THYM	cis	rs904251	0.772	rs1224127	ENSG00000279942.1	RP1-153P14.7	-5.88	6.16e-08	0.000107	-0.75	-0.52	Cognitive performance;	chr6:37449780	chr6:37567716~37571460:+
THYM	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	5.88	6.17e-08	0.000107	0.79	0.52	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
THYM	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-5.88	6.18e-08	0.000107	-0.52	-0.52	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
THYM	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-5.88	6.24e-08	0.000108	-0.76	-0.52	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
THYM	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-5.88	6.24e-08	0.000108	-0.46	-0.52	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-5.88	6.24e-08	0.000108	-0.46	-0.52	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
THYM	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-5.88	6.26e-08	0.000108	-0.39	-0.52	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	5.88	6.26e-08	0.000108	0.39	0.52	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
THYM	cis	rs886716	0.507	rs34784196	ENSG00000122548.5	KIAA0087	5.88	6.26e-08	0.000108	0.56	0.52	Smoking behavior;	chr7:26534828	chr7:26533121~26538788:-
THYM	cis	rs5760092	0.755	rs3884794	ENSG00000218537.1	MIF-AS1	5.88	6.29e-08	0.000109	0.76	0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23894426~23898930:-
THYM	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	5.88	6.32e-08	0.000109	0.53	0.52	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
THYM	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	5.88	6.33e-08	0.000109	0.55	0.52	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
THYM	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	5.88	6.34e-08	0.00011	0.64	0.52	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
THYM	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	5.88	6.34e-08	0.00011	0.84	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
THYM	cis	rs995834	0.957	rs2109066	ENSG00000260725.1	AC005307.1	-5.88	6.35e-08	0.00011	-0.49	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344420	chr19:28418483~28429490:-
THYM	cis	rs995834	0.957	rs2159327	ENSG00000260725.1	AC005307.1	-5.88	6.35e-08	0.00011	-0.49	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344664	chr19:28418483~28429490:-
THYM	cis	rs995834	0.957	rs7248916	ENSG00000260725.1	AC005307.1	-5.88	6.35e-08	0.00011	-0.49	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344916	chr19:28418483~28429490:-
THYM	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	5.88	6.37e-08	0.00011	0.51	0.52	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
THYM	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	5.87	6.4e-08	0.00011	0.38	0.52	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
THYM	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	5.87	6.41e-08	0.000111	0.41	0.52	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
THYM	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-5.87	6.44e-08	0.000111	-0.7	-0.52	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
THYM	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	5.87	6.46e-08	0.000111	0.64	0.52	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	5.87	6.46e-08	0.000111	0.64	0.52	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
THYM	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-5.87	6.47e-08	0.000112	-0.62	-0.52	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
THYM	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-5.87	6.47e-08	0.000112	-0.62	-0.52	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
THYM	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	5.87	6.48e-08	0.000112	0.52	0.52	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
THYM	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-5.87	6.52e-08	0.000112	-0.62	-0.52	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
THYM	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-5.87	6.52e-08	0.000112	-0.39	-0.52	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-5.87	6.52e-08	0.000112	-0.39	-0.52	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
THYM	cis	rs1560104	0.619	rs3829519	ENSG00000259899.1	CTD-3037G24.3	-5.87	6.52e-08	0.000112	-0.64	-0.52	Obesity-related traits;	chr16:12614854	chr16:12560756~12611044:-
THYM	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-5.87	6.54e-08	0.000113	-0.74	-0.52	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
THYM	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-5.87	6.54e-08	0.000113	-0.45	-0.52	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
THYM	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	5.87	6.56e-08	0.000113	0.62	0.52	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
THYM	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	5.87	6.58e-08	0.000113	0.82	0.52	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
THYM	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
THYM	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
THYM	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
THYM	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
THYM	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-5.87	6.6e-08	0.000114	-0.63	-0.52	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
THYM	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	5.87	6.62e-08	0.000114	0.39	0.52	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
THYM	cis	rs3740713	1	rs3740713	ENSG00000256464.1	YWHABP2	5.86	6.66e-08	0.000114	0.91	0.52	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr11:18490243~18490955:-
THYM	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	5.86	6.66e-08	0.000114	0.38	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
THYM	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	5.86	6.72e-08	0.000115	0.46	0.52	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
THYM	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	5.86	6.73e-08	0.000115	0.46	0.52	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
THYM	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	5.86	6.74e-08	0.000116	0.91	0.52	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
THYM	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	5.86	6.75e-08	0.000116	0.63	0.52	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
THYM	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	5.86	6.75e-08	0.000116	0.48	0.52	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
THYM	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-5.86	6.75e-08	0.000116	-0.61	-0.52	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
THYM	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-5.86	6.75e-08	0.000116	-0.61	-0.52	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
THYM	cis	rs904251	0.772	rs10692	ENSG00000279942.1	RP1-153P14.7	-5.86	6.76e-08	0.000116	-0.75	-0.52	Cognitive performance;	chr6:37483138	chr6:37567716~37571460:+
THYM	cis	rs904251	0.772	rs756202	ENSG00000279942.1	RP1-153P14.7	-5.86	6.76e-08	0.000116	-0.75	-0.52	Cognitive performance;	chr6:37492574	chr6:37567716~37571460:+
THYM	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-5.86	6.76e-08	0.000116	-0.54	-0.52	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
THYM	cis	rs747334	0.502	rs10881873	ENSG00000225519.1	RP11-236B18.2	5.86	6.76e-08	0.000116	0.46	0.52	Fibroblast growth factor basic levels;	chr10:90972524	chr10:90994620~91006390:+
THYM	cis	rs747334	0.502	rs1439094	ENSG00000225519.1	RP11-236B18.2	-5.86	6.76e-08	0.000116	-0.46	-0.52	Fibroblast growth factor basic levels;	chr10:90974424	chr10:90994620~91006390:+
THYM	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-5.86	6.79e-08	0.000116	-0.56	-0.52	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
THYM	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-5.86	6.82e-08	0.000117	-0.46	-0.52	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-5.86	6.82e-08	0.000117	-0.46	-0.52	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	5.86	6.82e-08	0.000117	0.46	0.52	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
THYM	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-5.86	6.83e-08	0.000117	-0.91	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
THYM	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	5.86	6.84e-08	0.000117	0.78	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
THYM	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-5.86	6.85e-08	0.000117	-0.52	-0.52	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
THYM	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	5.86	6.87e-08	0.000117	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	5.86	6.87e-08	0.000117	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	5.86	6.87e-08	0.000117	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-5.86	6.87e-08	0.000117	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
THYM	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	5.86	6.89e-08	0.000118	0.63	0.52	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
THYM	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-5.86	6.89e-08	0.000118	-0.81	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
THYM	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-5.86	6.9e-08	0.000118	-0.62	-0.52	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-5.86	6.91e-08	0.000118	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-5.86	6.91e-08	0.000118	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
THYM	cis	rs7702057	0.53	rs3946989	ENSG00000271918.1	CTD-2287O16.5	5.86	6.91e-08	0.000118	0.78	0.52	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs1567331	ENSG00000271918.1	CTD-2287O16.5	5.86	6.91e-08	0.000118	0.78	0.52	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs1567332	ENSG00000271918.1	CTD-2287O16.5	5.86	6.91e-08	0.000118	0.78	0.52	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs6890263	ENSG00000271918.1	CTD-2287O16.5	5.86	6.91e-08	0.000118	0.78	0.52	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs17138848	ENSG00000271918.1	CTD-2287O16.5	5.86	6.91e-08	0.000118	0.78	0.52	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116083807~116085416:-
THYM	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-5.86	6.92e-08	0.000118	-1	-0.52	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
THYM	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-5.86	6.92e-08	0.000118	-0.67	-0.52	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
THYM	cis	rs17772222	0.655	rs7160717	ENSG00000258983.2	RP11-507K2.2	5.86	6.92e-08	0.000118	0.59	0.52	Coronary artery calcification;	chr14:88498232	chr14:88499334~88515502:+
THYM	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-5.85	6.97e-08	0.000119	-0.58	-0.52	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
THYM	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-5.85	6.97e-08	0.000119	-0.61	-0.52	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
THYM	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-5.85	6.99e-08	0.000119	-0.75	-0.52	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
THYM	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	5.85	7.06e-08	0.00012	0.68	0.52	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
THYM	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	5.85	7.11e-08	0.000121	0.63	0.52	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
THYM	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	5.85	7.11e-08	0.000121	0.51	0.52	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	5.85	7.11e-08	0.000121	0.51	0.52	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	5.85	7.11e-08	0.000121	0.51	0.52	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
THYM	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-5.85	7.12e-08	0.000121	-0.43	-0.52	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
THYM	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	5.85	7.14e-08	0.000121	0.68	0.52	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
THYM	cis	rs950169	0.84	rs72748702	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84246494	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs4338765	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84248084	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs62028133	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84250623	chr15:84398316~84411701:-
THYM	cis	rs950169	0.723	rs17589320	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84251244	chr15:84398316~84411701:-
THYM	cis	rs950169	0.8	rs4842847	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84262447	chr15:84398316~84411701:-
THYM	cis	rs950169	0.881	rs4842852	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84387263	chr15:84398316~84411701:-
THYM	cis	rs950169	0.84	rs4842853	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84387606	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs4842946	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84387633	chr15:84398316~84411701:-
THYM	cis	rs950169	0.84	rs4842854	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84387641	chr15:84398316~84411701:-
THYM	cis	rs950169	0.84	rs2896002	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84390423	chr15:84398316~84411701:-
THYM	cis	rs950169	0.887	rs3860265	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84390487	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs2033284	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84391575	chr15:84398316~84411701:-
THYM	cis	rs950169	0.724	rs11632668	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84393989	chr15:84398316~84411701:-
THYM	cis	rs950169	0.881	rs34591918	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84396135	chr15:84398316~84411701:-
THYM	cis	rs950169	0.887	rs12903946	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84399732	chr15:84398316~84411701:-
THYM	cis	rs950169	0.887	rs35986397	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84400409	chr15:84398316~84411701:-
THYM	cis	rs950169	0.887	rs62029593	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84400482	chr15:84398316~84411701:-
THYM	cis	rs950169	0.81	rs62029594	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84400554	chr15:84398316~84411701:-
THYM	cis	rs950169	0.84	rs62029595	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84400603	chr15:84398316~84411701:-
THYM	cis	rs950169	0.881	rs62029596	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84400736	chr15:84398316~84411701:-
THYM	cis	rs950169	0.881	rs4081123	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84401537	chr15:84398316~84411701:-
THYM	cis	rs950169	0.881	rs62029599	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84401867	chr15:84398316~84411701:-
THYM	cis	rs950169	0.8	rs4099846	ENSG00000235370.6	DNM1P51	5.85	7.2e-08	0.000122	0.67	0.52	Schizophrenia;	chr15:84402196	chr15:84398316~84411701:-
THYM	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	5.85	7.21e-08	0.000122	0.44	0.52	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
THYM	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-5.85	7.22e-08	0.000122	-0.61	-0.52	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
THYM	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	5.85	7.23e-08	0.000122	1	0.52	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
THYM	cis	rs2283792	0.846	rs240051	ENSG00000228050.1	TOP3BP1	5.85	7.24e-08	0.000123	0.57	0.52	Multiple sclerosis;	chr22:21909763	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.846	rs240053	ENSG00000228050.1	TOP3BP1	5.85	7.24e-08	0.000123	0.57	0.52	Multiple sclerosis;	chr22:21911000	chr22:22223187~22224566:-
THYM	cis	rs7560272	0.501	rs2421674	ENSG00000273245.1	RP11-434P11.2	-5.85	7.24e-08	0.000123	-0.6	-0.52	Schizophrenia;	chr2:73728305	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs12713793	ENSG00000273245.1	RP11-434P11.2	-5.85	7.24e-08	0.000123	-0.6	-0.52	Schizophrenia;	chr2:73728987	chr2:73750256~73750786:-
THYM	cis	rs2283792	0.718	rs239918	ENSG00000228050.1	TOP3BP1	5.85	7.26e-08	0.000123	0.57	0.52	Multiple sclerosis;	chr22:21959457	chr22:22223187~22224566:-
THYM	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-5.85	7.27e-08	0.000123	-0.61	-0.52	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-5.85	7.27e-08	0.000123	-0.61	-0.52	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
THYM	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-5.84	7.28e-08	0.000123	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-5.84	7.28e-08	0.000123	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
THYM	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-5.84	7.29e-08	0.000123	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
THYM	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	5.84	7.3e-08	0.000123	0.5	0.52	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
THYM	cis	rs11157436	0.958	rs2204963	ENSG00000211813.2	TRAV34	5.84	7.31e-08	0.000123	0.4	0.52	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22207522~22208129:+
THYM	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-5.84	7.31e-08	0.000123	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-5.84	7.31e-08	0.000123	-0.56	-0.52	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
THYM	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	5.84	7.34e-08	0.000123	0.43	0.52	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	5.84	7.34e-08	0.000123	0.43	0.52	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	5.84	7.34e-08	0.000123	0.43	0.52	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
THYM	cis	rs17772222	0.63	rs10873392	ENSG00000258983.2	RP11-507K2.2	-5.84	7.35e-08	0.000124	-0.57	-0.52	Coronary artery calcification;	chr14:88545124	chr14:88499334~88515502:+
THYM	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	5.84	7.37e-08	0.000124	0.46	0.52	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	5.84	7.37e-08	0.000124	0.46	0.52	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	5.84	7.37e-08	0.000124	0.46	0.52	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
THYM	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	5.84	7.38e-08	0.000124	0.97	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	5.84	7.38e-08	0.000124	0.97	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	5.84	7.38e-08	0.000124	0.97	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	5.84	7.38e-08	0.000124	0.97	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	5.84	7.38e-08	0.000124	0.97	0.52	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
THYM	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	5.84	7.39e-08	0.000124	0.52	0.52	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
THYM	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-5.84	7.4e-08	0.000124	-0.39	-0.52	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-5.84	7.4e-08	0.000124	-0.39	-0.52	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-5.84	7.4e-08	0.000124	-0.39	-0.52	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-5.84	7.4e-08	0.000124	-0.39	-0.52	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
THYM	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	5.84	7.4e-08	0.000124	0.68	0.52	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
THYM	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	5.84	7.41e-08	0.000124	0.65	0.52	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
THYM	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	5.84	7.41e-08	0.000124	0.49	0.52	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	5.84	7.41e-08	0.000124	0.49	0.52	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
THYM	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	5.84	7.43e-08	0.000125	0.43	0.52	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	5.84	7.43e-08	0.000125	0.43	0.52	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
THYM	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.84	7.44e-08	0.000125	0.48	0.52	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
THYM	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	5.84	7.46e-08	0.000125	0.65	0.52	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
THYM	cis	rs4718428	0.705	rs4718430	ENSG00000273142.1	RP11-458F8.4	-5.84	7.51e-08	0.000126	-0.4	-0.52	Corneal structure;	chr7:66967037	chr7:66902857~66906297:+
THYM	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	5.84	7.53e-08	0.000126	0.4	0.52	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
THYM	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	5.84	7.54e-08	0.000126	0.56	0.52	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
THYM	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-5.84	7.54e-08	0.000126	-0.8	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
THYM	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	5.84	7.54e-08	0.000126	0.43	0.52	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
THYM	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-5.84	7.59e-08	0.000127	-0.4	-0.52	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
THYM	cis	rs4273100	1	rs868698	ENSG00000228157.4	AC007952.5	5.83	7.61e-08	0.000127	0.79	0.52	Schizophrenia;	chr17:19281898	chr17:19092974~19096837:+
THYM	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	5.83	7.62e-08	0.000127	0.48	0.52	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
THYM	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-5.83	7.63e-08	0.000128	-0.61	-0.52	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-5.83	7.63e-08	0.000128	-0.61	-0.52	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
THYM	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-5.83	7.65e-08	0.000128	-0.52	-0.52	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
THYM	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	5.83	7.65e-08	0.000128	0.52	0.52	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
THYM	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	5.83	7.65e-08	0.000128	0.52	0.52	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
THYM	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	5.83	7.65e-08	0.000128	0.52	0.52	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
THYM	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	5.83	7.65e-08	0.000128	0.52	0.52	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
THYM	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	5.83	7.65e-08	0.000128	0.52	0.52	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
THYM	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-5.83	7.67e-08	0.000128	-0.39	-0.52	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-5.83	7.67e-08	0.000128	-0.39	-0.52	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-5.83	7.67e-08	0.000128	-0.39	-0.52	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-5.83	7.67e-08	0.000128	-0.39	-0.52	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-5.83	7.67e-08	0.000128	-0.39	-0.52	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
THYM	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	5.83	7.67e-08	0.000128	0.51	0.52	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	5.83	7.67e-08	0.000128	0.51	0.52	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	5.83	7.67e-08	0.000128	0.51	0.52	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	5.83	7.67e-08	0.000128	0.51	0.52	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
THYM	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	5.83	7.68e-08	0.000128	0.52	0.52	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
THYM	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-5.83	7.69e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
THYM	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	5.83	7.69e-08	0.000128	0.52	0.52	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
THYM	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	5.83	7.71e-08	0.000128	0.55	0.52	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
THYM	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-5.83	7.71e-08	0.000128	-0.55	-0.52	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
THYM	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-5.83	7.74e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-5.83	7.74e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-5.83	7.74e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-5.83	7.74e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-5.83	7.74e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-5.83	7.74e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-5.83	7.74e-08	0.000128	-0.37	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	5.83	7.74e-08	0.000128	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
THYM	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-5.83	7.75e-08	0.000129	-0.61	-0.52	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	5.83	7.75e-08	0.000129	0.61	0.52	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	5.83	7.75e-08	0.000129	0.61	0.52	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
THYM	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	5.83	7.76e-08	0.000129	0.37	0.52	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
THYM	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-5.83	7.82e-08	0.00013	-0.4	-0.52	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
THYM	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-5.83	7.84e-08	0.00013	-0.46	-0.52	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
THYM	cis	rs5760092	0.842	rs5760103	ENSG00000218537.1	MIF-AS1	5.83	7.87e-08	0.00013	0.78	0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23894426~23898930:-
THYM	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	5.83	7.88e-08	0.00013	0.43	0.52	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
THYM	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-5.83	7.88e-08	0.00013	-0.39	-0.52	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-5.83	7.88e-08	0.00013	-0.38	-0.52	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
THYM	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	5.82	7.96e-08	0.000132	0.52	0.51	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
THYM	cis	rs8396	0.96	rs17843902	ENSG00000271817.2	U3	5.82	7.97e-08	0.000132	0.39	0.51	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158719996	chr4:158700691~158700909:+
THYM	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-5.82	7.97e-08	0.000132	-0.59	-0.51	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
THYM	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	5.82	7.97e-08	0.000132	0.38	0.51	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
THYM	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	5.82	7.97e-08	0.000132	0.38	0.51	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	5.82	7.97e-08	0.000132	0.38	0.51	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	5.82	7.97e-08	0.000132	0.38	0.51	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	5.82	7.97e-08	0.000132	0.38	0.51	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
THYM	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-5.82	7.98e-08	0.000132	-0.53	-0.51	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
THYM	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	5.82	7.98e-08	0.000132	0.46	0.51	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
THYM	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-5.82	8e-08	0.000132	-0.67	-0.51	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
THYM	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	5.82	8.03e-08	0.000133	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	5.82	8.04e-08	0.000133	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	5.82	8.04e-08	0.000133	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	5.82	8.04e-08	0.000133	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	5.82	8.04e-08	0.000133	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	5.82	8.04e-08	0.000133	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
THYM	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-5.82	8.06e-08	0.000133	-0.63	-0.51	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
THYM	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-5.82	8.06e-08	0.000133	-0.63	-0.51	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
THYM	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	5.82	8.06e-08	0.000133	0.67	0.51	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
THYM	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-5.82	8.07e-08	0.000133	-0.59	-0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
THYM	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-5.82	8.07e-08	0.000133	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
THYM	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-5.82	8.08e-08	0.000133	-0.61	-0.51	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
THYM	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-5.82	8.08e-08	0.000133	-0.46	-0.51	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-5.82	8.08e-08	0.000133	-0.46	-0.51	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-5.82	8.08e-08	0.000133	-0.46	-0.51	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
THYM	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	5.82	8.14e-08	0.000134	0.68	0.51	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
THYM	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	5.82	8.17e-08	0.000135	0.49	0.51	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
THYM	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	5.82	8.17e-08	0.000135	0.66	0.51	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
THYM	cis	rs2108622	0.64	rs58858790	ENSG00000267453.5	AC004791.2	-5.82	8.18e-08	0.000135	-0.62	-0.51	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15863463	chr19:15851993~15864904:-
THYM	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	5.82	8.19e-08	0.000135	0.55	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
THYM	cis	rs9532669	0.889	rs7320344	ENSG00000176268.5	CYCSP34	5.82	8.25e-08	0.000136	0.47	0.51	Cervical cancer;	chr13:40885502	chr13:40863599~40863902:-
THYM	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-5.82	8.28e-08	0.000136	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-5.82	8.28e-08	0.000136	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
THYM	cis	rs13256369	0.865	rs13282523	ENSG00000253893.2	FAM85B	-5.82	8.28e-08	0.000136	-0.68	-0.51	Obesity-related traits;	chr8:8719783	chr8:8167819~8226614:-
THYM	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-5.81	8.3e-08	0.000136	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	5.81	8.3e-08	0.000136	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-5.81	8.34e-08	0.000137	-0.38	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
THYM	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-5.81	8.35e-08	0.000137	-0.74	-0.51	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
THYM	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-5.81	8.38e-08	0.000138	-0.84	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
THYM	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	5.81	8.42e-08	0.000138	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
THYM	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-5.81	8.49e-08	0.000139	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-5.81	8.49e-08	0.000139	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
THYM	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	5.81	8.51e-08	0.000139	0.71	0.51	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
THYM	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-5.81	8.55e-08	0.00014	-1.11	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
THYM	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	5.81	8.56e-08	0.00014	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	5.81	8.56e-08	0.00014	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	5.81	8.56e-08	0.00014	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	5.81	8.56e-08	0.00014	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
THYM	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	5.81	8.63e-08	0.000141	0.4	0.51	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
THYM	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-5.81	8.64e-08	0.000141	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-5.81	8.64e-08	0.000141	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	5.81	8.66e-08	0.000141	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
THYM	cis	rs7560272	0.501	rs4852978	ENSG00000273245.1	RP11-434P11.2	-5.81	8.67e-08	0.000141	-0.61	-0.51	Schizophrenia;	chr2:73715983	chr2:73750256~73750786:-
THYM	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	5.81	8.67e-08	0.000141	0.48	0.51	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
THYM	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-5.81	8.67e-08	0.000141	-0.53	-0.51	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
THYM	cis	rs17772222	0.63	rs12437422	ENSG00000258983.2	RP11-507K2.2	-5.8	8.68e-08	0.000141	-0.57	-0.51	Coronary artery calcification;	chr14:88529621	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.605	rs4899955	ENSG00000258983.2	RP11-507K2.2	-5.8	8.68e-08	0.000141	-0.57	-0.51	Coronary artery calcification;	chr14:88530381	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.63	rs8017811	ENSG00000258983.2	RP11-507K2.2	-5.8	8.68e-08	0.000141	-0.57	-0.51	Coronary artery calcification;	chr14:88534559	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.63	rs4904454	ENSG00000258983.2	RP11-507K2.2	-5.8	8.68e-08	0.000141	-0.57	-0.51	Coronary artery calcification;	chr14:88537777	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.63	rs2033418	ENSG00000258983.2	RP11-507K2.2	-5.8	8.68e-08	0.000141	-0.57	-0.51	Coronary artery calcification;	chr14:88539331	chr14:88499334~88515502:+
THYM	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	5.8	8.68e-08	0.000142	0.65	0.51	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
THYM	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	5.8	8.7e-08	0.000142	0.48	0.51	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	5.8	8.7e-08	0.000142	0.48	0.51	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	5.8	8.7e-08	0.000142	0.48	0.51	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	5.8	8.7e-08	0.000142	0.48	0.51	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
THYM	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-5.8	8.71e-08	0.000142	-0.69	-0.51	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
THYM	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-5.8	8.71e-08	0.000142	-0.73	-0.51	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
THYM	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-5.8	8.71e-08	0.000142	-0.73	-0.51	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
THYM	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-5.8	8.71e-08	0.000142	-0.57	-0.51	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
THYM	cis	rs904251	0.523	rs2776872	ENSG00000227920.2	RP1-153P14.5	-5.8	8.73e-08	0.000142	-0.68	-0.51	Cognitive performance;	chr6:37515011	chr6:37545145~37550860:+
THYM	cis	rs904251	0.523	rs1757191	ENSG00000227920.2	RP1-153P14.5	-5.8	8.73e-08	0.000142	-0.68	-0.51	Cognitive performance;	chr6:37515095	chr6:37545145~37550860:+
THYM	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	5.8	8.74e-08	0.000142	0.47	0.51	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
THYM	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	5.8	8.75e-08	0.000143	0.59	0.51	Height;	chr6:109375548	chr6:109382795~109383666:+
THYM	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-5.8	8.76e-08	0.000143	-0.48	-0.51	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
THYM	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-5.8	8.8e-08	0.000143	-0.39	-0.51	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
THYM	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	5.8	8.83e-08	0.000144	0.8	0.51	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
THYM	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-5.8	8.85e-08	0.000144	-0.38	-0.51	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
THYM	cis	rs995834	0.622	rs2159074	ENSG00000260725.1	AC005307.1	5.8	8.87e-08	0.000144	0.55	0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407490	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs10408649	ENSG00000260725.1	AC005307.1	-5.8	8.87e-08	0.000144	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405965	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs6508824	ENSG00000260725.1	AC005307.1	-5.8	8.87e-08	0.000144	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406925	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs8111081	ENSG00000260725.1	AC005307.1	-5.8	8.87e-08	0.000144	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407156	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs10407317	ENSG00000260725.1	AC005307.1	-5.8	8.87e-08	0.000144	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28411352	chr19:28418483~28429490:-
THYM	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	5.8	8.88e-08	0.000144	0.97	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
THYM	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	5.8	8.9e-08	0.000145	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	5.8	8.9e-08	0.000145	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	5.8	8.9e-08	0.000145	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	5.8	8.9e-08	0.000145	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	5.8	8.9e-08	0.000145	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
THYM	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	5.8	8.92e-08	0.000145	0.42	0.51	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
THYM	cis	rs904251	1	rs904251	ENSG00000227920.2	RP1-153P14.5	-5.8	8.93e-08	0.000145	-0.71	-0.51	Cognitive performance;	chr6:37483920	chr6:37545145~37550860:+
THYM	cis	rs904251	0.523	rs2797799	ENSG00000227920.2	RP1-153P14.5	-5.8	8.95e-08	0.000145	-0.68	-0.51	Cognitive performance;	chr6:37515844	chr6:37545145~37550860:+
THYM	cis	rs904251	0.504	rs1757188	ENSG00000227920.2	RP1-153P14.5	-5.8	8.95e-08	0.000145	-0.68	-0.51	Cognitive performance;	chr6:37516032	chr6:37545145~37550860:+
THYM	cis	rs904251	0.522	rs882322	ENSG00000227920.2	RP1-153P14.5	-5.8	8.95e-08	0.000145	-0.68	-0.51	Cognitive performance;	chr6:37516327	chr6:37545145~37550860:+
THYM	cis	rs1757171	0.542	rs1757186	ENSG00000227920.2	RP1-153P14.5	-5.8	8.95e-08	0.000145	-0.68	-0.51	Cognitive performance;	chr6:37516335	chr6:37545145~37550860:+
THYM	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-5.8	8.95e-08	0.000145	-0.59	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
THYM	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-5.8	8.95e-08	0.000145	-0.59	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
THYM	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-5.8	8.97e-08	0.000146	-0.53	-0.51	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
THYM	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-5.8	8.99e-08	0.000146	-0.59	-0.51	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
THYM	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	5.8	9.01e-08	0.000146	0.79	0.51	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
THYM	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	5.8	9.01e-08	0.000146	0.79	0.51	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
THYM	cis	rs995834	0.585	rs10404961	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28417370	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs10419520	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419267	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs4806402	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420314	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs10419336	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420386	chr19:28418483~28429490:-
THYM	cis	rs995834	0.551	rs1558124	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420672	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs10403634	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28422714	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs10409773	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423090	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs8101242	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423341	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs720924	ENSG00000260725.1	AC005307.1	-5.8	9.03e-08	0.000147	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424180	chr19:28418483~28429490:-
THYM	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	5.8	9.05e-08	0.000147	0.68	0.51	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
THYM	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	5.8	9.06e-08	0.000147	0.68	0.51	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	5.8	9.06e-08	0.000147	0.68	0.51	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
THYM	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-5.79	9.08e-08	0.000147	-0.58	-0.51	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
THYM	cis	rs7560272	0.501	rs13003035	ENSG00000273245.1	RP11-434P11.2	-5.79	9.09e-08	0.000147	-0.58	-0.51	Schizophrenia;	chr2:73730100	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs12992607	ENSG00000273245.1	RP11-434P11.2	-5.79	9.09e-08	0.000147	-0.58	-0.51	Schizophrenia;	chr2:73732833	chr2:73750256~73750786:-
THYM	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-5.79	9.09e-08	0.000147	-0.42	-0.51	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
THYM	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	5.79	9.1e-08	0.000147	0.73	0.51	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
THYM	cis	rs5760092	0.755	rs4585126	ENSG00000272787.1	KB-226F1.2	5.79	9.14e-08	0.000148	0.67	0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23969211~23969873:+
THYM	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	5.79	9.15e-08	0.000148	0.52	0.51	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-5.79	9.15e-08	0.000148	-0.52	-0.51	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
THYM	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-5.79	9.17e-08	0.000148	-0.48	-0.51	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
THYM	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	5.79	9.19e-08	0.000149	0.57	0.51	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
THYM	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	5.79	9.19e-08	0.000149	0.47	0.51	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
THYM	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109494237	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109496073	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109498586	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109499759	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109501402	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109501429	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109503623	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109507271	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	5.79	9.23e-08	0.000149	0.61	0.51	Height;	chr6:109518783	chr6:109382795~109383666:+
THYM	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-5.79	9.29e-08	0.00015	-0.59	-0.51	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
THYM	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-5.79	9.29e-08	0.00015	-0.59	-0.51	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-5.79	9.29e-08	0.00015	-0.59	-0.51	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-5.79	9.29e-08	0.00015	-0.59	-0.51	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
THYM	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-5.79	9.31e-08	0.00015	-0.63	-0.51	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
THYM	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	5.79	9.33e-08	0.000151	0.63	0.51	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
THYM	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	5.79	9.34e-08	0.000151	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
THYM	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-5.79	9.34e-08	0.000151	-0.41	-0.51	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
THYM	cis	rs8396	0.96	rs6839534	ENSG00000271817.2	U3	5.79	9.35e-08	0.000151	0.39	0.51	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158716843	chr4:158700691~158700909:+
THYM	cis	rs17391705	1	rs17391552	ENSG00000243806.1	RPL7P18	5.79	9.38e-08	0.000151	1.07	0.51	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94785059	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs17391705	ENSG00000243806.1	RPL7P18	5.79	9.38e-08	0.000151	1.07	0.51	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94785742	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs113735093	ENSG00000243806.1	RPL7P18	5.79	9.38e-08	0.000151	1.07	0.51	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94787819	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs80075452	ENSG00000243806.1	RPL7P18	5.79	9.38e-08	0.000151	1.07	0.51	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94790316	chr5:94825961~94826694:-
THYM	cis	rs17391705	0.744	rs76350173	ENSG00000243806.1	RPL7P18	5.79	9.38e-08	0.000151	1.07	0.51	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94790583	chr5:94825961~94826694:-
THYM	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-5.79	9.38e-08	0.000151	-0.48	-0.51	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
THYM	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-5.79	9.38e-08	0.000151	-0.48	-0.51	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
THYM	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	5.79	9.39e-08	0.000151	0.48	0.51	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
THYM	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	5.79	9.42e-08	0.000152	0.73	0.51	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
THYM	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-5.79	9.44e-08	0.000152	-0.41	-0.51	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
THYM	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	5.79	9.45e-08	0.000152	0.67	0.51	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
THYM	cis	rs9535495	0.965	rs4523838	ENSG00000200711.1	RNA5SP28	-5.79	9.45e-08	0.000152	-0.58	-0.51	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50810472	chr13:50812988~50813106:-
THYM	cis	rs9535495	0.965	rs9535492	ENSG00000200711.1	RNA5SP28	-5.79	9.45e-08	0.000152	-0.58	-0.51	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50810480	chr13:50812988~50813106:-
THYM	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-5.79	9.46e-08	0.000152	-0.68	-0.51	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
THYM	cis	rs9535495	0.931	rs1841677	ENSG00000200711.1	RNA5SP28	-5.78	9.48e-08	0.000152	-0.58	-0.51	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50812753	chr13:50812988~50813106:-
THYM	cis	rs67383717	0.643	rs72756397	ENSG00000175611.10	LINC00476	-5.78	9.49e-08	0.000153	-0.53	-0.51	Parkinson's disease (pesticide exposure interaction);	chr9:95790861	chr9:95759231~95875977:-
THYM	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-5.78	9.52e-08	0.000153	-0.4	-0.51	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
THYM	cis	rs1155848	0.892	rs9574421	ENSG00000227354.5	RBM26-AS1	5.78	9.53e-08	0.000153	0.83	0.51	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79406205	chr13:79406309~79424328:+
THYM	cis	rs1155848	0.892	rs2296286	ENSG00000227354.5	RBM26-AS1	5.78	9.53e-08	0.000153	0.83	0.51	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79406474	chr13:79406309~79424328:+
THYM	cis	rs2729354	0.779	rs2511984	ENSG00000265566.2	RN7SL605P	-5.78	9.61e-08	0.000154	-0.75	-0.51	Blood protein levels;	chr11:57511260	chr11:57528085~57528365:-
THYM	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-5.78	9.63e-08	0.000155	-0.64	-0.51	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
THYM	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
THYM	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	5.78	9.63e-08	0.000155	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
THYM	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	5.78	9.65e-08	0.000155	0.46	0.51	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
THYM	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-5.78	9.67e-08	0.000155	-0.67	-0.51	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
THYM	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-5.78	9.7e-08	0.000156	-0.61	-0.51	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
THYM	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-5.78	9.72e-08	0.000156	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	5.78	9.72e-08	0.000156	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
THYM	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	5.78	9.73e-08	0.000156	0.69	0.51	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
THYM	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	5.78	9.76e-08	0.000156	0.62	0.51	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	5.78	9.76e-08	0.000156	0.62	0.51	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
THYM	cis	rs17772222	0.606	rs449338	ENSG00000258983.2	RP11-507K2.2	-5.78	9.76e-08	0.000156	-0.56	-0.51	Coronary artery calcification;	chr14:88411690	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.675	rs845758	ENSG00000258983.2	RP11-507K2.2	-5.78	9.76e-08	0.000156	-0.56	-0.51	Coronary artery calcification;	chr14:88433746	chr14:88499334~88515502:+
THYM	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-5.78	9.78e-08	0.000156	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
THYM	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	5.78	9.81e-08	0.000157	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	5.78	9.81e-08	0.000157	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	5.78	9.82e-08	0.000157	0.48	0.51	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
THYM	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-5.78	9.83e-08	0.000157	-0.77	-0.51	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
THYM	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-5.78	9.84e-08	0.000157	-0.92	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
THYM	cis	rs950169	0.922	rs11639244	ENSG00000235370.6	DNM1P51	5.78	9.84e-08	0.000157	0.67	0.51	Schizophrenia;	chr15:84163898	chr15:84398316~84411701:-
THYM	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-5.78	9.85e-08	0.000157	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-5.78	9.85e-08	0.000157	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	5.78	9.86e-08	0.000157	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
THYM	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	5.78	9.87e-08	0.000157	0.47	0.51	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	5.78	9.87e-08	0.000157	0.47	0.51	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
THYM	cis	rs747334	0.502	rs10785983	ENSG00000225519.1	RP11-236B18.2	5.78	9.87e-08	0.000157	0.45	0.51	Fibroblast growth factor basic levels;	chr10:90972909	chr10:90994620~91006390:+
THYM	cis	rs747334	0.502	rs1439095	ENSG00000225519.1	RP11-236B18.2	5.78	9.87e-08	0.000157	0.45	0.51	Fibroblast growth factor basic levels;	chr10:90973408	chr10:90994620~91006390:+
THYM	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-5.78	9.88e-08	0.000158	-0.63	-0.51	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
THYM	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-5.77	9.91e-08	0.000158	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-5.77	9.91e-08	0.000158	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	5.77	9.91e-08	0.000158	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
THYM	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	5.77	9.93e-08	0.000158	0.5	0.51	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
THYM	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-5.77	1e-07	0.000159	-0.55	-0.51	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
THYM	cis	rs17772222	0.651	rs865285	ENSG00000258983.2	RP11-507K2.2	-5.77	1e-07	0.000159	-0.56	-0.51	Coronary artery calcification;	chr14:88391138	chr14:88499334~88515502:+
THYM	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	5.77	1e-07	0.000159	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
THYM	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	5.77	1.01e-07	0.00016	0.66	0.51	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	5.77	1.01e-07	0.00016	0.66	0.51	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	5.77	1.01e-07	0.00016	0.66	0.51	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
THYM	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-5.77	1.01e-07	0.00016	-0.64	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
THYM	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	5.77	1.01e-07	0.00016	0.52	0.51	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
THYM	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	5.77	1.01e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	5.77	1.01e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
THYM	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	5.77	1.01e-07	0.00016	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
THYM	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-5.77	1.01e-07	0.00016	-0.53	-0.51	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
THYM	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-5.77	1.01e-07	0.00016	-0.53	-0.51	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
THYM	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	5.77	1.02e-07	0.00016	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
THYM	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
THYM	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
THYM	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	5.77	1.02e-07	0.00016	0.39	0.51	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
THYM	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-5.77	1.02e-07	0.00016	-0.39	-0.51	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-5.77	1.02e-07	0.00016	-0.39	-0.51	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-5.77	1.02e-07	0.00016	-0.39	-0.51	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-5.77	1.02e-07	0.00016	-0.39	-0.51	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
THYM	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-5.77	1.02e-07	0.00016	-0.39	-0.51	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-5.77	1.02e-07	0.00016	-0.39	-0.51	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
THYM	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	5.77	1.02e-07	0.000161	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	5.77	1.02e-07	0.000161	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
THYM	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-5.77	1.03e-07	0.000162	-0.59	-0.51	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
THYM	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	5.77	1.03e-07	0.000162	0.66	0.51	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
THYM	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	5.77	1.03e-07	0.000162	0.62	0.51	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
THYM	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	5.77	1.03e-07	0.000162	1.1	0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
THYM	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-5.77	1.03e-07	0.000163	-0.45	-0.51	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
THYM	cis	rs904251	0.772	rs2252920	ENSG00000279942.1	RP1-153P14.7	-5.77	1.03e-07	0.000163	-0.74	-0.51	Cognitive performance;	chr6:37450551	chr6:37567716~37571460:+
THYM	cis	rs4927850	0.958	rs2044599	ENSG00000231464.1	AC024937.4	5.76	1.03e-07	0.000163	0.66	0.51	Pancreatic cancer;	chr3:196009869	chr3:195996738~195998233:+
THYM	cis	rs4927850	1	rs4927704	ENSG00000231464.1	AC024937.4	5.76	1.03e-07	0.000163	0.66	0.51	Pancreatic cancer;	chr3:196011357	chr3:195996738~195998233:+
THYM	cis	rs4927850	1	rs4927848	ENSG00000231464.1	AC024937.4	5.76	1.03e-07	0.000163	0.66	0.51	Pancreatic cancer;	chr3:196011535	chr3:195996738~195998233:+
THYM	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	5.76	1.04e-07	0.000163	0.45	0.51	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
THYM	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	5.76	1.04e-07	0.000164	0.46	0.51	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	5.76	1.04e-07	0.000164	0.46	0.51	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
THYM	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	5.76	1.04e-07	0.000164	0.45	0.51	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
THYM	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-5.76	1.04e-07	0.000164	-0.67	-0.51	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
THYM	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-5.76	1.04e-07	0.000164	-0.67	-0.51	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
THYM	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-5.76	1.04e-07	0.000164	-0.67	-0.51	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
THYM	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	5.76	1.04e-07	0.000164	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	5.76	1.04e-07	0.000164	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-5.76	1.04e-07	0.000164	-0.96	-0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
THYM	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	5.76	1.05e-07	0.000165	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
THYM	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	5.76	1.05e-07	0.000165	0.96	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
THYM	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-5.76	1.05e-07	0.000165	-0.6	-0.51	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
THYM	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	5.76	1.06e-07	0.000166	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	5.76	1.06e-07	0.000166	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	5.76	1.06e-07	0.000166	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
THYM	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	5.76	1.06e-07	0.000166	0.79	0.51	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
THYM	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-5.76	1.06e-07	0.000167	-1.15	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
THYM	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-5.76	1.06e-07	0.000167	-0.76	-0.51	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
THYM	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-5.76	1.06e-07	0.000167	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
THYM	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-5.76	1.06e-07	0.000167	-0.54	-0.51	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
THYM	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-5.76	1.07e-07	0.000168	-0.53	-0.51	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
THYM	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-5.76	1.08e-07	0.000169	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-5.76	1.08e-07	0.000169	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
THYM	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	5.75	1.08e-07	0.00017	0.37	0.51	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
THYM	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	5.75	1.08e-07	0.00017	0.47	0.51	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
THYM	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-5.75	1.08e-07	0.00017	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-5.75	1.08e-07	0.00017	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
THYM	cis	rs17772222	0.682	rs4904452	ENSG00000258983.2	RP11-507K2.2	-5.75	1.09e-07	0.00017	-0.57	-0.51	Coronary artery calcification;	chr14:88517329	chr14:88499334~88515502:+
THYM	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	5.75	1.09e-07	0.000171	0.63	0.51	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
THYM	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-5.75	1.1e-07	0.000171	-0.46	-0.51	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
THYM	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	5.75	1.1e-07	0.000172	0.44	0.51	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
THYM	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-5.75	1.1e-07	0.000172	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	5.75	1.1e-07	0.000172	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	5.75	1.1e-07	0.000172	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	5.75	1.1e-07	0.000172	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
THYM	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	5.75	1.1e-07	0.000173	0.45	0.51	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
THYM	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-5.75	1.11e-07	0.000173	-0.69	-0.51	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
THYM	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	5.75	1.11e-07	0.000173	0.69	0.51	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
THYM	cis	rs1560104	0.576	rs7186185	ENSG00000259899.1	CTD-3037G24.3	-5.75	1.11e-07	0.000173	-0.63	-0.51	Obesity-related traits;	chr16:12614985	chr16:12560756~12611044:-
THYM	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-5.75	1.11e-07	0.000173	-0.51	-0.51	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
THYM	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	5.75	1.11e-07	0.000173	0.41	0.51	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
THYM	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	5.75	1.11e-07	0.000174	0.47	0.51	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	5.75	1.11e-07	0.000174	0.47	0.51	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	5.75	1.11e-07	0.000174	0.47	0.51	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	5.75	1.11e-07	0.000174	0.47	0.51	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	5.75	1.11e-07	0.000174	0.47	0.51	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	5.75	1.11e-07	0.000174	0.47	0.51	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	5.75	1.11e-07	0.000174	0.47	0.51	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
THYM	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-5.75	1.11e-07	0.000174	-0.77	-0.51	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
THYM	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	5.75	1.12e-07	0.000175	0.61	0.51	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
THYM	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	5.75	1.12e-07	0.000175	0.49	0.51	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
THYM	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-5.75	1.12e-07	0.000175	-0.46	-0.51	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
THYM	cis	rs2283792	0.812	rs240066	ENSG00000228050.1	TOP3BP1	-5.75	1.12e-07	0.000175	-0.57	-0.51	Multiple sclerosis;	chr22:21938623	chr22:22223187~22224566:-
THYM	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	5.75	1.12e-07	0.000175	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	5.75	1.12e-07	0.000175	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	5.75	1.12e-07	0.000175	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
THYM	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-5.75	1.12e-07	0.000175	-0.86	-0.51	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
THYM	cis	rs886716	0.507	rs35682591	ENSG00000122548.5	KIAA0087	5.75	1.13e-07	0.000176	0.55	0.51	Smoking behavior;	chr7:26527711	chr7:26533121~26538788:-
THYM	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-5.75	1.13e-07	0.000176	-0.37	-0.51	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
THYM	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-5.74	1.13e-07	0.000176	-0.78	-0.51	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
THYM	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-5.74	1.13e-07	0.000176	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
THYM	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	5.74	1.13e-07	0.000177	0.67	0.51	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	5.74	1.13e-07	0.000177	0.67	0.51	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	5.74	1.13e-07	0.000177	0.67	0.51	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	5.74	1.13e-07	0.000177	0.67	0.51	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	5.74	1.13e-07	0.000177	0.67	0.51	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	5.74	1.13e-07	0.000177	0.67	0.51	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
THYM	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-5.74	1.14e-07	0.000177	-0.6	-0.51	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
THYM	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	5.74	1.14e-07	0.000177	0.48	0.51	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	5.74	1.14e-07	0.000177	0.48	0.51	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	5.74	1.14e-07	0.000177	0.48	0.51	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
THYM	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	5.74	1.14e-07	0.000178	0.5	0.51	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	5.74	1.14e-07	0.000178	0.5	0.51	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
THYM	cis	rs7560272	0.501	rs11891140	ENSG00000273245.1	RP11-434P11.2	-5.74	1.14e-07	0.000178	-0.61	-0.51	Schizophrenia;	chr2:73716957	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs12713789	ENSG00000273245.1	RP11-434P11.2	-5.74	1.14e-07	0.000178	-0.61	-0.51	Schizophrenia;	chr2:73718473	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs12713790	ENSG00000273245.1	RP11-434P11.2	-5.74	1.14e-07	0.000178	-0.61	-0.51	Schizophrenia;	chr2:73718484	chr2:73750256~73750786:-
THYM	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	5.74	1.14e-07	0.000178	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-5.74	1.15e-07	0.000179	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
THYM	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-5.74	1.16e-07	0.00018	-1.02	-0.51	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	5.74	1.16e-07	0.00018	1.02	0.51	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
THYM	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-5.74	1.16e-07	0.00018	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
THYM	cis	rs8396	0.883	rs17843929	ENSG00000271817.2	U3	5.74	1.16e-07	0.00018	0.43	0.51	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158715961	chr4:158700691~158700909:+
THYM	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-5.74	1.16e-07	0.000181	-0.62	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
THYM	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-5.74	1.16e-07	0.000181	-0.38	-0.51	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-5.74	1.16e-07	0.000181	-0.38	-0.51	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-5.74	1.16e-07	0.000181	-0.38	-0.51	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-5.74	1.16e-07	0.000181	-0.38	-0.51	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-5.74	1.16e-07	0.000181	-0.38	-0.51	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-5.74	1.16e-07	0.000181	-0.38	-0.51	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
THYM	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-5.74	1.17e-07	0.000181	-0.66	-0.51	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
THYM	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-5.74	1.17e-07	0.000181	-0.66	-0.51	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
THYM	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-5.74	1.17e-07	0.000181	-0.66	-0.51	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
THYM	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-5.74	1.17e-07	0.000181	-0.66	-0.51	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
THYM	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-5.74	1.17e-07	0.000181	-0.66	-0.51	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
THYM	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-5.74	1.17e-07	0.000181	-0.66	-0.51	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
THYM	cis	rs995834	0.622	rs1029661	ENSG00000260725.1	AC005307.1	-5.74	1.17e-07	0.000181	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406394	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs7249889	ENSG00000260725.1	AC005307.1	-5.74	1.17e-07	0.000181	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406402	chr19:28418483~28429490:-
THYM	cis	rs7829975	0.545	rs13261926	ENSG00000253893.2	FAM85B	5.74	1.17e-07	0.000181	0.62	0.51	Mood instability;	chr8:8694100	chr8:8167819~8226614:-
THYM	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-5.74	1.17e-07	0.000181	-0.47	-0.51	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
THYM	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	5.74	1.17e-07	0.000181	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	5.74	1.17e-07	0.000181	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-5.74	1.17e-07	0.000181	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-5.74	1.17e-07	0.000181	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-5.74	1.17e-07	0.000181	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-5.74	1.17e-07	0.000181	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	5.74	1.17e-07	0.000181	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	5.74	1.18e-07	0.000182	0.47	0.51	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
THYM	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	5.74	1.18e-07	0.000182	0.47	0.51	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
THYM	cis	rs17391705	1	rs17390854	ENSG00000243806.1	RPL7P18	5.73	1.18e-07	0.000183	1.06	0.51	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94759189	chr5:94825961~94826694:-
THYM	cis	rs747334	0.502	rs1439093	ENSG00000225519.1	RP11-236B18.2	5.73	1.19e-07	0.000183	0.46	0.51	Fibroblast growth factor basic levels;	chr10:90974560	chr10:90994620~91006390:+
THYM	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	5.73	1.19e-07	0.000184	0.54	0.51	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
THYM	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-5.73	1.19e-07	0.000184	-0.65	-0.51	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
THYM	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	5.73	1.19e-07	0.000184	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	5.73	1.19e-07	0.000184	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
THYM	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	5.73	1.2e-07	0.000185	0.63	0.51	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
THYM	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	5.73	1.2e-07	0.000185	0.74	0.51	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
THYM	cis	rs2834288	0.5	rs881230	ENSG00000237945.6	LINC00649	5.73	1.2e-07	0.000185	0.41	0.51	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33915534~33977691:+
THYM	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-5.73	1.2e-07	0.000185	-0.38	-0.51	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	5.73	1.2e-07	0.000185	0.38	0.51	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-5.73	1.2e-07	0.000185	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	5.73	1.21e-07	0.000186	0.5	0.51	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	5.73	1.21e-07	0.000186	0.5	0.51	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	5.73	1.21e-07	0.000186	0.5	0.51	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	5.73	1.21e-07	0.000186	0.5	0.51	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	5.73	1.21e-07	0.000186	0.5	0.51	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
THYM	cis	rs9326248	0.513	rs1263164	ENSG00000254851.1	RP11-109L13.1	-5.73	1.21e-07	0.000186	-0.65	-0.51	Blood protein levels;	chr11:116804575	chr11:117135528~117138582:+
THYM	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-5.73	1.21e-07	0.000186	-0.43	-0.51	Depression;	chr6:28205175	chr6:28115628~28116551:+
THYM	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	5.73	1.21e-07	0.000187	0.36	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
THYM	cis	rs7209700	0.547	rs8078614	ENSG00000228782.6	CTD-2026D20.3	-5.73	1.21e-07	0.000187	-0.75	-0.51	IgG glycosylation;	chr17:47274139	chr17:47450568~47492492:-
THYM	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-5.73	1.21e-07	0.000187	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-5.73	1.21e-07	0.000187	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-5.73	1.21e-07	0.000187	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-5.73	1.21e-07	0.000187	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
THYM	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-5.73	1.22e-07	0.000187	-0.59	-0.51	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
THYM	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-5.73	1.22e-07	0.000187	-0.59	-0.51	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
THYM	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-5.73	1.22e-07	0.000187	-0.59	-0.51	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
THYM	cis	rs7772486	0.558	rs702316	ENSG00000235652.6	RP11-545I5.3	-5.73	1.22e-07	0.000187	-0.4	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145683541	chr6:145799409~145886585:+
THYM	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-5.73	1.22e-07	0.000188	-0.59	-0.51	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
THYM	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-5.73	1.23e-07	0.000189	-0.65	-0.51	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
THYM	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-5.73	1.23e-07	0.000189	-0.47	-0.51	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
THYM	cis	rs7560272	0.501	rs6755500	ENSG00000273245.1	RP11-434P11.2	-5.72	1.23e-07	0.00019	-0.6	-0.51	Schizophrenia;	chr2:73715106	chr2:73750256~73750786:-
THYM	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-5.72	1.23e-07	0.00019	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-5.72	1.23e-07	0.00019	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
THYM	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	5.72	1.24e-07	0.00019	0.73	0.51	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
THYM	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	5.72	1.24e-07	0.00019	0.73	0.51	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
THYM	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	5.72	1.24e-07	0.00019	0.73	0.51	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
THYM	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-5.72	1.24e-07	0.000191	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
THYM	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	5.72	1.24e-07	0.000191	0.67	0.51	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
THYM	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-5.72	1.24e-07	0.000191	-0.59	-0.51	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
THYM	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-5.72	1.25e-07	0.000192	-0.61	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
THYM	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	5.72	1.25e-07	0.000192	0.76	0.51	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
THYM	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	5.72	1.26e-07	0.000192	0.62	0.51	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
THYM	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	5.72	1.26e-07	0.000193	0.96	0.51	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
THYM	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-5.72	1.26e-07	0.000193	-0.69	-0.51	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
THYM	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	5.72	1.26e-07	0.000193	0.38	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
THYM	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-5.72	1.27e-07	0.000194	-0.38	-0.51	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-5.72	1.27e-07	0.000194	-0.38	-0.51	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-5.72	1.27e-07	0.000194	-0.38	-0.51	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
THYM	cis	rs995834	0.585	rs720923	ENSG00000260725.1	AC005307.1	-5.72	1.27e-07	0.000194	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423935	chr19:28418483~28429490:-
THYM	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	5.72	1.27e-07	0.000194	0.47	0.51	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	5.72	1.27e-07	0.000194	0.47	0.51	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
THYM	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-5.72	1.27e-07	0.000194	-0.65	-0.51	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
THYM	cis	rs17772222	0.63	rs1344747	ENSG00000258983.2	RP11-507K2.2	-5.72	1.27e-07	0.000194	-0.57	-0.51	Coronary artery calcification;	chr14:88548091	chr14:88499334~88515502:+
THYM	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	5.72	1.27e-07	0.000195	0.47	0.51	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
THYM	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	5.72	1.28e-07	0.000195	0.79	0.51	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
THYM	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-5.72	1.28e-07	0.000196	-0.91	-0.51	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-5.72	1.28e-07	0.000196	-0.91	-0.51	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
THYM	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	5.71	1.29e-07	0.000196	0.54	0.51	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
THYM	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	5.71	1.29e-07	0.000197	0.55	0.51	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
THYM	cis	rs2283792	0.792	rs151680	ENSG00000228050.1	TOP3BP1	5.71	1.29e-07	0.000197	0.59	0.51	Multiple sclerosis;	chr22:21918869	chr22:22223187~22224566:-
THYM	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	5.71	1.29e-07	0.000197	0.96	0.51	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
THYM	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-5.71	1.29e-07	0.000197	-0.6	-0.51	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
THYM	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-5.71	1.3e-07	0.000197	-0.61	-0.51	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-5.71	1.3e-07	0.000197	-0.61	-0.51	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
THYM	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-5.71	1.3e-07	0.000197	-0.61	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
THYM	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-5.71	1.3e-07	0.000197	-0.61	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
THYM	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-5.71	1.3e-07	0.000197	-0.61	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
THYM	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	5.71	1.3e-07	0.000198	0.55	0.51	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
THYM	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	5.71	1.3e-07	0.000198	0.52	0.51	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	5.71	1.3e-07	0.000198	0.52	0.51	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
THYM	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	5.71	1.3e-07	0.000199	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	5.71	1.3e-07	0.000199	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
THYM	cis	rs4273100	0.646	rs4924990	ENSG00000228157.4	AC007952.5	-5.71	1.31e-07	2e-04	-0.84	-0.51	Schizophrenia;	chr17:19391511	chr17:19092974~19096837:+
THYM	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-5.71	1.32e-07	2e-04	-0.72	-0.51	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
THYM	cis	rs11157436	0.918	rs1983518	ENSG00000211813.2	TRAV34	5.71	1.32e-07	2e-04	0.37	0.51	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149336	chr14:22207522~22208129:+
THYM	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-5.71	1.32e-07	2e-04	-0.38	-0.51	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-5.71	1.32e-07	2e-04	-0.38	-0.51	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
THYM	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-5.71	1.32e-07	2e-04	-0.38	-0.51	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
THYM	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	5.71	1.32e-07	0.000201	0.55	0.51	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
THYM	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	5.71	1.32e-07	0.000201	0.38	0.51	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
THYM	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-5.71	1.32e-07	0.000201	-0.62	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
THYM	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-5.71	1.32e-07	0.000201	-0.4	-0.51	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
THYM	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-5.71	1.33e-07	0.000202	-0.65	-0.51	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
THYM	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-5.71	1.33e-07	0.000202	-0.43	-0.51	Depression;	chr6:28197412	chr6:28115628~28116551:+
THYM	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-5.71	1.33e-07	0.000202	-0.43	-0.51	Depression;	chr6:28198669	chr6:28115628~28116551:+
THYM	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-5.71	1.33e-07	0.000202	-0.65	-0.51	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-5.71	1.33e-07	0.000202	-0.65	-0.51	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-5.71	1.33e-07	0.000202	-0.65	-0.51	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-5.71	1.33e-07	0.000202	-0.65	-0.51	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
THYM	cis	rs673078	0.66	rs7301950	ENSG00000275759.1	RP11-131L12.3	-5.71	1.34e-07	0.000203	-0.95	-0.51	Glucose homeostasis traits;	chr12:118170634	chr12:118428281~118428870:+
THYM	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	5.71	1.34e-07	0.000203	0.39	0.51	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
THYM	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	5.71	1.34e-07	0.000203	0.36	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	5.71	1.34e-07	0.000203	0.36	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-5.71	1.34e-07	0.000203	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
THYM	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	5.71	1.34e-07	0.000203	0.65	0.51	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
THYM	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-5.71	1.34e-07	0.000203	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
THYM	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-5.71	1.34e-07	0.000203	-0.67	-0.51	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
THYM	cis	rs4273100	0.688	rs28582509	ENSG00000262319.1	CTC-457L16.2	-5.7	1.34e-07	0.000204	-0.67	-0.51	Schizophrenia;	chr17:19261866	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.688	rs4924967	ENSG00000262319.1	CTC-457L16.2	-5.7	1.34e-07	0.000204	-0.67	-0.51	Schizophrenia;	chr17:19268883	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.688	rs28760541	ENSG00000262319.1	CTC-457L16.2	-5.7	1.34e-07	0.000204	-0.67	-0.51	Schizophrenia;	chr17:19269192	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.688	rs1467028	ENSG00000262319.1	CTC-457L16.2	-5.7	1.34e-07	0.000204	-0.67	-0.51	Schizophrenia;	chr17:19271561	chr17:19141017~19143689:-
THYM	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-5.7	1.35e-07	0.000204	-0.9	-0.51	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
THYM	cis	rs7829975	0.684	rs546603	ENSG00000253893.2	FAM85B	5.7	1.35e-07	0.000204	0.67	0.51	Mood instability;	chr8:8738328	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	5.7	1.35e-07	0.000204	0.67	0.51	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
THYM	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-5.7	1.35e-07	0.000205	-1.14	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
THYM	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	5.7	1.36e-07	0.000205	0.67	0.51	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
THYM	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	5.7	1.36e-07	0.000205	0.96	0.51	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	5.7	1.36e-07	0.000205	0.96	0.51	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	5.7	1.36e-07	0.000205	0.96	0.51	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	5.7	1.36e-07	0.000205	0.96	0.51	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	5.7	1.36e-07	0.000205	0.96	0.51	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	5.7	1.36e-07	0.000205	0.96	0.51	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
THYM	cis	rs7560272	0.501	rs6750494	ENSG00000273245.1	RP11-434P11.2	-5.7	1.36e-07	0.000205	-0.61	-0.51	Schizophrenia;	chr2:73719369	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs12615807	ENSG00000273245.1	RP11-434P11.2	-5.7	1.36e-07	0.000205	-0.61	-0.51	Schizophrenia;	chr2:73720456	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs10191988	ENSG00000273245.1	RP11-434P11.2	-5.7	1.36e-07	0.000205	-0.61	-0.51	Schizophrenia;	chr2:73720660	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs2006997	ENSG00000273245.1	RP11-434P11.2	-5.7	1.36e-07	0.000205	-0.61	-0.51	Schizophrenia;	chr2:73720719	chr2:73750256~73750786:-
THYM	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	5.7	1.36e-07	0.000206	0.37	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
THYM	cis	rs1155848	0.892	rs1977354	ENSG00000227354.5	RBM26-AS1	5.7	1.37e-07	0.000207	0.82	0.51	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79383273	chr13:79406309~79424328:+
THYM	cis	rs1155848	0.892	rs3742121	ENSG00000227354.5	RBM26-AS1	5.7	1.37e-07	0.000207	0.82	0.51	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79387009	chr13:79406309~79424328:+
THYM	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-5.7	1.37e-07	0.000207	-0.6	-0.51	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
THYM	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-5.7	1.37e-07	0.000208	-0.37	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
THYM	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-5.7	1.38e-07	0.000208	-0.88	-0.51	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
THYM	cis	rs4691139	0.903	rs6812591	ENSG00000250227.1	TRIM60P14	5.7	1.38e-07	0.000208	0.6	0.51	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999023	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.903	rs6812776	ENSG00000250227.1	TRIM60P14	5.7	1.38e-07	0.000208	0.6	0.51	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999097	chr4:164915565~164916983:+
THYM	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-5.7	1.38e-07	0.000209	-0.37	-0.51	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
THYM	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-5.7	1.39e-07	0.000209	-0.38	-0.51	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
THYM	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-5.7	1.39e-07	0.00021	-0.38	-0.51	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
THYM	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-5.7	1.39e-07	0.00021	-0.38	-0.51	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-5.7	1.39e-07	0.00021	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-5.7	1.39e-07	0.00021	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-5.7	1.39e-07	0.00021	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-5.7	1.39e-07	0.00021	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
THYM	cis	rs995834	0.826	rs10419909	ENSG00000267243.4	AC005307.3	-5.7	1.39e-07	0.00021	-0.46	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395848	chr19:28435388~28727777:-
THYM	cis	rs995834	0.826	rs8112121	ENSG00000267243.4	AC005307.3	-5.7	1.39e-07	0.00021	-0.46	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396047	chr19:28435388~28727777:-
THYM	cis	rs995834	0.826	rs6508819	ENSG00000267243.4	AC005307.3	-5.7	1.39e-07	0.00021	-0.46	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396068	chr19:28435388~28727777:-
THYM	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	5.7	1.39e-07	0.00021	0.7	0.51	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
THYM	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-5.69	1.4e-07	0.000211	-0.36	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
THYM	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-5.69	1.41e-07	0.000212	-0.58	-0.51	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-5.69	1.41e-07	0.000212	-0.58	-0.51	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-5.69	1.41e-07	0.000212	-0.58	-0.51	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
THYM	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-5.69	1.41e-07	0.000212	-0.58	-0.51	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-5.69	1.41e-07	0.000212	-0.58	-0.51	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
THYM	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-5.69	1.41e-07	0.000212	-0.58	-0.51	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
THYM	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-5.69	1.41e-07	0.000212	-0.58	-0.51	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
THYM	cis	rs995834	0.552	rs7251838	ENSG00000260725.1	AC005307.1	-5.69	1.41e-07	0.000212	-0.55	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424805	chr19:28418483~28429490:-
THYM	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-5.69	1.41e-07	0.000212	-0.6	-0.51	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-5.69	1.41e-07	0.000212	-0.6	-0.51	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-5.69	1.41e-07	0.000212	-0.6	-0.51	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-5.69	1.41e-07	0.000212	-0.6	-0.51	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-5.69	1.41e-07	0.000212	-0.6	-0.51	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
THYM	cis	rs4273100	0.688	rs1533034	ENSG00000262319.1	CTC-457L16.2	-5.69	1.42e-07	0.000213	-0.67	-0.51	Schizophrenia;	chr17:19249862	chr17:19141017~19143689:-
THYM	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	5.69	1.42e-07	0.000213	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	5.69	1.42e-07	0.000213	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	5.69	1.42e-07	0.000213	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	5.69	1.42e-07	0.000213	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	5.69	1.42e-07	0.000213	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	5.69	1.42e-07	0.000213	0.68	0.51	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
THYM	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	5.69	1.43e-07	0.000214	0.47	0.51	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
THYM	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-5.69	1.43e-07	0.000214	-0.62	-0.51	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-5.69	1.43e-07	0.000214	-0.62	-0.51	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-5.69	1.43e-07	0.000214	-0.62	-0.51	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
THYM	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-5.69	1.43e-07	0.000215	-0.58	-0.51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
THYM	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-5.69	1.44e-07	0.000215	-0.4	-0.51	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
THYM	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	5.69	1.44e-07	0.000216	0.48	0.51	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
THYM	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-5.69	1.44e-07	0.000216	-0.79	-0.51	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
THYM	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-5.69	1.44e-07	0.000216	-0.79	-0.51	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
THYM	cis	rs4273100	0.605	rs28591622	ENSG00000262319.1	CTC-457L16.2	-5.69	1.44e-07	0.000216	-0.66	-0.51	Schizophrenia;	chr17:19272004	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.688	rs12939947	ENSG00000262319.1	CTC-457L16.2	-5.69	1.44e-07	0.000216	-0.66	-0.51	Schizophrenia;	chr17:19301218	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.688	rs4924980	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19301550	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.607	rs8072587	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19307760	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.646	rs11652784	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19313948	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.646	rs1472932	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19317353	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.607	rs1043809	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19336119	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.688	rs4143829	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19338192	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.646	rs4924987	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19343762	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.573	rs4924783	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19350668	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.564	rs10445411	ENSG00000262319.1	CTC-457L16.2	5.69	1.44e-07	0.000216	0.66	0.51	Schizophrenia;	chr17:19362484	chr17:19141017~19143689:-
THYM	cis	rs747334	0.502	rs11186407	ENSG00000225519.1	RP11-236B18.2	5.69	1.45e-07	0.000216	0.46	0.51	Fibroblast growth factor basic levels;	chr10:90981960	chr10:90994620~91006390:+
THYM	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-5.69	1.45e-07	0.000216	-0.73	-0.51	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
THYM	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	5.69	1.45e-07	0.000217	0.58	0.51	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
THYM	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-5.69	1.45e-07	0.000217	-0.57	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
THYM	cis	rs7115242	0.699	rs17174502	ENSG00000254851.1	RP11-109L13.1	5.69	1.45e-07	0.000217	0.94	0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116888939	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.699	rs12285074	ENSG00000254851.1	RP11-109L13.1	5.69	1.45e-07	0.000217	0.94	0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891312	chr11:117135528~117138582:+
THYM	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	5.69	1.46e-07	0.000218	0.61	0.51	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
THYM	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	5.69	1.46e-07	0.000219	0.36	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
THYM	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-5.68	1.47e-07	0.000219	-0.37	-0.51	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
THYM	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-5.68	1.47e-07	0.000219	-0.59	-0.51	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
THYM	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-5.68	1.47e-07	0.000219	-0.59	-0.51	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
THYM	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-5.68	1.47e-07	0.000219	-0.59	-0.51	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
THYM	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-5.68	1.47e-07	0.000219	-0.59	-0.51	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
THYM	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-5.68	1.47e-07	0.000219	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
THYM	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	5.68	1.47e-07	0.00022	0.42	0.51	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
THYM	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	5.68	1.48e-07	0.00022	0.98	0.51	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
THYM	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	5.68	1.48e-07	0.000221	0.87	0.51	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	5.68	1.48e-07	0.000221	0.87	0.51	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
THYM	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	5.68	1.48e-07	0.000221	0.57	0.51	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
THYM	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-5.68	1.49e-07	0.000221	-0.54	-0.51	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
THYM	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	5.68	1.49e-07	0.000222	0.47	0.51	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
THYM	cis	rs995834	0.622	rs2159078	ENSG00000260725.1	AC005307.1	-5.68	1.49e-07	0.000222	-0.53	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404431	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs2869481	ENSG00000260725.1	AC005307.1	-5.68	1.49e-07	0.000222	-0.53	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404927	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs2869482	ENSG00000260725.1	AC005307.1	-5.68	1.49e-07	0.000222	-0.53	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405261	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs10407917	ENSG00000260725.1	AC005307.1	-5.68	1.49e-07	0.000222	-0.53	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405441	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs10408833	ENSG00000260725.1	AC005307.1	-5.68	1.49e-07	0.000222	-0.53	-0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405825	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs2159077	ENSG00000260725.1	AC005307.1	5.68	1.49e-07	0.000222	0.53	0.51	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404348	chr19:28418483~28429490:-
THYM	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	5.68	1.49e-07	0.000223	0.36	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
THYM	cis	rs6782228	0.527	rs6767383	ENSG00000277250.1	Metazoa_SRP	-5.68	1.5e-07	0.000223	-0.66	-0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128673681~128674021:-
THYM	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-5.68	1.5e-07	0.000223	-0.48	-0.51	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-5.68	1.5e-07	0.000223	-0.48	-0.51	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
THYM	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-5.68	1.5e-07	0.000223	-0.48	-0.51	Migraine;	chr4:56956882	chr4:56960927~56961373:-
THYM	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-5.68	1.5e-07	0.000223	-0.48	-0.51	Migraine;	chr4:56957291	chr4:56960927~56961373:-
THYM	cis	rs950169	0.96	rs35159785	ENSG00000235370.6	DNM1P51	5.68	1.5e-07	0.000223	0.66	0.51	Schizophrenia;	chr15:84135262	chr15:84398316~84411701:-
THYM	cis	rs66486766	1	rs66486766	ENSG00000235370.6	DNM1P51	5.68	1.5e-07	0.000223	0.66	0.51	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84398316~84411701:-
THYM	cis	rs944990	0.597	rs11789176	ENSG00000227603.1	RP11-165J3.6	5.68	1.5e-07	0.000224	0.44	0.51	Body mass index;	chr9:93433884	chr9:93435332~93437121:-
THYM	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-5.68	1.51e-07	0.000224	-0.64	-0.51	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
THYM	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	5.68	1.51e-07	0.000225	0.46	0.51	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
THYM	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-5.68	1.51e-07	0.000225	-0.54	-0.51	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
THYM	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-5.68	1.51e-07	0.000225	-0.58	-0.51	Height;	chr3:53074760	chr3:53064283~53065091:-
THYM	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	5.68	1.51e-07	0.000225	0.42	0.51	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
THYM	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	5.68	1.52e-07	0.000225	0.55	0.51	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	5.68	1.52e-07	0.000225	0.55	0.51	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	5.68	1.52e-07	0.000225	0.55	0.51	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	5.68	1.52e-07	0.000225	0.55	0.51	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	5.68	1.52e-07	0.000225	0.55	0.51	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	5.68	1.52e-07	0.000225	0.55	0.51	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	5.68	1.52e-07	0.000225	0.55	0.51	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
THYM	cis	rs4908760	0.64	rs3795310	ENSG00000232912.4	RP5-1115A15.1	-5.68	1.52e-07	0.000226	-0.48	-0.51	Vitiligo;	chr1:8371547	chr1:8424645~8434838:+
THYM	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-5.68	1.52e-07	0.000226	-0.48	-0.51	Migraine;	chr4:56937339	chr4:56960927~56961373:-
THYM	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-5.68	1.52e-07	0.000226	-0.48	-0.51	Migraine;	chr4:56940917	chr4:56960927~56961373:-
THYM	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-5.68	1.52e-07	0.000226	-0.48	-0.51	Migraine;	chr4:56943905	chr4:56960927~56961373:-
THYM	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-5.68	1.52e-07	0.000226	-0.48	-0.51	Migraine;	chr4:56950140	chr4:56960927~56961373:-
THYM	cis	rs17772222	0.63	rs12436642	ENSG00000258983.2	RP11-507K2.2	-5.68	1.53e-07	0.000226	-0.57	-0.51	Coronary artery calcification;	chr14:88559032	chr14:88499334~88515502:+
THYM	cis	rs9535495	1	rs9535496	ENSG00000200711.1	RNA5SP28	-5.68	1.53e-07	0.000226	-0.58	-0.51	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50815033	chr13:50812988~50813106:-
THYM	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-5.67	1.54e-07	0.000228	-0.61	-0.51	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
THYM	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-5.67	1.54e-07	0.000228	-0.96	-0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
THYM	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	5.67	1.54e-07	0.000228	0.37	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
THYM	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-5.67	1.54e-07	0.000228	-0.6	-0.51	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
THYM	cis	rs904251	0.523	rs1776455	ENSG00000227920.2	RP1-153P14.5	-5.67	1.54e-07	0.000228	-0.69	-0.51	Cognitive performance;	chr6:37515147	chr6:37545145~37550860:+
THYM	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-5.67	1.55e-07	0.000229	-0.39	-0.5	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
THYM	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	5.67	1.56e-07	0.00023	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
THYM	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-5.67	1.57e-07	0.000232	-0.66	-0.5	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
THYM	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-5.67	1.57e-07	0.000232	-0.73	-0.5	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
THYM	cis	rs7927592	0.673	rs2510392	ENSG00000212093.1	AP000807.1	5.67	1.57e-07	0.000232	0.46	0.5	Total body bone mineral density;	chr11:68626989	chr11:68506083~68506166:-
THYM	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-5.67	1.57e-07	0.000233	-0.67	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
THYM	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-5.67	1.58e-07	0.000233	-0.65	-0.5	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
THYM	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	5.67	1.58e-07	0.000233	0.37	0.5	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
THYM	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	5.67	1.58e-07	0.000233	0.37	0.5	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
THYM	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	5.67	1.58e-07	0.000233	0.37	0.5	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
THYM	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-5.67	1.58e-07	0.000233	-0.38	-0.5	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
THYM	cis	rs9535495	0.965	rs4312209	ENSG00000200711.1	RNA5SP28	-5.67	1.59e-07	0.000234	-0.59	-0.5	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50812144	chr13:50812988~50813106:-
THYM	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	5.67	1.59e-07	0.000235	0.47	0.5	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
THYM	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-5.67	1.59e-07	0.000235	-0.67	-0.5	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
THYM	cis	rs2283792	0.687	rs381849	ENSG00000228050.1	TOP3BP1	5.66	1.61e-07	0.000237	0.56	0.5	Multiple sclerosis;	chr22:21951341	chr22:22223187~22224566:-
THYM	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-5.66	1.61e-07	0.000237	-0.79	-0.5	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
THYM	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	5.66	1.61e-07	0.000238	0.42	0.5	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
THYM	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
THYM	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
THYM	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
THYM	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
THYM	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
THYM	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
THYM	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
THYM	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
THYM	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
THYM	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-5.66	1.61e-07	0.000238	-0.42	-0.5	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
THYM	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	5.66	1.61e-07	0.000238	0.61	0.5	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
THYM	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	5.66	1.62e-07	0.000238	0.51	0.5	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
THYM	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-5.66	1.62e-07	0.000239	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
THYM	cis	rs950169	0.545	rs4354897	ENSG00000235370.6	DNM1P51	5.66	1.62e-07	0.000239	0.68	0.5	Schizophrenia;	chr15:83976219	chr15:84398316~84411701:-
THYM	cis	rs747334	0.502	rs12217709	ENSG00000225519.1	RP11-236B18.2	5.66	1.62e-07	0.000239	0.45	0.5	Fibroblast growth factor basic levels;	chr10:90985873	chr10:90994620~91006390:+
THYM	cis	rs747334	0.502	rs7081190	ENSG00000225519.1	RP11-236B18.2	5.66	1.62e-07	0.000239	0.45	0.5	Fibroblast growth factor basic levels;	chr10:90986487	chr10:90994620~91006390:+
THYM	cis	rs747334	0.502	rs7080368	ENSG00000225519.1	RP11-236B18.2	-5.66	1.62e-07	0.000239	-0.45	-0.5	Fibroblast growth factor basic levels;	chr10:90986036	chr10:90994620~91006390:+
THYM	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	5.66	1.63e-07	0.00024	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	5.66	1.63e-07	0.00024	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	5.66	1.63e-07	0.00024	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
THYM	cis	rs2562456	0.755	rs2914646	ENSG00000268081.1	RP11-678G14.2	-5.66	1.63e-07	0.00024	-0.7	-0.5	Pain;	chr19:21454359	chr19:21554640~21569237:-
THYM	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-5.66	1.63e-07	0.00024	-0.61	-0.5	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
THYM	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-5.66	1.63e-07	0.00024	-0.57	-0.5	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
THYM	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	5.66	1.65e-07	0.000243	0.37	0.5	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
THYM	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	5.66	1.65e-07	0.000243	0.37	0.5	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
THYM	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	5.66	1.65e-07	0.000243	0.37	0.5	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
THYM	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	5.66	1.65e-07	0.000243	0.37	0.5	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-5.66	1.65e-07	0.000243	-0.37	-0.5	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-5.66	1.65e-07	0.000243	-0.37	-0.5	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
THYM	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-5.66	1.65e-07	0.000243	-0.37	-0.5	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
THYM	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-5.66	1.65e-07	0.000243	-0.37	-0.5	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
THYM	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-5.66	1.65e-07	0.000243	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
THYM	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-5.66	1.66e-07	0.000244	-0.54	-0.5	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
THYM	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-5.66	1.66e-07	0.000244	-0.6	-0.5	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
THYM	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	5.65	1.67e-07	0.000245	0.57	0.5	Height;	chr3:53073764	chr3:53064283~53065091:-
THYM	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-5.65	1.68e-07	0.000246	-0.37	-0.5	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	5.65	1.68e-07	0.000247	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	5.65	1.68e-07	0.000247	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-5.65	1.68e-07	0.000247	-0.37	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-5.65	1.68e-07	0.000247	-0.37	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-5.65	1.68e-07	0.000247	-0.37	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
THYM	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
THYM	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
THYM	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-5.65	1.69e-07	0.000247	-0.67	-0.5	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	5.65	1.69e-07	0.000247	0.67	0.5	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	5.65	1.69e-07	0.000247	0.67	0.5	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
THYM	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	5.65	1.69e-07	0.000247	0.67	0.5	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
THYM	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-5.65	1.69e-07	0.000248	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
THYM	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-5.65	1.69e-07	0.000248	-0.44	-0.5	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
THYM	cis	rs1560104	0.597	rs11075126	ENSG00000259899.1	CTD-3037G24.3	-5.65	1.7e-07	0.000249	-0.62	-0.5	Obesity-related traits;	chr16:12613117	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.597	rs4781297	ENSG00000259899.1	CTD-3037G24.3	-5.65	1.7e-07	0.000249	-0.62	-0.5	Obesity-related traits;	chr16:12613347	chr16:12560756~12611044:-
THYM	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	5.65	1.7e-07	0.000249	0.56	0.5	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
THYM	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-5.65	1.7e-07	0.00025	-0.61	-0.5	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
THYM	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	5.65	1.71e-07	0.00025	0.45	0.5	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
THYM	cis	rs904251	0.523	rs2797794	ENSG00000227920.2	RP1-153P14.5	-5.65	1.71e-07	0.000251	-0.7	-0.5	Cognitive performance;	chr6:37512828	chr6:37545145~37550860:+
THYM	cis	rs904251	0.504	rs2797795	ENSG00000227920.2	RP1-153P14.5	-5.65	1.71e-07	0.000251	-0.7	-0.5	Cognitive performance;	chr6:37512907	chr6:37545145~37550860:+
THYM	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-5.65	1.71e-07	0.000251	-0.45	-0.5	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-5.65	1.71e-07	0.000251	-0.45	-0.5	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-5.65	1.71e-07	0.000251	-0.45	-0.5	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
THYM	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-5.65	1.71e-07	0.000251	-0.61	-0.5	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
THYM	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-5.65	1.72e-07	0.000251	-0.6	-0.5	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
THYM	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	5.65	1.72e-07	0.000252	0.59	0.5	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
THYM	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	5.65	1.72e-07	0.000252	0.52	0.5	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
THYM	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	5.65	1.73e-07	0.000253	0.95	0.5	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	5.65	1.73e-07	0.000253	0.95	0.5	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	5.65	1.73e-07	0.000253	0.95	0.5	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	5.65	1.73e-07	0.000253	0.95	0.5	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
THYM	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	5.65	1.73e-07	0.000253	0.58	0.5	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
THYM	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-5.65	1.73e-07	0.000253	-0.61	-0.5	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
THYM	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-5.65	1.73e-07	0.000253	-0.46	-0.5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
THYM	cis	rs1560104	0.597	rs881667	ENSG00000259899.1	CTD-3037G24.3	-5.65	1.73e-07	0.000254	-0.6	-0.5	Obesity-related traits;	chr16:12618569	chr16:12560756~12611044:-
THYM	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.65	1.74e-07	0.000254	-0.53	-0.5	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
THYM	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-5.65	1.74e-07	0.000254	-0.61	-0.5	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
THYM	cis	rs17772222	0.793	rs7143853	ENSG00000258983.2	RP11-507K2.2	5.65	1.74e-07	0.000254	0.64	0.5	Coronary artery calcification;	chr14:88578477	chr14:88499334~88515502:+
THYM	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-5.64	1.74e-07	0.000255	-0.37	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-5.64	1.74e-07	0.000255	-0.37	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
THYM	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-5.64	1.75e-07	0.000255	-0.6	-0.5	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
THYM	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	5.64	1.75e-07	0.000256	0.95	0.5	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
THYM	cis	rs11722228	0.522	rs1109472	ENSG00000261490.1	RP11-448G15.3	5.64	1.75e-07	0.000256	0.5	0.5	Urate levels;Serum uric acid levels;Gout;	chr4:10132824	chr4:10068089~10073019:-
THYM	cis	rs995834	0.622	rs4806395	ENSG00000267243.4	AC005307.3	-5.64	1.75e-07	0.000256	-0.49	-0.5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28416529	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs8102434	ENSG00000267243.4	AC005307.3	-5.64	1.75e-07	0.000256	-0.49	-0.5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28418061	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs10413972	ENSG00000267243.4	AC005307.3	-5.64	1.75e-07	0.000256	-0.49	-0.5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419219	chr19:28435388~28727777:-
THYM	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-5.64	1.75e-07	0.000256	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	5.64	1.75e-07	0.000256	0.47	0.5	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	5.64	1.75e-07	0.000256	0.47	0.5	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
THYM	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	5.64	1.76e-07	0.000256	0.47	0.5	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
THYM	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
THYM	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
THYM	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-5.64	1.76e-07	0.000256	-0.89	-0.5	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
THYM	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-5.64	1.76e-07	0.000256	-0.45	-0.5	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
THYM	cis	rs904251	0.523	rs2797796	ENSG00000227920.2	RP1-153P14.5	-5.64	1.76e-07	0.000256	-0.68	-0.5	Cognitive performance;	chr6:37513110	chr6:37545145~37550860:+
THYM	cis	rs904251	0.523	rs2776870	ENSG00000227920.2	RP1-153P14.5	-5.64	1.76e-07	0.000256	-0.68	-0.5	Cognitive performance;	chr6:37513588	chr6:37545145~37550860:+
THYM	cis	rs904251	0.523	rs2797798	ENSG00000227920.2	RP1-153P14.5	-5.64	1.76e-07	0.000256	-0.68	-0.5	Cognitive performance;	chr6:37513661	chr6:37545145~37550860:+
THYM	cis	rs904251	0.523	rs2776871	ENSG00000227920.2	RP1-153P14.5	-5.64	1.76e-07	0.000256	-0.68	-0.5	Cognitive performance;	chr6:37513983	chr6:37545145~37550860:+
THYM	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-5.64	1.76e-07	0.000257	-0.61	-0.5	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
THYM	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	5.64	1.76e-07	0.000257	0.57	0.5	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
THYM	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	5.64	1.76e-07	0.000257	0.46	0.5	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
THYM	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	5.64	1.77e-07	0.000258	0.41	0.5	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	5.64	1.77e-07	0.000258	0.41	0.5	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	5.64	1.77e-07	0.000258	0.41	0.5	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
THYM	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	5.64	1.77e-07	0.000258	0.41	0.5	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	5.64	1.78e-07	0.000258	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
THYM	cis	rs7690978	1	rs7690978	ENSG00000249717.1	RP11-44F21.3	5.64	1.78e-07	0.000258	0.68	0.5	Interferon gamma-induced protein 10 levels;	chr4:75066634	chr4:74955974~74970362:-
THYM	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	5.64	1.78e-07	0.000258	0.52	0.5	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
THYM	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-5.64	1.78e-07	0.000259	-0.73	-0.5	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
THYM	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28123153	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28124529	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28127577	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28131566	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28133900	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28136698	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28136856	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28137418	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28138363	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28138981	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-5.64	1.78e-07	0.000259	-0.49	-0.5	Depression;	chr6:28139012	chr6:28115628~28116551:+
THYM	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	5.64	1.78e-07	0.000259	0.37	0.5	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
THYM	cis	rs11157436	0.918	rs12437004	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149461	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.874	rs35951144	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149973	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.918	rs1983522	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150588	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.918	rs12586393	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150815	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.918	rs2178788	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150916	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.83	rs61972214	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22152416	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.918	rs11157426	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153691	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.918	rs11157427	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154291	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.792	rs12433875	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154490	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.918	rs3811285	ENSG00000211813.2	TRAV34	5.64	1.79e-07	0.000259	0.37	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155322	chr14:22207522~22208129:+
THYM	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	5.64	1.79e-07	0.00026	0.65	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
THYM	cis	rs950169	0.579	rs62027818	ENSG00000235370.6	DNM1P51	5.64	1.79e-07	0.00026	0.69	0.5	Schizophrenia;	chr15:83992393	chr15:84398316~84411701:-
THYM	cis	rs950169	0.579	rs12912716	ENSG00000235370.6	DNM1P51	5.64	1.79e-07	0.00026	0.69	0.5	Schizophrenia;	chr15:83995511	chr15:84398316~84411701:-
THYM	cis	rs950169	0.579	rs12913054	ENSG00000235370.6	DNM1P51	5.64	1.79e-07	0.00026	0.69	0.5	Schizophrenia;	chr15:83995704	chr15:84398316~84411701:-
THYM	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	5.64	1.79e-07	0.00026	0.37	0.5	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
THYM	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	5.64	1.8e-07	0.000261	0.8	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	5.64	1.8e-07	0.000261	0.8	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
THYM	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-5.64	1.8e-07	0.000261	-0.39	-0.5	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-5.64	1.8e-07	0.000261	-0.39	-0.5	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-5.64	1.8e-07	0.000261	-0.39	-0.5	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
THYM	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-5.64	1.8e-07	0.000261	-0.61	-0.5	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-5.64	1.8e-07	0.000261	-0.61	-0.5	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-5.64	1.8e-07	0.000261	-0.61	-0.5	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-5.64	1.8e-07	0.000261	-0.61	-0.5	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-5.64	1.8e-07	0.000261	-0.61	-0.5	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-5.64	1.8e-07	0.000261	-0.61	-0.5	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-5.64	1.8e-07	0.000261	-0.61	-0.5	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
THYM	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-5.64	1.8e-07	0.000261	-0.59	-0.5	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
THYM	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	5.64	1.8e-07	0.000261	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
THYM	cis	rs2834288	0.5	rs2051189	ENSG00000237945.6	LINC00649	5.64	1.8e-07	0.000262	0.41	0.5	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33915534~33977691:+
THYM	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-5.64	1.81e-07	0.000262	-0.73	-0.5	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
THYM	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-5.64	1.81e-07	0.000262	-0.72	-0.5	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
THYM	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	5.64	1.81e-07	0.000262	0.66	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
THYM	cis	rs7115242	0.66	rs236911	ENSG00000254851.1	RP11-109L13.1	5.64	1.81e-07	0.000262	0.85	0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117214554	chr11:117135528~117138582:+
THYM	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-5.64	1.82e-07	0.000264	-0.53	-0.5	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-5.64	1.82e-07	0.000264	-0.53	-0.5	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
THYM	cis	rs17772222	0.839	rs2274735	ENSG00000258983.2	RP11-507K2.2	5.63	1.83e-07	0.000265	0.57	0.5	Coronary artery calcification;	chr14:88505414	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	5.63	1.83e-07	0.000265	0.59	0.5	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
THYM	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
THYM	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	5.63	1.85e-07	0.000267	0.95	0.5	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
THYM	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	5.63	1.86e-07	0.000268	0.87	0.5	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
THYM	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-5.63	1.86e-07	0.000269	-0.62	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	5.63	1.86e-07	0.000269	0.62	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	5.63	1.86e-07	0.000269	0.62	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	5.63	1.86e-07	0.000269	0.62	0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
THYM	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-5.63	1.87e-07	0.000269	-0.55	-0.5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
THYM	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	5.63	1.87e-07	0.00027	0.4	0.5	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	5.63	1.87e-07	0.00027	0.4	0.5	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	5.63	1.87e-07	0.00027	0.4	0.5	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
THYM	cis	rs9535495	0.863	rs9535494	ENSG00000200711.1	RNA5SP28	-5.63	1.87e-07	0.00027	-0.58	-0.5	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50811803	chr13:50812988~50813106:-
THYM	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	5.63	1.87e-07	0.00027	0.95	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
THYM	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	5.63	1.88e-07	0.00027	0.56	0.5	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
THYM	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-5.63	1.88e-07	0.000271	-0.62	-0.5	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
THYM	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	5.63	1.88e-07	0.000271	0.75	0.5	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
THYM	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	5.63	1.88e-07	0.000271	0.41	0.5	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
THYM	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-5.63	1.89e-07	0.000272	-0.46	-0.5	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
THYM	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	5.63	1.89e-07	0.000272	0.62	0.5	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
THYM	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-5.63	1.89e-07	0.000272	-0.67	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-5.63	1.89e-07	0.000272	-0.67	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-5.63	1.89e-07	0.000272	-0.67	-0.5	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-5.63	1.89e-07	0.000272	-0.67	-0.5	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-5.63	1.89e-07	0.000272	-0.67	-0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
THYM	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	5.63	1.89e-07	0.000273	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
THYM	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	5.63	1.89e-07	0.000273	0.74	0.5	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
THYM	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	5.63	1.89e-07	0.000273	0.74	0.5	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
THYM	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	5.63	1.9e-07	0.000273	0.63	0.5	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
THYM	cis	rs17772222	0.63	rs7146241	ENSG00000258983.2	RP11-507K2.2	-5.63	1.9e-07	0.000274	-0.57	-0.5	Coronary artery calcification;	chr14:88551622	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.63	rs930181	ENSG00000258983.2	RP11-507K2.2	-5.63	1.9e-07	0.000274	-0.57	-0.5	Coronary artery calcification;	chr14:88552364	chr14:88499334~88515502:+
THYM	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	5.62	1.9e-07	0.000274	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	5.62	1.9e-07	0.000274	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
THYM	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-5.62	1.91e-07	0.000275	-0.44	-0.5	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
THYM	cis	rs747334	0.502	rs7088999	ENSG00000225519.1	RP11-236B18.2	5.62	1.91e-07	0.000275	0.44	0.5	Fibroblast growth factor basic levels;	chr10:90970491	chr10:90994620~91006390:+
THYM	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	5.62	1.91e-07	0.000275	0.58	0.5	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
THYM	cis	rs7702057	0.53	rs1567330	ENSG00000271918.1	CTD-2287O16.5	5.62	1.92e-07	0.000275	0.77	0.5	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116083807~116085416:-
THYM	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	5.62	1.92e-07	0.000275	0.6	0.5	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	5.62	1.92e-07	0.000275	0.6	0.5	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	5.62	1.92e-07	0.000275	0.6	0.5	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	5.62	1.92e-07	0.000275	0.6	0.5	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
THYM	cis	rs17772222	0.56	rs3742681	ENSG00000258983.2	RP11-507K2.2	-5.62	1.92e-07	0.000275	-0.57	-0.5	Coronary artery calcification;	chr14:88554903	chr14:88499334~88515502:+
THYM	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-5.62	1.92e-07	0.000275	-0.54	-0.5	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
THYM	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-5.62	1.92e-07	0.000275	-0.94	-0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	5.62	1.92e-07	0.000275	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
THYM	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-5.62	1.93e-07	0.000276	-0.6	-0.5	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
THYM	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	5.62	1.93e-07	0.000276	0.87	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
THYM	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	5.62	1.94e-07	0.000277	0.72	0.5	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
THYM	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	5.62	1.94e-07	0.000277	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
THYM	cis	rs5760092	0.755	rs915589	ENSG00000272787.1	KB-226F1.2	5.62	1.96e-07	0.000279	0.68	0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23969211~23969873:+
THYM	cis	rs7560272	0.538	rs12052539	ENSG00000273245.1	RP11-434P11.2	5.62	1.96e-07	0.000279	0.61	0.5	Schizophrenia;	chr2:73710026	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs1806683	ENSG00000273245.1	RP11-434P11.2	5.62	1.96e-07	0.000279	0.61	0.5	Schizophrenia;	chr2:73712685	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs4852977	ENSG00000273245.1	RP11-434P11.2	-5.62	1.96e-07	0.000279	-0.61	-0.5	Schizophrenia;	chr2:73711168	chr2:73750256~73750786:-
THYM	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	5.62	1.96e-07	0.000279	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	5.62	1.96e-07	0.000279	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	5.62	1.96e-07	0.000279	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	5.62	1.96e-07	0.000279	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	5.62	1.96e-07	0.000279	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
THYM	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-5.62	1.97e-07	0.00028	-0.5	-0.5	Temperament;	chr17:14007232	chr17:14024514~14025488:+
THYM	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	5.62	1.98e-07	0.000281	0.65	0.5	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
THYM	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	5.62	1.98e-07	0.000281	0.65	0.5	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
THYM	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-5.62	1.98e-07	0.000281	-0.6	-0.5	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
THYM	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-5.62	1.98e-07	0.000281	-0.6	-0.5	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
THYM	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-5.62	1.98e-07	0.000281	-0.6	-0.5	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
THYM	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-5.62	1.98e-07	0.000281	-0.6	-0.5	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
THYM	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-5.62	1.98e-07	0.000281	-0.6	-0.5	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
THYM	cis	rs747334	0.502	rs2178206	ENSG00000225519.1	RP11-236B18.2	5.62	1.98e-07	0.000281	0.44	0.5	Fibroblast growth factor basic levels;	chr10:90958074	chr10:90994620~91006390:+
THYM	cis	rs747334	0.791	rs1334581	ENSG00000225519.1	RP11-236B18.2	5.62	1.98e-07	0.000281	0.44	0.5	Fibroblast growth factor basic levels;	chr10:90961099	chr10:90994620~91006390:+
THYM	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	5.62	1.98e-07	0.000282	0.57	0.5	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
THYM	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	5.62	1.98e-07	0.000282	0.57	0.5	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
THYM	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	5.61	1.99e-07	0.000282	0.65	0.5	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
THYM	cis	rs11992186	0.597	rs11781841	ENSG00000253893.2	FAM85B	5.61	1.99e-07	0.000282	0.65	0.5	Neuroticism;	chr8:8737753	chr8:8167819~8226614:-
THYM	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-5.61	1.99e-07	0.000282	-0.59	-0.5	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
THYM	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-5.61	2e-07	0.000284	-0.68	-0.5	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-5.61	2e-07	0.000284	-0.68	-0.5	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
THYM	cis	rs7927592	0.731	rs11228275	ENSG00000212093.1	AP000807.1	-5.61	2e-07	0.000284	-0.45	-0.5	Total body bone mineral density;	chr11:68536512	chr11:68506083~68506166:-
THYM	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	5.61	2e-07	0.000284	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
THYM	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-5.61	2e-07	0.000284	-0.37	-0.5	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-5.61	2e-07	0.000284	-0.37	-0.5	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
THYM	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-5.61	2e-07	0.000284	-0.37	-0.5	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
THYM	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-5.61	2e-07	0.000284	-0.37	-0.5	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
THYM	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	5.61	2.01e-07	0.000285	0.67	0.5	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
THYM	cis	rs7560272	0.538	rs11126415	ENSG00000273245.1	RP11-434P11.2	-5.61	2.01e-07	0.000285	-0.61	-0.5	Schizophrenia;	chr2:73709373	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs12053242	ENSG00000273245.1	RP11-434P11.2	-5.61	2.01e-07	0.000285	-0.61	-0.5	Schizophrenia;	chr2:73710041	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.513	rs7558546	ENSG00000273245.1	RP11-434P11.2	-5.61	2.01e-07	0.000285	-0.61	-0.5	Schizophrenia;	chr2:73710605	chr2:73750256~73750786:-
THYM	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-5.61	2.02e-07	0.000286	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
THYM	cis	rs11157436	0.958	rs1041859	ENSG00000211813.2	TRAV34	5.61	2.03e-07	0.000288	0.4	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs1041860	ENSG00000211813.2	TRAV34	5.61	2.03e-07	0.000288	0.4	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs764161	ENSG00000211813.2	TRAV34	5.61	2.03e-07	0.000288	0.4	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.958	rs12433649	ENSG00000211813.2	TRAV34	5.61	2.03e-07	0.000288	0.4	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22207522~22208129:+
THYM	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	5.61	2.03e-07	0.000288	0.85	0.5	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
THYM	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-5.61	2.04e-07	0.000288	-0.47	-0.5	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
THYM	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-5.61	2.04e-07	0.000288	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
THYM	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-5.61	2.05e-07	0.000289	-0.42	-0.5	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-5.61	2.05e-07	0.000289	-0.42	-0.5	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-5.61	2.05e-07	0.000289	-0.42	-0.5	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	5.61	2.05e-07	0.000289	0.42	0.5	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	5.61	2.05e-07	0.000289	0.42	0.5	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	5.61	2.05e-07	0.000289	0.42	0.5	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
THYM	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	5.61	2.05e-07	0.000289	0.45	0.5	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-5.61	2.05e-07	0.000289	-0.45	-0.5	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
THYM	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	5.61	2.05e-07	0.00029	0.83	0.5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
THYM	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	5.61	2.06e-07	0.000291	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	5.61	2.06e-07	0.000291	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	5.61	2.07e-07	0.000292	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-5.61	2.07e-07	0.000292	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
THYM	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-5.6	2.07e-07	0.000293	-0.53	-0.5	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
THYM	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-5.6	2.07e-07	0.000293	-0.53	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	5.6	2.07e-07	0.000293	0.53	0.5	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
THYM	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	5.6	2.08e-07	0.000293	0.93	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
THYM	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	5.6	2.08e-07	0.000293	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	5.6	2.08e-07	0.000293	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	5.6	2.08e-07	0.000293	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	5.6	2.08e-07	0.000293	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	5.6	2.08e-07	0.000293	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	5.6	2.08e-07	0.000293	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	5.6	2.08e-07	0.000293	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.673	rs498782	ENSG00000212093.1	AP000807.1	5.6	2.08e-07	0.000293	0.46	0.5	Total body bone mineral density;	chr11:68508383	chr11:68506083~68506166:-
THYM	cis	rs2283792	0.567	rs2027789	ENSG00000228050.1	TOP3BP1	5.6	2.08e-07	0.000293	0.58	0.5	Multiple sclerosis;	chr22:21933490	chr22:22223187~22224566:-
THYM	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	5.6	2.08e-07	0.000293	0.91	0.5	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
THYM	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	5.6	2.08e-07	0.000293	0.91	0.5	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
THYM	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	5.6	2.08e-07	0.000294	0.64	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	5.6	2.08e-07	0.000294	0.64	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
THYM	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-5.6	2.08e-07	0.000294	-0.44	-0.5	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-5.6	2.08e-07	0.000294	-0.44	-0.5	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-5.6	2.08e-07	0.000294	-0.44	-0.5	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-5.6	2.08e-07	0.000294	-0.44	-0.5	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-5.6	2.08e-07	0.000294	-0.44	-0.5	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-5.6	2.08e-07	0.000294	-0.44	-0.5	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-5.6	2.08e-07	0.000294	-0.44	-0.5	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
THYM	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-5.6	2.09e-07	0.000294	-0.59	-0.5	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
THYM	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	5.6	2.09e-07	0.000294	0.44	0.5	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
THYM	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-5.6	2.09e-07	0.000295	-0.63	-0.5	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
THYM	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-5.6	2.1e-07	0.000296	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
THYM	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-5.6	2.1e-07	0.000296	-0.49	-0.5	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
THYM	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-5.6	2.1e-07	0.000296	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-5.6	2.1e-07	0.000296	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-5.6	2.1e-07	0.000296	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-5.6	2.1e-07	0.000296	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-5.6	2.1e-07	0.000296	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
THYM	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	5.6	2.12e-07	0.000298	0.45	0.5	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	5.6	2.12e-07	0.000298	0.45	0.5	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
THYM	cis	rs995834	0.743	rs1860211	ENSG00000260725.1	AC005307.1	-5.6	2.12e-07	0.000298	-0.5	-0.5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28386236	chr19:28418483~28429490:-
THYM	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-5.6	2.12e-07	0.000298	-0.56	-0.5	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
THYM	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-5.6	2.12e-07	0.000298	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
THYM	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-5.6	2.12e-07	0.000298	-0.6	-0.5	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
THYM	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-5.6	2.12e-07	0.000298	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
THYM	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	5.6	2.12e-07	0.000298	0.86	0.5	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
THYM	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-5.6	2.12e-07	0.000299	-0.76	-0.5	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
THYM	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	5.6	2.14e-07	0.000301	0.58	0.5	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
THYM	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-5.6	2.14e-07	0.000301	-0.52	-0.5	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
THYM	cis	rs944990	0.64	rs10821131	ENSG00000227603.1	RP11-165J3.6	5.6	2.15e-07	0.000302	0.44	0.5	Body mass index;	chr9:93466540	chr9:93435332~93437121:-
THYM	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	5.6	2.15e-07	0.000303	0.57	0.5	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
THYM	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	5.6	2.16e-07	0.000303	0.48	0.5	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
THYM	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-5.59	2.17e-07	0.000304	-0.66	-0.5	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
THYM	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	5.59	2.18e-07	0.000306	0.37	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
THYM	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	5.59	2.18e-07	0.000306	0.94	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
THYM	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	5.59	2.18e-07	0.000306	0.93	0.5	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
THYM	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	5.59	2.18e-07	0.000306	0.93	0.5	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
THYM	cis	rs950169	0.579	rs11633088	ENSG00000235370.6	DNM1P51	-5.59	2.19e-07	0.000306	-0.68	-0.5	Schizophrenia;	chr15:84003429	chr15:84398316~84411701:-
THYM	cis	rs950169	0.614	rs12911536	ENSG00000235370.6	DNM1P51	5.59	2.19e-07	0.000306	0.68	0.5	Schizophrenia;	chr15:84004278	chr15:84398316~84411701:-
THYM	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	5.59	2.19e-07	0.000306	0.57	0.5	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	5.59	2.19e-07	0.000306	0.57	0.5	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	5.59	2.19e-07	0.000306	0.57	0.5	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	5.59	2.19e-07	0.000306	0.57	0.5	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
THYM	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	5.59	2.2e-07	0.000307	0.41	0.5	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
THYM	cis	rs1560104	0.597	rs7187433	ENSG00000259899.1	CTD-3037G24.3	-5.59	2.21e-07	0.000308	-0.57	-0.5	Obesity-related traits;	chr16:12615251	chr16:12560756~12611044:-
THYM	cis	rs189798	0.807	rs330905	ENSG00000253893.2	FAM85B	-5.59	2.21e-07	0.000308	-0.66	-0.5	Myopia (pathological);	chr8:9136041	chr8:8167819~8226614:-
THYM	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	5.59	2.22e-07	0.00031	0.47	0.5	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
THYM	cis	rs28785552	0.8	rs10853855	ENSG00000250731.1	TPM3P6	-5.59	2.22e-07	0.00031	-0.69	-0.5	Response to paliperidone in schizophrenia (PANSS score);	chr19:52729040	chr19:53479350~53480091:+
THYM	cis	rs28785552	0.8	rs1971063	ENSG00000250731.1	TPM3P6	-5.59	2.22e-07	0.00031	-0.69	-0.5	Response to paliperidone in schizophrenia (PANSS score);	chr19:52729601	chr19:53479350~53480091:+
THYM	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	5.59	2.23e-07	0.000311	0.58	0.5	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	5.59	2.23e-07	0.000311	0.58	0.5	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	5.59	2.23e-07	0.000311	0.58	0.5	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	5.59	2.23e-07	0.000311	0.58	0.5	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	5.59	2.23e-07	0.000311	0.58	0.5	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	5.59	2.23e-07	0.000311	0.58	0.5	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	5.59	2.23e-07	0.000311	0.58	0.5	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
THYM	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-5.59	2.23e-07	0.000311	-0.6	-0.5	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
THYM	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	5.59	2.24e-07	0.000312	0.46	0.5	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
THYM	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-5.59	2.25e-07	0.000312	-0.57	-0.5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
THYM	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-5.59	2.25e-07	0.000313	-0.45	-0.5	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-5.59	2.25e-07	0.000313	-0.45	-0.5	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-5.59	2.25e-07	0.000313	-0.45	-0.5	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
THYM	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-5.59	2.25e-07	0.000313	-0.45	-0.5	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
THYM	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	5.59	2.25e-07	0.000313	0.4	0.5	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
THYM	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28070115	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28071237	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28071808	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28074687	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28076559	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28076704	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28078391	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28080757	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28080760	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28082231	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28082261	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28082984	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28083994	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28084025	chr6:28115628~28116551:+
THYM	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28085319	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28089816	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28090857	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28091439	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28091659	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28092227	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28093966	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28094014	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28096077	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28096855	chr6:28115628~28116551:+
THYM	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28099759	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28100648	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28104824	chr6:28115628~28116551:+
THYM	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28107222	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-5.59	2.26e-07	0.000314	-0.49	-0.5	Depression;	chr6:28108492	chr6:28115628~28116551:+
THYM	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	5.58	2.28e-07	0.000316	0.47	0.5	Depression;	chr6:28199145	chr6:28115628~28116551:+
THYM	cis	rs7829975	0.501	rs4840353	ENSG00000253893.2	FAM85B	5.58	2.28e-07	0.000317	0.64	0.5	Mood instability;	chr8:8723060	chr8:8167819~8226614:-
THYM	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Depression;	chr6:28112175	chr6:28115628~28116551:+
THYM	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Depression;	chr6:28113616	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Depression;	chr6:28113851	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Depression;	chr6:28114487	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Depression;	chr6:28114933	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Depression;	chr6:28115743	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Depression;	chr6:28116411	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-5.58	2.29e-07	0.000317	-0.48	-0.5	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
THYM	cis	rs904251	0.523	rs12202055	ENSG00000227920.2	RP1-153P14.5	-5.58	2.29e-07	0.000317	-0.65	-0.5	Cognitive performance;	chr6:37518304	chr6:37545145~37550860:+
THYM	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-5.58	2.29e-07	0.000318	-0.87	-0.5	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-5.58	2.29e-07	0.000318	-0.87	-0.5	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-5.58	2.29e-07	0.000318	-0.87	-0.5	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
THYM	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-5.58	2.29e-07	0.000318	-0.87	-0.5	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
THYM	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-5.58	2.3e-07	0.000318	-0.59	-0.5	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
THYM	cis	rs7560272	0.501	rs12624267	ENSG00000273245.1	RP11-434P11.2	-5.58	2.31e-07	0.00032	-0.57	-0.5	Schizophrenia;	chr2:73759804	chr2:73750256~73750786:-
THYM	cis	rs5760092	0.627	rs6519489	ENSG00000272787.1	KB-226F1.2	5.58	2.31e-07	0.00032	0.69	0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23969211~23969873:+
THYM	cis	rs1560104	0.576	rs11640886	ENSG00000259899.1	CTD-3037G24.3	-5.58	2.32e-07	0.000321	-0.62	-0.5	Obesity-related traits;	chr16:12615377	chr16:12560756~12611044:-
THYM	cis	rs7560272	0.512	rs2421677	ENSG00000273245.1	RP11-434P11.2	-5.58	2.33e-07	0.000322	-0.57	-0.5	Schizophrenia;	chr2:73738790	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.501	rs2421676	ENSG00000273245.1	RP11-434P11.2	-5.58	2.33e-07	0.000322	-0.57	-0.5	Schizophrenia;	chr2:73738960	chr2:73750256~73750786:-
THYM	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-5.58	2.33e-07	0.000322	-0.53	-0.5	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	5.58	2.33e-07	0.000322	0.6	0.5	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
THYM	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	5.58	2.34e-07	0.000323	0.37	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	5.58	2.34e-07	0.000324	0.37	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
THYM	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	5.58	2.35e-07	0.000324	0.4	0.5	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-5.58	2.35e-07	0.000324	-0.4	-0.5	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
THYM	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	5.58	2.35e-07	0.000324	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
THYM	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	5.58	2.35e-07	0.000324	0.59	0.5	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
THYM	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	5.58	2.36e-07	0.000325	0.5	0.5	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
THYM	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	5.57	2.37e-07	0.000327	0.38	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
THYM	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	5.57	2.37e-07	0.000327	0.38	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
THYM	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-5.57	2.38e-07	0.000328	-0.9	-0.5	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-5.57	2.38e-07	0.000328	-0.9	-0.5	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
THYM	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-5.57	2.38e-07	0.000329	-0.44	-0.5	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
THYM	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-5.57	2.39e-07	0.000329	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
THYM	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	5.57	2.39e-07	0.000329	0.85	0.5	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
THYM	cis	rs904251	0.772	rs1812186	ENSG00000279942.1	RP1-153P14.7	-5.57	2.39e-07	0.000329	-0.72	-0.5	Cognitive performance;	chr6:37498140	chr6:37567716~37571460:+
THYM	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	5.57	2.41e-07	0.000331	0.58	0.5	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
THYM	cis	rs1757171	0.504	rs11969056	ENSG00000227920.2	RP1-153P14.5	-5.57	2.41e-07	0.000332	-0.67	-0.5	Cognitive performance;	chr6:37516509	chr6:37545145~37550860:+
THYM	cis	rs950169	0.84	rs62019457	ENSG00000235370.6	DNM1P51	5.57	2.42e-07	0.000332	0.6	0.5	Schizophrenia;	chr15:84558911	chr15:84398316~84411701:-
THYM	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-5.57	2.42e-07	0.000332	-0.72	-0.5	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
THYM	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-5.57	2.42e-07	0.000332	-0.72	-0.5	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
THYM	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-5.57	2.42e-07	0.000332	-0.72	-0.5	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
THYM	cis	rs995834	0.789	rs10410807	ENSG00000267243.4	AC005307.3	-5.57	2.42e-07	0.000333	-0.47	-0.5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28410408	chr19:28435388~28727777:-
THYM	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-5.57	2.43e-07	0.000333	-0.45	-0.5	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-5.57	2.43e-07	0.000333	-0.45	-0.5	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	5.57	2.43e-07	0.000333	0.45	0.5	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	5.57	2.43e-07	0.000333	0.45	0.5	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	5.57	2.43e-07	0.000333	0.45	0.5	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
THYM	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-5.57	2.44e-07	0.000335	-0.43	-0.5	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-5.57	2.44e-07	0.000335	-0.43	-0.5	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
THYM	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-5.57	2.44e-07	0.000336	-0.45	-0.5	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
THYM	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	5.57	2.45e-07	0.000337	0.6	0.5	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
THYM	cis	rs1729407	1	rs1729407	ENSG00000254851.1	RP11-109L13.1	-5.57	2.45e-07	0.000337	-0.59	-0.5	Apolipoprotein A-IV levels;	chr11:116806654	chr11:117135528~117138582:+
THYM	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-5.57	2.45e-07	0.000337	-0.59	-0.5	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
THYM	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	5.57	2.46e-07	0.000338	0.41	0.5	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-5.57	2.46e-07	0.000338	-0.41	-0.5	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-5.57	2.46e-07	0.000338	-0.41	-0.5	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-5.57	2.46e-07	0.000338	-0.41	-0.5	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
THYM	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-5.57	2.46e-07	0.000338	-0.41	-0.5	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
THYM	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	5.57	2.46e-07	0.000338	0.55	0.5	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
THYM	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	5.56	2.47e-07	0.000339	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
THYM	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	5.56	2.48e-07	0.00034	0.6	0.5	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
THYM	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	5.56	2.48e-07	0.00034	0.64	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	5.56	2.48e-07	0.00034	0.64	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	5.56	2.48e-07	0.00034	0.64	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-5.56	2.48e-07	0.00034	-0.64	-0.5	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-5.56	2.48e-07	0.00034	-0.64	-0.5	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
THYM	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	5.56	2.49e-07	0.00034	0.67	0.5	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
THYM	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-5.56	2.49e-07	0.000341	-0.51	-0.5	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
THYM	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-5.56	2.49e-07	0.000341	-0.88	-0.5	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-5.56	2.49e-07	0.000341	-0.88	-0.5	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
THYM	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	5.56	2.49e-07	0.000341	0.39	0.5	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	5.56	2.49e-07	0.000341	0.39	0.5	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	5.56	2.49e-07	0.000341	0.37	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
THYM	cis	rs42490	0.899	rs1397308	ENSG00000251136.7	RP11-37B2.1	5.56	2.5e-07	0.000341	0.4	0.5	Leprosy;	chr8:89628493	chr8:89609409~89757727:-
THYM	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-5.56	2.51e-07	0.000343	-0.66	-0.5	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
THYM	cis	rs995834	0.703	rs4806356	ENSG00000260725.1	AC005307.1	-5.56	2.51e-07	0.000343	-0.53	-0.5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397536	chr19:28418483~28429490:-
THYM	cis	rs950169	0.579	rs881983	ENSG00000235370.6	DNM1P51	5.56	2.52e-07	0.000344	0.69	0.5	Schizophrenia;	chr15:83978556	chr15:84398316~84411701:-
THYM	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-5.56	2.52e-07	0.000344	-0.46	-0.5	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
THYM	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	5.56	2.52e-07	0.000344	0.65	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
THYM	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-5.56	2.53e-07	0.000345	-0.24	-0.5	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
THYM	cis	rs7702057	0.53	rs3087831	ENSG00000271918.1	CTD-2287O16.5	5.56	2.54e-07	0.000347	0.74	0.5	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs3087832	ENSG00000271918.1	CTD-2287O16.5	5.56	2.54e-07	0.000347	0.74	0.5	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs73780832	ENSG00000271918.1	CTD-2287O16.5	5.56	2.54e-07	0.000347	0.74	0.5	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs17138850	ENSG00000271918.1	CTD-2287O16.5	5.56	2.54e-07	0.000347	0.74	0.5	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116083807~116085416:-
THYM	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-5.56	2.56e-07	0.000349	-0.91	-0.5	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-5.56	2.56e-07	0.000349	-0.91	-0.5	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
THYM	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-5.56	2.57e-07	0.000349	-0.51	-0.5	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
THYM	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-5.55	2.58e-07	0.000351	-0.77	-0.5	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
THYM	cis	rs950169	0.649	rs12911612	ENSG00000235370.6	DNM1P51	5.55	2.59e-07	0.000352	0.69	0.5	Schizophrenia;	chr15:84022262	chr15:84398316~84411701:-
THYM	cis	rs950169	0.649	rs12905952	ENSG00000235370.6	DNM1P51	5.55	2.59e-07	0.000352	0.69	0.5	Schizophrenia;	chr15:84022509	chr15:84398316~84411701:-
THYM	cis	rs950169	0.61	rs34529571	ENSG00000235370.6	DNM1P51	5.55	2.59e-07	0.000352	0.69	0.5	Schizophrenia;	chr15:84023055	chr15:84398316~84411701:-
THYM	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	5.55	2.61e-07	0.000354	0.42	0.5	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
THYM	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-5.55	2.61e-07	0.000355	-0.75	-0.5	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
THYM	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	5.55	2.61e-07	0.000355	0.61	0.5	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
THYM	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	5.55	2.63e-07	0.000356	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	5.55	2.63e-07	0.000356	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	5.55	2.63e-07	0.000356	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-5.55	2.63e-07	0.000356	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-5.55	2.63e-07	0.000356	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-5.55	2.63e-07	0.000356	-0.36	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
THYM	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-5.55	2.63e-07	0.000357	-0.5	-0.5	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
THYM	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-5.55	2.65e-07	0.00036	-0.65	-0.5	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
THYM	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-5.55	2.66e-07	0.00036	-0.59	-0.5	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-5.55	2.66e-07	0.00036	-0.59	-0.5	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
THYM	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-5.55	2.66e-07	0.000361	-0.5	-0.5	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
THYM	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	5.55	2.67e-07	0.000362	0.66	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
THYM	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-5.55	2.67e-07	0.000362	-0.54	-0.5	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
THYM	cis	rs7927592	0.731	rs488381	ENSG00000212093.1	AP000807.1	-5.55	2.67e-07	0.000363	-0.45	-0.5	Total body bone mineral density;	chr11:68524225	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-5.55	2.67e-07	0.000363	-0.45	-0.5	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
THYM	cis	rs17772222	0.651	rs1950280	ENSG00000258983.2	RP11-507K2.2	-5.55	2.68e-07	0.000363	-0.54	-0.5	Coronary artery calcification;	chr14:88366259	chr14:88499334~88515502:+
THYM	cis	rs6570726	0.537	rs1280279	ENSG00000235652.6	RP11-545I5.3	5.55	2.68e-07	0.000363	0.39	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145562912	chr6:145799409~145886585:+
THYM	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	5.54	2.69e-07	0.000363	0.59	0.5	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
THYM	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
THYM	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
THYM	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-5.54	2.69e-07	0.000363	-0.59	-0.5	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
THYM	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	5.54	2.69e-07	0.000364	0.74	0.5	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
THYM	cis	rs4691139	0.903	rs13127188	ENSG00000250227.1	TRIM60P14	5.54	2.69e-07	0.000364	0.6	0.5	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997524	chr4:164915565~164916983:+
THYM	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-5.54	2.7e-07	0.000365	-0.57	-0.5	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
THYM	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	5.54	2.7e-07	0.000365	0.61	0.5	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
THYM	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	5.54	2.7e-07	0.000365	0.9	0.5	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
THYM	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	5.54	2.7e-07	0.000366	0.71	0.5	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
THYM	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	5.54	2.71e-07	0.000366	0.4	0.5	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
THYM	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	5.54	2.72e-07	0.000367	0.46	0.5	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
THYM	cis	rs11157436	0.918	rs1983520	ENSG00000211813.2	TRAV34	5.54	2.73e-07	0.000368	0.36	0.5	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150390	chr14:22207522~22208129:+
THYM	cis	rs7829975	0.523	rs9644774	ENSG00000253893.2	FAM85B	5.54	2.73e-07	0.000369	0.61	0.5	Mood instability;	chr8:8702322	chr8:8167819~8226614:-
THYM	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	5.54	2.73e-07	0.000369	0.5	0.5	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
THYM	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	5.54	2.73e-07	0.000369	0.49	0.5	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
THYM	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	5.54	2.74e-07	0.00037	0.96	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	5.54	2.74e-07	0.00037	0.96	0.5	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
THYM	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-5.54	2.75e-07	0.000371	-0.66	-0.5	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
THYM	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-5.54	2.75e-07	0.000371	-1.01	-0.5	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
THYM	cis	rs747334	0.846	rs4933629	ENSG00000225519.1	RP11-236B18.2	5.54	2.75e-07	0.000371	0.44	0.5	Fibroblast growth factor basic levels;	chr10:90959448	chr10:90994620~91006390:+
THYM	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-5.54	2.75e-07	0.000372	-0.59	-0.5	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
THYM	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-5.54	2.75e-07	0.000372	-0.59	-0.5	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
THYM	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-5.54	2.75e-07	0.000372	-0.59	-0.5	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
THYM	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	5.54	2.76e-07	0.000372	0.5	0.5	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
THYM	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	5.54	2.76e-07	0.000372	0.5	0.5	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
THYM	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	5.54	2.76e-07	0.000372	0.5	0.5	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
THYM	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	5.54	2.76e-07	0.000372	0.5	0.5	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
THYM	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	5.54	2.76e-07	0.000372	0.5	0.5	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
THYM	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	5.54	2.76e-07	0.000372	0.5	0.5	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
THYM	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	5.54	2.76e-07	0.000372	0.66	0.5	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
THYM	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-5.54	2.77e-07	0.000373	-0.9	-0.5	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-5.54	2.77e-07	0.000373	-0.9	-0.5	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
THYM	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-5.54	2.77e-07	0.000373	-0.41	-0.5	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
THYM	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	5.54	2.78e-07	0.000374	0.58	0.5	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
THYM	cis	rs763121	0.815	rs4821799	ENSG00000273076.1	RP3-508I15.22	5.54	2.78e-07	0.000375	0.62	0.5	Menopause (age at onset);	chr22:38625321	chr22:38743495~38743910:+
THYM	cis	rs4273100	1	rs12602286	ENSG00000228157.4	AC007952.5	-5.54	2.8e-07	0.000377	-0.77	-0.5	Schizophrenia;	chr17:19333641	chr17:19092974~19096837:+
THYM	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	5.54	2.8e-07	0.000377	0.36	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
THYM	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	5.54	2.8e-07	0.000377	0.96	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
THYM	cis	rs7690978	1	rs7690978	ENSG00000248165.1	RP11-44F21.2	5.54	2.8e-07	0.000377	0.67	0.5	Interferon gamma-induced protein 10 levels;	chr4:75066634	chr4:74993877~75034824:-
THYM	cis	rs6782228	0.509	rs6780447	ENSG00000277250.1	Metazoa_SRP	-5.53	2.82e-07	0.000379	-0.64	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128673681~128674021:-
THYM	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-5.53	2.82e-07	0.000379	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-5.53	2.82e-07	0.000379	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-5.53	2.82e-07	0.000379	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-5.53	2.82e-07	0.000379	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-5.53	2.82e-07	0.000379	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-5.53	2.82e-07	0.000379	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-5.53	2.82e-07	0.000379	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
THYM	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-5.53	2.82e-07	0.00038	-0.71	-0.5	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
THYM	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-5.53	2.83e-07	0.000381	-0.54	-0.5	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
THYM	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	5.53	2.83e-07	0.000381	0.6	0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
THYM	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-5.53	2.83e-07	0.000381	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
THYM	cis	rs7182621	0.793	rs12904168	ENSG00000182397.13	DNM1P46	5.53	2.84e-07	0.000381	0.55	0.5	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99790156~99806927:-
THYM	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-5.53	2.85e-07	0.000383	-0.71	-0.5	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
THYM	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	5.53	2.85e-07	0.000383	0.9	0.5	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
THYM	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-5.53	2.85e-07	0.000383	-0.59	-0.5	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
THYM	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-5.53	2.86e-07	0.000383	-0.74	-0.5	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
THYM	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-5.53	2.86e-07	0.000383	-0.74	-0.5	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
THYM	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-5.53	2.87e-07	0.000385	-0.6	-0.5	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
THYM	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	5.53	2.87e-07	0.000385	0.6	0.5	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
THYM	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-5.53	2.88e-07	0.000387	-0.44	-0.5	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
THYM	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-5.53	2.89e-07	0.000387	-0.6	-0.5	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
THYM	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-5.53	2.91e-07	0.00039	-0.56	-0.5	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
THYM	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	5.53	2.92e-07	0.00039	0.61	0.5	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
THYM	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	5.53	2.92e-07	0.00039	0.66	0.5	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	5.53	2.92e-07	0.00039	0.66	0.5	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
THYM	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	5.53	2.92e-07	0.00039	0.66	0.5	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
THYM	cis	rs17772222	0.682	rs7142053	ENSG00000258983.2	RP11-507K2.2	5.53	2.92e-07	0.000391	0.56	0.5	Coronary artery calcification;	chr14:88511594	chr14:88499334~88515502:+
THYM	cis	rs950169	0.686	rs12906474	ENSG00000235370.6	DNM1P51	5.53	2.92e-07	0.000391	0.6	0.5	Schizophrenia;	chr15:84566006	chr15:84398316~84411701:-
THYM	cis	rs950169	0.81	rs2879976	ENSG00000235370.6	DNM1P51	5.53	2.92e-07	0.000391	0.6	0.5	Schizophrenia;	chr15:84566347	chr15:84398316~84411701:-
THYM	cis	rs7829975	0.501	rs74345345	ENSG00000253893.2	FAM85B	5.52	2.94e-07	0.000392	0.63	0.5	Mood instability;	chr8:8720925	chr8:8167819~8226614:-
THYM	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
THYM	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
THYM	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
THYM	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	5.52	2.94e-07	0.000392	0.79	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
THYM	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-5.52	2.94e-07	0.000393	-0.58	-0.5	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
THYM	cis	rs7182621	0.767	rs11247132	ENSG00000182397.13	DNM1P46	5.52	2.94e-07	0.000393	0.63	0.5	Colonoscopy-negative controls vs population controls;	chr15:99875536	chr15:99790156~99806927:-
THYM	cis	rs7829975	0.628	rs1109618	ENSG00000253893.2	FAM85B	5.52	2.94e-07	0.000393	0.63	0.5	Mood instability;	chr8:8713854	chr8:8167819~8226614:-
THYM	cis	rs4273100	0.79	rs60166680	ENSG00000228157.4	AC007952.5	5.52	2.95e-07	0.000394	0.79	0.49	Schizophrenia;	chr17:19374231	chr17:19092974~19096837:+
THYM	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-5.52	2.95e-07	0.000394	-0.94	-0.49	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
THYM	cis	rs7560272	0.538	rs7599453	ENSG00000273245.1	RP11-434P11.2	-5.52	2.96e-07	0.000395	-0.6	-0.49	Schizophrenia;	chr2:73710774	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs3980695	ENSG00000273245.1	RP11-434P11.2	-5.52	2.96e-07	0.000395	-0.6	-0.49	Schizophrenia;	chr2:73712425	chr2:73750256~73750786:-
THYM	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-5.52	2.97e-07	0.000396	-0.62	-0.49	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
THYM	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-5.52	2.98e-07	0.000398	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-5.52	2.98e-07	0.000398	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
THYM	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	5.52	2.99e-07	0.000399	0.36	0.49	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
THYM	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-5.52	2.99e-07	0.000399	-0.5	-0.49	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
THYM	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	5.52	2.99e-07	0.000399	0.5	0.49	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
THYM	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-5.52	3e-07	4e-04	-0.5	-0.49	Temperament;	chr17:14003617	chr17:14024514~14025488:+
THYM	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-5.52	3.01e-07	0.000401	-0.47	-0.49	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
THYM	cis	rs9535495	0.802	rs7326822	ENSG00000200711.1	RNA5SP28	-5.52	3.04e-07	0.000405	-0.57	-0.49	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50818449	chr13:50812988~50813106:-
THYM	cis	rs11157436	1	rs72638482	ENSG00000211813.2	TRAV34	5.52	3.04e-07	0.000405	0.37	0.49	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22207522~22208129:+
THYM	cis	rs11157436	1	rs12587166	ENSG00000211813.2	TRAV34	5.52	3.04e-07	0.000405	0.37	0.49	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22207522~22208129:+
THYM	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-5.51	3.07e-07	0.000408	-0.92	-0.49	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
THYM	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	5.51	3.07e-07	0.000409	0.38	0.49	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
THYM	cis	rs904251	0.772	rs2776906	ENSG00000227920.2	RP1-153P14.5	-5.51	3.09e-07	0.000411	-0.75	-0.49	Cognitive performance;	chr6:37463981	chr6:37545145~37550860:+
THYM	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-5.51	3.1e-07	0.000412	-0.65	-0.49	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	5.51	3.1e-07	0.000412	0.65	0.49	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	5.51	3.1e-07	0.000412	0.65	0.49	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	5.51	3.1e-07	0.000412	0.65	0.49	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
THYM	cis	rs4691139	0.903	rs6835415	ENSG00000250227.1	TRIM60P14	5.51	3.1e-07	0.000412	0.59	0.49	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998932	chr4:164915565~164916983:+
THYM	cis	rs1560104	0.597	rs17227296	ENSG00000259899.1	CTD-3037G24.3	-5.51	3.1e-07	0.000412	-0.59	-0.49	Obesity-related traits;	chr16:12618342	chr16:12560756~12611044:-
THYM	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-5.51	3.11e-07	0.000412	-0.55	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-5.51	3.11e-07	0.000412	-0.55	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
THYM	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-5.51	3.12e-07	0.000414	-0.66	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
THYM	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	5.51	3.12e-07	0.000414	0.46	0.49	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	5.51	3.12e-07	0.000414	0.46	0.49	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	5.51	3.12e-07	0.000414	0.46	0.49	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	5.51	3.12e-07	0.000414	0.46	0.49	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	5.51	3.12e-07	0.000414	0.46	0.49	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
THYM	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-5.51	3.13e-07	0.000415	-0.52	-0.49	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
THYM	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	5.51	3.13e-07	0.000415	0.73	0.49	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
THYM	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-5.51	3.14e-07	0.000416	-0.47	-0.49	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-5.51	3.14e-07	0.000416	-0.47	-0.49	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-5.51	3.14e-07	0.000416	-0.47	-0.49	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-5.51	3.14e-07	0.000416	-0.47	-0.49	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
THYM	cis	rs995834	0.784	rs12983816	ENSG00000260725.1	AC005307.1	-5.51	3.14e-07	0.000416	-0.5	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387019	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs2190992	ENSG00000260725.1	AC005307.1	-5.51	3.14e-07	0.000416	-0.5	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28389894	chr19:28418483~28429490:-
THYM	cis	rs995834	0.661	rs8100368	ENSG00000260725.1	AC005307.1	-5.51	3.14e-07	0.000416	-0.5	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28390727	chr19:28418483~28429490:-
THYM	cis	rs995834	0.703	rs10853718	ENSG00000260725.1	AC005307.1	-5.51	3.14e-07	0.000416	-0.5	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392058	chr19:28418483~28429490:-
THYM	cis	rs995834	0.664	rs10411350	ENSG00000260725.1	AC005307.1	-5.51	3.14e-07	0.000416	-0.5	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393737	chr19:28418483~28429490:-
THYM	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-5.51	3.14e-07	0.000417	-0.41	-0.49	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-5.51	3.14e-07	0.000417	-0.41	-0.49	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	5.51	3.14e-07	0.000417	0.41	0.49	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
THYM	cis	rs9532669	0.963	rs9566607	ENSG00000176268.5	CYCSP34	-5.51	3.15e-07	0.000417	-0.46	-0.49	Cervical cancer;	chr13:40921788	chr13:40863599~40863902:-
THYM	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	5.51	3.16e-07	0.000418	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
THYM	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	5.51	3.16e-07	0.000418	0.57	0.49	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-5.51	3.16e-07	0.000418	-0.57	-0.49	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-5.51	3.16e-07	0.000418	-0.57	-0.49	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
THYM	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-5.51	3.17e-07	0.000419	-0.62	-0.49	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
THYM	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-5.51	3.19e-07	0.000421	-0.44	-0.49	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-5.51	3.19e-07	0.000421	-0.44	-0.49	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
THYM	cis	rs10829156	0.607	rs7908550	ENSG00000240291.1	RP11-499P20.2	5.5	3.2e-07	0.000423	0.44	0.49	Sudden cardiac arrest;	chr10:18573282	chr10:18513115~18545651:-
THYM	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	5.5	3.21e-07	0.000423	0.45	0.49	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
THYM	cis	rs8396	1	rs6536365	ENSG00000271817.2	U3	5.5	3.21e-07	0.000423	0.37	0.49	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158711141	chr4:158700691~158700909:+
THYM	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-5.5	3.22e-07	0.000424	-0.4	-0.49	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
THYM	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-5.5	3.22e-07	0.000424	-0.48	-0.49	Depression;	chr6:28110254	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-5.5	3.22e-07	0.000424	-0.48	-0.49	Depression;	chr6:28111382	chr6:28115628~28116551:+
THYM	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-5.5	3.22e-07	0.000424	-0.48	-0.49	Depression;	chr6:28111650	chr6:28115628~28116551:+
THYM	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-5.5	3.23e-07	0.000426	-0.42	-0.49	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
THYM	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	5.5	3.23e-07	0.000426	0.37	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
THYM	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-5.5	3.24e-07	0.000427	-0.88	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
THYM	cis	rs9535495	1	rs9535497	ENSG00000200711.1	RNA5SP28	-5.5	3.24e-07	0.000427	-0.57	-0.49	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50816110	chr13:50812988~50813106:-
THYM	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	5.5	3.25e-07	0.000428	0.65	0.49	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
THYM	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	5.5	3.26e-07	0.000429	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
THYM	cis	rs9535495	1	rs9535495	ENSG00000200711.1	RNA5SP28	-5.5	3.26e-07	0.000429	-0.57	-0.49	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50814824	chr13:50812988~50813106:-
THYM	cis	rs9535495	0.965	rs11148198	ENSG00000200711.1	RNA5SP28	-5.5	3.27e-07	0.00043	-0.57	-0.49	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50813145	chr13:50812988~50813106:-
THYM	cis	rs2834288	0.5	rs2834305	ENSG00000237945.6	LINC00649	5.5	3.27e-07	0.00043	0.39	0.49	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33915534~33977691:+
THYM	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	5.5	3.28e-07	0.000431	0.58	0.49	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
THYM	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-5.5	3.28e-07	0.000431	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-5.5	3.28e-07	0.000431	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
THYM	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	5.5	3.28e-07	0.000432	0.78	0.49	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
THYM	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-5.5	3.29e-07	0.000433	-0.67	-0.49	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
THYM	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-5.5	3.3e-07	0.000433	-0.58	-0.49	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
THYM	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-5.49	3.33e-07	0.000436	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-5.49	3.33e-07	0.000436	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-5.49	3.33e-07	0.000436	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-5.49	3.33e-07	0.000436	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-5.49	3.33e-07	0.000436	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-5.49	3.33e-07	0.000436	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
THYM	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	5.49	3.34e-07	0.000436	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
THYM	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-5.49	3.35e-07	0.000437	-0.42	-0.49	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
THYM	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	5.49	3.35e-07	0.000438	0.56	0.49	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	5.49	3.35e-07	0.000438	0.56	0.49	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	5.49	3.35e-07	0.000438	0.56	0.49	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	5.49	3.35e-07	0.000438	0.56	0.49	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	5.49	3.35e-07	0.000438	0.56	0.49	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	5.49	3.35e-07	0.000438	0.56	0.49	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	5.49	3.35e-07	0.000438	0.56	0.49	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
THYM	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-5.49	3.35e-07	0.000438	-0.61	-0.49	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
THYM	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-5.49	3.38e-07	0.000441	-0.79	-0.49	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
THYM	cis	rs2921073	0.51	rs2976944	ENSG00000253893.2	FAM85B	-5.49	3.4e-07	0.000443	-0.65	-0.49	Parkinson's disease;	chr8:8413404	chr8:8167819~8226614:-
THYM	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	5.49	3.41e-07	0.000444	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	5.49	3.41e-07	0.000444	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
THYM	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-5.49	3.41e-07	0.000445	-0.65	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
THYM	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	5.49	3.42e-07	0.000445	0.46	0.49	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
THYM	cis	rs453301	0.564	rs28649568	ENSG00000253893.2	FAM85B	5.49	3.43e-07	0.000447	0.65	0.49	Joint mobility (Beighton score);	chr8:9102161	chr8:8167819~8226614:-
THYM	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-5.49	3.44e-07	0.000447	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
THYM	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	5.49	3.45e-07	0.000449	0.41	0.49	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
THYM	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	5.49	3.46e-07	0.000449	0.95	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	5.49	3.46e-07	0.000449	0.95	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	5.49	3.46e-07	0.000449	0.95	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
THYM	cis	rs11722228	0.522	rs12503195	ENSG00000261490.1	RP11-448G15.3	5.49	3.46e-07	0.000449	0.48	0.49	Urate levels;Serum uric acid levels;Gout;	chr4:10081148	chr4:10068089~10073019:-
THYM	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	5.49	3.47e-07	0.00045	0.48	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
THYM	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-5.48	3.48e-07	0.000451	-0.65	-0.49	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
THYM	cis	rs9535495	1	rs9526692	ENSG00000200711.1	RNA5SP28	-5.48	3.49e-07	0.000453	-0.57	-0.49	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50816311	chr13:50812988~50813106:-
THYM	cis	rs9535495	0.895	rs9526693	ENSG00000200711.1	RNA5SP28	-5.48	3.49e-07	0.000453	-0.57	-0.49	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50816636	chr13:50812988~50813106:-
THYM	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	3.49e-07	0.000453	-0.42	-0.49	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
THYM	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	5.48	3.5e-07	0.000454	0.44	0.49	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
THYM	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	5.48	3.52e-07	0.000456	0.45	0.49	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
THYM	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-5.48	3.53e-07	0.000457	-0.45	-0.49	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
THYM	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-5.48	3.54e-07	0.000458	-0.7	-0.49	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
THYM	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-5.48	3.54e-07	0.000458	-0.65	-0.49	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
THYM	cis	rs6782228	0.527	rs7426806	ENSG00000277250.1	Metazoa_SRP	-5.48	3.55e-07	0.000459	-0.64	-0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128673681~128674021:-
THYM	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	5.48	3.55e-07	0.00046	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
THYM	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-5.48	3.57e-07	0.000462	-0.58	-0.49	Height;	chr6:109497253	chr6:109382795~109383666:+
THYM	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-5.48	3.57e-07	0.000462	-0.81	-0.49	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
THYM	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.51	rs216402	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs216439	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs216442	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs79607958	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs75136574	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs77544470	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	5.48	3.58e-07	0.000463	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	5.48	3.59e-07	0.000464	0.76	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	5.48	3.59e-07	0.000464	0.76	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	5.48	3.59e-07	0.000464	0.76	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	5.48	3.59e-07	0.000464	0.76	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	5.48	3.59e-07	0.000464	0.76	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	5.48	3.59e-07	0.000464	0.76	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	5.48	3.59e-07	0.000464	0.76	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
THYM	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	5.48	3.6e-07	0.000465	0.43	0.49	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
THYM	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-5.48	3.61e-07	0.000466	-0.53	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
THYM	cis	rs7829975	0.51	rs11773943	ENSG00000253893.2	FAM85B	5.48	3.61e-07	0.000466	0.6	0.49	Mood instability;	chr8:8698408	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.51	rs36095989	ENSG00000253893.2	FAM85B	5.48	3.61e-07	0.000466	0.6	0.49	Mood instability;	chr8:8700352	chr8:8167819~8226614:-
THYM	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	5.48	3.62e-07	0.000467	0.46	0.49	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	5.48	3.62e-07	0.000467	0.46	0.49	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	5.48	3.62e-07	0.000467	0.46	0.49	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
THYM	cis	rs13256369	1	rs13256369	ENSG00000253893.2	FAM85B	-5.48	3.62e-07	0.000468	-0.71	-0.49	Obesity-related traits;	chr8:8719869	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	5.47	3.63e-07	0.000469	0.59	0.49	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
THYM	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-5.47	3.65e-07	0.00047	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
THYM	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	5.47	3.65e-07	0.000471	0.43	0.49	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
THYM	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-5.47	3.66e-07	0.000471	-0.62	-0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
THYM	cis	rs1560104	0.597	rs735820	ENSG00000259899.1	CTD-3037G24.3	-5.47	3.66e-07	0.000471	-0.59	-0.49	Obesity-related traits;	chr16:12618269	chr16:12560756~12611044:-
THYM	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-5.47	3.67e-07	0.000472	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	5.47	3.67e-07	0.000472	0.58	0.49	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
THYM	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-5.47	3.67e-07	0.000472	-0.45	-0.49	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
THYM	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	5.47	3.67e-07	0.000472	0.8	0.49	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
THYM	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	5.47	3.68e-07	0.000474	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
THYM	cis	rs5771242	0.845	rs2295225	ENSG00000273253.2	RP3-402G11.26	-5.47	3.68e-07	0.000474	-0.67	-0.49	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50180368	chr22:50199090~50200837:-
THYM	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-5.47	3.7e-07	0.000475	-0.62	-0.49	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
THYM	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	5.47	3.7e-07	0.000476	0.59	0.49	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
THYM	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-5.47	3.72e-07	0.000478	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-5.47	3.72e-07	0.000478	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
THYM	cis	rs11577318	0.579	rs12131370	ENSG00000225854.2	RP11-569G9.7	-5.47	3.73e-07	0.000479	-0.68	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26371939	chr1:26326688~26327033:+
THYM	cis	rs11577318	0.528	rs11247935	ENSG00000225854.2	RP11-569G9.7	-5.47	3.73e-07	0.000479	-0.68	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26372131	chr1:26326688~26327033:+
THYM	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	5.47	3.73e-07	0.000479	0.65	0.49	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
THYM	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	5.47	3.74e-07	0.00048	0.59	0.49	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
THYM	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	5.47	3.75e-07	0.000481	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	5.47	3.75e-07	0.000481	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-5.47	3.75e-07	0.000481	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
THYM	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-5.47	3.76e-07	0.000482	-0.6	-0.49	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
THYM	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	5.47	3.77e-07	0.000484	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
THYM	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-5.47	3.78e-07	0.000484	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
THYM	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	5.47	3.78e-07	0.000485	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-5.47	3.78e-07	0.000485	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
THYM	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	5.46	3.8e-07	0.000486	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	5.46	3.8e-07	0.000486	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	5.46	3.8e-07	0.000486	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	5.46	3.8e-07	0.000486	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	5.46	3.8e-07	0.000486	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
THYM	cis	rs973796	0.966	rs55694701	ENSG00000236296.6	GUSBP5	5.46	3.82e-07	0.000488	0.58	0.49	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:144461375	chr4:143559472~143649305:+
THYM	cis	rs995758	0.512	rs56268708	ENSG00000236296.6	GUSBP5	5.46	3.82e-07	0.000488	0.58	0.49	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144461380	chr4:143559472~143649305:+
THYM	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-5.46	3.82e-07	0.000488	-0.57	-0.49	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
THYM	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	5.46	3.82e-07	0.000488	0.47	0.49	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
THYM	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-5.46	3.82e-07	0.000489	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
THYM	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	5.46	3.82e-07	0.000489	0.39	0.49	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
THYM	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	5.46	3.83e-07	0.000489	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
THYM	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-5.46	3.84e-07	0.00049	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
THYM	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	5.46	3.84e-07	0.000491	0.58	0.49	Height;	chr6:109458989	chr6:109382795~109383666:+
THYM	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	5.46	3.85e-07	0.000492	0.62	0.49	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
THYM	cis	rs2562456	0.833	rs2968076	ENSG00000268081.1	RP11-678G14.2	-5.46	3.85e-07	0.000492	-0.67	-0.49	Pain;	chr19:21454299	chr19:21554640~21569237:-
THYM	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	5.46	3.86e-07	0.000493	0.56	0.49	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
THYM	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	5.46	3.86e-07	0.000493	0.56	0.49	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
THYM	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	5.46	3.87e-07	0.000493	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
THYM	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-5.46	3.87e-07	0.000493	-0.41	-0.49	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
THYM	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	5.46	3.87e-07	0.000493	0.41	0.49	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
THYM	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	5.46	3.87e-07	0.000493	0.41	0.49	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
THYM	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-5.46	3.87e-07	0.000493	-0.61	-0.49	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
THYM	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-5.46	3.87e-07	0.000493	-0.56	-0.49	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
THYM	cis	rs904251	0.523	rs1776454	ENSG00000227920.2	RP1-153P14.5	-5.46	3.87e-07	0.000493	-0.66	-0.49	Cognitive performance;	chr6:37514323	chr6:37545145~37550860:+
THYM	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	5.46	3.89e-07	0.000495	0.76	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
THYM	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	5.46	3.89e-07	0.000495	0.76	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
THYM	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	5.46	3.89e-07	0.000495	0.76	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
THYM	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	5.46	3.89e-07	0.000495	0.43	0.49	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
THYM	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	5.46	3.9e-07	0.000496	0.45	0.49	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.786	rs7093907	ENSG00000240291.1	RP11-499P20.2	5.46	3.9e-07	0.000496	0.45	0.49	Sudden cardiac arrest;	chr10:18587225	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.66	rs4338439	ENSG00000240291.1	RP11-499P20.2	5.46	3.9e-07	0.000496	0.45	0.49	Sudden cardiac arrest;	chr10:18594220	chr10:18513115~18545651:-
THYM	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	5.46	3.91e-07	0.000497	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	5.46	3.91e-07	0.000497	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	5.46	3.91e-07	0.000497	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	5.46	3.91e-07	0.000497	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	5.46	3.91e-07	0.000497	0.88	0.49	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
THYM	cis	rs995834	0.664	rs8109361	ENSG00000260725.1	AC005307.1	-5.46	3.92e-07	0.000498	-0.5	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395343	chr19:28418483~28429490:-
THYM	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	5.46	3.93e-07	5e-04	0.44	0.49	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	5.46	3.93e-07	5e-04	0.44	0.49	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	5.46	3.93e-07	5e-04	0.44	0.49	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	5.46	3.93e-07	5e-04	0.44	0.49	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
THYM	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	5.45	3.96e-07	0.000503	0.57	0.49	Height;	chr6:109494148	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	5.45	3.96e-07	0.000503	0.57	0.49	Height;	chr6:109495102	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	5.45	3.96e-07	0.000503	0.57	0.49	Height;	chr6:109496680	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	5.45	3.96e-07	0.000503	0.57	0.49	Height;	chr6:109497088	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	5.45	3.96e-07	0.000503	0.57	0.49	Height;	chr6:109498751	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	5.45	3.96e-07	0.000503	0.57	0.49	Height;	chr6:109500687	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-5.45	3.96e-07	0.000503	-0.57	-0.49	Height;	chr6:109501793	chr6:109382795~109383666:+
THYM	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-5.45	3.97e-07	0.000503	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-5.45	3.97e-07	0.000503	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-5.45	3.97e-07	0.000503	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-5.45	3.97e-07	0.000503	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-5.45	3.97e-07	0.000503	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	5.45	3.97e-07	0.000503	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	5.45	3.97e-07	0.000503	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	5.45	3.97e-07	0.000503	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	5.45	3.97e-07	0.000503	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	5.45	3.97e-07	0.000503	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
THYM	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-5.45	3.97e-07	0.000504	-0.54	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-5.45	3.97e-07	0.000504	-0.54	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-5.45	3.97e-07	0.000504	-0.54	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-5.45	3.97e-07	0.000504	-0.54	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-5.45	3.97e-07	0.000504	-0.54	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-5.45	3.97e-07	0.000504	-0.54	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
THYM	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	5.45	3.98e-07	0.000505	0.38	0.49	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	5.45	3.98e-07	0.000505	0.38	0.49	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
THYM	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-5.45	3.98e-07	0.000505	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
THYM	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	5.45	3.98e-07	0.000505	0.56	0.49	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
THYM	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-5.45	3.99e-07	0.000505	-0.57	-0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
THYM	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	5.45	3.99e-07	0.000505	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
THYM	cis	rs995758	0.519	rs2130499	ENSG00000236296.6	GUSBP5	5.45	3.99e-07	0.000506	0.57	0.49	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144467682	chr4:143559472~143649305:+
THYM	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-5.45	4e-07	0.000507	-0.65	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-5.45	4e-07	0.000507	-0.65	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
THYM	cis	rs2562456	0.833	rs8106025	ENSG00000268081.1	RP11-678G14.2	-5.45	4.02e-07	0.000508	-0.67	-0.49	Pain;	chr19:21451922	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs2650819	ENSG00000268081.1	RP11-678G14.2	-5.45	4.02e-07	0.000508	-0.67	-0.49	Pain;	chr19:21456071	chr19:21554640~21569237:-
THYM	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	5.45	4.04e-07	0.000511	0.46	0.49	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
THYM	cis	rs950169	1	rs11638297	ENSG00000235370.6	DNM1P51	5.45	4.04e-07	0.000511	0.6	0.49	Schizophrenia;	chr15:84113665	chr15:84398316~84411701:-
THYM	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-5.45	4.05e-07	0.000512	-0.4	-0.49	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
THYM	cis	rs11722228	0.594	rs10939663	ENSG00000261490.1	RP11-448G15.3	5.45	4.05e-07	0.000513	0.52	0.49	Urate levels;Serum uric acid levels;Gout;	chr4:10030892	chr4:10068089~10073019:-
THYM	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-5.45	4.06e-07	0.000513	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
THYM	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	5.45	4.06e-07	0.000513	0.65	0.49	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
THYM	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-5.45	4.07e-07	0.000515	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
THYM	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	5.45	4.08e-07	0.000515	0.45	0.49	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
THYM	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-5.45	4.09e-07	0.000517	-0.44	-0.49	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-5.45	4.09e-07	0.000517	-0.44	-0.49	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-5.45	4.09e-07	0.000517	-0.44	-0.49	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
THYM	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	5.45	4.09e-07	0.000517	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
THYM	cis	rs1560104	0.536	rs9933641	ENSG00000259899.1	CTD-3037G24.3	-5.45	4.1e-07	0.000517	-0.57	-0.49	Obesity-related traits;	chr16:12615413	chr16:12560756~12611044:-
THYM	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	5.45	4.1e-07	0.000517	0.56	0.49	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
THYM	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-5.45	4.1e-07	0.000517	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-5.45	4.1e-07	0.000517	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-5.45	4.1e-07	0.000517	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-5.45	4.1e-07	0.000517	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-5.45	4.1e-07	0.000517	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-5.45	4.1e-07	0.000517	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-5.45	4.1e-07	0.000517	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	5.45	4.1e-07	0.000517	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	5.45	4.1e-07	0.000517	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	5.45	4.1e-07	0.000517	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	5.45	4.1e-07	0.000517	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
THYM	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	5.44	4.15e-07	0.000523	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	5.44	4.15e-07	0.000523	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
THYM	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-5.44	4.15e-07	0.000523	-0.55	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-5.44	4.15e-07	0.000523	-0.55	-0.49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
THYM	cis	rs950169	0.922	rs11630760	ENSG00000235370.6	DNM1P51	5.44	4.15e-07	0.000523	0.63	0.49	Schizophrenia;	chr15:84570106	chr15:84398316~84411701:-
THYM	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-5.44	4.16e-07	0.000524	-0.49	-0.49	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
THYM	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-5.44	4.17e-07	0.000525	-0.59	-0.49	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-5.44	4.17e-07	0.000525	-0.59	-0.49	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
THYM	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	5.44	4.18e-07	0.000526	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
THYM	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-5.44	4.18e-07	0.000526	-0.54	-0.49	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
THYM	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	5.44	4.18e-07	0.000526	0.45	0.49	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
THYM	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	5.44	4.19e-07	0.000526	0.59	0.49	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
THYM	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-5.44	4.19e-07	0.000526	-0.88	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
THYM	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	5.44	4.19e-07	0.000527	0.39	0.49	Cancer;	chr7:142407435	chr7:142554836~142555318:+
THYM	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	5.44	4.21e-07	0.000528	0.65	0.49	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
THYM	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	5.44	4.21e-07	0.000529	0.38	0.49	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
THYM	cis	rs1560104	0.556	rs7188416	ENSG00000259899.1	CTD-3037G24.3	-5.44	4.21e-07	0.000529	-0.57	-0.49	Obesity-related traits;	chr16:12615754	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.576	rs12708761	ENSG00000259899.1	CTD-3037G24.3	-5.44	4.21e-07	0.000529	-0.57	-0.49	Obesity-related traits;	chr16:12617077	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.597	rs13338316	ENSG00000259899.1	CTD-3037G24.3	-5.44	4.21e-07	0.000529	-0.57	-0.49	Obesity-related traits;	chr16:12617168	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.597	rs13333850	ENSG00000259899.1	CTD-3037G24.3	-5.44	4.21e-07	0.000529	-0.57	-0.49	Obesity-related traits;	chr16:12617231	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.597	rs13334919	ENSG00000259899.1	CTD-3037G24.3	-5.44	4.21e-07	0.000529	-0.57	-0.49	Obesity-related traits;	chr16:12617300	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.597	rs13338716	ENSG00000259899.1	CTD-3037G24.3	-5.44	4.21e-07	0.000529	-0.57	-0.49	Obesity-related traits;	chr16:12617477	chr16:12560756~12611044:-
THYM	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	5.44	4.21e-07	0.000529	0.46	0.49	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
THYM	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-5.44	4.22e-07	0.00053	-0.67	-0.49	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
THYM	cis	rs11577318	0.579	rs11247936	ENSG00000225854.2	RP11-569G9.7	-5.44	4.22e-07	0.00053	-0.67	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26372393	chr1:26326688~26327033:+
THYM	cis	rs10129255	0.613	rs916546	ENSG00000254329.1	IGHVII-60-1	5.44	4.22e-07	0.00053	0.51	0.49	Kawasaki disease;	chr14:106654441	chr14:106637718~106637973:-
THYM	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	5.44	4.25e-07	0.000533	0.64	0.49	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	5.44	4.25e-07	0.000533	0.64	0.49	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	5.44	4.25e-07	0.000533	0.64	0.49	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
THYM	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	5.44	4.25e-07	0.000534	0.54	0.49	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
THYM	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	5.44	4.26e-07	0.000534	0.39	0.49	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	5.44	4.26e-07	0.000534	0.39	0.49	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	5.44	4.26e-07	0.000534	0.39	0.49	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	5.44	4.26e-07	0.000534	0.39	0.49	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	5.44	4.26e-07	0.000534	0.39	0.49	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	5.44	4.26e-07	0.000534	0.39	0.49	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	5.44	4.26e-07	0.000534	0.39	0.49	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-5.44	4.26e-07	0.000534	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
THYM	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-5.44	4.26e-07	0.000535	-0.44	-0.49	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-5.44	4.26e-07	0.000535	-0.44	-0.49	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
THYM	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-5.44	4.26e-07	0.000535	-0.56	-0.49	Height;	chr6:109360458	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	5.44	4.26e-07	0.000535	0.56	0.49	Height;	chr6:109360263	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	5.44	4.26e-07	0.000535	0.56	0.49	Height;	chr6:109361200	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	5.44	4.26e-07	0.000535	0.56	0.49	Height;	chr6:109367335	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	5.44	4.26e-07	0.000535	0.56	0.49	Height;	chr6:109368228	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	5.44	4.26e-07	0.000535	0.56	0.49	Height;	chr6:109370741	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	5.44	4.26e-07	0.000535	0.56	0.49	Height;	chr6:109371524	chr6:109382795~109383666:+
THYM	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-5.44	4.28e-07	0.000537	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-5.44	4.28e-07	0.000537	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-5.44	4.28e-07	0.000537	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-5.44	4.28e-07	0.000537	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
THYM	cis	rs1560104	0.576	rs7202727	ENSG00000259899.1	CTD-3037G24.3	-5.44	4.28e-07	0.000537	-0.6	-0.49	Obesity-related traits;	chr16:12614087	chr16:12560756~12611044:-
THYM	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	5.44	4.29e-07	0.000537	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
THYM	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	5.44	4.29e-07	0.000538	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
THYM	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-5.44	4.3e-07	0.000538	-0.5	-0.49	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
THYM	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-5.44	4.3e-07	0.000539	-0.57	-0.49	Height;	chr6:109636120	chr6:109382795~109383666:+
THYM	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	5.43	4.31e-07	0.000539	0.51	0.49	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
THYM	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-5.43	4.31e-07	0.000539	-0.44	-0.49	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
THYM	cis	rs7560272	0.538	rs4241257	ENSG00000273245.1	RP11-434P11.2	-5.43	4.33e-07	0.000542	-0.59	-0.49	Schizophrenia;	chr2:73711480	chr2:73750256~73750786:-
THYM	cis	rs1560104	0.576	rs7186154	ENSG00000259899.1	CTD-3037G24.3	-5.43	4.34e-07	0.000543	-0.57	-0.49	Obesity-related traits;	chr16:12615650	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.597	rs12162027	ENSG00000259899.1	CTD-3037G24.3	-5.43	4.34e-07	0.000543	-0.61	-0.49	Obesity-related traits;	chr16:12616235	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.556	rs59670495	ENSG00000259899.1	CTD-3037G24.3	-5.43	4.34e-07	0.000543	-0.61	-0.49	Obesity-related traits;	chr16:12617241	chr16:12560756~12611044:-
THYM	cis	rs11157436	0.958	rs764160	ENSG00000211813.2	TRAV34	5.43	4.34e-07	0.000543	0.39	0.49	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22207522~22208129:+
THYM	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-5.43	4.35e-07	0.000544	-0.55	-0.49	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
THYM	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-5.43	4.36e-07	0.000545	-0.45	-0.49	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	5.43	4.36e-07	0.000545	0.45	0.49	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	5.43	4.36e-07	0.000545	0.45	0.49	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	5.43	4.36e-07	0.000545	0.45	0.49	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	5.43	4.36e-07	0.000545	0.45	0.49	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	5.43	4.36e-07	0.000545	0.45	0.49	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	5.43	4.36e-07	0.000545	0.45	0.49	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
THYM	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	5.43	4.37e-07	0.000546	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
THYM	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	5.43	4.37e-07	0.000546	0.5	0.49	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
THYM	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	5.43	4.37e-07	0.000546	0.5	0.49	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
THYM	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	5.43	4.37e-07	0.000546	0.43	0.49	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
THYM	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	5.43	4.39e-07	0.000546	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
THYM	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	5.43	4.39e-07	0.000546	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
THYM	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	5.43	4.4e-07	0.000547	0.5	0.49	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
THYM	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-5.43	4.4e-07	0.000547	-0.56	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
THYM	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	5.43	4.4e-07	0.000547	0.54	0.49	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	5.43	4.4e-07	0.000547	0.54	0.49	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
THYM	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	5.43	4.41e-07	0.000548	0.36	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
THYM	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	5.43	4.42e-07	0.000549	0.56	0.49	Height;	chr6:109715504	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	5.43	4.42e-07	0.000549	0.56	0.49	Height;	chr6:109715560	chr6:109382795~109383666:+
THYM	cis	rs1560104	0.536	rs12708760	ENSG00000259899.1	CTD-3037G24.3	-5.43	4.42e-07	0.000549	-0.56	-0.49	Obesity-related traits;	chr16:12617071	chr16:12560756~12611044:-
THYM	cis	rs11992186	0.57	rs17628941	ENSG00000253893.2	FAM85B	5.43	4.43e-07	0.00055	0.66	0.49	Neuroticism;	chr8:8730024	chr8:8167819~8226614:-
THYM	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-5.43	4.43e-07	0.00055	-0.38	-0.49	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
THYM	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	5.43	4.43e-07	0.00055	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
THYM	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-5.43	4.43e-07	0.00055	-0.7	-0.49	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
THYM	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	5.43	4.43e-07	0.000551	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	5.43	4.43e-07	0.000551	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
THYM	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	5.43	4.45e-07	0.000552	0.55	0.49	Height;	chr6:109351795	chr6:109382795~109383666:+
THYM	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	5.43	4.45e-07	0.000553	0.67	0.49	Pain;	chr19:21468580	chr19:21554640~21569237:-
THYM	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	5.43	4.46e-07	0.000553	0.6	0.49	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
THYM	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	5.43	4.46e-07	0.000553	0.6	0.49	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
THYM	cis	rs12439619	0.883	rs62012045	ENSG00000274376.3	ADAMTS7P1	5.43	4.46e-07	0.000554	0.5	0.49	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.921	rs56042848	ENSG00000274376.3	ADAMTS7P1	5.43	4.46e-07	0.000554	0.5	0.49	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82298553~82334609:+
THYM	cis	rs75422866	0.85	rs73111210	ENSG00000257433.4	RP1-197B17.3	5.43	4.47e-07	0.000554	0.94	0.49	Pneumonia;	chr12:47576949	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.85	rs73111212	ENSG00000257433.4	RP1-197B17.3	5.43	4.47e-07	0.000554	0.94	0.49	Pneumonia;	chr12:47577638	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.85	rs73111216	ENSG00000257433.4	RP1-197B17.3	5.43	4.47e-07	0.000554	0.94	0.49	Pneumonia;	chr12:47577671	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.85	rs73111217	ENSG00000257433.4	RP1-197B17.3	5.43	4.47e-07	0.000554	0.94	0.49	Pneumonia;	chr12:47577693	chr12:47706085~47742294:+
THYM	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	5.43	4.47e-07	0.000555	0.7	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
THYM	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-5.43	4.47e-07	0.000555	-0.38	-0.49	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
THYM	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	5.43	4.47e-07	0.000555	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
THYM	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-5.42	4.5e-07	0.000558	-0.43	-0.49	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
THYM	cis	rs1426063	0.61	rs72862239	ENSG00000249717.1	RP11-44F21.3	5.42	4.51e-07	0.000559	1.33	0.49	QT interval;	chr4:75071967	chr4:74955974~74970362:-
THYM	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	5.42	4.51e-07	0.000559	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
THYM	cis	rs7927592	0.763	rs3740628	ENSG00000222339.1	AP000807.2	5.42	4.53e-07	0.000562	0.58	0.49	Total body bone mineral density;	chr11:68613947	chr11:68505572~68505651:-
THYM	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-5.42	4.53e-07	0.000562	-0.35	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
THYM	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	5.42	4.54e-07	0.000563	0.64	0.49	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	5.42	4.54e-07	0.000563	0.64	0.49	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	5.42	4.54e-07	0.000563	0.64	0.49	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
THYM	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-5.42	4.55e-07	0.000563	-0.59	-0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
THYM	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	5.42	4.55e-07	0.000563	0.57	0.49	Height;	chr6:109494760	chr6:109382795~109383666:+
THYM	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	5.42	4.55e-07	0.000563	0.83	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
THYM	cis	rs2562456	0.833	rs2968078	ENSG00000268081.1	RP11-678G14.2	-5.42	4.55e-07	0.000563	-0.66	-0.49	Pain;	chr19:21458942	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.755	rs2650773	ENSG00000268081.1	RP11-678G14.2	-5.42	4.55e-07	0.000563	-0.66	-0.49	Pain;	chr19:21461286	chr19:21554640~21569237:-
THYM	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	5.42	4.56e-07	0.000564	0.94	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
THYM	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	5.42	4.57e-07	0.000565	0.54	0.49	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
THYM	cis	rs13256369	1	rs873064	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8714870	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs873063	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8714937	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs4841016	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8715051	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs10103769	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8715526	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs4840351	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8715638	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs4840352	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8715998	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs13267501	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8716548	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.95	rs13270006	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8716687	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs7004438	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8716869	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs10095733	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8717136	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs13271966	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8717962	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.76	rs7816171	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8718325	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.76	rs7839473	ENSG00000253893.2	FAM85B	-5.42	4.59e-07	0.000567	-0.7	-0.49	Obesity-related traits;	chr8:8718326	chr8:8167819~8226614:-
THYM	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-5.42	4.6e-07	0.000568	-0.85	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
THYM	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-5.42	4.6e-07	0.000568	-0.56	-0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-5.42	4.6e-07	0.000568	-0.56	-0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
THYM	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	5.42	4.6e-07	0.000568	0.6	0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
THYM	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	5.42	4.6e-07	0.000568	0.6	0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
THYM	cis	rs4273100	0.541	rs7501702	ENSG00000262319.1	CTC-457L16.2	5.42	4.6e-07	0.000569	0.64	0.49	Schizophrenia;	chr17:19390414	chr17:19141017~19143689:-
THYM	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	5.42	4.6e-07	0.000569	0.88	0.49	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
THYM	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-5.42	4.6e-07	0.000569	-0.56	-0.49	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
THYM	cis	rs35398779	1	rs35398779	ENSG00000231645.2	KRT17P6	-5.42	4.61e-07	0.000569	-0.6	-0.49	Platelet count;	chr17:19949782	chr17:20512560~20517479:-
THYM	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109526846	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109533040	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109534269	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109584789	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109586733	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109588639	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109589051	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109592105	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109608105	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109618620	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109620772	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109634150	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109640141	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109642186	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109646187	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109652694	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109655791	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109672088	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109676091	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109690255	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109693890	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109694672	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	5.42	4.62e-07	0.00057	0.56	0.49	Height;	chr6:109706514	chr6:109382795~109383666:+
THYM	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	5.42	4.62e-07	0.00057	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
THYM	cis	rs2739330	0.587	rs4820571	ENSG00000272787.1	KB-226F1.2	-5.42	4.66e-07	0.000574	-0.55	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23969211~23969873:+
THYM	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-5.42	4.66e-07	0.000574	-0.41	-0.49	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
THYM	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	5.42	4.67e-07	0.000575	0.5	0.49	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-5.42	4.67e-07	0.000575	-0.5	-0.49	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
THYM	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-5.42	4.67e-07	0.000575	-0.5	-0.49	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
THYM	cis	rs2834288	0.613	rs2834297	ENSG00000237945.6	LINC00649	-5.42	4.67e-07	0.000576	-0.4	-0.49	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33915534~33977691:+
THYM	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	5.42	4.68e-07	0.000576	0.36	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	5.42	4.68e-07	0.000576	0.36	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	5.42	4.68e-07	0.000576	0.36	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	5.42	4.68e-07	0.000576	0.36	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
THYM	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	5.42	4.68e-07	0.000577	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
THYM	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-5.41	4.69e-07	0.000578	-0.48	-0.49	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
THYM	cis	rs995834	0.703	rs4806354	ENSG00000260725.1	AC005307.1	-5.41	4.7e-07	0.000579	-0.52	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396974	chr19:28418483~28429490:-
THYM	cis	rs995834	0.703	rs4806355	ENSG00000260725.1	AC005307.1	-5.41	4.7e-07	0.000579	-0.52	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396997	chr19:28418483~28429490:-
THYM	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-5.41	4.7e-07	0.000579	-0.86	-0.49	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
THYM	cis	rs783540	0.872	rs2678445	ENSG00000278603.1	RP13-608F4.5	-5.41	4.7e-07	0.000579	-0.6	-0.49	Schizophrenia;	chr15:82577391	chr15:82472203~82472426:+
THYM	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	5.41	4.71e-07	0.000579	0.64	0.49	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	5.41	4.71e-07	0.000579	0.64	0.49	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	5.41	4.71e-07	0.000579	0.64	0.49	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	5.41	4.71e-07	0.000579	0.64	0.49	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	5.41	4.71e-07	0.000579	0.64	0.49	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	5.41	4.71e-07	0.000579	0.64	0.49	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
THYM	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	5.41	4.71e-07	0.000579	0.44	0.49	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	5.41	4.71e-07	0.000579	0.44	0.49	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	5.41	4.71e-07	0.000579	0.44	0.49	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
THYM	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	5.41	4.71e-07	0.00058	0.5	0.49	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
THYM	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-5.41	4.71e-07	0.00058	-0.57	-0.49	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
THYM	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-5.41	4.72e-07	0.00058	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
THYM	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-5.41	4.73e-07	0.000581	-0.59	-0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
THYM	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	5.41	4.73e-07	0.000581	0.46	0.49	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-5.41	4.73e-07	0.000581	-0.46	-0.49	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
THYM	cis	rs995834	0.742	rs4806342	ENSG00000260725.1	AC005307.1	-5.41	4.74e-07	0.000583	-0.49	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384461	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs11083471	ENSG00000260725.1	AC005307.1	-5.41	4.74e-07	0.000583	-0.49	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28385094	chr19:28418483~28429490:-
THYM	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	5.41	4.75e-07	0.000584	0.53	0.49	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
THYM	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	5.41	4.75e-07	0.000584	0.53	0.49	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
THYM	cis	rs7702057	0.53	rs7728055	ENSG00000271918.1	CTD-2287O16.5	5.41	4.79e-07	0.000588	0.78	0.49	Amyotrophic lateral sclerosis;	chr5:116078170	chr5:116083807~116085416:-
THYM	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-5.41	4.8e-07	0.000589	-0.64	-0.49	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
THYM	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	5.41	4.81e-07	0.000591	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
THYM	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-5.41	4.82e-07	0.000591	-0.52	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
THYM	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	5.41	4.82e-07	0.000591	0.45	0.49	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	5.41	4.82e-07	0.000591	0.45	0.49	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	5.41	4.82e-07	0.000591	0.45	0.49	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	5.41	4.82e-07	0.000591	0.45	0.49	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
THYM	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	5.41	4.83e-07	0.000592	0.39	0.49	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
THYM	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	5.41	4.83e-07	0.000592	0.88	0.49	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
THYM	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-5.41	4.83e-07	0.000592	-0.6	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
THYM	cis	rs12682352	0.605	rs60707155	ENSG00000253893.2	FAM85B	-5.41	4.85e-07	0.000595	-0.6	-0.49	Neuroticism;	chr8:8866905	chr8:8167819~8226614:-
THYM	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-5.41	4.86e-07	0.000595	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-5.41	4.86e-07	0.000595	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-5.41	4.86e-07	0.000595	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-5.41	4.86e-07	0.000595	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
THYM	cis	rs950169	0.887	rs71395453	ENSG00000235370.6	DNM1P51	5.41	4.88e-07	0.000597	0.63	0.49	Schizophrenia;	chr15:84570259	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs11633075	ENSG00000235370.6	DNM1P51	5.41	4.88e-07	0.000597	0.63	0.49	Schizophrenia;	chr15:84570741	chr15:84398316~84411701:-
THYM	cis	rs950169	0.922	rs12912934	ENSG00000235370.6	DNM1P51	5.41	4.88e-07	0.000597	0.63	0.49	Schizophrenia;	chr15:84571216	chr15:84398316~84411701:-
THYM	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	5.41	4.89e-07	0.000598	0.46	0.49	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
THYM	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	5.4	4.89e-07	0.000599	0.46	0.49	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
THYM	cis	rs2562456	0.755	rs2562421	ENSG00000268081.1	RP11-678G14.2	-5.4	4.91e-07	0.000601	-0.67	-0.49	Pain;	chr19:21448502	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs2562420	ENSG00000268081.1	RP11-678G14.2	-5.4	4.91e-07	0.000601	-0.67	-0.49	Pain;	chr19:21448503	chr19:21554640~21569237:-
THYM	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	5.4	4.91e-07	0.000601	0.46	0.49	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	5.4	4.91e-07	0.000601	0.46	0.49	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	5.4	4.91e-07	0.000601	0.46	0.49	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	5.4	4.91e-07	0.000601	0.46	0.49	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	5.4	4.92e-07	0.000601	0.46	0.49	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
THYM	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	5.4	4.92e-07	0.000601	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
THYM	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-5.4	4.92e-07	0.000601	-0.64	-0.49	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
THYM	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-5.4	4.92e-07	0.000601	-0.64	-0.49	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
THYM	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	5.4	4.93e-07	0.000601	0.42	0.49	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
THYM	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
THYM	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
THYM	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
THYM	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
THYM	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-5.4	4.93e-07	0.000601	-0.42	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
THYM	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-5.4	4.93e-07	0.000601	-0.65	-0.49	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
THYM	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	5.4	4.93e-07	0.000601	0.48	0.49	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
THYM	cis	rs3740713	1	rs79199586	ENSG00000256464.1	YWHABP2	5.4	4.94e-07	0.000601	0.83	0.49	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr11:18490243~18490955:-
THYM	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	5.4	4.95e-07	0.000601	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-5.4	4.95e-07	0.000601	-0.87	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
THYM	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	5.4	4.95e-07	0.000601	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
THYM	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	5.4	4.96e-07	0.000602	0.46	0.49	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
THYM	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	5.4	4.96e-07	0.000603	0.41	0.49	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
THYM	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-5.4	4.97e-07	0.000603	-0.75	-0.49	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
THYM	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	5.4	4.97e-07	0.000604	0.55	0.49	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
THYM	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	5.4	4.99e-07	0.000606	0.88	0.49	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
THYM	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	5.4	5e-07	0.000607	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	5.4	5e-07	0.000607	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-5.4	5e-07	0.000607	-0.87	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
THYM	cis	rs995834	0.664	rs8110139	ENSG00000260725.1	AC005307.1	-5.4	5.02e-07	0.000609	-0.52	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395640	chr19:28418483~28429490:-
THYM	cis	rs950169	1	rs950169	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84037709	chr15:84398316~84411701:-
THYM	cis	rs950169	0.92	rs2135551	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84039099	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs12902672	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84048234	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs1818950	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84053769	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs12903820	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84055068	chr15:84398316~84411701:-
THYM	cis	rs950169	0.919	rs12915589	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84065712	chr15:84398316~84411701:-
THYM	cis	rs950169	0.959	rs66801143	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84067905	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs35648189	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84071996	chr15:84398316~84411701:-
THYM	cis	rs950169	0.92	rs17300048	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84080725	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs1848093	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84086775	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs12915234	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84089549	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs34751999	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84089667	chr15:84398316~84411701:-
THYM	cis	rs950169	0.919	rs17300292	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84093816	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs12916348	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84096775	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs35297609	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84104144	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs62026530	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84107088	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs11638394	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84110176	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs35658069	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84111394	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs79318564	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84117398	chr15:84398316~84411701:-
THYM	cis	rs950169	1	rs1911155	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84118883	chr15:84398316~84411701:-
THYM	cis	rs950169	0.92	rs12915390	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84123317	chr15:84398316~84411701:-
THYM	cis	rs950169	0.959	rs12911210	ENSG00000235370.6	DNM1P51	5.4	5.02e-07	0.000609	0.61	0.49	Schizophrenia;	chr15:84123331	chr15:84398316~84411701:-
THYM	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	5.4	5.03e-07	0.00061	0.52	0.49	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-5.4	5.03e-07	0.00061	-0.52	-0.49	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
THYM	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	5.4	5.03e-07	0.00061	0.63	0.49	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
THYM	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	5.4	5.04e-07	0.00061	0.58	0.49	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-5.4	5.04e-07	0.00061	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
THYM	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	5.4	5.04e-07	0.00061	0.86	0.49	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
THYM	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	5.4	5.06e-07	0.000612	0.4	0.49	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
THYM	cis	rs9473147	0.516	rs1931837	ENSG00000270761.1	RP11-385F7.1	-5.4	5.07e-07	0.000613	-0.44	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47474641	chr6:47477243~47477572:-
THYM	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	5.4	5.07e-07	0.000613	0.5	0.49	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
THYM	cis	rs995834	1	rs995834	ENSG00000267243.4	AC005307.3	-5.4	5.08e-07	0.000614	-0.42	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375689	chr19:28435388~28727777:-
THYM	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	5.4	5.09e-07	0.000615	0.64	0.49	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
THYM	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-5.4	5.09e-07	0.000615	-0.6	-0.49	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
THYM	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	5.4	5.1e-07	0.000616	0.46	0.49	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	5.4	5.1e-07	0.000616	0.46	0.49	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	5.4	5.1e-07	0.000616	0.46	0.49	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	5.4	5.1e-07	0.000616	0.46	0.49	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	5.4	5.1e-07	0.000616	0.46	0.49	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-5.4	5.1e-07	0.000616	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
THYM	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	5.39	5.1e-07	0.000616	0.35	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
THYM	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	5.39	5.11e-07	0.000617	0.58	0.49	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
THYM	cis	rs995834	0.622	rs2159076	ENSG00000260725.1	AC005307.1	-5.39	5.11e-07	0.000617	-0.5	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403929	chr19:28418483~28429490:-
THYM	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	5.39	5.12e-07	0.000618	0.44	0.49	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
THYM	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-5.39	5.14e-07	0.000621	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
THYM	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	5.39	5.15e-07	0.000622	0.72	0.49	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
THYM	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	5.39	5.16e-07	0.000622	0.55	0.49	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
THYM	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-5.39	5.16e-07	0.000622	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
THYM	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	5.39	5.19e-07	0.000625	0.58	0.49	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
THYM	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-5.39	5.2e-07	0.000626	-0.46	-0.49	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-5.39	5.2e-07	0.000626	-0.46	-0.49	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
THYM	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	5.39	5.2e-07	0.000626	0.57	0.49	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
THYM	cis	rs2834288	0.5	rs2834304	ENSG00000237945.6	LINC00649	5.39	5.2e-07	0.000626	0.4	0.49	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33915534~33977691:+
THYM	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	5.39	5.22e-07	0.000627	0.5	0.49	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
THYM	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	5.39	5.23e-07	0.000629	0.43	0.49	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	5.39	5.23e-07	0.000629	0.43	0.49	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	5.39	5.23e-07	0.000629	0.43	0.49	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	5.39	5.23e-07	0.000629	0.43	0.49	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
THYM	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	5.39	5.25e-07	0.00063	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	5.39	5.25e-07	0.00063	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	5.39	5.25e-07	0.00063	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	5.39	5.25e-07	0.00063	0.93	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
THYM	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-5.39	5.26e-07	0.000631	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
THYM	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-5.39	5.26e-07	0.000631	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
THYM	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	5.39	5.27e-07	0.000633	0.73	0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
THYM	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-5.39	5.28e-07	0.000633	-0.5	-0.49	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
THYM	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-5.39	5.28e-07	0.000633	-0.66	-0.49	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
THYM	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-5.39	5.28e-07	0.000633	-0.58	-0.49	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
THYM	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-5.39	5.28e-07	0.000634	-0.53	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-5.39	5.28e-07	0.000634	-0.53	-0.49	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
THYM	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-5.39	5.29e-07	0.000634	-0.43	-0.49	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
THYM	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-5.39	5.29e-07	0.000634	-0.36	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	5.39	5.29e-07	0.000635	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	5.39	5.29e-07	0.000635	0.36	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
THYM	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-5.39	5.3e-07	0.000635	-0.5	-0.49	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-5.39	5.3e-07	0.000635	-0.5	-0.49	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
THYM	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-5.39	5.32e-07	0.000637	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-5.39	5.32e-07	0.000637	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-5.39	5.32e-07	0.000637	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-5.39	5.32e-07	0.000637	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-5.39	5.32e-07	0.000637	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	5.39	5.32e-07	0.000637	0.58	0.49	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	5.39	5.32e-07	0.000637	0.58	0.49	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	5.39	5.32e-07	0.000637	0.58	0.49	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	5.39	5.32e-07	0.000637	0.58	0.49	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	5.39	5.32e-07	0.000637	0.58	0.49	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
THYM	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-5.39	5.32e-07	0.000637	-0.5	-0.49	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
THYM	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-5.38	5.34e-07	0.000639	-0.7	-0.49	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
THYM	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	5.38	5.35e-07	0.00064	0.39	0.49	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
THYM	cis	rs11157436	0.918	rs12433895	ENSG00000211813.2	TRAV34	5.38	5.35e-07	0.000641	0.35	0.49	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154577	chr14:22207522~22208129:+
THYM	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	5.38	5.37e-07	0.000642	0.57	0.49	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	5.38	5.37e-07	0.000642	0.57	0.49	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	5.38	5.37e-07	0.000642	0.57	0.49	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	5.38	5.37e-07	0.000642	0.57	0.49	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	5.38	5.37e-07	0.000642	0.57	0.49	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
THYM	cis	rs6782228	0.585	rs6774515	ENSG00000277250.1	Metazoa_SRP	-5.38	5.37e-07	0.000642	-0.63	-0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.565	rs12695509	ENSG00000277250.1	Metazoa_SRP	-5.38	5.37e-07	0.000642	-0.63	-0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.565	rs11719239	ENSG00000277250.1	Metazoa_SRP	-5.38	5.37e-07	0.000642	-0.63	-0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs2001950	ENSG00000277250.1	Metazoa_SRP	-5.38	5.37e-07	0.000642	-0.63	-0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128673681~128674021:-
THYM	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	5.38	5.39e-07	0.000644	0.47	0.49	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-5.38	5.39e-07	0.000644	-0.47	-0.49	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
THYM	cis	rs7182621	0.622	rs12904160	ENSG00000182397.13	DNM1P46	5.38	5.39e-07	0.000644	0.53	0.49	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99790156~99806927:-
THYM	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-5.38	5.4e-07	0.000645	-0.64	-0.49	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-5.38	5.4e-07	0.000645	-0.64	-0.49	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
THYM	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	5.38	5.41e-07	0.000645	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
THYM	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-5.38	5.42e-07	0.000646	-0.5	-0.49	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
THYM	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-5.38	5.42e-07	0.000646	-0.59	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
THYM	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-5.38	5.42e-07	0.000646	-0.59	-0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	5.38	5.42e-07	0.000646	0.59	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
THYM	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-5.38	5.44e-07	0.000648	-0.86	-0.49	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
THYM	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	5.38	5.46e-07	0.000651	0.6	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
THYM	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	5.38	5.48e-07	0.000652	0.46	0.49	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
THYM	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	5.38	5.49e-07	0.000653	0.41	0.49	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
THYM	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-5.38	5.49e-07	0.000653	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-5.38	5.49e-07	0.000653	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-5.38	5.49e-07	0.000653	-0.46	-0.49	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
THYM	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	5.38	5.5e-07	0.000654	0.76	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
THYM	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	5.38	5.51e-07	0.000656	0.59	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
THYM	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	5.38	5.53e-07	0.000657	0.36	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	5.38	5.53e-07	0.000657	0.36	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
THYM	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-5.38	5.53e-07	0.000658	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
THYM	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-5.38	5.53e-07	0.000658	-0.56	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
THYM	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	5.38	5.53e-07	0.000658	0.56	0.48	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
THYM	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-5.38	5.54e-07	0.000658	-0.64	-0.48	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
THYM	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-5.38	5.54e-07	0.000658	-0.64	-0.48	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
THYM	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-5.38	5.55e-07	0.000659	-0.53	-0.48	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
THYM	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-5.37	5.57e-07	0.000661	-0.35	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
THYM	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	5.37	5.57e-07	0.000661	0.44	0.48	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
THYM	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-5.37	5.59e-07	0.000663	-0.71	-0.48	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
THYM	cis	rs904251	0.504	rs9380677	ENSG00000227920.2	RP1-153P14.5	-5.37	5.59e-07	0.000663	-0.65	-0.48	Cognitive performance;	chr6:37512590	chr6:37545145~37550860:+
THYM	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	5.37	5.6e-07	0.000663	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
THYM	cis	rs13256369	0.762	rs13278972	ENSG00000253893.2	FAM85B	-5.37	5.61e-07	0.000664	-0.66	-0.48	Obesity-related traits;	chr8:8739670	chr8:8167819~8226614:-
THYM	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-5.37	5.62e-07	0.000665	-0.46	-0.48	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-5.37	5.62e-07	0.000665	-0.46	-0.48	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
THYM	cis	rs904251	0.507	rs11756941	ENSG00000204110.6	RP1-153P14.8	-5.37	5.62e-07	0.000665	-0.78	-0.48	Cognitive performance;	chr6:37448443	chr6:37507348~37535616:+
THYM	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	5.37	5.62e-07	0.000666	0.54	0.48	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
THYM	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-5.37	5.64e-07	0.000667	-0.46	-0.48	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
THYM	cis	rs7927592	0.546	rs497261	ENSG00000212093.1	AP000807.1	5.37	5.67e-07	0.000671	0.42	0.48	Total body bone mineral density;	chr11:68424776	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.546	rs599083	ENSG00000212093.1	AP000807.1	5.37	5.67e-07	0.000671	0.42	0.48	Total body bone mineral density;	chr11:68424878	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.546	rs683978	ENSG00000212093.1	AP000807.1	5.37	5.67e-07	0.000671	0.42	0.48	Total body bone mineral density;	chr11:68424953	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.546	rs554734	ENSG00000212093.1	AP000807.1	5.37	5.67e-07	0.000671	0.42	0.48	Total body bone mineral density;	chr11:68425050	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	5.37	5.67e-07	0.000671	0.42	0.48	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
THYM	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-5.37	5.71e-07	0.000675	-0.53	-0.48	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
THYM	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	5.37	5.72e-07	0.000676	0.59	0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
THYM	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-5.37	5.73e-07	0.000677	-0.58	-0.48	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
THYM	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	5.37	5.73e-07	0.000677	0.44	0.48	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
THYM	cis	rs13256369	1	rs9329166	ENSG00000253893.2	FAM85B	-5.37	5.74e-07	0.000678	-0.66	-0.48	Obesity-related traits;	chr8:8719145	chr8:8167819~8226614:-
THYM	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	5.37	5.75e-07	0.000679	0.43	0.48	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
THYM	cis	rs1550115	0.524	rs113939247	ENSG00000271936.1	RP11-443B20.1	-5.37	5.76e-07	0.00068	-0.39	-0.48	Coronary artery disease;	chr2:24806310	chr2:24825610~24826717:+
THYM	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-5.37	5.78e-07	0.000682	-0.52	-0.48	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
THYM	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	5.37	5.78e-07	0.000682	0.52	0.48	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
THYM	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	5.37	5.79e-07	0.000683	0.57	0.48	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
THYM	cis	rs995834	0.622	rs4805188	ENSG00000260725.1	AC005307.1	-5.37	5.79e-07	0.000683	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400780	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs4806363	ENSG00000260725.1	AC005307.1	-5.37	5.79e-07	0.000683	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400810	chr19:28418483~28429490:-
THYM	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	5.36	5.8e-07	0.000684	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
THYM	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	5.36	5.81e-07	0.000685	0.62	0.48	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
THYM	cis	rs2283792	0.846	rs240049	ENSG00000224086.5	LL22NC03-86G7.1	-5.36	5.82e-07	0.000686	-0.44	-0.48	Multiple sclerosis;	chr22:21906236	chr22:21938293~21977632:+
THYM	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	5.36	5.82e-07	0.000686	0.66	0.48	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	5.36	5.82e-07	0.000686	0.66	0.48	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
THYM	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	5.36	5.82e-07	0.000686	0.66	0.48	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	5.36	5.82e-07	0.000686	0.66	0.48	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	5.36	5.82e-07	0.000686	0.66	0.48	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
THYM	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	5.36	5.83e-07	0.000688	0.44	0.48	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
THYM	cis	rs10129255	0.544	rs61997583	ENSG00000254329.1	IGHVII-60-1	5.36	5.87e-07	0.000689	0.48	0.48	Kawasaki disease;	chr14:106654351	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.585	rs2008440	ENSG00000254329.1	IGHVII-60-1	5.36	5.87e-07	0.000689	0.48	0.48	Kawasaki disease;	chr14:106654988	chr14:106637718~106637973:-
THYM	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	5.36	5.88e-07	0.000689	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
THYM	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-5.36	5.88e-07	0.000689	-0.74	-0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
THYM	cis	rs11577318	0.579	rs11548246	ENSG00000225854.2	RP11-569G9.7	-5.36	5.9e-07	0.000689	-0.68	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26370675	chr1:26326688~26327033:+
THYM	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-5.36	5.9e-07	0.00069	-0.39	-0.48	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-5.36	5.9e-07	0.00069	-0.39	-0.48	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-5.36	5.9e-07	0.00069	-0.39	-0.48	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-5.36	5.9e-07	0.00069	-0.39	-0.48	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-5.36	5.9e-07	0.00069	-0.39	-0.48	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	5.36	5.9e-07	0.00069	0.39	0.48	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	5.36	5.9e-07	0.00069	0.39	0.48	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	5.36	5.9e-07	0.00069	0.39	0.48	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	5.36	5.9e-07	0.00069	0.39	0.48	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	5.36	5.9e-07	0.00069	0.39	0.48	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	5.36	5.9e-07	0.00069	0.39	0.48	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
THYM	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-5.36	5.9e-07	0.00069	-0.73	-0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
THYM	cis	rs11157436	0.958	rs3811277	ENSG00000211813.2	TRAV34	5.36	5.9e-07	0.00069	0.39	0.48	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22207522~22208129:+
THYM	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	5.36	5.93e-07	0.000693	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
THYM	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	5.36	5.94e-07	0.000694	0.45	0.48	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
THYM	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-5.36	5.94e-07	0.000694	-0.69	-0.48	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
THYM	cis	rs75422866	0.85	rs73111226	ENSG00000257433.4	RP1-197B17.3	5.36	5.95e-07	0.000695	0.94	0.48	Pneumonia;	chr12:47582204	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.702	rs12426387	ENSG00000257433.4	RP1-197B17.3	5.36	5.95e-07	0.000695	0.94	0.48	Pneumonia;	chr12:47582915	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.85	rs12423789	ENSG00000257433.4	RP1-197B17.3	5.36	5.95e-07	0.000695	0.94	0.48	Pneumonia;	chr12:47583112	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.702	rs73111229	ENSG00000257433.4	RP1-197B17.3	5.36	5.95e-07	0.000695	0.94	0.48	Pneumonia;	chr12:47583333	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.85	rs73111231	ENSG00000257433.4	RP1-197B17.3	5.36	5.95e-07	0.000695	0.94	0.48	Pneumonia;	chr12:47584539	chr12:47706085~47742294:+
THYM	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-5.36	5.96e-07	0.000696	-0.64	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-5.36	5.96e-07	0.000696	-0.64	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
THYM	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.36	5.97e-07	0.000696	0.43	0.48	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
THYM	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-5.36	5.97e-07	0.000697	-0.64	-0.48	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
THYM	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-5.36	5.97e-07	0.000697	-0.64	-0.48	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
THYM	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	5.36	5.99e-07	0.000698	1.04	0.48	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
THYM	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	5.36	5.99e-07	0.000699	0.65	0.48	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
THYM	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-5.36	6.01e-07	7e-04	-0.56	-0.48	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
THYM	cis	rs995834	0.622	rs10424022	ENSG00000260725.1	AC005307.1	-5.36	6.04e-07	0.000704	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401351	chr19:28418483~28429490:-
THYM	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-5.35	6.05e-07	0.000705	-0.49	-0.48	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
THYM	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	5.35	6.06e-07	0.000706	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
THYM	cis	rs3738443	0.645	rs11811599	ENSG00000227671.4	RP11-488L18.4	-5.35	6.06e-07	0.000706	-0.28	-0.48	Alcohol dependence;	chr1:247203133	chr1:247189851~247210856:-
THYM	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-5.35	6.07e-07	0.000707	-0.6	-0.48	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
THYM	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-5.35	6.1e-07	0.00071	-0.55	-0.48	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
THYM	cis	rs1560104	0.597	rs4781299	ENSG00000259899.1	CTD-3037G24.3	-5.35	6.1e-07	0.00071	-0.59	-0.48	Obesity-related traits;	chr16:12613756	chr16:12560756~12611044:-
THYM	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	5.35	6.17e-07	0.000718	0.91	0.48	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	5.35	6.17e-07	0.000718	0.91	0.48	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
THYM	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-5.35	6.17e-07	0.000718	-0.34	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	5.35	6.17e-07	0.000718	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
THYM	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	5.35	6.17e-07	0.000718	0.5	0.48	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
THYM	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	5.35	6.2e-07	0.00072	0.63	0.48	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
THYM	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	5.35	6.2e-07	0.00072	0.39	0.48	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
THYM	cis	rs9907295	0.591	rs2107538	ENSG00000270977.1	AC015849.16	-5.35	6.2e-07	0.00072	-0.57	-0.48	Fibroblast growth factor basic levels;	chr17:35880776	chr17:35893707~35911023:-
THYM	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-5.35	6.2e-07	0.00072	-0.49	-0.48	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
THYM	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	5.35	6.21e-07	0.00072	0.63	0.48	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
THYM	cis	rs17772222	0.63	rs2778936	ENSG00000258983.2	RP11-507K2.2	-5.35	6.21e-07	0.000721	-0.53	-0.48	Coronary artery calcification;	chr14:88505959	chr14:88499334~88515502:+
THYM	cis	rs904251	0.523	rs10947675	ENSG00000227920.2	RP1-153P14.5	-5.35	6.22e-07	0.000722	-0.64	-0.48	Cognitive performance;	chr6:37512196	chr6:37545145~37550860:+
THYM	cis	rs7702057	0.53	rs4921060	ENSG00000271918.1	CTD-2287O16.5	5.35	6.23e-07	0.000723	0.78	0.48	Amyotrophic lateral sclerosis;	chr5:116109004	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs58510083	ENSG00000271918.1	CTD-2287O16.5	5.35	6.23e-07	0.000723	0.78	0.48	Amyotrophic lateral sclerosis;	chr5:116109101	chr5:116083807~116085416:-
THYM	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	5.35	6.23e-07	0.000723	0.46	0.48	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	5.35	6.23e-07	0.000723	0.46	0.48	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	5.35	6.23e-07	0.000723	0.46	0.48	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	5.35	6.23e-07	0.000723	0.46	0.48	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
THYM	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	5.35	6.23e-07	0.000723	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
THYM	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-5.35	6.24e-07	0.000724	-0.49	-0.48	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
THYM	cis	rs1426063	0.858	rs11931653	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75080856	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs55775471	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75081074	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs9990627	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75081244	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs10026994	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75081551	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs6830936	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75083952	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs11936768	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75084506	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs72662426	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75084828	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs6823982	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75084961	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs6837969	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75085005	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs6843217	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75085201	chr4:74955974~74970362:-
THYM	cis	rs1426063	0.858	rs7666182	ENSG00000249717.1	RP11-44F21.3	5.35	6.26e-07	0.000726	1.01	0.48	QT interval;	chr4:75090989	chr4:74955974~74970362:-
THYM	cis	rs995834	0.789	rs11083486	ENSG00000267243.4	AC005307.3	-5.35	6.29e-07	0.000729	-0.45	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407449	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs10421826	ENSG00000267243.4	AC005307.3	-5.35	6.29e-07	0.000729	-0.45	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28408275	chr19:28435388~28727777:-
THYM	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-5.34	6.35e-07	0.000735	-0.64	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-5.34	6.35e-07	0.000735	-0.64	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-5.34	6.35e-07	0.000735	-0.64	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
THYM	cis	rs12439619	0.921	rs4778672	ENSG00000274376.3	ADAMTS7P1	-5.34	6.36e-07	0.000735	-0.49	-0.48	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82298553~82334609:+
THYM	cis	rs950169	0.92	rs11637666	ENSG00000235370.6	DNM1P51	5.34	6.36e-07	0.000736	0.64	0.48	Schizophrenia;	chr15:84035122	chr15:84398316~84411701:-
THYM	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-5.34	6.46e-07	0.000745	-0.59	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
THYM	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-5.34	6.46e-07	0.000746	-0.41	-0.48	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-5.34	6.46e-07	0.000746	-0.41	-0.48	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	5.34	6.46e-07	0.000746	0.41	0.48	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
THYM	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	5.34	6.46e-07	0.000746	0.64	0.48	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
THYM	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-5.34	6.47e-07	0.000746	-0.43	-0.48	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
THYM	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	5.34	6.48e-07	0.000747	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
THYM	cis	rs1155848	0.803	rs61966637	ENSG00000227354.5	RBM26-AS1	5.34	6.48e-07	0.000747	0.8	0.48	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79327074	chr13:79406309~79424328:+
THYM	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-5.34	6.48e-07	0.000747	-0.5	-0.48	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
THYM	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-5.34	6.48e-07	0.000747	-0.5	-0.48	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
THYM	cis	rs2562456	0.833	rs516519	ENSG00000268081.1	RP11-678G14.2	-5.34	6.53e-07	0.000752	-0.66	-0.48	Pain;	chr19:21298730	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs552800	ENSG00000268081.1	RP11-678G14.2	-5.34	6.53e-07	0.000752	-0.66	-0.48	Pain;	chr19:21301840	chr19:21554640~21569237:-
THYM	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-5.34	6.56e-07	0.000755	-0.43	-0.48	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
THYM	cis	rs10829156	0.732	rs10828834	ENSG00000240291.1	RP11-499P20.2	5.34	6.56e-07	0.000756	0.43	0.48	Sudden cardiac arrest;	chr10:18523505	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.732	rs7100884	ENSG00000240291.1	RP11-499P20.2	5.34	6.56e-07	0.000756	0.43	0.48	Sudden cardiac arrest;	chr10:18523768	chr10:18513115~18545651:-
THYM	cis	rs4663866	0.803	rs77594519	ENSG00000186235.9	AC016757.3	5.34	6.57e-07	0.000756	1.07	0.48	Irritable bowel syndrome;	chr2:238223917	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs35648651	ENSG00000186235.9	AC016757.3	5.34	6.57e-07	0.000756	1.07	0.48	Irritable bowel syndrome;	chr2:238225202	chr2:238224552~238231677:-
THYM	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-5.34	6.58e-07	0.000757	-0.43	-0.48	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
THYM	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	5.34	6.58e-07	0.000757	0.54	0.48	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
THYM	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	5.33	6.58e-07	0.000758	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
THYM	cis	rs4273100	1	rs16960499	ENSG00000228157.4	AC007952.5	5.33	6.59e-07	0.000759	0.75	0.48	Schizophrenia;	chr17:19299719	chr17:19092974~19096837:+
THYM	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
THYM	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
THYM	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
THYM	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	5.33	6.61e-07	0.00076	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-5.33	6.61e-07	0.00076	-0.64	-0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
THYM	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	5.33	6.61e-07	0.00076	0.39	0.48	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	5.33	6.61e-07	0.00076	0.39	0.48	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	5.33	6.61e-07	0.00076	0.39	0.48	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	5.33	6.61e-07	0.00076	0.39	0.48	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
THYM	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	5.33	6.61e-07	0.00076	0.61	0.48	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
THYM	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	5.33	6.61e-07	0.00076	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	5.33	6.61e-07	0.00076	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	5.33	6.61e-07	0.00076	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	5.33	6.62e-07	0.000761	0.46	0.48	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
THYM	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	5.33	6.64e-07	0.000763	0.49	0.48	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
THYM	cis	rs13256369	0.851	rs13267036	ENSG00000253893.2	FAM85B	-5.33	6.67e-07	0.000766	-0.68	-0.48	Obesity-related traits;	chr8:8709175	chr8:8167819~8226614:-
THYM	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	5.33	6.68e-07	0.000767	0.66	0.48	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
THYM	cis	rs9535495	0.93	rs2061624	ENSG00000200711.1	RNA5SP28	-5.33	6.68e-07	0.000767	-0.56	-0.48	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50813404	chr13:50812988~50813106:-
THYM	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-5.33	6.7e-07	0.000769	-0.56	-0.48	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-5.33	6.7e-07	0.000769	-0.56	-0.48	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	5.33	6.7e-07	0.000769	0.56	0.48	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
THYM	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	5.33	6.73e-07	0.000772	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	5.33	6.73e-07	0.000772	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
THYM	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	5.33	6.73e-07	0.000772	0.45	0.48	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
THYM	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	5.33	6.74e-07	0.000772	0.43	0.48	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
THYM	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-5.33	6.76e-07	0.000775	-0.36	-0.48	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
THYM	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	5.33	6.76e-07	0.000775	0.62	0.48	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
THYM	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	5.33	6.76e-07	0.000775	0.43	0.48	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	5.33	6.76e-07	0.000775	0.43	0.48	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	5.33	6.76e-07	0.000775	0.43	0.48	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	5.33	6.76e-07	0.000775	0.43	0.48	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	5.33	6.76e-07	0.000775	0.43	0.48	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
THYM	cis	rs7927592	0.513	rs531163	ENSG00000222339.1	AP000807.2	5.33	6.77e-07	0.000775	0.53	0.48	Total body bone mineral density;	chr11:68427028	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.513	rs630225	ENSG00000222339.1	AP000807.2	5.33	6.77e-07	0.000775	0.53	0.48	Total body bone mineral density;	chr11:68427143	chr11:68505572~68505651:-
THYM	cis	rs525592	1	rs525592	ENSG00000222339.1	AP000807.2	5.33	6.77e-07	0.000775	0.53	0.48	Bone mineral density;	chr11:68427636	chr11:68505572~68505651:-
THYM	cis	rs13256369	1	rs10098234	ENSG00000253893.2	FAM85B	-5.33	6.77e-07	0.000776	-0.67	-0.48	Obesity-related traits;	chr8:8719182	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs10088439	ENSG00000253893.2	FAM85B	-5.33	6.77e-07	0.000776	-0.67	-0.48	Obesity-related traits;	chr8:8719189	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs4841017	ENSG00000253893.2	FAM85B	-5.33	6.77e-07	0.000776	-0.67	-0.48	Obesity-related traits;	chr8:8719583	chr8:8167819~8226614:-
THYM	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	5.33	6.77e-07	0.000776	0.42	0.48	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
THYM	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	5.33	6.78e-07	0.000777	0.58	0.48	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
THYM	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-5.33	6.78e-07	0.000777	-0.52	-0.48	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
THYM	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	5.33	6.79e-07	0.000777	0.69	0.48	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
THYM	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	5.33	6.79e-07	0.000777	0.69	0.48	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
THYM	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	5.33	6.79e-07	0.000777	0.69	0.48	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
THYM	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	5.33	6.79e-07	0.000777	0.69	0.48	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
THYM	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	5.33	6.79e-07	0.000777	0.69	0.48	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
THYM	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	5.33	6.79e-07	0.000777	0.69	0.48	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
THYM	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	5.33	6.79e-07	0.000778	0.57	0.48	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
THYM	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-5.33	6.8e-07	0.000778	-0.57	-0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
THYM	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-5.33	6.8e-07	0.000778	-0.57	-0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
THYM	cis	rs7829975	0.542	rs7844374	ENSG00000253893.2	FAM85B	5.33	6.8e-07	0.000779	0.58	0.48	Mood instability;	chr8:8941174	chr8:8167819~8226614:-
THYM	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-5.33	6.8e-07	0.000779	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
THYM	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	5.33	6.82e-07	0.000781	0.55	0.48	Height;	chr6:109546439	chr6:109382795~109383666:+
THYM	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	5.33	6.82e-07	0.000781	0.55	0.48	Height;	chr6:109551060	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	5.33	6.82e-07	0.000781	0.55	0.48	Height;	chr6:109558247	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	5.33	6.82e-07	0.000781	0.55	0.48	Height;	chr6:109564443	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	5.33	6.82e-07	0.000781	0.55	0.48	Height;	chr6:109571489	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	5.33	6.82e-07	0.000781	0.55	0.48	Height;	chr6:109576414	chr6:109382795~109383666:+
THYM	cis	rs973796	0.966	rs62334742	ENSG00000236296.6	GUSBP5	5.33	6.84e-07	0.000783	0.57	0.48	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:144459481	chr4:143559472~143649305:+
THYM	cis	rs973796	0.966	rs1505770	ENSG00000236296.6	GUSBP5	5.33	6.84e-07	0.000783	0.57	0.48	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:144459650	chr4:143559472~143649305:+
THYM	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	5.32	6.86e-07	0.000785	0.84	0.48	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
THYM	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	5.32	6.88e-07	0.000787	0.58	0.48	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	5.32	6.88e-07	0.000787	0.58	0.48	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
THYM	cis	rs28785552	0.769	rs11669363	ENSG00000250731.1	TPM3P6	-5.32	6.91e-07	0.00079	-0.66	-0.48	Response to paliperidone in schizophrenia (PANSS score);	chr19:52729068	chr19:53479350~53480091:+
THYM	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	5.32	6.91e-07	0.00079	0.75	0.48	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
THYM	cis	rs995834	0.622	rs8102417	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397409	chr19:28418483~28429490:-
THYM	cis	rs995834	0.704	rs4806358	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397907	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs4806359	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398042	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs7252140	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398110	chr19:28418483~28429490:-
THYM	cis	rs995834	0.663	rs7252145	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398119	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs4806360	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398277	chr19:28418483~28429490:-
THYM	cis	rs995834	0.585	rs1558121	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398522	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs2159075	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398551	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs2079593	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398973	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs1558122	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399320	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs1558123	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399355	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs7257975	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399556	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs7246622	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399578	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs7258662	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400902	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs7246754	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400913	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs4806368	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402133	chr19:28418483~28429490:-
THYM	cis	rs995834	0.622	rs4806369	ENSG00000260725.1	AC005307.1	-5.32	6.93e-07	0.000792	-0.51	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402569	chr19:28418483~28429490:-
THYM	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	5.32	6.95e-07	0.000794	0.47	0.48	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	5.32	6.95e-07	0.000794	0.47	0.48	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	5.32	6.95e-07	0.000794	0.47	0.48	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	5.32	6.95e-07	0.000794	0.47	0.48	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
THYM	cis	rs3740713	0.669	rs34740438	ENSG00000256464.1	YWHABP2	5.32	6.95e-07	0.000794	0.84	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr11:18490243~18490955:-
THYM	cis	rs995834	0.664	rs1476762	ENSG00000260725.1	AC005307.1	-5.32	6.96e-07	0.000795	-0.49	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394427	chr19:28418483~28429490:-
THYM	cis	rs950169	0.959	rs12902070	ENSG00000235370.6	DNM1P51	5.32	6.97e-07	0.000796	0.61	0.48	Schizophrenia;	chr15:84124806	chr15:84398316~84411701:-
THYM	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	5.32	6.97e-07	0.000796	0.49	0.48	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
THYM	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	5.32	6.98e-07	0.000796	0.55	0.48	Height;	chr6:109507364	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	5.32	6.98e-07	0.000796	0.55	0.48	Height;	chr6:109507366	chr6:109382795~109383666:+
THYM	cis	rs7927592	0.546	rs497261	ENSG00000222339.1	AP000807.2	5.32	6.98e-07	0.000797	0.53	0.48	Total body bone mineral density;	chr11:68424776	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.546	rs599083	ENSG00000222339.1	AP000807.2	5.32	6.98e-07	0.000797	0.53	0.48	Total body bone mineral density;	chr11:68424878	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.546	rs683978	ENSG00000222339.1	AP000807.2	5.32	6.98e-07	0.000797	0.53	0.48	Total body bone mineral density;	chr11:68424953	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.546	rs554734	ENSG00000222339.1	AP000807.2	5.32	6.98e-07	0.000797	0.53	0.48	Total body bone mineral density;	chr11:68425050	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.513	rs3853616	ENSG00000222339.1	AP000807.2	5.32	6.98e-07	0.000797	0.53	0.48	Total body bone mineral density;	chr11:68430784	chr11:68505572~68505651:-
THYM	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-5.32	6.99e-07	0.000797	-0.46	-0.48	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
THYM	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-5.32	7e-07	0.000799	-0.4	-0.48	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
THYM	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	5.32	7.01e-07	8e-04	0.81	0.48	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	5.32	7.01e-07	8e-04	0.81	0.48	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	5.32	7.01e-07	8e-04	0.81	0.48	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
THYM	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-5.32	7.02e-07	0.000801	-0.63	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-5.32	7.02e-07	0.000801	-0.63	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-5.32	7.02e-07	0.000801	-0.63	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	5.32	7.02e-07	0.000801	0.63	0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-5.32	7.02e-07	0.000801	-0.63	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-5.32	7.02e-07	0.000801	-0.63	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-5.32	7.02e-07	0.000801	-0.63	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-5.32	7.02e-07	0.000801	-0.63	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
THYM	cis	rs4948275	0.53	rs2139778	ENSG00000237233.2	TMEM26-AS1	5.32	7.03e-07	0.000801	0.51	0.48	Night sleep phenotypes;	chr10:61375185	chr10:61452639~61481956:+
THYM	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	5.32	7.03e-07	0.000801	0.36	0.48	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	5.32	7.03e-07	0.000801	0.36	0.48	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	5.32	7.03e-07	0.000801	0.36	0.48	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	5.32	7.03e-07	0.000801	0.36	0.48	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	5.32	7.03e-07	0.000801	0.36	0.48	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	5.32	7.03e-07	0.000801	0.36	0.48	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
THYM	cis	rs1560104	0.597	rs4780468	ENSG00000259899.1	CTD-3037G24.3	-5.32	7.04e-07	0.000802	-0.55	-0.48	Obesity-related traits;	chr16:12620390	chr16:12560756~12611044:-
THYM	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	5.32	7.05e-07	0.000803	0.36	0.48	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
THYM	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	5.32	7.05e-07	0.000803	0.36	0.48	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
THYM	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	5.32	7.05e-07	0.000803	0.36	0.48	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
THYM	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	5.32	7.09e-07	0.000807	0.59	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
THYM	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	5.32	7.09e-07	0.000807	0.59	0.48	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
THYM	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	5.32	7.09e-07	0.000807	0.59	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
THYM	cis	rs995834	0.957	rs8105942	ENSG00000267243.4	AC005307.3	-5.32	7.09e-07	0.000807	-0.42	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28359455	chr19:28435388~28727777:-
THYM	cis	rs7208859	0.623	rs9906957	ENSG00000266490.1	CTD-2349P21.9	5.32	7.1e-07	0.000809	0.84	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9915139	ENSG00000266490.1	CTD-2349P21.9	5.32	7.1e-07	0.000809	0.84	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30792372~30792833:+
THYM	cis	rs17391705	1	rs2216601	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94767939	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs114151147	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94770530	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs111531074	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94770632	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs17391069	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94770859	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs17331879	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94770970	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs1394599	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94771461	chr5:94825961~94826694:-
THYM	cis	rs17391705	1	rs12109605	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94778822	chr5:94825961~94826694:-
THYM	cis	rs17391705	0.744	rs77587867	ENSG00000243806.1	RPL7P18	5.32	7.12e-07	0.00081	1.03	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94778881	chr5:94825961~94826694:-
THYM	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	5.32	7.13e-07	0.000811	0.52	0.48	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
THYM	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-5.32	7.13e-07	0.000812	-0.73	-0.48	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
THYM	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-5.32	7.13e-07	0.000812	-0.38	-0.48	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
THYM	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	5.32	7.15e-07	0.000813	0.51	0.48	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
THYM	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	5.32	7.15e-07	0.000813	0.51	0.48	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
THYM	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	5.32	7.15e-07	0.000814	0.52	0.48	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
THYM	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	5.31	7.18e-07	0.000817	0.36	0.48	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
THYM	cis	rs7702057	0.53	rs56953556	ENSG00000271918.1	CTD-2287O16.5	5.31	7.21e-07	0.000819	0.73	0.48	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116083807~116085416:-
THYM	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-5.31	7.22e-07	0.00082	-0.72	-0.48	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-5.31	7.22e-07	0.00082	-0.72	-0.48	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-5.31	7.22e-07	0.00082	-0.72	-0.48	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
THYM	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-5.31	7.22e-07	0.000821	-0.62	-0.48	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
THYM	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	5.31	7.28e-07	0.000826	0.55	0.48	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
THYM	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-5.31	7.28e-07	0.000826	-0.86	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
THYM	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-5.31	7.28e-07	0.000826	-0.86	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
THYM	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-5.31	7.28e-07	0.000826	-0.86	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
THYM	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-5.31	7.28e-07	0.000826	-0.86	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
THYM	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-5.31	7.28e-07	0.000826	-0.86	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
THYM	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-5.31	7.28e-07	0.000826	-0.86	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
THYM	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-5.31	7.28e-07	0.000826	-0.86	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
THYM	cis	rs7702057	0.53	rs1129495	ENSG00000271918.1	CTD-2287O16.5	5.31	7.29e-07	0.000827	0.79	0.48	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs61105089	ENSG00000271918.1	CTD-2287O16.5	5.31	7.29e-07	0.000827	0.79	0.48	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs2136213	ENSG00000271918.1	CTD-2287O16.5	5.31	7.29e-07	0.000827	0.79	0.48	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs61672521	ENSG00000271918.1	CTD-2287O16.5	5.31	7.29e-07	0.000827	0.79	0.48	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116083807~116085416:-
THYM	cis	rs12682352	0.652	rs3789843	ENSG00000253893.2	FAM85B	-5.31	7.3e-07	0.000828	-0.61	-0.48	Neuroticism;	chr8:8866747	chr8:8167819~8226614:-
THYM	cis	rs12682352	0.652	rs3827806	ENSG00000253893.2	FAM85B	-5.31	7.3e-07	0.000828	-0.61	-0.48	Neuroticism;	chr8:8866766	chr8:8167819~8226614:-
THYM	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-5.31	7.3e-07	0.000828	-0.43	-0.48	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
THYM	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	5.31	7.35e-07	0.000833	0.4	0.48	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
THYM	cis	rs2562456	0.833	rs2928211	ENSG00000268081.1	RP11-678G14.2	-5.31	7.35e-07	0.000833	-0.66	-0.48	Pain;	chr19:21358495	chr19:21554640~21569237:-
THYM	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-5.31	7.36e-07	0.000835	-0.68	-0.48	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
THYM	cis	rs5769707	0.967	rs2051626	ENSG00000264139.1	MIR3667	-5.31	7.37e-07	0.000835	-0.55	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49543393~49543466:-
THYM	cis	rs2834288	0.5	rs881231	ENSG00000237945.6	LINC00649	5.31	7.37e-07	0.000835	0.39	0.48	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33915534~33977691:+
THYM	cis	rs2562456	0.793	rs2562474	ENSG00000268081.1	RP11-678G14.2	-5.31	7.37e-07	0.000835	-0.65	-0.48	Pain;	chr19:21463480	chr19:21554640~21569237:-
THYM	cis	rs673078	0.66	rs7301950	ENSG00000275409.1	RP11-131L12.4	-5.31	7.38e-07	0.000836	-0.71	-0.48	Glucose homeostasis traits;	chr12:118170634	chr12:118430147~118430699:+
THYM	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	5.31	7.39e-07	0.000837	0.53	0.48	Height;	chr6:109741670	chr6:109382795~109383666:+
THYM	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	5.31	7.39e-07	0.000837	0.59	0.48	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
THYM	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	5.31	7.39e-07	0.000837	0.87	0.48	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
THYM	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	5.31	7.41e-07	0.000838	0.47	0.48	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
THYM	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	5.31	7.41e-07	0.000839	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
THYM	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-5.31	7.42e-07	0.000839	-0.38	-0.48	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
THYM	cis	rs950169	0.512	rs4374136	ENSG00000235370.6	DNM1P51	5.31	7.42e-07	0.00084	0.64	0.48	Schizophrenia;	chr15:83976255	chr15:84398316~84411701:-
THYM	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	5.31	7.43e-07	0.000841	0.54	0.48	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
THYM	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	5.31	7.46e-07	0.000843	0.43	0.48	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-5.31	7.46e-07	0.000843	-0.42	-0.48	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-5.31	7.46e-07	0.000843	-0.42	-0.48	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
THYM	cis	rs7560272	0.538	rs4852976	ENSG00000273245.1	RP11-434P11.2	-5.31	7.46e-07	0.000844	-0.56	-0.48	Schizophrenia;	chr2:73709195	chr2:73750256~73750786:-
THYM	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	5.31	7.46e-07	0.000844	0.5	0.48	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
THYM	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-5.31	7.47e-07	0.000844	-0.43	-0.48	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
THYM	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	5.3	7.48e-07	0.000846	0.57	0.48	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
THYM	cis	rs17772222	0.651	rs12586714	ENSG00000258983.2	RP11-507K2.2	5.3	7.49e-07	0.000846	0.54	0.48	Coronary artery calcification;	chr14:88360497	chr14:88499334~88515502:+
THYM	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	5.3	7.49e-07	0.000847	0.54	0.48	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
THYM	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	5.3	7.51e-07	0.000849	0.64	0.48	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
THYM	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-5.3	7.53e-07	0.000851	-0.6	-0.48	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
THYM	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	5.3	7.55e-07	0.000852	0.38	0.48	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
THYM	cis	rs11577318	0.537	rs12030833	ENSG00000225854.2	RP11-569G9.7	-5.3	7.55e-07	0.000852	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26362729	chr1:26326688~26327033:+
THYM	cis	rs11577318	0.579	rs10794532	ENSG00000225854.2	RP11-569G9.7	-5.3	7.55e-07	0.000852	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26367769	chr1:26326688~26327033:+
THYM	cis	rs11577318	0.579	rs11247934	ENSG00000225854.2	RP11-569G9.7	-5.3	7.55e-07	0.000852	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26369267	chr1:26326688~26327033:+
THYM	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	5.3	7.55e-07	0.000852	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	5.3	7.56e-07	0.000853	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
THYM	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	5.3	7.58e-07	0.000856	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	5.3	7.58e-07	0.000856	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
THYM	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	5.3	7.6e-07	0.000857	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
THYM	cis	rs17772222	0.636	rs3850390	ENSG00000258983.2	RP11-507K2.2	5.3	7.6e-07	0.000858	0.68	0.48	Coronary artery calcification;	chr14:88829185	chr14:88499334~88515502:+
THYM	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-5.3	7.61e-07	0.000858	-0.61	-0.48	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
THYM	cis	rs11157436	0.958	rs6572313	ENSG00000211813.2	TRAV34	5.3	7.62e-07	0.00086	0.37	0.48	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22207522~22208129:+
THYM	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-5.3	7.64e-07	0.000862	-0.6	-0.48	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
THYM	cis	rs950169	0.922	rs17531523	ENSG00000235370.6	DNM1P51	5.3	7.65e-07	0.000863	0.63	0.48	Schizophrenia;	chr15:84589218	chr15:84398316~84411701:-
THYM	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	5.3	7.67e-07	0.000864	0.57	0.48	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
THYM	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-5.3	7.69e-07	0.000866	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-5.3	7.69e-07	0.000866	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-5.3	7.69e-07	0.000866	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
THYM	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	5.3	7.69e-07	0.000866	0.96	0.48	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
THYM	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	5.3	7.69e-07	0.000866	0.96	0.48	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
THYM	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-5.3	7.69e-07	0.000866	-0.43	-0.48	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-5.3	7.69e-07	0.000866	-0.43	-0.48	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-5.3	7.69e-07	0.000866	-0.43	-0.48	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
THYM	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-5.3	7.69e-07	0.000866	-0.43	-0.48	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
THYM	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-5.3	7.73e-07	0.000869	-0.61	-0.48	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
THYM	cis	rs7927592	0.513	rs7950129	ENSG00000222339.1	AP000807.2	5.3	7.73e-07	0.000869	0.51	0.48	Total body bone mineral density;	chr11:68435435	chr11:68505572~68505651:-
THYM	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-5.3	7.78e-07	0.000875	-0.71	-0.48	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
THYM	cis	rs28785552	0.8	rs10853854	ENSG00000250731.1	TPM3P6	5.29	7.79e-07	0.000875	0.65	0.48	Response to paliperidone in schizophrenia (PANSS score);	chr19:52728875	chr19:53479350~53480091:+
THYM	cis	rs10129255	0.557	rs72622064	ENSG00000254329.1	IGHVII-60-1	5.29	7.79e-07	0.000876	0.48	0.48	Kawasaki disease;	chr14:106651784	chr14:106637718~106637973:-
THYM	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	5.29	7.8e-07	0.000876	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	5.29	7.8e-07	0.000876	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
THYM	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	5.29	7.8e-07	0.000876	0.84	0.48	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	5.29	7.8e-07	0.000876	0.84	0.48	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	5.29	7.8e-07	0.000876	0.84	0.48	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	5.29	7.8e-07	0.000876	0.84	0.48	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
THYM	cis	rs950169	0.92	rs34672825	ENSG00000235370.6	DNM1P51	5.29	7.81e-07	0.000877	0.64	0.48	Schizophrenia;	chr15:84034718	chr15:84398316~84411701:-
THYM	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-5.29	7.83e-07	0.000879	-0.58	-0.48	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
THYM	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	5.29	7.83e-07	0.000879	0.49	0.48	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
THYM	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	5.29	7.83e-07	0.000879	0.49	0.48	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
THYM	cis	rs17826219	0.568	rs59858012	ENSG00000266490.1	CTD-2349P21.9	5.29	7.84e-07	0.00088	0.96	0.48	Body mass index;	chr17:30751564	chr17:30792372~30792833:+
THYM	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	5.29	7.85e-07	0.000881	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	5.29	7.85e-07	0.000881	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	5.29	7.85e-07	0.000881	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	5.29	7.85e-07	0.000881	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
THYM	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	5.29	7.86e-07	0.000882	0.36	0.48	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
THYM	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	5.29	7.88e-07	0.000884	0.63	0.48	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
THYM	cis	rs3740713	0.669	rs2896526	ENSG00000256464.1	YWHABP2	5.29	7.91e-07	0.000887	0.82	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr11:18490243~18490955:-
THYM	cis	rs5769707	0.967	rs9616327	ENSG00000264139.1	MIR3667	-5.29	7.92e-07	0.000887	-0.55	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49543393~49543466:-
THYM	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	5.29	7.95e-07	0.00089	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-5.29	7.95e-07	0.000891	-0.35	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-5.29	7.95e-07	0.000891	-0.35	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-5.29	7.95e-07	0.000891	-0.35	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
THYM	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-5.29	7.95e-07	0.000891	-0.54	-0.48	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
THYM	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-5.29	7.95e-07	0.000891	-0.54	-0.48	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
THYM	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	5.29	7.95e-07	0.000891	0.54	0.48	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
THYM	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-5.29	7.96e-07	0.000891	-0.57	-0.48	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
THYM	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	5.29	7.98e-07	0.000894	0.63	0.48	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
THYM	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-5.29	8e-07	0.000896	-0.4	-0.48	Breast cancer;	chr11:743813	chr11:781645~782105:+
THYM	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	5.29	8.01e-07	0.000897	0.65	0.48	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
THYM	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	5.29	8.03e-07	0.000898	0.53	0.48	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
THYM	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	5.29	8.07e-07	0.000903	0.47	0.48	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
THYM	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	5.29	8.08e-07	0.000904	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
THYM	cis	rs9535495	0.931	rs1841676	ENSG00000200711.1	RNA5SP28	5.29	8.08e-07	0.000904	0.54	0.48	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50825622	chr13:50812988~50813106:-
THYM	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-5.29	8.08e-07	0.000904	-0.35	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
THYM	cis	rs995834	0.585	rs10404961	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28417370	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs10419520	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28419267	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs4806402	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420314	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs10419336	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420386	chr19:28435388~28727777:-
THYM	cis	rs995834	0.551	rs1558124	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28420672	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs10403634	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28422714	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs10409773	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423090	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs8101242	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423341	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs720924	ENSG00000267243.4	AC005307.3	-5.28	8.13e-07	0.000908	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424180	chr19:28435388~28727777:-
THYM	cis	rs13256369	0.95	rs13255655	ENSG00000253893.2	FAM85B	-5.28	8.17e-07	0.000913	-0.68	-0.48	Obesity-related traits;	chr8:8720226	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.853	rs13256216	ENSG00000253893.2	FAM85B	-5.28	8.17e-07	0.000913	-0.68	-0.48	Obesity-related traits;	chr8:8720373	chr8:8167819~8226614:-
THYM	cis	rs1560104	0.549	rs7201160	ENSG00000259899.1	CTD-3037G24.3	-5.28	8.18e-07	0.000913	-0.6	-0.48	Obesity-related traits;	chr16:12614022	chr16:12560756~12611044:-
THYM	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-5.28	8.18e-07	0.000914	-0.44	-0.48	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
THYM	cis	rs5760092	0.755	rs3884794	ENSG00000272787.1	KB-226F1.2	-5.28	8.19e-07	0.000915	-0.65	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23969211~23969873:+
THYM	cis	rs13256369	0.802	rs35382339	ENSG00000253893.2	FAM85B	-5.28	8.23e-07	0.000918	-0.68	-0.48	Obesity-related traits;	chr8:8701745	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs11781257	ENSG00000253893.2	FAM85B	-5.28	8.23e-07	0.000918	-0.68	-0.48	Obesity-related traits;	chr8:8702153	chr8:8167819~8226614:-
THYM	cis	rs4591358	0.569	rs6718998	ENSG00000223466.1	AC064834.2	-5.28	8.23e-07	0.000918	-0.68	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195578245	chr2:195533035~195538681:+
THYM	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	5.28	8.26e-07	0.000921	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	5.28	8.26e-07	0.000921	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
THYM	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-5.28	8.28e-07	0.000923	-0.33	-0.48	Height;	chr11:118809363	chr11:118791254~118793137:+
THYM	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
THYM	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
THYM	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	5.28	8.31e-07	0.000925	0.53	0.48	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
THYM	cis	rs995834	0.661	rs11882204	ENSG00000260725.1	AC005307.1	-5.28	8.35e-07	0.00093	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347263	chr19:28418483~28429490:-
THYM	cis	rs995834	0.661	rs8101988	ENSG00000260725.1	AC005307.1	-5.28	8.35e-07	0.00093	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348975	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs758507	ENSG00000260725.1	AC005307.1	-5.28	8.35e-07	0.00093	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350158	chr19:28418483~28429490:-
THYM	cis	rs995834	0.701	rs2903968	ENSG00000260725.1	AC005307.1	-5.28	8.35e-07	0.00093	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350613	chr19:28418483~28429490:-
THYM	cis	rs995834	0.701	rs8103281	ENSG00000260725.1	AC005307.1	-5.28	8.35e-07	0.00093	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358547	chr19:28418483~28429490:-
THYM	cis	rs995834	0.509	rs11666682	ENSG00000260725.1	AC005307.1	-5.28	8.35e-07	0.00093	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358650	chr19:28418483~28429490:-
THYM	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	5.28	8.36e-07	0.00093	0.53	0.48	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
THYM	cis	rs17772222	0.597	rs17700296	ENSG00000258983.2	RP11-507K2.2	5.28	8.38e-07	0.000932	0.68	0.48	Coronary artery calcification;	chr14:88840976	chr14:88499334~88515502:+
THYM	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	5.28	8.43e-07	0.000937	0.62	0.48	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
THYM	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	5.28	8.46e-07	0.00094	0.38	0.48	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
THYM	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	5.27	8.47e-07	0.000941	0.58	0.48	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
THYM	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	5.27	8.48e-07	0.000942	0.49	0.48	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	5.27	8.48e-07	0.000942	0.49	0.48	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
THYM	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	5.27	8.48e-07	0.000942	0.49	0.48	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	5.27	8.48e-07	0.000942	0.49	0.48	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
THYM	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	5.27	8.48e-07	0.000942	0.49	0.48	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	5.27	8.48e-07	0.000942	0.49	0.48	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
THYM	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	5.27	8.48e-07	0.000942	0.49	0.48	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
THYM	cis	rs4948275	0.53	rs10994747	ENSG00000237233.2	TMEM26-AS1	5.27	8.49e-07	0.000943	0.51	0.48	Night sleep phenotypes;	chr10:61390164	chr10:61452639~61481956:+
THYM	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	5.27	8.5e-07	0.000943	0.59	0.48	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
THYM	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	5.27	8.5e-07	0.000943	0.59	0.48	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
THYM	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	5.27	8.5e-07	0.000943	0.59	0.48	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
THYM	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	5.27	8.5e-07	0.000943	0.59	0.48	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
THYM	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-5.27	8.53e-07	0.000946	-0.42	-0.48	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-5.27	8.53e-07	0.000946	-0.42	-0.48	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-5.27	8.53e-07	0.000946	-0.42	-0.48	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	5.27	8.53e-07	0.000946	0.42	0.48	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	5.27	8.53e-07	0.000946	0.42	0.48	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
THYM	cis	rs9907295	0.818	rs7211393	ENSG00000270977.1	AC015849.16	-5.27	8.54e-07	0.000947	-0.56	-0.48	Fibroblast growth factor basic levels;	chr17:35885124	chr17:35893707~35911023:-
THYM	cis	rs11577318	0.626	rs11806568	ENSG00000225854.2	RP11-569G9.7	-5.27	8.54e-07	0.000948	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26360346	chr1:26326688~26327033:+
THYM	cis	rs11577318	0.579	rs35456934	ENSG00000225854.2	RP11-569G9.7	-5.27	8.54e-07	0.000948	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26360373	chr1:26326688~26327033:+
THYM	cis	rs11577318	0.538	rs10902745	ENSG00000225854.2	RP11-569G9.7	-5.27	8.54e-07	0.000948	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26360579	chr1:26326688~26327033:+
THYM	cis	rs7702057	0.53	rs17138841	ENSG00000271918.1	CTD-2287O16.5	5.27	8.56e-07	0.000949	0.78	0.48	Amyotrophic lateral sclerosis;	chr5:116077109	chr5:116083807~116085416:-
THYM	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	5.27	8.57e-07	0.00095	0.41	0.48	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
THYM	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-5.27	8.6e-07	0.000953	-0.34	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.513	rs901823	ENSG00000222339.1	AP000807.2	5.27	8.63e-07	0.000956	0.52	0.48	Total body bone mineral density;	chr11:68438110	chr11:68505572~68505651:-
THYM	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-5.27	8.63e-07	0.000956	-0.43	-0.48	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
THYM	cis	rs995834	0.912	rs2868970	ENSG00000267243.4	AC005307.3	-5.27	8.64e-07	0.000957	-0.43	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393432	chr19:28435388~28727777:-
THYM	cis	rs995834	0.828	rs10403516	ENSG00000267243.4	AC005307.3	-5.27	8.64e-07	0.000957	-0.43	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393842	chr19:28435388~28727777:-
THYM	cis	rs13256369	0.802	rs1060107	ENSG00000253893.2	FAM85B	-5.27	8.66e-07	0.000959	-0.68	-0.48	Obesity-related traits;	chr8:8703889	chr8:8167819~8226614:-
THYM	cis	rs4262	0.632	rs180238	ENSG00000278388.1	GS1-345D13.1	5.27	8.67e-07	0.00096	0.5	0.48	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93921135	chr7:93914987~93915108:+
THYM	cis	rs4273100	1	rs57433322	ENSG00000228157.4	AC007952.5	5.27	8.72e-07	0.000966	0.74	0.48	Schizophrenia;	chr17:19238269	chr17:19092974~19096837:+
THYM	cis	rs904251	0.772	rs1224127	ENSG00000227920.2	RP1-153P14.5	-5.27	8.73e-07	0.000966	-0.72	-0.48	Cognitive performance;	chr6:37449780	chr6:37545145~37550860:+
THYM	cis	rs17391705	1	rs17390561	ENSG00000243806.1	RPL7P18	5.27	8.74e-07	0.000967	1.02	0.48	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94755574	chr5:94825961~94826694:-
THYM	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	5.27	8.74e-07	0.000967	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	5.27	8.74e-07	0.000967	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	5.27	8.74e-07	0.000967	0.64	0.48	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
THYM	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-5.27	8.76e-07	0.000968	-0.62	-0.48	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
THYM	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	5.27	8.76e-07	0.000968	0.39	0.48	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	5.27	8.76e-07	0.000968	0.39	0.48	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	5.27	8.76e-07	0.000968	0.39	0.48	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
THYM	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	5.27	8.76e-07	0.000968	0.39	0.48	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	5.27	8.76e-07	0.000968	0.39	0.48	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	5.27	8.76e-07	0.000968	0.39	0.48	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
THYM	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-5.27	8.78e-07	0.00097	-0.53	-0.48	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
THYM	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	5.27	8.81e-07	0.000973	0.43	0.48	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
THYM	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-5.26	8.85e-07	0.000977	-0.53	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
THYM	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	5.26	8.87e-07	0.000979	0.39	0.48	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
THYM	cis	rs13256369	1	rs13266699	ENSG00000253893.2	FAM85B	5.26	8.88e-07	0.00098	0.68	0.48	Obesity-related traits;	chr8:8712803	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs12547721	ENSG00000253893.2	FAM85B	-5.26	8.88e-07	0.00098	-0.68	-0.48	Obesity-related traits;	chr8:8713161	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs1109619	ENSG00000253893.2	FAM85B	-5.26	8.88e-07	0.00098	-0.68	-0.48	Obesity-related traits;	chr8:8714106	chr8:8167819~8226614:-
THYM	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	5.26	8.89e-07	0.000981	0.42	0.48	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
THYM	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	5.26	8.9e-07	0.000981	0.43	0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	5.26	8.9e-07	0.000981	0.43	0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
THYM	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-5.26	8.9e-07	0.000981	-0.43	-0.48	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
THYM	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	5.26	8.91e-07	0.000982	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
THYM	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	5.26	8.91e-07	0.000982	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.673	rs498782	ENSG00000222339.1	AP000807.2	5.26	8.94e-07	0.000985	0.55	0.48	Total body bone mineral density;	chr11:68508383	chr11:68505572~68505651:-
THYM	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	5.26	8.94e-07	0.000985	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
THYM	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-5.26	8.95e-07	0.000986	-0.45	-0.48	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
THYM	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	5.26	8.95e-07	0.000986	0.52	0.48	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
THYM	cis	rs2283792	0.677	rs13340063	ENSG00000224086.5	LL22NC03-86G7.1	5.26	8.96e-07	0.000987	0.45	0.48	Multiple sclerosis;	chr22:21742717	chr22:21938293~21977632:+
THYM	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	5.26	8.98e-07	0.000989	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	5.26	8.98e-07	0.000989	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
THYM	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-5.26	8.98e-07	0.000989	-0.73	-0.48	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
THYM	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	5.26	8.99e-07	0.00099	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	5.26	8.99e-07	0.00099	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	5.26	8.99e-07	0.00099	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	5.26	8.99e-07	0.00099	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
THYM	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	5.26	9e-07	0.00099	0.42	0.48	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	5.26	9e-07	0.00099	0.42	0.48	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
THYM	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	5.26	9e-07	0.000991	0.6	0.48	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
THYM	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-5.26	9e-07	0.000991	-0.54	-0.48	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
THYM	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	5.26	9.01e-07	0.000991	0.64	0.48	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
THYM	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	5.26	9.01e-07	0.000992	0.35	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
THYM	cis	rs13256369	1	rs13282915	ENSG00000253893.2	FAM85B	-5.26	9.03e-07	0.000993	-0.69	-0.48	Obesity-related traits;	chr8:8713381	chr8:8167819~8226614:-
THYM	cis	rs3740713	0.669	rs78098319	ENSG00000256464.1	YWHABP2	5.26	9.05e-07	0.000995	0.83	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438604	ENSG00000256464.1	YWHABP2	5.26	9.08e-07	0.000998	0.82	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr11:18490243~18490955:-
THYM	cis	rs10129255	0.642	rs11624918	ENSG00000254329.1	IGHVII-60-1	5.26	9.1e-07	0.000999	0.49	0.48	Kawasaki disease;	chr14:106664672	chr14:106637718~106637973:-
THYM	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-5.26	9.1e-07	0.000999	-0.38	-0.48	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
THYM	cis	rs4845570	1	rs6681093	ENSG00000203288.3	RP11-98D18.9	-5.26	9.11e-07	0.001	-0.49	-0.48	Coronary artery disease;	chr1:151782808	chr1:151790804~151794402:+
THYM	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	5.26	9.12e-07	0.001	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	5.26	9.12e-07	0.001	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	5.26	9.12e-07	0.001	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
THYM	cis	rs950169	0.8	rs34302901	ENSG00000235370.6	DNM1P51	5.26	9.13e-07	0.001	0.57	0.48	Schizophrenia;	chr15:84567712	chr15:84398316~84411701:-
THYM	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	5.26	9.14e-07	0.001	0.68	0.48	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
THYM	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	5.26	9.14e-07	0.001	0.54	0.48	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
THYM	cis	rs1560104	0.518	rs11645483	ENSG00000259899.1	CTD-3037G24.3	-5.26	9.15e-07	0.001	-0.6	-0.48	Obesity-related traits;	chr16:12615400	chr16:12560756~12611044:-
THYM	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	5.26	9.17e-07	0.001	0.42	0.48	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	5.26	9.17e-07	0.001	0.42	0.48	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	5.26	9.17e-07	0.001	0.42	0.48	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	5.26	9.17e-07	0.001	0.42	0.48	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
THYM	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
THYM	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
THYM	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
THYM	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
THYM	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
THYM	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
THYM	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
THYM	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	5.26	9.17e-07	0.001	0.49	0.48	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-5.26	9.17e-07	0.001	-0.49	-0.48	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
THYM	cis	rs7927592	0.763	rs10896351	ENSG00000222339.1	AP000807.2	5.26	9.18e-07	0.00101	0.56	0.48	Total body bone mineral density;	chr11:68619428	chr11:68505572~68505651:-
THYM	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-5.25	9.24e-07	0.00101	-0.6	-0.48	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
THYM	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-5.25	9.28e-07	0.00102	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
THYM	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-5.25	9.29e-07	0.00102	-0.44	-0.48	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
THYM	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	5.25	9.3e-07	0.00102	0.63	0.48	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
THYM	cis	rs7927592	0.763	rs10791982	ENSG00000222339.1	AP000807.2	-5.25	9.3e-07	0.00102	-0.56	-0.48	Total body bone mineral density;	chr11:68570196	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.731	rs7108376	ENSG00000222339.1	AP000807.2	-5.25	9.3e-07	0.00102	-0.56	-0.48	Total body bone mineral density;	chr11:68580402	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.731	rs11228288	ENSG00000222339.1	AP000807.2	5.25	9.3e-07	0.00102	0.56	0.48	Total body bone mineral density;	chr11:68586082	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.763	rs2513277	ENSG00000222339.1	AP000807.2	5.25	9.3e-07	0.00102	0.56	0.48	Total body bone mineral density;	chr11:68593419	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.763	rs4340059	ENSG00000222339.1	AP000807.2	5.25	9.3e-07	0.00102	0.56	0.48	Total body bone mineral density;	chr11:68594965	chr11:68505572~68505651:-
THYM	cis	rs2834288	0.645	rs2032313	ENSG00000237945.6	LINC00649	5.25	9.31e-07	0.00102	0.41	0.48	Gut microbiota (bacterial taxa);	chr21:33981946	chr21:33915534~33977691:+
THYM	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	5.25	9.32e-07	0.00102	0.45	0.48	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
THYM	cis	rs1426063	0.858	rs10004802	ENSG00000249717.1	RP11-44F21.3	5.25	9.34e-07	0.00102	1	0.48	QT interval;	chr4:75084413	chr4:74955974~74970362:-
THYM	cis	rs13256369	0.951	rs13270852	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8709343	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.901	rs4841015	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8709630	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs13271698	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8710029	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs12550458	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8710322	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs12545771	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8710467	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.95	rs12548792	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8710521	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.901	rs13251887	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8711168	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs885000	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8711365	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs883648	ENSG00000253893.2	FAM85B	-5.25	9.34e-07	0.00102	-0.68	-0.48	Obesity-related traits;	chr8:8712011	chr8:8167819~8226614:-
THYM	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-5.25	9.35e-07	0.00102	-0.33	-0.48	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
THYM	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	5.25	9.35e-07	0.00102	0.52	0.48	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
THYM	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	5.25	9.35e-07	0.00102	0.52	0.48	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
THYM	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	5.25	9.36e-07	0.00102	0.53	0.48	Height;	chr6:109354092	chr6:109382795~109383666:+
THYM	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	5.25	9.37e-07	0.00102	0.39	0.48	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
THYM	cis	rs995834	0.743	rs4555267	ENSG00000260725.1	AC005307.1	-5.25	9.39e-07	0.00102	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28374933	chr19:28418483~28429490:-
THYM	cis	rs995834	0.784	rs4141219	ENSG00000260725.1	AC005307.1	-5.25	9.39e-07	0.00102	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375247	chr19:28418483~28429490:-
THYM	cis	rs995834	0.789	rs2041195	ENSG00000260725.1	AC005307.1	-5.25	9.39e-07	0.00102	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376305	chr19:28418483~28429490:-
THYM	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	5.25	9.4e-07	0.00103	0.35	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
THYM	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	5.25	9.41e-07	0.00103	0.53	0.48	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
THYM	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-5.25	9.43e-07	0.00103	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-5.25	9.43e-07	0.00103	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-5.25	9.43e-07	0.00103	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-5.25	9.43e-07	0.00103	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-5.25	9.43e-07	0.00103	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-5.25	9.43e-07	0.00103	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-5.25	9.43e-07	0.00103	-0.58	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
THYM	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	5.25	9.43e-07	0.00103	0.58	0.48	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
THYM	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	5.25	9.44e-07	0.00103	0.44	0.48	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	5.25	9.44e-07	0.00103	0.44	0.48	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
THYM	cis	rs7702057	0.53	rs74583480	ENSG00000271918.1	CTD-2287O16.5	5.25	9.45e-07	0.00103	0.69	0.48	Amyotrophic lateral sclerosis;	chr5:116085200	chr5:116083807~116085416:-
THYM	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	5.25	9.47e-07	0.00103	0.45	0.48	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
THYM	cis	rs3740713	1	rs73436638	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436642	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436645	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr11:18490243~18490955:-
THYM	cis	rs3740713	0.925	rs73436650	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436655	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr11:18490243~18490955:-
THYM	cis	rs3740713	0.92	rs80254575	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436662	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436666	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs113725670	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436682	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436685	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs2056781	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73436701	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438607	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438611	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs75010364	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs2643872	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs75381502	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438627	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438631	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438634	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs113036885	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs112410494	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs74741949	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs113497813	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs76586692	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs61081934	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs57311859	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr11:18490243~18490955:-
THYM	cis	rs3740713	0.92	rs112818034	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr11:18490243~18490955:-
THYM	cis	rs3740713	0.92	rs112973292	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr11:18490243~18490955:-
THYM	cis	rs3740713	0.92	rs73438656	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr11:18490243~18490955:-
THYM	cis	rs3740713	0.92	rs73438659	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs76708296	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438666	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438668	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs16935424	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438674	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs78549183	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs75647856	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438687	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs74663287	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438690	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438695	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438697	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs76062966	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs114330751	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438699	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73440604	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73440606	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73440610	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73440615	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs75740864	ENSG00000256464.1	YWHABP2	5.25	9.53e-07	0.00104	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr11:18490243~18490955:-
THYM	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	5.25	9.53e-07	0.00104	0.41	0.48	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.513	rs630225	ENSG00000212093.1	AP000807.1	5.25	9.53e-07	0.00104	0.41	0.48	Total body bone mineral density;	chr11:68427143	chr11:68506083~68506166:-
THYM	cis	rs525592	1	rs525592	ENSG00000212093.1	AP000807.1	5.25	9.53e-07	0.00104	0.41	0.48	Bone mineral density;	chr11:68427636	chr11:68506083~68506166:-
THYM	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-5.25	9.55e-07	0.00104	-0.62	-0.48	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
THYM	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-5.25	9.59e-07	0.00104	-0.62	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
THYM	cis	rs950169	0.544	rs2036949	ENSG00000235370.6	DNM1P51	5.24	9.61e-07	0.00104	0.64	0.48	Schizophrenia;	chr15:84620374	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs11635597	ENSG00000235370.6	DNM1P51	5.24	9.61e-07	0.00104	0.64	0.48	Schizophrenia;	chr15:84622468	chr15:84398316~84411701:-
THYM	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	5.24	9.62e-07	0.00104	0.49	0.48	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	5.24	9.62e-07	0.00104	0.49	0.48	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
THYM	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	5.24	9.62e-07	0.00104	0.49	0.48	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	5.24	9.62e-07	0.00104	0.49	0.48	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	5.24	9.62e-07	0.00104	0.49	0.48	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
THYM	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-5.24	9.64e-07	0.00105	-0.67	-0.48	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
THYM	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	5.24	9.67e-07	0.00105	0.41	0.48	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
THYM	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-5.24	9.71e-07	0.00105	-0.58	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
THYM	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	5.24	9.71e-07	0.00105	0.58	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
THYM	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	5.24	9.71e-07	0.00105	0.58	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
THYM	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	5.24	9.71e-07	0.00105	0.58	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	5.24	9.71e-07	0.00105	0.58	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
THYM	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	5.24	9.71e-07	0.00105	0.44	0.48	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-5.24	9.71e-07	0.00105	-0.44	-0.48	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
THYM	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	5.24	9.74e-07	0.00105	0.42	0.48	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
THYM	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	5.24	9.74e-07	0.00106	0.63	0.48	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
THYM	cis	rs995834	0.622	rs2159074	ENSG00000267243.4	AC005307.3	5.24	9.76e-07	0.00106	0.47	0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407490	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs10408649	ENSG00000267243.4	AC005307.3	-5.24	9.76e-07	0.00106	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405965	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs6508824	ENSG00000267243.4	AC005307.3	-5.24	9.76e-07	0.00106	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406925	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs8111081	ENSG00000267243.4	AC005307.3	-5.24	9.76e-07	0.00106	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28407156	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs10407317	ENSG00000267243.4	AC005307.3	-5.24	9.76e-07	0.00106	-0.47	-0.48	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28411352	chr19:28435388~28727777:-
THYM	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-5.24	9.79e-07	0.00106	-0.59	-0.48	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
THYM	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	5.24	9.79e-07	0.00106	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	5.24	9.79e-07	0.00106	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	5.24	9.79e-07	0.00106	0.34	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-5.24	9.79e-07	0.00106	-0.34	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-5.24	9.79e-07	0.00106	-0.34	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
THYM	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-5.24	9.81e-07	0.00106	-0.58	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-5.24	9.81e-07	0.00106	-0.58	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
THYM	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-5.24	9.81e-07	0.00106	-0.58	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
THYM	cis	rs3740713	0.719	rs78515595	ENSG00000256464.1	YWHABP2	5.24	9.81e-07	0.00106	0.81	0.48	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr11:18490243~18490955:-
THYM	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	5.24	9.82e-07	0.00106	0.67	0.48	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
THYM	cis	rs4715166	0.773	rs6458720	ENSG00000215022.6	RP1-257A7.4	-5.24	9.83e-07	0.00106	-0.45	-0.48	Hip geometry;	chr6:13224845	chr6:13264861~13295586:-
THYM	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	5.24	9.83e-07	0.00106	0.53	0.48	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	5.24	9.83e-07	0.00106	0.53	0.48	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	5.24	9.83e-07	0.00106	0.53	0.48	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	5.24	9.83e-07	0.00106	0.53	0.48	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	5.24	9.83e-07	0.00106	0.53	0.48	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	5.24	9.83e-07	0.00106	0.53	0.48	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
THYM	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-5.24	9.84e-07	0.00106	-0.91	-0.48	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-5.24	9.84e-07	0.00106	-0.91	-0.48	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
THYM	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
THYM	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	5.24	9.86e-07	0.00106	0.44	0.48	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
THYM	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	5.24	9.86e-07	0.00106	0.39	0.48	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
THYM	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-5.24	9.86e-07	0.00107	-0.44	-0.48	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
THYM	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-5.24	9.88e-07	0.00107	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
THYM	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	5.24	9.88e-07	0.00107	0.52	0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
THYM	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-5.24	9.88e-07	0.00107	-0.42	-0.48	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
THYM	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-5.24	9.89e-07	0.00107	-0.65	-0.48	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-5.24	9.89e-07	0.00107	-0.65	-0.48	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-5.24	9.89e-07	0.00107	-0.65	-0.48	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-5.24	9.89e-07	0.00107	-0.65	-0.48	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
THYM	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	5.24	9.89e-07	0.00107	0.54	0.48	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
THYM	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	5.24	9.89e-07	0.00107	0.44	0.48	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
THYM	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-5.24	9.89e-07	0.00107	-0.62	-0.48	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
THYM	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-5.24	9.93e-07	0.00107	-0.39	-0.48	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
THYM	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	5.24	9.95e-07	0.00107	0.53	0.48	Height;	chr6:109358227	chr6:109382795~109383666:+
THYM	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	5.24	9.96e-07	0.00107	0.41	0.48	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
THYM	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	5.24	9.96e-07	0.00107	0.59	0.48	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
THYM	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	5.24	9.96e-07	0.00107	0.59	0.48	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
THYM	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-5.24	9.98e-07	0.00108	-0.46	-0.48	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	5.24	9.98e-07	0.00108	0.46	0.48	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
THYM	cis	rs1550576	0.5	rs4646583	ENSG00000274719.1	RP11-86K22.2	-5.24	9.98e-07	0.00108	-0.92	-0.48	Hypertension;	chr15:58014353	chr15:57990217~57990636:-
THYM	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-5.24	1e-06	0.00108	-0.91	-0.48	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
THYM	cis	rs17772222	0.755	rs12435019	ENSG00000258983.2	RP11-507K2.2	5.24	1e-06	0.00108	0.54	0.48	Coronary artery calcification;	chr14:88365074	chr14:88499334~88515502:+
THYM	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	5.23	1e-06	0.00108	1.02	0.48	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
THYM	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	5.23	1e-06	0.00108	0.54	0.48	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
THYM	cis	rs7927592	0.731	rs10896350	ENSG00000222339.1	AP000807.2	5.23	1.01e-06	0.00108	0.56	0.48	Total body bone mineral density;	chr11:68618905	chr11:68505572~68505651:-
THYM	cis	rs1550576	0.568	rs4646608	ENSG00000274719.1	RP11-86K22.2	5.23	1.01e-06	0.00108	0.96	0.48	Hypertension;	chr15:57983539	chr15:57990217~57990636:-
THYM	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.23	1.01e-06	0.00108	0.71	0.48	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
THYM	cis	rs904251	0.523	rs9349039	ENSG00000227920.2	RP1-153P14.5	-5.23	1.01e-06	0.00108	-0.66	-0.48	Cognitive performance;	chr6:37512616	chr6:37545145~37550860:+
THYM	cis	rs904251	0.523	rs9366935	ENSG00000227920.2	RP1-153P14.5	-5.23	1.01e-06	0.00108	-0.66	-0.48	Cognitive performance;	chr6:37512628	chr6:37545145~37550860:+
THYM	cis	rs4478858	0.743	rs11578422	ENSG00000260386.4	LINC01225	5.23	1.01e-06	0.00108	0.25	0.48	Alcohol dependence;	chr1:31234451	chr1:31500085~31540885:+
THYM	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	5.23	1.01e-06	0.00109	0.45	0.48	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
THYM	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	5.23	1.01e-06	0.00109	0.49	0.47	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-5.23	1.01e-06	0.00109	-0.49	-0.47	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
THYM	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-5.23	1.01e-06	0.00109	-0.45	-0.47	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
THYM	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	5.23	1.01e-06	0.00109	0.45	0.47	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	5.23	1.01e-06	0.00109	0.45	0.47	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
THYM	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	5.23	1.01e-06	0.00109	0.37	0.47	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
THYM	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-5.23	1.01e-06	0.00109	-0.55	-0.47	Height;	chr6:109731677	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	5.23	1.01e-06	0.00109	0.54	0.47	Height;	chr6:109739615	chr6:109382795~109383666:+
THYM	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-5.23	1.03e-06	0.0011	-0.69	-0.47	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
THYM	cis	rs4273100	0.646	rs6587216	ENSG00000262319.1	CTC-457L16.2	5.23	1.03e-06	0.0011	0.61	0.47	Schizophrenia;	chr17:19321084	chr17:19141017~19143689:-
THYM	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	5.23	1.03e-06	0.0011	0.45	0.47	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
THYM	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-5.23	1.03e-06	0.0011	-0.4	-0.47	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-5.23	1.03e-06	0.0011	-0.4	-0.47	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
THYM	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	5.23	1.03e-06	0.00111	0.58	0.47	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
THYM	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	5.23	1.03e-06	0.00111	0.57	0.47	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
THYM	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	5.23	1.03e-06	0.00111	0.53	0.47	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
THYM	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	5.23	1.03e-06	0.00111	0.34	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
THYM	cis	rs13256369	0.802	rs11249884	ENSG00000253893.2	FAM85B	5.23	1.03e-06	0.00111	0.67	0.47	Obesity-related traits;	chr8:8704042	chr8:8167819~8226614:-
THYM	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-5.23	1.04e-06	0.00111	-0.6	-0.47	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
THYM	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	5.23	1.04e-06	0.00111	0.58	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
THYM	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-5.23	1.04e-06	0.00111	-0.58	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
THYM	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	5.23	1.04e-06	0.00112	0.35	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
THYM	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	5.23	1.04e-06	0.00112	0.56	0.47	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
THYM	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	5.22	1.05e-06	0.00112	0.54	0.47	Height;	chr6:109740895	chr6:109382795~109383666:+
THYM	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	5.22	1.05e-06	0.00112	0.49	0.47	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
THYM	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs28825455	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143707593	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	5.22	1.05e-06	0.00113	0.54	0.47	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	5.22	1.06e-06	0.00113	0.52	0.47	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	5.22	1.06e-06	0.00113	0.52	0.47	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	5.22	1.06e-06	0.00113	0.52	0.47	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	5.22	1.06e-06	0.00113	0.52	0.47	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	5.22	1.06e-06	0.00113	0.52	0.47	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	5.22	1.06e-06	0.00113	0.52	0.47	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	5.22	1.06e-06	0.00113	0.52	0.47	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
THYM	cis	rs13256369	1	rs7820159	ENSG00000253893.2	FAM85B	-5.22	1.06e-06	0.00113	-0.68	-0.47	Obesity-related traits;	chr8:8718705	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs7843488	ENSG00000253893.2	FAM85B	-5.22	1.06e-06	0.00113	-0.68	-0.47	Obesity-related traits;	chr8:8718707	chr8:8167819~8226614:-
THYM	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	5.22	1.06e-06	0.00113	0.8	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
THYM	cis	rs4835473	0.808	rs11725413	ENSG00000251600.4	RP11-673E1.1	-5.22	1.06e-06	0.00113	-0.52	-0.47	Immature fraction of reticulocytes;	chr4:143943366	chr4:143912331~143982454:+
THYM	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-5.22	1.06e-06	0.00113	-0.86	-0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
THYM	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-5.22	1.06e-06	0.00113	-0.68	-0.47	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
THYM	cis	rs4713118	0.516	rs6931858	ENSG00000182477.5	OR2B8P	5.22	1.07e-06	0.00114	0.69	0.47	Parkinson's disease;	chr6:28110633	chr6:28053228~28054165:-
THYM	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	5.22	1.07e-06	0.00114	0.35	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
THYM	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	5.22	1.07e-06	0.00114	0.57	0.47	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
THYM	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	5.22	1.07e-06	0.00114	0.52	0.47	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	5.22	1.07e-06	0.00114	0.52	0.47	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
THYM	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-5.22	1.07e-06	0.00114	-0.38	-0.47	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
THYM	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	5.22	1.07e-06	0.00114	0.79	0.47	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
THYM	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-5.22	1.07e-06	0.00114	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-5.22	1.07e-06	0.00114	-0.58	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
THYM	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	5.22	1.08e-06	0.00115	0.53	0.47	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
THYM	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	5.22	1.08e-06	0.00115	0.53	0.47	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
THYM	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-5.22	1.08e-06	0.00115	-0.33	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
THYM	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-5.22	1.09e-06	0.00116	-0.67	-0.47	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-5.22	1.09e-06	0.00116	-0.67	-0.47	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
THYM	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	5.22	1.09e-06	0.00116	0.58	0.47	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
THYM	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	5.22	1.09e-06	0.00116	0.58	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
THYM	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	5.22	1.09e-06	0.00116	0.6	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
THYM	cis	rs904251	0.58	rs62408367	ENSG00000279942.1	RP1-153P14.7	-5.21	1.09e-06	0.00116	-0.61	-0.47	Cognitive performance;	chr6:37477037	chr6:37567716~37571460:+
THYM	cis	rs995834	0.743	rs7256207	ENSG00000260725.1	AC005307.1	5.21	1.09e-06	0.00116	0.47	0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356775	chr19:28418483~28429490:-
THYM	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-5.21	1.09e-06	0.00116	-0.43	-0.47	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
THYM	cis	rs10829156	0.732	rs1917823	ENSG00000240291.1	RP11-499P20.2	5.21	1.1e-06	0.00117	0.44	0.47	Sudden cardiac arrest;	chr10:18528184	chr10:18513115~18545651:-
THYM	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	5.21	1.11e-06	0.00118	0.61	0.47	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	5.21	1.11e-06	0.00118	0.61	0.47	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-5.21	1.11e-06	0.00118	-0.61	-0.47	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
THYM	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-5.21	1.11e-06	0.00118	-0.55	-0.47	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
THYM	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-5.21	1.11e-06	0.00118	-0.59	-0.47	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
THYM	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	5.21	1.12e-06	0.00118	0.63	0.47	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
THYM	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	5.21	1.12e-06	0.00118	0.58	0.47	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
THYM	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-5.21	1.12e-06	0.00118	-0.85	-0.47	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-5.21	1.12e-06	0.00118	-0.85	-0.47	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
THYM	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	5.21	1.12e-06	0.00119	0.43	0.47	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
THYM	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	5.21	1.12e-06	0.00119	0.63	0.47	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
THYM	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	5.21	1.12e-06	0.00119	0.85	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
THYM	cis	rs11157436	0.958	rs12432733	ENSG00000211813.2	TRAV34	5.21	1.12e-06	0.00119	0.39	0.47	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22207522~22208129:+
THYM	cis	rs904251	0.504	rs12202664	ENSG00000227920.2	RP1-153P14.5	-5.21	1.12e-06	0.00119	-0.6	-0.47	Cognitive performance;	chr6:37513422	chr6:37545145~37550860:+
THYM	cis	rs950169	0.58	rs17598114	ENSG00000235370.6	DNM1P51	5.21	1.13e-06	0.00119	0.63	0.47	Schizophrenia;	chr15:84628086	chr15:84398316~84411701:-
THYM	cis	rs1560104	0.597	rs17227492	ENSG00000259899.1	CTD-3037G24.3	-5.21	1.13e-06	0.00119	-0.55	-0.47	Obesity-related traits;	chr16:12620186	chr16:12560756~12611044:-
THYM	cis	rs1560104	0.5	rs11075127	ENSG00000259899.1	CTD-3037G24.3	-5.21	1.13e-06	0.00119	-0.55	-0.47	Obesity-related traits;	chr16:12620700	chr16:12560756~12611044:-
THYM	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-5.21	1.13e-06	0.00119	-0.45	-0.47	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
THYM	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-5.21	1.13e-06	0.0012	-0.61	-0.47	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-5.21	1.13e-06	0.0012	-0.61	-0.47	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-5.21	1.13e-06	0.0012	-0.61	-0.47	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-5.21	1.13e-06	0.0012	-0.61	-0.47	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
THYM	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	5.21	1.13e-06	0.0012	0.47	0.47	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
THYM	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-5.21	1.13e-06	0.0012	-0.61	-0.47	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	5.21	1.13e-06	0.0012	0.61	0.47	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	5.21	1.13e-06	0.0012	0.61	0.47	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
THYM	cis	rs1550115	0.524	rs72792190	ENSG00000271936.1	RP11-443B20.1	-5.21	1.13e-06	0.0012	-0.39	-0.47	Coronary artery disease;	chr2:24828858	chr2:24825610~24826717:+
THYM	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	5.21	1.14e-06	0.0012	0.42	0.47	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
THYM	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	5.21	1.14e-06	0.0012	0.42	0.47	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
THYM	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-5.2	1.14e-06	0.0012	-0.47	-0.47	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	5.2	1.14e-06	0.0012	0.47	0.47	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
THYM	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-5.2	1.14e-06	0.0012	-0.57	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-5.2	1.14e-06	0.0012	-0.57	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	5.2	1.14e-06	0.0012	0.57	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
THYM	cis	rs11157436	1	rs2293731	ENSG00000211813.2	TRAV34	5.2	1.14e-06	0.00121	0.37	0.47	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22207522~22208129:+
THYM	cis	rs12682352	0.535	rs12677550	ENSG00000253893.2	FAM85B	5.2	1.15e-06	0.00121	0.58	0.47	Neuroticism;	chr8:8786812	chr8:8167819~8226614:-
THYM	cis	rs4713118	0.621	rs9295755	ENSG00000182477.5	OR2B8P	-5.2	1.15e-06	0.00121	-0.66	-0.47	Parkinson's disease;	chr6:28065396	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.621	rs4713132	ENSG00000182477.5	OR2B8P	5.2	1.15e-06	0.00121	0.66	0.47	Parkinson's disease;	chr6:28066257	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.621	rs4713133	ENSG00000182477.5	OR2B8P	5.2	1.15e-06	0.00121	0.66	0.47	Parkinson's disease;	chr6:28066263	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.621	rs4713134	ENSG00000182477.5	OR2B8P	5.2	1.15e-06	0.00121	0.66	0.47	Parkinson's disease;	chr6:28066343	chr6:28053228~28054165:-
THYM	cis	rs763121	0.962	rs5757130	ENSG00000273076.1	RP3-508I15.22	5.2	1.15e-06	0.00122	0.57	0.47	Menopause (age at onset);	chr22:38541789	chr22:38743495~38743910:+
THYM	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	5.2	1.15e-06	0.00122	0.33	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	5.2	1.15e-06	0.00122	0.35	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
THYM	cis	rs4273100	0.834	rs59415593	ENSG00000228157.4	AC007952.5	5.2	1.15e-06	0.00122	0.73	0.47	Schizophrenia;	chr17:19319911	chr17:19092974~19096837:+
THYM	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-5.2	1.15e-06	0.00122	-0.63	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
THYM	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-5.2	1.15e-06	0.00122	-0.61	-0.47	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
THYM	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-5.2	1.15e-06	0.00122	-0.55	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
THYM	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-5.2	1.16e-06	0.00122	-0.62	-0.47	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-5.2	1.16e-06	0.00122	-0.62	-0.47	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
THYM	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	5.2	1.16e-06	0.00123	0.9	0.47	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
THYM	cis	rs995834	0.701	rs6508799	ENSG00000260725.1	AC005307.1	-5.2	1.16e-06	0.00123	-0.47	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28360493	chr19:28418483~28429490:-
THYM	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	5.2	1.16e-06	0.00123	0.53	0.47	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	5.2	1.16e-06	0.00123	0.53	0.47	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
THYM	cis	rs11157436	1	rs3811278	ENSG00000211813.2	TRAV34	5.2	1.16e-06	0.00123	0.38	0.47	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22207522~22208129:+
THYM	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.2	1.16e-06	0.00123	0.57	0.47	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
THYM	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-5.2	1.16e-06	0.00123	-0.63	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-5.2	1.16e-06	0.00123	-0.63	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
THYM	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-5.2	1.16e-06	0.00123	-0.63	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
THYM	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-5.2	1.16e-06	0.00123	-0.63	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
THYM	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	5.2	1.16e-06	0.00123	0.61	0.47	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
THYM	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-5.2	1.17e-06	0.00123	-0.64	-0.47	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
THYM	cis	rs992157	0.932	rs10203039	ENSG00000261338.2	RP11-378A13.1	5.2	1.17e-06	0.00123	0.62	0.47	Colorectal cancer;	chr2:218322644	chr2:218255319~218257366:+
THYM	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-5.2	1.17e-06	0.00123	-0.49	-0.47	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-5.2	1.17e-06	0.00123	-0.49	-0.47	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-5.2	1.17e-06	0.00123	-0.49	-0.47	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
THYM	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	5.2	1.17e-06	0.00123	0.58	0.47	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
THYM	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	5.2	1.17e-06	0.00123	0.52	0.47	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	5.2	1.17e-06	0.00123	0.52	0.47	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	5.2	1.17e-06	0.00123	0.52	0.47	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	5.2	1.17e-06	0.00123	0.52	0.47	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	5.2	1.17e-06	0.00123	0.52	0.47	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
THYM	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	5.2	1.17e-06	0.00124	0.49	0.47	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
THYM	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	5.2	1.17e-06	0.00124	0.49	0.47	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
THYM	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	5.2	1.18e-06	0.00124	0.43	0.47	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
THYM	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	5.2	1.18e-06	0.00124	0.63	0.47	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	5.2	1.18e-06	0.00124	0.63	0.47	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
THYM	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	5.2	1.18e-06	0.00124	0.63	0.47	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
THYM	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	5.2	1.18e-06	0.00124	0.53	0.47	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
THYM	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-5.2	1.18e-06	0.00124	-0.41	-0.47	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
THYM	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-5.2	1.18e-06	0.00124	-0.45	-0.47	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-5.2	1.18e-06	0.00124	-0.45	-0.47	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-5.2	1.18e-06	0.00124	-0.45	-0.47	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-5.2	1.18e-06	0.00124	-0.45	-0.47	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-5.2	1.18e-06	0.00124	-0.45	-0.47	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
THYM	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	5.2	1.18e-06	0.00124	0.34	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	5.2	1.18e-06	0.00124	0.34	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
THYM	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-5.2	1.18e-06	0.00124	-0.42	-0.47	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
THYM	cis	rs950169	0.544	rs62021193	ENSG00000235370.6	DNM1P51	5.2	1.18e-06	0.00125	0.63	0.47	Schizophrenia;	chr15:84627352	chr15:84398316~84411701:-
THYM	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-5.2	1.18e-06	0.00125	-0.56	-0.47	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
THYM	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-5.2	1.18e-06	0.00125	-0.75	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
THYM	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	5.19	1.19e-06	0.00125	0.48	0.47	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
THYM	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-5.19	1.19e-06	0.00125	-0.61	-0.47	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
THYM	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	5.19	1.19e-06	0.00125	0.43	0.47	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
THYM	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-5.19	1.19e-06	0.00125	-0.83	-0.47	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
THYM	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	5.19	1.2e-06	0.00126	0.61	0.47	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	5.19	1.2e-06	0.00126	0.61	0.47	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-5.19	1.2e-06	0.00126	-0.61	-0.47	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-5.19	1.2e-06	0.00126	-0.61	-0.47	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-5.19	1.2e-06	0.00126	-0.61	-0.47	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
THYM	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-5.19	1.2e-06	0.00126	-0.61	-0.47	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-5.19	1.2e-06	0.00126	-0.61	-0.47	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
THYM	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-5.19	1.2e-06	0.00126	-0.54	-0.47	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	5.19	1.2e-06	0.00126	0.54	0.47	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	5.19	1.2e-06	0.00126	0.54	0.47	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
THYM	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	5.19	1.2e-06	0.00126	0.42	0.47	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
THYM	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-5.19	1.2e-06	0.00126	-0.87	-0.47	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
THYM	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-5.19	1.2e-06	0.00126	-0.61	-0.47	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-5.19	1.2e-06	0.00126	-0.61	-0.47	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-5.19	1.2e-06	0.00126	-0.62	-0.47	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-5.19	1.2e-06	0.00126	-0.62	-0.47	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-5.19	1.2e-06	0.00126	-0.62	-0.47	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
THYM	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	5.19	1.21e-06	0.00127	0.42	0.47	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	5.19	1.21e-06	0.00127	0.42	0.47	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
THYM	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-5.19	1.21e-06	0.00127	-0.6	-0.47	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
THYM	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	5.19	1.21e-06	0.00127	0.43	0.47	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
THYM	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	5.19	1.21e-06	0.00127	0.52	0.47	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
THYM	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	5.19	1.21e-06	0.00127	0.52	0.47	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
THYM	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	5.19	1.21e-06	0.00127	0.48	0.47	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
THYM	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-5.19	1.21e-06	0.00127	-0.37	-0.47	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-5.19	1.21e-06	0.00127	-0.37	-0.47	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
THYM	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-5.19	1.21e-06	0.00127	-0.37	-0.47	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
THYM	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	5.19	1.22e-06	0.00127	0.57	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
THYM	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	5.19	1.22e-06	0.00128	0.47	0.47	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
THYM	cis	rs950169	0.58	rs1061737	ENSG00000235370.6	DNM1P51	5.19	1.22e-06	0.00128	0.63	0.47	Schizophrenia;	chr15:84640559	chr15:84398316~84411701:-
THYM	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-5.19	1.22e-06	0.00128	-0.9	-0.47	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
THYM	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	5.19	1.23e-06	0.00128	0.61	0.47	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-5.19	1.23e-06	0.00128	-0.61	-0.47	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
THYM	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	5.19	1.23e-06	0.00128	0.6	0.47	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
THYM	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	5.19	1.23e-06	0.00128	0.46	0.47	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	5.19	1.23e-06	0.00128	0.46	0.47	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	5.19	1.23e-06	0.00128	0.46	0.47	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	5.19	1.23e-06	0.00128	0.46	0.47	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	5.19	1.23e-06	0.00128	0.46	0.47	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	5.19	1.23e-06	0.00128	0.46	0.47	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
THYM	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-5.19	1.23e-06	0.00128	-0.39	-0.47	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-5.19	1.23e-06	0.00128	-0.39	-0.47	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-5.19	1.23e-06	0.00128	-0.39	-0.47	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
THYM	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	5.19	1.23e-06	0.00129	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
THYM	cis	rs4663866	1	rs6734408	ENSG00000186235.9	AC016757.3	5.19	1.23e-06	0.00129	1.04	0.47	Irritable bowel syndrome;	chr2:238228840	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.901	rs4663298	ENSG00000186235.9	AC016757.3	5.19	1.23e-06	0.00129	1.04	0.47	Irritable bowel syndrome;	chr2:238231266	chr2:238224552~238231677:-
THYM	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	5.19	1.23e-06	0.00129	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
THYM	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	5.19	1.23e-06	0.00129	0.48	0.47	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
THYM	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-5.19	1.23e-06	0.00129	-0.49	-0.47	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
THYM	cis	rs853679	0.517	rs17711344	ENSG00000182477.5	OR2B8P	-5.18	1.24e-06	0.00129	-0.66	-0.47	Depression;	chr6:28109824	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9393884	ENSG00000182477.5	OR2B8P	5.18	1.24e-06	0.00129	0.66	0.47	Depression;	chr6:28079011	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9393887	ENSG00000182477.5	OR2B8P	5.18	1.24e-06	0.00129	0.66	0.47	Depression;	chr6:28091242	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9380052	ENSG00000182477.5	OR2B8P	5.18	1.24e-06	0.00129	0.66	0.47	Depression;	chr6:28096845	chr6:28053228~28054165:-
THYM	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	5.18	1.24e-06	0.00129	0.45	0.47	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	5.18	1.24e-06	0.00129	0.45	0.47	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	5.18	1.24e-06	0.00129	0.45	0.47	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
THYM	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-5.18	1.24e-06	0.00129	-0.46	-0.47	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
THYM	cis	rs13256369	1	rs10110591	ENSG00000253893.2	FAM85B	5.18	1.24e-06	0.0013	0.66	0.47	Obesity-related traits;	chr8:8719098	chr8:8167819~8226614:-
THYM	cis	rs995834	0.957	rs2109066	ENSG00000267243.4	AC005307.3	-5.18	1.24e-06	0.0013	-0.41	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344420	chr19:28435388~28727777:-
THYM	cis	rs995834	0.957	rs2159327	ENSG00000267243.4	AC005307.3	-5.18	1.24e-06	0.0013	-0.41	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344664	chr19:28435388~28727777:-
THYM	cis	rs995834	0.957	rs7248916	ENSG00000267243.4	AC005307.3	-5.18	1.24e-06	0.0013	-0.41	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28344916	chr19:28435388~28727777:-
THYM	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-5.18	1.24e-06	0.0013	-0.58	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-5.18	1.24e-06	0.0013	-0.58	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-5.18	1.24e-06	0.0013	-0.58	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
THYM	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	5.18	1.25e-06	0.0013	0.59	0.47	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
THYM	cis	rs2661868	0.788	rs2708631	ENSG00000232912.4	RP5-1115A15.1	-5.18	1.25e-06	0.0013	-0.5	-0.47	Life satisfaction;	chr1:8403450	chr1:8424645~8434838:+
THYM	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.65	-0.47	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.65	-0.47	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.65	-0.47	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.65	-0.47	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.65	-0.47	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.65	-0.47	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
THYM	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	5.18	1.25e-06	0.0013	0.87	0.47	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
THYM	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.63	-0.47	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.63	-0.47	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.63	-0.47	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.63	-0.47	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-5.18	1.25e-06	0.0013	-0.63	-0.47	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
THYM	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-5.18	1.25e-06	0.00131	-0.58	-0.47	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
THYM	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-5.18	1.25e-06	0.00131	-0.57	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
THYM	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	5.18	1.26e-06	0.00131	0.58	0.47	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
THYM	cis	rs950169	0.922	rs11633534	ENSG00000235370.6	DNM1P51	5.18	1.26e-06	0.00131	0.61	0.47	Schizophrenia;	chr15:84581411	chr15:84398316~84411701:-
THYM	cis	rs950169	0.65	rs12902052	ENSG00000235370.6	DNM1P51	5.18	1.26e-06	0.00131	0.61	0.47	Schizophrenia;	chr15:84582607	chr15:84398316~84411701:-
THYM	cis	rs17772222	0.636	rs77528165	ENSG00000258983.2	RP11-507K2.2	5.18	1.26e-06	0.00131	0.67	0.47	Coronary artery calcification;	chr14:88794249	chr14:88499334~88515502:+
THYM	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-5.18	1.26e-06	0.00131	-0.58	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
THYM	cis	rs4718428	0.705	rs4718430	ENSG00000226824.5	RP4-756H11.3	-5.18	1.26e-06	0.00131	-0.7	-0.47	Corneal structure;	chr7:66967037	chr7:66654538~66669855:+
THYM	cis	rs995834	0.588	rs56239696	ENSG00000267320.4	AC005780.1	5.18	1.27e-06	0.00132	0.79	0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28409628	chr19:28316705~28386204:-
THYM	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-5.18	1.27e-06	0.00132	-0.77	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
THYM	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-5.18	1.27e-06	0.00132	-0.77	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-5.18	1.27e-06	0.00132	-0.77	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-5.18	1.27e-06	0.00132	-0.77	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
THYM	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-5.18	1.27e-06	0.00132	-0.36	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
THYM	cis	rs3096299	0.967	rs3102383	ENSG00000274627.1	RP11-104N10.2	5.18	1.28e-06	0.00133	0.53	0.47	Multiple myeloma (IgH translocation);	chr16:89344887	chr16:89516797~89522217:+
THYM	cis	rs4835473	0.9	rs10003922	ENSG00000251600.4	RP11-673E1.1	-5.18	1.28e-06	0.00133	-0.51	-0.47	Immature fraction of reticulocytes;	chr4:143921235	chr4:143912331~143982454:+
THYM	cis	rs9309473	0.5	rs4286298	ENSG00000163016.8	ALMS1P	-5.18	1.28e-06	0.00133	-0.55	-0.47	Metabolite levels;	chr2:73654981	chr2:73644919~73685576:+
THYM	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	5.18	1.28e-06	0.00133	0.64	0.47	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
THYM	cis	rs890448	0.93	rs11937097	ENSG00000254531.1	FLJ20021	-5.18	1.28e-06	0.00133	-0.39	-0.47	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101460780	chr4:101347780~101348883:+
THYM	cis	rs2562456	0.833	rs1781872	ENSG00000268081.1	RP11-678G14.2	5.18	1.29e-06	0.00133	0.69	0.47	Pain;	chr19:21294601	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs1626404	ENSG00000268081.1	RP11-678G14.2	5.18	1.29e-06	0.00133	0.69	0.47	Pain;	chr19:21300986	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs1781867	ENSG00000268081.1	RP11-678G14.2	5.18	1.29e-06	0.00133	0.69	0.47	Pain;	chr19:21304368	chr19:21554640~21569237:-
THYM	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	5.17	1.29e-06	0.00134	0.58	0.47	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
THYM	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-5.17	1.29e-06	0.00134	-0.62	-0.47	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
THYM	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	5.17	1.29e-06	0.00134	0.62	0.47	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
THYM	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-5.17	1.29e-06	0.00134	-0.62	-0.47	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
THYM	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-5.17	1.29e-06	0.00134	-0.62	-0.47	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
THYM	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-5.17	1.29e-06	0.00134	-0.62	-0.47	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
THYM	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-5.17	1.29e-06	0.00134	-0.62	-0.47	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
THYM	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	5.17	1.29e-06	0.00134	0.48	0.47	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	5.17	1.29e-06	0.00134	0.48	0.47	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	5.17	1.29e-06	0.00134	0.48	0.47	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	5.17	1.29e-06	0.00134	0.48	0.47	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
THYM	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	5.17	1.29e-06	0.00134	0.84	0.47	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
THYM	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	5.17	1.29e-06	0.00134	0.52	0.47	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	5.17	1.29e-06	0.00134	0.52	0.47	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-5.17	1.29e-06	0.00134	-0.52	-0.47	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
THYM	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-5.17	1.29e-06	0.00134	-0.5	-0.47	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
THYM	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-5.17	1.3e-06	0.00134	-0.5	-0.47	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
THYM	cis	rs7927592	0.731	rs488381	ENSG00000222339.1	AP000807.2	-5.17	1.3e-06	0.00134	-0.54	-0.47	Total body bone mineral density;	chr11:68524225	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.731	rs2840367	ENSG00000222339.1	AP000807.2	-5.17	1.3e-06	0.00134	-0.54	-0.47	Total body bone mineral density;	chr11:68534633	chr11:68505572~68505651:-
THYM	cis	rs189798	0.845	rs330904	ENSG00000253893.2	FAM85B	5.17	1.3e-06	0.00134	0.63	0.47	Myopia (pathological);	chr8:9134315	chr8:8167819~8226614:-
THYM	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-5.17	1.3e-06	0.00134	-0.63	-0.47	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
THYM	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	5.17	1.3e-06	0.00135	0.51	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
THYM	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	5.17	1.3e-06	0.00135	0.38	0.47	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
THYM	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	5.17	1.31e-06	0.00135	0.74	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
THYM	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	5.17	1.31e-06	0.00135	0.65	0.47	Depression;	chr6:28251492	chr6:28176188~28176674:+
THYM	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	5.17	1.31e-06	0.00135	0.52	0.47	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
THYM	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-5.17	1.31e-06	0.00135	-0.39	-0.47	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
THYM	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	5.17	1.31e-06	0.00135	0.45	0.47	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
THYM	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-5.17	1.31e-06	0.00135	-0.48	-0.47	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
THYM	cis	rs13256369	0.901	rs12681298	ENSG00000253893.2	FAM85B	5.17	1.31e-06	0.00135	0.67	0.47	Obesity-related traits;	chr8:8708725	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs34762800	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8701784	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.708	rs11783670	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8701884	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.755	rs11776987	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8701891	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs11995449	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8702388	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs2280560	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8703092	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs4840350	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8703932	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs1060106	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8703942	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs11249883	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8704027	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs12681925	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8704139	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs12680019	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8704188	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.708	rs11249886	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8704511	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs11249887	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8704674	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.755	rs12550057	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8704758	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.755	rs12680167	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8704957	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs13281933	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8705155	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs13280101	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8705263	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs13255789	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8705281	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.756	rs13282580	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8705393	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs13256404	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8705464	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.756	rs13280759	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8705485	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs13258283	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8706120	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs13249700	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8706127	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs13254997	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8706243	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs13255061	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8706324	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs12541477	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8706385	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs13266562	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8706555	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs13256611	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8706831	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs11786125	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8707060	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs11249888	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8707424	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.851	rs11249889	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8707482	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.951	rs10503394	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8708265	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.951	rs13260947	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8708373	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.951	rs13259955	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8708375	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.802	rs12681326	ENSG00000253893.2	FAM85B	-5.17	1.31e-06	0.00135	-0.67	-0.47	Obesity-related traits;	chr8:8708879	chr8:8167819~8226614:-
THYM	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-5.17	1.31e-06	0.00136	-0.57	-0.47	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
THYM	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-5.17	1.32e-06	0.00136	-0.83	-0.47	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
THYM	cis	rs944990	0.576	rs10821135	ENSG00000227603.1	RP11-165J3.6	5.17	1.32e-06	0.00136	0.4	0.47	Body mass index;	chr9:93476296	chr9:93435332~93437121:-
THYM	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	5.17	1.32e-06	0.00136	0.63	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	5.17	1.32e-06	0.00136	0.63	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	5.17	1.32e-06	0.00136	0.63	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
THYM	cis	rs950169	0.922	rs11638445	ENSG00000235370.6	DNM1P51	5.17	1.32e-06	0.00136	0.62	0.47	Schizophrenia;	chr15:84594463	chr15:84398316~84411701:-
THYM	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	5.17	1.32e-06	0.00136	0.61	0.47	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
THYM	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	5.17	1.32e-06	0.00136	0.43	0.47	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
THYM	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-5.17	1.33e-06	0.00136	-0.53	-0.47	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
THYM	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	5.17	1.33e-06	0.00136	0.4	0.47	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
THYM	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	5.17	1.33e-06	0.00136	0.47	0.47	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	5.17	1.33e-06	0.00136	0.47	0.47	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	5.17	1.33e-06	0.00136	0.47	0.47	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
THYM	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	5.17	1.33e-06	0.00136	0.43	0.47	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
THYM	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	5.17	1.33e-06	0.00137	0.64	0.47	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
THYM	cis	rs11168351	0.927	rs7971880	ENSG00000240399.1	RP1-228P16.1	5.17	1.33e-06	0.00137	0.48	0.47	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48054813~48055591:-
THYM	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	5.17	1.33e-06	0.00137	0.4	0.47	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
THYM	cis	rs944990	0.576	rs6479484	ENSG00000227603.1	RP11-165J3.6	5.17	1.33e-06	0.00137	0.4	0.47	Body mass index;	chr9:93454288	chr9:93435332~93437121:-
THYM	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-5.17	1.33e-06	0.00137	-0.62	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
THYM	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	5.17	1.33e-06	0.00137	0.55	0.47	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
THYM	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	5.17	1.33e-06	0.00137	0.47	0.47	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	5.17	1.33e-06	0.00137	0.47	0.47	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
THYM	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-5.17	1.34e-06	0.00137	-0.55	-0.47	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
THYM	cis	rs67180937	0.882	rs17163313	ENSG00000272750.1	RP11-378J18.8	-5.17	1.34e-06	0.00137	-0.61	-0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222626283	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-5.17	1.34e-06	0.00137	-0.61	-0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
THYM	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	5.17	1.34e-06	0.00138	0.41	0.47	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
THYM	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-5.17	1.34e-06	0.00138	-0.53	-0.47	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
THYM	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-5.17	1.34e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-5.17	1.34e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-5.17	1.34e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-5.17	1.34e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-5.17	1.34e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-5.17	1.34e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-5.17	1.34e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
THYM	cis	rs7772486	0.875	rs1331645	ENSG00000235652.6	RP11-545I5.3	5.17	1.34e-06	0.00138	0.34	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145799409~145886585:+
THYM	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-5.16	1.34e-06	0.00138	-0.56	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
THYM	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-5.16	1.35e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-5.16	1.35e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-5.16	1.35e-06	0.00138	-0.38	-0.47	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
THYM	cis	rs7826238	0.543	rs2976908	ENSG00000253893.2	FAM85B	-5.16	1.35e-06	0.00138	-0.58	-0.47	Systolic blood pressure;	chr8:8488264	chr8:8167819~8226614:-
THYM	cis	rs904251	0.523	rs9369005	ENSG00000227920.2	RP1-153P14.5	-5.16	1.35e-06	0.00138	-0.6	-0.47	Cognitive performance;	chr6:37515333	chr6:37545145~37550860:+
THYM	cis	rs7182621	0.774	rs12101368	ENSG00000182397.13	DNM1P46	5.16	1.35e-06	0.00138	0.56	0.47	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99790156~99806927:-
THYM	cis	rs599083	0.59	rs10791984	ENSG00000212093.1	AP000807.1	-5.16	1.35e-06	0.00139	-0.42	-0.47	Bone mineral density (spine);	chr11:68640367	chr11:68506083~68506166:-
THYM	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-5.16	1.36e-06	0.0014	-0.43	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-5.16	1.36e-06	0.0014	-0.43	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
THYM	cis	rs995834	0.743	rs4806332	ENSG00000260725.1	AC005307.1	-5.16	1.36e-06	0.0014	-0.45	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28366100	chr19:28418483~28429490:-
THYM	cis	rs995834	0.589	rs6508802	ENSG00000260725.1	AC005307.1	-5.16	1.36e-06	0.0014	-0.47	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362304	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs758313	ENSG00000260725.1	AC005307.1	-5.16	1.36e-06	0.0014	-0.47	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363094	chr19:28418483~28429490:-
THYM	cis	rs995834	0.742	rs1155575	ENSG00000260725.1	AC005307.1	-5.16	1.36e-06	0.0014	-0.47	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28369526	chr19:28418483~28429490:-
THYM	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-5.16	1.36e-06	0.0014	-0.6	-0.47	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-5.16	1.36e-06	0.0014	-0.6	-0.47	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
THYM	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	5.16	1.37e-06	0.0014	0.53	0.47	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
THYM	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-5.16	1.37e-06	0.0014	-0.57	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
THYM	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	5.16	1.37e-06	0.00141	0.44	0.47	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
THYM	cis	rs1560104	0.597	rs12708757	ENSG00000259899.1	CTD-3037G24.3	-5.16	1.37e-06	0.00141	-0.58	-0.47	Obesity-related traits;	chr16:12616724	chr16:12560756~12611044:-
THYM	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-5.16	1.38e-06	0.00142	-0.35	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
THYM	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-5.16	1.38e-06	0.00142	-0.45	-0.47	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
THYM	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-5.16	1.38e-06	0.00142	-0.45	-0.47	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
THYM	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-5.16	1.39e-06	0.00142	-0.42	-0.47	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
THYM	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	5.16	1.39e-06	0.00142	0.75	0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
THYM	cis	rs1550576	0.568	rs78794515	ENSG00000274719.1	RP11-86K22.2	5.16	1.39e-06	0.00142	0.92	0.47	Hypertension;	chr15:57995275	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.5	rs4646601	ENSG00000274719.1	RP11-86K22.2	5.16	1.39e-06	0.00142	0.92	0.47	Hypertension;	chr15:58002691	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs4646591	ENSG00000274719.1	RP11-86K22.2	5.16	1.39e-06	0.00142	0.92	0.47	Hypertension;	chr15:58010804	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs55866609	ENSG00000274719.1	RP11-86K22.2	5.16	1.39e-06	0.00142	0.92	0.47	Hypertension;	chr15:58018808	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs55665781	ENSG00000274719.1	RP11-86K22.2	5.16	1.39e-06	0.00142	0.92	0.47	Hypertension;	chr15:58018952	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs117240207	ENSG00000274719.1	RP11-86K22.2	5.16	1.39e-06	0.00142	0.92	0.47	Hypertension;	chr15:58019984	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs7495284	ENSG00000274719.1	RP11-86K22.2	5.16	1.39e-06	0.00142	0.92	0.47	Hypertension;	chr15:58025139	chr15:57990217~57990636:-
THYM	cis	rs7182621	0.509	rs12917012	ENSG00000182397.13	DNM1P46	5.16	1.39e-06	0.00142	0.51	0.47	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99790156~99806927:-
THYM	cis	rs2562456	0.793	rs279807	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21283020	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.752	rs279809	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21284729	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62110071	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21288101	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs11667392	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21289806	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs7246339	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21292495	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs55899865	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21298933	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs11667103	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21303839	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs62107469	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21312699	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs61445561	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21321230	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs57299552	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21321326	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs76688173	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21321856	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs74711277	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21322641	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62107479	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21323962	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62107531	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21326263	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs55756795	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21327257	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs57250002	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21344048	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62109218	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21346059	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62109223	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21349591	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62109225	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21353861	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs62109226	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21354111	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs62109227	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21354128	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs62109228	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21354129	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs8102783	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21355751	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs2061916	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21358906	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs4359573	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21359494	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62110367	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21365829	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.755	rs11670868	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21373613	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs55961038	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21375205	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs2358993	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21375367	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11672583	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21379363	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs17680605	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21379646	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs55875743	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21383393	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62110416	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21401924	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs2359145	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21409791	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs112195516	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21410849	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11666447	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21416270	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11666525	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21416503	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs62110424	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21416835	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs3853837	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21419172	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs3853838	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21419192	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62110426	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21420124	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs11666213	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21422843	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs2650776	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21430595	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs2562416	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21430609	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62110428	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21430854	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62110429	ENSG00000268081.1	RP11-678G14.2	5.16	1.39e-06	0.00142	0.69	0.47	Pain;	chr19:21430984	chr19:21554640~21569237:-
THYM	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	5.16	1.39e-06	0.00142	0.46	0.47	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	5.16	1.39e-06	0.00142	0.46	0.47	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	5.16	1.39e-06	0.00142	0.46	0.47	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	5.16	1.39e-06	0.00142	0.46	0.47	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
THYM	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-5.16	1.39e-06	0.00142	-0.48	-0.47	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-5.16	1.39e-06	0.00142	-0.48	-0.47	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
THYM	cis	rs1560104	0.597	rs4781300	ENSG00000259899.1	CTD-3037G24.3	-5.16	1.39e-06	0.00142	-0.57	-0.47	Obesity-related traits;	chr16:12613866	chr16:12560756~12611044:-
THYM	cis	rs13256369	0.802	rs12153	ENSG00000253893.2	FAM85B	-5.15	1.4e-06	0.00143	-0.68	-0.47	Obesity-related traits;	chr8:8703399	chr8:8167819~8226614:-
THYM	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	5.15	1.41e-06	0.00143	0.61	0.47	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
THYM	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	5.15	1.41e-06	0.00143	0.61	0.47	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
THYM	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	5.15	1.41e-06	0.00143	0.64	0.47	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
THYM	cis	rs11168351	0.927	rs10875716	ENSG00000240399.1	RP1-228P16.1	5.15	1.41e-06	0.00144	0.48	0.47	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48054813~48055591:-
THYM	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	5.15	1.41e-06	0.00144	0.57	0.47	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
THYM	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-5.15	1.41e-06	0.00144	-0.41	-0.47	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
THYM	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-5.15	1.41e-06	0.00144	-0.54	-0.47	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs10027246	ENSG00000251600.4	RP11-673E1.1	-5.15	1.42e-06	0.00144	-0.52	-0.47	Immature fraction of reticulocytes;	chr4:143935069	chr4:143912331~143982454:+
THYM	cis	rs1426063	0.61	rs72862239	ENSG00000248165.1	RP11-44F21.2	5.15	1.42e-06	0.00145	1.28	0.47	QT interval;	chr4:75071967	chr4:74993877~75034824:-
THYM	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-5.15	1.42e-06	0.00145	-0.58	-0.47	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
THYM	cis	rs28785552	0.589	rs7257371	ENSG00000250731.1	TPM3P6	-5.15	1.42e-06	0.00145	-0.62	-0.47	Response to paliperidone in schizophrenia (PANSS score);	chr19:52740657	chr19:53479350~53480091:+
THYM	cis	rs28785552	0.589	rs11669056	ENSG00000250731.1	TPM3P6	-5.15	1.42e-06	0.00145	-0.62	-0.47	Response to paliperidone in schizophrenia (PANSS score);	chr19:52741190	chr19:53479350~53480091:+
THYM	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-5.15	1.43e-06	0.00145	-0.32	-0.47	Height;	chr11:118808920	chr11:118791254~118793137:+
THYM	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	5.15	1.43e-06	0.00145	0.67	0.47	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
THYM	cis	rs13256369	0.708	rs9644772	ENSG00000253893.2	FAM85B	-5.15	1.43e-06	0.00146	-0.68	-0.47	Obesity-related traits;	chr8:8700175	chr8:8167819~8226614:-
THYM	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-5.15	1.43e-06	0.00146	-0.43	-0.47	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
THYM	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	5.15	1.43e-06	0.00146	0.59	0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
THYM	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	5.15	1.44e-06	0.00146	0.52	0.47	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	5.15	1.44e-06	0.00146	0.52	0.47	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
THYM	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	5.15	1.44e-06	0.00146	0.66	0.47	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
THYM	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-5.15	1.44e-06	0.00146	-0.34	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
THYM	cis	rs995834	0.622	rs1029661	ENSG00000267243.4	AC005307.3	-5.15	1.44e-06	0.00146	-0.46	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406394	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs7249889	ENSG00000267243.4	AC005307.3	-5.15	1.44e-06	0.00146	-0.46	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28406402	chr19:28435388~28727777:-
THYM	cis	rs4853012	0.941	rs4852329	ENSG00000257702.3	LBX2-AS1	5.15	1.44e-06	0.00147	0.56	0.47	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74502595~74504678:+
THYM	cis	rs13256369	0.95	rs13248096	ENSG00000253893.2	FAM85B	-5.15	1.45e-06	0.00148	-0.67	-0.47	Obesity-related traits;	chr8:8719966	chr8:8167819~8226614:-
THYM	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-5.15	1.46e-06	0.00148	-0.76	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
THYM	cis	rs2658782	0.704	rs2658766	ENSG00000279684.1	RP11-755E23.2	-5.15	1.46e-06	0.00148	-0.88	-0.47	Pulmonary function decline;	chr11:93499063	chr11:93286629~93288903:-
THYM	cis	rs4853012	0.752	rs13413795	ENSG00000257702.3	LBX2-AS1	5.15	1.46e-06	0.00148	0.52	0.47	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74502595~74504678:+
THYM	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	5.14	1.46e-06	0.00148	0.34	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
THYM	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	5.14	1.46e-06	0.00148	0.57	0.47	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
THYM	cis	rs904251	0.525	rs12200378	ENSG00000227920.2	RP1-153P14.5	-5.14	1.46e-06	0.00148	-0.62	-0.47	Cognitive performance;	chr6:37457528	chr6:37545145~37550860:+
THYM	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-5.14	1.46e-06	0.00149	-0.55	-0.47	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
THYM	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-5.14	1.47e-06	0.00149	-0.4	-0.47	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	5.14	1.47e-06	0.00149	0.4	0.47	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-5.14	1.47e-06	0.00149	-0.4	-0.47	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-5.14	1.47e-06	0.00149	-0.4	-0.47	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-5.14	1.47e-06	0.00149	-0.4	-0.47	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-5.14	1.47e-06	0.00149	-0.4	-0.47	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-5.14	1.47e-06	0.00149	-0.4	-0.47	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
THYM	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-5.14	1.47e-06	0.00149	-0.4	-0.47	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
THYM	cis	rs10829156	0.786	rs7077786	ENSG00000240291.1	RP11-499P20.2	5.14	1.47e-06	0.00149	0.43	0.47	Sudden cardiac arrest;	chr10:18603453	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.741	rs9731044	ENSG00000240291.1	RP11-499P20.2	5.14	1.47e-06	0.00149	0.43	0.47	Sudden cardiac arrest;	chr10:18605356	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.538	rs61840846	ENSG00000240291.1	RP11-499P20.2	5.14	1.47e-06	0.00149	0.43	0.47	Sudden cardiac arrest;	chr10:18606393	chr10:18513115~18545651:-
THYM	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-5.14	1.47e-06	0.00149	-0.42	-0.47	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
THYM	cis	rs13287066	0.692	rs72743489	ENSG00000227603.1	RP11-165J3.6	5.14	1.47e-06	0.00149	0.39	0.47	Intelligence (multi-trait analysis);	chr9:93406201	chr9:93435332~93437121:-
THYM	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	5.14	1.48e-06	0.00149	0.44	0.47	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
THYM	cis	rs7772486	0.742	rs4896851	ENSG00000235652.6	RP11-545I5.3	-5.14	1.48e-06	0.0015	-0.33	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145957823	chr6:145799409~145886585:+
THYM	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-5.14	1.48e-06	0.0015	-0.38	-0.47	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
THYM	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-5.14	1.48e-06	0.0015	-0.59	-0.47	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
THYM	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-5.14	1.49e-06	0.0015	-0.86	-0.47	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
THYM	cis	rs10129255	0.613	rs36005652	ENSG00000254329.1	IGHVII-60-1	5.14	1.49e-06	0.0015	0.46	0.47	Kawasaki disease;	chr14:106651223	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.53	rs35069612	ENSG00000254329.1	IGHVII-60-1	5.14	1.49e-06	0.0015	0.46	0.47	Kawasaki disease;	chr14:106651364	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.528	rs61997578	ENSG00000254329.1	IGHVII-60-1	5.14	1.49e-06	0.0015	0.46	0.47	Kawasaki disease;	chr14:106651717	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.56	rs61997579	ENSG00000254329.1	IGHVII-60-1	5.14	1.49e-06	0.0015	0.46	0.47	Kawasaki disease;	chr14:106651755	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.528	rs17113214	ENSG00000254329.1	IGHVII-60-1	5.14	1.49e-06	0.0015	0.46	0.47	Kawasaki disease;	chr14:106651954	chr14:106637718~106637973:-
THYM	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-5.14	1.49e-06	0.00151	-0.61	-0.47	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
THYM	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-5.14	1.49e-06	0.00151	-0.59	-0.47	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
THYM	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-5.14	1.49e-06	0.00151	-0.59	-0.47	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
THYM	cis	rs2658782	0.704	rs2605614	ENSG00000279684.1	RP11-755E23.2	-5.14	1.5e-06	0.00151	-0.87	-0.47	Pulmonary function decline;	chr11:93499579	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.615	rs2605615	ENSG00000279684.1	RP11-755E23.2	-5.14	1.5e-06	0.00151	-0.87	-0.47	Pulmonary function decline;	chr11:93499902	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-5.14	1.5e-06	0.00151	-0.87	-0.47	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
THYM	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	5.14	1.5e-06	0.00151	0.52	0.47	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
THYM	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-5.14	1.5e-06	0.00152	-0.63	-0.47	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
THYM	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-5.14	1.5e-06	0.00152	-0.35	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-5.14	1.5e-06	0.00152	-0.35	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
THYM	cis	rs3740713	0.925	rs55727925	ENSG00000256464.1	YWHABP2	5.14	1.51e-06	0.00152	0.81	0.47	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr11:18490243~18490955:-
THYM	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	5.14	1.51e-06	0.00152	0.41	0.47	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	5.14	1.51e-06	0.00152	0.41	0.47	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	5.14	1.51e-06	0.00152	0.41	0.47	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-5.14	1.51e-06	0.00152	-0.41	-0.47	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
THYM	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	5.14	1.51e-06	0.00152	0.33	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
THYM	cis	rs1560104	0.536	rs12446050	ENSG00000259899.1	CTD-3037G24.3	5.14	1.51e-06	0.00152	0.55	0.47	Obesity-related traits;	chr16:12621408	chr16:12560756~12611044:-
THYM	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
THYM	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-5.14	1.52e-06	0.00153	-0.39	-0.47	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
THYM	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	5.14	1.52e-06	0.00153	0.35	0.47	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
THYM	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	5.14	1.52e-06	0.00153	0.35	0.47	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
THYM	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	5.14	1.52e-06	0.00153	0.35	0.47	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
THYM	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-5.14	1.52e-06	0.00153	-0.42	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-5.14	1.52e-06	0.00153	-0.42	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-5.14	1.52e-06	0.00153	-0.42	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-5.14	1.52e-06	0.00153	-0.42	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-5.14	1.52e-06	0.00153	-0.42	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
THYM	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	5.14	1.52e-06	0.00153	0.43	0.47	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
THYM	cis	rs7927592	0.763	rs7120876	ENSG00000222339.1	AP000807.2	5.13	1.53e-06	0.00154	0.54	0.47	Total body bone mineral density;	chr11:68493930	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.763	rs7129248	ENSG00000222339.1	AP000807.2	5.13	1.53e-06	0.00154	0.54	0.47	Total body bone mineral density;	chr11:68495808	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.763	rs11822059	ENSG00000222339.1	AP000807.2	5.13	1.53e-06	0.00154	0.54	0.47	Total body bone mineral density;	chr11:68533354	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.626	rs11228279	ENSG00000222339.1	AP000807.2	-5.13	1.53e-06	0.00154	-0.54	-0.47	Total body bone mineral density;	chr11:68542212	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.763	rs10896340	ENSG00000222339.1	AP000807.2	-5.13	1.53e-06	0.00154	-0.54	-0.47	Total body bone mineral density;	chr11:68545177	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	5.13	1.53e-06	0.00154	0.48	0.47	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
THYM	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	5.13	1.53e-06	0.00154	0.47	0.47	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
THYM	cis	rs747334	0.58	rs4933634	ENSG00000225519.1	RP11-236B18.2	-5.13	1.53e-06	0.00154	-0.42	-0.47	Fibroblast growth factor basic levels;	chr10:90977001	chr10:90994620~91006390:+
THYM	cis	rs747334	0.58	rs747335	ENSG00000225519.1	RP11-236B18.2	5.13	1.53e-06	0.00154	0.42	0.47	Fibroblast growth factor basic levels;	chr10:90985108	chr10:90994620~91006390:+
THYM	cis	rs950169	0.58	rs17532346	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84628264	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs11634322	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84628978	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs4603535	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84630641	chr15:84398316~84411701:-
THYM	cis	rs950169	0.541	rs10795	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84634066	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs36126054	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84634492	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs11633762	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84643921	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs11630887	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84649784	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs11636189	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84650323	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs35516100	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84652199	chr15:84398316~84411701:-
THYM	cis	rs950169	0.58	rs62021208	ENSG00000235370.6	DNM1P51	5.13	1.53e-06	0.00154	0.62	0.47	Schizophrenia;	chr15:84653013	chr15:84398316~84411701:-
THYM	cis	rs7182621	0.846	rs12915935	ENSG00000182397.13	DNM1P46	5.13	1.53e-06	0.00154	0.55	0.47	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99790156~99806927:-
THYM	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	5.13	1.53e-06	0.00154	0.35	0.47	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
THYM	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	5.13	1.53e-06	0.00154	0.47	0.47	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
THYM	cis	rs1560104	0.597	rs735819	ENSG00000259899.1	CTD-3037G24.3	5.13	1.54e-06	0.00154	0.53	0.47	Obesity-related traits;	chr16:12618370	chr16:12560756~12611044:-
THYM	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	5.13	1.54e-06	0.00154	0.58	0.47	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
THYM	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	5.13	1.54e-06	0.00154	0.58	0.47	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
THYM	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	5.13	1.54e-06	0.00154	0.42	0.47	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
THYM	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	5.13	1.54e-06	0.00154	0.52	0.47	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	5.13	1.54e-06	0.00154	0.52	0.47	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	5.13	1.54e-06	0.00154	0.52	0.47	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	5.13	1.54e-06	0.00154	0.52	0.47	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
THYM	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	5.13	1.54e-06	0.00155	0.35	0.47	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
THYM	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	5.13	1.54e-06	0.00155	0.35	0.47	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
THYM	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-5.13	1.54e-06	0.00155	-0.6	-0.47	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-5.13	1.54e-06	0.00155	-0.6	-0.47	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
THYM	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-5.13	1.54e-06	0.00155	-0.5	-0.47	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
THYM	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	5.13	1.55e-06	0.00155	0.47	0.47	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
THYM	cis	rs904251	0.6	rs1874736	ENSG00000227920.2	RP1-153P14.5	-5.13	1.55e-06	0.00155	-0.62	-0.47	Cognitive performance;	chr6:37480218	chr6:37545145~37550860:+
THYM	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	5.13	1.55e-06	0.00155	0.47	0.47	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
THYM	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-5.13	1.56e-06	0.00156	-0.35	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-5.13	1.56e-06	0.00156	-0.35	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
THYM	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	5.13	1.56e-06	0.00156	0.57	0.47	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
THYM	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	5.13	1.56e-06	0.00156	0.43	0.47	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
THYM	cis	rs66823261	0.778	rs2906332	ENSG00000223508.5	RPL23AP53	5.13	1.56e-06	0.00156	0.6	0.47	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:213186~232231:-
THYM	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-5.13	1.56e-06	0.00156	-0.74	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-5.13	1.56e-06	0.00156	-0.74	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs6004657	ENSG00000272977.1	CTA-390C10.10	-5.13	1.56e-06	0.00156	-0.74	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25476218~25479971:+
THYM	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-5.13	1.56e-06	0.00156	-0.74	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
THYM	cis	rs9309473	0.519	rs2421670	ENSG00000163016.8	ALMS1P	-5.13	1.56e-06	0.00157	-0.54	-0.47	Metabolite levels;	chr2:73659534	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs12618600	ENSG00000163016.8	ALMS1P	-5.13	1.56e-06	0.00157	-0.54	-0.47	Metabolite levels;	chr2:73663555	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.5	rs2421582	ENSG00000163016.8	ALMS1P	-5.13	1.56e-06	0.00157	-0.54	-0.47	Metabolite levels;	chr2:73671293	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs2421583	ENSG00000163016.8	ALMS1P	-5.13	1.56e-06	0.00157	-0.54	-0.47	Metabolite levels;	chr2:73671658	chr2:73644919~73685576:+
THYM	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-5.13	1.57e-06	0.00157	-0.58	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
THYM	cis	rs2661868	0.918	rs2636314	ENSG00000232912.4	RP5-1115A15.1	-5.13	1.57e-06	0.00157	-0.49	-0.47	Life satisfaction;	chr1:8380583	chr1:8424645~8434838:+
THYM	cis	rs904251	0.772	rs10692	ENSG00000227920.2	RP1-153P14.5	-5.13	1.57e-06	0.00157	-0.71	-0.47	Cognitive performance;	chr6:37483138	chr6:37545145~37550860:+
THYM	cis	rs904251	0.772	rs756202	ENSG00000227920.2	RP1-153P14.5	-5.13	1.57e-06	0.00157	-0.71	-0.47	Cognitive performance;	chr6:37492574	chr6:37545145~37550860:+
THYM	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	5.13	1.57e-06	0.00157	0.35	0.47	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
THYM	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-5.13	1.57e-06	0.00157	-0.63	-0.47	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
THYM	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-5.13	1.57e-06	0.00157	-0.57	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-5.13	1.57e-06	0.00157	-0.57	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-5.13	1.57e-06	0.00157	-0.57	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
THYM	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-5.13	1.58e-06	0.00157	-0.41	-0.47	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
THYM	cis	rs7829975	0.502	rs11785183	ENSG00000253893.2	FAM85B	5.13	1.58e-06	0.00158	0.59	0.47	Mood instability;	chr8:8708447	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.539	rs883647	ENSG00000253893.2	FAM85B	5.13	1.58e-06	0.00158	0.59	0.47	Mood instability;	chr8:8712214	chr8:8167819~8226614:-
THYM	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	5.13	1.58e-06	0.00158	0.53	0.47	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
THYM	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	5.13	1.58e-06	0.00158	0.57	0.47	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-5.13	1.58e-06	0.00158	-0.57	-0.47	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
THYM	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	5.13	1.58e-06	0.00158	0.43	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
THYM	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-5.13	1.58e-06	0.00158	-0.43	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
THYM	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-5.13	1.58e-06	0.00158	-0.43	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
THYM	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-5.13	1.58e-06	0.00158	-0.43	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
THYM	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	5.12	1.59e-06	0.00158	0.43	0.47	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
THYM	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	5.12	1.59e-06	0.00158	0.67	0.47	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
THYM	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	5.12	1.59e-06	0.00159	0.65	0.47	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
THYM	cis	rs7927592	0.763	rs1193699	ENSG00000222339.1	AP000807.2	5.12	1.59e-06	0.00159	0.57	0.47	Total body bone mineral density;	chr11:68482012	chr11:68505572~68505651:-
THYM	cis	rs75422866	0.85	rs73111220	ENSG00000257433.4	RP1-197B17.3	5.12	1.6e-06	0.00159	0.91	0.47	Pneumonia;	chr12:47578764	chr12:47706085~47742294:+
THYM	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	5.12	1.6e-06	0.00159	0.38	0.47	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
THYM	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	5.12	1.6e-06	0.00159	0.38	0.47	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	5.12	1.6e-06	0.00159	0.38	0.47	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	5.12	1.6e-06	0.00159	0.38	0.47	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	5.12	1.6e-06	0.00159	0.38	0.47	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-5.12	1.6e-06	0.00159	-0.38	-0.47	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-5.12	1.6e-06	0.00159	-0.38	-0.47	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-5.12	1.6e-06	0.00159	-0.38	-0.47	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-5.12	1.6e-06	0.00159	-0.38	-0.47	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.774	rs2748503	ENSG00000235652.6	RP11-545I5.3	5.12	1.6e-06	0.00159	0.33	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145973906	chr6:145799409~145886585:+
THYM	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-5.12	1.6e-06	0.0016	-0.5	-0.47	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
THYM	cis	rs904251	0.523	rs10807184	ENSG00000227920.2	RP1-153P14.5	-5.12	1.6e-06	0.0016	-0.59	-0.47	Cognitive performance;	chr6:37515937	chr6:37545145~37550860:+
THYM	cis	rs904251	0.561	rs1757189	ENSG00000227920.2	RP1-153P14.5	-5.12	1.6e-06	0.0016	-0.59	-0.47	Cognitive performance;	chr6:37515951	chr6:37545145~37550860:+
THYM	cis	rs1757171	0.542	rs3818985	ENSG00000227920.2	RP1-153P14.5	-5.12	1.6e-06	0.0016	-0.59	-0.47	Cognitive performance;	chr6:37516438	chr6:37545145~37550860:+
THYM	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	5.12	1.6e-06	0.0016	0.49	0.47	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
THYM	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	5.12	1.6e-06	0.0016	0.49	0.47	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
THYM	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-5.12	1.61e-06	0.0016	-0.52	-0.47	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
THYM	cis	rs995834	0.552	rs7251838	ENSG00000267243.4	AC005307.3	-5.12	1.61e-06	0.0016	-0.46	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28424805	chr19:28435388~28727777:-
THYM	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	5.12	1.61e-06	0.0016	0.7	0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.12	1.61e-06	0.0016	0.7	0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
THYM	cis	rs73198271	0.751	rs617813	ENSG00000253893.2	FAM85B	5.12	1.61e-06	0.0016	0.7	0.47	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8167819~8226614:-
THYM	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-5.12	1.61e-06	0.00161	-0.38	-0.47	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
THYM	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	5.12	1.61e-06	0.00161	0.48	0.47	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
THYM	cis	rs6782228	0.606	rs6775270	ENSG00000277250.1	Metazoa_SRP	-5.12	1.62e-06	0.00161	-0.6	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs6807019	ENSG00000277250.1	Metazoa_SRP	-5.12	1.62e-06	0.00161	-0.6	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs4857861	ENSG00000277250.1	Metazoa_SRP	-5.12	1.62e-06	0.00161	-0.6	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs4857919	ENSG00000277250.1	Metazoa_SRP	-5.12	1.62e-06	0.00161	-0.6	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128673681~128674021:-
THYM	cis	rs42490	0.576	rs376962	ENSG00000251136.7	RP11-37B2.1	-5.12	1.63e-06	0.00162	-0.38	-0.47	Leprosy;	chr8:89862004	chr8:89609409~89757727:-
THYM	cis	rs42490	0.576	rs386587	ENSG00000251136.7	RP11-37B2.1	-5.12	1.63e-06	0.00162	-0.38	-0.47	Leprosy;	chr8:89862772	chr8:89609409~89757727:-
THYM	cis	rs42490	0.576	rs381456	ENSG00000251136.7	RP11-37B2.1	-5.12	1.63e-06	0.00162	-0.38	-0.47	Leprosy;	chr8:89865176	chr8:89609409~89757727:-
THYM	cis	rs10129255	0.517	rs11625572	ENSG00000254329.1	IGHVII-60-1	5.12	1.63e-06	0.00162	0.46	0.47	Kawasaki disease;	chr14:106656426	chr14:106637718~106637973:-
THYM	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	5.12	1.63e-06	0.00162	0.52	0.47	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
THYM	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	5.12	1.64e-06	0.00163	0.47	0.47	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	5.12	1.64e-06	0.00163	0.47	0.47	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
THYM	cis	rs7927592	0.731	rs643609	ENSG00000222339.1	AP000807.2	5.12	1.64e-06	0.00163	0.56	0.47	Total body bone mineral density;	chr11:68474365	chr11:68505572~68505651:-
THYM	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-5.12	1.64e-06	0.00163	-0.57	-0.47	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-5.12	1.64e-06	0.00163	-0.57	-0.47	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-5.12	1.64e-06	0.00163	-0.57	-0.47	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
THYM	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	5.12	1.64e-06	0.00163	0.72	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	5.12	1.64e-06	0.00163	0.72	0.47	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
THYM	cis	rs13256369	0.901	rs12679831	ENSG00000253893.2	FAM85B	-5.12	1.64e-06	0.00163	-0.68	-0.47	Obesity-related traits;	chr8:8708901	chr8:8167819~8226614:-
THYM	cis	rs13256369	0.901	rs12681327	ENSG00000253893.2	FAM85B	-5.12	1.64e-06	0.00163	-0.68	-0.47	Obesity-related traits;	chr8:8708904	chr8:8167819~8226614:-
THYM	cis	rs5769707	1	rs5769707	ENSG00000264139.1	MIR3667	-5.12	1.64e-06	0.00163	-0.52	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49543393~49543466:-
THYM	cis	rs5769707	0.904	rs7288869	ENSG00000264139.1	MIR3667	-5.12	1.64e-06	0.00163	-0.52	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49543393~49543466:-
THYM	cis	rs17772222	0.63	rs7141608	ENSG00000258983.2	RP11-507K2.2	-5.12	1.64e-06	0.00163	-0.51	-0.47	Coronary artery calcification;	chr14:88514045	chr14:88499334~88515502:+
THYM	cis	rs7560272	0.538	rs12619258	ENSG00000273245.1	RP11-434P11.2	-5.12	1.64e-06	0.00163	-0.59	-0.47	Schizophrenia;	chr2:73708788	chr2:73750256~73750786:-
THYM	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-5.12	1.64e-06	0.00163	-0.61	-0.47	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
THYM	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	5.12	1.64e-06	0.00163	0.52	0.47	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
THYM	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-5.12	1.65e-06	0.00163	-0.62	-0.47	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	5.12	1.65e-06	0.00163	0.62	0.47	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
THYM	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-5.12	1.65e-06	0.00163	-0.43	-0.47	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
THYM	cis	rs7772486	0.594	rs6901864	ENSG00000235652.6	RP11-545I5.3	-5.12	1.65e-06	0.00163	-0.34	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145701914	chr6:145799409~145886585:+
THYM	cis	rs5769707	0.935	rs5770594	ENSG00000264139.1	MIR3667	-5.12	1.65e-06	0.00163	-0.52	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49543393~49543466:-
THYM	cis	rs5769707	0.967	rs4524218	ENSG00000264139.1	MIR3667	-5.12	1.65e-06	0.00163	-0.52	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49543393~49543466:-
THYM	cis	rs890448	0.896	rs1863573	ENSG00000254531.1	FLJ20021	-5.12	1.65e-06	0.00163	-0.39	-0.47	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101480630	chr4:101347780~101348883:+
THYM	cis	rs890448	0.86	rs6826588	ENSG00000254531.1	FLJ20021	-5.12	1.65e-06	0.00163	-0.39	-0.47	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101481713	chr4:101347780~101348883:+
THYM	cis	rs890448	0.896	rs3974654	ENSG00000254531.1	FLJ20021	-5.12	1.65e-06	0.00163	-0.39	-0.47	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101482523	chr4:101347780~101348883:+
THYM	cis	rs890448	0.86	rs6833608	ENSG00000254531.1	FLJ20021	-5.12	1.65e-06	0.00163	-0.39	-0.47	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101482978	chr4:101347780~101348883:+
THYM	cis	rs890448	0.896	rs1016127	ENSG00000254531.1	FLJ20021	-5.12	1.65e-06	0.00163	-0.39	-0.47	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101484796	chr4:101347780~101348883:+
THYM	cis	rs890448	0.86	rs1863575	ENSG00000254531.1	FLJ20021	-5.12	1.65e-06	0.00163	-0.39	-0.47	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101485952	chr4:101347780~101348883:+
THYM	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-5.12	1.65e-06	0.00164	-0.59	-0.47	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
THYM	cis	rs7927592	0.717	rs7126451	ENSG00000222339.1	AP000807.2	-5.12	1.65e-06	0.00164	-0.54	-0.47	Total body bone mineral density;	chr11:68489918	chr11:68505572~68505651:-
THYM	cis	rs7702057	0.53	rs7703978	ENSG00000271918.1	CTD-2287O16.5	5.11	1.65e-06	0.00164	0.74	0.47	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116083807~116085416:-
THYM	cis	rs995834	0.585	rs720923	ENSG00000267243.4	AC005307.3	-5.11	1.66e-06	0.00164	-0.46	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28423935	chr19:28435388~28727777:-
THYM	cis	rs904251	0.6	rs11756241	ENSG00000227920.2	RP1-153P14.5	-5.11	1.66e-06	0.00164	-0.62	-0.47	Cognitive performance;	chr6:37477325	chr6:37545145~37550860:+
THYM	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	5.11	1.67e-06	0.00165	0.51	0.47	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	5.11	1.67e-06	0.00165	0.51	0.47	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
THYM	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	5.11	1.67e-06	0.00166	0.57	0.47	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	5.11	1.67e-06	0.00166	0.57	0.47	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
THYM	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	5.11	1.67e-06	0.00166	0.57	0.47	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	5.11	1.67e-06	0.00166	0.57	0.47	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
THYM	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	5.11	1.67e-06	0.00166	0.56	0.47	Height;	chr6:109490935	chr6:109382795~109383666:+
THYM	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-5.11	1.68e-06	0.00166	-0.4	-0.47	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
THYM	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	5.11	1.69e-06	0.00167	0.51	0.47	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
THYM	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-5.11	1.69e-06	0.00167	-0.89	-0.47	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-5.11	1.69e-06	0.00167	-0.89	-0.47	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-5.11	1.69e-06	0.00167	-0.89	-0.47	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-5.11	1.69e-06	0.00167	-0.89	-0.47	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
THYM	cis	rs10129255	0.5	rs2105989	ENSG00000254329.1	IGHVII-60-1	5.11	1.69e-06	0.00167	0.41	0.47	Kawasaki disease;	chr14:106682199	chr14:106637718~106637973:-
THYM	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-5.11	1.69e-06	0.00167	-0.57	-0.47	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
THYM	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-5.11	1.69e-06	0.00167	-0.57	-0.47	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
THYM	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-5.11	1.69e-06	0.00167	-0.57	-0.47	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
THYM	cis	rs6782228	0.606	rs10048945	ENSG00000277250.1	Metazoa_SRP	-5.11	1.7e-06	0.00167	-0.59	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128673681~128674021:-
THYM	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-5.11	1.7e-06	0.00167	-0.45	-0.47	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
THYM	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-5.11	1.7e-06	0.00168	-0.54	-0.47	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
THYM	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-5.11	1.71e-06	0.00168	-0.83	-0.47	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
THYM	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	5.11	1.72e-06	0.00169	0.59	0.47	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
THYM	cis	rs73198271	0.737	rs565203	ENSG00000253893.2	FAM85B	5.11	1.72e-06	0.00169	0.67	0.47	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.737	rs535094	ENSG00000253893.2	FAM85B	5.11	1.72e-06	0.00169	0.67	0.47	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.765	rs534103	ENSG00000253893.2	FAM85B	5.11	1.72e-06	0.00169	0.67	0.47	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:8167819~8226614:-
THYM	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-5.11	1.72e-06	0.00169	-0.43	-0.47	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
THYM	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-5.11	1.72e-06	0.00169	-0.64	-0.47	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
THYM	cis	rs17772222	0.597	rs17700521	ENSG00000258983.2	RP11-507K2.2	5.11	1.72e-06	0.00169	0.66	0.47	Coronary artery calcification;	chr14:88849531	chr14:88499334~88515502:+
THYM	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-5.11	1.72e-06	0.00169	-0.42	-0.47	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
THYM	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	5.11	1.72e-06	0.00169	0.42	0.47	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
THYM	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	5.1	1.72e-06	0.00169	0.4	0.47	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
THYM	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	5.1	1.72e-06	0.00169	0.4	0.47	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
THYM	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	5.1	1.72e-06	0.00169	0.4	0.47	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
THYM	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	5.1	1.72e-06	0.0017	0.43	0.47	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
THYM	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	5.1	1.72e-06	0.0017	0.51	0.47	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
THYM	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	5.1	1.73e-06	0.0017	0.39	0.47	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
THYM	cis	rs13256369	0.851	rs11249890	ENSG00000253893.2	FAM85B	-5.1	1.73e-06	0.0017	-0.68	-0.47	Obesity-related traits;	chr8:8707735	chr8:8167819~8226614:-
THYM	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	5.1	1.73e-06	0.0017	0.58	0.47	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
THYM	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	5.1	1.73e-06	0.0017	0.56	0.47	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
THYM	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	5.1	1.73e-06	0.0017	0.61	0.47	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
THYM	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	5.1	1.73e-06	0.0017	0.61	0.47	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
THYM	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	5.1	1.75e-06	0.00172	0.58	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
THYM	cis	rs1550576	0.568	rs4646637	ENSG00000274719.1	RP11-86K22.2	5.1	1.75e-06	0.00172	0.95	0.47	Hypertension;	chr15:57958797	chr15:57990217~57990636:-
THYM	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-5.1	1.75e-06	0.00172	-0.69	-0.47	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-5.1	1.75e-06	0.00172	-0.69	-0.47	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
THYM	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-5.1	1.75e-06	0.00172	-0.39	-0.47	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
THYM	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-5.1	1.75e-06	0.00172	-0.53	-0.47	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-5.1	1.75e-06	0.00172	-0.53	-0.47	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	5.1	1.75e-06	0.00172	0.53	0.47	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	5.1	1.75e-06	0.00172	0.53	0.47	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	5.1	1.75e-06	0.00172	0.53	0.47	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	5.1	1.75e-06	0.00172	0.53	0.47	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
THYM	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-5.1	1.75e-06	0.00172	-0.81	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
THYM	cis	rs4853012	0.941	rs4852329	ENSG00000272183.1	RP11-523H20.3	5.1	1.75e-06	0.00172	0.67	0.47	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74501717~74502365:+
THYM	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-5.1	1.76e-06	0.00173	-0.58	-0.47	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
THYM	cis	rs9907295	0.591	rs3760327	ENSG00000270977.1	AC015849.16	-5.1	1.76e-06	0.00173	-0.56	-0.47	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35893707~35911023:-
THYM	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	5.1	1.76e-06	0.00173	0.35	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
THYM	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.1	1.76e-06	0.00173	0.68	0.47	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
THYM	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-5.1	1.76e-06	0.00173	-0.34	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
THYM	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-5.1	1.77e-06	0.00173	-0.6	-0.47	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-5.1	1.77e-06	0.00173	-0.6	-0.47	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
THYM	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	5.1	1.77e-06	0.00173	0.78	0.47	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
THYM	cis	rs42490	0.576	rs390536	ENSG00000251136.7	RP11-37B2.1	-5.1	1.77e-06	0.00174	-0.38	-0.47	Leprosy;	chr8:89857122	chr8:89609409~89757727:-
THYM	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	5.1	1.77e-06	0.00174	0.4	0.47	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
THYM	cis	rs7560272	0.501	rs11126417	ENSG00000273245.1	RP11-434P11.2	5.1	1.78e-06	0.00174	0.58	0.47	Schizophrenia;	chr2:73747188	chr2:73750256~73750786:-
THYM	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-5.1	1.78e-06	0.00174	-0.34	-0.47	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
THYM	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	5.1	1.78e-06	0.00174	0.74	0.47	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
THYM	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	5.1	1.78e-06	0.00175	0.63	0.47	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
THYM	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-5.1	1.78e-06	0.00175	-0.56	-0.47	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
THYM	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	5.1	1.78e-06	0.00175	0.45	0.47	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
THYM	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	5.1	1.78e-06	0.00175	0.45	0.47	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
THYM	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	5.1	1.79e-06	0.00175	0.47	0.47	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	5.1	1.79e-06	0.00175	0.47	0.47	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
THYM	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	5.1	1.79e-06	0.00175	0.47	0.47	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	5.1	1.79e-06	0.00175	0.47	0.47	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	5.1	1.79e-06	0.00175	0.47	0.47	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
THYM	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	5.09	1.8e-06	0.00176	0.52	0.47	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
THYM	cis	rs2562456	0.833	rs11669790	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21328980	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62107534	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21329389	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs7258473	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21331795	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs2219839	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21333520	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62107539	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21334910	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs76646508	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21335247	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs77576302	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21335385	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62107540	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21335693	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62107541	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21335733	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs56179986	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21337882	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs4429400	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21338163	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs1932087	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21338625	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11666828	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21342218	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11671609	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21342769	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs62109212	ENSG00000268081.1	RP11-678G14.2	5.09	1.8e-06	0.00176	0.69	0.47	Pain;	chr19:21343716	chr19:21554640~21569237:-
THYM	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	5.09	1.81e-06	0.00177	0.43	0.47	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	5.09	1.81e-06	0.00177	0.43	0.47	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	5.09	1.81e-06	0.00177	0.43	0.47	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
THYM	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	5.09	1.81e-06	0.00177	0.59	0.47	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
THYM	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-5.09	1.81e-06	0.00177	-0.33	-0.47	Height;	chr11:118703185	chr11:118791254~118793137:+
THYM	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-5.09	1.81e-06	0.00177	-0.33	-0.47	Height;	chr11:118703207	chr11:118791254~118793137:+
THYM	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-5.09	1.81e-06	0.00177	-0.33	-0.47	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
THYM	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-5.09	1.81e-06	0.00177	-0.33	-0.47	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
THYM	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-5.09	1.81e-06	0.00177	-0.33	-0.47	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
THYM	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-5.09	1.81e-06	0.00177	-0.33	-0.47	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
THYM	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	5.09	1.81e-06	0.00177	0.33	0.47	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
THYM	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	5.09	1.81e-06	0.00177	0.58	0.47	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	5.09	1.81e-06	0.00177	0.58	0.47	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
THYM	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-5.09	1.82e-06	0.00177	-0.49	-0.46	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
THYM	cis	rs995834	0.743	rs2015841	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28345899	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs10415623	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346878	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs10416153	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347155	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs8108726	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347425	chr19:28418483~28429490:-
THYM	cis	rs995834	0.701	rs6508784	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347560	chr19:28418483~28429490:-
THYM	cis	rs995834	0.701	rs8111880	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348171	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs8112315	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348498	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs8111630	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348642	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs11670286	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348909	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs758314	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363165	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs726845	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363761	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs2868967	ENSG00000260725.1	AC005307.1	-5.09	1.82e-06	0.00178	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372690	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs6508794	ENSG00000260725.1	AC005307.1	5.09	1.82e-06	0.00178	0.45	0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356703	chr19:28418483~28429490:-
THYM	cis	rs995834	0.661	rs4407171	ENSG00000260725.1	AC005307.1	5.09	1.82e-06	0.00178	0.45	0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372452	chr19:28418483~28429490:-
THYM	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	5.09	1.83e-06	0.00178	0.66	0.46	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
THYM	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-5.09	1.83e-06	0.00178	-0.48	-0.46	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
THYM	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	5.09	1.83e-06	0.00178	0.42	0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
THYM	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-5.09	1.83e-06	0.00178	-0.42	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
THYM	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-5.09	1.83e-06	0.00178	-0.48	-0.46	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
THYM	cis	rs992157	0.932	rs4672884	ENSG00000261338.2	RP11-378A13.1	-5.09	1.83e-06	0.00179	-0.6	-0.46	Colorectal cancer;	chr2:218317758	chr2:218255319~218257366:+
THYM	cis	rs4845570	0.764	rs12141652	ENSG00000203288.3	RP11-98D18.9	-5.09	1.83e-06	0.00179	-0.62	-0.46	Coronary artery disease;	chr1:151744235	chr1:151790804~151794402:+
THYM	cis	rs4845570	0.764	rs12122917	ENSG00000203288.3	RP11-98D18.9	-5.09	1.83e-06	0.00179	-0.62	-0.46	Coronary artery disease;	chr1:151744236	chr1:151790804~151794402:+
THYM	cis	rs4845570	0.834	rs13376155	ENSG00000203288.3	RP11-98D18.9	-5.09	1.83e-06	0.00179	-0.62	-0.46	Coronary artery disease;	chr1:151748794	chr1:151790804~151794402:+
THYM	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	5.09	1.84e-06	0.00179	0.59	0.46	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
THYM	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-5.09	1.84e-06	0.00179	-0.38	-0.46	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
THYM	cis	rs8059260	0.551	rs8061043	ENSG00000274038.1	RP11-66H6.4	-5.09	1.84e-06	0.00179	-0.62	-0.46	Alcohol consumption over the past year;	chr16:11067072	chr16:11056556~11057034:+
THYM	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	5.09	1.84e-06	0.0018	0.4	0.46	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
THYM	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-5.09	1.85e-06	0.0018	-0.38	-0.46	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
THYM	cis	rs4713118	0.621	rs10484403	ENSG00000182477.5	OR2B8P	5.09	1.85e-06	0.0018	0.64	0.46	Parkinson's disease;	chr6:28065745	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-5.09	1.85e-06	0.0018	-0.38	-0.46	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-5.09	1.85e-06	0.0018	-0.38	-0.46	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-5.09	1.85e-06	0.0018	-0.38	-0.46	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-5.09	1.85e-06	0.0018	-0.38	-0.46	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
THYM	cis	rs4478858	0.775	rs6701861	ENSG00000260386.4	LINC01225	5.09	1.85e-06	0.0018	0.24	0.46	Alcohol dependence;	chr1:31235278	chr1:31500085~31540885:+
THYM	cis	rs4691139	0.903	rs13127378	ENSG00000250227.1	TRIM60P14	5.09	1.85e-06	0.00181	0.55	0.46	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997485	chr4:164915565~164916983:+
THYM	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	5.09	1.86e-06	0.00181	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
THYM	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	5.09	1.86e-06	0.00181	0.57	0.46	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
THYM	cis	rs4273100	0.688	rs12938803	ENSG00000262319.1	CTC-457L16.2	5.09	1.86e-06	0.00181	0.6	0.46	Schizophrenia;	chr17:19301119	chr17:19141017~19143689:-
THYM	cis	rs5771242	1	rs5771242	ENSG00000273253.2	RP3-402G11.26	-5.09	1.87e-06	0.00182	-0.64	-0.46	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50223440	chr22:50199090~50200837:-
THYM	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	5.09	1.87e-06	0.00182	0.51	0.46	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
THYM	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-5.09	1.87e-06	0.00182	-0.37	-0.46	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
THYM	cis	rs4273100	0.646	rs2296981	ENSG00000262319.1	CTC-457L16.2	5.09	1.87e-06	0.00182	0.6	0.46	Schizophrenia;	chr17:19310022	chr17:19141017~19143689:-
THYM	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	5.08	1.88e-06	0.00183	0.47	0.46	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
THYM	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	5.08	1.88e-06	0.00183	0.47	0.46	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
THYM	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	5.08	1.88e-06	0.00183	0.47	0.46	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
THYM	cis	rs7208859	0.623	rs9899692	ENSG00000266490.1	CTD-2349P21.9	5.08	1.88e-06	0.00183	0.91	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30792372~30792833:+
THYM	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	5.08	1.88e-06	0.00183	0.54	0.46	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
THYM	cis	rs7927592	0.513	rs556442	ENSG00000212093.1	AP000807.1	-5.08	1.88e-06	0.00183	-0.4	-0.46	Total body bone mineral density;	chr11:68425222	chr11:68506083~68506166:-
THYM	cis	rs890448	0.826	rs6532939	ENSG00000254531.1	FLJ20021	-5.08	1.89e-06	0.00184	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101478052	chr4:101347780~101348883:+
THYM	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	5.08	1.89e-06	0.00184	0.41	0.46	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
THYM	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	5.08	1.89e-06	0.00184	0.4	0.46	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
THYM	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	5.08	1.9e-06	0.00184	0.51	0.46	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
THYM	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	5.08	1.9e-06	0.00184	0.62	0.46	Depression;	chr6:28364057	chr6:28176188~28176674:+
THYM	cis	rs4853012	0.887	rs77148265	ENSG00000257702.3	LBX2-AS1	5.08	1.9e-06	0.00184	0.54	0.46	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74502595~74504678:+
THYM	cis	rs1550576	0.568	rs4646618	ENSG00000274719.1	RP11-86K22.2	5.08	1.9e-06	0.00184	0.92	0.46	Hypertension;	chr15:57966226	chr15:57990217~57990636:-
THYM	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	5.08	1.92e-06	0.00186	0.5	0.46	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
THYM	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-5.08	1.92e-06	0.00186	-0.43	-0.46	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-5.08	1.92e-06	0.00186	-0.43	-0.46	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
THYM	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	5.08	1.92e-06	0.00186	0.66	0.46	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
THYM	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	5.08	1.92e-06	0.00187	0.39	0.46	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
THYM	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	5.08	1.92e-06	0.00187	0.39	0.46	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
THYM	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-5.08	1.93e-06	0.00187	-0.6	-0.46	AIDS;	chr2:105300178	chr2:105324210~105330529:+
THYM	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-5.08	1.93e-06	0.00187	-0.6	-0.46	AIDS;	chr2:105311539	chr2:105324210~105330529:+
THYM	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-5.08	1.93e-06	0.00187	-0.6	-0.46	AIDS;	chr2:105313444	chr2:105324210~105330529:+
THYM	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-5.08	1.93e-06	0.00187	-0.6	-0.46	AIDS;	chr2:105319955	chr2:105324210~105330529:+
THYM	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-5.08	1.93e-06	0.00187	-0.6	-0.46	AIDS;	chr2:105321650	chr2:105324210~105330529:+
THYM	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-5.08	1.93e-06	0.00187	-0.6	-0.46	AIDS;	chr2:105333211	chr2:105324210~105330529:+
THYM	cis	rs8067545	0.611	rs2042046	ENSG00000230528.6	NOS2P3	-5.08	1.94e-06	0.00188	-0.38	-0.46	Schizophrenia;	chr17:20115528	chr17:20436337~20447249:+
THYM	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.08	1.94e-06	0.00188	-0.42	-0.46	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.08	1.94e-06	0.00188	-0.42	-0.46	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-5.08	1.94e-06	0.00188	-0.42	-0.46	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
THYM	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-5.08	1.95e-06	0.00189	-0.61	-0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
THYM	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	5.07	1.95e-06	0.00189	0.47	0.46	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
THYM	cis	rs7927592	0.763	rs596494	ENSG00000222339.1	AP000807.2	5.07	1.96e-06	0.00189	0.55	0.46	Total body bone mineral density;	chr11:68483586	chr11:68505572~68505651:-
THYM	cis	rs1560104	0.576	rs11645674	ENSG00000259899.1	CTD-3037G24.3	5.07	1.96e-06	0.00189	0.54	0.46	Obesity-related traits;	chr16:12615117	chr16:12560756~12611044:-
THYM	cis	rs890448	0.93	rs57302549	ENSG00000254531.1	FLJ20021	-5.07	1.96e-06	0.0019	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101450675	chr4:101347780~101348883:+
THYM	cis	rs890448	0.895	rs55962826	ENSG00000254531.1	FLJ20021	-5.07	1.96e-06	0.0019	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101450988	chr4:101347780~101348883:+
THYM	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	5.07	1.97e-06	0.0019	0.4	0.46	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
THYM	cis	rs6570726	0.526	rs72994723	ENSG00000235652.6	RP11-545I5.3	-5.07	1.97e-06	0.0019	-0.32	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145401812	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.526	rs9376928	ENSG00000235652.6	RP11-545I5.3	-5.07	1.97e-06	0.0019	-0.32	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145403267	chr6:145799409~145886585:+
THYM	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	5.07	1.97e-06	0.00191	0.51	0.46	Height;	chr6:109346560	chr6:109382795~109383666:+
THYM	cis	rs4478858	0.839	rs10798834	ENSG00000260386.4	LINC01225	5.07	1.97e-06	0.00191	0.25	0.46	Alcohol dependence;	chr1:31236130	chr1:31500085~31540885:+
THYM	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73271869	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73271872	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs55724095	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs56146117	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.568	rs9903854	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Body mass index;	chr17:30826980	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.568	rs9907834	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Body mass index;	chr17:30826995	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs80355557	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9911173	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs73271887	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9898858	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs55658077	ENSG00000266490.1	CTD-2349P21.9	5.07	1.98e-06	0.00191	0.92	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30792372~30792833:+
THYM	cis	rs10129255	0.528	rs8008320	ENSG00000254329.1	IGHVII-60-1	5.07	1.98e-06	0.00191	0.45	0.46	Kawasaki disease;	chr14:106652124	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.584	rs11161001	ENSG00000254329.1	IGHVII-60-1	5.07	1.98e-06	0.00191	0.45	0.46	Kawasaki disease;	chr14:106652664	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.507	rs58656539	ENSG00000254329.1	IGHVII-60-1	5.07	1.98e-06	0.00191	0.45	0.46	Kawasaki disease;	chr14:106653262	chr14:106637718~106637973:-
THYM	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	5.07	1.99e-06	0.00192	0.5	0.46	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
THYM	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-5.07	1.99e-06	0.00192	-0.52	-0.46	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
THYM	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-5.07	2e-06	0.00193	-0.58	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
THYM	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-5.07	2e-06	0.00193	-0.58	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
THYM	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	5.07	2e-06	0.00193	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
THYM	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	5.07	2.01e-06	0.00194	0.53	0.46	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
THYM	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	5.07	2.01e-06	0.00194	0.43	0.46	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	5.07	2.01e-06	0.00194	0.43	0.46	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	5.07	2.01e-06	0.00194	0.43	0.46	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
THYM	cis	rs4908768	0.535	rs2661868	ENSG00000232912.4	RP5-1115A15.1	-5.07	2.01e-06	0.00194	-0.48	-0.46	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8409729	chr1:8424645~8434838:+
THYM	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	5.07	2.01e-06	0.00194	0.42	0.46	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
THYM	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	5.07	2.02e-06	0.00194	0.42	0.46	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	5.07	2.02e-06	0.00194	0.42	0.46	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	5.07	2.02e-06	0.00194	0.42	0.46	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	5.07	2.02e-06	0.00194	0.42	0.46	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
THYM	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-5.07	2.02e-06	0.00195	-0.62	-0.46	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
THYM	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-5.07	2.02e-06	0.00195	-0.43	-0.46	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
THYM	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	5.07	2.02e-06	0.00195	0.6	0.46	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	5.07	2.02e-06	0.00195	0.6	0.46	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	5.07	2.02e-06	0.00195	0.6	0.46	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	5.07	2.02e-06	0.00195	0.6	0.46	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	5.07	2.02e-06	0.00195	0.6	0.46	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
THYM	cis	rs3740713	1	rs12289603	ENSG00000256464.1	YWHABP2	5.07	2.02e-06	0.00195	0.79	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr11:18490243~18490955:-
THYM	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-5.07	2.03e-06	0.00195	-0.39	-0.46	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-5.07	2.03e-06	0.00195	-0.39	-0.46	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
THYM	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-5.07	2.03e-06	0.00195	-0.37	-0.46	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-5.07	2.03e-06	0.00195	-0.37	-0.46	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-5.07	2.03e-06	0.00195	-0.37	-0.46	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-5.07	2.03e-06	0.00195	-0.37	-0.46	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-5.07	2.03e-06	0.00195	-0.37	-0.46	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-5.07	2.03e-06	0.00195	-0.37	-0.46	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-5.07	2.03e-06	0.00195	-0.37	-0.46	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
THYM	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	5.07	2.03e-06	0.00195	0.53	0.46	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
THYM	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-5.07	2.03e-06	0.00196	-0.58	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
THYM	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-5.07	2.03e-06	0.00196	-0.49	-0.46	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
THYM	cis	rs1930961	0.558	rs5996951	ENSG00000100058.11	CRYBB2P1	5.07	2.03e-06	0.00196	0.56	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25448105~25520854:+
THYM	cis	rs1930961	0.558	rs12160908	ENSG00000100058.11	CRYBB2P1	5.07	2.03e-06	0.00196	0.56	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25448105~25520854:+
THYM	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	5.06	2.03e-06	0.00196	0.64	0.46	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
THYM	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-5.06	2.03e-06	0.00196	-0.56	-0.46	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
THYM	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	5.06	2.03e-06	0.00196	0.42	0.46	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
THYM	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	5.06	2.04e-06	0.00196	0.65	0.46	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
THYM	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	5.06	2.04e-06	0.00196	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
THYM	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-5.06	2.05e-06	0.00197	-0.87	-0.46	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-5.06	2.05e-06	0.00197	-0.87	-0.46	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
THYM	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-5.06	2.05e-06	0.00197	-0.45	-0.46	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
THYM	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-5.06	2.06e-06	0.00198	-0.43	-0.46	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-5.06	2.06e-06	0.00198	-0.43	-0.46	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-5.06	2.06e-06	0.00198	-0.43	-0.46	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
THYM	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	5.06	2.06e-06	0.00198	0.43	0.46	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
THYM	cis	rs73108077	0.92	rs6057657	ENSG00000277112.2	RP11-755J8.1	5.06	2.06e-06	0.00198	0.64	0.46	Red blood cell density in sickle cell anemia;	chr20:31376027	chr20:30681825~30723932:-
THYM	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	5.06	2.06e-06	0.00198	0.35	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	5.06	2.06e-06	0.00198	0.35	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	5.06	2.06e-06	0.00198	0.35	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
THYM	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	5.06	2.06e-06	0.00198	0.38	0.46	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
THYM	cis	rs10129255	0.5	rs9324092	ENSG00000253703.1	IGHV1-68	5.06	2.06e-06	0.00198	0.5	0.46	Kawasaki disease;	chr14:106683806	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs4774008	ENSG00000253703.1	IGHV1-68	-5.06	2.06e-06	0.00198	-0.5	-0.46	Kawasaki disease;	chr14:106681273	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs10143242	ENSG00000253703.1	IGHV1-68	-5.06	2.06e-06	0.00198	-0.5	-0.46	Kawasaki disease;	chr14:106681814	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs1024350	ENSG00000253703.1	IGHV1-68	-5.06	2.06e-06	0.00198	-0.5	-0.46	Kawasaki disease;	chr14:106685105	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.518	rs7143784	ENSG00000253703.1	IGHV1-68	-5.06	2.06e-06	0.00198	-0.5	-0.46	Kawasaki disease;	chr14:106687277	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs2105991	ENSG00000253703.1	IGHV1-68	-5.06	2.06e-06	0.00198	-0.5	-0.46	Kawasaki disease;	chr14:106682022	chr14:106703852~106704146:-
THYM	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-5.06	2.06e-06	0.00198	-0.53	-0.46	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-5.06	2.06e-06	0.00198	-0.53	-0.46	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
THYM	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-5.06	2.07e-06	0.00199	-0.62	-0.46	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
THYM	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-5.06	2.07e-06	0.00199	-0.62	-0.46	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
THYM	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	5.06	2.07e-06	0.00199	0.37	0.46	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
THYM	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	5.06	2.07e-06	0.00199	0.58	0.46	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
THYM	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	5.06	2.07e-06	0.00199	0.58	0.46	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
THYM	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	5.06	2.08e-06	0.002	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	5.06	2.08e-06	0.002	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
THYM	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-5.06	2.08e-06	0.002	-0.49	-0.46	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
THYM	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-5.06	2.08e-06	0.002	-0.36	-0.46	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
THYM	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-5.06	2.08e-06	0.002	-0.97	-0.46	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
THYM	cis	rs4713118	0.621	rs9295756	ENSG00000182477.5	OR2B8P	5.06	2.09e-06	0.002	0.65	0.46	Parkinson's disease;	chr6:28065618	chr6:28053228~28054165:-
THYM	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-5.06	2.09e-06	0.002	-0.79	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
THYM	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-5.06	2.09e-06	0.002	-0.41	-0.46	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
THYM	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	5.06	2.09e-06	0.002	0.44	0.46	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	5.06	2.09e-06	0.002	0.44	0.46	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	5.06	2.09e-06	0.002	0.44	0.46	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
THYM	cis	rs9907295	0.591	rs8069014	ENSG00000270977.1	AC015849.16	-5.06	2.09e-06	0.00201	-0.6	-0.46	Fibroblast growth factor basic levels;	chr17:35872994	chr17:35893707~35911023:-
THYM	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	5.06	2.09e-06	0.00201	0.58	0.46	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
THYM	cis	rs599083	0.573	rs3018713	ENSG00000222339.1	AP000807.2	5.06	2.09e-06	0.00201	0.54	0.46	Bone mineral density (spine);	chr11:68623518	chr11:68505572~68505651:-
THYM	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	5.06	2.1e-06	0.00201	0.56	0.46	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
THYM	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	2.1e-06	0.00201	-0.41	-0.46	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	2.1e-06	0.00201	-0.41	-0.46	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	2.1e-06	0.00201	-0.41	-0.46	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	2.1e-06	0.00201	-0.41	-0.46	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
THYM	cis	rs4478858	0.775	rs6701667	ENSG00000260386.4	LINC01225	5.06	2.1e-06	0.00202	0.24	0.46	Alcohol dependence;	chr1:31235124	chr1:31500085~31540885:+
THYM	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-5.06	2.11e-06	0.00202	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
THYM	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-5.06	2.11e-06	0.00202	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	5.06	2.11e-06	0.00202	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
THYM	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-5.06	2.11e-06	0.00202	-0.42	-0.46	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
THYM	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-5.06	2.11e-06	0.00202	-0.56	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
THYM	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-5.06	2.12e-06	0.00202	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-5.06	2.12e-06	0.00202	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
THYM	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-5.06	2.12e-06	0.00202	-0.49	-0.46	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-5.06	2.12e-06	0.00202	-0.49	-0.46	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
THYM	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	5.05	2.12e-06	0.00202	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
THYM	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-5.05	2.12e-06	0.00203	-0.62	-0.46	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-5.05	2.12e-06	0.00203	-0.62	-0.46	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
THYM	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	5.05	2.12e-06	0.00203	0.63	0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
THYM	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	5.05	2.12e-06	0.00203	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
THYM	cis	rs8113308	0.81	rs56029016	ENSG00000269235.1	ZNF350-AS1	5.05	2.12e-06	0.00203	0.52	0.46	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949209	chr19:51949134~51981367:+
THYM	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-5.05	2.12e-06	0.00203	-0.62	-0.46	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-5.05	2.12e-06	0.00203	-0.62	-0.46	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
THYM	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	5.05	2.13e-06	0.00203	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	5.05	2.13e-06	0.00203	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	5.05	2.13e-06	0.00203	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	5.05	2.13e-06	0.00203	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	5.05	2.13e-06	0.00203	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
THYM	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	5.05	2.13e-06	0.00203	0.56	0.46	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
THYM	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-5.05	2.13e-06	0.00203	-0.41	-0.46	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-5.05	2.13e-06	0.00203	-0.41	-0.46	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-5.05	2.13e-06	0.00203	-0.41	-0.46	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-5.05	2.13e-06	0.00203	-0.41	-0.46	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-5.05	2.13e-06	0.00203	-0.41	-0.46	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-5.05	2.13e-06	0.00203	-0.41	-0.46	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-5.05	2.13e-06	0.00203	-0.41	-0.46	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
THYM	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	5.05	2.13e-06	0.00204	0.51	0.46	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
THYM	cis	rs6887276	0.538	rs35897671	ENSG00000245937.6	LINC01184	-5.05	2.13e-06	0.00204	-0.44	-0.46	Height;	chr5:128014053	chr5:127940426~128083172:-
THYM	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	5.05	2.13e-06	0.00204	0.43	0.46	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
THYM	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	5.05	2.14e-06	0.00204	0.52	0.46	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	5.05	2.14e-06	0.00204	0.52	0.46	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
THYM	cis	rs890448	0.93	rs2471677	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101458438	chr4:101347780~101348883:+
THYM	cis	rs890448	0.895	rs2465896	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101463875	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs2433312	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101464975	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs2471675	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101467385	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs2433313	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101467784	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs10011201	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101470298	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs28863533	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101488397	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs6532941	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101492469	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs10012311	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101493140	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs4699220	ENSG00000254531.1	FLJ20021	-5.05	2.14e-06	0.00204	-0.39	-0.46	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101495282	chr4:101347780~101348883:+
THYM	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	5.05	2.14e-06	0.00204	0.61	0.46	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
THYM	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	5.05	2.14e-06	0.00204	0.61	0.46	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
THYM	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	5.05	2.14e-06	0.00204	0.7	0.46	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
THYM	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-5.05	2.14e-06	0.00205	-0.77	-0.46	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
THYM	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-5.05	2.15e-06	0.00205	-0.47	-0.46	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
THYM	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	5.05	2.15e-06	0.00205	0.8	0.46	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
THYM	cis	rs7772486	0.84	rs2814864	ENSG00000235652.6	RP11-545I5.3	5.05	2.15e-06	0.00205	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146023910	chr6:145799409~145886585:+
THYM	cis	rs1550115	0.524	rs1550116	ENSG00000271936.1	RP11-443B20.1	-5.05	2.15e-06	0.00205	-0.37	-0.46	Coronary artery disease;	chr2:24799729	chr2:24825610~24826717:+
THYM	cis	rs4908768	0.535	rs2748456	ENSG00000232912.4	RP5-1115A15.1	-5.05	2.15e-06	0.00205	-0.5	-0.46	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406690	chr1:8424645~8434838:+
THYM	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-5.05	2.16e-06	0.00206	-0.69	-0.46	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-5.05	2.16e-06	0.00206	-0.69	-0.46	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-5.05	2.16e-06	0.00206	-0.69	-0.46	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
THYM	cis	rs4273100	0.512	rs2233072	ENSG00000262319.1	CTC-457L16.2	5.05	2.16e-06	0.00206	0.61	0.46	Schizophrenia;	chr17:19378515	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.512	rs973650	ENSG00000262319.1	CTC-457L16.2	5.05	2.16e-06	0.00206	0.61	0.46	Schizophrenia;	chr17:19388472	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.541	rs973649	ENSG00000262319.1	CTC-457L16.2	5.05	2.16e-06	0.00206	0.61	0.46	Schizophrenia;	chr17:19388755	chr17:19141017~19143689:-
THYM	cis	rs4273100	0.512	rs7502682	ENSG00000262319.1	CTC-457L16.2	5.05	2.16e-06	0.00206	0.61	0.46	Schizophrenia;	chr17:19392137	chr17:19141017~19143689:-
THYM	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	5.05	2.16e-06	0.00206	0.6	0.46	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	5.05	2.16e-06	0.00206	0.6	0.46	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
THYM	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	5.05	2.17e-06	0.00207	0.5	0.46	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
THYM	cis	rs3740713	1	rs73440634	ENSG00000256464.1	YWHABP2	5.05	2.17e-06	0.00207	0.79	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73440636	ENSG00000256464.1	YWHABP2	5.05	2.17e-06	0.00207	0.79	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr11:18490243~18490955:-
THYM	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	5.05	2.17e-06	0.00207	0.58	0.46	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
THYM	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	5.05	2.17e-06	0.00207	0.54	0.46	Height;	chr6:109446728	chr6:109382795~109383666:+
THYM	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-5.05	2.17e-06	0.00207	-0.36	-0.46	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
THYM	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-5.05	2.18e-06	0.00207	-0.57	-0.46	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
THYM	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
THYM	cis	rs7927592	0.731	rs2156463	ENSG00000222339.1	AP000807.2	5.05	2.18e-06	0.00207	0.54	0.46	Total body bone mineral density;	chr11:68618843	chr11:68505572~68505651:-
THYM	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	5.05	2.18e-06	0.00207	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
THYM	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	5.05	2.18e-06	0.00207	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-5.05	2.18e-06	0.00207	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
THYM	cis	rs995834	0.622	rs2159077	ENSG00000267243.4	AC005307.3	5.05	2.19e-06	0.00208	0.45	0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404348	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs2159078	ENSG00000267243.4	AC005307.3	-5.05	2.19e-06	0.00208	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404431	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs2869481	ENSG00000267243.4	AC005307.3	-5.05	2.19e-06	0.00208	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28404927	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs2869482	ENSG00000267243.4	AC005307.3	-5.05	2.19e-06	0.00208	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405261	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs10407917	ENSG00000267243.4	AC005307.3	-5.05	2.19e-06	0.00208	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405441	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs10408833	ENSG00000267243.4	AC005307.3	-5.05	2.19e-06	0.00208	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28405825	chr19:28435388~28727777:-
THYM	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-5.05	2.19e-06	0.00208	-0.61	-0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
THYM	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	5.05	2.19e-06	0.00208	0.34	0.46	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
THYM	cis	rs5771242	0.769	rs4838865	ENSG00000273253.2	RP3-402G11.26	-5.05	2.19e-06	0.00208	-0.64	-0.46	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50226183	chr22:50199090~50200837:-
THYM	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	5.05	2.2e-06	0.00209	0.35	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	5.05	2.2e-06	0.00209	0.35	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	5.05	2.2e-06	0.00209	0.35	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
THYM	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	5.05	2.2e-06	0.00209	0.64	0.46	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
THYM	cis	rs4845570	1	rs6673002	ENSG00000203288.3	RP11-98D18.9	5.05	2.2e-06	0.00209	0.55	0.46	Coronary artery disease;	chr1:151770799	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs3790514	ENSG00000203288.3	RP11-98D18.9	-5.05	2.2e-06	0.00209	-0.55	-0.46	Coronary artery disease;	chr1:151771692	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs7416415	ENSG00000203288.3	RP11-98D18.9	5.05	2.2e-06	0.00209	0.55	0.46	Coronary artery disease;	chr1:151785322	chr1:151790804~151794402:+
THYM	cis	rs3738443	0.52	rs1771932	ENSG00000227671.4	RP11-488L18.4	-5.05	2.2e-06	0.00209	-0.27	-0.46	Alcohol dependence;	chr1:247218747	chr1:247189851~247210856:-
THYM	cis	rs9907295	0.636	rs4251703	ENSG00000270977.1	AC015849.16	-5.04	2.21e-06	0.0021	-0.57	-0.46	Fibroblast growth factor basic levels;	chr17:35807954	chr17:35893707~35911023:-
THYM	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-5.04	2.21e-06	0.0021	-0.57	-0.46	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
THYM	cis	rs7772486	0.811	rs2777475	ENSG00000235652.6	RP11-545I5.3	5.04	2.22e-06	0.0021	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145983467	chr6:145799409~145886585:+
THYM	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	5.04	2.22e-06	0.0021	0.41	0.46	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
THYM	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-5.04	2.22e-06	0.00211	-0.53	-0.46	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
THYM	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-5.04	2.22e-06	0.00211	-0.58	-0.46	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
THYM	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-5.04	2.22e-06	0.00211	-0.56	-0.46	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-5.04	2.22e-06	0.00211	-0.56	-0.46	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
THYM	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-5.04	2.23e-06	0.00211	-0.7	-0.46	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
THYM	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
THYM	cis	rs886716	0.507	rs730956	ENSG00000122548.5	KIAA0087	5.04	2.23e-06	0.00211	0.51	0.46	Smoking behavior;	chr7:26535354	chr7:26533121~26538788:-
THYM	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-5.04	2.23e-06	0.00211	-0.54	-0.46	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	5.04	2.23e-06	0.00211	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
THYM	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	5.04	2.24e-06	0.00212	0.57	0.46	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
THYM	cis	rs61160187	0.51	rs10072745	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.527	rs6449500	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:60866457~60866935:-
THYM	cis	rs4700393	0.967	rs921897	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Intelligence (multi-trait analysis);	chr5:60793310	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs10076679	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795124	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.527	rs10076742	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.527	rs6890201	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795365	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs6875456	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795503	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs6894750	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795729	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs6876335	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795991	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs6449501	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60796860	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs4235481	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797560	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.505	rs4235482	ENSG00000272308.1	RP11-231G3.1	-5.04	2.24e-06	0.00212	-0.41	-0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797785	chr5:60866457~60866935:-
THYM	cis	rs4948275	0.51	rs10994740	ENSG00000237233.2	TMEM26-AS1	5.04	2.24e-06	0.00212	0.47	0.46	Night sleep phenotypes;	chr10:61367881	chr10:61452639~61481956:+
THYM	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-5.04	2.24e-06	0.00212	-0.41	-0.46	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
THYM	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-5.04	2.25e-06	0.00213	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	5.04	2.25e-06	0.00213	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	5.04	2.25e-06	0.00213	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	5.04	2.25e-06	0.00213	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	5.04	2.25e-06	0.00213	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	5.04	2.25e-06	0.00213	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
THYM	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-5.04	2.25e-06	0.00213	-0.6	-0.46	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
THYM	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-5.04	2.25e-06	0.00213	-0.58	-0.46	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
THYM	cis	rs904251	0.965	rs1317563	ENSG00000227920.2	RP1-153P14.5	-5.04	2.25e-06	0.00213	-0.64	-0.46	Cognitive performance;	chr6:37484078	chr6:37545145~37550860:+
THYM	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	5.04	2.26e-06	0.00214	0.4	0.46	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
THYM	cis	rs10829156	0.898	rs6482565	ENSG00000240291.1	RP11-499P20.2	5.04	2.26e-06	0.00214	0.41	0.46	Sudden cardiac arrest;	chr10:18611664	chr10:18513115~18545651:-
THYM	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-5.04	2.27e-06	0.00214	-0.45	-0.46	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
THYM	cis	rs1550576	0.568	rs117694347	ENSG00000274719.1	RP11-86K22.2	5.04	2.27e-06	0.00214	0.94	0.46	Hypertension;	chr15:57978755	chr15:57990217~57990636:-
THYM	cis	rs7927592	0.513	rs556442	ENSG00000222339.1	AP000807.2	-5.04	2.27e-06	0.00215	-0.5	-0.46	Total body bone mineral density;	chr11:68425222	chr11:68505572~68505651:-
THYM	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-5.04	2.27e-06	0.00215	-0.5	-0.46	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
THYM	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	5.04	2.28e-06	0.00215	0.64	0.46	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
THYM	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-5.04	2.28e-06	0.00216	-0.68	-0.46	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
THYM	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-5.04	2.28e-06	0.00216	-0.58	-0.46	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-5.04	2.29e-06	0.00216	-0.62	-0.46	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
THYM	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	5.04	2.29e-06	0.00216	0.43	0.46	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
THYM	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-5.04	2.29e-06	0.00216	-0.36	-0.46	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
THYM	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-5.04	2.29e-06	0.00216	-0.42	-0.46	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
THYM	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-5.04	2.29e-06	0.00216	-0.54	-0.46	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
THYM	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	5.03	2.3e-06	0.00217	0.49	0.46	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
THYM	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-5.03	2.3e-06	0.00217	-0.4	-0.46	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
THYM	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	2.3e-06	0.00217	-0.41	-0.46	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	2.3e-06	0.00217	-0.41	-0.46	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	2.3e-06	0.00217	-0.41	-0.46	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	2.3e-06	0.00217	-0.41	-0.46	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	2.3e-06	0.00217	-0.41	-0.46	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	2.3e-06	0.00217	-0.41	-0.46	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
THYM	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	5.03	2.31e-06	0.00218	0.41	0.46	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
THYM	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	5.03	2.31e-06	0.00218	0.48	0.46	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
THYM	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-5.03	2.31e-06	0.00218	-0.54	-0.46	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
THYM	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	5.03	2.31e-06	0.00218	0.43	0.46	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
THYM	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	5.03	2.32e-06	0.00219	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	5.03	2.32e-06	0.00219	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	5.03	2.32e-06	0.00219	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
THYM	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	5.03	2.32e-06	0.00219	0.7	0.46	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	5.03	2.32e-06	0.00219	0.7	0.46	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
THYM	cis	rs10129255	0.518	rs8009594	ENSG00000254329.1	IGHVII-60-1	5.03	2.33e-06	0.00219	0.39	0.46	Kawasaki disease;	chr14:106777494	chr14:106637718~106637973:-
THYM	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-5.03	2.33e-06	0.00219	-0.54	-0.46	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
THYM	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	5.03	2.33e-06	0.00219	0.41	0.46	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
THYM	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	5.03	2.33e-06	0.00219	0.57	0.46	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	5.03	2.33e-06	0.00219	0.57	0.46	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	5.03	2.33e-06	0.00219	0.57	0.46	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	5.03	2.33e-06	0.00219	0.57	0.46	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
THYM	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	5.03	2.33e-06	0.0022	0.49	0.46	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
THYM	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	5.03	2.33e-06	0.0022	0.58	0.46	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
THYM	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-5.03	2.33e-06	0.0022	-0.58	-0.46	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
THYM	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-5.03	2.33e-06	0.0022	-0.58	-0.46	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
THYM	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-5.03	2.33e-06	0.0022	-0.64	-0.46	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
THYM	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-5.03	2.34e-06	0.0022	-0.56	-0.46	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-5.03	2.34e-06	0.0022	-0.56	-0.46	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-5.03	2.34e-06	0.0022	-0.56	-0.46	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
THYM	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-5.03	2.34e-06	0.00221	-0.69	-0.46	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
THYM	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	5.03	2.34e-06	0.00221	0.54	0.46	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
THYM	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	2.34e-06	0.00221	-0.41	-0.46	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
THYM	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-5.03	2.36e-06	0.00222	-0.42	-0.46	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-5.03	2.36e-06	0.00222	-0.42	-0.46	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
THYM	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	5.03	2.37e-06	0.00223	0.62	0.46	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	5.03	2.37e-06	0.00223	0.62	0.46	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
THYM	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	5.03	2.37e-06	0.00223	0.48	0.46	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
THYM	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-5.03	2.38e-06	0.00224	-0.57	-0.46	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
THYM	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-5.03	2.38e-06	0.00224	-0.58	-0.46	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
THYM	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-5.03	2.38e-06	0.00224	-0.6	-0.46	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
THYM	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-5.03	2.38e-06	0.00224	-0.46	-0.46	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	5.03	2.38e-06	0.00224	0.46	0.46	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	5.03	2.38e-06	0.00224	0.46	0.46	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	5.03	2.38e-06	0.00224	0.46	0.46	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
THYM	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-5.03	2.38e-06	0.00224	-0.84	-0.46	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
THYM	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	5.03	2.38e-06	0.00224	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	5.03	2.38e-06	0.00224	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	5.03	2.38e-06	0.00224	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	5.03	2.38e-06	0.00224	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	5.03	2.38e-06	0.00224	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
THYM	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-5.03	2.38e-06	0.00224	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
THYM	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-5.03	2.38e-06	0.00224	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
THYM	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-5.03	2.38e-06	0.00224	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
THYM	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	5.03	2.39e-06	0.00224	0.52	0.46	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
THYM	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	5.03	2.39e-06	0.00224	0.52	0.46	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
THYM	cis	rs7927592	0.763	rs624003	ENSG00000222339.1	AP000807.2	5.03	2.39e-06	0.00225	0.55	0.46	Total body bone mineral density;	chr11:68463772	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.763	rs10896326	ENSG00000222339.1	AP000807.2	5.03	2.39e-06	0.00225	0.55	0.46	Total body bone mineral density;	chr11:68467103	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.763	rs10896327	ENSG00000222339.1	AP000807.2	5.03	2.39e-06	0.00225	0.55	0.46	Total body bone mineral density;	chr11:68467807	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	5.03	2.39e-06	0.00225	0.43	0.46	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	5.03	2.39e-06	0.00225	0.43	0.46	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
THYM	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-5.02	2.39e-06	0.00225	-0.56	-0.46	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
THYM	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-5.02	2.39e-06	0.00225	-0.56	-0.46	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
THYM	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	5.02	2.41e-06	0.00226	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
THYM	cis	rs10829156	0.838	rs1027194	ENSG00000240291.1	RP11-499P20.2	5.02	2.41e-06	0.00226	0.45	0.46	Sudden cardiac arrest;	chr10:18682336	chr10:18513115~18545651:-
THYM	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	5.02	2.41e-06	0.00226	0.55	0.46	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
THYM	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	5.02	2.41e-06	0.00226	0.55	0.46	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
THYM	cis	rs3740713	1	rs73436668	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs60376560	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73438686	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs75487138	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73440614	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs1848048	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs16935432	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs73440625	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr11:18490243~18490955:-
THYM	cis	rs3740713	1	rs76599129	ENSG00000256464.1	YWHABP2	5.02	2.42e-06	0.00226	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr11:18490243~18490955:-
THYM	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	5.02	2.42e-06	0.00227	0.51	0.46	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
THYM	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-5.02	2.42e-06	0.00227	-0.59	-0.46	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
THYM	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	5.02	2.43e-06	0.00227	0.52	0.46	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
THYM	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	5.02	2.43e-06	0.00227	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	5.02	2.43e-06	0.00227	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
THYM	cis	rs3862435	0.572	rs2589967	ENSG00000259212.1	CTD-3065B20.2	-5.02	2.43e-06	0.00228	-0.66	-0.46	Response to exercise (triglyceride level interaction);	chr15:90364644	chr15:90595840~90596447:-
THYM	cis	rs7702057	0.53	rs17138834	ENSG00000271918.1	CTD-2287O16.5	-5.02	2.44e-06	0.00228	-0.7	-0.46	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116083807~116085416:-
THYM	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	5.02	2.44e-06	0.00229	0.56	0.46	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
THYM	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	5.02	2.44e-06	0.00229	0.46	0.46	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
THYM	cis	rs2562456	0.793	rs627522	ENSG00000268081.1	RP11-678G14.2	5.02	2.46e-06	0.0023	0.62	0.46	Pain;	chr19:21313002	chr19:21554640~21569237:-
THYM	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-5.02	2.46e-06	0.0023	-0.52	-0.46	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
THYM	cis	rs4273100	0.512	rs1355128	ENSG00000262319.1	CTC-457L16.2	5.02	2.46e-06	0.0023	0.61	0.46	Schizophrenia;	chr17:19395831	chr17:19141017~19143689:-
THYM	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	5.02	2.47e-06	0.00231	0.59	0.46	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
THYM	cis	rs42490	0.536	rs366867	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89851946	chr8:89609409~89757727:-
THYM	cis	rs42490	0.609	rs367640	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89852168	chr8:89609409~89757727:-
THYM	cis	rs42490	0.576	rs425140	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89852397	chr8:89609409~89757727:-
THYM	cis	rs42490	0.576	rs377897	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89852734	chr8:89609409~89757727:-
THYM	cis	rs42490	0.576	rs432457	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89853680	chr8:89609409~89757727:-
THYM	cis	rs42490	0.536	rs379015	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89856245	chr8:89609409~89757727:-
THYM	cis	rs42490	0.576	rs388866	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89856604	chr8:89609409~89757727:-
THYM	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	5.02	2.47e-06	0.00231	0.43	0.46	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
THYM	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-5.02	2.47e-06	0.00231	-0.39	-0.46	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-5.02	2.47e-06	0.00231	-0.39	-0.46	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-5.02	2.47e-06	0.00231	-0.39	-0.46	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-5.02	2.47e-06	0.00231	-0.39	-0.46	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-5.02	2.47e-06	0.00231	-0.39	-0.46	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
THYM	cis	rs42490	0.553	rs380425	ENSG00000251136.7	RP11-37B2.1	-5.02	2.47e-06	0.00231	-0.38	-0.46	Leprosy;	chr8:89849814	chr8:89609409~89757727:-
THYM	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	5.02	2.47e-06	0.00231	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	5.02	2.47e-06	0.00231	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	5.02	2.47e-06	0.00231	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	5.02	2.47e-06	0.00231	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	5.02	2.47e-06	0.00231	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	5.02	2.47e-06	0.00231	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	5.02	2.47e-06	0.00231	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
THYM	cis	rs3738443	0.672	rs6691539	ENSG00000227671.4	RP11-488L18.4	-5.02	2.48e-06	0.00232	-0.26	-0.46	Alcohol dependence;	chr1:247209370	chr1:247189851~247210856:-
THYM	cis	rs3740713	1	rs73440637	ENSG00000256464.1	YWHABP2	5.02	2.48e-06	0.00232	0.78	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr11:18490243~18490955:-
THYM	cis	rs995834	0.743	rs28579409	ENSG00000260725.1	AC005307.1	-5.02	2.49e-06	0.00232	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347315	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs8108624	ENSG00000260725.1	AC005307.1	-5.02	2.49e-06	0.00232	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347359	chr19:28418483~28429490:-
THYM	cis	rs995834	0.743	rs8108711	ENSG00000260725.1	AC005307.1	-5.02	2.49e-06	0.00232	-0.45	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347390	chr19:28418483~28429490:-
THYM	cis	rs7702057	0.53	rs17138866	ENSG00000271918.1	CTD-2287O16.5	5.02	2.49e-06	0.00232	0.74	0.46	Amyotrophic lateral sclerosis;	chr5:116088914	chr5:116083807~116085416:-
THYM	cis	rs7702057	0.53	rs59429923	ENSG00000271918.1	CTD-2287O16.5	5.02	2.49e-06	0.00232	0.74	0.46	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116083807~116085416:-
THYM	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	5.02	2.49e-06	0.00232	0.58	0.46	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
THYM	cis	rs4835473	0.932	rs9308176	ENSG00000251600.4	RP11-673E1.1	-5.02	2.49e-06	0.00232	-0.5	-0.46	Immature fraction of reticulocytes;	chr4:144072718	chr4:143912331~143982454:+
THYM	cis	rs4853012	0.838	rs2177707	ENSG00000257702.3	LBX2-AS1	5.02	2.49e-06	0.00232	0.52	0.46	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74502595~74504678:+
THYM	cis	rs4853012	0.887	rs2280642	ENSG00000257702.3	LBX2-AS1	5.02	2.49e-06	0.00232	0.52	0.46	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74502595~74504678:+
THYM	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	5.02	2.49e-06	0.00232	0.47	0.46	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
THYM	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-5.02	2.49e-06	0.00233	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
THYM	cis	rs7927592	0.513	rs689075	ENSG00000222339.1	AP000807.2	5.02	2.49e-06	0.00233	0.5	0.46	Total body bone mineral density;	chr11:68426964	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.513	rs608343	ENSG00000222339.1	AP000807.2	5.02	2.49e-06	0.00233	0.5	0.46	Total body bone mineral density;	chr11:68429362	chr11:68505572~68505651:-
THYM	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	5.01	2.5e-06	0.00233	0.53	0.46	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
THYM	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-5.01	2.5e-06	0.00233	-0.66	-0.46	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
THYM	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	5.01	2.5e-06	0.00233	0.44	0.46	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
THYM	cis	rs2834288	0.536	rs762357	ENSG00000237945.6	LINC00649	5.01	2.51e-06	0.00234	0.41	0.46	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33915534~33977691:+
THYM	cis	rs61160187	0.583	rs6449503	ENSG00000272308.1	RP11-231G3.1	5.01	2.51e-06	0.00234	0.42	0.46	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60866457~60866935:-
THYM	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-5.01	2.51e-06	0.00234	-0.59	-0.46	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
THYM	cis	rs13256369	0.951	rs12679360	ENSG00000253893.2	FAM85B	5.01	2.51e-06	0.00234	0.59	0.46	Obesity-related traits;	chr8:8708759	chr8:8167819~8226614:-
THYM	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-5.01	2.51e-06	0.00234	-0.7	-0.46	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
THYM	cis	rs3738443	0.52	rs6699577	ENSG00000227671.4	RP11-488L18.4	-5.01	2.51e-06	0.00234	-0.27	-0.46	Alcohol dependence;	chr1:247224152	chr1:247189851~247210856:-
THYM	cis	rs7560272	0.501	rs11894953	ENSG00000273245.1	RP11-434P11.2	5.01	2.52e-06	0.00235	0.52	0.46	Schizophrenia;	chr2:73737504	chr2:73750256~73750786:-
THYM	cis	rs1020064	0.609	rs2576748	ENSG00000235319.1	AC012360.4	5.01	2.52e-06	0.00235	0.61	0.46	AIDS;	chr2:105294801	chr2:105324210~105330529:+
THYM	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-5.01	2.52e-06	0.00235	-0.52	-0.46	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
THYM	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-5.01	2.52e-06	0.00235	-0.85	-0.46	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-5.01	2.52e-06	0.00235	-0.85	-0.46	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
THYM	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-5.01	2.52e-06	0.00235	-0.6	-0.46	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-5.01	2.52e-06	0.00235	-0.6	-0.46	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-5.01	2.52e-06	0.00235	-0.6	-0.46	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
THYM	cis	rs8059260	0.541	rs16958028	ENSG00000274038.1	RP11-66H6.4	-5.01	2.53e-06	0.00235	-0.78	-0.46	Alcohol consumption over the past year;	chr16:11082811	chr16:11056556~11057034:+
THYM	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-5.01	2.53e-06	0.00235	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-5.01	2.53e-06	0.00235	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
THYM	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	5.01	2.53e-06	0.00236	0.39	0.46	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
THYM	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	5.01	2.53e-06	0.00236	0.39	0.46	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
THYM	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	5.01	2.53e-06	0.00236	0.39	0.46	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
THYM	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	5.01	2.53e-06	0.00236	0.39	0.46	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
THYM	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	5.01	2.53e-06	0.00236	0.39	0.46	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
THYM	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-5.01	2.54e-06	0.00236	-0.44	-0.46	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
THYM	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	5.01	2.54e-06	0.00237	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	5.01	2.54e-06	0.00237	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
THYM	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	5.01	2.55e-06	0.00237	0.55	0.46	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
THYM	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-5.01	2.56e-06	0.00238	-0.55	-0.46	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
THYM	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-5.01	2.56e-06	0.00238	-0.38	-0.46	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-5.01	2.56e-06	0.00238	-0.38	-0.46	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
THYM	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	5.01	2.56e-06	0.00238	0.67	0.46	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
THYM	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	5.01	2.56e-06	0.00238	0.67	0.46	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
THYM	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-5.01	2.56e-06	0.00238	-0.55	-0.46	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
THYM	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-5.01	2.57e-06	0.00239	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-5.01	2.57e-06	0.00239	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-5.01	2.58e-06	0.0024	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-5.01	2.58e-06	0.0024	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-5.01	2.58e-06	0.0024	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-5.01	2.58e-06	0.0024	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-5.01	2.58e-06	0.0024	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-5.01	2.58e-06	0.0024	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
THYM	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-5.01	2.58e-06	0.0024	-0.45	-0.46	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
THYM	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-5.01	2.58e-06	0.0024	-0.45	-0.46	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
THYM	cis	rs950169	0.922	rs62021167	ENSG00000235370.6	DNM1P51	5.01	2.58e-06	0.0024	0.59	0.46	Schizophrenia;	chr15:84574820	chr15:84398316~84411701:-
THYM	cis	rs7927592	0.513	rs607887	ENSG00000222339.1	AP000807.2	5.01	2.58e-06	0.0024	0.5	0.46	Total body bone mineral density;	chr11:68429493	chr11:68505572~68505651:-
THYM	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	5.01	2.6e-06	0.00241	0.59	0.46	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
THYM	cis	rs10129255	0.53	rs8008811	ENSG00000254329.1	IGHVII-60-1	5.01	2.6e-06	0.00241	0.45	0.46	Kawasaki disease;	chr14:106652273	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.542	rs8009795	ENSG00000254329.1	IGHVII-60-1	5.01	2.6e-06	0.00241	0.45	0.46	Kawasaki disease;	chr14:106652287	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.528	rs8008831	ENSG00000254329.1	IGHVII-60-1	5.01	2.6e-06	0.00241	0.45	0.46	Kawasaki disease;	chr14:106652290	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.613	rs11161000	ENSG00000254329.1	IGHVII-60-1	5.01	2.6e-06	0.00241	0.45	0.46	Kawasaki disease;	chr14:106652584	chr14:106637718~106637973:-
THYM	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
THYM	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-5.01	2.6e-06	0.00241	-0.37	-0.46	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
THYM	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-5.01	2.6e-06	0.00241	-0.51	-0.46	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-5.01	2.6e-06	0.00241	-0.51	-0.46	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-5.01	2.6e-06	0.00241	-0.51	-0.46	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-5.01	2.6e-06	0.00241	-0.51	-0.46	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-5.01	2.6e-06	0.00241	-0.51	-0.46	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-5.01	2.6e-06	0.00241	-0.51	-0.46	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
THYM	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	5.01	2.6e-06	0.00241	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
THYM	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-5	2.6e-06	0.00242	-0.65	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
THYM	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-5	2.61e-06	0.00242	-0.61	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
THYM	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	5	2.61e-06	0.00242	0.56	0.46	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	5	2.61e-06	0.00242	0.56	0.46	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
THYM	cis	rs7989332	1	rs7329823	ENSG00000279065.1	RP11-264J4.10	-5	2.61e-06	0.00242	-0.55	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20475988	chr13:20194412~20196005:+
THYM	cis	rs7989332	1	rs7989332	ENSG00000279065.1	RP11-264J4.10	-5	2.61e-06	0.00242	-0.55	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20476436	chr13:20194412~20196005:+
THYM	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-5	2.62e-06	0.00243	-0.55	-0.46	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
THYM	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-5	2.62e-06	0.00243	-0.55	-0.46	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
THYM	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-5	2.63e-06	0.00244	-0.55	-0.46	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
THYM	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	5	2.63e-06	0.00244	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
THYM	cis	rs13256369	0.802	rs11249885	ENSG00000253893.2	FAM85B	-5	2.64e-06	0.00244	-0.66	-0.46	Obesity-related traits;	chr8:8704498	chr8:8167819~8226614:-
THYM	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	5	2.64e-06	0.00245	0.37	0.46	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
THYM	cis	rs4853012	0.941	rs2421752	ENSG00000257702.3	LBX2-AS1	5	2.64e-06	0.00245	0.53	0.46	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74502595~74504678:+
THYM	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-5	2.64e-06	0.00245	-0.37	-0.46	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
THYM	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-5	2.64e-06	0.00245	-0.42	-0.46	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
THYM	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-5	2.65e-06	0.00245	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
THYM	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-5	2.65e-06	0.00246	-0.54	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
THYM	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-5	2.66e-06	0.00246	-0.41	-0.46	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
THYM	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	5	2.66e-06	0.00246	0.52	0.46	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	5	2.66e-06	0.00246	0.52	0.46	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.591	rs6822129	ENSG00000251600.4	RP11-673E1.1	-5	2.66e-06	0.00246	-0.5	-0.46	Immature fraction of reticulocytes;	chr4:144058755	chr4:143912331~143982454:+
THYM	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	5	2.66e-06	0.00246	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	5	2.66e-06	0.00246	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
THYM	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	5	2.66e-06	0.00246	0.68	0.46	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
THYM	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	5	2.66e-06	0.00246	0.6	0.46	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
THYM	cis	rs7927592	0.673	rs2510392	ENSG00000222339.1	AP000807.2	5	2.66e-06	0.00247	0.53	0.46	Total body bone mineral density;	chr11:68626989	chr11:68505572~68505651:-
THYM	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	5	2.67e-06	0.00247	0.65	0.46	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
THYM	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	5	2.67e-06	0.00247	0.65	0.46	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
THYM	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	5	2.67e-06	0.00247	0.65	0.46	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
THYM	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	5	2.67e-06	0.00247	0.55	0.46	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
THYM	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	5	2.67e-06	0.00247	0.55	0.46	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
THYM	cis	rs453301	0.653	rs2953806	ENSG00000253893.2	FAM85B	-5	2.67e-06	0.00247	-0.6	-0.46	Joint mobility (Beighton score);	chr8:9056614	chr8:8167819~8226614:-
THYM	cis	rs10829156	0.898	rs7923072	ENSG00000240291.1	RP11-499P20.2	5	2.68e-06	0.00247	0.41	0.46	Sudden cardiac arrest;	chr10:18649305	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	5	2.68e-06	0.00247	0.41	0.46	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.947	rs10764661	ENSG00000240291.1	RP11-499P20.2	5	2.68e-06	0.00247	0.41	0.46	Sudden cardiac arrest;	chr10:18659018	chr10:18513115~18545651:-
THYM	cis	rs10829156	1	rs10829157	ENSG00000240291.1	RP11-499P20.2	5	2.68e-06	0.00247	0.41	0.46	Sudden cardiac arrest;	chr10:18662534	chr10:18513115~18545651:-
THYM	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-5	2.68e-06	0.00247	-0.43	-0.46	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-5	2.68e-06	0.00247	-0.43	-0.46	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-5	2.68e-06	0.00247	-0.43	-0.46	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
THYM	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	5	2.68e-06	0.00247	0.43	0.46	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
THYM	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-5	2.68e-06	0.00248	-0.66	-0.46	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-5	2.68e-06	0.00248	-0.66	-0.46	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-5	2.68e-06	0.00248	-0.66	-0.46	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
THYM	cis	rs5769707	0.967	rs739248	ENSG00000264139.1	MIR3667	-5	2.69e-06	0.00248	-0.5	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49543393~49543466:-
THYM	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	5	2.69e-06	0.00248	0.55	0.46	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
THYM	cis	rs995834	0.743	rs1860211	ENSG00000267243.4	AC005307.3	-5	2.69e-06	0.00248	-0.42	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28386236	chr19:28435388~28727777:-
THYM	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	5	2.69e-06	0.00249	0.79	0.46	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
THYM	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	5	2.69e-06	0.00249	0.36	0.46	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
THYM	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-5	2.69e-06	0.00249	-0.82	-0.46	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
THYM	cis	rs7927592	0.763	rs7119422	ENSG00000222339.1	AP000807.2	-5	2.7e-06	0.00249	-0.52	-0.46	Total body bone mineral density;	chr11:68563686	chr11:68505572~68505651:-
THYM	cis	rs3740713	0.614	rs117636459	ENSG00000256464.1	YWHABP2	5	2.7e-06	0.00249	0.97	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18391261	chr11:18490243~18490955:-
THYM	cis	rs17391705	1	rs6556853	ENSG00000243806.1	RPL7P18	5	2.71e-06	0.0025	0.92	0.46	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:94758617	chr5:94825961~94826694:-
THYM	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	4.99	2.72e-06	0.00251	0.51	0.46	Height;	chr6:109732518	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	4.99	2.72e-06	0.00251	0.51	0.46	Height;	chr6:109738307	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	4.99	2.72e-06	0.00251	0.51	0.46	Height;	chr6:109738751	chr6:109382795~109383666:+
THYM	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	4.99	2.72e-06	0.00251	0.38	0.46	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
THYM	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-4.99	2.73e-06	0.00252	-0.74	-0.46	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
THYM	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-4.99	2.73e-06	0.00252	-0.55	-0.46	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
THYM	cis	rs4845570	0.92	rs6694952	ENSG00000203288.3	RP11-98D18.9	4.99	2.73e-06	0.00252	0.52	0.46	Coronary artery disease;	chr1:151787655	chr1:151790804~151794402:+
THYM	cis	rs867371	0.896	rs8033831	ENSG00000255769.6	GOLGA2P10	-4.99	2.74e-06	0.00253	-0.42	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472993~82513950:-
THYM	cis	rs2953805	1	rs2953805	ENSG00000253893.2	FAM85B	-4.99	2.75e-06	0.00253	-0.6	-0.46	Morning vs. evening chronotype;Neuroticism;	chr8:9057247	chr8:8167819~8226614:-
THYM	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	4.99	2.76e-06	0.00254	0.6	0.46	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
THYM	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	4.99	2.76e-06	0.00254	0.53	0.46	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
THYM	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	4.99	2.76e-06	0.00254	0.53	0.46	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
THYM	cis	rs1061377	0.862	rs12508577	ENSG00000249685.1	RP11-360F5.3	4.99	2.76e-06	0.00254	0.46	0.46	Uric acid levels;	chr4:39107779	chr4:39133913~39135608:+
THYM	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	4.99	2.76e-06	0.00255	0.46	0.46	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
THYM	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-4.99	2.76e-06	0.00255	-0.81	-0.46	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
THYM	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-4.99	2.77e-06	0.00255	-0.61	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
THYM	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-4.99	2.77e-06	0.00255	-0.55	-0.46	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
THYM	cis	rs763121	0.962	rs2071887	ENSG00000273076.1	RP3-508I15.22	4.99	2.77e-06	0.00255	0.56	0.46	Menopause (age at onset);	chr22:38483005	chr22:38743495~38743910:+
THYM	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-4.99	2.77e-06	0.00255	-0.41	-0.46	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
THYM	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-4.99	2.77e-06	0.00255	-0.57	-0.46	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
THYM	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.99	2.77e-06	0.00255	0.41	0.46	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
THYM	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-4.99	2.78e-06	0.00256	-0.33	-0.46	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
THYM	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-4.99	2.78e-06	0.00256	-0.62	-0.46	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
THYM	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	4.99	2.78e-06	0.00256	0.62	0.46	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
THYM	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	4.99	2.78e-06	0.00256	0.61	0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
THYM	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	4.99	2.79e-06	0.00256	0.57	0.46	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
THYM	cis	rs7927592	0.546	rs638076	ENSG00000222339.1	AP000807.2	4.99	2.8e-06	0.00257	0.48	0.46	Total body bone mineral density;	chr11:68435112	chr11:68505572~68505651:-
THYM	cis	rs904251	0.772	rs2252920	ENSG00000227920.2	RP1-153P14.5	-4.99	2.8e-06	0.00257	-0.69	-0.46	Cognitive performance;	chr6:37450551	chr6:37545145~37550860:+
THYM	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-4.99	2.81e-06	0.00258	-0.56	-0.46	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
THYM	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	4.99	2.82e-06	0.00258	0.34	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
THYM	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	4.99	2.82e-06	0.00259	0.42	0.46	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
THYM	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-4.99	2.82e-06	0.00259	-0.59	-0.46	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	4.98	2.83e-06	0.0026	0.59	0.46	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
THYM	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-4.98	2.84e-06	0.00261	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
THYM	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-4.98	2.84e-06	0.00261	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
THYM	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	4.98	2.85e-06	0.00261	0.63	0.46	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
THYM	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-4.98	2.85e-06	0.00261	-0.38	-0.46	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-4.98	2.85e-06	0.00261	-0.38	-0.46	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
THYM	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-4.98	2.86e-06	0.00262	-0.34	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
THYM	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-4.98	2.86e-06	0.00262	-0.6	-0.46	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
THYM	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-4.98	2.86e-06	0.00262	-0.62	-0.46	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
THYM	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	4.98	2.86e-06	0.00262	0.39	0.46	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	4.98	2.86e-06	0.00262	0.39	0.46	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
THYM	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	4.98	2.87e-06	0.00263	0.38	0.46	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
THYM	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	4.98	2.87e-06	0.00263	0.5	0.46	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
THYM	cis	rs972578	0.837	rs5996246	ENSG00000215347.3	SLC25A5P1	-4.98	2.87e-06	0.00263	-0.36	-0.46	Mean platelet volume;	chr22:42901415	chr22:42001069~42001966:-
THYM	cis	rs9309473	0.5	rs6546862	ENSG00000163016.8	ALMS1P	-4.98	2.87e-06	0.00263	-0.52	-0.46	Metabolite levels;	chr2:73633221	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs4852951	ENSG00000163016.8	ALMS1P	-4.98	2.87e-06	0.00263	-0.52	-0.46	Metabolite levels;	chr2:73642669	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs12991161	ENSG00000163016.8	ALMS1P	-4.98	2.87e-06	0.00263	-0.52	-0.46	Metabolite levels;	chr2:73644244	chr2:73644919~73685576:+
THYM	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-4.98	2.88e-06	0.00264	-0.55	-0.46	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
THYM	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	4.98	2.88e-06	0.00264	0.52	0.46	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	4.98	2.88e-06	0.00264	0.52	0.46	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	4.98	2.88e-06	0.00264	0.52	0.46	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	4.98	2.88e-06	0.00264	0.52	0.46	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
THYM	cis	rs11971779	0.774	rs7785906	ENSG00000273391.1	RP11-634H22.1	4.98	2.88e-06	0.00264	0.35	0.46	Diisocyanate-induced asthma;	chr7:139437906	chr7:139359032~139359566:-
THYM	cis	rs9535495	0.965	rs7326839	ENSG00000200711.1	RNA5SP28	-4.98	2.89e-06	0.00265	-0.53	-0.46	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50824330	chr13:50812988~50813106:-
THYM	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	4.98	2.89e-06	0.00265	0.46	0.46	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
THYM	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-4.98	2.9e-06	0.00265	-0.42	-0.46	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
THYM	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	4.98	2.9e-06	0.00266	0.44	0.46	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
THYM	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	4.98	2.9e-06	0.00266	0.42	0.46	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
THYM	cis	rs995834	0.588	rs56239696	ENSG00000260725.1	AC005307.1	4.98	2.91e-06	0.00266	0.7	0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28409628	chr19:28418483~28429490:-
THYM	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-4.98	2.91e-06	0.00266	-0.8	-0.46	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
THYM	cis	rs4835473	0.932	rs1813908	ENSG00000251600.4	RP11-673E1.1	4.98	2.91e-06	0.00267	0.51	0.46	Immature fraction of reticulocytes;	chr4:143728174	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	4.98	2.91e-06	0.00267	0.51	0.46	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1839449	ENSG00000251600.4	RP11-673E1.1	4.98	2.91e-06	0.00267	0.51	0.46	Immature fraction of reticulocytes;	chr4:143730222	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	4.98	2.91e-06	0.00267	0.51	0.46	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	4.98	2.91e-06	0.00267	0.51	0.46	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs6537170	ENSG00000251600.4	RP11-673E1.1	4.98	2.91e-06	0.00267	0.52	0.46	Immature fraction of reticulocytes;	chr4:143691747	chr4:143912331~143982454:+
THYM	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	4.98	2.92e-06	0.00267	0.61	0.46	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
THYM	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	4.98	2.92e-06	0.00267	0.51	0.46	Height;	chr6:109747119	chr6:109382795~109383666:+
THYM	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	4.98	2.92e-06	0.00267	0.51	0.46	Height;	chr6:109747411	chr6:109382795~109383666:+
THYM	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	4.98	2.92e-06	0.00267	0.51	0.46	Height;	chr6:109748819	chr6:109382795~109383666:+
THYM	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	4.98	2.92e-06	0.00267	0.51	0.46	Height;	chr6:109749564	chr6:109382795~109383666:+
THYM	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	4.98	2.92e-06	0.00267	0.51	0.46	Height;	chr6:109763331	chr6:109382795~109383666:+
THYM	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	4.98	2.92e-06	0.00267	0.42	0.46	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
THYM	cis	rs6591341	0.515	rs599301	ENSG00000212093.1	AP000807.1	4.98	2.93e-06	0.00268	0.39	0.46	Lean body mass;	chr11:68422477	chr11:68506083~68506166:-
THYM	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	4.98	2.93e-06	0.00268	0.35	0.46	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
THYM	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	4.98	2.93e-06	0.00268	0.39	0.46	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
THYM	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-4.97	2.94e-06	0.00269	-0.87	-0.46	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
THYM	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-4.97	2.94e-06	0.00269	-0.36	-0.46	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
THYM	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.94e-06	0.00269	-0.41	-0.46	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.94e-06	0.00269	-0.41	-0.46	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.94e-06	0.00269	-0.41	-0.46	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
THYM	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	4.97	2.95e-06	0.00269	0.45	0.46	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
THYM	cis	rs10129255	0.518	rs10150460	ENSG00000253703.1	IGHV1-68	4.97	2.95e-06	0.00269	0.5	0.46	Kawasaki disease;	chr14:106677179	chr14:106703852~106704146:-
THYM	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-4.97	2.95e-06	0.0027	-0.4	-0.46	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
THYM	cis	rs10129255	0.53	rs11624912	ENSG00000253703.1	IGHV1-68	-4.97	2.95e-06	0.0027	-0.5	-0.46	Kawasaki disease;	chr14:106673891	chr14:106703852~106704146:-
THYM	cis	rs453301	0.574	rs10081437	ENSG00000253893.2	FAM85B	4.97	2.95e-06	0.0027	0.59	0.46	Joint mobility (Beighton score);	chr8:9091469	chr8:8167819~8226614:-
THYM	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	4.97	2.95e-06	0.0027	0.58	0.46	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
THYM	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	4.97	2.96e-06	0.0027	0.5	0.46	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
THYM	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-4.97	2.96e-06	0.0027	-0.41	-0.46	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
THYM	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-4.97	2.96e-06	0.00271	-0.46	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
THYM	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-4.97	2.97e-06	0.00271	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
THYM	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-4.97	2.97e-06	0.00271	-0.61	-0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
THYM	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-4.97	2.97e-06	0.00271	-0.61	-0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
THYM	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-4.97	2.97e-06	0.00271	-0.32	-0.46	Height;	chr11:118791319	chr11:118791254~118793137:+
THYM	cis	rs28785552	1	rs28785552	ENSG00000250731.1	TPM3P6	-4.97	2.97e-06	0.00271	-0.65	-0.46	Response to paliperidone in schizophrenia (PANSS score);	chr19:52730908	chr19:53479350~53480091:+
THYM	cis	rs28785552	0.769	rs28796114	ENSG00000250731.1	TPM3P6	-4.97	2.97e-06	0.00271	-0.65	-0.46	Response to paliperidone in schizophrenia (PANSS score);	chr19:52731066	chr19:53479350~53480091:+
THYM	cis	rs10129255	0.536	rs17113249	ENSG00000253703.1	IGHV1-68	-4.97	2.97e-06	0.00271	-0.5	-0.46	Kawasaki disease;	chr14:106678273	chr14:106703852~106704146:-
THYM	cis	rs1560104	0.597	rs12708758	ENSG00000259899.1	CTD-3037G24.3	-4.97	2.98e-06	0.00271	-0.57	-0.46	Obesity-related traits;	chr16:12616844	chr16:12560756~12611044:-
THYM	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	4.97	2.98e-06	0.00271	0.7	0.46	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
THYM	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-4.97	2.98e-06	0.00272	-0.56	-0.46	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
THYM	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-4.97	2.98e-06	0.00272	-0.33	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
THYM	cis	rs944990	0.576	rs3901421	ENSG00000227603.1	RP11-165J3.6	4.97	2.99e-06	0.00272	0.39	0.46	Body mass index;	chr9:93442256	chr9:93435332~93437121:-
THYM	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	4.97	2.99e-06	0.00272	0.62	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
THYM	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	4.97	2.99e-06	0.00273	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
THYM	cis	rs6570726	1	rs450076	ENSG00000235652.6	RP11-545I5.3	4.97	2.99e-06	0.00273	0.33	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145799409~145886585:+
THYM	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	4.97	2.99e-06	0.00273	0.64	0.46	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
THYM	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	4.97	3e-06	0.00273	0.52	0.46	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
THYM	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-4.97	3e-06	0.00273	-0.44	-0.46	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
THYM	cis	rs1757171	0.542	rs3818986	ENSG00000227920.2	RP1-153P14.5	-4.97	3.01e-06	0.00274	-0.58	-0.46	Cognitive performance;	chr6:37516573	chr6:37545145~37550860:+
THYM	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-4.97	3.01e-06	0.00274	-0.64	-0.46	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
THYM	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	4.97	3.01e-06	0.00274	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
THYM	cis	rs189798	0.807	rs330909	ENSG00000253893.2	FAM85B	-4.97	3.02e-06	0.00275	-0.65	-0.46	Myopia (pathological);	chr8:9137877	chr8:8167819~8226614:-
THYM	cis	rs4853012	0.887	rs6737314	ENSG00000257702.3	LBX2-AS1	4.97	3.04e-06	0.00276	0.52	0.46	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74502595~74504678:+
THYM	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-4.97	3.04e-06	0.00277	-0.55	-0.46	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
THYM	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	4.97	3.05e-06	0.00277	0.5	0.46	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
THYM	cis	rs9907295	0.591	rs4239252	ENSG00000270977.1	AC015849.16	4.97	3.05e-06	0.00277	0.53	0.46	Fibroblast growth factor basic levels;	chr17:35836561	chr17:35893707~35911023:-
THYM	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-4.97	3.05e-06	0.00277	-0.81	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
THYM	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-4.97	3.05e-06	0.00277	-0.45	-0.46	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
THYM	cis	rs34773007	0.577	rs35626653	ENSG00000272817.1	RP11-402D21.2	-4.97	3.06e-06	0.00277	-0.61	-0.46	Type 2 diabetes;	chr10:92784269	chr10:91908131~91909348:+
THYM	cis	rs9535495	0.965	rs1323884	ENSG00000200711.1	RNA5SP28	-4.97	3.06e-06	0.00277	-0.52	-0.46	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50827857	chr13:50812988~50813106:-
THYM	cis	rs2117029	1	rs2293445	ENSG00000258017.1	RP11-386G11.10	-4.97	3.06e-06	0.00277	-0.5	-0.46	Intelligence (multi-trait analysis);	chr12:49005079	chr12:49127782~49147869:+
THYM	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-4.96	3.06e-06	0.00277	-0.61	-0.46	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
THYM	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-4.96	3.07e-06	0.00277	-0.35	-0.46	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
THYM	cis	rs4845570	0.92	rs10788809	ENSG00000203288.3	RP11-98D18.9	4.96	3.07e-06	0.00277	0.55	0.46	Coronary artery disease;	chr1:151788316	chr1:151790804~151794402:+
THYM	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	4.96	3.07e-06	0.00277	0.41	0.46	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	4.96	3.07e-06	0.00277	0.41	0.46	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	4.96	3.07e-06	0.00277	0.41	0.46	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-4.96	3.07e-06	0.00277	-0.41	-0.46	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
THYM	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	4.96	3.08e-06	0.00278	0.99	0.46	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
THYM	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	4.96	3.08e-06	0.00278	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	4.96	3.08e-06	0.00278	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	4.96	3.08e-06	0.00278	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
THYM	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	4.96	3.09e-06	0.00279	0.39	0.46	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
THYM	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	4.96	3.09e-06	0.00279	0.39	0.46	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
THYM	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-4.96	3.09e-06	0.00279	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
THYM	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-4.96	3.09e-06	0.00279	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
THYM	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-4.96	3.09e-06	0.00279	-0.39	-0.46	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
THYM	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	4.96	3.09e-06	0.00279	0.7	0.46	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
THYM	cis	rs904251	0.6	rs4714068	ENSG00000227920.2	RP1-153P14.5	-4.96	3.09e-06	0.00279	-0.61	-0.46	Cognitive performance;	chr6:37487866	chr6:37545145~37550860:+
THYM	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	4.96	3.1e-06	0.0028	0.39	0.46	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
THYM	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	4.96	3.11e-06	0.0028	0.61	0.46	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	4.96	3.11e-06	0.0028	0.61	0.46	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
THYM	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-4.96	3.11e-06	0.0028	-0.61	-0.46	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
THYM	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	4.96	3.11e-06	0.0028	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	4.96	3.11e-06	0.0028	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
THYM	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-4.96	3.11e-06	0.0028	-0.41	-0.46	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
THYM	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	4.96	3.11e-06	0.00281	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
THYM	cis	rs189798	0.807	rs12785	ENSG00000253893.2	FAM85B	-4.96	3.12e-06	0.00281	-0.64	-0.46	Myopia (pathological);	chr8:9137426	chr8:8167819~8226614:-
THYM	cis	rs5769707	0.967	rs9616701	ENSG00000264139.1	MIR3667	-4.96	3.12e-06	0.00281	-0.5	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49543393~49543466:-
THYM	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	4.96	3.12e-06	0.00281	0.72	0.46	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
THYM	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	4.96	3.12e-06	0.00281	0.72	0.46	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
THYM	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	4.96	3.13e-06	0.00282	0.32	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
THYM	cis	rs4691139	0.903	rs6812176	ENSG00000250227.1	TRIM60P14	4.96	3.14e-06	0.00282	0.54	0.46	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998820	chr4:164915565~164916983:+
THYM	cis	rs66823261	0.741	rs7841786	ENSG00000223508.5	RPL23AP53	4.96	3.14e-06	0.00282	0.57	0.46	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:213186~232231:-
THYM	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	4.96	3.15e-06	0.00283	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	4.96	3.15e-06	0.00283	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	4.96	3.15e-06	0.00283	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	4.96	3.15e-06	0.00283	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
THYM	cis	rs904251	0.772	rs1812186	ENSG00000227920.2	RP1-153P14.5	-4.96	3.15e-06	0.00283	-0.69	-0.46	Cognitive performance;	chr6:37498140	chr6:37545145~37550860:+
THYM	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	4.96	3.15e-06	0.00283	0.45	0.46	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
THYM	cis	rs4853012	0.838	rs72915068	ENSG00000257702.3	LBX2-AS1	4.96	3.15e-06	0.00283	0.51	0.46	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74502595~74504678:+
THYM	cis	rs4908768	0.535	rs2708628	ENSG00000232912.4	RP5-1115A15.1	-4.96	3.16e-06	0.00284	-0.48	-0.46	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8390388	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.535	rs2784738	ENSG00000232912.4	RP5-1115A15.1	-4.96	3.16e-06	0.00284	-0.48	-0.46	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406157	chr1:8424645~8434838:+
THYM	cis	rs7927592	0.513	rs653056	ENSG00000222339.1	AP000807.2	4.96	3.17e-06	0.00285	0.48	0.46	Total body bone mineral density;	chr11:68436157	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	4.96	3.18e-06	0.00286	0.4	0.46	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
THYM	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	4.96	3.18e-06	0.00286	0.4	0.46	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
THYM	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	4.96	3.18e-06	0.00286	0.61	0.46	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	4.96	3.18e-06	0.00286	0.61	0.46	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
THYM	cis	rs10829156	0.796	rs6482567	ENSG00000240291.1	RP11-499P20.2	4.96	3.18e-06	0.00286	0.41	0.46	Sudden cardiac arrest;	chr10:18625860	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.755	rs10732437	ENSG00000240291.1	RP11-499P20.2	4.96	3.18e-06	0.00286	0.41	0.46	Sudden cardiac arrest;	chr10:18626973	chr10:18513115~18545651:-
THYM	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	4.95	3.19e-06	0.00287	0.46	0.46	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
THYM	cis	rs944990	0.597	rs10821162	ENSG00000227603.1	RP11-165J3.6	4.95	3.19e-06	0.00287	0.39	0.46	Body mass index;	chr9:93579042	chr9:93435332~93437121:-
THYM	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	4.95	3.19e-06	0.00287	0.89	0.46	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
THYM	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	4.95	3.2e-06	0.00287	0.4	0.46	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
THYM	cis	rs9309473	0.539	rs7574268	ENSG00000163016.8	ALMS1P	-4.95	3.2e-06	0.00287	-0.51	-0.46	Metabolite levels;	chr2:73677745	chr2:73644919~73685576:+
THYM	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-4.95	3.2e-06	0.00288	-0.42	-0.46	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
THYM	cis	rs992157	0.764	rs3731861	ENSG00000261338.2	RP11-378A13.1	-4.95	3.2e-06	0.00288	-0.59	-0.45	Colorectal cancer;	chr2:218326533	chr2:218255319~218257366:+
THYM	cis	rs4835473	0.9	rs3856989	ENSG00000251600.4	RP11-673E1.1	4.95	3.2e-06	0.00288	0.51	0.45	Immature fraction of reticulocytes;	chr4:143921752	chr4:143912331~143982454:+
THYM	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	4.95	3.2e-06	0.00288	0.41	0.45	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
THYM	cis	rs4835473	0.897	rs1450249	ENSG00000251600.4	RP11-673E1.1	4.95	3.21e-06	0.00288	0.52	0.45	Immature fraction of reticulocytes;	chr4:143724425	chr4:143912331~143982454:+
THYM	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-4.95	3.22e-06	0.00289	-0.59	-0.45	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
THYM	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	4.95	3.22e-06	0.00289	0.42	0.45	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
THYM	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	4.95	3.23e-06	0.0029	0.97	0.45	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	4.95	3.23e-06	0.0029	0.97	0.45	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	4.95	3.23e-06	0.0029	0.97	0.45	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	4.95	3.23e-06	0.0029	0.97	0.45	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
THYM	cis	rs6570726	0.526	rs4896805	ENSG00000235652.6	RP11-545I5.3	-4.95	3.23e-06	0.0029	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145414293	chr6:145799409~145886585:+
THYM	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-4.95	3.24e-06	0.00291	-0.61	-0.45	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
THYM	cis	rs9907295	0.584	rs7215845	ENSG00000270977.1	AC015849.16	-4.95	3.24e-06	0.00291	-0.55	-0.45	Fibroblast growth factor basic levels;	chr17:35894698	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.591	rs4796128	ENSG00000270977.1	AC015849.16	-4.95	3.24e-06	0.00291	-0.55	-0.45	Fibroblast growth factor basic levels;	chr17:35899268	chr17:35893707~35911023:-
THYM	cis	rs7702057	0.53	rs17138879	ENSG00000271918.1	CTD-2287O16.5	-4.95	3.26e-06	0.00292	-0.73	-0.45	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116083807~116085416:-
THYM	cis	rs4713118	0.621	rs9368548	ENSG00000182477.5	OR2B8P	4.95	3.27e-06	0.00293	0.65	0.45	Parkinson's disease;	chr6:28066959	chr6:28053228~28054165:-
THYM	cis	rs5769707	0.967	rs2071904	ENSG00000264139.1	MIR3667	-4.95	3.27e-06	0.00293	-0.5	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49543393~49543466:-
THYM	cis	rs5769707	0.846	rs5770610	ENSG00000264139.1	MIR3667	-4.95	3.27e-06	0.00293	-0.5	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49543393~49543466:-
THYM	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-4.95	3.27e-06	0.00293	-0.53	-0.45	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
THYM	cis	rs4262	0.617	rs180239	ENSG00000278388.1	GS1-345D13.1	-4.95	3.27e-06	0.00293	-0.48	-0.45	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93921103	chr7:93914987~93915108:+
THYM	cis	rs7605378	0.528	rs812760	ENSG00000232732.8	AC073043.1	-4.95	3.28e-06	0.00294	-0.63	-0.45	Osteoporosis;	chr2:199859649	chr2:199867396~199911159:-
THYM	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-4.95	3.28e-06	0.00294	-0.41	-0.45	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
THYM	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-4.95	3.28e-06	0.00294	-0.4	-0.45	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
THYM	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	4.95	3.29e-06	0.00295	0.54	0.45	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
THYM	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	4.95	3.29e-06	0.00295	0.62	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	4.95	3.29e-06	0.00295	0.62	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
THYM	cis	rs61160187	0.51	rs6872863	ENSG00000272308.1	RP11-231G3.1	-4.95	3.29e-06	0.00295	-0.41	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792321	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.527	rs6873181	ENSG00000272308.1	RP11-231G3.1	-4.95	3.29e-06	0.00295	-0.41	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792423	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.527	rs6894672	ENSG00000272308.1	RP11-231G3.1	-4.95	3.29e-06	0.00295	-0.41	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792428	chr5:60866457~60866935:-
THYM	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	4.95	3.3e-06	0.00295	0.52	0.45	Height;	chr6:109423238	chr6:109382795~109383666:+
THYM	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-4.95	3.3e-06	0.00295	-0.33	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
THYM	cis	rs3740713	0.669	rs113003553	ENSG00000256464.1	YWHABP2	4.95	3.31e-06	0.00296	0.79	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr11:18490243~18490955:-
THYM	cis	rs3740713	0.592	rs73434674	ENSG00000256464.1	YWHABP2	4.95	3.31e-06	0.00296	0.79	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr11:18490243~18490955:-
THYM	cis	rs904251	0.6	rs12211110	ENSG00000227920.2	RP1-153P14.5	-4.95	3.31e-06	0.00296	-0.61	-0.45	Cognitive performance;	chr6:37498456	chr6:37545145~37550860:+
THYM	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	4.95	3.31e-06	0.00296	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
THYM	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-4.95	3.31e-06	0.00296	-0.72	-0.45	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
THYM	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-4.95	3.32e-06	0.00297	-0.58	-0.45	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
THYM	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-4.95	3.32e-06	0.00297	-0.58	-0.45	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
THYM	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-4.95	3.32e-06	0.00297	-0.58	-0.45	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
THYM	cis	rs950169	0.614	rs12903883	ENSG00000235370.6	DNM1P51	4.95	3.32e-06	0.00297	0.63	0.45	Schizophrenia;	chr15:84011801	chr15:84398316~84411701:-
THYM	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-4.94	3.32e-06	0.00297	-0.71	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	4.94	3.32e-06	0.00297	0.71	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
THYM	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	4.94	3.32e-06	0.00297	0.55	0.45	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
THYM	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-4.94	3.32e-06	0.00297	-0.55	-0.45	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
THYM	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-4.94	3.32e-06	0.00297	-0.55	-0.45	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
THYM	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	4.94	3.33e-06	0.00297	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	4.94	3.33e-06	0.00297	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	4.94	3.33e-06	0.00297	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	4.94	3.33e-06	0.00297	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
THYM	cis	rs4835473	0.932	rs7683686	ENSG00000249741.2	RP11-673E1.3	4.94	3.33e-06	0.00298	0.36	0.45	Immature fraction of reticulocytes;	chr4:143784352	chr4:143911514~143912053:-
THYM	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	4.94	3.33e-06	0.00298	0.56	0.45	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	4.94	3.33e-06	0.00298	0.56	0.45	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
THYM	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	4.94	3.34e-06	0.00298	0.73	0.45	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
THYM	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	4.94	3.34e-06	0.00298	0.6	0.45	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
THYM	cis	rs1790761	0.692	rs10444362	ENSG00000231793.4	DOC2GP	-4.94	3.34e-06	0.00298	-0.4	-0.45	Mean corpuscular volume;	chr11:67565619	chr11:67612653~67616257:-
THYM	cis	rs1790761	0.692	rs638140	ENSG00000231793.4	DOC2GP	-4.94	3.34e-06	0.00298	-0.4	-0.45	Mean corpuscular volume;	chr11:67566387	chr11:67612653~67616257:-
THYM	cis	rs1790761	0.692	rs1269981	ENSG00000231793.4	DOC2GP	-4.94	3.34e-06	0.00298	-0.4	-0.45	Mean corpuscular volume;	chr11:67567488	chr11:67612653~67616257:-
THYM	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-4.94	3.34e-06	0.00298	-0.4	-0.45	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-4.94	3.34e-06	0.00298	-0.4	-0.45	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
THYM	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	4.94	3.35e-06	0.00299	0.45	0.45	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
THYM	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-4.94	3.35e-06	0.00299	-0.56	-0.45	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
THYM	cis	rs4663866	1	rs71426508	ENSG00000186235.9	AC016757.3	4.94	3.35e-06	0.00299	1.09	0.45	Irritable bowel syndrome;	chr2:238229126	chr2:238224552~238231677:-
THYM	cis	rs189798	1	rs189798	ENSG00000253893.2	FAM85B	4.94	3.36e-06	0.003	0.56	0.45	Myopia (pathological);	chr8:9133067	chr8:8167819~8226614:-
THYM	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	4.94	3.36e-06	0.003	0.49	0.45	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
THYM	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	4.94	3.37e-06	0.00301	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	4.94	3.37e-06	0.00301	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
THYM	cis	rs11157436	0.846	rs12435431	ENSG00000211813.2	TRAV34	4.94	3.37e-06	0.00301	0.36	0.45	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22207522~22208129:+
THYM	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.94	3.37e-06	0.00301	0.42	0.45	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
THYM	cis	rs4715166	0.926	rs12205644	ENSG00000215022.6	RP1-257A7.4	-4.94	3.37e-06	0.00301	-0.42	-0.45	Hip geometry;	chr6:13223764	chr6:13264861~13295586:-
THYM	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-4.94	3.37e-06	0.00301	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-4.94	3.37e-06	0.00301	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-4.94	3.37e-06	0.00301	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-4.94	3.37e-06	0.00301	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-4.94	3.37e-06	0.00301	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	4.94	3.37e-06	0.00301	0.55	0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
THYM	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-4.94	3.38e-06	0.00301	-0.64	-0.45	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
THYM	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-4.94	3.38e-06	0.00301	-0.36	-0.45	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-4.94	3.38e-06	0.00301	-0.36	-0.45	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-4.94	3.38e-06	0.00301	-0.36	-0.45	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
THYM	cis	rs2117029	1	rs10783299	ENSG00000258017.1	RP11-386G11.10	-4.94	3.39e-06	0.00302	-0.51	-0.45	Intelligence (multi-trait analysis);	chr12:48996894	chr12:49127782~49147869:+
THYM	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-4.94	3.39e-06	0.00302	-0.6	-0.45	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
THYM	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	4.94	3.39e-06	0.00302	0.72	0.45	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
THYM	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	4.94	3.39e-06	0.00302	0.58	0.45	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
THYM	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-4.94	3.4e-06	0.00303	-0.4	-0.45	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
THYM	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-4.94	3.4e-06	0.00303	-0.41	-0.45	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
THYM	cis	rs13256369	1	rs12550762	ENSG00000253893.2	FAM85B	-4.94	3.4e-06	0.00303	-0.63	-0.45	Obesity-related traits;	chr8:8719025	chr8:8167819~8226614:-
THYM	cis	rs13256369	1	rs9329165	ENSG00000253893.2	FAM85B	4.94	3.4e-06	0.00303	0.63	0.45	Obesity-related traits;	chr8:8719132	chr8:8167819~8226614:-
THYM	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-4.94	3.41e-06	0.00304	-0.52	-0.45	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
THYM	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	4.94	3.41e-06	0.00304	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
THYM	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-4.94	3.42e-06	0.00304	-0.56	-0.45	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-4.94	3.42e-06	0.00304	-0.56	-0.45	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
THYM	cis	rs6751744	0.855	rs7585513	ENSG00000226266.5	AC009961.3	-4.94	3.42e-06	0.00305	-0.56	-0.45	Dysphagia;	chr2:159550379	chr2:159670708~159712435:-
THYM	cis	rs853679	0.517	rs36078605	ENSG00000182477.5	OR2B8P	4.94	3.42e-06	0.00305	0.64	0.45	Depression;	chr6:28110254	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9393891	ENSG00000182477.5	OR2B8P	4.94	3.42e-06	0.00305	0.64	0.45	Depression;	chr6:28111382	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9468286	ENSG00000182477.5	OR2B8P	4.94	3.42e-06	0.00305	0.64	0.45	Depression;	chr6:28111650	chr6:28053228~28054165:-
THYM	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	4.94	3.43e-06	0.00306	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
THYM	cis	rs9309473	0.519	rs2421667	ENSG00000163016.8	ALMS1P	-4.94	3.44e-06	0.00307	-0.56	-0.45	Metabolite levels;	chr2:73605332	chr2:73644919~73685576:+
THYM	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-4.94	3.45e-06	0.00307	-0.53	-0.45	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-4.94	3.45e-06	0.00307	-0.53	-0.45	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
THYM	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	4.94	3.45e-06	0.00307	0.41	0.45	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
THYM	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	4.94	3.45e-06	0.00307	0.72	0.45	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
THYM	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-4.94	3.45e-06	0.00307	-0.61	-0.45	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
THYM	cis	rs4853012	0.887	rs2122290	ENSG00000257702.3	LBX2-AS1	4.94	3.46e-06	0.00308	0.53	0.45	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74502595~74504678:+
THYM	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-4.93	3.47e-06	0.00308	-0.42	-0.45	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
THYM	cis	rs526231	0.667	rs187580	ENSG00000175749.11	EIF3KP1	4.93	3.47e-06	0.00308	0.67	0.45	Primary biliary cholangitis;	chr5:103291654	chr5:103032376~103033031:+
THYM	cis	rs10829156	0.945	rs8181345	ENSG00000240291.1	RP11-499P20.2	4.93	3.47e-06	0.00309	0.4	0.45	Sudden cardiac arrest;	chr10:18678689	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.945	rs10829199	ENSG00000240291.1	RP11-499P20.2	4.93	3.47e-06	0.00309	0.4	0.45	Sudden cardiac arrest;	chr10:18679012	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.945	rs10741131	ENSG00000240291.1	RP11-499P20.2	4.93	3.47e-06	0.00309	0.4	0.45	Sudden cardiac arrest;	chr10:18683130	chr10:18513115~18545651:-
THYM	cis	rs3862435	0.518	rs2444061	ENSG00000259212.1	CTD-3065B20.2	-4.93	3.47e-06	0.00309	-0.65	-0.45	Response to exercise (triglyceride level interaction);	chr15:90366207	chr15:90595840~90596447:-
THYM	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-4.93	3.48e-06	0.00309	-0.56	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
THYM	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-4.93	3.48e-06	0.00309	-0.55	-0.45	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
THYM	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-4.93	3.49e-06	0.0031	-0.56	-0.45	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
THYM	cis	rs741668	0.641	rs4942472	ENSG00000235903.6	CPB2-AS1	-4.93	3.49e-06	0.0031	-0.48	-0.45	Cerebrospinal fluid clusterin levels;	chr13:46070980	chr13:46052806~46113332:+
THYM	cis	rs9309473	0.519	rs13027816	ENSG00000163016.8	ALMS1P	-4.93	3.5e-06	0.00311	-0.51	-0.45	Metabolite levels;	chr2:73670564	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs2421584	ENSG00000163016.8	ALMS1P	-4.93	3.5e-06	0.00311	-0.51	-0.45	Metabolite levels;	chr2:73671725	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs2421586	ENSG00000163016.8	ALMS1P	-4.93	3.5e-06	0.00311	-0.51	-0.45	Metabolite levels;	chr2:73672592	chr2:73644919~73685576:+
THYM	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	4.93	3.5e-06	0.00311	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
THYM	cis	rs4853012	0.838	rs4563249	ENSG00000257702.3	LBX2-AS1	4.93	3.5e-06	0.00311	0.49	0.45	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74502595~74504678:+
THYM	cis	rs10129255	0.518	rs2006284	ENSG00000253703.1	IGHV1-68	-4.93	3.52e-06	0.00312	-0.5	-0.45	Kawasaki disease;	chr14:106676185	chr14:106703852~106704146:-
THYM	cis	rs950169	0.58	rs11634320	ENSG00000235370.6	DNM1P51	-4.93	3.52e-06	0.00313	-0.6	-0.45	Schizophrenia;	chr15:84628952	chr15:84398316~84411701:-
THYM	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-4.93	3.52e-06	0.00313	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-4.93	3.52e-06	0.00313	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
THYM	cis	rs890448	0.897	rs2953534	ENSG00000254531.1	FLJ20021	-4.93	3.52e-06	0.00313	-0.38	-0.45	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101454897	chr4:101347780~101348883:+
THYM	cis	rs995834	0.743	rs28579409	ENSG00000267243.4	AC005307.3	-4.93	3.52e-06	0.00313	-0.4	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347315	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs8108624	ENSG00000267243.4	AC005307.3	-4.93	3.52e-06	0.00313	-0.4	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347359	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs8108711	ENSG00000267243.4	AC005307.3	-4.93	3.52e-06	0.00313	-0.4	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347390	chr19:28435388~28727777:-
THYM	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	4.93	3.53e-06	0.00313	0.41	0.45	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
THYM	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-4.93	3.53e-06	0.00313	-0.53	-0.45	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
THYM	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-4.93	3.53e-06	0.00313	-0.53	-0.45	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
THYM	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-4.93	3.53e-06	0.00313	-0.5	-0.45	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
THYM	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-4.93	3.53e-06	0.00313	-0.5	-0.45	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
THYM	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	4.93	3.55e-06	0.00315	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
THYM	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	4.93	3.57e-06	0.00316	0.43	0.45	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
THYM	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-4.93	3.57e-06	0.00316	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-4.93	3.57e-06	0.00316	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-4.93	3.57e-06	0.00316	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-4.93	3.57e-06	0.00316	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-4.93	3.57e-06	0.00316	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.618	rs12499429	ENSG00000251600.4	RP11-673E1.1	-4.93	3.57e-06	0.00316	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143889914	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.801	rs28715976	ENSG00000251600.4	RP11-673E1.1	-4.93	3.57e-06	0.00316	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143891603	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs4835343	ENSG00000251600.4	RP11-673E1.1	4.93	3.57e-06	0.00316	0.51	0.45	Immature fraction of reticulocytes;	chr4:143866038	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.831	rs1579816	ENSG00000251600.4	RP11-673E1.1	4.93	3.57e-06	0.00316	0.51	0.45	Immature fraction of reticulocytes;	chr4:143866772	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4240334	ENSG00000251600.4	RP11-673E1.1	4.93	3.57e-06	0.00316	0.51	0.45	Immature fraction of reticulocytes;	chr4:143871352	chr4:143912331~143982454:+
THYM	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	4.93	3.58e-06	0.00317	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
THYM	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	4.93	3.58e-06	0.00317	0.51	0.45	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
THYM	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	4.93	3.58e-06	0.00317	0.6	0.45	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
THYM	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	4.93	3.59e-06	0.00317	0.54	0.45	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	4.93	3.59e-06	0.00317	0.54	0.45	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	4.93	3.59e-06	0.00317	0.54	0.45	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	4.93	3.59e-06	0.00317	0.54	0.45	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
THYM	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	4.93	3.59e-06	0.00317	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
THYM	cis	rs4700393	0.967	rs4700394	ENSG00000272308.1	RP11-231G3.1	4.93	3.59e-06	0.00317	0.4	0.45	Intelligence (multi-trait analysis);	chr5:60821375	chr5:60866457~60866935:-
THYM	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	4.93	3.6e-06	0.00318	0.51	0.45	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
THYM	cis	rs8067545	0.611	rs2703807	ENSG00000230528.6	NOS2P3	4.93	3.6e-06	0.00318	0.38	0.45	Schizophrenia;	chr17:20205876	chr17:20436337~20447249:+
THYM	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	4.93	3.6e-06	0.00318	0.56	0.45	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
THYM	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-4.93	3.6e-06	0.00318	-0.59	-0.45	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
THYM	cis	rs10129255	0.5	rs4774189	ENSG00000253703.1	IGHV1-68	-4.92	3.61e-06	0.00319	-0.49	-0.45	Kawasaki disease;	chr14:106768275	chr14:106703852~106704146:-
THYM	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	4.92	3.62e-06	0.0032	0.52	0.45	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
THYM	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	4.92	3.63e-06	0.00321	0.46	0.45	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
THYM	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	4.92	3.64e-06	0.00321	0.6	0.45	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
THYM	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	4.92	3.65e-06	0.00322	0.57	0.45	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
THYM	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-4.92	3.65e-06	0.00323	-0.36	-0.45	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-4.92	3.65e-06	0.00323	-0.36	-0.45	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-4.92	3.65e-06	0.00323	-0.36	-0.45	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-4.92	3.65e-06	0.00323	-0.36	-0.45	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-4.92	3.65e-06	0.00323	-0.36	-0.45	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
THYM	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-4.92	3.66e-06	0.00323	-0.54	-0.45	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
THYM	cis	rs7202877	0.706	rs42472	ENSG00000261783.1	RP11-252K23.2	4.92	3.66e-06	0.00323	0.61	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75439422	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs247447	ENSG00000261783.1	RP11-252K23.2	4.92	3.66e-06	0.00323	0.61	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75452750	chr16:75379818~75381260:-
THYM	cis	rs61160187	0.51	rs4482855	ENSG00000272308.1	RP11-231G3.1	-4.92	3.67e-06	0.00324	-0.4	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800670	chr5:60866457~60866935:-
THYM	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	4.92	3.67e-06	0.00324	0.59	0.45	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
THYM	cis	rs12908161	0.96	rs34452033	ENSG00000235370.6	DNM1P51	4.92	3.67e-06	0.00324	0.61	0.45	Schizophrenia;	chr15:84678762	chr15:84398316~84411701:-
THYM	cis	rs1550576	0.5	rs35016264	ENSG00000274719.1	RP11-86K22.2	4.92	3.67e-06	0.00324	0.8	0.45	Hypertension;	chr15:57959648	chr15:57990217~57990636:-
THYM	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	4.92	3.67e-06	0.00324	0.4	0.45	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
THYM	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-4.92	3.68e-06	0.00324	-0.47	-0.45	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
THYM	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	4.92	3.68e-06	0.00324	0.72	0.45	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
THYM	cis	rs2562456	0.833	rs11667361	ENSG00000268081.1	RP11-678G14.2	4.92	3.69e-06	0.00325	0.62	0.45	Pain;	chr19:21356580	chr19:21554640~21569237:-
THYM	cis	rs73198271	0.722	rs488566	ENSG00000253893.2	FAM85B	4.92	3.7e-06	0.00326	0.72	0.45	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8782065	chr8:8167819~8226614:-
THYM	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	4.92	3.71e-06	0.00327	0.54	0.45	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
THYM	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	4.92	3.72e-06	0.00328	0.39	0.45	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
THYM	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	4.92	3.72e-06	0.00328	0.55	0.45	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-4.92	3.72e-06	0.00328	-0.55	-0.45	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
THYM	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-4.92	3.72e-06	0.00328	-0.53	-0.45	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
THYM	cis	rs3796619	0.503	rs13147452	ENSG00000215367.9	TMED11P	4.92	3.73e-06	0.00328	0.43	0.45	Recombination rate (males);	chr4:1084336	chr4:1115197~1153726:-
THYM	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	4.92	3.73e-06	0.00328	0.59	0.45	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
THYM	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-4.92	3.73e-06	0.00329	-0.57	-0.45	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
THYM	cis	rs8062405	0.592	rs12919058	ENSG00000259982.1	CDC37P1	-4.92	3.74e-06	0.00329	-0.63	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28916497	chr16:28700294~28701540:-
THYM	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	4.92	3.74e-06	0.00329	0.57	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
THYM	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	4.92	3.75e-06	0.0033	0.41	0.45	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	4.92	3.75e-06	0.0033	0.41	0.45	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	4.92	3.75e-06	0.0033	0.41	0.45	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-4.92	3.75e-06	0.0033	-0.41	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
THYM	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	4.91	3.75e-06	0.0033	0.62	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	4.91	3.75e-06	0.0033	0.62	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
THYM	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	4.91	3.76e-06	0.0033	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs377143	ENSG00000235652.6	RP11-545I5.3	4.91	3.76e-06	0.00331	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145799409~145886585:+
THYM	cis	rs997154	0.544	rs60950807	ENSG00000279656.1	RP11-298I3.6	-4.91	3.76e-06	0.00331	-0.69	-0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23013195	chr14:23023083~23024217:-
THYM	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-4.91	3.77e-06	0.00331	-0.52	-0.45	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
THYM	cis	rs2117029	0.898	rs10875914	ENSG00000258017.1	RP11-386G11.10	-4.91	3.77e-06	0.00331	-0.49	-0.45	Intelligence (multi-trait analysis);	chr12:49028311	chr12:49127782~49147869:+
THYM	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-4.91	3.77e-06	0.00331	-0.51	-0.45	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
THYM	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-4.91	3.77e-06	0.00331	-0.4	-0.45	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	4.91	3.77e-06	0.00331	0.4	0.45	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
THYM	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-4.91	3.77e-06	0.00331	-0.36	-0.45	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-4.91	3.77e-06	0.00331	-0.36	-0.45	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
THYM	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-4.91	3.77e-06	0.00331	-0.72	-0.45	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
THYM	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-4.91	3.77e-06	0.00331	-0.72	-0.45	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
THYM	cis	rs4845570	1	rs4845570	ENSG00000203288.3	RP11-98D18.9	4.91	3.77e-06	0.00331	0.54	0.45	Coronary artery disease;	chr1:151786628	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs4845356	ENSG00000203288.3	RP11-98D18.9	4.91	3.77e-06	0.00331	0.54	0.45	Coronary artery disease;	chr1:151786747	chr1:151790804~151794402:+
THYM	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-4.91	3.79e-06	0.00332	-0.41	-0.45	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
THYM	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	4.91	3.79e-06	0.00333	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
THYM	cis	rs11157436	0.918	rs1983519	ENSG00000211813.2	TRAV34	4.91	3.79e-06	0.00333	0.36	0.45	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22207522~22208129:+
THYM	cis	rs4853012	0.838	rs12619982	ENSG00000257702.3	LBX2-AS1	4.91	3.8e-06	0.00333	0.5	0.45	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74502595~74504678:+
THYM	cis	rs61160187	0.51	rs6893642	ENSG00000272308.1	RP11-231G3.1	-4.91	3.8e-06	0.00333	-0.4	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs3936423	ENSG00000272308.1	RP11-231G3.1	-4.91	3.8e-06	0.00333	-0.4	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.51	rs1445293	ENSG00000272308.1	RP11-231G3.1	-4.91	3.8e-06	0.00333	-0.4	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60866457~60866935:-
THYM	cis	rs11971779	0.838	rs4728468	ENSG00000273391.1	RP11-634H22.1	4.91	3.8e-06	0.00333	0.34	0.45	Diisocyanate-induced asthma;	chr7:139438232	chr7:139359032~139359566:-
THYM	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-4.91	3.81e-06	0.00334	-0.41	-0.45	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
THYM	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	4.91	3.81e-06	0.00334	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
THYM	cis	rs11971779	0.793	rs9632774	ENSG00000273391.1	RP11-634H22.1	4.91	3.81e-06	0.00334	0.37	0.45	Diisocyanate-induced asthma;	chr7:139452816	chr7:139359032~139359566:-
THYM	cis	rs10129255	0.54	rs35046566	ENSG00000254329.1	IGHVII-60-1	4.91	3.81e-06	0.00334	0.44	0.45	Kawasaki disease;	chr14:106651018	chr14:106637718~106637973:-
THYM	cis	rs950169	0.519	rs7237	ENSG00000235370.6	DNM1P51	4.91	3.81e-06	0.00334	0.64	0.45	Schizophrenia;	chr15:84643346	chr15:84398316~84411701:-
THYM	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-4.91	3.81e-06	0.00334	-0.36	-0.45	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-4.91	3.81e-06	0.00334	-0.36	-0.45	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-4.91	3.81e-06	0.00334	-0.36	-0.45	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-4.91	3.81e-06	0.00334	-0.36	-0.45	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
THYM	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-4.91	3.82e-06	0.00334	-0.54	-0.45	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
THYM	cis	rs61160187	0.51	rs10077663	ENSG00000272308.1	RP11-231G3.1	-4.91	3.83e-06	0.00336	-0.4	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60866457~60866935:-
THYM	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	4.91	3.83e-06	0.00336	0.55	0.45	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
THYM	cis	rs12908161	1	rs11638290	ENSG00000235370.6	DNM1P51	4.91	3.83e-06	0.00336	0.61	0.45	Schizophrenia;	chr15:84684405	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.959	rs34028043	ENSG00000235370.6	DNM1P51	4.91	3.83e-06	0.00336	0.61	0.45	Schizophrenia;	chr15:84688354	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.959	rs34784022	ENSG00000235370.6	DNM1P51	4.91	3.83e-06	0.00336	0.61	0.45	Schizophrenia;	chr15:84688675	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.959	rs12908699	ENSG00000235370.6	DNM1P51	4.91	3.83e-06	0.00336	0.61	0.45	Schizophrenia;	chr15:84697172	chr15:84398316~84411701:-
THYM	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	4.91	3.84e-06	0.00336	0.39	0.45	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
THYM	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	4.91	3.84e-06	0.00337	0.79	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
THYM	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	4.91	3.85e-06	0.00337	0.45	0.45	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
THYM	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	4.91	3.85e-06	0.00337	0.34	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
THYM	cis	rs992157	0.764	rs2891077	ENSG00000261338.2	RP11-378A13.1	4.91	3.85e-06	0.00337	0.58	0.45	Colorectal cancer;	chr2:218319707	chr2:218255319~218257366:+
THYM	cis	rs992157	0.73	rs2891078	ENSG00000261338.2	RP11-378A13.1	4.91	3.85e-06	0.00337	0.58	0.45	Colorectal cancer;	chr2:218319709	chr2:218255319~218257366:+
THYM	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	4.91	3.85e-06	0.00337	0.51	0.45	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	4.91	3.85e-06	0.00337	0.51	0.45	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	4.91	3.85e-06	0.00337	0.51	0.45	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	4.91	3.85e-06	0.00337	0.51	0.45	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	4.91	3.85e-06	0.00337	0.51	0.45	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
THYM	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	4.91	3.86e-06	0.00337	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
THYM	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	4.91	3.86e-06	0.00337	0.57	0.45	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	4.91	3.86e-06	0.00337	0.57	0.45	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
THYM	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	4.91	3.86e-06	0.00338	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-4.91	3.86e-06	0.00338	-0.33	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
THYM	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	4.91	3.86e-06	0.00338	0.45	0.45	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
THYM	cis	rs7202877	0.706	rs247436	ENSG00000261783.1	RP11-252K23.2	4.91	3.87e-06	0.00338	0.59	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75412073	chr16:75379818~75381260:-
THYM	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-4.91	3.87e-06	0.00339	-0.37	-0.45	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
THYM	cis	rs7202877	0.706	rs247450	ENSG00000261783.1	RP11-252K23.2	4.91	3.88e-06	0.00339	0.61	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75456119	chr16:75379818~75381260:-
THYM	cis	rs7772486	0.84	rs854144	ENSG00000235652.6	RP11-545I5.3	-4.91	3.88e-06	0.00339	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146039744	chr6:145799409~145886585:+
THYM	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-4.91	3.88e-06	0.00339	-0.59	-0.45	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
THYM	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-4.91	3.88e-06	0.00339	-0.59	-0.45	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
THYM	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-4.91	3.88e-06	0.0034	-0.59	-0.45	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
THYM	cis	rs2834288	0.618	rs9977699	ENSG00000237945.6	LINC00649	-4.91	3.89e-06	0.0034	-0.39	-0.45	Gut microbiota (bacterial taxa);	chr21:33978601	chr21:33915534~33977691:+
THYM	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	4.91	3.9e-06	0.00341	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	4.91	3.9e-06	0.00341	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	4.91	3.9e-06	0.00341	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	4.91	3.9e-06	0.00341	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	4.91	3.9e-06	0.00341	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
THYM	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	4.9	3.91e-06	0.00341	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
THYM	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-4.9	3.91e-06	0.00342	-0.55	-0.45	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
THYM	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	4.9	3.91e-06	0.00342	0.51	0.45	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	4.9	3.92e-06	0.00342	0.51	0.45	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
THYM	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-4.9	3.92e-06	0.00342	-0.43	-0.45	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	4.9	3.92e-06	0.00342	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	4.9	3.92e-06	0.00342	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	4.9	3.92e-06	0.00342	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	4.9	3.92e-06	0.00342	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	4.9	3.92e-06	0.00342	0.43	0.45	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
THYM	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	4.9	3.92e-06	0.00342	0.53	0.45	Height;	chr6:109452743	chr6:109382795~109383666:+
THYM	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-4.9	3.92e-06	0.00342	-0.41	-0.45	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
THYM	cis	rs4663866	1	rs4663865	ENSG00000186235.9	AC016757.3	-4.9	3.92e-06	0.00342	-0.98	-0.45	Irritable bowel syndrome;	chr2:238237319	chr2:238224552~238231677:-
THYM	cis	rs7202877	0.706	rs247434	ENSG00000261783.1	RP11-252K23.2	4.9	3.92e-06	0.00343	0.58	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75411406	chr16:75379818~75381260:-
THYM	cis	rs9309473	0.5	rs2421668	ENSG00000163016.8	ALMS1P	-4.9	3.93e-06	0.00343	-0.52	-0.45	Metabolite levels;	chr2:73657969	chr2:73644919~73685576:+
THYM	cis	rs13287066	0.692	rs7020852	ENSG00000227603.1	RP11-165J3.6	4.9	3.94e-06	0.00344	0.37	0.45	Intelligence (multi-trait analysis);	chr9:93400978	chr9:93435332~93437121:-
THYM	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-4.9	3.95e-06	0.00345	-0.55	-0.45	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
THYM	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-4.9	3.95e-06	0.00345	-0.37	-0.45	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-4.9	3.95e-06	0.00345	-0.37	-0.45	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-4.9	3.95e-06	0.00345	-0.37	-0.45	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-4.9	3.95e-06	0.00345	-0.37	-0.45	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-4.9	3.95e-06	0.00345	-0.37	-0.45	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
THYM	cis	rs8067545	0.604	rs55705283	ENSG00000230528.6	NOS2P3	-4.9	3.96e-06	0.00345	-0.36	-0.45	Schizophrenia;	chr17:20123825	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703803	ENSG00000230528.6	NOS2P3	4.9	3.96e-06	0.00345	0.37	0.45	Schizophrenia;	chr17:20203756	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703812	ENSG00000230528.6	NOS2P3	4.9	3.96e-06	0.00345	0.37	0.45	Schizophrenia;	chr17:20211490	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703814	ENSG00000230528.6	NOS2P3	4.9	3.96e-06	0.00345	0.37	0.45	Schizophrenia;	chr17:20213838	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs12942568	ENSG00000230528.6	NOS2P3	4.9	3.96e-06	0.00345	0.37	0.45	Schizophrenia;	chr17:20214580	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2526482	ENSG00000230528.6	NOS2P3	4.9	3.96e-06	0.00345	0.37	0.45	Schizophrenia;	chr17:20215820	chr17:20436337~20447249:+
THYM	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	4.9	3.97e-06	0.00346	0.51	0.45	Height;	chr6:109506513	chr6:109382795~109383666:+
THYM	cis	rs3796619	0.503	rs1466216	ENSG00000215367.9	TMED11P	-4.9	3.98e-06	0.00347	-0.43	-0.45	Recombination rate (males);	chr4:1078119	chr4:1115197~1153726:-
THYM	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	4.9	3.98e-06	0.00347	0.55	0.45	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
THYM	cis	rs4478858	0.806	rs6686845	ENSG00000260386.4	LINC01225	4.9	3.98e-06	0.00347	0.25	0.45	Alcohol dependence;	chr1:31235949	chr1:31500085~31540885:+
THYM	cis	rs10129255	0.5	rs7161740	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106776119	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.556	rs6576222	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106776442	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.536	rs6576223	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106776448	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs988134	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106776698	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs988133	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106776724	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs8009612	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106777510	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.556	rs8010005	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106777987	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.556	rs6576224	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106777997	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs8010020	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106778016	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs6576225	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106778120	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs6576226	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106778135	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs6576230	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106778539	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs10136903	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106778866	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs11847766	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106779186	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs12590732	ENSG00000254329.1	IGHVII-60-1	-4.9	3.99e-06	0.00347	-0.39	-0.45	Kawasaki disease;	chr14:106779612	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs8022547	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106781985	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs8006888	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106782219	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.536	rs10142951	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106782337	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs59939897	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106783414	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs6576231	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106783693	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs8014529	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106784065	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs12101190	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106784149	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs8004895	ENSG00000254329.1	IGHVII-60-1	4.9	3.99e-06	0.00347	0.39	0.45	Kawasaki disease;	chr14:106785139	chr14:106637718~106637973:-
THYM	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	4.9	3.99e-06	0.00347	0.59	0.45	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
THYM	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-4.9	3.99e-06	0.00347	-0.41	-0.45	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
THYM	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-4.9	3.99e-06	0.00347	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
THYM	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-4.9	4e-06	0.00348	-0.6	-0.45	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
THYM	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	4.9	4.01e-06	0.00349	0.54	0.45	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
THYM	cis	rs56104184	0.725	rs4347731	ENSG00000197813.5	CTC-301O7.4	4.9	4.02e-06	0.00349	0.78	0.45	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48881897	chr19:49331617~49340303:-
THYM	cis	rs8067545	0.611	rs7216599	ENSG00000230528.6	NOS2P3	-4.9	4.02e-06	0.0035	-0.36	-0.45	Schizophrenia;	chr17:20112287	chr17:20436337~20447249:+
THYM	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	4.9	4.02e-06	0.0035	0.54	0.45	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
THYM	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	4.9	4.02e-06	0.0035	0.51	0.45	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
THYM	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	4.9	4.04e-06	0.00351	0.4	0.45	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
THYM	cis	rs890448	0.861	rs9307256	ENSG00000254531.1	FLJ20021	-4.9	4.04e-06	0.00351	-0.4	-0.45	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101454111	chr4:101347780~101348883:+
THYM	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-4.9	4.05e-06	0.00351	-0.43	-0.45	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
THYM	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-4.9	4.05e-06	0.00351	-0.5	-0.45	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
THYM	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	4.9	4.05e-06	0.00351	0.5	0.45	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
THYM	cis	rs13256369	0.95	rs1522839	ENSG00000253893.2	FAM85B	-4.9	4.05e-06	0.00351	-0.65	-0.45	Obesity-related traits;	chr8:8722943	chr8:8167819~8226614:-
THYM	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	4.9	4.05e-06	0.00352	0.52	0.45	Height;	chr6:109428824	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	4.9	4.05e-06	0.00352	0.52	0.45	Height;	chr6:109429207	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	4.9	4.05e-06	0.00352	0.52	0.45	Height;	chr6:109438349	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	4.9	4.05e-06	0.00352	0.52	0.45	Height;	chr6:109441033	chr6:109382795~109383666:+
THYM	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-4.9	4.05e-06	0.00352	-0.58	-0.45	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
THYM	cis	rs8067545	0.516	rs4925086	ENSG00000230528.6	NOS2P3	-4.89	4.07e-06	0.00353	-0.36	-0.45	Schizophrenia;	chr17:20110146	chr17:20436337~20447249:+
THYM	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	4.89	4.07e-06	0.00353	0.52	0.45	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	4.89	4.07e-06	0.00353	0.52	0.45	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-4.89	4.07e-06	0.00353	-0.52	-0.45	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
THYM	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	4.89	4.08e-06	0.00354	0.55	0.45	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
THYM	cis	rs9907295	0.748	rs55767296	ENSG00000270871.1	AC015849.19	4.89	4.08e-06	0.00354	0.5	0.45	Fibroblast growth factor basic levels;	chr17:35850524	chr17:35816717~35830293:-
THYM	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	4.89	4.1e-06	0.00356	0.39	0.45	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
THYM	cis	rs6782228	0.606	rs7613073	ENSG00000277250.1	Metazoa_SRP	-4.89	4.11e-06	0.00356	-0.59	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.628	rs7641584	ENSG00000277250.1	Metazoa_SRP	-4.89	4.11e-06	0.00356	-0.59	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128673681~128674021:-
THYM	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	4.89	4.11e-06	0.00357	0.54	0.45	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
THYM	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	4.89	4.12e-06	0.00357	0.45	0.45	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
THYM	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	4.89	4.12e-06	0.00358	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	4.89	4.12e-06	0.00358	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
THYM	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	4.89	4.12e-06	0.00358	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
THYM	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	4.89	4.12e-06	0.00358	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
THYM	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	4.89	4.12e-06	0.00358	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
THYM	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	4.89	4.12e-06	0.00358	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
THYM	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-4.89	4.13e-06	0.00358	-0.4	-0.45	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
THYM	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-4.89	4.13e-06	0.00358	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
THYM	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	4.89	4.14e-06	0.00358	0.53	0.45	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
THYM	cis	rs2562456	0.641	rs62107468	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21307177	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs2154302	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21307609	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs73537884	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21321908	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs78467454	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21321930	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs55790393	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21323382	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs11672341	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21324502	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs11673234	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21324800	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs11673320	ENSG00000268081.1	RP11-678G14.2	4.89	4.14e-06	0.00358	0.64	0.45	Pain;	chr19:21324801	chr19:21554640~21569237:-
THYM	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	4.89	4.14e-06	0.00359	0.47	0.45	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
THYM	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	4.89	4.14e-06	0.00359	0.55	0.45	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
THYM	cis	rs9309473	0.539	rs6732440	ENSG00000163016.8	ALMS1P	-4.89	4.15e-06	0.00359	-0.54	-0.45	Metabolite levels;	chr2:73599972	chr2:73644919~73685576:+
THYM	cis	rs34773007	0.623	rs71480840	ENSG00000272817.1	RP11-402D21.2	-4.89	4.15e-06	0.00359	-0.57	-0.45	Type 2 diabetes;	chr10:92784225	chr10:91908131~91909348:+
THYM	cis	rs28785552	0.966	rs7247272	ENSG00000250731.1	TPM3P6	4.89	4.15e-06	0.00359	0.64	0.45	Response to paliperidone in schizophrenia (PANSS score);	chr19:52733078	chr19:53479350~53480091:+
THYM	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-4.89	4.15e-06	0.00359	-0.75	-0.45	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
THYM	cis	rs3738443	0.594	rs6664697	ENSG00000227671.4	RP11-488L18.4	4.89	4.16e-06	0.0036	0.26	0.45	Alcohol dependence;	chr1:247217308	chr1:247189851~247210856:-
THYM	cis	rs3738443	0.569	rs6704060	ENSG00000227671.4	RP11-488L18.4	-4.89	4.16e-06	0.0036	-0.26	-0.45	Alcohol dependence;	chr1:247218222	chr1:247189851~247210856:-
THYM	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-4.89	4.16e-06	0.0036	-0.41	-0.45	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
THYM	cis	rs1606355	0.725	rs1553953	ENSG00000230519.2	RP11-1060J15.5	4.89	4.16e-06	0.0036	0.76	0.45	Metabolite levels (Pyroglutamine);	chr12:28680344	chr12:27702338~27702906:+
THYM	cis	rs8067545	0.578	rs4925087	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20121269	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs11868116	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20126280	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs12936443	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20130133	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs6587219	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20131218	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs9893832	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20134960	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs7219908	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20139723	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs8078716	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20140978	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs8066143	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20145042	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.578	rs62066870	ENSG00000230528.6	NOS2P3	-4.89	4.17e-06	0.00361	-0.36	-0.45	Schizophrenia;	chr17:20160445	chr17:20436337~20447249:+
THYM	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-4.89	4.17e-06	0.00361	-0.5	-0.45	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-4.89	4.17e-06	0.00361	-0.5	-0.45	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
THYM	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	4.89	4.17e-06	0.00361	0.5	0.45	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
THYM	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	4.89	4.18e-06	0.00361	0.53	0.45	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	4.89	4.18e-06	0.00361	0.53	0.45	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
THYM	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	4.89	4.18e-06	0.00361	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	4.89	4.18e-06	0.00361	0.61	0.45	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
THYM	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	4.89	4.19e-06	0.00362	0.73	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	4.89	4.19e-06	0.00362	0.73	0.45	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	4.89	4.19e-06	0.00362	0.73	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	4.89	4.19e-06	0.00362	0.73	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
THYM	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-4.89	4.19e-06	0.00362	-0.55	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
THYM	cis	rs763121	1	rs138457	ENSG00000273076.1	RP3-508I15.22	-4.89	4.2e-06	0.00363	-0.53	-0.45	Menopause (age at onset);	chr22:38502046	chr22:38743495~38743910:+
THYM	cis	rs763121	1	rs763121	ENSG00000273076.1	RP3-508I15.22	-4.89	4.2e-06	0.00363	-0.55	-0.45	Menopause (age at onset);	chr22:38483935	chr22:38743495~38743910:+
THYM	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	4.89	4.2e-06	0.00363	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
THYM	cis	rs4853012	0.941	rs7571083	ENSG00000257702.3	LBX2-AS1	4.89	4.22e-06	0.00364	0.52	0.45	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74502595~74504678:+
THYM	cis	rs8067545	0.611	rs9898080	ENSG00000230528.6	NOS2P3	-4.89	4.22e-06	0.00365	-0.37	-0.45	Schizophrenia;	chr17:20131944	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.518	rs7222987	ENSG00000230528.6	NOS2P3	-4.89	4.22e-06	0.00365	-0.37	-0.45	Schizophrenia;	chr17:20152452	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs1974745	ENSG00000230528.6	NOS2P3	-4.89	4.22e-06	0.00365	-0.37	-0.45	Schizophrenia;	chr17:20156511	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.578	rs4925091	ENSG00000230528.6	NOS2P3	-4.89	4.22e-06	0.00365	-0.37	-0.45	Schizophrenia;	chr17:20163675	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs16960697	ENSG00000230528.6	NOS2P3	-4.89	4.23e-06	0.00365	-0.36	-0.45	Schizophrenia;	chr17:20124405	chr17:20436337~20447249:+
THYM	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-4.88	4.24e-06	0.00366	-0.43	-0.45	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
THYM	cis	rs7202877	0.706	rs40217	ENSG00000261783.1	RP11-252K23.2	4.88	4.25e-06	0.00367	0.6	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75446168	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs1540	ENSG00000261783.1	RP11-252K23.2	4.88	4.25e-06	0.00367	0.6	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75447287	chr16:75379818~75381260:-
THYM	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	4.88	4.25e-06	0.00367	0.55	0.45	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
THYM	cis	rs5760092	0.842	rs5751763	ENSG00000272787.1	KB-226F1.2	-4.88	4.25e-06	0.00367	-0.63	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905606	chr22:23969211~23969873:+
THYM	cis	rs2787702	0.5	rs11598488	ENSG00000237233.2	TMEM26-AS1	4.88	4.26e-06	0.00367	0.63	0.45	Response to taxane treatment (placlitaxel);	chr10:61576492	chr10:61452639~61481956:+
THYM	cis	rs6782228	0.675	rs6806687	ENSG00000277250.1	Metazoa_SRP	4.88	4.26e-06	0.00368	0.57	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128673681~128674021:-
THYM	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-4.88	4.26e-06	0.00368	-0.44	-0.45	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
THYM	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	4.88	4.27e-06	0.00368	0.59	0.45	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
THYM	cis	rs2562456	0.833	rs61035285	ENSG00000268081.1	RP11-678G14.2	4.88	4.28e-06	0.00369	0.63	0.45	Pain;	chr19:21329475	chr19:21554640~21569237:-
THYM	cis	rs1606355	0.665	rs73081662	ENSG00000230519.2	RP11-1060J15.5	-4.88	4.28e-06	0.00369	-0.76	-0.45	Metabolite levels (Pyroglutamine);	chr12:28688242	chr12:27702338~27702906:+
THYM	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-4.88	4.28e-06	0.00369	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
THYM	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	4.88	4.28e-06	0.00369	0.53	0.45	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	4.88	4.28e-06	0.00369	0.53	0.45	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
THYM	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	4.88	4.29e-06	0.0037	0.58	0.45	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	4.88	4.29e-06	0.0037	0.58	0.45	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
THYM	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	4.88	4.29e-06	0.0037	0.54	0.45	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	4.88	4.29e-06	0.0037	0.54	0.45	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	4.88	4.29e-06	0.0037	0.54	0.45	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
THYM	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	4.88	4.3e-06	0.00371	0.95	0.45	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
THYM	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	4.88	4.3e-06	0.00371	0.95	0.45	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
THYM	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-4.88	4.3e-06	0.00371	-0.59	-0.45	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
THYM	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
THYM	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	4.88	4.31e-06	0.00371	0.58	0.45	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-4.88	4.31e-06	0.00371	-0.58	-0.45	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-4.88	4.31e-06	0.00371	-0.58	-0.45	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
THYM	cis	rs7044106	0.537	rs4434680	ENSG00000238181.2	AHCYP2	-4.88	4.31e-06	0.00371	-0.51	-0.45	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120720673~120721972:+
THYM	cis	rs6782228	0.675	rs9813845	ENSG00000277250.1	Metazoa_SRP	-4.88	4.32e-06	0.00372	-0.59	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128673681~128674021:-
THYM	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	4.88	4.32e-06	0.00372	0.54	0.45	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	4.88	4.32e-06	0.00372	0.54	0.45	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
THYM	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-4.88	4.32e-06	0.00372	-0.47	-0.45	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
THYM	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-4.88	4.33e-06	0.00372	-0.94	-0.45	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
THYM	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-4.88	4.33e-06	0.00372	-0.55	-0.45	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
THYM	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-4.88	4.33e-06	0.00372	-0.55	-0.45	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
THYM	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-4.88	4.33e-06	0.00372	-0.55	-0.45	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
THYM	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-4.88	4.33e-06	0.00372	-0.55	-0.45	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
THYM	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-4.88	4.33e-06	0.00372	-0.55	-0.45	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
THYM	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-4.88	4.33e-06	0.00372	-0.55	-0.45	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
THYM	cis	rs12908161	0.959	rs1051168	ENSG00000235370.6	DNM1P51	4.88	4.33e-06	0.00372	0.6	0.45	Schizophrenia;	chr15:84657289	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.959	rs2175567	ENSG00000235370.6	DNM1P51	4.88	4.33e-06	0.00372	0.6	0.45	Schizophrenia;	chr15:84657715	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.92	rs12904605	ENSG00000235370.6	DNM1P51	4.88	4.33e-06	0.00372	0.6	0.45	Schizophrenia;	chr15:84658188	chr15:84398316~84411701:-
THYM	cis	rs6570726	0.846	rs446031	ENSG00000235652.6	RP11-545I5.3	4.88	4.34e-06	0.00372	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	4.88	4.34e-06	0.00372	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	4.88	4.34e-06	0.00372	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	4.88	4.34e-06	0.00372	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	4.88	4.34e-06	0.00372	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
THYM	cis	rs2787702	0.5	rs11591943	ENSG00000237233.2	TMEM26-AS1	4.88	4.34e-06	0.00373	0.63	0.45	Response to taxane treatment (placlitaxel);	chr10:61560817	chr10:61452639~61481956:+
THYM	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	4.88	4.34e-06	0.00373	0.7	0.45	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
THYM	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-4.88	4.35e-06	0.00374	-0.43	-0.45	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
THYM	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	4.88	4.35e-06	0.00374	0.51	0.45	Height;	chr6:109706740	chr6:109382795~109383666:+
THYM	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-4.88	4.36e-06	0.00374	-0.36	-0.45	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-4.88	4.36e-06	0.00374	-0.36	-0.45	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-4.88	4.36e-06	0.00374	-0.36	-0.45	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-4.88	4.36e-06	0.00374	-0.36	-0.45	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
THYM	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-4.88	4.37e-06	0.00374	-0.52	-0.45	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
THYM	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-4.88	4.37e-06	0.00374	-0.52	-0.45	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
THYM	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-4.88	4.37e-06	0.00374	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
THYM	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	4.88	4.39e-06	0.00376	0.73	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
THYM	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-4.88	4.4e-06	0.00377	-0.38	-0.45	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
THYM	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-4.88	4.4e-06	0.00377	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
THYM	cis	rs2289328	1	rs2289328	ENSG00000223313.1	RNU6-516P	-4.88	4.4e-06	0.00377	-0.6	-0.45	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40413218	chr15:40529570~40529673:+
THYM	cis	rs995834	0.743	rs7256207	ENSG00000267243.4	AC005307.3	4.88	4.4e-06	0.00377	0.41	0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356775	chr19:28435388~28727777:-
THYM	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	4.88	4.41e-06	0.00377	0.56	0.45	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	4.88	4.41e-06	0.00377	0.56	0.45	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	4.88	4.41e-06	0.00377	0.56	0.45	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	4.88	4.41e-06	0.00377	0.56	0.45	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	4.88	4.41e-06	0.00377	0.57	0.45	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
THYM	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-4.87	4.41e-06	0.00377	-0.49	-0.45	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
THYM	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-4.87	4.43e-06	0.00378	-0.43	-0.45	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-4.87	4.43e-06	0.00378	-0.43	-0.45	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-4.87	4.43e-06	0.00378	-0.43	-0.45	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-4.87	4.43e-06	0.00378	-0.43	-0.45	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
THYM	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	4.87	4.43e-06	0.00378	0.62	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
THYM	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-4.87	4.43e-06	0.00378	-0.36	-0.45	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-4.87	4.43e-06	0.00378	-0.36	-0.45	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-4.87	4.43e-06	0.00378	-0.36	-0.45	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-4.87	4.43e-06	0.00378	-0.36	-0.45	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
THYM	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-4.87	4.44e-06	0.00378	-0.52	-0.45	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
THYM	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
THYM	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	4.87	4.45e-06	0.00379	0.58	0.45	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
THYM	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	4.87	4.45e-06	0.00379	0.49	0.45	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
THYM	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	4.87	4.46e-06	0.0038	0.49	0.45	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
THYM	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	4.87	4.46e-06	0.0038	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
THYM	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-4.87	4.47e-06	0.0038	-0.58	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs17178460	ENSG00000223466.1	AC064834.2	-4.87	4.47e-06	0.0038	-0.58	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195555365	chr2:195533035~195538681:+
THYM	cis	rs10129255	0.576	rs2157616	ENSG00000253703.1	IGHV1-68	-4.87	4.47e-06	0.0038	-0.49	-0.45	Kawasaki disease;	chr14:106767802	chr14:106703852~106704146:-
THYM	cis	rs4835473	0.932	rs10857415	ENSG00000251600.4	RP11-673E1.1	4.87	4.47e-06	0.0038	0.5	0.45	Immature fraction of reticulocytes;	chr4:143908753	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1973608	ENSG00000251600.4	RP11-673E1.1	4.87	4.47e-06	0.0038	0.5	0.45	Immature fraction of reticulocytes;	chr4:143913057	chr4:143912331~143982454:+
THYM	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-4.87	4.48e-06	0.00381	-0.62	-0.45	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	4.87	4.48e-06	0.00381	0.62	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	4.87	4.48e-06	0.00381	0.62	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
THYM	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-4.87	4.48e-06	0.00381	-0.37	-0.45	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-4.87	4.48e-06	0.00381	-0.37	-0.45	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-4.87	4.48e-06	0.00381	-0.37	-0.45	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
THYM	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-4.87	4.48e-06	0.00381	-0.37	-0.45	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
THYM	cis	rs4853012	1	rs4853012	ENSG00000257702.3	LBX2-AS1	4.87	4.49e-06	0.00382	0.57	0.45	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74502595~74504678:+
THYM	cis	rs4835473	0.838	rs12507468	ENSG00000251600.4	RP11-673E1.1	-4.87	4.49e-06	0.00382	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143908061	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1849135	ENSG00000251600.4	RP11-673E1.1	-4.87	4.49e-06	0.00382	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143912279	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1849136	ENSG00000251600.4	RP11-673E1.1	-4.87	4.49e-06	0.00382	-0.51	-0.45	Immature fraction of reticulocytes;	chr4:143912380	chr4:143912331~143982454:+
THYM	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-4.87	4.52e-06	0.00384	-0.58	-0.45	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
THYM	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-4.87	4.52e-06	0.00385	-0.37	-0.45	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
THYM	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	4.87	4.53e-06	0.00385	0.6	0.45	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
THYM	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	4.87	4.53e-06	0.00385	0.57	0.45	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
THYM	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	4.87	4.54e-06	0.00385	0.6	0.45	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
THYM	cis	rs295140	0.566	rs295141	ENSG00000232732.8	AC073043.1	4.87	4.54e-06	0.00385	0.57	0.45	QT interval;	chr2:200298833	chr2:199867396~199911159:-
THYM	cis	rs526231	0.644	rs35797	ENSG00000175749.11	EIF3KP1	-4.87	4.54e-06	0.00386	-0.55	-0.45	Primary biliary cholangitis;	chr5:103278626	chr5:103032376~103033031:+
THYM	cis	rs3740713	1	rs35593189	ENSG00000256464.1	YWHABP2	4.87	4.54e-06	0.00386	0.74	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr11:18490243~18490955:-
THYM	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-4.87	4.54e-06	0.00386	-0.4	-0.45	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
THYM	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-4.87	4.55e-06	0.00386	-0.66	-0.45	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
THYM	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	4.87	4.56e-06	0.00387	0.56	0.45	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
THYM	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	4.87	4.56e-06	0.00387	0.56	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
THYM	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-4.87	4.57e-06	0.00388	-0.54	-0.45	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
THYM	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-4.87	4.58e-06	0.00389	-0.46	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
THYM	cis	rs2283792	0.967	rs743409	ENSG00000228050.1	TOP3BP1	4.87	4.58e-06	0.00389	0.5	0.45	Multiple sclerosis;	chr22:21774926	chr22:22223187~22224566:-
THYM	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-4.87	4.59e-06	0.00389	-0.4	-0.45	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-4.87	4.59e-06	0.00389	-0.4	-0.45	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-4.87	4.59e-06	0.00389	-0.4	-0.45	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-4.87	4.59e-06	0.00389	-0.4	-0.45	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
THYM	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-4.87	4.59e-06	0.00389	-0.31	-0.45	Height;	chr11:118781100	chr11:118791254~118793137:+
THYM	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	4.86	4.6e-06	0.0039	0.36	0.45	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-4.86	4.6e-06	0.0039	-0.36	-0.45	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
THYM	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	4.86	4.6e-06	0.0039	0.36	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
THYM	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	4.86	4.6e-06	0.0039	0.5	0.45	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	4.86	4.6e-06	0.0039	0.5	0.45	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	4.86	4.6e-06	0.0039	0.5	0.45	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	4.86	4.6e-06	0.0039	0.5	0.45	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	4.86	4.6e-06	0.0039	0.5	0.45	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	4.86	4.6e-06	0.0039	0.5	0.45	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	4.86	4.6e-06	0.0039	0.5	0.45	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-4.86	4.6e-06	0.0039	-0.5	-0.45	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
THYM	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-4.86	4.6e-06	0.0039	-0.69	-0.45	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
THYM	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	4.86	4.61e-06	0.00391	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	4.86	4.61e-06	0.00391	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
THYM	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	4.86	4.61e-06	0.00391	0.57	0.45	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
THYM	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-4.86	4.61e-06	0.00391	-0.52	-0.45	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
THYM	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	4.86	4.62e-06	0.00391	0.34	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
THYM	cis	rs440932	1	rs378974	ENSG00000253893.2	FAM85B	-4.86	4.63e-06	0.00392	-0.57	-0.45	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8167819~8226614:-
THYM	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-4.86	4.63e-06	0.00392	-0.5	-0.45	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-4.86	4.63e-06	0.00392	-0.5	-0.45	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-4.86	4.63e-06	0.00392	-0.5	-0.45	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
THYM	cis	rs295140	0.605	rs296818	ENSG00000232732.8	AC073043.1	-4.86	4.64e-06	0.00392	-0.57	-0.45	QT interval;	chr2:200312221	chr2:199867396~199911159:-
THYM	cis	rs295140	0.605	rs159320	ENSG00000232732.8	AC073043.1	-4.86	4.64e-06	0.00392	-0.57	-0.45	QT interval;	chr2:200323052	chr2:199867396~199911159:-
THYM	cis	rs295140	0.526	rs295113	ENSG00000232732.8	AC073043.1	-4.86	4.64e-06	0.00392	-0.57	-0.45	QT interval;	chr2:200333093	chr2:199867396~199911159:-
THYM	cis	rs295140	0.605	rs295149	ENSG00000232732.8	AC073043.1	4.86	4.64e-06	0.00393	0.58	0.45	QT interval;	chr2:200310521	chr2:199867396~199911159:-
THYM	cis	rs995834	0.661	rs11882204	ENSG00000267243.4	AC005307.3	-4.86	4.65e-06	0.00394	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347263	chr19:28435388~28727777:-
THYM	cis	rs995834	0.661	rs8101988	ENSG00000267243.4	AC005307.3	-4.86	4.65e-06	0.00394	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348975	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs758507	ENSG00000267243.4	AC005307.3	-4.86	4.65e-06	0.00394	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350158	chr19:28435388~28727777:-
THYM	cis	rs995834	0.701	rs2903968	ENSG00000267243.4	AC005307.3	-4.86	4.65e-06	0.00394	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28350613	chr19:28435388~28727777:-
THYM	cis	rs995834	0.701	rs8103281	ENSG00000267243.4	AC005307.3	-4.86	4.65e-06	0.00394	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358547	chr19:28435388~28727777:-
THYM	cis	rs995834	0.509	rs11666682	ENSG00000267243.4	AC005307.3	-4.86	4.65e-06	0.00394	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28358650	chr19:28435388~28727777:-
THYM	cis	rs9376098	0.763	rs7746481	ENSG00000232876.1	CTA-212D2.2	-4.86	4.65e-06	0.00394	-0.5	-0.45	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135162673	chr6:135055033~135060550:+
THYM	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	4.86	4.66e-06	0.00394	0.6	0.45	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
THYM	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	4.86	4.66e-06	0.00394	0.45	0.45	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
THYM	cis	rs6570726	0.934	rs9484995	ENSG00000235652.6	RP11-545I5.3	-4.86	4.67e-06	0.00395	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145799409~145886585:+
THYM	cis	rs7202877	0.656	rs247427	ENSG00000261783.1	RP11-252K23.2	4.86	4.69e-06	0.00396	0.59	0.45	Type 1 diabetes;Type 2 diabetes;	chr16:75405234	chr16:75379818~75381260:-
THYM	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	4.86	4.69e-06	0.00396	0.58	0.45	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
THYM	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	4.86	4.69e-06	0.00396	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	4.86	4.69e-06	0.00396	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	4.86	4.69e-06	0.00396	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
THYM	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-4.86	4.71e-06	0.00398	-0.39	-0.45	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
THYM	cis	rs10463554	0.675	rs444020	ENSG00000175749.11	EIF3KP1	4.86	4.71e-06	0.00398	0.56	0.45	Parkinson's disease;	chr5:103092139	chr5:103032376~103033031:+
THYM	cis	rs2562456	0.833	rs56187954	ENSG00000268081.1	RP11-678G14.2	4.86	4.71e-06	0.00398	0.61	0.45	Pain;	chr19:21345258	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs7258099	ENSG00000268081.1	RP11-678G14.2	4.86	4.71e-06	0.00398	0.61	0.45	Pain;	chr19:21352941	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62109229	ENSG00000268081.1	RP11-678G14.2	4.86	4.71e-06	0.00398	0.61	0.45	Pain;	chr19:21354380	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11670815	ENSG00000268081.1	RP11-678G14.2	4.86	4.71e-06	0.00398	0.61	0.45	Pain;	chr19:21356515	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11666540	ENSG00000268081.1	RP11-678G14.2	4.86	4.71e-06	0.00398	0.61	0.45	Pain;	chr19:21356550	chr19:21554640~21569237:-
THYM	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-4.86	4.72e-06	0.00398	-0.85	-0.45	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
THYM	cis	rs9907295	0.818	rs11658222	ENSG00000270871.1	AC015849.19	4.86	4.72e-06	0.00399	0.49	0.45	Fibroblast growth factor basic levels;	chr17:35825092	chr17:35816717~35830293:-
THYM	cis	rs1550576	0.568	rs16953355	ENSG00000274719.1	RP11-86K22.2	4.86	4.72e-06	0.00399	0.86	0.45	Hypertension;	chr15:57947676	chr15:57990217~57990636:-
THYM	cis	rs12908161	0.92	rs35738019	ENSG00000235370.6	DNM1P51	4.86	4.73e-06	0.004	0.6	0.45	Schizophrenia;	chr15:84736979	chr15:84398316~84411701:-
THYM	cis	rs867371	1	rs1392976	ENSG00000276710.3	CSPG4P8	4.86	4.73e-06	0.004	0.45	0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs11855089	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs1174543	ENSG00000276710.3	CSPG4P8	4.86	4.73e-06	0.004	0.45	0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs9944197	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs8037224	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs8042464	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs7166570	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs7173339	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs1501372	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs1846911	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82459472~82477258:+
THYM	cis	rs867371	0.929	rs7176075	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs8041868	ENSG00000276710.3	CSPG4P8	-4.86	4.73e-06	0.004	-0.45	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82459472~82477258:+
THYM	cis	rs9907295	0.901	rs9907121	ENSG00000270871.1	AC015849.19	4.86	4.74e-06	0.004	0.49	0.45	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs4796118	ENSG00000270871.1	AC015849.19	4.86	4.74e-06	0.004	0.49	0.45	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs9914401	ENSG00000270871.1	AC015849.19	4.86	4.74e-06	0.004	0.49	0.45	Fibroblast growth factor basic levels;	chr17:35861810	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs9898152	ENSG00000270871.1	AC015849.19	4.86	4.74e-06	0.004	0.49	0.45	Fibroblast growth factor basic levels;	chr17:35869211	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs78023535	ENSG00000270871.1	AC015849.19	4.86	4.74e-06	0.004	0.49	0.45	Fibroblast growth factor basic levels;	chr17:35869598	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs4795095	ENSG00000270871.1	AC015849.19	4.86	4.74e-06	0.004	0.49	0.45	Fibroblast growth factor basic levels;	chr17:35870296	chr17:35816717~35830293:-
THYM	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	4.86	4.74e-06	0.004	0.56	0.45	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
THYM	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	4.86	4.74e-06	0.004	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
THYM	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-4.86	4.74e-06	0.004	-0.37	-0.45	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
THYM	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-4.86	4.74e-06	0.004	-0.37	-0.45	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
THYM	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	4.86	4.75e-06	0.00401	0.41	0.45	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
THYM	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-4.86	4.76e-06	0.00401	-0.61	-0.45	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
THYM	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-4.86	4.76e-06	0.00402	-0.79	-0.45	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-4.86	4.76e-06	0.00402	-0.79	-0.45	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
THYM	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	4.86	4.77e-06	0.00403	0.39	0.45	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
THYM	cis	rs3738443	0.545	rs12566906	ENSG00000227671.4	RP11-488L18.4	-4.86	4.78e-06	0.00403	-0.26	-0.45	Alcohol dependence;	chr1:247224904	chr1:247189851~247210856:-
THYM	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-4.85	4.78e-06	0.00404	-0.66	-0.45	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
THYM	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-4.85	4.79e-06	0.00404	-0.39	-0.45	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
THYM	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	4.85	4.8e-06	0.00404	0.53	0.45	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
THYM	cis	rs34773007	0.514	rs2497338	ENSG00000272817.1	RP11-402D21.2	4.85	4.8e-06	0.00404	0.53	0.45	Type 2 diabetes;	chr10:92779203	chr10:91908131~91909348:+
THYM	cis	rs944990	0.557	rs10821155	ENSG00000227603.1	RP11-165J3.6	4.85	4.8e-06	0.00405	0.39	0.45	Body mass index;	chr9:93541996	chr9:93435332~93437121:-
THYM	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-4.85	4.8e-06	0.00405	-0.5	-0.45	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
THYM	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	4.85	4.81e-06	0.00405	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
THYM	cis	rs10160246	0.935	rs41420651	ENSG00000255418.4	RP11-266A24.1	4.85	4.81e-06	0.00405	0.52	0.45	Cancer;	chr11:23153344	chr11:23164900~23203161:+
THYM	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-4.85	4.82e-06	0.00406	-0.34	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
THYM	cis	rs4715166	0.926	rs4715167	ENSG00000215022.6	RP1-257A7.4	4.85	4.82e-06	0.00406	0.41	0.45	Hip geometry;	chr6:13220090	chr6:13264861~13295586:-
THYM	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	4.85	4.82e-06	0.00406	0.45	0.45	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
THYM	cis	rs12908161	1	rs62021219	ENSG00000235370.6	DNM1P51	4.85	4.82e-06	0.00406	0.6	0.45	Schizophrenia;	chr15:84712928	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs34900908	ENSG00000235370.6	DNM1P51	4.85	4.82e-06	0.00406	0.6	0.45	Schizophrenia;	chr15:84714368	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs35524990	ENSG00000235370.6	DNM1P51	4.85	4.82e-06	0.00406	0.6	0.45	Schizophrenia;	chr15:84714972	chr15:84398316~84411701:-
THYM	cis	rs904251	0.6	rs2270687	ENSG00000227920.2	RP1-153P14.5	-4.85	4.83e-06	0.00407	-0.6	-0.45	Cognitive performance;	chr6:37450487	chr6:37545145~37550860:+
THYM	cis	rs2562456	0.833	rs2650801	ENSG00000268081.1	RP11-678G14.2	4.85	4.83e-06	0.00407	0.66	0.45	Pain;	chr19:21452553	chr19:21554640~21569237:-
THYM	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-4.85	4.83e-06	0.00407	-0.58	-0.45	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
THYM	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	4.85	4.84e-06	0.00407	0.55	0.45	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
THYM	cis	rs295140	0.507	rs4673814	ENSG00000232732.8	AC073043.1	4.85	4.85e-06	0.00408	0.54	0.45	QT interval;	chr2:200243410	chr2:199867396~199911159:-
THYM	cis	rs295140	0.507	rs1369842	ENSG00000232732.8	AC073043.1	4.85	4.85e-06	0.00408	0.54	0.45	QT interval;	chr2:200244264	chr2:199867396~199911159:-
THYM	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	4.85	4.85e-06	0.00408	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	4.85	4.85e-06	0.00408	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	4.85	4.85e-06	0.00408	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	4.85	4.85e-06	0.00408	0.33	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
THYM	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	4.85	4.86e-06	0.00409	0.56	0.45	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
THYM	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-4.85	4.86e-06	0.00409	-0.55	-0.45	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
THYM	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-4.85	4.86e-06	0.00409	-0.33	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
THYM	cis	rs7223966	1	rs16947005	ENSG00000240280.5	TCAM1P	4.85	4.88e-06	0.0041	0.66	0.45	Hip circumference adjusted for BMI;Body mass index;	chr17:63625629	chr17:63849292~63864379:+
THYM	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-4.85	4.88e-06	0.0041	-0.39	-0.45	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-4.85	4.88e-06	0.0041	-0.39	-0.45	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
THYM	cis	rs10129255	0.5	rs34326748	ENSG00000253703.1	IGHV1-68	-4.85	4.89e-06	0.00411	-0.48	-0.45	Kawasaki disease;	chr14:106782523	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs10143385	ENSG00000253703.1	IGHV1-68	-4.85	4.89e-06	0.00411	-0.48	-0.45	Kawasaki disease;	chr14:106782559	chr14:106703852~106704146:-
THYM	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-4.85	4.89e-06	0.00411	-0.34	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
THYM	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	4.85	4.89e-06	0.00411	0.57	0.45	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
THYM	cis	rs2283792	0.967	rs5999823	ENSG00000228050.1	TOP3BP1	4.85	4.89e-06	0.00411	0.48	0.45	Multiple sclerosis;	chr22:21856587	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.935	rs2283794	ENSG00000228050.1	TOP3BP1	4.85	4.89e-06	0.00411	0.48	0.45	Multiple sclerosis;	chr22:21858180	chr22:22223187~22224566:-
THYM	cis	rs1519814	0.74	rs7845541	ENSG00000254343.2	RP11-760H22.2	-4.85	4.89e-06	0.00411	-0.64	-0.45	Breast cancer;	chr8:120032154	chr8:120052180~120056201:+
THYM	cis	rs10129255	0.558	rs115933609	ENSG00000254329.1	IGHVII-60-1	4.85	4.9e-06	0.00412	0.44	0.45	Kawasaki disease;	chr14:106650465	chr14:106637718~106637973:-
THYM	cis	rs3740713	0.748	rs35292478	ENSG00000256464.1	YWHABP2	4.85	4.91e-06	0.00413	0.76	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr11:18490243~18490955:-
THYM	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-4.85	4.91e-06	0.00413	-0.61	-0.45	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
THYM	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	4.85	4.92e-06	0.00414	0.73	0.45	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
THYM	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-4.85	4.93e-06	0.00414	-0.57	-0.45	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
THYM	cis	rs7772486	0.777	rs1546966	ENSG00000235652.6	RP11-545I5.3	4.85	4.93e-06	0.00414	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146064882	chr6:145799409~145886585:+
THYM	cis	rs4698048	0.51	rs12509714	ENSG00000261490.1	RP11-448G15.3	4.85	4.94e-06	0.00415	0.38	0.45	Skin aging (microtopography measurement);	chr4:10105467	chr4:10068089~10073019:-
THYM	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-4.85	4.94e-06	0.00415	-0.58	-0.45	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
THYM	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	4.85	4.94e-06	0.00415	0.82	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	4.85	4.94e-06	0.00415	0.82	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	4.85	4.94e-06	0.00415	0.82	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
THYM	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	4.85	4.94e-06	0.00415	0.4	0.45	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
THYM	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	4.85	4.94e-06	0.00415	0.4	0.45	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
THYM	cis	rs1426063	1	rs10022563	ENSG00000248165.1	RP11-44F21.2	4.85	4.96e-06	0.00415	0.84	0.45	QT interval;	chr4:75100989	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs28515115	ENSG00000248165.1	RP11-44F21.2	4.85	4.96e-06	0.00415	0.84	0.45	QT interval;	chr4:75101904	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs10026801	ENSG00000248165.1	RP11-44F21.2	4.85	4.96e-06	0.00415	0.84	0.45	QT interval;	chr4:75103167	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs10033857	ENSG00000248165.1	RP11-44F21.2	4.85	4.96e-06	0.00415	0.84	0.45	QT interval;	chr4:75103208	chr4:74993877~75034824:-
THYM	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
THYM	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
THYM	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	4.85	4.96e-06	0.00415	0.58	0.45	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
THYM	cis	rs10129255	0.5	rs7159033	ENSG00000253703.1	IGHV1-68	-4.85	4.97e-06	0.00416	-0.5	-0.45	Kawasaki disease;	chr14:106701709	chr14:106703852~106704146:-
THYM	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-4.85	4.97e-06	0.00416	-0.32	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
THYM	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-4.84	4.98e-06	0.00417	-0.53	-0.45	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
THYM	cis	rs6750047	0.628	rs2855655	ENSG00000227770.1	RPL7P12	-4.84	4.99e-06	0.00418	-0.58	-0.45	Cutaneous malignant melanoma;Melanoma;	chr2:38077346	chr2:38231568~38232317:+
THYM	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-4.84	5e-06	0.00419	-0.57	-0.45	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
THYM	cis	rs890448	0.965	rs11944753	ENSG00000254531.1	FLJ20021	-4.84	5e-06	0.00419	-0.37	-0.45	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101503451	chr4:101347780~101348883:+
THYM	cis	rs890448	0.93	rs6532938	ENSG00000254531.1	FLJ20021	4.84	5e-06	0.00419	0.37	0.45	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101468422	chr4:101347780~101348883:+
THYM	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	4.84	5e-06	0.00419	0.82	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
THYM	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	4.84	5.01e-06	0.00419	0.41	0.45	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
THYM	cis	rs295140	0.506	rs4673855	ENSG00000232732.8	AC073043.1	4.84	5.01e-06	0.0042	0.56	0.45	QT interval;	chr2:200271420	chr2:199867396~199911159:-
THYM	cis	rs2834288	0.613	rs2040113	ENSG00000237945.6	LINC00649	4.84	5.02e-06	0.0042	0.36	0.45	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33915534~33977691:+
THYM	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-4.84	5.03e-06	0.00421	-0.47	-0.45	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-4.84	5.03e-06	0.00421	-0.47	-0.45	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
THYM	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-4.84	5.03e-06	0.00421	-0.47	-0.45	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
THYM	cis	rs4713118	0.629	rs203888	ENSG00000182477.5	OR2B8P	4.84	5.03e-06	0.00421	0.64	0.45	Parkinson's disease;	chr6:28053811	chr6:28053228~28054165:-
THYM	cis	rs526231	0.857	rs13190417	ENSG00000175749.11	EIF3KP1	4.84	5.04e-06	0.00421	0.57	0.45	Primary biliary cholangitis;	chr5:103327625	chr5:103032376~103033031:+
THYM	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-4.84	5.05e-06	0.00422	-0.59	-0.45	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
THYM	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-4.84	5.05e-06	0.00422	-0.53	-0.45	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
THYM	cis	rs1023500	0.596	rs133350	ENSG00000227370.1	RP4-669P10.19	4.84	5.05e-06	0.00422	0.52	0.45	Schizophrenia;	chr22:42033045	chr22:42132543~42132998:+
THYM	cis	rs2834288	0.5	rs766423	ENSG00000237945.6	LINC00649	4.84	5.07e-06	0.00424	0.4	0.45	Gut microbiota (bacterial taxa);	chr21:33962711	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.536	rs762356	ENSG00000237945.6	LINC00649	4.84	5.07e-06	0.00424	0.4	0.45	Gut microbiota (bacterial taxa);	chr21:33964582	chr21:33915534~33977691:+
THYM	cis	rs11017328	0.5	rs11017293	ENSG00000236303.2	RP11-540N6.1	-4.84	5.08e-06	0.00424	-0.63	-0.45	Conotruncal heart defects;	chr10:130510958	chr10:130439067~130483154:+
THYM	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-4.84	5.08e-06	0.00424	-0.57	-0.45	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
THYM	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-4.84	5.09e-06	0.00425	-0.76	-0.45	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
THYM	cis	rs494459	0.536	rs7103067	ENSG00000278376.1	RP11-158I9.8	-4.84	5.09e-06	0.00425	-0.32	-0.45	Height;	chr11:118852670	chr11:118791254~118793137:+
THYM	cis	rs5771242	0.685	rs2341367	ENSG00000273253.2	RP3-402G11.26	-4.84	5.09e-06	0.00425	-0.6	-0.45	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50192797	chr22:50199090~50200837:-
THYM	cis	rs5771242	0.685	rs4084289	ENSG00000273253.2	RP3-402G11.26	-4.84	5.09e-06	0.00425	-0.6	-0.45	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50196691	chr22:50199090~50200837:-
THYM	cis	rs9914578	0.943	rs7225843	ENSG00000236838.2	AC090617.1	4.84	5.09e-06	0.00425	0.69	0.45	Body mass index;	chr17:2098531	chr17:2213697~2214414:+
THYM	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	4.84	5.1e-06	0.00426	0.57	0.45	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	4.84	5.1e-06	0.00426	0.57	0.45	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
THYM	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-4.84	5.1e-06	0.00426	-0.54	-0.45	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
THYM	cis	rs1972460	0.506	rs62012050	ENSG00000274376.3	ADAMTS7P1	4.84	5.1e-06	0.00426	0.44	0.45	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82298553~82334609:+
THYM	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	4.84	5.11e-06	0.00426	0.66	0.45	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
THYM	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-4.84	5.11e-06	0.00426	-0.41	-0.45	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-4.84	5.11e-06	0.00426	-0.41	-0.45	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-4.84	5.11e-06	0.00426	-0.41	-0.45	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-4.84	5.11e-06	0.00426	-0.41	-0.45	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
THYM	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-4.84	5.11e-06	0.00426	-0.41	-0.45	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
THYM	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	4.84	5.12e-06	0.00427	0.6	0.45	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
THYM	cis	rs42490	0.653	rs40247	ENSG00000251136.7	RP11-37B2.1	-4.84	5.13e-06	0.00428	-0.38	-0.45	Leprosy;	chr8:89789744	chr8:89609409~89757727:-
THYM	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	4.84	5.13e-06	0.00428	0.49	0.45	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	4.84	5.13e-06	0.00428	0.49	0.45	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	4.84	5.13e-06	0.00428	0.49	0.45	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
THYM	cis	rs2787702	0.5	rs28793568	ENSG00000237233.2	TMEM26-AS1	4.84	5.13e-06	0.00428	0.64	0.45	Response to taxane treatment (placlitaxel);	chr10:61584797	chr10:61452639~61481956:+
THYM	cis	rs12439619	0.739	rs4778988	ENSG00000274376.3	ADAMTS7P1	4.84	5.14e-06	0.00428	0.46	0.45	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82298553~82334609:+
THYM	cis	rs12439619	1	rs35152457	ENSG00000274376.3	ADAMTS7P1	4.84	5.14e-06	0.00428	0.46	0.45	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82298553~82334609:+
THYM	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	4.84	5.15e-06	0.00429	0.45	0.45	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
THYM	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-4.84	5.15e-06	0.00429	-0.4	-0.45	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
THYM	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	4.84	5.15e-06	0.00429	0.56	0.45	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
THYM	cis	rs5760092	0.755	rs5760096	ENSG00000272787.1	KB-226F1.2	-4.84	5.15e-06	0.0043	-0.58	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23905123	chr22:23969211~23969873:+
THYM	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	4.84	5.16e-06	0.0043	0.42	0.45	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
THYM	cis	rs9535495	0.965	rs7322681	ENSG00000200711.1	RNA5SP28	-4.84	5.16e-06	0.0043	-0.51	-0.45	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50827040	chr13:50812988~50813106:-
THYM	cis	rs5760092	0.842	rs5760103	ENSG00000272787.1	KB-226F1.2	-4.84	5.18e-06	0.00432	-0.63	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906594	chr22:23969211~23969873:+
THYM	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	4.83	5.19e-06	0.00432	0.53	0.45	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	4.83	5.19e-06	0.00432	0.53	0.45	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
THYM	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-4.83	5.2e-06	0.00433	-0.54	-0.45	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
THYM	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-4.83	5.2e-06	0.00433	-0.47	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
THYM	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	4.83	5.21e-06	0.00434	0.51	0.45	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
THYM	cis	rs10463554	0.824	rs34374	ENSG00000175749.11	EIF3KP1	4.83	5.21e-06	0.00434	0.56	0.45	Parkinson's disease;	chr5:103068317	chr5:103032376~103033031:+
THYM	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	4.83	5.23e-06	0.00435	0.56	0.45	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
THYM	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-4.83	5.23e-06	0.00435	-0.31	-0.45	Height;	chr11:118786602	chr11:118791254~118793137:+
THYM	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-4.83	5.24e-06	0.00436	-0.4	-0.45	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-4.83	5.24e-06	0.00436	-0.4	-0.45	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-4.83	5.24e-06	0.00436	-0.4	-0.45	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-4.83	5.24e-06	0.00436	-0.4	-0.45	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-4.83	5.24e-06	0.00436	-0.4	-0.45	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
THYM	cis	rs1426063	1	rs11941556	ENSG00000249717.1	RP11-44F21.3	4.83	5.24e-06	0.00436	0.98	0.45	QT interval;	chr4:75093825	chr4:74955974~74970362:-
THYM	cis	rs1426063	1	rs10022814	ENSG00000249717.1	RP11-44F21.3	4.83	5.24e-06	0.00436	0.98	0.45	QT interval;	chr4:75094704	chr4:74955974~74970362:-
THYM	cis	rs1426063	1	rs10029141	ENSG00000249717.1	RP11-44F21.3	4.83	5.24e-06	0.00436	0.98	0.45	QT interval;	chr4:75097437	chr4:74955974~74970362:-
THYM	cis	rs1426063	1	rs10030850	ENSG00000249717.1	RP11-44F21.3	4.83	5.24e-06	0.00436	0.98	0.45	QT interval;	chr4:75099199	chr4:74955974~74970362:-
THYM	cis	rs1426063	1	rs9993589	ENSG00000249717.1	RP11-44F21.3	4.83	5.24e-06	0.00436	0.98	0.45	QT interval;	chr4:75099556	chr4:74955974~74970362:-
THYM	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	4.83	5.25e-06	0.00437	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
THYM	cis	rs10829156	0.898	rs10741120	ENSG00000240291.1	RP11-499P20.2	4.83	5.26e-06	0.00438	0.4	0.45	Sudden cardiac arrest;	chr10:18641063	chr10:18513115~18545651:-
THYM	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-4.83	5.26e-06	0.00438	-0.58	-0.45	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
THYM	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	4.83	5.26e-06	0.00438	0.58	0.45	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	4.83	5.26e-06	0.00438	0.58	0.45	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	4.83	5.26e-06	0.00438	0.58	0.45	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	4.83	5.26e-06	0.00438	0.58	0.45	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	4.83	5.26e-06	0.00438	0.58	0.45	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
THYM	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-4.83	5.27e-06	0.00438	-0.7	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
THYM	cis	rs4908768	0.581	rs2784739	ENSG00000232912.4	RP5-1115A15.1	-4.83	5.27e-06	0.00438	-0.47	-0.45	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8437498	chr1:8424645~8434838:+
THYM	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-4.83	5.27e-06	0.00438	-0.5	-0.45	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
THYM	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	4.83	5.28e-06	0.00439	0.68	0.45	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	4.83	5.28e-06	0.00439	0.68	0.45	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	4.83	5.28e-06	0.00439	0.68	0.45	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
THYM	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	4.83	5.29e-06	0.00439	0.31	0.45	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
THYM	cis	rs9659323	0.65	rs61528304	ENSG00000231365.4	RP11-418J17.1	-4.83	5.29e-06	0.0044	-0.47	-0.45	Body mass index;	chr1:118920976	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.613	rs72705339	ENSG00000231365.4	RP11-418J17.1	-4.83	5.29e-06	0.0044	-0.47	-0.45	Body mass index;	chr1:118929246	chr1:119140396~119275973:+
THYM	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	4.83	5.3e-06	0.0044	0.42	0.45	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
THYM	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	4.83	5.31e-06	0.0044	0.52	0.45	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
THYM	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	4.83	5.31e-06	0.0044	0.5	0.45	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
THYM	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-4.83	5.32e-06	0.00441	-0.69	-0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
THYM	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	4.83	5.32e-06	0.00441	0.52	0.45	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	4.83	5.32e-06	0.00441	0.52	0.45	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	4.83	5.32e-06	0.00441	0.52	0.45	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	4.83	5.32e-06	0.00441	0.52	0.45	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
THYM	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-4.83	5.32e-06	0.00441	-0.5	-0.45	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
THYM	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	4.83	5.32e-06	0.00441	0.54	0.45	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
THYM	cis	rs9659323	0.622	rs6689568	ENSG00000231365.4	RP11-418J17.1	-4.83	5.33e-06	0.00442	-0.47	-0.45	Body mass index;	chr1:118960338	chr1:119140396~119275973:+
THYM	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-4.83	5.33e-06	0.00442	-0.61	-0.45	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
THYM	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	4.83	5.33e-06	0.00442	0.42	0.45	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
THYM	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	4.83	5.33e-06	0.00442	0.52	0.45	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
THYM	cis	rs995834	0.784	rs12983816	ENSG00000267243.4	AC005307.3	-4.83	5.34e-06	0.00442	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28387019	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs2190992	ENSG00000267243.4	AC005307.3	-4.83	5.34e-06	0.00442	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28389894	chr19:28435388~28727777:-
THYM	cis	rs995834	0.661	rs8100368	ENSG00000267243.4	AC005307.3	-4.83	5.34e-06	0.00442	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28390727	chr19:28435388~28727777:-
THYM	cis	rs995834	0.703	rs10853718	ENSG00000267243.4	AC005307.3	-4.83	5.34e-06	0.00442	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28392058	chr19:28435388~28727777:-
THYM	cis	rs995834	0.664	rs10411350	ENSG00000267243.4	AC005307.3	-4.83	5.34e-06	0.00442	-0.41	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28393737	chr19:28435388~28727777:-
THYM	cis	rs9907295	0.901	rs4795096	ENSG00000270977.1	AC015849.16	-4.83	5.34e-06	0.00443	-0.6	-0.45	Fibroblast growth factor basic levels;	chr17:35888821	chr17:35893707~35911023:-
THYM	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	4.83	5.35e-06	0.00444	0.42	0.45	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
THYM	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	4.83	5.36e-06	0.00444	0.59	0.45	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
THYM	cis	rs6591341	0.515	rs599301	ENSG00000222339.1	AP000807.2	4.83	5.36e-06	0.00444	0.48	0.45	Lean body mass;	chr11:68422477	chr11:68505572~68505651:-
THYM	cis	rs8113308	1	rs8105440	ENSG00000269235.1	ZNF350-AS1	4.83	5.36e-06	0.00444	0.44	0.45	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948647	chr19:51949134~51981367:+
THYM	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-4.83	5.38e-06	0.00446	-0.39	-0.45	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
THYM	cis	rs9376098	0.825	rs6922541	ENSG00000232876.1	CTA-212D2.2	-4.83	5.38e-06	0.00446	-0.48	-0.45	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161681	chr6:135055033~135060550:+
THYM	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-4.83	5.39e-06	0.00446	-0.65	-0.45	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
THYM	cis	rs9659323	0.717	rs61806238	ENSG00000231365.4	RP11-418J17.1	-4.82	5.41e-06	0.00447	-0.47	-0.45	Body mass index;	chr1:118993755	chr1:119140396~119275973:+
THYM	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-4.82	5.42e-06	0.00448	-0.54	-0.45	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	4.82	5.42e-06	0.00448	0.54	0.45	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	4.82	5.42e-06	0.00448	0.54	0.45	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	4.82	5.42e-06	0.00448	0.54	0.45	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	4.82	5.42e-06	0.00448	0.54	0.45	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	4.82	5.42e-06	0.00448	0.54	0.45	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	4.82	5.42e-06	0.00448	0.54	0.45	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
THYM	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-4.82	5.42e-06	0.00448	-0.67	-0.45	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
THYM	cis	rs11838725	1	rs11838725	ENSG00000176268.5	CYCSP34	4.82	5.42e-06	0.00448	0.41	0.45	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40863599~40863902:-
THYM	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	4.82	5.43e-06	0.00449	0.58	0.45	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	4.82	5.43e-06	0.00449	0.58	0.45	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	4.82	5.43e-06	0.00449	0.58	0.45	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	4.82	5.43e-06	0.00449	0.58	0.45	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	4.82	5.43e-06	0.00449	0.58	0.45	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	4.82	5.43e-06	0.00449	0.58	0.45	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	4.82	5.43e-06	0.00449	0.58	0.45	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
THYM	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-4.82	5.44e-06	0.00449	-0.52	-0.45	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
THYM	cis	rs2283792	0.967	rs11704205	ENSG00000228050.1	TOP3BP1	4.82	5.44e-06	0.00449	0.49	0.45	Multiple sclerosis;	chr22:21790964	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.967	rs5999550	ENSG00000228050.1	TOP3BP1	4.82	5.44e-06	0.00449	0.49	0.45	Multiple sclerosis;	chr22:21796997	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs2266967	ENSG00000228050.1	TOP3BP1	4.82	5.44e-06	0.00449	0.49	0.45	Multiple sclerosis;	chr22:21802500	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs5999515	ENSG00000228050.1	TOP3BP1	-4.82	5.44e-06	0.00449	-0.49	-0.45	Multiple sclerosis;	chr22:21790812	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs5749986	ENSG00000228050.1	TOP3BP1	-4.82	5.44e-06	0.00449	-0.49	-0.45	Multiple sclerosis;	chr22:21803372	chr22:22223187~22224566:-
THYM	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	4.82	5.45e-06	0.0045	0.42	0.45	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	4.82	5.45e-06	0.0045	0.42	0.45	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	4.82	5.45e-06	0.0045	0.42	0.45	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
THYM	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	4.82	5.45e-06	0.0045	0.42	0.45	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
THYM	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-4.82	5.46e-06	0.00451	-0.64	-0.45	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
THYM	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	4.82	5.46e-06	0.00451	0.39	0.45	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
THYM	cis	rs5742933	1	rs6719224	ENSG00000273240.1	RP11-455J20.3	-4.82	5.46e-06	0.00451	-0.71	-0.45	Ferritin levels;	chr2:189769545	chr2:189763859~189764456:-
THYM	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-4.82	5.46e-06	0.00451	-0.43	-0.45	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
THYM	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-4.82	5.47e-06	0.00452	-0.31	-0.45	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
THYM	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-4.82	5.47e-06	0.00452	-0.31	-0.45	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
THYM	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-4.82	5.47e-06	0.00452	-0.31	-0.45	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
THYM	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-4.82	5.47e-06	0.00452	-0.31	-0.45	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
THYM	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-4.82	5.47e-06	0.00452	-0.31	-0.45	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
THYM	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	4.82	5.47e-06	0.00452	0.5	0.45	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
THYM	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	4.82	5.48e-06	0.00453	0.61	0.45	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
THYM	cis	rs4715166	0.859	rs10948546	ENSG00000215022.6	RP1-257A7.4	4.82	5.49e-06	0.00453	0.41	0.45	Hip geometry;	chr6:13223132	chr6:13264861~13295586:-
THYM	cis	rs1550115	0.524	rs6713448	ENSG00000271936.1	RP11-443B20.1	-4.82	5.49e-06	0.00453	-0.38	-0.45	Coronary artery disease;	chr2:24832577	chr2:24825610~24826717:+
THYM	cis	rs9659323	0.65	rs12066653	ENSG00000231365.4	RP11-418J17.1	-4.82	5.49e-06	0.00453	-0.47	-0.45	Body mass index;	chr1:118939885	chr1:119140396~119275973:+
THYM	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-4.82	5.49e-06	0.00453	-0.32	-0.45	Height;	chr11:118742526	chr11:118791254~118793137:+
THYM	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	4.82	5.5e-06	0.00454	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
THYM	cis	rs944990	0.538	rs10115234	ENSG00000227603.1	RP11-165J3.6	-4.82	5.52e-06	0.00455	-0.38	-0.45	Body mass index;	chr9:93538990	chr9:93435332~93437121:-
THYM	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	4.82	5.54e-06	0.00457	0.5	0.45	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
THYM	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	4.82	5.55e-06	0.00457	0.39	0.45	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	4.82	5.55e-06	0.00457	0.39	0.45	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-4.82	5.55e-06	0.00457	-0.39	-0.45	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
THYM	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	4.82	5.55e-06	0.00457	0.43	0.45	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
THYM	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	4.82	5.55e-06	0.00457	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	4.82	5.55e-06	0.00457	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	4.82	5.55e-06	0.00457	0.32	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
THYM	cis	rs2115630	0.653	rs61394864	ENSG00000275120.1	RP11-182J1.17	-4.82	5.57e-06	0.00458	-0.51	-0.44	P wave terminal force;	chr15:84626943	chr15:84599434~84606463:-
THYM	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-4.82	5.57e-06	0.00459	-0.64	-0.44	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
THYM	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-4.82	5.58e-06	0.00459	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
THYM	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	4.82	5.58e-06	0.00459	0.6	0.44	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
THYM	cis	rs526231	0.697	rs168820	ENSG00000175749.11	EIF3KP1	4.82	5.58e-06	0.00459	0.6	0.44	Primary biliary cholangitis;	chr5:103306972	chr5:103032376~103033031:+
THYM	cis	rs7927592	0.701	rs12226585	ENSG00000222339.1	AP000807.2	-4.82	5.59e-06	0.0046	-0.5	-0.44	Total body bone mineral density;	chr11:68490393	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.672	rs10501398	ENSG00000222339.1	AP000807.2	-4.82	5.59e-06	0.0046	-0.5	-0.44	Total body bone mineral density;	chr11:68564247	chr11:68505572~68505651:-
THYM	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	4.82	5.59e-06	0.0046	0.53	0.44	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
THYM	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-4.82	5.59e-06	0.0046	-0.56	-0.44	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
THYM	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	4.82	5.59e-06	0.0046	0.42	0.44	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
THYM	cis	rs4691139	0.619	rs7441550	ENSG00000250227.1	TRIM60P14	4.82	5.61e-06	0.00462	0.54	0.44	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003160	chr4:164915565~164916983:+
THYM	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	4.81	5.62e-06	0.00462	0.72	0.44	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
THYM	cis	rs9535495	0.965	rs9568478	ENSG00000200711.1	RNA5SP28	-4.81	5.62e-06	0.00462	-0.52	-0.44	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50832873	chr13:50812988~50813106:-
THYM	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	4.81	5.62e-06	0.00463	0.58	0.44	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	4.81	5.62e-06	0.00463	0.58	0.44	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
THYM	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	4.81	5.62e-06	0.00463	0.58	0.44	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
THYM	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-4.81	5.63e-06	0.00463	-0.54	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
THYM	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-4.81	5.63e-06	0.00463	-0.54	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
THYM	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-4.81	5.63e-06	0.00463	-0.39	-0.44	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-4.81	5.63e-06	0.00463	-0.39	-0.44	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-4.81	5.63e-06	0.00463	-0.39	-0.44	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
THYM	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-4.81	5.63e-06	0.00463	-0.62	-0.44	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
THYM	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	4.81	5.64e-06	0.00464	0.48	0.44	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	4.81	5.64e-06	0.00464	0.48	0.44	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	4.81	5.64e-06	0.00464	0.48	0.44	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	4.81	5.64e-06	0.00464	0.48	0.44	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
THYM	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	4.81	5.65e-06	0.00465	0.43	0.44	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	4.81	5.65e-06	0.00465	0.43	0.44	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
THYM	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	4.81	5.65e-06	0.00465	0.43	0.44	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	4.81	5.65e-06	0.00465	0.43	0.44	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	4.81	5.65e-06	0.00465	0.43	0.44	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
THYM	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	4.81	5.65e-06	0.00465	0.43	0.44	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
THYM	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	4.81	5.66e-06	0.00465	0.49	0.44	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	4.81	5.66e-06	0.00465	0.49	0.44	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	4.81	5.66e-06	0.00465	0.49	0.44	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	4.81	5.66e-06	0.00465	0.49	0.44	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
THYM	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-4.81	5.69e-06	0.00467	-0.5	-0.44	Height;	chr6:109444615	chr6:109382795~109383666:+
THYM	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-4.81	5.69e-06	0.00468	-0.56	-0.44	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
THYM	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-4.81	5.7e-06	0.00468	-0.53	-0.44	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
THYM	cis	rs9907295	0.688	rs2735475	ENSG00000270977.1	AC015849.16	-4.81	5.7e-06	0.00468	-0.55	-0.44	Fibroblast growth factor basic levels;	chr17:35931003	chr17:35893707~35911023:-
THYM	cis	rs6500550	0.851	rs11646287	ENSG00000276754.1	RP11-461A8.5	4.81	5.7e-06	0.00468	0.5	0.44	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3669343	chr16:3686998~3687380:+
THYM	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	4.81	5.7e-06	0.00468	0.56	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	4.81	5.7e-06	0.00468	0.56	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	4.81	5.7e-06	0.00468	0.56	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	4.81	5.7e-06	0.00468	0.56	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	4.81	5.7e-06	0.00468	0.56	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
THYM	cis	rs1476670	1	rs1476670	ENSG00000234694.1	RP1-92O14.3	4.81	5.7e-06	0.00468	0.71	0.44	Eotaxin levels;	chr1:44042523	chr1:43354684~43358658:-
THYM	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	4.81	5.7e-06	0.00468	0.52	0.44	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
THYM	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	4.81	5.71e-06	0.00469	0.87	0.44	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
THYM	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	4.81	5.72e-06	0.00469	0.51	0.44	Height;	chr6:109414295	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	4.81	5.72e-06	0.00469	0.51	0.44	Height;	chr6:109416225	chr6:109382795~109383666:+
THYM	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
THYM	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	4.81	5.73e-06	0.0047	0.54	0.44	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
THYM	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	4.81	5.74e-06	0.00471	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	4.81	5.74e-06	0.00471	0.82	0.44	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
THYM	cis	rs6782228	0.675	rs9841987	ENSG00000277250.1	Metazoa_SRP	-4.81	5.75e-06	0.00471	-0.59	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.675	rs56141228	ENSG00000277250.1	Metazoa_SRP	-4.81	5.75e-06	0.00471	-0.59	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.651	rs9852825	ENSG00000277250.1	Metazoa_SRP	-4.81	5.75e-06	0.00471	-0.59	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.651	rs9289332	ENSG00000277250.1	Metazoa_SRP	-4.81	5.75e-06	0.00471	-0.59	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128673681~128674021:-
THYM	cis	rs10829156	1	rs10829156	ENSG00000240291.1	RP11-499P20.2	4.81	5.76e-06	0.00472	0.39	0.44	Sudden cardiac arrest;	chr10:18661626	chr10:18513115~18545651:-
THYM	cis	rs13287066	0.692	rs10761225	ENSG00000227603.1	RP11-165J3.6	4.81	5.76e-06	0.00472	0.36	0.44	Intelligence (multi-trait analysis);	chr9:93404358	chr9:93435332~93437121:-
THYM	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-4.81	5.76e-06	0.00472	-0.67	-0.44	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
THYM	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	4.81	5.77e-06	0.00473	0.53	0.44	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
THYM	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	4.81	5.77e-06	0.00473	0.53	0.44	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
THYM	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	4.81	5.77e-06	0.00473	0.51	0.44	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
THYM	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-4.81	5.77e-06	0.00473	-0.49	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
THYM	cis	rs526231	0.824	rs253753	ENSG00000175749.11	EIF3KP1	4.81	5.77e-06	0.00473	0.55	0.44	Primary biliary cholangitis;	chr5:103322120	chr5:103032376~103033031:+
THYM	cis	rs12908161	1	rs12905057	ENSG00000235370.6	DNM1P51	4.81	5.77e-06	0.00473	0.6	0.44	Schizophrenia;	chr15:84667534	chr15:84398316~84411701:-
THYM	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	4.81	5.78e-06	0.00474	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
THYM	cis	rs7605378	0.658	rs4673507	ENSG00000232732.8	AC073043.1	-4.81	5.8e-06	0.00475	-0.62	-0.44	Osteoporosis;	chr2:199845444	chr2:199867396~199911159:-
THYM	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	4.81	5.8e-06	0.00475	0.41	0.44	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
THYM	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	4.81	5.81e-06	0.00476	0.41	0.44	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
THYM	cis	rs9659323	0.596	rs6656528	ENSG00000231365.4	RP11-418J17.1	-4.81	5.82e-06	0.00476	-0.46	-0.44	Body mass index;	chr1:118934971	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.65	rs17013645	ENSG00000231365.4	RP11-418J17.1	-4.81	5.82e-06	0.00476	-0.46	-0.44	Body mass index;	chr1:118942226	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.622	rs28653656	ENSG00000231365.4	RP11-418J17.1	-4.81	5.82e-06	0.00476	-0.46	-0.44	Body mass index;	chr1:118943807	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.65	rs12086486	ENSG00000231365.4	RP11-418J17.1	-4.81	5.82e-06	0.00476	-0.46	-0.44	Body mass index;	chr1:118946419	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.65	rs12093893	ENSG00000231365.4	RP11-418J17.1	-4.81	5.82e-06	0.00476	-0.46	-0.44	Body mass index;	chr1:118948196	chr1:119140396~119275973:+
THYM	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	4.81	5.82e-06	0.00476	0.48	0.44	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
THYM	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-4.81	5.83e-06	0.00477	-0.68	-0.44	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
THYM	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-4.81	5.83e-06	0.00477	-0.51	-0.44	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
THYM	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-4.81	5.83e-06	0.00477	-0.51	-0.44	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
THYM	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	4.81	5.83e-06	0.00478	0.35	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
THYM	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	4.81	5.83e-06	0.00478	0.53	0.44	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	4.81	5.83e-06	0.00478	0.53	0.44	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	4.81	5.83e-06	0.00478	0.53	0.44	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
THYM	cis	rs4835473	0.715	rs1849124	ENSG00000251600.4	RP11-673E1.1	4.81	5.85e-06	0.00478	0.5	0.44	Immature fraction of reticulocytes;	chr4:143978494	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.689	rs1849123	ENSG00000251600.4	RP11-673E1.1	4.81	5.85e-06	0.00478	0.5	0.44	Immature fraction of reticulocytes;	chr4:143978495	chr4:143912331~143982454:+
THYM	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-4.8	5.85e-06	0.00478	-0.39	-0.44	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
THYM	cis	rs7202877	0.706	rs247438	ENSG00000261783.1	RP11-252K23.2	4.8	5.85e-06	0.00479	0.57	0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75398751	chr16:75379818~75381260:-
THYM	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	4.8	5.86e-06	0.00479	0.43	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
THYM	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-4.8	5.87e-06	0.0048	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
THYM	cis	rs35542019	1	rs35542019	ENSG00000237945.6	LINC00649	4.8	5.88e-06	0.00481	0.37	0.44	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33915534~33977691:+
THYM	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-4.8	5.89e-06	0.00481	-0.53	-0.44	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
THYM	cis	rs17711722	0.522	rs62469933	ENSG00000232906.1	RP11-746P2.3	4.8	5.89e-06	0.00482	0.43	0.44	Calcium levels;	chr7:65800652	chr7:65355934~65357176:+
THYM	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	4.8	5.9e-06	0.00482	0.42	0.44	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
THYM	cis	rs5769707	0.935	rs1109320	ENSG00000264139.1	MIR3667	-4.8	5.91e-06	0.00483	-0.5	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49543393~49543466:-
THYM	cis	rs5769707	0.839	rs73176988	ENSG00000264139.1	MIR3667	-4.8	5.91e-06	0.00483	-0.5	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49543393~49543466:-
THYM	cis	rs5769707	0.967	rs17182154	ENSG00000264139.1	MIR3667	-4.8	5.91e-06	0.00483	-0.5	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49543393~49543466:-
THYM	cis	rs5769707	0.967	rs763127	ENSG00000264139.1	MIR3667	-4.8	5.91e-06	0.00483	-0.5	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49543393~49543466:-
THYM	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	4.8	5.91e-06	0.00483	0.33	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
THYM	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-4.8	5.91e-06	0.00483	-0.61	-0.44	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
THYM	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-4.8	5.92e-06	0.00484	-0.58	-0.44	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
THYM	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	4.8	5.92e-06	0.00484	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
THYM	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	4.8	5.93e-06	0.00484	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
THYM	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-4.8	5.94e-06	0.00485	-0.63	-0.44	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
THYM	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-4.8	5.95e-06	0.00486	-0.48	-0.44	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-4.8	5.95e-06	0.00486	-0.48	-0.44	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
THYM	cis	rs17711722	0.522	rs6957759	ENSG00000232906.1	RP11-746P2.3	4.8	5.95e-06	0.00486	0.43	0.44	Calcium levels;	chr7:65806798	chr7:65355934~65357176:+
THYM	cis	rs4908768	0.539	rs7537982	ENSG00000232912.4	RP5-1115A15.1	4.8	5.96e-06	0.00487	0.43	0.44	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8424645~8434838:+
THYM	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-4.8	5.97e-06	0.00488	-0.67	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
THYM	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	4.8	5.98e-06	0.00488	0.41	0.44	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
THYM	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-4.8	5.98e-06	0.00488	-0.6	-0.44	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
THYM	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	4.8	5.98e-06	0.00488	0.58	0.44	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
THYM	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	4.8	5.98e-06	0.00488	0.51	0.44	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	4.8	5.98e-06	0.00488	0.51	0.44	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
THYM	cis	rs2283792	0.846	rs240049	ENSG00000228050.1	TOP3BP1	4.8	5.99e-06	0.00489	0.5	0.44	Multiple sclerosis;	chr22:21906236	chr22:22223187~22224566:-
THYM	cis	rs867371	1	rs7181655	ENSG00000276710.3	CSPG4P8	-4.8	5.99e-06	0.00489	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs7180584	ENSG00000276710.3	CSPG4P8	-4.8	5.99e-06	0.00489	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs6495642	ENSG00000276710.3	CSPG4P8	-4.8	5.99e-06	0.00489	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82459472~82477258:+
THYM	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	4.8	5.99e-06	0.00489	0.7	0.44	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
THYM	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-4.8	6.01e-06	0.0049	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
THYM	cis	rs5760092	0.717	rs5760101	ENSG00000272787.1	KB-226F1.2	-4.8	6.02e-06	0.00491	-0.58	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23906525	chr22:23969211~23969873:+
THYM	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-4.8	6.05e-06	0.00493	-0.48	-0.44	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
THYM	cis	rs160451	0.934	rs34036322	ENSG00000251136.7	RP11-37B2.1	4.8	6.05e-06	0.00493	0.37	0.44	Leprosy;	chr8:89654670	chr8:89609409~89757727:-
THYM	cis	rs160451	0.966	rs1603289	ENSG00000251136.7	RP11-37B2.1	4.8	6.05e-06	0.00493	0.37	0.44	Leprosy;	chr8:89655405	chr8:89609409~89757727:-
THYM	cis	rs160451	0.966	rs2101854	ENSG00000251136.7	RP11-37B2.1	4.8	6.05e-06	0.00493	0.37	0.44	Leprosy;	chr8:89663517	chr8:89609409~89757727:-
THYM	cis	rs3738443	0.594	rs60050650	ENSG00000227671.4	RP11-488L18.4	-4.8	6.05e-06	0.00493	-0.25	-0.44	Alcohol dependence;	chr1:247213474	chr1:247189851~247210856:-
THYM	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	4.8	6.05e-06	0.00493	0.48	0.44	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	4.8	6.05e-06	0.00493	0.48	0.44	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
THYM	cis	rs12681366	0.801	rs12549544	ENSG00000253704.1	RP11-267M23.4	4.8	6.05e-06	0.00493	0.58	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs12682524	ENSG00000253704.1	RP11-267M23.4	4.8	6.05e-06	0.00493	0.58	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94553722~94569745:+
THYM	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	4.8	6.05e-06	0.00493	0.53	0.44	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
THYM	cis	rs2562456	0.752	rs7258562	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21331762	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs7260065	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21334175	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs55920089	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21337891	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs4334427	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21338090	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs4644962	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21338125	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.754	rs58338799	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21339009	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.793	rs7259396	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21340661	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.678	rs7260140	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21340723	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs11880624	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21341028	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.833	rs62107547	ENSG00000268081.1	RP11-678G14.2	4.8	6.06e-06	0.00493	0.6	0.44	Pain;	chr19:21341245	chr19:21554640~21569237:-
THYM	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	4.8	6.06e-06	0.00494	0.44	0.44	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
THYM	cis	rs9535495	0.965	rs7988805	ENSG00000200711.1	RNA5SP28	-4.8	6.07e-06	0.00495	-0.5	-0.44	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50830764	chr13:50812988~50813106:-
THYM	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-4.79	6.09e-06	0.00496	-0.52	-0.44	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
THYM	cis	rs6696239	0.513	rs903684	ENSG00000227711.2	RP11-275O4.5	-4.79	6.09e-06	0.00496	-0.4	-0.44	Height;	chr1:227509398	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.531	rs2644140	ENSG00000227711.2	RP11-275O4.5	-4.79	6.09e-06	0.00496	-0.4	-0.44	Height;	chr1:227509680	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.531	rs2018401	ENSG00000227711.2	RP11-275O4.5	-4.79	6.09e-06	0.00496	-0.4	-0.44	Height;	chr1:227509952	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.531	rs951083	ENSG00000227711.2	RP11-275O4.5	-4.79	6.09e-06	0.00496	-0.4	-0.44	Height;	chr1:227512770	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.531	rs2644150	ENSG00000227711.2	RP11-275O4.5	-4.79	6.09e-06	0.00496	-0.4	-0.44	Height;	chr1:227514120	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.531	rs2644151	ENSG00000227711.2	RP11-275O4.5	-4.79	6.09e-06	0.00496	-0.4	-0.44	Height;	chr1:227514993	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2492635	ENSG00000227711.2	RP11-275O4.5	-4.79	6.09e-06	0.00496	-0.4	-0.44	Height;	chr1:227517134	chr1:227509028~227520477:-
THYM	cis	rs904251	0.698	rs2646926	ENSG00000279942.1	RP1-153P14.7	-4.79	6.1e-06	0.00496	-0.65	-0.44	Cognitive performance;	chr6:37457212	chr6:37567716~37571460:+
THYM	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	4.79	6.1e-06	0.00496	0.6	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
THYM	cis	rs2115630	1	rs7183401	ENSG00000275120.1	RP11-182J1.17	-4.79	6.11e-06	0.00497	-0.53	-0.44	P wave terminal force;	chr15:84828713	chr15:84599434~84606463:-
THYM	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	4.79	6.11e-06	0.00497	0.32	0.44	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
THYM	cis	rs763121	0.962	rs6001159	ENSG00000273076.1	RP3-508I15.22	4.79	6.11e-06	0.00497	0.55	0.44	Menopause (age at onset);	chr22:38570482	chr22:38743495~38743910:+
THYM	cis	rs995834	0.588	rs56239696	ENSG00000266928.1	CTB-70G10.1	4.79	6.12e-06	0.00498	0.8	0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28409628	chr19:28294093~28313500:-
THYM	cis	rs890448	0.9	rs7673593	ENSG00000254531.1	FLJ20021	-4.79	6.12e-06	0.00498	-0.38	-0.44	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101522212	chr4:101347780~101348883:+
THYM	cis	rs890448	0.84	rs1426540	ENSG00000254531.1	FLJ20021	-4.79	6.12e-06	0.00498	-0.38	-0.44	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101524619	chr4:101347780~101348883:+
THYM	cis	rs10129255	0.557	rs4043727	ENSG00000254329.1	IGHVII-60-1	4.79	6.12e-06	0.00498	0.44	0.44	Kawasaki disease;	chr14:106649820	chr14:106637718~106637973:-
THYM	cis	rs4835473	0.897	rs1391189	ENSG00000251600.4	RP11-673E1.1	-4.79	6.12e-06	0.00498	-0.5	-0.44	Immature fraction of reticulocytes;	chr4:143690951	chr4:143912331~143982454:+
THYM	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	4.79	6.12e-06	0.00498	0.58	0.44	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
THYM	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	4.79	6.13e-06	0.00499	0.59	0.44	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
THYM	cis	rs11017328	0.5	rs6482804	ENSG00000236303.2	RP11-540N6.1	-4.79	6.13e-06	0.00499	-0.62	-0.44	Conotruncal heart defects;	chr10:130506551	chr10:130439067~130483154:+
THYM	cis	rs11017328	0.5	rs4545449	ENSG00000236303.2	RP11-540N6.1	-4.79	6.13e-06	0.00499	-0.62	-0.44	Conotruncal heart defects;	chr10:130506670	chr10:130439067~130483154:+
THYM	cis	rs4853012	1	rs4853012	ENSG00000272183.1	RP11-523H20.3	4.79	6.14e-06	0.00499	0.67	0.44	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74501717~74502365:+
THYM	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	4.79	6.14e-06	0.00499	0.55	0.44	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
THYM	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	4.79	6.14e-06	0.00499	0.55	0.44	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
THYM	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	4.79	6.14e-06	0.00499	0.55	0.44	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
THYM	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	4.79	6.14e-06	0.00499	0.55	0.44	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
THYM	cis	rs4845570	1	rs1054479	ENSG00000203288.3	RP11-98D18.9	-4.79	6.16e-06	0.00501	-0.53	-0.44	Coronary artery disease;	chr1:151773603	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs6683364	ENSG00000203288.3	RP11-98D18.9	-4.79	6.16e-06	0.00501	-0.53	-0.44	Coronary artery disease;	chr1:151773726	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs7542898	ENSG00000203288.3	RP11-98D18.9	-4.79	6.16e-06	0.00501	-0.53	-0.44	Coronary artery disease;	chr1:151781146	chr1:151790804~151794402:+
THYM	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	4.79	6.16e-06	0.00501	0.56	0.44	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	4.79	6.16e-06	0.00501	0.56	0.44	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	4.79	6.16e-06	0.00501	0.56	0.44	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	4.79	6.16e-06	0.00501	0.56	0.44	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
THYM	cis	rs995834	0.743	rs2015841	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28345899	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs10415623	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28346878	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs10416153	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347155	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs8108726	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347425	chr19:28435388~28727777:-
THYM	cis	rs995834	0.701	rs6508784	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28347560	chr19:28435388~28727777:-
THYM	cis	rs995834	0.701	rs8111880	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348171	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs8112315	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348498	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs8111630	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348642	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs11670286	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28348909	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs758314	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363165	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs726845	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363761	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs2868967	ENSG00000267243.4	AC005307.3	-4.79	6.17e-06	0.00501	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372690	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs6508794	ENSG00000267243.4	AC005307.3	4.79	6.17e-06	0.00501	0.4	0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28356703	chr19:28435388~28727777:-
THYM	cis	rs995834	0.661	rs4407171	ENSG00000267243.4	AC005307.3	4.79	6.17e-06	0.00501	0.4	0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28372452	chr19:28435388~28727777:-
THYM	cis	rs7044106	0.537	rs10818474	ENSG00000238181.2	AHCYP2	-4.79	6.2e-06	0.00503	-0.48	-0.44	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120720673~120721972:+
THYM	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	4.79	6.2e-06	0.00503	0.54	0.44	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
THYM	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	4.79	6.22e-06	0.00505	0.6	0.44	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
THYM	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	4.79	6.22e-06	0.00505	0.51	0.44	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
THYM	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	4.79	6.23e-06	0.00506	0.55	0.44	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
THYM	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	4.79	6.23e-06	0.00506	0.57	0.44	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
THYM	cis	rs12908161	1	rs35316992	ENSG00000235370.6	DNM1P51	4.79	6.25e-06	0.00507	0.59	0.44	Schizophrenia;	chr15:84704902	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs4643294	ENSG00000235370.6	DNM1P51	4.79	6.25e-06	0.00507	0.59	0.44	Schizophrenia;	chr15:84707022	chr15:84398316~84411701:-
THYM	cis	rs10805346	0.531	rs12498927	ENSG00000261490.1	RP11-448G15.3	-4.79	6.26e-06	0.00507	-0.39	-0.44	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10113899	chr4:10068089~10073019:-
THYM	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
THYM	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
THYM	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
THYM	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	4.79	6.26e-06	0.00507	0.57	0.44	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
THYM	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-4.79	6.26e-06	0.00507	-0.67	-0.44	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
THYM	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-4.79	6.27e-06	0.00508	-0.56	-0.44	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
THYM	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-4.79	6.27e-06	0.00508	-0.36	-0.44	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
THYM	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-4.79	6.27e-06	0.00508	-0.36	-0.44	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
THYM	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-4.79	6.29e-06	0.00509	-0.5	-0.44	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
THYM	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-4.79	6.29e-06	0.00509	-0.41	-0.44	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
THYM	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-4.79	6.29e-06	0.00509	-0.41	-0.44	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
THYM	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-4.79	6.29e-06	0.00509	-0.41	-0.44	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
THYM	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-4.79	6.29e-06	0.00509	-0.41	-0.44	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
THYM	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-4.79	6.29e-06	0.00509	-0.41	-0.44	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
THYM	cis	rs13256369	0.802	rs12541520	ENSG00000253893.2	FAM85B	-4.79	6.3e-06	0.0051	-0.64	-0.44	Obesity-related traits;	chr8:8706636	chr8:8167819~8226614:-
THYM	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	4.79	6.3e-06	0.0051	0.55	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
THYM	cis	rs10411161	1	rs72626249	ENSG00000269483.1	AC006272.1	4.79	6.3e-06	0.0051	0.61	0.44	Breast cancer;	chr19:51861622	chr19:51839924~51843324:-
THYM	cis	rs526231	0.764	rs183707	ENSG00000175749.11	EIF3KP1	4.79	6.3e-06	0.0051	0.57	0.44	Primary biliary cholangitis;	chr5:103305081	chr5:103032376~103033031:+
THYM	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	4.79	6.31e-06	0.0051	0.83	0.44	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
THYM	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-4.79	6.31e-06	0.00511	-0.31	-0.44	Height;	chr11:118749988	chr11:118791254~118793137:+
THYM	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	4.79	6.31e-06	0.00511	0.31	0.44	Height;	chr11:118758322	chr11:118791254~118793137:+
THYM	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	4.79	6.32e-06	0.00511	0.4	0.44	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
THYM	cis	rs7223966	1	rs8064261	ENSG00000240280.5	TCAM1P	-4.79	6.32e-06	0.00512	-0.67	-0.44	Hip circumference adjusted for BMI;Body mass index;	chr17:63627852	chr17:63849292~63864379:+
THYM	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	4.79	6.33e-06	0.00512	0.53	0.44	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
THYM	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	4.79	6.33e-06	0.00512	0.53	0.44	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
THYM	cis	rs12908161	0.959	rs17598603	ENSG00000235370.6	DNM1P51	-4.79	6.33e-06	0.00512	-0.59	-0.44	Schizophrenia;	chr15:84656980	chr15:84398316~84411701:-
THYM	cis	rs7617773	1	rs9832957	ENSG00000228638.1	FCF1P2	4.78	6.34e-06	0.00513	0.47	0.44	Coronary artery disease;	chr3:48143776	chr3:48290793~48291375:-
THYM	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	4.78	6.34e-06	0.00513	0.62	0.44	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
THYM	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-4.78	6.34e-06	0.00513	-0.34	-0.44	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
THYM	cis	rs4591358	0.689	rs72927784	ENSG00000223466.1	AC064834.2	-4.78	6.35e-06	0.00513	-0.56	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195550329	chr2:195533035~195538681:+
THYM	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	4.78	6.35e-06	0.00514	0.71	0.44	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
THYM	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	4.78	6.37e-06	0.00515	0.34	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
THYM	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	4.78	6.38e-06	0.00516	0.34	0.44	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
THYM	cis	rs7209700	0.745	rs8074348	ENSG00000228782.6	CTD-2026D20.3	-4.78	6.39e-06	0.00516	-0.54	-0.44	IgG glycosylation;	chr17:47276047	chr17:47450568~47492492:-
THYM	cis	rs7209700	0.862	rs2015729	ENSG00000228782.6	CTD-2026D20.3	-4.78	6.39e-06	0.00516	-0.54	-0.44	IgG glycosylation;	chr17:47277127	chr17:47450568~47492492:-
THYM	cis	rs7209700	0.894	rs7212751	ENSG00000228782.6	CTD-2026D20.3	-4.78	6.39e-06	0.00516	-0.54	-0.44	IgG glycosylation;	chr17:47278133	chr17:47450568~47492492:-
THYM	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	4.78	6.39e-06	0.00516	0.81	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	4.78	6.39e-06	0.00516	0.81	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	4.78	6.39e-06	0.00516	0.81	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	4.78	6.39e-06	0.00516	0.81	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
THYM	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-4.78	6.39e-06	0.00516	-0.35	-0.44	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
THYM	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	4.78	6.39e-06	0.00516	0.56	0.44	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
THYM	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-4.78	6.39e-06	0.00516	-0.56	-0.44	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
THYM	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-4.78	6.39e-06	0.00516	-0.56	-0.44	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
THYM	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-4.78	6.39e-06	0.00516	-0.56	-0.44	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
THYM	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-4.78	6.39e-06	0.00516	-0.56	-0.44	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
THYM	cis	rs5769707	0.967	rs5769698	ENSG00000264139.1	MIR3667	-4.78	6.43e-06	0.00519	-0.5	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49543393~49543466:-
THYM	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	4.78	6.43e-06	0.00519	0.47	0.44	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
THYM	cis	rs12908161	1	rs36033486	ENSG00000235370.6	DNM1P51	4.78	6.43e-06	0.00519	0.59	0.44	Schizophrenia;	chr15:84776461	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs12908549	ENSG00000235370.6	DNM1P51	4.78	6.43e-06	0.00519	0.59	0.44	Schizophrenia;	chr15:84779120	chr15:84398316~84411701:-
THYM	cis	rs9659323	0.65	rs10802064	ENSG00000231365.4	RP11-418J17.1	-4.78	6.43e-06	0.00519	-0.46	-0.44	Body mass index;	chr1:118915514	chr1:119140396~119275973:+
THYM	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-4.78	6.44e-06	0.0052	-0.46	-0.44	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
THYM	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-4.78	6.45e-06	0.0052	-0.76	-0.44	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
THYM	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	4.78	6.47e-06	0.00521	0.44	0.44	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
THYM	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	4.78	6.47e-06	0.00522	0.5	0.44	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	4.78	6.47e-06	0.00522	0.5	0.44	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	4.78	6.47e-06	0.00522	0.5	0.44	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
THYM	cis	rs2115630	0.755	rs7169629	ENSG00000275120.1	RP11-182J1.17	4.78	6.48e-06	0.00522	0.49	0.44	P wave terminal force;	chr15:84648043	chr15:84599434~84606463:-
THYM	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-4.78	6.48e-06	0.00522	-0.53	-0.44	Depression;	chr6:28111963	chr6:28115628~28116551:+
THYM	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-4.78	6.49e-06	0.00522	-0.42	-0.44	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
THYM	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-4.78	6.51e-06	0.00524	-0.46	-0.44	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-4.78	6.51e-06	0.00524	-0.46	-0.44	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
THYM	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-4.78	6.51e-06	0.00524	-0.46	-0.44	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
THYM	cis	rs561341	0.941	rs2428336	ENSG00000265798.5	RP11-271K11.5	4.78	6.53e-06	0.00525	0.53	0.44	Hip circumference adjusted for BMI;	chr17:31963558	chr17:31038575~31059121:-
THYM	cis	rs9535495	0.965	rs1951856	ENSG00000200711.1	RNA5SP28	-4.78	6.54e-06	0.00526	-0.5	-0.44	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50820492	chr13:50812988~50813106:-
THYM	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-4.78	6.54e-06	0.00526	-0.61	-0.44	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
THYM	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	4.78	6.55e-06	0.00527	0.61	0.44	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
THYM	cis	rs73108077	1	rs73105971	ENSG00000277112.2	RP11-755J8.1	-4.78	6.55e-06	0.00527	-0.61	-0.44	Red blood cell density in sickle cell anemia;	chr20:31369934	chr20:30681825~30723932:-
THYM	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-4.78	6.56e-06	0.00528	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-4.78	6.56e-06	0.00528	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
THYM	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	4.78	6.57e-06	0.00528	0.68	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	4.78	6.57e-06	0.00528	0.68	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	4.78	6.57e-06	0.00528	0.68	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	4.78	6.57e-06	0.00528	0.68	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	4.78	6.57e-06	0.00528	0.68	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	4.78	6.57e-06	0.00528	0.68	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	4.78	6.57e-06	0.00528	0.68	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
THYM	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-4.78	6.58e-06	0.00529	-0.55	-0.44	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
THYM	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	4.78	6.59e-06	0.0053	0.5	0.44	Height;	chr6:109347707	chr6:109382795~109383666:+
THYM	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-4.77	6.6e-06	0.0053	-0.52	-0.44	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	4.77	6.6e-06	0.0053	0.52	0.44	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	4.77	6.6e-06	0.0053	0.52	0.44	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	4.77	6.6e-06	0.0053	0.52	0.44	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
THYM	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	4.77	6.6e-06	0.00531	0.57	0.44	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	4.77	6.6e-06	0.00531	0.57	0.44	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	4.77	6.6e-06	0.00531	0.57	0.44	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	4.77	6.6e-06	0.00531	0.57	0.44	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
THYM	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-4.77	6.61e-06	0.00531	-0.4	-0.44	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
THYM	cis	rs4835473	0.742	rs1838519	ENSG00000249741.2	RP11-673E1.3	-4.77	6.61e-06	0.00531	-0.4	-0.44	Immature fraction of reticulocytes;	chr4:143972242	chr4:143911514~143912053:-
THYM	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	4.77	6.61e-06	0.00531	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
THYM	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	4.77	6.63e-06	0.00532	0.42	0.44	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
THYM	cis	rs9907295	0.688	rs4572457	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35813645	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.581	rs4251751	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35823733	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.748	rs4251752	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35823900	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.71	rs4796113	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35832562	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs4796114	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35832653	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs3785764	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35833760	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.748	rs78672421	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35837325	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs4796115	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35841315	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.71	rs9894083	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35842151	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs78905197	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs3760326	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35853493	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs9898132	ENSG00000270871.1	AC015849.19	4.77	6.63e-06	0.00532	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35869187	chr17:35816717~35830293:-
THYM	cis	rs904251	0.507	rs11756941	ENSG00000279942.1	RP1-153P14.7	-4.77	6.64e-06	0.00533	-0.72	-0.44	Cognitive performance;	chr6:37448443	chr6:37567716~37571460:+
THYM	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-4.77	6.65e-06	0.00534	-0.39	-0.44	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-4.77	6.65e-06	0.00534	-0.39	-0.44	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
THYM	cis	rs2117029	0.965	rs2241726	ENSG00000258017.1	RP11-386G11.10	-4.77	6.66e-06	0.00534	-0.47	-0.44	Intelligence (multi-trait analysis);	chr12:49050762	chr12:49127782~49147869:+
THYM	cis	rs13160562	0.623	rs26509	ENSG00000272109.1	CTD-2260A17.3	4.77	6.67e-06	0.00535	0.51	0.44	Alcohol dependence;	chr5:96746976	chr5:96804353~96806105:+
THYM	cis	rs9907295	0.748	rs4795091	ENSG00000270871.1	AC015849.19	4.77	6.67e-06	0.00535	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35814874	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.71	rs4795092	ENSG00000270871.1	AC015849.19	4.77	6.67e-06	0.00535	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35814967	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs4251729	ENSG00000270871.1	AC015849.19	4.77	6.67e-06	0.00535	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35818348	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.605	rs11652192	ENSG00000270871.1	AC015849.19	4.77	6.67e-06	0.00535	0.5	0.44	Fibroblast growth factor basic levels;	chr17:35833174	chr17:35816717~35830293:-
THYM	cis	rs957448	0.796	rs72674824	ENSG00000253704.1	RP11-267M23.4	4.77	6.67e-06	0.00535	0.59	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94477053	chr8:94553722~94569745:+
THYM	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	4.77	6.68e-06	0.00535	0.98	0.44	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
THYM	cis	rs7202877	0.656	rs3851736	ENSG00000261783.1	RP11-252K23.2	-4.77	6.69e-06	0.00536	-0.62	-0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75353434	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.572	rs8051611	ENSG00000261783.1	RP11-252K23.2	-4.77	6.69e-06	0.00536	-0.62	-0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75355035	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs4993971	ENSG00000261783.1	RP11-252K23.2	4.77	6.69e-06	0.00536	0.62	0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75377736	chr16:75379818~75381260:-
THYM	cis	rs6672530	0.5	rs2313219	ENSG00000227711.2	RP11-275O4.5	4.77	6.69e-06	0.00536	0.4	0.44	Hip circumference adjusted for BMI;	chr1:227508223	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.55	rs2313218	ENSG00000227711.2	RP11-275O4.5	4.77	6.69e-06	0.00536	0.4	0.44	Height;	chr1:227508224	chr1:227509028~227520477:-
THYM	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	4.77	6.7e-06	0.00537	0.32	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
THYM	cis	rs972578	0.837	rs5759017	ENSG00000215347.3	SLC25A5P1	-4.77	6.7e-06	0.00537	-0.35	-0.44	Mean platelet volume;	chr22:42900318	chr22:42001069~42001966:-
THYM	cis	rs853679	0.517	rs9380047	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28070115	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs7755442	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28071237	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs4713135	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28071808	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs12174753	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28074687	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs55747925	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28076559	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs56310871	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28076704	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs34716816	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28078391	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9380049	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28080757	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9380050	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28080760	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9393885	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28082231	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9393886	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28082261	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.515	rs9368549	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Parkinson's disease;	chr6:28082269	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs56364346	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28082984	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9357061	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28083994	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9368550	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28084025	chr6:28053228~28054165:-
THYM	cis	rs853679	0.542	rs2295594	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28085319	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs2273564	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28089816	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs1853097	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28090857	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9393888	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28091439	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs3734573	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28091659	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9357063	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28092227	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs3823180	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28093966	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9368551	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28094014	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9393890	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28096077	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9366715	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28096855	chr6:28053228~28054165:-
THYM	cis	rs853679	0.598	rs9380054	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28099759	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.547	rs2116981	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Parkinson's disease;	chr6:28100173	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9368552	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28100648	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs2281588	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28104824	chr6:28053228~28054165:-
THYM	cis	rs853679	0.542	rs34131763	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28107222	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs35193936	ENSG00000182477.5	OR2B8P	4.77	6.7e-06	0.00537	0.63	0.44	Depression;	chr6:28108492	chr6:28053228~28054165:-
THYM	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	4.77	6.7e-06	0.00537	0.41	0.44	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
THYM	cis	rs972578	0.806	rs8140272	ENSG00000215347.3	SLC25A5P1	-4.77	6.71e-06	0.00537	-0.35	-0.44	Mean platelet volume;	chr22:42826236	chr22:42001069~42001966:-
THYM	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-4.77	6.72e-06	0.00538	-0.71	-0.44	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-4.77	6.72e-06	0.00538	-0.71	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
THYM	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-4.77	6.72e-06	0.00538	-0.71	-0.44	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
THYM	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	4.77	6.72e-06	0.00538	0.71	0.44	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
THYM	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	4.77	6.72e-06	0.00538	0.71	0.44	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
THYM	cis	rs4853012	0.941	rs78128123	ENSG00000257702.3	LBX2-AS1	4.77	6.72e-06	0.00538	0.52	0.44	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74502595~74504678:+
THYM	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	4.77	6.73e-06	0.00539	0.47	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
THYM	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	4.77	6.73e-06	0.00539	0.47	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
THYM	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-4.77	6.73e-06	0.00539	-0.47	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
THYM	cis	rs995834	0.742	rs4805164	ENSG00000260725.1	AC005307.1	-4.77	6.73e-06	0.00539	-0.45	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28340111	chr19:28418483~28429490:-
THYM	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	4.77	6.73e-06	0.00539	0.61	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	4.77	6.73e-06	0.00539	0.61	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
THYM	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-4.77	6.75e-06	0.0054	-0.35	-0.44	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-4.77	6.75e-06	0.0054	-0.35	-0.44	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
THYM	cis	rs992157	0.764	rs1870123	ENSG00000261338.2	RP11-378A13.1	4.77	6.75e-06	0.0054	0.56	0.44	Colorectal cancer;	chr2:218322975	chr2:218255319~218257366:+
THYM	cis	rs4713118	0.662	rs9393881	ENSG00000182477.5	OR2B8P	4.77	6.75e-06	0.0054	0.64	0.44	Parkinson's disease;	chr6:28055973	chr6:28053228~28054165:-
THYM	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	4.77	6.76e-06	0.00541	0.69	0.44	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
THYM	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
THYM	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	4.77	6.77e-06	0.00541	0.5	0.44	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
THYM	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-4.77	6.77e-06	0.00542	-0.31	-0.44	Height;	chr11:118761813	chr11:118791254~118793137:+
THYM	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-4.77	6.77e-06	0.00542	-0.31	-0.44	Height;	chr11:118764443	chr11:118791254~118793137:+
THYM	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	4.77	6.78e-06	0.00542	0.39	0.44	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
THYM	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
THYM	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	4.77	6.79e-06	0.00542	0.42	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
THYM	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	4.77	6.8e-06	0.00543	0.44	0.44	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
THYM	cis	rs1560104	0.536	rs34480785	ENSG00000259899.1	CTD-3037G24.3	-4.77	6.82e-06	0.00545	-0.52	-0.44	Obesity-related traits;	chr16:12624032	chr16:12560756~12611044:-
THYM	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-4.77	6.82e-06	0.00545	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-4.77	6.82e-06	0.00545	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
THYM	cis	rs10129255	0.5	rs8004923	ENSG00000254329.1	IGHVII-60-1	4.77	6.83e-06	0.00545	0.38	0.44	Kawasaki disease;	chr14:106785926	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs6576232	ENSG00000254329.1	IGHVII-60-1	4.77	6.83e-06	0.00545	0.38	0.44	Kawasaki disease;	chr14:106787090	chr14:106637718~106637973:-
THYM	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-4.77	6.83e-06	0.00546	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	4.77	6.83e-06	0.00546	0.49	0.44	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
THYM	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-4.77	6.84e-06	0.00546	-0.35	-0.44	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-4.77	6.84e-06	0.00546	-0.35	-0.44	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-4.77	6.84e-06	0.00546	-0.35	-0.44	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-4.77	6.84e-06	0.00546	-0.35	-0.44	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-4.77	6.84e-06	0.00546	-0.35	-0.44	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-4.77	6.84e-06	0.00546	-0.35	-0.44	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-4.77	6.84e-06	0.00546	-0.35	-0.44	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	4.77	6.84e-06	0.00546	0.35	0.44	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
THYM	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	4.77	6.85e-06	0.00547	0.58	0.44	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
THYM	cis	rs7044106	0.537	rs10739573	ENSG00000238181.2	AHCYP2	-4.77	6.85e-06	0.00547	-0.5	-0.44	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120720673~120721972:+
THYM	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-4.77	6.86e-06	0.00547	-0.52	-0.44	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
THYM	cis	rs7242404	0.57	rs888262	ENSG00000260302.1	RP11-973H7.1	-4.77	6.86e-06	0.00547	-0.31	-0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12750219	chr18:12774651~12775923:-
THYM	cis	rs7242404	0.509	rs11080597	ENSG00000260302.1	RP11-973H7.1	4.77	6.86e-06	0.00547	0.31	0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12751429	chr18:12774651~12775923:-
THYM	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	4.77	6.86e-06	0.00547	0.57	0.44	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
THYM	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	4.77	6.86e-06	0.00547	0.52	0.44	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
THYM	cis	rs2115630	0.818	rs7176522	ENSG00000275120.1	RP11-182J1.17	-4.77	6.86e-06	0.00547	-0.52	-0.44	P wave terminal force;	chr15:84672152	chr15:84599434~84606463:-
THYM	cis	rs9907295	0.818	rs2280789	ENSG00000270977.1	AC015849.16	-4.76	6.87e-06	0.00548	-0.59	-0.44	Fibroblast growth factor basic levels;	chr17:35879999	chr17:35893707~35911023:-
THYM	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	4.76	6.87e-06	0.00548	0.6	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	4.76	6.87e-06	0.00548	0.6	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	4.76	6.87e-06	0.00548	0.6	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
THYM	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	4.76	6.87e-06	0.00548	0.6	0.44	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
THYM	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	4.76	6.88e-06	0.00548	0.57	0.44	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	4.76	6.88e-06	0.00548	0.57	0.44	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
THYM	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-4.76	6.88e-06	0.00548	-0.57	-0.44	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
THYM	cis	rs7989332	1	rs7320606	ENSG00000279065.1	RP11-264J4.10	-4.76	6.88e-06	0.00548	-0.54	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20478382	chr13:20194412~20196005:+
THYM	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-4.76	6.89e-06	0.00548	-0.35	-0.44	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-4.76	6.89e-06	0.00548	-0.35	-0.44	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
THYM	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-4.76	6.89e-06	0.00549	-0.54	-0.44	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
THYM	cis	rs1560104	0.536	rs11075131	ENSG00000259899.1	CTD-3037G24.3	-4.76	6.9e-06	0.00549	-0.52	-0.44	Obesity-related traits;	chr16:12623130	chr16:12560756~12611044:-
THYM	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-4.76	6.9e-06	0.0055	-0.4	-0.44	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
THYM	cis	rs7617773	0.925	rs34513961	ENSG00000228638.1	FCF1P2	-4.76	6.9e-06	0.0055	-0.5	-0.44	Coronary artery disease;	chr3:48132163	chr3:48290793~48291375:-
THYM	cis	rs867371	1	rs8041924	ENSG00000276710.3	CSPG4P8	-4.76	6.91e-06	0.0055	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs2088858	ENSG00000276710.3	CSPG4P8	-4.76	6.91e-06	0.0055	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs4778982	ENSG00000276710.3	CSPG4P8	-4.76	6.91e-06	0.0055	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs2867579	ENSG00000276710.3	CSPG4P8	-4.76	6.91e-06	0.0055	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs881308	ENSG00000276710.3	CSPG4P8	-4.76	6.91e-06	0.0055	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82459472~82477258:+
THYM	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	4.76	6.91e-06	0.0055	0.55	0.44	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
THYM	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-4.76	6.92e-06	0.00551	-0.56	-0.44	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
THYM	cis	rs995834	0.703	rs4806356	ENSG00000267243.4	AC005307.3	-4.76	6.92e-06	0.00551	-0.43	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397536	chr19:28435388~28727777:-
THYM	cis	rs6890684	0.569	rs34627	ENSG00000272308.1	RP11-231G3.1	-4.76	6.92e-06	0.00551	-0.38	-0.44	Intelligence (multi-trait analysis);	chr5:61232979	chr5:60866457~60866935:-
THYM	cis	rs6890684	0.569	rs159360	ENSG00000272308.1	RP11-231G3.1	-4.76	6.92e-06	0.00551	-0.38	-0.44	Intelligence (multi-trait analysis);	chr5:61233623	chr5:60866457~60866935:-
THYM	cis	rs7701440	0.512	rs10939886	ENSG00000272308.1	RP11-231G3.1	-4.76	6.92e-06	0.00551	-0.38	-0.44	Educational attainment;	chr5:61235738	chr5:60866457~60866935:-
THYM	cis	rs7701440	0.508	rs476099	ENSG00000272308.1	RP11-231G3.1	-4.76	6.92e-06	0.00551	-0.38	-0.44	Educational attainment;	chr5:61237147	chr5:60866457~60866935:-
THYM	cis	rs9659323	0.65	rs1155949	ENSG00000231365.4	RP11-418J17.1	-4.76	6.93e-06	0.00551	-0.46	-0.44	Body mass index;	chr1:118953956	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.596	rs11589179	ENSG00000231365.4	RP11-418J17.1	-4.76	6.93e-06	0.00551	-0.46	-0.44	Body mass index;	chr1:118954962	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.65	rs10923705	ENSG00000231365.4	RP11-418J17.1	-4.76	6.93e-06	0.00551	-0.46	-0.44	Body mass index;	chr1:118955781	chr1:119140396~119275973:+
THYM	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	4.76	6.93e-06	0.00551	0.98	0.44	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
THYM	cis	rs7701440	0.512	rs7444594	ENSG00000272308.1	RP11-231G3.1	-4.76	6.94e-06	0.00552	-0.38	-0.44	Educational attainment;	chr5:61238832	chr5:60866457~60866935:-
THYM	cis	rs6890684	0.569	rs6864489	ENSG00000272308.1	RP11-231G3.1	-4.76	6.94e-06	0.00552	-0.38	-0.44	Intelligence (multi-trait analysis);	chr5:61250143	chr5:60866457~60866935:-
THYM	cis	rs853679	0.55	rs9295762	ENSG00000182477.5	OR2B8P	-4.76	6.94e-06	0.00552	-0.64	-0.44	Depression;	chr6:28187640	chr6:28053228~28054165:-
THYM	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	4.76	6.94e-06	0.00552	0.38	0.44	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
THYM	cis	rs7701440	0.512	rs7443733	ENSG00000272308.1	RP11-231G3.1	-4.76	6.94e-06	0.00552	-0.38	-0.44	Educational attainment;	chr5:61238155	chr5:60866457~60866935:-
THYM	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-4.76	6.97e-06	0.00554	-0.6	-0.44	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
THYM	cis	rs42490	0.789	rs51331	ENSG00000251136.7	RP11-37B2.1	-4.76	7e-06	0.00556	-0.36	-0.44	Leprosy;	chr8:89801900	chr8:89609409~89757727:-
THYM	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	4.76	7e-06	0.00556	0.36	0.44	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
THYM	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	4.76	7.01e-06	0.00557	0.56	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
THYM	cis	rs61160187	0.51	rs4700393	ENSG00000272308.1	RP11-231G3.1	-4.76	7.02e-06	0.00557	-0.4	-0.44	Educational attainment (years of education);Educational attainment (college completion);	chr5:60802440	chr5:60866457~60866935:-
THYM	cis	rs72793342	1	rs72793342	ENSG00000235560.3	AC002310.12	-4.76	7.03e-06	0.00558	-0.37	-0.44	RANTES levels;	chr16:30537031	chr16:30534752~30537144:+
THYM	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	4.76	7.03e-06	0.00558	0.59	0.44	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
THYM	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-4.76	7.04e-06	0.00559	-0.52	-0.44	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
THYM	cis	rs3822625	0.541	rs76679228	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56903684	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs6450410	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56910874	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs2271202	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56912714	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs75167082	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56915577	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs1466010	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56917329	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs1466007	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56917812	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs12654125	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56919926	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs3756586	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56921369	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs74865790	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56923871	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs12657064	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56925172	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs79354983	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56925710	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs113772507	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56929449	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs16886510	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56932618	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs78075120	ENSG00000271828.1	CTD-2310F14.1	4.76	7.05e-06	0.00559	0.84	0.44	Breast cancer (early onset);	chr5:56932640	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs16886496	ENSG00000271828.1	CTD-2310F14.1	-4.76	7.05e-06	0.00559	-0.84	-0.44	Breast cancer (early onset);	chr5:56921702	chr5:56927874~56929573:+
THYM	cis	rs4853012	0.838	rs72911122	ENSG00000257702.3	LBX2-AS1	4.76	7.05e-06	0.00559	0.48	0.44	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74502595~74504678:+
THYM	cis	rs4853012	0.838	rs59570457	ENSG00000257702.3	LBX2-AS1	4.76	7.05e-06	0.00559	0.48	0.44	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74502595~74504678:+
THYM	cis	rs4853012	0.838	rs6707729	ENSG00000257702.3	LBX2-AS1	4.76	7.05e-06	0.00559	0.48	0.44	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74502595~74504678:+
THYM	cis	rs1950357	0.553	rs1160547	ENSG00000258601.1	RP11-81F13.2	4.76	7.06e-06	0.0056	0.44	0.44	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36747149	chr14:36808871~36828729:+
THYM	cis	rs2834288	0.5	rs7283594	ENSG00000237945.6	LINC00649	-4.76	7.06e-06	0.0056	-0.38	-0.44	Gut microbiota (bacterial taxa);	chr21:33962798	chr21:33915534~33977691:+
THYM	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-4.76	7.07e-06	0.00561	-0.45	-0.44	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
THYM	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-4.76	7.07e-06	0.00561	-0.45	-0.44	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
THYM	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-4.76	7.07e-06	0.00561	-0.45	-0.44	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
THYM	cis	rs995834	0.742	rs1971674	ENSG00000260725.1	AC005307.1	-4.76	7.08e-06	0.00561	-0.44	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28343033	chr19:28418483~28429490:-
THYM	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	4.76	7.08e-06	0.00562	0.55	0.44	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	4.76	7.08e-06	0.00562	0.55	0.44	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	4.76	7.08e-06	0.00562	0.55	0.44	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	4.76	7.08e-06	0.00562	0.55	0.44	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
THYM	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-4.76	7.11e-06	0.00563	-0.77	-0.44	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
THYM	cis	rs4853012	1	rs2280643	ENSG00000257702.3	LBX2-AS1	4.76	7.13e-06	0.00564	0.48	0.44	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74502595~74504678:+
THYM	cis	rs4853012	0.887	rs2280644	ENSG00000257702.3	LBX2-AS1	4.76	7.13e-06	0.00564	0.48	0.44	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74502595~74504678:+
THYM	cis	rs904251	0.734	rs2797790	ENSG00000279942.1	RP1-153P14.7	4.76	7.13e-06	0.00565	0.64	0.44	Cognitive performance;	chr6:37479299	chr6:37567716~37571460:+
THYM	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
THYM	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	4.75	7.15e-06	0.00566	0.59	0.44	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
THYM	cis	rs9376098	0.825	rs7764187	ENSG00000232876.1	CTA-212D2.2	-4.75	7.15e-06	0.00566	-0.49	-0.44	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135162604	chr6:135055033~135060550:+
THYM	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	4.75	7.16e-06	0.00567	0.67	0.44	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
THYM	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.638	rs6732435	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541501	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs59017643	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546835	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs2173773	ENSG00000223466.1	AC064834.2	-4.75	7.19e-06	0.00568	-0.55	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549701	chr2:195533035~195538681:+
THYM	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	4.75	7.2e-06	0.00569	0.53	0.44	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
THYM	cis	rs957448	0.748	rs12680342	ENSG00000253704.1	RP11-267M23.4	4.75	7.2e-06	0.00569	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94347410	chr8:94553722~94569745:+
THYM	cis	rs995834	0.742	rs4806342	ENSG00000267243.4	AC005307.3	-4.75	7.2e-06	0.00569	-0.41	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28384461	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs11083471	ENSG00000267243.4	AC005307.3	-4.75	7.2e-06	0.00569	-0.41	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28385094	chr19:28435388~28727777:-
THYM	cis	rs8113308	1	rs7246064	ENSG00000269235.1	ZNF350-AS1	4.75	7.2e-06	0.00569	0.43	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939009	chr19:51949134~51981367:+
THYM	cis	rs8113308	1	rs6509600	ENSG00000269235.1	ZNF350-AS1	4.75	7.2e-06	0.00569	0.43	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939336	chr19:51949134~51981367:+
THYM	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-4.75	7.21e-06	0.00569	-0.58	-0.44	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
THYM	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	4.75	7.21e-06	0.0057	0.48	0.44	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
THYM	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
THYM	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
THYM	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	4.75	7.22e-06	0.0057	0.57	0.44	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
THYM	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-4.75	7.23e-06	0.00571	-0.54	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
THYM	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-4.75	7.24e-06	0.00571	-0.58	-0.44	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
THYM	cis	rs992157	0.764	rs1870124	ENSG00000261338.2	RP11-378A13.1	4.75	7.25e-06	0.00573	0.57	0.44	Colorectal cancer;	chr2:218323017	chr2:218255319~218257366:+
THYM	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-4.75	7.28e-06	0.00574	-0.55	-0.44	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
THYM	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-4.75	7.28e-06	0.00574	-0.55	-0.44	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
THYM	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-4.75	7.28e-06	0.00574	-0.55	-0.44	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-4.75	7.28e-06	0.00574	-0.55	-0.44	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-4.75	7.28e-06	0.00574	-0.55	-0.44	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
THYM	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	4.75	7.3e-06	0.00576	0.45	0.44	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
THYM	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	4.75	7.3e-06	0.00576	0.45	0.44	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	4.75	7.3e-06	0.00576	0.45	0.44	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
THYM	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-4.75	7.3e-06	0.00576	-0.45	-0.44	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-4.75	7.3e-06	0.00576	-0.45	-0.44	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
THYM	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-4.75	7.32e-06	0.00577	-0.42	-0.44	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
THYM	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-4.75	7.32e-06	0.00577	-0.56	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
THYM	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-4.75	7.33e-06	0.00578	-0.46	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
THYM	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	4.75	7.33e-06	0.00578	0.43	0.44	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
THYM	cis	rs9535495	0.93	rs7989991	ENSG00000200711.1	RNA5SP28	-4.75	7.34e-06	0.00579	-0.48	-0.44	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50809807	chr13:50812988~50813106:-
THYM	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	4.75	7.34e-06	0.00579	0.52	0.44	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
THYM	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-4.75	7.34e-06	0.00579	-0.56	-0.44	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
THYM	cis	rs11017328	0.5	rs10829754	ENSG00000236303.2	RP11-540N6.1	-4.75	7.36e-06	0.0058	-0.6	-0.44	Conotruncal heart defects;	chr10:130500363	chr10:130439067~130483154:+
THYM	cis	rs4853012	0.775	rs12465641	ENSG00000257702.3	LBX2-AS1	-4.75	7.38e-06	0.00581	-0.51	-0.44	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74502595~74504678:+
THYM	cis	rs8113308	0.81	rs10411484	ENSG00000269235.1	ZNF350-AS1	4.75	7.38e-06	0.00581	0.54	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940152	chr19:51949134~51981367:+
THYM	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	4.75	7.39e-06	0.00582	0.51	0.44	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
THYM	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
THYM	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
THYM	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
THYM	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
THYM	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
THYM	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
THYM	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
THYM	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
THYM	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
THYM	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
THYM	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-4.75	7.39e-06	0.00582	-0.46	-0.44	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
THYM	cis	rs599083	0.59	rs10791984	ENSG00000222339.1	AP000807.2	-4.75	7.41e-06	0.00583	-0.49	-0.44	Bone mineral density (spine);	chr11:68640367	chr11:68505572~68505651:-
THYM	cis	rs12908161	1	rs17601029	ENSG00000235370.6	DNM1P51	4.75	7.41e-06	0.00583	0.59	0.44	Schizophrenia;	chr15:84804478	chr15:84398316~84411701:-
THYM	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	4.75	7.41e-06	0.00583	0.41	0.44	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
THYM	cis	rs9876781	1	rs9883759	ENSG00000244380.1	RP11-24C3.2	4.75	7.41e-06	0.00583	0.59	0.44	Longevity;	chr3:48422209	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs6442120	ENSG00000244380.1	RP11-24C3.2	4.75	7.41e-06	0.00583	0.59	0.44	Longevity;	chr3:48423094	chr3:48440352~48446656:-
THYM	cis	rs9876781	0.9	rs1037773	ENSG00000244380.1	RP11-24C3.2	4.75	7.41e-06	0.00583	0.59	0.44	Longevity;	chr3:48426493	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs2279077	ENSG00000244380.1	RP11-24C3.2	4.75	7.41e-06	0.00583	0.59	0.44	Longevity;	chr3:48432839	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs1109227	ENSG00000244380.1	RP11-24C3.2	4.75	7.41e-06	0.00583	0.59	0.44	Longevity;	chr3:48437797	chr3:48440352~48446656:-
THYM	cis	rs9876781	0.967	rs9876891	ENSG00000244380.1	RP11-24C3.2	4.75	7.41e-06	0.00583	0.59	0.44	Longevity;	chr3:48440024	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs3774808	ENSG00000244380.1	RP11-24C3.2	4.75	7.41e-06	0.00583	0.59	0.44	Longevity;	chr3:48440237	chr3:48440352~48446656:-
THYM	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	4.75	7.41e-06	0.00583	0.78	0.44	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
THYM	cis	rs9535495	1	rs7990306	ENSG00000200711.1	RNA5SP28	-4.75	7.42e-06	0.00583	-0.49	-0.44	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50809874	chr13:50812988~50813106:-
THYM	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	4.75	7.42e-06	0.00583	0.75	0.44	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
THYM	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	4.75	7.42e-06	0.00583	0.51	0.44	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
THYM	cis	rs4835473	0.932	rs1450235	ENSG00000251600.4	RP11-673E1.1	4.75	7.43e-06	0.00583	0.49	0.44	Immature fraction of reticulocytes;	chr4:143782927	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs4054616	ENSG00000251600.4	RP11-673E1.1	4.75	7.43e-06	0.00583	0.49	0.44	Immature fraction of reticulocytes;	chr4:143837472	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs2323325	ENSG00000251600.4	RP11-673E1.1	4.75	7.43e-06	0.00583	0.49	0.44	Immature fraction of reticulocytes;	chr4:143837561	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.8	rs4835330	ENSG00000251600.4	RP11-673E1.1	4.75	7.43e-06	0.00583	0.49	0.44	Immature fraction of reticulocytes;	chr4:143846303	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.736	rs6851661	ENSG00000251600.4	RP11-673E1.1	4.75	7.43e-06	0.00583	0.49	0.44	Immature fraction of reticulocytes;	chr4:143850587	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11730929	ENSG00000251600.4	RP11-673E1.1	-4.75	7.43e-06	0.00583	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143834795	chr4:143912331~143982454:+
THYM	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-4.74	7.43e-06	0.00583	-0.43	-0.44	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
THYM	cis	rs2115630	0.691	rs61322921	ENSG00000275120.1	RP11-182J1.17	-4.74	7.44e-06	0.00583	-0.51	-0.44	P wave terminal force;	chr15:84620407	chr15:84599434~84606463:-
THYM	cis	rs12439619	1	rs12439619	ENSG00000274376.3	ADAMTS7P1	4.74	7.44e-06	0.00583	0.45	0.44	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82298553~82334609:+
THYM	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	4.74	7.45e-06	0.00584	0.57	0.44	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
THYM	cis	rs950169	0.84	rs12905223	ENSG00000235370.6	DNM1P51	4.74	7.46e-06	0.00585	0.56	0.44	Schizophrenia;	chr15:84571037	chr15:84398316~84411701:-
THYM	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-4.74	7.46e-06	0.00585	-0.58	-0.44	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
THYM	cis	rs10129255	0.536	rs6576201	ENSG00000253703.1	IGHV1-68	4.74	7.46e-06	0.00585	0.49	0.44	Kawasaki disease;	chr14:106683696	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.556	rs9324093	ENSG00000253703.1	IGHV1-68	-4.74	7.46e-06	0.00585	-0.49	-0.44	Kawasaki disease;	chr14:106683893	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.536	rs8004835	ENSG00000253703.1	IGHV1-68	-4.74	7.46e-06	0.00585	-0.49	-0.44	Kawasaki disease;	chr14:106686361	chr14:106703852~106704146:-
THYM	cis	rs2115630	0.645	rs3825877	ENSG00000275120.1	RP11-182J1.17	-4.74	7.46e-06	0.00585	-0.51	-0.44	P wave terminal force;	chr15:84631400	chr15:84599434~84606463:-
THYM	cis	rs2115630	0.645	rs3825878	ENSG00000275120.1	RP11-182J1.17	-4.74	7.46e-06	0.00585	-0.51	-0.44	P wave terminal force;	chr15:84631524	chr15:84599434~84606463:-
THYM	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-4.74	7.46e-06	0.00585	-0.51	-0.44	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
THYM	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	4.74	7.47e-06	0.00586	0.52	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-4.74	7.47e-06	0.00586	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-4.74	7.47e-06	0.00586	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-4.74	7.47e-06	0.00586	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-4.74	7.47e-06	0.00586	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-4.74	7.47e-06	0.00586	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-4.74	7.47e-06	0.00586	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-4.74	7.47e-06	0.00586	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
THYM	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-4.74	7.48e-06	0.00586	-0.47	-0.44	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
THYM	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-4.74	7.48e-06	0.00586	-0.65	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
THYM	cis	rs10463554	0.501	rs6860813	ENSG00000175749.11	EIF3KP1	4.74	7.48e-06	0.00586	0.5	0.44	Parkinson's disease;	chr5:103353125	chr5:103032376~103033031:+
THYM	cis	rs10129255	0.509	rs756583	ENSG00000253703.1	IGHV1-68	-4.74	7.49e-06	0.00587	-0.49	-0.44	Kawasaki disease;	chr14:106680002	chr14:106703852~106704146:-
THYM	cis	rs7851726	0.738	rs4744370	ENSG00000232063.1	RP11-307E17.8	-4.74	7.49e-06	0.00587	-0.46	-0.44	Urinary albumin-to-creatinine ratio;	chr9:94715511	chr9:94332476~94360948:+
THYM	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	4.74	7.49e-06	0.00587	0.58	0.44	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
THYM	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	4.74	7.49e-06	0.00587	0.58	0.44	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
THYM	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	4.74	7.51e-06	0.00588	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	4.74	7.51e-06	0.00588	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	4.74	7.51e-06	0.00588	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
THYM	cis	rs4835473	0.897	rs36083752	ENSG00000251600.4	RP11-673E1.1	-4.74	7.51e-06	0.00588	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143693377	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs35162238	ENSG00000251600.4	RP11-673E1.1	-4.74	7.51e-06	0.00588	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143693518	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs1545437	ENSG00000251600.4	RP11-673E1.1	-4.74	7.51e-06	0.00588	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143696689	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs61427459	ENSG00000251600.4	RP11-673E1.1	-4.74	7.51e-06	0.00588	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143699605	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs11100802	ENSG00000251600.4	RP11-673E1.1	-4.74	7.51e-06	0.00588	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143700046	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	4.74	7.51e-06	0.00588	0.51	0.44	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7657088	ENSG00000251600.4	RP11-673E1.1	-4.74	7.51e-06	0.00588	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143701877	chr4:143912331~143982454:+
THYM	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	4.74	7.53e-06	0.0059	0.5	0.44	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
THYM	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	4.74	7.53e-06	0.0059	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
THYM	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	4.74	7.53e-06	0.0059	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
THYM	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	4.74	7.53e-06	0.0059	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
THYM	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	4.74	7.53e-06	0.0059	0.32	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
THYM	cis	rs1519814	0.74	rs2326433	ENSG00000254343.2	RP11-760H22.2	-4.74	7.54e-06	0.0059	-0.63	-0.44	Breast cancer;	chr8:120031484	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.74	rs4348544	ENSG00000254343.2	RP11-760H22.2	-4.74	7.54e-06	0.0059	-0.63	-0.44	Breast cancer;	chr8:120031851	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.702	rs4871032	ENSG00000254343.2	RP11-760H22.2	4.74	7.54e-06	0.0059	0.63	0.44	Breast cancer;	chr8:120029835	chr8:120052180~120056201:+
THYM	cis	rs4478858	0.654	rs113490486	ENSG00000260386.4	LINC01225	4.74	7.55e-06	0.00591	0.24	0.44	Alcohol dependence;	chr1:31240016	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.602	rs6425723	ENSG00000260386.4	LINC01225	4.74	7.55e-06	0.00591	0.24	0.44	Alcohol dependence;	chr1:31242357	chr1:31500085~31540885:+
THYM	cis	rs10129255	0.536	rs10139058	ENSG00000253703.1	IGHV1-68	-4.74	7.56e-06	0.00592	-0.49	-0.44	Kawasaki disease;	chr14:106685899	chr14:106703852~106704146:-
THYM	cis	rs295140	0.605	rs159321	ENSG00000232732.8	AC073043.1	4.74	7.57e-06	0.00592	0.57	0.44	QT interval;	chr2:200319990	chr2:199867396~199911159:-
THYM	cis	rs2662776	1	rs10753609	ENSG00000232995.6	RGS5	-4.74	7.57e-06	0.00592	-0.38	-0.44	Lead levels in blood;	chr1:163190547	chr1:163244505~163321894:-
THYM	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	4.74	7.58e-06	0.00593	0.43	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
THYM	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-4.74	7.58e-06	0.00593	-0.38	-0.44	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-4.74	7.58e-06	0.00593	-0.38	-0.44	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
THYM	cis	rs4663866	1	rs4663866	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238242174	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.908	rs35093813	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238245124	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs4663867	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238251323	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs4663868	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238252450	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs71426509	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238266693	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs13026475	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238269814	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs71426510	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238270268	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs6741269	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238270777	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.803	rs71426511	ENSG00000186235.9	AC016757.3	4.74	7.59e-06	0.00593	1	0.44	Irritable bowel syndrome;	chr2:238271559	chr2:238224552~238231677:-
THYM	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-4.74	7.6e-06	0.00595	-0.51	-0.44	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
THYM	cis	rs7989332	1	rs4769117	ENSG00000279065.1	RP11-264J4.10	-4.74	7.61e-06	0.00595	-0.54	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20480585	chr13:20194412~20196005:+
THYM	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	4.74	7.64e-06	0.00597	0.69	0.44	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
THYM	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-4.74	7.65e-06	0.00598	-0.51	-0.44	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
THYM	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-4.74	7.65e-06	0.00598	-0.54	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
THYM	cis	rs7937127	0.649	rs56109100	ENSG00000254907.1	RP11-484D2.2	4.74	7.67e-06	0.00599	0.68	0.44	Fibrinogen levels;	chr11:43325490	chr11:43328748~43359296:-
THYM	cis	rs4908768	0.539	rs6666191	ENSG00000232912.4	RP5-1115A15.1	4.74	7.67e-06	0.00599	0.44	0.44	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8424645~8434838:+
THYM	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	4.74	7.67e-06	0.00599	0.47	0.44	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	4.74	7.67e-06	0.00599	0.47	0.44	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	4.74	7.67e-06	0.00599	0.47	0.44	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
THYM	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	4.74	7.68e-06	0.006	0.45	0.44	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
THYM	cis	rs7429990	0.833	rs3732530	ENSG00000229759.1	MRPS18AP1	-4.74	7.68e-06	0.006	-0.36	-0.44	Educational attainment (years of education);	chr3:47577463	chr3:48256350~48256938:-
THYM	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	4.74	7.69e-06	0.006	0.64	0.44	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
THYM	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	4.74	7.69e-06	0.00601	0.37	0.44	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
THYM	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	4.74	7.69e-06	0.00601	0.45	0.44	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
THYM	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	4.74	7.69e-06	0.00601	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
THYM	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	4.74	7.69e-06	0.00601	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
THYM	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-4.74	7.7e-06	0.00601	-0.41	-0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
THYM	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-4.74	7.71e-06	0.00602	-0.5	-0.44	Height;	chr6:109405874	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	4.74	7.71e-06	0.00602	0.5	0.44	Height;	chr6:109382524	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	4.74	7.71e-06	0.00602	0.5	0.44	Height;	chr6:109384228	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	4.74	7.71e-06	0.00602	0.5	0.44	Height;	chr6:109385087	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	4.74	7.71e-06	0.00602	0.5	0.44	Height;	chr6:109387685	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	4.74	7.71e-06	0.00602	0.5	0.44	Height;	chr6:109388256	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	4.74	7.71e-06	0.00602	0.5	0.44	Height;	chr6:109407148	chr6:109382795~109383666:+
THYM	cis	rs6657613	0.967	rs7550758	ENSG00000186715.9	MST1L	-4.74	7.72e-06	0.00602	-0.55	-0.44	Hip circumference adjusted for BMI;	chr1:17000934	chr1:16754910~16770237:-
THYM	cis	rs6657613	1	rs6657613	ENSG00000186715.9	MST1L	-4.74	7.72e-06	0.00602	-0.55	-0.44	Hip circumference adjusted for BMI;	chr1:17001705	chr1:16754910~16770237:-
THYM	cis	rs5769707	0.967	rs2187891	ENSG00000264139.1	MIR3667	-4.74	7.72e-06	0.00603	-0.49	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49543393~49543466:-
THYM	cis	rs4853012	0.838	rs4429500	ENSG00000257702.3	LBX2-AS1	4.74	7.73e-06	0.00603	0.46	0.44	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74502595~74504678:+
THYM	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	4.74	7.73e-06	0.00603	0.35	0.44	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-4.74	7.73e-06	0.00603	-0.35	-0.44	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-4.74	7.73e-06	0.00603	-0.35	-0.44	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-4.74	7.73e-06	0.00603	-0.35	-0.44	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
THYM	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-4.74	7.73e-06	0.00603	-0.35	-0.44	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-4.74	7.73e-06	0.00603	-0.35	-0.44	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-4.74	7.73e-06	0.00603	-0.35	-0.44	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-4.74	7.73e-06	0.00603	-0.35	-0.44	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
THYM	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	4.73	7.74e-06	0.00604	0.36	0.44	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	4.73	7.74e-06	0.00604	0.36	0.44	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	4.73	7.74e-06	0.00604	0.36	0.44	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	4.73	7.74e-06	0.00604	0.36	0.44	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	4.73	7.74e-06	0.00604	0.36	0.44	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
THYM	cis	rs12655019	0.92	rs74455703	ENSG00000271828.1	CTD-2310F14.1	4.73	7.74e-06	0.00604	0.85	0.44	Breast cancer (early onset);	chr5:56949442	chr5:56927874~56929573:+
THYM	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	4.73	7.75e-06	0.00605	0.57	0.44	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	4.73	7.75e-06	0.00605	0.57	0.44	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	4.73	7.75e-06	0.00605	0.57	0.44	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	4.73	7.75e-06	0.00605	0.57	0.44	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
THYM	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	4.73	7.75e-06	0.00605	0.57	0.44	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	4.73	7.75e-06	0.00605	0.57	0.44	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	4.73	7.75e-06	0.00605	0.57	0.44	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
THYM	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	4.73	7.76e-06	0.00605	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	4.73	7.76e-06	0.00605	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	4.73	7.76e-06	0.00605	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
THYM	cis	rs7937127	0.744	rs5743236	ENSG00000254907.1	RP11-484D2.2	4.73	7.76e-06	0.00605	0.69	0.44	Fibrinogen levels;	chr11:43326772	chr11:43328748~43359296:-
THYM	cis	rs10129255	0.5	rs1974468	ENSG00000254329.1	IGHVII-60-1	4.73	7.77e-06	0.00605	0.38	0.44	Kawasaki disease;	chr14:106686149	chr14:106637718~106637973:-
THYM	cis	rs17253792	0.822	rs17746106	ENSG00000186615.9	KTN1-AS1	-4.73	7.77e-06	0.00606	-0.82	-0.44	Putamen volume;	chr14:55602450	chr14:55499278~55580110:-
THYM	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	4.73	7.77e-06	0.00606	0.49	0.44	Height;	chr6:109415411	chr6:109382795~109383666:+
THYM	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	4.73	7.78e-06	0.00606	0.58	0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
THYM	cis	rs10129255	0.5	rs8021941	ENSG00000254329.1	IGHVII-60-1	4.73	7.79e-06	0.00607	0.38	0.44	Kawasaki disease;	chr14:106781490	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs10142931	ENSG00000254329.1	IGHVII-60-1	4.73	7.79e-06	0.00607	0.38	0.44	Kawasaki disease;	chr14:106782288	chr14:106637718~106637973:-
THYM	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	4.73	7.8e-06	0.00608	0.56	0.44	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
THYM	cis	rs950169	0.58	rs2271431	ENSG00000235370.6	DNM1P51	4.73	7.84e-06	0.00611	0.58	0.44	Schizophrenia;	chr15:84646233	chr15:84398316~84411701:-
THYM	cis	rs9907295	0.818	rs4796112	ENSG00000270871.1	AC015849.19	-4.73	7.85e-06	0.00611	-0.47	-0.44	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs9303692	ENSG00000270871.1	AC015849.19	-4.73	7.85e-06	0.00611	-0.4	-0.44	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.748	rs4251719	ENSG00000270871.1	AC015849.19	4.73	7.85e-06	0.00611	0.4	0.44	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.748	rs4251769	ENSG00000270871.1	AC015849.19	4.73	7.85e-06	0.00611	0.4	0.44	Fibroblast growth factor basic levels;	chr17:35837523	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs4795093	ENSG00000270871.1	AC015849.19	4.73	7.85e-06	0.00611	0.4	0.44	Fibroblast growth factor basic levels;	chr17:35853137	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs2306630	ENSG00000270871.1	AC015849.19	4.73	7.85e-06	0.00611	0.4	0.44	Fibroblast growth factor basic levels;	chr17:35855337	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs9909416	ENSG00000270871.1	AC015849.19	4.73	7.85e-06	0.00611	0.4	0.44	Fibroblast growth factor basic levels;	chr17:35870979	chr17:35816717~35830293:-
THYM	cis	rs4835473	0.932	rs4092718	ENSG00000246448.2	RP13-578N3.3	4.73	7.85e-06	0.00611	0.56	0.44	Immature fraction of reticulocytes;	chr4:143799637	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs4585249	ENSG00000249741.2	RP11-673E1.3	4.73	7.86e-06	0.00611	0.37	0.44	Immature fraction of reticulocytes;	chr4:143981173	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34617134	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143983606	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.736	rs11724009	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143984291	chr4:143911514~143912053:-
THYM	cis	rs4323050	0.514	rs28647406	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.604	rs11938387	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143984476	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.798	rs11100829	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143984761	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1511425	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143985122	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1849120	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143985337	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4835476	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143985517	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1828502	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143985797	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7668698	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143986333	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6537231	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143986489	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1877234	ENSG00000249741.2	RP11-673E1.3	-4.73	7.86e-06	0.00611	-0.37	-0.44	Immature fraction of reticulocytes;	chr4:143986774	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1877235	ENSG00000249741.2	RP11-673E1.3	4.73	7.86e-06	0.00611	0.37	0.44	Immature fraction of reticulocytes;	chr4:143986961	chr4:143911514~143912053:-
THYM	cis	rs8113308	1	rs8113308	ENSG00000269235.1	ZNF350-AS1	4.73	7.87e-06	0.00612	0.43	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942133	chr19:51949134~51981367:+
THYM	cis	rs10129255	0.536	rs3944157	ENSG00000253703.1	IGHV1-68	-4.73	7.87e-06	0.00612	-0.49	-0.44	Kawasaki disease;	chr14:106682286	chr14:106703852~106704146:-
THYM	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-4.73	7.88e-06	0.00613	-0.42	-0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
THYM	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	4.73	7.89e-06	0.00613	0.51	0.44	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
THYM	cis	rs9907295	0.818	rs4251737	ENSG00000270871.1	AC015849.19	4.73	7.9e-06	0.00614	0.4	0.44	Fibroblast growth factor basic levels;	chr17:35819814	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs9889874	ENSG00000270871.1	AC015849.19	4.73	7.9e-06	0.00614	0.4	0.44	Fibroblast growth factor basic levels;	chr17:35875293	chr17:35816717~35830293:-
THYM	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-4.73	7.9e-06	0.00614	-0.47	-0.44	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
THYM	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	4.73	7.94e-06	0.00617	0.56	0.44	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
THYM	cis	rs995834	0.701	rs6508799	ENSG00000267243.4	AC005307.3	-4.73	7.95e-06	0.00618	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28360493	chr19:28435388~28727777:-
THYM	cis	rs9907295	0.591	rs3817655	ENSG00000270977.1	AC015849.16	4.73	7.95e-06	0.00618	0.59	0.44	Fibroblast growth factor basic levels;	chr17:35872637	chr17:35893707~35911023:-
THYM	cis	rs7202877	0.706	rs8046184	ENSG00000261783.1	RP11-252K23.2	-4.73	7.95e-06	0.00618	-0.61	-0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75377827	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs4888393	ENSG00000261783.1	RP11-252K23.2	-4.73	7.95e-06	0.00618	-0.61	-0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75379775	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.656	rs4888394	ENSG00000261783.1	RP11-252K23.2	-4.73	7.95e-06	0.00618	-0.61	-0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75379811	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.611	rs4888395	ENSG00000261783.1	RP11-252K23.2	-4.73	7.95e-06	0.00618	-0.61	-0.44	Type 1 diabetes;Type 2 diabetes;	chr16:75379817	chr16:75379818~75381260:-
THYM	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-4.73	7.96e-06	0.00618	-0.78	-0.44	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
THYM	cis	rs867371	0.964	rs7169961	ENSG00000276710.3	CSPG4P8	-4.73	7.97e-06	0.00619	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs6495643	ENSG00000276710.3	CSPG4P8	-4.73	7.97e-06	0.00619	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82459472~82477258:+
THYM	cis	rs8177876	0.749	rs76892049	ENSG00000261838.4	RP11-303E16.6	4.73	7.98e-06	0.0062	0.95	0.44	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81069854~81076598:+
THYM	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-4.73	7.99e-06	0.0062	-0.47	-0.44	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	4.73	7.99e-06	0.0062	0.47	0.44	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	4.73	7.99e-06	0.0062	0.47	0.44	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	4.73	7.99e-06	0.0062	0.47	0.44	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
THYM	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	4.73	7.99e-06	0.0062	0.52	0.44	Height;	chr6:109370985	chr6:109382795~109383666:+
THYM	cis	rs7927592	0.731	rs11228275	ENSG00000222339.1	AP000807.2	-4.73	8e-06	0.00621	-0.5	-0.44	Total body bone mineral density;	chr11:68536512	chr11:68505572~68505651:-
THYM	cis	rs4663866	1	rs4663300	ENSG00000186235.9	AC016757.3	4.73	8e-06	0.00621	0.98	0.44	Irritable bowel syndrome;	chr2:238272850	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs13033501	ENSG00000186235.9	AC016757.3	4.73	8e-06	0.00621	0.98	0.44	Irritable bowel syndrome;	chr2:238273219	chr2:238224552~238231677:-
THYM	cis	rs4663866	1	rs34897410	ENSG00000186235.9	AC016757.3	4.73	8e-06	0.00621	0.98	0.44	Irritable bowel syndrome;	chr2:238273482	chr2:238224552~238231677:-
THYM	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	4.73	8.02e-06	0.00622	0.37	0.44	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
THYM	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	4.73	8.03e-06	0.00623	0.5	0.44	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
THYM	cis	rs7849270	0.84	rs12346996	ENSG00000268707.1	RP11-247A12.7	-4.73	8.03e-06	0.00623	-0.59	-0.44	Blood metabolite ratios;	chr9:129078577	chr9:129170434~129170940:+
THYM	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-4.73	8.04e-06	0.00624	-0.48	-0.44	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
THYM	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	4.73	8.05e-06	0.00624	0.61	0.44	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
THYM	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	4.72	8.06e-06	0.00625	0.54	0.44	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
THYM	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-4.72	8.06e-06	0.00625	-0.46	-0.44	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
THYM	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-4.72	8.09e-06	0.00627	-0.39	-0.44	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
THYM	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-4.72	8.09e-06	0.00627	-0.39	-0.44	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
THYM	cis	rs4908760	0.965	rs1884352	ENSG00000232912.4	RP5-1115A15.1	4.72	8.11e-06	0.00629	0.44	0.44	Vitiligo;	chr1:8477229	chr1:8424645~8434838:+
THYM	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	4.72	8.13e-06	0.0063	0.35	0.44	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
THYM	cis	rs1529093	1	rs12105278	ENSG00000222043.2	AC079305.10	-4.72	8.13e-06	0.0063	-0.36	-0.44	Non-alcoholic fatty liver disease histology (other);	chr2:177064463	chr2:177264359~177265515:+
THYM	cis	rs1529093	1	rs1358622	ENSG00000222043.2	AC079305.10	-4.72	8.13e-06	0.0063	-0.36	-0.44	Non-alcoholic fatty liver disease histology (other);	chr2:177065461	chr2:177264359~177265515:+
THYM	cis	rs13287066	0.692	rs4563950	ENSG00000227603.1	RP11-165J3.6	4.72	8.14e-06	0.0063	0.36	0.44	Intelligence (multi-trait analysis);	chr9:93405359	chr9:93435332~93437121:-
THYM	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-4.72	8.14e-06	0.00631	-0.63	-0.44	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
THYM	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-4.72	8.15e-06	0.00632	-0.39	-0.44	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
THYM	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	4.72	8.17e-06	0.00633	0.33	0.44	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
THYM	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	4.72	8.17e-06	0.00633	0.33	0.44	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
THYM	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	4.72	8.17e-06	0.00633	0.33	0.44	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
THYM	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	4.72	8.17e-06	0.00633	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
THYM	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	4.72	8.18e-06	0.00633	0.45	0.44	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
THYM	cis	rs361433	0.541	rs7793482	ENSG00000253534.1	TRBV6-8	4.72	8.19e-06	0.00634	0.48	0.44	Capecitabine sensitivity;	chr7:142490440	chr7:142507382~142507810:+
THYM	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	4.72	8.21e-06	0.00636	0.54	0.44	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
THYM	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	4.72	8.22e-06	0.00636	0.49	0.44	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-4.72	8.22e-06	0.00636	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-4.72	8.22e-06	0.00636	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-4.72	8.22e-06	0.00636	-0.49	-0.44	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
THYM	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-4.72	8.23e-06	0.00637	-0.49	-0.44	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
THYM	cis	rs4927850	0.829	rs6768483	ENSG00000231464.1	AC024937.4	4.72	8.23e-06	0.00637	0.59	0.44	Pancreatic cancer;	chr3:196019092	chr3:195996738~195998233:+
THYM	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-4.72	8.24e-06	0.00637	-0.48	-0.44	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-4.72	8.24e-06	0.00637	-0.48	-0.44	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-4.72	8.24e-06	0.00637	-0.48	-0.44	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-4.72	8.24e-06	0.00637	-0.48	-0.44	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-4.72	8.24e-06	0.00637	-0.48	-0.44	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-4.72	8.24e-06	0.00637	-0.48	-0.44	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
THYM	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	4.72	8.24e-06	0.00637	0.36	0.44	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
THYM	cis	rs853679	0.517	rs9283884	ENSG00000182477.5	OR2B8P	-4.72	8.26e-06	0.00638	-0.64	-0.44	Depression;	chr6:28167882	chr6:28053228~28054165:-
THYM	cis	rs4700393	0.517	rs13158594	ENSG00000272308.1	RP11-231G3.1	4.72	8.26e-06	0.00639	0.56	0.44	Intelligence (multi-trait analysis);	chr5:60794183	chr5:60866457~60866935:-
THYM	cis	rs4700393	0.517	rs12523070	ENSG00000272308.1	RP11-231G3.1	4.72	8.26e-06	0.00639	0.56	0.44	Intelligence (multi-trait analysis);	chr5:60795496	chr5:60866457~60866935:-
THYM	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	4.72	8.28e-06	0.00639	0.64	0.44	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
THYM	cis	rs992157	0.932	rs1870125	ENSG00000261338.2	RP11-378A13.1	4.72	8.3e-06	0.00641	0.57	0.44	Colorectal cancer;	chr2:218323178	chr2:218255319~218257366:+
THYM	cis	rs992157	0.932	rs10194082	ENSG00000261338.2	RP11-378A13.1	4.72	8.3e-06	0.00641	0.57	0.44	Colorectal cancer;	chr2:218323854	chr2:218255319~218257366:+
THYM	cis	rs992157	0.932	rs1473901	ENSG00000261338.2	RP11-378A13.1	4.72	8.3e-06	0.00641	0.57	0.44	Colorectal cancer;	chr2:218324115	chr2:218255319~218257366:+
THYM	cis	rs4713118	0.662	rs156744	ENSG00000182477.5	OR2B8P	4.72	8.3e-06	0.00641	0.58	0.44	Parkinson's disease;	chr6:27999496	chr6:28053228~28054165:-
THYM	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-4.72	8.31e-06	0.00642	-0.51	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-4.72	8.31e-06	0.00642	-0.51	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
THYM	cis	rs4948275	0.55	rs10994742	ENSG00000237233.2	TMEM26-AS1	4.72	8.34e-06	0.00644	0.46	0.44	Night sleep phenotypes;	chr10:61372482	chr10:61452639~61481956:+
THYM	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-4.72	8.34e-06	0.00644	-0.69	-0.44	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
THYM	cis	rs972578	0.837	rs1018448	ENSG00000215347.3	SLC25A5P1	-4.72	8.36e-06	0.00645	-0.35	-0.44	Mean platelet volume;	chr22:42810944	chr22:42001069~42001966:-
THYM	cis	rs8113308	0.81	rs17695737	ENSG00000269235.1	ZNF350-AS1	4.72	8.36e-06	0.00645	0.53	0.44	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51949134~51981367:+
THYM	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	4.71	8.38e-06	0.00647	0.57	0.44	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
THYM	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-4.71	8.39e-06	0.00647	-0.36	-0.44	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
THYM	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-4.71	8.39e-06	0.00647	-0.4	-0.44	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
THYM	cis	rs995834	0.743	rs4555267	ENSG00000267243.4	AC005307.3	-4.71	8.4e-06	0.00648	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28374933	chr19:28435388~28727777:-
THYM	cis	rs995834	0.784	rs4141219	ENSG00000267243.4	AC005307.3	-4.71	8.4e-06	0.00648	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28375247	chr19:28435388~28727777:-
THYM	cis	rs995834	0.789	rs2041195	ENSG00000267243.4	AC005307.3	-4.71	8.4e-06	0.00648	-0.4	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28376305	chr19:28435388~28727777:-
THYM	cis	rs4478858	0.647	rs12752761	ENSG00000260386.4	LINC01225	4.71	8.4e-06	0.00648	0.24	0.44	Alcohol dependence;	chr1:31238041	chr1:31500085~31540885:+
THYM	cis	rs1320333	0.772	rs35181861	ENSG00000233296.1	AC092159.2	4.71	8.41e-06	0.00648	0.76	0.44	Obesity-related traits;	chr2:679483	chr2:677186~697371:+
THYM	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	4.71	8.41e-06	0.00648	0.76	0.44	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
THYM	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	4.71	8.41e-06	0.00648	0.76	0.44	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
THYM	cis	rs8067545	0.967	rs1034904	ENSG00000231645.2	KRT17P6	4.71	8.41e-06	0.00649	0.5	0.44	Schizophrenia;	chr17:20024386	chr17:20512560~20517479:-
THYM	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	4.71	8.41e-06	0.00649	0.57	0.44	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
THYM	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	4.71	8.42e-06	0.0065	0.77	0.44	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
THYM	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-4.71	8.42e-06	0.0065	-0.77	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
THYM	cis	rs526231	0.857	rs2569013	ENSG00000175749.11	EIF3KP1	4.71	8.43e-06	0.00651	0.55	0.44	Primary biliary cholangitis;	chr5:103305870	chr5:103032376~103033031:+
THYM	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	4.71	8.44e-06	0.00651	0.6	0.44	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
THYM	cis	rs950169	0.614	rs765524	ENSG00000235370.6	DNM1P51	4.71	8.46e-06	0.00652	0.63	0.44	Schizophrenia;	chr15:84013030	chr15:84398316~84411701:-
THYM	cis	rs950169	0.881	rs72750843	ENSG00000235370.6	DNM1P51	4.71	8.46e-06	0.00653	0.56	0.44	Schizophrenia;	chr15:84592552	chr15:84398316~84411701:-
THYM	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-4.71	8.52e-06	0.00656	-0.56	-0.44	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
THYM	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-4.71	8.53e-06	0.00657	-0.41	-0.44	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
THYM	cis	rs73198271	0.74	rs10094270	ENSG00000253893.2	FAM85B	4.71	8.53e-06	0.00657	0.7	0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.773	rs66618176	ENSG00000253893.2	FAM85B	4.71	8.53e-06	0.00657	0.7	0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs28521727	ENSG00000253893.2	FAM85B	4.71	8.53e-06	0.00657	0.7	0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs28402110	ENSG00000253893.2	FAM85B	4.71	8.53e-06	0.00657	0.7	0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10098636	ENSG00000253893.2	FAM85B	4.71	8.53e-06	0.00657	0.7	0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10112989	ENSG00000253893.2	FAM85B	4.71	8.53e-06	0.00657	0.7	0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10113326	ENSG00000253893.2	FAM85B	4.71	8.53e-06	0.00657	0.7	0.44	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8167819~8226614:-
THYM	cis	rs9659323	0.623	rs12091291	ENSG00000231365.4	RP11-418J17.1	4.71	8.54e-06	0.00657	0.45	0.44	Body mass index;	chr1:118936205	chr1:119140396~119275973:+
THYM	cis	rs9659323	0.689	rs10923716	ENSG00000231365.4	RP11-418J17.1	-4.71	8.54e-06	0.00657	-0.45	-0.44	Body mass index;	chr1:118993496	chr1:119140396~119275973:+
THYM	cis	rs12681366	0.761	rs2197003	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs2921386	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs2919668	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs2011246	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs1372048	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs2043988	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs2919658	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs2919657	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs55963151	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs6981551	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs72674819	ENSG00000253704.1	RP11-267M23.4	4.71	8.54e-06	0.00657	0.57	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94468072	chr8:94553722~94569745:+
THYM	cis	rs5769707	0.933	rs2157444	ENSG00000264139.1	MIR3667	-4.71	8.54e-06	0.00657	-0.49	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49543393~49543466:-
THYM	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	4.71	8.54e-06	0.00657	0.49	0.44	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	4.71	8.54e-06	0.00657	0.49	0.44	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
THYM	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	4.71	8.56e-06	0.00658	0.46	0.44	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
THYM	cis	rs4478858	0.647	rs10798835	ENSG00000260386.4	LINC01225	4.71	8.56e-06	0.00658	0.24	0.44	Alcohol dependence;	chr1:31236208	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.647	rs10798836	ENSG00000260386.4	LINC01225	4.71	8.56e-06	0.00658	0.24	0.44	Alcohol dependence;	chr1:31236367	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.647	rs6425720	ENSG00000260386.4	LINC01225	4.71	8.56e-06	0.00658	0.24	0.44	Alcohol dependence;	chr1:31236708	chr1:31500085~31540885:+
THYM	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	4.71	8.58e-06	0.00659	0.78	0.44	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
THYM	cis	rs4835473	0.932	rs10025527	ENSG00000249741.2	RP11-673E1.3	-4.71	8.58e-06	0.00659	-0.38	-0.44	Immature fraction of reticulocytes;	chr4:143968391	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs3872	ENSG00000249741.2	RP11-673E1.3	-4.71	8.58e-06	0.00659	-0.38	-0.44	Immature fraction of reticulocytes;	chr4:143968788	chr4:143911514~143912053:-
THYM	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	4.71	8.59e-06	0.0066	0.55	0.44	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
THYM	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	4.71	8.6e-06	0.00661	0.62	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	4.71	8.61e-06	0.00661	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
THYM	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-4.71	8.63e-06	0.00662	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-4.71	8.63e-06	0.00662	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-4.71	8.63e-06	0.00662	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-4.71	8.63e-06	0.00662	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-4.71	8.63e-06	0.00662	-0.52	-0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
THYM	cis	rs4948275	0.55	rs7082786	ENSG00000237233.2	TMEM26-AS1	4.71	8.66e-06	0.00665	0.45	0.44	Night sleep phenotypes;	chr10:61417232	chr10:61452639~61481956:+
THYM	cis	rs2253762	0.609	rs10887057	ENSG00000276742.1	RP11-500G22.4	4.71	8.68e-06	0.00666	0.52	0.44	Breast cancer;	chr10:122043799	chr10:121956782~121957098:+
THYM	cis	rs1529093	1	rs11674536	ENSG00000222043.2	AC079305.10	-4.71	8.68e-06	0.00667	-0.36	-0.44	Non-alcoholic fatty liver disease histology (other);	chr2:177057011	chr2:177264359~177265515:+
THYM	cis	rs1529093	0.967	rs62173652	ENSG00000222043.2	AC079305.10	-4.71	8.68e-06	0.00667	-0.36	-0.44	Non-alcoholic fatty liver disease histology (other);	chr2:177057794	chr2:177264359~177265515:+
THYM	cis	rs858239	0.73	rs858279	ENSG00000226816.2	AC005082.12	4.7	8.71e-06	0.00668	0.64	0.44	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23206013~23208045:+
THYM	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-4.7	8.72e-06	0.00669	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-4.7	8.72e-06	0.00669	-0.51	-0.44	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
THYM	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-4.7	8.72e-06	0.00669	-0.43	-0.44	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-4.7	8.72e-06	0.00669	-0.43	-0.44	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-4.7	8.72e-06	0.00669	-0.43	-0.44	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
THYM	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	4.7	8.72e-06	0.00669	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
THYM	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	4.7	8.72e-06	0.00669	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
THYM	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	4.7	8.72e-06	0.00669	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
THYM	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	4.7	8.72e-06	0.00669	0.56	0.44	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
THYM	cis	rs56307353	0.691	rs11084924	ENSG00000180846.7	CSNK1G2-AS1	4.7	8.72e-06	0.00669	0.46	0.44	Coronary artery disease;	chr19:1968572	chr19:1952531~1954586:-
THYM	cis	rs4948275	0.53	rs2393853	ENSG00000237233.2	TMEM26-AS1	4.7	8.74e-06	0.0067	0.45	0.44	Night sleep phenotypes;	chr10:61407930	chr10:61452639~61481956:+
THYM	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	4.7	8.75e-06	0.0067	0.34	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
THYM	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-4.7	8.75e-06	0.00671	-0.65	-0.44	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
THYM	cis	rs8059260	0.736	rs77334546	ENSG00000274038.1	RP11-66H6.4	-4.7	8.76e-06	0.00671	-0.8	-0.44	Alcohol consumption over the past year;	chr16:10970061	chr16:11056556~11057034:+
THYM	cis	rs67180937	0.631	rs1909195	ENSG00000272750.1	RP11-378J18.8	-4.7	8.76e-06	0.00671	-0.62	-0.44	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623985	chr1:222658867~222661512:-
THYM	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	4.7	8.76e-06	0.00671	0.41	0.44	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
THYM	cis	rs853679	0.55	rs1233701	ENSG00000182477.5	OR2B8P	-4.7	8.77e-06	0.00672	-0.61	-0.44	Depression;	chr6:28200948	chr6:28053228~28054165:-
THYM	cis	rs7701440	0.512	rs40506	ENSG00000272308.1	RP11-231G3.1	-4.7	8.79e-06	0.00673	-0.38	-0.44	Educational attainment;	chr5:61229383	chr5:60866457~60866935:-
THYM	cis	rs7701440	0.512	rs34631	ENSG00000272308.1	RP11-231G3.1	-4.7	8.79e-06	0.00673	-0.38	-0.44	Educational attainment;	chr5:61230499	chr5:60866457~60866935:-
THYM	cis	rs904251	0.734	rs2797790	ENSG00000227920.2	RP1-153P14.5	4.7	8.8e-06	0.00673	0.66	0.44	Cognitive performance;	chr6:37479299	chr6:37545145~37550860:+
THYM	cis	rs4908768	0.539	rs6670508	ENSG00000232912.4	RP5-1115A15.1	4.7	8.8e-06	0.00674	0.43	0.44	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8424645~8434838:+
THYM	cis	rs2283792	1	rs2283792	ENSG00000228050.1	TOP3BP1	4.7	8.81e-06	0.00674	0.48	0.44	Multiple sclerosis;	chr22:21776836	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.935	rs8141851	ENSG00000228050.1	TOP3BP1	4.7	8.81e-06	0.00674	0.48	0.44	Multiple sclerosis;	chr22:21812161	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs6518986	ENSG00000228050.1	TOP3BP1	4.7	8.81e-06	0.00674	0.48	0.44	Multiple sclerosis;	chr22:21831058	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs1892846	ENSG00000228050.1	TOP3BP1	4.7	8.81e-06	0.00674	0.48	0.44	Multiple sclerosis;	chr22:21832190	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs1892848	ENSG00000228050.1	TOP3BP1	4.7	8.81e-06	0.00674	0.48	0.44	Multiple sclerosis;	chr22:21832273	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs5999750	ENSG00000228050.1	TOP3BP1	4.7	8.81e-06	0.00674	0.48	0.44	Multiple sclerosis;	chr22:21833720	chr22:22223187~22224566:-
THYM	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-4.7	8.81e-06	0.00675	-0.41	-0.44	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
THYM	cis	rs4908769	0.627	rs301798	ENSG00000232912.4	RP5-1115A15.1	4.7	8.82e-06	0.00675	0.46	0.44	Allergy;	chr1:8428505	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.66	rs159962	ENSG00000232912.4	RP5-1115A15.1	4.7	8.82e-06	0.00675	0.46	0.44	Allergy;	chr1:8430923	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.66	rs301801	ENSG00000232912.4	RP5-1115A15.1	4.7	8.82e-06	0.00675	0.46	0.44	Allergy;	chr1:8435885	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.66	rs172531	ENSG00000232912.4	RP5-1115A15.1	-4.7	8.82e-06	0.00675	-0.46	-0.44	Allergy;	chr1:8435530	chr1:8424645~8434838:+
THYM	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	4.7	8.84e-06	0.00677	0.44	0.44	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
THYM	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-4.7	8.84e-06	0.00677	-0.48	-0.44	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
THYM	cis	rs74225573	1	rs74225573	ENSG00000230337.1	RP4-635E18.6	-4.7	8.86e-06	0.00677	-0.79	-0.44	Corneal curvature;	chr1:11220937	chr1:11099675~11102100:+
THYM	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-4.7	8.87e-06	0.00678	-0.45	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
THYM	cis	rs62158211	1	rs62158211	ENSG00000237753.1	AC079922.3	-4.7	8.89e-06	0.00679	-0.34	-0.44	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr2:112641832~112645690:-
THYM	cis	rs7242404	0.57	rs12457255	ENSG00000260302.1	RP11-973H7.1	4.7	8.9e-06	0.00679	0.31	0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12759977	chr18:12774651~12775923:-
THYM	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	4.7	8.91e-06	0.0068	0.57	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
THYM	cis	rs440932	1	rs365309	ENSG00000253893.2	FAM85B	4.7	8.95e-06	0.00683	0.56	0.44	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8167819~8226614:-
THYM	cis	rs7849270	0.84	rs3118639	ENSG00000268707.1	RP11-247A12.7	4.7	8.96e-06	0.00683	0.59	0.44	Blood metabolite ratios;	chr9:129093324	chr9:129170434~129170940:+
THYM	cis	rs995834	0.622	rs2159076	ENSG00000267243.4	AC005307.3	-4.7	8.97e-06	0.00684	-0.41	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28403929	chr19:28435388~28727777:-
THYM	cis	rs4713118	0.629	rs203889	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28053997	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.629	rs203890	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28054470	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9357060	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28056708	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9468271	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28056792	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9380045	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28057501	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.616	rs9348789	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28057708	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9468274	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28058299	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9468275	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28058358	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9468276	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28059910	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9468277	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28060612	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9468278	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28060704	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs13218430	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28062059	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs9380046	ENSG00000182477.5	OR2B8P	4.7	8.98e-06	0.00684	0.61	0.44	Parkinson's disease;	chr6:28062721	chr6:28053228~28054165:-
THYM	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	4.7	8.98e-06	0.00684	0.51	0.44	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
THYM	cis	rs1023500	0.551	rs2301521	ENSG00000227370.1	RP4-669P10.19	4.7	8.98e-06	0.00684	0.52	0.44	Schizophrenia;	chr22:42027106	chr22:42132543~42132998:+
THYM	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-4.7	9.01e-06	0.00686	-0.43	-0.44	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-4.7	9.01e-06	0.00686	-0.43	-0.44	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-4.7	9.01e-06	0.00686	-0.43	-0.44	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	4.7	9.01e-06	0.00686	0.43	0.44	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
THYM	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	4.7	9.01e-06	0.00686	0.61	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
THYM	cis	rs7560272	0.538	rs11126415	ENSG00000163016.8	ALMS1P	-4.7	9.01e-06	0.00686	-0.56	-0.44	Schizophrenia;	chr2:73709373	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs12053242	ENSG00000163016.8	ALMS1P	-4.7	9.01e-06	0.00686	-0.56	-0.44	Schizophrenia;	chr2:73710041	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.513	rs7558546	ENSG00000163016.8	ALMS1P	-4.7	9.01e-06	0.00686	-0.56	-0.44	Schizophrenia;	chr2:73710605	chr2:73644919~73685576:+
THYM	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
THYM	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-4.7	9.03e-06	0.00687	-0.36	-0.44	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
THYM	cis	rs4925386	0.959	rs6121989	ENSG00000273619.1	RP5-908M14.9	4.7	9.03e-06	0.00687	0.32	0.44	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62386303~62386970:-
THYM	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	4.7	9.03e-06	0.00687	0.57	0.44	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	4.7	9.03e-06	0.00687	0.57	0.44	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	4.7	9.03e-06	0.00687	0.57	0.44	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	4.7	9.03e-06	0.00687	0.57	0.44	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	4.7	9.03e-06	0.00687	0.57	0.44	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
THYM	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-4.7	9.05e-06	0.00688	-0.4	-0.44	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
THYM	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-4.7	9.05e-06	0.00689	-0.35	-0.44	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-4.7	9.05e-06	0.00689	-0.35	-0.44	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
THYM	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-4.7	9.06e-06	0.00689	-0.48	-0.44	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
THYM	cis	rs7560272	0.538	rs17350056	ENSG00000273245.1	RP11-434P11.2	-4.7	9.06e-06	0.00689	-0.52	-0.44	Schizophrenia;	chr2:73695750	chr2:73750256~73750786:-
THYM	cis	rs4478858	0.684	rs17440445	ENSG00000260386.4	LINC01225	-4.69	9.06e-06	0.00689	-0.24	-0.44	Alcohol dependence;	chr1:31249715	chr1:31500085~31540885:+
THYM	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	4.69	9.1e-06	0.00692	0.42	0.44	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	4.69	9.1e-06	0.00692	0.42	0.44	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
THYM	cis	rs9876781	1	rs9881491	ENSG00000244380.1	RP11-24C3.2	4.69	9.1e-06	0.00692	0.59	0.44	Longevity;	chr3:48446507	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs13091785	ENSG00000244380.1	RP11-24C3.2	4.69	9.1e-06	0.00692	0.59	0.44	Longevity;	chr3:48452692	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs6776700	ENSG00000244380.1	RP11-24C3.2	4.69	9.1e-06	0.00692	0.59	0.44	Longevity;	chr3:48455358	chr3:48440352~48446656:-
THYM	cis	rs9876781	0.967	rs7618883	ENSG00000244380.1	RP11-24C3.2	4.69	9.1e-06	0.00692	0.59	0.44	Longevity;	chr3:48457056	chr3:48440352~48446656:-
THYM	cis	rs1550576	0.568	rs117459785	ENSG00000274719.1	RP11-86K22.2	4.69	9.13e-06	0.00694	0.91	0.44	Hypertension;	chr15:57981011	chr15:57990217~57990636:-
THYM	cis	rs7560272	0.502	rs4513320	ENSG00000273245.1	RP11-434P11.2	-4.69	9.14e-06	0.00694	-0.53	-0.44	Schizophrenia;	chr2:73693614	chr2:73750256~73750786:-
THYM	cis	rs853679	0.517	rs16893666	ENSG00000182477.5	OR2B8P	-4.69	9.14e-06	0.00694	-0.59	-0.44	Depression;	chr6:28086929	chr6:28053228~28054165:-
THYM	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	4.69	9.15e-06	0.00695	0.71	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
THYM	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	4.69	9.15e-06	0.00695	0.71	0.44	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
THYM	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-4.69	9.16e-06	0.00695	-0.38	-0.44	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
THYM	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	4.69	9.16e-06	0.00695	0.6	0.44	Depression;	chr6:28407125	chr6:28176188~28176674:+
THYM	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-4.69	9.19e-06	0.00697	-0.53	-0.44	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
THYM	cis	rs10129255	0.5	rs34326748	ENSG00000254329.1	IGHVII-60-1	4.69	9.2e-06	0.00697	0.38	0.44	Kawasaki disease;	chr14:106782523	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs10143385	ENSG00000254329.1	IGHVII-60-1	4.69	9.2e-06	0.00697	0.38	0.44	Kawasaki disease;	chr14:106782559	chr14:106637718~106637973:-
THYM	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	4.69	9.2e-06	0.00698	0.36	0.44	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
THYM	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-4.69	9.2e-06	0.00698	-0.54	-0.44	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
THYM	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	4.69	9.21e-06	0.00698	0.55	0.44	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
THYM	cis	rs56307353	0.718	rs4807181	ENSG00000180846.7	CSNK1G2-AS1	4.69	9.22e-06	0.00698	0.46	0.44	Coronary artery disease;	chr19:1965916	chr19:1952531~1954586:-
THYM	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	4.69	9.22e-06	0.00698	0.54	0.44	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
THYM	cis	rs17711722	0.522	rs4642526	ENSG00000232906.1	RP11-746P2.3	4.69	9.22e-06	0.00699	0.43	0.44	Calcium levels;	chr7:65751755	chr7:65355934~65357176:+
THYM	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-4.69	9.24e-06	0.007	-0.56	-0.44	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
THYM	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-4.69	9.25e-06	0.00701	-0.57	-0.44	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-4.69	9.25e-06	0.00701	-0.57	-0.44	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-4.69	9.25e-06	0.00701	-0.57	-0.44	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
THYM	cis	rs9926296	0.744	rs164749	ENSG00000274627.1	RP11-104N10.2	4.69	9.25e-06	0.00701	0.49	0.44	Vitiligo;	chr16:89641816	chr16:89516797~89522217:+
THYM	cis	rs2834288	0.535	rs9982605	ENSG00000237945.6	LINC00649	4.69	9.26e-06	0.00701	0.38	0.44	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33915534~33977691:+
THYM	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-4.69	9.26e-06	0.00701	-0.53	-0.44	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
THYM	cis	rs904251	0.698	rs2646926	ENSG00000227920.2	RP1-153P14.5	-4.69	9.26e-06	0.00701	-0.66	-0.44	Cognitive performance;	chr6:37457212	chr6:37545145~37550860:+
THYM	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	4.69	9.27e-06	0.00702	0.31	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
THYM	cis	rs28785552	0.765	rs28850924	ENSG00000250731.1	TPM3P6	-4.69	9.28e-06	0.00702	-0.62	-0.44	Response to paliperidone in schizophrenia (PANSS score);	chr19:52731070	chr19:53479350~53480091:+
THYM	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	4.69	9.28e-06	0.00702	0.56	0.44	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	4.69	9.28e-06	0.00702	0.56	0.44	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	4.69	9.28e-06	0.00702	0.56	0.44	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	4.69	9.28e-06	0.00702	0.56	0.44	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	4.69	9.28e-06	0.00702	0.56	0.44	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	4.69	9.28e-06	0.00702	0.56	0.44	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	4.69	9.28e-06	0.00702	0.56	0.44	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
THYM	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	4.69	9.3e-06	0.00703	0.31	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
THYM	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-4.69	9.3e-06	0.00703	-0.33	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
THYM	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	4.69	9.31e-06	0.00704	0.54	0.44	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
THYM	cis	rs995834	0.743	rs4806332	ENSG00000267243.4	AC005307.3	-4.69	9.31e-06	0.00704	-0.38	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28366100	chr19:28435388~28727777:-
THYM	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	4.69	9.34e-06	0.00705	0.44	0.44	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
THYM	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-4.69	9.34e-06	0.00706	-0.48	-0.44	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
THYM	cis	rs867371	1	rs13380317	ENSG00000276710.3	CSPG4P8	4.69	9.34e-06	0.00706	0.44	0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82459472~82477258:+
THYM	cis	rs867371	1	rs13380319	ENSG00000276710.3	CSPG4P8	-4.69	9.34e-06	0.00706	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82459472~82477258:+
THYM	cis	rs867371	0.896	rs6495647	ENSG00000276710.3	CSPG4P8	-4.69	9.34e-06	0.00706	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82459472~82477258:+
THYM	cis	rs867371	0.892	rs4344697	ENSG00000276710.3	CSPG4P8	-4.69	9.34e-06	0.00706	-0.44	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82459472~82477258:+
THYM	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-4.69	9.35e-06	0.00706	-0.38	-0.44	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
THYM	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-4.69	9.35e-06	0.00706	-0.43	-0.44	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
THYM	cis	rs9834970	0.566	rs4327336	ENSG00000234073.1	AC011816.1	-4.69	9.37e-06	0.00708	-0.46	-0.44	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36854779	chr3:36880184~36880729:-
THYM	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	4.69	9.38e-06	0.00708	0.35	0.44	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
THYM	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-4.69	9.39e-06	0.00709	-0.38	-0.44	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-4.69	9.39e-06	0.00709	-0.38	-0.44	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-4.69	9.39e-06	0.00709	-0.38	-0.44	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-4.69	9.39e-06	0.00709	-0.38	-0.44	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-4.69	9.39e-06	0.00709	-0.38	-0.44	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
THYM	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-4.69	9.39e-06	0.00709	-0.38	-0.44	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-4.69	9.39e-06	0.00709	-0.38	-0.44	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
THYM	cis	rs867371	0.929	rs1045508	ENSG00000276710.3	CSPG4P8	4.69	9.41e-06	0.0071	0.43	0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82459472~82477258:+
THYM	cis	rs867371	0.929	rs7173852	ENSG00000276710.3	CSPG4P8	-4.69	9.41e-06	0.0071	-0.43	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82459472~82477258:+
THYM	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-4.69	9.43e-06	0.00711	-0.37	-0.44	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
THYM	cis	rs9500256	0.967	rs4928431	ENSG00000272316.1	XXbac-BPGBPG55C20.2	-4.68	9.44e-06	0.00712	-0.34	-0.44	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57908560~57913911:-
THYM	cis	rs7242404	0.57	rs11664306	ENSG00000260302.1	RP11-973H7.1	4.68	9.45e-06	0.00713	0.31	0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12753487	chr18:12774651~12775923:-
THYM	cis	rs7242404	0.57	rs12964137	ENSG00000260302.1	RP11-973H7.1	4.68	9.45e-06	0.00713	0.31	0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12753638	chr18:12774651~12775923:-
THYM	cis	rs7242404	0.57	rs1833325	ENSG00000260302.1	RP11-973H7.1	4.68	9.45e-06	0.00713	0.31	0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12755582	chr18:12774651~12775923:-
THYM	cis	rs7242404	0.57	rs11662231	ENSG00000260302.1	RP11-973H7.1	4.68	9.45e-06	0.00713	0.31	0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12758033	chr18:12774651~12775923:-
THYM	cis	rs7242404	0.57	rs11660242	ENSG00000260302.1	RP11-973H7.1	-4.68	9.45e-06	0.00713	-0.31	-0.44	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12761429	chr18:12774651~12775923:-
THYM	cis	rs797680	0.586	rs2281525	ENSG00000223745.6	RP4-717I23.3	4.68	9.45e-06	0.00713	0.38	0.44	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93129749	chr1:93262186~93346025:-
THYM	cis	rs11017328	0.5	rs11017290	ENSG00000236303.2	RP11-540N6.1	-4.68	9.45e-06	0.00713	-0.62	-0.44	Conotruncal heart defects;	chr10:130505656	chr10:130439067~130483154:+
THYM	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-4.68	9.47e-06	0.00714	-0.34	-0.44	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
THYM	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-4.68	9.47e-06	0.00714	-0.31	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
THYM	cis	rs10129255	0.5	rs10131875	ENSG00000254329.1	IGHVII-60-1	4.68	9.48e-06	0.00714	0.38	0.43	Kawasaki disease;	chr14:106792798	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs11628999	ENSG00000254329.1	IGHVII-60-1	4.68	9.48e-06	0.00714	0.38	0.43	Kawasaki disease;	chr14:106800208	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs11627315	ENSG00000254329.1	IGHVII-60-1	4.68	9.48e-06	0.00714	0.38	0.43	Kawasaki disease;	chr14:106802182	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs7157975	ENSG00000254329.1	IGHVII-60-1	4.68	9.48e-06	0.00714	0.38	0.43	Kawasaki disease;	chr14:106804049	chr14:106637718~106637973:-
THYM	cis	rs2283792	0.967	rs5749998	ENSG00000228050.1	TOP3BP1	4.68	9.48e-06	0.00714	0.49	0.43	Multiple sclerosis;	chr22:21808085	chr22:22223187~22224566:-
THYM	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-4.68	9.49e-06	0.00715	-0.45	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
THYM	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-4.68	9.49e-06	0.00715	-0.56	-0.43	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
THYM	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-4.68	9.49e-06	0.00715	-0.38	-0.43	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
THYM	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-4.68	9.5e-06	0.00715	-0.57	-0.43	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
THYM	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-4.68	9.5e-06	0.00715	-0.48	-0.43	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
THYM	cis	rs7560272	0.512	rs13026192	ENSG00000163016.8	ALMS1P	-4.68	9.5e-06	0.00715	-0.56	-0.43	Schizophrenia;	chr2:73699945	chr2:73644919~73685576:+
THYM	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	4.68	9.51e-06	0.00716	0.57	0.43	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
THYM	cis	rs995834	0.742	rs2868965	ENSG00000260725.1	AC005307.1	4.68	9.51e-06	0.00716	0.42	0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362886	chr19:28418483~28429490:-
THYM	cis	rs7246967	0.673	rs12979264	ENSG00000198153.8	ZNF849P	-4.68	9.52e-06	0.00716	-0.6	-0.43	Bronchopulmonary dysplasia;	chr19:22682332	chr19:22685167~22686732:+
THYM	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-4.68	9.52e-06	0.00716	-0.36	-0.43	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
THYM	cis	rs160451	0.966	rs12216864	ENSG00000251136.7	RP11-37B2.1	4.68	9.52e-06	0.00716	0.36	0.43	Leprosy;	chr8:89665895	chr8:89609409~89757727:-
THYM	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	4.68	9.52e-06	0.00716	0.36	0.43	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
THYM	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	4.68	9.52e-06	0.00716	0.36	0.43	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
THYM	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	4.68	9.52e-06	0.00716	0.36	0.43	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
THYM	cis	rs42490	0.528	rs10956209	ENSG00000251136.7	RP11-37B2.1	4.68	9.52e-06	0.00716	0.36	0.43	Leprosy;	chr8:89670923	chr8:89609409~89757727:-
THYM	cis	rs160451	0.899	rs218887	ENSG00000251136.7	RP11-37B2.1	4.68	9.52e-06	0.00716	0.36	0.43	Leprosy;	chr8:89679295	chr8:89609409~89757727:-
THYM	cis	rs42490	0.528	rs7004089	ENSG00000251136.7	RP11-37B2.1	4.68	9.52e-06	0.00716	0.36	0.43	Leprosy;	chr8:89688329	chr8:89609409~89757727:-
THYM	cis	rs8067545	0.641	rs175922	ENSG00000231645.2	KRT17P6	-4.68	9.52e-06	0.00716	-0.53	-0.43	Schizophrenia;	chr17:19922266	chr17:20512560~20517479:-
THYM	cis	rs526231	0.736	rs6886092	ENSG00000175749.11	EIF3KP1	4.68	9.52e-06	0.00717	0.54	0.43	Primary biliary cholangitis;	chr5:103298328	chr5:103032376~103033031:+
THYM	cis	rs1550576	0.5	rs12591835	ENSG00000274719.1	RP11-86K22.2	4.68	9.54e-06	0.00718	0.89	0.43	Hypertension;	chr15:58042711	chr15:57990217~57990636:-
THYM	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	4.68	9.54e-06	0.00718	0.55	0.43	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
THYM	cis	rs995834	0.664	rs8109361	ENSG00000267243.4	AC005307.3	-4.68	9.55e-06	0.00718	-0.41	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395343	chr19:28435388~28727777:-
THYM	cis	rs10411161	1	rs10411161	ENSG00000269483.1	AC006272.1	4.68	9.55e-06	0.00718	0.59	0.43	Breast cancer;	chr19:51869723	chr19:51839924~51843324:-
THYM	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	4.68	9.55e-06	0.00718	0.42	0.43	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
THYM	cis	rs4713118	0.629	rs203887	ENSG00000182477.5	OR2B8P	4.68	9.56e-06	0.00719	0.62	0.43	Parkinson's disease;	chr6:28053491	chr6:28053228~28054165:-
THYM	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
THYM	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
THYM	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	4.68	9.56e-06	0.00719	0.55	0.43	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
THYM	cis	rs10129255	0.557	rs11628292	ENSG00000254329.1	IGHVII-60-1	4.68	9.58e-06	0.0072	0.44	0.43	Kawasaki disease;	chr14:106650018	chr14:106637718~106637973:-
THYM	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	4.68	9.58e-06	0.0072	0.52	0.43	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
THYM	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	4.68	9.59e-06	0.00721	0.33	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
THYM	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	4.68	9.59e-06	0.00721	0.55	0.43	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
THYM	cis	rs1550576	0.5	rs12594236	ENSG00000274719.1	RP11-86K22.2	4.68	9.6e-06	0.00721	0.82	0.43	Hypertension;	chr15:57938956	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs76603029	ENSG00000274719.1	RP11-86K22.2	4.68	9.6e-06	0.00721	0.82	0.43	Hypertension;	chr15:57939768	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs79537969	ENSG00000274719.1	RP11-86K22.2	4.68	9.6e-06	0.00721	0.82	0.43	Hypertension;	chr15:57940625	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs76840195	ENSG00000274719.1	RP11-86K22.2	4.68	9.6e-06	0.00721	0.82	0.43	Hypertension;	chr15:57940769	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs7161823	ENSG00000274719.1	RP11-86K22.2	4.68	9.6e-06	0.00721	0.82	0.43	Hypertension;	chr15:57941593	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs1078777	ENSG00000274719.1	RP11-86K22.2	4.68	9.6e-06	0.00721	0.82	0.43	Hypertension;	chr15:57942015	chr15:57990217~57990636:-
THYM	cis	rs4845570	1	rs3811415	ENSG00000203288.3	RP11-98D18.9	-4.68	9.61e-06	0.00722	-0.53	-0.43	Coronary artery disease;	chr1:151791291	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs11586946	ENSG00000203288.3	RP11-98D18.9	-4.68	9.61e-06	0.00722	-0.53	-0.43	Coronary artery disease;	chr1:151797330	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs11585294	ENSG00000203288.3	RP11-98D18.9	-4.68	9.61e-06	0.00722	-0.53	-0.43	Coronary artery disease;	chr1:151797411	chr1:151790804~151794402:+
THYM	cis	rs4908768	0.52	rs7520025	ENSG00000232912.4	RP5-1115A15.1	4.68	9.61e-06	0.00722	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8424645~8434838:+
THYM	cis	rs4273100	0.526	rs2074280	ENSG00000262319.1	CTC-457L16.2	-4.68	9.61e-06	0.00722	-0.65	-0.43	Schizophrenia;	chr17:19014602	chr17:19141017~19143689:-
THYM	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	4.68	9.61e-06	0.00722	0.34	0.43	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
THYM	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-4.68	9.62e-06	0.00722	-0.51	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
THYM	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-4.68	9.64e-06	0.00723	-0.4	-0.43	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
THYM	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	4.68	9.65e-06	0.00724	0.57	0.43	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
THYM	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-4.68	9.65e-06	0.00725	-0.53	-0.43	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-4.68	9.65e-06	0.00725	-0.53	-0.43	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
THYM	cis	rs12439619	0.846	rs62011975	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.846	rs62012004	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.739	rs62012046	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.774	rs62012047	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.81	rs62012049	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.846	rs62012056	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.846	rs62012059	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.846	rs62010071	ENSG00000274376.3	ADAMTS7P1	4.68	9.66e-06	0.00725	0.49	0.43	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82298553~82334609:+
THYM	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	4.68	9.67e-06	0.00725	0.49	0.43	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-4.68	9.67e-06	0.00725	-0.49	-0.43	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
THYM	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-4.68	9.67e-06	0.00726	-0.52	-0.43	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-4.68	9.67e-06	0.00726	-0.52	-0.43	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
THYM	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-4.68	9.67e-06	0.00726	-0.52	-0.43	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
THYM	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-4.68	9.68e-06	0.00726	-0.6	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
THYM	cis	rs1023500	0.573	rs133381	ENSG00000205702.9	CYP2D7	4.68	9.68e-06	0.00726	0.39	0.43	Schizophrenia;	chr22:42074604	chr22:42140203~42144577:-
THYM	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	4.68	9.69e-06	0.00727	0.49	0.43	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	4.68	9.69e-06	0.00727	0.49	0.43	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
THYM	cis	rs4908768	0.501	rs6577502	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs1473420	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs11121201	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.86	rs11121202	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Vitiligo;	chr1:8579298	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs1934138	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs7526171	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs6675443	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.52	rs6681362	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs1318218	ENSG00000232912.4	RP5-1115A15.1	4.68	9.72e-06	0.00729	0.44	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs6577499	ENSG00000232912.4	RP5-1115A15.1	-4.68	9.72e-06	0.00729	-0.44	-0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8424645~8434838:+
THYM	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-4.68	9.74e-06	0.0073	-0.31	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
THYM	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-4.68	9.74e-06	0.0073	-0.4	-0.43	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
THYM	cis	rs10805346	0.501	rs4604059	ENSG00000261490.1	RP11-448G15.3	-4.68	9.75e-06	0.00731	-0.38	-0.43	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10113441	chr4:10068089~10073019:-
THYM	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	4.68	9.79e-06	0.00733	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
THYM	cis	rs12701220	0.595	rs12532837	ENSG00000229043.2	AC091729.9	-4.68	9.81e-06	0.00734	-0.71	-0.43	Bronchopulmonary dysplasia;	chr7:1083215	chr7:1160374~1165267:+
THYM	cis	rs4845570	0.85	rs4618976	ENSG00000203288.3	RP11-98D18.9	4.68	9.81e-06	0.00734	0.53	0.43	Coronary artery disease;	chr1:151794112	chr1:151790804~151794402:+
THYM	cis	rs4845570	1	rs6659705	ENSG00000203288.3	RP11-98D18.9	-4.68	9.81e-06	0.00734	-0.53	-0.43	Coronary artery disease;	chr1:151797274	chr1:151790804~151794402:+
THYM	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	4.67	9.81e-06	0.00734	0.48	0.43	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-4.67	9.81e-06	0.00734	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-4.67	9.81e-06	0.00734	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-4.67	9.81e-06	0.00734	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-4.67	9.81e-06	0.00734	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-4.67	9.81e-06	0.00734	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
THYM	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	4.67	9.82e-06	0.00734	0.47	0.43	Height;	chr6:109332929	chr6:109382795~109383666:+
THYM	cis	rs6570726	0.935	rs398060	ENSG00000235652.6	RP11-545I5.3	-4.67	9.82e-06	0.00734	-0.31	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145799409~145886585:+
THYM	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	4.67	9.83e-06	0.00735	0.56	0.43	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	4.67	9.83e-06	0.00735	0.56	0.43	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	4.67	9.83e-06	0.00735	0.56	0.43	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	4.67	9.83e-06	0.00735	0.53	0.43	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
THYM	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-4.67	9.83e-06	0.00735	-0.49	-0.43	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
THYM	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-4.67	9.85e-06	0.00736	-0.55	-0.43	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
THYM	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-4.67	9.85e-06	0.00736	-0.46	-0.43	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
THYM	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-4.67	9.85e-06	0.00736	-0.49	-0.43	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-4.67	9.85e-06	0.00736	-0.49	-0.43	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
THYM	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	4.67	9.85e-06	0.00736	0.64	0.43	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
THYM	cis	rs4663866	0.901	rs2304672	ENSG00000186235.9	AC016757.3	-4.67	9.85e-06	0.00736	-0.97	-0.43	Irritable bowel syndrome;	chr2:238277948	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.901	rs3739066	ENSG00000186235.9	AC016757.3	4.67	9.85e-06	0.00736	0.97	0.43	Irritable bowel syndrome;	chr2:238275483	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.901	rs71426512	ENSG00000186235.9	AC016757.3	4.67	9.85e-06	0.00736	0.97	0.43	Irritable bowel syndrome;	chr2:238278487	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.901	rs76312449	ENSG00000186235.9	AC016757.3	4.67	9.85e-06	0.00736	0.97	0.43	Irritable bowel syndrome;	chr2:238282265	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.901	rs34040298	ENSG00000186235.9	AC016757.3	4.67	9.85e-06	0.00736	0.97	0.43	Irritable bowel syndrome;	chr2:238282966	chr2:238224552~238231677:-
THYM	cis	rs4663866	0.901	rs35390666	ENSG00000186235.9	AC016757.3	4.67	9.85e-06	0.00736	0.97	0.43	Irritable bowel syndrome;	chr2:238284937	chr2:238224552~238231677:-
THYM	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	4.67	9.89e-06	0.00739	0.53	0.43	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
THYM	cis	rs8067545	0.611	rs2703805	ENSG00000230528.6	NOS2P3	4.67	9.9e-06	0.0074	0.36	0.43	Schizophrenia;	chr17:20204460	chr17:20436337~20447249:+
THYM	cis	rs4908768	0.539	rs11121204	ENSG00000232912.4	RP5-1115A15.1	-4.67	9.91e-06	0.0074	-0.43	-0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8424645~8434838:+
THYM	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	4.67	9.91e-06	0.0074	0.31	0.43	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
THYM	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-4.67	9.94e-06	0.00742	-0.56	-0.43	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
THYM	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-4.67	9.94e-06	0.00742	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
THYM	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-4.67	9.94e-06	0.00742	-0.52	-0.43	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
THYM	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	4.67	9.94e-06	0.00742	0.52	0.43	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
THYM	cis	rs1850744	0.51	rs12646317	ENSG00000250268.3	ALG1L14P	-4.67	9.95e-06	0.00742	-1.19	-0.43	Economic and political preferences;	chr4:9564218	chr4:9166297~9170270:-
THYM	cis	rs11603020	0.95	rs78364821	ENSG00000265566.2	RN7SL605P	-4.67	9.95e-06	0.00743	-0.61	-0.43	Blood protein levels;	chr11:57603269	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.95	rs28362950	ENSG00000265566.2	RN7SL605P	-4.67	9.95e-06	0.00743	-0.61	-0.43	Blood protein levels;	chr11:57604445	chr11:57528085~57528365:-
THYM	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	4.67	9.96e-06	0.00743	0.35	0.43	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
THYM	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	4.67	9.97e-06	0.00744	0.54	0.43	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
THYM	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-4.67	9.97e-06	0.00744	-0.46	-0.43	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
THYM	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-4.67	9.97e-06	0.00744	-0.46	-0.43	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
THYM	cis	rs1426063	0.748	rs7654088	ENSG00000249717.1	RP11-44F21.3	-4.67	9.98e-06	0.00744	-0.63	-0.43	QT interval;	chr4:75107103	chr4:74955974~74970362:-
THYM	cis	rs11637339	0.517	rs755439	ENSG00000259760.1	RP11-20G13.2	-4.67	9.98e-06	0.00744	-0.58	-0.43	Cervical cancer;	chr15:99478508	chr15:99396613~99401315:-
THYM	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-4.67	9.99e-06	0.00745	-0.51	-0.43	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
THYM	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	4.67	1e-05	0.00745	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
THYM	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	4.67	1e-05	0.00745	0.54	0.43	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
THYM	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	4.67	1e-05	0.00746	0.43	0.43	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
THYM	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	4.67	1e-05	0.00746	0.43	0.43	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
THYM	cis	rs10805346	0.505	rs35995899	ENSG00000261490.1	RP11-448G15.3	4.67	1e-05	0.00747	0.38	0.43	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10111238	chr4:10068089~10073019:-
THYM	cis	rs4478858	0.735	rs10914368	ENSG00000260386.4	LINC01225	4.67	1e-05	0.00747	0.24	0.43	Alcohol dependence;	chr1:31375090	chr1:31500085~31540885:+
THYM	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-4.67	1e-05	0.00748	-0.58	-0.43	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
THYM	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	4.67	1e-05	0.00748	0.55	0.43	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
THYM	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	4.67	1e-05	0.00748	0.53	0.43	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
THYM	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	4.67	1.01e-05	0.00749	0.55	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
THYM	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-4.67	1.01e-05	0.0075	-0.48	-0.43	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
THYM	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-4.67	1.01e-05	0.0075	-0.48	-0.43	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
THYM	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-4.67	1.01e-05	0.0075	-0.48	-0.43	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
THYM	cis	rs42490	0.653	rs40453	ENSG00000251136.7	RP11-37B2.1	-4.67	1.01e-05	0.0075	-0.36	-0.43	Leprosy;	chr8:89789817	chr8:89609409~89757727:-
THYM	cis	rs42490	0.752	rs400411	ENSG00000251136.7	RP11-37B2.1	-4.67	1.01e-05	0.0075	-0.36	-0.43	Leprosy;	chr8:89789871	chr8:89609409~89757727:-
THYM	cis	rs42490	0.738	rs39509	ENSG00000251136.7	RP11-37B2.1	-4.67	1.01e-05	0.0075	-0.36	-0.43	Leprosy;	chr8:89791937	chr8:89609409~89757727:-
THYM	cis	rs42490	0.752	rs411279	ENSG00000251136.7	RP11-37B2.1	-4.67	1.01e-05	0.0075	-0.36	-0.43	Leprosy;	chr8:89795929	chr8:89609409~89757727:-
THYM	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	4.67	1.01e-05	0.00751	0.3	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
THYM	cis	rs7605378	0.528	rs281780	ENSG00000232732.8	AC073043.1	-4.67	1.01e-05	0.00751	-0.59	-0.43	Osteoporosis;	chr2:199891608	chr2:199867396~199911159:-
THYM	cis	rs7605378	0.528	rs1704190	ENSG00000232732.8	AC073043.1	-4.67	1.01e-05	0.00751	-0.59	-0.43	Osteoporosis;	chr2:199895906	chr2:199867396~199911159:-
THYM	cis	rs7605378	0.528	rs281787	ENSG00000232732.8	AC073043.1	4.67	1.01e-05	0.00751	0.59	0.43	Osteoporosis;	chr2:199919515	chr2:199867396~199911159:-
THYM	cis	rs7605378	0.528	rs7592587	ENSG00000232732.8	AC073043.1	-4.67	1.01e-05	0.00751	-0.59	-0.43	Osteoporosis;	chr2:199921793	chr2:199867396~199911159:-
THYM	cis	rs7605378	0.528	rs1704191	ENSG00000232732.8	AC073043.1	-4.67	1.01e-05	0.00751	-0.59	-0.43	Osteoporosis;	chr2:199951670	chr2:199867396~199911159:-
THYM	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-4.67	1.01e-05	0.00752	-0.74	-0.43	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-4.67	1.01e-05	0.00752	-0.74	-0.43	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-4.67	1.01e-05	0.00752	-0.74	-0.43	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
THYM	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-4.67	1.01e-05	0.00752	-0.74	-0.43	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
THYM	cis	rs11157436	0.914	rs7142794	ENSG00000211813.2	TRAV34	4.67	1.01e-05	0.00752	0.36	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22207522~22208129:+
THYM	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	4.67	1.01e-05	0.00752	0.32	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
THYM	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-4.67	1.01e-05	0.00752	-0.36	-0.43	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-4.67	1.01e-05	0.00752	-0.36	-0.43	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-4.67	1.01e-05	0.00752	-0.36	-0.43	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
THYM	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-4.67	1.01e-05	0.00752	-0.36	-0.43	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
THYM	cis	rs8113308	0.689	rs8112515	ENSG00000269235.1	ZNF350-AS1	4.67	1.01e-05	0.00752	0.45	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987997	chr19:51949134~51981367:+
THYM	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-4.67	1.01e-05	0.00753	-0.55	-0.43	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
THYM	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	4.67	1.01e-05	0.00753	0.59	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
THYM	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-4.67	1.01e-05	0.00753	-0.59	-0.43	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
THYM	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	4.67	1.01e-05	0.00753	0.42	0.43	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
THYM	cis	rs10411161	1	rs10412080	ENSG00000269483.1	AC006272.1	4.67	1.02e-05	0.00753	0.58	0.43	Breast cancer;	chr19:51870255	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs3848562	ENSG00000269483.1	AC006272.1	-4.67	1.02e-05	0.00753	-0.58	-0.43	Breast cancer;	chr19:51876582	chr19:51839924~51843324:-
THYM	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	4.67	1.02e-05	0.00754	0.44	0.43	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
THYM	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	4.67	1.02e-05	0.00754	0.44	0.43	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
THYM	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	4.67	1.02e-05	0.00754	0.44	0.43	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
THYM	cis	rs7560272	0.538	rs4852975	ENSG00000273245.1	RP11-434P11.2	-4.67	1.02e-05	0.00755	-0.52	-0.43	Schizophrenia;	chr2:73705338	chr2:73750256~73750786:-
THYM	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	4.67	1.02e-05	0.00756	0.51	0.43	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
THYM	cis	rs12655019	0.92	rs7731829	ENSG00000271828.1	CTD-2310F14.1	4.67	1.02e-05	0.00756	0.83	0.43	Breast cancer (early onset);	chr5:56911884	chr5:56927874~56929573:+
THYM	cis	rs7560272	0.538	rs12052539	ENSG00000163016.8	ALMS1P	4.66	1.02e-05	0.00757	0.56	0.43	Schizophrenia;	chr2:73710026	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs1806683	ENSG00000163016.8	ALMS1P	4.66	1.02e-05	0.00757	0.56	0.43	Schizophrenia;	chr2:73712685	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs4852977	ENSG00000163016.8	ALMS1P	-4.66	1.02e-05	0.00757	-0.56	-0.43	Schizophrenia;	chr2:73711168	chr2:73644919~73685576:+
THYM	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-4.66	1.02e-05	0.00758	-0.38	-0.43	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
THYM	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-4.66	1.02e-05	0.00759	-0.46	-0.43	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
THYM	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-4.66	1.02e-05	0.00759	-0.45	-0.43	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
THYM	cis	rs3862435	0.518	rs2601166	ENSG00000259212.1	CTD-3065B20.2	-4.66	1.02e-05	0.00759	-0.65	-0.43	Response to exercise (triglyceride level interaction);	chr15:90367947	chr15:90595840~90596447:-
THYM	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-4.66	1.03e-05	0.0076	-0.64	-0.43	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-4.66	1.03e-05	0.0076	-0.64	-0.43	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-4.66	1.03e-05	0.0076	-0.64	-0.43	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-4.66	1.03e-05	0.0076	-0.64	-0.43	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-4.66	1.03e-05	0.0076	-0.64	-0.43	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	4.66	1.03e-05	0.0076	0.64	0.43	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
THYM	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	4.66	1.03e-05	0.0076	0.44	0.43	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
THYM	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	4.66	1.03e-05	0.0076	0.49	0.43	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
THYM	cis	rs42490	0.635	rs42186	ENSG00000251136.7	RP11-37B2.1	-4.66	1.03e-05	0.00761	-0.34	-0.43	Leprosy;	chr8:89827257	chr8:89609409~89757727:-
THYM	cis	rs42490	0.7	rs40250	ENSG00000251136.7	RP11-37B2.1	-4.66	1.03e-05	0.00761	-0.34	-0.43	Leprosy;	chr8:89828779	chr8:89609409~89757727:-
THYM	cis	rs42490	0.7	rs419890	ENSG00000251136.7	RP11-37B2.1	-4.66	1.03e-05	0.00761	-0.34	-0.43	Leprosy;	chr8:89829012	chr8:89609409~89757727:-
THYM	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	4.66	1.03e-05	0.00761	0.42	0.43	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
THYM	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-4.66	1.03e-05	0.00761	-0.42	-0.43	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
THYM	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	4.66	1.03e-05	0.00762	0.63	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	4.66	1.03e-05	0.00762	0.63	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
THYM	cis	rs6570726	0.526	rs7755237	ENSG00000235652.6	RP11-545I5.3	-4.66	1.03e-05	0.00763	-0.3	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145410716	chr6:145799409~145886585:+
THYM	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	4.66	1.03e-05	0.00764	0.55	0.43	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
THYM	cis	rs6696239	0.513	rs2492634	ENSG00000227711.2	RP11-275O4.5	4.66	1.03e-05	0.00764	0.39	0.43	Height;	chr1:227517157	chr1:227509028~227520477:-
THYM	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	4.66	1.03e-05	0.00765	0.44	0.43	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
THYM	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-4.66	1.04e-05	0.00766	-0.63	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
THYM	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	4.66	1.04e-05	0.00766	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
THYM	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-4.66	1.04e-05	0.00767	-0.34	-0.43	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
THYM	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	4.66	1.04e-05	0.00767	0.95	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
THYM	cis	rs9549367	0.577	rs3024713	ENSG00000269125.1	RP11-98F14.11	-4.66	1.04e-05	0.00768	-0.66	-0.43	Platelet distribution width;	chr13:113159007	chr13:113165002~113165183:-
THYM	cis	rs42490	0.536	rs365871	ENSG00000251136.7	RP11-37B2.1	-4.66	1.04e-05	0.00769	-0.34	-0.43	Leprosy;	chr8:89861458	chr8:89609409~89757727:-
THYM	cis	rs42490	0.536	rs386857	ENSG00000251136.7	RP11-37B2.1	-4.66	1.04e-05	0.00769	-0.34	-0.43	Leprosy;	chr8:89862824	chr8:89609409~89757727:-
THYM	cis	rs42490	0.536	rs400571	ENSG00000251136.7	RP11-37B2.1	-4.66	1.04e-05	0.00769	-0.34	-0.43	Leprosy;	chr8:89863336	chr8:89609409~89757727:-
THYM	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	4.66	1.04e-05	0.00771	0.49	0.43	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-4.66	1.05e-05	0.00772	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-4.66	1.05e-05	0.00772	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-4.66	1.05e-05	0.00772	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-4.66	1.05e-05	0.00772	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
THYM	cis	rs62158211	1	rs4618068	ENSG00000237753.1	AC079922.3	-4.66	1.05e-05	0.00772	-0.34	-0.43	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113351778	chr2:112641832~112645690:-
THYM	cis	rs62158211	1	rs1807282	ENSG00000237753.1	AC079922.3	-4.66	1.05e-05	0.00772	-0.34	-0.43	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113352459	chr2:112641832~112645690:-
THYM	cis	rs10129255	0.5	rs4774189	ENSG00000254329.1	IGHVII-60-1	4.66	1.05e-05	0.00772	0.38	0.43	Kawasaki disease;	chr14:106768275	chr14:106637718~106637973:-
THYM	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	4.66	1.05e-05	0.00773	0.56	0.43	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	4.66	1.05e-05	0.00773	0.56	0.43	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	4.66	1.05e-05	0.00773	0.56	0.43	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	4.66	1.05e-05	0.00773	0.56	0.43	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	4.66	1.05e-05	0.00773	0.56	0.43	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	4.66	1.05e-05	0.00773	0.56	0.43	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	4.66	1.05e-05	0.00773	0.56	0.43	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
THYM	cis	rs9549367	0.577	rs3024711	ENSG00000269125.1	RP11-98F14.11	-4.66	1.05e-05	0.00773	-0.67	-0.43	Platelet distribution width;	chr13:113158954	chr13:113165002~113165183:-
THYM	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	4.66	1.05e-05	0.00773	0.66	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
THYM	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	4.66	1.05e-05	0.00773	0.66	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
THYM	cis	rs12908161	0.959	rs34342559	ENSG00000275120.1	RP11-182J1.17	4.66	1.05e-05	0.00773	0.58	0.43	Schizophrenia;	chr15:84788040	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.959	rs62019472	ENSG00000275120.1	RP11-182J1.17	4.66	1.05e-05	0.00773	0.58	0.43	Schizophrenia;	chr15:84788262	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.959	rs35557864	ENSG00000275120.1	RP11-182J1.17	4.66	1.05e-05	0.00773	0.58	0.43	Schizophrenia;	chr15:84788398	chr15:84599434~84606463:-
THYM	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-4.66	1.05e-05	0.00774	-0.57	-0.43	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
THYM	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-4.66	1.05e-05	0.00775	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-4.66	1.05e-05	0.00775	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-4.66	1.05e-05	0.00775	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-4.66	1.05e-05	0.00775	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-4.66	1.05e-05	0.00775	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-4.66	1.05e-05	0.00775	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
THYM	cis	rs561341	0.941	rs112569713	ENSG00000265798.5	RP11-271K11.5	4.66	1.05e-05	0.00775	0.51	0.43	Hip circumference adjusted for BMI;	chr17:31944719	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs8069199	ENSG00000265798.5	RP11-271K11.5	4.66	1.05e-05	0.00775	0.51	0.43	Hip circumference adjusted for BMI;	chr17:31954826	chr17:31038575~31059121:-
THYM	cis	rs561341	0.882	rs111484028	ENSG00000265798.5	RP11-271K11.5	4.66	1.05e-05	0.00775	0.51	0.43	Hip circumference adjusted for BMI;	chr17:31960682	chr17:31038575~31059121:-
THYM	cis	rs561341	0.505	rs548298	ENSG00000265798.5	RP11-271K11.5	4.66	1.05e-05	0.00775	0.51	0.43	Hip circumference adjusted for BMI;	chr17:31970475	chr17:31038575~31059121:-
THYM	cis	rs561341	0.714	rs547473	ENSG00000265798.5	RP11-271K11.5	4.66	1.05e-05	0.00775	0.51	0.43	Hip circumference adjusted for BMI;	chr17:31970541	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs546519	ENSG00000265798.5	RP11-271K11.5	4.66	1.05e-05	0.00775	0.51	0.43	Hip circumference adjusted for BMI;	chr17:31970663	chr17:31038575~31059121:-
THYM	cis	rs935334	0.866	rs12587652	ENSG00000258454.1	RP11-361H10.3	-4.66	1.05e-05	0.00776	-0.56	-0.43	Blood pressure;	chr14:76222270	chr14:76235817~76263474:+
THYM	cis	rs935334	0.877	rs2197480	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76159099	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs1900120	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76160173	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2543383	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76160360	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2543384	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76160958	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs1900122	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76163174	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2591092	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76163790	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2591094	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76165992	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs8005686	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76167624	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs12437310	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76176414	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs4304957	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76181229	chr14:76235817~76263474:+
THYM	cis	rs935334	0.825	rs4389088	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76181254	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs4442739	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76181302	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2121070	ENSG00000258454.1	RP11-361H10.3	4.66	1.05e-05	0.00776	0.56	0.43	Blood pressure;	chr14:76184421	chr14:76235817~76263474:+
THYM	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	4.66	1.05e-05	0.00777	0.53	0.43	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
THYM	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	4.66	1.05e-05	0.00777	0.53	0.43	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
THYM	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	4.66	1.05e-05	0.00777	0.75	0.43	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
THYM	cis	rs7242404	0.57	rs2096863	ENSG00000260302.1	RP11-973H7.1	4.66	1.05e-05	0.00777	0.31	0.43	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12762351	chr18:12774651~12775923:-
THYM	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	4.66	1.05e-05	0.00777	0.33	0.43	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
THYM	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	4.66	1.06e-05	0.00779	0.34	0.43	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	4.66	1.06e-05	0.00779	0.34	0.43	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	4.66	1.06e-05	0.00779	0.34	0.43	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
THYM	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-4.66	1.06e-05	0.00779	-0.46	-0.43	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
THYM	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-4.66	1.06e-05	0.0078	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
THYM	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	4.66	1.06e-05	0.0078	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	4.66	1.06e-05	0.0078	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	4.66	1.06e-05	0.0078	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	4.66	1.06e-05	0.0078	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	4.66	1.06e-05	0.0078	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	4.66	1.06e-05	0.0078	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	4.66	1.06e-05	0.0078	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
THYM	cis	rs853679	0.517	rs6922063	ENSG00000182477.5	OR2B8P	4.66	1.06e-05	0.00781	0.6	0.43	Depression;	chr6:28126588	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs2275508	ENSG00000182477.5	OR2B8P	4.66	1.06e-05	0.00781	0.6	0.43	Depression;	chr6:28126953	chr6:28053228~28054165:-
THYM	cis	rs2662776	0.521	rs2815268	ENSG00000232995.6	RGS5	-4.65	1.06e-05	0.00783	-0.4	-0.43	Lead levels in blood;	chr1:163190945	chr1:163244505~163321894:-
THYM	cis	rs9420	0.528	rs7102271	ENSG00000265566.2	RN7SL605P	-4.65	1.06e-05	0.00783	-0.57	-0.43	Schizophrenia;	chr11:57629352	chr11:57528085~57528365:-
THYM	cis	rs9420	0.528	rs73480556	ENSG00000265566.2	RN7SL605P	-4.65	1.06e-05	0.00783	-0.57	-0.43	Schizophrenia;	chr11:57632989	chr11:57528085~57528365:-
THYM	cis	rs4715166	1	rs4715166	ENSG00000215022.6	RP1-257A7.4	-4.65	1.06e-05	0.00783	-0.41	-0.43	Hip geometry;	chr6:13215826	chr6:13264861~13295586:-
THYM	cis	rs4323050	0.546	rs13124157	ENSG00000249741.2	RP11-673E1.3	-4.65	1.07e-05	0.00784	-0.37	-0.43	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13147170	ENSG00000249741.2	RP11-673E1.3	-4.65	1.07e-05	0.00784	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143975848	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13147184	ENSG00000249741.2	RP11-673E1.3	-4.65	1.07e-05	0.00784	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143975873	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.8	rs13124170	ENSG00000249741.2	RP11-673E1.3	-4.65	1.07e-05	0.00784	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143975951	chr4:143911514~143912053:-
THYM	cis	rs4908769	0.624	rs1763838	ENSG00000232912.4	RP5-1115A15.1	4.65	1.07e-05	0.00784	0.46	0.43	Allergy;	chr1:8413271	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs1763839	ENSG00000232912.4	RP5-1115A15.1	4.65	1.07e-05	0.00784	0.46	0.43	Allergy;	chr1:8413276	chr1:8424645~8434838:+
THYM	cis	rs11017328	0.541	rs56758630	ENSG00000236303.2	RP11-540N6.1	-4.65	1.07e-05	0.00784	-0.62	-0.43	Conotruncal heart defects;	chr10:130500171	chr10:130439067~130483154:+
THYM	cis	rs2283792	0.967	rs3810609	ENSG00000228050.1	TOP3BP1	4.65	1.07e-05	0.00785	0.46	0.43	Multiple sclerosis;	chr22:21758513	chr22:22223187~22224566:-
THYM	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-4.65	1.07e-05	0.00785	-0.92	-0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
THYM	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	4.65	1.07e-05	0.00785	0.57	0.43	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	4.65	1.07e-05	0.00785	0.57	0.43	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
THYM	cis	rs4700393	0.517	rs71592686	ENSG00000272308.1	RP11-231G3.1	4.65	1.07e-05	0.00786	0.53	0.43	Intelligence (multi-trait analysis);	chr5:60825444	chr5:60866457~60866935:-
THYM	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	4.65	1.07e-05	0.00786	0.33	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
THYM	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	4.65	1.07e-05	0.00786	0.33	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
THYM	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	4.65	1.07e-05	0.00787	0.57	0.43	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	4.65	1.07e-05	0.00787	0.57	0.43	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
THYM	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	4.65	1.07e-05	0.00787	0.57	0.43	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
THYM	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	4.65	1.07e-05	0.00787	0.53	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
THYM	cis	rs12908161	1	rs12903134	ENSG00000235370.6	DNM1P51	4.65	1.07e-05	0.00788	0.58	0.43	Schizophrenia;	chr15:84794468	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs35726233	ENSG00000235370.6	DNM1P51	4.65	1.07e-05	0.00788	0.58	0.43	Schizophrenia;	chr15:84794569	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs35960805	ENSG00000235370.6	DNM1P51	4.65	1.07e-05	0.00788	0.58	0.43	Schizophrenia;	chr15:84800749	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs12912388	ENSG00000235370.6	DNM1P51	4.65	1.07e-05	0.00788	0.58	0.43	Schizophrenia;	chr15:84801319	chr15:84398316~84411701:-
THYM	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	4.65	1.07e-05	0.00788	0.56	0.43	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	4.65	1.07e-05	0.00788	0.56	0.43	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	4.65	1.07e-05	0.00788	0.56	0.43	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
THYM	cis	rs3812049	0.784	rs3749748	ENSG00000245937.6	LINC01184	-4.65	1.07e-05	0.00788	-0.45	-0.43	Lymphocyte counts;Red cell distribution width;	chr5:128014857	chr5:127940426~128083172:-
THYM	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	4.65	1.07e-05	0.00789	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
THYM	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	4.65	1.07e-05	0.00789	0.55	0.43	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
THYM	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-4.65	1.07e-05	0.00789	-0.41	-0.43	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
THYM	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	4.65	1.08e-05	0.00789	0.55	0.43	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	4.65	1.08e-05	0.00789	0.55	0.43	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
THYM	cis	rs7223966	1	rs8077265	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63655367	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs6504173	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63657696	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs7216798	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63663603	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9908044	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63669672	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs8068603	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63677851	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9899788	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63679024	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9903903	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63684684	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9901507	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63688164	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs15637	ENSG00000240280.5	TCAM1P	-4.65	1.08e-05	0.00791	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63694690	chr17:63849292~63864379:+
THYM	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-4.65	1.08e-05	0.00791	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-4.65	1.08e-05	0.00791	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
THYM	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-4.65	1.08e-05	0.00792	-0.45	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
THYM	cis	rs10129255	0.5	rs2027903	ENSG00000254329.1	IGHVII-60-1	4.65	1.08e-05	0.00793	0.38	0.43	Kawasaki disease;	chr14:106807047	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs28378320	ENSG00000254329.1	IGHVII-60-1	4.65	1.08e-05	0.00793	0.38	0.43	Kawasaki disease;	chr14:106808609	chr14:106637718~106637973:-
THYM	cis	rs2834288	0.535	rs8129694	ENSG00000237945.6	LINC00649	-4.65	1.08e-05	0.00793	-0.38	-0.43	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.535	rs7275560	ENSG00000237945.6	LINC00649	-4.65	1.08e-05	0.00793	-0.38	-0.43	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.535	rs2834306	ENSG00000237945.6	LINC00649	-4.65	1.08e-05	0.00793	-0.38	-0.43	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33915534~33977691:+
THYM	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-4.65	1.08e-05	0.00794	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
THYM	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	4.65	1.08e-05	0.00794	0.81	0.43	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
THYM	cis	rs4908769	0.66	rs302714	ENSG00000232912.4	RP5-1115A15.1	4.65	1.08e-05	0.00795	0.47	0.43	Allergy;	chr1:8426071	chr1:8424645~8434838:+
THYM	cis	rs73198271	0.74	rs11781430	ENSG00000253893.2	FAM85B	4.65	1.09e-05	0.00797	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.7	rs10090152	ENSG00000253893.2	FAM85B	4.65	1.09e-05	0.00797	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8167819~8226614:-
THYM	cis	rs2787702	0.5	rs72827301	ENSG00000237233.2	TMEM26-AS1	4.65	1.09e-05	0.00797	0.61	0.43	Response to taxane treatment (placlitaxel);	chr10:61550794	chr10:61452639~61481956:+
THYM	cis	rs2787702	0.5	rs72822011	ENSG00000237233.2	TMEM26-AS1	4.65	1.09e-05	0.00797	0.61	0.43	Response to taxane treatment (placlitaxel);	chr10:61573852	chr10:61452639~61481956:+
THYM	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-4.65	1.09e-05	0.00797	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
THYM	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-4.65	1.09e-05	0.00797	-0.39	-0.43	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
THYM	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	4.65	1.09e-05	0.00798	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
THYM	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	4.65	1.09e-05	0.00798	0.57	0.43	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
THYM	cis	rs9500256	0.903	rs726783	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.65	1.09e-05	0.00799	0.34	0.43	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57908560~57913911:-
THYM	cis	rs7560272	0.723	rs7585119	ENSG00000163016.8	ALMS1P	4.65	1.09e-05	0.00799	0.51	0.43	Schizophrenia;	chr2:73497552	chr2:73644919~73685576:+
THYM	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	4.65	1.09e-05	0.00799	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
THYM	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	4.65	1.09e-05	0.00799	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	4.65	1.09e-05	0.00799	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	4.65	1.09e-05	0.00799	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	4.65	1.09e-05	0.00799	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	4.65	1.09e-05	0.00799	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	4.65	1.09e-05	0.00799	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
THYM	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	4.65	1.09e-05	0.00799	0.59	0.43	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
THYM	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-4.65	1.1e-05	0.00801	-0.56	-0.43	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
THYM	cis	rs853679	0.517	rs6932109	ENSG00000182477.5	OR2B8P	-4.65	1.1e-05	0.00803	-0.6	-0.43	Depression;	chr6:28110525	chr6:28053228~28054165:-
THYM	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	4.65	1.1e-05	0.00803	0.51	0.43	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
THYM	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	4.65	1.1e-05	0.00805	0.56	0.43	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
THYM	cis	rs3811273	0.614	rs6572349	ENSG00000211816.2	TRAV38-1	-4.65	1.1e-05	0.00805	-0.38	-0.43	Periodontal disease-related phenotypes;	chr14:22268365	chr14:22271968~22272563:+
THYM	cis	rs12655019	0.92	rs12514633	ENSG00000271828.1	CTD-2310F14.1	4.65	1.1e-05	0.00806	0.83	0.43	Breast cancer (early onset);	chr5:56940186	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs16886525	ENSG00000271828.1	CTD-2310F14.1	4.65	1.1e-05	0.00806	0.83	0.43	Breast cancer (early onset);	chr5:56941838	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs75713680	ENSG00000271828.1	CTD-2310F14.1	4.65	1.1e-05	0.00806	0.83	0.43	Breast cancer (early onset);	chr5:56942377	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs76797434	ENSG00000271828.1	CTD-2310F14.1	4.65	1.1e-05	0.00806	0.83	0.43	Breast cancer (early onset);	chr5:56945862	chr5:56927874~56929573:+
THYM	cis	rs4853012	0.941	rs78128123	ENSG00000272183.1	RP11-523H20.3	4.65	1.1e-05	0.00806	0.61	0.43	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74501717~74502365:+
THYM	cis	rs9309473	0.5	rs2421668	ENSG00000273245.1	RP11-434P11.2	-4.65	1.1e-05	0.00806	-0.47	-0.43	Metabolite levels;	chr2:73657969	chr2:73750256~73750786:-
THYM	cis	rs4835473	0.932	rs1450235	ENSG00000249741.2	RP11-673E1.3	-4.64	1.11e-05	0.00806	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143782927	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs4054616	ENSG00000249741.2	RP11-673E1.3	-4.64	1.11e-05	0.00806	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143837472	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs2323325	ENSG00000249741.2	RP11-673E1.3	-4.64	1.11e-05	0.00806	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143837561	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.8	rs4835330	ENSG00000249741.2	RP11-673E1.3	-4.64	1.11e-05	0.00806	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143846303	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.736	rs6851661	ENSG00000249741.2	RP11-673E1.3	-4.64	1.11e-05	0.00806	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143850587	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs62337619	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143742083	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13152443	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143742492	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs9685306	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143748843	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13107719	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143752034	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs2323194	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143752879	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35055653	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143754836	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35017645	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143760196	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13129993	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143763076	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7697916	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143765628	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1580002	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143766507	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13117421	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143769405	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11724752	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143769473	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs34521499	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143777628	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs34264936	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143780294	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13140028	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143782195	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34324222	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143784572	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.808	rs6836630	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143801068	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13101541	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143806590	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17695238	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143820720	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs35809032	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143824797	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17763107	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143828512	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17695782	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143830311	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34917094	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143832003	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11736609	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143832876	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11730929	ENSG00000249741.2	RP11-673E1.3	4.64	1.11e-05	0.00806	0.37	0.43	Immature fraction of reticulocytes;	chr4:143834795	chr4:143911514~143912053:-
THYM	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	4.64	1.11e-05	0.00807	0.38	0.43	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
THYM	cis	rs7937127	0.744	rs72898983	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43338864	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.696	rs72898993	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43352649	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72898994	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43357020	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.696	rs72898996	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43359775	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.649	rs4132524	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43366611	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72900904	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43371534	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs17508556	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43375340	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs11607970	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43383832	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72900916	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43386781	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.696	rs11601684	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43389017	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs10501297	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43400172	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72900934	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43410740	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs11602575	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43411957	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72900981	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43469757	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.696	rs7114180	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43471236	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs1115492	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43478005	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs55931860	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43478592	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs7104153	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43478744	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72901001	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43481151	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.696	rs11606175	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43481445	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.696	rs72902705	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43483152	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72902709	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43483383	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs72902715	ENSG00000254907.1	RP11-484D2.2	4.64	1.11e-05	0.00807	0.66	0.43	Fibrinogen levels;	chr11:43491230	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs11602173	ENSG00000254907.1	RP11-484D2.2	-4.64	1.11e-05	0.00807	-0.66	-0.43	Fibrinogen levels;	chr11:43460399	chr11:43328748~43359296:-
THYM	cis	rs10129255	0.957	rs8009464	ENSG00000254329.1	IGHVII-60-1	4.64	1.11e-05	0.00807	0.44	0.43	Kawasaki disease;	chr14:106777611	chr14:106637718~106637973:-
THYM	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	4.64	1.11e-05	0.00807	0.47	0.43	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00807	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
THYM	cis	rs2562456	0.876	rs10424079	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21406377	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.876	rs2359144	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21407834	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.834	rs13346641	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21409481	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.876	rs4638726	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21409710	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.839	rs2562411	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21419181	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.876	rs2650844	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21419288	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.876	rs2562413	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21420084	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.916	rs1967182	ENSG00000268081.1	RP11-678G14.2	4.64	1.11e-05	0.00807	0.61	0.43	Pain;	chr19:21420337	chr19:21554640~21569237:-
THYM	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-4.64	1.11e-05	0.00808	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
THYM	cis	rs4908760	0.965	rs10864356	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Vitiligo;	chr1:8509812	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs11121194	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs6577494	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.899	rs6577496	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Vitiligo;	chr1:8521168	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.868	rs12131864	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Vitiligo;	chr1:8531103	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs1463050	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs35865480	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs6702060	ENSG00000232912.4	RP5-1115A15.1	4.64	1.12e-05	0.00809	0.43	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8424645~8434838:+
THYM	cis	rs9834970	0.588	rs4441609	ENSG00000234073.1	AC011816.1	-4.64	1.12e-05	0.00809	-0.46	-0.43	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36851226	chr3:36880184~36880729:-
THYM	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	4.64	1.12e-05	0.00809	0.59	0.43	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
THYM	cis	rs972578	0.806	rs5758955	ENSG00000215347.3	SLC25A5P1	-4.64	1.12e-05	0.00811	-0.35	-0.43	Mean platelet volume;	chr22:42821143	chr22:42001069~42001966:-
THYM	cis	rs2562456	0.834	rs2650848	ENSG00000268081.1	RP11-678G14.2	4.64	1.12e-05	0.00811	0.62	0.43	Pain;	chr19:21403835	chr19:21554640~21569237:-
THYM	cis	rs7849270	0.918	rs746873	ENSG00000268707.1	RP11-247A12.7	4.64	1.12e-05	0.00811	0.58	0.43	Blood metabolite ratios;	chr9:129102671	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs746872	ENSG00000268707.1	RP11-247A12.7	4.64	1.12e-05	0.00811	0.58	0.43	Blood metabolite ratios;	chr9:129102748	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3124498	ENSG00000268707.1	RP11-247A12.7	4.64	1.12e-05	0.00811	0.58	0.43	Blood metabolite ratios;	chr9:129103214	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3124499	ENSG00000268707.1	RP11-247A12.7	4.64	1.12e-05	0.00811	0.58	0.43	Blood metabolite ratios;	chr9:129106712	chr9:129170434~129170940:+
THYM	cis	rs904251	0.561	rs4714070	ENSG00000227920.2	RP1-153P14.5	-4.64	1.12e-05	0.00811	-0.6	-0.43	Cognitive performance;	chr6:37505422	chr6:37545145~37550860:+
THYM	cis	rs904251	0.561	rs4714071	ENSG00000227920.2	RP1-153P14.5	-4.64	1.12e-05	0.00811	-0.6	-0.43	Cognitive performance;	chr6:37506617	chr6:37545145~37550860:+
THYM	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-4.64	1.12e-05	0.00812	-0.51	-0.43	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
THYM	cis	rs4853012	0.887	rs2122290	ENSG00000272183.1	RP11-523H20.3	4.64	1.12e-05	0.00812	0.61	0.43	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74501717~74502365:+
THYM	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	4.64	1.12e-05	0.00812	0.55	0.43	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
THYM	cis	rs62184315	0.58	rs62185872	ENSG00000273240.1	RP11-455J20.3	-4.64	1.12e-05	0.00812	-0.7	-0.43	Alcohol dependence (age at onset);	chr2:189690033	chr2:189763859~189764456:-
THYM	cis	rs7242404	0.549	rs2105665	ENSG00000260302.1	RP11-973H7.1	4.64	1.12e-05	0.00812	0.31	0.43	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12762046	chr18:12774651~12775923:-
THYM	cis	rs2243480	1	rs4718269	ENSG00000228409.4	CCT6P1	-4.64	1.13e-05	0.00812	-0.51	-0.43	Diabetic kidney disease;	chr7:65735810	chr7:65751142~65763354:+
THYM	cis	rs4908768	0.501	rs6668508	ENSG00000232912.4	RP5-1115A15.1	4.64	1.13e-05	0.00813	0.43	0.43	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8424645~8434838:+
THYM	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-4.64	1.13e-05	0.00815	-0.45	-0.43	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	4.64	1.13e-05	0.00815	0.45	0.43	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
THYM	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	4.64	1.14e-05	0.00821	0.32	0.43	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
THYM	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-4.64	1.14e-05	0.00821	-0.32	-0.43	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
THYM	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-4.64	1.14e-05	0.00821	-0.56	-0.43	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-4.64	1.14e-05	0.00821	-0.56	-0.43	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-4.64	1.14e-05	0.00821	-0.56	-0.43	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
THYM	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	4.64	1.15e-05	0.00821	0.51	0.43	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
THYM	cis	rs4715166	0.884	rs1008462	ENSG00000215022.6	RP1-257A7.4	4.64	1.15e-05	0.00822	0.4	0.43	Hip geometry;	chr6:13218666	chr6:13264861~13295586:-
THYM	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-4.64	1.15e-05	0.00822	-0.55	-0.43	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
THYM	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-4.64	1.15e-05	0.00822	-0.55	-0.43	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
THYM	cis	rs9834970	0.566	rs4328757	ENSG00000234073.1	AC011816.1	-4.64	1.15e-05	0.00822	-0.44	-0.43	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36896689	chr3:36880184~36880729:-
THYM	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-4.63	1.15e-05	0.00823	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-4.63	1.15e-05	0.00823	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-4.63	1.15e-05	0.00823	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-4.63	1.15e-05	0.00823	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-4.63	1.15e-05	0.00823	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-4.63	1.15e-05	0.00823	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-4.63	1.15e-05	0.00823	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
THYM	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	4.63	1.15e-05	0.00824	0.49	0.43	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
THYM	cis	rs7605378	0.528	rs281767	ENSG00000232732.8	AC073043.1	-4.63	1.15e-05	0.00824	-0.59	-0.43	Osteoporosis;	chr2:199958558	chr2:199867396~199911159:-
THYM	cis	rs7605378	0.528	rs281791	ENSG00000232732.8	AC073043.1	4.63	1.15e-05	0.00824	0.59	0.43	Osteoporosis;	chr2:199985679	chr2:199867396~199911159:-
THYM	cis	rs7560272	0.538	rs13000788	ENSG00000273245.1	RP11-434P11.2	-4.63	1.15e-05	0.00825	-0.52	-0.43	Schizophrenia;	chr2:73691185	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs6732812	ENSG00000273245.1	RP11-434P11.2	-4.63	1.15e-05	0.00825	-0.52	-0.43	Schizophrenia;	chr2:73695348	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs17434634	ENSG00000273245.1	RP11-434P11.2	-4.63	1.15e-05	0.00825	-0.52	-0.43	Schizophrenia;	chr2:73695799	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs7370393	ENSG00000273245.1	RP11-434P11.2	-4.63	1.15e-05	0.00825	-0.52	-0.43	Schizophrenia;	chr2:73698509	chr2:73750256~73750786:-
THYM	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-4.63	1.16e-05	0.00827	-0.42	-0.43	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
THYM	cis	rs4478858	0.684	rs11578407	ENSG00000260386.4	LINC01225	4.63	1.16e-05	0.00828	0.24	0.43	Alcohol dependence;	chr1:31255696	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs12403136	ENSG00000260386.4	LINC01225	4.63	1.16e-05	0.00828	0.24	0.43	Alcohol dependence;	chr1:31256073	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs3753374	ENSG00000260386.4	LINC01225	4.63	1.16e-05	0.00828	0.24	0.43	Alcohol dependence;	chr1:31267821	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs3737755	ENSG00000260386.4	LINC01225	4.63	1.16e-05	0.00828	0.24	0.43	Alcohol dependence;	chr1:31271321	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs12135540	ENSG00000260386.4	LINC01225	4.63	1.16e-05	0.00828	0.24	0.43	Alcohol dependence;	chr1:31291846	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs12725881	ENSG00000260386.4	LINC01225	-4.63	1.16e-05	0.00828	-0.24	-0.43	Alcohol dependence;	chr1:31263276	chr1:31500085~31540885:+
THYM	cis	rs995834	0.585	rs8106726	ENSG00000260725.1	AC005307.1	-4.63	1.16e-05	0.00828	-0.46	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397316	chr19:28418483~28429490:-
THYM	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-4.63	1.16e-05	0.00829	-0.37	-0.43	Breast cancer;	chr11:743813	chr11:777578~784297:+
THYM	cis	rs2739330	0.732	rs5760175	ENSG00000272787.1	KB-226F1.2	-4.63	1.16e-05	0.0083	-0.49	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23969211~23969873:+
THYM	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-4.63	1.16e-05	0.0083	-0.42	-0.43	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
THYM	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-4.63	1.16e-05	0.0083	-0.3	-0.43	Height;	chr11:118747911	chr11:118791254~118793137:+
THYM	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-4.63	1.16e-05	0.0083	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
THYM	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-4.63	1.16e-05	0.00831	-0.67	-0.43	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
THYM	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-4.63	1.17e-05	0.00832	-0.53	-0.43	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
THYM	cis	rs9376098	0.825	rs6569999	ENSG00000232876.1	CTA-212D2.2	4.63	1.17e-05	0.00832	0.48	0.43	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161428	chr6:135055033~135060550:+
THYM	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	4.63	1.17e-05	0.00832	0.55	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
THYM	cis	rs7560272	0.538	rs4852976	ENSG00000163016.8	ALMS1P	-4.63	1.17e-05	0.00833	-0.53	-0.43	Schizophrenia;	chr2:73709195	chr2:73644919~73685576:+
THYM	cis	rs7989332	0.961	rs7321826	ENSG00000279065.1	RP11-264J4.10	-4.63	1.17e-05	0.00833	-0.53	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20479227	chr13:20194412~20196005:+
THYM	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	4.63	1.17e-05	0.00833	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
THYM	cis	rs2115630	0.641	rs11073613	ENSG00000275120.1	RP11-182J1.17	-4.63	1.17e-05	0.00833	-0.49	-0.43	P wave terminal force;	chr15:84642662	chr15:84599434~84606463:-
THYM	cis	rs8059260	0.736	rs76818150	ENSG00000274038.1	RP11-66H6.4	-4.63	1.17e-05	0.00836	-0.75	-0.43	Alcohol consumption over the past year;	chr16:10955006	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs113433437	ENSG00000274038.1	RP11-66H6.4	-4.63	1.17e-05	0.00836	-0.75	-0.43	Alcohol consumption over the past year;	chr16:10959438	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs8046423	ENSG00000274038.1	RP11-66H6.4	-4.63	1.17e-05	0.00836	-0.75	-0.43	Alcohol consumption over the past year;	chr16:10964016	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs77599345	ENSG00000274038.1	RP11-66H6.4	-4.63	1.17e-05	0.00836	-0.75	-0.43	Alcohol consumption over the past year;	chr16:10964707	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.736	rs79361721	ENSG00000274038.1	RP11-66H6.4	-4.63	1.17e-05	0.00836	-0.75	-0.43	Alcohol consumption over the past year;	chr16:10968082	chr16:11056556~11057034:+
THYM	cis	rs3862435	0.572	rs2589969	ENSG00000259212.1	CTD-3065B20.2	-4.63	1.17e-05	0.00838	-0.64	-0.43	Response to exercise (triglyceride level interaction);	chr15:90364819	chr15:90595840~90596447:-
THYM	cis	rs4663866	0.908	rs2304670	ENSG00000186235.9	AC016757.3	4.63	1.17e-05	0.00838	0.95	0.43	Irritable bowel syndrome;	chr2:238256995	chr2:238224552~238231677:-
THYM	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-4.63	1.18e-05	0.00839	-0.42	-0.43	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
THYM	cis	rs2834288	0.535	rs13049489	ENSG00000237945.6	LINC00649	4.63	1.18e-05	0.0084	0.38	0.43	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.535	rs7278341	ENSG00000237945.6	LINC00649	4.63	1.18e-05	0.0084	0.38	0.43	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.535	rs7279183	ENSG00000237945.6	LINC00649	4.63	1.18e-05	0.0084	0.38	0.43	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33915534~33977691:+
THYM	cis	rs10931896	0.531	rs296801	ENSG00000232732.8	AC073043.1	-4.63	1.18e-05	0.0084	-0.52	-0.43	Systolic blood pressure;	chr2:200278089	chr2:199867396~199911159:-
THYM	cis	rs10805346	0.558	rs12506562	ENSG00000261490.1	RP11-448G15.3	4.63	1.18e-05	0.00842	0.37	0.43	Urate levels in obese individuals;Urate levels in overweight individuals;	chr4:10105330	chr4:10068089~10073019:-
THYM	cis	rs17445774	0.857	rs6435043	ENSG00000232732.8	AC073043.1	-4.63	1.18e-05	0.00842	-0.56	-0.43	LDL cholesterol to HDL cholesterol ratio;	chr2:200036251	chr2:199867396~199911159:-
THYM	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-4.63	1.18e-05	0.00842	-0.37	-0.43	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
THYM	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	4.63	1.18e-05	0.00843	0.54	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
THYM	cis	rs4835473	0.897	rs2089835	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143965127	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.639	rs28674022	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143966409	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs28423022	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143966416	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs35888177	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143966863	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10033382	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143967103	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7667092	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143968604	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs3874	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143968795	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2323417	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143969108	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs11931330	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143970808	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.549	rs11940719	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143970855	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.83	rs7692672	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143971048	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.766	rs6537222	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143971459	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs6537223	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143971541	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.615	rs6857432	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143971912	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.831	rs7689328	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143973768	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.831	rs7694353	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143973787	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.798	rs34353812	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143973949	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.831	rs10428468	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143974104	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.75	rs57610804	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143974341	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13148097	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143976238	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs28377887	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143977075	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6826862	ENSG00000249741.2	RP11-673E1.3	-4.63	1.18e-05	0.00843	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143978180	chr4:143911514~143912053:-
THYM	cis	rs7560272	0.538	rs17434655	ENSG00000273245.1	RP11-434P11.2	4.63	1.19e-05	0.00843	0.51	0.43	Schizophrenia;	chr2:73695962	chr2:73750256~73750786:-
THYM	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	4.63	1.19e-05	0.00843	0.57	0.43	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
THYM	cis	rs8067545	0.611	rs2526466	ENSG00000230528.6	NOS2P3	4.63	1.19e-05	0.00843	0.36	0.43	Schizophrenia;	chr17:20261938	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs1992561	ENSG00000230528.6	NOS2P3	4.63	1.19e-05	0.00843	0.36	0.43	Schizophrenia;	chr17:20315806	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs7222984	ENSG00000230528.6	NOS2P3	-4.63	1.19e-05	0.00843	-0.36	-0.43	Schizophrenia;	chr17:20116381	chr17:20436337~20447249:+
THYM	cis	rs7223966	1	rs7211213	ENSG00000240280.5	TCAM1P	-4.63	1.19e-05	0.00844	-0.65	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63692096	chr17:63849292~63864379:+
THYM	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	4.63	1.19e-05	0.00844	0.51	0.43	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-4.63	1.19e-05	0.00844	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-4.63	1.19e-05	0.00844	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-4.63	1.19e-05	0.00844	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
THYM	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	4.63	1.19e-05	0.00844	0.52	0.43	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
THYM	cis	rs910316	0.503	rs12894709	ENSG00000258646.1	RP11-950C14.3	-4.63	1.19e-05	0.00844	-0.37	-0.43	Height;	chr14:74975031	chr14:75004719~75008481:-
THYM	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	4.63	1.19e-05	0.00844	0.44	0.43	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
THYM	cis	rs4663866	1	rs2304668	ENSG00000186235.9	AC016757.3	4.63	1.19e-05	0.00844	1.05	0.43	Irritable bowel syndrome;	chr2:238259807	chr2:238224552~238231677:-
THYM	cis	rs9914578	1	rs4061660	ENSG00000236838.2	AC090617.1	4.63	1.19e-05	0.00844	0.65	0.43	Body mass index;	chr17:2101083	chr17:2213697~2214414:+
THYM	cis	rs950169	0.96	rs12905475	ENSG00000235370.6	DNM1P51	4.62	1.2e-05	0.00844	0.56	0.43	Schizophrenia;	chr15:84131743	chr15:84398316~84411701:-
THYM	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	4.62	1.2e-05	0.00846	0.92	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
THYM	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	4.62	1.2e-05	0.00846	0.4	0.43	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
THYM	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-4.62	1.2e-05	0.00848	-0.62	-0.43	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
THYM	cis	rs9907295	0.818	rs4796109	ENSG00000270871.1	AC015849.19	4.62	1.2e-05	0.00848	0.48	0.43	Fibroblast growth factor basic levels;	chr17:35811904	chr17:35816717~35830293:-
THYM	cis	rs34792	0.688	rs170168	ENSG00000262380.1	CTB-193M12.3	4.62	1.2e-05	0.00848	0.54	0.43	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507138	chr16:15683290~15684570:+
THYM	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-4.62	1.2e-05	0.00849	-0.48	-0.43	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
THYM	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	4.62	1.21e-05	0.0085	0.52	0.43	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	4.62	1.21e-05	0.0085	0.52	0.43	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	4.62	1.21e-05	0.0085	0.52	0.43	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
THYM	cis	rs4478858	0.611	rs6425721	ENSG00000260386.4	LINC01225	4.62	1.21e-05	0.00852	0.24	0.43	Alcohol dependence;	chr1:31241960	chr1:31500085~31540885:+
THYM	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	4.62	1.21e-05	0.00852	0.55	0.43	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	4.62	1.21e-05	0.00852	0.55	0.43	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	4.62	1.21e-05	0.00852	0.55	0.43	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
THYM	cis	rs73198271	0.681	rs35457364	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.641	rs34473848	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.601	rs11997731	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.681	rs11987924	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10100066	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10110711	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10103163	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.599	rs10103169	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.7	rs10103282	ENSG00000253893.2	FAM85B	4.62	1.21e-05	0.00852	0.63	0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-4.62	1.21e-05	0.00852	-0.63	-0.43	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
THYM	cis	rs858239	0.669	rs1618339	ENSG00000226816.2	AC005082.12	4.62	1.21e-05	0.00852	0.62	0.43	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23206013~23208045:+
THYM	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	4.62	1.21e-05	0.00852	0.58	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
THYM	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-4.62	1.21e-05	0.00853	-0.54	-0.43	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
THYM	cis	rs4835473	0.831	rs4452380	ENSG00000249741.2	RP11-673E1.3	-4.62	1.21e-05	0.00854	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143972856	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs36018946	ENSG00000249741.2	RP11-673E1.3	4.62	1.21e-05	0.00854	0.37	0.43	Immature fraction of reticulocytes;	chr4:143980942	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13101531	ENSG00000249741.2	RP11-673E1.3	4.62	1.21e-05	0.00854	0.37	0.43	Immature fraction of reticulocytes;	chr4:143982197	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs28668841	ENSG00000249741.2	RP11-673E1.3	4.62	1.21e-05	0.00854	0.37	0.43	Immature fraction of reticulocytes;	chr4:143982530	chr4:143911514~143912053:-
THYM	cis	rs10129255	0.5	rs1974468	ENSG00000253703.1	IGHV1-68	-4.62	1.21e-05	0.00854	-0.47	-0.43	Kawasaki disease;	chr14:106686149	chr14:106703852~106704146:-
THYM	cis	rs1023500	0.505	rs2143139	ENSG00000227370.1	RP4-669P10.19	4.62	1.21e-05	0.00854	0.53	0.43	Schizophrenia;	chr22:42218395	chr22:42132543~42132998:+
THYM	cis	rs10931896	0.531	rs295118	ENSG00000232732.8	AC073043.1	-4.62	1.21e-05	0.00854	-0.51	-0.43	Systolic blood pressure;	chr2:200279281	chr2:199867396~199911159:-
THYM	cis	rs10931896	0.531	rs295117	ENSG00000232732.8	AC073043.1	-4.62	1.21e-05	0.00854	-0.51	-0.43	Systolic blood pressure;	chr2:200282105	chr2:199867396~199911159:-
THYM	cis	rs9309473	0.5	rs12472502	ENSG00000163016.8	ALMS1P	-4.62	1.22e-05	0.00855	-0.48	-0.43	Metabolite levels;	chr2:73632057	chr2:73644919~73685576:+
THYM	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-4.62	1.22e-05	0.00856	-0.52	-0.43	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
THYM	cis	rs9903692	0.909	rs1468270	ENSG00000266601.1	RP11-6N17.3	-4.62	1.22e-05	0.00856	-0.4	-0.43	Pulse pressure;	chr17:48047829	chr17:47929682~47933106:-
THYM	cis	rs17711722	0.523	rs313812	ENSG00000232906.1	RP11-746P2.3	-4.62	1.22e-05	0.00857	-0.42	-0.43	Calcium levels;	chr7:66040056	chr7:65355934~65357176:+
THYM	cis	rs5769707	0.777	rs739243	ENSG00000264139.1	MIR3667	-4.62	1.22e-05	0.00858	-0.47	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49543393~49543466:-
THYM	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	4.62	1.22e-05	0.00859	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	4.62	1.22e-05	0.00859	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	4.62	1.22e-05	0.00859	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	4.62	1.22e-05	0.00859	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
THYM	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	4.62	1.22e-05	0.00859	0.57	0.43	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
THYM	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-4.62	1.22e-05	0.0086	-0.54	-0.43	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
THYM	cis	rs2283792	0.73	rs738858	ENSG00000228050.1	TOP3BP1	4.62	1.22e-05	0.0086	0.48	0.43	Multiple sclerosis;	chr22:21926544	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.73	rs2329884	ENSG00000228050.1	TOP3BP1	4.62	1.22e-05	0.0086	0.48	0.43	Multiple sclerosis;	chr22:21927890	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.73	rs2083565	ENSG00000228050.1	TOP3BP1	4.62	1.22e-05	0.0086	0.48	0.43	Multiple sclerosis;	chr22:21929985	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.73	rs2027790	ENSG00000228050.1	TOP3BP1	4.62	1.22e-05	0.0086	0.48	0.43	Multiple sclerosis;	chr22:21933592	chr22:22223187~22224566:-
THYM	cis	rs1426063	0.748	rs10005117	ENSG00000249717.1	RP11-44F21.3	4.62	1.23e-05	0.0086	0.65	0.43	QT interval;	chr4:75108281	chr4:74955974~74970362:-
THYM	cis	rs526231	0.644	rs386352	ENSG00000175749.11	EIF3KP1	4.62	1.23e-05	0.00862	0.56	0.43	Primary biliary cholangitis;	chr5:103280006	chr5:103032376~103033031:+
THYM	cis	rs526231	0.67	rs253756	ENSG00000175749.11	EIF3KP1	4.62	1.23e-05	0.00862	0.56	0.43	Primary biliary cholangitis;	chr5:103284771	chr5:103032376~103033031:+
THYM	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	4.62	1.23e-05	0.00862	0.56	0.43	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
THYM	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-4.62	1.23e-05	0.00862	-0.6	-0.43	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
THYM	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-4.62	1.23e-05	0.00863	-0.37	-0.43	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
THYM	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-4.62	1.23e-05	0.00863	-0.37	-0.43	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
THYM	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-4.62	1.23e-05	0.00863	-0.43	-0.43	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
THYM	cis	rs10411161	1	rs8106929	ENSG00000269483.1	AC006272.1	4.62	1.23e-05	0.00863	0.58	0.43	Breast cancer;	chr19:51865214	chr19:51839924~51843324:-
THYM	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-4.62	1.23e-05	0.00863	-0.44	-0.43	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
THYM	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	4.62	1.23e-05	0.00863	0.51	0.43	Height;	chr6:109430398	chr6:109382795~109383666:+
THYM	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	4.62	1.23e-05	0.00863	0.66	0.43	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
THYM	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-4.62	1.23e-05	0.00864	-0.35	-0.43	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
THYM	cis	rs7209700	0.778	rs3851807	ENSG00000228782.6	CTD-2026D20.3	-4.62	1.23e-05	0.00865	-0.52	-0.43	IgG glycosylation;	chr17:47274153	chr17:47450568~47492492:-
THYM	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-4.62	1.23e-05	0.00866	-0.53	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
THYM	cis	rs4835473	0.932	rs6852502	ENSG00000249741.2	RP11-673E1.3	-4.62	1.23e-05	0.00866	-0.36	-0.43	Immature fraction of reticulocytes;	chr4:143987174	chr4:143911514~143912053:-
THYM	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	4.62	1.24e-05	0.0087	0.32	0.43	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
THYM	cis	rs4835473	0.897	rs7682204	ENSG00000249741.2	RP11-673E1.3	-4.62	1.24e-05	0.0087	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143966306	chr4:143911514~143912053:-
THYM	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-4.62	1.24e-05	0.00871	-0.58	-0.43	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
THYM	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	4.62	1.24e-05	0.00871	0.51	0.43	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
THYM	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	4.61	1.24e-05	0.00872	0.55	0.43	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
THYM	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	4.61	1.24e-05	0.00872	0.55	0.43	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
THYM	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-4.61	1.25e-05	0.00875	-0.3	-0.43	Height;	chr11:118760944	chr11:118791254~118793137:+
THYM	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	4.61	1.25e-05	0.00876	0.52	0.43	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
THYM	cis	rs7617773	0.925	rs6442105	ENSG00000228638.1	FCF1P2	4.61	1.25e-05	0.00877	0.46	0.43	Coronary artery disease;	chr3:48140836	chr3:48290793~48291375:-
THYM	cis	rs12681366	0.801	rs2930956	ENSG00000253704.1	RP11-267M23.4	4.61	1.25e-05	0.00877	0.57	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94553722~94569745:+
THYM	cis	rs1550576	0.568	rs56066922	ENSG00000274719.1	RP11-86K22.2	4.61	1.25e-05	0.00877	0.83	0.43	Hypertension;	chr15:57944611	chr15:57990217~57990636:-
THYM	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-4.61	1.25e-05	0.00878	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
THYM	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	4.61	1.25e-05	0.00878	0.56	0.43	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
THYM	cis	rs9309473	0.519	rs35421685	ENSG00000163016.8	ALMS1P	-4.61	1.25e-05	0.00878	-0.51	-0.43	Metabolite levels;	chr2:73683011	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs7606947	ENSG00000163016.8	ALMS1P	4.61	1.25e-05	0.00878	0.51	0.43	Metabolite levels;	chr2:73682691	chr2:73644919~73685576:+
THYM	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	4.61	1.26e-05	0.00879	0.54	0.43	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
THYM	cis	rs1642645	0.831	rs4660212	ENSG00000228452.1	RP5-994D16.9	4.61	1.26e-05	0.00882	0.57	0.43	Left ventricular obstructive tract defect (maternal effect);	chr1:42030728	chr1:42775813~42776790:-
THYM	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	4.61	1.26e-05	0.00882	0.44	0.43	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
THYM	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	4.61	1.26e-05	0.00882	0.32	0.43	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
THYM	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	4.61	1.26e-05	0.00882	0.32	0.43	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
THYM	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	4.61	1.26e-05	0.00882	0.32	0.43	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
THYM	cis	rs1061377	0.513	rs2566162	ENSG00000249685.1	RP11-360F5.3	4.61	1.26e-05	0.00882	0.45	0.43	Uric acid levels;	chr4:39126453	chr4:39133913~39135608:+
THYM	cis	rs4925386	0.802	rs6142735	ENSG00000273619.1	RP5-908M14.9	-4.61	1.26e-05	0.00884	-0.35	-0.43	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62386303~62386970:-
THYM	cis	rs8067545	0.611	rs2526465	ENSG00000230528.6	NOS2P3	4.61	1.26e-05	0.00885	0.35	0.43	Schizophrenia;	chr17:20264298	chr17:20436337~20447249:+
THYM	cis	rs2115630	0.936	rs11073663	ENSG00000275120.1	RP11-182J1.17	-4.61	1.27e-05	0.00885	-0.5	-0.43	P wave terminal force;	chr15:84717037	chr15:84599434~84606463:-
THYM	cis	rs6782228	0.585	rs2712392	ENSG00000277250.1	Metazoa_SRP	-4.61	1.27e-05	0.00886	-0.59	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128673681~128674021:-
THYM	cis	rs62246343	0.719	rs1973243	ENSG00000254485.4	RP11-380O24.1	4.61	1.27e-05	0.00887	0.64	0.43	Fibrinogen levels;	chr3:9450592	chr3:9292588~9363303:-
THYM	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	4.61	1.27e-05	0.00887	0.52	0.43	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
THYM	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	4.61	1.27e-05	0.00888	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
THYM	cis	rs8062405	0.728	rs11642449	ENSG00000259982.1	CDC37P1	4.61	1.27e-05	0.00889	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.728	rs8056890	ENSG00000259982.1	CDC37P1	4.61	1.27e-05	0.00889	0.6	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28700294~28701540:-
THYM	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-4.61	1.27e-05	0.00889	-0.46	-0.43	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
THYM	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	4.61	1.27e-05	0.00889	0.33	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
THYM	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-4.61	1.27e-05	0.00889	-0.67	-0.43	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-4.61	1.27e-05	0.00889	-0.67	-0.43	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
THYM	cis	rs11096990	0.855	rs2566183	ENSG00000249685.1	RP11-360F5.3	-4.61	1.27e-05	0.0089	-0.43	-0.43	Cognitive function;	chr4:39162288	chr4:39133913~39135608:+
THYM	cis	rs2834288	0.5	rs7283594	ENSG00000273102.1	AP000569.9	-4.61	1.27e-05	0.0089	-0.46	-0.43	Gut microbiota (bacterial taxa);	chr21:33962798	chr21:33967101~33968573:-
THYM	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	4.61	1.28e-05	0.00891	0.59	0.43	Depression;	chr6:28399846	chr6:28176188~28176674:+
THYM	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	4.61	1.28e-05	0.00891	0.59	0.43	Depression;	chr6:28402301	chr6:28176188~28176674:+
THYM	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-4.61	1.28e-05	0.00894	-0.46	-0.43	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
THYM	cis	rs2911132	0.564	rs13181579	ENSG00000272109.1	CTD-2260A17.3	-4.61	1.28e-05	0.00894	-0.56	-0.43	Urate levels (BMI interaction);	chr5:96755234	chr5:96804353~96806105:+
THYM	cis	rs2911132	0.564	rs28580505	ENSG00000272109.1	CTD-2260A17.3	-4.61	1.28e-05	0.00894	-0.56	-0.43	Urate levels (BMI interaction);	chr5:96765516	chr5:96804353~96806105:+
THYM	cis	rs2911132	0.621	rs28432918	ENSG00000272109.1	CTD-2260A17.3	-4.61	1.28e-05	0.00894	-0.56	-0.43	Urate levels (BMI interaction);	chr5:96765522	chr5:96804353~96806105:+
THYM	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-4.61	1.28e-05	0.00895	-0.57	-0.43	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
THYM	cis	rs1550576	0.568	rs117530007	ENSG00000274719.1	RP11-86K22.2	4.61	1.28e-05	0.00896	0.88	0.43	Hypertension;	chr15:58045152	chr15:57990217~57990636:-
THYM	cis	rs5769707	0.967	rs763126	ENSG00000264139.1	MIR3667	4.61	1.29e-05	0.00897	0.47	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49543393~49543466:-
THYM	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-4.61	1.29e-05	0.00898	-0.39	-0.43	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
THYM	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-4.61	1.29e-05	0.00898	-0.39	-0.43	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
THYM	cis	rs526231	0.764	rs599447	ENSG00000175749.11	EIF3KP1	4.61	1.29e-05	0.00898	0.54	0.43	Primary biliary cholangitis;	chr5:103302154	chr5:103032376~103033031:+
THYM	cis	rs526231	0.764	rs2569014	ENSG00000175749.11	EIF3KP1	4.61	1.29e-05	0.00898	0.54	0.43	Primary biliary cholangitis;	chr5:103302398	chr5:103032376~103033031:+
THYM	cis	rs526231	0.725	rs487937	ENSG00000175749.11	EIF3KP1	4.61	1.29e-05	0.00898	0.54	0.43	Primary biliary cholangitis;	chr5:103302541	chr5:103032376~103033031:+
THYM	cis	rs526231	0.764	rs2116755	ENSG00000175749.11	EIF3KP1	4.61	1.29e-05	0.00898	0.54	0.43	Primary biliary cholangitis;	chr5:103314187	chr5:103032376~103033031:+
THYM	cis	rs526231	0.764	rs372564	ENSG00000175749.11	EIF3KP1	4.61	1.29e-05	0.00898	0.54	0.43	Primary biliary cholangitis;	chr5:103314823	chr5:103032376~103033031:+
THYM	cis	rs9309473	0.539	rs6732440	ENSG00000273245.1	RP11-434P11.2	-4.61	1.29e-05	0.00899	-0.5	-0.43	Metabolite levels;	chr2:73599972	chr2:73750256~73750786:-
THYM	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	4.61	1.29e-05	0.00899	0.57	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
THYM	cis	rs61774743	0.754	rs11581271	ENSG00000229901.1	RP11-399E6.4	-4.61	1.29e-05	0.009	-0.4	-0.43	Intelligence (multi-trait analysis);	chr1:41369389	chr1:41375004~41375669:-
THYM	cis	rs995834	0.703	rs4806354	ENSG00000267243.4	AC005307.3	-4.61	1.29e-05	0.009	-0.42	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396974	chr19:28435388~28727777:-
THYM	cis	rs995834	0.703	rs4806355	ENSG00000267243.4	AC005307.3	-4.61	1.29e-05	0.009	-0.42	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28396997	chr19:28435388~28727777:-
THYM	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-4.6	1.29e-05	0.00902	-0.46	-0.43	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
THYM	cis	rs8067545	0.611	rs2703800	ENSG00000230528.6	NOS2P3	-4.6	1.29e-05	0.00902	-0.35	-0.43	Schizophrenia;	chr17:20183249	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.586	rs2526478	ENSG00000230528.6	NOS2P3	-4.6	1.29e-05	0.00902	-0.35	-0.43	Schizophrenia;	chr17:20227139	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs12603372	ENSG00000230528.6	NOS2P3	-4.6	1.29e-05	0.00902	-0.35	-0.43	Schizophrenia;	chr17:20278253	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs10491107	ENSG00000230528.6	NOS2P3	-4.6	1.29e-05	0.00902	-0.35	-0.43	Schizophrenia;	chr17:20284861	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2526486	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20198313	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.586	rs2703819	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20218088	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.562	rs2526481	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20223705	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703771	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20226841	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2526477	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20227880	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs7219615	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20229245	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2526476	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20230976	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703775	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20231153	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703776	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20234396	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703777	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20235578	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703781	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20241401	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs757494	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20247027	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703786	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20253056	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs733794	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20254644	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703788	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20256373	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2158472	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20268211	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.586	rs3850779	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20268559	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.586	rs11657161	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20277402	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.563	rs3850780	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20278589	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs11653630	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20285733	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs12949481	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20287661	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs77449863	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20288547	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs12938355	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20291904	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.636	rs11204300	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20292125	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs11653869	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20294273	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.586	rs57837691	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20299760	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs1373146	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20303362	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.516	rs11869258	ENSG00000230528.6	NOS2P3	4.6	1.29e-05	0.00902	0.35	0.43	Schizophrenia;	chr17:20303585	chr17:20436337~20447249:+
THYM	cis	rs2562456	0.833	rs4321312	ENSG00000268081.1	RP11-678G14.2	4.6	1.29e-05	0.00902	0.58	0.43	Pain;	chr19:21336614	chr19:21554640~21569237:-
THYM	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-4.6	1.3e-05	0.00902	-0.5	-0.43	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
THYM	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	4.6	1.3e-05	0.00903	0.52	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
THYM	cis	rs10129255	0.5	rs8011115	ENSG00000254329.1	IGHVII-60-1	4.6	1.3e-05	0.00906	0.38	0.43	Kawasaki disease;	chr14:106786292	chr14:106637718~106637973:-
THYM	cis	rs6887276	0.504	rs1003136	ENSG00000245937.6	LINC01184	4.6	1.3e-05	0.00907	0.4	0.43	Height;	chr5:128012123	chr5:127940426~128083172:-
THYM	cis	rs17711722	0.565	rs4717276	ENSG00000232906.1	RP11-746P2.3	4.6	1.3e-05	0.00907	0.43	0.43	Calcium levels;	chr7:65829754	chr7:65355934~65357176:+
THYM	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-4.6	1.31e-05	0.00911	-0.74	-0.43	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
THYM	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-4.6	1.31e-05	0.00911	-0.57	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
THYM	cis	rs972578	0.868	rs2413727	ENSG00000215347.3	SLC25A5P1	-4.6	1.31e-05	0.00912	-0.34	-0.43	Mean platelet volume;	chr22:42896108	chr22:42001069~42001966:-
THYM	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	4.6	1.31e-05	0.00912	0.41	0.43	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
THYM	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	4.6	1.31e-05	0.00912	0.43	0.43	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
THYM	cis	rs4663866	0.901	rs3739067	ENSG00000186235.9	AC016757.3	4.6	1.31e-05	0.00913	1.02	0.43	Irritable bowel syndrome;	chr2:238275562	chr2:238224552~238231677:-
THYM	cis	rs992157	0.764	rs10193189	ENSG00000261338.2	RP11-378A13.1	4.6	1.31e-05	0.00914	0.56	0.43	Colorectal cancer;	chr2:218322880	chr2:218255319~218257366:+
THYM	cis	rs950169	0.58	rs17598114	ENSG00000275120.1	RP11-182J1.17	4.6	1.32e-05	0.00917	0.57	0.43	Schizophrenia;	chr15:84628086	chr15:84599434~84606463:-
THYM	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	4.6	1.32e-05	0.00917	0.78	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
THYM	cis	rs8177876	0.658	rs75422577	ENSG00000261838.4	RP11-303E16.6	4.6	1.32e-05	0.00919	0.96	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	4.6	1.32e-05	0.00919	0.96	0.43	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
THYM	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-4.6	1.32e-05	0.00921	-0.4	-0.43	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
THYM	cis	rs7223966	0.921	rs11655493	ENSG00000240280.5	TCAM1P	-4.6	1.33e-05	0.00921	-0.65	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63655692	chr17:63849292~63864379:+
THYM	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	4.6	1.33e-05	0.00922	0.48	0.43	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
THYM	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	4.6	1.33e-05	0.00923	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
THYM	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-4.6	1.33e-05	0.00923	-0.59	-0.43	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
THYM	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	4.6	1.33e-05	0.00923	0.4	0.43	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
THYM	cis	rs8067545	0.586	rs8080649	ENSG00000230528.6	NOS2P3	-4.6	1.33e-05	0.00924	-0.36	-0.43	Schizophrenia;	chr17:20166364	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs1859407	ENSG00000230528.6	NOS2P3	4.6	1.33e-05	0.00924	0.36	0.43	Schizophrenia;	chr17:20174824	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.586	rs2526463	ENSG00000230528.6	NOS2P3	4.6	1.33e-05	0.00924	0.36	0.43	Schizophrenia;	chr17:20174984	chr17:20436337~20447249:+
THYM	cis	rs7560272	0.723	rs7562047	ENSG00000163016.8	ALMS1P	4.6	1.33e-05	0.00925	0.5	0.43	Schizophrenia;	chr2:73498041	chr2:73644919~73685576:+
THYM	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	4.6	1.33e-05	0.00927	0.37	0.43	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
THYM	cis	rs11168351	0.75	rs11168366	ENSG00000240399.1	RP1-228P16.1	-4.6	1.34e-05	0.00928	-0.41	-0.43	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48054813~48055591:-
THYM	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	4.6	1.34e-05	0.00928	0.54	0.43	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
THYM	cis	rs1023500	0.551	rs133379	ENSG00000227370.1	RP4-669P10.19	4.6	1.34e-05	0.00929	0.51	0.43	Schizophrenia;	chr22:42072531	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.506	rs6002625	ENSG00000227370.1	RP4-669P10.19	-4.6	1.34e-05	0.00929	-0.51	-0.43	Schizophrenia;	chr22:42121685	chr22:42132543~42132998:+
THYM	cis	rs189798	0.738	rs330908	ENSG00000253893.2	FAM85B	-4.6	1.34e-05	0.0093	-0.56	-0.43	Myopia (pathological);	chr8:9137656	chr8:8167819~8226614:-
THYM	cis	rs9527	1	rs9527	ENSG00000272933.1	RP11-47A8.5	4.6	1.34e-05	0.0093	0.48	0.43	Arsenic metabolism;	chr10:102863821	chr10:102642792~102644140:-
THYM	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	4.6	1.34e-05	0.0093	0.73	0.43	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
THYM	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	4.6	1.34e-05	0.0093	0.73	0.43	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
THYM	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	4.6	1.34e-05	0.0093	0.73	0.43	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
THYM	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-4.6	1.34e-05	0.0093	-0.73	-0.43	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
THYM	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	4.6	1.34e-05	0.0093	0.31	0.43	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
THYM	cis	rs7560272	0.538	rs4852972	ENSG00000273245.1	RP11-434P11.2	-4.6	1.34e-05	0.0093	-0.52	-0.43	Schizophrenia;	chr2:73689545	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs2421575	ENSG00000273245.1	RP11-434P11.2	-4.6	1.34e-05	0.0093	-0.52	-0.43	Schizophrenia;	chr2:73692395	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs13014700	ENSG00000273245.1	RP11-434P11.2	-4.6	1.34e-05	0.0093	-0.52	-0.43	Schizophrenia;	chr2:73692994	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.512	rs13015885	ENSG00000273245.1	RP11-434P11.2	-4.6	1.34e-05	0.0093	-0.52	-0.43	Schizophrenia;	chr2:73693355	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs35767294	ENSG00000273245.1	RP11-434P11.2	-4.6	1.34e-05	0.0093	-0.52	-0.43	Schizophrenia;	chr2:73695707	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs13006448	ENSG00000273245.1	RP11-434P11.2	-4.6	1.34e-05	0.0093	-0.52	-0.43	Schizophrenia;	chr2:73697297	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.502	rs13013228	ENSG00000273245.1	RP11-434P11.2	-4.6	1.34e-05	0.0093	-0.52	-0.43	Schizophrenia;	chr2:73698089	chr2:73750256~73750786:-
THYM	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-4.59	1.34e-05	0.0093	-0.38	-0.43	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
THYM	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	1.34e-05	0.0093	-0.39	-0.43	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
THYM	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-4.59	1.34e-05	0.0093	-0.53	-0.43	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
THYM	cis	rs2738048	1	rs2702908	ENSG00000233531.1	DEFA10P	4.59	1.35e-05	0.00931	0.49	0.43	IgA nephropathy;	chr8:6967092	chr8:6968141~6969113:-
THYM	cis	rs4908769	0.66	rs301803	ENSG00000232912.4	RP5-1115A15.1	4.59	1.35e-05	0.00931	0.46	0.43	Allergy;	chr1:8438620	chr1:8424645~8434838:+
THYM	cis	rs9309473	0.519	rs13022145	ENSG00000163016.8	ALMS1P	-4.59	1.35e-05	0.00931	-0.48	-0.43	Metabolite levels;	chr2:73636346	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs4852950	ENSG00000163016.8	ALMS1P	-4.59	1.35e-05	0.00931	-0.48	-0.43	Metabolite levels;	chr2:73637543	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.5	rs4852952	ENSG00000163016.8	ALMS1P	-4.59	1.35e-05	0.00931	-0.48	-0.43	Metabolite levels;	chr2:73642780	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.5	rs4852953	ENSG00000163016.8	ALMS1P	-4.59	1.35e-05	0.00931	-0.48	-0.43	Metabolite levels;	chr2:73642781	chr2:73644919~73685576:+
THYM	cis	rs4835473	0.864	rs2323418	ENSG00000249741.2	RP11-673E1.3	-4.59	1.35e-05	0.00931	-0.36	-0.43	Immature fraction of reticulocytes;	chr4:143969141	chr4:143911514~143912053:-
THYM	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	4.59	1.35e-05	0.00932	0.37	0.43	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
THYM	cis	rs8067545	0.641	rs203458	ENSG00000231645.2	KRT17P6	-4.59	1.35e-05	0.00932	-0.51	-0.43	Schizophrenia;	chr17:19913585	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs2108978	ENSG00000231645.2	KRT17P6	-4.59	1.35e-05	0.00932	-0.51	-0.43	Schizophrenia;	chr17:19958145	chr17:20512560~20517479:-
THYM	cis	rs995834	0.742	rs1971674	ENSG00000267243.4	AC005307.3	-4.59	1.35e-05	0.00932	-0.39	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28343033	chr19:28435388~28727777:-
THYM	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	4.59	1.35e-05	0.00933	0.67	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
THYM	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-4.59	1.35e-05	0.00935	-0.51	-0.43	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
THYM	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	4.59	1.35e-05	0.00935	0.51	0.43	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
THYM	cis	rs8067545	0.611	rs2013443	ENSG00000230528.6	NOS2P3	-4.59	1.35e-05	0.00935	-0.35	-0.43	Schizophrenia;	chr17:20119796	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs7212500	ENSG00000230528.6	NOS2P3	-4.59	1.35e-05	0.00935	-0.35	-0.43	Schizophrenia;	chr17:20142345	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.578	rs9901336	ENSG00000230528.6	NOS2P3	-4.59	1.35e-05	0.00935	-0.35	-0.43	Schizophrenia;	chr17:20160877	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs4925090	ENSG00000230528.6	NOS2P3	-4.59	1.35e-05	0.00935	-0.35	-0.43	Schizophrenia;	chr17:20163318	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs9907516	ENSG00000230528.6	NOS2P3	-4.59	1.35e-05	0.00935	-0.35	-0.43	Schizophrenia;	chr17:20167177	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.611	rs2703795	ENSG00000230528.6	NOS2P3	4.59	1.35e-05	0.00935	0.35	0.43	Schizophrenia;	chr17:20173828	chr17:20436337~20447249:+
THYM	cis	rs9907295	0.818	rs2280789	ENSG00000270871.1	AC015849.19	4.59	1.35e-05	0.00935	0.38	0.43	Fibroblast growth factor basic levels;	chr17:35879999	chr17:35816717~35830293:-
THYM	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	4.59	1.35e-05	0.00935	0.56	0.43	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
THYM	cis	rs950169	0.544	rs2036949	ENSG00000275120.1	RP11-182J1.17	4.59	1.36e-05	0.00936	0.58	0.43	Schizophrenia;	chr15:84620374	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs11635597	ENSG00000275120.1	RP11-182J1.17	4.59	1.36e-05	0.00936	0.58	0.43	Schizophrenia;	chr15:84622468	chr15:84599434~84606463:-
THYM	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	4.59	1.36e-05	0.00936	0.34	0.43	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
THYM	cis	rs8067545	0.641	rs203457	ENSG00000231645.2	KRT17P6	4.59	1.36e-05	0.00937	0.51	0.43	Schizophrenia;	chr17:19915025	chr17:20512560~20517479:-
THYM	cis	rs10129255	0.5	rs4600373	ENSG00000253703.1	IGHV1-68	-4.59	1.36e-05	0.00938	-0.47	-0.43	Kawasaki disease;	chr14:106704809	chr14:106703852~106704146:-
THYM	cis	rs995834	0.589	rs6508802	ENSG00000267243.4	AC005307.3	-4.59	1.36e-05	0.00938	-0.39	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362304	chr19:28435388~28727777:-
THYM	cis	rs995834	0.743	rs758313	ENSG00000267243.4	AC005307.3	-4.59	1.36e-05	0.00938	-0.39	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28363094	chr19:28435388~28727777:-
THYM	cis	rs995834	0.742	rs1155575	ENSG00000267243.4	AC005307.3	-4.59	1.36e-05	0.00938	-0.39	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28369526	chr19:28435388~28727777:-
THYM	cis	rs853679	0.55	rs1237875	ENSG00000272009.1	RP1-313I6.12	4.59	1.36e-05	0.00939	0.54	0.43	Depression;	chr6:28205232	chr6:28078792~28081130:-
THYM	cis	rs4835473	0.932	rs12503900	ENSG00000251600.4	RP11-673E1.1	-4.59	1.36e-05	0.0094	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:143812459	chr4:143912331~143982454:+
THYM	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-4.59	1.36e-05	0.0094	-0.45	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
THYM	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-4.59	1.36e-05	0.0094	-0.45	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
THYM	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-4.59	1.36e-05	0.0094	-0.5	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-4.59	1.36e-05	0.0094	-0.5	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
THYM	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-4.59	1.36e-05	0.0094	-0.53	-0.43	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
THYM	cis	rs950169	0.544	rs62021193	ENSG00000275120.1	RP11-182J1.17	4.59	1.36e-05	0.00941	0.58	0.43	Schizophrenia;	chr15:84627352	chr15:84599434~84606463:-
THYM	cis	rs8067545	0.641	rs203481	ENSG00000231645.2	KRT17P6	-4.59	1.37e-05	0.00943	-0.51	-0.43	Schizophrenia;	chr17:19925415	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.616	rs203477	ENSG00000231645.2	KRT17P6	-4.59	1.37e-05	0.00943	-0.51	-0.43	Schizophrenia;	chr17:19928506	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs850623	ENSG00000231645.2	KRT17P6	-4.59	1.37e-05	0.00943	-0.51	-0.43	Schizophrenia;	chr17:19933817	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs169412	ENSG00000231645.2	KRT17P6	-4.59	1.37e-05	0.00943	-0.51	-0.43	Schizophrenia;	chr17:19948562	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs4925060	ENSG00000231645.2	KRT17P6	-4.59	1.37e-05	0.00943	-0.51	-0.43	Schizophrenia;	chr17:19959945	chr17:20512560~20517479:-
THYM	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	4.59	1.37e-05	0.00944	0.31	0.43	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
THYM	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	4.59	1.37e-05	0.00944	0.57	0.43	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
THYM	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	4.59	1.37e-05	0.00944	0.67	0.43	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
THYM	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	4.59	1.37e-05	0.00944	0.67	0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
THYM	cis	rs7937127	0.744	rs2862958	ENSG00000254907.1	RP11-484D2.2	4.59	1.37e-05	0.00945	0.62	0.43	Fibrinogen levels;	chr11:43497572	chr11:43328748~43359296:-
THYM	cis	rs10411161	1	rs10414104	ENSG00000269483.1	AC006272.1	4.59	1.37e-05	0.00946	0.57	0.43	Breast cancer;	chr19:51864879	chr19:51839924~51843324:-
THYM	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	4.59	1.37e-05	0.00946	0.34	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
THYM	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	4.59	1.37e-05	0.00946	0.34	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
THYM	cis	rs4478858	0.611	rs1007012	ENSG00000260386.4	LINC01225	4.59	1.37e-05	0.00946	0.24	0.43	Alcohol dependence;	chr1:31237221	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.647	rs1007013	ENSG00000260386.4	LINC01225	4.59	1.37e-05	0.00946	0.24	0.43	Alcohol dependence;	chr1:31237423	chr1:31500085~31540885:+
THYM	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-4.59	1.38e-05	0.00947	-0.57	-0.43	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
THYM	cis	rs4835473	0.932	rs11100824	ENSG00000249741.2	RP11-673E1.3	-4.59	1.38e-05	0.00948	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143964845	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.592	rs11100825	ENSG00000249741.2	RP11-673E1.3	-4.59	1.38e-05	0.00948	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143964903	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs2089837	ENSG00000249741.2	RP11-673E1.3	-4.59	1.38e-05	0.00948	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143965038	chr4:143911514~143912053:-
THYM	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	4.59	1.38e-05	0.00948	0.53	0.43	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
THYM	cis	rs12908161	1	rs34570071	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84736981	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs60957376	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84737561	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs11632465	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84738814	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.96	rs17599989	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84742305	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.96	rs62019463	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84744856	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs62019464	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84751238	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs12910012	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84755431	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs12899981	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84759142	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.92	rs35758837	ENSG00000235370.6	DNM1P51	4.59	1.38e-05	0.00948	0.57	0.43	Schizophrenia;	chr15:84768151	chr15:84398316~84411701:-
THYM	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	4.59	1.38e-05	0.00948	0.52	0.43	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
THYM	cis	rs6040076	0.817	rs6032925	ENSG00000230506.1	RP11-416N4.4	4.59	1.38e-05	0.00949	0.48	0.43	Pulse pressure;Birth weight;	chr20:10710826	chr20:10173520~10196990:+
THYM	cis	rs5742933	0.69	rs16831821	ENSG00000273240.1	RP11-455J20.3	-4.59	1.38e-05	0.00949	-0.71	-0.43	Ferritin levels;	chr2:189641087	chr2:189763859~189764456:-
THYM	cis	rs4853012	0.838	rs61521879	ENSG00000257702.3	LBX2-AS1	4.59	1.38e-05	0.00949	0.47	0.43	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74502595~74504678:+
THYM	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-4.59	1.38e-05	0.0095	-0.37	-0.43	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
THYM	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-4.59	1.38e-05	0.0095	-0.59	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
THYM	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-4.59	1.38e-05	0.00951	-0.4	-0.43	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
THYM	cis	rs4853012	0.838	rs4452177	ENSG00000257702.3	LBX2-AS1	4.59	1.38e-05	0.00952	0.46	0.43	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74502595~74504678:+
THYM	cis	rs4853012	0.838	rs60705299	ENSG00000257702.3	LBX2-AS1	4.59	1.38e-05	0.00952	0.46	0.43	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74502595~74504678:+
THYM	cis	rs4853012	0.838	rs6715351	ENSG00000257702.3	LBX2-AS1	4.59	1.38e-05	0.00952	0.46	0.43	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74502595~74504678:+
THYM	cis	rs9309473	0.519	rs2421670	ENSG00000273245.1	RP11-434P11.2	-4.59	1.39e-05	0.00952	-0.47	-0.43	Metabolite levels;	chr2:73659534	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs12618600	ENSG00000273245.1	RP11-434P11.2	-4.59	1.39e-05	0.00952	-0.47	-0.43	Metabolite levels;	chr2:73663555	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.5	rs2421582	ENSG00000273245.1	RP11-434P11.2	-4.59	1.39e-05	0.00952	-0.47	-0.43	Metabolite levels;	chr2:73671293	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs2421583	ENSG00000273245.1	RP11-434P11.2	-4.59	1.39e-05	0.00952	-0.47	-0.43	Metabolite levels;	chr2:73671658	chr2:73750256~73750786:-
THYM	cis	rs972578	0.804	rs5758948	ENSG00000215347.3	SLC25A5P1	-4.59	1.39e-05	0.00953	-0.35	-0.43	Mean platelet volume;	chr22:42799290	chr22:42001069~42001966:-
THYM	cis	rs972578	0.804	rs2179872	ENSG00000215347.3	SLC25A5P1	-4.59	1.39e-05	0.00953	-0.35	-0.43	Mean platelet volume;	chr22:42799691	chr22:42001069~42001966:-
THYM	cis	rs2338	0.625	rs9378638	ENSG00000218027.2	RP11-157J24.1	-4.59	1.39e-05	0.00954	-0.51	-0.43	Response to platinum-based agents;	chr6:1578955	chr6:1513698~1515289:-
THYM	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	4.59	1.39e-05	0.00954	0.55	0.43	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
THYM	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-4.59	1.39e-05	0.00954	-0.51	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-4.59	1.39e-05	0.00954	-0.51	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-4.59	1.39e-05	0.00954	-0.51	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
THYM	cis	rs2243480	1	rs4718270	ENSG00000228409.4	CCT6P1	4.59	1.39e-05	0.00956	0.53	0.43	Diabetic kidney disease;	chr7:65737415	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.901	rs2900904	ENSG00000228409.4	CCT6P1	4.59	1.39e-05	0.00956	0.53	0.43	Diabetic kidney disease;	chr7:65739282	chr7:65751142~65763354:+
THYM	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	4.59	1.39e-05	0.00957	0.35	0.43	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	4.59	1.39e-05	0.00957	0.35	0.43	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	4.59	1.39e-05	0.00957	0.35	0.43	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	4.59	1.39e-05	0.00957	0.35	0.43	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	4.59	1.39e-05	0.00957	0.35	0.43	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
THYM	cis	rs34792	0.688	rs153786	ENSG00000262380.1	CTB-193M12.3	4.59	1.39e-05	0.00957	0.53	0.43	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499857	chr16:15683290~15684570:+
THYM	cis	rs34792	0.626	rs153788	ENSG00000262380.1	CTB-193M12.3	4.59	1.39e-05	0.00957	0.53	0.43	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15500346	chr16:15683290~15684570:+
THYM	cis	rs995834	0.742	rs4805164	ENSG00000267243.4	AC005307.3	-4.58	1.4e-05	0.0096	-0.4	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28340111	chr19:28435388~28727777:-
THYM	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-4.58	1.4e-05	0.00962	-0.44	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
THYM	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-4.58	1.4e-05	0.00962	-0.57	-0.43	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-4.58	1.4e-05	0.00962	-0.57	-0.43	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
THYM	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-4.58	1.4e-05	0.00962	-0.57	-0.43	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
THYM	cis	rs7223966	1	rs9901112	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63653257	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs2874121	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63653664	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9909992	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63654571	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs8074771	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63658505	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs8070650	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63666680	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs992416	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63668545	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs11079508	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63672706	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs12325866	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63678614	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9912904	ENSG00000240280.5	TCAM1P	-4.58	1.4e-05	0.00962	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63686174	chr17:63849292~63864379:+
THYM	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-4.58	1.4e-05	0.00962	-0.53	-0.43	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-4.58	1.4e-05	0.00962	-0.53	-0.43	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
THYM	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	4.58	1.4e-05	0.00962	0.55	0.43	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
THYM	cis	rs935334	1	rs2543382	ENSG00000258454.1	RP11-361H10.3	4.58	1.4e-05	0.00963	0.55	0.43	Blood pressure;	chr14:76158544	chr14:76235817~76263474:+
THYM	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	4.58	1.4e-05	0.00963	0.57	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	4.58	1.4e-05	0.00963	0.57	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
THYM	cis	rs1642645	0.831	rs12042133	ENSG00000228452.1	RP5-994D16.9	4.58	1.41e-05	0.00964	0.55	0.43	Left ventricular obstructive tract defect (maternal effect);	chr1:42033694	chr1:42775813~42776790:-
THYM	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-4.58	1.41e-05	0.00964	-0.35	-0.43	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
THYM	cis	rs42490	1	rs42490	ENSG00000251136.7	RP11-37B2.1	-4.58	1.41e-05	0.00964	-0.35	-0.43	Leprosy;	chr8:89766285	chr8:89609409~89757727:-
THYM	cis	rs42490	0.966	rs40377	ENSG00000251136.7	RP11-37B2.1	-4.58	1.41e-05	0.00964	-0.35	-0.43	Leprosy;	chr8:89769725	chr8:89609409~89757727:-
THYM	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-4.58	1.41e-05	0.00964	-0.4	-0.43	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
THYM	cis	rs12439619	0.846	rs7496227	ENSG00000274376.3	ADAMTS7P1	4.58	1.41e-05	0.00965	0.48	0.43	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82298553~82334609:+
THYM	cis	rs73108077	1	rs58925751	ENSG00000277112.2	RP11-755J8.1	-4.58	1.41e-05	0.00967	-0.71	-0.43	Red blood cell density in sickle cell anemia;	chr20:31459409	chr20:30681825~30723932:-
THYM	cis	rs526231	0.857	rs415657	ENSG00000175749.11	EIF3KP1	-4.58	1.41e-05	0.00969	-0.53	-0.43	Primary biliary cholangitis;	chr5:103329295	chr5:103032376~103033031:+
THYM	cis	rs1426063	0.668	rs6534595	ENSG00000248165.1	RP11-44F21.2	4.58	1.42e-05	0.00969	0.63	0.43	QT interval;	chr4:75104432	chr4:74993877~75034824:-
THYM	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-4.58	1.42e-05	0.0097	-0.53	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
THYM	cis	rs7202877	0.706	rs37605	ENSG00000261783.1	RP11-252K23.2	4.58	1.42e-05	0.00971	0.61	0.43	Type 1 diabetes;Type 2 diabetes;	chr16:75472674	chr16:75379818~75381260:-
THYM	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-4.58	1.42e-05	0.00972	-0.52	-0.43	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
THYM	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	4.58	1.42e-05	0.00972	0.55	0.43	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	4.58	1.42e-05	0.00973	0.56	0.43	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
THYM	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	4.58	1.42e-05	0.00973	0.39	0.43	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
THYM	cis	rs2235573	0.805	rs132934	ENSG00000272669.1	RP3-508I15.21	-4.58	1.42e-05	0.00973	-0.28	-0.43	Glioma;Glioblastoma;	chr22:38093551	chr22:38742625~38743115:+
THYM	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-4.58	1.42e-05	0.00975	-0.51	-0.43	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
THYM	cis	rs904251	0.647	rs2776908	ENSG00000279942.1	RP1-153P14.7	-4.58	1.43e-05	0.00976	-0.66	-0.43	Cognitive performance;	chr6:37467081	chr6:37567716~37571460:+
THYM	cis	rs4835473	0.715	rs1849124	ENSG00000249741.2	RP11-673E1.3	-4.58	1.43e-05	0.00976	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143978494	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.689	rs1849123	ENSG00000249741.2	RP11-673E1.3	-4.58	1.43e-05	0.00976	-0.37	-0.43	Immature fraction of reticulocytes;	chr4:143978495	chr4:143911514~143912053:-
THYM	cis	rs10129255	0.5	rs2105989	ENSG00000253703.1	IGHV1-68	-4.58	1.43e-05	0.00977	-0.47	-0.43	Kawasaki disease;	chr14:106682199	chr14:106703852~106704146:-
THYM	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	4.58	1.43e-05	0.00977	0.5	0.43	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
THYM	cis	rs2253762	0.645	rs11200366	ENSG00000276742.1	RP11-500G22.4	-4.58	1.43e-05	0.00978	-0.5	-0.43	Breast cancer;	chr10:122044170	chr10:121956782~121957098:+
THYM	cis	rs8067545	0.641	rs203455	ENSG00000231645.2	KRT17P6	-4.58	1.43e-05	0.00978	-0.51	-0.43	Schizophrenia;	chr17:19917872	chr17:20512560~20517479:-
THYM	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	4.58	1.43e-05	0.0098	0.54	0.43	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
THYM	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	4.58	1.43e-05	0.0098	0.54	0.43	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	4.58	1.43e-05	0.0098	0.54	0.43	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	4.58	1.43e-05	0.0098	0.54	0.43	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
THYM	cis	rs2911132	0.621	rs17480169	ENSG00000272109.1	CTD-2260A17.3	-4.58	1.44e-05	0.00981	-0.56	-0.43	Urate levels (BMI interaction);	chr5:96753363	chr5:96804353~96806105:+
THYM	cis	rs7701440	0.512	rs2055375	ENSG00000272308.1	RP11-231G3.1	4.58	1.44e-05	0.00984	0.37	0.43	Educational attainment;	chr5:61235393	chr5:60866457~60866935:-
THYM	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-4.58	1.44e-05	0.00984	-0.37	-0.43	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
THYM	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	4.58	1.45e-05	0.00988	0.5	0.43	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
THYM	cis	rs9834970	0.588	rs28522146	ENSG00000234073.1	AC011816.1	-4.58	1.45e-05	0.0099	-0.45	-0.43	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36865331	chr3:36880184~36880729:-
THYM	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	4.58	1.45e-05	0.00991	0.69	0.43	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
THYM	cis	rs17711722	0.565	rs73372653	ENSG00000232906.1	RP11-746P2.3	4.58	1.45e-05	0.00991	0.42	0.43	Calcium levels;	chr7:65977808	chr7:65355934~65357176:+
THYM	cis	rs7937127	0.744	rs72902723	ENSG00000254907.1	RP11-484D2.2	4.57	1.45e-05	0.00992	0.6	0.43	Fibrinogen levels;	chr11:43497105	chr11:43328748~43359296:-
THYM	cis	rs7202877	0.656	rs9923834	ENSG00000261783.1	RP11-252K23.2	-4.57	1.45e-05	0.00993	-0.6	-0.43	Type 1 diabetes;Type 2 diabetes;	chr16:75473355	chr16:75379818~75381260:-
THYM	cis	rs7937127	0.557	rs72898959	ENSG00000254907.1	RP11-484D2.2	4.57	1.46e-05	0.00995	0.65	0.43	Fibrinogen levels;	chr11:43308887	chr11:43328748~43359296:-
THYM	cis	rs73108077	0.736	rs6119276	ENSG00000277112.2	RP11-755J8.1	-4.57	1.46e-05	0.00995	-0.55	-0.43	Red blood cell density in sickle cell anemia;	chr20:31363733	chr20:30681825~30723932:-
THYM	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-4.57	1.46e-05	0.00996	-0.39	-0.43	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-4.57	1.46e-05	0.00996	-0.39	-0.43	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-4.57	1.46e-05	0.00996	-0.39	-0.43	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
THYM	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-4.57	1.46e-05	0.00998	-0.49	-0.43	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
THYM	cis	rs13134327	0.513	rs7679687	ENSG00000251600.4	RP11-673E1.1	-4.57	1.46e-05	0.00999	-0.48	-0.43	Glycated hemoglobin levels;	chr4:144024031	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.618	rs7685385	ENSG00000251600.4	RP11-673E1.1	-4.57	1.46e-05	0.00999	-0.48	-0.43	Immature fraction of reticulocytes;	chr4:144029851	chr4:143912331~143982454:+
THYM	cis	rs10888838	0.938	rs11206304	ENSG00000198711.5	SSBP3-AS1	-4.57	1.47e-05	0.01	-0.29	-0.43	Mitochondrial DNA levels;	chr1:54213646	chr1:54236440~54239063:+
THYM	cis	rs440932	1	rs440932	ENSG00000253893.2	FAM85B	-4.57	1.47e-05	0.01	-0.55	-0.43	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8167819~8226614:-
THYM	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-4.57	1.47e-05	0.01	-0.58	-0.43	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
THYM	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	4.57	1.47e-05	0.01	0.53	0.43	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	4.57	1.47e-05	0.01	0.53	0.43	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
THYM	cis	rs9914578	0.943	rs3760231	ENSG00000236838.2	AC090617.1	4.57	1.47e-05	0.01	0.64	0.43	Body mass index;	chr17:2111690	chr17:2213697~2214414:+
THYM	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-4.57	1.47e-05	0.01	-0.47	-0.43	Depression;	chr6:27871968	chr6:28115628~28116551:+
THYM	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-4.57	1.47e-05	0.01	-0.53	-0.43	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
THYM	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-4.57	1.47e-05	0.01	-0.53	-0.43	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
THYM	cis	rs904251	0.686	rs2776911	ENSG00000227920.2	RP1-153P14.5	-4.57	1.47e-05	0.01	-0.64	-0.43	Cognitive performance;	chr6:37472174	chr6:37545145~37550860:+
THYM	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	4.57	1.47e-05	0.0101	0.52	0.43	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
THYM	cis	rs4691139	0.619	rs2139218	ENSG00000250227.1	TRIM60P14	4.57	1.48e-05	0.0101	0.51	0.43	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001275	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.595	rs10000199	ENSG00000250227.1	TRIM60P14	4.57	1.48e-05	0.0101	0.51	0.43	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001813	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.557	rs4485779	ENSG00000250227.1	TRIM60P14	4.57	1.48e-05	0.0101	0.51	0.43	Ovarian cancer in BRCA1 mutation carriers;	chr4:165002877	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.634	rs4583719	ENSG00000250227.1	TRIM60P14	4.57	1.48e-05	0.0101	0.51	0.43	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003505	chr4:164915565~164916983:+
THYM	cis	rs42490	1	rs431264	ENSG00000251136.7	RP11-37B2.1	-4.57	1.48e-05	0.0101	-0.35	-0.43	Leprosy;	chr8:89765282	chr8:89609409~89757727:-
THYM	cis	rs2115630	1	rs55646601	ENSG00000275120.1	RP11-182J1.17	-4.57	1.48e-05	0.0101	-0.51	-0.43	P wave terminal force;	chr15:84780337	chr15:84599434~84606463:-
THYM	cis	rs34773007	0.514	rs2488084	ENSG00000272817.1	RP11-402D21.2	4.57	1.48e-05	0.0101	0.46	0.43	Type 2 diabetes;	chr10:92776096	chr10:91908131~91909348:+
THYM	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	4.57	1.48e-05	0.0101	0.33	0.43	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
THYM	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-4.57	1.48e-05	0.0101	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-4.57	1.48e-05	0.0101	-0.47	-0.43	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
THYM	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-4.57	1.48e-05	0.0101	-0.69	-0.43	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
THYM	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-4.57	1.48e-05	0.0101	-0.51	-0.43	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
THYM	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-4.57	1.48e-05	0.0101	-0.39	-0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	4.57	1.48e-05	0.0101	0.39	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
THYM	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	4.57	1.48e-05	0.0101	0.54	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
THYM	cis	rs202072	0.676	rs202048	ENSG00000272379.1	RP1-257A7.5	4.57	1.48e-05	0.0101	0.64	0.43	HIV-1 viral setpoint;	chr6:13274269	chr6:13290018~13290490:-
THYM	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	4.57	1.48e-05	0.0101	0.48	0.43	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
THYM	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-4.57	1.49e-05	0.0101	-0.45	-0.43	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
THYM	cis	rs7223966	1	rs6504171	ENSG00000240280.5	TCAM1P	-4.57	1.49e-05	0.0102	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63632650	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs7209435	ENSG00000240280.5	TCAM1P	-4.57	1.49e-05	0.0102	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63635604	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9903897	ENSG00000240280.5	TCAM1P	-4.57	1.49e-05	0.0102	-0.64	-0.43	Hip circumference adjusted for BMI;Body mass index;	chr17:63639345	chr17:63849292~63864379:+
THYM	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-4.57	1.5e-05	0.0102	-0.33	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
THYM	cis	rs10411161	1	rs10402988	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51859851	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs2867318	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51860219	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs6509581	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51860629	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs8108477	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51861649	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs8109345	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51861680	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs8108583	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51861724	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs4514789	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51862401	chr19:51839924~51843324:-
THYM	cis	rs10411161	0.935	rs8107422	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51865522	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs8111316	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51865816	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs10402727	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51867126	chr19:51839924~51843324:-
THYM	cis	rs10411161	1	rs10409331	ENSG00000269483.1	AC006272.1	4.57	1.5e-05	0.0102	0.57	0.43	Breast cancer;	chr19:51867709	chr19:51839924~51843324:-
THYM	cis	rs6782228	0.606	rs4634140	ENSG00000277250.1	Metazoa_SRP	4.57	1.5e-05	0.0102	0.58	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128673681~128674021:-
THYM	cis	rs8059260	0.541	rs35126143	ENSG00000274038.1	RP11-66H6.4	-4.57	1.5e-05	0.0102	-0.76	-0.43	Alcohol consumption over the past year;	chr16:11070455	chr16:11056556~11057034:+
THYM	cis	rs2283792	1	rs9607287	ENSG00000228050.1	TOP3BP1	4.57	1.5e-05	0.0102	0.47	0.43	Multiple sclerosis;	chr22:21809136	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs3788332	ENSG00000228050.1	TOP3BP1	4.57	1.5e-05	0.0102	0.47	0.43	Multiple sclerosis;	chr22:21817278	chr22:22223187~22224566:-
THYM	cis	rs4835473	0.932	rs1849113	ENSG00000249741.2	RP11-673E1.3	4.57	1.5e-05	0.0102	0.4	0.43	Immature fraction of reticulocytes;	chr4:143962512	chr4:143911514~143912053:-
THYM	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-4.57	1.5e-05	0.0102	-0.77	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
THYM	cis	rs8067545	0.75	rs4925069	ENSG00000230528.6	NOS2P3	-4.57	1.51e-05	0.0102	-0.34	-0.43	Schizophrenia;	chr17:20050218	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.685	rs4479309	ENSG00000230528.6	NOS2P3	-4.57	1.51e-05	0.0102	-0.34	-0.43	Schizophrenia;	chr17:20068270	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs4925072	ENSG00000230528.6	NOS2P3	4.57	1.51e-05	0.0102	0.34	0.43	Schizophrenia;	chr17:20053586	chr17:20436337~20447249:+
THYM	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-4.57	1.51e-05	0.0102	-0.52	-0.43	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
THYM	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-4.57	1.51e-05	0.0102	-0.5	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
THYM	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-4.57	1.51e-05	0.0102	-0.5	-0.43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
THYM	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	4.57	1.51e-05	0.0102	0.51	0.43	Height;	chr6:109449796	chr6:109382795~109383666:+
THYM	cis	rs12439619	0.846	rs62013464	ENSG00000274376.3	ADAMTS7P1	4.57	1.51e-05	0.0102	0.48	0.43	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82298553~82334609:+
THYM	cis	rs12429252	1	rs12429252	ENSG00000238121.4	LINC00426	-4.56	1.51e-05	0.0102	-0.37	-0.43	Fractional exhaled nitric oxide (childhood);	chr13:30342126	chr13:30340270~30377145:-
THYM	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	4.56	1.51e-05	0.0103	0.7	0.43	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
THYM	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	4.56	1.51e-05	0.0103	0.51	0.43	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	4.56	1.51e-05	0.0103	0.51	0.43	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	4.56	1.51e-05	0.0103	0.51	0.43	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	4.56	1.51e-05	0.0103	0.51	0.43	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	4.56	1.51e-05	0.0103	0.51	0.43	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
THYM	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	4.56	1.51e-05	0.0103	0.56	0.43	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
THYM	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	4.56	1.52e-05	0.0103	0.31	0.43	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
THYM	cis	rs56307353	0.653	rs4807189	ENSG00000180846.7	CSNK1G2-AS1	4.56	1.52e-05	0.0103	0.45	0.43	Coronary artery disease;	chr19:1976641	chr19:1952531~1954586:-
THYM	cis	rs2911132	0.568	rs3797814	ENSG00000272109.1	CTD-2260A17.3	-4.56	1.52e-05	0.0103	-0.54	-0.43	Urate levels (BMI interaction);	chr5:96756222	chr5:96804353~96806105:+
THYM	cis	rs2911132	0.564	rs7356594	ENSG00000272109.1	CTD-2260A17.3	-4.56	1.52e-05	0.0103	-0.54	-0.43	Urate levels (BMI interaction);	chr5:96760485	chr5:96804353~96806105:+
THYM	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	4.56	1.52e-05	0.0103	0.47	0.43	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
THYM	cis	rs12554020	0.786	rs3893381	ENSG00000227603.1	RP11-165J3.6	-4.56	1.52e-05	0.0103	-0.52	-0.43	Schizophrenia;	chr9:93519576	chr9:93435332~93437121:-
THYM	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	4.56	1.53e-05	0.0103	0.67	0.43	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
THYM	cis	rs1606355	0.895	rs789009	ENSG00000230519.2	RP11-1060J15.5	4.56	1.53e-05	0.0103	0.65	0.43	Metabolite levels (Pyroglutamine);	chr12:28695031	chr12:27702338~27702906:+
THYM	cis	rs2408955	0.522	rs3997	ENSG00000240399.1	RP1-228P16.1	-4.56	1.53e-05	0.0103	-0.39	-0.43	Glycated hemoglobin levels;	chr12:48087804	chr12:48054813~48055591:-
THYM	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-4.56	1.53e-05	0.0104	-0.3	-0.43	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
THYM	cis	rs863345	0.604	rs10908651	ENSG00000236656.1	RP11-144L1.4	-4.56	1.53e-05	0.0104	-0.27	-0.43	Pneumococcal bacteremia;	chr1:158481482	chr1:158474454~158494886:-
THYM	cis	rs867371	0.896	rs8033831	ENSG00000276710.3	CSPG4P8	-4.56	1.53e-05	0.0104	-0.43	-0.43	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82459472~82477258:+
THYM	cis	rs7937127	0.744	rs72902711	ENSG00000254907.1	RP11-484D2.2	4.56	1.54e-05	0.0104	0.65	0.43	Fibrinogen levels;	chr11:43484897	chr11:43328748~43359296:-
THYM	cis	rs9309473	0.519	rs2421574	ENSG00000273245.1	RP11-434P11.2	-4.56	1.54e-05	0.0104	-0.48	-0.43	Metabolite levels;	chr2:73681640	chr2:73750256~73750786:-
THYM	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	4.56	1.54e-05	0.0104	0.54	0.43	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
THYM	cis	rs6672530	0.518	rs6683151	ENSG00000227711.2	RP11-275O4.5	-4.56	1.54e-05	0.0104	-0.37	-0.43	Hip circumference adjusted for BMI;	chr1:227623813	chr1:227509028~227520477:-
THYM	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-4.56	1.54e-05	0.0104	-0.3	-0.43	Height;	chr11:118773873	chr11:118791254~118793137:+
THYM	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	4.56	1.54e-05	0.0104	0.54	0.43	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
THYM	cis	rs7202877	0.706	rs247443	ENSG00000261783.1	RP11-252K23.2	4.56	1.55e-05	0.0104	0.59	0.43	Type 1 diabetes;Type 2 diabetes;	chr16:75431175	chr16:75379818~75381260:-
THYM	cis	rs11096990	0.855	rs2566172	ENSG00000249685.1	RP11-360F5.3	-4.56	1.55e-05	0.0105	-0.43	-0.43	Cognitive function;	chr4:39150943	chr4:39133913~39135608:+
THYM	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	4.56	1.55e-05	0.0105	0.55	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	4.56	1.55e-05	0.0105	0.55	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
THYM	cis	rs995834	0.664	rs8110139	ENSG00000267243.4	AC005307.3	-4.56	1.55e-05	0.0105	-0.41	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28395640	chr19:28435388~28727777:-
THYM	cis	rs11157436	0.918	rs7159024	ENSG00000211813.2	TRAV34	4.56	1.55e-05	0.0105	0.36	0.43	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22207522~22208129:+
THYM	cis	rs1790761	0.658	rs684928	ENSG00000231793.4	DOC2GP	-4.56	1.55e-05	0.0105	-0.38	-0.43	Mean corpuscular volume;	chr11:67562271	chr11:67612653~67616257:-
THYM	cis	rs9907295	0.748	rs4251719	ENSG00000270977.1	AC015849.16	-4.56	1.55e-05	0.0105	-0.59	-0.43	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.748	rs4251769	ENSG00000270977.1	AC015849.16	-4.56	1.55e-05	0.0105	-0.59	-0.43	Fibroblast growth factor basic levels;	chr17:35837523	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs4795093	ENSG00000270977.1	AC015849.16	-4.56	1.55e-05	0.0105	-0.59	-0.43	Fibroblast growth factor basic levels;	chr17:35853137	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs2306630	ENSG00000270977.1	AC015849.16	-4.56	1.55e-05	0.0105	-0.59	-0.43	Fibroblast growth factor basic levels;	chr17:35855337	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs9909416	ENSG00000270977.1	AC015849.16	-4.56	1.55e-05	0.0105	-0.59	-0.43	Fibroblast growth factor basic levels;	chr17:35870979	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs9303692	ENSG00000270977.1	AC015849.16	4.56	1.55e-05	0.0105	0.59	0.43	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35893707~35911023:-
THYM	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-4.56	1.56e-05	0.0105	-0.75	-0.43	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
THYM	cis	rs1023500	0.573	rs13057094	ENSG00000227370.1	RP4-669P10.19	4.56	1.56e-05	0.0105	0.51	0.43	Schizophrenia;	chr22:42074313	chr22:42132543~42132998:+
THYM	cis	rs9876781	1	rs9838618	ENSG00000244380.1	RP11-24C3.2	4.56	1.56e-05	0.0105	0.56	0.43	Longevity;	chr3:48445949	chr3:48440352~48446656:-
THYM	cis	rs4908769	0.66	rs159961	ENSG00000232912.4	RP5-1115A15.1	4.56	1.56e-05	0.0105	0.45	0.43	Allergy;	chr1:8424168	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.66	rs301797	ENSG00000232912.4	RP5-1115A15.1	4.56	1.56e-05	0.0105	0.45	0.43	Allergy;	chr1:8427263	chr1:8424645~8434838:+
THYM	cis	rs34792	0.626	rs153784	ENSG00000262380.1	CTB-193M12.3	4.56	1.56e-05	0.0105	0.53	0.43	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508734	chr16:15683290~15684570:+
THYM	cis	rs61774743	0.754	rs11578963	ENSG00000229901.1	RP11-399E6.4	4.56	1.57e-05	0.0106	0.39	0.43	Intelligence (multi-trait analysis);	chr1:41368511	chr1:41375004~41375669:-
THYM	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	4.56	1.57e-05	0.0106	0.41	0.43	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	4.56	1.57e-05	0.0106	0.41	0.43	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	4.56	1.57e-05	0.0106	0.41	0.43	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	4.56	1.57e-05	0.0106	0.41	0.43	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
THYM	cis	rs11096990	0.855	rs2566184	ENSG00000249685.1	RP11-360F5.3	-4.56	1.57e-05	0.0106	-0.42	-0.43	Cognitive function;	chr4:39162700	chr4:39133913~39135608:+
THYM	cis	rs11637339	0.517	rs755440	ENSG00000259760.1	RP11-20G13.2	4.55	1.57e-05	0.0106	0.5	0.43	Cervical cancer;	chr15:99478535	chr15:99396613~99401315:-
THYM	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	4.55	1.57e-05	0.0106	0.51	0.43	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	4.55	1.57e-05	0.0106	0.51	0.43	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
THYM	cis	rs10276381	1	rs10276381	ENSG00000253187.2	HOXA10-AS	-4.55	1.57e-05	0.0106	-0.38	-0.43	Crohn's disease;	chr7:28150502	chr7:27168619~27171915:+
THYM	cis	rs10276381	0.786	rs73089302	ENSG00000253187.2	HOXA10-AS	4.55	1.57e-05	0.0106	0.38	0.43	Crohn's disease;	chr7:28147515	chr7:27168619~27171915:+
THYM	cis	rs10276381	1	rs10263857	ENSG00000253187.2	HOXA10-AS	4.55	1.57e-05	0.0106	0.38	0.43	Crohn's disease;	chr7:28147665	chr7:27168619~27171915:+
THYM	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-4.55	1.57e-05	0.0106	-0.44	-0.43	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
THYM	cis	rs12908161	1	rs12908161	ENSG00000235370.6	DNM1P51	4.55	1.58e-05	0.0106	0.57	0.43	Schizophrenia;	chr15:84664594	chr15:84398316~84411701:-
THYM	cis	rs295140	0.605	rs10931893	ENSG00000232732.8	AC073043.1	4.55	1.58e-05	0.0106	0.53	0.43	QT interval;	chr2:200249929	chr2:199867396~199911159:-
THYM	cis	rs295140	0.585	rs4233996	ENSG00000232732.8	AC073043.1	4.55	1.58e-05	0.0106	0.53	0.43	QT interval;	chr2:200266505	chr2:199867396~199911159:-
THYM	cis	rs8067545	0.641	rs397969	ENSG00000231645.2	KRT17P6	-4.55	1.58e-05	0.0106	-0.5	-0.43	Schizophrenia;	chr17:19900934	chr17:20512560~20517479:-
THYM	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	4.55	1.58e-05	0.0106	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
THYM	cis	rs42490	0.789	rs383592	ENSG00000251136.7	RP11-37B2.1	-4.55	1.58e-05	0.0106	-0.34	-0.43	Leprosy;	chr8:89792100	chr8:89609409~89757727:-
THYM	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-4.55	1.58e-05	0.0106	-0.53	-0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
THYM	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-4.55	1.58e-05	0.0106	-0.45	-0.43	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
THYM	cis	rs12908161	1	rs58416181	ENSG00000235370.6	DNM1P51	4.55	1.58e-05	0.0107	0.56	0.43	Schizophrenia;	chr15:84721230	chr15:84398316~84411701:-
THYM	cis	rs8113308	0.81	rs8105110	ENSG00000269235.1	ZNF350-AS1	4.55	1.59e-05	0.0107	0.49	0.43	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948863	chr19:51949134~51981367:+
THYM	cis	rs12439619	0.508	rs17354842	ENSG00000255769.6	GOLGA2P10	4.55	1.59e-05	0.0107	0.41	0.43	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472993~82513950:-
THYM	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-4.55	1.59e-05	0.0107	-0.47	-0.43	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
THYM	cis	rs5771225	0.505	rs2341111	ENSG00000273253.2	RP3-402G11.26	-4.55	1.59e-05	0.0107	-0.53	-0.42	Late-onset Alzheimer's disease;	chr22:50251893	chr22:50199090~50200837:-
THYM	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-4.55	1.59e-05	0.0107	-0.39	-0.42	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
THYM	cis	rs7178424	0.742	rs12916268	ENSG00000259251.2	RP11-643M14.1	-4.55	1.59e-05	0.0107	-0.44	-0.42	Height;	chr15:61883443	chr15:62060503~62062434:+
THYM	cis	rs12554020	1	rs55846141	ENSG00000227603.1	RP11-165J3.6	4.55	1.59e-05	0.0107	0.6	0.42	Schizophrenia;	chr9:93427679	chr9:93435332~93437121:-
THYM	cis	rs2738048	1	rs2702910	ENSG00000233531.1	DEFA10P	4.55	1.59e-05	0.0107	0.49	0.42	IgA nephropathy;	chr8:6966369	chr8:6968141~6969113:-
THYM	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	4.55	1.6e-05	0.0108	0.4	0.42	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
THYM	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-4.55	1.6e-05	0.0108	-0.4	-0.42	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
THYM	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	4.55	1.6e-05	0.0108	0.41	0.42	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	4.55	1.6e-05	0.0108	0.41	0.42	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	4.55	1.6e-05	0.0108	0.41	0.42	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
THYM	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-4.55	1.61e-05	0.0108	-0.41	-0.42	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
THYM	cis	rs4835473	0.932	rs7683686	ENSG00000246448.2	RP13-578N3.3	4.55	1.61e-05	0.0108	0.51	0.42	Immature fraction of reticulocytes;	chr4:143784352	chr4:143700257~143865072:+
THYM	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	4.55	1.61e-05	0.0108	0.54	0.42	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
THYM	cis	rs8067545	0.559	rs3874846	ENSG00000230528.6	NOS2P3	-4.55	1.61e-05	0.0108	-0.34	-0.42	Schizophrenia;	chr17:20394232	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.641	rs203450	ENSG00000231645.2	KRT17P6	-4.55	1.61e-05	0.0108	-0.5	-0.42	Schizophrenia;	chr17:19919757	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs860335	ENSG00000231645.2	KRT17P6	-4.55	1.61e-05	0.0108	-0.5	-0.42	Schizophrenia;	chr17:19934366	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.616	rs203470	ENSG00000231645.2	KRT17P6	-4.55	1.61e-05	0.0108	-0.5	-0.42	Schizophrenia;	chr17:19955313	chr17:20512560~20517479:-
THYM	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	4.55	1.61e-05	0.0108	0.55	0.42	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	4.55	1.61e-05	0.0108	0.55	0.42	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	4.55	1.61e-05	0.0108	0.55	0.42	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
THYM	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	4.55	1.61e-05	0.0108	0.5	0.42	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	4.55	1.61e-05	0.0108	0.54	0.42	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
THYM	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-4.55	1.61e-05	0.0108	-0.57	-0.42	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
THYM	cis	rs10129255	0.518	rs12590732	ENSG00000253703.1	IGHV1-68	4.55	1.62e-05	0.0108	0.46	0.42	Kawasaki disease;	chr14:106779612	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs7161740	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106776119	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.556	rs6576222	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106776442	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.536	rs6576223	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106776448	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs988134	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106776698	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs988133	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106776724	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.518	rs8009612	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106777510	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.556	rs8010005	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106777987	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.556	rs6576224	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106777997	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.518	rs8010020	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106778016	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs6576225	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106778120	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs6576226	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106778135	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs6576230	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106778539	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.518	rs10136903	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106778866	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.518	rs11847766	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106779186	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs8022547	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106781985	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs8006888	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106782219	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.536	rs10142951	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106782337	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs59939897	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106783414	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs6576231	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106783693	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs8014529	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106784065	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs12101190	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106784149	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.518	rs8004895	ENSG00000253703.1	IGHV1-68	-4.55	1.62e-05	0.0108	-0.46	-0.42	Kawasaki disease;	chr14:106785139	chr14:106703852~106704146:-
THYM	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-4.55	1.62e-05	0.0108	-0.45	-0.42	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-4.55	1.62e-05	0.0108	-0.45	-0.42	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-4.55	1.62e-05	0.0108	-0.45	-0.42	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
THYM	cis	rs6570726	0.967	rs9497316	ENSG00000235652.6	RP11-545I5.3	-4.55	1.62e-05	0.0109	-0.3	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145799409~145886585:+
THYM	cis	rs4835473	0.663	rs4835115	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143979308	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs4257604	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143980261	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs35599924	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143980602	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4516663	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143980791	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.8	rs2089839	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143980955	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4835118	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143981994	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4835471	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143982153	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs4835119	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143982210	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4835472	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143982398	chr4:143911514~143912053:-
THYM	cis	rs4835473	1	rs4835473	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143982419	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs4835474	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143982444	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6847869	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143982881	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs6846984	ENSG00000249741.2	RP11-673E1.3	-4.55	1.62e-05	0.0109	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143983098	chr4:143911514~143912053:-
THYM	cis	rs6570726	0.526	rs4895674	ENSG00000235652.6	RP11-545I5.3	-4.55	1.62e-05	0.0109	-0.31	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145414724	chr6:145799409~145886585:+
THYM	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-4.55	1.62e-05	0.0109	-0.54	-0.42	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
THYM	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	4.55	1.62e-05	0.0109	0.4	0.42	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
THYM	cis	rs11168351	0.926	rs10875719	ENSG00000240399.1	RP1-228P16.1	4.55	1.62e-05	0.0109	0.4	0.42	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48054813~48055591:-
THYM	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-4.55	1.62e-05	0.0109	-0.61	-0.42	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-4.55	1.62e-05	0.0109	-0.61	-0.42	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-4.55	1.62e-05	0.0109	-0.61	-0.42	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-4.55	1.62e-05	0.0109	-0.61	-0.42	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-4.55	1.62e-05	0.0109	-0.61	-0.42	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-4.55	1.62e-05	0.0109	-0.61	-0.42	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
THYM	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-4.55	1.62e-05	0.0109	-0.61	-0.42	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
THYM	cis	rs34773007	0.623	rs34566437	ENSG00000272817.1	RP11-402D21.2	-4.55	1.62e-05	0.0109	-0.53	-0.42	Type 2 diabetes;	chr10:92790195	chr10:91908131~91909348:+
THYM	cis	rs34773007	0.577	rs67412949	ENSG00000272817.1	RP11-402D21.2	-4.55	1.62e-05	0.0109	-0.53	-0.42	Type 2 diabetes;	chr10:92790889	chr10:91908131~91909348:+
THYM	cis	rs34773007	0.623	rs55880030	ENSG00000272817.1	RP11-402D21.2	-4.55	1.62e-05	0.0109	-0.53	-0.42	Type 2 diabetes;	chr10:92796240	chr10:91908131~91909348:+
THYM	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	4.55	1.62e-05	0.0109	0.37	0.42	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
THYM	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-4.55	1.62e-05	0.0109	-0.51	-0.42	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
THYM	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	4.55	1.62e-05	0.0109	0.36	0.42	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
THYM	cis	rs7849270	0.798	rs6478861	ENSG00000268707.1	RP11-247A12.7	-4.55	1.63e-05	0.0109	-0.57	-0.42	Blood metabolite ratios;	chr9:129092024	chr9:129170434~129170940:+
THYM	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
THYM	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
THYM	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	4.55	1.63e-05	0.0109	0.3	0.42	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
THYM	cis	rs2738048	1	rs2702909	ENSG00000233531.1	DEFA10P	4.54	1.63e-05	0.0109	0.49	0.42	IgA nephropathy;	chr8:6966703	chr8:6968141~6969113:-
THYM	cis	rs4835473	0.932	rs5016160	ENSG00000249741.2	RP11-673E1.3	-4.54	1.63e-05	0.0109	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143738305	chr4:143911514~143912053:-
THYM	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-4.54	1.64e-05	0.011	-0.35	-0.42	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
THYM	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-4.54	1.64e-05	0.011	-0.35	-0.42	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
THYM	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	4.54	1.64e-05	0.011	0.42	0.42	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
THYM	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-4.54	1.64e-05	0.011	-0.42	-0.42	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
THYM	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	4.54	1.64e-05	0.011	0.42	0.42	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
THYM	cis	rs9309473	0.5	rs4286298	ENSG00000273245.1	RP11-434P11.2	-4.54	1.64e-05	0.011	-0.47	-0.42	Metabolite levels;	chr2:73654981	chr2:73750256~73750786:-
THYM	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-4.54	1.64e-05	0.011	-0.4	-0.42	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
THYM	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	4.54	1.64e-05	0.011	0.58	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
THYM	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	4.54	1.64e-05	0.011	0.33	0.42	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
THYM	cis	rs7429990	0.833	rs2280567	ENSG00000229759.1	MRPS18AP1	-4.54	1.64e-05	0.011	-0.34	-0.42	Educational attainment (years of education);	chr3:47572923	chr3:48256350~48256938:-
THYM	cis	rs4908768	0.539	rs1381928	ENSG00000232912.4	RP5-1115A15.1	4.54	1.65e-05	0.011	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8630874	chr1:8424645~8434838:+
THYM	cis	rs9834970	0.588	rs4642070	ENSG00000234073.1	AC011816.1	-4.54	1.65e-05	0.011	-0.45	-0.42	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36859453	chr3:36880184~36880729:-
THYM	cis	rs3015497	0.594	rs35637875	ENSG00000270062.1	RP11-248J18.3	4.54	1.65e-05	0.011	0.31	0.42	Mean platelet volume;	chr14:50665815	chr14:50723777~50724272:-
THYM	cis	rs995834	0.664	rs1476762	ENSG00000267243.4	AC005307.3	-4.54	1.65e-05	0.011	-0.39	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28394427	chr19:28435388~28727777:-
THYM	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	4.54	1.65e-05	0.011	0.56	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
THYM	cis	rs4835473	0.932	rs4835120	ENSG00000249741.2	RP11-673E1.3	-4.54	1.65e-05	0.0111	-0.37	-0.42	Immature fraction of reticulocytes;	chr4:143982370	chr4:143911514~143912053:-
THYM	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	4.54	1.66e-05	0.0111	0.46	0.42	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
THYM	cis	rs9879311	0.866	rs775017	ENSG00000240288.6	GHRLOS	4.54	1.66e-05	0.0111	0.45	0.42	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10357280	chr3:10285754~10293449:+
THYM	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	4.54	1.66e-05	0.0111	0.5	0.42	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
THYM	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	4.54	1.66e-05	0.0111	0.52	0.42	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	4.54	1.66e-05	0.0111	0.52	0.42	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	4.54	1.66e-05	0.0111	0.52	0.42	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
THYM	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	4.54	1.66e-05	0.0111	0.67	0.42	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
THYM	cis	rs1584120	0.62	rs11046805	ENSG00000256321.4	RP11-153K16.1	-4.54	1.66e-05	0.0111	-0.48	-0.42	Pelvic organ prolapse (moderate/severe);	chr12:23119544	chr12:23099368~23191587:+
THYM	cis	rs1584120	0.62	rs11046807	ENSG00000256321.4	RP11-153K16.1	-4.54	1.66e-05	0.0111	-0.48	-0.42	Pelvic organ prolapse (moderate/severe);	chr12:23121069	chr12:23099368~23191587:+
THYM	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-4.54	1.67e-05	0.0111	-0.53	-0.42	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
THYM	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-4.54	1.67e-05	0.0111	-0.53	-0.42	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
THYM	cis	rs7772486	0.654	rs9376958	ENSG00000235652.6	RP11-545I5.3	-4.54	1.67e-05	0.0111	-0.31	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145701904	chr6:145799409~145886585:+
THYM	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	4.54	1.67e-05	0.0111	0.6	0.42	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
THYM	cis	rs4908768	0.539	rs7547411	ENSG00000232912.4	RP5-1115A15.1	4.54	1.67e-05	0.0111	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs1061039	ENSG00000232912.4	RP5-1115A15.1	4.54	1.67e-05	0.0111	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs1809332	ENSG00000232912.4	RP5-1115A15.1	4.54	1.67e-05	0.0111	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs4480384	ENSG00000232912.4	RP5-1115A15.1	4.54	1.67e-05	0.0111	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8424645~8434838:+
THYM	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	4.54	1.67e-05	0.0111	0.36	0.42	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
THYM	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	4.54	1.67e-05	0.0111	0.52	0.42	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
THYM	cis	rs7223966	0.96	rs113155878	ENSG00000240280.5	TCAM1P	-4.54	1.67e-05	0.0112	-0.65	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63629200	chr17:63849292~63864379:+
THYM	cis	rs9907295	0.818	rs4251737	ENSG00000270977.1	AC015849.16	-4.54	1.67e-05	0.0112	-0.59	-0.42	Fibroblast growth factor basic levels;	chr17:35819814	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs9889874	ENSG00000270977.1	AC015849.16	-4.54	1.67e-05	0.0112	-0.59	-0.42	Fibroblast growth factor basic levels;	chr17:35875293	chr17:35893707~35911023:-
THYM	cis	rs6087771	0.714	rs6058259	ENSG00000230613.1	HM13-AS1	4.54	1.67e-05	0.0112	0.57	0.42	Putamen volume;Subcortical brain region volumes;	chr20:31647499	chr20:31567707~31573263:-
THYM	cis	rs6087771	0.747	rs6058261	ENSG00000230613.1	HM13-AS1	4.54	1.67e-05	0.0112	0.57	0.42	Putamen volume;Subcortical brain region volumes;	chr20:31647667	chr20:31567707~31573263:-
THYM	cis	rs6087771	0.662	rs6058298	ENSG00000230613.1	HM13-AS1	4.54	1.67e-05	0.0112	0.57	0.42	Putamen volume;Subcortical brain region volumes;	chr20:31660113	chr20:31567707~31573263:-
THYM	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-4.54	1.67e-05	0.0112	-0.53	-0.42	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
THYM	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-4.54	1.67e-05	0.0112	-0.53	-0.42	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
THYM	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-4.54	1.67e-05	0.0112	-0.53	-0.42	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
THYM	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-4.54	1.67e-05	0.0112	-0.53	-0.42	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
THYM	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-4.54	1.67e-05	0.0112	-0.53	-0.42	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
THYM	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-4.54	1.67e-05	0.0112	-0.53	-0.42	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
THYM	cis	rs3811273	0.614	rs6572352	ENSG00000211816.2	TRAV38-1	-4.54	1.68e-05	0.0112	-0.37	-0.42	Periodontal disease-related phenotypes;	chr14:22268440	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs6572353	ENSG00000211816.2	TRAV38-1	-4.54	1.68e-05	0.0112	-0.37	-0.42	Periodontal disease-related phenotypes;	chr14:22268461	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs6572354	ENSG00000211816.2	TRAV38-1	-4.54	1.68e-05	0.0112	-0.37	-0.42	Periodontal disease-related phenotypes;	chr14:22268462	chr14:22271968~22272563:+
THYM	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	4.54	1.68e-05	0.0112	0.59	0.42	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
THYM	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-4.54	1.68e-05	0.0112	-0.45	-0.42	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
THYM	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-4.54	1.68e-05	0.0112	-0.45	-0.42	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
THYM	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	4.54	1.68e-05	0.0112	0.58	0.42	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
THYM	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	4.54	1.68e-05	0.0112	0.58	0.42	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
THYM	cis	rs7976269	0.609	rs2349574	ENSG00000275476.1	RP11-996F15.4	-4.54	1.68e-05	0.0112	-0.48	-0.42	Male-pattern baldness;	chr12:29053805	chr12:29277397~29277882:-
THYM	cis	rs2834288	0.535	rs13049489	ENSG00000273102.1	AP000569.9	4.54	1.68e-05	0.0112	0.46	0.42	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.535	rs7278341	ENSG00000273102.1	AP000569.9	4.54	1.68e-05	0.0112	0.46	0.42	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.535	rs7279183	ENSG00000273102.1	AP000569.9	4.54	1.68e-05	0.0112	0.46	0.42	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33967101~33968573:-
THYM	cis	rs4835473	0.932	rs35598827	ENSG00000249741.2	RP11-673E1.3	4.54	1.68e-05	0.0112	0.36	0.42	Immature fraction of reticulocytes;	chr4:143729605	chr4:143911514~143912053:-
THYM	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	4.54	1.68e-05	0.0112	0.58	0.42	Depression;	chr6:28428413	chr6:28176188~28176674:+
THYM	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	4.54	1.68e-05	0.0112	0.58	0.42	Depression;	chr6:28430971	chr6:28176188~28176674:+
THYM	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	4.54	1.68e-05	0.0112	0.58	0.42	Depression;	chr6:28431469	chr6:28176188~28176674:+
THYM	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	4.54	1.68e-05	0.0112	0.58	0.42	Depression;	chr6:28432562	chr6:28176188~28176674:+
THYM	cis	rs7223966	1	rs8081612	ENSG00000240280.5	TCAM1P	4.54	1.68e-05	0.0112	0.62	0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63647335	chr17:63849292~63864379:+
THYM	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	4.54	1.68e-05	0.0112	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	4.54	1.68e-05	0.0112	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	4.54	1.68e-05	0.0112	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	4.54	1.68e-05	0.0112	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
THYM	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-4.54	1.68e-05	0.0112	-0.56	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
THYM	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-4.54	1.69e-05	0.0112	-0.42	-0.42	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
THYM	cis	rs7631605	0.905	rs9823617	ENSG00000272334.1	RP11-129K12.1	-4.54	1.69e-05	0.0112	-0.45	-0.42	Cerebrospinal P-tau181p levels;	chr3:37157859	chr3:36973117~36973672:-
THYM	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-4.54	1.69e-05	0.0112	-0.33	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
THYM	cis	rs12554020	0.581	rs4255201	ENSG00000227603.1	RP11-165J3.6	4.54	1.69e-05	0.0112	0.63	0.42	Schizophrenia;	chr9:93401055	chr9:93435332~93437121:-
THYM	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	4.54	1.69e-05	0.0113	0.91	0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
THYM	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	4.54	1.69e-05	0.0113	0.54	0.42	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
THYM	cis	rs11722228	0.893	rs6449144	ENSG00000261490.1	RP11-448G15.3	-4.54	1.69e-05	0.0113	-0.45	-0.42	Urate levels;Serum uric acid levels;Gout;	chr4:9943026	chr4:10068089~10073019:-
THYM	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-4.54	1.7e-05	0.0113	-0.46	-0.42	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
THYM	cis	rs2834288	0.535	rs4816468	ENSG00000237945.6	LINC00649	4.54	1.7e-05	0.0113	0.37	0.42	Gut microbiota (bacterial taxa);	chr21:33952235	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.535	rs4816469	ENSG00000237945.6	LINC00649	4.54	1.7e-05	0.0113	0.37	0.42	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.536	rs8129513	ENSG00000237945.6	LINC00649	4.54	1.7e-05	0.0113	0.37	0.42	Gut microbiota (bacterial taxa);	chr21:33952615	chr21:33915534~33977691:+
THYM	cis	rs7560272	0.588	rs4852959	ENSG00000163016.8	ALMS1P	-4.53	1.7e-05	0.0113	-0.48	-0.42	Schizophrenia;	chr2:73653474	chr2:73644919~73685576:+
THYM	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-4.53	1.7e-05	0.0113	-0.33	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
THYM	cis	rs9309473	0.519	rs2421667	ENSG00000273245.1	RP11-434P11.2	-4.53	1.7e-05	0.0113	-0.5	-0.42	Metabolite levels;	chr2:73605332	chr2:73750256~73750786:-
THYM	cis	rs9907295	0.901	rs11652536	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35891043	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs9789051	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35892000	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs3809769	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35892484	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs76016589	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35892923	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs4796124	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35893280	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs11656556	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35894090	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.818	rs11653204	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35894538	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.792	rs4796125	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35894847	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs74622050	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35895939	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs79730543	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35896537	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs4796127	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35899127	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs11868801	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35900047	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs4796130	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35904264	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.685	rs4796131	ENSG00000270871.1	AC015849.19	4.53	1.71e-05	0.0114	0.47	0.42	Fibroblast growth factor basic levels;	chr17:35904812	chr17:35816717~35830293:-
THYM	cis	rs4908768	0.501	rs7520617	ENSG00000232912.4	RP5-1115A15.1	4.53	1.71e-05	0.0114	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs6577491	ENSG00000232912.4	RP5-1115A15.1	4.53	1.71e-05	0.0114	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs6577492	ENSG00000232912.4	RP5-1115A15.1	4.53	1.71e-05	0.0114	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8515005	chr1:8424645~8434838:+
THYM	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-4.53	1.71e-05	0.0114	-0.52	-0.42	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
THYM	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	4.53	1.71e-05	0.0114	0.42	0.42	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
THYM	cis	rs526231	0.718	rs402962	ENSG00000175749.11	EIF3KP1	4.53	1.71e-05	0.0114	0.56	0.42	Primary biliary cholangitis;	chr5:103288307	chr5:103032376~103033031:+
THYM	cis	rs9914578	1	rs9914577	ENSG00000236838.2	AC090617.1	4.53	1.71e-05	0.0114	0.64	0.42	Body mass index;	chr17:2101836	chr17:2213697~2214414:+
THYM	cis	rs9914578	1	rs9914578	ENSG00000236838.2	AC090617.1	4.53	1.71e-05	0.0114	0.64	0.42	Body mass index;	chr17:2101842	chr17:2213697~2214414:+
THYM	cis	rs9914578	0.943	rs9904872	ENSG00000236838.2	AC090617.1	4.53	1.71e-05	0.0114	0.64	0.42	Body mass index;	chr17:2101947	chr17:2213697~2214414:+
THYM	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-4.53	1.71e-05	0.0114	-0.51	-0.42	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-4.53	1.71e-05	0.0114	-0.51	-0.42	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-4.53	1.71e-05	0.0114	-0.51	-0.42	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-4.53	1.71e-05	0.0114	-0.51	-0.42	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
THYM	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-4.53	1.71e-05	0.0114	-0.52	-0.42	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
THYM	cis	rs28785552	0.897	rs7259466	ENSG00000250731.1	TPM3P6	-4.53	1.72e-05	0.0114	-0.6	-0.42	Response to paliperidone in schizophrenia (PANSS score);	chr19:52736116	chr19:53479350~53480091:+
THYM	cis	rs7242404	0.57	rs11080598	ENSG00000260302.1	RP11-973H7.1	4.53	1.72e-05	0.0114	0.3	0.42	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12751824	chr18:12774651~12775923:-
THYM	cis	rs1550115	1	rs4665719	ENSG00000271936.1	RP11-443B20.1	-4.53	1.72e-05	0.0114	-0.3	-0.42	Coronary artery disease;	chr2:24794991	chr2:24825610~24826717:+
THYM	cis	rs1550115	1	rs1550115	ENSG00000271936.1	RP11-443B20.1	4.53	1.72e-05	0.0114	0.3	0.42	Coronary artery disease;	chr2:24818751	chr2:24825610~24826717:+
THYM	cis	rs10740039	0.583	rs10740042	ENSG00000254271.1	RP11-131N11.4	4.53	1.72e-05	0.0114	0.51	0.42	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60736828	chr10:60734342~60741828:+
THYM	cis	rs12439619	0.846	rs62012003	ENSG00000274376.3	ADAMTS7P1	4.53	1.72e-05	0.0114	0.47	0.42	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.768	rs28694364	ENSG00000274376.3	ADAMTS7P1	4.53	1.72e-05	0.0114	0.47	0.42	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.81	rs28876157	ENSG00000274376.3	ADAMTS7P1	4.53	1.72e-05	0.0114	0.47	0.42	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.774	rs2867649	ENSG00000274376.3	ADAMTS7P1	4.53	1.72e-05	0.0114	0.47	0.42	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.846	rs28697264	ENSG00000274376.3	ADAMTS7P1	4.53	1.72e-05	0.0114	0.47	0.42	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82298553~82334609:+
THYM	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	4.53	1.72e-05	0.0114	0.31	0.42	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
THYM	cis	rs7631605	0.905	rs17811658	ENSG00000272334.1	RP11-129K12.1	-4.53	1.73e-05	0.0115	-0.45	-0.42	Cerebrospinal P-tau181p levels;	chr3:37172713	chr3:36973117~36973672:-
THYM	cis	rs4835473	0.868	rs4350958	ENSG00000249741.2	RP11-673E1.3	-4.53	1.73e-05	0.0115	-0.39	-0.42	Immature fraction of reticulocytes;	chr4:143744656	chr4:143911514~143912053:-
THYM	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-4.53	1.73e-05	0.0115	-0.58	-0.42	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
THYM	cis	rs9903692	0.909	rs11079806	ENSG00000266601.1	RP11-6N17.3	-4.53	1.73e-05	0.0115	-0.38	-0.42	Pulse pressure;	chr17:48065318	chr17:47929682~47933106:-
THYM	cis	rs4835473	0.831	rs4125544	ENSG00000249741.2	RP11-673E1.3	-4.53	1.73e-05	0.0115	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143962542	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs12507633	ENSG00000249741.2	RP11-673E1.3	-4.53	1.73e-05	0.0115	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143962730	chr4:143911514~143912053:-
THYM	cis	rs72802342	0.541	rs185052	ENSG00000261783.1	RP11-252K23.2	4.53	1.73e-05	0.0115	0.59	0.42	Advanced age-related macular degeneration;	chr16:75433165	chr16:75379818~75381260:-
THYM	cis	rs7772486	0.712	rs1292335	ENSG00000235652.6	RP11-545I5.3	4.53	1.73e-05	0.0115	0.3	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145799409~145886585:+
THYM	cis	rs61270009	0.955	rs12654702	ENSG00000247828.6	TMEM161B-AS1	4.53	1.74e-05	0.0115	0.35	0.42	Depressive symptoms;	chr5:88402882	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs2410766	ENSG00000247828.6	TMEM161B-AS1	4.53	1.74e-05	0.0115	0.35	0.42	Depressive symptoms;	chr5:88405666	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs6874182	ENSG00000247828.6	TMEM161B-AS1	4.53	1.74e-05	0.0115	0.35	0.42	Depressive symptoms;	chr5:88407268	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs12523282	ENSG00000247828.6	TMEM161B-AS1	4.53	1.74e-05	0.0115	0.35	0.42	Depressive symptoms;	chr5:88407679	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs12651891	ENSG00000247828.6	TMEM161B-AS1	4.53	1.74e-05	0.0115	0.35	0.42	Depressive symptoms;	chr5:88408187	chr5:88268895~88436685:+
THYM	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	4.53	1.74e-05	0.0115	0.33	0.42	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
THYM	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	4.53	1.74e-05	0.0115	0.3	0.42	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
THYM	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	4.53	1.74e-05	0.0115	0.31	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
THYM	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	4.53	1.74e-05	0.0115	0.31	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
THYM	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	4.53	1.75e-05	0.0115	0.29	0.42	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
THYM	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	4.53	1.75e-05	0.0115	0.29	0.42	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	4.53	1.75e-05	0.0115	0.29	0.42	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
THYM	cis	rs12908161	1	rs35316992	ENSG00000275120.1	RP11-182J1.17	4.53	1.75e-05	0.0115	0.57	0.42	Schizophrenia;	chr15:84704902	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs4643294	ENSG00000275120.1	RP11-182J1.17	4.53	1.75e-05	0.0115	0.57	0.42	Schizophrenia;	chr15:84707022	chr15:84599434~84606463:-
THYM	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	4.53	1.75e-05	0.0116	0.61	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
THYM	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	4.53	1.75e-05	0.0116	0.61	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
THYM	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	4.53	1.75e-05	0.0116	0.53	0.42	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	4.53	1.75e-05	0.0116	0.53	0.42	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
THYM	cis	rs10829156	0.699	rs4747353	ENSG00000225527.1	RP11-383B4.4	-4.53	1.75e-05	0.0116	-0.49	-0.42	Sudden cardiac arrest;	chr10:18548028	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.66	rs10764587	ENSG00000225527.1	RP11-383B4.4	-4.53	1.75e-05	0.0116	-0.49	-0.42	Sudden cardiac arrest;	chr10:18548901	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.625	rs10828906	ENSG00000225527.1	RP11-383B4.4	-4.53	1.75e-05	0.0116	-0.49	-0.42	Sudden cardiac arrest;	chr10:18552866	chr10:18531849~18533336:-
THYM	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	4.53	1.75e-05	0.0116	0.65	0.42	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
THYM	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-4.53	1.75e-05	0.0116	-0.54	-0.42	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
THYM	cis	rs9500256	0.967	rs1012500	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.53	1.75e-05	0.0116	0.33	0.42	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57908560~57913911:-
THYM	cis	rs9500256	1	rs9500256	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.53	1.75e-05	0.0116	0.33	0.42	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57908560~57913911:-
THYM	cis	rs9500256	0.966	rs1322446	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.53	1.75e-05	0.0116	0.33	0.42	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57908560~57913911:-
THYM	cis	rs9535495	0.965	rs7318077	ENSG00000200711.1	RNA5SP28	-4.53	1.75e-05	0.0116	-0.5	-0.42	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50835229	chr13:50812988~50813106:-
THYM	cis	rs6121246	0.529	rs6060144	ENSG00000230613.1	HM13-AS1	4.53	1.75e-05	0.0116	0.71	0.42	Mean corpuscular hemoglobin;	chr20:31590821	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.529	rs112367115	ENSG00000230613.1	HM13-AS1	4.53	1.75e-05	0.0116	0.71	0.42	Mean corpuscular hemoglobin;	chr20:31590824	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.529	rs6060145	ENSG00000230613.1	HM13-AS1	4.53	1.75e-05	0.0116	0.71	0.42	Mean corpuscular hemoglobin;	chr20:31590828	chr20:31567707~31573263:-
THYM	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-4.53	1.75e-05	0.0116	-0.42	-0.42	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
THYM	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-4.53	1.75e-05	0.0116	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
THYM	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	4.53	1.76e-05	0.0116	0.53	0.42	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	4.53	1.76e-05	0.0116	0.53	0.42	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	4.53	1.76e-05	0.0116	0.53	0.42	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
THYM	cis	rs1426063	1	rs1426063	ENSG00000248165.1	RP11-44F21.2	-4.53	1.76e-05	0.0116	-0.78	-0.42	QT interval;	chr4:75105711	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs17000242	ENSG00000248165.1	RP11-44F21.2	4.53	1.76e-05	0.0116	0.78	0.42	QT interval;	chr4:75103857	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs7666371	ENSG00000248165.1	RP11-44F21.2	4.53	1.76e-05	0.0116	0.78	0.42	QT interval;	chr4:75104325	chr4:74993877~75034824:-
THYM	cis	rs1426063	1	rs6829858	ENSG00000248165.1	RP11-44F21.2	4.53	1.76e-05	0.0116	0.78	0.42	QT interval;	chr4:75105202	chr4:74993877~75034824:-
THYM	cis	rs34773007	0.514	rs34081169	ENSG00000272817.1	RP11-402D21.2	-4.53	1.76e-05	0.0116	-0.54	-0.42	Type 2 diabetes;	chr10:92777528	chr10:91908131~91909348:+
THYM	cis	rs2283792	1	rs5999521	ENSG00000228050.1	TOP3BP1	4.53	1.76e-05	0.0116	0.47	0.42	Multiple sclerosis;	chr22:21792110	chr22:22223187~22224566:-
THYM	cis	rs7223966	1	rs11871767	ENSG00000240280.5	TCAM1P	-4.52	1.77e-05	0.0117	-0.64	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63621363	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9912201	ENSG00000240280.5	TCAM1P	-4.52	1.77e-05	0.0117	-0.65	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63685848	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs3817181	ENSG00000240280.5	TCAM1P	-4.52	1.77e-05	0.0117	-0.65	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63699178	chr17:63849292~63864379:+
THYM	cis	rs12908161	0.96	rs34452033	ENSG00000275120.1	RP11-182J1.17	4.52	1.77e-05	0.0117	0.58	0.42	Schizophrenia;	chr15:84678762	chr15:84599434~84606463:-
THYM	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-4.52	1.77e-05	0.0117	-0.48	-0.42	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
THYM	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-4.52	1.77e-05	0.0117	-0.53	-0.42	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
THYM	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	4.52	1.77e-05	0.0117	0.36	0.42	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
THYM	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	4.52	1.77e-05	0.0117	0.36	0.42	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
THYM	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	4.52	1.77e-05	0.0117	0.36	0.42	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
THYM	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	4.52	1.77e-05	0.0117	0.36	0.42	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
THYM	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	4.52	1.77e-05	0.0117	0.36	0.42	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
THYM	cis	rs2911132	0.564	rs17401719	ENSG00000272109.1	CTD-2260A17.3	4.52	1.77e-05	0.0117	0.54	0.42	Urate levels (BMI interaction);	chr5:96753342	chr5:96804353~96806105:+
THYM	cis	rs113835537	0.569	rs17496586	ENSG00000255517.5	CTD-3074O7.5	-4.52	1.78e-05	0.0117	-0.39	-0.42	Airway imaging phenotypes;	chr11:66548041	chr11:66473490~66480233:-
THYM	cis	rs7789940	0.904	rs73140040	ENSG00000205583.12	STAG3L1	-4.52	1.78e-05	0.0117	-0.35	-0.42	Multiple sclerosis;	chr7:76306923	chr7:75359194~75395383:+
THYM	cis	rs8067545	1	rs9891739	ENSG00000231645.2	KRT17P6	-4.52	1.78e-05	0.0117	-0.48	-0.42	Schizophrenia;	chr17:20038864	chr17:20512560~20517479:-
THYM	cis	rs561341	0.941	rs8066558	ENSG00000265798.5	RP11-271K11.5	4.52	1.78e-05	0.0117	0.5	0.42	Hip circumference adjusted for BMI;	chr17:31945860	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs2470267	ENSG00000265798.5	RP11-271K11.5	4.52	1.78e-05	0.0117	0.5	0.42	Hip circumference adjusted for BMI;	chr17:31947113	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs521919	ENSG00000265798.5	RP11-271K11.5	4.52	1.78e-05	0.0117	0.5	0.42	Hip circumference adjusted for BMI;	chr17:31971020	chr17:31038575~31059121:-
THYM	cis	rs526231	0.819	rs2288788	ENSG00000175749.11	EIF3KP1	4.52	1.78e-05	0.0117	0.55	0.42	Primary biliary cholangitis;	chr5:103264868	chr5:103032376~103033031:+
THYM	cis	rs8067545	0.611	rs2107565	ENSG00000230528.6	NOS2P3	4.52	1.78e-05	0.0117	0.35	0.42	Schizophrenia;	chr17:20185179	chr17:20436337~20447249:+
THYM	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	4.52	1.78e-05	0.0118	0.41	0.42	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	4.52	1.78e-05	0.0118	0.41	0.42	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
THYM	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-4.52	1.79e-05	0.0118	-0.58	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
THYM	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	4.52	1.79e-05	0.0118	0.64	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
THYM	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	4.52	1.79e-05	0.0118	0.47	0.42	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
THYM	cis	rs4853012	0.838	rs60964317	ENSG00000257702.3	LBX2-AS1	4.52	1.79e-05	0.0118	0.45	0.42	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74502595~74504678:+
THYM	cis	rs10129255	0.5	rs4774008	ENSG00000254329.1	IGHVII-60-1	4.52	1.79e-05	0.0118	0.37	0.42	Kawasaki disease;	chr14:106681273	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs10143242	ENSG00000254329.1	IGHVII-60-1	4.52	1.79e-05	0.0118	0.37	0.42	Kawasaki disease;	chr14:106681814	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs1024350	ENSG00000254329.1	IGHVII-60-1	4.52	1.79e-05	0.0118	0.37	0.42	Kawasaki disease;	chr14:106685105	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.518	rs7143784	ENSG00000254329.1	IGHVII-60-1	4.52	1.79e-05	0.0118	0.37	0.42	Kawasaki disease;	chr14:106687277	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.5	rs9324092	ENSG00000254329.1	IGHVII-60-1	-4.52	1.79e-05	0.0118	-0.37	-0.42	Kawasaki disease;	chr14:106683806	chr14:106637718~106637973:-
THYM	cis	rs1606355	0.725	rs73091584	ENSG00000230519.2	RP11-1060J15.5	-4.52	1.8e-05	0.0118	-0.73	-0.42	Metabolite levels (Pyroglutamine);	chr12:28642605	chr12:27702338~27702906:+
THYM	cis	rs1606355	0.725	rs73091591	ENSG00000230519.2	RP11-1060J15.5	-4.52	1.8e-05	0.0118	-0.73	-0.42	Metabolite levels (Pyroglutamine);	chr12:28644573	chr12:27702338~27702906:+
THYM	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-4.52	1.8e-05	0.0118	-0.41	-0.42	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
THYM	cis	rs9309473	0.519	rs35421685	ENSG00000273245.1	RP11-434P11.2	-4.52	1.8e-05	0.0118	-0.48	-0.42	Metabolite levels;	chr2:73683011	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs7606947	ENSG00000273245.1	RP11-434P11.2	4.52	1.8e-05	0.0118	0.48	0.42	Metabolite levels;	chr2:73682691	chr2:73750256~73750786:-
THYM	cis	rs12908161	1	rs12911736	ENSG00000235370.6	DNM1P51	4.52	1.81e-05	0.0119	0.56	0.42	Schizophrenia;	chr15:84696777	chr15:84398316~84411701:-
THYM	cis	rs10129255	0.5	rs2105991	ENSG00000254329.1	IGHVII-60-1	4.52	1.81e-05	0.0119	0.37	0.42	Kawasaki disease;	chr14:106682022	chr14:106637718~106637973:-
THYM	cis	rs1023500	0.551	rs2854837	ENSG00000227370.1	RP4-669P10.19	4.52	1.81e-05	0.0119	0.5	0.42	Schizophrenia;	chr22:42062477	chr22:42132543~42132998:+
THYM	cis	rs10129255	0.646	rs55995061	ENSG00000254329.1	IGHVII-60-1	4.52	1.82e-05	0.0119	0.44	0.42	Kawasaki disease;	chr14:106799309	chr14:106637718~106637973:-
THYM	cis	rs2408955	0.561	rs11168365	ENSG00000240399.1	RP1-228P16.1	-4.52	1.82e-05	0.012	-0.4	-0.42	Glycated hemoglobin levels;	chr12:48027989	chr12:48054813~48055591:-
THYM	cis	rs4835473	0.864	rs4835343	ENSG00000249741.2	RP11-673E1.3	-4.52	1.82e-05	0.012	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143866038	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.831	rs1579816	ENSG00000249741.2	RP11-673E1.3	-4.52	1.82e-05	0.012	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143866772	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4240334	ENSG00000249741.2	RP11-673E1.3	-4.52	1.82e-05	0.012	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143871352	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17750042	ENSG00000249741.2	RP11-673E1.3	4.52	1.82e-05	0.012	0.36	0.42	Immature fraction of reticulocytes;	chr4:143726691	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1375989	ENSG00000249741.2	RP11-673E1.3	4.52	1.82e-05	0.012	0.36	0.42	Immature fraction of reticulocytes;	chr4:143726893	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34570929	ENSG00000249741.2	RP11-673E1.3	4.52	1.82e-05	0.012	0.36	0.42	Immature fraction of reticulocytes;	chr4:143730766	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs17750172	ENSG00000249741.2	RP11-673E1.3	4.52	1.82e-05	0.012	0.36	0.42	Immature fraction of reticulocytes;	chr4:143731094	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs5025156	ENSG00000249741.2	RP11-673E1.3	4.52	1.82e-05	0.012	0.36	0.42	Immature fraction of reticulocytes;	chr4:143738025	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.618	rs12499429	ENSG00000249741.2	RP11-673E1.3	4.52	1.82e-05	0.012	0.36	0.42	Immature fraction of reticulocytes;	chr4:143889914	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.801	rs28715976	ENSG00000249741.2	RP11-673E1.3	4.52	1.82e-05	0.012	0.36	0.42	Immature fraction of reticulocytes;	chr4:143891603	chr4:143911514~143912053:-
THYM	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-4.52	1.82e-05	0.012	-0.44	-0.42	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
THYM	cis	rs7005380	0.62	rs7387694	ENSG00000245330.4	KB-1471A8.1	4.52	1.82e-05	0.012	0.59	0.42	Interstitial lung disease;	chr8:119885261	chr8:119867419~119874488:-
THYM	cis	rs12681366	0.881	rs10464877	ENSG00000253704.1	RP11-267M23.4	4.52	1.82e-05	0.012	0.55	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94385615	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.881	rs2381793	ENSG00000253704.1	RP11-267M23.4	4.52	1.82e-05	0.012	0.55	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94388167	chr8:94553722~94569745:+
THYM	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	4.52	1.83e-05	0.012	0.47	0.42	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
THYM	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-4.52	1.83e-05	0.012	-0.4	-0.42	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
THYM	cis	rs863345	0.604	rs1894040	ENSG00000236656.1	RP11-144L1.4	-4.52	1.83e-05	0.012	-0.27	-0.42	Pneumococcal bacteremia;	chr1:158486546	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1873509	ENSG00000236656.1	RP11-144L1.4	-4.52	1.83e-05	0.012	-0.27	-0.42	Pneumococcal bacteremia;	chr1:158491773	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1342946	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158483397	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs6427438	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158484940	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908653	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158485563	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908654	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158486000	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264981	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158486100	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1894038	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158486157	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1157525	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158487463	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1157524	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158487508	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs1418844	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158487779	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs12075903	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158489142	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2023632	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158489244	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1342947	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158489924	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs950487	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158490340	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs6427439	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158490567	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs10908655	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158491109	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908656	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158491226	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1873511	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158491576	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1873510	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158491628	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs949397	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158492161	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs949398	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158492193	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264983	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158492428	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs6664542	ENSG00000236656.1	RP11-144L1.4	4.52	1.83e-05	0.012	0.27	0.42	Pneumococcal bacteremia;	chr1:158492641	chr1:158474454~158494886:-
THYM	cis	rs4835473	0.8	rs1849122	ENSG00000249741.2	RP11-673E1.3	-4.52	1.83e-05	0.012	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143978699	chr4:143911514~143912053:-
THYM	cis	rs972578	0.747	rs5758977	ENSG00000215347.3	SLC25A5P1	-4.52	1.83e-05	0.012	-0.35	-0.42	Mean platelet volume;	chr22:42840122	chr22:42001069~42001966:-
THYM	cis	rs9903692	0.779	rs2285863	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48048616	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs12936731	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48050997	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.909	rs9899275	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48051953	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs12450620	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48052892	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs7212202	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48055361	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs34750858	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48055575	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs875065	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48062207	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs875066	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48062370	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs2051821	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48066153	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.909	rs8078125	ENSG00000266601.1	RP11-6N17.3	-4.52	1.83e-05	0.012	-0.4	-0.42	Pulse pressure;	chr17:48068347	chr17:47929682~47933106:-
THYM	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-4.52	1.83e-05	0.012	-0.89	-0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
THYM	cis	rs2117029	1	rs11168839	ENSG00000258017.1	RP11-386G11.10	4.51	1.84e-05	0.012	0.47	0.42	Intelligence (multi-trait analysis);	chr12:49063852	chr12:49127782~49147869:+
THYM	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	4.51	1.84e-05	0.012	0.47	0.42	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	4.51	1.84e-05	0.012	0.47	0.42	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	4.51	1.84e-05	0.012	0.47	0.42	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	4.51	1.84e-05	0.012	0.47	0.42	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
THYM	cis	rs7209700	0.708	rs2292699	ENSG00000228782.6	CTD-2026D20.3	4.51	1.84e-05	0.0121	0.49	0.42	IgG glycosylation;	chr17:47284929	chr17:47450568~47492492:-
THYM	cis	rs957448	0.503	rs752460	ENSG00000253704.1	RP11-267M23.4	4.51	1.84e-05	0.0121	0.56	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.801	rs4735293	ENSG00000253704.1	RP11-267M23.4	4.51	1.84e-05	0.0121	0.56	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94553722~94569745:+
THYM	cis	rs11096990	0.855	rs2566177	ENSG00000249685.1	RP11-360F5.3	-4.51	1.85e-05	0.0121	-0.42	-0.42	Cognitive function;	chr4:39154558	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2711934	ENSG00000249685.1	RP11-360F5.3	-4.51	1.85e-05	0.0121	-0.42	-0.42	Cognitive function;	chr4:39156254	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2711935	ENSG00000249685.1	RP11-360F5.3	-4.51	1.85e-05	0.0121	-0.42	-0.42	Cognitive function;	chr4:39160837	chr4:39133913~39135608:+
THYM	cis	rs10129255	0.5	rs2027902	ENSG00000254329.1	IGHVII-60-1	4.51	1.85e-05	0.0121	0.37	0.42	Kawasaki disease;	chr14:106807157	chr14:106637718~106637973:-
THYM	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	4.51	1.85e-05	0.0121	0.43	0.42	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
THYM	cis	rs4925386	1	rs6089351	ENSG00000273619.1	RP5-908M14.9	4.51	1.85e-05	0.0121	0.32	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62386303~62386970:-
THYM	cis	rs4925386	1	rs4925382	ENSG00000273619.1	RP5-908M14.9	4.51	1.85e-05	0.0121	0.32	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62386303~62386970:-
THYM	cis	rs4925386	1	rs6121990	ENSG00000273619.1	RP5-908M14.9	4.51	1.85e-05	0.0121	0.32	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62386303~62386970:-
THYM	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	4.51	1.85e-05	0.0121	0.32	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
THYM	cis	rs34792	0.678	rs153787	ENSG00000262380.1	CTB-193M12.3	-4.51	1.86e-05	0.0121	-0.52	-0.42	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:15683290~15684570:+
THYM	cis	rs34792	0.688	rs13339072	ENSG00000262380.1	CTB-193M12.3	4.51	1.86e-05	0.0121	0.52	0.42	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15504090	chr16:15683290~15684570:+
THYM	cis	rs17772222	0.582	rs12050316	ENSG00000258983.2	RP11-507K2.2	4.51	1.86e-05	0.0121	0.46	0.42	Coronary artery calcification;	chr14:88522097	chr14:88499334~88515502:+
THYM	cis	rs2739330	0.731	rs5751792	ENSG00000272787.1	KB-226F1.2	-4.51	1.86e-05	0.0122	-0.48	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23969211~23969873:+
THYM	cis	rs741668	0.641	rs9534306	ENSG00000235903.6	CPB2-AS1	4.51	1.86e-05	0.0122	0.44	0.42	Cerebrospinal fluid clusterin levels;	chr13:46069100	chr13:46052806~46113332:+
THYM	cis	rs741668	0.641	rs1022951	ENSG00000235903.6	CPB2-AS1	4.51	1.86e-05	0.0122	0.44	0.42	Cerebrospinal fluid clusterin levels;	chr13:46075319	chr13:46052806~46113332:+
THYM	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-4.51	1.86e-05	0.0122	-0.47	-0.42	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	4.51	1.86e-05	0.0122	0.47	0.42	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
THYM	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	4.51	1.87e-05	0.0122	0.43	0.42	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
THYM	cis	rs12701220	0.503	rs12702047	ENSG00000229043.2	AC091729.9	-4.51	1.87e-05	0.0122	-0.75	-0.42	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1160374~1165267:+
THYM	cis	rs2921073	0.604	rs2979140	ENSG00000253893.2	FAM85B	-4.51	1.87e-05	0.0122	-0.59	-0.42	Parkinson's disease;	chr8:8409692	chr8:8167819~8226614:-
THYM	cis	rs7223966	1	rs6504169	ENSG00000240280.5	TCAM1P	-4.51	1.87e-05	0.0122	-0.64	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63631785	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs16947014	ENSG00000240280.5	TCAM1P	-4.51	1.87e-05	0.0122	-0.64	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63641672	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs7223672	ENSG00000240280.5	TCAM1P	-4.51	1.87e-05	0.0122	-0.64	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63643205	chr17:63849292~63864379:+
THYM	cis	rs6706785	0.748	rs1994353	ENSG00000196758.3	AC079612.1	4.51	1.87e-05	0.0122	0.39	0.42	Conotruncal heart defects;	chr2:239528558	chr2:239578301~239586094:+
THYM	cis	rs1550576	0.568	rs78624056	ENSG00000274719.1	RP11-86K22.2	4.51	1.87e-05	0.0122	0.8	0.42	Hypertension;	chr15:57940718	chr15:57990217~57990636:-
THYM	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	4.51	1.88e-05	0.0123	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	4.51	1.88e-05	0.0123	0.57	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
THYM	cis	rs2562456	0.516	rs56072098	ENSG00000268081.1	RP11-678G14.2	-4.51	1.88e-05	0.0123	-0.54	-0.42	Pain;	chr19:21469158	chr19:21554640~21569237:-
THYM	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-4.51	1.88e-05	0.0123	-0.57	-0.42	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-4.51	1.88e-05	0.0123	-0.57	-0.42	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
THYM	cis	rs1550576	0.568	rs79993339	ENSG00000274719.1	RP11-86K22.2	4.51	1.88e-05	0.0123	0.8	0.42	Hypertension;	chr15:57931513	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs12593050	ENSG00000274719.1	RP11-86K22.2	4.51	1.88e-05	0.0123	0.8	0.42	Hypertension;	chr15:57932075	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs16977858	ENSG00000274719.1	RP11-86K22.2	4.51	1.88e-05	0.0123	0.8	0.42	Hypertension;	chr15:57932723	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs56404147	ENSG00000274719.1	RP11-86K22.2	4.51	1.88e-05	0.0123	0.8	0.42	Hypertension;	chr15:57932889	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs55749260	ENSG00000274719.1	RP11-86K22.2	4.51	1.88e-05	0.0123	0.8	0.42	Hypertension;	chr15:57933295	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs79875011	ENSG00000274719.1	RP11-86K22.2	4.51	1.88e-05	0.0123	0.8	0.42	Hypertension;	chr15:57934064	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs10518951	ENSG00000274719.1	RP11-86K22.2	4.51	1.88e-05	0.0123	0.8	0.42	Hypertension;	chr15:57941924	chr15:57990217~57990636:-
THYM	cis	rs10483853	0.579	rs58546337	ENSG00000258695.2	RP3-414A15.2	-4.51	1.89e-05	0.0123	-0.6	-0.42	Coronary artery calcification;	chr14:73483753	chr14:73522878~73530610:+
THYM	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	4.51	1.89e-05	0.0123	0.61	0.42	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
THYM	cis	rs995834	0.622	rs10424022	ENSG00000267243.4	AC005307.3	-4.51	1.89e-05	0.0123	-0.41	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28401351	chr19:28435388~28727777:-
THYM	cis	rs17772222	0.63	rs12433739	ENSG00000258983.2	RP11-507K2.2	4.51	1.89e-05	0.0123	0.49	0.42	Coronary artery calcification;	chr14:88331704	chr14:88499334~88515502:+
THYM	cis	rs7182621	1	rs7182621	ENSG00000182397.13	DNM1P46	-4.51	1.89e-05	0.0123	-0.47	-0.42	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99790156~99806927:-
THYM	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-4.51	1.89e-05	0.0123	-0.53	-0.42	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
THYM	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-4.51	1.89e-05	0.0123	-0.37	-0.42	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
THYM	cis	rs9907295	0.748	rs11868785	ENSG00000270871.1	AC015849.19	4.51	1.9e-05	0.0124	0.36	0.42	Fibroblast growth factor basic levels;	chr17:35812214	chr17:35816717~35830293:-
THYM	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-4.51	1.9e-05	0.0124	-0.49	-0.42	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
THYM	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-4.51	1.9e-05	0.0124	-0.45	-0.42	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
THYM	cis	rs12681366	0.881	rs12674614	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.881	rs3019145	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.881	rs2931631	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.881	rs3019155	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.843	rs3019156	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94409552	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.843	rs3019147	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94412804	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.881	rs2960121	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.881	rs3019149	ENSG00000253704.1	RP11-267M23.4	4.51	1.91e-05	0.0124	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94553722~94569745:+
THYM	cis	rs4853012	0.838	rs61521879	ENSG00000272183.1	RP11-523H20.3	4.51	1.91e-05	0.0124	0.55	0.42	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74501717~74502365:+
THYM	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	4.5	1.91e-05	0.0124	0.32	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
THYM	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	4.5	1.92e-05	0.0125	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
THYM	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	4.5	1.92e-05	0.0125	0.55	0.42	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
THYM	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-4.5	1.92e-05	0.0125	-0.5	-0.42	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
THYM	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.5	1.92e-05	0.0125	0.41	0.42	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
THYM	cis	rs4948275	0.55	rs7904815	ENSG00000237233.2	TMEM26-AS1	4.5	1.92e-05	0.0125	0.43	0.42	Night sleep phenotypes;	chr10:61376854	chr10:61452639~61481956:+
THYM	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	4.5	1.92e-05	0.0125	0.52	0.42	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
THYM	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	4.5	1.92e-05	0.0125	0.52	0.42	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	4.5	1.92e-05	0.0125	0.52	0.42	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
THYM	cis	rs4835473	0.868	rs4350958	ENSG00000246448.2	RP13-578N3.3	-4.5	1.92e-05	0.0125	-0.58	-0.42	Immature fraction of reticulocytes;	chr4:143744656	chr4:143700257~143865072:+
THYM	cis	rs6696239	0.513	rs4653849	ENSG00000227711.2	RP11-275O4.5	-4.5	1.93e-05	0.0125	-0.37	-0.42	Height;	chr1:227541299	chr1:227509028~227520477:-
THYM	cis	rs4835473	0.639	rs5029916	ENSG00000249741.2	RP11-673E1.3	-4.5	1.93e-05	0.0125	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143990684	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1988206	ENSG00000249741.2	RP11-673E1.3	-4.5	1.93e-05	0.0125	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143991344	chr4:143911514~143912053:-
THYM	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	4.5	1.93e-05	0.0126	0.55	0.42	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
THYM	cis	rs2283792	1	rs5749806	ENSG00000228050.1	TOP3BP1	4.5	1.93e-05	0.0126	0.46	0.42	Multiple sclerosis;	chr22:21752329	chr22:22223187~22224566:-
THYM	cis	rs11157436	0.697	rs4334205	ENSG00000211813.2	TRAV34	-4.5	1.93e-05	0.0126	-0.3	-0.42	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155699	chr14:22207522~22208129:+
THYM	cis	rs7208859	0.673	rs1347360	ENSG00000266490.1	CTD-2349P21.9	4.5	1.94e-05	0.0126	0.72	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30792372~30792833:+
THYM	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	4.5	1.94e-05	0.0126	0.48	0.42	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	4.5	1.94e-05	0.0126	0.48	0.42	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
THYM	cis	rs1976403	0.633	rs1780322	ENSG00000227001.3	NBPF2P	4.5	1.94e-05	0.0126	0.37	0.42	Liver enzyme levels (alkaline phosphatase);	chr1:21496583	chr1:21424625~21427967:-
THYM	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	4.5	1.94e-05	0.0126	0.53	0.42	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	4.5	1.94e-05	0.0126	0.53	0.42	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	4.5	1.94e-05	0.0126	0.53	0.42	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
THYM	cis	rs7560272	0.538	rs12233112	ENSG00000273245.1	RP11-434P11.2	-4.5	1.94e-05	0.0126	-0.5	-0.42	Schizophrenia;	chr2:73704637	chr2:73750256~73750786:-
THYM	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-4.5	1.94e-05	0.0126	-0.52	-0.42	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
THYM	cis	rs8067545	0.717	rs9907788	ENSG00000230528.6	NOS2P3	-4.5	1.95e-05	0.0126	-0.34	-0.42	Schizophrenia;	chr17:20105590	chr17:20436337~20447249:+
THYM	cis	rs7560272	0.723	rs1083919	ENSG00000163016.8	ALMS1P	-4.5	1.95e-05	0.0127	-0.49	-0.42	Schizophrenia;	chr2:73486736	chr2:73644919~73685576:+
THYM	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-4.5	1.95e-05	0.0127	-0.51	-0.42	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
THYM	cis	rs8067545	0.75	rs7223305	ENSG00000230528.6	NOS2P3	-4.5	1.95e-05	0.0127	-0.34	-0.42	Schizophrenia;	chr17:20087673	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs7208635	ENSG00000230528.6	NOS2P3	-4.5	1.95e-05	0.0127	-0.34	-0.42	Schizophrenia;	chr17:20087677	chr17:20436337~20447249:+
THYM	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-4.5	1.95e-05	0.0127	-0.36	-0.42	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
THYM	cis	rs1023500	0.505	rs134878	ENSG00000227370.1	RP4-669P10.19	4.5	1.95e-05	0.0127	0.51	0.42	Schizophrenia;	chr22:42267868	chr22:42132543~42132998:+
THYM	cis	rs10829156	0.947	rs7081435	ENSG00000240291.1	RP11-499P20.2	4.5	1.96e-05	0.0127	0.37	0.42	Sudden cardiac arrest;	chr10:18667411	chr10:18513115~18545651:-
THYM	cis	rs8067545	0.616	rs203465	ENSG00000231645.2	KRT17P6	-4.5	1.96e-05	0.0127	-0.51	-0.42	Schizophrenia;	chr17:19907407	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs203462	ENSG00000231645.2	KRT17P6	-4.5	1.96e-05	0.0127	-0.51	-0.42	Schizophrenia;	chr17:19909228	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs203460	ENSG00000231645.2	KRT17P6	-4.5	1.96e-05	0.0127	-0.51	-0.42	Schizophrenia;	chr17:19911973	chr17:20512560~20517479:-
THYM	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	4.5	1.96e-05	0.0127	0.52	0.42	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
THYM	cis	rs7210990	0.866	rs11078333	ENSG00000275413.1	CTC-529I10.1	4.5	1.96e-05	0.0127	0.42	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16146312	chr17:16023323~16023653:-
THYM	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	4.5	1.96e-05	0.0127	0.56	0.42	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
THYM	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	4.5	1.96e-05	0.0127	0.35	0.42	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
THYM	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	4.5	1.96e-05	0.0127	0.35	0.42	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
THYM	cis	rs1061377	0.513	rs2566166	ENSG00000249685.1	RP11-360F5.3	-4.5	1.96e-05	0.0127	-0.42	-0.42	Uric acid levels;	chr4:39148404	chr4:39133913~39135608:+
THYM	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-4.5	1.97e-05	0.0127	-0.38	-0.42	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
THYM	cis	rs853679	0.517	rs868987	ENSG00000272009.1	RP1-313I6.12	4.5	1.97e-05	0.0127	0.53	0.42	Depression;	chr6:28142370	chr6:28078792~28081130:-
THYM	cis	rs2283792	0.73	rs894095	ENSG00000228050.1	TOP3BP1	4.5	1.97e-05	0.0127	0.47	0.42	Multiple sclerosis;	chr22:21928404	chr22:22223187~22224566:-
THYM	cis	rs10829156	0.699	rs1917209	ENSG00000225527.1	RP11-383B4.4	-4.5	1.97e-05	0.0127	-0.49	-0.42	Sudden cardiac arrest;	chr10:18543631	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.699	rs10764584	ENSG00000225527.1	RP11-383B4.4	4.5	1.97e-05	0.0127	0.49	0.42	Sudden cardiac arrest;	chr10:18546396	chr10:18531849~18533336:-
THYM	cis	rs8067545	1	rs4925065	ENSG00000231645.2	KRT17P6	-4.5	1.97e-05	0.0127	-0.49	-0.42	Schizophrenia;	chr17:20011233	chr17:20512560~20517479:-
THYM	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-4.5	1.97e-05	0.0128	-0.53	-0.42	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
THYM	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	4.5	1.97e-05	0.0128	0.54	0.42	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
THYM	cis	rs3738443	0.645	rs55768801	ENSG00000227671.4	RP11-488L18.4	-4.5	1.97e-05	0.0128	-0.25	-0.42	Alcohol dependence;	chr1:247199688	chr1:247189851~247210856:-
THYM	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	4.5	1.97e-05	0.0128	0.53	0.42	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	4.5	1.97e-05	0.0128	0.53	0.42	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
THYM	cis	rs2911132	0.564	rs731827	ENSG00000272109.1	CTD-2260A17.3	-4.5	1.98e-05	0.0128	-0.54	-0.42	Urate levels (BMI interaction);	chr5:96751311	chr5:96804353~96806105:+
THYM	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-4.5	1.98e-05	0.0128	-0.53	-0.42	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	4.5	1.98e-05	0.0128	0.53	0.42	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	4.5	1.98e-05	0.0128	0.53	0.42	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	4.5	1.98e-05	0.0128	0.53	0.42	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	4.5	1.98e-05	0.0128	0.53	0.42	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
THYM	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-4.5	1.98e-05	0.0128	-0.37	-0.42	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
THYM	cis	rs8067545	0.641	rs203479	ENSG00000231645.2	KRT17P6	-4.5	1.98e-05	0.0128	-0.51	-0.42	Schizophrenia;	chr17:19925998	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs1638525	ENSG00000231645.2	KRT17P6	-4.5	1.98e-05	0.0128	-0.51	-0.42	Schizophrenia;	chr17:19945281	chr17:20512560~20517479:-
THYM	cis	rs56307353	0.753	rs62129495	ENSG00000180846.7	CSNK1G2-AS1	4.5	1.98e-05	0.0128	0.43	0.42	Coronary artery disease;	chr19:1962790	chr19:1952531~1954586:-
THYM	cis	rs10829156	0.625	rs7082235	ENSG00000225527.1	RP11-383B4.4	-4.5	1.98e-05	0.0128	-0.49	-0.42	Sudden cardiac arrest;	chr10:18536765	chr10:18531849~18533336:-
THYM	cis	rs4835473	0.932	rs7693772	ENSG00000249741.2	RP11-673E1.3	-4.5	1.98e-05	0.0128	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143965614	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4260486	ENSG00000249741.2	RP11-673E1.3	-4.5	1.98e-05	0.0128	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143987556	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs12649594	ENSG00000249741.2	RP11-673E1.3	-4.5	1.98e-05	0.0128	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143989307	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs13101482	ENSG00000249741.2	RP11-673E1.3	-4.5	1.98e-05	0.0128	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143989463	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs13135472	ENSG00000249741.2	RP11-673E1.3	-4.5	1.98e-05	0.0128	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143989465	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1849118	ENSG00000249741.2	RP11-673E1.3	-4.5	1.98e-05	0.0128	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143989822	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.663	rs1511423	ENSG00000249741.2	RP11-673E1.3	-4.5	1.98e-05	0.0128	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143990136	chr4:143911514~143912053:-
THYM	cis	rs7223966	1	rs8075257	ENSG00000240280.5	TCAM1P	-4.5	1.98e-05	0.0128	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63651390	chr17:63849292~63864379:+
THYM	cis	rs4554975	0.545	rs11183661	ENSG00000274723.1	RP11-618L22.1	-4.5	1.98e-05	0.0128	-0.34	-0.42	Metabolite levels (small molecules and protein measures);	chr12:46937241	chr12:46970504~46972155:+
THYM	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	4.49	1.98e-05	0.0128	0.43	0.42	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
THYM	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-4.49	1.99e-05	0.0128	-0.45	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
THYM	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-4.49	1.99e-05	0.0128	-0.45	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
THYM	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	4.49	1.99e-05	0.0128	0.69	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
THYM	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-4.49	1.99e-05	0.0129	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
THYM	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-4.49	1.99e-05	0.0129	-0.48	-0.42	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
THYM	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-4.49	1.99e-05	0.0129	-0.53	-0.42	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-4.49	1.99e-05	0.0129	-0.53	-0.42	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
THYM	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-4.49	1.99e-05	0.0129	-0.53	-0.42	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
THYM	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	4.49	1.99e-05	0.0129	0.53	0.42	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
THYM	cis	rs8067545	1	rs2108980	ENSG00000231645.2	KRT17P6	-4.49	1.99e-05	0.0129	-0.49	-0.42	Schizophrenia;	chr17:20017205	chr17:20512560~20517479:-
THYM	cis	rs8067545	1	rs4925067	ENSG00000231645.2	KRT17P6	-4.49	1.99e-05	0.0129	-0.49	-0.42	Schizophrenia;	chr17:20017909	chr17:20512560~20517479:-
THYM	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
THYM	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
THYM	cis	rs9309473	0.5	rs4852308	ENSG00000163016.8	ALMS1P	-4.49	1.99e-05	0.0129	-0.5	-0.42	Metabolite levels;	chr2:73606908	chr2:73644919~73685576:+
THYM	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	4.49	1.99e-05	0.0129	0.9	0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.749	rs58144189	ENSG00000261838.4	RP11-303E16.6	4.49	1.99e-05	0.0129	0.9	0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.749	rs1035541	ENSG00000261838.4	RP11-303E16.6	4.49	1.99e-05	0.0129	0.9	0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs56166222	ENSG00000261838.4	RP11-303E16.6	4.49	1.99e-05	0.0129	0.9	0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81069854~81076598:+
THYM	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	4.49	1.99e-05	0.0129	0.58	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
THYM	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	4.49	1.99e-05	0.0129	0.48	0.42	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
THYM	cis	rs56307353	0.753	rs34318825	ENSG00000180846.7	CSNK1G2-AS1	4.49	1.99e-05	0.0129	0.43	0.42	Coronary artery disease;	chr19:1961343	chr19:1952531~1954586:-
THYM	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-4.49	2e-05	0.0129	-0.3	-0.42	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
THYM	cis	rs9402743	0.634	rs9494306	ENSG00000236703.1	MYB-AS1	-4.49	2e-05	0.0129	-0.29	-0.42	Systemic lupus erythematosus;	chr6:135622823	chr6:135195083~135195995:-
THYM	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	4.49	2e-05	0.0129	0.45	0.42	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
THYM	cis	rs4908760	0.965	rs301814	ENSG00000232912.4	RP5-1115A15.1	4.49	2e-05	0.0129	0.42	0.42	Vitiligo;	chr1:8450517	chr1:8424645~8434838:+
THYM	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	4.49	2e-05	0.0129	0.52	0.42	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	4.49	2e-05	0.0129	0.52	0.42	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
THYM	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	4.49	2.01e-05	0.0129	0.47	0.42	QT interval;	chr12:29284120	chr12:29280418~29317848:-
THYM	cis	rs12439619	0.508	rs8032033	ENSG00000255769.6	GOLGA2P10	-4.49	2.01e-05	0.013	-0.39	-0.42	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472993~82513950:-
THYM	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-4.49	2.01e-05	0.013	-0.36	-0.42	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
THYM	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-4.49	2.01e-05	0.013	-0.39	-0.42	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
THYM	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	4.49	2.01e-05	0.013	0.36	0.42	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
THYM	cis	rs61270009	0.818	rs6452786	ENSG00000247828.6	TMEM161B-AS1	4.49	2.01e-05	0.013	0.35	0.42	Depressive symptoms;	chr5:88409022	chr5:88268895~88436685:+
THYM	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	4.49	2.01e-05	0.013	0.55	0.42	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
THYM	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-4.49	2.01e-05	0.013	-0.54	-0.42	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-4.49	2.01e-05	0.013	-0.54	-0.42	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
THYM	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.49	2.02e-05	0.013	0.41	0.42	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	4.49	2.02e-05	0.013	0.41	0.42	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
THYM	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	4.49	2.02e-05	0.013	0.52	0.42	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
THYM	cis	rs10888838	0.941	rs11206305	ENSG00000198711.5	SSBP3-AS1	4.49	2.02e-05	0.013	0.29	0.42	Mitochondrial DNA levels;	chr1:54222538	chr1:54236440~54239063:+
THYM	cis	rs4908760	0.566	rs7532459	ENSG00000232912.4	RP5-1115A15.1	4.49	2.02e-05	0.013	0.41	0.42	Vitiligo;	chr1:8617714	chr1:8424645~8434838:+
THYM	cis	rs7937127	0.744	rs11602193	ENSG00000254907.1	RP11-484D2.2	-4.49	2.02e-05	0.013	-0.65	-0.42	Fibrinogen levels;	chr11:43486606	chr11:43328748~43359296:-
THYM	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	4.49	2.03e-05	0.013	0.36	0.42	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
THYM	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	4.49	2.03e-05	0.013	0.48	0.42	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	4.49	2.03e-05	0.013	0.48	0.42	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
THYM	cis	rs4834770	1	rs4834770	ENSG00000249244.1	RP11-548H18.2	4.49	2.03e-05	0.013	0.32	0.42	Blood protein levels;	chr4:119320694	chr4:119391831~119395335:-
THYM	cis	rs4834770	1	rs6823963	ENSG00000249244.1	RP11-548H18.2	4.49	2.03e-05	0.013	0.32	0.42	Blood protein levels;	chr4:119321009	chr4:119391831~119395335:-
THYM	cis	rs4834770	1	rs4834771	ENSG00000249244.1	RP11-548H18.2	4.49	2.03e-05	0.013	0.32	0.42	Blood protein levels;	chr4:119321617	chr4:119391831~119395335:-
THYM	cis	rs4834770	1	rs1397613	ENSG00000249244.1	RP11-548H18.2	4.49	2.03e-05	0.013	0.32	0.42	Blood protein levels;	chr4:119321774	chr4:119391831~119395335:-
THYM	cis	rs4834770	1	rs6857641	ENSG00000249244.1	RP11-548H18.2	4.49	2.03e-05	0.013	0.32	0.42	Blood protein levels;	chr4:119322356	chr4:119391831~119395335:-
THYM	cis	rs4834770	1	rs2282688	ENSG00000249244.1	RP11-548H18.2	4.49	2.03e-05	0.013	0.32	0.42	Blood protein levels;	chr4:119322567	chr4:119391831~119395335:-
THYM	cis	rs4834770	1	rs10034579	ENSG00000249244.1	RP11-548H18.2	4.49	2.03e-05	0.013	0.32	0.42	Blood protein levels;	chr4:119322874	chr4:119391831~119395335:-
THYM	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-4.49	2.03e-05	0.013	-0.55	-0.42	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
THYM	cis	rs12701220	0.503	rs12531999	ENSG00000229043.2	AC091729.9	-4.49	2.03e-05	0.013	-0.66	-0.42	Bronchopulmonary dysplasia;	chr7:1141965	chr7:1160374~1165267:+
THYM	cis	rs9402743	0.709	rs9373136	ENSG00000236703.1	MYB-AS1	-4.49	2.03e-05	0.0131	-0.29	-0.42	Systemic lupus erythematosus;	chr6:135617531	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.678	rs965191	ENSG00000236703.1	MYB-AS1	-4.49	2.03e-05	0.0131	-0.29	-0.42	Systemic lupus erythematosus;	chr6:135618363	chr6:135195083~135195995:-
THYM	cis	rs1529093	1	rs16864877	ENSG00000222043.2	AC079305.10	-4.49	2.03e-05	0.0131	-0.35	-0.42	Non-alcoholic fatty liver disease histology (other);	chr2:177044464	chr2:177264359~177265515:+
THYM	cis	rs1529093	1	rs1529093	ENSG00000222043.2	AC079305.10	-4.49	2.03e-05	0.0131	-0.35	-0.42	Non-alcoholic fatty liver disease histology (other);	chr2:177044867	chr2:177264359~177265515:+
THYM	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	4.49	2.04e-05	0.0131	0.36	0.42	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
THYM	cis	rs10276381	1	rs10260837	ENSG00000253187.2	HOXA10-AS	4.49	2.04e-05	0.0131	0.38	0.42	Crohn's disease;	chr7:28141510	chr7:27168619~27171915:+
THYM	cis	rs10276381	1	rs10280937	ENSG00000253187.2	HOXA10-AS	4.49	2.04e-05	0.0131	0.38	0.42	Crohn's disease;	chr7:28142687	chr7:27168619~27171915:+
THYM	cis	rs10276381	1	rs10281214	ENSG00000253187.2	HOXA10-AS	4.49	2.04e-05	0.0131	0.38	0.42	Crohn's disease;	chr7:28145925	chr7:27168619~27171915:+
THYM	cis	rs10276381	1	rs7796417	ENSG00000253187.2	HOXA10-AS	4.49	2.04e-05	0.0131	0.38	0.42	Crohn's disease;	chr7:28146500	chr7:27168619~27171915:+
THYM	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-4.49	2.04e-05	0.0131	-0.44	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
THYM	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-4.49	2.04e-05	0.0131	-0.44	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
THYM	cis	rs935334	1	rs8006048	ENSG00000258454.1	RP11-361H10.3	4.49	2.04e-05	0.0131	0.54	0.42	Blood pressure;	chr14:76217165	chr14:76235817~76263474:+
THYM	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-4.49	2.04e-05	0.0131	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
THYM	cis	rs4835473	0.932	rs4287958	ENSG00000249741.2	RP11-673E1.3	-4.49	2.04e-05	0.0131	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143987719	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4125545	ENSG00000249741.2	RP11-673E1.3	-4.49	2.04e-05	0.0131	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143988650	chr4:143911514~143912053:-
THYM	cis	rs9309473	0.539	rs7574268	ENSG00000273245.1	RP11-434P11.2	-4.49	2.04e-05	0.0131	-0.45	-0.42	Metabolite levels;	chr2:73677745	chr2:73750256~73750786:-
THYM	cis	rs56307353	0.781	rs10425937	ENSG00000180846.7	CSNK1G2-AS1	4.49	2.04e-05	0.0131	0.43	0.42	Coronary artery disease;	chr19:1959022	chr19:1952531~1954586:-
THYM	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-4.49	2.04e-05	0.0131	-0.48	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
THYM	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-4.49	2.04e-05	0.0131	-0.48	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
THYM	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-4.49	2.04e-05	0.0131	-0.48	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-4.49	2.04e-05	0.0131	-0.48	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	4.49	2.04e-05	0.0131	0.48	0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
THYM	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-4.49	2.05e-05	0.0131	-0.3	-0.42	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
THYM	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-4.49	2.05e-05	0.0131	-0.3	-0.42	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
THYM	cis	rs4478858	0.684	rs1546375	ENSG00000260386.4	LINC01225	4.49	2.05e-05	0.0132	0.23	0.42	Alcohol dependence;	chr1:31293121	chr1:31500085~31540885:+
THYM	cis	rs7223966	1	rs6504170	ENSG00000240280.5	TCAM1P	-4.49	2.05e-05	0.0132	-0.64	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63631808	chr17:63849292~63864379:+
THYM	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-4.49	2.05e-05	0.0132	-0.51	-0.42	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
THYM	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-4.49	2.06e-05	0.0132	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
THYM	cis	rs34792	0.688	rs153785	ENSG00000262380.1	CTB-193M12.3	-4.49	2.06e-05	0.0132	-0.52	-0.42	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:15683290~15684570:+
THYM	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-4.49	2.06e-05	0.0132	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
THYM	cis	rs6657613	0.873	rs9435731	ENSG00000186715.9	MST1L	-4.48	2.06e-05	0.0132	-0.54	-0.42	Hip circumference adjusted for BMI;	chr1:16979534	chr1:16754910~16770237:-
THYM	cis	rs6657613	0.873	rs2284746	ENSG00000186715.9	MST1L	-4.48	2.06e-05	0.0132	-0.54	-0.42	Hip circumference adjusted for BMI;	chr1:16980180	chr1:16754910~16770237:-
THYM	cis	rs4908768	0.501	rs2016084	ENSG00000232912.4	RP5-1115A15.1	4.48	2.06e-05	0.0132	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs12756257	ENSG00000232912.4	RP5-1115A15.1	4.48	2.06e-05	0.0132	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs6663123	ENSG00000232912.4	RP5-1115A15.1	4.48	2.06e-05	0.0132	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs922366	ENSG00000232912.4	RP5-1115A15.1	4.48	2.06e-05	0.0132	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs11121205	ENSG00000232912.4	RP5-1115A15.1	4.48	2.06e-05	0.0132	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.539	rs2100888	ENSG00000232912.4	RP5-1115A15.1	4.48	2.06e-05	0.0132	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8424645~8434838:+
THYM	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-4.48	2.06e-05	0.0132	-0.41	-0.42	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
THYM	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	4.48	2.06e-05	0.0132	0.56	0.42	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	4.48	2.06e-05	0.0132	0.56	0.42	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
THYM	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	4.48	2.06e-05	0.0132	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	4.48	2.06e-05	0.0132	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	4.48	2.06e-05	0.0132	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	4.48	2.06e-05	0.0132	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	4.48	2.06e-05	0.0132	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
THYM	cis	rs7223966	1	rs16947042	ENSG00000240280.5	TCAM1P	-4.48	2.07e-05	0.0132	-0.62	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63689097	chr17:63849292~63864379:+
THYM	cis	rs972578	0.806	rs738397	ENSG00000215347.3	SLC25A5P1	-4.48	2.07e-05	0.0133	-0.32	-0.42	Mean platelet volume;	chr22:42899265	chr22:42001069~42001966:-
THYM	cis	rs7202877	0.706	rs37602	ENSG00000261783.1	RP11-252K23.2	4.48	2.07e-05	0.0133	0.56	0.42	Type 1 diabetes;Type 2 diabetes;	chr16:75471148	chr16:75379818~75381260:-
THYM	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-4.48	2.07e-05	0.0133	-0.4	-0.42	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
THYM	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-4.48	2.07e-05	0.0133	-0.4	-0.42	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
THYM	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-4.48	2.07e-05	0.0133	-0.4	-0.42	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
THYM	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-4.48	2.07e-05	0.0133	-0.52	-0.42	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
THYM	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	4.48	2.07e-05	0.0133	0.39	0.42	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	4.48	2.07e-05	0.0133	0.39	0.42	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	4.48	2.07e-05	0.0133	0.39	0.42	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
THYM	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	4.48	2.07e-05	0.0133	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
THYM	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	4.48	2.07e-05	0.0133	0.47	0.42	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
THYM	cis	rs10129255	0.518	rs8009594	ENSG00000253703.1	IGHV1-68	-4.48	2.07e-05	0.0133	-0.45	-0.42	Kawasaki disease;	chr14:106777494	chr14:106703852~106704146:-
THYM	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	4.48	2.08e-05	0.0133	0.48	0.42	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
THYM	cis	rs6040076	0.817	rs2179688	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10707224	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.781	rs2143621	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10707476	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs2143616	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10709443	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs2143617	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10709507	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs2179686	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10709646	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs2327295	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10710116	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.781	rs1883800	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10710132	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs6032923	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10710647	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.79	rs6032924	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10710704	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.781	rs6032926	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10710842	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs6032927	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10711553	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.781	rs973542	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10711911	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs6077888	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10712341	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs6040102	ENSG00000230506.1	RP11-416N4.4	4.48	2.08e-05	0.0133	0.48	0.42	Pulse pressure;Birth weight;	chr20:10712865	chr20:10173520~10196990:+
THYM	cis	rs4663866	0.901	rs35713061	ENSG00000186235.9	AC016757.3	4.48	2.08e-05	0.0133	0.96	0.42	Irritable bowel syndrome;	chr2:238275133	chr2:238224552~238231677:-
THYM	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-4.48	2.08e-05	0.0133	-0.35	-0.42	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
THYM	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-4.48	2.08e-05	0.0133	-0.29	-0.42	Height;	chr11:118737823	chr11:118791254~118793137:+
THYM	cis	rs62184315	0.536	rs62183651	ENSG00000273240.1	RP11-455J20.3	-4.48	2.08e-05	0.0133	-0.71	-0.42	Alcohol dependence (age at onset);	chr2:189647251	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs62183652	ENSG00000273240.1	RP11-455J20.3	-4.48	2.08e-05	0.0133	-0.71	-0.42	Alcohol dependence (age at onset);	chr2:189648877	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs62183653	ENSG00000273240.1	RP11-455J20.3	-4.48	2.08e-05	0.0133	-0.71	-0.42	Alcohol dependence (age at onset);	chr2:189650099	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs72920421	ENSG00000273240.1	RP11-455J20.3	-4.48	2.08e-05	0.0133	-0.71	-0.42	Alcohol dependence (age at onset);	chr2:189650292	chr2:189763859~189764456:-
THYM	cis	rs972578	0.868	rs1076118	ENSG00000215347.3	SLC25A5P1	4.48	2.08e-05	0.0133	0.34	0.42	Mean platelet volume;	chr22:42903704	chr22:42001069~42001966:-
THYM	cis	rs9309473	0.519	rs2421574	ENSG00000163016.8	ALMS1P	-4.48	2.08e-05	0.0133	-0.49	-0.42	Metabolite levels;	chr2:73681640	chr2:73644919~73685576:+
THYM	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-4.48	2.09e-05	0.0133	-0.45	-0.42	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-4.48	2.09e-05	0.0133	-0.45	-0.42	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-4.48	2.09e-05	0.0133	-0.45	-0.42	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
THYM	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	4.48	2.09e-05	0.0133	0.43	0.42	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
THYM	cis	rs71281886	1	rs71281886	ENSG00000229759.1	MRPS18AP1	4.48	2.09e-05	0.0134	0.38	0.42	Breast cancer;	chr3:48311088	chr3:48256350~48256938:-
THYM	cis	rs4908760	0.965	rs7542312	ENSG00000232912.4	RP5-1115A15.1	4.48	2.09e-05	0.0134	0.41	0.42	Vitiligo;	chr1:8513412	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.899	rs61783642	ENSG00000232912.4	RP5-1115A15.1	4.48	2.09e-05	0.0134	0.41	0.42	Vitiligo;	chr1:8531338	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs1463051	ENSG00000232912.4	RP5-1115A15.1	-4.48	2.09e-05	0.0134	-0.41	-0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.931	rs1463049	ENSG00000232912.4	RP5-1115A15.1	4.48	2.09e-05	0.0134	0.41	0.42	Vitiligo;	chr1:8537049	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs11121199	ENSG00000232912.4	RP5-1115A15.1	4.48	2.09e-05	0.0134	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8424645~8434838:+
THYM	cis	rs9309473	0.5	rs6757996	ENSG00000163016.8	ALMS1P	4.48	2.09e-05	0.0134	0.5	0.42	Metabolite levels;	chr2:73545124	chr2:73644919~73685576:+
THYM	cis	rs4845570	0.92	rs11810571	ENSG00000203288.3	RP11-98D18.9	4.48	2.09e-05	0.0134	0.49	0.42	Coronary artery disease;	chr1:151789832	chr1:151790804~151794402:+
THYM	cis	rs4554975	0.514	rs1986584	ENSG00000274723.1	RP11-618L22.1	-4.48	2.09e-05	0.0134	-0.34	-0.42	Metabolite levels (small molecules and protein measures);	chr12:46909419	chr12:46970504~46972155:+
THYM	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-4.48	2.09e-05	0.0134	-0.35	-0.42	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
THYM	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	4.48	2.1e-05	0.0134	0.39	0.42	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
THYM	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	4.48	2.1e-05	0.0134	0.39	0.42	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
THYM	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	4.48	2.1e-05	0.0134	0.39	0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
THYM	cis	rs10799445	0.55	rs12023298	ENSG00000227711.2	RP11-275O4.5	4.48	2.1e-05	0.0134	0.38	0.42	Height;	chr1:227541713	chr1:227509028~227520477:-
THYM	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	4.48	2.1e-05	0.0134	0.53	0.42	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	4.48	2.1e-05	0.0134	0.53	0.42	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
THYM	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-4.48	2.1e-05	0.0134	-0.6	-0.42	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
THYM	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	4.48	2.1e-05	0.0134	0.52	0.42	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	4.48	2.1e-05	0.0134	0.52	0.42	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	4.48	2.1e-05	0.0134	0.52	0.42	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	4.48	2.1e-05	0.0134	0.52	0.42	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	4.48	2.1e-05	0.0134	0.52	0.42	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
THYM	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	4.48	2.1e-05	0.0134	0.41	0.42	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
THYM	cis	rs12439619	0.705	rs4778665	ENSG00000274376.3	ADAMTS7P1	4.48	2.11e-05	0.0135	0.48	0.42	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82298553~82334609:+
THYM	cis	rs7223966	1	rs73337598	ENSG00000240280.5	TCAM1P	-4.48	2.11e-05	0.0135	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63655216	chr17:63849292~63864379:+
THYM	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-4.48	2.11e-05	0.0135	-0.49	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
THYM	cis	rs1426063	0.748	rs6534607	ENSG00000249717.1	RP11-44F21.3	4.48	2.11e-05	0.0135	0.63	0.42	QT interval;	chr4:75106366	chr4:74955974~74970362:-
THYM	cis	rs7223966	1	rs8073373	ENSG00000240280.5	TCAM1P	-4.48	2.11e-05	0.0135	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63625960	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs7220821	ENSG00000240280.5	TCAM1P	-4.48	2.11e-05	0.0135	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63626787	chr17:63849292~63864379:+
THYM	cis	rs7267979	0.844	rs8184820	ENSG00000276952.1	RP5-965G21.6	-4.48	2.11e-05	0.0135	-0.49	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25284915~25285588:-
THYM	cis	rs7267979	0.773	rs6132821	ENSG00000276952.1	RP5-965G21.6	4.48	2.11e-05	0.0135	0.49	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25284915~25285588:-
THYM	cis	rs7267979	0.873	rs6132822	ENSG00000276952.1	RP5-965G21.6	4.48	2.11e-05	0.0135	0.49	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25284915~25285588:-
THYM	cis	rs7267979	0.844	rs1555330	ENSG00000276952.1	RP5-965G21.6	4.48	2.11e-05	0.0135	0.49	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25284915~25285588:-
THYM	cis	rs7267979	0.844	rs6107017	ENSG00000276952.1	RP5-965G21.6	4.48	2.11e-05	0.0135	0.49	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25284915~25285588:-
THYM	cis	rs7267979	0.844	rs6132824	ENSG00000276952.1	RP5-965G21.6	4.48	2.11e-05	0.0135	0.49	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25284915~25285588:-
THYM	cis	rs7267979	0.739	rs6138555	ENSG00000276952.1	RP5-965G21.6	4.48	2.11e-05	0.0135	0.49	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25284915~25285588:-
THYM	cis	rs9309473	0.519	rs13009035	ENSG00000163016.8	ALMS1P	-4.48	2.11e-05	0.0135	-0.5	-0.42	Metabolite levels;	chr2:73618582	chr2:73644919~73685576:+
THYM	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-4.48	2.12e-05	0.0135	-0.52	-0.42	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-4.48	2.12e-05	0.0135	-0.52	-0.42	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
THYM	cis	rs2662776	1	rs10753607	ENSG00000232995.6	RGS5	4.48	2.12e-05	0.0135	0.36	0.42	Lead levels in blood;	chr1:163189038	chr1:163244505~163321894:-
THYM	cis	rs2662776	1	rs7355070	ENSG00000232995.6	RGS5	4.48	2.12e-05	0.0135	0.36	0.42	Lead levels in blood;	chr1:163189706	chr1:163244505~163321894:-
THYM	cis	rs2662776	1	rs10753608	ENSG00000232995.6	RGS5	4.48	2.12e-05	0.0135	0.36	0.42	Lead levels in blood;	chr1:163190261	chr1:163244505~163321894:-
THYM	cis	rs17711722	0.565	rs4275112	ENSG00000232906.1	RP11-746P2.3	-4.48	2.13e-05	0.0136	-0.43	-0.42	Calcium levels;	chr7:65733651	chr7:65355934~65357176:+
THYM	cis	rs4948275	0.773	rs2650697	ENSG00000237233.2	TMEM26-AS1	-4.48	2.13e-05	0.0136	-0.51	-0.42	Night sleep phenotypes;	chr10:61536585	chr10:61452639~61481956:+
THYM	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	4.48	2.13e-05	0.0136	0.53	0.42	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
THYM	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-4.48	2.13e-05	0.0136	-0.29	-0.42	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
THYM	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-4.48	2.13e-05	0.0136	-0.29	-0.42	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
THYM	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-4.48	2.13e-05	0.0136	-0.29	-0.42	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
THYM	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-4.48	2.13e-05	0.0136	-0.29	-0.42	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
THYM	cis	rs8067545	0.75	rs4925081	ENSG00000230528.6	NOS2P3	4.48	2.13e-05	0.0136	0.34	0.42	Schizophrenia;	chr17:20088680	chr17:20436337~20447249:+
THYM	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	4.48	2.13e-05	0.0136	0.75	0.42	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
THYM	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-4.48	2.13e-05	0.0136	-0.49	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
THYM	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-4.48	2.13e-05	0.0136	-0.49	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
THYM	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-4.48	2.13e-05	0.0136	-0.49	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
THYM	cis	rs6706785	0.547	rs7557010	ENSG00000196758.3	AC079612.1	4.48	2.13e-05	0.0136	0.41	0.42	Conotruncal heart defects;	chr2:239517088	chr2:239578301~239586094:+
THYM	cis	rs4654049	1	rs1809879	ENSG00000188460.4	ACTBP11	4.48	2.13e-05	0.0136	0.53	0.42	Cancer;	chr1:224590669	chr1:223863726~223864851:-
THYM	cis	rs4654049	1	rs2405310	ENSG00000188460.4	ACTBP11	4.48	2.13e-05	0.0136	0.53	0.42	Cancer;	chr1:224590774	chr1:223863726~223864851:-
THYM	cis	rs4853012	0.838	rs12619982	ENSG00000272183.1	RP11-523H20.3	4.48	2.14e-05	0.0136	0.56	0.42	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74501717~74502365:+
THYM	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	4.47	2.14e-05	0.0136	0.69	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
THYM	cis	rs8067545	1	rs8065337	ENSG00000231645.2	KRT17P6	-4.47	2.14e-05	0.0136	-0.49	-0.42	Schizophrenia;	chr17:20038566	chr17:20512560~20517479:-
THYM	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	4.47	2.14e-05	0.0137	0.36	0.42	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
THYM	cis	rs9876781	1	rs6442119	ENSG00000244380.1	RP11-24C3.2	4.47	2.14e-05	0.0137	0.54	0.42	Longevity;	chr3:48398713	chr3:48440352~48446656:-
THYM	cis	rs6087771	0.926	rs6058431	ENSG00000230613.1	HM13-AS1	4.47	2.14e-05	0.0137	0.57	0.42	Putamen volume;Subcortical brain region volumes;	chr20:31709330	chr20:31567707~31573263:-
THYM	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	4.47	2.14e-05	0.0137	0.44	0.42	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-4.47	2.14e-05	0.0137	-0.44	-0.42	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
THYM	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-4.47	2.14e-05	0.0137	-0.44	-0.42	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
THYM	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-4.47	2.16e-05	0.0137	-0.53	-0.42	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
THYM	cis	rs972578	0.84	rs8138151	ENSG00000215347.3	SLC25A5P1	-4.47	2.16e-05	0.0137	-0.33	-0.42	Mean platelet volume;	chr22:42989997	chr22:42001069~42001966:-
THYM	cis	rs7223966	1	rs17549954	ENSG00000240280.5	TCAM1P	-4.47	2.16e-05	0.0137	-0.65	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63629672	chr17:63849292~63864379:+
THYM	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	4.47	2.16e-05	0.0137	0.42	0.42	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	4.47	2.16e-05	0.0137	0.42	0.42	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
THYM	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-4.47	2.16e-05	0.0137	-0.43	-0.42	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
THYM	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-4.47	2.16e-05	0.0138	-0.44	-0.42	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
THYM	cis	rs10129255	0.5	rs8004923	ENSG00000253703.1	IGHV1-68	-4.47	2.16e-05	0.0138	-0.45	-0.42	Kawasaki disease;	chr14:106785926	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs6576232	ENSG00000253703.1	IGHV1-68	-4.47	2.16e-05	0.0138	-0.45	-0.42	Kawasaki disease;	chr14:106787090	chr14:106703852~106704146:-
THYM	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-4.47	2.17e-05	0.0138	-0.36	-0.42	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-4.47	2.17e-05	0.0138	-0.36	-0.42	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
THYM	cis	rs1023500	0.596	rs5758562	ENSG00000227370.1	RP4-669P10.19	4.47	2.17e-05	0.0138	0.5	0.42	Schizophrenia;	chr22:42052234	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.596	rs5751209	ENSG00000227370.1	RP4-669P10.19	4.47	2.17e-05	0.0138	0.5	0.42	Schizophrenia;	chr22:42055599	chr22:42132543~42132998:+
THYM	cis	rs4948275	0.773	rs2787732	ENSG00000237233.2	TMEM26-AS1	4.47	2.17e-05	0.0138	0.49	0.42	Night sleep phenotypes;	chr10:61487841	chr10:61452639~61481956:+
THYM	cis	rs7560272	0.538	rs7599453	ENSG00000163016.8	ALMS1P	-4.47	2.17e-05	0.0138	-0.53	-0.42	Schizophrenia;	chr2:73710774	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs3980695	ENSG00000163016.8	ALMS1P	-4.47	2.17e-05	0.0138	-0.53	-0.42	Schizophrenia;	chr2:73712425	chr2:73644919~73685576:+
THYM	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	4.47	2.17e-05	0.0138	0.52	0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
THYM	cis	rs972578	1	rs4140554	ENSG00000215347.3	SLC25A5P1	4.47	2.17e-05	0.0138	0.32	0.42	Mean platelet volume;	chr22:42959250	chr22:42001069~42001966:-
THYM	cis	rs4835473	0.868	rs1822841	ENSG00000249741.2	RP11-673E1.3	-4.47	2.17e-05	0.0138	-0.34	-0.42	Immature fraction of reticulocytes;	chr4:143921485	chr4:143911514~143912053:-
THYM	cis	rs4908769	0.624	rs3765971	ENSG00000232912.4	RP5-1115A15.1	-4.47	2.18e-05	0.0138	-0.45	-0.42	Allergy;	chr1:8385300	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs2120461	ENSG00000232912.4	RP5-1115A15.1	-4.47	2.18e-05	0.0138	-0.45	-0.42	Allergy;	chr1:8387662	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.553	rs301792	ENSG00000232912.4	RP5-1115A15.1	4.47	2.18e-05	0.0138	0.45	0.42	Allergy;	chr1:8408218	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs301790	ENSG00000232912.4	RP5-1115A15.1	4.47	2.18e-05	0.0138	0.45	0.42	Allergy;	chr1:8409224	chr1:8424645~8434838:+
THYM	cis	rs8067545	1	rs4925066	ENSG00000231645.2	KRT17P6	-4.47	2.18e-05	0.0139	-0.48	-0.42	Schizophrenia;	chr17:20011979	chr17:20512560~20517479:-
THYM	cis	rs8067545	1	rs28807825	ENSG00000231645.2	KRT17P6	-4.47	2.18e-05	0.0139	-0.48	-0.42	Schizophrenia;	chr17:20039537	chr17:20512560~20517479:-
THYM	cis	rs8067545	1	rs3909258	ENSG00000231645.2	KRT17P6	-4.47	2.18e-05	0.0139	-0.48	-0.42	Schizophrenia;	chr17:20042506	chr17:20512560~20517479:-
THYM	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	4.47	2.18e-05	0.0139	0.5	0.42	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	4.47	2.18e-05	0.0139	0.5	0.42	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	4.47	2.18e-05	0.0139	0.5	0.42	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	4.47	2.18e-05	0.0139	0.5	0.42	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	4.47	2.18e-05	0.0139	0.5	0.42	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	4.47	2.18e-05	0.0139	0.5	0.42	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	4.47	2.18e-05	0.0139	0.5	0.42	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
THYM	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-4.47	2.19e-05	0.0139	-0.45	-0.42	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-4.47	2.19e-05	0.0139	-0.45	-0.42	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-4.47	2.19e-05	0.0139	-0.45	-0.42	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-4.47	2.19e-05	0.0139	-0.45	-0.42	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-4.47	2.19e-05	0.0139	-0.45	-0.42	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
THYM	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	4.47	2.19e-05	0.0139	0.53	0.42	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	4.47	2.19e-05	0.0139	0.53	0.42	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-4.47	2.19e-05	0.0139	-0.53	-0.42	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-4.47	2.19e-05	0.0139	-0.53	-0.42	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-4.47	2.19e-05	0.0139	-0.53	-0.42	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-4.47	2.19e-05	0.0139	-0.53	-0.42	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-4.47	2.19e-05	0.0139	-0.53	-0.42	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
THYM	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-4.47	2.19e-05	0.0139	-0.31	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
THYM	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	4.47	2.19e-05	0.0139	0.52	0.42	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
THYM	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-4.47	2.19e-05	0.0139	-0.3	-0.42	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-4.47	2.19e-05	0.0139	-0.3	-0.42	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-4.47	2.19e-05	0.0139	-0.3	-0.42	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
THYM	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-4.47	2.19e-05	0.0139	-0.3	-0.42	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-4.47	2.19e-05	0.0139	-0.3	-0.42	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-4.47	2.19e-05	0.0139	-0.3	-0.42	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
THYM	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
THYM	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
THYM	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	4.47	2.19e-05	0.0139	0.3	0.42	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
THYM	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-4.47	2.19e-05	0.0139	-0.56	-0.42	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
THYM	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-4.47	2.2e-05	0.0139	-0.58	-0.42	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-4.47	2.2e-05	0.0139	-0.58	-0.42	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
THYM	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.47	2.2e-05	0.0139	0.42	0.42	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
THYM	cis	rs9402743	0.671	rs2327650	ENSG00000236703.1	MYB-AS1	-4.47	2.2e-05	0.014	-0.28	-0.42	Systemic lupus erythematosus;	chr6:135630279	chr6:135195083~135195995:-
THYM	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	4.47	2.21e-05	0.014	0.39	0.42	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.596	rs133352	ENSG00000227370.1	RP4-669P10.19	4.47	2.21e-05	0.014	0.5	0.42	Schizophrenia;	chr22:42038018	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.551	rs133355	ENSG00000227370.1	RP4-669P10.19	4.47	2.21e-05	0.014	0.5	0.42	Schizophrenia;	chr22:42044281	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.552	rs5758566	ENSG00000227370.1	RP4-669P10.19	4.47	2.21e-05	0.014	0.5	0.42	Schizophrenia;	chr22:42058350	chr22:42132543~42132998:+
THYM	cis	rs4691139	0.658	rs12510282	ENSG00000250227.1	TRIM60P14	4.47	2.21e-05	0.014	0.51	0.42	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003257	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.658	rs12502594	ENSG00000250227.1	TRIM60P14	4.47	2.21e-05	0.014	0.51	0.42	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003273	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.658	rs12502595	ENSG00000250227.1	TRIM60P14	4.47	2.21e-05	0.014	0.51	0.42	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003290	chr4:164915565~164916983:+
THYM	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-4.47	2.21e-05	0.014	-0.31	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
THYM	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-4.47	2.21e-05	0.014	-0.52	-0.42	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
THYM	cis	rs35542019	1	rs35542019	ENSG00000273102.1	AP000569.9	4.47	2.21e-05	0.014	0.44	0.42	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33967101~33968573:-
THYM	cis	rs2739330	0.761	rs5760176	ENSG00000272787.1	KB-226F1.2	4.47	2.21e-05	0.014	0.47	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23969211~23969873:+
THYM	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-4.47	2.22e-05	0.014	-0.36	-0.42	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
THYM	cis	rs12908161	1	rs62021219	ENSG00000275120.1	RP11-182J1.17	4.47	2.22e-05	0.014	0.56	0.42	Schizophrenia;	chr15:84712928	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs34900908	ENSG00000275120.1	RP11-182J1.17	4.47	2.22e-05	0.014	0.56	0.42	Schizophrenia;	chr15:84714368	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs35524990	ENSG00000275120.1	RP11-182J1.17	4.47	2.22e-05	0.014	0.56	0.42	Schizophrenia;	chr15:84714972	chr15:84599434~84606463:-
THYM	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-4.47	2.22e-05	0.0141	-0.43	-0.42	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
THYM	cis	rs561341	1	rs56903735	ENSG00000265798.5	RP11-271K11.5	4.47	2.22e-05	0.0141	0.49	0.42	Hip circumference adjusted for BMI;	chr17:31927374	chr17:31038575~31059121:-
THYM	cis	rs972578	0.791	rs4822243	ENSG00000215347.3	SLC25A5P1	-4.47	2.22e-05	0.0141	-0.33	-0.42	Mean platelet volume;	chr22:42987497	chr22:42001069~42001966:-
THYM	cis	rs972578	0.936	rs2267486	ENSG00000215347.3	SLC25A5P1	-4.47	2.22e-05	0.0141	-0.33	-0.42	Mean platelet volume;	chr22:42988011	chr22:42001069~42001966:-
THYM	cis	rs972578	0.806	rs8137128	ENSG00000215347.3	SLC25A5P1	-4.47	2.22e-05	0.0141	-0.33	-0.42	Mean platelet volume;	chr22:42989990	chr22:42001069~42001966:-
THYM	cis	rs5758511	0.514	rs5751211	ENSG00000227370.1	RP4-669P10.19	4.47	2.22e-05	0.0141	0.55	0.42	Birth weight;	chr22:42090052	chr22:42132543~42132998:+
THYM	cis	rs5758511	0.514	rs5758580	ENSG00000227370.1	RP4-669P10.19	4.47	2.22e-05	0.0141	0.55	0.42	Birth weight;	chr22:42097871	chr22:42132543~42132998:+
THYM	cis	rs5758511	0.514	rs3985938	ENSG00000227370.1	RP4-669P10.19	4.47	2.22e-05	0.0141	0.55	0.42	Birth weight;	chr22:42115723	chr22:42132543~42132998:+
THYM	cis	rs5758511	0.514	rs5758586	ENSG00000227370.1	RP4-669P10.19	4.47	2.22e-05	0.0141	0.55	0.42	Birth weight;	chr22:42121467	chr22:42132543~42132998:+
THYM	cis	rs5758511	0.514	rs5751222	ENSG00000227370.1	RP4-669P10.19	4.47	2.22e-05	0.0141	0.55	0.42	Birth weight;	chr22:42121918	chr22:42132543~42132998:+
THYM	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-4.47	2.22e-05	0.0141	-0.4	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
THYM	cis	rs7560272	0.723	rs780395	ENSG00000163016.8	ALMS1P	-4.47	2.22e-05	0.0141	-0.49	-0.42	Schizophrenia;	chr2:73473726	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.695	rs780394	ENSG00000163016.8	ALMS1P	-4.47	2.22e-05	0.0141	-0.49	-0.42	Schizophrenia;	chr2:73473803	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.723	rs1083923	ENSG00000163016.8	ALMS1P	-4.47	2.22e-05	0.0141	-0.49	-0.42	Schizophrenia;	chr2:73476247	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs1083922	ENSG00000163016.8	ALMS1P	-4.47	2.22e-05	0.0141	-0.49	-0.42	Metabolite levels;	chr2:73476876	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.539	rs6745560	ENSG00000163016.8	ALMS1P	4.47	2.22e-05	0.0141	0.49	0.42	Metabolite levels;	chr2:73599990	chr2:73644919~73685576:+
THYM	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	4.46	2.23e-05	0.0141	0.36	0.42	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
THYM	cis	rs6674176	0.597	rs12127737	ENSG00000237950.1	RP11-7O11.3	4.46	2.23e-05	0.0141	0.44	0.42	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43936893	chr1:43944370~43946551:-
THYM	cis	rs9420	0.528	rs11607122	ENSG00000265566.2	RN7SL605P	-4.46	2.23e-05	0.0141	-0.54	-0.42	Schizophrenia;	chr11:57622264	chr11:57528085~57528365:-
THYM	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-4.46	2.23e-05	0.0141	-0.3	-0.42	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-4.46	2.23e-05	0.0141	-0.3	-0.42	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-4.46	2.23e-05	0.0141	-0.3	-0.42	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
THYM	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-4.46	2.23e-05	0.0141	-0.44	-0.42	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
THYM	cis	rs7605378	0.752	rs769960	ENSG00000232732.8	AC073043.1	4.46	2.23e-05	0.0141	0.58	0.42	Osteoporosis;	chr2:199845983	chr2:199867396~199911159:-
THYM	cis	rs8177876	0.749	rs12927828	ENSG00000261838.4	RP11-303E16.6	4.46	2.23e-05	0.0141	0.83	0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81069854~81076598:+
THYM	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	4.46	2.23e-05	0.0141	0.52	0.42	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
THYM	cis	rs1550115	1	rs2082881	ENSG00000271936.1	RP11-443B20.1	4.46	2.24e-05	0.0142	0.3	0.42	Coronary artery disease;	chr2:24815399	chr2:24825610~24826717:+
THYM	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-4.46	2.24e-05	0.0142	-0.47	-0.42	Height;	chr6:109380015	chr6:109382795~109383666:+
THYM	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	4.46	2.24e-05	0.0142	0.44	0.42	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
THYM	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-4.46	2.25e-05	0.0142	-0.3	-0.42	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-4.46	2.25e-05	0.0142	-0.3	-0.42	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-4.46	2.25e-05	0.0142	-0.3	-0.42	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
THYM	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-4.46	2.25e-05	0.0142	-0.56	-0.42	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
THYM	cis	rs972578	0.747	rs5758975	ENSG00000215347.3	SLC25A5P1	-4.46	2.25e-05	0.0142	-0.35	-0.42	Mean platelet volume;	chr22:42837259	chr22:42001069~42001966:-
THYM	cis	rs8177876	0.686	rs2602402	ENSG00000261838.4	RP11-303E16.6	4.46	2.25e-05	0.0142	0.85	0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052725	chr16:81069854~81076598:+
THYM	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-4.46	2.25e-05	0.0143	-0.49	-0.42	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
THYM	cis	rs9907295	0.688	rs9890583	ENSG00000270977.1	AC015849.16	-4.46	2.26e-05	0.0143	-0.62	-0.42	Fibroblast growth factor basic levels;	chr17:35919389	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.688	rs2376287	ENSG00000270977.1	AC015849.16	-4.46	2.26e-05	0.0143	-0.62	-0.42	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.688	rs4796133	ENSG00000270977.1	AC015849.16	-4.46	2.26e-05	0.0143	-0.62	-0.42	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.688	rs7213636	ENSG00000270977.1	AC015849.16	-4.46	2.26e-05	0.0143	-0.62	-0.42	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.688	rs28722787	ENSG00000270977.1	AC015849.16	-4.46	2.26e-05	0.0143	-0.62	-0.42	Fibroblast growth factor basic levels;	chr17:35922795	chr17:35893707~35911023:-
THYM	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	4.46	2.26e-05	0.0143	0.52	0.42	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
THYM	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	4.46	2.26e-05	0.0143	0.56	0.42	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
THYM	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-4.46	2.26e-05	0.0143	-0.53	-0.42	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
THYM	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-4.46	2.26e-05	0.0143	-0.53	-0.42	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
THYM	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	4.46	2.26e-05	0.0143	0.57	0.42	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-4.46	2.26e-05	0.0143	-0.57	-0.42	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	4.46	2.26e-05	0.0143	0.57	0.42	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	4.46	2.26e-05	0.0143	0.57	0.42	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
THYM	cis	rs9659323	0.689	rs7545737	ENSG00000231365.4	RP11-418J17.1	4.46	2.26e-05	0.0143	0.43	0.42	Body mass index;	chr1:118991200	chr1:119140396~119275973:+
THYM	cis	rs1061377	0.513	rs6840214	ENSG00000249685.1	RP11-360F5.3	-4.46	2.26e-05	0.0143	-0.44	-0.42	Uric acid levels;	chr4:39118999	chr4:39133913~39135608:+
THYM	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	4.46	2.26e-05	0.0143	0.82	0.42	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
THYM	cis	rs7976269	0.609	rs4141946	ENSG00000275476.1	RP11-996F15.4	-4.46	2.27e-05	0.0143	-0.48	-0.42	Male-pattern baldness;	chr12:29066432	chr12:29277397~29277882:-
THYM	cis	rs17711722	0.51	rs11767457	ENSG00000232906.1	RP11-746P2.3	4.46	2.27e-05	0.0143	0.4	0.42	Calcium levels;	chr7:65825628	chr7:65355934~65357176:+
THYM	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-4.46	2.27e-05	0.0143	-0.37	-0.42	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
THYM	cis	rs904251	0.58	rs62408367	ENSG00000227920.2	RP1-153P14.5	-4.46	2.27e-05	0.0143	-0.56	-0.42	Cognitive performance;	chr6:37477037	chr6:37545145~37550860:+
THYM	cis	rs12908161	1	rs11638290	ENSG00000275120.1	RP11-182J1.17	4.46	2.27e-05	0.0143	0.57	0.42	Schizophrenia;	chr15:84684405	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.959	rs34028043	ENSG00000275120.1	RP11-182J1.17	4.46	2.27e-05	0.0143	0.57	0.42	Schizophrenia;	chr15:84688354	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.959	rs34784022	ENSG00000275120.1	RP11-182J1.17	4.46	2.27e-05	0.0143	0.57	0.42	Schizophrenia;	chr15:84688675	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.959	rs12908699	ENSG00000275120.1	RP11-182J1.17	4.46	2.27e-05	0.0143	0.57	0.42	Schizophrenia;	chr15:84697172	chr15:84599434~84606463:-
THYM	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	4.46	2.27e-05	0.0143	0.47	0.42	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
THYM	cis	rs10829156	0.699	rs6482516	ENSG00000225527.1	RP11-383B4.4	-4.46	2.27e-05	0.0143	-0.49	-0.42	Sudden cardiac arrest;	chr10:18550421	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.66	rs11014830	ENSG00000225527.1	RP11-383B4.4	-4.46	2.27e-05	0.0143	-0.49	-0.42	Sudden cardiac arrest;	chr10:18551504	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.66	rs10828901	ENSG00000225527.1	RP11-383B4.4	-4.46	2.27e-05	0.0143	-0.49	-0.42	Sudden cardiac arrest;	chr10:18552161	chr10:18531849~18533336:-
THYM	cis	rs11157436	0.602	rs2032441	ENSG00000211812.1	TRAV26-2	-4.46	2.28e-05	0.0144	-0.25	-0.42	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157682	chr14:22202583~22203368:+
THYM	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	4.46	2.28e-05	0.0144	0.6	0.42	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
THYM	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	4.46	2.28e-05	0.0144	0.6	0.42	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
THYM	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	4.46	2.28e-05	0.0144	0.42	0.42	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
THYM	cis	rs8067545	0.611	rs8071274	ENSG00000230528.6	NOS2P3	4.46	2.28e-05	0.0144	0.34	0.42	Schizophrenia;	chr17:20313615	chr17:20436337~20447249:+
THYM	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	4.46	2.28e-05	0.0144	0.83	0.42	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
THYM	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	4.46	2.28e-05	0.0144	0.6	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
THYM	cis	rs3743162	0.553	rs12900463	ENSG00000235370.6	DNM1P51	4.46	2.28e-05	0.0144	0.56	0.42	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84398316~84411701:-
THYM	cis	rs3743162	0.553	rs12915656	ENSG00000235370.6	DNM1P51	4.46	2.28e-05	0.0144	0.56	0.42	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84398316~84411701:-
THYM	cis	rs34792	0.688	rs153782	ENSG00000262380.1	CTB-193M12.3	-4.46	2.28e-05	0.0144	-0.53	-0.42	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:15683290~15684570:+
THYM	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	4.46	2.28e-05	0.0144	0.36	0.42	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
THYM	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	4.46	2.28e-05	0.0144	0.36	0.42	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
THYM	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	4.46	2.29e-05	0.0145	0.54	0.42	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	4.46	2.29e-05	0.0145	0.54	0.42	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	4.46	2.29e-05	0.0145	0.54	0.42	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	4.46	2.29e-05	0.0145	0.54	0.42	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	4.46	2.29e-05	0.0145	0.54	0.42	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
THYM	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-4.46	2.3e-05	0.0145	-0.31	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
THYM	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	4.46	2.3e-05	0.0145	0.52	0.42	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
THYM	cis	rs1550576	0.568	rs78297201	ENSG00000274719.1	RP11-86K22.2	4.46	2.3e-05	0.0145	0.79	0.42	Hypertension;	chr15:57941443	chr15:57990217~57990636:-
THYM	cis	rs9309473	0.5	rs1528169	ENSG00000163016.8	ALMS1P	-4.46	2.3e-05	0.0145	-0.49	-0.42	Metabolite levels;	chr2:73442058	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs7598901	ENSG00000163016.8	ALMS1P	-4.46	2.3e-05	0.0145	-0.49	-0.42	Metabolite levels;	chr2:73448717	chr2:73644919~73685576:+
THYM	cis	rs42490	1	rs40544	ENSG00000251136.7	RP11-37B2.1	-4.46	2.3e-05	0.0145	-0.34	-0.42	Leprosy;	chr8:89768867	chr8:89609409~89757727:-
THYM	cis	rs8067545	0.641	rs1479129	ENSG00000231645.2	KRT17P6	-4.46	2.31e-05	0.0145	-0.5	-0.42	Schizophrenia;	chr17:19942456	chr17:20512560~20517479:-
THYM	cis	rs4835473	0.742	rs7695853	ENSG00000251600.4	RP11-673E1.1	4.46	2.31e-05	0.0145	0.46	0.42	Immature fraction of reticulocytes;	chr4:143883243	chr4:143912331~143982454:+
THYM	cis	rs17711722	0.528	rs73138179	ENSG00000232906.1	RP11-746P2.3	4.46	2.31e-05	0.0145	0.4	0.42	Calcium levels;	chr7:65829495	chr7:65355934~65357176:+
THYM	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	4.46	2.31e-05	0.0146	0.64	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
THYM	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.46	2.31e-05	0.0146	0.42	0.42	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	4.46	2.31e-05	0.0146	0.42	0.42	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.46	2.31e-05	0.0146	0.42	0.42	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
THYM	cis	rs972578	0.967	rs1883314	ENSG00000215347.3	SLC25A5P1	-4.46	2.31e-05	0.0146	-0.33	-0.42	Mean platelet volume;	chr22:42978801	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5759070	ENSG00000215347.3	SLC25A5P1	-4.46	2.31e-05	0.0146	-0.33	-0.42	Mean platelet volume;	chr22:42979695	chr22:42001069~42001966:-
THYM	cis	rs7208859	0.623	rs426434	ENSG00000266490.1	CTD-2349P21.9	4.45	2.32e-05	0.0146	0.72	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30792372~30792833:+
THYM	cis	rs11096990	0.855	rs4974986	ENSG00000249685.1	RP11-360F5.3	-4.45	2.32e-05	0.0146	-0.41	-0.42	Cognitive function;	chr4:39165308	chr4:39133913~39135608:+
THYM	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-4.45	2.33e-05	0.0146	-0.82	-0.42	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
THYM	cis	rs73198271	0.74	rs10109886	ENSG00000253893.2	FAM85B	4.45	2.33e-05	0.0146	0.62	0.42	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8167819~8226614:-
THYM	cis	rs34773007	0.559	rs12779884	ENSG00000272817.1	RP11-402D21.2	-4.45	2.33e-05	0.0147	-0.47	-0.42	Type 2 diabetes;	chr10:92782416	chr10:91908131~91909348:+
THYM	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-4.45	2.33e-05	0.0147	-0.51	-0.42	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
THYM	cis	rs28785552	0.931	rs8113078	ENSG00000250731.1	TPM3P6	-4.45	2.33e-05	0.0147	-0.59	-0.42	Response to paliperidone in schizophrenia (PANSS score);	chr19:52735831	chr19:53479350~53480091:+
THYM	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-4.45	2.33e-05	0.0147	-0.29	-0.42	Height;	chr11:118737916	chr11:118791254~118793137:+
THYM	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	4.45	2.34e-05	0.0147	0.49	0.42	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
THYM	cis	rs10129255	0.785	rs10150044	ENSG00000254329.1	IGHVII-60-1	4.45	2.34e-05	0.0147	0.43	0.42	Kawasaki disease;	chr14:106775695	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10137980	ENSG00000254329.1	IGHVII-60-1	4.45	2.34e-05	0.0147	0.43	0.42	Kawasaki disease;	chr14:106775735	chr14:106637718~106637973:-
THYM	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-4.45	2.34e-05	0.0147	-0.49	-0.42	Depression;	chr6:28129415	chr6:28115628~28116551:+
THYM	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	4.45	2.35e-05	0.0147	0.41	0.42	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	4.45	2.35e-05	0.0147	0.41	0.42	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
THYM	cis	rs995834	0.622	rs8102417	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397409	chr19:28435388~28727777:-
THYM	cis	rs995834	0.704	rs4806358	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28397907	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs4806359	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398042	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs7252140	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398110	chr19:28435388~28727777:-
THYM	cis	rs995834	0.663	rs7252145	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398119	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs4806360	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398277	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs1558121	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398522	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs2159075	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398551	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs2079593	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28398973	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs1558122	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399320	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs1558123	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399355	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs7257975	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399556	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs7246622	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28399578	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs7258662	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400902	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs7246754	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400913	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs4806368	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402133	chr19:28435388~28727777:-
THYM	cis	rs995834	0.622	rs4806369	ENSG00000267243.4	AC005307.3	-4.45	2.35e-05	0.0147	-0.4	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28402569	chr19:28435388~28727777:-
THYM	cis	rs9309473	0.519	rs13017182	ENSG00000163016.8	ALMS1P	-4.45	2.36e-05	0.0148	-0.46	-0.42	Metabolite levels;	chr2:73663877	chr2:73644919~73685576:+
THYM	cis	rs4835473	0.8	rs1849117	ENSG00000249741.2	RP11-673E1.3	-4.45	2.36e-05	0.0148	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143989791	chr4:143911514~143912053:-
THYM	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-4.45	2.36e-05	0.0148	-0.48	-0.42	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
THYM	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-4.45	2.36e-05	0.0148	-0.29	-0.42	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
THYM	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-4.45	2.36e-05	0.0148	-0.54	-0.42	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
THYM	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-4.45	2.36e-05	0.0148	-0.54	-0.42	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
THYM	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-4.45	2.37e-05	0.0149	-0.55	-0.42	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
THYM	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-4.45	2.37e-05	0.0149	-0.53	-0.42	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
THYM	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-4.45	2.37e-05	0.0149	-0.3	-0.42	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
THYM	cis	rs217727	0.818	rs2525883	ENSG00000226416.1	MRPL23-AS1	4.45	2.37e-05	0.0149	0.48	0.42	Breast cancer;	chr11:2000750	chr11:1983237~1989920:-
THYM	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	4.45	2.38e-05	0.0149	0.54	0.42	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
THYM	cis	rs17036350	1	rs17036350	ENSG00000230337.1	RP4-635E18.6	-4.45	2.38e-05	0.0149	-0.75	-0.42	Corneal curvature;	chr1:11111169	chr1:11099675~11102100:+
THYM	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-4.45	2.38e-05	0.0149	-0.42	-0.42	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
THYM	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-4.45	2.38e-05	0.0149	-0.34	-0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
THYM	cis	rs4925386	0.759	rs2427293	ENSG00000273619.1	RP5-908M14.9	4.45	2.38e-05	0.0149	0.34	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62386303~62386970:-
THYM	cis	rs9959145	0.543	rs11664013	ENSG00000267199.1	RP11-861E21.2	-4.45	2.38e-05	0.0149	-0.6	-0.42	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12438890~12448205:+
THYM	cis	rs9876781	1	rs11130170	ENSG00000244380.1	RP11-24C3.2	4.45	2.39e-05	0.0149	0.54	0.42	Longevity;	chr3:48408490	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs10470686	ENSG00000244380.1	RP11-24C3.2	4.45	2.39e-05	0.0149	0.54	0.42	Longevity;	chr3:48408549	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs13314659	ENSG00000244380.1	RP11-24C3.2	-4.45	2.39e-05	0.0149	-0.54	-0.42	Longevity;	chr3:48407742	chr3:48440352~48446656:-
THYM	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	4.45	2.39e-05	0.0149	0.32	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
THYM	cis	rs9879311	0.966	rs28113	ENSG00000240288.6	GHRLOS	4.45	2.39e-05	0.0149	0.42	0.42	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358959	chr3:10285754~10293449:+
THYM	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	4.45	2.4e-05	0.015	0.29	0.42	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	4.45	2.4e-05	0.015	0.29	0.42	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
THYM	cis	rs8067545	0.611	rs2189709	ENSG00000230528.6	NOS2P3	4.45	2.4e-05	0.015	0.34	0.42	Schizophrenia;	chr17:20179913	chr17:20436337~20447249:+
THYM	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-4.45	2.4e-05	0.015	-0.57	-0.42	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	4.45	2.4e-05	0.015	0.57	0.42	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
THYM	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-4.45	2.4e-05	0.015	-0.61	-0.42	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
THYM	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-4.45	2.4e-05	0.015	-0.32	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
THYM	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	4.45	2.4e-05	0.015	0.32	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
THYM	cis	rs7927592	0.913	rs3740631	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68574254	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs3824850	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68574405	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs3740629	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68576125	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs11228287	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68582286	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs10896346	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68585203	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs10896347	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68585659	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs6591344	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68593405	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7123564	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68594696	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7127948	ENSG00000222339.1	AP000807.2	4.45	2.4e-05	0.015	0.53	0.42	Total body bone mineral density;	chr11:68595594	chr11:68505572~68505651:-
THYM	cis	rs11971779	0.666	rs6467847	ENSG00000273391.1	RP11-634H22.1	4.45	2.4e-05	0.015	0.34	0.42	Diisocyanate-induced asthma;	chr7:139394690	chr7:139359032~139359566:-
THYM	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-4.44	2.4e-05	0.015	-0.53	-0.42	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
THYM	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-4.44	2.4e-05	0.015	-0.53	-0.42	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
THYM	cis	rs561341	0.941	rs2428338	ENSG00000265798.5	RP11-271K11.5	4.44	2.41e-05	0.015	0.49	0.42	Hip circumference adjusted for BMI;	chr17:31972610	chr17:31038575~31059121:-
THYM	cis	rs1061377	0.513	rs2712000	ENSG00000249685.1	RP11-360F5.3	4.44	2.41e-05	0.015	0.44	0.42	Uric acid levels;	chr4:39135462	chr4:39133913~39135608:+
THYM	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	4.44	2.41e-05	0.015	0.39	0.42	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
THYM	cis	rs4835473	0.838	rs12507468	ENSG00000249741.2	RP11-673E1.3	4.44	2.41e-05	0.0151	0.36	0.42	Immature fraction of reticulocytes;	chr4:143908061	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1849135	ENSG00000249741.2	RP11-673E1.3	4.44	2.41e-05	0.0151	0.36	0.42	Immature fraction of reticulocytes;	chr4:143912279	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1849136	ENSG00000249741.2	RP11-673E1.3	4.44	2.41e-05	0.0151	0.36	0.42	Immature fraction of reticulocytes;	chr4:143912380	chr4:143911514~143912053:-
THYM	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-4.44	2.41e-05	0.0151	-0.3	-0.42	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
THYM	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-4.44	2.41e-05	0.0151	-0.3	-0.42	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
THYM	cis	rs2562456	0.917	rs2562466	ENSG00000268081.1	RP11-678G14.2	-4.44	2.41e-05	0.0151	-0.53	-0.42	Pain;	chr19:21531402	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs2562468	ENSG00000268081.1	RP11-678G14.2	-4.44	2.41e-05	0.0151	-0.53	-0.42	Pain;	chr19:21532048	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs2562471	ENSG00000268081.1	RP11-678G14.2	-4.44	2.41e-05	0.0151	-0.53	-0.42	Pain;	chr19:21533017	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs2681377	ENSG00000268081.1	RP11-678G14.2	-4.44	2.41e-05	0.0151	-0.53	-0.42	Pain;	chr19:21533718	chr19:21554640~21569237:-
THYM	cis	rs7005380	0.6	rs13267652	ENSG00000245330.4	KB-1471A8.1	4.44	2.42e-05	0.0151	0.58	0.42	Interstitial lung disease;	chr8:119878346	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13275528	ENSG00000245330.4	KB-1471A8.1	4.44	2.42e-05	0.0151	0.58	0.42	Interstitial lung disease;	chr8:119878617	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs28669275	ENSG00000245330.4	KB-1471A8.1	4.44	2.42e-05	0.0151	0.58	0.42	Interstitial lung disease;	chr8:119889713	chr8:119867419~119874488:-
THYM	cis	rs4835473	0.932	rs13130345	ENSG00000249741.2	RP11-673E1.3	-4.44	2.42e-05	0.0151	-0.35	-0.42	Immature fraction of reticulocytes;	chr4:143920939	chr4:143911514~143912053:-
THYM	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-4.44	2.42e-05	0.0151	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	4.44	2.42e-05	0.0151	0.42	0.42	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	4.44	2.42e-05	0.0151	0.42	0.42	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
THYM	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	4.44	2.42e-05	0.0151	0.62	0.42	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
THYM	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-4.44	2.42e-05	0.0151	-0.47	-0.42	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
THYM	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-4.44	2.42e-05	0.0151	-0.47	-0.42	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
THYM	cis	rs1519814	0.696	rs2326434	ENSG00000254343.2	RP11-760H22.2	-4.44	2.42e-05	0.0151	-0.61	-0.42	Breast cancer;	chr8:120035559	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.696	rs6985424	ENSG00000254343.2	RP11-760H22.2	-4.44	2.42e-05	0.0151	-0.61	-0.42	Breast cancer;	chr8:120050737	chr8:120052180~120056201:+
THYM	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	4.44	2.42e-05	0.0151	0.63	0.42	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
THYM	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	4.44	2.42e-05	0.0151	0.63	0.42	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
THYM	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	4.44	2.42e-05	0.0151	0.63	0.42	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
THYM	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	4.44	2.42e-05	0.0151	0.63	0.42	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
THYM	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	4.44	2.42e-05	0.0151	0.63	0.42	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
THYM	cis	rs10208649	0.611	rs3929001	ENSG00000272156.1	RP11-477N3.1	-4.44	2.42e-05	0.0151	-0.63	-0.42	Body mass index;	chr2:54055750	chr2:54082554~54085066:+
THYM	cis	rs897984	0.542	rs4468641	ENSG00000260911.2	RP11-196G11.2	4.44	2.42e-05	0.0151	0.36	0.42	Dementia with Lewy bodies;	chr16:31085555	chr16:31043150~31049868:+
THYM	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	4.44	2.43e-05	0.0151	0.51	0.42	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
THYM	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	4.44	2.43e-05	0.0151	0.51	0.42	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	4.44	2.43e-05	0.0151	0.51	0.42	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
THYM	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	4.44	2.43e-05	0.0151	0.51	0.42	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
THYM	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-4.44	2.43e-05	0.0151	-0.36	-0.42	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
THYM	cis	rs7223966	1	rs1877316	ENSG00000240280.5	TCAM1P	-4.44	2.43e-05	0.0151	-0.62	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63689520	chr17:63849292~63864379:+
THYM	cis	rs61270009	0.955	rs415449	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88231533	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs415302	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88231628	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs780398	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88234112	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs780399	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88237160	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.913	rs380670	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88243132	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs379430	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88243275	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs780401	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88244393	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs383385	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88246065	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs396702	ENSG00000247828.6	TMEM161B-AS1	-4.44	2.43e-05	0.0151	-0.35	-0.42	Depressive symptoms;	chr5:88247486	chr5:88268895~88436685:+
THYM	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	4.44	2.43e-05	0.0151	0.52	0.42	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
THYM	cis	rs7560272	0.723	rs1320374	ENSG00000273245.1	RP11-434P11.2	-4.44	2.43e-05	0.0151	-0.47	-0.42	Schizophrenia;	chr2:73601183	chr2:73750256~73750786:-
THYM	cis	rs526231	0.756	rs2561479	ENSG00000175749.11	EIF3KP1	4.44	2.43e-05	0.0151	0.53	0.42	Primary biliary cholangitis;	chr5:103286176	chr5:103032376~103033031:+
THYM	cis	rs4948275	0.773	rs2787736	ENSG00000237233.2	TMEM26-AS1	-4.44	2.43e-05	0.0151	-0.49	-0.42	Night sleep phenotypes;	chr10:61490694	chr10:61452639~61481956:+
THYM	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-4.44	2.43e-05	0.0152	-0.58	-0.42	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
THYM	cis	rs4654049	1	rs10916652	ENSG00000188460.4	ACTBP11	4.44	2.43e-05	0.0152	0.53	0.42	Cancer;	chr1:224594285	chr1:223863726~223864851:-
THYM	cis	rs4654049	1	rs991834	ENSG00000188460.4	ACTBP11	4.44	2.43e-05	0.0152	0.53	0.42	Cancer;	chr1:224594369	chr1:223863726~223864851:-
THYM	cis	rs2235573	0.868	rs6001001	ENSG00000272669.1	RP3-508I15.21	-4.44	2.43e-05	0.0152	-0.27	-0.42	Glioma;Glioblastoma;	chr22:38103516	chr22:38742625~38743115:+
THYM	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-4.44	2.44e-05	0.0152	-0.42	-0.42	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
THYM	cis	rs9834970	0.588	rs9985296	ENSG00000234073.1	AC011816.1	4.44	2.44e-05	0.0152	0.44	0.42	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36848130	chr3:36880184~36880729:-
THYM	cis	rs8059260	0.673	rs77240340	ENSG00000274038.1	RP11-66H6.4	-4.44	2.44e-05	0.0152	-0.62	-0.42	Alcohol consumption over the past year;	chr16:10945778	chr16:11056556~11057034:+
THYM	cis	rs3020736	0.5	rs7292241	ENSG00000227370.1	RP4-669P10.19	-4.44	2.44e-05	0.0152	-0.48	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs5996111	ENSG00000227370.1	RP4-669P10.19	-4.44	2.44e-05	0.0152	-0.48	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42132543~42132998:+
THYM	cis	rs8059260	0.673	rs8056854	ENSG00000274038.1	RP11-66H6.4	-4.44	2.45e-05	0.0152	-0.61	-0.42	Alcohol consumption over the past year;	chr16:10947858	chr16:11056556~11057034:+
THYM	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	4.44	2.45e-05	0.0152	0.53	0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
THYM	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	4.44	2.45e-05	0.0152	0.38	0.42	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
THYM	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	4.44	2.45e-05	0.0152	0.52	0.42	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
THYM	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	4.44	2.45e-05	0.0152	0.52	0.42	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
THYM	cis	rs950169	0.58	rs1061737	ENSG00000275120.1	RP11-182J1.17	4.44	2.45e-05	0.0152	0.56	0.42	Schizophrenia;	chr15:84640559	chr15:84599434~84606463:-
THYM	cis	rs4700393	0.517	rs17332108	ENSG00000272308.1	RP11-231G3.1	-4.44	2.45e-05	0.0152	-0.53	-0.42	Intelligence (multi-trait analysis);	chr5:60836057	chr5:60866457~60866935:-
THYM	cis	rs4700393	0.517	rs71592685	ENSG00000272308.1	RP11-231G3.1	4.44	2.45e-05	0.0152	0.53	0.42	Intelligence (multi-trait analysis);	chr5:60825411	chr5:60866457~60866935:-
THYM	cis	rs4700393	0.517	rs12516248	ENSG00000272308.1	RP11-231G3.1	4.44	2.45e-05	0.0152	0.53	0.42	Intelligence (multi-trait analysis);	chr5:60835824	chr5:60866457~60866935:-
THYM	cis	rs7223966	1	rs11658740	ENSG00000240280.5	TCAM1P	-4.44	2.45e-05	0.0152	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63673709	chr17:63849292~63864379:+
THYM	cis	rs1550576	0.568	rs74017072	ENSG00000274719.1	RP11-86K22.2	4.44	2.45e-05	0.0152	0.8	0.42	Hypertension;	chr15:57942669	chr15:57990217~57990636:-
THYM	cis	rs4715166	0.798	rs4715169	ENSG00000215022.6	RP1-257A7.4	4.44	2.45e-05	0.0152	0.39	0.42	Hip geometry;	chr6:13223996	chr6:13264861~13295586:-
THYM	cis	rs4715166	0.926	rs7749528	ENSG00000215022.6	RP1-257A7.4	4.44	2.45e-05	0.0152	0.39	0.42	Hip geometry;	chr6:13224591	chr6:13264861~13295586:-
THYM	cis	rs4715166	0.926	rs2840336	ENSG00000215022.6	RP1-257A7.4	4.44	2.45e-05	0.0152	0.39	0.42	Hip geometry;	chr6:13225563	chr6:13264861~13295586:-
THYM	cis	rs3743162	0.553	rs4842994	ENSG00000235370.6	DNM1P51	-4.44	2.45e-05	0.0153	-0.55	-0.42	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84398316~84411701:-
THYM	cis	rs8031584	0.56	rs7171208	ENSG00000270015.1	RP11-540B6.6	4.44	2.45e-05	0.0153	0.22	0.42	Huntington's disease progression;	chr15:30906726	chr15:30926514~30928407:+
THYM	cis	rs8031584	0.56	rs1056118	ENSG00000270015.1	RP11-540B6.6	4.44	2.45e-05	0.0153	0.22	0.42	Huntington's disease progression;	chr15:30911583	chr15:30926514~30928407:+
THYM	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	4.44	2.45e-05	0.0153	0.22	0.42	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
THYM	cis	rs8031584	0.541	rs2959037	ENSG00000270015.1	RP11-540B6.6	4.44	2.45e-05	0.0153	0.22	0.42	Huntington's disease progression;	chr15:30925961	chr15:30926514~30928407:+
THYM	cis	rs8031584	0.505	rs2959036	ENSG00000270015.1	RP11-540B6.6	4.44	2.45e-05	0.0153	0.22	0.42	Huntington's disease progression;	chr15:30927539	chr15:30926514~30928407:+
THYM	cis	rs8031584	0.541	rs2955777	ENSG00000270015.1	RP11-540B6.6	4.44	2.45e-05	0.0153	0.22	0.42	Huntington's disease progression;	chr15:30927585	chr15:30926514~30928407:+
THYM	cis	rs7246967	0.673	rs9676498	ENSG00000198153.8	ZNF849P	-4.44	2.45e-05	0.0153	-0.55	-0.42	Bronchopulmonary dysplasia;	chr19:22727708	chr19:22685167~22686732:+
THYM	cis	rs7178424	0.875	rs7172967	ENSG00000259251.2	RP11-643M14.1	4.44	2.46e-05	0.0153	0.43	0.42	Height;	chr15:61926369	chr15:62060503~62062434:+
THYM	cis	rs4908760	0.965	rs12080583	ENSG00000232912.4	RP5-1115A15.1	4.44	2.46e-05	0.0153	0.41	0.42	Vitiligo;	chr1:8464817	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs12061328	ENSG00000232912.4	RP5-1115A15.1	4.44	2.46e-05	0.0153	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs6577488	ENSG00000232912.4	RP5-1115A15.1	4.44	2.46e-05	0.0153	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs4351668	ENSG00000232912.4	RP5-1115A15.1	4.44	2.46e-05	0.0153	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs7551849	ENSG00000232912.4	RP5-1115A15.1	4.44	2.46e-05	0.0153	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs12046643	ENSG00000232912.4	RP5-1115A15.1	4.44	2.46e-05	0.0153	0.41	0.42	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.965	rs10864353	ENSG00000232912.4	RP5-1115A15.1	4.44	2.46e-05	0.0153	0.41	0.42	Vitiligo;	chr1:8489656	chr1:8424645~8434838:+
THYM	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-4.44	2.46e-05	0.0153	-0.57	-0.42	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
THYM	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	4.44	2.46e-05	0.0153	0.57	0.42	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
THYM	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
THYM	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	4.44	2.46e-05	0.0153	0.35	0.42	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	4.44	2.46e-05	0.0153	0.35	0.42	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-4.44	2.46e-05	0.0153	-0.35	-0.42	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
THYM	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-4.44	2.47e-05	0.0153	-0.44	-0.42	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
THYM	cis	rs4554975	0.514	rs11183672	ENSG00000274723.1	RP11-618L22.1	4.44	2.47e-05	0.0153	0.33	0.42	Metabolite levels (small molecules and protein measures);	chr12:46957283	chr12:46970504~46972155:+
THYM	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-4.44	2.47e-05	0.0153	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-4.44	2.47e-05	0.0153	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-4.44	2.47e-05	0.0153	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-4.44	2.47e-05	0.0153	-0.46	-0.42	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
THYM	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	4.44	2.48e-05	0.0154	0.53	0.42	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
THYM	cis	rs1023500	0.505	rs134874	ENSG00000227370.1	RP4-669P10.19	4.44	2.48e-05	0.0154	0.51	0.42	Schizophrenia;	chr22:42265138	chr22:42132543~42132998:+
THYM	cis	rs4925386	1	rs2151512	ENSG00000273619.1	RP5-908M14.9	4.44	2.48e-05	0.0154	0.31	0.42	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62386303~62386970:-
THYM	cis	rs7223966	1	rs6504168	ENSG00000240280.5	TCAM1P	-4.44	2.48e-05	0.0154	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63620109	chr17:63849292~63864379:+
THYM	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-4.44	2.48e-05	0.0154	-0.55	-0.42	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
THYM	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	4.44	2.48e-05	0.0154	0.33	0.42	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
THYM	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	4.44	2.48e-05	0.0154	0.56	0.42	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
THYM	cis	rs35888008	1	rs62029105	ENSG00000261267.1	RP11-44I10.3	4.44	2.48e-05	0.0154	0.56	0.42	Major depressive disorder;	chr16:49421565	chr16:48559661~48587403:+
THYM	cis	rs2834288	0.535	rs8132681	ENSG00000237945.6	LINC00649	4.44	2.48e-05	0.0154	0.37	0.42	Gut microbiota (bacterial taxa);	chr21:33950035	chr21:33915534~33977691:+
THYM	cis	rs4948275	0.679	rs10994772	ENSG00000237233.2	TMEM26-AS1	-4.44	2.48e-05	0.0154	-0.49	-0.42	Night sleep phenotypes;	chr10:61456117	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.742	rs2937153	ENSG00000237233.2	TMEM26-AS1	-4.44	2.48e-05	0.0154	-0.49	-0.42	Night sleep phenotypes;	chr10:61478029	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2650709	ENSG00000237233.2	TMEM26-AS1	-4.44	2.48e-05	0.0154	-0.49	-0.42	Night sleep phenotypes;	chr10:61483034	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.709	rs2249921	ENSG00000237233.2	TMEM26-AS1	-4.44	2.48e-05	0.0154	-0.49	-0.42	Night sleep phenotypes;	chr10:61487354	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2787731	ENSG00000237233.2	TMEM26-AS1	-4.44	2.48e-05	0.0154	-0.49	-0.42	Night sleep phenotypes;	chr10:61487775	chr10:61452639~61481956:+
THYM	cis	rs1550576	0.568	rs1372367	ENSG00000274719.1	RP11-86K22.2	4.44	2.49e-05	0.0154	0.81	0.42	Hypertension;	chr15:57943783	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.5	rs35385267	ENSG00000274719.1	RP11-86K22.2	4.44	2.49e-05	0.0154	0.81	0.42	Hypertension;	chr15:57943892	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs12592773	ENSG00000274719.1	RP11-86K22.2	4.44	2.49e-05	0.0154	0.81	0.42	Hypertension;	chr15:57943991	chr15:57990217~57990636:-
THYM	cis	rs2283792	1	rs6928	ENSG00000228050.1	TOP3BP1	4.44	2.49e-05	0.0154	0.45	0.42	Multiple sclerosis;	chr22:21760715	chr22:22223187~22224566:-
THYM	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-4.44	2.49e-05	0.0154	-0.54	-0.42	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
THYM	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-4.44	2.49e-05	0.0154	-0.44	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
THYM	cis	rs7631605	0.905	rs9869432	ENSG00000272334.1	RP11-129K12.1	-4.44	2.49e-05	0.0154	-0.45	-0.42	Cerebrospinal P-tau181p levels;	chr3:37155110	chr3:36973117~36973672:-
THYM	cis	rs9907295	0.901	rs2107540	ENSG00000270871.1	AC015849.19	4.44	2.49e-05	0.0154	0.48	0.42	Fibroblast growth factor basic levels;	chr17:35893516	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs28739295	ENSG00000270871.1	AC015849.19	4.44	2.49e-05	0.0154	0.48	0.42	Fibroblast growth factor basic levels;	chr17:35895812	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs56294660	ENSG00000270871.1	AC015849.19	4.44	2.49e-05	0.0154	0.48	0.42	Fibroblast growth factor basic levels;	chr17:35901470	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs28550999	ENSG00000270871.1	AC015849.19	4.44	2.49e-05	0.0154	0.48	0.42	Fibroblast growth factor basic levels;	chr17:35902887	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs74780070	ENSG00000270871.1	AC015849.19	4.44	2.49e-05	0.0154	0.48	0.42	Fibroblast growth factor basic levels;	chr17:35903521	chr17:35816717~35830293:-
THYM	cis	rs7178424	0.875	rs7179506	ENSG00000259251.2	RP11-643M14.1	-4.44	2.5e-05	0.0155	-0.45	-0.42	Height;	chr15:61895756	chr15:62060503~62062434:+
THYM	cis	rs4835473	0.771	rs4261935	ENSG00000249741.2	RP11-673E1.3	-4.43	2.5e-05	0.0155	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143979751	chr4:143911514~143912053:-
THYM	cis	rs13068223	0.503	rs34277251	ENSG00000243926.1	TIPARP-AS1	4.43	2.5e-05	0.0155	0.34	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156671862~156674378:-
THYM	cis	rs7223966	0.96	rs2319990	ENSG00000240280.5	TCAM1P	-4.43	2.5e-05	0.0155	-0.64	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63628037	chr17:63849292~63864379:+
THYM	cis	rs10129255	0.957	rs10150241	ENSG00000254329.1	IGHVII-60-1	-4.43	2.5e-05	0.0155	-0.43	-0.42	Kawasaki disease;	chr14:106775945	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs12590667	ENSG00000254329.1	IGHVII-60-1	-4.43	2.5e-05	0.0155	-0.43	-0.42	Kawasaki disease;	chr14:106779223	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10141052	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106776528	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10140904	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106776558	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10141009	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106776695	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.912	rs6576227	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106778202	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs6576228	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106778401	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs11846893	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106779068	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs12590799	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106779713	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10136781	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106780451	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs8022165	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106781682	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.917	rs8022493	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106781820	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10142918	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106782206	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10142859	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106782238	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs12589190	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106783079	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs7493713	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106783685	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.912	rs35468694	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106784199	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs8019272	ENSG00000254329.1	IGHVII-60-1	4.43	2.5e-05	0.0155	0.43	0.42	Kawasaki disease;	chr14:106784709	chr14:106637718~106637973:-
THYM	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-4.43	2.51e-05	0.0155	-0.21	-0.42	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
THYM	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	4.43	2.51e-05	0.0155	0.39	0.42	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
THYM	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-4.43	2.51e-05	0.0156	-0.39	-0.42	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
THYM	cis	rs1426063	0.748	rs6534607	ENSG00000248165.1	RP11-44F21.2	4.43	2.51e-05	0.0156	0.62	0.42	QT interval;	chr4:75106366	chr4:74993877~75034824:-
THYM	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-4.43	2.52e-05	0.0156	-0.55	-0.42	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
THYM	cis	rs62246343	0.654	rs7631372	ENSG00000254485.4	RP11-380O24.1	4.43	2.52e-05	0.0156	0.63	0.42	Fibrinogen levels;	chr3:9451631	chr3:9292588~9363303:-
THYM	cis	rs9309473	0.5	rs11688718	ENSG00000163016.8	ALMS1P	4.43	2.52e-05	0.0156	0.49	0.42	Metabolite levels;	chr2:73533812	chr2:73644919~73685576:+
THYM	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-4.43	2.52e-05	0.0156	-0.39	-0.42	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
THYM	cis	rs62246343	0.719	rs62246305	ENSG00000254485.4	RP11-380O24.1	4.43	2.52e-05	0.0156	0.64	0.42	Fibrinogen levels;	chr3:9416565	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs56782786	ENSG00000254485.4	RP11-380O24.1	4.43	2.52e-05	0.0156	0.64	0.42	Fibrinogen levels;	chr3:9425388	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs62246308	ENSG00000254485.4	RP11-380O24.1	4.43	2.52e-05	0.0156	0.64	0.42	Fibrinogen levels;	chr3:9427603	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs1152314	ENSG00000254485.4	RP11-380O24.1	4.43	2.52e-05	0.0156	0.64	0.42	Fibrinogen levels;	chr3:9450656	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs73130116	ENSG00000254485.4	RP11-380O24.1	4.43	2.52e-05	0.0156	0.64	0.42	Fibrinogen levels;	chr3:9452827	chr3:9292588~9363303:-
THYM	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	4.43	2.52e-05	0.0156	0.55	0.42	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
THYM	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-4.43	2.52e-05	0.0156	-0.53	-0.42	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
THYM	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	4.43	2.52e-05	0.0156	0.72	0.42	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
THYM	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	4.43	2.52e-05	0.0156	0.72	0.42	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
THYM	cis	rs9907295	1	rs9913488	ENSG00000270871.1	AC015849.19	4.43	2.52e-05	0.0156	0.46	0.42	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9912571	ENSG00000270871.1	AC015849.19	4.43	2.52e-05	0.0156	0.46	0.42	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9912793	ENSG00000270871.1	AC015849.19	4.43	2.52e-05	0.0156	0.46	0.42	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs11655533	ENSG00000270871.1	AC015849.19	4.43	2.52e-05	0.0156	0.46	0.42	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9908011	ENSG00000270871.1	AC015849.19	4.43	2.52e-05	0.0156	0.46	0.42	Fibroblast growth factor basic levels;	chr17:35908371	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9908525	ENSG00000270871.1	AC015849.19	4.43	2.52e-05	0.0156	0.46	0.42	Fibroblast growth factor basic levels;	chr17:35908605	chr17:35816717~35830293:-
THYM	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-4.43	2.52e-05	0.0156	-0.41	-0.42	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
THYM	cis	rs4478858	0.735	rs11576603	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31301184	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs4949382	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31303884	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs10798842	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31305801	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.663	rs11591060	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31307165	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.662	rs6425735	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31311098	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs7523509	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31315482	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs4949384	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31319294	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs11590120	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31319477	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.698	rs6655946	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31332881	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs10914360	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31344629	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs6679360	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31345089	chr1:31500085~31540885:+
THYM	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	4.43	2.53e-05	0.0156	0.63	0.42	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
THYM	cis	rs950169	0.58	rs17532346	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84628264	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs11634322	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84628978	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs4603535	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84630641	chr15:84599434~84606463:-
THYM	cis	rs950169	0.541	rs10795	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84634066	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs36126054	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84634492	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs11633762	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84643921	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs11630887	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84649784	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs11636189	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84650323	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs35516100	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84652199	chr15:84599434~84606463:-
THYM	cis	rs950169	0.58	rs62021208	ENSG00000275120.1	RP11-182J1.17	4.43	2.53e-05	0.0156	0.56	0.42	Schizophrenia;	chr15:84653013	chr15:84599434~84606463:-
THYM	cis	rs7223966	0.96	rs7212379	ENSG00000240280.5	TCAM1P	-4.43	2.53e-05	0.0156	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63628762	chr17:63849292~63864379:+
THYM	cis	rs6890684	0.544	rs194369	ENSG00000272308.1	RP11-231G3.1	-4.43	2.53e-05	0.0156	-0.35	-0.42	Intelligence (multi-trait analysis);	chr5:61203358	chr5:60866457~60866935:-
THYM	cis	rs2055375	0.818	rs190947	ENSG00000272308.1	RP11-231G3.1	-4.43	2.53e-05	0.0156	-0.35	-0.42	Intelligence (multi-trait analysis);	chr5:61209988	chr5:60866457~60866935:-
THYM	cis	rs6890684	0.503	rs256377	ENSG00000272308.1	RP11-231G3.1	-4.43	2.53e-05	0.0156	-0.35	-0.42	Intelligence (multi-trait analysis);	chr5:61210447	chr5:60866457~60866935:-
THYM	cis	rs6890684	0.544	rs34634	ENSG00000272308.1	RP11-231G3.1	-4.43	2.53e-05	0.0156	-0.35	-0.42	Intelligence (multi-trait analysis);	chr5:61217739	chr5:60866457~60866935:-
THYM	cis	rs6890684	0.551	rs589794	ENSG00000272308.1	RP11-231G3.1	-4.43	2.53e-05	0.0156	-0.35	-0.42	Intelligence (multi-trait analysis);	chr5:61220292	chr5:60866457~60866935:-
THYM	cis	rs6890684	0.576	rs702565	ENSG00000272308.1	RP11-231G3.1	-4.43	2.53e-05	0.0156	-0.35	-0.42	Intelligence (multi-trait analysis);	chr5:61221243	chr5:60866457~60866935:-
THYM	cis	rs6890684	0.544	rs581318	ENSG00000272308.1	RP11-231G3.1	4.43	2.53e-05	0.0156	0.35	0.42	Intelligence (multi-trait analysis);	chr5:61219967	chr5:60866457~60866935:-
THYM	cis	rs1790761	0.667	rs658768	ENSG00000231793.4	DOC2GP	-4.43	2.53e-05	0.0156	-0.37	-0.42	Mean corpuscular volume;	chr11:67570337	chr11:67612653~67616257:-
THYM	cis	rs1790761	0.667	rs591434	ENSG00000231793.4	DOC2GP	-4.43	2.53e-05	0.0156	-0.37	-0.42	Mean corpuscular volume;	chr11:67570343	chr11:67612653~67616257:-
THYM	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-4.43	2.53e-05	0.0156	-0.42	-0.42	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
THYM	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	4.43	2.53e-05	0.0156	0.49	0.42	Height;	chr6:109454855	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	4.43	2.53e-05	0.0156	0.49	0.42	Height;	chr6:109465229	chr6:109382795~109383666:+
THYM	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-4.43	2.53e-05	0.0156	-0.68	-0.42	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
THYM	cis	rs4835473	0.771	rs4443231	ENSG00000249741.2	RP11-673E1.3	-4.43	2.53e-05	0.0156	-0.36	-0.42	Immature fraction of reticulocytes;	chr4:143979501	chr4:143911514~143912053:-
THYM	cis	rs56804039	0.895	rs11776995	ENSG00000253893.2	FAM85B	4.43	2.53e-05	0.0156	0.61	0.42	Cervical cancer;	chr8:8528037	chr8:8167819~8226614:-
THYM	cis	rs61270009	0.955	rs4269995	ENSG00000247828.6	TMEM161B-AS1	4.43	2.53e-05	0.0156	0.35	0.42	Depressive symptoms;	chr5:88405406	chr5:88268895~88436685:+
THYM	cis	rs1426063	0.668	rs6534595	ENSG00000249717.1	RP11-44F21.3	4.43	2.53e-05	0.0156	0.61	0.42	QT interval;	chr4:75104432	chr4:74955974~74970362:-
THYM	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	4.43	2.53e-05	0.0156	0.39	0.42	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
THYM	cis	rs4478858	0.735	rs12408524	ENSG00000260386.4	LINC01225	4.43	2.53e-05	0.0156	0.23	0.42	Alcohol dependence;	chr1:31363006	chr1:31500085~31540885:+
THYM	cis	rs12902680	0.706	rs6493194	ENSG00000259520.4	CTD-2651B20.3	4.43	2.53e-05	0.0156	0.42	0.42	Neuroticism;	chr15:46177235	chr15:45251580~45279251:-
THYM	cis	rs34792	0.688	rs153783	ENSG00000262380.1	CTB-193M12.3	-4.43	2.54e-05	0.0156	-0.52	-0.42	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508509	chr16:15683290~15684570:+
THYM	cis	rs8177876	0.749	rs2602407	ENSG00000261838.4	RP11-303E16.6	-4.43	2.54e-05	0.0156	-0.84	-0.42	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059141	chr16:81069854~81076598:+
THYM	cis	rs792448	0.545	rs6668866	ENSG00000229983.1	RP11-15I11.2	-4.43	2.54e-05	0.0157	-0.32	-0.42	White blood cell count (basophil);	chr1:212231605	chr1:212168207~212190259:+
THYM	cis	rs4700393	0.517	rs13183561	ENSG00000272308.1	RP11-231G3.1	4.43	2.54e-05	0.0157	0.53	0.42	Intelligence (multi-trait analysis);	chr5:60803976	chr5:60866457~60866935:-
THYM	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	4.43	2.55e-05	0.0157	0.29	0.42	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
THYM	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-4.43	2.55e-05	0.0157	-0.45	-0.42	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-4.43	2.55e-05	0.0157	-0.45	-0.42	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
THYM	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	4.43	2.55e-05	0.0157	0.51	0.42	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
THYM	cis	rs863345	0.608	rs11265013	ENSG00000236656.1	RP11-144L1.4	4.43	2.55e-05	0.0157	0.27	0.42	Pneumococcal bacteremia;	chr1:158529835	chr1:158474454~158494886:-
THYM	cis	rs863345	0.535	rs12064570	ENSG00000236656.1	RP11-144L1.4	4.43	2.55e-05	0.0157	0.27	0.42	Pneumococcal bacteremia;	chr1:158529841	chr1:158474454~158494886:-
THYM	cis	rs863345	0.535	rs12068285	ENSG00000236656.1	RP11-144L1.4	4.43	2.55e-05	0.0157	0.27	0.42	Pneumococcal bacteremia;	chr1:158529842	chr1:158474454~158494886:-
THYM	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	4.43	2.55e-05	0.0157	0.44	0.42	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
THYM	cis	rs28785552	0.931	rs10424385	ENSG00000250731.1	TPM3P6	-4.43	2.56e-05	0.0157	-0.59	-0.42	Response to paliperidone in schizophrenia (PANSS score);	chr19:52735880	chr19:53479350~53480091:+
THYM	cis	rs28785552	0.897	rs10424736	ENSG00000250731.1	TPM3P6	-4.43	2.56e-05	0.0157	-0.59	-0.42	Response to paliperidone in schizophrenia (PANSS score);	chr19:52735923	chr19:53479350~53480091:+
THYM	cis	rs7005380	0.58	rs1467044	ENSG00000245330.4	KB-1471A8.1	4.43	2.56e-05	0.0158	0.59	0.42	Interstitial lung disease;	chr8:119874801	chr8:119867419~119874488:-
THYM	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	4.43	2.56e-05	0.0158	0.55	0.42	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	4.43	2.56e-05	0.0158	0.55	0.42	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
THYM	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	4.43	2.56e-05	0.0158	0.55	0.42	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
THYM	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	4.43	2.56e-05	0.0158	0.3	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
THYM	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	4.43	2.56e-05	0.0158	0.58	0.42	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
THYM	cis	rs4835473	0.932	rs12503900	ENSG00000249741.2	RP11-673E1.3	4.43	2.57e-05	0.0158	0.35	0.42	Immature fraction of reticulocytes;	chr4:143812459	chr4:143911514~143912053:-
THYM	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-4.43	2.57e-05	0.0158	-0.49	-0.42	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
THYM	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	4.43	2.57e-05	0.0158	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
THYM	cis	rs12908161	1	rs36033486	ENSG00000275120.1	RP11-182J1.17	4.43	2.57e-05	0.0158	0.56	0.42	Schizophrenia;	chr15:84776461	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs12908549	ENSG00000275120.1	RP11-182J1.17	4.43	2.57e-05	0.0158	0.56	0.42	Schizophrenia;	chr15:84779120	chr15:84599434~84606463:-
THYM	cis	rs7976269	0.583	rs4931131	ENSG00000275476.1	RP11-996F15.4	-4.43	2.58e-05	0.0159	-0.47	-0.42	Male-pattern baldness;	chr12:29015898	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs6487744	ENSG00000275476.1	RP11-996F15.4	-4.43	2.58e-05	0.0159	-0.47	-0.42	Male-pattern baldness;	chr12:29030756	chr12:29277397~29277882:-
THYM	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-4.43	2.59e-05	0.0159	-0.34	-0.42	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs4916905	ENSG00000247828.6	TMEM161B-AS1	4.43	2.59e-05	0.0159	0.34	0.42	Depressive symptoms;	chr5:88362244	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	4.43	2.59e-05	0.0159	0.34	0.42	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
THYM	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-4.43	2.59e-05	0.0159	-0.44	-0.42	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-4.43	2.59e-05	0.0159	-0.44	-0.42	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-4.43	2.59e-05	0.0159	-0.44	-0.42	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-4.43	2.59e-05	0.0159	-0.44	-0.42	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
THYM	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	4.43	2.59e-05	0.0159	0.82	0.42	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
THYM	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-4.43	2.59e-05	0.0159	-0.58	-0.42	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
THYM	cis	rs897984	0.806	rs1046276	ENSG00000275263.1	RP11-1072A3.4	4.43	2.59e-05	0.0159	0.36	0.42	Dementia with Lewy bodies;	chr16:30903305	chr16:30956872~30957199:-
THYM	cis	rs61160187	0.51	rs10057395	ENSG00000272308.1	RP11-231G3.1	-4.43	2.59e-05	0.0159	-0.38	-0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792967	chr5:60866457~60866935:-
THYM	cis	rs17742757	0.521	rs2736324	ENSG00000255354.1	RP11-148O21.2	-4.43	2.59e-05	0.0159	-0.42	-0.42	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11470673	chr8:11558466~11560020:-
THYM	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	4.43	2.59e-05	0.0159	0.83	0.42	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
THYM	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	4.43	2.59e-05	0.0159	0.35	0.42	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
THYM	cis	rs1550576	0.568	rs80051811	ENSG00000274719.1	RP11-86K22.2	4.43	2.59e-05	0.0159	0.79	0.42	Hypertension;	chr15:58017906	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs8041300	ENSG00000274719.1	RP11-86K22.2	4.43	2.59e-05	0.0159	0.79	0.42	Hypertension;	chr15:58023739	chr15:57990217~57990636:-
THYM	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	4.42	2.6e-05	0.016	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
THYM	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	4.42	2.6e-05	0.016	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
THYM	cis	rs526231	0.756	rs448086	ENSG00000175749.11	EIF3KP1	4.42	2.6e-05	0.016	0.54	0.42	Primary biliary cholangitis;	chr5:103287880	chr5:103032376~103033031:+
THYM	cis	rs526231	0.756	rs556560	ENSG00000175749.11	EIF3KP1	-4.42	2.6e-05	0.016	-0.54	-0.42	Primary biliary cholangitis;	chr5:103288223	chr5:103032376~103033031:+
THYM	cis	rs526231	0.756	rs35804	ENSG00000175749.11	EIF3KP1	4.42	2.6e-05	0.016	0.54	0.42	Primary biliary cholangitis;	chr5:103289634	chr5:103032376~103033031:+
THYM	cis	rs7223966	1	rs11542436	ENSG00000240280.5	TCAM1P	-4.42	2.6e-05	0.016	-0.63	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63701329	chr17:63849292~63864379:+
THYM	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	4.42	2.6e-05	0.016	0.54	0.42	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
THYM	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	4.42	2.6e-05	0.016	0.29	0.42	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
THYM	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	4.42	2.6e-05	0.016	0.29	0.42	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	4.42	2.6e-05	0.016	0.29	0.42	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
THYM	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	4.42	2.6e-05	0.016	0.29	0.42	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	4.42	2.6e-05	0.016	0.29	0.42	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	4.42	2.6e-05	0.016	0.29	0.42	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
THYM	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
THYM	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
THYM	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
THYM	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
THYM	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
THYM	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
THYM	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
THYM	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
THYM	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
THYM	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-4.42	2.6e-05	0.016	-0.29	-0.42	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
THYM	cis	rs2243480	1	rs6460260	ENSG00000228409.4	CCT6P1	-4.42	2.6e-05	0.016	-0.53	-0.42	Diabetic kidney disease;	chr7:65750468	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs6460261	ENSG00000228409.4	CCT6P1	-4.42	2.6e-05	0.016	-0.53	-0.42	Diabetic kidney disease;	chr7:65750593	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.908	rs4718273	ENSG00000228409.4	CCT6P1	-4.42	2.6e-05	0.016	-0.53	-0.42	Diabetic kidney disease;	chr7:65751112	chr7:65751142~65763354:+
THYM	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-4.42	2.6e-05	0.016	-0.5	-0.42	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
THYM	cis	rs7223966	1	rs11079509	ENSG00000240280.5	TCAM1P	-4.42	2.6e-05	0.016	-0.67	-0.42	Hip circumference adjusted for BMI;Body mass index;	chr17:63684788	chr17:63849292~63864379:+
THYM	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-4.42	2.6e-05	0.016	-0.42	-0.42	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-4.42	2.6e-05	0.016	-0.42	-0.42	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
THYM	cis	rs8067545	0.967	rs4924801	ENSG00000231645.2	KRT17P6	-4.42	2.61e-05	0.016	-0.48	-0.42	Schizophrenia;	chr17:20017757	chr17:20512560~20517479:-
THYM	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	4.42	2.61e-05	0.016	0.44	0.42	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
THYM	cis	rs17685	0.753	rs2302438	ENSG00000280388.1	RP11-229D13.3	-4.42	2.61e-05	0.016	-0.41	-0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76047747	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs7804598	ENSG00000280388.1	RP11-229D13.3	-4.42	2.61e-05	0.016	-0.41	-0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76073260	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs59659102	ENSG00000280388.1	RP11-229D13.3	-4.42	2.61e-05	0.016	-0.41	-0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76080796	chr7:76043977~76045963:-
THYM	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-4.42	2.61e-05	0.016	-0.56	-0.42	Depression;	chr6:28422360	chr6:28176188~28176674:+
THYM	cis	rs17685	0.753	rs1104879	ENSG00000280388.1	RP11-229D13.3	-4.42	2.62e-05	0.016	-0.42	-0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76056250	chr7:76043977~76045963:-
THYM	cis	rs17685	0.796	rs3757594	ENSG00000280388.1	RP11-229D13.3	4.42	2.62e-05	0.016	0.42	0.42	Coffee consumption (cups per day);Coffee consumption;	chr7:76049326	chr7:76043977~76045963:-
THYM	cis	rs7188861	0.681	rs8050084	ENSG00000260318.1	COX6CP1	-4.42	2.62e-05	0.016	-0.89	-0.42	HDL cholesterol;	chr16:11313423	chr16:11903923~11904137:-
THYM	cis	rs17711722	0.523	rs365896	ENSG00000232906.1	RP11-746P2.3	-4.42	2.62e-05	0.016	-0.41	-0.42	Calcium levels;	chr7:66045710	chr7:65355934~65357176:+
THYM	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-4.42	2.62e-05	0.016	-0.45	-0.42	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
THYM	cis	rs853679	0.517	rs6932109	ENSG00000272009.1	RP1-313I6.12	4.42	2.62e-05	0.0161	0.53	0.41	Depression;	chr6:28110525	chr6:28078792~28081130:-
THYM	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-4.42	2.63e-05	0.0161	-0.34	-0.41	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-4.42	2.63e-05	0.0161	-0.34	-0.41	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-4.42	2.63e-05	0.0161	-0.34	-0.41	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-4.42	2.63e-05	0.0161	-0.34	-0.41	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-4.42	2.63e-05	0.0161	-0.34	-0.41	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
THYM	cis	rs6570726	1	rs6570699	ENSG00000235652.6	RP11-545I5.3	4.42	2.63e-05	0.0161	0.3	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145799409~145886585:+
THYM	cis	rs6570726	1	rs1935615	ENSG00000235652.6	RP11-545I5.3	4.42	2.63e-05	0.0161	0.3	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145799409~145886585:+
THYM	cis	rs6570726	0.902	rs4895678	ENSG00000235652.6	RP11-545I5.3	4.42	2.63e-05	0.0161	0.3	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145799409~145886585:+
THYM	cis	rs9907295	0.681	rs9912284	ENSG00000270871.1	AC015849.19	4.42	2.63e-05	0.0161	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs4796120	ENSG00000270977.1	AC015849.16	4.42	2.63e-05	0.0161	0.7	0.41	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35893707~35911023:-
THYM	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	4.42	2.63e-05	0.0161	0.93	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
THYM	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-4.42	2.63e-05	0.0161	-0.53	-0.41	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-4.42	2.63e-05	0.0161	-0.53	-0.41	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-4.42	2.63e-05	0.0161	-0.53	-0.41	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
THYM	cis	rs7208859	0.673	rs11652370	ENSG00000266490.1	CTD-2349P21.9	4.42	2.64e-05	0.0161	0.71	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs56846352	ENSG00000266490.1	CTD-2349P21.9	4.42	2.64e-05	0.0161	0.71	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs7211776	ENSG00000266490.1	CTD-2349P21.9	4.42	2.64e-05	0.0161	0.71	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9912122	ENSG00000266490.1	CTD-2349P21.9	4.42	2.64e-05	0.0161	0.71	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30792372~30792833:+
THYM	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-4.42	2.64e-05	0.0161	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
THYM	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-4.42	2.64e-05	0.0162	-0.32	-0.41	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
THYM	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	4.42	2.64e-05	0.0162	0.55	0.41	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
THYM	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-4.42	2.64e-05	0.0162	-0.43	-0.41	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
THYM	cis	rs1061377	0.748	rs1964345	ENSG00000249685.1	RP11-360F5.3	4.42	2.64e-05	0.0162	0.41	0.41	Uric acid levels;	chr4:39104793	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.748	rs1964347	ENSG00000249685.1	RP11-360F5.3	4.42	2.64e-05	0.0162	0.41	0.41	Uric acid levels;	chr4:39104956	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	4.42	2.64e-05	0.0162	0.41	0.41	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
THYM	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	4.42	2.65e-05	0.0162	0.52	0.41	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
THYM	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-4.42	2.65e-05	0.0162	-0.52	-0.41	Height;	chr11:118703185	chr11:118704607~118750263:+
THYM	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-4.42	2.65e-05	0.0162	-0.52	-0.41	Height;	chr11:118703207	chr11:118704607~118750263:+
THYM	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-4.42	2.65e-05	0.0162	-0.52	-0.41	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
THYM	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-4.42	2.65e-05	0.0162	-0.52	-0.41	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
THYM	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-4.42	2.65e-05	0.0162	-0.52	-0.41	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
THYM	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-4.42	2.65e-05	0.0162	-0.52	-0.41	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
THYM	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-4.42	2.65e-05	0.0162	-0.44	-0.41	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
THYM	cis	rs8067545	1	rs8067545	ENSG00000231645.2	KRT17P6	-4.42	2.65e-05	0.0162	-0.48	-0.41	Schizophrenia;	chr17:20009397	chr17:20512560~20517479:-
THYM	cis	rs853679	0.55	rs1233699	ENSG00000272009.1	RP1-313I6.12	-4.42	2.65e-05	0.0162	-0.52	-0.41	Depression;	chr6:28201380	chr6:28078792~28081130:-
THYM	cis	rs10129255	0.5	rs8011115	ENSG00000253703.1	IGHV1-68	-4.42	2.65e-05	0.0162	-0.45	-0.41	Kawasaki disease;	chr14:106786292	chr14:106703852~106704146:-
THYM	cis	rs7560272	0.723	rs1320374	ENSG00000163016.8	ALMS1P	-4.42	2.65e-05	0.0162	-0.49	-0.41	Schizophrenia;	chr2:73601183	chr2:73644919~73685576:+
THYM	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	4.42	2.65e-05	0.0162	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
THYM	cis	rs10888838	0.938	rs12033727	ENSG00000198711.5	SSBP3-AS1	4.42	2.65e-05	0.0162	0.28	0.41	Mitochondrial DNA levels;	chr1:54214083	chr1:54236440~54239063:+
THYM	cis	rs10888838	1	rs1410896	ENSG00000198711.5	SSBP3-AS1	4.42	2.65e-05	0.0162	0.28	0.41	Mitochondrial DNA levels;	chr1:54217341	chr1:54236440~54239063:+
THYM	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-4.42	2.65e-05	0.0162	-0.44	-0.41	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
THYM	cis	rs7202877	0.706	rs247437	ENSG00000261783.1	RP11-252K23.2	4.42	2.66e-05	0.0162	0.53	0.41	Type 1 diabetes;Type 2 diabetes;	chr16:75397377	chr16:75379818~75381260:-
THYM	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	4.42	2.66e-05	0.0163	0.79	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
THYM	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	4.42	2.66e-05	0.0163	0.56	0.41	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
THYM	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	4.42	2.66e-05	0.0163	0.56	0.41	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
THYM	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	4.42	2.66e-05	0.0163	0.56	0.41	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
THYM	cis	rs2267681	0.603	rs194152	ENSG00000240889.1	NDUFB2-AS1	4.42	2.66e-05	0.0163	0.52	0.41	Cervical cancer;	chr7:139840137	chr7:140695336~140697077:-
THYM	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-4.42	2.66e-05	0.0163	-0.43	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
THYM	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	4.42	2.66e-05	0.0163	0.39	0.41	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	4.42	2.66e-05	0.0163	0.39	0.41	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
THYM	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-4.42	2.66e-05	0.0163	-0.43	-0.41	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
THYM	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-4.42	2.66e-05	0.0163	-0.43	-0.41	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
THYM	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-4.42	2.67e-05	0.0163	-0.32	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
THYM	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-4.42	2.67e-05	0.0163	-0.32	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
THYM	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-4.42	2.67e-05	0.0163	-0.5	-0.41	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
THYM	cis	rs9309473	0.519	rs13027816	ENSG00000273245.1	RP11-434P11.2	-4.42	2.67e-05	0.0163	-0.45	-0.41	Metabolite levels;	chr2:73670564	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs2421584	ENSG00000273245.1	RP11-434P11.2	-4.42	2.67e-05	0.0163	-0.45	-0.41	Metabolite levels;	chr2:73671725	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs2421586	ENSG00000273245.1	RP11-434P11.2	-4.42	2.67e-05	0.0163	-0.45	-0.41	Metabolite levels;	chr2:73672592	chr2:73750256~73750786:-
THYM	cis	rs8067545	1	rs8071730	ENSG00000231645.2	KRT17P6	-4.42	2.67e-05	0.0163	-0.48	-0.41	Schizophrenia;	chr17:20029418	chr17:20512560~20517479:-
THYM	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-4.42	2.67e-05	0.0163	-0.52	-0.41	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
THYM	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	4.42	2.68e-05	0.0163	0.4	0.41	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
THYM	cis	rs62184315	0.536	rs5742985	ENSG00000273240.1	RP11-455J20.3	-4.42	2.68e-05	0.0163	-0.7	-0.41	Alcohol dependence (age at onset);	chr2:189796383	chr2:189763859~189764456:-
THYM	cis	rs853679	0.517	rs868987	ENSG00000182477.5	OR2B8P	-4.42	2.68e-05	0.0164	-0.57	-0.41	Depression;	chr6:28142370	chr6:28053228~28054165:-
THYM	cis	rs17711722	0.503	rs453835	ENSG00000232906.1	RP11-746P2.3	-4.42	2.68e-05	0.0164	-0.4	-0.41	Calcium levels;	chr7:66046172	chr7:65355934~65357176:+
THYM	cis	rs7937127	0.696	rs11607472	ENSG00000254907.1	RP11-484D2.2	4.42	2.68e-05	0.0164	0.65	0.41	Fibrinogen levels;	chr11:43323201	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.744	rs55637777	ENSG00000254907.1	RP11-484D2.2	4.42	2.68e-05	0.0164	0.65	0.41	Fibrinogen levels;	chr11:43405323	chr11:43328748~43359296:-
THYM	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	4.42	2.68e-05	0.0164	0.46	0.41	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
THYM	cis	rs12908161	0.959	rs11637728	ENSG00000235370.6	DNM1P51	4.42	2.69e-05	0.0164	0.55	0.41	Schizophrenia;	chr15:84660161	chr15:84398316~84411701:-
THYM	cis	rs7223966	1	rs11658329	ENSG00000240280.5	TCAM1P	4.42	2.69e-05	0.0164	0.62	0.41	Hip circumference adjusted for BMI;Body mass index;	chr17:63685671	chr17:63849292~63864379:+
THYM	cis	rs4853012	0.838	rs4452177	ENSG00000272183.1	RP11-523H20.3	4.42	2.69e-05	0.0164	0.54	0.41	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74501717~74502365:+
THYM	cis	rs4853012	0.838	rs60705299	ENSG00000272183.1	RP11-523H20.3	4.42	2.69e-05	0.0164	0.54	0.41	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74501717~74502365:+
THYM	cis	rs4853012	0.838	rs6715351	ENSG00000272183.1	RP11-523H20.3	4.42	2.69e-05	0.0164	0.54	0.41	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74501717~74502365:+
THYM	cis	rs11696739	0.583	rs2243602	ENSG00000234282.1	RP4-673D20.4	-4.42	2.69e-05	0.0164	-0.4	-0.41	Mean platelet volume;	chr20:1566096	chr20:1722045~1722537:-
THYM	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	4.42	2.69e-05	0.0164	0.41	0.41	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
THYM	cis	rs4835473	0.932	rs1849112	ENSG00000249741.2	RP11-673E1.3	-4.42	2.7e-05	0.0164	-0.35	-0.41	Immature fraction of reticulocytes;	chr4:143962502	chr4:143911514~143912053:-
THYM	cis	rs935334	1	rs2543387	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76162703	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2360977	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76188138	chr14:76235817~76263474:+
THYM	cis	rs935334	0.935	rs1900124	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76190323	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs4899586	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76194513	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs11159183	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76196559	chr14:76235817~76263474:+
THYM	cis	rs935334	0.877	rs7158766	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76197208	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs6574278	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76197495	chr14:76235817~76263474:+
THYM	cis	rs935334	0.935	rs6574279	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76197595	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2121071	ENSG00000258454.1	RP11-361H10.3	4.41	2.7e-05	0.0165	0.53	0.41	Blood pressure;	chr14:76199134	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs1900125	ENSG00000258454.1	RP11-361H10.3	-4.41	2.7e-05	0.0165	-0.53	-0.41	Blood pressure;	chr14:76191127	chr14:76235817~76263474:+
THYM	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-4.41	2.7e-05	0.0165	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
THYM	cis	rs7246967	0.541	rs16999009	ENSG00000198153.8	ZNF849P	4.41	2.7e-05	0.0165	0.55	0.41	Bronchopulmonary dysplasia;	chr19:22726856	chr19:22685167~22686732:+
THYM	cis	rs901683	0.702	rs73292848	ENSG00000230869.1	CTGLF10P	-4.41	2.7e-05	0.0165	-1.21	-0.41	Mean corpuscular volume;Red blood cell traits;	chr10:45674304	chr10:45678692~45700532:+
THYM	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	4.41	2.7e-05	0.0165	0.47	0.41	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
THYM	cis	rs910316	0.763	rs175057	ENSG00000258646.1	RP11-950C14.3	4.41	2.71e-05	0.0165	0.37	0.41	Height;	chr14:75022929	chr14:75004719~75008481:-
THYM	cis	rs10129255	0.589	rs78599641	ENSG00000254329.1	IGHVII-60-1	4.41	2.71e-05	0.0165	0.4	0.41	Kawasaki disease;	chr14:106637576	chr14:106637718~106637973:-
THYM	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	4.41	2.71e-05	0.0165	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
THYM	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	4.41	2.71e-05	0.0165	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
THYM	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-4.41	2.71e-05	0.0165	-0.54	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
THYM	cis	rs4835473	0.524	rs4404495	ENSG00000249741.2	RP11-673E1.3	-4.41	2.71e-05	0.0165	-0.36	-0.41	Immature fraction of reticulocytes;	chr4:143979791	chr4:143911514~143912053:-
THYM	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-4.41	2.71e-05	0.0165	-0.57	-0.41	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
THYM	cis	rs4853012	0.838	rs4429500	ENSG00000272183.1	RP11-523H20.3	4.41	2.71e-05	0.0165	0.53	0.41	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74501717~74502365:+
THYM	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	4.41	2.71e-05	0.0165	0.49	0.41	Height;	chr6:109469907	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	4.41	2.71e-05	0.0165	0.49	0.41	Height;	chr6:109479396	chr6:109382795~109383666:+
THYM	cis	rs4908768	0.501	rs6677736	ENSG00000232912.4	RP5-1115A15.1	4.41	2.71e-05	0.0165	0.41	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8424645~8434838:+
THYM	cis	rs13160562	0.666	rs26481	ENSG00000272109.1	CTD-2260A17.3	-4.41	2.72e-05	0.0165	-0.5	-0.41	Alcohol dependence;	chr5:96767648	chr5:96804353~96806105:+
THYM	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	4.41	2.72e-05	0.0165	0.34	0.41	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
THYM	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	4.41	2.72e-05	0.0166	0.4	0.41	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	4.41	2.72e-05	0.0166	0.4	0.41	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	4.41	2.72e-05	0.0166	0.4	0.41	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
THYM	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	4.41	2.72e-05	0.0166	0.4	0.41	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
THYM	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-4.41	2.72e-05	0.0166	-0.46	-0.41	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
THYM	cis	rs3822625	0.541	rs12655019	ENSG00000271828.1	CTD-2310F14.1	4.41	2.72e-05	0.0166	0.81	0.41	Breast cancer (early onset);	chr5:56899963	chr5:56927874~56929573:+
THYM	cis	rs3822625	0.541	rs12657353	ENSG00000271828.1	CTD-2310F14.1	4.41	2.72e-05	0.0166	0.81	0.41	Breast cancer (early onset);	chr5:56900449	chr5:56927874~56929573:+
THYM	cis	rs7178424	0.774	rs13379947	ENSG00000259251.2	RP11-643M14.1	4.41	2.72e-05	0.0166	0.41	0.41	Height;	chr15:61892602	chr15:62060503~62062434:+
THYM	cis	rs12325245	0.536	rs12931124	ENSG00000276259.1	RP11-481J2.4	4.41	2.72e-05	0.0166	0.87	0.41	Schizophrenia;	chr16:58586159	chr16:58522970~58523842:+
THYM	cis	rs12325245	0.536	rs34161389	ENSG00000276259.1	RP11-481J2.4	4.41	2.72e-05	0.0166	0.87	0.41	Schizophrenia;	chr16:58588700	chr16:58522970~58523842:+
THYM	cis	rs12325245	0.536	rs12925676	ENSG00000276259.1	RP11-481J2.4	4.41	2.72e-05	0.0166	0.87	0.41	Schizophrenia;	chr16:58591422	chr16:58522970~58523842:+
THYM	cis	rs12325245	0.536	rs12931051	ENSG00000276259.1	RP11-481J2.4	4.41	2.72e-05	0.0166	0.87	0.41	Schizophrenia;	chr16:58592630	chr16:58522970~58523842:+
THYM	cis	rs12325245	0.536	rs8058781	ENSG00000276259.1	RP11-481J2.4	4.41	2.72e-05	0.0166	0.87	0.41	Schizophrenia;	chr16:58619934	chr16:58522970~58523842:+
THYM	cis	rs12325245	0.536	rs71389028	ENSG00000276259.1	RP11-481J2.4	4.41	2.72e-05	0.0166	0.87	0.41	Schizophrenia;	chr16:58629356	chr16:58522970~58523842:+
THYM	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	4.41	2.72e-05	0.0166	0.41	0.41	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.748	rs1036033	ENSG00000249685.1	RP11-360F5.3	4.41	2.72e-05	0.0166	0.42	0.41	Uric acid levels;	chr4:39105295	chr4:39133913~39135608:+
THYM	cis	rs9309473	0.519	rs1881246	ENSG00000163016.8	ALMS1P	-4.41	2.73e-05	0.0166	-0.49	-0.41	Metabolite levels;	chr2:73422994	chr2:73644919~73685576:+
THYM	cis	rs12908161	1	rs35630683	ENSG00000235370.6	DNM1P51	4.41	2.73e-05	0.0166	0.56	0.41	Schizophrenia;	chr15:84806000	chr15:84398316~84411701:-
THYM	cis	rs35828350	1	rs35828350	ENSG00000235370.6	DNM1P51	4.41	2.73e-05	0.0166	0.56	0.41	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs56864281	ENSG00000235370.6	DNM1P51	4.41	2.73e-05	0.0166	0.56	0.41	Schizophrenia;	chr15:84814418	chr15:84398316~84411701:-
THYM	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-4.41	2.73e-05	0.0166	-0.34	-0.41	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
THYM	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
THYM	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
THYM	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
THYM	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
THYM	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	4.41	2.74e-05	0.0166	0.36	0.41	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
THYM	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-4.41	2.74e-05	0.0166	-0.36	-0.41	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-4.41	2.74e-05	0.0166	-0.36	-0.41	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
THYM	cis	rs3822625	0.541	rs112793966	ENSG00000271828.1	CTD-2310F14.1	4.41	2.74e-05	0.0166	0.81	0.41	Breast cancer (early onset);	chr5:56908291	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs16886497	ENSG00000271828.1	CTD-2310F14.1	4.41	2.74e-05	0.0166	0.81	0.41	Breast cancer (early onset);	chr5:56924887	chr5:56927874~56929573:+
THYM	cis	rs12655019	0.92	rs76869724	ENSG00000271828.1	CTD-2310F14.1	4.41	2.74e-05	0.0166	0.81	0.41	Breast cancer (early onset);	chr5:56932668	chr5:56927874~56929573:+
THYM	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-4.41	2.74e-05	0.0166	-0.42	-0.41	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
THYM	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	4.41	2.74e-05	0.0166	0.42	0.41	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
THYM	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	4.41	2.74e-05	0.0166	0.42	0.41	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
THYM	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	4.41	2.74e-05	0.0166	0.42	0.41	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
THYM	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-4.41	2.74e-05	0.0166	-0.51	-0.41	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
THYM	cis	rs12908161	0.959	rs17534709	ENSG00000235370.6	DNM1P51	4.41	2.74e-05	0.0167	0.56	0.41	Schizophrenia;	chr15:84771166	chr15:84398316~84411701:-
THYM	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-4.41	2.74e-05	0.0167	-0.45	-0.41	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
THYM	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-4.41	2.74e-05	0.0167	-0.45	-0.41	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
THYM	cis	rs2408955	0.522	rs11168408	ENSG00000240399.1	RP1-228P16.1	-4.41	2.74e-05	0.0167	-0.39	-0.41	Glycated hemoglobin levels;	chr12:48104544	chr12:48054813~48055591:-
THYM	cis	rs4908768	0.501	rs7527389	ENSG00000232912.4	RP5-1115A15.1	4.41	2.74e-05	0.0167	0.41	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs7518608	ENSG00000232912.4	RP5-1115A15.1	4.41	2.74e-05	0.0167	0.41	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8424645~8434838:+
THYM	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	4.41	2.75e-05	0.0167	0.31	0.41	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
THYM	cis	rs7223966	1	rs8080211	ENSG00000240280.5	TCAM1P	-4.41	2.75e-05	0.0167	-0.64	-0.41	Hip circumference adjusted for BMI;Body mass index;	chr17:63652522	chr17:63849292~63864379:+
THYM	cis	rs863345	0.604	rs6689657	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158492719	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs879637	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158492907	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs879635	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158493118	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs1342949	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158493505	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1342950	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158493933	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12044283	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494043	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12044288	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494073	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12034004	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494095	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2051450	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494272	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2051451	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494475	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1342952	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494640	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1342954	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494758	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs4614256	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494821	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs4373761	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494844	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs4609418	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158494938	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264984	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495200	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12078065	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495273	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264985	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495376	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908657	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495453	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908658	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495466	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10797011	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495581	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10797012	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495695	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10797013	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158495716	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908660	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158496399	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7555174	ENSG00000236656.1	RP11-144L1.4	4.41	2.76e-05	0.0167	0.27	0.41	Pneumococcal bacteremia;	chr1:158517636	chr1:158474454~158494886:-
THYM	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.41	2.76e-05	0.0167	-0.34	-0.41	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-4.41	2.76e-05	0.0167	-0.34	-0.41	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
THYM	cis	rs1065852	0.906	rs9611734	ENSG00000227370.1	RP4-669P10.19	4.41	2.76e-05	0.0168	0.54	0.41	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42106066	chr22:42132543~42132998:+
THYM	cis	rs4713118	0.662	rs464312	ENSG00000182477.5	OR2B8P	4.41	2.76e-05	0.0168	0.54	0.41	Parkinson's disease;	chr6:27999813	chr6:28053228~28054165:-
THYM	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	4.41	2.76e-05	0.0168	0.43	0.41	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
THYM	cis	rs12304921	0.748	rs56353532	ENSG00000277201.1	AC087884.1	4.41	2.76e-05	0.0168	0.41	0.41	Type 2 diabetes;	chr12:50970949	chr12:51049921~51050025:+
THYM	cis	rs10888838	1	rs2026045	ENSG00000198711.5	SSBP3-AS1	4.41	2.77e-05	0.0168	0.27	0.41	Mitochondrial DNA levels;	chr1:54219522	chr1:54236440~54239063:+
THYM	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-4.41	2.77e-05	0.0168	-0.53	-0.41	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
THYM	cis	rs1023500	0.552	rs133368	ENSG00000227370.1	RP4-669P10.19	4.41	2.77e-05	0.0168	0.49	0.41	Schizophrenia;	chr22:42067685	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs133370	ENSG00000227370.1	RP4-669P10.19	4.41	2.77e-05	0.0168	0.49	0.41	Schizophrenia;	chr22:42069256	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.551	rs133371	ENSG00000227370.1	RP4-669P10.19	4.41	2.77e-05	0.0168	0.49	0.41	Schizophrenia;	chr22:42069570	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs133374	ENSG00000227370.1	RP4-669P10.19	4.41	2.77e-05	0.0168	0.49	0.41	Schizophrenia;	chr22:42069937	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs133378	ENSG00000227370.1	RP4-669P10.19	4.41	2.77e-05	0.0168	0.49	0.41	Schizophrenia;	chr22:42071691	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs133382	ENSG00000227370.1	RP4-669P10.19	4.41	2.77e-05	0.0168	0.49	0.41	Schizophrenia;	chr22:42075770	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs1807494	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Schizophrenia;	chr22:42078134	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs4147641	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs4147640	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs1801311	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.507	rs6002600	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Schizophrenia;	chr22:42092902	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002601	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002604	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs5996109	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs5996110	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs9620026	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs28791586	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs2839708	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6519306	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002614	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs2413669	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002618	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.551	rs61665536	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Schizophrenia;	chr22:42116609	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs2413672	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002623	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs11090076	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs8138678	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs764481	ENSG00000227370.1	RP4-669P10.19	-4.41	2.77e-05	0.0168	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42132543~42132998:+
THYM	cis	rs10129255	0.5	rs7159033	ENSG00000254329.1	IGHVII-60-1	4.41	2.77e-05	0.0168	0.37	0.41	Kawasaki disease;	chr14:106701709	chr14:106637718~106637973:-
THYM	cis	rs17711722	0.528	rs73138179	ENSG00000228409.4	CCT6P1	-4.41	2.78e-05	0.0168	-0.28	-0.41	Calcium levels;	chr7:65829495	chr7:65751142~65763354:+
THYM	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	4.41	2.78e-05	0.0168	0.41	0.41	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
THYM	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-4.41	2.78e-05	0.0168	-0.46	-0.41	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
THYM	cis	rs4853012	0.752	rs13413795	ENSG00000257800.1	FNBP1P1	4.41	2.78e-05	0.0168	0.31	0.41	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74120680~74123218:+
THYM	cis	rs7560272	0.538	rs2001436	ENSG00000273245.1	RP11-434P11.2	-4.41	2.78e-05	0.0168	-0.5	-0.41	Schizophrenia;	chr2:73701838	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.512	rs12998980	ENSG00000273245.1	RP11-434P11.2	-4.41	2.78e-05	0.0168	-0.5	-0.41	Schizophrenia;	chr2:73703599	chr2:73750256~73750786:-
THYM	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-4.41	2.78e-05	0.0168	-0.51	-0.41	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.879	rs7046990	ENSG00000268707.1	RP11-247A12.7	-4.41	2.78e-05	0.0168	-0.51	-0.41	Blood metabolite ratios;	chr9:129093859	chr9:129170434~129170940:+
THYM	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	4.41	2.78e-05	0.0168	0.65	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-4.41	2.78e-05	0.0168	-0.65	-0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	4.41	2.78e-05	0.0168	0.65	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	4.41	2.78e-05	0.0168	0.65	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	4.41	2.78e-05	0.0168	0.65	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
THYM	cis	rs4845570	0.831	rs11588634	ENSG00000203288.3	RP11-98D18.9	-4.41	2.79e-05	0.0169	-0.54	-0.41	Coronary artery disease;	chr1:151808210	chr1:151790804~151794402:+
THYM	cis	rs4845570	0.831	rs11588258	ENSG00000203288.3	RP11-98D18.9	-4.41	2.79e-05	0.0169	-0.54	-0.41	Coronary artery disease;	chr1:151808252	chr1:151790804~151794402:+
THYM	cis	rs17445774	1	rs17445774	ENSG00000232732.8	AC073043.1	4.41	2.79e-05	0.0169	0.54	0.41	LDL cholesterol to HDL cholesterol ratio;	chr2:199994526	chr2:199867396~199911159:-
THYM	cis	rs2834288	0.535	rs8132681	ENSG00000273102.1	AP000569.9	4.41	2.79e-05	0.0169	0.45	0.41	Gut microbiota (bacterial taxa);	chr21:33950035	chr21:33967101~33968573:-
THYM	cis	rs564343	0.583	rs571374	ENSG00000255320.1	RP11-755F10.1	-4.41	2.79e-05	0.0169	-0.46	-0.41	Obesity (early onset extreme);	chr11:66050121	chr11:66244840~66246239:-
THYM	cis	rs9876781	1	rs3214041	ENSG00000244380.1	RP11-24C3.2	4.41	2.79e-05	0.0169	0.54	0.41	Longevity;	chr3:48413059	chr3:48440352~48446656:-
THYM	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-4.41	2.79e-05	0.0169	-0.35	-0.41	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-4.41	2.79e-05	0.0169	-0.35	-0.41	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-4.41	2.79e-05	0.0169	-0.35	-0.41	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
THYM	cis	rs7246967	0.673	rs7245540	ENSG00000198153.8	ZNF849P	-4.41	2.8e-05	0.0169	-0.54	-0.41	Bronchopulmonary dysplasia;	chr19:22698702	chr19:22685167~22686732:+
THYM	cis	rs7202877	0.706	rs467780	ENSG00000261783.1	RP11-252K23.2	4.41	2.8e-05	0.0169	0.54	0.41	Type 1 diabetes;Type 2 diabetes;	chr16:75403240	chr16:75379818~75381260:-
THYM	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	4.4	2.8e-05	0.0169	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
THYM	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	4.4	2.8e-05	0.0169	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
THYM	cis	rs12681366	0.881	rs12682038	ENSG00000253704.1	RP11-267M23.4	4.4	2.8e-05	0.017	0.53	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94393252	chr8:94553722~94569745:+
THYM	cis	rs12554020	0.685	rs55893789	ENSG00000227603.1	RP11-165J3.6	4.4	2.81e-05	0.017	0.6	0.41	Schizophrenia;	chr9:93408608	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.681	rs78759589	ENSG00000227603.1	RP11-165J3.6	4.4	2.81e-05	0.017	0.6	0.41	Schizophrenia;	chr9:93409518	chr9:93435332~93437121:-
THYM	cis	rs12554020	0.786	rs75395683	ENSG00000227603.1	RP11-165J3.6	4.4	2.81e-05	0.017	0.6	0.41	Schizophrenia;	chr9:93415128	chr9:93435332~93437121:-
THYM	cis	rs10129255	0.957	rs8014696	ENSG00000253703.1	IGHV1-68	4.4	2.82e-05	0.017	0.55	0.41	Kawasaki disease;	chr14:106769752	chr14:106703852~106704146:-
THYM	cis	rs7560272	0.564	rs4852939	ENSG00000163016.8	ALMS1P	4.4	2.82e-05	0.017	0.46	0.41	Schizophrenia;	chr2:73629642	chr2:73644919~73685576:+
THYM	cis	rs4835473	0.9	rs10003922	ENSG00000249741.2	RP11-673E1.3	4.4	2.82e-05	0.017	0.34	0.41	Immature fraction of reticulocytes;	chr4:143921235	chr4:143911514~143912053:-
THYM	cis	rs1606355	0.725	rs61415449	ENSG00000230519.2	RP11-1060J15.5	-4.4	2.82e-05	0.017	-0.72	-0.41	Metabolite levels (Pyroglutamine);	chr12:28648812	chr12:27702338~27702906:+
THYM	cis	rs1606355	0.673	rs73093670	ENSG00000230519.2	RP11-1060J15.5	-4.4	2.82e-05	0.017	-0.72	-0.41	Metabolite levels (Pyroglutamine);	chr12:28649762	chr12:27702338~27702906:+
THYM	cis	rs1606355	0.725	rs2175614	ENSG00000230519.2	RP11-1060J15.5	-4.4	2.82e-05	0.017	-0.72	-0.41	Metabolite levels (Pyroglutamine);	chr12:28662855	chr12:27702338~27702906:+
THYM	cis	rs1606355	0.725	rs11613575	ENSG00000230519.2	RP11-1060J15.5	-4.4	2.82e-05	0.017	-0.72	-0.41	Metabolite levels (Pyroglutamine);	chr12:28666469	chr12:27702338~27702906:+
THYM	cis	rs1606355	0.725	rs73081643	ENSG00000230519.2	RP11-1060J15.5	-4.4	2.82e-05	0.017	-0.72	-0.41	Metabolite levels (Pyroglutamine);	chr12:28672922	chr12:27702338~27702906:+
THYM	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-4.4	2.82e-05	0.0171	-0.47	-0.41	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
THYM	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-4.4	2.83e-05	0.0171	-0.36	-0.41	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
THYM	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	4.4	2.83e-05	0.0171	0.5	0.41	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
THYM	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	4.4	2.83e-05	0.0171	0.5	0.41	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
THYM	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	4.4	2.83e-05	0.0171	0.5	0.41	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
THYM	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	4.4	2.83e-05	0.0171	0.5	0.41	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
THYM	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	4.4	2.83e-05	0.0171	0.5	0.41	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
THYM	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	4.4	2.83e-05	0.0171	0.5	0.41	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
THYM	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-4.4	2.84e-05	0.0171	-0.47	-0.41	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
THYM	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-4.4	2.84e-05	0.0171	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
THYM	cis	rs9611565	0.84	rs3788584	ENSG00000273366.1	CTA-989H11.1	4.4	2.84e-05	0.0171	0.5	0.41	Vitiligo;	chr22:41383069	chr22:42278188~42278846:+
THYM	cis	rs9611565	0.765	rs767593	ENSG00000273366.1	CTA-989H11.1	4.4	2.84e-05	0.0171	0.5	0.41	Vitiligo;	chr22:41383967	chr22:42278188~42278846:+
THYM	cis	rs73001065	0.711	rs58489806	ENSG00000267220.1	CTC-260E6.9	4.4	2.84e-05	0.0171	0.98	0.41	LDL cholesterol;	chr19:19346108	chr19:20131894~20151908:-
THYM	cis	rs7208859	0.623	rs8082537	ENSG00000266490.1	CTD-2349P21.9	4.4	2.84e-05	0.0171	0.7	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.561	rs11655876	ENSG00000266490.1	CTD-2349P21.9	4.4	2.84e-05	0.0171	0.7	0.41	Body mass index;	chr17:30690132	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9907197	ENSG00000266490.1	CTD-2349P21.9	4.4	2.84e-05	0.0171	0.7	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9915963	ENSG00000266490.1	CTD-2349P21.9	4.4	2.84e-05	0.0171	0.7	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30792372~30792833:+
THYM	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-4.4	2.84e-05	0.0171	-0.42	-0.41	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
THYM	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-4.4	2.84e-05	0.0171	-0.36	-0.41	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
THYM	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-4.4	2.84e-05	0.0171	-0.39	-0.41	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
THYM	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-4.4	2.84e-05	0.0171	-0.39	-0.41	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
THYM	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-4.4	2.85e-05	0.0171	-0.61	-0.41	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
THYM	cis	rs10518325	0.892	rs62328062	ENSG00000260404.2	RP11-384K6.6	4.4	2.85e-05	0.0171	0.44	0.41	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118692988	chr4:118591773~118633729:+
THYM	cis	rs10518325	0.892	rs62328103	ENSG00000260404.2	RP11-384K6.6	4.4	2.85e-05	0.0171	0.44	0.41	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118701677	chr4:118591773~118633729:+
THYM	cis	rs1439840	0.803	rs6750930	ENSG00000213239.3	NPM1P32	4.4	2.85e-05	0.0172	1.01	0.41	QT interval (sulfonylurea treatment interaction);	chr2:122645828	chr2:121708512~121709115:-
THYM	cis	rs1439840	1	rs10203851	ENSG00000213239.3	NPM1P32	4.4	2.85e-05	0.0172	1.01	0.41	QT interval (sulfonylurea treatment interaction);	chr2:122650163	chr2:121708512~121709115:-
THYM	cis	rs1023500	0.596	rs5751204	ENSG00000227370.1	RP4-669P10.19	4.4	2.85e-05	0.0172	0.49	0.41	Schizophrenia;	chr22:42037797	chr22:42132543~42132998:+
THYM	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	4.4	2.85e-05	0.0172	0.51	0.41	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
THYM	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	4.4	2.85e-05	0.0172	0.51	0.41	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
THYM	cis	rs9611519	1	rs5758268	ENSG00000235513.1	RP4-756G23.5	4.4	2.86e-05	0.0172	0.35	0.41	Neuroticism;	chr22:41226415	chr22:41209122~41217627:-
THYM	cis	rs61774743	0.557	rs4660192	ENSG00000229901.1	RP11-399E6.4	-4.4	2.86e-05	0.0172	-0.41	-0.41	Intelligence (multi-trait analysis);	chr1:41376678	chr1:41375004~41375669:-
THYM	cis	rs3811273	0.614	rs4981418	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265131	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs4982593	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265205	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs6572344	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265267	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7146368	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265436	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7151848	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265503	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.667	rs7147374	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265607	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7145658	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265772	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7152255	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265774	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7147116	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265811	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.505	rs7145836	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22265875	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7157477	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22266229	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7152167	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22266254	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs4982594	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22266671	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs4982595	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22266915	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs10150341	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22267213	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs10150343	ENSG00000211816.2	TRAV38-1	-4.4	2.86e-05	0.0172	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22267219	chr14:22271968~22272563:+
THYM	cis	rs2338	0.769	rs9328061	ENSG00000218027.2	RP11-157J24.1	-4.4	2.86e-05	0.0172	-0.48	-0.41	Response to platinum-based agents;	chr6:1579978	chr6:1513698~1515289:-
THYM	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	4.4	2.87e-05	0.0172	0.4	0.41	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
THYM	cis	rs11017328	0.521	rs12354753	ENSG00000236303.2	RP11-540N6.1	-4.4	2.87e-05	0.0173	-0.59	-0.41	Conotruncal heart defects;	chr10:130490371	chr10:130439067~130483154:+
THYM	cis	rs4908769	0.624	rs894875	ENSG00000232912.4	RP5-1115A15.1	-4.4	2.87e-05	0.0173	-0.44	-0.41	Allergy;	chr1:8372076	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs6678140	ENSG00000232912.4	RP5-1115A15.1	-4.4	2.87e-05	0.0173	-0.44	-0.41	Allergy;	chr1:8376742	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs2708633	ENSG00000232912.4	RP5-1115A15.1	-4.4	2.87e-05	0.0173	-0.44	-0.41	Allergy;	chr1:8379565	chr1:8424645~8434838:+
THYM	cis	rs2834288	0.535	rs9982605	ENSG00000273102.1	AP000569.9	4.4	2.87e-05	0.0173	0.45	0.41	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33967101~33968573:-
THYM	cis	rs10129255	1	rs10129319	ENSG00000253703.1	IGHV1-68	-4.4	2.87e-05	0.0173	-0.52	-0.41	Kawasaki disease;	chr14:106767996	chr14:106703852~106704146:-
THYM	cis	rs12908161	1	rs12905057	ENSG00000275120.1	RP11-182J1.17	4.4	2.88e-05	0.0173	0.56	0.41	Schizophrenia;	chr15:84667534	chr15:84599434~84606463:-
THYM	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-4.4	2.88e-05	0.0173	-0.58	-0.41	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
THYM	cis	rs440932	0.798	rs330942	ENSG00000253893.2	FAM85B	-4.4	2.88e-05	0.0173	-0.51	-0.41	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8167819~8226614:-
THYM	cis	rs9611565	0.802	rs132916	ENSG00000231993.1	EP300-AS1	-4.4	2.88e-05	0.0173	-0.39	-0.41	Vitiligo;	chr22:41410764	chr22:41174591~41197456:-
THYM	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-4.4	2.88e-05	0.0173	-0.5	-0.41	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
THYM	cis	rs4835473	0.932	rs4092718	ENSG00000249741.2	RP11-673E1.3	4.4	2.88e-05	0.0173	0.35	0.41	Immature fraction of reticulocytes;	chr4:143799637	chr4:143911514~143912053:-
THYM	cis	rs10129255	0.518	rs2006284	ENSG00000254329.1	IGHVII-60-1	4.4	2.88e-05	0.0173	0.37	0.41	Kawasaki disease;	chr14:106676185	chr14:106637718~106637973:-
THYM	cis	rs12439619	0.846	rs28470877	ENSG00000274376.3	ADAMTS7P1	4.4	2.89e-05	0.0174	0.47	0.41	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82298553~82334609:+
THYM	cis	rs853679	0.517	rs16893666	ENSG00000272009.1	RP1-313I6.12	4.4	2.89e-05	0.0174	0.52	0.41	Depression;	chr6:28086929	chr6:28078792~28081130:-
THYM	cis	rs12681366	0.839	rs3019280	ENSG00000253704.1	RP11-267M23.4	4.4	2.89e-05	0.0174	0.54	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.839	rs3019281	ENSG00000253704.1	RP11-267M23.4	4.4	2.89e-05	0.0174	0.54	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.839	rs3019282	ENSG00000253704.1	RP11-267M23.4	4.4	2.89e-05	0.0174	0.54	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:94553722~94569745:+
THYM	cis	rs13396519	0.748	rs11902863	ENSG00000260077.1	RP11-254F7.2	-4.4	2.89e-05	0.0174	-0.44	-0.41	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:10890566	chr2:10039092~10040663:-
THYM	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	4.4	2.89e-05	0.0174	0.42	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	4.4	2.89e-05	0.0174	0.42	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	4.4	2.89e-05	0.0174	0.42	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	4.4	2.89e-05	0.0174	0.42	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	4.4	2.89e-05	0.0174	0.42	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
THYM	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	4.4	2.89e-05	0.0174	0.42	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
THYM	cis	rs1584120	0.57	rs11046795	ENSG00000256321.4	RP11-153K16.1	4.4	2.89e-05	0.0174	0.47	0.41	Pelvic organ prolapse (moderate/severe);	chr12:23109161	chr12:23099368~23191587:+
THYM	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-4.4	2.89e-05	0.0174	-0.3	-0.41	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
THYM	cis	rs7209700	0.547	rs55845779	ENSG00000228782.6	CTD-2026D20.3	-4.4	2.89e-05	0.0174	-0.65	-0.41	IgG glycosylation;	chr17:47277385	chr17:47450568~47492492:-
THYM	cis	rs7209700	0.547	rs7217214	ENSG00000228782.6	CTD-2026D20.3	-4.4	2.89e-05	0.0174	-0.65	-0.41	IgG glycosylation;	chr17:47277861	chr17:47450568~47492492:-
THYM	cis	rs7209700	0.547	rs11649785	ENSG00000228782.6	CTD-2026D20.3	-4.4	2.89e-05	0.0174	-0.65	-0.41	IgG glycosylation;	chr17:47278354	chr17:47450568~47492492:-
THYM	cis	rs4835473	0.932	rs12505628	ENSG00000249741.2	RP11-673E1.3	4.4	2.89e-05	0.0174	0.36	0.41	Immature fraction of reticulocytes;	chr4:143758468	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs12505663	ENSG00000249741.2	RP11-673E1.3	4.4	2.89e-05	0.0174	0.36	0.41	Immature fraction of reticulocytes;	chr4:143758491	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs12513078	ENSG00000249741.2	RP11-673E1.3	4.4	2.89e-05	0.0174	0.36	0.41	Immature fraction of reticulocytes;	chr4:143758494	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs12505665	ENSG00000249741.2	RP11-673E1.3	4.4	2.89e-05	0.0174	0.36	0.41	Immature fraction of reticulocytes;	chr4:143758515	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs12509716	ENSG00000249741.2	RP11-673E1.3	4.4	2.89e-05	0.0174	0.36	0.41	Immature fraction of reticulocytes;	chr4:143758520	chr4:143911514~143912053:-
THYM	cis	rs61270009	0.955	rs12514004	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88269979	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs768705	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88272893	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs4916899	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88292209	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs35300532	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88293219	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.818	rs4916718	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88316825	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs78909929	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88344154	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs12653830	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88353712	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs11748768	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88354818	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs11750391	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88356255	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.863	rs35339529	ENSG00000247828.6	TMEM161B-AS1	4.4	2.89e-05	0.0174	0.34	0.41	Depressive symptoms;	chr5:88360284	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs410354	ENSG00000247828.6	TMEM161B-AS1	-4.4	2.89e-05	0.0174	-0.34	-0.41	Depressive symptoms;	chr5:88254467	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs780404	ENSG00000247828.6	TMEM161B-AS1	-4.4	2.89e-05	0.0174	-0.34	-0.41	Depressive symptoms;	chr5:88256675	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs375514	ENSG00000247828.6	TMEM161B-AS1	-4.4	2.89e-05	0.0174	-0.34	-0.41	Depressive symptoms;	chr5:88259477	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.908	rs780405	ENSG00000247828.6	TMEM161B-AS1	-4.4	2.89e-05	0.0174	-0.34	-0.41	Depressive symptoms;	chr5:88260522	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs377958	ENSG00000247828.6	TMEM161B-AS1	-4.4	2.89e-05	0.0174	-0.34	-0.41	Depressive symptoms;	chr5:88267571	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.913	rs402114	ENSG00000247828.6	TMEM161B-AS1	-4.4	2.89e-05	0.0174	-0.34	-0.41	Depressive symptoms;	chr5:88268106	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs13172095	ENSG00000247828.6	TMEM161B-AS1	-4.4	2.89e-05	0.0174	-0.34	-0.41	Depressive symptoms;	chr5:88295130	chr5:88268895~88436685:+
THYM	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-4.4	2.9e-05	0.0174	-0.28	-0.41	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
THYM	cis	rs2853333	0.558	rs2284148	ENSG00000268947.1	AD000684.2	4.4	2.9e-05	0.0174	0.36	0.41	Red blood cell count;	chr19:35274521	chr19:35262846~35264804:+
THYM	cis	rs10129255	0.957	rs8014696	ENSG00000254329.1	IGHVII-60-1	-4.4	2.9e-05	0.0174	-0.44	-0.41	Kawasaki disease;	chr14:106769752	chr14:106637718~106637973:-
THYM	cis	rs1519814	0.696	rs7386139	ENSG00000254343.2	RP11-760H22.2	-4.4	2.9e-05	0.0174	-0.63	-0.41	Breast cancer;	chr8:120015180	chr8:120052180~120056201:+
THYM	cis	rs8067545	0.75	rs4924804	ENSG00000230528.6	NOS2P3	-4.4	2.9e-05	0.0174	-0.35	-0.41	Schizophrenia;	chr17:20088526	chr17:20436337~20447249:+
THYM	cis	rs11096990	0.855	rs2566173	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39151111	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2043102	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39151292	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2711986	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39152258	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.75	rs2465242	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39153796	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2465243	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39154036	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2566176	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39154373	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2566178	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39155194	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.819	rs2435528	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39155916	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2711933	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39156090	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2566179	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39156413	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2566180	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39157381	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2566181	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39157987	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.819	rs1367297	ENSG00000249685.1	RP11-360F5.3	-4.4	2.91e-05	0.0174	-0.41	-0.41	Cognitive function;	chr4:39159614	chr4:39133913~39135608:+
THYM	cis	rs5752326	1	rs2157586	ENSG00000261188.1	CTA-445C9.14	-4.4	2.91e-05	0.0174	-0.81	-0.41	Ischemic stroke;	chr22:26499095	chr22:26512537~26514568:+
THYM	cis	rs61270009	0.955	rs454693	ENSG00000247828.6	TMEM161B-AS1	4.4	2.91e-05	0.0175	0.34	0.41	Depressive symptoms;	chr5:88248396	chr5:88268895~88436685:+
THYM	cis	rs7178424	0.743	rs8032681	ENSG00000259251.2	RP11-643M14.1	-4.39	2.91e-05	0.0175	-0.42	-0.41	Height;	chr15:61870044	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.742	rs12908081	ENSG00000259251.2	RP11-643M14.1	-4.39	2.91e-05	0.0175	-0.42	-0.41	Height;	chr15:61870065	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.742	rs1981916	ENSG00000259251.2	RP11-643M14.1	-4.39	2.91e-05	0.0175	-0.42	-0.41	Height;	chr15:61879280	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.742	rs1981917	ENSG00000259251.2	RP11-643M14.1	-4.39	2.91e-05	0.0175	-0.42	-0.41	Height;	chr15:61879707	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.711	rs4283171	ENSG00000259251.2	RP11-643M14.1	-4.39	2.91e-05	0.0175	-0.42	-0.41	Height;	chr15:61880185	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.742	rs2414755	ENSG00000259251.2	RP11-643M14.1	-4.39	2.91e-05	0.0175	-0.42	-0.41	Height;	chr15:61880230	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.742	rs12915825	ENSG00000259251.2	RP11-643M14.1	-4.39	2.91e-05	0.0175	-0.42	-0.41	Height;	chr15:61883437	chr15:62060503~62062434:+
THYM	cis	rs4908768	0.501	rs6577513	ENSG00000232912.4	RP5-1115A15.1	4.39	2.92e-05	0.0175	0.4	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8642694	chr1:8424645~8434838:+
THYM	cis	rs11722228	0.964	rs10939614	ENSG00000261490.1	RP11-448G15.3	-4.39	2.92e-05	0.0175	-0.44	-0.41	Urate levels;Serum uric acid levels;Gout;	chr4:9924989	chr4:10068089~10073019:-
THYM	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-4.39	2.92e-05	0.0175	-0.51	-0.41	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
THYM	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-4.39	2.92e-05	0.0175	-0.44	-0.41	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
THYM	cis	rs4713118	0.516	rs7739216	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Parkinson's disease;	chr6:28112168	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs35512245	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Depression;	chr6:28112175	chr6:28053228~28054165:-
THYM	cis	rs853679	0.542	rs9393892	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Depression;	chr6:28113616	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9380055	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Depression;	chr6:28113851	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9368553	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Depression;	chr6:28114487	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9368554	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Depression;	chr6:28114933	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs4713137	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Depression;	chr6:28115743	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9348793	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Depression;	chr6:28116411	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.586	rs6905516	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Parkinson's disease;	chr6:28118700	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.586	rs6905522	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Parkinson's disease;	chr6:28118701	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.586	rs9468290	ENSG00000182477.5	OR2B8P	4.39	2.92e-05	0.0175	0.58	0.41	Parkinson's disease;	chr6:28119896	chr6:28053228~28054165:-
THYM	cis	rs3780486	0.505	rs10217267	ENSG00000225693.1	LAGE3P1	4.39	2.92e-05	0.0175	0.47	0.41	IgG glycosylation;	chr9:33146530	chr9:33019682~33020165:-
THYM	cis	rs3780486	0.505	rs959749	ENSG00000225693.1	LAGE3P1	4.39	2.92e-05	0.0175	0.47	0.41	IgG glycosylation;	chr9:33147860	chr9:33019682~33020165:-
THYM	cis	rs3780486	0.541	rs10738909	ENSG00000225693.1	LAGE3P1	4.39	2.92e-05	0.0175	0.47	0.41	IgG glycosylation;	chr9:33148836	chr9:33019682~33020165:-
THYM	cis	rs3780486	0.505	rs10758194	ENSG00000225693.1	LAGE3P1	4.39	2.92e-05	0.0175	0.47	0.41	IgG glycosylation;	chr9:33157421	chr9:33019682~33020165:-
THYM	cis	rs3780486	0.522	rs1328898	ENSG00000225693.1	LAGE3P1	4.39	2.92e-05	0.0175	0.47	0.41	IgG glycosylation;	chr9:33163273	chr9:33019682~33020165:-
THYM	cis	rs3780486	0.505	rs10813958	ENSG00000225693.1	LAGE3P1	4.39	2.92e-05	0.0175	0.47	0.41	IgG glycosylation;	chr9:33165987	chr9:33019682~33020165:-
THYM	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-4.39	2.92e-05	0.0175	-0.5	-0.41	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
THYM	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-4.39	2.93e-05	0.0175	-0.55	-0.41	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
THYM	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	4.39	2.93e-05	0.0176	0.39	0.41	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	4.39	2.93e-05	0.0176	0.39	0.41	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
THYM	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	4.39	2.93e-05	0.0176	0.33	0.41	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
THYM	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	4.39	2.93e-05	0.0176	0.44	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
THYM	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-4.39	2.93e-05	0.0176	-0.44	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
THYM	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	4.39	2.93e-05	0.0176	0.41	0.41	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
THYM	cis	rs6706785	0.66	rs2411921	ENSG00000196758.3	AC079612.1	4.39	2.93e-05	0.0176	0.38	0.41	Conotruncal heart defects;	chr2:239530030	chr2:239578301~239586094:+
THYM	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-4.39	2.94e-05	0.0176	-0.51	-0.41	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-4.39	2.94e-05	0.0176	-0.51	-0.41	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
THYM	cis	rs7178424	0.84	rs4774427	ENSG00000259251.2	RP11-643M14.1	4.39	2.94e-05	0.0176	0.44	0.41	Height;	chr15:61925245	chr15:62060503~62062434:+
THYM	cis	rs11017328	0.541	rs4561119	ENSG00000236303.2	RP11-540N6.1	-4.39	2.95e-05	0.0176	-0.59	-0.41	Conotruncal heart defects;	chr10:130498274	chr10:130439067~130483154:+
THYM	cis	rs11017328	0.5	rs4570502	ENSG00000236303.2	RP11-540N6.1	-4.39	2.95e-05	0.0176	-0.59	-0.41	Conotruncal heart defects;	chr10:130498557	chr10:130439067~130483154:+
THYM	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-4.39	2.95e-05	0.0176	-0.44	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
THYM	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-4.39	2.95e-05	0.0176	-0.44	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
THYM	cis	rs12908161	1	rs17600551	ENSG00000235370.6	DNM1P51	4.39	2.95e-05	0.0177	0.55	0.41	Schizophrenia;	chr15:84776027	chr15:84398316~84411701:-
THYM	cis	rs12908161	1	rs62019469	ENSG00000235370.6	DNM1P51	4.39	2.95e-05	0.0177	0.55	0.41	Schizophrenia;	chr15:84777989	chr15:84398316~84411701:-
THYM	cis	rs4760854	0.639	rs3863373	ENSG00000257815.4	RP11-611E13.2	4.39	2.95e-05	0.0177	0.32	0.41	IgG glycosylation;	chr12:70894616	chr12:69904033~70243360:-
THYM	cis	rs73198271	0.855	rs57301822	ENSG00000253893.2	FAM85B	4.39	2.95e-05	0.0177	0.61	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8167819~8226614:-
THYM	cis	rs12902680	0.706	rs1434684	ENSG00000259520.4	CTD-2651B20.3	-4.39	2.95e-05	0.0177	-0.43	-0.41	Neuroticism;	chr15:46176134	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12442716	ENSG00000259520.4	CTD-2651B20.3	4.39	2.95e-05	0.0177	0.43	0.41	Neuroticism;	chr15:46188676	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.677	rs28570540	ENSG00000259520.4	CTD-2651B20.3	4.39	2.95e-05	0.0177	0.43	0.41	Neuroticism;	chr15:46189983	chr15:45251580~45279251:-
THYM	cis	rs1061377	0.748	rs12506723	ENSG00000249685.1	RP11-360F5.3	4.39	2.95e-05	0.0177	0.4	0.41	Uric acid levels;	chr4:39103152	chr4:39133913~39135608:+
THYM	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-4.39	2.96e-05	0.0177	-0.52	-0.41	Pain;	chr19:21521677	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.874	rs2562408	ENSG00000268081.1	RP11-678G14.2	-4.39	2.96e-05	0.0177	-0.52	-0.41	Pain;	chr19:21527079	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.874	rs2562417	ENSG00000268081.1	RP11-678G14.2	-4.39	2.96e-05	0.0177	-0.52	-0.41	Pain;	chr19:21528400	chr19:21554640~21569237:-
THYM	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	4.39	2.96e-05	0.0177	0.49	0.41	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
THYM	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	4.39	2.96e-05	0.0177	0.41	0.41	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
THYM	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-4.39	2.96e-05	0.0177	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-4.39	2.96e-05	0.0177	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-4.39	2.96e-05	0.0177	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-4.39	2.96e-05	0.0177	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-4.39	2.96e-05	0.0177	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
THYM	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	4.39	2.96e-05	0.0177	0.47	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
THYM	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-4.39	2.97e-05	0.0177	-0.47	-0.41	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
THYM	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-4.39	2.97e-05	0.0178	-0.47	-0.41	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
THYM	cis	rs6121246	0.559	rs10439607	ENSG00000230613.1	HM13-AS1	4.39	2.97e-05	0.0178	0.55	0.41	Mean corpuscular hemoglobin;	chr20:31670738	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs6060652	ENSG00000230613.1	HM13-AS1	4.39	2.97e-05	0.0178	0.55	0.41	Mean corpuscular hemoglobin;	chr20:31679042	chr20:31567707~31573263:-
THYM	cis	rs2267681	0.544	rs6951759	ENSG00000240889.1	NDUFB2-AS1	-4.39	2.97e-05	0.0178	-0.51	-0.41	Cervical cancer;	chr7:139807769	chr7:140695336~140697077:-
THYM	cis	rs7927592	0.871	rs17603185	ENSG00000222339.1	AP000807.2	4.39	2.97e-05	0.0178	0.52	0.41	Total body bone mineral density;	chr11:68608773	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs2236708	ENSG00000222339.1	AP000807.2	4.39	2.97e-05	0.0178	0.52	0.41	Total body bone mineral density;	chr11:68610577	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs4988291	ENSG00000222339.1	AP000807.2	4.39	2.97e-05	0.0178	0.52	0.41	Total body bone mineral density;	chr11:68614139	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.871	rs12941	ENSG00000222339.1	AP000807.2	4.39	2.97e-05	0.0178	0.52	0.41	Total body bone mineral density;	chr11:68614725	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs11228293	ENSG00000222339.1	AP000807.2	4.39	2.97e-05	0.0178	0.52	0.41	Total body bone mineral density;	chr11:68617178	chr11:68505572~68505651:-
THYM	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	4.39	2.98e-05	0.0178	0.38	0.41	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
THYM	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	4.39	2.98e-05	0.0178	0.78	0.41	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
THYM	cis	rs4908760	0.864	rs6701331	ENSG00000232912.4	RP5-1115A15.1	4.39	2.98e-05	0.0178	0.42	0.41	Vitiligo;	chr1:8610147	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.827	rs7513420	ENSG00000232912.4	RP5-1115A15.1	4.39	2.98e-05	0.0178	0.42	0.41	Vitiligo;	chr1:8620985	chr1:8424645~8434838:+
THYM	cis	rs4835473	0.932	rs4305468	ENSG00000249741.2	RP11-673E1.3	4.39	2.98e-05	0.0178	0.35	0.41	Immature fraction of reticulocytes;	chr4:143987315	chr4:143911514~143912053:-
THYM	cis	rs7202877	0.61	rs468079	ENSG00000261783.1	RP11-252K23.2	4.39	2.98e-05	0.0178	0.54	0.41	Type 1 diabetes;Type 2 diabetes;	chr16:75394576	chr16:75379818~75381260:-
THYM	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-4.39	2.98e-05	0.0178	-0.44	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
THYM	cis	rs10129255	0.576	rs2157616	ENSG00000254329.1	IGHVII-60-1	4.39	2.99e-05	0.0179	0.36	0.41	Kawasaki disease;	chr14:106767802	chr14:106637718~106637973:-
THYM	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	4.39	2.99e-05	0.0179	0.61	0.41	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
THYM	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	4.39	2.99e-05	0.0179	0.5	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
THYM	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	4.39	2.99e-05	0.0179	0.5	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
THYM	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	4.39	2.99e-05	0.0179	0.48	0.41	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
THYM	cis	rs4554975	0.514	rs10785646	ENSG00000274723.1	RP11-618L22.1	4.39	2.99e-05	0.0179	0.32	0.41	Metabolite levels (small molecules and protein measures);	chr12:46957064	chr12:46970504~46972155:+
THYM	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	4.39	2.99e-05	0.0179	0.55	0.41	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	4.39	2.99e-05	0.0179	0.55	0.41	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
THYM	cis	rs397969	0.646	rs1638526	ENSG00000231645.2	KRT17P6	-4.39	2.99e-05	0.0179	-0.51	-0.41	Platelet count;	chr17:19945137	chr17:20512560~20517479:-
THYM	cis	rs10971721	0.643	rs7040130	ENSG00000227301.1	RP11-384P7.5	4.39	2.99e-05	0.0179	0.85	0.41	Body mass index;	chr9:33785075	chr9:33719690~33722555:+
THYM	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	4.39	2.99e-05	0.0179	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
THYM	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	4.39	2.99e-05	0.0179	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
THYM	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	4.39	2.99e-05	0.0179	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
THYM	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	4.39	2.99e-05	0.0179	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
THYM	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	4.39	2.99e-05	0.0179	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
THYM	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-4.39	2.99e-05	0.0179	-0.35	-0.41	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
THYM	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-4.39	3e-05	0.0179	-0.29	-0.41	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
THYM	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-4.39	3e-05	0.0179	-0.53	-0.41	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-4.39	3e-05	0.0179	-0.53	-0.41	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-4.39	3e-05	0.0179	-0.53	-0.41	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
THYM	cis	rs17685	0.753	rs2302435	ENSG00000280388.1	RP11-229D13.3	4.39	3e-05	0.0179	0.43	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76047669	chr7:76043977~76045963:-
THYM	cis	rs17685	0.725	rs2302436	ENSG00000280388.1	RP11-229D13.3	4.39	3e-05	0.0179	0.43	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76047670	chr7:76043977~76045963:-
THYM	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	4.39	3e-05	0.0179	0.51	0.41	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
THYM	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-4.39	3e-05	0.0179	-0.51	-0.41	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	4.39	3e-05	0.0179	0.51	0.41	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
THYM	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	4.39	3e-05	0.0179	0.51	0.41	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
THYM	cis	rs7927592	0.913	rs7106010	ENSG00000222339.1	AP000807.2	4.39	3e-05	0.0179	0.52	0.41	Total body bone mineral density;	chr11:68597744	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs3758643	ENSG00000222339.1	AP000807.2	4.39	3e-05	0.0179	0.52	0.41	Total body bone mineral density;	chr11:68599725	chr11:68505572~68505651:-
THYM	cis	rs728616	0.614	rs61860414	ENSG00000225484.5	NUTM2B-AS1	-4.39	3.01e-05	0.0179	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79663088~79826594:-
THYM	cis	rs1023500	0.573	rs133381	ENSG00000227370.1	RP4-669P10.19	4.39	3.01e-05	0.0179	0.48	0.41	Schizophrenia;	chr22:42074604	chr22:42132543~42132998:+
THYM	cis	rs10028773	0.632	rs34481394	ENSG00000245958.5	RP11-33B1.1	-4.39	3.01e-05	0.018	-0.35	-0.41	Educational attainment;	chr4:119327219	chr4:119454791~119552025:+
THYM	cis	rs10028773	0.666	rs35231872	ENSG00000245958.5	RP11-33B1.1	-4.39	3.01e-05	0.018	-0.35	-0.41	Educational attainment;	chr4:119327221	chr4:119454791~119552025:+
THYM	cis	rs10028773	0.7	rs35653026	ENSG00000245958.5	RP11-33B1.1	-4.39	3.01e-05	0.018	-0.35	-0.41	Educational attainment;	chr4:119327223	chr4:119454791~119552025:+
THYM	cis	rs8067545	0.75	rs6587215	ENSG00000230528.6	NOS2P3	-4.39	3.01e-05	0.018	-0.34	-0.41	Schizophrenia;	chr17:20077466	chr17:20436337~20447249:+
THYM	cis	rs8177876	0.749	rs804895	ENSG00000261838.4	RP11-303E16.6	-4.39	3.01e-05	0.018	-0.84	-0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81066108	chr16:81069854~81076598:+
THYM	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-4.39	3.02e-05	0.018	-0.35	-0.41	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
THYM	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	4.39	3.02e-05	0.018	0.48	0.41	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
THYM	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-4.39	3.02e-05	0.018	-0.4	-0.41	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
THYM	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	4.39	3.02e-05	0.018	0.42	0.41	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
THYM	cis	rs6782228	0.675	rs4443194	ENSG00000277250.1	Metazoa_SRP	-4.39	3.02e-05	0.018	-0.55	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.675	rs4857918	ENSG00000277250.1	Metazoa_SRP	-4.39	3.02e-05	0.018	-0.55	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128673681~128674021:-
THYM	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	4.38	3.03e-05	0.018	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
THYM	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	4.38	3.03e-05	0.018	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
THYM	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	4.38	3.03e-05	0.018	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
THYM	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	4.38	3.03e-05	0.018	0.28	0.41	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
THYM	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-4.38	3.03e-05	0.018	-0.46	-0.41	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-4.38	3.03e-05	0.018	-0.46	-0.41	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-4.38	3.03e-05	0.018	-0.46	-0.41	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-4.38	3.03e-05	0.018	-0.46	-0.41	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-4.38	3.03e-05	0.018	-0.46	-0.41	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
THYM	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	4.38	3.03e-05	0.0181	0.5	0.41	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
THYM	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	4.38	3.03e-05	0.0181	0.51	0.41	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	4.38	3.03e-05	0.0181	0.51	0.41	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
THYM	cis	rs7605378	1	rs769957	ENSG00000232732.8	AC073043.1	-4.38	3.03e-05	0.0181	-0.53	-0.41	Osteoporosis;	chr2:199830801	chr2:199867396~199911159:-
THYM	cis	rs7605378	1	rs769958	ENSG00000232732.8	AC073043.1	-4.38	3.03e-05	0.0181	-0.53	-0.41	Osteoporosis;	chr2:199831178	chr2:199867396~199911159:-
THYM	cis	rs131777	0.575	rs131760	ENSG00000205559.3	CHKB-AS1	-4.38	3.03e-05	0.0181	-0.42	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50583026~50583877:+
THYM	cis	rs935334	1	rs4903386	ENSG00000258454.1	RP11-361H10.3	4.38	3.04e-05	0.0181	0.53	0.41	Blood pressure;	chr14:76203315	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs2121075	ENSG00000258454.1	RP11-361H10.3	4.38	3.04e-05	0.0181	0.53	0.41	Blood pressure;	chr14:76209197	chr14:76235817~76263474:+
THYM	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	4.38	3.04e-05	0.0181	0.92	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
THYM	cis	rs9914578	1	rs10459917	ENSG00000236838.2	AC090617.1	-4.38	3.04e-05	0.0181	-0.62	-0.41	Body mass index;	chr17:2106458	chr17:2213697~2214414:+
THYM	cis	rs9914578	1	rs8082647	ENSG00000236838.2	AC090617.1	-4.38	3.04e-05	0.0181	-0.62	-0.41	Body mass index;	chr17:2107303	chr17:2213697~2214414:+
THYM	cis	rs9914578	1	rs9915112	ENSG00000236838.2	AC090617.1	4.38	3.04e-05	0.0181	0.62	0.41	Body mass index;	chr17:2104532	chr17:2213697~2214414:+
THYM	cis	rs9914578	1	rs62067978	ENSG00000236838.2	AC090617.1	4.38	3.04e-05	0.0181	0.62	0.41	Body mass index;	chr17:2109764	chr17:2213697~2214414:+
THYM	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-4.38	3.04e-05	0.0181	-0.55	-0.41	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
THYM	cis	rs8177876	0.749	rs935942	ENSG00000261838.4	RP11-303E16.6	-4.38	3.05e-05	0.0181	-0.83	-0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81069854~81076598:+
THYM	cis	rs12902680	0.706	rs12905848	ENSG00000259520.4	CTD-2651B20.3	4.38	3.05e-05	0.0182	0.43	0.41	Neuroticism;	chr15:46200185	chr15:45251580~45279251:-
THYM	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	4.38	3.05e-05	0.0182	0.61	0.41	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
THYM	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	4.38	3.05e-05	0.0182	0.61	0.41	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
THYM	cis	rs7560272	0.538	rs2012574	ENSG00000273245.1	RP11-434P11.2	-4.38	3.06e-05	0.0182	-0.49	-0.41	Schizophrenia;	chr2:73701239	chr2:73750256~73750786:-
THYM	cis	rs6040076	0.817	rs6104651	ENSG00000230506.1	RP11-416N4.4	4.38	3.06e-05	0.0182	0.46	0.41	Pulse pressure;Birth weight;	chr20:10723703	chr20:10173520~10196990:+
THYM	cis	rs4908769	0.624	rs2708630	ENSG00000232912.4	RP5-1115A15.1	-4.38	3.06e-05	0.0182	-0.44	-0.41	Allergy;	chr1:8387344	chr1:8424645~8434838:+
THYM	cis	rs301801	0.803	rs2661863	ENSG00000232912.4	RP5-1115A15.1	-4.38	3.06e-05	0.0182	-0.44	-0.41	Optic cup area;Vertical cup-disc ratio;	chr1:8392665	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.588	rs2784737	ENSG00000232912.4	RP5-1115A15.1	-4.38	3.06e-05	0.0182	-0.44	-0.41	Allergy;	chr1:8403116	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs2708632	ENSG00000232912.4	RP5-1115A15.1	-4.38	3.06e-05	0.0182	-0.44	-0.41	Allergy;	chr1:8404449	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs301791	ENSG00000232912.4	RP5-1115A15.1	-4.38	3.06e-05	0.0182	-0.44	-0.41	Allergy;	chr1:8408312	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs301796	ENSG00000232912.4	RP5-1115A15.1	4.38	3.06e-05	0.0182	0.44	0.41	Allergy;	chr1:8406670	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.587	rs301795	ENSG00000232912.4	RP5-1115A15.1	4.38	3.06e-05	0.0182	0.44	0.41	Allergy;	chr1:8407293	chr1:8424645~8434838:+
THYM	cis	rs4908769	0.624	rs301789	ENSG00000232912.4	RP5-1115A15.1	4.38	3.06e-05	0.0182	0.44	0.41	Allergy;	chr1:8409277	chr1:8424645~8434838:+
THYM	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	4.38	3.06e-05	0.0182	0.38	0.41	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
THYM	cis	rs2283792	1	rs3810610	ENSG00000228050.1	TOP3BP1	4.38	3.06e-05	0.0182	0.46	0.41	Multiple sclerosis;	chr22:21761209	chr22:22223187~22224566:-
THYM	cis	rs2283792	1	rs13943	ENSG00000228050.1	TOP3BP1	4.38	3.06e-05	0.0182	0.46	0.41	Multiple sclerosis;	chr22:21761913	chr22:22223187~22224566:-
THYM	cis	rs863345	0.604	rs12025831	ENSG00000236656.1	RP11-144L1.4	4.38	3.06e-05	0.0182	0.27	0.41	Pneumococcal bacteremia;	chr1:158526492	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs1117125	ENSG00000236656.1	RP11-144L1.4	4.38	3.06e-05	0.0182	0.27	0.41	Pneumococcal bacteremia;	chr1:158539606	chr1:158474454~158494886:-
THYM	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	4.38	3.06e-05	0.0182	0.31	0.41	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
THYM	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-4.38	3.07e-05	0.0183	-0.36	-0.41	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-4.38	3.07e-05	0.0183	-0.36	-0.41	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
THYM	cis	rs6570726	0.526	rs9403699	ENSG00000235652.6	RP11-545I5.3	4.38	3.07e-05	0.0183	0.29	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145409549	chr6:145799409~145886585:+
THYM	cis	rs12908161	1	rs35808647	ENSG00000235370.6	DNM1P51	4.38	3.07e-05	0.0183	0.55	0.41	Schizophrenia;	chr15:84834210	chr15:84398316~84411701:-
THYM	cis	rs3811273	0.614	rs7153774	ENSG00000211816.2	TRAV38-1	4.38	3.07e-05	0.0183	0.33	0.41	Periodontal disease-related phenotypes;	chr14:22263044	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.568	rs4981417	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22261486	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs12589726	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22262396	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs12587104	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22262556	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7150591	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22262926	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7154715	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22263528	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs7156203	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22263640	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs10149605	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22263646	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.667	rs10152083	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22263764	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.73	rs10152089	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22263774	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs9944149	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22263875	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs9944066	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264001	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs9943971	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264098	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs9943999	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264135	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs9944001	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264193	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.504	rs9943972	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264267	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.554	rs12586764	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264564	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs12588618	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264645	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs8003694	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264736	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs4982592	ENSG00000211816.2	TRAV38-1	-4.38	3.07e-05	0.0183	-0.33	-0.41	Periodontal disease-related phenotypes;	chr14:22264791	chr14:22271968~22272563:+
THYM	cis	rs7560272	0.538	rs12233115	ENSG00000273245.1	RP11-434P11.2	-4.38	3.08e-05	0.0183	-0.5	-0.41	Schizophrenia;	chr2:73704764	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.538	rs11126414	ENSG00000273245.1	RP11-434P11.2	-4.38	3.08e-05	0.0183	-0.5	-0.41	Schizophrenia;	chr2:73704917	chr2:73750256~73750786:-
THYM	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-4.38	3.08e-05	0.0183	-0.41	-0.41	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
THYM	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	4.38	3.08e-05	0.0183	0.46	0.41	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-4.38	3.08e-05	0.0183	-0.46	-0.41	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
THYM	cis	rs8056742	0.908	rs55757943	ENSG00000261243.1	RP11-517C16.4	4.38	3.08e-05	0.0183	0.68	0.41	Amyotrophic lateral sclerosis;	chr16:85060655	chr16:84495599~84497495:+
THYM	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	4.38	3.08e-05	0.0183	0.52	0.41	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	4.38	3.08e-05	0.0183	0.52	0.41	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
THYM	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	4.38	3.08e-05	0.0183	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
THYM	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	4.38	3.09e-05	0.0183	0.52	0.41	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
THYM	cis	rs4908760	0.73	rs10779704	ENSG00000232912.4	RP5-1115A15.1	4.38	3.09e-05	0.0183	0.42	0.41	Vitiligo;	chr1:8633478	chr1:8424645~8434838:+
THYM	cis	rs4853012	0.838	rs72915068	ENSG00000272183.1	RP11-523H20.3	4.38	3.09e-05	0.0183	0.55	0.41	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74501717~74502365:+
THYM	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	4.38	3.09e-05	0.0183	0.55	0.41	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	4.38	3.09e-05	0.0183	0.55	0.41	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
THYM	cis	rs904251	0.605	rs4257849	ENSG00000279942.1	RP1-153P14.7	-4.38	3.09e-05	0.0184	-0.6	-0.41	Cognitive performance;	chr6:37443193	chr6:37567716~37571460:+
THYM	cis	rs904251	0.686	rs1224128	ENSG00000279942.1	RP1-153P14.7	-4.38	3.09e-05	0.0184	-0.6	-0.41	Cognitive performance;	chr6:37447900	chr6:37567716~37571460:+
THYM	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	4.38	3.09e-05	0.0184	0.53	0.41	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	4.38	3.09e-05	0.0184	0.53	0.41	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
THYM	cis	rs1023500	0.573	rs133377	ENSG00000227370.1	RP4-669P10.19	4.38	3.09e-05	0.0184	0.48	0.41	Schizophrenia;	chr22:42070946	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.551	rs2859438	ENSG00000227370.1	RP4-669P10.19	4.38	3.09e-05	0.0184	0.48	0.41	Schizophrenia;	chr22:42070976	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs4822088	ENSG00000227370.1	RP4-669P10.19	4.38	3.09e-05	0.0184	0.48	0.41	Schizophrenia;	chr22:42074585	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs2269524	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Schizophrenia;	chr22:42079699	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs6002592	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Schizophrenia;	chr22:42080750	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs4147638	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002597	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002603	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002605	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs6002616	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs7364293	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42132543~42132998:+
THYM	cis	rs3020736	0.5	rs8143153	ENSG00000227370.1	RP4-669P10.19	-4.38	3.09e-05	0.0184	-0.48	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42132543~42132998:+
THYM	cis	rs1023500	0.573	rs8135801	ENSG00000227370.1	RP4-669P10.19	-4.38	3.1e-05	0.0184	-0.49	-0.41	Schizophrenia;	chr22:42079564	chr22:42132543~42132998:+
THYM	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-4.38	3.1e-05	0.0184	-0.55	-0.41	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
THYM	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-4.38	3.1e-05	0.0184	-0.55	-0.41	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
THYM	cis	rs995834	0.622	rs4805188	ENSG00000267243.4	AC005307.3	-4.38	3.1e-05	0.0184	-0.4	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400780	chr19:28435388~28727777:-
THYM	cis	rs995834	0.585	rs4806363	ENSG00000267243.4	AC005307.3	-4.38	3.1e-05	0.0184	-0.4	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28400810	chr19:28435388~28727777:-
THYM	cis	rs10829156	0.732	rs7075678	ENSG00000225527.1	RP11-383B4.4	-4.38	3.1e-05	0.0184	-0.54	-0.41	Sudden cardiac arrest;	chr10:18585174	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.786	rs7093907	ENSG00000225527.1	RP11-383B4.4	-4.38	3.1e-05	0.0184	-0.54	-0.41	Sudden cardiac arrest;	chr10:18587225	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.66	rs4338439	ENSG00000225527.1	RP11-383B4.4	-4.38	3.1e-05	0.0184	-0.54	-0.41	Sudden cardiac arrest;	chr10:18594220	chr10:18531849~18533336:-
THYM	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-4.38	3.1e-05	0.0184	-0.45	-0.41	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
THYM	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	-4.38	3.11e-05	0.0184	-0.48	-0.41	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
THYM	cis	rs3020736	0.519	rs5996116	ENSG00000227370.1	RP4-669P10.19	-4.38	3.11e-05	0.0184	-0.49	-0.41	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42132543~42132998:+
THYM	cis	rs561341	0.714	rs75861674	ENSG00000265798.5	RP11-271K11.5	4.38	3.11e-05	0.0185	0.49	0.41	Hip circumference adjusted for BMI;	chr17:31977298	chr17:31038575~31059121:-
THYM	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	4.38	3.11e-05	0.0185	0.5	0.41	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
THYM	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	4.38	3.12e-05	0.0185	0.47	0.41	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
THYM	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-4.38	3.12e-05	0.0185	-0.6	-0.41	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
THYM	cis	rs9309473	0.5	rs6546862	ENSG00000273245.1	RP11-434P11.2	-4.38	3.12e-05	0.0185	-0.45	-0.41	Metabolite levels;	chr2:73633221	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs4852951	ENSG00000273245.1	RP11-434P11.2	-4.38	3.12e-05	0.0185	-0.45	-0.41	Metabolite levels;	chr2:73642669	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs12991161	ENSG00000273245.1	RP11-434P11.2	-4.38	3.12e-05	0.0185	-0.45	-0.41	Metabolite levels;	chr2:73644244	chr2:73750256~73750786:-
THYM	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-4.38	3.12e-05	0.0185	-0.54	-0.41	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
THYM	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	4.38	3.12e-05	0.0185	0.45	0.41	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
THYM	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	4.38	3.13e-05	0.0185	0.47	0.41	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
THYM	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	4.38	3.13e-05	0.0185	0.52	0.41	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	4.38	3.13e-05	0.0185	0.52	0.41	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	4.38	3.13e-05	0.0185	0.52	0.41	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	4.38	3.13e-05	0.0185	0.52	0.41	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	4.38	3.13e-05	0.0185	0.52	0.41	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
THYM	cis	rs1023500	0.573	rs2413666	ENSG00000227370.1	RP4-669P10.19	4.38	3.13e-05	0.0185	0.49	0.41	Schizophrenia;	chr22:42063618	chr22:42132543~42132998:+
THYM	cis	rs11096990	0.821	rs2711991	ENSG00000249685.1	RP11-360F5.3	-4.38	3.13e-05	0.0186	-0.41	-0.41	Cognitive function;	chr4:39149733	chr4:39133913~39135608:+
THYM	cis	rs9420	0.528	rs11229077	ENSG00000265566.2	RN7SL605P	4.38	3.14e-05	0.0186	0.55	0.41	Schizophrenia;	chr11:57631599	chr11:57528085~57528365:-
THYM	cis	rs9420	0.528	rs7117896	ENSG00000265566.2	RN7SL605P	-4.38	3.14e-05	0.0186	-0.55	-0.41	Schizophrenia;	chr11:57621078	chr11:57528085~57528365:-
THYM	cis	rs9420	0.528	rs10896632	ENSG00000265566.2	RN7SL605P	-4.38	3.14e-05	0.0186	-0.55	-0.41	Schizophrenia;	chr11:57622829	chr11:57528085~57528365:-
THYM	cis	rs9420	0.528	rs11229080	ENSG00000265566.2	RN7SL605P	-4.38	3.14e-05	0.0186	-0.55	-0.41	Schizophrenia;	chr11:57632038	chr11:57528085~57528365:-
THYM	cis	rs853679	0.517	rs1340004	ENSG00000182477.5	OR2B8P	4.38	3.14e-05	0.0186	0.62	0.41	Depression;	chr6:28135913	chr6:28053228~28054165:-
THYM	cis	rs6964833	0.554	rs2527366	ENSG00000123965.13	PMS2P5	-4.38	3.14e-05	0.0186	-0.45	-0.41	Menarche (age at onset);	chr7:74684615	chr7:74894116~74897835:+
THYM	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-4.38	3.14e-05	0.0186	-0.3	-0.41	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
THYM	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	4.38	3.14e-05	0.0186	0.59	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
THYM	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	4.38	3.14e-05	0.0186	0.42	0.41	Temperament;	chr17:13996939	chr17:14024514~14025488:+
THYM	cis	rs9926296	0.744	rs154657	ENSG00000274627.1	RP11-104N10.2	-4.38	3.14e-05	0.0186	-0.49	-0.41	Vitiligo;	chr16:89641688	chr16:89516797~89522217:+
THYM	cis	rs728616	0.614	rs1998374	ENSG00000225484.5	NUTM2B-AS1	-4.38	3.14e-05	0.0186	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79942966	chr10:79663088~79826594:-
THYM	cis	rs728616	0.614	rs10887199	ENSG00000225484.5	NUTM2B-AS1	-4.38	3.14e-05	0.0186	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79943078	chr10:79663088~79826594:-
THYM	cis	rs3753275	0.684	rs1826583	ENSG00000230679.1	ENO1-AS1	4.37	3.14e-05	0.0186	0.48	0.41	Educational attainment;	chr1:8818422	chr1:8878835~8879894:+
THYM	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	4.37	3.14e-05	0.0186	0.33	0.41	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
THYM	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-4.37	3.14e-05	0.0186	-0.55	-0.41	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
THYM	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	4.37	3.14e-05	0.0186	0.54	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-4.37	3.14e-05	0.0186	-0.54	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-4.37	3.14e-05	0.0186	-0.54	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
THYM	cis	rs1519814	0.696	rs4871031	ENSG00000254343.2	RP11-760H22.2	-4.37	3.15e-05	0.0186	-0.63	-0.41	Breast cancer;	chr8:120019538	chr8:120052180~120056201:+
THYM	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	4.37	3.15e-05	0.0186	0.38	0.41	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
THYM	cis	rs733592	0.599	rs12819124	ENSG00000240399.1	RP1-228P16.1	4.37	3.15e-05	0.0186	0.38	0.41	Plateletcrit;	chr12:48015271	chr12:48054813~48055591:-
THYM	cis	rs7223966	1	rs13380863	ENSG00000240280.5	TCAM1P	-4.37	3.15e-05	0.0187	-0.63	-0.41	Hip circumference adjusted for BMI;Body mass index;	chr17:63703433	chr17:63849292~63864379:+
THYM	cis	rs2562456	0.72	rs6511250	ENSG00000268081.1	RP11-678G14.2	-4.37	3.16e-05	0.0187	-0.52	-0.41	Pain;	chr19:21473244	chr19:21554640~21569237:-
THYM	cis	rs4908760	0.864	rs12136766	ENSG00000232912.4	RP5-1115A15.1	4.37	3.16e-05	0.0187	0.41	0.41	Vitiligo;	chr1:8603762	chr1:8424645~8434838:+
THYM	cis	rs7617773	0.925	rs35942721	ENSG00000228638.1	FCF1P2	-4.37	3.16e-05	0.0187	-0.45	-0.41	Coronary artery disease;	chr3:48131579	chr3:48290793~48291375:-
THYM	cis	rs3738443	0.678	rs6680707	ENSG00000227671.4	RP11-488L18.4	-4.37	3.16e-05	0.0187	-0.24	-0.41	Alcohol dependence;	chr1:247213648	chr1:247189851~247210856:-
THYM	cis	rs4835473	0.9	rs71612420	ENSG00000249741.2	RP11-673E1.3	4.37	3.16e-05	0.0187	0.35	0.41	Immature fraction of reticulocytes;	chr4:143779107	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4835013	ENSG00000249741.2	RP11-673E1.3	-4.37	3.16e-05	0.0187	-0.35	-0.41	Immature fraction of reticulocytes;	chr4:143748485	chr4:143911514~143912053:-
THYM	cis	rs1023500	0.596	rs133369	ENSG00000227370.1	RP4-669P10.19	4.37	3.17e-05	0.0187	0.48	0.41	Schizophrenia;	chr22:42067810	chr22:42132543~42132998:+
THYM	cis	rs9907295	0.688	rs4796135	ENSG00000270977.1	AC015849.16	-4.37	3.17e-05	0.0187	-0.61	-0.41	Fibroblast growth factor basic levels;	chr17:35924236	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.688	rs4796136	ENSG00000270977.1	AC015849.16	-4.37	3.17e-05	0.0187	-0.61	-0.41	Fibroblast growth factor basic levels;	chr17:35924397	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.688	rs4796137	ENSG00000270977.1	AC015849.16	-4.37	3.17e-05	0.0187	-0.61	-0.41	Fibroblast growth factor basic levels;	chr17:35924448	chr17:35893707~35911023:-
THYM	cis	rs12736701	0.677	rs75540220	ENSG00000226084.5	RP4-706A16.3	4.37	3.17e-05	0.0187	0.94	0.41	Type 2 diabetes (age of onset);	chr1:77404323	chr1:77129114~77129668:+
THYM	cis	rs12736701	0.572	rs76328008	ENSG00000226084.5	RP4-706A16.3	4.37	3.17e-05	0.0187	0.94	0.41	Type 2 diabetes (age of onset);	chr1:77404327	chr1:77129114~77129668:+
THYM	cis	rs4835473	0.932	rs6813011	ENSG00000249741.2	RP11-673E1.3	-4.37	3.17e-05	0.0187	-0.35	-0.41	Immature fraction of reticulocytes;	chr4:143914496	chr4:143911514~143912053:-
THYM	cis	rs494459	0.536	rs57719838	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118854014	chr11:118791254~118793137:+
THYM	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118855233	chr11:118791254~118793137:+
THYM	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118855938	chr11:118791254~118793137:+
THYM	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118856460	chr11:118791254~118793137:+
THYM	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118856623	chr11:118791254~118793137:+
THYM	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118857611	chr11:118791254~118793137:+
THYM	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118859432	chr11:118791254~118793137:+
THYM	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118860890	chr11:118791254~118793137:+
THYM	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-4.37	3.17e-05	0.0187	-0.29	-0.41	Height;	chr11:118861053	chr11:118791254~118793137:+
THYM	cis	rs4908760	0.832	rs11121209	ENSG00000232912.4	RP5-1115A15.1	4.37	3.17e-05	0.0187	0.41	0.41	Vitiligo;	chr1:8626803	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.864	rs6674832	ENSG00000232912.4	RP5-1115A15.1	4.37	3.17e-05	0.0187	0.41	0.41	Vitiligo;	chr1:8631820	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.864	rs1463052	ENSG00000232912.4	RP5-1115A15.1	4.37	3.17e-05	0.0187	0.41	0.41	Vitiligo;	chr1:8641172	chr1:8424645~8434838:+
THYM	cis	rs9879311	0.966	rs4684684	ENSG00000240288.6	GHRLOS	4.37	3.17e-05	0.0187	0.43	0.41	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369660	chr3:10285754~10293449:+
THYM	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	4.37	3.17e-05	0.0187	0.43	0.41	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
THYM	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	4.37	3.17e-05	0.0187	0.43	0.41	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
THYM	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	4.37	3.17e-05	0.0187	0.55	0.41	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
THYM	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	4.37	3.18e-05	0.0188	0.5	0.41	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
THYM	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	4.37	3.18e-05	0.0188	0.5	0.41	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
THYM	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	4.37	3.18e-05	0.0188	0.61	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
THYM	cis	rs13160562	0.666	rs28096	ENSG00000272109.1	CTD-2260A17.3	-4.37	3.18e-05	0.0188	-0.52	-0.41	Alcohol dependence;	chr5:96773540	chr5:96804353~96806105:+
THYM	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	4.37	3.18e-05	0.0188	0.65	0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
THYM	cis	rs3753275	0.624	rs7555126	ENSG00000230679.1	ENO1-AS1	4.37	3.18e-05	0.0188	0.49	0.41	Educational attainment;	chr1:8811426	chr1:8878835~8879894:+
THYM	cis	rs6696239	0.513	rs2018828	ENSG00000227711.2	RP11-275O4.5	4.37	3.18e-05	0.0188	0.37	0.41	Height;	chr1:227508301	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs2018654	ENSG00000227711.2	RP11-275O4.5	4.37	3.18e-05	0.0188	0.37	0.41	Hip circumference adjusted for BMI;	chr1:227508332	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs903690	ENSG00000227711.2	RP11-275O4.5	4.37	3.18e-05	0.0188	0.37	0.41	Height;	chr1:227534009	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs7539914	ENSG00000227711.2	RP11-275O4.5	4.37	3.18e-05	0.0188	0.37	0.41	Hip circumference adjusted for BMI;	chr1:227536210	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs7528094	ENSG00000227711.2	RP11-275O4.5	-4.37	3.18e-05	0.0188	-0.37	-0.41	Height;	chr1:227548538	chr1:227509028~227520477:-
THYM	cis	rs7583236	0.5	rs6728352	ENSG00000179818.12	PCBP1-AS1	-4.37	3.18e-05	0.0188	-0.76	-0.41	Obesity-related traits;	chr2:70116300	chr2:69962263~70103220:-
THYM	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-4.37	3.19e-05	0.0188	-0.43	-0.41	Temperament;	chr17:14015466	chr17:14024514~14025488:+
THYM	cis	rs1550115	0.524	rs13416733	ENSG00000271936.1	RP11-443B20.1	-4.37	3.19e-05	0.0188	-0.35	-0.41	Coronary artery disease;	chr2:24833630	chr2:24825610~24826717:+
THYM	cis	rs2115630	0.967	rs8027779	ENSG00000275120.1	RP11-182J1.17	-4.37	3.19e-05	0.0188	-0.49	-0.41	P wave terminal force;	chr15:84712154	chr15:84599434~84606463:-
THYM	cis	rs3780486	0.505	rs7868663	ENSG00000225693.1	LAGE3P1	4.37	3.19e-05	0.0188	0.48	0.41	IgG glycosylation;	chr9:33141231	chr9:33019682~33020165:-
THYM	cis	rs4908760	0.792	rs11121215	ENSG00000232912.4	RP5-1115A15.1	4.37	3.19e-05	0.0188	0.39	0.41	Vitiligo;	chr1:8673069	chr1:8424645~8434838:+
THYM	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	4.37	3.19e-05	0.0188	0.53	0.41	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
THYM	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	4.37	3.19e-05	0.0188	0.53	0.41	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
THYM	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	4.37	3.19e-05	0.0188	0.53	0.41	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
THYM	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	4.37	3.19e-05	0.0188	0.5	0.41	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
THYM	cis	rs4591358	0.608	rs72927762	ENSG00000223466.1	AC064834.2	-4.37	3.19e-05	0.0188	-0.64	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544921	chr2:195533035~195538681:+
THYM	cis	rs2267681	0.603	rs2267679	ENSG00000240889.1	NDUFB2-AS1	-4.37	3.2e-05	0.0189	-0.51	-0.41	Cervical cancer;	chr7:139839419	chr7:140695336~140697077:-
THYM	cis	rs2267681	0.603	rs12534299	ENSG00000240889.1	NDUFB2-AS1	4.37	3.2e-05	0.0189	0.51	0.41	Cervical cancer;	chr7:139838723	chr7:140695336~140697077:-
THYM	cis	rs7178424	0.875	rs28411984	ENSG00000259251.2	RP11-643M14.1	4.37	3.2e-05	0.0189	0.44	0.41	Height;	chr15:61929393	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.84	rs11071642	ENSG00000259251.2	RP11-643M14.1	-4.37	3.2e-05	0.0189	-0.44	-0.41	Height;	chr15:61937157	chr15:62060503~62062434:+
THYM	cis	rs4276643	0.522	rs4732788	ENSG00000253875.1	RP11-16P20.3	4.37	3.21e-05	0.0189	0.35	0.41	Low vWF levels;	chr8:27922451	chr8:27733338~27756426:+
THYM	cis	rs863345	0.565	rs7551497	ENSG00000236656.1	RP11-144L1.4	4.37	3.21e-05	0.0189	0.26	0.41	Pneumococcal bacteremia;	chr1:158475135	chr1:158474454~158494886:-
THYM	cis	rs863345	0.527	rs7514555	ENSG00000236656.1	RP11-144L1.4	4.37	3.21e-05	0.0189	0.26	0.41	Pneumococcal bacteremia;	chr1:158475348	chr1:158474454~158494886:-
THYM	cis	rs863345	0.565	rs2220633	ENSG00000236656.1	RP11-144L1.4	4.37	3.21e-05	0.0189	0.26	0.41	Pneumococcal bacteremia;	chr1:158475482	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264976	ENSG00000236656.1	RP11-144L1.4	4.37	3.21e-05	0.0189	0.26	0.41	Pneumococcal bacteremia;	chr1:158477137	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264977	ENSG00000236656.1	RP11-144L1.4	4.37	3.21e-05	0.0189	0.26	0.41	Pneumococcal bacteremia;	chr1:158478062	chr1:158474454~158494886:-
THYM	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
THYM	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	4.37	3.21e-05	0.0189	0.54	0.41	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
THYM	cis	rs7242404	0.527	rs34946503	ENSG00000260302.1	RP11-973H7.1	4.37	3.21e-05	0.0189	0.29	0.41	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12756232	chr18:12774651~12775923:-
THYM	cis	rs9907295	0.71	rs28912068	ENSG00000270977.1	AC015849.16	-4.37	3.21e-05	0.0189	-0.64	-0.41	Fibroblast growth factor basic levels;	chr17:35881967	chr17:35893707~35911023:-
THYM	cis	rs71281886	1	rs71281886	ENSG00000228638.1	FCF1P2	-4.37	3.22e-05	0.0189	-0.45	-0.41	Breast cancer;	chr3:48311088	chr3:48290793~48291375:-
THYM	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	4.37	3.22e-05	0.0189	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-4.37	3.22e-05	0.0189	-0.6	-0.41	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	4.37	3.22e-05	0.0189	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	4.37	3.22e-05	0.0189	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	4.37	3.22e-05	0.0189	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	4.37	3.22e-05	0.0189	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
THYM	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	4.37	3.22e-05	0.0189	0.4	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
THYM	cis	rs11139399	0.613	rs1471723	ENSG00000233926.1	RP11-154D17.1	-4.37	3.22e-05	0.0189	-0.51	-0.41	Hippocampal atrophy;	chr9:81722132	chr9:81689713~81776900:+
THYM	cis	rs11139399	0.552	rs10867800	ENSG00000233926.1	RP11-154D17.1	-4.37	3.22e-05	0.0189	-0.51	-0.41	Hippocampal atrophy;	chr9:81722438	chr9:81689713~81776900:+
THYM	cis	rs1550576	0.568	rs12594689	ENSG00000274719.1	RP11-86K22.2	4.37	3.22e-05	0.019	0.79	0.41	Hypertension;	chr15:57922184	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs12595264	ENSG00000274719.1	RP11-86K22.2	4.37	3.22e-05	0.019	0.79	0.41	Hypertension;	chr15:57922790	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs56280454	ENSG00000274719.1	RP11-86K22.2	4.37	3.22e-05	0.019	0.79	0.41	Hypertension;	chr15:57923078	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs35912910	ENSG00000274719.1	RP11-86K22.2	4.37	3.22e-05	0.019	0.79	0.41	Hypertension;	chr15:57924016	chr15:57990217~57990636:-
THYM	cis	rs8067545	0.641	rs119672	ENSG00000231645.2	KRT17P6	-4.37	3.22e-05	0.019	-0.49	-0.41	Schizophrenia;	chr17:19915288	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.641	rs203466	ENSG00000231645.2	KRT17P6	4.37	3.22e-05	0.019	0.49	0.41	Schizophrenia;	chr17:19906640	chr17:20512560~20517479:-
THYM	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	4.37	3.22e-05	0.019	0.54	0.41	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
THYM	cis	rs7560272	0.538	rs17434655	ENSG00000163016.8	ALMS1P	4.37	3.23e-05	0.019	0.51	0.41	Schizophrenia;	chr2:73695962	chr2:73644919~73685576:+
THYM	cis	rs12908161	1	rs12903134	ENSG00000275120.1	RP11-182J1.17	4.37	3.23e-05	0.019	0.56	0.41	Schizophrenia;	chr15:84794468	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs35726233	ENSG00000275120.1	RP11-182J1.17	4.37	3.23e-05	0.019	0.56	0.41	Schizophrenia;	chr15:84794569	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs35960805	ENSG00000275120.1	RP11-182J1.17	4.37	3.23e-05	0.019	0.56	0.41	Schizophrenia;	chr15:84800749	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs12912388	ENSG00000275120.1	RP11-182J1.17	4.37	3.23e-05	0.019	0.56	0.41	Schizophrenia;	chr15:84801319	chr15:84599434~84606463:-
THYM	cis	rs1642645	0.793	rs7546128	ENSG00000228452.1	RP5-994D16.9	-4.37	3.23e-05	0.019	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42007988	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs3856259	ENSG00000228452.1	RP5-994D16.9	-4.37	3.23e-05	0.019	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42009832	chr1:42775813~42776790:-
THYM	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-4.37	3.23e-05	0.019	-0.49	-0.41	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
THYM	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	4.37	3.23e-05	0.019	0.49	0.41	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
THYM	cis	rs17253792	0.558	rs10083353	ENSG00000186615.9	KTN1-AS1	-4.37	3.23e-05	0.019	-0.79	-0.41	Putamen volume;	chr14:55599652	chr14:55499278~55580110:-
THYM	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-4.37	3.24e-05	0.019	-0.4	-0.41	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-4.37	3.24e-05	0.019	-0.4	-0.41	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-4.37	3.24e-05	0.019	-0.4	-0.41	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
THYM	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-4.37	3.24e-05	0.019	-0.4	-0.41	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
THYM	cis	rs1595825	0.891	rs4422151	ENSG00000222017.1	AC011997.1	-4.37	3.24e-05	0.0191	-0.45	-0.41	Ulcerative colitis;	chr2:197679459	chr2:197693106~197774823:+
THYM	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-4.37	3.25e-05	0.0191	-0.72	-0.41	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
THYM	cis	rs3812049	0.784	rs2250127	ENSG00000245937.6	LINC01184	-4.37	3.25e-05	0.0191	-0.43	-0.41	Lymphocyte counts;Red cell distribution width;	chr5:128053152	chr5:127940426~128083172:-
THYM	cis	rs7560272	0.538	rs2001436	ENSG00000163016.8	ALMS1P	-4.37	3.25e-05	0.0191	-0.52	-0.41	Schizophrenia;	chr2:73701838	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.512	rs12998980	ENSG00000163016.8	ALMS1P	-4.37	3.25e-05	0.0191	-0.52	-0.41	Schizophrenia;	chr2:73703599	chr2:73644919~73685576:+
THYM	cis	rs9527	1	rs12416687	ENSG00000272933.1	RP11-47A8.5	4.37	3.25e-05	0.0191	0.47	0.41	Arsenic metabolism;	chr10:102869254	chr10:102642792~102644140:-
THYM	cis	rs4554975	0.514	rs7963326	ENSG00000274723.1	RP11-618L22.1	-4.37	3.25e-05	0.0191	-0.33	-0.41	Metabolite levels (small molecules and protein measures);	chr12:46908278	chr12:46970504~46972155:+
THYM	cis	rs42235	0.571	rs42042	ENSG00000221520.1	MIR1285-1	-4.37	3.25e-05	0.0191	-0.3	-0.41	Height;Hip circumference adjusted for BMI;	chr7:92617798	chr7:92204015~92204098:-
THYM	cis	rs4554975	0.514	rs10881009	ENSG00000274723.1	RP11-618L22.1	-4.37	3.26e-05	0.0191	-0.33	-0.41	Metabolite levels (small molecules and protein measures);	chr12:46906861	chr12:46970504~46972155:+
THYM	cis	rs7178424	0.846	rs13379492	ENSG00000259251.2	RP11-643M14.1	-4.37	3.26e-05	0.0191	-0.44	-0.41	Height;	chr15:61892437	chr15:62060503~62062434:+
THYM	cis	rs4554975	0.514	rs7295618	ENSG00000274723.1	RP11-618L22.1	-4.36	3.26e-05	0.0192	-0.34	-0.41	Metabolite levels (small molecules and protein measures);	chr12:46925802	chr12:46970504~46972155:+
THYM	cis	rs34792	0.637	rs1684547	ENSG00000262380.1	CTB-193M12.3	4.36	3.26e-05	0.0192	0.51	0.41	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15480604	chr16:15683290~15684570:+
THYM	cis	rs453301	0.686	rs17702602	ENSG00000253893.2	FAM85B	4.36	3.27e-05	0.0192	0.52	0.41	Joint mobility (Beighton score);	chr8:9051086	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.813	rs56007835	ENSG00000253893.2	FAM85B	4.36	3.27e-05	0.0192	0.64	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8167819~8226614:-
THYM	cis	rs6710503	0.711	rs62140562	ENSG00000271936.1	RP11-443B20.1	-4.36	3.27e-05	0.0192	-0.28	-0.41	Lung cancer in ever smokers;Breast cancer;	chr2:24798168	chr2:24825610~24826717:+
THYM	cis	rs3780486	0.505	rs1411609	ENSG00000225693.1	LAGE3P1	4.36	3.28e-05	0.0192	0.48	0.41	IgG glycosylation;	chr9:33137305	chr9:33019682~33020165:-
THYM	cis	rs6964833	0.554	rs2527367	ENSG00000123965.13	PMS2P5	-4.36	3.28e-05	0.0192	-0.46	-0.41	Menarche (age at onset);	chr7:74684804	chr7:74894116~74897835:+
THYM	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-4.36	3.28e-05	0.0193	-0.47	-0.41	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-4.36	3.28e-05	0.0193	-0.47	-0.41	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	4.36	3.28e-05	0.0193	0.47	0.41	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	4.36	3.28e-05	0.0193	0.47	0.41	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
THYM	cis	rs10129255	0.5	rs8021941	ENSG00000253703.1	IGHV1-68	-4.36	3.28e-05	0.0193	-0.45	-0.41	Kawasaki disease;	chr14:106781490	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs10142931	ENSG00000253703.1	IGHV1-68	-4.36	3.28e-05	0.0193	-0.45	-0.41	Kawasaki disease;	chr14:106782288	chr14:106703852~106704146:-
THYM	cis	rs12701220	0.817	rs59471534	ENSG00000229043.2	AC091729.9	-4.36	3.28e-05	0.0193	-0.67	-0.41	Bronchopulmonary dysplasia;	chr7:1045588	chr7:1160374~1165267:+
THYM	cis	rs12908161	0.959	rs34342559	ENSG00000235370.6	DNM1P51	4.36	3.28e-05	0.0193	0.55	0.41	Schizophrenia;	chr15:84788040	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.959	rs62019472	ENSG00000235370.6	DNM1P51	4.36	3.28e-05	0.0193	0.55	0.41	Schizophrenia;	chr15:84788262	chr15:84398316~84411701:-
THYM	cis	rs12908161	0.959	rs35557864	ENSG00000235370.6	DNM1P51	4.36	3.28e-05	0.0193	0.55	0.41	Schizophrenia;	chr15:84788398	chr15:84398316~84411701:-
THYM	cis	rs7178424	0.711	rs11635569	ENSG00000259251.2	RP11-643M14.1	-4.36	3.29e-05	0.0193	-0.42	-0.41	Height;	chr15:61921398	chr15:62060503~62062434:+
THYM	cis	rs34091987	0.622	rs2193052	ENSG00000256124.4	LINC01152	4.36	3.29e-05	0.0193	0.48	0.41	Nose size;	chr17:72029996	chr17:72030291~72041297:+
THYM	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-4.36	3.29e-05	0.0193	-0.37	-0.41	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-4.36	3.29e-05	0.0193	-0.37	-0.41	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-4.36	3.29e-05	0.0193	-0.37	-0.41	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-4.36	3.29e-05	0.0193	-0.37	-0.41	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
THYM	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	4.36	3.29e-05	0.0193	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
THYM	cis	rs10829156	0.699	rs10828879	ENSG00000225527.1	RP11-383B4.4	-4.36	3.29e-05	0.0193	-0.47	-0.41	Sudden cardiac arrest;	chr10:18546425	chr10:18531849~18533336:-
THYM	cis	rs728616	0.541	rs61860401	ENSG00000225484.5	NUTM2B-AS1	-4.36	3.29e-05	0.0193	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:79663088~79826594:-
THYM	cis	rs728616	0.614	rs55768100	ENSG00000225484.5	NUTM2B-AS1	-4.36	3.29e-05	0.0193	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79663088~79826594:-
THYM	cis	rs728616	0.614	rs58606426	ENSG00000225484.5	NUTM2B-AS1	-4.36	3.29e-05	0.0193	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:79663088~79826594:-
THYM	cis	rs728616	0.614	rs57966752	ENSG00000225484.5	NUTM2B-AS1	-4.36	3.29e-05	0.0193	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:79663088~79826594:-
THYM	cis	rs728616	0.614	rs61860413	ENSG00000225484.5	NUTM2B-AS1	-4.36	3.29e-05	0.0193	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79663088~79826594:-
THYM	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-4.36	3.29e-05	0.0193	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
THYM	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-4.36	3.29e-05	0.0193	-0.54	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
THYM	cis	rs4478858	0.684	rs10798837	ENSG00000260386.4	LINC01225	4.36	3.3e-05	0.0193	0.22	0.41	Alcohol dependence;	chr1:31246493	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs10798838	ENSG00000260386.4	LINC01225	4.36	3.3e-05	0.0193	0.22	0.41	Alcohol dependence;	chr1:31246603	chr1:31500085~31540885:+
THYM	cis	rs7937127	0.696	rs1001459	ENSG00000254907.1	RP11-484D2.2	4.36	3.3e-05	0.0194	0.56	0.41	Fibrinogen levels;	chr11:43516986	chr11:43328748~43359296:-
THYM	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-4.36	3.3e-05	0.0194	-0.47	-0.41	QT interval;	chr12:29343291	chr12:29280418~29317848:-
THYM	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-4.36	3.31e-05	0.0194	-0.47	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
THYM	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	4.36	3.31e-05	0.0194	0.53	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
THYM	cis	rs5743467	1	rs5743467	ENSG00000233238.1	DEFA9P	-4.36	3.31e-05	0.0194	-0.45	-0.41	Plasma kynurenine to tryptophan ratio in major depressive disorder;Plasma kynurenine levels in major depressive disorder;	chr8:6874007	chr8:6959289~6960161:-
THYM	cis	rs2342371	0.539	rs35959625	ENSG00000242086.7	LINC00969	-4.36	3.31e-05	0.0194	-0.54	-0.41	Fat distribution (HIV);	chr3:196405070	chr3:195658062~195739964:+
THYM	cis	rs2243480	0.908	rs55876148	ENSG00000228409.4	CCT6P1	4.36	3.31e-05	0.0194	0.52	0.41	Diabetic kidney disease;	chr7:65914813	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs56016656	ENSG00000228409.4	CCT6P1	4.36	3.31e-05	0.0194	0.52	0.41	Diabetic kidney disease;	chr7:65918494	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.803	rs55700941	ENSG00000228409.4	CCT6P1	4.36	3.31e-05	0.0194	0.52	0.41	Diabetic kidney disease;	chr7:65924813	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs56291018	ENSG00000228409.4	CCT6P1	4.36	3.31e-05	0.0194	0.52	0.41	Diabetic kidney disease;	chr7:65925352	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs36033484	ENSG00000228409.4	CCT6P1	4.36	3.31e-05	0.0194	0.52	0.41	Diabetic kidney disease;	chr7:65925571	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs34193460	ENSG00000228409.4	CCT6P1	4.36	3.31e-05	0.0194	0.52	0.41	Diabetic kidney disease;	chr7:65928123	chr7:65751142~65763354:+
THYM	cis	rs7412746	0.658	rs4537557	ENSG00000220323.3	HIST2H2BD	-4.36	3.32e-05	0.0194	-0.4	-0.41	Melanoma;	chr1:150761960	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs2864869	ENSG00000220323.3	HIST2H2BD	-4.36	3.32e-05	0.0194	-0.4	-0.41	Melanoma;	chr1:150762179	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.634	rs3754212	ENSG00000220323.3	HIST2H2BD	-4.36	3.32e-05	0.0194	-0.4	-0.41	Melanoma;	chr1:150765724	chr1:149843041~149843533:+
THYM	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-4.36	3.32e-05	0.0194	-0.42	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
THYM	cis	rs12701220	0.901	rs12701708	ENSG00000229043.2	AC091729.9	-4.36	3.32e-05	0.0194	-0.68	-0.41	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.901	rs12701713	ENSG00000229043.2	AC091729.9	-4.36	3.32e-05	0.0194	-0.68	-0.41	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.901	rs12701710	ENSG00000229043.2	AC091729.9	4.36	3.32e-05	0.0194	0.68	0.41	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1160374~1165267:+
THYM	cis	rs7397814	0.558	rs4764447	ENSG00000255753.1	RP11-22B23.2	-4.36	3.33e-05	0.0195	-0.42	-0.41	IgG glycosylation;	chr12:9426513	chr12:9314402~9316173:-
THYM	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	4.36	3.33e-05	0.0195	0.5	0.41	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	4.36	3.33e-05	0.0195	0.5	0.41	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
THYM	cis	rs7196129	0.801	rs2285459	ENSG00000183604.13	SMG1P5	4.36	3.33e-05	0.0195	0.34	0.41	Monocyte count;	chr16:30484091	chr16:30267553~30335374:-
THYM	cis	rs9903692	0.908	rs8066391	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48117934	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.908	rs11079809	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48120859	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs3744346	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48121514	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.908	rs7222136	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48122230	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs1010228	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48122986	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs1860866	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48123669	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.908	rs9807087	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48126776	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs7209730	ENSG00000266601.1	RP11-6N17.3	4.36	3.33e-05	0.0195	0.39	0.41	Pulse pressure;	chr17:48130137	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs11651097	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48069677	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs7224014	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48073499	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs2240122	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48075197	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.738	rs35202025	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48075355	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs7217496	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48076840	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs9747001	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48077307	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.909	rs12952163	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48082029	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.648	rs35361214	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48087729	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.697	rs6504024	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48088224	chr17:47929682~47933106:-
THYM	cis	rs9903692	1	rs9903692	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48196567	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs9909933	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48202870	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.909	rs2325885	ENSG00000266601.1	RP11-6N17.3	-4.36	3.33e-05	0.0195	-0.39	-0.41	Pulse pressure;	chr17:48213013	chr17:47929682~47933106:-
THYM	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-4.36	3.34e-05	0.0195	-0.37	-0.41	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
THYM	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	4.36	3.34e-05	0.0195	0.35	0.41	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
THYM	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	4.36	3.34e-05	0.0195	0.35	0.41	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
THYM	cis	rs11976180	1	rs2951368	ENSG00000244479.5	OR2A1-AS1	4.36	3.34e-05	0.0195	0.37	0.41	Obesity-related traits;	chr7:144055728	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2961115	ENSG00000244479.5	OR2A1-AS1	4.36	3.34e-05	0.0195	0.37	0.41	Obesity-related traits;	chr7:144056278	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2951364	ENSG00000244479.5	OR2A1-AS1	4.36	3.34e-05	0.0195	0.37	0.41	Obesity-related traits;	chr7:144057390	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2951363	ENSG00000244479.5	OR2A1-AS1	4.36	3.34e-05	0.0195	0.37	0.41	Obesity-related traits;	chr7:144057631	chr7:144251264~144356181:-
THYM	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-4.36	3.34e-05	0.0195	-0.43	-0.41	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
THYM	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-4.36	3.34e-05	0.0195	-0.43	-0.41	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
THYM	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-4.36	3.34e-05	0.0195	-0.43	-0.41	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
THYM	cis	rs11574514	0.661	rs76160073	ENSG00000260891.1	RP11-96D1.5	-4.36	3.35e-05	0.0196	-0.48	-0.41	Crohn's disease;	chr16:67786343	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117546864	ENSG00000260891.1	RP11-96D1.5	-4.36	3.35e-05	0.0196	-0.48	-0.41	Crohn's disease;	chr16:67786349	chr16:68212401~68221671:-
THYM	cis	rs11574514	0.59	rs118108102	ENSG00000260891.1	RP11-96D1.5	-4.36	3.35e-05	0.0196	-0.48	-0.41	Crohn's disease;	chr16:67810568	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs62636658	ENSG00000260891.1	RP11-96D1.5	-4.36	3.35e-05	0.0196	-0.48	-0.41	Crohn's disease;	chr16:67821204	chr16:68212401~68221671:-
THYM	cis	rs972578	1	rs5759067	ENSG00000215347.3	SLC25A5P1	-4.36	3.35e-05	0.0196	-0.32	-0.41	Mean platelet volume;	chr22:42976793	chr22:42001069~42001966:-
THYM	cis	rs986417	0.818	rs7156107	ENSG00000258670.1	RP11-1042B17.3	4.36	3.35e-05	0.0196	0.37	0.41	Gut microbiota (bacterial taxa);	chr14:60592435	chr14:60515119~60554916:+
THYM	cis	rs7560272	0.564	rs10496190	ENSG00000163016.8	ALMS1P	-4.36	3.36e-05	0.0196	-0.48	-0.41	Schizophrenia;	chr2:73411695	chr2:73644919~73685576:+
THYM	cis	rs7178424	0.806	rs4775453	ENSG00000259251.2	RP11-643M14.1	4.36	3.37e-05	0.0197	0.41	0.41	Height;	chr15:61925192	chr15:62060503~62062434:+
THYM	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	4.36	3.37e-05	0.0197	0.38	0.41	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
THYM	cis	rs4737732	0.614	rs13275844	ENSG00000254006.4	RP11-1D12.2	4.36	3.37e-05	0.0197	0.43	0.41	Stem cell growth factor beta levels;	chr8:65440569	chr8:64801236~64817573:-
THYM	cis	rs8113308	0.81	rs8104281	ENSG00000269235.1	ZNF350-AS1	4.36	3.37e-05	0.0197	0.48	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939766	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs8104121	ENSG00000269235.1	ZNF350-AS1	4.36	3.37e-05	0.0197	0.48	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939810	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs8104323	ENSG00000269235.1	ZNF350-AS1	4.36	3.37e-05	0.0197	0.48	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939992	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs8108525	ENSG00000269235.1	ZNF350-AS1	4.36	3.37e-05	0.0197	0.48	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940883	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs7258701	ENSG00000269235.1	ZNF350-AS1	4.36	3.37e-05	0.0197	0.48	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51941816	chr19:51949134~51981367:+
THYM	cis	rs7246967	0.736	rs411131	ENSG00000198153.8	ZNF849P	-4.36	3.37e-05	0.0197	-0.52	-0.41	Bronchopulmonary dysplasia;	chr19:22810637	chr19:22685167~22686732:+
THYM	cis	rs9876781	0.872	rs11797	ENSG00000244380.1	RP11-24C3.2	4.36	3.38e-05	0.0197	0.55	0.41	Longevity;	chr3:48467186	chr3:48440352~48446656:-
THYM	cis	rs1023500	0.529	rs133375	ENSG00000227370.1	RP4-669P10.19	4.36	3.38e-05	0.0197	0.48	0.41	Schizophrenia;	chr22:42070505	chr22:42132543~42132998:+
THYM	cis	rs4760854	0.639	rs3923630	ENSG00000257815.4	RP11-611E13.2	4.36	3.38e-05	0.0197	0.32	0.41	IgG glycosylation;	chr12:70895395	chr12:69904033~70243360:-
THYM	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	4.36	3.38e-05	0.0197	0.4	0.41	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
THYM	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	4.36	3.39e-05	0.0198	0.51	0.41	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
THYM	cis	rs4835473	0.897	rs34380794	ENSG00000249741.2	RP11-673E1.3	4.36	3.39e-05	0.0198	0.34	0.41	Immature fraction of reticulocytes;	chr4:143735800	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.75	rs56372690	ENSG00000249741.2	RP11-673E1.3	4.36	3.39e-05	0.0198	0.34	0.41	Immature fraction of reticulocytes;	chr4:143735816	chr4:143911514~143912053:-
THYM	cis	rs9728717	1	rs59536255	ENSG00000226970.2	RP11-82H13.2	-4.36	3.39e-05	0.0198	-0.61	-0.41	Economic and political preferences (time);	chr1:84821134	chr1:84244334~84244577:+
THYM	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	4.35	3.39e-05	0.0198	0.5	0.41	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	4.35	3.39e-05	0.0198	0.5	0.41	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	4.35	3.39e-05	0.0198	0.5	0.41	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
THYM	cis	rs5769707	0.749	rs7286706	ENSG00000264139.1	MIR3667	-4.35	3.4e-05	0.0198	-0.45	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49543393~49543466:-
THYM	cis	rs62246343	0.719	rs73115804	ENSG00000254485.4	RP11-380O24.1	4.35	3.4e-05	0.0198	0.63	0.41	Fibrinogen levels;	chr3:9399858	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs62246276	ENSG00000254485.4	RP11-380O24.1	4.35	3.4e-05	0.0198	0.63	0.41	Fibrinogen levels;	chr3:9403489	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs62246301	ENSG00000254485.4	RP11-380O24.1	4.35	3.4e-05	0.0198	0.63	0.41	Fibrinogen levels;	chr3:9409599	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs62246302	ENSG00000254485.4	RP11-380O24.1	4.35	3.4e-05	0.0198	0.63	0.41	Fibrinogen levels;	chr3:9411761	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs62246303	ENSG00000254485.4	RP11-380O24.1	4.35	3.4e-05	0.0198	0.63	0.41	Fibrinogen levels;	chr3:9413078	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.719	rs6767213	ENSG00000254485.4	RP11-380O24.1	4.35	3.4e-05	0.0198	0.63	0.41	Fibrinogen levels;	chr3:9415588	chr3:9292588~9363303:-
THYM	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	4.35	3.4e-05	0.0198	0.54	0.41	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
THYM	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	4.35	3.4e-05	0.0198	0.52	0.41	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
THYM	cis	rs9611519	1	rs4820433	ENSG00000235513.1	RP4-756G23.5	4.35	3.4e-05	0.0198	0.35	0.41	Neuroticism;	chr22:41211061	chr22:41209122~41217627:-
THYM	cis	rs9926296	0.712	rs2434872	ENSG00000274627.1	RP11-104N10.2	4.35	3.4e-05	0.0198	0.49	0.41	Vitiligo;	chr16:89650507	chr16:89516797~89522217:+
THYM	cis	rs7223966	1	rs113134232	ENSG00000240280.5	TCAM1P	-4.35	3.41e-05	0.0198	-0.66	-0.41	Hip circumference adjusted for BMI;Body mass index;	chr17:63638101	chr17:63849292~63864379:+
THYM	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-4.35	3.41e-05	0.0198	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
THYM	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-4.35	3.41e-05	0.0198	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
THYM	cis	rs131777	0.577	rs5770928	ENSG00000205559.3	CHKB-AS1	-4.35	3.41e-05	0.0199	-0.43	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50583026~50583877:+
THYM	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	4.35	3.41e-05	0.0199	0.54	0.41	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
THYM	cis	rs11096990	0.819	rs2381225	ENSG00000249685.1	RP11-360F5.3	-4.35	3.41e-05	0.0199	-0.4	-0.41	Cognitive function;	chr4:39158915	chr4:39133913~39135608:+
THYM	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-4.35	3.41e-05	0.0199	-0.52	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	4.35	3.41e-05	0.0199	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
THYM	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-4.35	3.41e-05	0.0199	-0.47	-0.41	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
THYM	cis	rs6506900	0.599	rs2912322	ENSG00000265888.1	DSCAS	-4.35	3.41e-05	0.0199	-0.43	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr18:31236305	chr18:31101588~31162789:+
THYM	cis	rs9926296	0.712	rs2437957	ENSG00000274627.1	RP11-104N10.2	4.35	3.42e-05	0.0199	0.49	0.41	Vitiligo;	chr16:89649240	chr16:89516797~89522217:+
THYM	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	4.35	3.42e-05	0.0199	0.3	0.41	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
THYM	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-4.35	3.42e-05	0.0199	-0.3	-0.41	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
THYM	cis	rs7631605	0.935	rs2241031	ENSG00000272334.1	RP11-129K12.1	-4.35	3.42e-05	0.0199	-0.42	-0.41	Cerebrospinal P-tau181p levels;	chr3:37048783	chr3:36973117~36973672:-
THYM	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-4.35	3.42e-05	0.0199	-0.55	-0.41	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-4.35	3.42e-05	0.0199	-0.55	-0.41	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
THYM	cis	rs4853012	0.838	rs72911122	ENSG00000272183.1	RP11-523H20.3	4.35	3.42e-05	0.0199	0.53	0.41	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74501717~74502365:+
THYM	cis	rs4853012	0.838	rs59570457	ENSG00000272183.1	RP11-523H20.3	4.35	3.42e-05	0.0199	0.53	0.41	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74501717~74502365:+
THYM	cis	rs4853012	0.838	rs6707729	ENSG00000272183.1	RP11-523H20.3	4.35	3.42e-05	0.0199	0.53	0.41	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74501717~74502365:+
THYM	cis	rs7927592	0.913	rs11228292	ENSG00000222339.1	AP000807.2	4.35	3.43e-05	0.02	0.53	0.41	Total body bone mineral density;	chr11:68612304	chr11:68505572~68505651:-
THYM	cis	rs62246343	0.605	rs4308263	ENSG00000254485.4	RP11-380O24.1	4.35	3.43e-05	0.02	0.53	0.41	Fibrinogen levels;	chr3:9415674	chr3:9292588~9363303:-
THYM	cis	rs62246343	0.605	rs34665459	ENSG00000254485.4	RP11-380O24.1	4.35	3.43e-05	0.02	0.53	0.41	Fibrinogen levels;	chr3:9423041	chr3:9292588~9363303:-
THYM	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	4.35	3.44e-05	0.02	0.5	0.41	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
THYM	cis	rs7178424	0.875	rs17271193	ENSG00000259251.2	RP11-643M14.1	-4.35	3.44e-05	0.02	-0.45	-0.41	Height;	chr15:61872969	chr15:62060503~62062434:+
THYM	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	4.35	3.44e-05	0.02	0.53	0.41	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
THYM	cis	rs4835473	0.771	rs4835097	ENSG00000249741.2	RP11-673E1.3	-4.35	3.45e-05	0.02	-0.35	-0.41	Immature fraction of reticulocytes;	chr4:143960687	chr4:143911514~143912053:-
THYM	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-4.35	3.45e-05	0.02	-0.49	-0.41	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
THYM	cis	rs75422866	0.541	rs61918136	ENSG00000257433.4	RP1-197B17.3	4.35	3.45e-05	0.0201	0.72	0.41	Pneumonia;	chr12:47566798	chr12:47706085~47742294:+
THYM	cis	rs1881744	0.588	rs78808618	ENSG00000257433.4	RP1-197B17.3	4.35	3.45e-05	0.0201	0.72	0.41	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47706085~47742294:+
THYM	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	4.35	3.46e-05	0.0201	0.3	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
THYM	cis	rs2834288	0.535	rs881228	ENSG00000237945.6	LINC00649	4.35	3.46e-05	0.0201	0.36	0.41	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33915534~33977691:+
THYM	cis	rs2834288	0.535	rs881229	ENSG00000237945.6	LINC00649	4.35	3.46e-05	0.0201	0.36	0.41	Gut microbiota (bacterial taxa);	chr21:33950417	chr21:33915534~33977691:+
THYM	cis	rs12902680	0.706	rs10519049	ENSG00000259520.4	CTD-2651B20.3	-4.35	3.46e-05	0.0201	-0.42	-0.41	Neuroticism;	chr15:46183959	chr15:45251580~45279251:-
THYM	cis	rs7631605	0.905	rs4678931	ENSG00000272334.1	RP11-129K12.1	-4.35	3.46e-05	0.0201	-0.42	-0.41	Cerebrospinal P-tau181p levels;	chr3:37052257	chr3:36973117~36973672:-
THYM	cis	rs1439840	1	rs13036235	ENSG00000213239.3	NPM1P32	4.35	3.46e-05	0.0201	1.09	0.41	QT interval (sulfonylurea treatment interaction);	chr2:122639961	chr2:121708512~121709115:-
THYM	cis	rs4835473	0.9	rs10025455	ENSG00000249741.2	RP11-673E1.3	4.35	3.47e-05	0.0202	0.35	0.41	Immature fraction of reticulocytes;	chr4:143998417	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.722	rs7666296	ENSG00000249741.2	RP11-673E1.3	4.35	3.47e-05	0.0202	0.35	0.41	Immature fraction of reticulocytes;	chr4:143999004	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.722	rs7662277	ENSG00000249741.2	RP11-673E1.3	4.35	3.47e-05	0.0202	0.35	0.41	Immature fraction of reticulocytes;	chr4:143999485	chr4:143911514~143912053:-
THYM	cis	rs17826219	0.706	rs609472	ENSG00000266490.1	CTD-2349P21.9	4.35	3.48e-05	0.0202	0.68	0.41	Body mass index;	chr17:30624409	chr17:30792372~30792833:+
THYM	cis	rs11696739	0.501	rs2243603	ENSG00000232528.3	RP4-673D20.3	4.35	3.48e-05	0.0202	0.56	0.41	Mean platelet volume;	chr20:1566265	chr20:1767957~1779995:-
THYM	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	4.35	3.48e-05	0.0202	0.38	0.41	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
THYM	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	4.35	3.48e-05	0.0202	0.66	0.41	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
THYM	cis	rs8177876	0.822	rs56119129	ENSG00000261838.4	RP11-303E16.6	4.35	3.49e-05	0.0202	0.88	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.731	rs77145371	ENSG00000261838.4	RP11-303E16.6	4.35	3.49e-05	0.0202	0.88	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.908	rs80187824	ENSG00000261838.4	RP11-303E16.6	4.35	3.49e-05	0.0202	0.88	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.731	rs74882687	ENSG00000261838.4	RP11-303E16.6	4.35	3.49e-05	0.0202	0.88	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.642	rs76909932	ENSG00000261838.4	RP11-303E16.6	4.35	3.49e-05	0.0202	0.88	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs8177939	ENSG00000261838.4	RP11-303E16.6	4.35	3.49e-05	0.0202	0.88	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81069854~81076598:+
THYM	cis	rs4591358	0.689	rs2102745	ENSG00000223466.1	AC064834.2	-4.35	3.49e-05	0.0202	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559315	chr2:195533035~195538681:+
THYM	cis	rs4908760	0.827	rs1463053	ENSG00000232912.4	RP5-1115A15.1	4.35	3.49e-05	0.0202	0.4	0.41	Vitiligo;	chr1:8644978	chr1:8424645~8434838:+
THYM	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	4.35	3.5e-05	0.0203	0.31	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
THYM	cis	rs7976269	0.537	rs4471475	ENSG00000275476.1	RP11-996F15.4	-4.35	3.5e-05	0.0203	-0.48	-0.41	Male-pattern baldness;	chr12:29022461	chr12:29277397~29277882:-
THYM	cis	rs1519814	0.736	rs7822384	ENSG00000254343.2	RP11-760H22.2	-4.35	3.5e-05	0.0203	-0.6	-0.41	Breast cancer;	chr8:120059550	chr8:120052180~120056201:+
THYM	cis	rs8067545	0.75	rs4005937	ENSG00000230528.6	NOS2P3	-4.35	3.5e-05	0.0203	-0.33	-0.41	Schizophrenia;	chr17:20056515	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs9897246	ENSG00000230528.6	NOS2P3	-4.35	3.5e-05	0.0203	-0.33	-0.41	Schizophrenia;	chr17:20062389	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs4267380	ENSG00000230528.6	NOS2P3	-4.35	3.5e-05	0.0203	-0.33	-0.41	Schizophrenia;	chr17:20068251	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs4924805	ENSG00000230528.6	NOS2P3	-4.35	3.5e-05	0.0203	-0.33	-0.41	Schizophrenia;	chr17:20093892	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs7208025	ENSG00000230528.6	NOS2P3	-4.35	3.5e-05	0.0203	-0.33	-0.41	Schizophrenia;	chr17:20094557	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs888423	ENSG00000230528.6	NOS2P3	-4.35	3.5e-05	0.0203	-0.33	-0.41	Schizophrenia;	chr17:20096096	chr17:20436337~20447249:+
THYM	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	4.35	3.5e-05	0.0203	0.49	0.41	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
THYM	cis	rs9535495	0.965	rs9568476	ENSG00000200711.1	RNA5SP28	-4.35	3.5e-05	0.0203	-0.47	-0.41	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50816706	chr13:50812988~50813106:-
THYM	cis	rs1790761	0.658	rs666328	ENSG00000231793.4	DOC2GP	-4.35	3.51e-05	0.0203	-0.37	-0.41	Mean corpuscular volume;	chr11:67568067	chr11:67612653~67616257:-
THYM	cis	rs1790761	0.667	rs11227837	ENSG00000231793.4	DOC2GP	-4.35	3.51e-05	0.0203	-0.37	-0.41	Mean corpuscular volume;	chr11:67568953	chr11:67612653~67616257:-
THYM	cis	rs4835473	0.864	rs7681559	ENSG00000249741.2	RP11-673E1.3	4.35	3.52e-05	0.0203	0.36	0.41	Immature fraction of reticulocytes;	chr4:143695248	chr4:143911514~143912053:-
THYM	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	4.34	3.52e-05	0.0204	0.45	0.41	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	4.34	3.52e-05	0.0204	0.45	0.41	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
THYM	cis	rs76455782	1	rs2526453	ENSG00000249465.1	RBMXP4	4.34	3.52e-05	0.0204	0.75	0.41	Common carotid intima-media thickness in HIV negative individuals;	chr4:109182179	chr4:109346326~109347459:-
THYM	cis	rs7209700	0.638	rs4629025	ENSG00000228782.6	CTD-2026D20.3	-4.34	3.52e-05	0.0204	-0.49	-0.41	IgG glycosylation;	chr17:47260069	chr17:47450568~47492492:-
THYM	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-4.34	3.52e-05	0.0204	-0.4	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
THYM	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-4.34	3.52e-05	0.0204	-0.4	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
THYM	cis	rs2115630	0.905	rs6496401	ENSG00000275120.1	RP11-182J1.17	-4.34	3.53e-05	0.0204	-0.48	-0.41	P wave terminal force;	chr15:84754562	chr15:84599434~84606463:-
THYM	cis	rs34091987	0.582	rs2193054	ENSG00000256124.4	LINC01152	4.34	3.53e-05	0.0204	0.47	0.41	Nose size;	chr17:72029668	chr17:72030291~72041297:+
THYM	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	4.34	3.53e-05	0.0204	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
THYM	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	4.34	3.53e-05	0.0204	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
THYM	cis	rs9907295	0.818	rs4251702	ENSG00000270977.1	AC015849.16	4.34	3.53e-05	0.0204	0.62	0.41	Fibroblast growth factor basic levels;	chr17:35807933	chr17:35893707~35911023:-
THYM	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	4.34	3.53e-05	0.0204	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	4.34	3.53e-05	0.0204	0.6	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
THYM	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	4.34	3.53e-05	0.0204	0.4	0.41	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
THYM	cis	rs7976269	0.515	rs9300183	ENSG00000275476.1	RP11-996F15.4	-4.34	3.54e-05	0.0204	-0.49	-0.41	Male-pattern baldness;	chr12:29002316	chr12:29277397~29277882:-
THYM	cis	rs6672530	0.518	rs2018651	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Hip circumference adjusted for BMI;	chr1:227508409	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs903683	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Hip circumference adjusted for BMI;	chr1:227508809	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs1495842	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227508893	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs11580570	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227509139	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs12040302	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227509464	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs976959	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227518601	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs12132444	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227521845	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs12042653	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227524509	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs4653846	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Hip circumference adjusted for BMI;	chr1:227524770	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs10916156	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Hip circumference adjusted for BMI;	chr1:227525576	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2201571	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227532250	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs4359006	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227533085	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs7551459	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Hip circumference adjusted for BMI;	chr1:227536317	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs1495845	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227538346	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs4653848	ENSG00000227711.2	RP11-275O4.5	4.34	3.54e-05	0.0204	0.37	0.41	Height;	chr1:227541210	chr1:227509028~227520477:-
THYM	cis	rs4835473	0.897	rs17693780	ENSG00000249741.2	RP11-673E1.3	4.34	3.54e-05	0.0204	0.34	0.41	Immature fraction of reticulocytes;	chr4:143737563	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs35556180	ENSG00000249741.2	RP11-673E1.3	4.34	3.54e-05	0.0204	0.34	0.41	Immature fraction of reticulocytes;	chr4:143737595	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs35377051	ENSG00000249741.2	RP11-673E1.3	4.34	3.54e-05	0.0204	0.34	0.41	Immature fraction of reticulocytes;	chr4:143737627	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs17018131	ENSG00000249741.2	RP11-673E1.3	4.34	3.54e-05	0.0204	0.34	0.41	Immature fraction of reticulocytes;	chr4:143737647	chr4:143911514~143912053:-
THYM	cis	rs6545883	0.525	rs1177274	ENSG00000273302.1	RP11-493E12.2	4.34	3.54e-05	0.0204	0.39	0.41	Tuberculosis;	chr2:61141397	chr2:61199979~61200769:+
THYM	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-4.34	3.54e-05	0.0205	-0.7	-0.41	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
THYM	cis	rs4835473	0.864	rs13145791	ENSG00000249741.2	RP11-673E1.3	4.34	3.54e-05	0.0205	0.33	0.41	Immature fraction of reticulocytes;	chr4:143735688	chr4:143911514~143912053:-
THYM	cis	rs1550576	0.568	rs16977865	ENSG00000274719.1	RP11-86K22.2	-4.34	3.54e-05	0.0205	-0.81	-0.41	Hypertension;	chr15:57952213	chr15:57990217~57990636:-
THYM	cis	rs8113308	0.688	rs7259507	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942475	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs7259622	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942484	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs73582180	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943284	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs8105910	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943815	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs11880193	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51945416	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs16983256	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946228	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs8100521	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946390	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs8100541	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946442	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs11879040	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946856	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs55810059	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51947475	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs7255377	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948085	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs7254930	ENSG00000269235.1	ZNF350-AS1	4.34	3.55e-05	0.0205	0.47	0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948274	chr19:51949134~51981367:+
THYM	cis	rs8113308	0.81	rs11881650	ENSG00000269235.1	ZNF350-AS1	-4.34	3.55e-05	0.0205	-0.47	-0.41	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946886	chr19:51949134~51981367:+
THYM	cis	rs4835473	0.864	rs5015762	ENSG00000249741.2	RP11-673E1.3	4.34	3.56e-05	0.0205	0.34	0.41	Immature fraction of reticulocytes;	chr4:143737773	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs5015761	ENSG00000249741.2	RP11-673E1.3	4.34	3.56e-05	0.0205	0.34	0.41	Immature fraction of reticulocytes;	chr4:143737791	chr4:143911514~143912053:-
THYM	cis	rs972578	0.837	rs6002963	ENSG00000215347.3	SLC25A5P1	-4.34	3.56e-05	0.0205	-0.34	-0.41	Mean platelet volume;	chr22:42850140	chr22:42001069~42001966:-
THYM	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-4.34	3.56e-05	0.0205	-0.3	-0.41	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
THYM	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-4.34	3.56e-05	0.0206	-0.43	-0.41	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
THYM	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-4.34	3.57e-05	0.0206	-0.49	-0.41	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-4.34	3.57e-05	0.0206	-0.49	-0.41	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-4.34	3.57e-05	0.0206	-0.49	-0.41	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-4.34	3.57e-05	0.0206	-0.49	-0.41	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	4.34	3.57e-05	0.0206	0.49	0.41	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
THYM	cis	rs9907295	1	rs9889274	ENSG00000270871.1	AC015849.19	4.34	3.57e-05	0.0206	0.48	0.41	Fibroblast growth factor basic levels;	chr17:35910397	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9891064	ENSG00000270871.1	AC015849.19	4.34	3.57e-05	0.0206	0.48	0.41	Fibroblast growth factor basic levels;	chr17:35913045	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9899870	ENSG00000270871.1	AC015849.19	4.34	3.57e-05	0.0206	0.48	0.41	Fibroblast growth factor basic levels;	chr17:35914438	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs11080360	ENSG00000270871.1	AC015849.19	4.34	3.57e-05	0.0206	0.48	0.41	Fibroblast growth factor basic levels;	chr17:35916086	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs11869976	ENSG00000270871.1	AC015849.19	4.34	3.57e-05	0.0206	0.48	0.41	Fibroblast growth factor basic levels;	chr17:35916492	chr17:35816717~35830293:-
THYM	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-4.34	3.57e-05	0.0206	-0.45	-0.41	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
THYM	cis	rs4352210	0.519	rs740992	ENSG00000236213.1	AC006369.2	4.34	3.58e-05	0.0206	0.44	0.41	RR interval (heart rate);	chr2:37583389	chr2:37600136~37646698:+
THYM	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-4.34	3.58e-05	0.0206	-0.51	-0.41	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
THYM	cis	rs7178424	0.875	rs2414753	ENSG00000259251.2	RP11-643M14.1	-4.34	3.58e-05	0.0206	-0.44	-0.41	Height;	chr15:61908775	chr15:62060503~62062434:+
THYM	cis	rs10129255	0.957	rs6576233	ENSG00000253703.1	IGHV1-68	-4.34	3.58e-05	0.0207	-0.52	-0.41	Kawasaki disease;	chr14:106787239	chr14:106703852~106704146:-
THYM	cis	rs1336900	0.513	rs56253522	ENSG00000220323.3	HIST2H2BD	-4.34	3.58e-05	0.0207	-0.4	-0.41	Blood protein levels;	chr1:150642393	chr1:149843041~149843533:+
THYM	cis	rs2115630	0.936	rs8033459	ENSG00000275120.1	RP11-182J1.17	-4.34	3.59e-05	0.0207	-0.48	-0.41	P wave terminal force;	chr15:84710027	chr15:84599434~84606463:-
THYM	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-4.34	3.59e-05	0.0207	-0.48	-0.41	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
THYM	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	4.34	3.59e-05	0.0207	0.59	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
THYM	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	4.34	3.59e-05	0.0207	0.46	0.41	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
THYM	cis	rs7005380	0.62	rs13282901	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119881561	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13260088	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119886525	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs10955940	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119890246	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10103058	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119890830	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10955941	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119891271	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs13257316	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119891494	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.58	rs12681623	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119891616	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13265367	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119891769	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10107251	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119892108	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10094587	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119892560	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13249122	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119893679	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13250594	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119894151	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13259990	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119894943	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13260933	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119895010	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs13261304	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119895180	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs4871772	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119895655	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs4871773	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119895671	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs4871012	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119895734	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs4871013	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119895750	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.579	rs7465181	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119896349	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7462250	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119896367	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7459671	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119896646	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13281299	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119897253	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7832923	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119897540	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6469861	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119897673	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6469862	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119897796	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6469863	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119897910	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6469864	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119897985	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6469865	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119897995	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6988011	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119898298	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs35272074	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119898543	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs10103660	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119898547	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6993375	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119899390	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs6993797	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119899405	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6989741	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119899914	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs13257252	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119899993	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10093230	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119900606	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs9649947	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119901117	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13279398	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119902030	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13277947	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119902192	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs13277992	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119902287	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13253140	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119902668	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs11777705	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119902992	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs12681402	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119903622	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7461290	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119904154	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.58	rs4073560	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119905148	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7002839	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119906508	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7006905	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119906683	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.58	rs13265546	ENSG00000245330.4	KB-1471A8.1	4.34	3.59e-05	0.0207	0.57	0.41	Interstitial lung disease;	chr8:119907735	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6987580	ENSG00000245330.4	KB-1471A8.1	-4.34	3.59e-05	0.0207	-0.57	-0.41	Interstitial lung disease;	chr8:119898140	chr8:119867419~119874488:-
THYM	cis	rs34091987	0.582	rs2193053	ENSG00000256124.4	LINC01152	4.34	3.59e-05	0.0207	0.47	0.41	Nose size;	chr17:72029790	chr17:72030291~72041297:+
THYM	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	4.34	3.59e-05	0.0207	0.55	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	4.34	3.59e-05	0.0207	0.55	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	4.34	3.59e-05	0.0207	0.55	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	4.34	3.59e-05	0.0207	0.55	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
THYM	cis	rs7976269	0.609	rs7310276	ENSG00000275476.1	RP11-996F15.4	4.34	3.6e-05	0.0207	0.46	0.41	Male-pattern baldness;	chr12:29054128	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs1344854	ENSG00000275476.1	RP11-996F15.4	4.34	3.6e-05	0.0207	0.46	0.41	Male-pattern baldness;	chr12:29065440	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs4931137	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29049701	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs2082943	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29050251	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10771470	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29050620	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10743641	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29050819	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs4930846	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29051306	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs2196482	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29052559	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs2217906	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29052626	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs4402335	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29052836	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs7135891	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29053944	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs2117994	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29054666	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.583	rs6487753	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29056103	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.583	rs6487754	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29056104	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs6487755	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29056156	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs4931141	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29057763	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs4931142	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29057877	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs2117993	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29060041	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10843300	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29060934	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs11050010	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29061952	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs2196480	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29062850	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.537	rs10743642	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29063557	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10771472	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29063930	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs7979788	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29064827	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.583	rs7955393	ENSG00000275476.1	RP11-996F15.4	-4.34	3.6e-05	0.0207	-0.46	-0.41	Male-pattern baldness;	chr12:29065773	chr12:29277397~29277882:-
THYM	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	4.34	3.6e-05	0.0207	0.52	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
THYM	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	4.34	3.6e-05	0.0207	0.54	0.41	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
THYM	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	4.34	3.6e-05	0.0207	0.54	0.41	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
THYM	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-4.34	3.61e-05	0.0207	-0.31	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
THYM	cis	rs7701440	0.512	rs12513581	ENSG00000272308.1	RP11-231G3.1	-4.34	3.61e-05	0.0207	-0.35	-0.41	Educational attainment;	chr5:61237380	chr5:60866457~60866935:-
THYM	cis	rs11096990	0.855	rs2711988	ENSG00000249685.1	RP11-360F5.3	-4.34	3.61e-05	0.0208	-0.4	-0.41	Cognitive function;	chr4:39151128	chr4:39133913~39135608:+
THYM	cis	rs28785552	0.897	rs34244888	ENSG00000250731.1	TPM3P6	-4.34	3.61e-05	0.0208	-0.57	-0.41	Response to paliperidone in schizophrenia (PANSS score);	chr19:52738975	chr19:53479350~53480091:+
THYM	cis	rs28785552	0.769	rs7253672	ENSG00000250731.1	TPM3P6	-4.34	3.61e-05	0.0208	-0.57	-0.41	Response to paliperidone in schizophrenia (PANSS score);	chr19:52739959	chr19:53479350~53480091:+
THYM	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-4.34	3.61e-05	0.0208	-0.54	-0.41	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
THYM	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	4.34	3.61e-05	0.0208	0.41	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
THYM	cis	rs9926296	0.744	rs164748	ENSG00000274627.1	RP11-104N10.2	4.34	3.62e-05	0.0208	0.49	0.41	Vitiligo;	chr16:89641884	chr16:89516797~89522217:+
THYM	cis	rs9926296	0.744	rs164747	ENSG00000274627.1	RP11-104N10.2	4.34	3.62e-05	0.0208	0.49	0.41	Vitiligo;	chr16:89642272	chr16:89516797~89522217:+
THYM	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-4.34	3.62e-05	0.0208	-0.42	-0.41	Temperament;	chr17:14033087	chr17:14024514~14025488:+
THYM	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs8177950	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.731	rs8177948	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.822	rs8177940	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.73	rs76656387	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.642	rs56032321	ENSG00000261838.4	RP11-303E16.6	4.34	3.62e-05	0.0208	0.87	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81069854~81076598:+
THYM	cis	rs73198271	0.74	rs1039910	ENSG00000253893.2	FAM85B	4.34	3.62e-05	0.0208	0.64	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs1039911	ENSG00000253893.2	FAM85B	4.34	3.62e-05	0.0208	0.64	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.74	rs3827807	ENSG00000253893.2	FAM85B	4.34	3.62e-05	0.0208	0.64	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8167819~8226614:-
THYM	cis	rs4835473	0.77	rs4835096	ENSG00000249741.2	RP11-673E1.3	-4.34	3.63e-05	0.0208	-0.35	-0.41	Immature fraction of reticulocytes;	chr4:143960685	chr4:143911514~143912053:-
THYM	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-4.34	3.63e-05	0.0208	-0.56	-0.41	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
THYM	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-4.34	3.63e-05	0.0208	-0.36	-0.41	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
THYM	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-4.34	3.64e-05	0.0209	-0.71	-0.41	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
THYM	cis	rs1642645	0.757	rs3845574	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42010903	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.793	rs4083557	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42012506	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs7541929	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42013722	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs10736422	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42014649	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.793	rs6695748	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42016036	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.793	rs4660211	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42018623	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs768613	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42019592	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs6689536	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42021852	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs6600396	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42023863	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs7535305	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42023931	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs2042064	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42025758	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs7529102	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42027651	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs11210563	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42028962	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.831	rs2886564	ENSG00000228452.1	RP5-994D16.9	-4.34	3.64e-05	0.0209	-0.54	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42031253	chr1:42775813~42776790:-
THYM	cis	rs7412746	0.658	rs7526489	ENSG00000220323.3	HIST2H2BD	-4.34	3.64e-05	0.0209	-0.4	-0.41	Melanoma;	chr1:150753762	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs12068264	ENSG00000220323.3	HIST2H2BD	-4.34	3.64e-05	0.0209	-0.4	-0.41	Melanoma;	chr1:150754853	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs2230061	ENSG00000220323.3	HIST2H2BD	-4.34	3.64e-05	0.0209	-0.4	-0.41	Melanoma;	chr1:150755063	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs2275235	ENSG00000220323.3	HIST2H2BD	-4.34	3.64e-05	0.0209	-0.4	-0.41	Melanoma;	chr1:150757803	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs11204723	ENSG00000220323.3	HIST2H2BD	-4.34	3.64e-05	0.0209	-0.4	-0.41	Melanoma;	chr1:150759142	chr1:149843041~149843533:+
THYM	cis	rs11722228	0.79	rs13126729	ENSG00000261490.1	RP11-448G15.3	-4.34	3.64e-05	0.0209	-0.44	-0.41	Urate levels;Serum uric acid levels;Gout;	chr4:9972562	chr4:10068089~10073019:-
THYM	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-4.34	3.64e-05	0.0209	-0.37	-0.41	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
THYM	cis	rs7849270	0.837	rs10819463	ENSG00000268707.1	RP11-247A12.7	-4.34	3.64e-05	0.0209	-0.5	-0.41	Blood metabolite ratios;	chr9:129100958	chr9:129170434~129170940:+
THYM	cis	rs10888838	1	rs10888840	ENSG00000198711.5	SSBP3-AS1	4.34	3.64e-05	0.0209	0.27	0.41	Mitochondrial DNA levels;	chr1:54217740	chr1:54236440~54239063:+
THYM	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-4.34	3.65e-05	0.0209	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-4.34	3.65e-05	0.0209	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-4.34	3.65e-05	0.0209	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-4.34	3.65e-05	0.0209	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
THYM	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-4.34	3.65e-05	0.0209	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
THYM	cis	rs7202877	0.61	rs3844219	ENSG00000261783.1	RP11-252K23.2	-4.34	3.65e-05	0.0209	-0.57	-0.41	Type 1 diabetes;Type 2 diabetes;	chr16:75336332	chr16:75379818~75381260:-
THYM	cis	rs10483853	0.579	rs10134243	ENSG00000258695.2	RP3-414A15.2	-4.33	3.66e-05	0.021	-0.6	-0.41	Coronary artery calcification;	chr14:73478444	chr14:73522878~73530610:+
THYM	cis	rs5742933	0.69	rs62183656	ENSG00000273240.1	RP11-455J20.3	-4.33	3.66e-05	0.021	-0.68	-0.41	Ferritin levels;	chr2:189669387	chr2:189763859~189764456:-
THYM	cis	rs5742933	0.69	rs62183658	ENSG00000273240.1	RP11-455J20.3	-4.33	3.66e-05	0.021	-0.68	-0.41	Ferritin levels;	chr2:189669491	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs62183659	ENSG00000273240.1	RP11-455J20.3	-4.33	3.66e-05	0.021	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189672131	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs62185869	ENSG00000273240.1	RP11-455J20.3	-4.33	3.66e-05	0.021	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189672330	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs56137655	ENSG00000273240.1	RP11-455J20.3	-4.33	3.66e-05	0.021	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189675844	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs16831873	ENSG00000273240.1	RP11-455J20.3	-4.33	3.66e-05	0.021	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189692172	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs62185874	ENSG00000273240.1	RP11-455J20.3	-4.33	3.66e-05	0.021	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189704288	chr2:189763859~189764456:-
THYM	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-4.33	3.66e-05	0.021	-0.49	-0.41	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
THYM	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-4.33	3.66e-05	0.021	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
THYM	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-4.33	3.66e-05	0.021	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
THYM	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-4.33	3.67e-05	0.021	-0.42	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
THYM	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	4.33	3.67e-05	0.021	0.29	0.41	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
THYM	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	4.33	3.67e-05	0.021	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	4.33	3.67e-05	0.021	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
THYM	cis	rs6121246	0.559	rs6087771	ENSG00000230613.1	HM13-AS1	4.33	3.67e-05	0.021	0.55	0.41	Mean corpuscular hemoglobin;	chr20:31718921	chr20:31567707~31573263:-
THYM	cis	rs2732480	1	rs2732480	ENSG00000240399.1	RP1-228P16.1	-4.33	3.68e-05	0.021	-0.4	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48054813~48055591:-
THYM	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-4.33	3.68e-05	0.0211	-0.58	-0.41	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
THYM	cis	rs17685	0.753	rs6976532	ENSG00000280388.1	RP11-229D13.3	-4.33	3.68e-05	0.0211	-0.41	-0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76043977~76045963:-
THYM	cis	rs17711722	0.51	rs11767457	ENSG00000228409.4	CCT6P1	-4.33	3.68e-05	0.0211	-0.28	-0.41	Calcium levels;	chr7:65825628	chr7:65751142~65763354:+
THYM	cis	rs8177876	0.749	rs11865207	ENSG00000261838.4	RP11-303E16.6	4.33	3.68e-05	0.0211	0.73	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81069854~81076598:+
THYM	cis	rs73198271	0.71	rs11779561	ENSG00000253893.2	FAM85B	4.33	3.68e-05	0.0211	0.59	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.71	rs11779565	ENSG00000253893.2	FAM85B	4.33	3.68e-05	0.0211	0.59	0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:8167819~8226614:-
THYM	cis	rs11891401	0.918	rs13031311	ENSG00000277998.1	RP11-452N17.1	-4.33	3.68e-05	0.0211	-0.52	-0.41	Blood pressure;	chr2:164211009	chr2:164573741~164574054:+
THYM	cis	rs9907295	0.71	rs28912068	ENSG00000270871.1	AC015849.19	4.33	3.69e-05	0.0211	0.43	0.41	Fibroblast growth factor basic levels;	chr17:35881967	chr17:35816717~35830293:-
THYM	cis	rs4853012	0.752	rs13413795	ENSG00000272183.1	RP11-523H20.3	4.33	3.69e-05	0.0211	0.54	0.41	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74501717~74502365:+
THYM	cis	rs7849270	0.879	rs10988200	ENSG00000268707.1	RP11-247A12.7	-4.33	3.69e-05	0.0211	-0.5	-0.41	Blood metabolite ratios;	chr9:129094306	chr9:129170434~129170940:+
THYM	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	4.33	3.69e-05	0.0211	0.53	0.41	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
THYM	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	4.33	3.69e-05	0.0211	0.49	0.41	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
THYM	cis	rs9907295	0.901	rs4795096	ENSG00000270871.1	AC015849.19	4.33	3.69e-05	0.0211	0.37	0.41	Fibroblast growth factor basic levels;	chr17:35888821	chr17:35816717~35830293:-
THYM	cis	rs6121246	0.58	rs6121016	ENSG00000230613.1	HM13-AS1	4.33	3.69e-05	0.0211	0.64	0.41	Mean corpuscular hemoglobin;	chr20:31657436	chr20:31567707~31573263:-
THYM	cis	rs1426063	0.614	rs17266308	ENSG00000249717.1	RP11-44F21.3	-4.33	3.69e-05	0.0211	-0.89	-0.41	QT interval;	chr4:75137695	chr4:74955974~74970362:-
THYM	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	4.33	3.69e-05	0.0211	0.81	0.41	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
THYM	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-4.33	3.7e-05	0.0211	-0.45	-0.41	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-4.33	3.7e-05	0.0211	-0.45	-0.41	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-4.33	3.7e-05	0.0211	-0.45	-0.41	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-4.33	3.7e-05	0.0211	-0.45	-0.41	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
THYM	cis	rs6674176	0.597	rs4031031	ENSG00000237950.1	RP11-7O11.3	4.33	3.7e-05	0.0211	0.41	0.41	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927861	chr1:43944370~43946551:-
THYM	cis	rs11574514	1	rs116908316	ENSG00000260891.1	RP11-96D1.5	-4.33	3.7e-05	0.0211	-0.5	-0.41	Crohn's disease;	chr16:67771052	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs78575122	ENSG00000260891.1	RP11-96D1.5	-4.33	3.7e-05	0.0211	-0.5	-0.41	Crohn's disease;	chr16:67835638	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs1113232	ENSG00000260891.1	RP11-96D1.5	-4.33	3.7e-05	0.0211	-0.5	-0.41	Crohn's disease;	chr16:67845924	chr16:68212401~68221671:-
THYM	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	4.33	3.7e-05	0.0211	0.54	0.41	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
THYM	cis	rs853679	0.517	rs1340004	ENSG00000199851.2	U3	4.33	3.7e-05	0.0212	0.6	0.41	Depression;	chr6:28135913	chr6:28015568~28015777:+
THYM	cis	rs7208859	0.673	rs2470251	ENSG00000266490.1	CTD-2349P21.9	4.33	3.7e-05	0.0212	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30792372~30792833:+
THYM	cis	rs7631605	0.905	rs9876116	ENSG00000272334.1	RP11-129K12.1	-4.33	3.7e-05	0.0212	-0.41	-0.41	Cerebrospinal P-tau181p levels;	chr3:37042249	chr3:36973117~36973672:-
THYM	cis	rs1550115	0.524	rs72792199	ENSG00000271936.1	RP11-443B20.1	-4.33	3.71e-05	0.0212	-0.34	-0.41	Coronary artery disease;	chr2:24833627	chr2:24825610~24826717:+
THYM	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-4.33	3.71e-05	0.0212	-0.53	-0.41	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
THYM	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-4.33	3.71e-05	0.0212	-0.53	-0.41	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
THYM	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-4.33	3.71e-05	0.0212	-0.53	-0.41	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
THYM	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-4.33	3.71e-05	0.0212	-0.53	-0.41	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
THYM	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	4.33	3.71e-05	0.0212	0.59	0.41	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
THYM	cis	rs11157436	0.846	rs12435431	ENSG00000211812.1	TRAV26-2	-4.33	3.72e-05	0.0212	-0.27	-0.41	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22202583~22203368:+
THYM	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	4.33	3.72e-05	0.0213	0.35	0.41	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
THYM	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	4.33	3.72e-05	0.0213	0.35	0.41	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
THYM	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	4.33	3.72e-05	0.0213	0.35	0.41	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
THYM	cis	rs4478858	0.698	rs10914370	ENSG00000260386.4	LINC01225	4.33	3.72e-05	0.0213	0.22	0.41	Alcohol dependence;	chr1:31382108	chr1:31500085~31540885:+
THYM	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	4.33	3.72e-05	0.0213	0.52	0.41	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
THYM	cis	rs61270009	0.955	rs4916907	ENSG00000247828.6	TMEM161B-AS1	4.33	3.72e-05	0.0213	0.34	0.41	Depressive symptoms;	chr5:88364163	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs12657776	ENSG00000247828.6	TMEM161B-AS1	4.33	3.72e-05	0.0213	0.34	0.41	Depressive symptoms;	chr5:88365776	chr5:88268895~88436685:+
THYM	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	4.33	3.72e-05	0.0213	0.44	0.41	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
THYM	cis	rs11017328	0.5	rs7099191	ENSG00000236303.2	RP11-540N6.1	-4.33	3.73e-05	0.0213	-0.55	-0.41	Conotruncal heart defects;	chr10:130519545	chr10:130439067~130483154:+
THYM	cis	rs11017328	0.5	rs7083875	ENSG00000236303.2	RP11-540N6.1	-4.33	3.73e-05	0.0213	-0.55	-0.41	Conotruncal heart defects;	chr10:130519546	chr10:130439067~130483154:+
THYM	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	4.33	3.73e-05	0.0213	0.39	0.41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
THYM	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	4.33	3.73e-05	0.0213	0.35	0.41	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
THYM	cis	rs7005380	0.62	rs10094455	ENSG00000245330.4	KB-1471A8.1	4.33	3.73e-05	0.0213	0.57	0.41	Interstitial lung disease;	chr8:119892436	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10094458	ENSG00000245330.4	KB-1471A8.1	4.33	3.73e-05	0.0213	0.57	0.41	Interstitial lung disease;	chr8:119892448	chr8:119867419~119874488:-
THYM	cis	rs4671400	0.571	rs28480287	ENSG00000273302.1	RP11-493E12.2	-4.33	3.73e-05	0.0213	-0.45	-0.41	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61262154	chr2:61199979~61200769:+
THYM	cis	rs4671400	0.571	rs62152270	ENSG00000273302.1	RP11-493E12.2	-4.33	3.73e-05	0.0213	-0.45	-0.41	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267125	chr2:61199979~61200769:+
THYM	cis	rs4671400	0.571	rs12615222	ENSG00000273302.1	RP11-493E12.2	-4.33	3.73e-05	0.0213	-0.45	-0.41	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267760	chr2:61199979~61200769:+
THYM	cis	rs4671400	0.571	rs4672429	ENSG00000273302.1	RP11-493E12.2	-4.33	3.73e-05	0.0213	-0.45	-0.41	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61268334	chr2:61199979~61200769:+
THYM	cis	rs1023500	0.505	rs134888	ENSG00000227370.1	RP4-669P10.19	4.33	3.74e-05	0.0213	0.48	0.41	Schizophrenia;	chr22:42278275	chr22:42132543~42132998:+
THYM	cis	rs2115630	1	rs10220733	ENSG00000275120.1	RP11-182J1.17	-4.33	3.74e-05	0.0213	-0.47	-0.41	P wave terminal force;	chr15:84737633	chr15:84599434~84606463:-
THYM	cis	rs2115630	1	rs1030863	ENSG00000275120.1	RP11-182J1.17	-4.33	3.74e-05	0.0213	-0.47	-0.41	P wave terminal force;	chr15:84739404	chr15:84599434~84606463:-
THYM	cis	rs10129255	0.789	rs4389062	ENSG00000254329.1	IGHVII-60-1	4.33	3.74e-05	0.0213	0.39	0.41	Kawasaki disease;	chr14:106704589	chr14:106637718~106637973:-
THYM	cis	rs4835473	0.9	rs13134869	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143782301	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs12508285	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143792642	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs7667544	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143793802	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6849896	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143794927	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6826665	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143795140	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs35998817	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143795355	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13134808	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143798339	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.808	rs6831401	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143801038	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.778	rs6853798	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143801153	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs12502940	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143812117	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs12503074	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143812560	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.778	rs2622380	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143814571	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35792820	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143814806	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs62337300	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143815897	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7697498	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143816854	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7656455	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143817005	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13133239	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143818894	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13106488	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143818969	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13105102	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143819046	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs13105118	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143819077	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35271123	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143819629	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1383443	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143819940	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7669198	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143821229	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs6834494	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143822257	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11734290	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143823636	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11734383	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143824093	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs11735295	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143824150	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs62337303	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143824967	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs6838981	ENSG00000249741.2	RP11-673E1.3	4.33	3.75e-05	0.0214	0.35	0.41	Immature fraction of reticulocytes;	chr4:143826484	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7670010	ENSG00000249741.2	RP11-673E1.3	-4.33	3.75e-05	0.0214	-0.35	-0.41	Immature fraction of reticulocytes;	chr4:143821679	chr4:143911514~143912053:-
THYM	cis	rs17685	0.753	rs10085567	ENSG00000280388.1	RP11-229D13.3	-4.33	3.75e-05	0.0214	-0.41	-0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76104888	chr7:76043977~76045963:-
THYM	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	4.33	3.75e-05	0.0214	0.32	0.41	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	4.33	3.75e-05	0.0214	0.32	0.41	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	4.33	3.75e-05	0.0214	0.32	0.41	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	4.33	3.75e-05	0.0214	0.32	0.41	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	4.33	3.75e-05	0.0214	0.32	0.41	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
THYM	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	4.33	3.75e-05	0.0214	0.52	0.41	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
THYM	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	4.33	3.75e-05	0.0214	0.52	0.41	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
THYM	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	4.33	3.76e-05	0.0214	0.47	0.41	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
THYM	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-4.33	3.76e-05	0.0214	-0.43	-0.41	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
THYM	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-4.33	3.76e-05	0.0214	-0.43	-0.41	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
THYM	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	4.33	3.76e-05	0.0214	0.43	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
THYM	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	4.33	3.76e-05	0.0214	0.43	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
THYM	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	4.33	3.76e-05	0.0214	0.43	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
THYM	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	4.33	3.76e-05	0.0214	0.43	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
THYM	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	4.33	3.76e-05	0.0214	0.43	0.41	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
THYM	cis	rs202072	0.818	rs405078	ENSG00000272379.1	RP1-257A7.5	4.33	3.76e-05	0.0214	0.55	0.41	HIV-1 viral setpoint;	chr6:13279635	chr6:13290018~13290490:-
THYM	cis	rs11096990	0.855	rs2711990	ENSG00000249685.1	RP11-360F5.3	-4.33	3.76e-05	0.0214	-0.4	-0.41	Cognitive function;	chr4:39150116	chr4:39133913~39135608:+
THYM	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	4.33	3.76e-05	0.0214	0.29	0.41	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
THYM	cis	rs8177812	0.759	rs2228083	ENSG00000271631.1	RP11-408O19.5	-4.33	3.76e-05	0.0214	-0.7	-0.41	Lead levels in blood;	chr9:113390660	chr9:112885158~112885767:+
THYM	cis	rs8177812	0.759	rs8177805	ENSG00000271631.1	RP11-408O19.5	-4.33	3.76e-05	0.0214	-0.7	-0.41	Lead levels in blood;	chr9:113390786	chr9:112885158~112885767:+
THYM	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	4.33	3.76e-05	0.0214	0.54	0.41	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
THYM	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-4.33	3.76e-05	0.0214	-0.4	-0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
THYM	cis	rs801193	0.591	rs9986881	ENSG00000228409.4	CCT6P1	-4.33	3.76e-05	0.0214	-0.29	-0.41	Aortic root size;	chr7:66708053	chr7:65751142~65763354:+
THYM	cis	rs7560272	0.538	rs12233112	ENSG00000163016.8	ALMS1P	-4.33	3.77e-05	0.0215	-0.51	-0.41	Schizophrenia;	chr2:73704637	chr2:73644919~73685576:+
THYM	cis	rs8067545	0.75	rs9915758	ENSG00000230528.6	NOS2P3	-4.33	3.77e-05	0.0215	-0.33	-0.41	Schizophrenia;	chr17:20061462	chr17:20436337~20447249:+
THYM	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-4.33	3.77e-05	0.0215	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
THYM	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	4.33	3.77e-05	0.0215	0.46	0.41	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
THYM	cis	rs1550115	1	rs2891409	ENSG00000271936.1	RP11-443B20.1	4.33	3.78e-05	0.0215	0.28	0.41	Coronary artery disease;	chr2:24794488	chr2:24825610~24826717:+
THYM	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-4.33	3.78e-05	0.0215	-0.32	-0.41	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
THYM	cis	rs7851726	0.69	rs10821404	ENSG00000232063.1	RP11-307E17.8	4.33	3.79e-05	0.0216	0.4	0.41	Urinary albumin-to-creatinine ratio;	chr9:94834583	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.69	rs4743969	ENSG00000232063.1	RP11-307E17.8	4.33	3.79e-05	0.0216	0.4	0.41	Urinary albumin-to-creatinine ratio;	chr9:94836684	chr9:94332476~94360948:+
THYM	cis	rs9907295	0.685	rs9909050	ENSG00000270977.1	AC015849.16	-4.33	3.79e-05	0.0216	-0.67	-0.41	Fibroblast growth factor basic levels;	chr17:35887129	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs59338510	ENSG00000270977.1	AC015849.16	-4.33	3.79e-05	0.0216	-0.67	-0.41	Fibroblast growth factor basic levels;	chr17:35888098	chr17:35893707~35911023:-
THYM	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-4.33	3.79e-05	0.0216	-0.47	-0.41	Depression;	chr6:28103220	chr6:28115628~28116551:+
THYM	cis	rs4760854	0.639	rs4760771	ENSG00000257815.4	RP11-611E13.2	4.33	3.79e-05	0.0216	0.32	0.41	IgG glycosylation;	chr12:70896162	chr12:69904033~70243360:-
THYM	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-4.33	3.79e-05	0.0216	-0.52	-0.41	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
THYM	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	4.33	3.8e-05	0.0216	0.35	0.41	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
THYM	cis	rs10129255	1	rs4612959	ENSG00000253703.1	IGHV1-68	-4.32	3.8e-05	0.0216	-0.52	-0.41	Kawasaki disease;	chr14:106767055	chr14:106703852~106704146:-
THYM	cis	rs10129255	1	rs10129407	ENSG00000253703.1	IGHV1-68	-4.32	3.8e-05	0.0216	-0.52	-0.41	Kawasaki disease;	chr14:106767956	chr14:106703852~106704146:-
THYM	cis	rs10129255	1	rs10129255	ENSG00000253703.1	IGHV1-68	4.32	3.8e-05	0.0216	0.52	0.41	Kawasaki disease;	chr14:106767970	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.879	rs10137103	ENSG00000254329.1	IGHVII-60-1	4.32	3.8e-05	0.0216	0.4	0.41	Kawasaki disease;	chr14:106703184	chr14:106637718~106637973:-
THYM	cis	rs4835473	0.932	rs2323193	ENSG00000249741.2	RP11-673E1.3	4.32	3.8e-05	0.0216	0.34	0.41	Immature fraction of reticulocytes;	chr4:143752812	chr4:143911514~143912053:-
THYM	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-4.32	3.8e-05	0.0216	-0.41	-0.41	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-4.32	3.8e-05	0.0216	-0.41	-0.41	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
THYM	cis	rs2408955	0.521	rs1476607	ENSG00000240399.1	RP1-228P16.1	-4.32	3.81e-05	0.0217	-0.39	-0.41	Glycated hemoglobin levels;	chr12:48131021	chr12:48054813~48055591:-
THYM	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-4.32	3.81e-05	0.0217	-0.35	-0.41	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
THYM	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-4.32	3.81e-05	0.0217	-0.32	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
THYM	cis	rs9527	1	rs4919690	ENSG00000272933.1	RP11-47A8.5	-4.32	3.81e-05	0.0217	-0.45	-0.41	Arsenic metabolism;	chr10:102856743	chr10:102642792~102644140:-
THYM	cis	rs7005380	0.6	rs13267896	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119908414	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs13275524	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119908701	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs6469867	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119909172	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.58	rs6469868	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119909601	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.606	rs6469869	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119909696	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6469870	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119909773	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6469871	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119909839	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs6469872	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119910007	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs7015470	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119910101	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs6995139	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119910157	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10217077	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119910943	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10217083	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119911045	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs939242	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119912030	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs939241	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119912297	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs10216503	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119912843	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7824545	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119913381	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7387264	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119913758	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.62	rs7388508	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119913913	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.6	rs1607624	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119917049	chr8:119867419~119874488:-
THYM	cis	rs10129255	0.518	rs10150460	ENSG00000254329.1	IGHVII-60-1	-4.32	3.82e-05	0.0217	-0.36	-0.41	Kawasaki disease;	chr14:106677179	chr14:106637718~106637973:-
THYM	cis	rs4835473	0.897	rs7676614	ENSG00000249741.2	RP11-673E1.3	4.32	3.82e-05	0.0217	0.36	0.41	Immature fraction of reticulocytes;	chr4:143695213	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.832	rs55935372	ENSG00000249741.2	RP11-673E1.3	4.32	3.82e-05	0.0217	0.36	0.41	Immature fraction of reticulocytes;	chr4:143700626	chr4:143911514~143912053:-
THYM	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-4.32	3.82e-05	0.0217	-0.36	-0.41	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-4.32	3.82e-05	0.0217	-0.36	-0.41	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-4.32	3.82e-05	0.0217	-0.36	-0.41	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	4.32	3.82e-05	0.0217	0.36	0.41	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
THYM	cis	rs1439840	1	rs10207328	ENSG00000213239.3	NPM1P32	4.32	3.82e-05	0.0217	0.99	0.41	QT interval (sulfonylurea treatment interaction);	chr2:122651178	chr2:121708512~121709115:-
THYM	cis	rs7631605	0.905	rs11916897	ENSG00000272334.1	RP11-129K12.1	-4.32	3.82e-05	0.0217	-0.43	-0.41	Cerebrospinal P-tau181p levels;	chr3:37169637	chr3:36973117~36973672:-
THYM	cis	rs7851726	0.69	rs7848139	ENSG00000232063.1	RP11-307E17.8	4.32	3.82e-05	0.0217	0.4	0.41	Urinary albumin-to-creatinine ratio;	chr9:94733185	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.676	rs10821398	ENSG00000232063.1	RP11-307E17.8	4.32	3.82e-05	0.0217	0.4	0.41	Urinary albumin-to-creatinine ratio;	chr9:94815277	chr9:94332476~94360948:+
THYM	cis	rs10993397	0.507	rs10993366	ENSG00000232063.1	RP11-307E17.8	4.32	3.82e-05	0.0217	0.4	0.41	Polycystic ovary syndrome;	chr9:94844308	chr9:94332476~94360948:+
THYM	cis	rs7005380	0.58	rs13263296	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119874305	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.58	rs10110216	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119875307	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.58	rs10110223	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119875326	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.58	rs11781657	ENSG00000245330.4	KB-1471A8.1	4.32	3.82e-05	0.0217	0.58	0.41	Interstitial lung disease;	chr8:119877002	chr8:119867419~119874488:-
THYM	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-4.32	3.82e-05	0.0217	-0.35	-0.41	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
THYM	cis	rs4478858	0.684	rs4949369	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31250998	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs10753245	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31258361	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs10798839	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31258911	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs7519766	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31262665	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs11579845	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31263401	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs4949202	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31263953	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.647	rs7524117	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31265569	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs4949373	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31268730	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs7544946	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31276889	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs7549245	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31279340	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs4949374	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31281664	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs3766289	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31287281	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs7521463	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31289089	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.611	rs7527645	ENSG00000260386.4	LINC01225	4.32	3.82e-05	0.0217	0.22	0.41	Alcohol dependence;	chr1:31290940	chr1:31500085~31540885:+
THYM	cis	rs1439840	1	rs34455092	ENSG00000213239.3	NPM1P32	4.32	3.83e-05	0.0217	1.12	0.41	QT interval (sulfonylurea treatment interaction);	chr2:122643491	chr2:121708512~121709115:-
THYM	cis	rs3015497	0.753	rs12881776	ENSG00000270062.1	RP11-248J18.3	4.32	3.83e-05	0.0217	0.3	0.41	Mean platelet volume;	chr14:50669612	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.626	rs7150204	ENSG00000270062.1	RP11-248J18.3	4.32	3.83e-05	0.0217	0.3	0.41	Mean platelet volume;	chr14:50670637	chr14:50723777~50724272:-
THYM	cis	rs972578	1	rs1569510	ENSG00000215347.3	SLC25A5P1	4.32	3.83e-05	0.0217	0.32	0.41	Mean platelet volume;	chr22:42963442	chr22:42001069~42001966:-
THYM	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	4.32	3.83e-05	0.0217	0.33	0.41	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
THYM	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	4.32	3.83e-05	0.0217	0.35	0.41	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
THYM	cis	rs2283792	0.871	rs8136867	ENSG00000228050.1	TOP3BP1	4.32	3.84e-05	0.0218	0.43	0.41	Multiple sclerosis;	chr22:21850504	chr22:22223187~22224566:-
THYM	cis	rs10518325	0.892	rs1489541	ENSG00000260404.2	RP11-384K6.6	-4.32	3.84e-05	0.0218	-0.44	-0.41	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118720855	chr4:118591773~118633729:+
THYM	cis	rs9907295	0.786	rs56344830	ENSG00000270871.1	AC015849.19	4.32	3.84e-05	0.0218	0.49	0.41	Fibroblast growth factor basic levels;	chr17:35903951	chr17:35816717~35830293:-
THYM	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-4.32	3.84e-05	0.0218	-0.35	-0.41	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
THYM	cis	rs10129255	0.957	rs28887506	ENSG00000254329.1	IGHVII-60-1	4.32	3.84e-05	0.0218	0.42	0.41	Kawasaki disease;	chr14:106785589	chr14:106637718~106637973:-
THYM	cis	rs7789940	0.904	rs12531348	ENSG00000205583.12	STAG3L1	-4.32	3.85e-05	0.0218	-0.36	-0.41	Multiple sclerosis;	chr7:76307874	chr7:75359194~75395383:+
THYM	cis	rs7789940	0.904	rs61294900	ENSG00000205583.12	STAG3L1	-4.32	3.85e-05	0.0218	-0.36	-0.41	Multiple sclerosis;	chr7:76307895	chr7:75359194~75395383:+
THYM	cis	rs7789940	0.904	rs7459185	ENSG00000205583.12	STAG3L1	4.32	3.85e-05	0.0218	0.36	0.41	Multiple sclerosis;	chr7:76305323	chr7:75359194~75395383:+
THYM	cis	rs4835473	0.897	rs35598237	ENSG00000249741.2	RP11-673E1.3	4.32	3.85e-05	0.0218	0.34	0.41	Immature fraction of reticulocytes;	chr4:143735961	chr4:143911514~143912053:-
THYM	cis	rs6674176	0.569	rs34830883	ENSG00000237950.1	RP11-7O11.3	4.32	3.86e-05	0.0219	0.44	0.41	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43939667	chr1:43944370~43946551:-
THYM	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	4.32	3.86e-05	0.0219	0.45	0.41	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	4.32	3.86e-05	0.0219	0.45	0.41	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	4.32	3.86e-05	0.0219	0.45	0.41	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
THYM	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	4.32	3.86e-05	0.0219	0.45	0.41	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
THYM	cis	rs17445774	1	rs1509833	ENSG00000232732.8	AC073043.1	-4.32	3.86e-05	0.0219	-0.54	-0.41	LDL cholesterol to HDL cholesterol ratio;	chr2:200000502	chr2:199867396~199911159:-
THYM	cis	rs4835473	0.9	rs10027246	ENSG00000249741.2	RP11-673E1.3	4.32	3.86e-05	0.0219	0.34	0.41	Immature fraction of reticulocytes;	chr4:143935069	chr4:143911514~143912053:-
THYM	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	4.32	3.86e-05	0.0219	0.55	0.41	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
THYM	cis	rs897984	0.762	rs8062719	ENSG00000275263.1	RP11-1072A3.4	4.32	3.86e-05	0.0219	0.35	0.41	Dementia with Lewy bodies;	chr16:30991343	chr16:30956872~30957199:-
THYM	cis	rs7560272	0.538	rs4241257	ENSG00000163016.8	ALMS1P	-4.32	3.87e-05	0.0219	-0.51	-0.41	Schizophrenia;	chr2:73711480	chr2:73644919~73685576:+
THYM	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	4.32	3.87e-05	0.0219	0.39	0.41	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	4.32	3.87e-05	0.0219	0.39	0.41	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	4.32	3.87e-05	0.0219	0.39	0.41	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
THYM	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	4.32	3.87e-05	0.0219	0.51	0.41	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	4.32	3.87e-05	0.0219	0.51	0.41	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
THYM	cis	rs17685	0.753	rs8200	ENSG00000280388.1	RP11-229D13.3	4.32	3.87e-05	0.0219	0.41	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76067288	chr7:76043977~76045963:-
THYM	cis	rs1790761	0.607	rs656652	ENSG00000231793.4	DOC2GP	-4.32	3.87e-05	0.0219	-0.37	-0.41	Mean corpuscular volume;	chr11:67576486	chr11:67612653~67616257:-
THYM	cis	rs1790761	0.632	rs625978	ENSG00000231793.4	DOC2GP	-4.32	3.87e-05	0.0219	-0.37	-0.41	Mean corpuscular volume;	chr11:67577193	chr11:67612653~67616257:-
THYM	cis	rs10129255	0.536	rs17113249	ENSG00000254329.1	IGHVII-60-1	4.32	3.87e-05	0.0219	0.36	0.41	Kawasaki disease;	chr14:106678273	chr14:106637718~106637973:-
THYM	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-4.32	3.87e-05	0.0219	-0.31	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
THYM	cis	rs2289328	0.943	rs3803359	ENSG00000223313.1	RNU6-516P	4.32	3.88e-05	0.022	0.52	0.41	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40370547	chr15:40529570~40529673:+
THYM	cis	rs10129255	0.53	rs11624912	ENSG00000254329.1	IGHVII-60-1	4.32	3.88e-05	0.022	0.36	0.41	Kawasaki disease;	chr14:106673891	chr14:106637718~106637973:-
THYM	cis	rs10131894	0.635	rs174997	ENSG00000258646.1	RP11-950C14.3	4.32	3.88e-05	0.022	0.35	0.41	Coronary artery disease;	chr14:74968103	chr14:75004719~75008481:-
THYM	cis	rs1642645	0.831	rs1327711	ENSG00000228452.1	RP5-994D16.9	-4.32	3.88e-05	0.022	-0.53	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42030278	chr1:42775813~42776790:-
THYM	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-4.32	3.88e-05	0.022	-0.4	-0.41	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
THYM	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-4.32	3.88e-05	0.022	-0.52	-0.41	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
THYM	cis	rs8177876	0.822	rs804902	ENSG00000261838.4	RP11-303E16.6	4.32	3.88e-05	0.022	0.74	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81069854~81076598:+
THYM	cis	rs12681366	1	rs12681366	ENSG00000253704.1	RP11-267M23.4	4.32	3.89e-05	0.022	0.51	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94389037	chr8:94553722~94569745:+
THYM	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-4.32	3.89e-05	0.022	-0.5	-0.41	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
THYM	cis	rs2235573	0.718	rs4373009	ENSG00000272669.1	RP3-508I15.21	4.32	3.89e-05	0.022	0.26	0.41	Glioma;Glioblastoma;	chr22:38094049	chr22:38742625~38743115:+
THYM	cis	rs2289328	0.941	rs11636147	ENSG00000223313.1	RNU6-516P	-4.32	3.9e-05	0.022	-0.58	-0.41	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40428929	chr15:40529570~40529673:+
THYM	cis	rs2289328	1	rs11634187	ENSG00000223313.1	RNU6-516P	-4.32	3.9e-05	0.022	-0.58	-0.41	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40430582	chr15:40529570~40529673:+
THYM	cis	rs73108077	1	rs12479885	ENSG00000277112.2	RP11-755J8.1	-4.32	3.9e-05	0.022	-0.7	-0.41	Red blood cell density in sickle cell anemia;	chr20:31398024	chr20:30681825~30723932:-
THYM	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-4.32	3.9e-05	0.0221	-0.45	-0.41	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-4.32	3.9e-05	0.0221	-0.45	-0.41	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
THYM	cis	rs10129255	0.557	rs72622064	ENSG00000253209.1	IGHV3-65	4.32	3.9e-05	0.0221	0.4	0.41	Kawasaki disease;	chr14:106651784	chr14:106666092~106666532:-
THYM	cis	rs453301	0.657	rs36056437	ENSG00000253893.2	FAM85B	4.32	3.9e-05	0.0221	0.52	0.41	Joint mobility (Beighton score);	chr8:8935355	chr8:8167819~8226614:-
THYM	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	4.32	3.91e-05	0.0221	0.54	0.41	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
THYM	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-4.32	3.91e-05	0.0221	-0.4	-0.41	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
THYM	cis	rs10829156	0.732	rs10741086	ENSG00000240291.1	RP11-499P20.2	4.32	3.91e-05	0.0221	0.39	0.41	Sudden cardiac arrest;	chr10:18505027	chr10:18513115~18545651:-
THYM	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
THYM	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
THYM	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
THYM	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-4.32	3.92e-05	0.0221	-0.46	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
THYM	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-4.32	3.92e-05	0.0221	-0.62	-0.41	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
THYM	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	4.32	3.92e-05	0.0221	0.62	0.41	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
THYM	cis	rs9611519	1	rs2273085	ENSG00000235513.1	RP4-756G23.5	4.32	3.92e-05	0.0221	0.35	0.41	Neuroticism;	chr22:41219372	chr22:41209122~41217627:-
THYM	cis	rs9611519	1	rs5758264	ENSG00000235513.1	RP4-756G23.5	4.32	3.92e-05	0.0221	0.35	0.41	Neuroticism;	chr22:41220280	chr22:41209122~41217627:-
THYM	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-4.32	3.92e-05	0.0221	-0.53	-0.41	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
THYM	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-4.32	3.92e-05	0.0221	-0.53	-0.41	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
THYM	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-4.32	3.92e-05	0.0221	-0.53	-0.41	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
THYM	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-4.32	3.92e-05	0.0221	-0.53	-0.41	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
THYM	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	4.32	3.93e-05	0.0222	0.35	0.41	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	4.32	3.93e-05	0.0222	0.35	0.41	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	4.32	3.93e-05	0.0222	0.35	0.41	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	4.32	3.93e-05	0.0222	0.35	0.41	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	4.32	3.93e-05	0.0222	0.35	0.41	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
THYM	cis	rs7202877	0.706	rs37599	ENSG00000261783.1	RP11-252K23.2	4.32	3.93e-05	0.0222	0.57	0.41	Type 1 diabetes;Type 2 diabetes;	chr16:75468234	chr16:75379818~75381260:-
THYM	cis	rs7849270	1	rs2768630	ENSG00000268707.1	RP11-247A12.7	4.32	3.93e-05	0.0222	0.53	0.41	Blood metabolite ratios;	chr9:129104109	chr9:129170434~129170940:+
THYM	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	4.32	3.94e-05	0.0222	0.46	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
THYM	cis	rs4908768	0.501	rs11121186	ENSG00000232912.4	RP5-1115A15.1	4.32	3.94e-05	0.0222	0.39	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs4908761	ENSG00000232912.4	RP5-1115A15.1	4.32	3.94e-05	0.0222	0.39	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs6669503	ENSG00000232912.4	RP5-1115A15.1	4.32	3.94e-05	0.0222	0.39	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8424645~8434838:+
THYM	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-4.32	3.94e-05	0.0222	-0.29	-0.41	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
THYM	cis	rs1900504	0.584	rs2915756	ENSG00000266200.5	PNLIPRP2	-4.31	3.95e-05	0.0223	-0.48	-0.41	Tonsillectomy;	chr10:116603428	chr10:116620953~116645143:+
THYM	cis	rs1900504	0.584	rs3010501	ENSG00000266200.5	PNLIPRP2	-4.31	3.95e-05	0.0223	-0.48	-0.41	Tonsillectomy;	chr10:116604130	chr10:116620953~116645143:+
THYM	cis	rs1900504	0.584	rs2915754	ENSG00000266200.5	PNLIPRP2	-4.31	3.95e-05	0.0223	-0.48	-0.41	Tonsillectomy;	chr10:116605306	chr10:116620953~116645143:+
THYM	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	4.31	3.95e-05	0.0223	0.88	0.41	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
THYM	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	4.31	3.95e-05	0.0223	0.51	0.41	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
THYM	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	4.31	3.95e-05	0.0223	0.51	0.41	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
THYM	cis	rs972578	0.967	rs1040427	ENSG00000215347.3	SLC25A5P1	4.31	3.95e-05	0.0223	0.32	0.41	Mean platelet volume;	chr22:42977564	chr22:42001069~42001966:-
THYM	cis	rs2140773	0.835	rs4973050	ENSG00000251791.1	SCARNA6	4.31	3.95e-05	0.0223	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr2:232649928	chr2:233288676~233288940:+
THYM	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	4.31	3.95e-05	0.0223	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
THYM	cis	rs9535495	0.896	rs1570603	ENSG00000200711.1	RNA5SP28	-4.31	3.96e-05	0.0223	-0.47	-0.41	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50811286	chr13:50812988~50813106:-
THYM	cis	rs6121246	0.559	rs1062794	ENSG00000230613.1	HM13-AS1	4.31	3.96e-05	0.0223	0.57	0.41	Mean corpuscular hemoglobin;	chr20:31793955	chr20:31567707~31573263:-
THYM	cis	rs5771242	0.776	rs6010198	ENSG00000273253.2	RP3-402G11.26	4.31	3.96e-05	0.0223	0.53	0.41	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:50199090~50200837:-
THYM	cis	rs7044106	1	rs7044106	ENSG00000238181.2	AHCYP2	-4.31	3.96e-05	0.0223	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120720673~120721972:+
THYM	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-4.31	3.96e-05	0.0224	-0.38	-0.41	Migraine;	chr4:56879297	chr4:56960927~56961373:-
THYM	cis	rs12902680	0.706	rs1465724	ENSG00000259520.4	CTD-2651B20.3	4.31	3.97e-05	0.0224	0.42	0.41	Neuroticism;	chr15:46222905	chr15:45251580~45279251:-
THYM	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	4.31	3.97e-05	0.0224	0.52	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
THYM	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-4.31	3.97e-05	0.0224	-0.45	-0.41	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-4.31	3.97e-05	0.0224	-0.45	-0.41	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
THYM	cis	rs12439619	0.693	rs7165536	ENSG00000274376.3	ADAMTS7P1	4.31	3.98e-05	0.0224	0.44	0.41	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82298553~82334609:+
THYM	cis	rs4852324	0.541	rs7568898	ENSG00000217702.2	RP11-287D1.4	4.31	3.98e-05	0.0224	0.82	0.41	Systemic lupus erythematosus;	chr2:74044450	chr2:74130583~74135395:+
THYM	cis	rs3753275	0.684	rs2401190	ENSG00000230679.1	ENO1-AS1	4.31	3.98e-05	0.0225	0.48	0.41	Educational attainment;	chr1:8758553	chr1:8878835~8879894:+
THYM	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	4.31	3.98e-05	0.0225	0.42	0.41	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	4.31	3.98e-05	0.0225	0.42	0.41	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
THYM	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	4.31	3.98e-05	0.0225	0.51	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	4.31	3.98e-05	0.0225	0.51	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
THYM	cis	rs4591358	0.689	rs12471810	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549969	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs2133860	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195551243	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs6759817	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553739	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs6760142	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553911	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs6434785	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195554142	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.638	rs16837243	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195556458	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927794	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195558607	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.638	rs6704955	ENSG00000223466.1	AC064834.2	-4.31	3.99e-05	0.0225	-0.51	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559393	chr2:195533035~195538681:+
THYM	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-4.31	3.99e-05	0.0225	-0.55	-0.41	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
THYM	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-4.31	3.99e-05	0.0225	-0.47	-0.41	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
THYM	cis	rs9309473	0.5	rs12472502	ENSG00000273245.1	RP11-434P11.2	-4.31	3.99e-05	0.0225	-0.43	-0.41	Metabolite levels;	chr2:73632057	chr2:73750256~73750786:-
THYM	cis	rs1642645	0.757	rs6600394	ENSG00000228452.1	RP5-994D16.9	-4.31	3.99e-05	0.0225	-0.53	-0.41	Left ventricular obstructive tract defect (maternal effect);	chr1:42006782	chr1:42775813~42776790:-
THYM	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-4.31	3.99e-05	0.0225	-0.47	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
THYM	cis	rs62184315	0.536	rs62185897	ENSG00000273240.1	RP11-455J20.3	-4.31	3.99e-05	0.0225	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189721279	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs2278591	ENSG00000273240.1	RP11-455J20.3	-4.31	3.99e-05	0.0225	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189755778	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs62184265	ENSG00000273240.1	RP11-455J20.3	-4.31	3.99e-05	0.0225	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189756231	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs16831972	ENSG00000273240.1	RP11-455J20.3	-4.31	3.99e-05	0.0225	-0.68	-0.41	Alcohol dependence (age at onset);	chr2:189756707	chr2:189763859~189764456:-
THYM	cis	rs875971	0.545	rs221986	ENSG00000164669.11	INTS4P1	4.31	4e-05	0.0225	0.59	0.41	Aortic root size;	chr7:66105323	chr7:65141225~65234216:+
THYM	cis	rs34012755	1	rs34012755	ENSG00000231645.2	KRT17P6	-4.31	4e-05	0.0225	-0.46	-0.41	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:20034096	chr17:20512560~20517479:-
THYM	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	4.31	4e-05	0.0225	0.29	0.41	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
THYM	cis	rs17253792	0.822	rs10142497	ENSG00000186615.9	KTN1-AS1	4.31	4.01e-05	0.0225	0.78	0.41	Putamen volume;	chr14:55581230	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17683656	ENSG00000186615.9	KTN1-AS1	4.31	4.01e-05	0.0225	0.78	0.41	Putamen volume;	chr14:55586643	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10083493	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55578693	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.732	rs10146604	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55579052	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10149408	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55579357	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28409547	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55581108	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28478195	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55581133	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10136155	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55582411	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs13379343	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55583487	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs13379340	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55583628	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs13379342	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55583734	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs13379353	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55583760	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10137340	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55584271	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76918910	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55592044	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77599953	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55592187	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10137364	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55593269	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17683728	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55593671	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76264681	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55593729	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17746033	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55595119	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs112374071	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55595201	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs8009608	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55595872	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76201070	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55596886	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10150498	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55597406	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76557162	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55597983	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.908	rs74354306	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55599060	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10133962	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55599370	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10083499	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55599872	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75437558	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55600080	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76267907	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55600251	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75232282	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55600572	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10083431	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55601630	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10083303	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55601803	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78820104	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55602136	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76055105	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55602409	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78386830	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55602506	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75115817	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55602819	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77990307	ENSG00000186615.9	KTN1-AS1	-4.31	4.01e-05	0.0225	-0.78	-0.41	Putamen volume;	chr14:55603331	chr14:55499278~55580110:-
THYM	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-4.31	4.01e-05	0.0225	-0.56	-0.41	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
THYM	cis	rs853679	0.76	rs9393910	ENSG00000216901.1	AL022393.7	4.31	4.01e-05	0.0225	0.69	0.41	Depression;	chr6:28240414	chr6:28176188~28176674:+
THYM	cis	rs853679	0.76	rs9368563	ENSG00000216901.1	AL022393.7	4.31	4.01e-05	0.0225	0.69	0.41	Depression;	chr6:28240780	chr6:28176188~28176674:+
THYM	cis	rs853679	0.76	rs9295768	ENSG00000216901.1	AL022393.7	4.31	4.01e-05	0.0225	0.69	0.41	Depression;	chr6:28241324	chr6:28176188~28176674:+
THYM	cis	rs853679	0.699	rs9468318	ENSG00000216901.1	AL022393.7	4.31	4.01e-05	0.0225	0.69	0.41	Depression;	chr6:28241753	chr6:28176188~28176674:+
THYM	cis	rs12681366	0.919	rs13248829	ENSG00000253704.1	RP11-267M23.4	4.31	4.01e-05	0.0225	0.53	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94553722~94569745:+
THYM	cis	rs73198271	0.653	rs10099808	ENSG00000253893.2	FAM85B	-4.31	4.01e-05	0.0225	-0.57	-0.41	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8167819~8226614:-
THYM	cis	rs4691139	0.658	rs6839773	ENSG00000250227.1	TRIM60P14	4.31	4.01e-05	0.0226	0.49	0.41	Ovarian cancer in BRCA1 mutation carriers;	chr4:165004694	chr4:164915565~164916983:+
THYM	cis	rs4691139	0.658	rs4691141	ENSG00000250227.1	TRIM60P14	4.31	4.01e-05	0.0226	0.49	0.41	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005070	chr4:164915565~164916983:+
THYM	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-4.31	4.02e-05	0.0226	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
THYM	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-4.31	4.02e-05	0.0226	-0.52	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
THYM	cis	rs728616	0.558	rs723192	ENSG00000225484.5	NUTM2B-AS1	-4.31	4.02e-05	0.0226	-0.52	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948257	chr10:79663088~79826594:-
THYM	cis	rs728616	0.614	rs958865	ENSG00000225484.5	NUTM2B-AS1	-4.31	4.02e-05	0.0226	-0.52	-0.41	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948273	chr10:79663088~79826594:-
THYM	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	4.31	4.02e-05	0.0226	0.42	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
THYM	cis	rs9907295	1	rs11653051	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35909166	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs11653016	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35909756	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9889977	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35910691	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9894799	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35911085	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9903590	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35911286	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9897665	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35911595	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9912049	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35912530	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9911016	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35913349	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9912894	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35913452	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9303693	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35913595	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9914468	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35913727	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9893004	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35913855	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9899215	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35914215	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9907145	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35915237	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9901195	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35915576	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.786	rs9901418	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35915699	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs11080361	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35916184	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs11080362	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35916224	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs16971670	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35916548	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9896658	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35916758	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9894314	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35916822	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9897095	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35916928	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9896265	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35916930	chr17:35816717~35830293:-
THYM	cis	rs9907295	1	rs9900236	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35917049	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.892	rs4795100	ENSG00000270871.1	AC015849.19	4.31	4.02e-05	0.0226	0.46	0.41	Fibroblast growth factor basic levels;	chr17:35917470	chr17:35816717~35830293:-
THYM	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	4.31	4.03e-05	0.0226	0.54	0.41	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
THYM	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-4.31	4.03e-05	0.0226	-0.54	-0.41	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
THYM	cis	rs397969	0.621	rs203449	ENSG00000231645.2	KRT17P6	-4.31	4.03e-05	0.0226	-0.49	-0.41	Platelet count;	chr17:19921308	chr17:20512560~20517479:-
THYM	cis	rs2880765	0.706	rs7172006	ENSG00000218052.5	ADAMTS7P4	-4.31	4.03e-05	0.0226	-0.54	-0.41	Coronary artery disease;	chr15:85510128	chr15:85255369~85330334:-
THYM	cis	rs7631605	0.905	rs4678943	ENSG00000272334.1	RP11-129K12.1	-4.31	4.03e-05	0.0226	-0.43	-0.41	Cerebrospinal P-tau181p levels;	chr3:37155864	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs9823120	ENSG00000272334.1	RP11-129K12.1	-4.31	4.03e-05	0.0226	-0.43	-0.41	Cerebrospinal P-tau181p levels;	chr3:37157559	chr3:36973117~36973672:-
THYM	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-4.31	4.03e-05	0.0227	-0.62	-0.41	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
THYM	cis	rs4478858	0.735	rs4949393	ENSG00000260386.4	LINC01225	4.31	4.04e-05	0.0227	0.22	0.41	Alcohol dependence;	chr1:31379028	chr1:31500085~31540885:+
THYM	cis	rs17711722	0.503	rs453835	ENSG00000228409.4	CCT6P1	4.31	4.04e-05	0.0227	0.28	0.41	Calcium levels;	chr7:66046172	chr7:65751142~65763354:+
THYM	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-4.31	4.04e-05	0.0227	-0.47	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
THYM	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-4.31	4.04e-05	0.0227	-0.47	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
THYM	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-4.31	4.04e-05	0.0227	-0.47	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
THYM	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	4.31	4.05e-05	0.0227	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	4.31	4.05e-05	0.0227	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
THYM	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	4.31	4.05e-05	0.0227	0.35	0.41	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
THYM	cis	rs62246343	0.719	rs62246275	ENSG00000254485.4	RP11-380O24.1	4.31	4.05e-05	0.0227	0.63	0.41	Fibrinogen levels;	chr3:9399496	chr3:9292588~9363303:-
THYM	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-4.31	4.05e-05	0.0227	-0.36	-0.41	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-4.31	4.05e-05	0.0227	-0.36	-0.41	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
THYM	cis	rs10129255	0.613	rs916546	ENSG00000253209.1	IGHV3-65	4.31	4.05e-05	0.0227	0.42	0.41	Kawasaki disease;	chr14:106654441	chr14:106666092~106666532:-
THYM	cis	rs4908769	0.624	rs301818	ENSG00000232912.4	RP5-1115A15.1	4.31	4.06e-05	0.0228	0.46	0.41	Allergy;	chr1:8443182	chr1:8424645~8434838:+
THYM	cis	rs61160187	0.698	rs11951503	ENSG00000272308.1	RP11-231G3.1	-4.31	4.06e-05	0.0228	-0.35	-0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:60623013	chr5:60866457~60866935:-
THYM	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-4.31	4.07e-05	0.0228	-0.49	-0.41	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
THYM	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	4.31	4.07e-05	0.0228	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
THYM	cis	rs8067545	0.75	rs3862152	ENSG00000230528.6	NOS2P3	-4.31	4.07e-05	0.0228	-0.33	-0.41	Schizophrenia;	chr17:20056380	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs11871651	ENSG00000230528.6	NOS2P3	-4.31	4.07e-05	0.0228	-0.33	-0.41	Schizophrenia;	chr17:20094112	chr17:20436337~20447249:+
THYM	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-4.31	4.07e-05	0.0228	-0.59	-0.41	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
THYM	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	4.31	4.07e-05	0.0228	0.42	0.41	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
THYM	cis	rs7560272	0.501	rs17350188	ENSG00000163016.8	ALMS1P	4.31	4.08e-05	0.0229	0.48	0.41	Schizophrenia;	chr2:73737715	chr2:73644919~73685576:+
THYM	cis	rs2732480	0.967	rs2732469	ENSG00000240399.1	RP1-228P16.1	4.31	4.08e-05	0.0229	0.41	0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48054813~48055591:-
THYM	cis	rs10131894	0.611	rs175000	ENSG00000258646.1	RP11-950C14.3	4.31	4.09e-05	0.0229	0.35	0.41	Coronary artery disease;	chr14:74969664	chr14:75004719~75008481:-
THYM	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	4.31	4.09e-05	0.0229	0.54	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
THYM	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	4.31	4.09e-05	0.0229	0.35	0.41	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
THYM	cis	rs7927592	0.913	rs7118897	ENSG00000222339.1	AP000807.2	4.3	4.1e-05	0.0229	0.51	0.41	Total body bone mineral density;	chr11:68593212	chr11:68505572~68505651:-
THYM	cis	rs11574514	0.661	rs35356834	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67662462	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117705890	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67680308	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs79407301	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67683361	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs118008021	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67688425	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs78563448	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67697301	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs75843134	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67733650	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117648818	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67757525	chr16:68212401~68221671:-
THYM	cis	rs11574514	0.661	rs117024179	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67761247	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117298895	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67849359	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs76649027	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67872091	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117875362	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67875545	chr16:68212401~68221671:-
THYM	cis	rs11574514	0.744	rs117539386	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67882144	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs118106500	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67897480	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs78033175	ENSG00000260891.1	RP11-96D1.5	-4.3	4.1e-05	0.0229	-0.49	-0.41	Crohn's disease;	chr16:67897528	chr16:68212401~68221671:-
THYM	cis	rs12908161	0.959	rs3748376	ENSG00000275120.1	RP11-182J1.17	4.3	4.1e-05	0.0229	0.56	0.41	Schizophrenia;	chr15:84785121	chr15:84599434~84606463:-
THYM	cis	rs1950357	0.589	rs2144317	ENSG00000258601.1	RP11-81F13.2	4.3	4.1e-05	0.0229	0.4	0.41	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36742752	chr14:36808871~36828729:+
THYM	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-4.3	4.1e-05	0.0229	-0.34	-0.41	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-4.3	4.1e-05	0.0229	-0.34	-0.41	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
THYM	cis	rs1426063	0.614	rs17266308	ENSG00000248165.1	RP11-44F21.2	-4.3	4.11e-05	0.023	-0.88	-0.41	QT interval;	chr4:75137695	chr4:74993877~75034824:-
THYM	cis	rs1167827	0.68	rs1167800	ENSG00000127957.15	PMS2P3	-4.3	4.11e-05	0.023	-0.42	-0.41	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75502930~75528148:-
THYM	cis	rs12439619	0.705	rs17354185	ENSG00000274376.3	ADAMTS7P1	-4.3	4.11e-05	0.023	-0.49	-0.41	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82298553~82334609:+
THYM	cis	rs17685	0.712	rs11770149	ENSG00000280388.1	RP11-229D13.3	-4.3	4.11e-05	0.023	-0.42	-0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:76043977~76045963:-
THYM	cis	rs3796619	1	rs1466215	ENSG00000215367.9	TMED11P	4.3	4.11e-05	0.023	0.39	0.41	Recombination rate (males);	chr4:1078432	chr4:1115197~1153726:-
THYM	cis	rs3796619	0.924	rs11940546	ENSG00000215367.9	TMED11P	4.3	4.11e-05	0.023	0.39	0.41	Recombination rate (males);	chr4:1078697	chr4:1115197~1153726:-
THYM	cis	rs3796619	1	rs1453605	ENSG00000215367.9	TMED11P	4.3	4.11e-05	0.023	0.39	0.41	Recombination rate (males);	chr4:1081983	chr4:1115197~1153726:-
THYM	cis	rs3796619	0.924	rs4690209	ENSG00000215367.9	TMED11P	4.3	4.11e-05	0.023	0.39	0.41	Recombination rate (males);	chr4:1083787	chr4:1115197~1153726:-
THYM	cis	rs3796619	0.961	rs62294748	ENSG00000215367.9	TMED11P	4.3	4.11e-05	0.023	0.39	0.41	Recombination rate (males);	chr4:1089211	chr4:1115197~1153726:-
THYM	cis	rs3796619	1	rs28620427	ENSG00000215367.9	TMED11P	4.3	4.11e-05	0.023	0.39	0.41	Recombination rate (males);	chr4:1092459	chr4:1115197~1153726:-
THYM	cis	rs3796619	1	rs11939380	ENSG00000215367.9	TMED11P	-4.3	4.11e-05	0.023	-0.39	-0.41	Recombination rate (males);	chr4:1093083	chr4:1115197~1153726:-
THYM	cis	rs7474896	0.616	rs1985260	ENSG00000120555.12	SEPT7P9	4.3	4.11e-05	0.023	0.6	0.41	Obesity (extreme);	chr10:38145162	chr10:38383069~38402916:-
THYM	cis	rs3811273	0.614	rs8020929	ENSG00000211816.2	TRAV38-1	-4.3	4.11e-05	0.023	-0.34	-0.41	Periodontal disease-related phenotypes;	chr14:22267444	chr14:22271968~22272563:+
THYM	cis	rs3811273	0.614	rs4982598	ENSG00000211816.2	TRAV38-1	-4.3	4.11e-05	0.023	-0.34	-0.41	Periodontal disease-related phenotypes;	chr14:22267740	chr14:22271968~22272563:+
THYM	cis	rs61270009	0.955	rs2305104	ENSG00000247828.6	TMEM161B-AS1	-4.3	4.12e-05	0.023	-0.34	-0.41	Depressive symptoms;	chr5:88324853	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	4.3	4.12e-05	0.023	0.34	0.41	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	4.3	4.12e-05	0.023	0.34	0.41	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	4.3	4.12e-05	0.023	0.34	0.41	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs12515274	ENSG00000247828.6	TMEM161B-AS1	4.3	4.12e-05	0.023	0.34	0.41	Depressive symptoms;	chr5:88359845	chr5:88268895~88436685:+
THYM	cis	rs5758511	0.689	rs62240864	ENSG00000205702.9	CYP2D7	4.3	4.12e-05	0.023	0.5	0.41	Birth weight;	chr22:42167883	chr22:42140203~42144577:-
THYM	cis	rs1584120	0.57	rs17361776	ENSG00000256321.4	RP11-153K16.1	4.3	4.12e-05	0.023	0.45	0.41	Pelvic organ prolapse (moderate/severe);	chr12:23108719	chr12:23099368~23191587:+
THYM	cis	rs1584120	0.57	rs10842122	ENSG00000256321.4	RP11-153K16.1	4.3	4.12e-05	0.023	0.45	0.41	Pelvic organ prolapse (moderate/severe);	chr12:23112929	chr12:23099368~23191587:+
THYM	cis	rs4908768	0.501	rs4908760	ENSG00000232912.4	RP5-1115A15.1	4.3	4.12e-05	0.023	0.4	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8466082	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs910581	ENSG00000232912.4	RP5-1115A15.1	4.3	4.12e-05	0.023	0.4	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469464	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs1024197	ENSG00000232912.4	RP5-1115A15.1	4.3	4.12e-05	0.023	0.4	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8476998	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.965	rs10864354	ENSG00000232912.4	RP5-1115A15.1	4.3	4.12e-05	0.023	0.4	0.41	Vitiligo;	chr1:8489681	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs7530745	ENSG00000232912.4	RP5-1115A15.1	4.3	4.12e-05	0.023	0.4	0.41	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497631	chr1:8424645~8434838:+
THYM	cis	rs17253792	0.822	rs10129890	ENSG00000186615.9	KTN1-AS1	-4.3	4.13e-05	0.023	-0.78	-0.41	Putamen volume;	chr14:55573695	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs12100949	ENSG00000186615.9	KTN1-AS1	-4.3	4.13e-05	0.023	-0.78	-0.41	Putamen volume;	chr14:55574069	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs12100753	ENSG00000186615.9	KTN1-AS1	-4.3	4.13e-05	0.023	-0.78	-0.41	Putamen volume;	chr14:55576152	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28481586	ENSG00000186615.9	KTN1-AS1	-4.3	4.13e-05	0.023	-0.78	-0.41	Putamen volume;	chr14:55587145	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10147380	ENSG00000186615.9	KTN1-AS1	-4.3	4.13e-05	0.023	-0.78	-0.41	Putamen volume;	chr14:55587636	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10147688	ENSG00000186615.9	KTN1-AS1	-4.3	4.13e-05	0.023	-0.78	-0.41	Putamen volume;	chr14:55587924	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10135426	ENSG00000186615.9	KTN1-AS1	-4.3	4.13e-05	0.023	-0.78	-0.41	Putamen volume;	chr14:55587926	chr14:55499278~55580110:-
THYM	cis	rs72799341	1	rs35675346	ENSG00000275263.1	RP11-1072A3.4	-4.3	4.13e-05	0.0231	-0.41	-0.41	Diastolic blood pressure;	chr16:30924760	chr16:30956872~30957199:-
THYM	cis	rs3753275	0.568	rs7533113	ENSG00000230679.1	ENO1-AS1	4.3	4.13e-05	0.0231	0.48	0.41	Educational attainment;	chr1:8753184	chr1:8878835~8879894:+
THYM	cis	rs10208649	0.611	rs75340524	ENSG00000272156.1	RP11-477N3.1	4.3	4.14e-05	0.0231	0.61	0.41	Body mass index;	chr2:54068793	chr2:54082554~54085066:+
THYM	cis	rs12410462	0.636	rs2819511	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227510773	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2644162	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227515696	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.636	rs2644154	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227516187	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2819508	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227516483	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.636	rs2814085	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227517775	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2453682	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227522680	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs1495851	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227523372	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.551	rs2819503	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227524787	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.551	rs2819502	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227524951	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.551	rs2814084	ENSG00000227711.2	RP11-275O4.5	-4.3	4.14e-05	0.0231	-0.41	-0.41	Major depressive disorder;	chr1:227526595	chr1:227509028~227520477:-
THYM	cis	rs9876781	1	rs13069724	ENSG00000244380.1	RP11-24C3.2	4.3	4.15e-05	0.0231	0.55	0.41	Longevity;	chr3:48436629	chr3:48440352~48446656:-
THYM	cis	rs9813712	0.597	rs10934931	ENSG00000228252.7	COL6A4P2	-4.3	4.15e-05	0.0231	-0.43	-0.41	Response to amphetamines;	chr3:130261365	chr3:130212823~130273806:+
THYM	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-4.3	4.15e-05	0.0231	-0.59	-0.41	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
THYM	cis	rs561341	0.941	rs2470236	ENSG00000265798.5	RP11-271K11.5	4.3	4.15e-05	0.0231	0.48	0.41	Hip circumference adjusted for BMI;	chr17:31977921	chr17:31038575~31059121:-
THYM	cis	rs561341	0.714	rs474455	ENSG00000265798.5	RP11-271K11.5	4.3	4.15e-05	0.0231	0.48	0.41	Hip circumference adjusted for BMI;	chr17:31985446	chr17:31038575~31059121:-
THYM	cis	rs561341	0.941	rs501773	ENSG00000265798.5	RP11-271K11.5	4.3	4.15e-05	0.0231	0.48	0.41	Hip circumference adjusted for BMI;	chr17:31987416	chr17:31038575~31059121:-
THYM	cis	rs561341	0.941	rs550213	ENSG00000265798.5	RP11-271K11.5	4.3	4.15e-05	0.0231	0.48	0.41	Hip circumference adjusted for BMI;	chr17:31990499	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs530715	ENSG00000265798.5	RP11-271K11.5	4.3	4.15e-05	0.0231	0.48	0.41	Hip circumference adjusted for BMI;	chr17:31993525	chr17:31038575~31059121:-
THYM	cis	rs4617118	1	rs72730217	ENSG00000254275.5	LINC00824	4.3	4.15e-05	0.0231	0.62	0.41	Acute lymphoblastic leukemia (childhood);	chr8:129144530	chr8:128405269~128564679:-
THYM	cis	rs72793342	0.651	rs8050463	ENSG00000235560.3	AC002310.12	4.3	4.15e-05	0.0231	0.33	0.41	RANTES levels;	chr16:30542838	chr16:30534752~30537144:+
THYM	cis	rs3796619	1	rs2290409	ENSG00000215367.9	TMED11P	-4.3	4.15e-05	0.0232	-0.39	-0.41	Recombination rate (males);	chr4:1073461	chr4:1115197~1153726:-
THYM	cis	rs3796619	1	rs4045481	ENSG00000215367.9	TMED11P	4.3	4.15e-05	0.0232	0.39	0.41	Recombination rate (males);	chr4:1096837	chr4:1115197~1153726:-
THYM	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-4.3	4.15e-05	0.0232	-0.42	-0.41	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
THYM	cis	rs12902680	0.677	rs1821474	ENSG00000259520.4	CTD-2651B20.3	4.3	4.15e-05	0.0232	0.42	0.41	Neuroticism;	chr15:46251520	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1821475	ENSG00000259520.4	CTD-2651B20.3	4.3	4.15e-05	0.0232	0.42	0.41	Neuroticism;	chr15:46251727	chr15:45251580~45279251:-
THYM	cis	rs853679	0.542	rs6934769	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28123153	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs17711801	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28124529	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.527	rs9461433	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Parkinson's disease;	chr6:28127394	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9468292	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28127577	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs1947863	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28131566	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs4713141	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28133900	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9380056	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28136698	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs9380057	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28136856	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs1947862	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28137418	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs6941992	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28138363	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.516	rs4713142	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Parkinson's disease;	chr6:28138569	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs4713143	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28138981	chr6:28053228~28054165:-
THYM	cis	rs853679	0.517	rs4713144	ENSG00000182477.5	OR2B8P	4.3	4.15e-05	0.0232	0.57	0.41	Depression;	chr6:28139012	chr6:28053228~28054165:-
THYM	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-4.3	4.16e-05	0.0232	-0.51	-0.41	Pain;	chr19:21499260	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-4.3	4.16e-05	0.0232	-0.51	-0.41	Pain;	chr19:21505137	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-4.3	4.16e-05	0.0232	-0.51	-0.41	Pain;	chr19:21505800	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-4.3	4.16e-05	0.0232	-0.51	-0.41	Pain;	chr19:21509773	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-4.3	4.16e-05	0.0232	-0.51	-0.41	Pain;	chr19:21510513	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-4.3	4.16e-05	0.0232	-0.51	-0.41	Pain;	chr19:21513185	chr19:21554640~21569237:-
THYM	cis	rs5758659	0.716	rs5758661	ENSG00000182057.4	OGFRP1	4.3	4.16e-05	0.0232	0.35	0.41	Cognitive function;	chr22:42228439	chr22:42269753~42275196:+
THYM	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	4.3	4.16e-05	0.0232	0.38	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
THYM	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	4.3	4.16e-05	0.0232	0.38	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
THYM	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	4.3	4.16e-05	0.0232	0.38	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
THYM	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	4.3	4.16e-05	0.0232	0.38	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
THYM	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	4.3	4.16e-05	0.0232	0.38	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
THYM	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	4.3	4.16e-05	0.0232	0.29	0.41	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
THYM	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	4.3	4.16e-05	0.0232	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
THYM	cis	rs4835473	0.863	rs13146607	ENSG00000249741.2	RP11-673E1.3	4.3	4.17e-05	0.0232	0.36	0.41	Immature fraction of reticulocytes;	chr4:143687283	chr4:143911514~143912053:-
THYM	cis	rs4845570	0.92	rs1521185	ENSG00000203288.3	RP11-98D18.9	4.3	4.17e-05	0.0232	0.47	0.41	Coronary artery disease;	chr1:151791573	chr1:151790804~151794402:+
THYM	cis	rs4845570	0.85	rs4504897	ENSG00000203288.3	RP11-98D18.9	4.3	4.17e-05	0.0232	0.47	0.41	Coronary artery disease;	chr1:151794375	chr1:151790804~151794402:+
THYM	cis	rs4845570	0.85	rs11204892	ENSG00000203288.3	RP11-98D18.9	4.3	4.17e-05	0.0232	0.47	0.41	Coronary artery disease;	chr1:151795572	chr1:151790804~151794402:+
THYM	cis	rs7202877	0.61	rs8053632	ENSG00000261783.1	RP11-252K23.2	-4.3	4.17e-05	0.0232	-0.57	-0.41	Type 1 diabetes;Type 2 diabetes;	chr16:75331042	chr16:75379818~75381260:-
THYM	cis	rs72802342	0.51	rs12932952	ENSG00000261783.1	RP11-252K23.2	-4.3	4.17e-05	0.0232	-0.57	-0.41	Advanced age-related macular degeneration;	chr16:75331588	chr16:75379818~75381260:-
THYM	cis	rs12410462	0.551	rs66938123	ENSG00000227711.2	RP11-275O4.5	-4.3	4.17e-05	0.0232	-0.4	-0.41	Major depressive disorder;	chr1:227620530	chr1:227509028~227520477:-
THYM	cis	rs17685	0.725	rs7795291	ENSG00000280388.1	RP11-229D13.3	-4.3	4.17e-05	0.0232	-0.41	-0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76095888	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs6954569	ENSG00000280388.1	RP11-229D13.3	-4.3	4.17e-05	0.0232	-0.41	-0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76109567	chr7:76043977~76045963:-
THYM	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-4.3	4.17e-05	0.0232	-0.43	-0.41	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-4.3	4.17e-05	0.0232	-0.43	-0.41	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
THYM	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-4.3	4.17e-05	0.0232	-0.43	-0.41	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
THYM	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-4.3	4.17e-05	0.0232	-0.43	-0.41	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-4.3	4.17e-05	0.0232	-0.43	-0.41	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
THYM	cis	rs17685	0.753	rs7788763	ENSG00000280388.1	RP11-229D13.3	4.3	4.18e-05	0.0232	0.41	0.41	Coffee consumption (cups per day);Coffee consumption;	chr7:76022347	chr7:76043977~76045963:-
THYM	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	4.3	4.18e-05	0.0232	0.48	0.41	Height;	chr6:109480428	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	4.3	4.18e-05	0.0232	0.48	0.41	Height;	chr6:109482392	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	4.3	4.18e-05	0.0232	0.48	0.41	Height;	chr6:109486036	chr6:109382795~109383666:+
THYM	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	4.3	4.18e-05	0.0232	0.8	0.41	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	4.3	4.18e-05	0.0232	0.8	0.41	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
THYM	cis	rs2717128	0.572	rs2717136	ENSG00000265778.2	RP11-17M16.2	-4.3	4.18e-05	0.0233	-0.87	-0.41	RR interval (heart rate);	chr18:77298920	chr18:76491652~76493918:+
THYM	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	4.3	4.18e-05	0.0233	0.51	0.41	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	4.3	4.18e-05	0.0233	0.51	0.41	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
THYM	cis	rs7178424	0.742	rs12906423	ENSG00000259251.2	RP11-643M14.1	-4.3	4.18e-05	0.0233	-0.42	-0.41	Height;	chr15:61911685	chr15:62060503~62062434:+
THYM	cis	rs11627756	0.645	rs4900550	ENSG00000243904.1	RP11-600F24.1	-4.3	4.19e-05	0.0233	-0.62	-0.41	Mean platelet volume;	chr14:102697118	chr14:103374033~103374916:-
THYM	cis	rs9876781	1	rs2362450	ENSG00000244380.1	RP11-24C3.2	4.3	4.19e-05	0.0233	0.55	0.41	Longevity;	chr3:48419904	chr3:48440352~48446656:-
THYM	cis	rs9876781	0.967	rs1459249	ENSG00000244380.1	RP11-24C3.2	4.3	4.19e-05	0.0233	0.55	0.41	Longevity;	chr3:48438208	chr3:48440352~48446656:-
THYM	cis	rs7475343	0.759	rs72778450	ENSG00000224034.1	RP11-445P17.8	-4.3	4.19e-05	0.0233	-0.76	-0.41	Intelligence;	chr10:5293870	chr10:5266033~5271236:-
THYM	cis	rs9907295	0.748	rs2526328	ENSG00000270977.1	AC015849.16	-4.3	4.19e-05	0.0233	-0.54	-0.41	Fibroblast growth factor basic levels;	chr17:35932348	chr17:35893707~35911023:-
THYM	cis	rs11017328	0.5	rs4520510	ENSG00000236303.2	RP11-540N6.1	-4.3	4.2e-05	0.0234	-0.59	-0.41	Conotruncal heart defects;	chr10:130496745	chr10:130439067~130483154:+
THYM	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	4.3	4.21e-05	0.0234	0.51	0.41	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
THYM	cis	rs3096299	0.838	rs3102384	ENSG00000274627.1	RP11-104N10.2	4.3	4.21e-05	0.0234	0.46	0.41	Multiple myeloma (IgH translocation);	chr16:89345253	chr16:89516797~89522217:+
THYM	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-4.3	4.21e-05	0.0234	-0.49	-0.41	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
THYM	cis	rs11574514	1	rs79631436	ENSG00000260891.1	RP11-96D1.5	-4.3	4.22e-05	0.0234	-0.5	-0.41	Crohn's disease;	chr16:67694466	chr16:68212401~68221671:-
THYM	cis	rs3811273	0.614	rs6572348	ENSG00000211816.2	TRAV38-1	-4.3	4.22e-05	0.0234	-0.35	-0.41	Periodontal disease-related phenotypes;	chr14:22268353	chr14:22271968~22272563:+
THYM	cis	rs11096990	0.855	rs2566170	ENSG00000249685.1	RP11-360F5.3	-4.3	4.22e-05	0.0234	-0.4	-0.41	Cognitive function;	chr4:39150757	chr4:39133913~39135608:+
THYM	cis	rs9876781	1	rs11130171	ENSG00000244380.1	RP11-24C3.2	4.3	4.22e-05	0.0234	0.55	0.41	Longevity;	chr3:48421052	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs9883927	ENSG00000244380.1	RP11-24C3.2	4.3	4.22e-05	0.0234	0.55	0.41	Longevity;	chr3:48422302	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs9817615	ENSG00000244380.1	RP11-24C3.2	4.3	4.22e-05	0.0234	0.55	0.41	Longevity;	chr3:48429347	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs2290822	ENSG00000244380.1	RP11-24C3.2	4.3	4.22e-05	0.0234	0.55	0.41	Longevity;	chr3:48431794	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs13076076	ENSG00000244380.1	RP11-24C3.2	4.3	4.22e-05	0.0234	0.55	0.41	Longevity;	chr3:48437629	chr3:48440352~48446656:-
THYM	cis	rs7246967	0.611	rs73030508	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22643230	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs73030511	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22643232	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34682021	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22643926	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs34897132	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22644089	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs60021625	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22646752	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs28787949	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22647554	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs67631531	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22647664	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.541	rs74169641	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22647774	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs56271774	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22648525	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs35740274	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22648611	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs4414616	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22649609	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs4627499	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22649831	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs1835993	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22650235	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs1835994	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22650243	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs12984634	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22650942	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs12984903	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22651079	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs2099341	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22651558	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs2361245	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22651728	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs2082445	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22651785	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs7250285	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22654306	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs66620859	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22654428	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs2885221	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22656585	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs2885222	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22657142	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs2915932	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22660899	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs11881740	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22661042	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs62118823	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22661264	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs73020703	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22661537	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs12980342	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22666555	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs3951784	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22669124	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs3951785	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22669126	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs7250608	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22670254	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7250620	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22670324	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs4244915	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22671336	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs8104052	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22675002	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs12975767	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22680007	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.604	rs12975793	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22680042	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs57013651	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22680225	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34795935	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22682386	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7252925	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22683006	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7253063	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22683095	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7254097	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22683098	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs3902164	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22683479	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs6511374	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22683568	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs8103875	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22684060	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs4933024	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22684261	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs8104327	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22684357	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs8104564	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22684405	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs8107724	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22684612	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs12973264	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22684947	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs597906	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22685403	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs35335083	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22686790	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs8102172	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22687217	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs8102006	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22687301	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs3853652	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22689111	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs3853653	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22689130	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs55932152	ENSG00000198153.8	ZNF849P	-4.3	4.23e-05	0.0234	-0.55	-0.41	Bronchopulmonary dysplasia;	chr19:22690626	chr19:22685167~22686732:+
THYM	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	4.3	4.23e-05	0.0234	0.6	0.41	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
THYM	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-4.3	4.23e-05	0.0234	-0.69	-0.41	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
THYM	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	4.3	4.24e-05	0.0235	0.33	0.41	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	4.3	4.24e-05	0.0235	0.33	0.41	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
THYM	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-4.3	4.24e-05	0.0235	-0.49	-0.41	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
THYM	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	4.3	4.24e-05	0.0235	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
THYM	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	4.3	4.24e-05	0.0235	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
THYM	cis	rs9611565	0.84	rs4822025	ENSG00000273366.1	CTA-989H11.1	4.3	4.25e-05	0.0235	0.48	0.41	Vitiligo;	chr22:41380642	chr22:42278188~42278846:+
THYM	cis	rs7474896	0.616	rs2505239	ENSG00000120555.12	SEPT7P9	4.3	4.25e-05	0.0235	0.59	0.41	Obesity (extreme);	chr10:38151837	chr10:38383069~38402916:-
THYM	cis	rs7474896	0.561	rs2474603	ENSG00000120555.12	SEPT7P9	4.3	4.25e-05	0.0235	0.59	0.41	Obesity (extreme);	chr10:38156754	chr10:38383069~38402916:-
THYM	cis	rs7474896	0.507	rs2474555	ENSG00000120555.12	SEPT7P9	4.3	4.25e-05	0.0235	0.59	0.41	Obesity (extreme);	chr10:38176292	chr10:38383069~38402916:-
THYM	cis	rs9876781	1	rs7636044	ENSG00000244380.1	RP11-24C3.2	4.3	4.25e-05	0.0235	0.55	0.41	Longevity;	chr3:48443151	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs4490383	ENSG00000244380.1	RP11-24C3.2	4.3	4.25e-05	0.0235	0.55	0.41	Longevity;	chr3:48443275	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs9876781	ENSG00000244380.1	RP11-24C3.2	4.3	4.25e-05	0.0235	0.55	0.41	Longevity;	chr3:48445934	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs6442123	ENSG00000244380.1	RP11-24C3.2	4.3	4.25e-05	0.0235	0.55	0.41	Longevity;	chr3:48458887	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs2242150	ENSG00000244380.1	RP11-24C3.2	-4.3	4.25e-05	0.0235	-0.55	-0.41	Longevity;	chr3:48464565	chr3:48440352~48446656:-
THYM	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	4.3	4.25e-05	0.0235	0.5	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
THYM	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	4.3	4.25e-05	0.0235	0.27	0.41	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
THYM	cis	rs62246343	0.605	rs4328788	ENSG00000254485.4	RP11-380O24.1	4.29	4.25e-05	0.0235	0.52	0.41	Fibrinogen levels;	chr3:9415577	chr3:9292588~9363303:-
THYM	cis	rs9309473	0.5	rs6757996	ENSG00000273245.1	RP11-434P11.2	4.29	4.25e-05	0.0235	0.46	0.41	Metabolite levels;	chr2:73545124	chr2:73750256~73750786:-
THYM	cis	rs5742933	1	rs62184283	ENSG00000273240.1	RP11-455J20.3	-4.29	4.25e-05	0.0235	-0.59	-0.41	Ferritin levels;	chr2:189801179	chr2:189763859~189764456:-
THYM	cis	rs34773007	1	rs34773007	ENSG00000272817.1	RP11-402D21.2	-4.29	4.25e-05	0.0235	-0.51	-0.41	Type 2 diabetes;	chr10:92898450	chr10:91908131~91909348:+
THYM	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	4.29	4.26e-05	0.0236	0.49	0.41	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	4.29	4.26e-05	0.0236	0.49	0.41	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
THYM	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-4.29	4.26e-05	0.0236	-0.43	-0.41	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
THYM	cis	rs7631605	0.809	rs3774327	ENSG00000272334.1	RP11-129K12.1	-4.29	4.26e-05	0.0236	-0.41	-0.41	Cerebrospinal P-tau181p levels;	chr3:37057876	chr3:36973117~36973672:-
THYM	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	4.29	4.26e-05	0.0236	0.44	0.4	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
THYM	cis	rs17253792	0.822	rs75763956	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55604458	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78522049	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55604485	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79022053	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55605003	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76555508	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55605150	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.908	rs9972177	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55606488	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs9972178	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55606762	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs9972180	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55607014	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10142757	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55607493	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10143002	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55607560	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs74968702	ENSG00000186615.9	KTN1-AS1	-4.29	4.26e-05	0.0236	-0.78	-0.4	Putamen volume;	chr14:55610100	chr14:55499278~55580110:-
THYM	cis	rs9728717	1	rs9728717	ENSG00000226970.2	RP11-82H13.2	-4.29	4.27e-05	0.0236	-0.62	-0.4	Economic and political preferences (time);	chr1:84824726	chr1:84244334~84244577:+
THYM	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	4.29	4.27e-05	0.0236	0.39	0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
THYM	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-4.29	4.27e-05	0.0236	-0.39	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
THYM	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-4.29	4.27e-05	0.0236	-0.39	-0.4	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
THYM	cis	rs4835473	0.932	rs35300159	ENSG00000249741.2	RP11-673E1.3	4.29	4.27e-05	0.0236	0.34	0.4	Immature fraction of reticulocytes;	chr4:143751768	chr4:143911514~143912053:-
THYM	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	4.29	4.27e-05	0.0236	0.48	0.4	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
THYM	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	4.29	4.27e-05	0.0236	0.52	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
THYM	cis	rs526231	0.963	rs12187443	ENSG00000175749.11	EIF3KP1	4.29	4.27e-05	0.0236	0.52	0.4	Primary biliary cholangitis;	chr5:103324699	chr5:103032376~103033031:+
THYM	cis	rs12681366	0.839	rs2931632	ENSG00000253704.1	RP11-267M23.4	4.29	4.28e-05	0.0237	0.52	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94553722~94569745:+
THYM	cis	rs890448	1	rs7695728	ENSG00000254531.1	FLJ20021	-4.29	4.28e-05	0.0237	-0.34	-0.4	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101513280	chr4:101347780~101348883:+
THYM	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-4.29	4.28e-05	0.0237	-0.54	-0.4	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
THYM	cis	rs6594535	0.663	rs6869021	ENSG00000253057.1	RN7SKP57	4.29	4.28e-05	0.0237	0.45	0.4	Chickenpox;	chr5:111703320	chr5:111719769~111720061:-
THYM	cis	rs6594535	0.663	rs10062378	ENSG00000253057.1	RN7SKP57	4.29	4.28e-05	0.0237	0.45	0.4	Chickenpox;	chr5:111704367	chr5:111719769~111720061:-
THYM	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-4.29	4.28e-05	0.0237	-0.57	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
THYM	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	4.29	4.28e-05	0.0237	0.35	0.4	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	4.29	4.28e-05	0.0237	0.35	0.4	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	4.29	4.28e-05	0.0237	0.35	0.4	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
THYM	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	4.29	4.28e-05	0.0237	0.35	0.4	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
THYM	cis	rs7927592	0.913	rs11228276	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68540057	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs67005337	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68540290	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs948316	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68542202	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.956	rs10896341	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68545712	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs67947146	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68547512	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7104345	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68549304	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs12284933	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68552021	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.871	rs11228284	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68555299	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.871	rs55953412	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68560815	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7102898	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68561402	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7109294	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68564625	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs2282563	ENSG00000222339.1	AP000807.2	4.29	4.28e-05	0.0237	0.49	0.4	Total body bone mineral density;	chr11:68565732	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs4316515	ENSG00000222339.1	AP000807.2	-4.29	4.28e-05	0.0237	-0.49	-0.4	Total body bone mineral density;	chr11:68541372	chr11:68505572~68505651:-
THYM	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	4.29	4.29e-05	0.0237	0.45	0.4	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
THYM	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-4.29	4.29e-05	0.0237	-0.71	-0.4	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
THYM	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-4.29	4.29e-05	0.0237	-0.38	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-4.29	4.29e-05	0.0237	-0.38	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
THYM	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-4.29	4.29e-05	0.0237	-0.38	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
THYM	cis	rs5769707	0.837	rs5770599	ENSG00000264139.1	MIR3667	-4.29	4.29e-05	0.0237	-0.47	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49543393~49543466:-
THYM	cis	rs5769707	0.837	rs5769709	ENSG00000264139.1	MIR3667	-4.29	4.29e-05	0.0237	-0.47	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49543393~49543466:-
THYM	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	4.29	4.29e-05	0.0237	0.5	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
THYM	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-4.29	4.29e-05	0.0237	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
THYM	cis	rs7683574	0.622	rs10005931	ENSG00000250942.1	ENPP7P11	4.29	4.29e-05	0.0237	0.38	0.4	Lung cancer;	chr4:9712723	chr4:9677308~9677934:+
THYM	cis	rs10131894	0.611	rs175002	ENSG00000258646.1	RP11-950C14.3	-4.29	4.3e-05	0.0237	-0.35	-0.4	Coronary artery disease;	chr14:74969763	chr14:75004719~75008481:-
THYM	cis	rs4478858	0.735	rs6679393	ENSG00000260386.4	LINC01225	4.29	4.3e-05	0.0237	0.22	0.4	Alcohol dependence;	chr1:31298097	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs1566963	ENSG00000260386.4	LINC01225	4.29	4.3e-05	0.0237	0.22	0.4	Alcohol dependence;	chr1:31299359	chr1:31500085~31540885:+
THYM	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	4.29	4.3e-05	0.0237	0.33	0.4	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
THYM	cis	rs7560272	0.695	rs780393	ENSG00000163016.8	ALMS1P	-4.29	4.3e-05	0.0238	-0.49	-0.4	Schizophrenia;	chr2:73474542	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.723	rs780391	ENSG00000163016.8	ALMS1P	-4.29	4.3e-05	0.0238	-0.49	-0.4	Schizophrenia;	chr2:73476777	chr2:73644919~73685576:+
THYM	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-4.29	4.31e-05	0.0238	-0.37	-0.4	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
THYM	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-4.29	4.31e-05	0.0238	-0.37	-0.4	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
THYM	cis	rs910316	0.934	rs7141705	ENSG00000258646.1	RP11-950C14.3	4.29	4.31e-05	0.0238	0.37	0.4	Height;	chr14:75188649	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs4903293	ENSG00000258646.1	RP11-950C14.3	4.29	4.31e-05	0.0238	0.37	0.4	Height;	chr14:75189865	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs4384542	ENSG00000258646.1	RP11-950C14.3	4.29	4.31e-05	0.0238	0.37	0.4	Height;	chr14:75191310	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs7146523	ENSG00000258646.1	RP11-950C14.3	4.29	4.31e-05	0.0238	0.37	0.4	Height;	chr14:75193177	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs8013444	ENSG00000258646.1	RP11-950C14.3	4.29	4.31e-05	0.0238	0.37	0.4	Height;	chr14:75195278	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs8007539	ENSG00000258646.1	RP11-950C14.3	4.29	4.31e-05	0.0238	0.37	0.4	Height;	chr14:75198250	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs11159121	ENSG00000258646.1	RP11-950C14.3	4.29	4.31e-05	0.0238	0.37	0.4	Height;	chr14:75199326	chr14:75004719~75008481:-
THYM	cis	rs5771225	0.563	rs738334	ENSG00000273253.2	RP3-402G11.26	-4.29	4.31e-05	0.0238	-0.5	-0.4	Late-onset Alzheimer's disease;	chr22:50249806	chr22:50199090~50200837:-
THYM	cis	rs5771225	0.544	rs1555048	ENSG00000273253.2	RP3-402G11.26	-4.29	4.31e-05	0.0238	-0.5	-0.4	Late-onset Alzheimer's disease;	chr22:50249919	chr22:50199090~50200837:-
THYM	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	4.29	4.31e-05	0.0238	0.58	0.4	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
THYM	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-4.29	4.31e-05	0.0238	-0.42	-0.4	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
THYM	cis	rs4691139	0.611	rs11100590	ENSG00000250227.1	TRIM60P14	4.29	4.31e-05	0.0238	0.49	0.4	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003635	chr4:164915565~164916983:+
THYM	cis	rs556990	0.57	rs5960	ENSG00000269125.1	RP11-98F14.11	4.29	4.31e-05	0.0238	0.6	0.4	Blood protein levels;	chr13:113147423	chr13:113165002~113165183:-
THYM	cis	rs7617773	0.746	rs4130995	ENSG00000228638.1	FCF1P2	-4.29	4.32e-05	0.0238	-0.39	-0.4	Coronary artery disease;	chr3:48316765	chr3:48290793~48291375:-
THYM	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-4.29	4.32e-05	0.0238	-0.29	-0.4	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
THYM	cis	rs17685	0.753	rs10476	ENSG00000280388.1	RP11-229D13.3	4.29	4.32e-05	0.0238	0.41	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76067102	chr7:76043977~76045963:-
THYM	cis	rs926326	0.954	rs212930	ENSG00000219682.4	RP3-425P12.4	-4.29	4.32e-05	0.0238	-0.61	-0.4	Platelet count;	chr6:25535408	chr6:25140003~25141403:+
THYM	cis	rs12908161	0.92	rs35738019	ENSG00000275120.1	RP11-182J1.17	4.29	4.32e-05	0.0238	0.55	0.4	Schizophrenia;	chr15:84736979	chr15:84599434~84606463:-
THYM	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	4.29	4.33e-05	0.0239	0.57	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
THYM	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	4.29	4.33e-05	0.0239	0.51	0.4	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
THYM	cis	rs7246967	0.673	rs34126042	ENSG00000198153.8	ZNF849P	-4.29	4.33e-05	0.0239	-0.54	-0.4	Bronchopulmonary dysplasia;	chr19:22726416	chr19:22685167~22686732:+
THYM	cis	rs10888838	0.941	rs10888841	ENSG00000198711.5	SSBP3-AS1	4.29	4.33e-05	0.0239	0.26	0.4	Mitochondrial DNA levels;	chr1:54221392	chr1:54236440~54239063:+
THYM	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	4.29	4.34e-05	0.0239	0.48	0.4	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
THYM	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-4.29	4.34e-05	0.0239	-0.49	-0.4	Pain;	chr19:21493313	chr19:21554640~21569237:-
THYM	cis	rs2289328	0.823	rs35565646	ENSG00000223313.1	RNU6-516P	-4.29	4.34e-05	0.0239	-0.52	-0.4	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40368314	chr15:40529570~40529673:+
THYM	cis	rs2289328	0.943	rs3803360	ENSG00000223313.1	RNU6-516P	-4.29	4.34e-05	0.0239	-0.52	-0.4	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40370468	chr15:40529570~40529673:+
THYM	cis	rs4853012	0.941	rs7571083	ENSG00000272183.1	RP11-523H20.3	4.29	4.35e-05	0.0239	0.56	0.4	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74501717~74502365:+
THYM	cis	rs526231	0.824	rs253755	ENSG00000175749.11	EIF3KP1	4.29	4.35e-05	0.0239	0.51	0.4	Primary biliary cholangitis;	chr5:103295232	chr5:103032376~103033031:+
THYM	cis	rs972578	1	rs1569508	ENSG00000215347.3	SLC25A5P1	-4.29	4.35e-05	0.0239	-0.31	-0.4	Mean platelet volume;	chr22:42963124	chr22:42001069~42001966:-
THYM	cis	rs972578	0.936	rs4822237	ENSG00000215347.3	SLC25A5P1	-4.29	4.35e-05	0.0239	-0.31	-0.4	Mean platelet volume;	chr22:42968649	chr22:42001069~42001966:-
THYM	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	4.29	4.35e-05	0.024	0.49	0.4	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	4.29	4.35e-05	0.024	0.49	0.4	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	4.29	4.35e-05	0.024	0.49	0.4	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
THYM	cis	rs7412746	0.658	rs6657388	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.39	-0.4	Melanoma;	chr1:150776310	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs7521898	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.4	-0.4	Tonsillectomy;	chr1:150735120	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs7511673	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.4	-0.4	Tonsillectomy;	chr1:150735160	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs72704603	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.4	-0.4	Tonsillectomy;	chr1:150735516	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs11204717	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.4	-0.4	Tonsillectomy;	chr1:150736653	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.611	rs111842513	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.4	-0.4	Melanoma;	chr1:150740450	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs1134067	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.4	-0.4	Tonsillectomy;	chr1:150748699	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs11587444	ENSG00000220323.3	HIST2H2BD	-4.29	4.35e-05	0.024	-0.4	-0.4	Tonsillectomy;	chr1:150750368	chr1:149843041~149843533:+
THYM	cis	rs1642645	0.831	rs6698877	ENSG00000228452.1	RP5-994D16.9	-4.29	4.36e-05	0.024	-0.53	-0.4	Left ventricular obstructive tract defect (maternal effect);	chr1:42034765	chr1:42775813~42776790:-
THYM	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	4.29	4.36e-05	0.024	0.49	0.4	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
THYM	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	4.29	4.37e-05	0.024	0.49	0.4	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
THYM	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	4.29	4.37e-05	0.024	0.42	0.4	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
THYM	cis	rs12902680	0.706	rs28605329	ENSG00000259520.4	CTD-2651B20.3	4.29	4.37e-05	0.0241	0.42	0.4	Neuroticism;	chr15:46220460	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs4287505	ENSG00000259520.4	CTD-2651B20.3	4.29	4.37e-05	0.0241	0.42	0.4	Neuroticism;	chr15:46221079	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.674	rs2043482	ENSG00000259520.4	CTD-2651B20.3	4.29	4.37e-05	0.0241	0.42	0.4	Neuroticism;	chr15:46221256	chr15:45251580~45279251:-
THYM	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	4.29	4.38e-05	0.0241	0.8	0.4	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
THYM	cis	rs7077446	0.733	rs6584475	ENSG00000269609.4	RPARP-AS1	4.29	4.38e-05	0.0241	0.3	0.4	Intelligence (multi-trait analysis);	chr10:102047036	chr10:102449817~102461106:+
THYM	cis	rs17685	0.725	rs6467993	ENSG00000280388.1	RP11-229D13.3	-4.29	4.38e-05	0.0241	-0.41	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76090032	chr7:76043977~76045963:-
THYM	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-4.29	4.38e-05	0.0241	-0.49	-0.4	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
THYM	cis	rs11096990	0.855	rs2566168	ENSG00000249685.1	RP11-360F5.3	-4.29	4.38e-05	0.0241	-0.4	-0.4	Cognitive function;	chr4:39150053	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2711989	ENSG00000249685.1	RP11-360F5.3	-4.29	4.38e-05	0.0241	-0.4	-0.4	Cognitive function;	chr4:39150416	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs2566169	ENSG00000249685.1	RP11-360F5.3	-4.29	4.38e-05	0.0241	-0.4	-0.4	Cognitive function;	chr4:39150420	chr4:39133913~39135608:+
THYM	cis	rs7927592	0.913	rs12283755	ENSG00000222339.1	AP000807.2	4.29	4.38e-05	0.0241	0.51	0.4	Total body bone mineral density;	chr11:68604190	chr11:68505572~68505651:-
THYM	cis	rs61270009	0.955	rs12657757	ENSG00000247828.6	TMEM161B-AS1	-4.29	4.38e-05	0.0241	-0.38	-0.4	Depressive symptoms;	chr5:88280952	chr5:88268895~88436685:+
THYM	cis	rs2911132	0.506	rs1862609	ENSG00000272109.1	CTD-2260A17.3	-4.29	4.38e-05	0.0241	-0.51	-0.4	Urate levels (BMI interaction);	chr5:96750986	chr5:96804353~96806105:+
THYM	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	4.29	4.38e-05	0.0241	0.51	0.4	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
THYM	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	4.29	4.38e-05	0.0241	0.53	0.4	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
THYM	cis	rs890448	0.624	rs1426538	ENSG00000254531.1	FLJ20021	-4.29	4.39e-05	0.0241	-0.35	-0.4	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101528748	chr4:101347780~101348883:+
THYM	cis	rs73198271	0.653	rs3827811	ENSG00000253893.2	FAM85B	4.29	4.4e-05	0.0242	0.59	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8167819~8226614:-
THYM	cis	rs7077446	0.708	rs6584470	ENSG00000269609.4	RPARP-AS1	4.29	4.41e-05	0.0242	0.3	0.4	Intelligence (multi-trait analysis);	chr10:102018605	chr10:102449817~102461106:+
THYM	cis	rs7077446	0.708	rs6584469	ENSG00000269609.4	RPARP-AS1	-4.29	4.41e-05	0.0242	-0.3	-0.4	Intelligence (multi-trait analysis);	chr10:102005456	chr10:102449817~102461106:+
THYM	cis	rs7247513	0.927	rs34956595	ENSG00000213290.4	PGK1P2	-4.29	4.41e-05	0.0242	-0.45	-0.4	Bipolar disorder;	chr19:12591983	chr19:12559571~12561105:+
THYM	cis	rs7247513	0.964	rs1864083	ENSG00000213290.4	PGK1P2	-4.29	4.41e-05	0.0242	-0.45	-0.4	Bipolar disorder;	chr19:12596488	chr19:12559571~12561105:+
THYM	cis	rs7247513	0.892	rs1864081	ENSG00000213290.4	PGK1P2	-4.29	4.41e-05	0.0242	-0.45	-0.4	Bipolar disorder;	chr19:12597164	chr19:12559571~12561105:+
THYM	cis	rs7247513	0.892	rs2861407	ENSG00000213290.4	PGK1P2	-4.29	4.41e-05	0.0242	-0.45	-0.4	Bipolar disorder;	chr19:12600681	chr19:12559571~12561105:+
THYM	cis	rs7246967	0.551	rs7248993	ENSG00000198153.8	ZNF849P	-4.28	4.42e-05	0.0243	-0.55	-0.4	Bronchopulmonary dysplasia;	chr19:22666350	chr19:22685167~22686732:+
THYM	cis	rs8062405	0.931	rs12928404	ENSG00000259982.1	CDC37P1	4.28	4.42e-05	0.0243	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28700294~28701540:-
THYM	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	4.28	4.42e-05	0.0243	0.5	0.4	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
THYM	cis	rs7246967	0.673	rs3951783	ENSG00000198153.8	ZNF849P	-4.28	4.42e-05	0.0243	-0.55	-0.4	Bronchopulmonary dysplasia;	chr19:22656462	chr19:22685167~22686732:+
THYM	cis	rs12902680	0.706	rs4258551	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46224943	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs4395017	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46224964	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs4477635	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46224988	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs2899391	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46225025	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs2043480	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46225594	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12904232	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46225778	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs2117406	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46225994	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs2117405	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46226100	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs17648704	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46226188	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12908983	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46226303	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12908987	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46226312	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28414679	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46226546	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs8038960	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46227586	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12443251	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46229348	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28433800	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46229397	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28725297	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46229667	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28661431	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46229770	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12917603	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46230088	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12903085	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46230303	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12438064	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46230517	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12438184	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46230798	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12902920	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46230905	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12907619	ENSG00000259520.4	CTD-2651B20.3	4.28	4.43e-05	0.0243	0.42	0.4	Neuroticism;	chr15:46231387	chr15:45251580~45279251:-
THYM	cis	rs9309473	0.5	rs2421664	ENSG00000163016.8	ALMS1P	-4.28	4.43e-05	0.0243	-0.44	-0.4	Metabolite levels;	chr2:73631754	chr2:73644919~73685576:+
THYM	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	4.28	4.44e-05	0.0244	0.42	0.4	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
THYM	cis	rs2834288	0.959	rs2834294	ENSG00000237945.6	LINC00649	-4.28	4.44e-05	0.0244	-0.35	-0.4	Gut microbiota (bacterial taxa);	chr21:33908326	chr21:33915534~33977691:+
THYM	cis	rs1519814	0.624	rs2176749	ENSG00000254343.2	RP11-760H22.2	-4.28	4.45e-05	0.0244	-0.62	-0.4	Breast cancer;	chr8:120020195	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.696	rs7813264	ENSG00000254343.2	RP11-760H22.2	-4.28	4.45e-05	0.0244	-0.62	-0.4	Breast cancer;	chr8:120020514	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.659	rs7817075	ENSG00000254343.2	RP11-760H22.2	-4.28	4.45e-05	0.0244	-0.62	-0.4	Breast cancer;	chr8:120020607	chr8:120052180~120056201:+
THYM	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-4.28	4.45e-05	0.0244	-0.56	-0.4	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
THYM	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-4.28	4.46e-05	0.0244	-0.5	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-4.28	4.46e-05	0.0244	-0.5	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-4.28	4.46e-05	0.0244	-0.5	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs55876968	ENSG00000223466.1	AC064834.2	-4.28	4.46e-05	0.0244	-0.5	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549015	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.689	rs55974440	ENSG00000223466.1	AC064834.2	-4.28	4.46e-05	0.0244	-0.5	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549056	chr2:195533035~195538681:+
THYM	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-4.28	4.46e-05	0.0245	-0.69	-0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
THYM	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-4.28	4.46e-05	0.0245	-0.49	-0.4	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
THYM	cis	rs2108622	0.727	rs62106156	ENSG00000279717.1	LLNLF-158E9.1	-4.28	4.46e-05	0.0245	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15904556~15907234:+
THYM	cis	rs61160187	0.698	rs1379116	ENSG00000272308.1	RP11-231G3.1	-4.28	4.46e-05	0.0245	-0.35	-0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60646573	chr5:60866457~60866935:-
THYM	cis	rs11603691	0.541	rs118188894	ENSG00000265566.2	RN7SL605P	-4.28	4.47e-05	0.0245	-1.08	-0.4	Low high density lipoprotein cholesterol levels;	chr11:57375151	chr11:57528085~57528365:-
THYM	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	4.28	4.47e-05	0.0245	0.38	0.4	Migraine;	chr4:56881468	chr4:56960927~56961373:-
THYM	cis	rs9876781	1	rs6784322	ENSG00000244380.1	RP11-24C3.2	4.28	4.47e-05	0.0245	0.56	0.4	Longevity;	chr3:48380745	chr3:48440352~48446656:-
THYM	cis	rs34773007	0.577	rs7896131	ENSG00000272817.1	RP11-402D21.2	4.28	4.47e-05	0.0245	0.48	0.4	Type 2 diabetes;	chr10:92789918	chr10:91908131~91909348:+
THYM	cis	rs9309473	0.5	rs11688718	ENSG00000273245.1	RP11-434P11.2	4.28	4.47e-05	0.0245	0.46	0.4	Metabolite levels;	chr2:73533812	chr2:73750256~73750786:-
THYM	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-4.28	4.48e-05	0.0245	-0.4	-0.4	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
THYM	cis	rs4835473	0.897	rs7662736	ENSG00000249741.2	RP11-673E1.3	-4.28	4.48e-05	0.0245	-0.35	-0.4	Immature fraction of reticulocytes;	chr4:143958036	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs13145976	ENSG00000251600.4	RP11-673E1.1	-4.28	4.48e-05	0.0245	-0.44	-0.4	Immature fraction of reticulocytes;	chr4:143735710	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs13114071	ENSG00000251600.4	RP11-673E1.1	-4.28	4.48e-05	0.0245	-0.44	-0.4	Immature fraction of reticulocytes;	chr4:143735728	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.897	rs13140654	ENSG00000251600.4	RP11-673E1.1	-4.28	4.48e-05	0.0245	-0.44	-0.4	Immature fraction of reticulocytes;	chr4:143735733	chr4:143912331~143982454:+
THYM	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	4.28	4.48e-05	0.0246	0.5	0.4	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
THYM	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-4.28	4.48e-05	0.0246	-0.57	-0.4	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
THYM	cis	rs853679	0.55	rs1233699	ENSG00000182477.5	OR2B8P	4.28	4.49e-05	0.0246	0.55	0.4	Depression;	chr6:28201380	chr6:28053228~28054165:-
THYM	cis	rs4845570	1	rs4845579	ENSG00000203288.3	RP11-98D18.9	-4.28	4.49e-05	0.0246	-0.47	-0.4	Coronary artery disease;	chr1:151797662	chr1:151790804~151794402:+
THYM	cis	rs9309473	0.519	rs6746971	ENSG00000163016.8	ALMS1P	4.28	4.49e-05	0.0246	0.48	0.4	Metabolite levels;	chr2:73442334	chr2:73644919~73685576:+
THYM	cis	rs12902680	0.706	rs8029525	ENSG00000259520.4	CTD-2651B20.3	4.28	4.5e-05	0.0246	0.41	0.4	Neuroticism;	chr15:46243862	chr15:45251580~45279251:-
THYM	cis	rs7246967	0.673	rs4932784	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22691449	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs4933026	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22691690	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs73022711	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22692602	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs73022713	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22693420	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs57027767	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22693733	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs62120313	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22694381	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7248107	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22695727	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs8102812	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22696441	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs8106215	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22696644	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs16994997	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22696808	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs34806882	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22697302	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs57736314	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22697470	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.604	rs58536761	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22697529	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs3853649	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22697658	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs3853650	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22697688	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs3844578	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22697808	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs3925175	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22698156	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs7257333	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22698347	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34342502	ENSG00000198153.8	ZNF849P	-4.28	4.5e-05	0.0246	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22698626	chr19:22685167~22686732:+
THYM	cis	rs9611565	0.527	rs2234053	ENSG00000273366.1	CTA-989H11.1	4.28	4.5e-05	0.0246	0.47	0.4	Vitiligo;	chr22:41381311	chr22:42278188~42278846:+
THYM	cis	rs9611565	0.802	rs2234058	ENSG00000273366.1	CTA-989H11.1	4.28	4.5e-05	0.0246	0.47	0.4	Vitiligo;	chr22:41381879	chr22:42278188~42278846:+
THYM	cis	rs9611565	0.84	rs2234059	ENSG00000273366.1	CTA-989H11.1	4.28	4.5e-05	0.0246	0.47	0.4	Vitiligo;	chr22:41381909	chr22:42278188~42278846:+
THYM	cis	rs526231	0.584	rs246914	ENSG00000175749.11	EIF3KP1	4.28	4.5e-05	0.0246	0.57	0.4	Primary biliary cholangitis;	chr5:103223706	chr5:103032376~103033031:+
THYM	cis	rs10411161	0.938	rs17778649	ENSG00000269483.1	AC006272.1	4.28	4.51e-05	0.0247	0.58	0.4	Breast cancer;	chr19:51878363	chr19:51839924~51843324:-
THYM	cis	rs3781264	1	rs3781264	ENSG00000273450.1	RP11-76P2.4	4.28	4.51e-05	0.0247	0.49	0.4	Esophageal cancer and gastric cancer;	chr10:94310618	chr10:94314907~94315327:-
THYM	cis	rs1950357	0.553	rs1160547	ENSG00000258690.1	RP11-81F13.1	4.28	4.51e-05	0.0247	0.35	0.4	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36747149	chr14:36788644~36807163:+
THYM	cis	rs8067545	0.75	rs4570919	ENSG00000230528.6	NOS2P3	-4.28	4.51e-05	0.0247	-0.33	-0.4	Schizophrenia;	chr17:20097502	chr17:20436337~20447249:+
THYM	cis	rs7412746	0.571	rs12402939	ENSG00000220323.3	HIST2H2BD	-4.28	4.52e-05	0.0247	-0.41	-0.4	Melanoma;	chr1:150642618	chr1:149843041~149843533:+
THYM	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	4.28	4.52e-05	0.0247	0.52	0.4	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
THYM	cis	rs7631605	0.809	rs10849	ENSG00000272334.1	RP11-129K12.1	-4.28	4.52e-05	0.0247	-0.4	-0.4	Cerebrospinal P-tau181p levels;	chr3:37053579	chr3:36973117~36973672:-
THYM	cis	rs12908161	0.853	rs12912342	ENSG00000275120.1	RP11-182J1.17	4.28	4.52e-05	0.0247	0.55	0.4	Schizophrenia;	chr15:84704985	chr15:84599434~84606463:-
THYM	cis	rs17685	0.593	rs56265719	ENSG00000280388.1	RP11-229D13.3	-4.28	4.52e-05	0.0247	-0.43	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:76043977~76045963:-
THYM	cis	rs7077446	0.502	rs10786660	ENSG00000269609.4	RPARP-AS1	4.28	4.53e-05	0.0247	0.3	0.4	Intelligence (multi-trait analysis);	chr10:102029920	chr10:102449817~102461106:+
THYM	cis	rs2364543	0.624	rs61774752	ENSG00000229901.1	RP11-399E6.4	-4.28	4.53e-05	0.0247	-0.4	-0.4	Intelligence (multi-trait analysis);	chr1:41381352	chr1:41375004~41375669:-
THYM	cis	rs6545883	0.503	rs1665272	ENSG00000273302.1	RP11-493E12.2	4.28	4.53e-05	0.0247	0.38	0.4	Tuberculosis;	chr2:61152151	chr2:61199979~61200769:+
THYM	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-4.28	4.53e-05	0.0247	-0.46	-0.4	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-4.28	4.53e-05	0.0247	-0.46	-0.4	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-4.28	4.53e-05	0.0247	-0.46	-0.4	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-4.28	4.53e-05	0.0247	-0.46	-0.4	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-4.28	4.53e-05	0.0247	-0.46	-0.4	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
THYM	cis	rs8067545	0.75	rs28666381	ENSG00000230528.6	NOS2P3	-4.28	4.53e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20081496	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs28603224	ENSG00000230528.6	NOS2P3	-4.28	4.53e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20081739	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs28637614	ENSG00000230528.6	NOS2P3	-4.28	4.53e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20081795	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs36077949	ENSG00000230528.6	NOS2P3	-4.28	4.53e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20082469	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs4925079	ENSG00000230528.6	NOS2P3	-4.28	4.53e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20083548	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs9896411	ENSG00000230528.6	NOS2P3	-4.28	4.53e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20084297	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs9897653	ENSG00000230528.6	NOS2P3	-4.28	4.53e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20084611	chr17:20436337~20447249:+
THYM	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	4.28	4.54e-05	0.0248	0.51	0.4	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	4.28	4.54e-05	0.0248	0.51	0.4	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
THYM	cis	rs12701220	0.817	rs1058727	ENSG00000229043.2	AC091729.9	-4.28	4.54e-05	0.0248	-0.63	-0.4	Bronchopulmonary dysplasia;	chr7:1047459	chr7:1160374~1165267:+
THYM	cis	rs7789940	0.809	rs12533836	ENSG00000205583.12	STAG3L1	-4.28	4.54e-05	0.0248	-0.32	-0.4	Multiple sclerosis;	chr7:76306305	chr7:75359194~75395383:+
THYM	cis	rs11139399	0.613	rs10780529	ENSG00000233926.1	RP11-154D17.1	-4.28	4.54e-05	0.0248	-0.51	-0.4	Hippocampal atrophy;	chr9:81723515	chr9:81689713~81776900:+
THYM	cis	rs11139399	0.566	rs7859813	ENSG00000233926.1	RP11-154D17.1	-4.28	4.54e-05	0.0248	-0.51	-0.4	Hippocampal atrophy;	chr9:81723526	chr9:81689713~81776900:+
THYM	cis	rs7223966	0.961	rs17631394	ENSG00000240280.5	TCAM1P	4.28	4.54e-05	0.0248	0.63	0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63568639	chr17:63849292~63864379:+
THYM	cis	rs4835473	0.863	rs11735239	ENSG00000249741.2	RP11-673E1.3	4.28	4.54e-05	0.0248	0.35	0.4	Immature fraction of reticulocytes;	chr4:143689372	chr4:143911514~143912053:-
THYM	cis	rs12908161	1	rs34570071	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84736981	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs60957376	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84737561	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs11632465	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84738814	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.96	rs62019463	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84744856	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs62019464	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84751238	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs12910012	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84755431	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs12899981	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84759142	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.92	rs35758837	ENSG00000275120.1	RP11-182J1.17	4.28	4.55e-05	0.0248	0.54	0.4	Schizophrenia;	chr15:84768151	chr15:84599434~84606463:-
THYM	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-4.28	4.55e-05	0.0248	-0.54	-0.4	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
THYM	cis	rs9914578	0.573	rs7213049	ENSG00000236838.2	AC090617.1	4.28	4.55e-05	0.0248	0.8	0.4	Body mass index;	chr17:2098363	chr17:2213697~2214414:+
THYM	cis	rs8067545	0.75	rs4925085	ENSG00000230528.6	NOS2P3	-4.28	4.55e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20096818	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs9944451	ENSG00000230528.6	NOS2P3	-4.28	4.55e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20098003	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs62067555	ENSG00000230528.6	NOS2P3	-4.28	4.55e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20098189	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.717	rs7207625	ENSG00000230528.6	NOS2P3	-4.28	4.55e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20098299	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs918228	ENSG00000230528.6	NOS2P3	-4.28	4.55e-05	0.0248	-0.33	-0.4	Schizophrenia;	chr17:20098699	chr17:20436337~20447249:+
THYM	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	4.28	4.56e-05	0.0248	0.41	0.4	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
THYM	cis	rs7560272	0.723	rs7585119	ENSG00000273245.1	RP11-434P11.2	4.28	4.56e-05	0.0249	0.45	0.4	Schizophrenia;	chr2:73497552	chr2:73750256~73750786:-
THYM	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-4.28	4.56e-05	0.0249	-0.42	-0.4	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
THYM	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-4.28	4.56e-05	0.0249	-0.42	-0.4	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
THYM	cis	rs7631605	0.905	rs7634972	ENSG00000272334.1	RP11-129K12.1	-4.28	4.57e-05	0.0249	-0.43	-0.4	Cerebrospinal P-tau181p levels;	chr3:37164225	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs9755599	ENSG00000272334.1	RP11-129K12.1	-4.28	4.57e-05	0.0249	-0.43	-0.4	Cerebrospinal P-tau181p levels;	chr3:37166701	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs11920928	ENSG00000272334.1	RP11-129K12.1	-4.28	4.57e-05	0.0249	-0.43	-0.4	Cerebrospinal P-tau181p levels;	chr3:37169383	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs931721	ENSG00000272334.1	RP11-129K12.1	-4.28	4.57e-05	0.0249	-0.43	-0.4	Cerebrospinal P-tau181p levels;	chr3:37170481	chr3:36973117~36973672:-
THYM	cis	rs2115630	1	rs11854313	ENSG00000275120.1	RP11-182J1.17	-4.28	4.57e-05	0.0249	-0.47	-0.4	P wave terminal force;	chr15:84760817	chr15:84599434~84606463:-
THYM	cis	rs8067545	0.75	rs4925077	ENSG00000230528.6	NOS2P3	-4.28	4.57e-05	0.0249	-0.33	-0.4	Schizophrenia;	chr17:20078963	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs34290687	ENSG00000230528.6	NOS2P3	-4.28	4.57e-05	0.0249	-0.33	-0.4	Schizophrenia;	chr17:20087898	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs4924803	ENSG00000230528.6	NOS2P3	-4.28	4.57e-05	0.0249	-0.33	-0.4	Schizophrenia;	chr17:20088493	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs11867585	ENSG00000230528.6	NOS2P3	-4.28	4.57e-05	0.0249	-0.33	-0.4	Schizophrenia;	chr17:20089294	chr17:20436337~20447249:+
THYM	cis	rs5760092	0.572	rs738806	ENSG00000272787.1	KB-226F1.2	-4.28	4.57e-05	0.0249	-0.52	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23969211~23969873:+
THYM	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-4.28	4.58e-05	0.025	-0.52	-0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
THYM	cis	rs4853012	0.887	rs6737314	ENSG00000272183.1	RP11-523H20.3	4.27	4.58e-05	0.025	0.56	0.4	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74501717~74502365:+
THYM	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	4.27	4.59e-05	0.025	0.5	0.4	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
THYM	cis	rs8067545	0.75	rs11869616	ENSG00000230528.6	NOS2P3	-4.27	4.59e-05	0.025	-0.33	-0.4	Schizophrenia;	chr17:20089400	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs11868084	ENSG00000230528.6	NOS2P3	-4.27	4.59e-05	0.025	-0.33	-0.4	Schizophrenia;	chr17:20089404	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.75	rs11870111	ENSG00000230528.6	NOS2P3	-4.27	4.59e-05	0.025	-0.33	-0.4	Schizophrenia;	chr17:20089425	chr17:20436337~20447249:+
THYM	cis	rs2115630	0.967	rs7171167	ENSG00000275120.1	RP11-182J1.17	-4.27	4.59e-05	0.025	-0.47	-0.4	P wave terminal force;	chr15:84695892	chr15:84599434~84606463:-
THYM	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	4.27	4.59e-05	0.025	0.51	0.4	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
THYM	cis	rs1950357	0.568	rs1159948	ENSG00000258601.1	RP11-81F13.2	4.27	4.59e-05	0.025	0.4	0.4	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36741469	chr14:36808871~36828729:+
THYM	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-4.27	4.6e-05	0.025	-0.4	-0.4	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-4.27	4.6e-05	0.025	-0.4	-0.4	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
THYM	cis	rs7560272	0.588	rs4852965	ENSG00000273245.1	RP11-434P11.2	-4.27	4.6e-05	0.0251	-0.47	-0.4	Schizophrenia;	chr2:73684042	chr2:73750256~73750786:-
THYM	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	4.27	4.6e-05	0.0251	0.34	0.4	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
THYM	cis	rs553086	0.558	rs486524	ENSG00000238041.3	RP11-59K5.1	4.27	4.6e-05	0.0251	0.57	0.4	Fear of severe pain;	chr11:57167058	chr11:56690465~56690723:+
THYM	cis	rs8067545	0.75	rs7208365	ENSG00000230528.6	NOS2P3	-4.27	4.61e-05	0.0251	-0.33	-0.4	Schizophrenia;	chr17:20094704	chr17:20436337~20447249:+
THYM	cis	rs7267979	0.866	rs2424699	ENSG00000276952.1	RP5-965G21.6	4.27	4.61e-05	0.0251	0.47	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25284915~25285588:-
THYM	cis	rs9876781	1	rs9849509	ENSG00000244380.1	RP11-24C3.2	4.27	4.61e-05	0.0251	0.55	0.4	Longevity;	chr3:48442021	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs60512868	ENSG00000244380.1	RP11-24C3.2	4.27	4.61e-05	0.0251	0.55	0.4	Longevity;	chr3:48442035	chr3:48440352~48446656:-
THYM	cis	rs11098499	0.863	rs3822190	ENSG00000250412.1	KLHL2P1	4.27	4.61e-05	0.0251	0.38	0.4	Corneal astigmatism;	chr4:119506943	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3822191	ENSG00000250412.1	KLHL2P1	4.27	4.61e-05	0.0251	0.38	0.4	Corneal astigmatism;	chr4:119506946	chr4:119334329~119378233:+
THYM	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	4.27	4.62e-05	0.0251	0.51	0.4	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	4.27	4.62e-05	0.0251	0.51	0.4	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
THYM	cis	rs7178424	0.935	rs8034335	ENSG00000259251.2	RP11-643M14.1	4.27	4.62e-05	0.0251	0.45	0.4	Height;	chr15:61995257	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.967	rs17271340	ENSG00000259251.2	RP11-643M14.1	-4.27	4.63e-05	0.0252	-0.45	-0.4	Height;	chr15:62055686	chr15:62060503~62062434:+
THYM	cis	rs9907295	0.786	rs56344830	ENSG00000270977.1	AC015849.16	-4.27	4.63e-05	0.0252	-0.72	-0.4	Fibroblast growth factor basic levels;	chr17:35903951	chr17:35893707~35911023:-
THYM	cis	rs7077446	0.708	rs2902541	ENSG00000269609.4	RPARP-AS1	4.27	4.63e-05	0.0252	0.3	0.4	Intelligence (multi-trait analysis);	chr10:102006021	chr10:102449817~102461106:+
THYM	cis	rs9907295	0.579	rs9899866	ENSG00000270871.1	AC015849.19	-4.27	4.64e-05	0.0252	-0.45	-0.4	Fibroblast growth factor basic levels;	chr17:35908466	chr17:35816717~35830293:-
THYM	cis	rs11577318	0.853	rs11247913	ENSG00000225854.2	RP11-569G9.7	4.27	4.64e-05	0.0252	0.5	0.4	Granulocyte percentage of myeloid white cells;	chr1:26322060	chr1:26326688~26327033:+
THYM	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	4.27	4.64e-05	0.0252	0.38	0.4	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	4.27	4.64e-05	0.0252	0.38	0.4	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.957	rs10141052	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106776528	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10140904	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106776558	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10141009	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106776695	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.912	rs6576227	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106778202	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs6576228	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106778401	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs11846893	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106779068	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs12590799	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106779713	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10136781	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106780451	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs8022165	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106781682	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.917	rs8022493	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106781820	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10142918	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106782206	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10142859	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106782238	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs12589190	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106783079	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs7493713	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106783685	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.912	rs35468694	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106784199	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs8019272	ENSG00000253703.1	IGHV1-68	-4.27	4.65e-05	0.0253	-0.52	-0.4	Kawasaki disease;	chr14:106784709	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10150241	ENSG00000253703.1	IGHV1-68	4.27	4.65e-05	0.0253	0.52	0.4	Kawasaki disease;	chr14:106775945	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs12590667	ENSG00000253703.1	IGHV1-68	4.27	4.65e-05	0.0253	0.52	0.4	Kawasaki disease;	chr14:106779223	chr14:106703852~106704146:-
THYM	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	4.27	4.65e-05	0.0253	0.37	0.4	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
THYM	cis	rs4835473	0.897	rs13135627	ENSG00000249741.2	RP11-673E1.3	4.27	4.65e-05	0.0253	0.35	0.4	Immature fraction of reticulocytes;	chr4:143691099	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs57648439	ENSG00000249741.2	RP11-673E1.3	4.27	4.65e-05	0.0253	0.35	0.4	Immature fraction of reticulocytes;	chr4:143691519	chr4:143911514~143912053:-
THYM	cis	rs972578	0.868	rs2273143	ENSG00000215347.3	SLC25A5P1	-4.27	4.65e-05	0.0253	-0.33	-0.4	Mean platelet volume;	chr22:42884644	chr22:42001069~42001966:-
THYM	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	4.27	4.66e-05	0.0253	0.8	0.4	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
THYM	cis	rs17685	0.753	rs4732542	ENSG00000280388.1	RP11-229D13.3	-4.27	4.66e-05	0.0253	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76033885	chr7:76043977~76045963:-
THYM	cis	rs972578	0.875	rs6519353	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42960124	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5759059	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42962486	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5751404	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42962731	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5751405	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42965073	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs2413737	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42965137	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5759060	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42965798	chr22:42001069~42001966:-
THYM	cis	rs972578	0.905	rs55682747	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42965922	chr22:42001069~42001966:-
THYM	cis	rs972578	0.905	rs56026835	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42967116	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5759062	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42967189	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs2267481	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42967883	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs11913527	ENSG00000215347.3	SLC25A5P1	-4.27	4.66e-05	0.0253	-0.31	-0.4	Mean platelet volume;	chr22:42968628	chr22:42001069~42001966:-
THYM	cis	rs7178424	0.742	rs12911564	ENSG00000259251.2	RP11-643M14.1	4.27	4.66e-05	0.0253	0.41	0.4	Height;	chr15:61919777	chr15:62060503~62062434:+
THYM	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	4.27	4.66e-05	0.0253	0.38	0.4	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
THYM	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	4.27	4.66e-05	0.0253	0.54	0.4	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
THYM	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-4.27	4.66e-05	0.0253	-0.54	-0.4	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
THYM	cis	rs12908161	1	rs58416181	ENSG00000275120.1	RP11-182J1.17	4.27	4.67e-05	0.0254	0.54	0.4	Schizophrenia;	chr15:84721230	chr15:84599434~84606463:-
THYM	cis	rs11017328	0.5	rs12414105	ENSG00000236303.2	RP11-540N6.1	-4.27	4.67e-05	0.0254	-0.57	-0.4	Conotruncal heart defects;	chr10:130494703	chr10:130439067~130483154:+
THYM	cis	rs11017328	0.541	rs34811496	ENSG00000236303.2	RP11-540N6.1	-4.27	4.67e-05	0.0254	-0.57	-0.4	Conotruncal heart defects;	chr10:130494800	chr10:130439067~130483154:+
THYM	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-4.27	4.67e-05	0.0254	-0.38	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-4.27	4.67e-05	0.0254	-0.38	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-4.27	4.67e-05	0.0254	-0.38	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-4.27	4.67e-05	0.0254	-0.38	-0.4	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
THYM	cis	rs6087771	0.65	rs6060395	ENSG00000230613.1	HM13-AS1	4.27	4.67e-05	0.0254	0.55	0.4	Putamen volume;Subcortical brain region volumes;	chr20:31632020	chr20:31567707~31573263:-
THYM	cis	rs1757171	0.534	rs2797793	ENSG00000279942.1	RP1-153P14.7	4.27	4.67e-05	0.0254	0.53	0.4	Cognitive performance;	chr6:37509486	chr6:37567716~37571460:+
THYM	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	4.27	4.67e-05	0.0254	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
THYM	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	4.27	4.67e-05	0.0254	0.52	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
THYM	cis	rs7546094	0.846	rs4838959	ENSG00000215866.6	LINC01356	4.27	4.67e-05	0.0254	0.52	0.4	Platelet distribution width;	chr1:112543099	chr1:112820170~112850643:-
THYM	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	-4.27	4.68e-05	0.0254	-0.46	-0.4	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
THYM	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-4.27	4.68e-05	0.0254	-0.41	-0.4	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
THYM	cis	rs995834	0.742	rs2868965	ENSG00000267243.4	AC005307.3	4.27	4.68e-05	0.0254	0.36	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28362886	chr19:28435388~28727777:-
THYM	cis	rs1559777	0.877	rs2274	ENSG00000274719.1	RP11-86K22.2	-4.27	4.68e-05	0.0254	-0.45	-0.4	Myopia (pathological);	chr15:57790501	chr15:57990217~57990636:-
THYM	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	4.27	4.68e-05	0.0254	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
THYM	cis	rs12681366	0.881	rs12676373	ENSG00000253704.1	RP11-267M23.4	4.27	4.68e-05	0.0254	0.53	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94349890	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.806	rs72672679	ENSG00000253704.1	RP11-267M23.4	4.27	4.68e-05	0.0254	0.53	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94368956	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.881	rs12675415	ENSG00000253704.1	RP11-267M23.4	4.27	4.68e-05	0.0254	0.53	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94371332	chr8:94553722~94569745:+
THYM	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-4.27	4.69e-05	0.0255	-0.43	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
THYM	cis	rs877819	0.583	rs2663030	ENSG00000228403.1	RP11-563N6.6	-4.27	4.69e-05	0.0255	-0.51	-0.4	Systemic lupus erythematosus;	chr10:48879413	chr10:48878022~48878649:+
THYM	cis	rs561341	1	rs7214017	ENSG00000265798.5	RP11-271K11.5	4.27	4.69e-05	0.0255	0.48	0.4	Hip circumference adjusted for BMI;	chr17:32005201	chr17:31038575~31059121:-
THYM	cis	rs17253792	0.915	rs78498383	ENSG00000186615.9	KTN1-AS1	-4.27	4.7e-05	0.0255	-0.76	-0.4	Putamen volume;	chr14:55710867	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs77252471	ENSG00000186615.9	KTN1-AS1	-4.27	4.7e-05	0.0255	-0.76	-0.4	Putamen volume;	chr14:55711357	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs78089630	ENSG00000186615.9	KTN1-AS1	-4.27	4.7e-05	0.0255	-0.76	-0.4	Putamen volume;	chr14:55711866	chr14:55499278~55580110:-
THYM	cis	rs17253792	1	rs28616134	ENSG00000186615.9	KTN1-AS1	-4.27	4.7e-05	0.0255	-0.76	-0.4	Putamen volume;	chr14:55712084	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs28663681	ENSG00000186615.9	KTN1-AS1	-4.27	4.7e-05	0.0255	-0.76	-0.4	Putamen volume;	chr14:55712102	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs28537145	ENSG00000186615.9	KTN1-AS1	-4.27	4.7e-05	0.0255	-0.76	-0.4	Putamen volume;	chr14:55712401	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs28375514	ENSG00000186615.9	KTN1-AS1	-4.27	4.7e-05	0.0255	-0.76	-0.4	Putamen volume;	chr14:55713223	chr14:55499278~55580110:-
THYM	cis	rs1550576	0.568	rs55757800	ENSG00000274719.1	RP11-86K22.2	4.27	4.7e-05	0.0255	0.78	0.4	Hypertension;	chr15:57998533	chr15:57990217~57990636:-
THYM	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-4.27	4.7e-05	0.0255	-0.42	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
THYM	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	4.27	4.71e-05	0.0255	0.41	0.4	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-4.27	4.71e-05	0.0255	-0.41	-0.4	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-4.27	4.71e-05	0.0255	-0.41	-0.4	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-4.27	4.71e-05	0.0255	-0.41	-0.4	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
THYM	cis	rs2812378	0.545	rs2297132	ENSG00000227852.1	RP11-156G14.6	-4.27	4.71e-05	0.0255	-0.44	-0.4	Rheumatoid arthritis;	chr9:34723184	chr9:35592786~35592951:+
THYM	cis	rs995834	0.742	rs2159326	ENSG00000267243.4	AC005307.3	-4.27	4.71e-05	0.0255	-0.39	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28338023	chr19:28435388~28727777:-
THYM	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-4.27	4.71e-05	0.0256	-0.48	-0.4	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
THYM	cis	rs6930781	0.633	rs9374147	ENSG00000219700.1	PTCHD3P3	-4.27	4.71e-05	0.0256	-0.45	-0.4	Major depression and alcohol dependence;	chr6:110036632	chr6:109288571~109290503:-
THYM	cis	rs1642645	0.872	rs7550500	ENSG00000228452.1	RP5-994D16.9	-4.27	4.73e-05	0.0256	-0.52	-0.4	Left ventricular obstructive tract defect (maternal effect);	chr1:42039851	chr1:42775813~42776790:-
THYM	cis	rs4835473	0.801	rs999049	ENSG00000249741.2	RP11-673E1.3	4.27	4.73e-05	0.0256	0.35	0.4	Immature fraction of reticulocytes;	chr4:143715440	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs13145976	ENSG00000249741.2	RP11-673E1.3	4.27	4.74e-05	0.0256	0.34	0.4	Immature fraction of reticulocytes;	chr4:143735710	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs13114071	ENSG00000249741.2	RP11-673E1.3	4.27	4.74e-05	0.0256	0.34	0.4	Immature fraction of reticulocytes;	chr4:143735728	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs13140654	ENSG00000249741.2	RP11-673E1.3	4.27	4.74e-05	0.0256	0.34	0.4	Immature fraction of reticulocytes;	chr4:143735733	chr4:143911514~143912053:-
THYM	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	4.27	4.74e-05	0.0256	0.46	0.4	Height;	chr6:109380457	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	4.27	4.74e-05	0.0256	0.46	0.4	Height;	chr6:109380990	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	4.27	4.74e-05	0.0256	0.46	0.4	Height;	chr6:109395761	chr6:109382795~109383666:+
THYM	cis	rs42490	0.664	rs39767	ENSG00000251136.7	RP11-37B2.1	-4.27	4.74e-05	0.0256	-0.32	-0.4	Leprosy;	chr8:89807770	chr8:89609409~89757727:-
THYM	cis	rs11577318	0.853	rs7416513	ENSG00000225854.2	RP11-569G9.7	4.27	4.74e-05	0.0256	0.49	0.4	Granulocyte percentage of myeloid white cells;	chr1:26321458	chr1:26326688~26327033:+
THYM	cis	rs4853012	0.838	rs2177707	ENSG00000272183.1	RP11-523H20.3	4.27	4.74e-05	0.0257	0.54	0.4	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74501717~74502365:+
THYM	cis	rs4853012	0.887	rs2280642	ENSG00000272183.1	RP11-523H20.3	4.27	4.74e-05	0.0257	0.54	0.4	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74501717~74502365:+
THYM	cis	rs8067545	0.559	rs3874846	ENSG00000231645.2	KRT17P6	-4.27	4.75e-05	0.0257	-0.47	-0.4	Schizophrenia;	chr17:20394232	chr17:20512560~20517479:-
THYM	cis	rs11098499	0.779	rs80242894	ENSG00000250412.1	KLHL2P1	4.27	4.75e-05	0.0257	0.39	0.4	Corneal astigmatism;	chr4:119454597	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs28634456	ENSG00000250412.1	KLHL2P1	4.27	4.75e-05	0.0257	0.39	0.4	Corneal astigmatism;	chr4:119454623	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs78332141	ENSG00000250412.1	KLHL2P1	4.27	4.75e-05	0.0257	0.39	0.4	Corneal astigmatism;	chr4:119454627	chr4:119334329~119378233:+
THYM	cis	rs7631605	0.87	rs11129746	ENSG00000272334.1	RP11-129K12.1	-4.27	4.75e-05	0.0257	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:36960481	chr3:36973117~36973672:-
THYM	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	4.27	4.76e-05	0.0257	0.5	0.4	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
THYM	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	4.26	4.76e-05	0.0257	0.53	0.4	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
THYM	cis	rs897984	0.762	rs1870293	ENSG00000275263.1	RP11-1072A3.4	4.26	4.76e-05	0.0257	0.35	0.4	Dementia with Lewy bodies;	chr16:30959620	chr16:30956872~30957199:-
THYM	cis	rs67517081	1	rs67517081	ENSG00000275263.1	RP11-1072A3.4	4.26	4.76e-05	0.0257	0.35	0.4	Mean corpuscular hemoglobin;	chr16:30976060	chr16:30956872~30957199:-
THYM	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	4.26	4.76e-05	0.0258	0.51	0.4	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
THYM	cis	rs526231	0.67	rs421946	ENSG00000175749.11	EIF3KP1	4.26	4.76e-05	0.0258	0.52	0.4	Primary biliary cholangitis;	chr5:103286340	chr5:103032376~103033031:+
THYM	cis	rs7637701	0.517	rs66538320	ENSG00000243926.1	TIPARP-AS1	4.26	4.77e-05	0.0258	0.32	0.4	Breast cancer;	chr3:156674346	chr3:156671862~156674378:-
THYM	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	4.26	4.77e-05	0.0258	0.46	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
THYM	cis	rs2115630	0.967	rs11073702	ENSG00000275120.1	RP11-182J1.17	-4.26	4.77e-05	0.0258	-0.47	-0.4	P wave terminal force;	chr15:84766840	chr15:84599434~84606463:-
THYM	cis	rs3096299	0.606	rs2965946	ENSG00000261118.1	RP11-104N10.1	4.26	4.77e-05	0.0258	0.49	0.4	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89492017~89504460:-
THYM	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	4.26	4.77e-05	0.0258	0.41	0.4	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
THYM	cis	rs9611519	1	rs3818003	ENSG00000235513.1	RP4-756G23.5	4.26	4.77e-05	0.0258	0.35	0.4	Neuroticism;	chr22:41213686	chr22:41209122~41217627:-
THYM	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-4.26	4.77e-05	0.0258	-0.54	-0.4	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
THYM	cis	rs2853333	0.622	rs2853332	ENSG00000268947.1	AD000684.2	4.26	4.77e-05	0.0258	0.35	0.4	Red blood cell count;	chr19:35255803	chr19:35262846~35264804:+
THYM	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	4.26	4.78e-05	0.0258	0.51	0.4	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
THYM	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
THYM	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-4.26	4.78e-05	0.0258	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	4.26	4.78e-05	0.0258	0.46	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
THYM	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	4.26	4.78e-05	0.0258	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	4.26	4.78e-05	0.0258	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	4.26	4.78e-05	0.0258	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	4.26	4.78e-05	0.0258	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	4.26	4.78e-05	0.0258	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
THYM	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	4.26	4.78e-05	0.0258	0.52	0.4	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
THYM	cis	rs7617773	0.539	rs2017858	ENSG00000228638.1	FCF1P2	-4.26	4.78e-05	0.0258	-0.38	-0.4	Coronary artery disease;	chr3:48340792	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs1471217	ENSG00000228638.1	FCF1P2	-4.26	4.78e-05	0.0258	-0.38	-0.4	Coronary artery disease;	chr3:48343405	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs13094496	ENSG00000228638.1	FCF1P2	-4.26	4.78e-05	0.0258	-0.38	-0.4	Coronary artery disease;	chr3:48345560	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs12486935	ENSG00000228638.1	FCF1P2	-4.26	4.78e-05	0.0258	-0.38	-0.4	Coronary artery disease;	chr3:48348674	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.563	rs62263035	ENSG00000228638.1	FCF1P2	-4.26	4.78e-05	0.0258	-0.38	-0.4	Coronary artery disease;	chr3:48350079	chr3:48290793~48291375:-
THYM	cis	rs17685	0.712	rs1859792	ENSG00000280388.1	RP11-229D13.3	-4.26	4.78e-05	0.0258	-0.42	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76159946	chr7:76043977~76045963:-
THYM	cis	rs12902680	0.706	rs1434681	ENSG00000259520.4	CTD-2651B20.3	4.26	4.79e-05	0.0259	0.42	0.4	Neuroticism;	chr15:46178020	chr15:45251580~45279251:-
THYM	cis	rs2283792	0.715	rs55891647	ENSG00000228050.1	TOP3BP1	4.26	4.79e-05	0.0259	0.44	0.4	Multiple sclerosis;	chr22:21824198	chr22:22223187~22224566:-
THYM	cis	rs2283792	0.935	rs9610375	ENSG00000228050.1	TOP3BP1	4.26	4.79e-05	0.0259	0.44	0.4	Multiple sclerosis;	chr22:21832804	chr22:22223187~22224566:-
THYM	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-4.26	4.79e-05	0.0259	-0.45	-0.4	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
THYM	cis	rs10129255	0.843	rs7142649	ENSG00000254329.1	IGHVII-60-1	4.26	4.79e-05	0.0259	0.4	0.4	Kawasaki disease;	chr14:106708870	chr14:106637718~106637973:-
THYM	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	4.26	4.8e-05	0.0259	0.5	0.4	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	4.26	4.8e-05	0.0259	0.5	0.4	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	4.26	4.8e-05	0.0259	0.5	0.4	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	4.26	4.8e-05	0.0259	0.5	0.4	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	4.26	4.8e-05	0.0259	0.5	0.4	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	4.26	4.8e-05	0.0259	0.5	0.4	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	4.26	4.8e-05	0.0259	0.5	0.4	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
THYM	cis	rs4835473	0.932	rs2218791	ENSG00000249741.2	RP11-673E1.3	4.26	4.8e-05	0.0259	0.33	0.4	Immature fraction of reticulocytes;	chr4:143749300	chr4:143911514~143912053:-
THYM	cis	rs11085466	1	rs75079001	ENSG00000268705.1	BNIP3P26	4.26	4.8e-05	0.0259	0.35	0.4	Colorectal or endometrial cancer;	chr19:21574573	chr19:21521343~21521896:-
THYM	cis	rs11085466	0.948	rs11668453	ENSG00000268705.1	BNIP3P26	4.26	4.8e-05	0.0259	0.35	0.4	Colorectal or endometrial cancer;	chr19:21576555	chr19:21521343~21521896:-
THYM	cis	rs11085466	1	rs75211977	ENSG00000268705.1	BNIP3P26	4.26	4.8e-05	0.0259	0.35	0.4	Colorectal or endometrial cancer;	chr19:21577399	chr19:21521343~21521896:-
THYM	cis	rs11085466	0.948	rs76881507	ENSG00000268705.1	BNIP3P26	4.26	4.8e-05	0.0259	0.35	0.4	Colorectal or endometrial cancer;	chr19:21579387	chr19:21521343~21521896:-
THYM	cis	rs11085466	1	rs73552468	ENSG00000268705.1	BNIP3P26	4.26	4.8e-05	0.0259	0.35	0.4	Colorectal or endometrial cancer;	chr19:21589295	chr19:21521343~21521896:-
THYM	cis	rs4713118	0.662	rs149946	ENSG00000182477.5	OR2B8P	-4.26	4.8e-05	0.0259	-0.57	-0.4	Parkinson's disease;	chr6:28002253	chr6:28053228~28054165:-
THYM	cis	rs4713118	0.662	rs149969	ENSG00000182477.5	OR2B8P	4.26	4.8e-05	0.0259	0.57	0.4	Parkinson's disease;	chr6:28009959	chr6:28053228~28054165:-
THYM	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-4.26	4.81e-05	0.0259	-0.51	-0.4	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
THYM	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-4.26	4.81e-05	0.0259	-0.51	-0.4	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
THYM	cis	rs3096299	0.583	rs2965949	ENSG00000261118.1	RP11-104N10.1	4.26	4.81e-05	0.026	0.49	0.4	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89492017~89504460:-
THYM	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	4.26	4.82e-05	0.026	0.3	0.4	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
THYM	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	4.26	4.82e-05	0.026	0.51	0.4	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
THYM	cis	rs7560272	0.538	rs13000788	ENSG00000163016.8	ALMS1P	-4.26	4.82e-05	0.026	-0.51	-0.4	Schizophrenia;	chr2:73691185	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs6732812	ENSG00000163016.8	ALMS1P	-4.26	4.82e-05	0.026	-0.51	-0.4	Schizophrenia;	chr2:73695348	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs17434634	ENSG00000163016.8	ALMS1P	-4.26	4.82e-05	0.026	-0.51	-0.4	Schizophrenia;	chr2:73695799	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs7370393	ENSG00000163016.8	ALMS1P	-4.26	4.82e-05	0.026	-0.51	-0.4	Schizophrenia;	chr2:73698509	chr2:73644919~73685576:+
THYM	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	4.26	4.83e-05	0.026	0.44	0.4	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
THYM	cis	rs4948275	0.806	rs1953748	ENSG00000237233.2	TMEM26-AS1	-4.26	4.83e-05	0.026	-0.47	-0.4	Night sleep phenotypes;	chr10:61494529	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2787738	ENSG00000237233.2	TMEM26-AS1	4.26	4.83e-05	0.026	0.47	0.4	Night sleep phenotypes;	chr10:61493601	chr10:61452639~61481956:+
THYM	cis	rs453301	0.597	rs7001187	ENSG00000253893.2	FAM85B	4.26	4.83e-05	0.026	0.52	0.4	Joint mobility (Beighton score);	chr8:8935272	chr8:8167819~8226614:-
THYM	cis	rs453301	0.631	rs13250781	ENSG00000253893.2	FAM85B	4.26	4.83e-05	0.026	0.52	0.4	Joint mobility (Beighton score);	chr8:8935833	chr8:8167819~8226614:-
THYM	cis	rs2911132	0.506	rs10037212	ENSG00000272109.1	CTD-2260A17.3	4.26	4.84e-05	0.0261	0.52	0.4	Urate levels (BMI interaction);	chr5:96749072	chr5:96804353~96806105:+
THYM	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-4.26	4.84e-05	0.0261	-0.42	-0.4	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
THYM	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-4.26	4.84e-05	0.0261	-0.31	-0.4	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
THYM	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-4.26	4.84e-05	0.0261	-0.31	-0.4	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
THYM	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	4.26	4.84e-05	0.0261	0.44	0.4	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
THYM	cis	rs4908768	0.501	rs1922983	ENSG00000232912.4	RP5-1115A15.1	4.26	4.84e-05	0.0261	0.39	0.4	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8424645~8434838:+
THYM	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	4.26	4.85e-05	0.0261	0.55	0.4	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	4.26	4.85e-05	0.0261	0.55	0.4	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
THYM	cis	rs910316	1	rs10136948	ENSG00000258646.1	RP11-950C14.3	-4.26	4.85e-05	0.0261	-0.37	-0.4	Height;	chr14:75044372	chr14:75004719~75008481:-
THYM	cis	rs1584120	0.57	rs10842123	ENSG00000256321.4	RP11-153K16.1	-4.26	4.85e-05	0.0261	-0.47	-0.4	Pelvic organ prolapse (moderate/severe);	chr12:23113358	chr12:23099368~23191587:+
THYM	cis	rs1584120	0.503	rs11046804	ENSG00000256321.4	RP11-153K16.1	-4.26	4.85e-05	0.0261	-0.47	-0.4	Pelvic organ prolapse (moderate/severe);	chr12:23117772	chr12:23099368~23191587:+
THYM	cis	rs972578	0.837	rs2413720	ENSG00000215347.3	SLC25A5P1	-4.26	4.85e-05	0.0261	-0.33	-0.4	Mean platelet volume;	chr22:42802253	chr22:42001069~42001966:-
THYM	cis	rs2235573	0.805	rs4821738	ENSG00000272669.1	RP3-508I15.21	-4.26	4.85e-05	0.0261	-0.26	-0.4	Glioma;Glioblastoma;	chr22:38104473	chr22:38742625~38743115:+
THYM	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-4.26	4.85e-05	0.0261	-0.71	-0.4	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
THYM	cis	rs2115630	0.905	rs1975277	ENSG00000275120.1	RP11-182J1.17	-4.26	4.86e-05	0.0261	-0.47	-0.4	P wave terminal force;	chr15:84786327	chr15:84599434~84606463:-
THYM	cis	rs7849270	0.879	rs7042928	ENSG00000268707.1	RP11-247A12.7	4.26	4.86e-05	0.0261	0.5	0.4	Blood metabolite ratios;	chr9:129092996	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.879	rs2229419	ENSG00000268707.1	RP11-247A12.7	4.26	4.86e-05	0.0261	0.5	0.4	Blood metabolite ratios;	chr9:129095351	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.837	rs4642748	ENSG00000268707.1	RP11-247A12.7	-4.26	4.86e-05	0.0261	-0.5	-0.4	Blood metabolite ratios;	chr9:129092668	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.692	rs4397510	ENSG00000268707.1	RP11-247A12.7	-4.26	4.86e-05	0.0261	-0.5	-0.4	Blood metabolite ratios;	chr9:129092671	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.879	rs10739741	ENSG00000268707.1	RP11-247A12.7	-4.26	4.86e-05	0.0261	-0.5	-0.4	Blood metabolite ratios;	chr9:129092881	chr9:129170434~129170940:+
THYM	cis	rs3096299	0.606	rs4785573	ENSG00000261118.1	RP11-104N10.1	4.26	4.86e-05	0.0261	0.48	0.4	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89492017~89504460:-
THYM	cis	rs4478858	0.735	rs10914344	ENSG00000260386.4	LINC01225	4.26	4.86e-05	0.0262	0.22	0.4	Alcohol dependence;	chr1:31296178	chr1:31500085~31540885:+
THYM	cis	rs7851726	0.668	rs7862219	ENSG00000232063.1	RP11-307E17.8	4.26	4.86e-05	0.0262	0.4	0.4	Urinary albumin-to-creatinine ratio;	chr9:94889948	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.668	rs10081676	ENSG00000232063.1	RP11-307E17.8	4.26	4.86e-05	0.0262	0.4	0.4	Urinary albumin-to-creatinine ratio;	chr9:94892954	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.646	rs10993387	ENSG00000232063.1	RP11-307E17.8	4.26	4.86e-05	0.0262	0.4	0.4	Urinary albumin-to-creatinine ratio;	chr9:94900214	chr9:94332476~94360948:+
THYM	cis	rs12902680	0.706	rs1434679	ENSG00000259520.4	CTD-2651B20.3	-4.26	4.86e-05	0.0262	-0.42	-0.4	Neuroticism;	chr15:46178632	chr15:45251580~45279251:-
THYM	cis	rs11603020	1	rs11603020	ENSG00000265566.2	RN7SL605P	4.26	4.87e-05	0.0262	0.56	0.4	Blood protein levels;	chr11:57606859	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.95	rs78624400	ENSG00000265566.2	RN7SL605P	-4.26	4.87e-05	0.0262	-0.56	-0.4	Blood protein levels;	chr11:57607990	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.95	rs3824988	ENSG00000265566.2	RN7SL605P	4.26	4.87e-05	0.0262	0.56	0.4	Blood protein levels;	chr11:57610495	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.851	rs10896631	ENSG00000265566.2	RN7SL605P	-4.26	4.87e-05	0.0262	-0.56	-0.4	Blood protein levels;	chr11:57613790	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.904	rs4926	ENSG00000265566.2	RN7SL605P	-4.26	4.87e-05	0.0262	-0.56	-0.4	Blood protein levels;	chr11:57614516	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.904	rs11606677	ENSG00000265566.2	RN7SL605P	-4.26	4.87e-05	0.0262	-0.56	-0.4	Blood protein levels;	chr11:57615904	chr11:57528085~57528365:-
THYM	cis	rs792448	0.545	rs6679796	ENSG00000229983.1	RP11-15I11.2	4.26	4.87e-05	0.0262	0.32	0.4	White blood cell count (basophil);	chr1:212229182	chr1:212168207~212190259:+
THYM	cis	rs792448	0.527	rs11119887	ENSG00000229983.1	RP11-15I11.2	4.26	4.87e-05	0.0262	0.32	0.4	White blood cell count (basophil);	chr1:212234220	chr1:212168207~212190259:+
THYM	cis	rs2243480	1	rs73142166	ENSG00000228409.4	CCT6P1	4.26	4.88e-05	0.0262	0.51	0.4	Diabetic kidney disease;	chr7:65910845	chr7:65751142~65763354:+
THYM	cis	rs10829156	0.66	rs7910506	ENSG00000225527.1	RP11-383B4.4	4.26	4.88e-05	0.0262	0.47	0.4	Sudden cardiac arrest;	chr10:18518128	chr10:18531849~18533336:-
THYM	cis	rs3781264	1	rs7096678	ENSG00000273450.1	RP11-76P2.4	4.26	4.88e-05	0.0263	0.49	0.4	Esophageal cancer and gastric cancer;	chr10:94309451	chr10:94314907~94315327:-
THYM	cis	rs3781264	1	rs11187851	ENSG00000273450.1	RP11-76P2.4	4.26	4.88e-05	0.0263	0.49	0.4	Esophageal cancer and gastric cancer;	chr10:94310118	chr10:94314907~94315327:-
THYM	cis	rs6696239	0.513	rs4653853	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Height;	chr1:227563901	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs4653514	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Height;	chr1:227565381	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs12025815	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Hip circumference adjusted for BMI;	chr1:227570371	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2088211	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Height;	chr1:227575956	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs10916169	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Hip circumference adjusted for BMI;	chr1:227577156	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs903697	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Height;	chr1:227579144	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2935155	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Height;	chr1:227585305	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs3010186	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227587125	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2999741	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227597504	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2999743	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227598205	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2935146	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227598332	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2999744	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227599667	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.568	rs2935147	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227600286	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.569	rs2999745	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227604838	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2999746	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227605784	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs3010196	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Hip circumference adjusted for BMI;	chr1:227606207	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.531	rs3010195	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227607008	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs3010194	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227608220	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs3010193	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227610621	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs3010192	ENSG00000227711.2	RP11-275O4.5	-4.26	4.88e-05	0.0263	-0.36	-0.4	Height;	chr1:227615350	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs3010191	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Height;	chr1:227615460	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs2935152	ENSG00000227711.2	RP11-275O4.5	4.26	4.88e-05	0.0263	0.36	0.4	Height;	chr1:227616000	chr1:227509028~227520477:-
THYM	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	4.26	4.89e-05	0.0263	0.51	0.4	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
THYM	cis	rs11017328	0.5	rs12359852	ENSG00000236303.2	RP11-540N6.1	-4.26	4.89e-05	0.0263	-0.58	-0.4	Conotruncal heart defects;	chr10:130516908	chr10:130439067~130483154:+
THYM	cis	rs2738048	0.724	rs2615768	ENSG00000233531.1	DEFA10P	4.26	4.89e-05	0.0263	0.47	0.4	IgA nephropathy;	chr8:6965084	chr8:6968141~6969113:-
THYM	cis	rs10829156	0.732	rs10828834	ENSG00000225527.1	RP11-383B4.4	-4.26	4.9e-05	0.0263	-0.52	-0.4	Sudden cardiac arrest;	chr10:18523505	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.732	rs7100884	ENSG00000225527.1	RP11-383B4.4	-4.26	4.9e-05	0.0263	-0.52	-0.4	Sudden cardiac arrest;	chr10:18523768	chr10:18531849~18533336:-
THYM	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	4.26	4.9e-05	0.0263	0.5	0.4	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
THYM	cis	rs34792	0.637	rs2450356	ENSG00000262380.1	CTB-193M12.3	-4.26	4.9e-05	0.0263	-0.5	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:15683290~15684570:+
THYM	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	4.26	4.9e-05	0.0263	0.42	0.4	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
THYM	cis	rs56307353	0.652	rs4807191	ENSG00000180846.7	CSNK1G2-AS1	-4.26	4.9e-05	0.0263	-0.44	-0.4	Coronary artery disease;	chr19:1990310	chr19:1952531~1954586:-
THYM	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	4.26	4.91e-05	0.0264	0.46	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
THYM	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-4.26	4.91e-05	0.0264	-0.35	-0.4	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
THYM	cis	rs2834288	0.535	rs8129694	ENSG00000273102.1	AP000569.9	-4.26	4.92e-05	0.0264	-0.44	-0.4	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.535	rs7275560	ENSG00000273102.1	AP000569.9	-4.26	4.92e-05	0.0264	-0.44	-0.4	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.535	rs2834306	ENSG00000273102.1	AP000569.9	-4.26	4.92e-05	0.0264	-0.44	-0.4	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33967101~33968573:-
THYM	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	4.26	4.92e-05	0.0264	0.5	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
THYM	cis	rs17253792	0.822	rs75399477	ENSG00000186615.9	KTN1-AS1	-4.26	4.92e-05	0.0264	-0.79	-0.4	Putamen volume;	chr14:55707695	chr14:55499278~55580110:-
THYM	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-4.26	4.92e-05	0.0264	-0.45	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
THYM	cis	rs12908161	0.515	rs12907646	ENSG00000235370.6	DNM1P51	4.26	4.93e-05	0.0264	0.53	0.4	Schizophrenia;	chr15:84860265	chr15:84398316~84411701:-
THYM	cis	rs7851726	0.668	rs10761361	ENSG00000232063.1	RP11-307E17.8	4.26	4.93e-05	0.0265	0.4	0.4	Urinary albumin-to-creatinine ratio;	chr9:94882260	chr9:94332476~94360948:+
THYM	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-4.26	4.94e-05	0.0265	-0.6	-0.4	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
THYM	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	4.25	4.94e-05	0.0265	0.45	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
THYM	cis	rs877819	0.583	rs1993985	ENSG00000228403.1	RP11-563N6.6	-4.25	4.94e-05	0.0265	-0.6	-0.4	Systemic lupus erythematosus;	chr10:48850986	chr10:48878022~48878649:+
THYM	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-4.25	4.94e-05	0.0265	-0.85	-0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
THYM	cis	rs11096990	0.819	rs2711992	ENSG00000249685.1	RP11-360F5.3	-4.25	4.95e-05	0.0265	-0.4	-0.4	Cognitive function;	chr4:39148651	chr4:39133913~39135608:+
THYM	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	4.25	4.95e-05	0.0265	0.44	0.4	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
THYM	cis	rs12701220	0.817	rs1058729	ENSG00000229043.2	AC091729.9	-4.25	4.95e-05	0.0265	-0.65	-0.4	Bronchopulmonary dysplasia;	chr7:1047647	chr7:1160374~1165267:+
THYM	cis	rs12701220	0.817	rs7798459	ENSG00000229043.2	AC091729.9	-4.25	4.95e-05	0.0265	-0.65	-0.4	Bronchopulmonary dysplasia;	chr7:1048329	chr7:1160374~1165267:+
THYM	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	4.25	4.95e-05	0.0265	0.35	0.4	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
THYM	cis	rs61774743	0.521	rs60144015	ENSG00000229901.1	RP11-399E6.4	-4.25	4.95e-05	0.0265	-0.4	-0.4	Intelligence (multi-trait analysis);	chr1:41379574	chr1:41375004~41375669:-
THYM	cis	rs61774743	0.557	rs4359027	ENSG00000229901.1	RP11-399E6.4	-4.25	4.95e-05	0.0265	-0.4	-0.4	Intelligence (multi-trait analysis);	chr1:41382624	chr1:41375004~41375669:-
THYM	cis	rs7851726	0.652	rs7847277	ENSG00000232063.1	RP11-307E17.8	4.25	4.95e-05	0.0265	0.4	0.4	Urinary albumin-to-creatinine ratio;	chr9:94851146	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.69	rs4744386	ENSG00000232063.1	RP11-307E17.8	4.25	4.95e-05	0.0265	0.4	0.4	Urinary albumin-to-creatinine ratio;	chr9:94852359	chr9:94332476~94360948:+
THYM	cis	rs12902680	0.706	rs2413806	ENSG00000259520.4	CTD-2651B20.3	4.25	4.96e-05	0.0266	0.42	0.4	Neuroticism;	chr15:46216111	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1865410	ENSG00000259520.4	CTD-2651B20.3	4.25	4.96e-05	0.0266	0.42	0.4	Neuroticism;	chr15:46216183	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1434673	ENSG00000259520.4	CTD-2651B20.3	4.25	4.96e-05	0.0266	0.42	0.4	Neuroticism;	chr15:46218683	chr15:45251580~45279251:-
THYM	cis	rs6674176	0.597	rs9326136	ENSG00000237950.1	RP11-7O11.3	-4.25	4.96e-05	0.0266	-0.42	-0.4	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43924720	chr1:43944370~43946551:-
THYM	cis	rs6674176	0.597	rs3762422	ENSG00000237950.1	RP11-7O11.3	4.25	4.96e-05	0.0266	0.42	0.4	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934860	chr1:43944370~43946551:-
THYM	cis	rs4276643	0.602	rs4732613	ENSG00000253875.1	RP11-16P20.3	-4.25	4.96e-05	0.0266	-0.35	-0.4	Low vWF levels;	chr8:27922294	chr8:27733338~27756426:+
THYM	cis	rs4835473	0.932	rs1813908	ENSG00000249741.2	RP11-673E1.3	-4.25	4.96e-05	0.0266	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143728174	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs4835454	ENSG00000249741.2	RP11-673E1.3	-4.25	4.96e-05	0.0266	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143730081	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1839449	ENSG00000249741.2	RP11-673E1.3	-4.25	4.96e-05	0.0266	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143730222	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1450250	ENSG00000249741.2	RP11-673E1.3	-4.25	4.96e-05	0.0266	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143731873	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7664248	ENSG00000249741.2	RP11-673E1.3	-4.25	4.96e-05	0.0266	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143732554	chr4:143911514~143912053:-
THYM	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	4.25	4.96e-05	0.0266	0.55	0.4	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
THYM	cis	rs4478858	0.735	rs6670067	ENSG00000260386.4	LINC01225	4.25	4.97e-05	0.0266	0.22	0.4	Alcohol dependence;	chr1:31370100	chr1:31500085~31540885:+
THYM	cis	rs7617480	0.61	rs4955420	ENSG00000270441.1	RP11-694I15.7	-4.25	4.97e-05	0.0266	-0.41	-0.4	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49140086~49160851:-
THYM	cis	rs853679	0.517	rs6922063	ENSG00000272009.1	RP1-313I6.12	-4.25	4.97e-05	0.0266	-0.52	-0.4	Depression;	chr6:28126588	chr6:28078792~28081130:-
THYM	cis	rs853679	0.517	rs2275508	ENSG00000272009.1	RP1-313I6.12	-4.25	4.97e-05	0.0266	-0.52	-0.4	Depression;	chr6:28126953	chr6:28078792~28081130:-
THYM	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-4.25	4.97e-05	0.0266	-0.52	-0.4	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
THYM	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-4.25	4.97e-05	0.0266	-0.52	-0.4	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
THYM	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-4.25	4.97e-05	0.0266	-0.52	-0.4	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
THYM	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-4.25	4.97e-05	0.0266	-0.52	-0.4	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
THYM	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	4.25	4.97e-05	0.0266	0.38	0.4	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	4.25	4.97e-05	0.0266	0.38	0.4	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	4.25	4.97e-05	0.0266	0.38	0.4	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	4.25	4.97e-05	0.0266	0.38	0.4	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
THYM	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-4.25	4.97e-05	0.0266	-0.43	-0.4	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
THYM	cis	rs910316	0.967	rs4899551	ENSG00000258646.1	RP11-950C14.3	4.25	4.98e-05	0.0266	0.36	0.4	Height;	chr14:75193543	chr14:75004719~75008481:-
THYM	cis	rs73108077	0.736	rs1997741	ENSG00000277112.2	RP11-755J8.1	-4.25	4.98e-05	0.0267	-0.52	-0.4	Red blood cell density in sickle cell anemia;	chr20:31323198	chr20:30681825~30723932:-
THYM	cis	rs7246967	0.673	rs4933027	ENSG00000198153.8	ZNF849P	4.25	4.98e-05	0.0267	0.53	0.4	Bronchopulmonary dysplasia;	chr19:22721170	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs2361260	ENSG00000198153.8	ZNF849P	4.25	4.98e-05	0.0267	0.53	0.4	Bronchopulmonary dysplasia;	chr19:22731342	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.542	rs56355379	ENSG00000198153.8	ZNF849P	-4.25	4.98e-05	0.0267	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22717653	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34376806	ENSG00000198153.8	ZNF849P	-4.25	4.98e-05	0.0267	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22718059	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.611	rs16999571	ENSG00000198153.8	ZNF849P	-4.25	4.98e-05	0.0267	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22721962	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs36029703	ENSG00000198153.8	ZNF849P	-4.25	4.98e-05	0.0267	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22723386	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs7249473	ENSG00000198153.8	ZNF849P	-4.25	4.98e-05	0.0267	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22723892	chr19:22685167~22686732:+
THYM	cis	rs3015497	0.648	rs10144512	ENSG00000270062.1	RP11-248J18.3	4.25	4.99e-05	0.0267	0.29	0.4	Mean platelet volume;	chr14:50615553	chr14:50723777~50724272:-
THYM	cis	rs995758	0.967	rs2130339	ENSG00000236296.6	GUSBP5	4.25	4.99e-05	0.0267	0.46	0.4	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144543733	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs6830832	ENSG00000236296.6	GUSBP5	4.25	4.99e-05	0.0267	0.46	0.4	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144544339	chr4:143559472~143649305:+
THYM	cis	rs995758	1	rs1489759	ENSG00000236296.6	GUSBP5	4.25	4.99e-05	0.0267	0.46	0.4	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144553321	chr4:143559472~143649305:+
THYM	cis	rs904251	0.686	rs2776911	ENSG00000279942.1	RP1-153P14.7	-4.25	4.99e-05	0.0267	-0.58	-0.4	Cognitive performance;	chr6:37472174	chr6:37567716~37571460:+
THYM	cis	rs10208649	0.611	rs12616263	ENSG00000272156.1	RP11-477N3.1	4.25	4.99e-05	0.0267	0.59	0.4	Body mass index;	chr2:54039235	chr2:54082554~54085066:+
THYM	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-4.25	5e-05	0.0267	-0.37	-0.4	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
THYM	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	4.25	5e-05	0.0267	0.49	0.4	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
THYM	cis	rs8056893	1	rs8056893	ENSG00000261469.1	RP11-96D1.6	-4.25	5e-05	0.0268	-0.35	-0.4	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68270489	chr16:68236845~68237667:-
THYM	cis	rs995834	0.742	rs2159326	ENSG00000260725.1	AC005307.1	-4.25	5e-05	0.0268	-0.42	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);	chr19:28338023	chr19:28418483~28429490:-
THYM	cis	rs1023500	0.505	rs134891	ENSG00000227370.1	RP4-669P10.19	4.25	5e-05	0.0268	0.48	0.4	Schizophrenia;	chr22:42279876	chr22:42132543~42132998:+
THYM	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-4.25	5e-05	0.0268	-0.37	-0.4	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
THYM	cis	rs17253792	0.822	rs77408754	ENSG00000186615.9	KTN1-AS1	-4.25	5e-05	0.0268	-0.79	-0.4	Putamen volume;	chr14:55615329	chr14:55499278~55580110:-
THYM	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	4.25	5.01e-05	0.0268	0.28	0.4	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
THYM	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	4.25	5.01e-05	0.0268	0.35	0.4	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
THYM	cis	rs4809760	0.553	rs56405223	ENSG00000229222.1	KRT18P4	4.25	5.01e-05	0.0268	0.51	0.4	Gut microbiota (beta diversity);	chr20:49868779	chr20:49956745~49958032:+
THYM	cis	rs2243480	0.711	rs2420172	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66170354	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs2420171	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66172773	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs6974723	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66172952	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs9769882	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66177938	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs6966322	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66181767	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs4145008	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66182524	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs4718315	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66183554	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs4718316	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66183744	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs4718317	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66183914	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs1873494	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66184912	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs6959002	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66185509	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs1546059	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66189722	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs2420170	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66191066	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs6958289	ENSG00000228409.4	CCT6P1	-4.25	5.01e-05	0.0268	-0.46	-0.4	Diabetic kidney disease;	chr7:66192124	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs35396113	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66030474	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs313809	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66034996	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs313814	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66038306	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs427044	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66043558	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs437889	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66044247	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs402418	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66044482	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.803	rs423187	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66044512	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs431318	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66046610	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs313803	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66049744	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs313802	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66051386	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.803	rs403089	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66052736	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs458291	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66055492	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs466983	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66055509	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs160643	ENSG00000228409.4	CCT6P1	4.25	5.01e-05	0.0268	0.46	0.4	Diabetic kidney disease;	chr7:66093235	chr7:65751142~65763354:+
THYM	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	4.25	5.01e-05	0.0268	0.41	0.4	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
THYM	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	4.25	5.01e-05	0.0268	0.41	0.4	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
THYM	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-4.25	5.01e-05	0.0268	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
THYM	cis	rs9834970	0.588	rs4296548	ENSG00000234073.1	AC011816.1	-4.25	5.01e-05	0.0268	-0.43	-0.4	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36874323	chr3:36880184~36880729:-
THYM	cis	rs8067545	0.611	rs9902032	ENSG00000230528.6	NOS2P3	-4.25	5.02e-05	0.0268	-0.33	-0.4	Schizophrenia;	chr17:20111865	chr17:20436337~20447249:+
THYM	cis	rs8067545	0.641	rs203482	ENSG00000231645.2	KRT17P6	-4.25	5.02e-05	0.0268	-0.48	-0.4	Schizophrenia;	chr17:19923897	chr17:20512560~20517479:-
THYM	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	4.25	5.02e-05	0.0268	0.33	0.4	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
THYM	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	4.25	5.02e-05	0.0268	0.33	0.4	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
THYM	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-4.25	5.02e-05	0.0268	-0.46	-0.4	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-4.25	5.02e-05	0.0268	-0.46	-0.4	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	4.25	5.02e-05	0.0268	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	4.25	5.02e-05	0.0268	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
THYM	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	4.25	5.02e-05	0.0268	0.58	0.4	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
THYM	cis	rs4948275	0.773	rs2606081	ENSG00000237233.2	TMEM26-AS1	-4.25	5.02e-05	0.0268	-0.49	-0.4	Night sleep phenotypes;	chr10:61532493	chr10:61452639~61481956:+
THYM	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	4.25	5.02e-05	0.0268	0.6	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
THYM	cis	rs7223966	1	rs2854219	ENSG00000240280.5	TCAM1P	-4.25	5.02e-05	0.0268	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63865322	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs2854218	ENSG00000240280.5	TCAM1P	-4.25	5.02e-05	0.0268	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63865580	chr17:63849292~63864379:+
THYM	cis	rs7631605	0.875	rs7638620	ENSG00000272334.1	RP11-129K12.1	-4.25	5.03e-05	0.0268	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37158594	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs6786857	ENSG00000272334.1	RP11-129K12.1	-4.25	5.03e-05	0.0268	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37163524	chr3:36973117~36973672:-
THYM	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-4.25	5.03e-05	0.0268	-0.42	-0.4	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
THYM	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-4.25	5.03e-05	0.0268	-0.51	-0.4	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
THYM	cis	rs7580658	0.614	rs2896888	ENSG00000236682.1	AC068282.3	-4.25	5.03e-05	0.0269	-0.49	-0.4	Protein C levels;	chr2:127208235	chr2:127389130~127400580:+
THYM	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	4.25	5.03e-05	0.0269	0.34	0.4	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
THYM	cis	rs7631605	0.837	rs6796640	ENSG00000272334.1	RP11-129K12.1	-4.25	5.03e-05	0.0269	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37171783	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs9829683	ENSG00000272334.1	RP11-129K12.1	-4.25	5.03e-05	0.0269	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37176131	chr3:36973117~36973672:-
THYM	cis	rs863345	0.647	rs923663	ENSG00000236656.1	RP11-144L1.4	-4.25	5.03e-05	0.0269	-0.26	-0.4	Pneumococcal bacteremia;	chr1:158537942	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11265021	ENSG00000236656.1	RP11-144L1.4	-4.25	5.03e-05	0.0269	-0.26	-0.4	Pneumococcal bacteremia;	chr1:158542020	chr1:158474454~158494886:-
THYM	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-4.25	5.04e-05	0.0269	-0.5	-0.4	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
THYM	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-4.25	5.04e-05	0.0269	-0.45	-0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
THYM	cis	rs42490	0.557	rs426240	ENSG00000251136.7	RP11-37B2.1	-4.25	5.04e-05	0.0269	-0.31	-0.4	Leprosy;	chr8:89834573	chr8:89609409~89757727:-
THYM	cis	rs2834288	0.535	rs4816468	ENSG00000273102.1	AP000569.9	4.25	5.04e-05	0.0269	0.44	0.4	Gut microbiota (bacterial taxa);	chr21:33952235	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.535	rs4816469	ENSG00000273102.1	AP000569.9	4.25	5.04e-05	0.0269	0.44	0.4	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.536	rs8129513	ENSG00000273102.1	AP000569.9	4.25	5.04e-05	0.0269	0.44	0.4	Gut microbiota (bacterial taxa);	chr21:33952615	chr21:33967101~33968573:-
THYM	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-4.25	5.05e-05	0.0269	-0.33	-0.4	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
THYM	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	4.25	5.05e-05	0.0269	0.46	0.4	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
THYM	cis	rs11971779	0.553	rs36002669	ENSG00000273391.1	RP11-634H22.1	4.25	5.05e-05	0.0269	0.33	0.4	Diisocyanate-induced asthma;	chr7:139428415	chr7:139359032~139359566:-
THYM	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-4.25	5.05e-05	0.0269	-0.38	-0.4	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
THYM	cis	rs853679	0.723	rs1736904	ENSG00000272009.1	RP1-313I6.12	-4.25	5.05e-05	0.0269	-0.49	-0.4	Depression;	chr6:28251492	chr6:28078792~28081130:-
THYM	cis	rs7202877	0.706	rs1074961	ENSG00000261783.1	RP11-252K23.2	-4.25	5.06e-05	0.027	-0.56	-0.4	Type 1 diabetes;Type 2 diabetes;	chr16:75355586	chr16:75379818~75381260:-
THYM	cis	rs73108077	0.736	rs6058637	ENSG00000277112.2	RP11-755J8.1	-4.25	5.06e-05	0.027	-0.52	-0.4	Red blood cell density in sickle cell anemia;	chr20:31325430	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6057561	ENSG00000277112.2	RP11-755J8.1	-4.25	5.06e-05	0.027	-0.52	-0.4	Red blood cell density in sickle cell anemia;	chr20:31327238	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6119830	ENSG00000277112.2	RP11-755J8.1	-4.25	5.06e-05	0.027	-0.52	-0.4	Red blood cell density in sickle cell anemia;	chr20:31327636	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6119831	ENSG00000277112.2	RP11-755J8.1	-4.25	5.06e-05	0.027	-0.52	-0.4	Red blood cell density in sickle cell anemia;	chr20:31328473	chr20:30681825~30723932:-
THYM	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-4.25	5.07e-05	0.027	-0.46	-0.4	QT interval;	chr12:29306357	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-4.25	5.07e-05	0.027	-0.46	-0.4	QT interval;	chr12:29306799	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-4.25	5.07e-05	0.027	-0.46	-0.4	QT interval;	chr12:29309811	chr12:29280418~29317848:-
THYM	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	4.25	5.07e-05	0.027	0.5	0.4	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	4.25	5.07e-05	0.027	0.5	0.4	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
THYM	cis	rs4845570	0.92	rs3811414	ENSG00000203288.3	RP11-98D18.9	-4.25	5.07e-05	0.027	-0.47	-0.4	Coronary artery disease;	chr1:151790770	chr1:151790804~151794402:+
THYM	cis	rs4478858	0.684	rs7515988	ENSG00000260386.4	LINC01225	-4.25	5.07e-05	0.027	-0.22	-0.4	Alcohol dependence;	chr1:31258214	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs2050816	ENSG00000260386.4	LINC01225	4.25	5.07e-05	0.027	0.22	0.4	Alcohol dependence;	chr1:31248861	chr1:31500085~31540885:+
THYM	cis	rs10829156	0.732	rs4747348	ENSG00000240291.1	RP11-499P20.2	4.25	5.07e-05	0.027	0.39	0.4	Sudden cardiac arrest;	chr10:18506126	chr10:18513115~18545651:-
THYM	cis	rs10829156	0.699	rs7911922	ENSG00000225527.1	RP11-383B4.4	-4.25	5.08e-05	0.0271	-0.46	-0.4	Sudden cardiac arrest;	chr10:18542768	chr10:18531849~18533336:-
THYM	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	4.25	5.09e-05	0.0271	0.61	0.4	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
THYM	cis	rs6750047	0.771	rs1056837	ENSG00000227770.1	RPL7P12	-4.25	5.09e-05	0.0271	-0.5	-0.4	Cutaneous malignant melanoma;Melanoma;	chr2:38071007	chr2:38231568~38232317:+
THYM	cis	rs8067545	0.935	rs7209734	ENSG00000231645.2	KRT17P6	-4.25	5.09e-05	0.0271	-0.47	-0.4	Schizophrenia;	chr17:20085230	chr17:20512560~20517479:-
THYM	cis	rs10988207	1	rs10988207	ENSG00000268707.1	RP11-247A12.7	-4.25	5.09e-05	0.0271	-0.49	-0.4	Red cell distribution width;	chr9:129104851	chr9:129170434~129170940:+
THYM	cis	rs7223966	0.921	rs2006123	ENSG00000240280.5	TCAM1P	-4.25	5.1e-05	0.0271	-0.58	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63881309	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.883	rs2955250	ENSG00000240280.5	TCAM1P	-4.25	5.1e-05	0.0271	-0.58	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63882380	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.921	rs34699959	ENSG00000240280.5	TCAM1P	-4.25	5.1e-05	0.0271	-0.58	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63883360	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.921	rs3020612	ENSG00000240280.5	TCAM1P	-4.25	5.1e-05	0.0271	-0.58	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63883518	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.883	rs2727317	ENSG00000240280.5	TCAM1P	-4.25	5.1e-05	0.0271	-0.58	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63883942	chr17:63849292~63864379:+
THYM	cis	rs3753275	0.624	rs6577524	ENSG00000230679.1	ENO1-AS1	4.25	5.1e-05	0.0271	0.48	0.4	Educational attainment;	chr1:8796913	chr1:8878835~8879894:+
THYM	cis	rs3753275	0.624	rs6664000	ENSG00000230679.1	ENO1-AS1	4.25	5.1e-05	0.0271	0.48	0.4	Educational attainment;	chr1:8798473	chr1:8878835~8879894:+
THYM	cis	rs4908768	0.501	rs2045820	ENSG00000232912.4	RP5-1115A15.1	4.25	5.1e-05	0.0271	0.38	0.4	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8424645~8434838:+
THYM	cis	rs397969	0.646	rs427033	ENSG00000231645.2	KRT17P6	-4.25	5.11e-05	0.0272	-0.49	-0.4	Platelet count;	chr17:19899931	chr17:20512560~20517479:-
THYM	cis	rs2289328	0.943	rs12905240	ENSG00000223313.1	RNU6-516P	-4.25	5.11e-05	0.0272	-0.52	-0.4	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40379944	chr15:40529570~40529673:+
THYM	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	4.25	5.11e-05	0.0272	0.31	0.4	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
THYM	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-4.25	5.11e-05	0.0272	-0.34	-0.4	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
THYM	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	4.25	5.11e-05	0.0272	0.32	0.4	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
THYM	cis	rs12439619	0.53	rs28883606	ENSG00000255769.6	GOLGA2P10	-4.25	5.11e-05	0.0272	-0.37	-0.4	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472993~82513950:-
THYM	cis	rs12439619	0.693	rs28665836	ENSG00000255769.6	GOLGA2P10	-4.25	5.11e-05	0.0272	-0.37	-0.4	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472993~82513950:-
THYM	cis	rs11098499	0.69	rs7674713	ENSG00000245958.5	RP11-33B1.1	-4.25	5.11e-05	0.0272	-0.35	-0.4	Corneal astigmatism;	chr4:119401102	chr4:119454791~119552025:+
THYM	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	4.25	5.12e-05	0.0272	0.5	0.4	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
THYM	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-4.25	5.12e-05	0.0272	-0.55	-0.4	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
THYM	cis	rs4478858	0.647	rs11581476	ENSG00000260386.4	LINC01225	4.25	5.12e-05	0.0272	0.22	0.4	Alcohol dependence;	chr1:31244828	chr1:31500085~31540885:+
THYM	cis	rs440932	0.565	rs19334	ENSG00000253893.2	FAM85B	-4.25	5.12e-05	0.0272	-0.49	-0.4	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8167819~8226614:-
THYM	cis	rs2243480	1	rs1404147	ENSG00000228409.4	CCT6P1	4.25	5.12e-05	0.0272	0.5	0.4	Diabetic kidney disease;	chr7:65799537	chr7:65751142~65763354:+
THYM	cis	rs12902680	0.674	rs12438211	ENSG00000259520.4	CTD-2651B20.3	4.25	5.12e-05	0.0272	0.42	0.4	Neuroticism;	chr15:46203219	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28470627	ENSG00000259520.4	CTD-2651B20.3	4.25	5.12e-05	0.0272	0.42	0.4	Neuroticism;	chr15:46207565	chr15:45251580~45279251:-
THYM	cis	rs4835473	0.897	rs1817027	ENSG00000249741.2	RP11-673E1.3	4.25	5.12e-05	0.0272	0.35	0.4	Immature fraction of reticulocytes;	chr4:143713336	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs11735341	ENSG00000249741.2	RP11-673E1.3	4.25	5.12e-05	0.0272	0.35	0.4	Immature fraction of reticulocytes;	chr4:143716030	chr4:143911514~143912053:-
THYM	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	4.25	5.12e-05	0.0272	0.32	0.4	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	4.25	5.12e-05	0.0272	0.32	0.4	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	4.25	5.12e-05	0.0272	0.32	0.4	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	4.25	5.12e-05	0.0272	0.32	0.4	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
THYM	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-4.25	5.13e-05	0.0273	-0.42	-0.4	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
THYM	cis	rs4835473	0.932	rs10857415	ENSG00000249741.2	RP11-673E1.3	-4.25	5.13e-05	0.0273	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143908753	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1973608	ENSG00000249741.2	RP11-673E1.3	-4.25	5.13e-05	0.0273	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143913057	chr4:143911514~143912053:-
THYM	cis	rs1606355	0.945	rs7312487	ENSG00000230519.2	RP11-1060J15.5	4.24	5.13e-05	0.0273	0.63	0.4	Metabolite levels (Pyroglutamine);	chr12:28684011	chr12:27702338~27702906:+
THYM	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-4.24	5.13e-05	0.0273	-0.51	-0.4	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
THYM	cis	rs3811273	0.614	rs6572346	ENSG00000211816.2	TRAV38-1	-4.24	5.14e-05	0.0273	-0.34	-0.4	Periodontal disease-related phenotypes;	chr14:22266389	chr14:22271968~22272563:+
THYM	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	4.24	5.14e-05	0.0273	0.51	0.4	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
THYM	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	4.24	5.14e-05	0.0273	0.51	0.4	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
THYM	cis	rs1550576	0.568	rs35056852	ENSG00000274719.1	RP11-86K22.2	-4.24	5.14e-05	0.0273	-0.74	-0.4	Hypertension;	chr15:58009358	chr15:57990217~57990636:-
THYM	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	4.24	5.15e-05	0.0273	0.54	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
THYM	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-4.24	5.15e-05	0.0274	-0.44	-0.4	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
THYM	cis	rs11668609	0.81	rs10407383	ENSG00000268442.1	CTD-2027I19.2	4.24	5.16e-05	0.0274	0.39	0.4	Response to taxane treatment (docetaxel);	chr19:24134099	chr19:24162370~24163425:-
THYM	cis	rs9813712	0.526	rs62281641	ENSG00000228252.7	COL6A4P2	-4.24	5.16e-05	0.0274	-0.42	-0.4	Response to amphetamines;	chr3:130235668	chr3:130212823~130273806:+
THYM	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-4.24	5.17e-05	0.0274	-0.42	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
THYM	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-4.24	5.17e-05	0.0274	-0.52	-0.4	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	4.24	5.17e-05	0.0274	0.52	0.4	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	4.24	5.17e-05	0.0274	0.52	0.4	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	4.24	5.17e-05	0.0274	0.52	0.4	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	4.24	5.17e-05	0.0274	0.52	0.4	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
THYM	cis	rs7475343	0.818	rs17399879	ENSG00000224034.1	RP11-445P17.8	-4.24	5.17e-05	0.0274	-0.75	-0.4	Intelligence;	chr10:5290335	chr10:5266033~5271236:-
THYM	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-4.24	5.17e-05	0.0274	-0.54	-0.4	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
THYM	cis	rs2841233	0.692	rs2028416	ENSG00000258811.1	CTD-3051D23.1	4.24	5.17e-05	0.0274	0.39	0.4	IgG glycosylation;	chr14:104882215	chr14:104842663~104845916:+
THYM	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	4.24	5.18e-05	0.0274	0.41	0.4	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-4.24	5.18e-05	0.0274	-0.41	-0.4	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
THYM	cis	rs7246967	0.551	rs16998998	ENSG00000198153.8	ZNF849P	-4.24	5.18e-05	0.0274	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22728314	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs9677019	ENSG00000198153.8	ZNF849P	-4.24	5.18e-05	0.0274	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22729857	chr19:22685167~22686732:+
THYM	cis	rs4853012	0.775	rs12465641	ENSG00000272183.1	RP11-523H20.3	-4.24	5.18e-05	0.0274	-0.56	-0.4	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74501717~74502365:+
THYM	cis	rs4478858	0.735	rs7523438	ENSG00000260386.4	LINC01225	-4.24	5.18e-05	0.0274	-0.21	-0.4	Alcohol dependence;	chr1:31315466	chr1:31500085~31540885:+
THYM	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	4.24	5.18e-05	0.0274	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
THYM	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	4.24	5.18e-05	0.0274	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
THYM	cis	rs8177876	0.658	rs2911158	ENSG00000261838.4	RP11-303E16.6	-4.24	5.19e-05	0.0275	-0.83	-0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057652	chr16:81069854~81076598:+
THYM	cis	rs8177876	0.749	rs2911159	ENSG00000261838.4	RP11-303E16.6	-4.24	5.19e-05	0.0275	-0.83	-0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057653	chr16:81069854~81076598:+
THYM	cis	rs877819	0.583	rs2940712	ENSG00000228403.1	RP11-563N6.6	-4.24	5.19e-05	0.0275	-0.51	-0.4	Systemic lupus erythematosus;	chr10:48848403	chr10:48878022~48878649:+
THYM	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-4.24	5.19e-05	0.0275	-0.52	-0.4	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
THYM	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	4.24	5.2e-05	0.0275	0.51	0.4	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
THYM	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	4.24	5.2e-05	0.0275	0.51	0.4	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	4.24	5.2e-05	0.0275	0.51	0.4	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
THYM	cis	rs9467773	0.549	rs9467805	ENSG00000261353.1	CTA-14H9.5	-4.24	5.2e-05	0.0275	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26527063~26527404:+
THYM	cis	rs9467773	0.62	rs9461275	ENSG00000261353.1	CTA-14H9.5	-4.24	5.2e-05	0.0275	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26527063~26527404:+
THYM	cis	rs9467773	0.62	rs6925087	ENSG00000261353.1	CTA-14H9.5	-4.24	5.2e-05	0.0275	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26527063~26527404:+
THYM	cis	rs9467773	0.62	rs4368798	ENSG00000261353.1	CTA-14H9.5	-4.24	5.2e-05	0.0275	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26527063~26527404:+
THYM	cis	rs9467773	0.62	rs9461276	ENSG00000261353.1	CTA-14H9.5	-4.24	5.2e-05	0.0275	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26527063~26527404:+
THYM	cis	rs9467773	0.595	rs7767847	ENSG00000261353.1	CTA-14H9.5	-4.24	5.2e-05	0.0275	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26527063~26527404:+
THYM	cis	rs9467773	0.62	rs3800303	ENSG00000261353.1	CTA-14H9.5	-4.24	5.2e-05	0.0275	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26527063~26527404:+
THYM	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	4.24	5.2e-05	0.0275	0.5	0.4	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
THYM	cis	rs10888838	0.938	rs747753	ENSG00000198711.5	SSBP3-AS1	4.24	5.21e-05	0.0275	0.28	0.4	Mitochondrial DNA levels;	chr1:54216816	chr1:54236440~54239063:+
THYM	cis	rs440932	0.747	rs330946	ENSG00000253893.2	FAM85B	-4.24	5.21e-05	0.0276	-0.51	-0.4	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8167819~8226614:-
THYM	cis	rs1550115	0.645	rs10865308	ENSG00000271936.1	RP11-443B20.1	4.24	5.21e-05	0.0276	0.32	0.4	Coronary artery disease;	chr2:24739268	chr2:24825610~24826717:+
THYM	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-4.24	5.21e-05	0.0276	-0.43	-0.4	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
THYM	cis	rs73344830	1	rs73344830	ENSG00000269609.4	RPARP-AS1	4.24	5.21e-05	0.0276	0.3	0.4	Educational attainment (years of education);Cognitive ability (multi-trait analysis);	chr10:102057071	chr10:102449817~102461106:+
THYM	cis	rs7077446	0.548	rs2786847	ENSG00000269609.4	RPARP-AS1	4.24	5.21e-05	0.0276	0.3	0.4	Intelligence (multi-trait analysis);	chr10:102063378	chr10:102449817~102461106:+
THYM	cis	rs7560272	0.501	rs13003035	ENSG00000163016.8	ALMS1P	-4.24	5.22e-05	0.0276	-0.47	-0.4	Schizophrenia;	chr2:73730100	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.501	rs12992607	ENSG00000163016.8	ALMS1P	-4.24	5.22e-05	0.0276	-0.47	-0.4	Schizophrenia;	chr2:73732833	chr2:73644919~73685576:+
THYM	cis	rs61160187	0.604	rs7704338	ENSG00000272308.1	RP11-231G3.1	-4.24	5.22e-05	0.0276	-0.33	-0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60690328	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.604	rs7719611	ENSG00000272308.1	RP11-231G3.1	-4.24	5.22e-05	0.0276	-0.33	-0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60692720	chr5:60866457~60866935:-
THYM	cis	rs7005380	0.733	rs9987332	ENSG00000245330.4	KB-1471A8.1	-4.24	5.23e-05	0.0276	-0.57	-0.4	Interstitial lung disease;	chr8:119921723	chr8:119867419~119874488:-
THYM	cis	rs8067545	0.75	rs4925080	ENSG00000230528.6	NOS2P3	-4.24	5.23e-05	0.0276	-0.33	-0.4	Schizophrenia;	chr17:20088525	chr17:20436337~20447249:+
THYM	cis	rs972578	0.836	rs738539	ENSG00000215347.3	SLC25A5P1	-4.24	5.23e-05	0.0276	-0.33	-0.4	Mean platelet volume;	chr22:42886795	chr22:42001069~42001966:-
THYM	cis	rs4835473	0.808	rs11725413	ENSG00000249741.2	RP11-673E1.3	4.24	5.23e-05	0.0276	0.34	0.4	Immature fraction of reticulocytes;	chr4:143943366	chr4:143911514~143912053:-
THYM	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	4.24	5.24e-05	0.0277	0.38	0.4	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
THYM	cis	rs7223966	1	rs752621	ENSG00000240280.5	TCAM1P	-4.24	5.24e-05	0.0277	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63824520	chr17:63849292~63864379:+
THYM	cis	rs4554975	0.516	rs10881011	ENSG00000274723.1	RP11-618L22.1	-4.24	5.24e-05	0.0277	-0.33	-0.4	Metabolite levels (small molecules and protein measures);	chr12:46932122	chr12:46970504~46972155:+
THYM	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-4.24	5.24e-05	0.0277	-0.35	-0.4	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
THYM	cis	rs3862435	0.518	rs2601169	ENSG00000259212.1	CTD-3065B20.2	-4.24	5.25e-05	0.0277	-0.63	-0.4	Response to exercise (triglyceride level interaction);	chr15:90370658	chr15:90595840~90596447:-
THYM	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	4.24	5.25e-05	0.0277	0.57	0.4	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
THYM	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	4.24	5.25e-05	0.0277	0.39	0.4	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
THYM	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-4.24	5.25e-05	0.0277	-0.4	-0.4	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
THYM	cis	rs8113308	1	rs8104737	ENSG00000269235.1	ZNF350-AS1	4.24	5.26e-05	0.0277	0.41	0.4	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938444	chr19:51949134~51981367:+
THYM	cis	rs17608059	0.566	rs59795106	ENSG00000141028.6	CDRT15P1	-4.24	5.26e-05	0.0277	-0.44	-0.4	Temperament;	chr17:14008740	chr17:14024514~14025488:+
THYM	cis	rs1223397	0.938	rs17767967	ENSG00000215022.6	RP1-257A7.4	-4.24	5.26e-05	0.0277	-0.49	-0.4	Blood pressure;	chr6:13281835	chr6:13264861~13295586:-
THYM	cis	rs9926296	0.744	rs352939	ENSG00000274627.1	RP11-104N10.2	4.24	5.26e-05	0.0278	0.46	0.4	Vitiligo;	chr16:89643970	chr16:89516797~89522217:+
THYM	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	4.24	5.26e-05	0.0278	0.34	0.4	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
THYM	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	4.24	5.26e-05	0.0278	0.34	0.4	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
THYM	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	4.24	5.26e-05	0.0278	0.34	0.4	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
THYM	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	4.24	5.26e-05	0.0278	0.34	0.4	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
THYM	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	4.24	5.26e-05	0.0278	0.34	0.4	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
THYM	cis	rs8177876	0.749	rs2970076	ENSG00000261838.4	RP11-303E16.6	4.24	5.26e-05	0.0278	0.79	0.4	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056211	chr16:81069854~81076598:+
THYM	cis	rs11157436	0.958	rs17183308	ENSG00000211812.1	TRAV26-2	-4.24	5.27e-05	0.0278	-0.26	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs2075494	ENSG00000211812.1	TRAV26-2	-4.24	5.27e-05	0.0278	-0.26	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs2242542	ENSG00000211812.1	TRAV26-2	-4.24	5.27e-05	0.0278	-0.26	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs17255537	ENSG00000211812.1	TRAV26-2	-4.24	5.27e-05	0.0278	-0.26	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.871	rs8003190	ENSG00000211812.1	TRAV26-2	-4.24	5.27e-05	0.0278	-0.26	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs17183356	ENSG00000211812.1	TRAV26-2	-4.24	5.27e-05	0.0278	-0.26	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22202583~22203368:+
THYM	cis	rs6087771	0.682	rs2038397	ENSG00000230613.1	HM13-AS1	4.24	5.27e-05	0.0278	0.54	0.4	Putamen volume;Subcortical brain region volumes;	chr20:31629956	chr20:31567707~31573263:-
THYM	cis	rs7927592	0.913	rs10896338	ENSG00000222339.1	AP000807.2	4.24	5.27e-05	0.0278	0.49	0.4	Total body bone mineral density;	chr11:68531892	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7115374	ENSG00000222339.1	AP000807.2	4.24	5.27e-05	0.0278	0.49	0.4	Total body bone mineral density;	chr11:68532608	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs67605986	ENSG00000222339.1	AP000807.2	4.24	5.27e-05	0.0278	0.49	0.4	Total body bone mineral density;	chr11:68533487	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs12285993	ENSG00000222339.1	AP000807.2	4.24	5.27e-05	0.0278	0.49	0.4	Total body bone mineral density;	chr11:68535070	chr11:68505572~68505651:-
THYM	cis	rs2662776	1	rs2662775	ENSG00000232995.6	RGS5	-4.24	5.27e-05	0.0278	-0.34	-0.4	Lead levels in blood;	chr1:163192277	chr1:163244505~163321894:-
THYM	cis	rs2662776	1	rs2814372	ENSG00000232995.6	RGS5	-4.24	5.27e-05	0.0278	-0.34	-0.4	Lead levels in blood;	chr1:163194834	chr1:163244505~163321894:-
THYM	cis	rs2662776	1	rs2662776	ENSG00000232995.6	RGS5	-4.24	5.27e-05	0.0278	-0.34	-0.4	Lead levels in blood;	chr1:163195239	chr1:163244505~163321894:-
THYM	cis	rs3862435	0.572	rs2601183	ENSG00000259212.1	CTD-3065B20.2	-4.24	5.28e-05	0.0278	-0.63	-0.4	Response to exercise (triglyceride level interaction);	chr15:90382489	chr15:90595840~90596447:-
THYM	cis	rs3862435	0.572	rs2601186	ENSG00000259212.1	CTD-3065B20.2	-4.24	5.28e-05	0.0278	-0.63	-0.4	Response to exercise (triglyceride level interaction);	chr15:90383689	chr15:90595840~90596447:-
THYM	cis	rs4262	0.505	rs180227	ENSG00000278388.1	GS1-345D13.1	-4.24	5.28e-05	0.0278	-0.43	-0.4	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93932053	chr7:93914987~93915108:+
THYM	cis	rs4262	0.505	rs180226	ENSG00000278388.1	GS1-345D13.1	-4.24	5.28e-05	0.0278	-0.43	-0.4	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93932548	chr7:93914987~93915108:+
THYM	cis	rs17253792	0.822	rs77315200	ENSG00000186615.9	KTN1-AS1	-4.24	5.29e-05	0.0279	-0.77	-0.4	Putamen volume;	chr14:55605925	chr14:55499278~55580110:-
THYM	cis	rs8067545	1	rs1860302	ENSG00000231645.2	KRT17P6	-4.24	5.29e-05	0.0279	-0.47	-0.4	Schizophrenia;	chr17:20011086	chr17:20512560~20517479:-
THYM	cis	rs8067545	1	rs7211535	ENSG00000231645.2	KRT17P6	-4.24	5.29e-05	0.0279	-0.47	-0.4	Schizophrenia;	chr17:20019051	chr17:20512560~20517479:-
THYM	cis	rs8067545	1	rs2108979	ENSG00000231645.2	KRT17P6	-4.24	5.29e-05	0.0279	-0.47	-0.4	Schizophrenia;	chr17:20025253	chr17:20512560~20517479:-
THYM	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-4.24	5.29e-05	0.0279	-0.47	-0.4	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
THYM	cis	rs12902680	0.706	rs1865409	ENSG00000259520.4	CTD-2651B20.3	4.24	5.29e-05	0.0279	0.41	0.4	Neuroticism;	chr15:46216203	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs4280177	ENSG00000259520.4	CTD-2651B20.3	4.24	5.29e-05	0.0279	0.41	0.4	Neuroticism;	chr15:46216319	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1434672	ENSG00000259520.4	CTD-2651B20.3	4.24	5.29e-05	0.0279	0.41	0.4	Neuroticism;	chr15:46218599	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1434674	ENSG00000259520.4	CTD-2651B20.3	4.24	5.29e-05	0.0279	0.41	0.4	Neuroticism;	chr15:46218731	chr15:45251580~45279251:-
THYM	cis	rs9611565	0.84	rs2234052	ENSG00000273366.1	CTA-989H11.1	4.24	5.3e-05	0.0279	0.46	0.4	Vitiligo;	chr22:41381237	chr22:42278188~42278846:+
THYM	cis	rs9611565	0.84	rs9607799	ENSG00000273366.1	CTA-989H11.1	4.24	5.3e-05	0.0279	0.46	0.4	Vitiligo;	chr22:41381554	chr22:42278188~42278846:+
THYM	cis	rs4948275	0.55	rs10994749	ENSG00000237233.2	TMEM26-AS1	4.24	5.31e-05	0.0279	0.41	0.4	Night sleep phenotypes;	chr10:61396464	chr10:61452639~61481956:+
THYM	cis	rs4908760	0.827	rs10864360	ENSG00000232912.4	RP5-1115A15.1	4.24	5.31e-05	0.028	0.37	0.4	Vitiligo;	chr1:8664463	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.501	rs11121212	ENSG00000232912.4	RP5-1115A15.1	4.24	5.31e-05	0.028	0.37	0.4	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665934	chr1:8424645~8434838:+
THYM	cis	rs4908768	0.52	rs6695867	ENSG00000232912.4	RP5-1115A15.1	4.24	5.31e-05	0.028	0.37	0.4	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8670720	chr1:8424645~8434838:+
THYM	cis	rs7560272	0.695	rs780393	ENSG00000273245.1	RP11-434P11.2	-4.24	5.31e-05	0.028	-0.47	-0.4	Schizophrenia;	chr2:73474542	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.723	rs780391	ENSG00000273245.1	RP11-434P11.2	-4.24	5.31e-05	0.028	-0.47	-0.4	Schizophrenia;	chr2:73476777	chr2:73750256~73750786:-
THYM	cis	rs4835473	0.864	rs13117932	ENSG00000249741.2	RP11-673E1.3	4.24	5.32e-05	0.028	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735873	chr4:143911514~143912053:-
THYM	cis	rs7976269	0.515	rs11049999	ENSG00000275476.1	RP11-996F15.4	-4.24	5.32e-05	0.028	-0.47	-0.4	Male-pattern baldness;	chr12:29042854	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.559	rs10771471	ENSG00000275476.1	RP11-996F15.4	-4.24	5.32e-05	0.028	-0.47	-0.4	Male-pattern baldness;	chr12:29050894	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.559	rs1344853	ENSG00000275476.1	RP11-996F15.4	-4.24	5.32e-05	0.028	-0.47	-0.4	Male-pattern baldness;	chr12:29058623	chr12:29277397~29277882:-
THYM	cis	rs397969	0.646	rs403021	ENSG00000231645.2	KRT17P6	-4.24	5.32e-05	0.028	-0.48	-0.4	Platelet count;	chr17:19903516	chr17:20512560~20517479:-
THYM	cis	rs4478858	0.684	rs1532861	ENSG00000260386.4	LINC01225	4.24	5.32e-05	0.028	0.22	0.4	Alcohol dependence;	chr1:31293644	chr1:31500085~31540885:+
THYM	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-4.24	5.32e-05	0.028	-0.44	-0.4	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
THYM	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	4.24	5.32e-05	0.028	0.44	0.4	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
THYM	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	4.24	5.32e-05	0.028	0.44	0.4	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
THYM	cis	rs1790761	0.692	rs614080	ENSG00000231793.4	DOC2GP	-4.24	5.32e-05	0.028	-0.36	-0.4	Mean corpuscular volume;	chr11:67579816	chr11:67612653~67616257:-
THYM	cis	rs9733	0.519	rs6700022	ENSG00000220323.3	HIST2H2BD	4.23	5.33e-05	0.028	0.4	0.4	Tonsillectomy;	chr1:150698008	chr1:149843041~149843533:+
THYM	cis	rs9733	0.544	rs72700902	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150660871	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs10788792	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150666096	chr1:149843041~149843533:+
THYM	cis	rs9733	0.527	rs11204694	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150680915	chr1:149843041~149843533:+
THYM	cis	rs9733	0.526	rs11204696	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150686245	chr1:149843041~149843533:+
THYM	cis	rs9733	0.526	rs11204698	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150687069	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.597	rs868751	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Melanoma;	chr1:150696938	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs2184833	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150703007	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs11807450	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150705243	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs1336899	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150706434	chr1:149843041~149843533:+
THYM	cis	rs9733	0.519	rs3768005	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Tonsillectomy;	chr1:150708512	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.611	rs11803940	ENSG00000220323.3	HIST2H2BD	-4.23	5.33e-05	0.028	-0.4	-0.4	Melanoma;	chr1:150713359	chr1:149843041~149843533:+
THYM	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-4.23	5.33e-05	0.028	-0.43	-0.4	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-4.23	5.33e-05	0.028	-0.43	-0.4	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-4.23	5.33e-05	0.028	-0.43	-0.4	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-4.23	5.33e-05	0.028	-0.43	-0.4	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
THYM	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-4.23	5.33e-05	0.028	-0.43	-0.4	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-4.23	5.33e-05	0.028	-0.43	-0.4	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-4.23	5.33e-05	0.028	-0.43	-0.4	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
THYM	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-4.23	5.34e-05	0.028	-0.56	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
THYM	cis	rs453301	0.631	rs11779804	ENSG00000253893.2	FAM85B	4.23	5.34e-05	0.028	0.51	0.4	Joint mobility (Beighton score);	chr8:8940442	chr8:8167819~8226614:-
THYM	cis	rs34773007	0.514	rs11187179	ENSG00000272817.1	RP11-402D21.2	-4.23	5.34e-05	0.0281	-0.5	-0.4	Type 2 diabetes;	chr10:92779696	chr10:91908131~91909348:+
THYM	cis	rs34773007	0.514	rs36016244	ENSG00000272817.1	RP11-402D21.2	-4.23	5.34e-05	0.0281	-0.5	-0.4	Type 2 diabetes;	chr10:92780059	chr10:91908131~91909348:+
THYM	cis	rs34773007	0.514	rs34478558	ENSG00000272817.1	RP11-402D21.2	-4.23	5.34e-05	0.0281	-0.5	-0.4	Type 2 diabetes;	chr10:92780116	chr10:91908131~91909348:+
THYM	cis	rs10129255	0.785	rs10150044	ENSG00000253703.1	IGHV1-68	-4.23	5.34e-05	0.0281	-0.52	-0.4	Kawasaki disease;	chr14:106775695	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10137980	ENSG00000253703.1	IGHV1-68	-4.23	5.34e-05	0.0281	-0.52	-0.4	Kawasaki disease;	chr14:106775735	chr14:106703852~106704146:-
THYM	cis	rs526231	0.786	rs171695	ENSG00000175749.11	EIF3KP1	4.23	5.34e-05	0.0281	0.52	0.4	Primary biliary cholangitis;	chr5:103296339	chr5:103032376~103033031:+
THYM	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	4.23	5.34e-05	0.0281	0.41	0.4	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
THYM	cis	rs12908161	1	rs35808647	ENSG00000275120.1	RP11-182J1.17	4.23	5.35e-05	0.0281	0.54	0.4	Schizophrenia;	chr15:84834210	chr15:84599434~84606463:-
THYM	cis	rs9611519	0.964	rs2179744	ENSG00000235513.1	RP4-756G23.5	4.23	5.35e-05	0.0281	0.35	0.4	Neuroticism;	chr22:41225710	chr22:41209122~41217627:-
THYM	cis	rs73108077	1	rs73105976	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31378130	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73108009	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31390409	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73108027	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31398778	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73108061	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31413650	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73108077	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31419056	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.92	rs73108088	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31424444	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73108095	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31428519	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73110016	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31432402	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs6059305	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31432624	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs115577082	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31433893	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.915	rs17328705	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31438570	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.915	rs73110028	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31439633	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.915	rs746053	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31440944	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116222	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31444393	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116224	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31444913	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116226	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31445905	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116229	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31446433	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116233	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31448538	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116235	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31449052	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs75231340	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31449114	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.92	rs45520534	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31450235	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.915	rs73116254	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31453983	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs5022146	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31454603	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116264	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31456926	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116268	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31461103	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs75774213	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31462439	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs73116272	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31467430	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs117762506	ENSG00000277112.2	RP11-755J8.1	-4.23	5.35e-05	0.0281	-0.69	-0.4	Red blood cell density in sickle cell anemia;	chr20:31467935	chr20:30681825~30723932:-
THYM	cis	rs7631605	0.935	rs4678945	ENSG00000272334.1	RP11-129K12.1	-4.23	5.36e-05	0.0281	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37197833	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs56304874	ENSG00000272334.1	RP11-129K12.1	-4.23	5.36e-05	0.0281	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37204492	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs55898028	ENSG00000272334.1	RP11-129K12.1	-4.23	5.36e-05	0.0281	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37206846	chr3:36973117~36973672:-
THYM	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-4.23	5.36e-05	0.0281	-0.51	-0.4	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
THYM	cis	rs4835473	0.932	rs1849115	ENSG00000249741.2	RP11-673E1.3	-4.23	5.37e-05	0.0282	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143989687	chr4:143911514~143912053:-
THYM	cis	rs2115630	0.967	rs10438428	ENSG00000275120.1	RP11-182J1.17	-4.23	5.37e-05	0.0282	-0.47	-0.4	P wave terminal force;	chr15:84787514	chr15:84599434~84606463:-
THYM	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-4.23	5.37e-05	0.0282	-0.3	-0.4	Depression;	chr6:28229408	chr6:28115628~28116551:+
THYM	cis	rs1933112	0.527	rs12090218	ENSG00000227777.1	RP4-738P11.3	-4.23	5.37e-05	0.0282	-0.41	-0.4	Blood protein levels;	chr1:168529966	chr1:168542737~168543354:+
THYM	cis	rs9309473	0.519	rs1815027	ENSG00000163016.8	ALMS1P	-4.23	5.37e-05	0.0282	-0.47	-0.4	Metabolite levels;	chr2:73604713	chr2:73644919~73685576:+
THYM	cis	rs8113308	0.81	rs8104626	ENSG00000269235.1	ZNF350-AS1	4.23	5.37e-05	0.0282	0.47	0.4	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51977364	chr19:51949134~51981367:+
THYM	cis	rs5769707	0.837	rs1573726	ENSG00000264139.1	MIR3667	-4.23	5.38e-05	0.0282	-0.46	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49543393~49543466:-
THYM	cis	rs9926296	0.682	rs645019	ENSG00000274627.1	RP11-104N10.2	4.23	5.38e-05	0.0282	0.48	0.4	Vitiligo;	chr16:89650475	chr16:89516797~89522217:+
THYM	cis	rs12439619	0.693	rs4778989	ENSG00000274376.3	ADAMTS7P1	4.23	5.39e-05	0.0282	0.43	0.4	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82298553~82334609:+
THYM	cis	rs564343	0.545	rs2241303	ENSG00000255320.1	RP11-755F10.1	-4.23	5.39e-05	0.0282	-0.45	-0.4	Obesity (early onset extreme);	chr11:66052190	chr11:66244840~66246239:-
THYM	cis	rs17253792	0.822	rs75288952	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55567292	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76192881	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55567936	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75999534	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55569695	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76612185	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55570988	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs117050012	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55572011	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs118027213	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55572358	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17683614	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55574340	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.555	rs17683626	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55574394	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77250916	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55575490	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78824140	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55575997	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78323463	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55578733	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs111467375	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55579441	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.731	rs79483151	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55582133	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78826571	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55582188	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.731	rs74823888	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55583082	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75016910	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55583748	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76472022	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55586942	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs74412558	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55587593	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs112238223	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55589426	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs80174205	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55591976	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78261053	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55595066	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.731	rs8008528	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55595334	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs8009239	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55595772	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79291233	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55598584	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.818	rs78393484	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55599084	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79398217	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55600632	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs80328469	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55600983	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77420254	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55602928	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78395034	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55603065	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75995456	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55606476	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs2147114	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55610400	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77555779	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55611712	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs74653073	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55612810	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75560658	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55613178	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs112308750	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55613355	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs8007065	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55614554	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs113692713	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55620706	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs113649689	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55621347	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs7145064	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55622142	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs7150841	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55622268	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75049893	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55622440	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78429067	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55625833	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77741349	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55630744	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.749	rs74979160	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55630850	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10483645	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55637048	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10483646	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55637154	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.642	rs10483648	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55637560	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79807559	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55641399	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs112418863	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55647361	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78922774	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55648584	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.731	rs3736876	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55653460	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.749	rs79713967	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55657468	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.749	rs17747301	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55658312	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17685078	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55660484	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17685102	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55662496	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77033617	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55663028	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76819679	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55667954	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs74940664	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55668347	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77182097	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55669977	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs45501402	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55673397	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76164147	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55673651	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs74935793	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55676559	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.749	rs45458197	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55678300	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10483650	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55678594	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75936910	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55682633	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78143160	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55683379	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78988988	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55685686	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17832365	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55686813	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17253716	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55686943	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17253723	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55687297	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77415412	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55687428	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17253730	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55691193	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77197405	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55692944	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79747476	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55693767	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17253744	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55695232	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17832371	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55695584	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs80321745	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55696229	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79483507	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55698000	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs76205307	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55699320	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78615025	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55701294	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79873916	ENSG00000186615.9	KTN1-AS1	-4.23	5.39e-05	0.0282	-0.79	-0.4	Putamen volume;	chr14:55705913	chr14:55499278~55580110:-
THYM	cis	rs17234274	0.667	rs59498762	ENSG00000255418.4	RP11-266A24.1	4.23	5.39e-05	0.0282	0.54	0.4	Cancer;	chr11:23151475	chr11:23164900~23203161:+
THYM	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	4.23	5.39e-05	0.0282	0.76	0.4	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
THYM	cis	rs17507216	0.958	rs72751643	ENSG00000274376.3	ADAMTS7P1	4.23	5.39e-05	0.0282	0.45	0.4	Excessive daytime sleepiness;	chr15:82559444	chr15:82298553~82334609:+
THYM	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-4.23	5.39e-05	0.0282	-0.34	-0.4	Breast cancer;	chr11:825777	chr11:781645~782105:+
THYM	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-4.23	5.39e-05	0.0282	-0.34	-0.4	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-4.23	5.39e-05	0.0282	-0.34	-0.4	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-4.23	5.39e-05	0.0282	-0.34	-0.4	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
THYM	cis	rs7223966	1	rs2854223	ENSG00000240280.5	TCAM1P	-4.23	5.39e-05	0.0283	-0.59	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63861654	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.96	rs2854222	ENSG00000240280.5	TCAM1P	-4.23	5.39e-05	0.0283	-0.59	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63861655	chr17:63849292~63864379:+
THYM	cis	rs61270009	0.955	rs10214154	ENSG00000247828.6	TMEM161B-AS1	-4.23	5.4e-05	0.0283	-0.33	-0.4	Depressive symptoms;	chr5:88249502	chr5:88268895~88436685:+
THYM	cis	rs7202877	0.656	rs977986	ENSG00000261783.1	RP11-252K23.2	-4.23	5.4e-05	0.0283	-0.55	-0.4	Type 1 diabetes;Type 2 diabetes;	chr16:75472798	chr16:75379818~75381260:-
THYM	cis	rs397969	0.646	rs203454	ENSG00000231645.2	KRT17P6	-4.23	5.4e-05	0.0283	-0.48	-0.4	Platelet count;	chr17:19918200	chr17:20512560~20517479:-
THYM	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	4.23	5.4e-05	0.0283	0.36	0.4	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
THYM	cis	rs1866758	0.576	rs685989	ENSG00000235358.1	RP11-399E6.1	4.23	5.4e-05	0.0283	0.43	0.4	Intraocular pressure;	chr1:41861170	chr1:41242373~41284861:+
THYM	cis	rs9309473	0.5	rs12996463	ENSG00000273245.1	RP11-434P11.2	-4.23	5.4e-05	0.0283	-0.47	-0.4	Metabolite levels;	chr2:73428368	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs2178154	ENSG00000273245.1	RP11-434P11.2	-4.23	5.4e-05	0.0283	-0.47	-0.4	Metabolite levels;	chr2:73434610	chr2:73750256~73750786:-
THYM	cis	rs4835473	0.742	rs7695853	ENSG00000249741.2	RP11-673E1.3	-4.23	5.41e-05	0.0283	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143883243	chr4:143911514~143912053:-
THYM	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-4.23	5.41e-05	0.0283	-0.49	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	4.23	5.41e-05	0.0283	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
THYM	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-4.23	5.41e-05	0.0283	-0.41	-0.4	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
THYM	cis	rs17253792	0.915	rs75862063	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55711051	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs77161327	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55711847	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs79100824	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55712888	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs79894275	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55713567	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs74580958	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55714793	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs75296402	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55715773	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs76952651	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55722276	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.915	rs76957332	ENSG00000186615.9	KTN1-AS1	-4.23	5.41e-05	0.0283	-0.75	-0.4	Putamen volume;	chr14:55728652	chr14:55499278~55580110:-
THYM	cis	rs4654049	1	rs2405313	ENSG00000188460.4	ACTBP11	4.23	5.41e-05	0.0283	0.52	0.4	Cancer;	chr1:224590879	chr1:223863726~223864851:-
THYM	cis	rs4356203	0.933	rs12801545	ENSG00000272034.1	SNORD14A	4.23	5.42e-05	0.0284	0.43	0.4	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17244629	chr11:17074654~17074744:-
THYM	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-4.23	5.43e-05	0.0284	-0.55	-0.4	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
THYM	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	4.23	5.43e-05	0.0284	0.51	0.4	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
THYM	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	4.23	5.43e-05	0.0284	0.51	0.4	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
THYM	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	4.23	5.43e-05	0.0284	0.51	0.4	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
THYM	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-4.23	5.44e-05	0.0284	-0.35	-0.4	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
THYM	cis	rs10208649	0.611	rs61740458	ENSG00000272156.1	RP11-477N3.1	4.23	5.44e-05	0.0285	0.6	0.4	Body mass index;	chr2:54065503	chr2:54082554~54085066:+
THYM	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	4.23	5.45e-05	0.0285	0.53	0.4	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
THYM	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	4.23	5.45e-05	0.0285	0.53	0.4	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
THYM	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	4.23	5.45e-05	0.0285	0.53	0.4	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	4.23	5.45e-05	0.0285	0.53	0.4	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	4.23	5.45e-05	0.0285	0.53	0.4	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
THYM	cis	rs11157436	1	rs11157436	ENSG00000211813.2	TRAV34	-4.23	5.45e-05	0.0285	-0.31	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22207522~22208129:+
THYM	cis	rs12681366	0.663	rs6980687	ENSG00000253704.1	RP11-267M23.4	4.23	5.45e-05	0.0285	0.47	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94469685	chr8:94553722~94569745:+
THYM	cis	rs11098499	0.863	rs17050695	ENSG00000250412.1	KLHL2P1	4.23	5.45e-05	0.0285	0.36	0.4	Corneal astigmatism;	chr4:119568372	chr4:119334329~119378233:+
THYM	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	4.23	5.46e-05	0.0285	0.53	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
THYM	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-4.23	5.46e-05	0.0285	-0.54	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
THYM	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	4.23	5.46e-05	0.0285	0.37	0.4	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
THYM	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	4.23	5.46e-05	0.0285	0.31	0.4	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
THYM	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	4.23	5.47e-05	0.0286	0.32	0.4	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
THYM	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	4.23	5.48e-05	0.0286	0.41	0.4	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
THYM	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	4.23	5.49e-05	0.0287	0.45	0.4	Height;	chr6:109421257	chr6:109382795~109383666:+
THYM	cis	rs7223966	0.881	rs3020608	ENSG00000240280.5	TCAM1P	-4.23	5.49e-05	0.0287	-0.59	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63902633	chr17:63849292~63864379:+
THYM	cis	rs1320333	1	rs1320333	ENSG00000233296.1	AC092159.2	4.23	5.5e-05	0.0287	0.73	0.4	Obesity-related traits;	chr2:679179	chr2:677186~697371:+
THYM	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	4.23	5.5e-05	0.0287	0.76	0.4	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
THYM	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	4.23	5.5e-05	0.0287	0.76	0.4	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
THYM	cis	rs950169	0.922	rs4842939	ENSG00000259683.1	RP11-182J1.14	-4.23	5.5e-05	0.0287	-0.38	-0.4	Schizophrenia;	chr15:84159214	chr15:84389729~84395903:+
THYM	cis	rs1550576	0.568	rs12593414	ENSG00000274719.1	RP11-86K22.2	4.23	5.5e-05	0.0287	0.77	0.4	Hypertension;	chr15:57944900	chr15:57990217~57990636:-
THYM	cis	rs12902680	0.674	rs12902214	ENSG00000259520.4	CTD-2651B20.3	4.23	5.51e-05	0.0287	0.41	0.4	Neuroticism;	chr15:46230464	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1560934	ENSG00000259520.4	CTD-2651B20.3	4.23	5.51e-05	0.0287	0.41	0.4	Neuroticism;	chr15:46232943	chr15:45251580~45279251:-
THYM	cis	rs9907295	0.685	rs9909050	ENSG00000270871.1	AC015849.19	4.23	5.51e-05	0.0287	0.44	0.4	Fibroblast growth factor basic levels;	chr17:35887129	chr17:35816717~35830293:-
THYM	cis	rs9907295	0.901	rs59338510	ENSG00000270871.1	AC015849.19	4.23	5.51e-05	0.0287	0.44	0.4	Fibroblast growth factor basic levels;	chr17:35888098	chr17:35816717~35830293:-
THYM	cis	rs4908760	0.864	rs1953827	ENSG00000232912.4	RP5-1115A15.1	4.23	5.51e-05	0.0287	0.39	0.4	Vitiligo;	chr1:8619789	chr1:8424645~8434838:+
THYM	cis	rs2854207	0.505	rs2466957	ENSG00000240280.5	TCAM1P	-4.23	5.51e-05	0.0287	-0.58	-0.4	Height;	chr17:63883870	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.961	rs112709843	ENSG00000240280.5	TCAM1P	-4.23	5.52e-05	0.0288	-0.61	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63759576	chr17:63849292~63864379:+
THYM	cis	rs890448	0.796	rs7434301	ENSG00000254531.1	FLJ20021	-4.23	5.52e-05	0.0288	-0.36	-0.4	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101445370	chr4:101347780~101348883:+
THYM	cis	rs7826238	0.517	rs35144760	ENSG00000253893.2	FAM85B	4.23	5.52e-05	0.0288	0.54	0.4	Systolic blood pressure;	chr8:8504213	chr8:8167819~8226614:-
THYM	cis	rs877819	0.583	rs2620880	ENSG00000228403.1	RP11-563N6.6	4.23	5.53e-05	0.0288	0.5	0.4	Systemic lupus erythematosus;	chr10:48877383	chr10:48878022~48878649:+
THYM	cis	rs9876781	1	rs9815103	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48372725	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs28824259	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48384185	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs12487542	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48384586	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs9864371	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48385276	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs73074358	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48385757	chr3:48440352~48446656:-
THYM	cis	rs9876781	0.967	rs34761139	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48386489	chr3:48440352~48446656:-
THYM	cis	rs9876781	0.868	rs9875280	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48387420	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs6796491	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48388977	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs9826195	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48392157	chr3:48440352~48446656:-
THYM	cis	rs9876781	0.967	rs9864815	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48392588	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs9809843	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48392923	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs1563736	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48395329	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs13071337	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48396724	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs6442118	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48398582	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs7651407	ENSG00000244380.1	RP11-24C3.2	4.22	5.53e-05	0.0288	0.52	0.4	Longevity;	chr3:48402409	chr3:48440352~48446656:-
THYM	cis	rs12025262	0.934	rs10924961	ENSG00000227671.4	RP11-488L18.4	4.22	5.53e-05	0.0288	0.21	0.4	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247198985	chr1:247189851~247210856:-
THYM	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-4.22	5.53e-05	0.0288	-0.31	-0.4	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
THYM	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-4.22	5.53e-05	0.0288	-0.31	-0.4	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
THYM	cis	rs4671400	0.543	rs62152274	ENSG00000273302.1	RP11-493E12.2	-4.22	5.54e-05	0.0288	-0.44	-0.4	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61272453	chr2:61199979~61200769:+
THYM	cis	rs4671400	0.571	rs62152275	ENSG00000273302.1	RP11-493E12.2	-4.22	5.54e-05	0.0288	-0.44	-0.4	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61275103	chr2:61199979~61200769:+
THYM	cis	rs7246967	0.736	rs436595	ENSG00000198153.8	ZNF849P	-4.22	5.54e-05	0.0288	-0.54	-0.4	Bronchopulmonary dysplasia;	chr19:22810243	chr19:22685167~22686732:+
THYM	cis	rs4835473	0.838	rs4583708	ENSG00000249741.2	RP11-673E1.3	4.22	5.54e-05	0.0288	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735610	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs12512649	ENSG00000249741.2	RP11-673E1.3	4.22	5.54e-05	0.0289	0.33	0.4	Immature fraction of reticulocytes;	chr4:143736745	chr4:143911514~143912053:-
THYM	cis	rs10829156	0.66	rs7918933	ENSG00000225527.1	RP11-383B4.4	-4.22	5.54e-05	0.0289	-0.47	-0.4	Sudden cardiac arrest;	chr10:18517434	chr10:18531849~18533336:-
THYM	cis	rs160451	0.934	rs160453	ENSG00000251136.7	RP11-37B2.1	4.22	5.54e-05	0.0289	0.36	0.4	Leprosy;	chr8:89652326	chr8:89609409~89757727:-
THYM	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	4.22	5.54e-05	0.0289	0.36	0.4	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
THYM	cis	rs726288	1	rs12259284	ENSG00000225484.5	NUTM2B-AS1	-4.22	5.55e-05	0.0289	-0.91	-0.4	Rheumatoid arthritis;	chr10:79927652	chr10:79663088~79826594:-
THYM	cis	rs7631605	0.905	rs11711937	ENSG00000272334.1	RP11-129K12.1	4.22	5.55e-05	0.0289	0.42	0.4	Cerebrospinal P-tau181p levels;	chr3:37183347	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs11711968	ENSG00000272334.1	RP11-129K12.1	-4.22	5.55e-05	0.0289	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37183476	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6786584	ENSG00000272334.1	RP11-129K12.1	-4.22	5.55e-05	0.0289	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37184237	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs12629462	ENSG00000272334.1	RP11-129K12.1	-4.22	5.55e-05	0.0289	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37185478	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs7616105	ENSG00000272334.1	RP11-129K12.1	-4.22	5.55e-05	0.0289	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37188031	chr3:36973117~36973672:-
THYM	cis	rs910316	0.763	rs735452	ENSG00000258646.1	RP11-950C14.3	4.22	5.56e-05	0.0289	0.35	0.4	Height;	chr14:75031281	chr14:75004719~75008481:-
THYM	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-4.22	5.56e-05	0.0289	-0.53	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
THYM	cis	rs7560272	0.538	rs2012574	ENSG00000163016.8	ALMS1P	-4.22	5.56e-05	0.0289	-0.5	-0.4	Schizophrenia;	chr2:73701239	chr2:73644919~73685576:+
THYM	cis	rs11098499	0.909	rs79026312	ENSG00000250412.1	KLHL2P1	4.22	5.56e-05	0.0289	0.38	0.4	Corneal astigmatism;	chr4:119519522	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs35111518	ENSG00000250412.1	KLHL2P1	4.22	5.56e-05	0.0289	0.38	0.4	Corneal astigmatism;	chr4:119519527	chr4:119334329~119378233:+
THYM	cis	rs3780486	0.522	rs10217770	ENSG00000225693.1	LAGE3P1	4.22	5.56e-05	0.0289	0.45	0.4	IgG glycosylation;	chr9:33146395	chr9:33019682~33020165:-
THYM	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	4.22	5.57e-05	0.029	0.51	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
THYM	cis	rs4835473	0.9	rs35311036	ENSG00000249741.2	RP11-673E1.3	4.22	5.57e-05	0.029	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734397	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs35906127	ENSG00000249741.2	RP11-673E1.3	4.22	5.57e-05	0.029	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734400	chr4:143911514~143912053:-
THYM	cis	rs910316	0.763	rs13712	ENSG00000258646.1	RP11-950C14.3	-4.22	5.57e-05	0.029	-0.35	-0.4	Height;	chr14:75017109	chr14:75004719~75008481:-
THYM	cis	rs950169	0.922	rs4586394	ENSG00000259683.1	RP11-182J1.14	-4.22	5.57e-05	0.029	-0.38	-0.4	Schizophrenia;	chr15:84153633	chr15:84389729~84395903:+
THYM	cis	rs950169	0.922	rs6603022	ENSG00000259683.1	RP11-182J1.14	-4.22	5.57e-05	0.029	-0.38	-0.4	Schizophrenia;	chr15:84161418	chr15:84389729~84395903:+
THYM	cis	rs950169	0.922	rs4842940	ENSG00000259683.1	RP11-182J1.14	-4.22	5.57e-05	0.029	-0.38	-0.4	Schizophrenia;	chr15:84162473	chr15:84389729~84395903:+
THYM	cis	rs950169	0.922	rs4842941	ENSG00000259683.1	RP11-182J1.14	-4.22	5.57e-05	0.029	-0.38	-0.4	Schizophrenia;	chr15:84162560	chr15:84389729~84395903:+
THYM	cis	rs950169	0.922	rs12911223	ENSG00000259683.1	RP11-182J1.14	-4.22	5.57e-05	0.029	-0.38	-0.4	Schizophrenia;	chr15:84162919	chr15:84389729~84395903:+
THYM	cis	rs950169	0.845	rs4106951	ENSG00000259683.1	RP11-182J1.14	4.22	5.57e-05	0.029	0.38	0.4	Schizophrenia;	chr15:84164642	chr15:84389729~84395903:+
THYM	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-4.22	5.58e-05	0.029	-0.55	-0.4	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
THYM	cis	rs13134327	0.513	rs7679687	ENSG00000249741.2	RP11-673E1.3	4.22	5.58e-05	0.029	0.34	0.4	Glycated hemoglobin levels;	chr4:144024031	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.618	rs7685385	ENSG00000249741.2	RP11-673E1.3	4.22	5.58e-05	0.029	0.34	0.4	Immature fraction of reticulocytes;	chr4:144029851	chr4:143911514~143912053:-
THYM	cis	rs7236477	0.71	rs3810006	ENSG00000265273.1	PGDP1	4.22	5.58e-05	0.029	0.85	0.4	Eosinophilic esophagitis (pediatric);	chr18:31317302	chr18:31962178~31963618:+
THYM	cis	rs7560272	0.682	rs2421546	ENSG00000163016.8	ALMS1P	-4.22	5.58e-05	0.029	-0.48	-0.4	Schizophrenia;	chr2:73413949	chr2:73644919~73685576:+
THYM	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	4.22	5.59e-05	0.029	0.54	0.4	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
THYM	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	4.22	5.59e-05	0.029	0.54	0.4	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
THYM	cis	rs1550576	0.568	rs77111251	ENSG00000274719.1	RP11-86K22.2	4.22	5.59e-05	0.0291	0.73	0.4	Hypertension;	chr15:57935192	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs1816779	ENSG00000274719.1	RP11-86K22.2	4.22	5.59e-05	0.0291	0.73	0.4	Hypertension;	chr15:57938299	chr15:57990217~57990636:-
THYM	cis	rs10129255	0.957	rs6576233	ENSG00000254329.1	IGHVII-60-1	4.22	5.59e-05	0.0291	0.41	0.4	Kawasaki disease;	chr14:106787239	chr14:106637718~106637973:-
THYM	cis	rs9467773	0.62	rs9467810	ENSG00000261353.1	CTA-14H9.5	-4.22	5.6e-05	0.0291	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26527063~26527404:+
THYM	cis	rs453301	0.631	rs28572014	ENSG00000253893.2	FAM85B	4.22	5.6e-05	0.0291	0.52	0.4	Joint mobility (Beighton score);	chr8:8936097	chr8:8167819~8226614:-
THYM	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	4.22	5.6e-05	0.0291	0.52	0.4	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
THYM	cis	rs11633886	0.565	rs1356881	ENSG00000273972.1	CTD-2306A12.1	4.22	5.6e-05	0.0291	0.48	0.4	Diisocyanate-induced asthma;	chr15:45781261	chr15:45702640~45703183:+
THYM	cis	rs1519814	0.696	rs7821842	ENSG00000254343.2	RP11-760H22.2	-4.22	5.6e-05	0.0291	-0.59	-0.4	Breast cancer;	chr8:120021743	chr8:120052180~120056201:+
THYM	cis	rs217727	0.524	rs7483477	ENSG00000226416.1	MRPL23-AS1	-4.22	5.6e-05	0.0291	-0.38	-0.4	Breast cancer;	chr11:1899025	chr11:1983237~1989920:-
THYM	cis	rs7560272	0.502	rs4513320	ENSG00000163016.8	ALMS1P	-4.22	5.6e-05	0.0291	-0.51	-0.4	Schizophrenia;	chr2:73693614	chr2:73644919~73685576:+
THYM	cis	rs863345	0.625	rs6663286	ENSG00000236656.1	RP11-144L1.4	4.22	5.61e-05	0.0291	0.26	0.4	Pneumococcal bacteremia;	chr1:158503935	chr1:158474454~158494886:-
THYM	cis	rs34773007	0.514	rs12355562	ENSG00000272817.1	RP11-402D21.2	-4.22	5.61e-05	0.0291	-0.47	-0.4	Type 2 diabetes;	chr10:92780698	chr10:91908131~91909348:+
THYM	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-4.22	5.61e-05	0.0291	-0.34	-0.4	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-4.22	5.61e-05	0.0291	-0.34	-0.4	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-4.22	5.61e-05	0.0291	-0.34	-0.4	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
THYM	cis	rs9876781	1	rs6794875	ENSG00000244380.1	RP11-24C3.2	4.22	5.61e-05	0.0291	0.55	0.4	Longevity;	chr3:48414217	chr3:48440352~48446656:-
THYM	cis	rs763121	0.925	rs5750654	ENSG00000273076.1	RP3-508I15.22	4.22	5.62e-05	0.0292	0.5	0.4	Menopause (age at onset);	chr22:38655423	chr22:38743495~38743910:+
THYM	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	4.22	5.62e-05	0.0292	0.43	0.4	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
THYM	cis	rs2115630	0.846	rs8024538	ENSG00000275120.1	RP11-182J1.17	-4.22	5.62e-05	0.0292	-0.46	-0.4	P wave terminal force;	chr15:84825188	chr15:84599434~84606463:-
THYM	cis	rs1865760	0.534	rs2032444	ENSG00000216331.1	HIST1H1PS1	4.22	5.62e-05	0.0292	0.59	0.4	Height;	chr6:26046516	chr6:26195566~26195771:+
THYM	cis	rs972578	0.837	rs5751390	ENSG00000215347.3	SLC25A5P1	-4.22	5.62e-05	0.0292	-0.32	-0.4	Mean platelet volume;	chr22:42863535	chr22:42001069~42001966:-
THYM	cis	rs972578	0.837	rs6002966	ENSG00000215347.3	SLC25A5P1	-4.22	5.62e-05	0.0292	-0.32	-0.4	Mean platelet volume;	chr22:42863849	chr22:42001069~42001966:-
THYM	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-4.22	5.62e-05	0.0292	-0.43	-0.4	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-4.22	5.62e-05	0.0292	-0.43	-0.4	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
THYM	cis	rs9467773	0.62	rs2101582	ENSG00000261353.1	CTA-14H9.5	-4.22	5.62e-05	0.0292	-0.29	-0.4	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26527063~26527404:+
THYM	cis	rs8067545	0.72	rs6587206	ENSG00000231645.2	KRT17P6	-4.22	5.62e-05	0.0292	-0.47	-0.4	Schizophrenia;	chr17:19978274	chr17:20512560~20517479:-
THYM	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-4.22	5.63e-05	0.0292	-0.34	-0.4	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
THYM	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-4.22	5.63e-05	0.0292	-0.31	-0.4	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
THYM	cis	rs1910358	0.554	rs2139793	ENSG00000248874.4	C5orf17	4.22	5.63e-05	0.0292	0.54	0.4	Venous thromboembolism (SNP x SNP interaction);	chr5:23748760	chr5:23951348~24178263:+
THYM	cis	rs2946505	0.516	rs2954193	ENSG00000251468.2	RP11-369K16.1	4.22	5.63e-05	0.0292	0.52	0.4	Migraine;	chr8:12960864	chr8:12958387~12962200:+
THYM	cis	rs10129255	0.544	rs61997583	ENSG00000253209.1	IGHV3-65	4.22	5.63e-05	0.0292	0.4	0.4	Kawasaki disease;	chr14:106654351	chr14:106666092~106666532:-
THYM	cis	rs10129255	0.585	rs2008440	ENSG00000253209.1	IGHV3-65	4.22	5.63e-05	0.0292	0.4	0.4	Kawasaki disease;	chr14:106654988	chr14:106666092~106666532:-
THYM	cis	rs910316	0.934	rs4903278	ENSG00000258646.1	RP11-950C14.3	-4.22	5.63e-05	0.0293	-0.37	-0.4	Height;	chr14:75068316	chr14:75004719~75008481:-
THYM	cis	rs295137	0.752	rs10931892	ENSG00000232732.8	AC073043.1	4.22	5.64e-05	0.0293	0.5	0.4	Asthma (bronchodilator response);	chr2:200240274	chr2:199867396~199911159:-
THYM	cis	rs295137	0.836	rs10804097	ENSG00000232732.8	AC073043.1	-4.22	5.64e-05	0.0293	-0.5	-0.4	Asthma (bronchodilator response);	chr2:200240201	chr2:199867396~199911159:-
THYM	cis	rs12304921	0.748	rs77433345	ENSG00000277201.1	AC087884.1	4.22	5.64e-05	0.0293	0.39	0.4	Type 2 diabetes;	chr12:50941799	chr12:51049921~51050025:+
THYM	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	4.22	5.64e-05	0.0293	0.68	0.4	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
THYM	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	4.22	5.64e-05	0.0293	0.68	0.4	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
THYM	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	4.22	5.64e-05	0.0293	0.68	0.4	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
THYM	cis	rs2662776	0.967	rs10753606	ENSG00000232995.6	RGS5	4.22	5.64e-05	0.0293	0.35	0.4	Lead levels in blood;	chr1:163186734	chr1:163244505~163321894:-
THYM	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-4.22	5.64e-05	0.0293	-0.67	-0.4	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
THYM	cis	rs9309711	0.813	rs11690865	ENSG00000225234.1	TRAPPC12-AS1	-4.22	5.64e-05	0.0293	-0.32	-0.4	Neurofibrillary tangles;	chr2:3468179	chr2:3481242~3482409:-
THYM	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	4.22	5.65e-05	0.0293	0.41	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
THYM	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	4.22	5.65e-05	0.0293	0.51	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
THYM	cis	rs2853333	0.622	rs2519962	ENSG00000268947.1	AD000684.2	4.22	5.65e-05	0.0293	0.34	0.4	Red blood cell count;	chr19:35261788	chr19:35262846~35264804:+
THYM	cis	rs2853333	0.6	rs916147	ENSG00000268947.1	AD000684.2	4.22	5.65e-05	0.0293	0.34	0.4	Red blood cell count;	chr19:35266347	chr19:35262846~35264804:+
THYM	cis	rs10829156	0.607	rs7908550	ENSG00000225527.1	RP11-383B4.4	-4.22	5.65e-05	0.0293	-0.51	-0.4	Sudden cardiac arrest;	chr10:18573282	chr10:18531849~18533336:-
THYM	cis	rs4478858	0.735	rs4949389	ENSG00000260386.4	LINC01225	-4.22	5.66e-05	0.0293	-0.22	-0.4	Alcohol dependence;	chr1:31351176	chr1:31500085~31540885:+
THYM	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-4.22	5.67e-05	0.0293	-0.55	-0.4	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-4.22	5.67e-05	0.0293	-0.55	-0.4	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
THYM	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-4.22	5.67e-05	0.0293	-0.32	-0.4	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
THYM	cis	rs1950357	0.589	rs2180090	ENSG00000258601.1	RP11-81F13.2	-4.22	5.67e-05	0.0293	-0.39	-0.4	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36742935	chr14:36808871~36828729:+
THYM	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-4.22	5.67e-05	0.0293	-0.41	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
THYM	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	4.22	5.67e-05	0.0293	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
THYM	cis	rs11247915	0.6	rs72649360	ENSG00000225854.2	RP11-569G9.7	4.22	5.68e-05	0.0293	0.48	0.4	Obesity-related traits;	chr1:26336413	chr1:26326688~26327033:+
THYM	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-4.22	5.68e-05	0.0293	-0.48	-0.4	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
THYM	cis	rs4835473	0.9	rs58106929	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143733166	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs7698963	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143733190	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs35230778	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734336	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs34772566	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734355	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs35419968	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734583	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs66634585	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734608	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs35016507	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734617	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs67600034	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734670	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35655934	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734697	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs35515006	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734705	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34525847	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143734970	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35277115	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735001	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34653324	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735058	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35947648	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735092	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs66474962	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735145	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs35800634	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735199	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs34505330	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735206	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4597770	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735239	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs4629390	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143735302	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34257944	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143736443	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13147386	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143736586	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13119602	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143736621	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs12509642	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143737080	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.801	rs76574827	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143737303	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.832	rs62337616	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143737307	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.832	rs66717029	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143737318	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs17750354	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143737352	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs17693768	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143737503	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs5015759	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738050	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs5015758	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738052	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs34569841	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738060	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs5015757	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143738144	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34950821	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738174	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13133444	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143738191	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13135034	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143738247	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs5016159	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143738362	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs5016158	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738472	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs5016157	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738587	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13134327	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143738642	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.808	rs13134564	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738763	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs13134571	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738771	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13139738	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738828	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17018165	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143738849	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.808	rs2060653	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143739132	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs67749935	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143739852	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs66934100	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143739872	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs4257605	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143740081	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4498094	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143740097	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4325971	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143740167	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4443230	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143740372	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4637344	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143740434	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs56277406	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143740620	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13143879	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143740901	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs36086465	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143742738	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs873430	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143742953	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs873431	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143743035	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs899903	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143743551	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2323191	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143744472	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs1375982	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143745764	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs4835237	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143746349	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs56084616	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143746697	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.966	rs11722639	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143746884	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.966	rs11722673	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143746946	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6821979	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143748091	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6838887	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143748130	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1982392	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143748604	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1982393	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143748736	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs9683880	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143748787	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs7687976	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143749171	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs7683287	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143749270	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.712	rs2198000	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143750005	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs2198002	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143750028	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6853460	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143750392	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6853676	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143750495	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6848393	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143750537	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs971390	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143751264	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs971391	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143751324	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs971392	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143751384	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs35978782	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143751713	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34060266	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143751766	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13139419	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143751862	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs13106052	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143751995	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13134401	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752008	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13106287	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752091	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13134679	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752187	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13108134	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752213	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs34406317	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752237	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35863996	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752260	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6836896	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752404	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2874983	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752589	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2874984	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752622	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs2323192	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143752646	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34152627	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143753205	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35670108	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143753280	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs6832005	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143754284	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs55963933	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143755048	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs35243309	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143755116	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs34790336	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143755284	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35740243	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143755395	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4395452	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143755678	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.741	rs6537180	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143755984	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.741	rs6537181	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143755995	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs6814065	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143756233	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs6816347	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143756674	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.808	rs6847256	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143757032	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs57413073	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143757852	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34732468	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143758009	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs12510395	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143758107	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs12513087	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143758551	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs12513119	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143758619	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs12513130	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143758666	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs935732	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143759164	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs7681891	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143759289	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs7681903	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143759326	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs7656753	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143759414	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs7656786	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143759455	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.771	rs34069296	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143759656	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs7687915	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143759801	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1993015	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760202	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs1993016	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760217	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1993017	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760285	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs1375983	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760423	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1375984	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760510	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1375985	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760556	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17018200	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760866	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11100805	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143760979	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11100806	ENSG00000249741.2	RP11-673E1.3	-4.22	5.68e-05	0.0293	-0.33	-0.4	Immature fraction of reticulocytes;	chr4:143761006	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.868	rs56115009	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761073	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs10857406	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761216	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10857407	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761226	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10857408	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761333	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs10857409	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761461	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10857410	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761566	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10857411	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761599	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1006406	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761710	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1562776	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143761999	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34697602	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143762499	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34618381	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143762612	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11100808	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143762728	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7661407	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143762982	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs4285038	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143763637	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1562777	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143763676	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1562778	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143763816	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1562779	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143763999	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1597441	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143764158	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1597442	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143764359	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1597443	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143764406	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1597444	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143764547	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs60038202	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143764662	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34886773	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143764678	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1450230	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765118	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34683160	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765227	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs72946226	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765238	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs34230433	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765253	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7696106	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765454	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7680045	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765470	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7696869	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765855	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7698287	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143765859	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11721495	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143767216	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11721523	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143767301	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6858195	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143768444	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1597445	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143768543	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs7689374	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143769567	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6537183	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143770441	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs12512202	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143771248	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6843671	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143772041	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs35395070	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143772283	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs34614750	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143772369	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35002497	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143772952	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13119630	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143773901	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1450233	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143774710	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4308330	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143774761	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs11725708	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143775683	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17762299	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143777196	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.838	rs56033497	ENSG00000249741.2	RP11-673E1.3	4.22	5.68e-05	0.0293	0.33	0.4	Immature fraction of reticulocytes;	chr4:143792341	chr4:143911514~143912053:-
THYM	cis	rs7223966	1	rs9893348	ENSG00000240280.5	TCAM1P	-4.22	5.68e-05	0.0293	-0.62	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63599175	chr17:63849292~63864379:+
THYM	cis	rs559928	0.692	rs876064	ENSG00000236935.1	AP003774.1	4.22	5.69e-05	0.0294	0.37	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64269561	chr11:64325050~64329504:-
THYM	cis	rs559928	0.642	rs2286615	ENSG00000236935.1	AP003774.1	4.22	5.69e-05	0.0294	0.37	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64271703	chr11:64325050~64329504:-
THYM	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	4.22	5.69e-05	0.0294	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	4.22	5.69e-05	0.0294	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
THYM	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-4.22	5.69e-05	0.0294	-0.36	-0.4	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
THYM	cis	rs910316	0.763	rs175036	ENSG00000258646.1	RP11-950C14.3	4.22	5.69e-05	0.0294	0.35	0.4	Height;	chr14:74997592	chr14:75004719~75008481:-
THYM	cis	rs910316	0.712	rs175037	ENSG00000258646.1	RP11-950C14.3	4.22	5.69e-05	0.0294	0.35	0.4	Height;	chr14:74998335	chr14:75004719~75008481:-
THYM	cis	rs910316	0.763	rs175047	ENSG00000258646.1	RP11-950C14.3	4.22	5.69e-05	0.0294	0.35	0.4	Height;	chr14:75012336	chr14:75004719~75008481:-
THYM	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-4.22	5.69e-05	0.0294	-0.38	-0.4	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
THYM	cis	rs9611565	0.729	rs203320	ENSG00000273366.1	CTA-989H11.1	4.22	5.7e-05	0.0294	0.45	0.4	Vitiligo;	chr22:41517473	chr22:42278188~42278846:+
THYM	cis	rs7976269	0.559	rs10771477	ENSG00000275476.1	RP11-996F15.4	-4.22	5.7e-05	0.0294	-0.44	-0.4	Male-pattern baldness;	chr12:29074137	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.559	rs10843307	ENSG00000275476.1	RP11-996F15.4	-4.22	5.7e-05	0.0294	-0.44	-0.4	Male-pattern baldness;	chr12:29074710	chr12:29277397~29277882:-
THYM	cis	rs9926296	0.744	rs6860	ENSG00000274627.1	RP11-104N10.2	4.22	5.7e-05	0.0294	0.48	0.4	Vitiligo;	chr16:89644712	chr16:89516797~89522217:+
THYM	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	4.22	5.7e-05	0.0294	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	4.22	5.7e-05	0.0294	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	4.22	5.7e-05	0.0294	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	4.22	5.7e-05	0.0294	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	4.22	5.7e-05	0.0294	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	4.22	5.7e-05	0.0294	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	4.22	5.7e-05	0.0294	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
THYM	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	4.22	5.7e-05	0.0294	0.34	0.4	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
THYM	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	4.22	5.7e-05	0.0294	0.34	0.4	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
THYM	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	4.22	5.7e-05	0.0294	0.34	0.4	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
THYM	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	4.22	5.7e-05	0.0294	0.34	0.4	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
THYM	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	4.22	5.7e-05	0.0294	0.34	0.4	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
THYM	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	4.22	5.7e-05	0.0294	0.34	0.4	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
THYM	cis	rs202072	0.769	rs495895	ENSG00000272379.1	RP1-257A7.5	4.22	5.71e-05	0.0294	0.53	0.4	HIV-1 viral setpoint;	chr6:13277683	chr6:13290018~13290490:-
THYM	cis	rs3781264	0.761	rs11187893	ENSG00000273450.1	RP11-76P2.4	-4.22	5.71e-05	0.0295	-0.5	-0.4	Esophageal cancer and gastric cancer;	chr10:94346222	chr10:94314907~94315327:-
THYM	cis	rs3781264	0.761	rs11187894	ENSG00000273450.1	RP11-76P2.4	4.22	5.71e-05	0.0295	0.5	0.4	Esophageal cancer and gastric cancer;	chr10:94346268	chr10:94314907~94315327:-
THYM	cis	rs2243480	1	rs7804223	ENSG00000228409.4	CCT6P1	-4.22	5.71e-05	0.0295	-0.47	-0.4	Diabetic kidney disease;	chr7:66199572	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs10807702	ENSG00000228409.4	CCT6P1	4.22	5.71e-05	0.0295	0.47	0.4	Diabetic kidney disease;	chr7:66302856	chr7:65751142~65763354:+
THYM	cis	rs950169	0.922	rs8037078	ENSG00000259683.1	RP11-182J1.14	-4.22	5.71e-05	0.0295	-0.37	-0.4	Schizophrenia;	chr15:84150119	chr15:84389729~84395903:+
THYM	cis	rs8067545	1	rs34291370	ENSG00000231645.2	KRT17P6	-4.22	5.71e-05	0.0295	-0.46	-0.4	Schizophrenia;	chr17:20039022	chr17:20512560~20517479:-
THYM	cis	rs4835473	0.932	rs5015760	ENSG00000249741.2	RP11-673E1.3	4.22	5.72e-05	0.0295	0.33	0.4	Immature fraction of reticulocytes;	chr4:143737955	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2323190	ENSG00000249741.2	RP11-673E1.3	4.22	5.72e-05	0.0295	0.33	0.4	Immature fraction of reticulocytes;	chr4:143744282	chr4:143911514~143912053:-
THYM	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-4.22	5.72e-05	0.0295	-0.37	-0.4	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
THYM	cis	rs12902680	0.706	rs28402192	ENSG00000259520.4	CTD-2651B20.3	4.22	5.72e-05	0.0295	0.42	0.4	Neuroticism;	chr15:46180832	chr15:45251580~45279251:-
THYM	cis	rs7412746	0.622	rs11552229	ENSG00000220323.3	HIST2H2BD	-4.22	5.72e-05	0.0295	-0.38	-0.4	Melanoma;	chr1:150811509	chr1:149843041~149843533:+
THYM	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	4.22	5.72e-05	0.0295	0.32	0.4	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
THYM	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	4.22	5.72e-05	0.0295	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	4.22	5.73e-05	0.0295	0.54	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	4.22	5.73e-05	0.0295	0.54	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
THYM	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
THYM	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-4.22	5.73e-05	0.0295	-0.39	-0.4	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
THYM	cis	rs12681366	0.881	rs3019150	ENSG00000253704.1	RP11-267M23.4	4.22	5.73e-05	0.0295	0.52	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.763	rs3019277	ENSG00000253704.1	RP11-267M23.4	4.22	5.73e-05	0.0295	0.52	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.839	rs3019278	ENSG00000253704.1	RP11-267M23.4	4.22	5.73e-05	0.0295	0.52	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.761	rs2930963	ENSG00000253704.1	RP11-267M23.4	4.22	5.73e-05	0.0295	0.52	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.839	rs2930964	ENSG00000253704.1	RP11-267M23.4	4.22	5.73e-05	0.0295	0.52	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94553722~94569745:+
THYM	cis	rs4835473	0.868	rs1828503	ENSG00000249741.2	RP11-673E1.3	4.22	5.73e-05	0.0295	0.34	0.4	Immature fraction of reticulocytes;	chr4:143993354	chr4:143911514~143912053:-
THYM	cis	rs7631605	0.905	rs11720064	ENSG00000272334.1	RP11-129K12.1	-4.22	5.74e-05	0.0296	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37060028	chr3:36973117~36973672:-
THYM	cis	rs1560104	0.871	rs4479213	ENSG00000259899.1	CTD-3037G24.3	4.21	5.74e-05	0.0296	0.5	0.4	Obesity-related traits;	chr16:12618447	chr16:12560756~12611044:-
THYM	cis	rs7851726	0.624	rs12338859	ENSG00000232063.1	RP11-307E17.8	-4.21	5.74e-05	0.0296	-0.39	-0.4	Urinary albumin-to-creatinine ratio;	chr9:94901338	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.624	rs12347649	ENSG00000232063.1	RP11-307E17.8	4.21	5.74e-05	0.0296	0.39	0.4	Urinary albumin-to-creatinine ratio;	chr9:94901286	chr9:94332476~94360948:+
THYM	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	4.21	5.74e-05	0.0296	0.38	0.4	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
THYM	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-4.21	5.74e-05	0.0296	-0.42	-0.4	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
THYM	cis	rs7927592	0.913	rs6591340	ENSG00000222339.1	AP000807.2	4.21	5.74e-05	0.0296	0.5	0.4	Total body bone mineral density;	chr11:68530168	chr11:68505572~68505651:-
THYM	cis	rs910316	0.904	rs7156089	ENSG00000258646.1	RP11-950C14.3	4.21	5.74e-05	0.0296	0.36	0.4	Height;	chr14:75178824	chr14:75004719~75008481:-
THYM	cis	rs12902680	0.739	rs1915157	ENSG00000259520.4	CTD-2651B20.3	4.21	5.75e-05	0.0296	0.44	0.4	Neuroticism;	chr15:46119102	chr15:45251580~45279251:-
THYM	cis	rs11696739	0.761	rs2254458	ENSG00000234282.1	RP4-673D20.4	-4.21	5.75e-05	0.0296	-0.42	-0.4	Mean platelet volume;	chr20:1570839	chr20:1722045~1722537:-
THYM	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	4.21	5.75e-05	0.0296	0.46	0.4	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
THYM	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	4.21	5.76e-05	0.0296	0.47	0.4	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
THYM	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-4.21	5.76e-05	0.0296	-0.44	-0.4	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-4.21	5.76e-05	0.0296	-0.44	-0.4	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-4.21	5.76e-05	0.0296	-0.44	-0.4	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-4.21	5.76e-05	0.0296	-0.44	-0.4	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-4.21	5.76e-05	0.0296	-0.44	-0.4	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-4.21	5.76e-05	0.0296	-0.44	-0.4	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-4.21	5.76e-05	0.0296	-0.44	-0.4	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
THYM	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	4.21	5.76e-05	0.0296	0.51	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
THYM	cis	rs10510102	0.507	rs12244092	ENSG00000276742.1	RP11-500G22.4	4.21	5.76e-05	0.0296	0.51	0.4	Breast cancer;	chr10:122005769	chr10:121956782~121957098:+
THYM	cis	rs1584120	0.62	rs11046814	ENSG00000256321.4	RP11-153K16.1	-4.21	5.76e-05	0.0296	-0.49	-0.4	Pelvic organ prolapse (moderate/severe);	chr12:23127707	chr12:23099368~23191587:+
THYM	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-4.21	5.76e-05	0.0296	-0.48	-0.4	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
THYM	cis	rs863345	0.565	rs10908668	ENSG00000236656.1	RP11-144L1.4	4.21	5.76e-05	0.0296	0.26	0.4	Pneumococcal bacteremia;	chr1:158532143	chr1:158474454~158494886:-
THYM	cis	rs863345	0.526	rs10908669	ENSG00000236656.1	RP11-144L1.4	4.21	5.76e-05	0.0296	0.26	0.4	Pneumococcal bacteremia;	chr1:158532148	chr1:158474454~158494886:-
THYM	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	4.21	5.76e-05	0.0296	0.34	0.4	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
THYM	cis	rs397969	0.621	rs203480	ENSG00000231645.2	KRT17P6	-4.21	5.78e-05	0.0297	-0.49	-0.4	Platelet count;	chr17:19925646	chr17:20512560~20517479:-
THYM	cis	rs397969	0.646	rs203478	ENSG00000231645.2	KRT17P6	-4.21	5.78e-05	0.0297	-0.49	-0.4	Platelet count;	chr17:19926529	chr17:20512560~20517479:-
THYM	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-4.21	5.78e-05	0.0297	-0.6	-0.4	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
THYM	cis	rs2662776	0.967	rs4291481	ENSG00000232995.6	RGS5	4.21	5.78e-05	0.0297	0.35	0.4	Lead levels in blood;	chr1:163182051	chr1:163244505~163321894:-
THYM	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-4.21	5.78e-05	0.0297	-0.48	-0.4	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
THYM	cis	rs1950357	0.589	rs2064547	ENSG00000258601.1	RP11-81F13.2	4.21	5.79e-05	0.0297	0.39	0.4	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36743778	chr14:36808871~36828729:+
THYM	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-4.21	5.79e-05	0.0297	-0.61	-0.4	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
THYM	cis	rs7223966	1	rs2013288	ENSG00000240280.5	TCAM1P	-4.21	5.79e-05	0.0298	-0.57	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63708544	chr17:63849292~63864379:+
THYM	cis	rs10208649	0.706	rs75833613	ENSG00000272156.1	RP11-477N3.1	4.21	5.79e-05	0.0298	0.6	0.4	Body mass index;	chr2:54065224	chr2:54082554~54085066:+
THYM	cis	rs10411161	1	rs3764540	ENSG00000269483.1	AC006272.1	4.21	5.79e-05	0.0298	0.58	0.4	Breast cancer;	chr19:51877428	chr19:51839924~51843324:-
THYM	cis	rs7202877	0.656	rs8048677	ENSG00000261783.1	RP11-252K23.2	-4.21	5.79e-05	0.0298	-0.55	-0.4	Type 1 diabetes;Type 2 diabetes;	chr16:75358130	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs8054586	ENSG00000261783.1	RP11-252K23.2	-4.21	5.79e-05	0.0298	-0.55	-0.4	Type 1 diabetes;Type 2 diabetes;	chr16:75376807	chr16:75379818~75381260:-
THYM	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	4.21	5.8e-05	0.0298	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
THYM	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-4.21	5.8e-05	0.0298	-0.52	-0.4	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
THYM	cis	rs4671400	0.543	rs10178135	ENSG00000273302.1	RP11-493E12.2	-4.21	5.8e-05	0.0298	-0.44	-0.4	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258132	chr2:61199979~61200769:+
THYM	cis	rs4671400	0.571	rs6738482	ENSG00000273302.1	RP11-493E12.2	-4.21	5.8e-05	0.0298	-0.44	-0.4	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267766	chr2:61199979~61200769:+
THYM	cis	rs7546094	0.905	rs10776755	ENSG00000215866.6	LINC01356	4.21	5.81e-05	0.0298	0.51	0.4	Platelet distribution width;	chr1:112540352	chr1:112820170~112850643:-
THYM	cis	rs9309473	0.5	rs12996463	ENSG00000163016.8	ALMS1P	-4.21	5.81e-05	0.0298	-0.49	-0.4	Metabolite levels;	chr2:73428368	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs2178154	ENSG00000163016.8	ALMS1P	-4.21	5.81e-05	0.0298	-0.49	-0.4	Metabolite levels;	chr2:73434610	chr2:73644919~73685576:+
THYM	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-4.21	5.81e-05	0.0298	-0.43	-0.4	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
THYM	cis	rs807029	0.577	rs3740489	ENSG00000273030.1	RP11-285F16.1	-4.21	5.81e-05	0.0298	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100412934~100413421:+
THYM	cis	rs7412746	0.503	rs72704639	ENSG00000220323.3	HIST2H2BD	-4.21	5.81e-05	0.0298	-0.37	-0.4	Melanoma;	chr1:150825859	chr1:149843041~149843533:+
THYM	cis	rs2245368	0.523	rs67814714	ENSG00000242435.1	UPK3BP1	4.21	5.82e-05	0.0299	0.57	0.4	Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;	chr7:76888105	chr7:77004662~77005774:+
THYM	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-4.21	5.82e-05	0.0299	-0.52	-0.4	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
THYM	cis	rs6575793	0.512	rs1888581	ENSG00000258904.1	RP11-638I2.2	4.21	5.83e-05	0.0299	0.4	0.4	Menarche (age at onset);	chr14:100576378	chr14:100263781~100265405:+
THYM	cis	rs763121	0.889	rs9607557	ENSG00000273076.1	RP3-508I15.22	4.21	5.83e-05	0.0299	0.5	0.4	Menopause (age at onset);	chr22:38644274	chr22:38743495~38743910:+
THYM	cis	rs972578	0.811	rs2284091	ENSG00000215347.3	SLC25A5P1	-4.21	5.83e-05	0.0299	-0.32	-0.4	Mean platelet volume;	chr22:42875498	chr22:42001069~42001966:-
THYM	cis	rs972578	0.837	rs2073199	ENSG00000215347.3	SLC25A5P1	-4.21	5.83e-05	0.0299	-0.32	-0.4	Mean platelet volume;	chr22:42879244	chr22:42001069~42001966:-
THYM	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	4.21	5.83e-05	0.0299	0.37	0.4	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
THYM	cis	rs935334	1	rs12879642	ENSG00000258454.1	RP11-361H10.3	4.21	5.83e-05	0.0299	0.53	0.4	Blood pressure;	chr14:76216624	chr14:76235817~76263474:+
THYM	cis	rs7976269	0.559	rs4930848	ENSG00000275476.1	RP11-996F15.4	-4.21	5.83e-05	0.0299	-0.46	-0.4	Male-pattern baldness;	chr12:29068441	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.559	rs10771473	ENSG00000275476.1	RP11-996F15.4	-4.21	5.83e-05	0.0299	-0.46	-0.4	Male-pattern baldness;	chr12:29068729	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.537	rs10843303	ENSG00000275476.1	RP11-996F15.4	-4.21	5.83e-05	0.0299	-0.46	-0.4	Male-pattern baldness;	chr12:29069435	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.537	rs2117992	ENSG00000275476.1	RP11-996F15.4	-4.21	5.83e-05	0.0299	-0.46	-0.4	Male-pattern baldness;	chr12:29070611	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.559	rs10843304	ENSG00000275476.1	RP11-996F15.4	-4.21	5.83e-05	0.0299	-0.46	-0.4	Male-pattern baldness;	chr12:29071226	chr12:29277397~29277882:-
THYM	cis	rs863345	0.604	rs1342948	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158493504	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1342953	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158494709	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264991	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158503071	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7544134	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158505631	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs34701257	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158511165	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12041348	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158512252	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12041350	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158512258	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264997	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158515692	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11264999	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158519070	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs10908662	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158519410	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7549581	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158519914	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7512592	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158520155	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10797018	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158520322	chr1:158474454~158494886:-
THYM	cis	rs863345	0.527	rs10797019	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158520431	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10797020	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158520534	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10797021	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158520551	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs10489833	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158520661	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11265003	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158520841	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs950260	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158521730	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2317969	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158521963	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7518808	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158522030	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs10908663	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158522331	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2157687	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158523210	chr1:158474454~158494886:-
THYM	cis	rs863345	0.548	rs1032352	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158523364	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7548349	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158523936	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7514968	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158524062	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7525362	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158524100	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs7515245	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158524320	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10797022	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158524403	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs12145401	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158524903	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs6663277	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158525211	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs6699473	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158525419	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs6674656	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158525641	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12118446	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158526445	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs10797023	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527289	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs6672789	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527349	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs10797024	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527373	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs6657638	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527394	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs6670343	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527468	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1578763	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527624	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1578762	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527650	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1578761	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158527782	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs6666609	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158528334	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs6666805	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158528515	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12120526	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158528614	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs11265006	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158528695	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11265008	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158528881	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11265010	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158529063	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12123305	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158529165	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12063320	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158529633	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12064489	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158529659	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs12063360	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158529704	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908665	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158530099	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs12119672	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158530495	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs59427353	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158530831	chr1:158474454~158494886:-
THYM	cis	rs863345	0.565	rs59188837	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158530846	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12059669	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158531690	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908670	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158532323	chr1:158474454~158494886:-
THYM	cis	rs863345	0.565	rs10908671	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158532370	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12075228	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158532466	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs11265014	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158533431	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11265015	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158533462	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11265016	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158533995	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908673	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534118	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs10908674	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534130	chr1:158474454~158494886:-
THYM	cis	rs863345	0.547	rs10908675	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534339	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7518708	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534484	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs7533071	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534689	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs7540999	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534780	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2873593	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534921	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2317970	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158534980	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2873594	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158535000	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs4575081	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158535047	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs4276920	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158535182	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs4313395	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158535345	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs4584390	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158536185	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs10908676	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158536373	chr1:158474454~158494886:-
THYM	cis	rs863345	0.584	rs11265018	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158536619	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12133791	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158536892	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12133794	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158536907	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs12122663	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158536934	chr1:158474454~158494886:-
THYM	cis	rs863345	0.565	rs2051665	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158537367	chr1:158474454~158494886:-
THYM	cis	rs863345	0.526	rs2051666	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158537370	chr1:158474454~158494886:-
THYM	cis	rs863345	0.526	rs2051067	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158537608	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs923664	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158537901	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2873595	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158538592	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs975118	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158541655	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs1342945	ENSG00000236656.1	RP11-144L1.4	4.21	5.83e-05	0.0299	0.26	0.4	Pneumococcal bacteremia;	chr1:158543122	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2054991	ENSG00000236656.1	RP11-144L1.4	-4.21	5.83e-05	0.0299	-0.26	-0.4	Pneumococcal bacteremia;	chr1:158536293	chr1:158474454~158494886:-
THYM	cis	rs2108622	0.649	rs113055956	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.711	rs113059233	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.683	rs111388185	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.683	rs112571591	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.647	rs111427692	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs12609468	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs12610967	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.711	rs12609820	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.668	rs62106153	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs12611242	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs12611308	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs12610189	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.711	rs113343664	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.701	rs118144071	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs8102532	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs62106155	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs62106157	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs62106158	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs7256877	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs7253873	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.559	rs7252638	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs7253684	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.727	rs55954696	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15904556~15907234:+
THYM	cis	rs2108622	0.683	rs56228205	ENSG00000279717.1	LLNLF-158E9.1	-4.21	5.84e-05	0.0299	-0.39	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15904556~15907234:+
THYM	cis	rs11157436	0.958	rs1041859	ENSG00000211812.1	TRAV26-2	-4.21	5.84e-05	0.0299	-0.27	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs1041860	ENSG00000211812.1	TRAV26-2	-4.21	5.84e-05	0.0299	-0.27	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs764161	ENSG00000211812.1	TRAV26-2	-4.21	5.84e-05	0.0299	-0.27	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs12433649	ENSG00000211812.1	TRAV26-2	-4.21	5.84e-05	0.0299	-0.27	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22202583~22203368:+
THYM	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	4.21	5.84e-05	0.0299	0.42	0.4	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
THYM	cis	rs4834770	1	rs4336213	ENSG00000249244.1	RP11-548H18.2	4.21	5.84e-05	0.0299	0.31	0.4	Blood protein levels;	chr4:119315314	chr4:119391831~119395335:-
THYM	cis	rs12908161	1	rs11637142	ENSG00000235370.6	DNM1P51	4.21	5.84e-05	0.0299	0.53	0.4	Schizophrenia;	chr15:84752696	chr15:84398316~84411701:-
THYM	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	4.21	5.85e-05	0.0299	0.5	0.4	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	4.21	5.85e-05	0.0299	0.5	0.4	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	4.21	5.85e-05	0.0299	0.5	0.4	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
THYM	cis	rs12666612	1	rs117427535	ENSG00000279048.1	RP11-511H23.2	4.21	5.85e-05	0.0299	0.57	0.4	Obesity-related traits;	chr7:18347637	chr7:17940503~17942922:+
THYM	cis	rs10129255	0.872	rs10133674	ENSG00000254329.1	IGHVII-60-1	4.21	5.85e-05	0.0299	0.38	0.4	Kawasaki disease;	chr14:106692788	chr14:106637718~106637973:-
THYM	cis	rs2911132	0.564	rs1057569	ENSG00000272109.1	CTD-2260A17.3	-4.21	5.85e-05	0.0299	-0.54	-0.4	Urate levels (BMI interaction);	chr5:96773906	chr5:96804353~96806105:+
THYM	cis	rs2911132	0.511	rs7063	ENSG00000272109.1	CTD-2260A17.3	-4.21	5.85e-05	0.0299	-0.54	-0.4	Urate levels (BMI interaction);	chr5:96774507	chr5:96804353~96806105:+
THYM	cis	rs2911132	0.511	rs3198304	ENSG00000272109.1	CTD-2260A17.3	-4.21	5.85e-05	0.0299	-0.54	-0.4	Urate levels (BMI interaction);	chr5:96775524	chr5:96804353~96806105:+
THYM	cis	rs2911132	0.511	rs13160562	ENSG00000272109.1	CTD-2260A17.3	-4.21	5.85e-05	0.0299	-0.54	-0.4	Urate levels (BMI interaction);	chr5:96775667	chr5:96804353~96806105:+
THYM	cis	rs9926296	0.744	rs460984	ENSG00000274627.1	RP11-104N10.2	4.21	5.85e-05	0.0299	0.48	0.4	Vitiligo;	chr16:89646766	chr16:89516797~89522217:+
THYM	cis	rs910316	0.934	rs8006587	ENSG00000258646.1	RP11-950C14.3	-4.21	5.85e-05	0.0299	-0.36	-0.4	Height;	chr14:75198236	chr14:75004719~75008481:-
THYM	cis	rs7178424	0.935	rs8034216	ENSG00000259251.2	RP11-643M14.1	4.21	5.85e-05	0.0299	0.44	0.4	Height;	chr15:61995329	chr15:62060503~62062434:+
THYM	cis	rs11098499	0.863	rs2306456	ENSG00000250412.1	KLHL2P1	4.21	5.85e-05	0.03	0.38	0.4	Corneal astigmatism;	chr4:119551267	chr4:119334329~119378233:+
THYM	cis	rs6026584	1	rs6026584	ENSG00000270951.1	RP1-309F20.4	4.21	5.86e-05	0.03	0.46	0.4	Renal function-related traits (BUN);	chr20:58894018	chr20:58876592~58876981:-
THYM	cis	rs1950357	0.589	rs1033594	ENSG00000258601.1	RP11-81F13.2	4.21	5.86e-05	0.03	0.39	0.4	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36742361	chr14:36808871~36828729:+
THYM	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	4.21	5.86e-05	0.03	0.52	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
THYM	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-4.21	5.87e-05	0.03	-0.69	-0.4	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
THYM	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	4.21	5.87e-05	0.03	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
THYM	cis	rs12410462	0.591	rs12080590	ENSG00000227711.2	RP11-275O4.5	4.21	5.88e-05	0.03	0.39	0.4	Major depressive disorder;	chr1:227572070	chr1:227509028~227520477:-
THYM	cis	rs6121246	0.559	rs10439608	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31671011	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6119652	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31671642	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060621	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31673759	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs12479491	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31677647	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6058352	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31681376	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060716	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31687044	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6121172	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31708292	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060857	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31712419	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs1484994	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31718172	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.512	rs45443696	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31723593	chr20:31567707~31573263:-
THYM	cis	rs6087771	0.89	rs6089056	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Putamen volume;Subcortical brain region volumes;	chr20:31737970	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060915	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31742503	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060919	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31744119	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060922	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31746106	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060932	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31762742	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.583	rs28815498	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31763757	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.512	rs6060938	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31775842	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.512	rs6060941	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31779580	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6087779	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31782763	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060944	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31784311	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060950	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31790228	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6087782	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31803777	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6058465	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31809888	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060962	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31810044	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.511	rs879982	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31810707	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6121243	ENSG00000230613.1	HM13-AS1	4.21	5.88e-05	0.03	0.56	0.4	Mean corpuscular hemoglobin;	chr20:31827291	chr20:31567707~31573263:-
THYM	cis	rs160451	1	rs160441	ENSG00000251136.7	RP11-37B2.1	4.21	5.88e-05	0.03	0.37	0.4	Leprosy;	chr8:89644760	chr8:89609409~89757727:-
THYM	cis	rs160451	1	rs160449	ENSG00000251136.7	RP11-37B2.1	4.21	5.88e-05	0.03	0.37	0.4	Leprosy;	chr8:89648287	chr8:89609409~89757727:-
THYM	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	4.21	5.88e-05	0.03	0.37	0.4	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
THYM	cis	rs10129255	0.879	rs7160512	ENSG00000254329.1	IGHVII-60-1	4.21	5.88e-05	0.03	0.38	0.4	Kawasaki disease;	chr14:106694574	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.879	rs7159157	ENSG00000254329.1	IGHVII-60-1	4.21	5.88e-05	0.03	0.38	0.4	Kawasaki disease;	chr14:106694578	chr14:106637718~106637973:-
THYM	cis	rs7208859	0.573	rs73267873	ENSG00000266490.1	CTD-2349P21.9	4.21	5.88e-05	0.0301	0.68	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.561	rs4085382	ENSG00000266490.1	CTD-2349P21.9	4.21	5.88e-05	0.0301	0.68	0.4	Body mass index;	chr17:30744184	chr17:30792372~30792833:+
THYM	cis	rs4671400	0.571	rs2421116	ENSG00000273302.1	RP11-493E12.2	-4.21	5.88e-05	0.0301	-0.44	-0.4	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61261276	chr2:61199979~61200769:+
THYM	cis	rs910316	0.726	rs175040	ENSG00000258646.1	RP11-950C14.3	4.21	5.89e-05	0.0301	0.35	0.4	Height;	chr14:75002852	chr14:75004719~75008481:-
THYM	cis	rs2289328	0.825	rs35777573	ENSG00000223313.1	RNU6-516P	-4.21	5.89e-05	0.0301	-0.57	-0.4	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40352045	chr15:40529570~40529673:+
THYM	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	4.21	5.89e-05	0.0301	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
THYM	cis	rs73198271	0.653	rs10087633	ENSG00000253893.2	FAM85B	4.21	5.89e-05	0.0301	0.56	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.653	rs10087742	ENSG00000253893.2	FAM85B	4.21	5.89e-05	0.0301	0.56	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8167819~8226614:-
THYM	cis	rs9535495	0.833	rs8000318	ENSG00000200711.1	RNA5SP28	-4.21	5.89e-05	0.0301	-0.46	-0.4	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50837985	chr13:50812988~50813106:-
THYM	cis	rs910316	1	rs175492	ENSG00000258646.1	RP11-950C14.3	-4.21	5.9e-05	0.0301	-0.37	-0.4	Height;	chr14:75078517	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs2300601	ENSG00000258646.1	RP11-950C14.3	-4.21	5.9e-05	0.0301	-0.36	-0.4	Height;	chr14:75172868	chr14:75004719~75008481:-
THYM	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-4.21	5.9e-05	0.0301	-0.34	-0.4	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-4.21	5.9e-05	0.0301	-0.34	-0.4	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-4.21	5.9e-05	0.0301	-0.34	-0.4	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-4.21	5.9e-05	0.0301	-0.34	-0.4	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-4.21	5.9e-05	0.0301	-0.34	-0.4	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	4.21	5.9e-05	0.0301	0.34	0.4	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
THYM	cis	rs12410462	0.591	rs72632830	ENSG00000227711.2	RP11-275O4.5	-4.21	5.9e-05	0.0301	-0.41	-0.4	Major depressive disorder;	chr1:227541196	chr1:227509028~227520477:-
THYM	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	4.21	5.91e-05	0.0302	0.76	0.4	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
THYM	cis	rs2662776	1	rs2999967	ENSG00000232995.6	RGS5	-4.21	5.91e-05	0.0302	-0.34	-0.4	Lead levels in blood;	chr1:163196886	chr1:163244505~163321894:-
THYM	cis	rs2662776	1	rs2999859	ENSG00000232995.6	RGS5	-4.21	5.91e-05	0.0302	-0.34	-0.4	Lead levels in blood;	chr1:163196933	chr1:163244505~163321894:-
THYM	cis	rs2662776	1	rs2999965	ENSG00000232995.6	RGS5	-4.21	5.91e-05	0.0302	-0.34	-0.4	Lead levels in blood;	chr1:163198509	chr1:163244505~163321894:-
THYM	cis	rs877819	0.583	rs1904595	ENSG00000228403.1	RP11-563N6.6	4.21	5.91e-05	0.0302	0.5	0.4	Systemic lupus erythematosus;	chr10:48877222	chr10:48878022~48878649:+
THYM	cis	rs877819	0.583	rs2663033	ENSG00000228403.1	RP11-563N6.6	-4.21	5.91e-05	0.0302	-0.5	-0.4	Systemic lupus erythematosus;	chr10:48876623	chr10:48878022~48878649:+
THYM	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-4.21	5.91e-05	0.0302	-0.54	-0.4	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-4.21	5.91e-05	0.0302	-0.54	-0.4	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
THYM	cis	rs1584120	0.62	rs11046812	ENSG00000256321.4	RP11-153K16.1	-4.21	5.91e-05	0.0302	-0.5	-0.4	Pelvic organ prolapse (moderate/severe);	chr12:23126673	chr12:23099368~23191587:+
THYM	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	4.21	5.92e-05	0.0302	0.49	0.4	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
THYM	cis	rs7631605	0.935	rs3733030	ENSG00000272334.1	RP11-129K12.1	-4.21	5.92e-05	0.0302	-0.41	-0.4	Cerebrospinal P-tau181p levels;	chr3:37129226	chr3:36973117~36973672:-
THYM	cis	rs7560272	0.723	rs7562047	ENSG00000273245.1	RP11-434P11.2	4.21	5.92e-05	0.0302	0.45	0.4	Schizophrenia;	chr2:73498041	chr2:73750256~73750786:-
THYM	cis	rs12439619	0.693	rs9944185	ENSG00000274376.3	ADAMTS7P1	4.21	5.93e-05	0.0302	0.42	0.4	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82298553~82334609:+
THYM	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	4.21	5.93e-05	0.0303	0.51	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
THYM	cis	rs2115630	0.936	rs6496318	ENSG00000275120.1	RP11-182J1.17	-4.21	5.93e-05	0.0303	-0.47	-0.4	P wave terminal force;	chr15:84671998	chr15:84599434~84606463:-
THYM	cis	rs12902680	0.706	rs2043481	ENSG00000259520.4	CTD-2651B20.3	-4.21	5.93e-05	0.0303	-0.41	-0.4	Neuroticism;	chr15:46225463	chr15:45251580~45279251:-
THYM	cis	rs28785552	0.796	rs8112908	ENSG00000250731.1	TPM3P6	-4.21	5.93e-05	0.0303	-0.59	-0.4	Response to paliperidone in schizophrenia (PANSS score);	chr19:52744788	chr19:53479350~53480091:+
THYM	cis	rs7429990	0.965	rs35689209	ENSG00000199476.1	Y_RNA	4.21	5.94e-05	0.0303	0.53	0.4	Educational attainment (years of education);	chr3:48078273	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs4858881	ENSG00000199476.1	Y_RNA	4.21	5.94e-05	0.0303	0.53	0.4	Educational attainment (years of education);	chr3:48082306	chr3:48288587~48288694:+
THYM	cis	rs12902680	0.706	rs28575923	ENSG00000259520.4	CTD-2651B20.3	4.21	5.94e-05	0.0303	0.41	0.4	Neuroticism;	chr15:46233411	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12440622	ENSG00000259520.4	CTD-2651B20.3	4.21	5.94e-05	0.0303	0.41	0.4	Neuroticism;	chr15:46233426	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12437760	ENSG00000259520.4	CTD-2651B20.3	4.21	5.94e-05	0.0303	0.41	0.4	Neuroticism;	chr15:46233446	chr15:45251580~45279251:-
THYM	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-4.21	5.94e-05	0.0303	-0.37	-0.4	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
THYM	cis	rs11098499	0.874	rs6822498	ENSG00000250412.1	KLHL2P1	4.21	5.95e-05	0.0303	0.38	0.4	Corneal astigmatism;	chr4:119199028	chr4:119334329~119378233:+
THYM	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	4.21	5.95e-05	0.0303	0.43	0.4	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
THYM	cis	rs4842666	0.915	rs11105368	ENSG00000258302.2	RP11-981P6.1	4.21	5.95e-05	0.0303	0.43	0.4	Blood pressure;	chr12:89680664	chr12:89561129~89594878:+
THYM	cis	rs4842666	0.765	rs4842675	ENSG00000258302.2	RP11-981P6.1	4.21	5.95e-05	0.0303	0.43	0.4	Blood pressure;	chr12:89681466	chr12:89561129~89594878:+
THYM	cis	rs4948275	0.693	rs2650729	ENSG00000237233.2	TMEM26-AS1	-4.21	5.95e-05	0.0303	-0.45	-0.4	Night sleep phenotypes;	chr10:61577411	chr10:61452639~61481956:+
THYM	cis	rs9652601	0.959	rs12927355	ENSG00000274038.1	RP11-66H6.4	-4.21	5.95e-05	0.0303	-0.43	-0.4	Systemic lupus erythematosus;	chr16:11100914	chr16:11056556~11057034:+
THYM	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-4.21	5.95e-05	0.0303	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
THYM	cis	rs4262	0.505	rs1019227	ENSG00000278388.1	GS1-345D13.1	4.21	5.95e-05	0.0304	0.43	0.4	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93933561	chr7:93914987~93915108:+
THYM	cis	rs4262	0.525	rs180229	ENSG00000278388.1	GS1-345D13.1	-4.21	5.95e-05	0.0304	-0.43	-0.4	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93929189	chr7:93914987~93915108:+
THYM	cis	rs4262	0.525	rs6961414	ENSG00000278388.1	GS1-345D13.1	-4.21	5.95e-05	0.0304	-0.43	-0.4	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93930005	chr7:93914987~93915108:+
THYM	cis	rs4262	0.505	rs180228	ENSG00000278388.1	GS1-345D13.1	-4.21	5.95e-05	0.0304	-0.43	-0.4	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93931601	chr7:93914987~93915108:+
THYM	cis	rs4262	0.505	rs180225	ENSG00000278388.1	GS1-345D13.1	-4.21	5.95e-05	0.0304	-0.43	-0.4	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93932987	chr7:93914987~93915108:+
THYM	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-4.21	5.95e-05	0.0304	-0.54	-0.4	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
THYM	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-4.21	5.95e-05	0.0304	-0.54	-0.4	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
THYM	cis	rs17711722	0.583	rs10085415	ENSG00000164669.11	INTS4P1	4.2	5.96e-05	0.0304	0.52	0.4	Calcium levels;	chr7:65628655	chr7:65141225~65234216:+
THYM	cis	rs5758659	0.716	rs2143138	ENSG00000182057.4	OGFRP1	4.2	5.96e-05	0.0304	0.34	0.4	Cognitive function;	chr22:42222334	chr22:42269753~42275196:+
THYM	cis	rs11976180	1	rs2951372	ENSG00000244479.5	OR2A1-AS1	4.2	5.96e-05	0.0304	0.36	0.4	Obesity-related traits;	chr7:144052410	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1320894	ENSG00000244479.5	OR2A1-AS1	4.2	5.96e-05	0.0304	0.36	0.4	Obesity-related traits;	chr7:144054709	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1320893	ENSG00000244479.5	OR2A1-AS1	4.2	5.96e-05	0.0304	0.36	0.4	Obesity-related traits;	chr7:144055019	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2951369	ENSG00000244479.5	OR2A1-AS1	4.2	5.96e-05	0.0304	0.36	0.4	Obesity-related traits;	chr7:144055545	chr7:144251264~144356181:-
THYM	cis	rs9309473	0.5	rs1528169	ENSG00000273245.1	RP11-434P11.2	-4.2	5.96e-05	0.0304	-0.45	-0.4	Metabolite levels;	chr2:73442058	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs7598901	ENSG00000273245.1	RP11-434P11.2	-4.2	5.96e-05	0.0304	-0.45	-0.4	Metabolite levels;	chr2:73448717	chr2:73750256~73750786:-
THYM	cis	rs295140	0.507	rs13019821	ENSG00000232732.8	AC073043.1	4.2	5.96e-05	0.0304	0.5	0.4	QT interval;	chr2:200242092	chr2:199867396~199911159:-
THYM	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	4.2	5.96e-05	0.0304	0.43	0.4	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
THYM	cis	rs17685	0.753	rs1639609	ENSG00000280388.1	RP11-229D13.3	-4.2	5.97e-05	0.0304	-0.39	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76054263	chr7:76043977~76045963:-
THYM	cis	rs11603020	0.95	rs28362949	ENSG00000265566.2	RN7SL605P	-4.2	5.98e-05	0.0305	-0.55	-0.4	Blood protein levels;	chr11:57604438	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.95	rs28362951	ENSG00000265566.2	RN7SL605P	-4.2	5.98e-05	0.0305	-0.55	-0.4	Blood protein levels;	chr11:57605053	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.95	rs11229066	ENSG00000265566.2	RN7SL605P	-4.2	5.98e-05	0.0305	-0.55	-0.4	Blood protein levels;	chr11:57607398	chr11:57528085~57528365:-
THYM	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	4.2	5.98e-05	0.0305	0.4	0.4	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
THYM	cis	rs1790761	0.504	rs61894496	ENSG00000231793.4	DOC2GP	-4.2	5.98e-05	0.0305	-0.38	-0.4	Mean corpuscular volume;	chr11:67624436	chr11:67612653~67616257:-
THYM	cis	rs9420	0.528	rs34052104	ENSG00000265566.2	RN7SL605P	-4.2	5.99e-05	0.0305	-0.56	-0.4	Schizophrenia;	chr11:57617046	chr11:57528085~57528365:-
THYM	cis	rs9420	0.528	rs11229075	ENSG00000265566.2	RN7SL605P	-4.2	5.99e-05	0.0305	-0.56	-0.4	Schizophrenia;	chr11:57623550	chr11:57528085~57528365:-
THYM	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-4.2	5.99e-05	0.0305	-0.46	-0.4	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
THYM	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	4.2	6e-05	0.0305	0.37	0.4	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
THYM	cis	rs4478858	0.735	rs6679365	ENSG00000260386.4	LINC01225	-4.2	6e-05	0.0305	-0.22	-0.4	Alcohol dependence;	chr1:31315019	chr1:31500085~31540885:+
THYM	cis	rs12681366	0.881	rs16916760	ENSG00000253704.1	RP11-267M23.4	4.2	6e-05	0.0306	0.52	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94356881	chr8:94553722~94569745:+
THYM	cis	rs2812378	0.527	rs4878588	ENSG00000227852.1	RP11-156G14.6	-4.2	6e-05	0.0306	-0.44	-0.4	Rheumatoid arthritis;	chr9:34723747	chr9:35592786~35592951:+
THYM	cis	rs2812378	0.564	rs3739881	ENSG00000227852.1	RP11-156G14.6	-4.2	6e-05	0.0306	-0.44	-0.4	Rheumatoid arthritis;	chr9:34724244	chr9:35592786~35592951:+
THYM	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	4.2	6e-05	0.0306	0.51	0.4	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
THYM	cis	rs7209700	0.708	rs2292865	ENSG00000228782.6	CTD-2026D20.3	-4.2	6.01e-05	0.0306	-0.47	-0.4	IgG glycosylation;	chr17:47287356	chr17:47450568~47492492:-
THYM	cis	rs7209700	0.708	rs15908	ENSG00000228782.6	CTD-2026D20.3	-4.2	6.01e-05	0.0306	-0.47	-0.4	IgG glycosylation;	chr17:47290971	chr17:47450568~47492492:-
THYM	cis	rs984222	0.501	rs1325941	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941193	chr1:119140396~119275973:+
THYM	cis	rs984222	0.501	rs1750333	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941315	chr1:119140396~119275973:+
THYM	cis	rs984222	0.501	rs1361906	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942021	chr1:119140396~119275973:+
THYM	cis	rs984222	0.501	rs1325943	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942984	chr1:119140396~119275973:+
THYM	cis	rs984222	0.501	rs1325945	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943148	chr1:119140396~119275973:+
THYM	cis	rs984222	0.529	rs1325946	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943299	chr1:119140396~119275973:+
THYM	cis	rs984222	0.501	rs1779420	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943840	chr1:119140396~119275973:+
THYM	cis	rs984222	0.501	rs1419289	ENSG00000231365.4	RP11-418J17.1	-4.2	6.02e-05	0.0306	-0.37	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118944613	chr1:119140396~119275973:+
THYM	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-4.2	6.02e-05	0.0306	-0.59	-0.4	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
THYM	cis	rs12304921	0.748	rs73090619	ENSG00000277201.1	AC087884.1	4.2	6.02e-05	0.0306	0.39	0.4	Type 2 diabetes;	chr12:50939250	chr12:51049921~51050025:+
THYM	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	4.2	6.02e-05	0.0306	0.52	0.4	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	4.2	6.02e-05	0.0306	0.52	0.4	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	4.2	6.02e-05	0.0306	0.52	0.4	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	4.2	6.02e-05	0.0306	0.52	0.4	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
THYM	cis	rs7178424	0.806	rs1425270	ENSG00000259251.2	RP11-643M14.1	4.2	6.02e-05	0.0306	0.42	0.4	Height;	chr15:61945511	chr15:62060503~62062434:+
THYM	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	4.2	6.02e-05	0.0307	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	4.2	6.02e-05	0.0307	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	4.2	6.02e-05	0.0307	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
THYM	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	4.2	6.02e-05	0.0307	0.38	0.4	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
THYM	cis	rs4908760	0.731	rs12075458	ENSG00000232912.4	RP5-1115A15.1	4.2	6.02e-05	0.0307	0.38	0.4	Vitiligo;	chr1:8698735	chr1:8424645~8434838:+
THYM	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-4.2	6.03e-05	0.0307	-0.45	-0.4	QT interval;	chr12:29310155	chr12:29280418~29317848:-
THYM	cis	rs6087771	0.642	rs6060403	ENSG00000230613.1	HM13-AS1	4.2	6.03e-05	0.0307	0.54	0.4	Putamen volume;Subcortical brain region volumes;	chr20:31633301	chr20:31567707~31573263:-
THYM	cis	rs6087771	0.642	rs6060411	ENSG00000230613.1	HM13-AS1	4.2	6.03e-05	0.0307	0.54	0.4	Putamen volume;Subcortical brain region volumes;	chr20:31634336	chr20:31567707~31573263:-
THYM	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	4.2	6.04e-05	0.0307	0.41	0.4	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-4.2	6.04e-05	0.0307	-0.41	-0.4	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-4.2	6.04e-05	0.0307	-0.41	-0.4	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
THYM	cis	rs10799445	0.568	rs3010190	ENSG00000227711.2	RP11-275O4.5	-4.2	6.04e-05	0.0307	-0.35	-0.4	Height;	chr1:227616609	chr1:227509028~227520477:-
THYM	cis	rs11098499	0.909	rs10026736	ENSG00000250412.1	KLHL2P1	4.2	6.04e-05	0.0307	0.39	0.4	Corneal astigmatism;	chr4:119463167	chr4:119334329~119378233:+
THYM	cis	rs4478858	0.735	rs12734617	ENSG00000260386.4	LINC01225	4.2	6.04e-05	0.0307	0.22	0.4	Alcohol dependence;	chr1:31350599	chr1:31500085~31540885:+
THYM	cis	rs453301	0.624	rs7014430	ENSG00000253893.2	FAM85B	-4.2	6.05e-05	0.0307	-0.48	-0.4	Joint mobility (Beighton score);	chr8:8970227	chr8:8167819~8226614:-
THYM	cis	rs9309473	0.519	rs13017182	ENSG00000273245.1	RP11-434P11.2	-4.2	6.05e-05	0.0308	-0.42	-0.4	Metabolite levels;	chr2:73663877	chr2:73750256~73750786:-
THYM	cis	rs995758	1	rs11100860	ENSG00000236296.6	GUSBP5	-4.2	6.05e-05	0.0308	-0.46	-0.4	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144557987	chr4:143559472~143649305:+
THYM	cis	rs4835473	0.8	rs1849133	ENSG00000249741.2	RP11-673E1.3	-4.2	6.05e-05	0.0308	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143958262	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs1849132	ENSG00000249741.2	RP11-673E1.3	-4.2	6.05e-05	0.0308	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143958309	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13123407	ENSG00000249741.2	RP11-673E1.3	-4.2	6.05e-05	0.0308	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143958713	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs61611095	ENSG00000249741.2	RP11-673E1.3	-4.2	6.05e-05	0.0308	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143958802	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs4835449	ENSG00000249741.2	RP11-673E1.3	-4.2	6.05e-05	0.0308	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143958830	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1838516	ENSG00000249741.2	RP11-673E1.3	-4.2	6.05e-05	0.0308	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143962082	chr4:143911514~143912053:-
THYM	cis	rs9549367	0.588	rs9549360	ENSG00000269125.1	RP11-98F14.11	-4.2	6.05e-05	0.0308	-0.58	-0.4	Platelet distribution width;	chr13:113238718	chr13:113165002~113165183:-
THYM	cis	rs7631605	0.935	rs9854641	ENSG00000272334.1	RP11-129K12.1	-4.2	6.06e-05	0.0308	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37176970	chr3:36973117~36973672:-
THYM	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	4.2	6.06e-05	0.0308	0.51	0.4	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
THYM	cis	rs728616	0.681	rs55838345	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80325364	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs61859191	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80331271	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs17678338	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80338390	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs61859196	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80349292	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs61859198	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80354872	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs61859199	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs1538818	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80363037	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs61859209	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs61859210	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80371712	chr10:79904898~79950336:+
THYM	cis	rs728616	0.614	rs17678737	ENSG00000242600.5	MBL1P	4.2	6.07e-05	0.0308	0.56	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80374229	chr10:79904898~79950336:+
THYM	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	4.2	6.07e-05	0.0308	0.37	0.4	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
THYM	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	4.2	6.07e-05	0.0308	0.37	0.4	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
THYM	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	4.2	6.07e-05	0.0308	0.37	0.4	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
THYM	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	4.2	6.07e-05	0.0308	0.37	0.4	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
THYM	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	4.2	6.07e-05	0.0308	0.37	0.4	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
THYM	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	4.2	6.07e-05	0.0308	0.37	0.4	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
THYM	cis	rs9402743	0.671	rs6901733	ENSG00000236703.1	MYB-AS1	-4.2	6.07e-05	0.0308	-0.27	-0.4	Systemic lupus erythematosus;	chr6:135619407	chr6:135195083~135195995:-
THYM	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-4.2	6.08e-05	0.0309	-0.52	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
THYM	cis	rs11098499	0.863	rs9997631	ENSG00000250412.1	KLHL2P1	4.2	6.08e-05	0.0309	0.38	0.4	Corneal astigmatism;	chr4:119548840	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs10018280	ENSG00000250412.1	KLHL2P1	4.2	6.08e-05	0.0309	0.38	0.4	Corneal astigmatism;	chr4:119556984	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs6534141	ENSG00000250412.1	KLHL2P1	4.2	6.08e-05	0.0309	0.38	0.4	Corneal astigmatism;	chr4:119564068	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs2127823	ENSG00000250412.1	KLHL2P1	4.2	6.08e-05	0.0309	0.38	0.4	Corneal astigmatism;	chr4:119564515	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775858	ENSG00000250412.1	KLHL2P1	4.2	6.08e-05	0.0309	0.38	0.4	Corneal astigmatism;	chr4:119564873	chr4:119334329~119378233:+
THYM	cis	rs7560272	0.538	rs17350056	ENSG00000163016.8	ALMS1P	-4.2	6.08e-05	0.0309	-0.5	-0.4	Schizophrenia;	chr2:73695750	chr2:73644919~73685576:+
THYM	cis	rs73198271	0.74	rs67766414	ENSG00000253893.2	FAM85B	4.2	6.08e-05	0.0309	0.62	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8167819~8226614:-
THYM	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	4.2	6.08e-05	0.0309	0.51	0.4	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
THYM	cis	rs2282300	0.739	rs1717772	ENSG00000254532.1	RP11-624D11.2	4.2	6.09e-05	0.0309	0.61	0.4	Morning vs. evening chronotype;	chr11:30318586	chr11:30044058~30084343:-
THYM	cis	rs1910358	0.554	rs62348285	ENSG00000248874.4	C5orf17	-4.2	6.09e-05	0.0309	-0.54	-0.4	Venous thromboembolism (SNP x SNP interaction);	chr5:23734408	chr5:23951348~24178263:+
THYM	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	4.2	6.09e-05	0.0309	0.45	0.4	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
THYM	cis	rs28785552	0.931	rs8112235	ENSG00000250731.1	TPM3P6	-4.2	6.09e-05	0.0309	-0.56	-0.4	Response to paliperidone in schizophrenia (PANSS score);	chr19:52735757	chr19:53479350~53480091:+
THYM	cis	rs9907295	0.681	rs9912284	ENSG00000270977.1	AC015849.16	-4.2	6.09e-05	0.0309	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35893707~35911023:-
THYM	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	4.2	6.09e-05	0.0309	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	4.2	6.09e-05	0.0309	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	4.2	6.09e-05	0.0309	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	4.2	6.09e-05	0.0309	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
THYM	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	4.2	6.09e-05	0.0309	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
THYM	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	4.2	6.09e-05	0.0309	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
THYM	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	4.2	6.09e-05	0.0309	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
THYM	cis	rs17253792	0.915	rs17832389	ENSG00000186615.9	KTN1-AS1	-4.2	6.1e-05	0.0309	-0.73	-0.4	Putamen volume;	chr14:55719118	chr14:55499278~55580110:-
THYM	cis	rs889398	0.771	rs8048550	ENSG00000226232.7	RP11-419C5.2	-4.2	6.1e-05	0.031	-0.36	-0.4	Body mass index;	chr16:69857856	chr16:69976388~69996188:-
THYM	cis	rs61160187	0.75	rs56166952	ENSG00000272308.1	RP11-231G3.1	-4.2	6.1e-05	0.031	-0.34	-0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60610568	chr5:60866457~60866935:-
THYM	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	4.2	6.11e-05	0.031	0.46	0.4	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
THYM	cis	rs9903692	0.657	rs1452665	ENSG00000266601.1	RP11-6N17.3	-4.2	6.11e-05	0.031	-0.37	-0.4	Pulse pressure;	chr17:48219789	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs9889470	ENSG00000266601.1	RP11-6N17.3	-4.2	6.11e-05	0.031	-0.37	-0.4	Pulse pressure;	chr17:48233713	chr17:47929682~47933106:-
THYM	cis	rs7209700	0.644	rs7214468	ENSG00000228782.6	CTD-2026D20.3	-4.2	6.12e-05	0.031	-0.47	-0.4	IgG glycosylation;	chr17:47293400	chr17:47450568~47492492:-
THYM	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-4.2	6.12e-05	0.031	-0.48	-0.4	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
THYM	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-4.2	6.13e-05	0.0311	-0.48	-0.4	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
THYM	cis	rs10129255	0.957	rs12590735	ENSG00000254329.1	IGHVII-60-1	4.2	6.14e-05	0.0311	0.41	0.4	Kawasaki disease;	chr14:106779660	chr14:106637718~106637973:-
THYM	cis	rs853679	0.599	rs149949	ENSG00000182477.5	OR2B8P	4.2	6.14e-05	0.0311	0.76	0.4	Depression;	chr6:28043738	chr6:28053228~28054165:-
THYM	cis	rs4478858	0.684	rs12121165	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31252695	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.647	rs11577679	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31253338	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.611	rs10914338	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31260935	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs2271074	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31261994	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs4949372	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31266010	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs7528066	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31276245	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs16834336	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31278665	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.735	rs11583123	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31278925	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs7549343	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31279413	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.709	rs7514640	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31279469	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs16865957	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31280506	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.684	rs2062951	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31290134	chr1:31500085~31540885:+
THYM	cis	rs4478858	0.647	rs4949380	ENSG00000260386.4	LINC01225	4.2	6.14e-05	0.0311	0.22	0.4	Alcohol dependence;	chr1:31291313	chr1:31500085~31540885:+
THYM	cis	rs12902680	0.706	rs8031523	ENSG00000259520.4	CTD-2651B20.3	4.2	6.14e-05	0.0311	0.41	0.4	Neuroticism;	chr15:46223045	chr15:45251580~45279251:-
THYM	cis	rs935334	1	rs2121067	ENSG00000258454.1	RP11-361H10.3	4.2	6.14e-05	0.0311	0.53	0.4	Blood pressure;	chr14:76151308	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs10137323	ENSG00000258454.1	RP11-361H10.3	-4.2	6.14e-05	0.0311	-0.53	-0.4	Blood pressure;	chr14:76219390	chr14:76235817~76263474:+
THYM	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	4.2	6.14e-05	0.0311	0.51	0.4	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
THYM	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	4.2	6.14e-05	0.0311	0.51	0.4	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
THYM	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	4.2	6.14e-05	0.0311	0.51	0.4	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
THYM	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	4.2	6.14e-05	0.0311	0.51	0.4	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
THYM	cis	rs12439619	0.693	rs17269819	ENSG00000274376.3	ADAMTS7P1	4.2	6.14e-05	0.0311	0.43	0.4	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.693	rs8034801	ENSG00000274376.3	ADAMTS7P1	4.2	6.14e-05	0.0311	0.43	0.4	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82298553~82334609:+
THYM	cis	rs12439619	0.693	rs28689861	ENSG00000274376.3	ADAMTS7P1	4.2	6.14e-05	0.0311	0.43	0.4	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82298553~82334609:+
THYM	cis	rs7927592	0.956	rs7113287	ENSG00000222339.1	AP000807.2	4.2	6.15e-05	0.0311	0.46	0.4	Total body bone mineral density;	chr11:68604718	chr11:68505572~68505651:-
THYM	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-4.2	6.15e-05	0.0311	-0.51	-0.4	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
THYM	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-4.2	6.15e-05	0.0311	-0.51	-0.4	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
THYM	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-4.2	6.15e-05	0.0311	-0.51	-0.4	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
THYM	cis	rs863345	0.565	rs12403685	ENSG00000236656.1	RP11-144L1.4	-4.2	6.15e-05	0.0311	-0.25	-0.4	Pneumococcal bacteremia;	chr1:158482609	chr1:158474454~158494886:-
THYM	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
THYM	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
THYM	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
THYM	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	4.2	6.15e-05	0.0311	0.51	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
THYM	cis	rs5771225	0.544	rs909688	ENSG00000273253.2	RP3-402G11.26	-4.2	6.15e-05	0.0312	-0.5	-0.4	Late-onset Alzheimer's disease;	chr22:50250601	chr22:50199090~50200837:-
THYM	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	4.2	6.15e-05	0.0312	0.47	0.4	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
THYM	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-4.2	6.15e-05	0.0312	-0.39	-0.4	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
THYM	cis	rs2911132	0.506	rs7705827	ENSG00000272109.1	CTD-2260A17.3	-4.2	6.16e-05	0.0312	-0.51	-0.4	Urate levels (BMI interaction);	chr5:96746729	chr5:96804353~96806105:+
THYM	cis	rs11098499	0.954	rs13145352	ENSG00000250412.1	KLHL2P1	-4.2	6.16e-05	0.0312	-0.38	-0.4	Corneal astigmatism;	chr4:119488808	chr4:119334329~119378233:+
THYM	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	4.2	6.17e-05	0.0312	0.51	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
THYM	cis	rs17685	0.753	rs1104878	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76056275	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs869805	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76059278	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs869806	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76059305	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs869804	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76059636	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs1637037	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76063609	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs11972240	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76064761	chr7:76043977~76045963:-
THYM	cis	rs17685	0.784	rs1637043	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76069781	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs1639617	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76072410	chr7:76043977~76045963:-
THYM	cis	rs17685	0.672	rs1639618	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76072669	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs1637044	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76074426	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs1639620	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76074772	chr7:76043977~76045963:-
THYM	cis	rs17685	0.672	rs1639623	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76078633	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs11982200	ENSG00000280388.1	RP11-229D13.3	-4.2	6.17e-05	0.0312	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76085565	chr7:76043977~76045963:-
THYM	cis	rs17685	0.725	rs4476928	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76012789	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs13240967	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76028879	chr7:76043977~76045963:-
THYM	cis	rs17685	0.725	rs6947068	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76032738	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs4728550	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76041670	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs13240404	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76046401	chr7:76043977~76045963:-
THYM	cis	rs17685	0.697	rs2302437	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76047698	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs3757593	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76049417	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs2868203	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76050708	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs2286830	ENSG00000280388.1	RP11-229D13.3	4.2	6.17e-05	0.0312	0.4	0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76064645	chr7:76043977~76045963:-
THYM	cis	rs1595825	0.628	rs6760078	ENSG00000222017.1	AC011997.1	-4.2	6.18e-05	0.0312	-0.44	-0.4	Ulcerative colitis;	chr2:197699018	chr2:197693106~197774823:+
THYM	cis	rs1595825	0.891	rs7592344	ENSG00000222017.1	AC011997.1	-4.2	6.18e-05	0.0312	-0.44	-0.4	Ulcerative colitis;	chr2:197707737	chr2:197693106~197774823:+
THYM	cis	rs1595825	0.891	rs7583917	ENSG00000222017.1	AC011997.1	-4.2	6.18e-05	0.0312	-0.44	-0.4	Ulcerative colitis;	chr2:197712226	chr2:197693106~197774823:+
THYM	cis	rs1595825	0.891	rs80178661	ENSG00000222017.1	AC011997.1	-4.2	6.18e-05	0.0312	-0.44	-0.4	Ulcerative colitis;	chr2:197717718	chr2:197693106~197774823:+
THYM	cis	rs1595825	0.891	rs16823148	ENSG00000222017.1	AC011997.1	-4.2	6.18e-05	0.0312	-0.44	-0.4	Ulcerative colitis;	chr2:197719485	chr2:197693106~197774823:+
THYM	cis	rs11139399	0.651	rs2086830	ENSG00000233926.1	RP11-154D17.1	-4.2	6.18e-05	0.0312	-0.48	-0.4	Hippocampal atrophy;	chr9:81730173	chr9:81689713~81776900:+
THYM	cis	rs11139399	0.626	rs2086831	ENSG00000233926.1	RP11-154D17.1	-4.2	6.18e-05	0.0312	-0.48	-0.4	Hippocampal atrophy;	chr9:81730211	chr9:81689713~81776900:+
THYM	cis	rs3780486	0.505	rs10813959	ENSG00000225693.1	LAGE3P1	-4.2	6.18e-05	0.0312	-0.46	-0.4	IgG glycosylation;	chr9:33166236	chr9:33019682~33020165:-
THYM	cis	rs995758	0.967	rs720484	ENSG00000236296.6	GUSBP5	4.2	6.18e-05	0.0312	0.46	0.4	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144541212	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs6537291	ENSG00000236296.6	GUSBP5	4.2	6.18e-05	0.0312	0.46	0.4	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144542922	chr4:143559472~143649305:+
THYM	cis	rs7223966	1	rs56383601	ENSG00000240280.5	TCAM1P	-4.2	6.18e-05	0.0312	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63852608	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs72848797	ENSG00000240280.5	TCAM1P	-4.2	6.18e-05	0.0312	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63857304	chr17:63849292~63864379:+
THYM	cis	rs4713118	0.516	rs6931858	ENSG00000199851.2	U3	4.19	6.18e-05	0.0312	0.55	0.4	Parkinson's disease;	chr6:28110633	chr6:28015568~28015777:+
THYM	cis	rs17685	0.712	rs4552844	ENSG00000280388.1	RP11-229D13.3	-4.19	6.19e-05	0.0312	-0.41	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76088777	chr7:76043977~76045963:-
THYM	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
THYM	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
THYM	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
THYM	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
THYM	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
THYM	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
THYM	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
THYM	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	4.19	6.19e-05	0.0313	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
THYM	cis	rs10888838	1	rs6621	ENSG00000198711.5	SSBP3-AS1	4.19	6.19e-05	0.0313	0.27	0.4	Mitochondrial DNA levels;	chr1:54218252	chr1:54236440~54239063:+
THYM	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-4.19	6.19e-05	0.0313	-0.38	-0.4	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-4.19	6.19e-05	0.0313	-0.38	-0.4	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
THYM	cis	rs17772222	0.63	rs61977024	ENSG00000258983.2	RP11-507K2.2	4.19	6.19e-05	0.0313	0.46	0.4	Coronary artery calcification;	chr14:88335961	chr14:88499334~88515502:+
THYM	cis	rs7631605	0.935	rs9819025	ENSG00000272334.1	RP11-129K12.1	-4.19	6.19e-05	0.0313	-0.4	-0.4	Cerebrospinal P-tau181p levels;	chr3:37031796	chr3:36973117~36973672:-
THYM	cis	rs910316	1	rs175512	ENSG00000258646.1	RP11-950C14.3	4.19	6.19e-05	0.0313	0.37	0.4	Height;	chr14:75056679	chr14:75004719~75008481:-
THYM	cis	rs4842666	0.831	rs12230074	ENSG00000258302.2	RP11-981P6.1	4.19	6.2e-05	0.0313	0.44	0.4	Blood pressure;	chr12:89697090	chr12:89561129~89594878:+
THYM	cis	rs16949788	1	rs78288367	ENSG00000261351.2	CTD-3185P2.1	-4.19	6.2e-05	0.0313	-0.66	-0.4	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66480383	chr15:66488658~66492109:-
THYM	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	4.19	6.2e-05	0.0313	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
THYM	cis	rs10129255	0.879	rs7159254	ENSG00000254329.1	IGHVII-60-1	4.19	6.2e-05	0.0313	0.39	0.4	Kawasaki disease;	chr14:106701846	chr14:106637718~106637973:-
THYM	cis	rs9309473	0.519	rs6730785	ENSG00000163016.8	ALMS1P	-4.19	6.2e-05	0.0313	-0.48	-0.4	Metabolite levels;	chr2:73415275	chr2:73644919~73685576:+
THYM	cis	rs11098499	0.954	rs3733524	ENSG00000250412.1	KLHL2P1	4.19	6.22e-05	0.0313	0.38	0.4	Corneal astigmatism;	chr4:119502574	chr4:119334329~119378233:+
THYM	cis	rs11577318	0.853	rs4526602	ENSG00000225854.2	RP11-569G9.7	4.19	6.22e-05	0.0313	0.48	0.4	Granulocyte percentage of myeloid white cells;	chr1:26321543	chr1:26326688~26327033:+
THYM	cis	rs11157436	1	rs2293731	ENSG00000211812.1	TRAV26-2	-4.19	6.22e-05	0.0314	-0.26	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22202583~22203368:+
THYM	cis	rs2243480	0.522	rs431168	ENSG00000228409.4	CCT6P1	4.19	6.22e-05	0.0314	0.52	0.4	Diabetic kidney disease;	chr7:66046617	chr7:65751142~65763354:+
THYM	cis	rs465969	1	rs13208890	ENSG00000231889.6	TRAF3IP2-AS1	4.19	6.22e-05	0.0314	0.37	0.4	Psoriasis;	chr6:111500620	chr6:111483511~111598302:+
THYM	cis	rs465969	0.744	rs36007392	ENSG00000231889.6	TRAF3IP2-AS1	4.19	6.22e-05	0.0314	0.37	0.4	Psoriasis;	chr6:111509287	chr6:111483511~111598302:+
THYM	cis	rs465969	1	rs13197107	ENSG00000231889.6	TRAF3IP2-AS1	4.19	6.22e-05	0.0314	0.37	0.4	Psoriasis;	chr6:111512031	chr6:111483511~111598302:+
THYM	cis	rs465969	0.546	rs77990243	ENSG00000231889.6	TRAF3IP2-AS1	4.19	6.22e-05	0.0314	0.37	0.4	Psoriasis;	chr6:111513183	chr6:111483511~111598302:+
THYM	cis	rs465969	0.744	rs71562296	ENSG00000231889.6	TRAF3IP2-AS1	4.19	6.22e-05	0.0314	0.37	0.4	Psoriasis;	chr6:111521444	chr6:111483511~111598302:+
THYM	cis	rs465969	0.744	rs6939657	ENSG00000231889.6	TRAF3IP2-AS1	4.19	6.22e-05	0.0314	0.37	0.4	Psoriasis;	chr6:111521822	chr6:111483511~111598302:+
THYM	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	4.19	6.23e-05	0.0314	0.51	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
THYM	cis	rs7208859	0.573	rs8078182	ENSG00000266490.1	CTD-2349P21.9	4.19	6.24e-05	0.0314	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30792372~30792833:+
THYM	cis	rs972578	0.967	rs4822236	ENSG00000215347.3	SLC25A5P1	-4.19	6.24e-05	0.0314	-0.3	-0.4	Mean platelet volume;	chr22:42962082	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs1569509	ENSG00000215347.3	SLC25A5P1	-4.19	6.24e-05	0.0314	-0.3	-0.4	Mean platelet volume;	chr22:42963255	chr22:42001069~42001966:-
THYM	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-4.19	6.24e-05	0.0314	-0.62	-0.4	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
THYM	cis	rs10208649	0.611	rs1974771	ENSG00000272156.1	RP11-477N3.1	4.19	6.24e-05	0.0314	0.6	0.4	Body mass index;	chr2:54051406	chr2:54082554~54085066:+
THYM	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-4.19	6.25e-05	0.0315	-0.46	-0.4	Height;	chr6:109485060	chr6:109382795~109383666:+
THYM	cis	rs35888008	1	rs62029124	ENSG00000261267.1	RP11-44I10.3	4.19	6.25e-05	0.0315	0.53	0.4	Major depressive disorder;	chr16:49447980	chr16:48559661~48587403:+
THYM	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	4.19	6.26e-05	0.0315	0.25	0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
THYM	cis	rs7223966	0.961	rs35844156	ENSG00000240280.5	TCAM1P	-4.19	6.26e-05	0.0315	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63760208	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs78172786	ENSG00000240280.5	TCAM1P	-4.19	6.26e-05	0.0315	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63769754	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs11079511	ENSG00000240280.5	TCAM1P	-4.19	6.26e-05	0.0315	-0.6	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63781177	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs8076717	ENSG00000240280.5	TCAM1P	4.19	6.26e-05	0.0315	0.6	0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63772941	chr17:63849292~63864379:+
THYM	cis	rs950169	0.58	rs11634320	ENSG00000275120.1	RP11-182J1.17	-4.19	6.27e-05	0.0315	-0.53	-0.4	Schizophrenia;	chr15:84628952	chr15:84599434~84606463:-
THYM	cis	rs7412746	0.658	rs10305711	ENSG00000220323.3	HIST2H2BD	-4.19	6.27e-05	0.0316	-0.38	-0.4	Melanoma;	chr1:150830520	chr1:149843041~149843533:+
THYM	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	4.19	6.27e-05	0.0316	0.52	0.4	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
THYM	cis	rs863345	0.565	rs6679056	ENSG00000236656.1	RP11-144L1.4	4.19	6.27e-05	0.0316	0.25	0.4	Pneumococcal bacteremia;	chr1:158480524	chr1:158474454~158494886:-
THYM	cis	rs1642645	0.597	rs1011281	ENSG00000228452.1	RP5-994D16.9	4.19	6.28e-05	0.0316	0.55	0.4	Left ventricular obstructive tract defect (maternal effect);	chr1:42105163	chr1:42775813~42776790:-
THYM	cis	rs7223966	0.515	rs2727315	ENSG00000240280.5	TCAM1P	-4.19	6.28e-05	0.0316	-0.59	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63884098	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.921	rs2727300	ENSG00000240280.5	TCAM1P	-4.19	6.28e-05	0.0316	-0.59	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63888038	chr17:63849292~63864379:+
THYM	cis	rs2834288	0.535	rs881228	ENSG00000273102.1	AP000569.9	4.19	6.28e-05	0.0316	0.43	0.4	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.535	rs881229	ENSG00000273102.1	AP000569.9	4.19	6.28e-05	0.0316	0.43	0.4	Gut microbiota (bacterial taxa);	chr21:33950417	chr21:33967101~33968573:-
THYM	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
THYM	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
THYM	cis	rs7312933	0.558	rs1796382	ENSG00000257225.1	RP11-328C8.4	4.19	6.28e-05	0.0316	0.45	0.4	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42447153	chr12:42459366~42466128:+
THYM	cis	rs7927592	0.956	rs10896348	ENSG00000222339.1	AP000807.2	4.19	6.28e-05	0.0316	0.46	0.4	Total body bone mineral density;	chr11:68589900	chr11:68505572~68505651:-
THYM	cis	rs7210990	0.836	rs2157992	ENSG00000275413.1	CTC-529I10.1	4.19	6.28e-05	0.0316	0.38	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16025571	chr17:16023323~16023653:-
THYM	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
THYM	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
THYM	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
THYM	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
THYM	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
THYM	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
THYM	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
THYM	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	4.19	6.28e-05	0.0316	0.52	0.4	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
THYM	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-4.19	6.28e-05	0.0316	-0.45	-0.4	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
THYM	cis	rs11085466	0.615	rs76695906	ENSG00000268705.1	BNIP3P26	4.19	6.29e-05	0.0316	0.34	0.4	Colorectal or endometrial cancer;	chr19:21583908	chr19:21521343~21521896:-
THYM	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-4.19	6.29e-05	0.0316	-0.47	-0.4	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
THYM	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-4.19	6.29e-05	0.0316	-0.49	-0.4	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
THYM	cis	rs7208859	0.673	rs999798	ENSG00000266490.1	CTD-2349P21.9	4.19	6.3e-05	0.0317	0.63	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30792372~30792833:+
THYM	cis	rs4835473	0.8	rs1849134	ENSG00000249741.2	RP11-673E1.3	-4.19	6.3e-05	0.0317	-0.34	-0.4	Immature fraction of reticulocytes;	chr4:143958260	chr4:143911514~143912053:-
THYM	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	4.19	6.3e-05	0.0317	0.31	0.4	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	4.19	6.3e-05	0.0317	0.31	0.4	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	4.19	6.3e-05	0.0317	0.31	0.4	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	4.19	6.3e-05	0.0317	0.31	0.4	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
THYM	cis	rs597539	0.545	rs3794027	ENSG00000250508.1	RP11-757G1.6	-4.19	6.31e-05	0.0317	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68929868	chr11:68870664~68874542:+
THYM	cis	rs10938353	0.68	rs17654223	ENSG00000273369.1	RP11-700J17.1	4.19	6.31e-05	0.0317	0.54	0.4	Body mass index;	chr4:44741551	chr4:44693946~44694386:-
THYM	cis	rs10938353	0.68	rs66829609	ENSG00000273369.1	RP11-700J17.1	4.19	6.31e-05	0.0317	0.54	0.4	Body mass index;	chr4:44769814	chr4:44693946~44694386:-
THYM	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	4.19	6.32e-05	0.0317	0.59	0.4	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
THYM	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-4.19	6.32e-05	0.0318	-0.39	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
THYM	cis	rs910316	0.726	rs61979167	ENSG00000258646.1	RP11-950C14.3	4.19	6.32e-05	0.0318	0.35	0.4	Height;	chr14:75196907	chr14:75004719~75008481:-
THYM	cis	rs2283792	0.776	rs9610458	ENSG00000228050.1	TOP3BP1	4.19	6.33e-05	0.0318	0.42	0.4	Multiple sclerosis;	chr22:21851064	chr22:22223187~22224566:-
THYM	cis	rs2292342	1	rs2292342	ENSG00000232871.7	SEC1P	-4.19	6.33e-05	0.0318	-0.81	-0.4	Elevated serum carcinoembryonic antigen levels;	chr19:48615114	chr19:48638071~48682245:+
THYM	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-4.19	6.33e-05	0.0318	-0.51	-0.4	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
THYM	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-4.19	6.33e-05	0.0318	-0.38	-0.4	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
THYM	cis	rs7246967	0.551	rs75360744	ENSG00000198153.8	ZNF849P	-4.19	6.34e-05	0.0318	-0.55	-0.4	Bronchopulmonary dysplasia;	chr19:22675154	chr19:22685167~22686732:+
THYM	cis	rs12902680	0.706	rs2413805	ENSG00000259520.4	CTD-2651B20.3	4.19	6.34e-05	0.0318	0.41	0.4	Neuroticism;	chr15:46225085	chr15:45251580~45279251:-
THYM	cis	rs6442522	0.737	rs905640	ENSG00000249786.6	EAF1-AS1	4.19	6.34e-05	0.0319	0.43	0.4	Uric acid levels;	chr3:15454333	chr3:15436171~15455940:-
THYM	cis	rs34792	0.604	rs12148985	ENSG00000262380.1	CTB-193M12.3	4.19	6.34e-05	0.0319	0.5	0.4	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15493052	chr16:15683290~15684570:+
THYM	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	4.19	6.34e-05	0.0319	0.29	0.4	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
THYM	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-4.19	6.35e-05	0.0319	-0.45	-0.4	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-4.19	6.35e-05	0.0319	-0.45	-0.4	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-4.19	6.35e-05	0.0319	-0.45	-0.4	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
THYM	cis	rs8067545	0.611	rs2042046	ENSG00000231645.2	KRT17P6	-4.19	6.35e-05	0.0319	-0.47	-0.4	Schizophrenia;	chr17:20115528	chr17:20512560~20517479:-
THYM	cis	rs73198271	0.71	rs7837843	ENSG00000253893.2	FAM85B	4.19	6.35e-05	0.0319	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.64	rs7838012	ENSG00000253893.2	FAM85B	4.19	6.35e-05	0.0319	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8167819~8226614:-
THYM	cis	rs1584120	0.57	rs10842120	ENSG00000256321.4	RP11-153K16.1	4.19	6.35e-05	0.0319	0.43	0.4	Pelvic organ prolapse (moderate/severe);	chr12:23105069	chr12:23099368~23191587:+
THYM	cis	rs863345	0.604	rs10908666	ENSG00000236656.1	RP11-144L1.4	4.19	6.35e-05	0.0319	0.26	0.4	Pneumococcal bacteremia;	chr1:158530308	chr1:158474454~158494886:-
THYM	cis	rs863345	0.564	rs10908667	ENSG00000236656.1	RP11-144L1.4	4.19	6.35e-05	0.0319	0.26	0.4	Pneumococcal bacteremia;	chr1:158530331	chr1:158474454~158494886:-
THYM	cis	rs877819	0.583	rs2620887	ENSG00000228403.1	RP11-563N6.6	-4.19	6.35e-05	0.0319	-0.51	-0.4	Systemic lupus erythematosus;	chr10:48852457	chr10:48878022~48878649:+
THYM	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	4.19	6.35e-05	0.0319	0.46	0.4	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
THYM	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	4.19	6.35e-05	0.0319	0.5	0.4	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
THYM	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-4.19	6.36e-05	0.0319	-0.46	-0.4	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
THYM	cis	rs3781264	0.761	rs12781451	ENSG00000273450.1	RP11-76P2.4	4.19	6.36e-05	0.0319	0.48	0.4	Esophageal cancer and gastric cancer;	chr10:94324163	chr10:94314907~94315327:-
THYM	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-4.19	6.36e-05	0.0319	-0.4	-0.4	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-4.19	6.36e-05	0.0319	-0.4	-0.4	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-4.19	6.36e-05	0.0319	-0.4	-0.4	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
THYM	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-4.19	6.36e-05	0.0319	-0.4	-0.4	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
THYM	cis	rs7210990	0.866	rs7216834	ENSG00000275413.1	CTC-529I10.1	-4.19	6.36e-05	0.0319	-0.39	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16129451	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs4791662	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16105558	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.836	rs1126148	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16112265	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.831	rs35622628	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16116714	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs12150017	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16120780	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.831	rs11078332	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16122754	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs11650678	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16124713	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs11655773	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16126985	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs1160109	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16129818	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs9891646	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16133547	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.764	rs9907313	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16145776	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs178659	ENSG00000275413.1	CTC-529I10.1	4.19	6.36e-05	0.0319	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16153128	chr17:16023323~16023653:-
THYM	cis	rs4835473	0.864	rs56084830	ENSG00000251600.4	RP11-673E1.1	-4.19	6.36e-05	0.0319	-0.46	-0.4	Immature fraction of reticulocytes;	chr4:143791943	chr4:143912331~143982454:+
THYM	cis	rs9907295	0.901	rs11652536	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35891043	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs9789051	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35892000	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs3809769	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35892484	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs76016589	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35892923	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs4796124	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35893280	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs11656556	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35894090	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs11653204	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35894538	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.792	rs4796125	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35894847	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs74622050	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35895939	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs79730543	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35896537	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs4796127	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35899127	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs11868801	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35900047	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs4796130	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35904264	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.685	rs4796131	ENSG00000270977.1	AC015849.16	-4.19	6.36e-05	0.0319	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35904812	chr17:35893707~35911023:-
THYM	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	4.19	6.36e-05	0.0319	0.34	0.4	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
THYM	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-4.19	6.36e-05	0.0319	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
THYM	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-4.19	6.37e-05	0.0319	-0.4	-0.4	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
THYM	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	4.19	6.38e-05	0.032	0.51	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	4.19	6.38e-05	0.032	0.51	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	4.19	6.38e-05	0.032	0.51	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
THYM	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-4.19	6.38e-05	0.032	-0.48	-0.4	Pain;	chr19:21475141	chr19:21554640~21569237:-
THYM	cis	rs2841233	0.681	rs2841235	ENSG00000258811.1	CTD-3051D23.1	4.19	6.38e-05	0.032	0.38	0.4	IgG glycosylation;	chr14:104882396	chr14:104842663~104845916:+
THYM	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	4.19	6.38e-05	0.032	0.37	0.4	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
THYM	cis	rs9949617	0.663	rs1276322	ENSG00000265943.1	RP11-739L10.1	4.19	6.39e-05	0.032	0.69	0.4	Hypertriglyceridemia;	chr18:23341165	chr18:22699481~22933764:-
THYM	cis	rs7560272	0.538	rs12619258	ENSG00000163016.8	ALMS1P	-4.19	6.39e-05	0.032	-0.52	-0.4	Schizophrenia;	chr2:73708788	chr2:73644919~73685576:+
THYM	cis	rs13179411	0.517	rs35096828	ENSG00000247627.2	MTND4P12	4.19	6.39e-05	0.032	0.53	0.4	Menarche (age at onset);	chr5:134561749	chr5:134926660~134928036:-
THYM	cis	rs13179411	0.517	rs10056247	ENSG00000247627.2	MTND4P12	4.19	6.39e-05	0.032	0.53	0.4	Menarche (age at onset);	chr5:134562446	chr5:134926660~134928036:-
THYM	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-4.19	6.4e-05	0.0321	-0.52	-0.4	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
THYM	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-4.19	6.4e-05	0.0321	-0.52	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
THYM	cis	rs7631605	0.905	rs9822082	ENSG00000272334.1	RP11-129K12.1	-4.19	6.41e-05	0.0321	-0.4	-0.4	Cerebrospinal P-tau181p levels;	chr3:37044713	chr3:36973117~36973672:-
THYM	cis	rs12902680	0.706	rs4337244	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46221124	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs8038453	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46227394	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12902287	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46230642	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28610582	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232174	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12913250	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232445	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.704	rs12913402	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232460	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12913410	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232470	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1560938	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232666	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1560937	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232714	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.674	rs1560936	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232715	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1560935	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232748	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1560933	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46232954	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs7162332	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46233631	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs7183216	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46233645	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1594905	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46233743	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28846506	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46234362	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12905547	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46234938	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12910424	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46235479	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12442584	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46236133	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12439680	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46236193	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs11070495	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46236393	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs11070496	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46236454	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs11070497	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46236627	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs2012440	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46237464	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs959373	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46237528	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12440517	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46238949	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12440519	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46238976	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12898547	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46239032	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12101942	ENSG00000259520.4	CTD-2651B20.3	4.19	6.41e-05	0.0321	0.41	0.4	Neuroticism;	chr15:46239828	chr15:45251580~45279251:-
THYM	cis	rs6121246	0.609	rs6060627	ENSG00000230613.1	HM13-AS1	4.18	6.42e-05	0.0321	0.53	0.4	Mean corpuscular hemoglobin;	chr20:31674356	chr20:31567707~31573263:-
THYM	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	4.18	6.42e-05	0.0321	0.47	0.4	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
THYM	cis	rs11633886	0.565	rs1402164	ENSG00000273972.1	CTD-2306A12.1	4.18	6.42e-05	0.0321	0.49	0.4	Diisocyanate-induced asthma;	chr15:45779974	chr15:45702640~45703183:+
THYM	cis	rs897984	0.684	rs6950	ENSG00000275263.1	RP11-1072A3.4	4.18	6.42e-05	0.0321	0.35	0.4	Dementia with Lewy bodies;	chr16:30984348	chr16:30956872~30957199:-
THYM	cis	rs897984	0.645	rs9938550	ENSG00000275263.1	RP11-1072A3.4	4.18	6.42e-05	0.0321	0.35	0.4	Dementia with Lewy bodies;	chr16:30987821	chr16:30956872~30957199:-
THYM	cis	rs897984	0.762	rs2305880	ENSG00000275263.1	RP11-1072A3.4	4.18	6.42e-05	0.0321	0.35	0.4	Dementia with Lewy bodies;	chr16:30988141	chr16:30956872~30957199:-
THYM	cis	rs897984	0.759	rs13708	ENSG00000275263.1	RP11-1072A3.4	4.18	6.42e-05	0.0321	0.35	0.4	Dementia with Lewy bodies;	chr16:30989488	chr16:30956872~30957199:-
THYM	cis	rs7246967	0.611	rs3931771	ENSG00000198153.8	ZNF849P	-4.18	6.42e-05	0.0321	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22714018	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.604	rs8107322	ENSG00000198153.8	ZNF849P	-4.18	6.42e-05	0.0321	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22714630	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7247191	ENSG00000198153.8	ZNF849P	-4.18	6.42e-05	0.0321	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22716783	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34425596	ENSG00000198153.8	ZNF849P	-4.18	6.42e-05	0.0321	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22716977	chr19:22685167~22686732:+
THYM	cis	rs7560272	0.723	rs1083919	ENSG00000273245.1	RP11-434P11.2	-4.18	6.43e-05	0.0322	-0.44	-0.4	Schizophrenia;	chr2:73486736	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	4.18	6.43e-05	0.0322	0.54	0.4	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
THYM	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-4.18	6.43e-05	0.0322	-0.52	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-4.18	6.43e-05	0.0322	-0.52	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
THYM	cis	rs7927592	0.913	rs10896329	ENSG00000222339.1	AP000807.2	4.18	6.43e-05	0.0322	0.51	0.4	Total body bone mineral density;	chr11:68482561	chr11:68505572~68505651:-
THYM	cis	rs12364620	1	rs12364620	ENSG00000222339.1	AP000807.2	4.18	6.43e-05	0.0322	0.51	0.4	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68505572~68505651:-
THYM	cis	rs853679	0.76	rs9357067	ENSG00000216901.1	AL022393.7	4.18	6.43e-05	0.0322	0.68	0.4	Depression;	chr6:28242515	chr6:28176188~28176674:+
THYM	cis	rs853679	0.76	rs967005	ENSG00000216901.1	AL022393.7	4.18	6.43e-05	0.0322	0.68	0.4	Depression;	chr6:28242910	chr6:28176188~28176674:+
THYM	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	4.18	6.44e-05	0.0322	0.36	0.4	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
THYM	cis	rs4352210	0.519	rs765372	ENSG00000236213.1	AC006369.2	4.18	6.44e-05	0.0322	0.43	0.4	RR interval (heart rate);	chr2:37582383	chr2:37600136~37646698:+
THYM	cis	rs10129255	0.957	rs28887506	ENSG00000253703.1	IGHV1-68	-4.18	6.45e-05	0.0323	-0.51	-0.4	Kawasaki disease;	chr14:106785589	chr14:106703852~106704146:-
THYM	cis	rs35888008	1	rs4785296	ENSG00000261267.1	RP11-44I10.3	4.18	6.45e-05	0.0323	0.51	0.4	Major depressive disorder;	chr16:49433323	chr16:48559661~48587403:+
THYM	cis	rs35888008	1	rs4785297	ENSG00000261267.1	RP11-44I10.3	4.18	6.45e-05	0.0323	0.51	0.4	Major depressive disorder;	chr16:49433720	chr16:48559661~48587403:+
THYM	cis	rs35888008	1	rs35888008	ENSG00000261267.1	RP11-44I10.3	4.18	6.45e-05	0.0323	0.51	0.4	Major depressive disorder;	chr16:49443361	chr16:48559661~48587403:+
THYM	cis	rs828999	0.715	rs11185295	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108168452	chr1:108200413~108202743:+
THYM	cis	rs828999	0.688	rs10218769	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108170622	chr1:108200413~108202743:+
THYM	cis	rs828999	0.628	rs10218750	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108170694	chr1:108200413~108202743:+
THYM	cis	rs828999	0.688	rs1340532	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108172389	chr1:108200413~108202743:+
THYM	cis	rs828999	0.642	rs10881512	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108175437	chr1:108200413~108202743:+
THYM	cis	rs828999	0.688	rs10881513	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108176577	chr1:108200413~108202743:+
THYM	cis	rs828999	0.715	rs34406538	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108176846	chr1:108200413~108202743:+
THYM	cis	rs828999	0.688	rs2053433	ENSG00000280186.1	RP11-483I13.6	-4.18	6.45e-05	0.0323	-0.47	-0.4	Monocyte percentage of white cells;	chr1:108181438	chr1:108200413~108202743:+
THYM	cis	rs1950357	0.589	rs1033593	ENSG00000258601.1	RP11-81F13.2	4.18	6.46e-05	0.0323	0.39	0.4	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36742280	chr14:36808871~36828729:+
THYM	cis	rs1950357	0.589	rs2064548	ENSG00000258601.1	RP11-81F13.2	4.18	6.46e-05	0.0323	0.39	0.4	Lobe attachment (rater-scored or self-reported);Lobe attachment (rater scored);	chr14:36743852	chr14:36808871~36828729:+
THYM	cis	rs10799445	0.508	rs10916179	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Height;	chr1:227630495	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.568	rs10799431	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Height;	chr1:227631423	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.547	rs10799432	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Height;	chr1:227632059	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.547	rs2093609	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Height;	chr1:227633282	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs2093610	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227633345	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs10916182	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227634239	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs10916183	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Height;	chr1:227634583	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs10916184	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227634684	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.5	rs10916185	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227634997	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.5	rs10799434	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227635214	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.5	rs10916187	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227635217	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.527	rs10799435	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Height;	chr1:227636221	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs6671825	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227677737	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs1407718	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227691562	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs11484723	ENSG00000227711.2	RP11-275O4.5	-4.18	6.46e-05	0.0323	-0.34	-0.4	Hip circumference adjusted for BMI;	chr1:227715357	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs1323022	ENSG00000227711.2	RP11-275O4.5	4.18	6.46e-05	0.0323	0.34	0.4	Hip circumference adjusted for BMI;	chr1:227688435	chr1:227509028~227520477:-
THYM	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-4.18	6.46e-05	0.0323	-0.5	-0.4	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	4.18	6.46e-05	0.0323	0.5	0.4	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	4.18	6.46e-05	0.0323	0.5	0.4	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
THYM	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	4.18	6.46e-05	0.0323	0.53	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
THYM	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	4.18	6.46e-05	0.0323	0.53	0.4	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
THYM	cis	rs3738443	0.599	rs6693807	ENSG00000227671.4	RP11-488L18.4	4.18	6.47e-05	0.0323	0.22	0.4	Alcohol dependence;	chr1:247230353	chr1:247189851~247210856:-
THYM	cis	rs7210990	0.766	rs12942295	ENSG00000275413.1	CTC-529I10.1	4.18	6.47e-05	0.0323	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16070530	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.836	rs9891379	ENSG00000275413.1	CTC-529I10.1	4.18	6.47e-05	0.0323	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16073244	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.836	rs9898313	ENSG00000275413.1	CTC-529I10.1	4.18	6.47e-05	0.0323	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16073818	chr17:16023323~16023653:-
THYM	cis	rs7560272	0.723	rs4346412	ENSG00000273245.1	RP11-434P11.2	4.18	6.48e-05	0.0324	0.43	0.4	Schizophrenia;	chr2:73616444	chr2:73750256~73750786:-
THYM	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	4.18	6.48e-05	0.0324	0.34	0.4	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
THYM	cis	rs10129255	1	rs10129319	ENSG00000254329.1	IGHVII-60-1	4.18	6.49e-05	0.0324	0.4	0.4	Kawasaki disease;	chr14:106767996	chr14:106637718~106637973:-
THYM	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	4.18	6.49e-05	0.0324	0.4	0.4	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
THYM	cis	rs17023900	0.588	rs79844519	ENSG00000281392.1	LINC00506	-4.18	6.49e-05	0.0324	-0.47	-0.4	Prostate cancer;	chr3:87089281	chr3:87089129~87157069:+
THYM	cis	rs7116495	0.786	rs1892919	ENSG00000248671.6	ALG1L9P	-4.18	6.49e-05	0.0324	-0.96	-0.4	Severe influenza A (H1N1) infection;	chr11:72001129	chr11:71794363~71818238:-
THYM	cis	rs7210990	0.866	rs11872032	ENSG00000275413.1	CTC-529I10.1	4.18	6.49e-05	0.0324	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16094459	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs7207889	ENSG00000275413.1	CTC-529I10.1	4.18	6.49e-05	0.0324	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16101054	chr17:16023323~16023653:-
THYM	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-4.18	6.49e-05	0.0324	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
THYM	cis	rs12902680	0.706	rs11070499	ENSG00000259520.4	CTD-2651B20.3	4.18	6.49e-05	0.0324	0.41	0.4	Neuroticism;	chr15:46246527	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs1836303	ENSG00000259520.4	CTD-2651B20.3	4.18	6.49e-05	0.0324	0.41	0.4	Neuroticism;	chr15:46246918	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12903920	ENSG00000259520.4	CTD-2651B20.3	4.18	6.49e-05	0.0324	0.41	0.4	Neuroticism;	chr15:46247174	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.644	rs12437536	ENSG00000259520.4	CTD-2651B20.3	4.18	6.49e-05	0.0324	0.41	0.4	Neuroticism;	chr15:46247625	chr15:45251580~45279251:-
THYM	cis	rs9879311	0.966	rs775018	ENSG00000240288.6	GHRLOS	4.18	6.49e-05	0.0324	0.41	0.4	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358461	chr3:10285754~10293449:+
THYM	cis	rs4835473	0.832	rs35398499	ENSG00000249741.2	RP11-673E1.3	4.18	6.5e-05	0.0324	0.34	0.4	Immature fraction of reticulocytes;	chr4:143737715	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.832	rs35763177	ENSG00000249741.2	RP11-673E1.3	4.18	6.5e-05	0.0324	0.34	0.4	Immature fraction of reticulocytes;	chr4:143737717	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.808	rs2060652	ENSG00000249741.2	RP11-673E1.3	4.18	6.5e-05	0.0324	0.34	0.4	Immature fraction of reticulocytes;	chr4:143739129	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs2060654	ENSG00000249741.2	RP11-673E1.3	4.18	6.5e-05	0.0324	0.34	0.4	Immature fraction of reticulocytes;	chr4:143739155	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2060655	ENSG00000249741.2	RP11-673E1.3	4.18	6.5e-05	0.0324	0.34	0.4	Immature fraction of reticulocytes;	chr4:143739159	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2060656	ENSG00000249741.2	RP11-673E1.3	4.18	6.5e-05	0.0324	0.34	0.4	Immature fraction of reticulocytes;	chr4:143739330	chr4:143911514~143912053:-
THYM	cis	rs9907295	1	rs9913488	ENSG00000270977.1	AC015849.16	-4.18	6.5e-05	0.0324	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs9912571	ENSG00000270977.1	AC015849.16	-4.18	6.5e-05	0.0324	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs9912793	ENSG00000270977.1	AC015849.16	-4.18	6.5e-05	0.0324	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs11655533	ENSG00000270977.1	AC015849.16	-4.18	6.5e-05	0.0324	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs9908011	ENSG00000270977.1	AC015849.16	-4.18	6.5e-05	0.0324	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35908371	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs9908525	ENSG00000270977.1	AC015849.16	-4.18	6.5e-05	0.0324	-0.66	-0.4	Fibroblast growth factor basic levels;	chr17:35908605	chr17:35893707~35911023:-
THYM	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	4.18	6.5e-05	0.0324	0.6	0.4	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
THYM	cis	rs1474476	1	rs6572278	ENSG00000211790.2	TRAV8-4	-4.18	6.5e-05	0.0324	-0.42	-0.4	Obesity-related traits;	chr14:22129373	chr14:21894433~21895030:+
THYM	cis	rs1474476	1	rs8010123	ENSG00000211790.2	TRAV8-4	-4.18	6.5e-05	0.0324	-0.42	-0.4	Obesity-related traits;	chr14:22134236	chr14:21894433~21895030:+
THYM	cis	rs1474476	0.935	rs2178787	ENSG00000211790.2	TRAV8-4	-4.18	6.5e-05	0.0324	-0.42	-0.4	Obesity-related traits;	chr14:22136460	chr14:21894433~21895030:+
THYM	cis	rs1474476	0.877	rs7151544	ENSG00000211790.2	TRAV8-4	-4.18	6.5e-05	0.0324	-0.42	-0.4	Obesity-related traits;	chr14:22139457	chr14:21894433~21895030:+
THYM	cis	rs1474476	1	rs1474476	ENSG00000211790.2	TRAV8-4	-4.18	6.5e-05	0.0324	-0.42	-0.4	Obesity-related traits;	chr14:22139542	chr14:21894433~21895030:+
THYM	cis	rs1474476	1	rs4517706	ENSG00000211790.2	TRAV8-4	4.18	6.5e-05	0.0324	0.42	0.4	Obesity-related traits;	chr14:22137787	chr14:21894433~21895030:+
THYM	cis	rs12902680	0.706	rs8041616	ENSG00000259520.4	CTD-2651B20.3	4.18	6.5e-05	0.0324	0.4	0.4	Neuroticism;	chr15:46217783	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs28412653	ENSG00000259520.4	CTD-2651B20.3	4.18	6.5e-05	0.0324	0.4	0.4	Neuroticism;	chr15:46218027	chr15:45251580~45279251:-
THYM	cis	rs910316	0.875	rs12588099	ENSG00000258646.1	RP11-950C14.3	-4.18	6.5e-05	0.0324	-0.37	-0.4	Height;	chr14:75127759	chr14:75004719~75008481:-
THYM	cis	rs7560272	0.723	rs4346412	ENSG00000163016.8	ALMS1P	4.18	6.5e-05	0.0324	0.45	0.4	Schizophrenia;	chr2:73616444	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.519	rs1881246	ENSG00000273245.1	RP11-434P11.2	-4.18	6.51e-05	0.0325	-0.44	-0.4	Metabolite levels;	chr2:73422994	chr2:73750256~73750786:-
THYM	cis	rs7210990	0.836	rs8080706	ENSG00000275413.1	CTC-529I10.1	4.18	6.51e-05	0.0325	0.39	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16088246	chr17:16023323~16023653:-
THYM	cis	rs7223966	1	rs56057198	ENSG00000240280.5	TCAM1P	-4.18	6.51e-05	0.0325	-0.62	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63655972	chr17:63849292~63864379:+
THYM	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	4.18	6.51e-05	0.0325	0.5	0.4	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	4.18	6.51e-05	0.0325	0.5	0.4	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
THYM	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	4.18	6.52e-05	0.0325	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
THYM	cis	rs495337	0.76	rs615868	ENSG00000229222.1	KRT18P4	-4.18	6.52e-05	0.0325	-0.47	-0.4	Psoriasis;	chr20:49902687	chr20:49956745~49958032:+
THYM	cis	rs7976269	0.537	rs10843308	ENSG00000275476.1	RP11-996F15.4	-4.18	6.52e-05	0.0325	-0.44	-0.4	Male-pattern baldness;	chr12:29075172	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10771478	ENSG00000275476.1	RP11-996F15.4	4.18	6.52e-05	0.0325	0.44	0.4	Male-pattern baldness;	chr12:29075351	chr12:29277397~29277882:-
THYM	cis	rs12902680	0.816	rs7165004	ENSG00000259520.4	CTD-2651B20.3	4.18	6.52e-05	0.0325	0.41	0.4	Neuroticism;	chr15:46038844	chr15:45251580~45279251:-
THYM	cis	rs6696239	0.513	rs10495276	ENSG00000227711.2	RP11-275O4.5	4.18	6.52e-05	0.0325	0.35	0.4	Height;	chr1:227549245	chr1:227509028~227520477:-
THYM	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-4.18	6.52e-05	0.0325	-0.39	-0.4	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
THYM	cis	rs7976269	0.609	rs10771474	ENSG00000275476.1	RP11-996F15.4	4.18	6.52e-05	0.0325	0.46	0.4	Male-pattern baldness;	chr12:29068776	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10771475	ENSG00000275476.1	RP11-996F15.4	-4.18	6.52e-05	0.0325	-0.46	-0.4	Male-pattern baldness;	chr12:29071077	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10843305	ENSG00000275476.1	RP11-996F15.4	-4.18	6.52e-05	0.0325	-0.46	-0.4	Male-pattern baldness;	chr12:29073147	chr12:29277397~29277882:-
THYM	cis	rs7976269	0.609	rs10843306	ENSG00000275476.1	RP11-996F15.4	-4.18	6.52e-05	0.0325	-0.46	-0.4	Male-pattern baldness;	chr12:29073417	chr12:29277397~29277882:-
THYM	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-4.18	6.53e-05	0.0325	-0.52	-0.4	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
THYM	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-4.18	6.53e-05	0.0325	-0.52	-0.4	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
THYM	cis	rs7631605	0.935	rs963078	ENSG00000272334.1	RP11-129K12.1	-4.18	6.53e-05	0.0326	-0.41	-0.4	Cerebrospinal P-tau181p levels;	chr3:37179018	chr3:36973117~36973672:-
THYM	cis	rs10740039	1	rs10740039	ENSG00000254271.1	RP11-131N11.4	4.18	6.53e-05	0.0326	0.44	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654924	chr10:60734342~60741828:+
THYM	cis	rs853679	0.55	rs1237875	ENSG00000182477.5	OR2B8P	-4.18	6.54e-05	0.0326	-0.54	-0.4	Depression;	chr6:28205232	chr6:28053228~28054165:-
THYM	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-4.18	6.54e-05	0.0326	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
THYM	cis	rs11098499	0.863	rs3822194	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119550493	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3822195	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119550505	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775854	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119550816	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs11947234	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119553704	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs6853998	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119554705	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs6858777	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119554811	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs11933966	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119555560	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs36040693	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119556461	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs11731756	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119557541	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs34308924	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119560276	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs2170276	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119564669	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1552092	ENSG00000250412.1	KLHL2P1	4.18	6.54e-05	0.0326	0.37	0.4	Corneal astigmatism;	chr4:119567341	chr4:119334329~119378233:+
THYM	cis	rs12049671	1	rs12414855	ENSG00000227076.1	RP11-4C20.4	4.18	6.55e-05	0.0326	0.65	0.4	Response to amphetamines;	chr10:127943116	chr10:127934698~127936167:+
THYM	cis	rs12049671	1	rs12414312	ENSG00000227076.1	RP11-4C20.4	4.18	6.55e-05	0.0326	0.65	0.4	Response to amphetamines;	chr10:127943195	chr10:127934698~127936167:+
THYM	cis	rs12049671	1	rs12414866	ENSG00000227076.1	RP11-4C20.4	4.18	6.55e-05	0.0326	0.65	0.4	Response to amphetamines;	chr10:127943241	chr10:127934698~127936167:+
THYM	cis	rs12049671	1	rs55831625	ENSG00000227076.1	RP11-4C20.4	4.18	6.55e-05	0.0326	0.65	0.4	Response to amphetamines;	chr10:127945799	chr10:127934698~127936167:+
THYM	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-4.18	6.55e-05	0.0326	-0.42	-0.4	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
THYM	cis	rs7223966	1	rs2665826	ENSG00000240280.5	TCAM1P	-4.18	6.56e-05	0.0326	-0.59	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63867564	chr17:63849292~63864379:+
THYM	cis	rs394563	0.81	rs480870	ENSG00000219487.2	RP11-365H23.1	4.18	6.56e-05	0.0326	0.46	0.4	Dupuytren's disease;	chr6:149463682	chr6:149112009~149112672:-
THYM	cis	rs394563	0.775	rs420430	ENSG00000219487.2	RP11-365H23.1	4.18	6.56e-05	0.0326	0.46	0.4	Dupuytren's disease;	chr6:149464403	chr6:149112009~149112672:-
THYM	cis	rs394563	0.775	rs448420	ENSG00000219487.2	RP11-365H23.1	4.18	6.56e-05	0.0326	0.46	0.4	Dupuytren's disease;	chr6:149464666	chr6:149112009~149112672:-
THYM	cis	rs1595825	0.891	rs7595819	ENSG00000222017.1	AC011997.1	4.18	6.56e-05	0.0327	0.44	0.4	Ulcerative colitis;	chr2:197678432	chr2:197693106~197774823:+
THYM	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	4.18	6.57e-05	0.0327	0.5	0.4	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
THYM	cis	rs1790761	0.692	rs1148883	ENSG00000231793.4	DOC2GP	-4.18	6.57e-05	0.0327	-0.37	-0.4	Mean corpuscular volume;	chr11:67537215	chr11:67612653~67616257:-
THYM	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-4.18	6.57e-05	0.0327	-0.41	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
THYM	cis	rs2342371	0.539	rs35959625	ENSG00000224769.1	AC069213.1	-4.18	6.58e-05	0.0327	-0.46	-0.4	Fat distribution (HIV);	chr3:196405070	chr3:195614947~195620233:+
THYM	cis	rs8062405	0.757	rs34835	ENSG00000259982.1	CDC37P1	4.18	6.58e-05	0.0328	0.49	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28487970	chr16:28700294~28701540:-
THYM	cis	rs9309473	0.539	rs6745560	ENSG00000273245.1	RP11-434P11.2	4.18	6.59e-05	0.0328	0.44	0.4	Metabolite levels;	chr2:73599990	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.723	rs780395	ENSG00000273245.1	RP11-434P11.2	-4.18	6.59e-05	0.0328	-0.44	-0.4	Schizophrenia;	chr2:73473726	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.695	rs780394	ENSG00000273245.1	RP11-434P11.2	-4.18	6.59e-05	0.0328	-0.44	-0.4	Schizophrenia;	chr2:73473803	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.723	rs1083923	ENSG00000273245.1	RP11-434P11.2	-4.18	6.59e-05	0.0328	-0.44	-0.4	Schizophrenia;	chr2:73476247	chr2:73750256~73750786:-
THYM	cis	rs9309473	0.519	rs1083922	ENSG00000273245.1	RP11-434P11.2	-4.18	6.59e-05	0.0328	-0.44	-0.4	Metabolite levels;	chr2:73476876	chr2:73750256~73750786:-
THYM	cis	rs6121246	0.512	rs6058384	ENSG00000230613.1	HM13-AS1	4.18	6.59e-05	0.0328	0.55	0.4	Mean corpuscular hemoglobin;	chr20:31688606	chr20:31567707~31573263:-
THYM	cis	rs7223966	1	rs7220892	ENSG00000240280.5	TCAM1P	-4.18	6.6e-05	0.0328	-0.57	-0.4	Hip circumference adjusted for BMI;Body mass index;	chr17:63830956	chr17:63849292~63864379:+
THYM	cis	rs7246967	0.611	rs7246424	ENSG00000198153.8	ZNF849P	-4.18	6.6e-05	0.0328	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22699383	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7249685	ENSG00000198153.8	ZNF849P	-4.18	6.6e-05	0.0328	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22699577	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs7249003	ENSG00000198153.8	ZNF849P	-4.18	6.6e-05	0.0328	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22705132	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs12971914	ENSG00000198153.8	ZNF849P	-4.18	6.6e-05	0.0328	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22706096	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs8105441	ENSG00000198153.8	ZNF849P	-4.18	6.6e-05	0.0328	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22708664	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs8112442	ENSG00000198153.8	ZNF849P	-4.18	6.6e-05	0.0328	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22710567	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs73022763	ENSG00000198153.8	ZNF849P	-4.18	6.6e-05	0.0328	-0.53	-0.4	Bronchopulmonary dysplasia;	chr19:22711414	chr19:22685167~22686732:+
THYM	cis	rs3753275	0.624	rs6577525	ENSG00000230679.1	ENO1-AS1	-4.18	6.61e-05	0.0328	-0.47	-0.4	Educational attainment;	chr1:8797045	chr1:8878835~8879894:+
THYM	cis	rs3753275	0.624	rs6577523	ENSG00000230679.1	ENO1-AS1	4.18	6.61e-05	0.0328	0.47	0.4	Educational attainment;	chr1:8776391	chr1:8878835~8879894:+
THYM	cis	rs7631605	0.875	rs28754348	ENSG00000272334.1	RP11-129K12.1	-4.18	6.61e-05	0.0329	-0.41	-0.4	Cerebrospinal P-tau181p levels;	chr3:37022237	chr3:36973117~36973672:-
THYM	cis	rs8035957	0.564	rs17651741	ENSG00000259747.1	RP11-275I4.2	-4.18	6.62e-05	0.0329	-0.51	-0.4	Type 1 diabetes;	chr15:38577465	chr15:38671847~38689191:+
THYM	cis	rs12304921	0.748	rs73090630	ENSG00000277201.1	AC087884.1	4.18	6.63e-05	0.0329	0.39	0.4	Type 2 diabetes;	chr12:50942030	chr12:51049921~51050025:+
THYM	cis	rs12304921	0.872	rs4768869	ENSG00000277201.1	AC087884.1	4.18	6.63e-05	0.0329	0.39	0.4	Type 2 diabetes;	chr12:50953246	chr12:51049921~51050025:+
THYM	cis	rs12304921	0.81	rs73090660	ENSG00000277201.1	AC087884.1	4.18	6.63e-05	0.0329	0.39	0.4	Type 2 diabetes;	chr12:50961378	chr12:51049921~51050025:+
THYM	cis	rs12304921	0.81	rs73090661	ENSG00000277201.1	AC087884.1	4.18	6.63e-05	0.0329	0.39	0.4	Type 2 diabetes;	chr12:50961459	chr12:51049921~51050025:+
THYM	cis	rs12304921	0.748	rs61005916	ENSG00000277201.1	AC087884.1	4.18	6.63e-05	0.0329	0.39	0.4	Type 2 diabetes;	chr12:50964163	chr12:51049921~51050025:+
THYM	cis	rs12304921	0.81	rs73092534	ENSG00000277201.1	AC087884.1	4.18	6.63e-05	0.0329	0.39	0.4	Type 2 diabetes;	chr12:50964597	chr12:51049921~51050025:+
THYM	cis	rs12304921	0.688	rs79111258	ENSG00000277201.1	AC087884.1	4.18	6.63e-05	0.0329	0.39	0.4	Type 2 diabetes;	chr12:50968095	chr12:51049921~51050025:+
THYM	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	4.18	6.63e-05	0.0329	0.48	0.4	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
THYM	cis	rs9467773	0.595	rs13207371	ENSG00000261353.1	CTA-14H9.5	-4.18	6.63e-05	0.0329	-0.3	-0.4	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26527063~26527404:+
THYM	cis	rs73198271	0.71	rs3827808	ENSG00000253893.2	FAM85B	4.18	6.63e-05	0.033	0.58	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8167819~8226614:-
THYM	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	4.18	6.63e-05	0.033	0.49	0.4	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
THYM	cis	rs9549367	0.756	rs9549702	ENSG00000269125.1	RP11-98F14.11	-4.18	6.64e-05	0.033	-0.48	-0.4	Platelet distribution width;	chr13:113227630	chr13:113165002~113165183:-
THYM	cis	rs6782228	0.675	rs2253151	ENSG00000277250.1	Metazoa_SRP	-4.18	6.65e-05	0.033	-0.54	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128673681~128674021:-
THYM	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-4.18	6.65e-05	0.033	-0.48	-0.4	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
THYM	cis	rs7631605	0.905	rs9852386	ENSG00000272334.1	RP11-129K12.1	-4.17	6.66e-05	0.033	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37180838	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6773752	ENSG00000272334.1	RP11-129K12.1	-4.17	6.66e-05	0.033	-0.42	-0.4	Cerebrospinal P-tau181p levels;	chr3:37184346	chr3:36973117~36973672:-
THYM	cis	rs1426063	0.748	rs7654088	ENSG00000248165.1	RP11-44F21.2	-4.17	6.66e-05	0.0331	-0.57	-0.4	QT interval;	chr4:75107103	chr4:74993877~75034824:-
THYM	cis	rs888468	0.962	rs7131828	ENSG00000255920.1	CCND2-AS2	-4.17	6.66e-05	0.0331	-0.34	-0.4	Response to cytadine analogues (cytosine arabinoside);	chr12:4423804	chr12:4252735~4275065:-
THYM	cis	rs888468	1	rs888468	ENSG00000255920.1	CCND2-AS2	-4.17	6.66e-05	0.0331	-0.34	-0.4	Response to cytadine analogues (cytosine arabinoside);	chr12:4424213	chr12:4252735~4275065:-
THYM	cis	rs11098499	0.863	rs1010740	ENSG00000250412.1	KLHL2P1	-4.17	6.66e-05	0.0331	-0.37	-0.4	Corneal astigmatism;	chr4:119542254	chr4:119334329~119378233:+
THYM	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-4.17	6.66e-05	0.0331	-0.49	-0.4	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
THYM	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	4.17	6.67e-05	0.0331	0.46	0.4	Height;	chr6:109332622	chr6:109382795~109383666:+
THYM	cis	rs12902680	0.706	rs12439490	ENSG00000259520.4	CTD-2651B20.3	4.17	6.68e-05	0.0331	0.42	0.4	Neuroticism;	chr15:46186744	chr15:45251580~45279251:-
THYM	cis	rs7631605	0.905	rs7615363	ENSG00000272334.1	RP11-129K12.1	-4.17	6.68e-05	0.0332	-0.41	-0.4	Cerebrospinal P-tau181p levels;	chr3:36964771	chr3:36973117~36973672:-
THYM	cis	rs910316	1	rs8017642	ENSG00000258646.1	RP11-950C14.3	-4.17	6.68e-05	0.0332	-0.36	-0.4	Height;	chr14:75124119	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4903284	ENSG00000258646.1	RP11-950C14.3	-4.17	6.68e-05	0.0332	-0.36	-0.4	Height;	chr14:75125780	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs12890371	ENSG00000258646.1	RP11-950C14.3	-4.17	6.68e-05	0.0332	-0.36	-0.4	Height;	chr14:75127136	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12889309	ENSG00000258646.1	RP11-950C14.3	-4.17	6.68e-05	0.0332	-0.36	-0.4	Height;	chr14:75127199	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4899546	ENSG00000258646.1	RP11-950C14.3	-4.17	6.68e-05	0.0332	-0.36	-0.4	Height;	chr14:75128243	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs2024653	ENSG00000258646.1	RP11-950C14.3	-4.17	6.68e-05	0.0332	-0.36	-0.4	Height;	chr14:75128451	chr14:75004719~75008481:-
THYM	cis	rs910316	0.935	rs3742771	ENSG00000258646.1	RP11-950C14.3	-4.17	6.68e-05	0.0332	-0.36	-0.4	Height;	chr14:75132944	chr14:75004719~75008481:-
THYM	cis	rs807029	0.533	rs67813203	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs67692077	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs12571302	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs2295716	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs722435	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs2863095	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs3740490	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs11190786	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs7902510	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs7903239	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100412934~100413421:+
THYM	cis	rs807029	0.544	rs55646950	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs750866	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs701834	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs701835	ENSG00000273030.1	RP11-285F16.1	-4.17	6.69e-05	0.0332	-0.47	-0.4	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100412934~100413421:+
THYM	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-4.17	6.69e-05	0.0332	-0.42	-0.4	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
THYM	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-4.17	6.69e-05	0.0332	-0.39	-0.4	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
THYM	cis	rs910316	1	rs3742780	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75038305	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12879542	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75040822	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4903275	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75045806	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10140851	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75045909	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs7303	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75053362	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10143132	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75059147	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10873275	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75064757	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs7156328	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75066238	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs7156105	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75075251	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12889472	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75077276	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12589815	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75077398	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12589876	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75077486	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs10246	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75077767	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4899544	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75079853	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4903279	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75079880	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12590452	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75082053	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs1043674	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75082667	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4903281	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75087658	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10142865	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75088921	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10142626	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75088933	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs7142235	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75093260	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12589376	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75094449	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs1071989	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75097956	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs9805979	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75099506	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs2010678	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75100475	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs4899545	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75101435	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs11845639	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75103590	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10146482	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75107384	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12897094	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75112713	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs3742773	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75112940	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs7145159	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75116565	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs28626045	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75122492	chr14:75004719~75008481:-
THYM	cis	rs910316	0.783	rs11850751	ENSG00000258646.1	RP11-950C14.3	-4.17	6.69e-05	0.0332	-0.36	-0.4	Height;	chr14:75123410	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs3742778	ENSG00000258646.1	RP11-950C14.3	4.17	6.69e-05	0.0332	0.36	0.4	Height;	chr14:75071514	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs8003506	ENSG00000258646.1	RP11-950C14.3	4.17	6.69e-05	0.0332	0.36	0.4	Height;	chr14:75119585	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs11623413	ENSG00000258646.1	RP11-950C14.3	4.17	6.69e-05	0.0332	0.36	0.4	Height;	chr14:75122121	chr14:75004719~75008481:-
THYM	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	4.17	6.69e-05	0.0332	0.53	0.4	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
THYM	cis	rs12410462	0.591	rs2814059	ENSG00000227711.2	RP11-275O4.5	-4.17	6.69e-05	0.0332	-0.41	-0.4	Major depressive disorder;	chr1:227533532	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2814060	ENSG00000227711.2	RP11-275O4.5	-4.17	6.69e-05	0.0332	-0.41	-0.4	Major depressive disorder;	chr1:227534527	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2819498	ENSG00000227711.2	RP11-275O4.5	-4.17	6.69e-05	0.0332	-0.41	-0.4	Major depressive disorder;	chr1:227536700	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2644161	ENSG00000227711.2	RP11-275O4.5	4.17	6.69e-05	0.0332	0.41	0.4	Major depressive disorder;	chr1:227518618	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs903695	ENSG00000227711.2	RP11-275O4.5	-4.17	6.7e-05	0.0332	-0.41	-0.4	Major depressive disorder;	chr1:227545368	chr1:227509028~227520477:-
THYM	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	4.17	6.7e-05	0.0332	0.32	0.4	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
THYM	cis	rs847577	0.832	rs1799068	ENSG00000238109.1	AC004893.10	-4.17	6.7e-05	0.0332	-0.33	-0.4	Breast cancer;	chr7:98077757	chr7:98998538~98999930:-
THYM	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	4.17	6.7e-05	0.0332	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
THYM	cis	rs17818399	0.781	rs13024534	ENSG00000279254.1	RP11-536C12.1	-4.17	6.7e-05	0.0332	-0.45	-0.4	Height;	chr2:46632247	chr2:46668870~46670778:+
THYM	cis	rs17818399	0.675	rs35949012	ENSG00000279254.1	RP11-536C12.1	-4.17	6.7e-05	0.0332	-0.45	-0.4	Height;	chr2:46633262	chr2:46668870~46670778:+
THYM	cis	rs17818399	0.815	rs17768018	ENSG00000279254.1	RP11-536C12.1	-4.17	6.7e-05	0.0332	-0.45	-0.4	Height;	chr2:46634872	chr2:46668870~46670778:+
THYM	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-4.17	6.7e-05	0.0332	-0.47	-0.4	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
THYM	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-4.17	6.7e-05	0.0332	-0.48	-0.4	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-4.17	6.7e-05	0.0332	-0.48	-0.4	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
THYM	cis	rs73198271	0.737	rs506960	ENSG00000253893.2	FAM85B	4.17	6.71e-05	0.0332	0.57	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8167819~8226614:-
THYM	cis	rs10799445	0.508	rs10916165	ENSG00000227711.2	RP11-275O4.5	4.17	6.71e-05	0.0332	0.35	0.4	Height;	chr1:227567234	chr1:227509028~227520477:-
THYM	cis	rs539096	0.5	rs2906457	ENSG00000237950.1	RP11-7O11.3	4.17	6.72e-05	0.0333	0.41	0.4	Intelligence (multi-trait analysis);	chr1:43872903	chr1:43944370~43946551:-
THYM	cis	rs539096	0.5	rs2527776	ENSG00000237950.1	RP11-7O11.3	4.17	6.72e-05	0.0333	0.41	0.4	Intelligence (multi-trait analysis);	chr1:43879620	chr1:43944370~43946551:-
THYM	cis	rs539096	0.5	rs803678	ENSG00000237950.1	RP11-7O11.3	4.17	6.72e-05	0.0333	0.41	0.4	Intelligence (multi-trait analysis);	chr1:43885226	chr1:43944370~43946551:-
THYM	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-4.17	6.72e-05	0.0333	-0.54	-0.4	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
THYM	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	4.17	6.73e-05	0.0333	0.31	0.4	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
THYM	cis	rs17685	0.523	rs10246583	ENSG00000280388.1	RP11-229D13.3	-4.17	6.73e-05	0.0333	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76117349	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs55812043	ENSG00000280388.1	RP11-229D13.3	-4.17	6.73e-05	0.0333	-0.4	-0.4	Coffee consumption (cups per day);Coffee consumption;	chr7:76117923	chr7:76043977~76045963:-
THYM	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	4.17	6.73e-05	0.0333	0.47	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
THYM	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	4.17	6.73e-05	0.0333	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	4.17	6.73e-05	0.0333	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	4.17	6.73e-05	0.0333	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	4.17	6.73e-05	0.0333	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
THYM	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	4.17	6.73e-05	0.0333	0.46	0.4	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
THYM	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-4.17	6.74e-05	0.0334	-0.42	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
THYM	cis	rs6696239	0.513	rs7542685	ENSG00000227711.2	RP11-275O4.5	4.17	6.74e-05	0.0334	0.35	0.4	Height;	chr1:227542752	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs1495847	ENSG00000227711.2	RP11-275O4.5	4.17	6.74e-05	0.0334	0.35	0.4	Hip circumference adjusted for BMI;	chr1:227546608	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs28407112	ENSG00000227711.2	RP11-275O4.5	4.17	6.74e-05	0.0334	0.35	0.4	Height;	chr1:227549051	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.531	rs10799423	ENSG00000227711.2	RP11-275O4.5	4.17	6.74e-05	0.0334	0.35	0.4	Height;	chr1:227549683	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs4653850	ENSG00000227711.2	RP11-275O4.5	4.17	6.74e-05	0.0334	0.35	0.4	Hip circumference adjusted for BMI;	chr1:227550187	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.55	rs7512348	ENSG00000227711.2	RP11-275O4.5	4.17	6.74e-05	0.0334	0.35	0.4	Height;	chr1:227552571	chr1:227509028~227520477:-
THYM	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	4.17	6.74e-05	0.0334	0.39	0.4	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
THYM	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-4.17	6.74e-05	0.0334	-0.39	-0.4	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
THYM	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-4.17	6.74e-05	0.0334	-0.35	-0.4	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.865	rs10213221	ENSG00000250412.1	KLHL2P1	4.17	6.74e-05	0.0334	0.37	0.4	Corneal astigmatism;	chr4:119334771	chr4:119334329~119378233:+
THYM	cis	rs3753275	0.509	rs4908513	ENSG00000230679.1	ENO1-AS1	4.17	6.75e-05	0.0334	0.47	0.4	Educational attainment;	chr1:8772315	chr1:8878835~8879894:+
THYM	cis	rs3753275	0.624	rs6577522	ENSG00000230679.1	ENO1-AS1	4.17	6.75e-05	0.0334	0.47	0.4	Educational attainment;	chr1:8774920	chr1:8878835~8879894:+
THYM	cis	rs3753275	0.624	rs7556144	ENSG00000230679.1	ENO1-AS1	4.17	6.75e-05	0.0334	0.47	0.4	Educational attainment;	chr1:8778672	chr1:8878835~8879894:+
THYM	cis	rs3753275	0.624	rs4908514	ENSG00000230679.1	ENO1-AS1	4.17	6.75e-05	0.0334	0.47	0.4	Educational attainment;	chr1:8784541	chr1:8878835~8879894:+
THYM	cis	rs3753275	0.624	rs1472228	ENSG00000230679.1	ENO1-AS1	4.17	6.75e-05	0.0334	0.47	0.4	Educational attainment;	chr1:8804621	chr1:8878835~8879894:+
THYM	cis	rs10829156	0.679	rs4748476	ENSG00000240291.1	RP11-499P20.2	4.17	6.75e-05	0.0334	0.38	0.4	Sudden cardiac arrest;	chr10:18503946	chr10:18513115~18545651:-
THYM	cis	rs3753275	0.624	rs10864366	ENSG00000230679.1	ENO1-AS1	-4.17	6.76e-05	0.0334	-0.46	-0.4	Educational attainment;	chr1:8772440	chr1:8878835~8879894:+
THYM	cis	rs9473147	0.586	rs7740538	ENSG00000270761.1	RP11-385F7.1	-4.17	6.77e-05	0.0335	-0.38	-0.4	Platelet distribution width;Mean platelet volume;	chr6:47665362	chr6:47477243~47477572:-
THYM	cis	rs1642645	0.872	rs348139	ENSG00000228452.1	RP5-994D16.9	-4.17	6.77e-05	0.0335	-0.54	-0.4	Left ventricular obstructive tract defect (maternal effect);	chr1:42005230	chr1:42775813~42776790:-
THYM	cis	rs7044106	0.791	rs735110	ENSG00000238181.2	AHCYP2	-4.17	6.78e-05	0.0335	-0.4	-0.4	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120720673~120721972:+
THYM	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-4.17	6.78e-05	0.0335	-0.46	-0.4	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
THYM	cis	rs8067545	0.611	rs2703803	ENSG00000231645.2	KRT17P6	4.17	6.78e-05	0.0335	0.46	0.4	Schizophrenia;	chr17:20203756	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs2703812	ENSG00000231645.2	KRT17P6	4.17	6.78e-05	0.0335	0.46	0.4	Schizophrenia;	chr17:20211490	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs2703814	ENSG00000231645.2	KRT17P6	4.17	6.78e-05	0.0335	0.46	0.4	Schizophrenia;	chr17:20213838	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs12942568	ENSG00000231645.2	KRT17P6	4.17	6.78e-05	0.0335	0.46	0.4	Schizophrenia;	chr17:20214580	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs2526482	ENSG00000231645.2	KRT17P6	4.17	6.78e-05	0.0335	0.46	0.4	Schizophrenia;	chr17:20215820	chr17:20512560~20517479:-
THYM	cis	rs7631605	0.905	rs7651903	ENSG00000272334.1	RP11-129K12.1	-4.17	6.79e-05	0.0336	-0.4	-0.4	Cerebrospinal P-tau181p levels;	chr3:36965195	chr3:36973117~36973672:-
THYM	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-4.17	6.79e-05	0.0336	-0.44	-0.4	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-4.17	6.79e-05	0.0336	-0.44	-0.4	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
THYM	cis	rs7209700	0.6	rs7218632	ENSG00000228782.6	CTD-2026D20.3	-4.17	6.79e-05	0.0336	-0.47	-0.4	IgG glycosylation;	chr17:47287787	chr17:47450568~47492492:-
THYM	cis	rs7225151	0.522	rs56229705	ENSG00000234327.6	AC012146.7	-4.17	6.8e-05	0.0336	-0.39	-0.4	Alzheimer's disease (late onset);	chr17:5111494	chr17:5111468~5115004:+
THYM	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	4.17	6.8e-05	0.0336	0.49	0.4	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	4.17	6.8e-05	0.0336	0.49	0.4	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	4.17	6.8e-05	0.0336	0.49	0.4	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	4.17	6.8e-05	0.0336	0.49	0.4	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
THYM	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	4.17	6.8e-05	0.0336	0.49	0.4	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
THYM	cis	rs7631605	0.905	rs58129217	ENSG00000272334.1	RP11-129K12.1	-4.17	6.8e-05	0.0336	-0.41	-0.4	Cerebrospinal P-tau181p levels;	chr3:36970133	chr3:36973117~36973672:-
THYM	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-4.17	6.8e-05	0.0336	-0.25	-0.4	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
THYM	cis	rs12908161	1	rs17601029	ENSG00000275120.1	RP11-182J1.17	4.17	6.81e-05	0.0336	0.53	0.4	Schizophrenia;	chr15:84804478	chr15:84599434~84606463:-
THYM	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-4.17	6.82e-05	0.0337	-0.43	-0.39	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
THYM	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-4.17	6.82e-05	0.0337	-0.62	-0.39	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
THYM	cis	rs6040076	0.817	rs6032919	ENSG00000230506.1	RP11-416N4.4	-4.17	6.82e-05	0.0337	-0.46	-0.39	Pulse pressure;Birth weight;	chr20:10700115	chr20:10173520~10196990:+
THYM	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-4.17	6.83e-05	0.0337	-0.44	-0.39	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
THYM	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	4.17	6.83e-05	0.0337	0.4	0.39	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
THYM	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-4.17	6.83e-05	0.0337	-0.52	-0.39	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
THYM	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-4.17	6.84e-05	0.0338	-0.4	-0.39	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
THYM	cis	rs561341	0.882	rs563539	ENSG00000265798.5	RP11-271K11.5	4.17	6.85e-05	0.0338	0.47	0.39	Hip circumference adjusted for BMI;	chr17:31980939	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs1557731	ENSG00000265798.5	RP11-271K11.5	4.17	6.85e-05	0.0338	0.47	0.39	Hip circumference adjusted for BMI;	chr17:31994548	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs537166	ENSG00000265798.5	RP11-271K11.5	4.17	6.85e-05	0.0338	0.47	0.39	Hip circumference adjusted for BMI;	chr17:31999808	chr17:31038575~31059121:-
THYM	cis	rs561341	1	rs68140514	ENSG00000265798.5	RP11-271K11.5	4.17	6.85e-05	0.0338	0.47	0.39	Hip circumference adjusted for BMI;	chr17:32008762	chr17:31038575~31059121:-
THYM	cis	rs73198271	0.563	rs3748143	ENSG00000253893.2	FAM85B	-4.17	6.85e-05	0.0338	-0.61	-0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797727	chr8:8167819~8226614:-
THYM	cis	rs9399135	0.627	rs6930223	ENSG00000232876.1	CTA-212D2.2	-4.17	6.86e-05	0.0338	-0.42	-0.39	Red blood cell count;	chr6:135103065	chr6:135055033~135060550:+
THYM	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	4.17	6.86e-05	0.0338	0.44	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
THYM	cis	rs6696239	0.513	rs1021554	ENSG00000227711.2	RP11-275O4.5	4.17	6.87e-05	0.0339	0.35	0.39	Height;	chr1:227556250	chr1:227509028~227520477:-
THYM	cis	rs6696239	0.513	rs1021553	ENSG00000227711.2	RP11-275O4.5	4.17	6.87e-05	0.0339	0.35	0.39	Height;	chr1:227556286	chr1:227509028~227520477:-
THYM	cis	rs10799445	0.531	rs6697867	ENSG00000227711.2	RP11-275O4.5	4.17	6.87e-05	0.0339	0.35	0.39	Height;	chr1:227557973	chr1:227509028~227520477:-
THYM	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	4.17	6.87e-05	0.0339	0.4	0.39	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
THYM	cis	rs9903692	0.954	rs6847	ENSG00000266601.1	RP11-6N17.3	4.17	6.87e-05	0.0339	0.36	0.39	Pulse pressure;	chr17:48070445	chr17:47929682~47933106:-
THYM	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	4.17	6.88e-05	0.0339	0.49	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
THYM	cis	rs3781264	0.848	rs6583935	ENSG00000273450.1	RP11-76P2.4	4.17	6.88e-05	0.0339	0.46	0.39	Esophageal cancer and gastric cancer;	chr10:94313568	chr10:94314907~94315327:-
THYM	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-4.17	6.88e-05	0.0339	-0.52	-0.39	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
THYM	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	4.17	6.88e-05	0.0339	0.44	0.39	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
THYM	cis	rs42490	0.664	rs372981	ENSG00000251136.7	RP11-37B2.1	-4.17	6.88e-05	0.0339	-0.32	-0.39	Leprosy;	chr8:89784740	chr8:89609409~89757727:-
THYM	cis	rs935334	1	rs2543376	ENSG00000258454.1	RP11-361H10.3	4.17	6.88e-05	0.0339	0.52	0.39	Blood pressure;	chr14:76143580	chr14:76235817~76263474:+
THYM	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	4.17	6.88e-05	0.0339	0.5	0.39	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
THYM	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	4.17	6.89e-05	0.034	0.34	0.39	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
THYM	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	4.17	6.89e-05	0.034	0.52	0.39	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
THYM	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	4.17	6.9e-05	0.034	0.49	0.39	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
THYM	cis	rs17253792	0.822	rs10148983	ENSG00000186615.9	KTN1-AS1	-4.17	6.9e-05	0.034	-0.78	-0.39	Putamen volume;	chr14:55585161	chr14:55499278~55580110:-
THYM	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	4.17	6.9e-05	0.034	0.41	0.39	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
THYM	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	4.17	6.9e-05	0.034	0.41	0.39	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
THYM	cis	rs12902680	0.674	rs28881185	ENSG00000259520.4	CTD-2651B20.3	4.16	6.91e-05	0.034	0.41	0.39	Neuroticism;	chr15:46159987	chr15:45251580~45279251:-
THYM	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	4.16	6.91e-05	0.034	0.41	0.39	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
THYM	cis	rs6121246	0.609	rs6089054	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31735338	chr20:31567707~31573263:-
THYM	cis	rs6087771	0.851	rs6087775	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Putamen volume;Subcortical brain region volumes;	chr20:31737962	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs4453755	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31743244	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs2376998	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31752860	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6058462	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31779871	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs6060948	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31788590	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060952	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31794305	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs6060955	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31797268	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs6089075	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31805081	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs1009453	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31817037	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6119728	ENSG00000230613.1	HM13-AS1	4.16	6.91e-05	0.034	0.54	0.39	Mean corpuscular hemoglobin;	chr20:31825318	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.609	rs2377317	ENSG00000230613.1	HM13-AS1	-4.16	6.91e-05	0.034	-0.54	-0.39	Mean corpuscular hemoglobin;	chr20:31814699	chr20:31567707~31573263:-
THYM	cis	rs2055375	0.601	rs34635	ENSG00000272308.1	RP11-231G3.1	4.16	6.91e-05	0.0341	0.36	0.39	Intelligence (multi-trait analysis);	chr5:61217674	chr5:60866457~60866935:-
THYM	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-4.16	6.92e-05	0.0341	-0.44	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
THYM	cis	rs7617773	0.817	rs17647717	ENSG00000228638.1	FCF1P2	-4.16	6.92e-05	0.0341	-0.43	-0.39	Coronary artery disease;	chr3:48263966	chr3:48290793~48291375:-
THYM	cis	rs12908161	0.959	rs12906348	ENSG00000275120.1	RP11-182J1.17	4.16	6.92e-05	0.0341	0.53	0.39	Schizophrenia;	chr15:84786190	chr15:84599434~84606463:-
THYM	cis	rs5742933	1	rs1317751	ENSG00000273240.1	RP11-455J20.3	-4.16	6.93e-05	0.0341	-0.61	-0.39	Ferritin levels;	chr2:189807898	chr2:189763859~189764456:-
THYM	cis	rs5742933	1	rs3791770	ENSG00000273240.1	RP11-455J20.3	-4.16	6.93e-05	0.0341	-0.61	-0.39	Ferritin levels;	chr2:189809109	chr2:189763859~189764456:-
THYM	cis	rs5742933	0.948	rs62184286	ENSG00000273240.1	RP11-455J20.3	-4.16	6.93e-05	0.0341	-0.61	-0.39	Ferritin levels;	chr2:189812147	chr2:189763859~189764456:-
THYM	cis	rs5742933	1	rs5743032	ENSG00000273240.1	RP11-455J20.3	-4.16	6.93e-05	0.0341	-0.61	-0.39	Ferritin levels;	chr2:189814077	chr2:189763859~189764456:-
THYM	cis	rs5742933	1	rs3791773	ENSG00000273240.1	RP11-455J20.3	-4.16	6.93e-05	0.0341	-0.61	-0.39	Ferritin levels;	chr2:189817906	chr2:189763859~189764456:-
THYM	cis	rs7178424	0.869	rs3784634	ENSG00000259251.2	RP11-643M14.1	4.16	6.93e-05	0.0341	0.44	0.39	Height;	chr15:61967438	chr15:62060503~62062434:+
THYM	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-4.16	6.93e-05	0.0341	-0.46	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
THYM	cis	rs6040076	0.817	rs2423512	ENSG00000230506.1	RP11-416N4.4	4.16	6.95e-05	0.0342	0.45	0.39	Pulse pressure;Birth weight;	chr20:10705728	chr20:10173520~10196990:+
THYM	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	4.16	6.95e-05	0.0342	0.45	0.39	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
THYM	cis	rs465969	0.744	rs34659678	ENSG00000231889.6	TRAF3IP2-AS1	4.16	6.96e-05	0.0342	0.41	0.39	Psoriasis;	chr6:111567337	chr6:111483511~111598302:+
THYM	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	4.16	6.96e-05	0.0342	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	4.16	6.96e-05	0.0342	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
THYM	cis	rs12999373	0.501	rs2867134	ENSG00000272342.1	RP13-539J13.1	-4.16	6.96e-05	0.0342	-0.47	-0.39	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:739588~740164:-
THYM	cis	rs797680	0.856	rs12030549	ENSG00000223745.6	RP4-717I23.3	4.16	6.97e-05	0.0342	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93203661	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs531358	ENSG00000223745.6	RP4-717I23.3	4.16	6.97e-05	0.0342	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93210454	chr1:93262186~93346025:-
THYM	cis	rs797680	0.786	rs555161	ENSG00000223745.6	RP4-717I23.3	4.16	6.97e-05	0.0342	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93210757	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs2765545	ENSG00000223745.6	RP4-717I23.3	4.16	6.97e-05	0.0342	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93211712	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs627779	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93218532	chr1:93262186~93346025:-
THYM	cis	rs797680	0.796	rs797661	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93221534	chr1:93262186~93346025:-
THYM	cis	rs797680	0.789	rs531514	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93234655	chr1:93262186~93346025:-
THYM	cis	rs797680	0.789	rs797671	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93234806	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs797672	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93236562	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs687394	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93248360	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs7512911	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93250261	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs637646	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93250826	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs797681	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93252189	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs682514	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93253873	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs693737	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93259367	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs602204	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93262022	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs535760	ENSG00000223745.6	RP4-717I23.3	-4.16	6.97e-05	0.0342	-0.34	-0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93263201	chr1:93262186~93346025:-
THYM	cis	rs7560272	0.501	rs4852978	ENSG00000163016.8	ALMS1P	-4.16	6.97e-05	0.0343	-0.49	-0.39	Schizophrenia;	chr2:73715983	chr2:73644919~73685576:+
THYM	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-4.16	6.98e-05	0.0343	-0.41	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
THYM	cis	rs9926296	0.744	rs154656	ENSG00000274627.1	RP11-104N10.2	4.16	6.99e-05	0.0343	0.46	0.39	Vitiligo;	chr16:89641595	chr16:89516797~89522217:+
THYM	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	4.16	6.99e-05	0.0343	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	4.16	6.99e-05	0.0343	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	4.16	6.99e-05	0.0343	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	4.16	6.99e-05	0.0343	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	4.16	6.99e-05	0.0343	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
THYM	cis	rs7631605	0.905	rs7622170	ENSG00000272334.1	RP11-129K12.1	-4.16	6.99e-05	0.0343	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:36975085	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs7611106	ENSG00000272334.1	RP11-129K12.1	-4.16	6.99e-05	0.0343	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:36975533	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs56198917	ENSG00000272334.1	RP11-129K12.1	-4.16	6.99e-05	0.0343	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:36976307	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs11720073	ENSG00000272334.1	RP11-129K12.1	-4.16	6.99e-05	0.0343	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:36977500	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs4678920	ENSG00000272334.1	RP11-129K12.1	-4.16	6.99e-05	0.0343	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:36979158	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs4678921	ENSG00000272334.1	RP11-129K12.1	-4.16	6.99e-05	0.0343	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:36981312	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs11714125	ENSG00000272334.1	RP11-129K12.1	-4.16	6.99e-05	0.0343	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:36982765	chr3:36973117~36973672:-
THYM	cis	rs4835473	0.897	rs6537170	ENSG00000249741.2	RP11-673E1.3	-4.16	6.99e-05	0.0344	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143691747	chr4:143911514~143912053:-
THYM	cis	rs7160151	0.621	rs2816756	ENSG00000274012.1	RN7SL2	4.16	7e-05	0.0344	0.56	0.39	C-reactive protein (red blood cell fatty acid level interaction);	chr14:49346437	chr14:49862550~49862849:-
THYM	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-4.16	7.01e-05	0.0344	-0.69	-0.39	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
THYM	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-4.16	7.01e-05	0.0344	-0.69	-0.39	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
THYM	cis	rs990871	0.962	rs3101337	ENSG00000227207.2	RPL31P12	-4.16	7.02e-05	0.0345	-0.55	-0.39	Subcutaneous adipose tissue;	chr1:72285451	chr1:72301472~72301829:+
THYM	cis	rs990871	1	rs3101336	ENSG00000227207.2	RPL31P12	-4.16	7.02e-05	0.0345	-0.55	-0.39	Subcutaneous adipose tissue;	chr1:72285502	chr1:72301472~72301829:+
THYM	cis	rs990871	1	rs2815765	ENSG00000227207.2	RPL31P12	-4.16	7.02e-05	0.0345	-0.55	-0.39	Subcutaneous adipose tissue;	chr1:72286547	chr1:72301472~72301829:+
THYM	cis	rs990871	1	rs2568952	ENSG00000227207.2	RPL31P12	-4.16	7.02e-05	0.0345	-0.55	-0.39	Subcutaneous adipose tissue;	chr1:72289422	chr1:72301472~72301829:+
THYM	cis	rs990871	1	rs2568958	ENSG00000227207.2	RPL31P12	-4.16	7.02e-05	0.0345	-0.55	-0.39	Subcutaneous adipose tissue;	chr1:72299433	chr1:72301472~72301829:+
THYM	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-4.16	7.02e-05	0.0345	-0.46	-0.39	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
THYM	cis	rs1023500	0.505	rs134885	ENSG00000227370.1	RP4-669P10.19	4.16	7.02e-05	0.0345	0.47	0.39	Schizophrenia;	chr22:42277805	chr22:42132543~42132998:+
THYM	cis	rs11971779	0.616	rs10269683	ENSG00000273391.1	RP11-634H22.1	4.16	7.03e-05	0.0345	0.32	0.39	Diisocyanate-induced asthma;	chr7:139416122	chr7:139359032~139359566:-
THYM	cis	rs11098499	0.863	rs10004484	ENSG00000250412.1	KLHL2P1	4.16	7.03e-05	0.0345	0.37	0.39	Corneal astigmatism;	chr4:119521273	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1155576	ENSG00000250412.1	KLHL2P1	4.16	7.03e-05	0.0345	0.37	0.39	Corneal astigmatism;	chr4:119529004	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs6858592	ENSG00000250412.1	KLHL2P1	4.16	7.03e-05	0.0345	0.37	0.39	Corneal astigmatism;	chr4:119537537	chr4:119334329~119378233:+
THYM	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	4.16	7.03e-05	0.0345	0.6	0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
THYM	cis	rs7560272	0.512	rs13026192	ENSG00000273245.1	RP11-434P11.2	-4.16	7.03e-05	0.0345	-0.48	-0.39	Schizophrenia;	chr2:73699945	chr2:73750256~73750786:-
THYM	cis	rs10129255	0.957	rs12590735	ENSG00000253703.1	IGHV1-68	-4.16	7.04e-05	0.0345	-0.5	-0.39	Kawasaki disease;	chr14:106779660	chr14:106703852~106704146:-
THYM	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	4.16	7.04e-05	0.0346	0.36	0.39	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
THYM	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	4.16	7.04e-05	0.0346	0.48	0.39	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	4.16	7.04e-05	0.0346	0.48	0.39	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	4.16	7.04e-05	0.0346	0.48	0.39	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
THYM	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-4.16	7.04e-05	0.0346	-0.74	-0.39	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
THYM	cis	rs8177876	0.584	rs2602404	ENSG00000261838.4	RP11-303E16.6	-4.16	7.04e-05	0.0346	-0.72	-0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056042	chr16:81069854~81076598:+
THYM	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-4.16	7.04e-05	0.0346	-0.49	-0.39	Pain;	chr19:21495996	chr19:21554640~21569237:-
THYM	cis	rs1474476	1	rs6572289	ENSG00000211790.2	TRAV8-4	-4.16	7.05e-05	0.0346	-0.42	-0.39	Obesity-related traits;	chr14:22141890	chr14:21894433~21895030:+
THYM	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	4.16	7.05e-05	0.0346	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
THYM	cis	rs61270009	0.955	rs17548339	ENSG00000247828.6	TMEM161B-AS1	4.16	7.05e-05	0.0346	0.33	0.39	Depressive symptoms;	chr5:88391761	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs34148755	ENSG00000247828.6	TMEM161B-AS1	4.16	7.05e-05	0.0346	0.33	0.39	Depressive symptoms;	chr5:88394130	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs16903122	ENSG00000247828.6	TMEM161B-AS1	4.16	7.05e-05	0.0346	0.33	0.39	Depressive symptoms;	chr5:88397744	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.955	rs10514300	ENSG00000247828.6	TMEM161B-AS1	4.16	7.05e-05	0.0346	0.33	0.39	Depressive symptoms;	chr5:88409465	chr5:88268895~88436685:+
THYM	cis	rs61270009	0.913	rs3733809	ENSG00000247828.6	TMEM161B-AS1	4.16	7.05e-05	0.0346	0.33	0.39	Depressive symptoms;	chr5:88410112	chr5:88268895~88436685:+
THYM	cis	rs17685	0.702	rs6960598	ENSG00000280388.1	RP11-229D13.3	-4.16	7.06e-05	0.0346	-0.42	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76143673	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs10235738	ENSG00000280388.1	RP11-229D13.3	-4.16	7.06e-05	0.0346	-0.42	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76144142	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs6953342	ENSG00000280388.1	RP11-229D13.3	-4.16	7.06e-05	0.0346	-0.42	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76147435	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs10952842	ENSG00000280388.1	RP11-229D13.3	-4.16	7.06e-05	0.0346	-0.42	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76151095	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs6464994	ENSG00000280388.1	RP11-229D13.3	-4.16	7.06e-05	0.0346	-0.42	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76155350	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs7794454	ENSG00000280388.1	RP11-229D13.3	4.16	7.06e-05	0.0346	0.42	0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:76043977~76045963:-
THYM	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-4.16	7.06e-05	0.0346	-0.58	-0.39	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
THYM	cis	rs8058578	0.775	rs8046391	ENSG00000260625.2	RP11-452L6.7	-4.16	7.06e-05	0.0346	-0.35	-0.39	Multiple myeloma;	chr16:30825327	chr16:31508471~31509256:+
THYM	cis	rs8058578	0.887	rs28421305	ENSG00000260625.2	RP11-452L6.7	-4.16	7.06e-05	0.0346	-0.35	-0.39	Multiple myeloma;	chr16:30826807	chr16:31508471~31509256:+
THYM	cis	rs10740039	1	rs10740040	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654985	chr10:60734342~60741828:+
THYM	cis	rs10740039	1	rs10761541	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655383	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.961	rs2083696	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60656430	chr10:60734342~60741828:+
THYM	cis	rs10740039	1	rs10821818	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657178	chr10:60734342~60741828:+
THYM	cis	rs10740039	0.883	rs6479722	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657923	chr10:60734342~60741828:+
THYM	cis	rs10740039	1	rs6479723	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658127	chr10:60734342~60741828:+
THYM	cis	rs10740039	1	rs10761545	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658811	chr10:60734342~60741828:+
THYM	cis	rs10740039	1	rs10994460	ENSG00000254271.1	RP11-131N11.4	4.16	7.06e-05	0.0346	0.43	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60659033	chr10:60734342~60741828:+
THYM	cis	rs7631605	0.819	rs4678922	ENSG00000272334.1	RP11-129K12.1	-4.16	7.06e-05	0.0346	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:36981373	chr3:36973117~36973672:-
THYM	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	4.16	7.07e-05	0.0346	0.58	0.39	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	4.16	7.07e-05	0.0346	0.58	0.39	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-4.16	7.07e-05	0.0346	-0.58	-0.39	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
THYM	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-4.16	7.07e-05	0.0347	-0.44	-0.39	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
THYM	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-4.16	7.07e-05	0.0347	-0.39	-0.39	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
THYM	cis	rs227275	0.525	rs9917919	ENSG00000251288.2	RP11-10L12.2	-4.16	7.09e-05	0.0347	-0.4	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102751401~102752641:+
THYM	cis	rs10129255	0.701	rs2005643	ENSG00000254329.1	IGHVII-60-1	4.16	7.09e-05	0.0347	0.38	0.39	Kawasaki disease;	chr14:106676288	chr14:106637718~106637973:-
THYM	cis	rs889398	0.683	rs8047682	ENSG00000226232.7	RP11-419C5.2	-4.16	7.09e-05	0.0348	-0.36	-0.39	Body mass index;	chr16:69879543	chr16:69976388~69996188:-
THYM	cis	rs990871	0.924	rs2568956	ENSG00000227207.2	RPL31P12	-4.16	7.09e-05	0.0348	-0.55	-0.39	Subcutaneous adipose tissue;	chr1:72298693	chr1:72301472~72301829:+
THYM	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-4.16	7.1e-05	0.0348	-0.47	-0.39	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
THYM	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-4.16	7.1e-05	0.0348	-0.47	-0.39	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
THYM	cis	rs42490	0.51	rs218917	ENSG00000251136.7	RP11-37B2.1	-4.16	7.1e-05	0.0348	-0.37	-0.39	Leprosy;	chr8:89688902	chr8:89609409~89757727:-
THYM	cis	rs7614738	1	rs7614738	ENSG00000226913.1	BSN-AS2	-4.16	7.1e-05	0.0348	-0.52	-0.39	Red cell distribution width;	chr3:49273698	chr3:49549306~49554366:-
THYM	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	4.16	7.11e-05	0.0348	0.5	0.39	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
THYM	cis	rs7631605	0.905	rs11714667	ENSG00000272334.1	RP11-129K12.1	-4.16	7.11e-05	0.0348	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:37180869	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6786906	ENSG00000272334.1	RP11-129K12.1	-4.16	7.11e-05	0.0348	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:37184525	chr3:36973117~36973672:-
THYM	cis	rs7560272	0.588	rs4852965	ENSG00000163016.8	ALMS1P	-4.16	7.11e-05	0.0348	-0.48	-0.39	Schizophrenia;	chr2:73684042	chr2:73644919~73685576:+
THYM	cis	rs11098499	0.863	rs10019674	ENSG00000250412.1	KLHL2P1	-4.16	7.11e-05	0.0348	-0.37	-0.39	Corneal astigmatism;	chr4:119522334	chr4:119334329~119378233:+
THYM	cis	rs9907295	0.901	rs2107540	ENSG00000270977.1	AC015849.16	-4.16	7.11e-05	0.0348	-0.69	-0.39	Fibroblast growth factor basic levels;	chr17:35893516	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs28739295	ENSG00000270977.1	AC015849.16	-4.16	7.11e-05	0.0348	-0.69	-0.39	Fibroblast growth factor basic levels;	chr17:35895812	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs56294660	ENSG00000270977.1	AC015849.16	-4.16	7.11e-05	0.0348	-0.69	-0.39	Fibroblast growth factor basic levels;	chr17:35901470	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs28550999	ENSG00000270977.1	AC015849.16	-4.16	7.11e-05	0.0348	-0.69	-0.39	Fibroblast growth factor basic levels;	chr17:35902887	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs74780070	ENSG00000270977.1	AC015849.16	-4.16	7.11e-05	0.0348	-0.69	-0.39	Fibroblast growth factor basic levels;	chr17:35903521	chr17:35893707~35911023:-
THYM	cis	rs910316	0.789	rs4899552	ENSG00000258646.1	RP11-950C14.3	4.16	7.12e-05	0.0348	0.35	0.39	Height;	chr14:75201218	chr14:75004719~75008481:-
THYM	cis	rs11157436	0.56	rs2031071	ENSG00000211813.2	TRAV34	4.16	7.12e-05	0.0349	0.28	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157547	chr14:22207522~22208129:+
THYM	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-4.16	7.12e-05	0.0349	-0.4	-0.39	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
THYM	cis	rs4948275	0.631	rs2814023	ENSG00000237233.2	TMEM26-AS1	-4.16	7.13e-05	0.0349	-0.45	-0.39	Night sleep phenotypes;	chr10:61593649	chr10:61452639~61481956:+
THYM	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-4.16	7.14e-05	0.0349	-0.39	-0.39	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
THYM	cis	rs7551732	0.516	rs36107151	ENSG00000279778.1	RP11-60A14.1	4.16	7.14e-05	0.0349	0.42	0.39	Height;	chr1:88644618	chr1:87805286~87808372:-
THYM	cis	rs10129255	0.5	rs10131875	ENSG00000253703.1	IGHV1-68	-4.16	7.15e-05	0.035	-0.43	-0.39	Kawasaki disease;	chr14:106792798	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs11628999	ENSG00000253703.1	IGHV1-68	-4.16	7.15e-05	0.035	-0.43	-0.39	Kawasaki disease;	chr14:106800208	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs11627315	ENSG00000253703.1	IGHV1-68	-4.16	7.15e-05	0.035	-0.43	-0.39	Kawasaki disease;	chr14:106802182	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.5	rs7157975	ENSG00000253703.1	IGHV1-68	-4.16	7.15e-05	0.035	-0.43	-0.39	Kawasaki disease;	chr14:106804049	chr14:106703852~106704146:-
THYM	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	4.16	7.15e-05	0.035	0.49	0.39	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	4.16	7.15e-05	0.035	0.49	0.39	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	4.16	7.15e-05	0.035	0.49	0.39	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
THYM	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	4.16	7.15e-05	0.035	0.4	0.39	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
THYM	cis	rs5769707	0.872	rs5770604	ENSG00000264139.1	MIR3667	-4.16	7.16e-05	0.035	-0.46	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49543393~49543466:-
THYM	cis	rs7223966	1	rs11657306	ENSG00000240280.5	TCAM1P	-4.16	7.16e-05	0.035	-0.59	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63627462	chr17:63849292~63864379:+
THYM	cis	rs4671400	0.516	rs62152277	ENSG00000273302.1	RP11-493E12.2	-4.15	7.17e-05	0.0351	-0.44	-0.39	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61276269	chr2:61199979~61200769:+
THYM	cis	rs12908161	0.683	rs12903256	ENSG00000275120.1	RP11-182J1.17	4.15	7.17e-05	0.0351	0.53	0.39	Schizophrenia;	chr15:84764910	chr15:84599434~84606463:-
THYM	cis	rs935334	1	rs935334	ENSG00000258454.1	RP11-361H10.3	4.15	7.17e-05	0.0351	0.51	0.39	Blood pressure;	chr14:76147335	chr14:76235817~76263474:+
THYM	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-4.15	7.17e-05	0.0351	-0.37	-0.39	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
THYM	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	4.15	7.17e-05	0.0351	0.37	0.39	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
THYM	cis	rs6040076	0.817	rs1033517	ENSG00000230506.1	RP11-416N4.4	-4.15	7.17e-05	0.0351	-0.46	-0.39	Pulse pressure;Birth weight;	chr20:10713877	chr20:10173520~10196990:+
THYM	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	4.15	7.17e-05	0.0351	0.38	0.39	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
THYM	cis	rs56104184	0.725	rs1466896	ENSG00000197813.5	CTC-301O7.4	4.15	7.18e-05	0.0351	0.61	0.39	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48881996	chr19:49331617~49340303:-
THYM	cis	rs599083	0.59	rs661988	ENSG00000222339.1	AP000807.2	4.15	7.18e-05	0.0351	0.5	0.39	Bone mineral density (spine);	chr11:68421783	chr11:68505572~68505651:-
THYM	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	4.15	7.18e-05	0.0351	0.49	0.39	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
THYM	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	4.15	7.18e-05	0.0351	0.49	0.39	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
THYM	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	4.15	7.18e-05	0.0351	0.49	0.39	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
THYM	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	4.15	7.18e-05	0.0351	0.46	0.39	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
THYM	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	4.15	7.18e-05	0.0351	0.46	0.39	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
THYM	cis	rs42490	0.59	rs441547	ENSG00000251136.7	RP11-37B2.1	-4.15	7.18e-05	0.0351	-0.3	-0.39	Leprosy;	chr8:89807954	chr8:89609409~89757727:-
THYM	cis	rs42490	0.614	rs441548	ENSG00000251136.7	RP11-37B2.1	-4.15	7.18e-05	0.0351	-0.3	-0.39	Leprosy;	chr8:89807955	chr8:89609409~89757727:-
THYM	cis	rs42490	0.614	rs402434	ENSG00000251136.7	RP11-37B2.1	-4.15	7.18e-05	0.0351	-0.3	-0.39	Leprosy;	chr8:89808088	chr8:89609409~89757727:-
THYM	cis	rs42490	0.614	rs452694	ENSG00000251136.7	RP11-37B2.1	-4.15	7.18e-05	0.0351	-0.3	-0.39	Leprosy;	chr8:89808293	chr8:89609409~89757727:-
THYM	cis	rs42490	0.59	rs447611	ENSG00000251136.7	RP11-37B2.1	-4.15	7.18e-05	0.0351	-0.3	-0.39	Leprosy;	chr8:89808359	chr8:89609409~89757727:-
THYM	cis	rs7631605	0.905	rs1392749	ENSG00000272334.1	RP11-129K12.1	4.15	7.2e-05	0.0352	0.41	0.39	Cerebrospinal P-tau181p levels;	chr3:37163700	chr3:36973117~36973672:-
THYM	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-4.15	7.2e-05	0.0352	-0.45	-0.39	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-4.15	7.2e-05	0.0352	-0.45	-0.39	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
THYM	cis	rs12410462	0.591	rs72748074	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227575585	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs67676707	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227579464	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs16847966	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227583313	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs965942	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227585273	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs12082414	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227598556	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2132366	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227599401	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs16847991	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227603395	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs6688145	ENSG00000227711.2	RP11-275O4.5	-4.15	7.2e-05	0.0352	-0.39	-0.39	Major depressive disorder;	chr1:227612459	chr1:227509028~227520477:-
THYM	cis	rs935334	1	rs2289836	ENSG00000258454.1	RP11-361H10.3	-4.15	7.2e-05	0.0352	-0.52	-0.39	Blood pressure;	chr14:76173782	chr14:76235817~76263474:+
THYM	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	4.15	7.2e-05	0.0352	0.51	0.39	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
THYM	cis	rs910316	0.789	rs12894419	ENSG00000258646.1	RP11-950C14.3	-4.15	7.21e-05	0.0352	-0.35	-0.39	Height;	chr14:75005099	chr14:75004719~75008481:-
THYM	cis	rs910316	0.763	rs4556	ENSG00000258646.1	RP11-950C14.3	-4.15	7.21e-05	0.0352	-0.35	-0.39	Height;	chr14:75009368	chr14:75004719~75008481:-
THYM	cis	rs4925386	0.84	rs6143034	ENSG00000273619.1	RP5-908M14.9	-4.15	7.21e-05	0.0352	-0.32	-0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62386303~62386970:-
THYM	cis	rs4925386	0.84	rs6142738	ENSG00000273619.1	RP5-908M14.9	4.15	7.21e-05	0.0352	0.32	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62386303~62386970:-
THYM	cis	rs4925386	0.84	rs6143035	ENSG00000273619.1	RP5-908M14.9	4.15	7.21e-05	0.0352	0.32	0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62386303~62386970:-
THYM	cis	rs9309473	0.528	rs2091022	ENSG00000163016.8	ALMS1P	4.15	7.21e-05	0.0352	0.52	0.39	Metabolite levels;	chr2:73337442	chr2:73644919~73685576:+
THYM	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	4.15	7.22e-05	0.0352	0.74	0.39	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
THYM	cis	rs7267979	0.816	rs3746337	ENSG00000276952.1	RP5-965G21.6	4.15	7.22e-05	0.0352	0.47	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25284915~25285588:-
THYM	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-4.15	7.22e-05	0.0353	-0.46	-0.39	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
THYM	cis	rs1790761	0.667	rs598811	ENSG00000231793.4	DOC2GP	-4.15	7.22e-05	0.0353	-0.36	-0.39	Mean corpuscular volume;	chr11:67544205	chr11:67612653~67616257:-
THYM	cis	rs1790761	0.692	rs611663	ENSG00000231793.4	DOC2GP	-4.15	7.22e-05	0.0353	-0.36	-0.39	Mean corpuscular volume;	chr11:67544750	chr11:67612653~67616257:-
THYM	cis	rs7267979	0.714	rs6132825	ENSG00000276952.1	RP5-965G21.6	4.15	7.23e-05	0.0353	0.45	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:25284915~25285588:-
THYM	cis	rs42490	0.59	rs39771	ENSG00000251136.7	RP11-37B2.1	-4.15	7.23e-05	0.0353	-0.3	-0.39	Leprosy;	chr8:89826378	chr8:89609409~89757727:-
THYM	cis	rs42490	0.625	rs43229	ENSG00000251136.7	RP11-37B2.1	-4.15	7.23e-05	0.0353	-0.3	-0.39	Leprosy;	chr8:89826558	chr8:89609409~89757727:-
THYM	cis	rs42490	0.625	rs438485	ENSG00000251136.7	RP11-37B2.1	-4.15	7.23e-05	0.0353	-0.3	-0.39	Leprosy;	chr8:89831190	chr8:89609409~89757727:-
THYM	cis	rs4835473	0.932	rs35164917	ENSG00000246448.2	RP13-578N3.3	-4.15	7.23e-05	0.0353	-0.5	-0.39	Immature fraction of reticulocytes;	chr4:143748891	chr4:143700257~143865072:+
THYM	cis	rs9425766	0.626	rs6691053	ENSG00000200674.1	RN7SKP160	4.15	7.23e-05	0.0353	0.49	0.39	Life satisfaction;	chr1:173899817	chr1:173791548~173791887:+
THYM	cis	rs17253792	0.732	rs79014965	ENSG00000186615.9	KTN1-AS1	-4.15	7.23e-05	0.0353	-0.77	-0.39	Putamen volume;	chr14:55650833	chr14:55499278~55580110:-
THYM	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	4.15	7.23e-05	0.0353	0.86	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
THYM	cis	rs7560272	0.588	rs4852959	ENSG00000273245.1	RP11-434P11.2	-4.15	7.24e-05	0.0354	-0.42	-0.39	Schizophrenia;	chr2:73653474	chr2:73750256~73750786:-
THYM	cis	rs17772222	0.561	rs8020376	ENSG00000258983.2	RP11-507K2.2	4.15	7.24e-05	0.0354	0.42	0.39	Coronary artery calcification;	chr14:88349823	chr14:88499334~88515502:+
THYM	cis	rs910316	0.737	rs175080	ENSG00000258646.1	RP11-950C14.3	4.15	7.25e-05	0.0354	0.35	0.39	Height;	chr14:75047125	chr14:75004719~75008481:-
THYM	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	4.15	7.25e-05	0.0354	0.42	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
THYM	cis	rs3015497	0.789	rs7147956	ENSG00000270062.1	RP11-248J18.3	4.15	7.25e-05	0.0354	0.28	0.39	Mean platelet volume;	chr14:50675887	chr14:50723777~50724272:-
THYM	cis	rs9907295	1	rs9889274	ENSG00000270977.1	AC015849.16	-4.15	7.25e-05	0.0354	-0.68	-0.39	Fibroblast growth factor basic levels;	chr17:35910397	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs9891064	ENSG00000270977.1	AC015849.16	-4.15	7.25e-05	0.0354	-0.68	-0.39	Fibroblast growth factor basic levels;	chr17:35913045	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs9899870	ENSG00000270977.1	AC015849.16	-4.15	7.25e-05	0.0354	-0.68	-0.39	Fibroblast growth factor basic levels;	chr17:35914438	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs11080360	ENSG00000270977.1	AC015849.16	-4.15	7.25e-05	0.0354	-0.68	-0.39	Fibroblast growth factor basic levels;	chr17:35916086	chr17:35893707~35911023:-
THYM	cis	rs9907295	1	rs11869976	ENSG00000270977.1	AC015849.16	-4.15	7.25e-05	0.0354	-0.68	-0.39	Fibroblast growth factor basic levels;	chr17:35916492	chr17:35893707~35911023:-
THYM	cis	rs62184315	0.52	rs62184268	ENSG00000273240.1	RP11-455J20.3	-4.15	7.26e-05	0.0354	-0.65	-0.39	Alcohol dependence (age at onset);	chr2:189767451	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs2289405	ENSG00000273240.1	RP11-455J20.3	-4.15	7.26e-05	0.0354	-0.65	-0.39	Alcohol dependence (age at onset);	chr2:189771313	chr2:189763859~189764456:-
THYM	cis	rs5742933	0.696	rs17271246	ENSG00000273240.1	RP11-455J20.3	-4.15	7.26e-05	0.0354	-0.65	-0.39	Ferritin levels;	chr2:189781481	chr2:189763859~189764456:-
THYM	cis	rs12908161	0.959	rs1051168	ENSG00000275120.1	RP11-182J1.17	4.15	7.26e-05	0.0354	0.53	0.39	Schizophrenia;	chr15:84657289	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.959	rs2175567	ENSG00000275120.1	RP11-182J1.17	4.15	7.26e-05	0.0354	0.53	0.39	Schizophrenia;	chr15:84657715	chr15:84599434~84606463:-
THYM	cis	rs12908161	0.92	rs12904605	ENSG00000275120.1	RP11-182J1.17	4.15	7.26e-05	0.0354	0.53	0.39	Schizophrenia;	chr15:84658188	chr15:84599434~84606463:-
THYM	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	4.15	7.27e-05	0.0355	0.52	0.39	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
THYM	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	4.15	7.27e-05	0.0355	0.52	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
THYM	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-4.15	7.28e-05	0.0355	-0.49	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
THYM	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	4.15	7.28e-05	0.0355	0.52	0.39	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
THYM	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-4.15	7.28e-05	0.0355	-0.36	-0.39	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
THYM	cis	rs12902680	0.739	rs1607725	ENSG00000259520.4	CTD-2651B20.3	4.15	7.28e-05	0.0355	0.42	0.39	Neuroticism;	chr15:46145787	chr15:45251580~45279251:-
THYM	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-4.15	7.29e-05	0.0355	-0.48	-0.39	Height;	chr11:118737916	chr11:118704607~118750263:+
THYM	cis	rs2115630	0.967	rs28595395	ENSG00000275120.1	RP11-182J1.17	-4.15	7.29e-05	0.0355	-0.46	-0.39	P wave terminal force;	chr15:84791721	chr15:84599434~84606463:-
THYM	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	4.15	7.29e-05	0.0355	0.55	0.39	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
THYM	cis	rs397969	0.646	rs6813	ENSG00000231645.2	KRT17P6	4.15	7.29e-05	0.0355	0.47	0.39	Platelet count;	chr17:19905132	chr17:20512560~20517479:-
THYM	cis	rs910316	0.967	rs175502	ENSG00000258646.1	RP11-950C14.3	4.15	7.3e-05	0.0356	0.37	0.39	Height;	chr14:75066976	chr14:75004719~75008481:-
THYM	cis	rs42490	0.614	rs445172	ENSG00000251136.7	RP11-37B2.1	-4.15	7.3e-05	0.0356	-0.3	-0.39	Leprosy;	chr8:89808322	chr8:89609409~89757727:-
THYM	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	4.15	7.3e-05	0.0356	0.51	0.39	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	4.15	7.3e-05	0.0356	0.51	0.39	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
THYM	cis	rs73108077	0.736	rs6058546	ENSG00000277112.2	RP11-755J8.1	-4.15	7.3e-05	0.0356	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31314582	chr20:30681825~30723932:-
THYM	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	4.15	7.31e-05	0.0356	0.48	0.39	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
THYM	cis	rs1790761	0.692	rs674783	ENSG00000231793.4	DOC2GP	-4.15	7.31e-05	0.0356	-0.35	-0.39	Mean corpuscular volume;	chr11:67571605	chr11:67612653~67616257:-
THYM	cis	rs950169	0.763	rs35372971	ENSG00000259683.1	RP11-182J1.14	4.15	7.32e-05	0.0357	0.37	0.39	Schizophrenia;	chr15:84387097	chr15:84389729~84395903:+
THYM	cis	rs910316	1	rs175449	ENSG00000258646.1	RP11-950C14.3	4.15	7.32e-05	0.0357	0.37	0.39	Height;	chr14:75124143	chr14:75004719~75008481:-
THYM	cis	rs910316	0.935	rs175448	ENSG00000258646.1	RP11-950C14.3	4.15	7.32e-05	0.0357	0.37	0.39	Height;	chr14:75124368	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs13099	ENSG00000258646.1	RP11-950C14.3	4.15	7.32e-05	0.0357	0.37	0.39	Height;	chr14:75132452	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs175479	ENSG00000258646.1	RP11-950C14.3	4.15	7.33e-05	0.0357	0.37	0.39	Height;	chr14:75095168	chr14:75004719~75008481:-
THYM	cis	rs12902680	0.706	rs28639752	ENSG00000259520.4	CTD-2651B20.3	4.15	7.33e-05	0.0357	0.41	0.39	Neuroticism;	chr15:46216501	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.739	rs28851955	ENSG00000259520.4	CTD-2651B20.3	4.15	7.33e-05	0.0357	0.42	0.39	Neuroticism;	chr15:46124085	chr15:45251580~45279251:-
THYM	cis	rs7631605	0.743	rs9839933	ENSG00000272334.1	RP11-129K12.1	-4.15	7.34e-05	0.0357	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37153671	chr3:36973117~36973672:-
THYM	cis	rs62246343	0.541	rs2596937	ENSG00000254485.4	RP11-380O24.1	4.15	7.34e-05	0.0357	0.5	0.39	Fibrinogen levels;	chr3:9439222	chr3:9292588~9363303:-
THYM	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	4.15	7.34e-05	0.0357	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	4.15	7.34e-05	0.0357	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	4.15	7.34e-05	0.0357	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	4.15	7.34e-05	0.0357	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	4.15	7.34e-05	0.0357	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	4.15	7.34e-05	0.0357	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	4.15	7.34e-05	0.0357	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
THYM	cis	rs7223966	1	rs28463311	ENSG00000240280.5	TCAM1P	-4.15	7.34e-05	0.0357	-0.59	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63842283	chr17:63849292~63864379:+
THYM	cis	rs877819	0.583	rs2620890	ENSG00000228403.1	RP11-563N6.6	-4.15	7.34e-05	0.0358	-0.5	-0.39	Systemic lupus erythematosus;	chr10:48851723	chr10:48878022~48878649:+
THYM	cis	rs877819	0.583	rs2889699	ENSG00000228403.1	RP11-563N6.6	-4.15	7.34e-05	0.0358	-0.5	-0.39	Systemic lupus erythematosus;	chr10:48854659	chr10:48878022~48878649:+
THYM	cis	rs4835473	0.838	rs4271960	ENSG00000249741.2	RP11-673E1.3	4.15	7.35e-05	0.0358	0.33	0.39	Immature fraction of reticulocytes;	chr4:143763591	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.808	rs2323198	ENSG00000249741.2	RP11-673E1.3	4.15	7.35e-05	0.0358	0.33	0.39	Immature fraction of reticulocytes;	chr4:143763595	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs2323199	ENSG00000249741.2	RP11-673E1.3	4.15	7.35e-05	0.0358	0.33	0.39	Immature fraction of reticulocytes;	chr4:143763606	chr4:143911514~143912053:-
THYM	cis	rs4948275	0.631	rs2606117	ENSG00000237233.2	TMEM26-AS1	-4.15	7.36e-05	0.0358	-0.44	-0.39	Night sleep phenotypes;	chr10:61592045	chr10:61452639~61481956:+
THYM	cis	rs9987353	0.522	rs2929466	ENSG00000253893.2	FAM85B	4.15	7.36e-05	0.0358	0.51	0.39	Recombination measurement;	chr8:9206389	chr8:8167819~8226614:-
THYM	cis	rs7182621	0.639	rs36069387	ENSG00000182397.13	DNM1P46	4.15	7.36e-05	0.0358	0.45	0.39	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99790156~99806927:-
THYM	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	4.15	7.37e-05	0.0358	0.46	0.39	Height;	chr6:109769861	chr6:109382795~109383666:+
THYM	cis	rs12902680	0.706	rs35416870	ENSG00000259520.4	CTD-2651B20.3	4.15	7.37e-05	0.0359	0.41	0.39	Neuroticism;	chr15:46147782	chr15:45251580~45279251:-
THYM	cis	rs17685	0.753	rs1637039	ENSG00000280388.1	RP11-229D13.3	-4.15	7.38e-05	0.0359	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76063691	chr7:76043977~76045963:-
THYM	cis	rs904251	0.686	rs931649	ENSG00000279942.1	RP1-153P14.7	-4.15	7.38e-05	0.0359	-0.56	-0.39	Cognitive performance;	chr6:37498303	chr6:37567716~37571460:+
THYM	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-4.15	7.38e-05	0.0359	-0.49	-0.39	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
THYM	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	4.15	7.38e-05	0.0359	0.49	0.39	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
THYM	cis	rs11976180	1	rs2961144	ENSG00000244479.5	OR2A1-AS1	-4.15	7.38e-05	0.0359	-0.35	-0.39	Obesity-related traits;	chr7:144050777	chr7:144251264~144356181:-
THYM	cis	rs7631605	0.935	rs2302503	ENSG00000272334.1	RP11-129K12.1	-4.15	7.38e-05	0.0359	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:37065979	chr3:36973117~36973672:-
THYM	cis	rs890448	0.896	rs9884436	ENSG00000254531.1	FLJ20021	-4.15	7.39e-05	0.0359	-0.34	-0.39	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101492114	chr4:101347780~101348883:+
THYM	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	4.15	7.39e-05	0.0359	0.5	0.39	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
THYM	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	4.15	7.39e-05	0.0359	0.5	0.39	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
THYM	cis	rs7246967	0.673	rs2112610	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34676724	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs16999580	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs55684269	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34003335	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs12974988	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs2194112	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs34907478	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs12985495	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs8103430	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs34174596	ENSG00000198153.8	ZNF849P	-4.15	7.4e-05	0.0359	-0.52	-0.39	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22685167~22686732:+
THYM	cis	rs12902680	0.706	rs28855391	ENSG00000259520.4	CTD-2651B20.3	4.15	7.4e-05	0.036	0.41	0.39	Neuroticism;	chr15:46179400	chr15:45251580~45279251:-
THYM	cis	rs11098499	0.82	rs13122709	ENSG00000250412.1	KLHL2P1	4.15	7.41e-05	0.036	0.38	0.39	Corneal astigmatism;	chr4:119634201	chr4:119334329~119378233:+
THYM	cis	rs7560272	0.723	rs6744697	ENSG00000163016.8	ALMS1P	4.15	7.41e-05	0.036	0.45	0.39	Schizophrenia;	chr2:73538311	chr2:73644919~73685576:+
THYM	cis	rs7631605	0.905	rs11717564	ENSG00000272334.1	RP11-129K12.1	-4.15	7.42e-05	0.036	-0.42	-0.39	Cerebrospinal P-tau181p levels;	chr3:37179397	chr3:36973117~36973672:-
THYM	cis	rs135150	0.588	rs130527	ENSG00000128254.12	C22orf24	-4.15	7.42e-05	0.036	-0.47	-0.39	Blood protein levels;	chr22:32767563	chr22:31933521~31945518:-
THYM	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	4.15	7.42e-05	0.036	0.42	0.39	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
THYM	cis	rs972578	0.806	rs5751386	ENSG00000215347.3	SLC25A5P1	-4.15	7.42e-05	0.036	-0.32	-0.39	Mean platelet volume;	chr22:42849339	chr22:42001069~42001966:-
THYM	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	4.15	7.43e-05	0.0361	0.49	0.39	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
THYM	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-4.14	7.44e-05	0.0361	-0.66	-0.39	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
THYM	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-4.14	7.44e-05	0.0361	-0.51	-0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
THYM	cis	rs7851726	0.69	rs10821392	ENSG00000232063.1	RP11-307E17.8	4.14	7.44e-05	0.0361	0.39	0.39	Urinary albumin-to-creatinine ratio;	chr9:94746625	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.69	rs7027708	ENSG00000232063.1	RP11-307E17.8	4.14	7.44e-05	0.0361	0.39	0.39	Urinary albumin-to-creatinine ratio;	chr9:94748390	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.646	rs10821393	ENSG00000232063.1	RP11-307E17.8	4.14	7.44e-05	0.0361	0.39	0.39	Urinary albumin-to-creatinine ratio;	chr9:94754478	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.646	rs10739983	ENSG00000232063.1	RP11-307E17.8	4.14	7.44e-05	0.0361	0.39	0.39	Urinary albumin-to-creatinine ratio;	chr9:94764002	chr9:94332476~94360948:+
THYM	cis	rs7851726	0.646	rs2031698	ENSG00000232063.1	RP11-307E17.8	4.14	7.44e-05	0.0361	0.39	0.39	Urinary albumin-to-creatinine ratio;	chr9:94779050	chr9:94332476~94360948:+
THYM	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-4.14	7.44e-05	0.0361	-0.47	-0.39	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
THYM	cis	rs3796619	1	rs55741287	ENSG00000215367.9	TMED11P	4.14	7.44e-05	0.0361	0.39	0.39	Recombination rate (males);	chr4:1100882	chr4:1115197~1153726:-
THYM	cis	rs7202877	0.706	rs2059257	ENSG00000261783.1	RP11-252K23.2	-4.14	7.45e-05	0.0361	-0.54	-0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75362478	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs8055609	ENSG00000261783.1	RP11-252K23.2	-4.14	7.45e-05	0.0361	-0.54	-0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75368190	chr16:75379818~75381260:-
THYM	cis	rs2235573	0.718	rs4373009	ENSG00000273096.1	RP3-508I15.20	4.14	7.46e-05	0.0361	0.31	0.39	Glioma;Glioblastoma;	chr22:38094049	chr22:38736610~38736792:-
THYM	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	4.14	7.46e-05	0.0361	0.51	0.39	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	4.14	7.46e-05	0.0361	0.51	0.39	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	4.14	7.46e-05	0.0361	0.51	0.39	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	4.14	7.46e-05	0.0361	0.51	0.39	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-4.14	7.46e-05	0.0361	-0.51	-0.39	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
THYM	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-4.14	7.46e-05	0.0361	-0.51	-0.39	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
THYM	cis	rs2911132	0.628	rs2032890	ENSG00000272109.1	CTD-2260A17.3	-4.14	7.46e-05	0.0361	-0.54	-0.39	Urate levels (BMI interaction);	chr5:96785448	chr5:96804353~96806105:+
THYM	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-4.14	7.46e-05	0.0361	-0.44	-0.39	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-4.14	7.46e-05	0.0361	-0.44	-0.39	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-4.14	7.46e-05	0.0361	-0.44	-0.39	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-4.14	7.46e-05	0.0361	-0.44	-0.39	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
THYM	cis	rs7429990	0.965	rs11130154	ENSG00000199476.1	Y_RNA	4.14	7.47e-05	0.0361	0.52	0.39	Educational attainment (years of education);	chr3:48027752	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs5012971	ENSG00000199476.1	Y_RNA	4.14	7.47e-05	0.0361	0.52	0.39	Educational attainment (years of education);	chr3:48033057	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.813	rs7637622	ENSG00000199476.1	Y_RNA	4.14	7.47e-05	0.0361	0.52	0.39	Educational attainment (years of education);	chr3:48051561	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs7627645	ENSG00000199476.1	Y_RNA	4.14	7.47e-05	0.0361	0.52	0.39	Educational attainment (years of education);	chr3:48051643	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs4858880	ENSG00000199476.1	Y_RNA	4.14	7.47e-05	0.0361	0.52	0.39	Educational attainment (years of education);	chr3:48062959	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.932	rs7620736	ENSG00000199476.1	Y_RNA	4.14	7.47e-05	0.0361	0.52	0.39	Educational attainment (years of education);	chr3:48068479	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs6791834	ENSG00000199476.1	Y_RNA	4.14	7.47e-05	0.0361	0.52	0.39	Educational attainment (years of education);	chr3:48073598	chr3:48288587~48288694:+
THYM	cis	rs904251	0.62	rs883372	ENSG00000279942.1	RP1-153P14.7	-4.14	7.47e-05	0.0361	-0.56	-0.39	Cognitive performance;	chr6:37509829	chr6:37567716~37571460:+
THYM	cis	rs972578	1	rs4822242	ENSG00000215347.3	SLC25A5P1	-4.14	7.47e-05	0.0361	-0.31	-0.39	Mean platelet volume;	chr22:42979433	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5759071	ENSG00000215347.3	SLC25A5P1	-4.14	7.47e-05	0.0361	-0.31	-0.39	Mean platelet volume;	chr22:42979944	chr22:42001069~42001966:-
THYM	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-4.14	7.47e-05	0.0361	-0.45	-0.39	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-4.14	7.47e-05	0.0361	-0.45	-0.39	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-4.14	7.47e-05	0.0361	-0.45	-0.39	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-4.14	7.47e-05	0.0361	-0.45	-0.39	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
THYM	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-4.14	7.47e-05	0.0361	-0.45	-0.39	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
THYM	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-4.14	7.47e-05	0.0361	-0.54	-0.39	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
THYM	cis	rs2243480	1	rs34136756	ENSG00000228409.4	CCT6P1	4.14	7.47e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65916269	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs34933526	ENSG00000228409.4	CCT6P1	4.14	7.47e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65918212	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs6949812	ENSG00000228409.4	CCT6P1	4.14	7.47e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65922114	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs6970243	ENSG00000228409.4	CCT6P1	4.14	7.47e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65923503	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs7794661	ENSG00000228409.4	CCT6P1	4.14	7.47e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65924743	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.708	rs35310401	ENSG00000228409.4	CCT6P1	4.14	7.47e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65925372	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs35058610	ENSG00000228409.4	CCT6P1	4.14	7.47e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65925938	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.831	rs7806717	ENSG00000228409.4	CCT6P1	-4.14	7.47e-05	0.0361	-0.49	-0.39	Diabetic kidney disease;	chr7:65928187	chr7:65751142~65763354:+
THYM	cis	rs6121246	0.909	rs6060679	ENSG00000230613.1	HM13-AS1	-4.14	7.48e-05	0.0361	-0.59	-0.39	Mean corpuscular hemoglobin;	chr20:31682969	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.821	rs3181073	ENSG00000230613.1	HM13-AS1	-4.14	7.48e-05	0.0361	-0.59	-0.39	Mean corpuscular hemoglobin;	chr20:31719396	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060960	ENSG00000230613.1	HM13-AS1	-4.14	7.48e-05	0.0361	-0.59	-0.39	Mean corpuscular hemoglobin;	chr20:31806714	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6119729	ENSG00000230613.1	HM13-AS1	-4.14	7.48e-05	0.0361	-0.59	-0.39	Mean corpuscular hemoglobin;	chr20:31825360	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs7272062	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31671342	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6119651	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31671443	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060633	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31675514	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs2376992	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31675615	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060644	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31677849	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.779	rs6060763	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31694420	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060821	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31706231	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.865	rs6058421	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31707210	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060870	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31715496	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.821	rs6121209	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31723455	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs57726761	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31726243	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.738	rs2376996	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31728864	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.821	rs7265413	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31730120	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.697	rs6060912	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31737952	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6089058	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31738535	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.821	rs6119718	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31743271	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.821	rs6058448	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31744593	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs8126355	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31744857	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060923	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31748852	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6058450	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31756108	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060929	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31758111	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6119720	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31759765	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6087778	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31766339	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6089071	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31790581	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs3203770	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31794512	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6058463	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31797389	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6119725	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31797754	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs1075698	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31800189	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.738	rs6121242	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31823074	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.954	rs6058470	ENSG00000230613.1	HM13-AS1	4.14	7.48e-05	0.0361	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31829024	chr20:31567707~31573263:-
THYM	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	4.14	7.48e-05	0.0361	0.31	0.39	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
THYM	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	4.14	7.48e-05	0.0361	0.54	0.39	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	4.14	7.48e-05	0.0361	0.54	0.39	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
THYM	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	4.14	7.49e-05	0.0361	0.55	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	4.14	7.49e-05	0.0361	0.55	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
THYM	cis	rs2243480	1	rs3885839	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65825416	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.901	rs3813708	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65840645	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs73142122	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65846311	chr7:65751142~65763354:+
THYM	cis	rs2243480	0.901	rs73142137	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65878455	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs13247184	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65893941	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs35283677	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65894246	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs35421653	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65898442	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs73142162	ENSG00000228409.4	CCT6P1	4.14	7.49e-05	0.0361	0.49	0.39	Diabetic kidney disease;	chr7:65909309	chr7:65751142~65763354:+
THYM	cis	rs910316	0.763	rs175490	ENSG00000258646.1	RP11-950C14.3	-4.14	7.49e-05	0.0361	-0.35	-0.39	Height;	chr14:75078982	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs175084	ENSG00000258646.1	RP11-950C14.3	4.14	7.49e-05	0.0361	0.35	0.39	Height;	chr14:75052472	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs175499	ENSG00000258646.1	RP11-950C14.3	4.14	7.49e-05	0.0361	0.35	0.39	Height;	chr14:75069224	chr14:75004719~75008481:-
THYM	cis	rs910316	0.789	rs175457	ENSG00000258646.1	RP11-950C14.3	4.14	7.49e-05	0.0361	0.35	0.39	Height;	chr14:75117804	chr14:75004719~75008481:-
THYM	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-4.14	7.49e-05	0.0361	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-4.14	7.49e-05	0.0361	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-4.14	7.49e-05	0.0361	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10242419	ENSG00000273391.1	RP11-634H22.1	-4.14	7.49e-05	0.0361	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139404634	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-4.14	7.49e-05	0.0361	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-4.14	7.49e-05	0.0361	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs6967932	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139337635	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7808740	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139344209	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10274480	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139367682	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	4.14	7.49e-05	0.0361	0.32	0.39	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
THYM	cis	rs17685	0.753	rs10264760	ENSG00000280388.1	RP11-229D13.3	-4.14	7.5e-05	0.0361	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76120376	chr7:76043977~76045963:-
THYM	cis	rs3015497	0.789	rs11621971	ENSG00000270062.1	RP11-248J18.3	-4.14	7.5e-05	0.0361	-0.27	-0.39	Mean platelet volume;	chr14:50657809	chr14:50723777~50724272:-
THYM	cis	rs11574514	1	rs75733050	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68068038	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs75739761	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68089011	chr16:68212401~68221671:-
THYM	cis	rs11574514	0.661	rs114329216	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68095198	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs78961715	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68097504	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs74817508	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68104446	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs116988148	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68113049	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117300105	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68136395	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs75788262	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68138587	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs116971206	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68139253	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs7195398	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68141386	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs118143176	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68150347	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117620519	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68160986	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs75126935	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68165096	chr16:68212401~68221671:-
THYM	cis	rs11574514	0.661	rs74775711	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68179777	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs78587942	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68182836	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs77055954	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68212525	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs1073632	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68214704	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117571960	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68237358	chr16:68212401~68221671:-
THYM	cis	rs11574514	0.661	rs117759106	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68241227	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs115391623	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68242161	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs79972507	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68248874	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs116886316	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68252388	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117199628	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68252435	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117164273	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68258713	chr16:68212401~68221671:-
THYM	cis	rs11574514	0.661	rs116844179	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68260097	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs117417273	ENSG00000260891.1	RP11-96D1.5	-4.14	7.5e-05	0.0361	-0.48	-0.39	Crohn's disease;	chr16:68265794	chr16:68212401~68221671:-
THYM	cis	rs9481169	0.557	rs33980500	ENSG00000231889.6	TRAF3IP2-AS1	4.14	7.51e-05	0.0361	0.35	0.39	Inflammatory skin disease;	chr6:111592059	chr6:111483511~111598302:+
THYM	cis	rs910316	0.763	rs175450	ENSG00000258646.1	RP11-950C14.3	4.14	7.51e-05	0.0362	0.35	0.39	Height;	chr14:75123637	chr14:75004719~75008481:-
THYM	cis	rs1223397	0.938	rs20500	ENSG00000215022.6	RP1-257A7.4	4.14	7.51e-05	0.0362	0.47	0.39	Blood pressure;	chr6:13294744	chr6:13264861~13295586:-
THYM	cis	rs10129255	1	rs10134517	ENSG00000253703.1	IGHV1-68	-4.14	7.51e-05	0.0362	-0.51	-0.39	Kawasaki disease;	chr14:106718498	chr14:106703852~106704146:-
THYM	cis	rs11157436	1	rs72638482	ENSG00000211812.1	TRAV26-2	-4.14	7.52e-05	0.0362	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22202583~22203368:+
THYM	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-4.14	7.52e-05	0.0362	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
THYM	cis	rs877819	0.583	rs2620881	ENSG00000228403.1	RP11-563N6.6	-4.14	7.52e-05	0.0362	-0.52	-0.39	Systemic lupus erythematosus;	chr10:48875066	chr10:48878022~48878649:+
THYM	cis	rs12902680	0.706	rs10162815	ENSG00000259520.4	CTD-2651B20.3	4.14	7.52e-05	0.0362	0.41	0.39	Neuroticism;	chr15:46169522	chr15:45251580~45279251:-
THYM	cis	rs2738048	0.883	rs2075836	ENSG00000233531.1	DEFA10P	-4.14	7.52e-05	0.0362	-0.41	-0.39	IgA nephropathy;	chr8:6951200	chr8:6968141~6969113:-
THYM	cis	rs6782228	0.509	rs4481172	ENSG00000277250.1	Metazoa_SRP	-4.14	7.53e-05	0.0362	-0.54	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128673681~128674021:-
THYM	cis	rs202072	0.652	rs1223393	ENSG00000272379.1	RP1-257A7.5	-4.14	7.53e-05	0.0362	-0.6	-0.39	HIV-1 viral setpoint;	chr6:13265102	chr6:13290018~13290490:-
THYM	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-4.14	7.53e-05	0.0362	-0.5	-0.39	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
THYM	cis	rs7429990	0.965	rs4599334	ENSG00000199476.1	Y_RNA	4.14	7.53e-05	0.0362	0.52	0.39	Educational attainment (years of education);	chr3:48024910	chr3:48288587~48288694:+
THYM	cis	rs10129255	0.957	rs8009948	ENSG00000254329.1	IGHVII-60-1	4.14	7.53e-05	0.0362	0.42	0.39	Kawasaki disease;	chr14:106805607	chr14:106637718~106637973:-
THYM	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-4.14	7.53e-05	0.0362	-0.58	-0.39	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
THYM	cis	rs453301	0.631	rs7843369	ENSG00000253893.2	FAM85B	4.14	7.54e-05	0.0363	0.51	0.39	Joint mobility (Beighton score);	chr8:8940276	chr8:8167819~8226614:-
THYM	cis	rs34792	0.889	rs2445475	ENSG00000262380.1	CTB-193M12.3	-4.14	7.55e-05	0.0363	-0.49	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508247	chr16:15683290~15684570:+
THYM	cis	rs4809760	0.532	rs2869936	ENSG00000229222.1	KRT18P4	4.14	7.55e-05	0.0363	0.5	0.39	Gut microbiota (beta diversity);	chr20:49877456	chr20:49956745~49958032:+
THYM	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	4.14	7.55e-05	0.0363	0.41	0.39	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
THYM	cis	rs11098499	0.874	rs28452522	ENSG00000250412.1	KLHL2P1	4.14	7.55e-05	0.0363	0.38	0.39	Corneal astigmatism;	chr4:119189629	chr4:119334329~119378233:+
THYM	cis	rs1584120	0.57	rs17459026	ENSG00000256321.4	RP11-153K16.1	-4.14	7.55e-05	0.0363	-0.44	-0.39	Pelvic organ prolapse (moderate/severe);	chr12:23107065	chr12:23099368~23191587:+
THYM	cis	rs34792	0.637	rs34793	ENSG00000262380.1	CTB-193M12.3	-4.14	7.55e-05	0.0363	-0.5	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15491779	chr16:15683290~15684570:+
THYM	cis	rs3781264	0.724	rs11558740	ENSG00000273450.1	RP11-76P2.4	4.14	7.56e-05	0.0363	0.48	0.39	Esophageal cancer and gastric cancer;	chr10:94333618	chr10:94314907~94315327:-
THYM	cis	rs7247513	0.701	rs8107642	ENSG00000213290.4	PGK1P2	-4.14	7.56e-05	0.0363	-0.4	-0.39	Bipolar disorder;	chr19:12655556	chr19:12559571~12561105:+
THYM	cis	rs11098499	0.874	rs13123591	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119184835	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs7661020	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119185827	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs9995277	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119187448	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs17839089	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119189914	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs6826823	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119190943	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs12509054	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119193920	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs10022508	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119194073	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs12502503	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119195100	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs6851169	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119196355	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.874	rs6832670	ENSG00000250412.1	KLHL2P1	4.14	7.56e-05	0.0364	0.38	0.39	Corneal astigmatism;	chr4:119197637	chr4:119334329~119378233:+
THYM	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-4.14	7.56e-05	0.0364	-0.53	-0.39	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
THYM	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	4.14	7.56e-05	0.0364	0.49	0.39	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
THYM	cis	rs6121246	0.559	rs6060599	ENSG00000230613.1	HM13-AS1	4.14	7.57e-05	0.0364	0.55	0.39	Mean corpuscular hemoglobin;	chr20:31669951	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6119650	ENSG00000230613.1	HM13-AS1	4.14	7.57e-05	0.0364	0.55	0.39	Mean corpuscular hemoglobin;	chr20:31670677	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.559	rs6060933	ENSG00000230613.1	HM13-AS1	4.14	7.57e-05	0.0364	0.55	0.39	Mean corpuscular hemoglobin;	chr20:31764100	chr20:31567707~31573263:-
THYM	cis	rs10193935	0.786	rs13416119	ENSG00000279873.2	LINC01126	4.14	7.57e-05	0.0364	0.46	0.39	Colonoscopy-negative controls vs population controls;	chr2:42235790	chr2:43227210~43228855:+
THYM	cis	rs853679	0.76	rs2299029	ENSG00000272009.1	RP1-313I6.12	-4.14	7.57e-05	0.0364	-0.55	-0.39	Depression;	chr6:28231053	chr6:28078792~28081130:-
THYM	cis	rs10129255	0.957	rs8009073	ENSG00000254329.1	IGHVII-60-1	4.14	7.58e-05	0.0364	0.41	0.39	Kawasaki disease;	chr14:106777278	chr14:106637718~106637973:-
THYM	cis	rs2115536	0.692	rs6495450	ENSG00000278600.1	RP11-81A1.6	-4.14	7.58e-05	0.0364	-0.31	-0.39	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79870157	chr15:79920195~79922455:-
THYM	cis	rs2562456	0.837	rs62110205	ENSG00000268081.1	RP11-678G14.2	4.14	7.59e-05	0.0365	0.51	0.39	Pain;	chr19:21577269	chr19:21554640~21569237:-
THYM	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	4.14	7.59e-05	0.0365	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
THYM	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	4.14	7.59e-05	0.0365	0.52	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
THYM	cis	rs13248545	0.6	rs7386669	ENSG00000253944.1	RP11-156K13.1	-4.14	7.59e-05	0.0365	-0.38	-0.39	Yeast infection;	chr8:17756286	chr8:17801345~17861069:+
THYM	cis	rs17685	0.671	rs10274404	ENSG00000280388.1	RP11-229D13.3	-4.14	7.6e-05	0.0365	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76077316	chr7:76043977~76045963:-
THYM	cis	rs972578	1	rs972577	ENSG00000215347.3	SLC25A5P1	-4.14	7.6e-05	0.0365	-0.31	-0.39	Mean platelet volume;	chr22:42991639	chr22:42001069~42001966:-
THYM	cis	rs2115536	0.64	rs934134	ENSG00000278600.1	RP11-81A1.6	-4.14	7.6e-05	0.0365	-0.31	-0.39	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79875876	chr15:79920195~79922455:-
THYM	cis	rs7210990	0.836	rs12947205	ENSG00000275413.1	CTC-529I10.1	4.14	7.6e-05	0.0365	0.39	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16090013	chr17:16023323~16023653:-
THYM	cis	rs394563	0.775	rs412894	ENSG00000219487.2	RP11-365H23.1	4.14	7.6e-05	0.0365	0.46	0.39	Dupuytren's disease;	chr6:149460039	chr6:149112009~149112672:-
THYM	cis	rs394563	0.717	rs548848	ENSG00000219487.2	RP11-365H23.1	4.14	7.6e-05	0.0365	0.46	0.39	Dupuytren's disease;	chr6:149460873	chr6:149112009~149112672:-
THYM	cis	rs394563	0.775	rs399673	ENSG00000219487.2	RP11-365H23.1	4.14	7.6e-05	0.0365	0.46	0.39	Dupuytren's disease;	chr6:149462085	chr6:149112009~149112672:-
THYM	cis	rs741668	0.759	rs12428399	ENSG00000235903.6	CPB2-AS1	4.14	7.6e-05	0.0365	0.47	0.39	Cerebrospinal fluid clusterin levels;	chr13:46060804	chr13:46052806~46113332:+
THYM	cis	rs13068223	0.617	rs13061457	ENSG00000243926.1	TIPARP-AS1	4.14	7.61e-05	0.0365	0.31	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156671862~156674378:-
THYM	cis	rs4842666	0.915	rs11105376	ENSG00000258302.2	RP11-981P6.1	4.14	7.61e-05	0.0365	0.43	0.39	Blood pressure;	chr12:89694991	chr12:89561129~89594878:+
THYM	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	4.14	7.61e-05	0.0365	0.51	0.39	Height;	chr6:109741085	chr6:109382795~109383666:+
THYM	cis	rs1023500	0.505	rs134899	ENSG00000227370.1	RP4-669P10.19	4.14	7.61e-05	0.0365	0.46	0.39	Schizophrenia;	chr22:42287024	chr22:42132543~42132998:+
THYM	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	4.14	7.61e-05	0.0365	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	4.14	7.61e-05	0.0365	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	4.14	7.61e-05	0.0365	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	4.14	7.61e-05	0.0365	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	4.14	7.61e-05	0.0365	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	4.14	7.61e-05	0.0365	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
THYM	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	4.14	7.61e-05	0.0365	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
THYM	cis	rs7116495	1	rs2845857	ENSG00000248671.6	ALG1L9P	-4.14	7.62e-05	0.0366	-0.98	-0.39	Severe influenza A (H1N1) infection;	chr11:72004169	chr11:71794363~71818238:-
THYM	cis	rs4691139	0.658	rs4691142	ENSG00000250227.1	TRIM60P14	4.14	7.62e-05	0.0366	0.47	0.39	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005634	chr4:164915565~164916983:+
THYM	cis	rs12902680	0.706	rs12899640	ENSG00000259520.4	CTD-2651B20.3	4.14	7.62e-05	0.0366	0.41	0.39	Neuroticism;	chr15:46154313	chr15:45251580~45279251:-
THYM	cis	rs4835473	0.897	rs2590034	ENSG00000249741.2	RP11-673E1.3	-4.14	7.62e-05	0.0366	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143926778	chr4:143911514~143912053:-
THYM	cis	rs7223966	1	rs8069687	ENSG00000240280.5	TCAM1P	4.14	7.62e-05	0.0366	0.57	0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63805663	chr17:63849292~63864379:+
THYM	cis	rs990871	1	rs2568960	ENSG00000227207.2	RPL31P12	-4.14	7.62e-05	0.0366	-0.54	-0.39	Subcutaneous adipose tissue;	chr1:72346566	chr1:72301472~72301829:+
THYM	cis	rs990871	1	rs2815753	ENSG00000227207.2	RPL31P12	-4.14	7.62e-05	0.0366	-0.54	-0.39	Subcutaneous adipose tissue;	chr1:72346641	chr1:72301472~72301829:+
THYM	cis	rs8067545	1	rs7218708	ENSG00000231645.2	KRT17P6	-4.14	7.63e-05	0.0366	-0.47	-0.39	Schizophrenia;	chr17:20023523	chr17:20512560~20517479:-
THYM	cis	rs935334	0.866	rs11850433	ENSG00000258454.1	RP11-361H10.3	-4.14	7.63e-05	0.0366	-0.52	-0.39	Blood pressure;	chr14:76215140	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs57844481	ENSG00000258454.1	RP11-361H10.3	-4.14	7.63e-05	0.0366	-0.52	-0.39	Blood pressure;	chr14:76218150	chr14:76235817~76263474:+
THYM	cis	rs877819	0.552	rs2620878	ENSG00000228403.1	RP11-563N6.6	-4.14	7.63e-05	0.0366	-0.5	-0.39	Systemic lupus erythematosus;	chr10:48879727	chr10:48878022~48878649:+
THYM	cis	rs4908760	0.795	rs6693009	ENSG00000232912.4	RP5-1115A15.1	4.14	7.64e-05	0.0366	0.37	0.39	Vitiligo;	chr1:8683651	chr1:8424645~8434838:+
THYM	cis	rs7976269	0.559	rs9651838	ENSG00000275476.1	RP11-996F15.4	4.14	7.64e-05	0.0367	0.48	0.39	Male-pattern baldness;	chr12:28999700	chr12:29277397~29277882:-
THYM	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-4.14	7.65e-05	0.0367	-0.47	-0.39	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-4.14	7.65e-05	0.0367	-0.47	-0.39	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-4.14	7.65e-05	0.0367	-0.47	-0.39	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-4.14	7.65e-05	0.0367	-0.47	-0.39	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-4.14	7.65e-05	0.0367	-0.47	-0.39	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-4.14	7.65e-05	0.0367	-0.47	-0.39	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-4.14	7.65e-05	0.0367	-0.47	-0.39	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
THYM	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	4.14	7.65e-05	0.0367	0.49	0.39	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
THYM	cis	rs62246343	0.605	rs3898760	ENSG00000254485.4	RP11-380O24.1	4.14	7.65e-05	0.0367	0.5	0.39	Fibrinogen levels;	chr3:9453435	chr3:9292588~9363303:-
THYM	cis	rs58904263	1	rs58904263	ENSG00000230613.1	HM13-AS1	4.14	7.66e-05	0.0367	0.59	0.39	Monocyte count;	chr20:31813603	chr20:31567707~31573263:-
THYM	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	4.14	7.66e-05	0.0367	0.32	0.39	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
THYM	cis	rs11098499	0.863	rs3775841	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119504622	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775843	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119506689	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775844	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119506878	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs7664986	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119508797	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.818	rs10008791	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119510314	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs11736416	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119510506	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775845	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119511292	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1383533	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119513421	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs2291185	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119513678	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs10030660	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119515549	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs13149407	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119516670	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs34868248	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119521275	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3822192	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119524565	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3733525	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119525893	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775847	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119526487	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775848	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119526569	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs10013305	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119529269	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs3775849	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119529753	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.818	rs7688802	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119530513	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs7695620	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119531621	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs12502389	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119533036	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.821	rs3775852	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119533401	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.82	rs6534140	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119534156	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs7657849	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119534339	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs10034450	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119534494	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1480939	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119535772	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1480940	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119536527	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs6835635	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119537712	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs58452170	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119538519	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1552095	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119539151	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs7678400	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119540802	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1480936	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119541706	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs11098531	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119543846	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs28718422	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119545149	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs12498539	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119547215	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.818	rs12498599	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119547348	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs10009626	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119548850	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs59732491	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119568433	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs11723090	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119569437	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs11098532	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119569571	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs13140391	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119582282	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs13140409	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119582305	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs6833334	ENSG00000250412.1	KLHL2P1	4.14	7.66e-05	0.0367	0.37	0.39	Corneal astigmatism;	chr4:119583072	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs1383532	ENSG00000250412.1	KLHL2P1	-4.14	7.66e-05	0.0367	-0.37	-0.39	Corneal astigmatism;	chr4:119513249	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.82	rs13128602	ENSG00000250412.1	KLHL2P1	-4.14	7.66e-05	0.0367	-0.37	-0.39	Corneal astigmatism;	chr4:119538211	chr4:119334329~119378233:+
THYM	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-4.14	7.66e-05	0.0367	-0.74	-0.39	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
THYM	cis	rs995758	1	rs12511230	ENSG00000236296.6	GUSBP5	4.14	7.66e-05	0.0367	0.46	0.39	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144550093	chr4:143559472~143649305:+
THYM	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	4.14	7.67e-05	0.0367	0.44	0.39	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
THYM	cis	rs972578	1	rs3819677	ENSG00000215347.3	SLC25A5P1	-4.14	7.67e-05	0.0367	-0.31	-0.39	Mean platelet volume;	chr22:42990685	chr22:42001069~42001966:-
THYM	cis	rs397969	0.646	rs203467	ENSG00000231645.2	KRT17P6	-4.14	7.67e-05	0.0367	-0.49	-0.39	Platelet count;	chr17:19906436	chr17:20512560~20517479:-
THYM	cis	rs2115536	0.692	rs8036559	ENSG00000278600.1	RP11-81A1.6	-4.14	7.67e-05	0.0367	-0.31	-0.39	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79878221	chr15:79920195~79922455:-
THYM	cis	rs11891401	0.959	rs13031308	ENSG00000277998.1	RP11-452N17.1	-4.14	7.67e-05	0.0367	-0.5	-0.39	Blood pressure;	chr2:164211007	chr2:164573741~164574054:+
THYM	cis	rs6930781	0.587	rs9372244	ENSG00000219700.1	PTCHD3P3	-4.14	7.67e-05	0.0367	-0.44	-0.39	Major depression and alcohol dependence;	chr6:110036155	chr6:109288571~109290503:-
THYM	cis	rs3781913	0.675	rs341051	ENSG00000228915.3	OR7E128P	-4.14	7.67e-05	0.0367	-0.42	-0.39	Rheumatoid arthritis;	chr11:72634860	chr11:71893410~71894433:+
THYM	cis	rs7223966	1	rs9747164	ENSG00000240280.5	TCAM1P	-4.14	7.68e-05	0.0368	-0.59	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63787427	chr17:63849292~63864379:+
THYM	cis	rs863345	0.967	rs10797028	ENSG00000236656.1	RP11-144L1.4	4.14	7.68e-05	0.0368	0.25	0.39	Pneumococcal bacteremia;	chr1:158553451	chr1:158474454~158494886:-
THYM	cis	rs564343	0.563	rs1642958	ENSG00000255320.1	RP11-755F10.1	-4.14	7.68e-05	0.0368	-0.44	-0.39	Obesity (early onset extreme);	chr11:66054502	chr11:66244840~66246239:-
THYM	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	4.14	7.68e-05	0.0368	0.48	0.39	Height;	chr11:118758322	chr11:118704607~118750263:+
THYM	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-4.14	7.68e-05	0.0368	-0.48	-0.39	Height;	chr11:118749988	chr11:118704607~118750263:+
THYM	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	4.14	7.69e-05	0.0368	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
THYM	cis	rs7560272	0.723	rs6722867	ENSG00000273245.1	RP11-434P11.2	4.14	7.69e-05	0.0368	0.44	0.39	Schizophrenia;	chr2:73589158	chr2:73750256~73750786:-
THYM	cis	rs972578	0.837	rs5758980	ENSG00000215347.3	SLC25A5P1	-4.14	7.69e-05	0.0368	-0.32	-0.39	Mean platelet volume;	chr22:42847950	chr22:42001069~42001966:-
THYM	cis	rs12902680	0.706	rs28499264	ENSG00000259520.4	CTD-2651B20.3	4.14	7.7e-05	0.0368	0.41	0.39	Neuroticism;	chr15:46204508	chr15:45251580~45279251:-
THYM	cis	rs7851726	0.668	rs10821410	ENSG00000232063.1	RP11-307E17.8	4.14	7.7e-05	0.0368	0.39	0.39	Urinary albumin-to-creatinine ratio;	chr9:94880731	chr9:94332476~94360948:+
THYM	cis	rs62184315	0.536	rs5743047	ENSG00000273240.1	RP11-455J20.3	4.14	7.7e-05	0.0368	0.65	0.39	Alcohol dependence (age at onset);	chr2:189819942	chr2:189763859~189764456:-
THYM	cis	rs62184315	0.536	rs56324258	ENSG00000273240.1	RP11-455J20.3	-4.14	7.7e-05	0.0368	-0.65	-0.39	Alcohol dependence (age at onset);	chr2:189811589	chr2:189763859~189764456:-
THYM	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-4.14	7.7e-05	0.0368	-0.4	-0.39	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
THYM	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-4.14	7.7e-05	0.0368	-0.4	-0.39	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
THYM	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-4.14	7.7e-05	0.0368	-0.48	-0.39	Height;	chr11:118737823	chr11:118704607~118750263:+
THYM	cis	rs9813712	0.595	rs6439226	ENSG00000228252.7	COL6A4P2	4.14	7.71e-05	0.0369	0.43	0.39	Response to amphetamines;	chr3:130283686	chr3:130212823~130273806:+
THYM	cis	rs7247513	0.859	rs35945052	ENSG00000213290.4	PGK1P2	-4.14	7.71e-05	0.0369	-0.44	-0.39	Bipolar disorder;	chr19:12592416	chr19:12559571~12561105:+
THYM	cis	rs7247513	0.93	rs34321000	ENSG00000213290.4	PGK1P2	-4.14	7.71e-05	0.0369	-0.44	-0.39	Bipolar disorder;	chr19:12602274	chr19:12559571~12561105:+
THYM	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	4.13	7.72e-05	0.0369	0.34	0.39	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
THYM	cis	rs17253792	0.822	rs112739186	ENSG00000186615.9	KTN1-AS1	-4.13	7.72e-05	0.0369	-0.8	-0.39	Putamen volume;	chr14:55598449	chr14:55499278~55580110:-
THYM	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	4.13	7.72e-05	0.0369	0.53	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
THYM	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	4.13	7.72e-05	0.0369	0.32	0.39	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
THYM	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-4.13	7.72e-05	0.0369	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-4.13	7.72e-05	0.0369	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-4.13	7.72e-05	0.0369	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-4.13	7.72e-05	0.0369	-0.32	-0.39	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	4.13	7.72e-05	0.0369	0.32	0.39	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
THYM	cis	rs9402743	0.671	rs9373138	ENSG00000236703.1	MYB-AS1	-4.13	7.72e-05	0.0369	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135630343	chr6:135195083~135195995:-
THYM	cis	rs12959333	0.772	rs12957327	ENSG00000274849.1	RP11-49I11.4	-4.13	7.73e-05	0.0369	-0.62	-0.39	Post bronchodilator FEV1;	chr18:35595091	chr18:36189824~36190272:+
THYM	cis	rs12681366	0.511	rs2919670	ENSG00000253704.1	RP11-267M23.4	4.13	7.73e-05	0.0369	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94444390	chr8:94553722~94569745:+
THYM	cis	rs7429990	0.965	rs2166770	ENSG00000199476.1	Y_RNA	-4.13	7.73e-05	0.0369	-0.54	-0.39	Educational attainment (years of education);	chr3:47964183	chr3:48288587~48288694:+
THYM	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	4.13	7.73e-05	0.0369	0.34	0.39	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-4.13	7.73e-05	0.0369	-0.34	-0.39	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-4.13	7.73e-05	0.0369	-0.34	-0.39	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-4.13	7.73e-05	0.0369	-0.34	-0.39	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
THYM	cis	rs202072	0.652	rs453695	ENSG00000272379.1	RP1-257A7.5	-4.13	7.74e-05	0.0369	-0.57	-0.39	HIV-1 viral setpoint;	chr6:13262274	chr6:13290018~13290490:-
THYM	cis	rs7927592	0.956	rs6591341	ENSG00000222339.1	AP000807.2	4.13	7.74e-05	0.0369	0.44	0.39	Total body bone mineral density;	chr11:68568010	chr11:68505572~68505651:-
THYM	cis	rs4908760	0.827	rs2401138	ENSG00000232912.4	RP5-1115A15.1	-4.13	7.74e-05	0.037	-0.38	-0.39	Vitiligo;	chr1:8644000	chr1:8424645~8434838:+
THYM	cis	rs7631605	0.874	rs6806252	ENSG00000272334.1	RP11-129K12.1	-4.13	7.75e-05	0.037	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37109497	chr3:36973117~36973672:-
THYM	cis	rs4835473	0.897	rs4835095	ENSG00000249741.2	RP11-673E1.3	-4.13	7.76e-05	0.037	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143960431	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.831	rs2667353	ENSG00000249741.2	RP11-673E1.3	-4.13	7.76e-05	0.037	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143960462	chr4:143911514~143912053:-
THYM	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	4.13	7.76e-05	0.037	0.48	0.39	Depression;	chr6:28379133	chr6:28176188~28176674:+
THYM	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	4.13	7.76e-05	0.037	0.48	0.39	Depression;	chr6:28379168	chr6:28176188~28176674:+
THYM	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	4.13	7.76e-05	0.037	0.48	0.39	Depression;	chr6:28386473	chr6:28176188~28176674:+
THYM	cis	rs9309473	0.5	rs10189578	ENSG00000163016.8	ALMS1P	4.13	7.77e-05	0.037	0.45	0.39	Metabolite levels;	chr2:73501482	chr2:73644919~73685576:+
THYM	cis	rs73198271	0.813	rs17697237	ENSG00000253893.2	FAM85B	-4.13	7.77e-05	0.0371	-0.58	-0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8167819~8226614:-
THYM	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	4.13	7.78e-05	0.0371	0.5	0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
THYM	cis	rs11574514	1	rs74851284	ENSG00000260891.1	RP11-96D1.5	-4.13	7.78e-05	0.0371	-0.48	-0.39	Crohn's disease;	chr16:68138665	chr16:68212401~68221671:-
THYM	cis	rs11574514	1	rs116580887	ENSG00000260891.1	RP11-96D1.5	-4.13	7.78e-05	0.0371	-0.48	-0.39	Crohn's disease;	chr16:68265599	chr16:68212401~68221671:-
THYM	cis	rs7223966	0.96	rs8082651	ENSG00000240280.5	TCAM1P	-4.13	7.78e-05	0.0371	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63597933	chr17:63849292~63864379:+
THYM	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	4.13	7.78e-05	0.0371	0.51	0.39	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
THYM	cis	rs1065852	0.526	rs11090066	ENSG00000273424.1	CTA-223H9.9	-4.13	7.79e-05	0.0371	-0.34	-0.39	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002191	chr22:41430934~41431375:+
THYM	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	4.13	7.79e-05	0.0372	0.6	0.39	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
THYM	cis	rs11139399	0.613	rs10867803	ENSG00000233926.1	RP11-154D17.1	-4.13	7.8e-05	0.0372	-0.47	-0.39	Hippocampal atrophy;	chr9:81726032	chr9:81689713~81776900:+
THYM	cis	rs11139399	0.613	rs11139380	ENSG00000233926.1	RP11-154D17.1	-4.13	7.8e-05	0.0372	-0.47	-0.39	Hippocampal atrophy;	chr9:81726061	chr9:81689713~81776900:+
THYM	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	4.13	7.8e-05	0.0372	0.46	0.39	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
THYM	cis	rs7560272	0.723	rs7609249	ENSG00000273245.1	RP11-434P11.2	4.13	7.8e-05	0.0372	0.45	0.39	Schizophrenia;	chr2:73586693	chr2:73750256~73750786:-
THYM	cis	rs7560272	0.723	rs6743576	ENSG00000273245.1	RP11-434P11.2	4.13	7.8e-05	0.0372	0.45	0.39	Schizophrenia;	chr2:73587206	chr2:73750256~73750786:-
THYM	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	4.13	7.8e-05	0.0372	0.52	0.39	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
THYM	cis	rs7617480	0.61	rs10865954	ENSG00000270441.1	RP11-694I15.7	-4.13	7.8e-05	0.0372	-0.4	-0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chr3:49140086~49160851:-
THYM	cis	rs910316	0.967	rs175498	ENSG00000258646.1	RP11-950C14.3	4.13	7.81e-05	0.0372	0.36	0.39	Height;	chr14:75069666	chr14:75004719~75008481:-
THYM	cis	rs9903692	0.779	rs6504025	ENSG00000266601.1	RP11-6N17.3	-4.13	7.81e-05	0.0372	-0.37	-0.39	Pulse pressure;	chr17:48088711	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs2109984	ENSG00000266601.1	RP11-6N17.3	-4.13	7.81e-05	0.0372	-0.37	-0.39	Pulse pressure;	chr17:48093737	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs8065670	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48096478	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.908	rs12950402	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48102752	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs11079808	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48102870	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs4794448	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48103445	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs68175794	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48103742	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.862	rs12943543	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48104003	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs4794451	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48107419	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.862	rs4794453	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48107564	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs8077860	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48107973	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs12941295	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48110825	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs8076380	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48113028	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.954	rs8080662	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48113457	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.789	rs12601675	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48113566	chr17:47929682~47933106:-
THYM	cis	rs9903692	0.754	rs12602948	ENSG00000266601.1	RP11-6N17.3	4.13	7.81e-05	0.0372	0.37	0.39	Pulse pressure;	chr17:48113567	chr17:47929682~47933106:-
THYM	cis	rs2283792	0.967	rs5755099	ENSG00000228050.1	TOP3BP1	4.13	7.81e-05	0.0372	0.43	0.39	Multiple sclerosis;	chr22:21770751	chr22:22223187~22224566:-
THYM	cis	rs3015497	0.586	rs7144714	ENSG00000270062.1	RP11-248J18.3	4.13	7.82e-05	0.0373	0.28	0.39	Mean platelet volume;	chr14:50611867	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.616	rs1389650	ENSG00000270062.1	RP11-248J18.3	4.13	7.82e-05	0.0373	0.28	0.39	Mean platelet volume;	chr14:50614731	chr14:50723777~50724272:-
THYM	cis	rs62184315	0.536	rs5742926	ENSG00000273240.1	RP11-455J20.3	-4.13	7.83e-05	0.0373	-0.64	-0.39	Alcohol dependence (age at onset);	chr2:189784079	chr2:189763859~189764456:-
THYM	cis	rs10067427	0.58	rs10035392	ENSG00000270225.1	RP11-475J5.4	4.13	7.83e-05	0.0373	0.48	0.39	Non-alcoholic fatty liver disease histology (lobular);	chr5:100148798	chr5:100052859~100053539:-
THYM	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-4.13	7.84e-05	0.0373	-0.39	-0.39	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-4.13	7.84e-05	0.0373	-0.39	-0.39	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
THYM	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-4.13	7.84e-05	0.0373	-0.54	-0.39	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
THYM	cis	rs7976269	0.609	rs1344855	ENSG00000275476.1	RP11-996F15.4	4.13	7.84e-05	0.0373	0.44	0.39	Male-pattern baldness;	chr12:29065605	chr12:29277397~29277882:-
THYM	cis	rs3780486	0.505	rs10117038	ENSG00000225693.1	LAGE3P1	4.13	7.84e-05	0.0374	0.46	0.39	IgG glycosylation;	chr9:33122628	chr9:33019682~33020165:-
THYM	cis	rs3780486	0.522	rs7029897	ENSG00000225693.1	LAGE3P1	4.13	7.84e-05	0.0374	0.46	0.39	IgG glycosylation;	chr9:33124044	chr9:33019682~33020165:-
THYM	cis	rs3780486	0.505	rs10758188	ENSG00000225693.1	LAGE3P1	-4.13	7.84e-05	0.0374	-0.46	-0.39	IgG glycosylation;	chr9:33123388	chr9:33019682~33020165:-
THYM	cis	rs9733	0.519	rs7529194	ENSG00000220323.3	HIST2H2BD	-4.13	7.85e-05	0.0374	-0.41	-0.39	Tonsillectomy;	chr1:150650144	chr1:149843041~149843533:+
THYM	cis	rs60180747	0.543	rs1871006	ENSG00000261318.1	RP11-653J6.1	4.13	7.85e-05	0.0374	0.43	0.39	Testicular germ cell tumor;	chr15:66255303	chr15:66278498~66293357:-
THYM	cis	rs11098499	0.908	rs9995234	ENSG00000250412.1	KLHL2P1	4.13	7.86e-05	0.0374	0.38	0.39	Corneal astigmatism;	chr4:119400672	chr4:119334329~119378233:+
THYM	cis	rs1519814	0.654	rs2139438	ENSG00000254343.2	RP11-760H22.2	-4.13	7.86e-05	0.0374	-0.61	-0.39	Breast cancer;	chr8:119995478	chr8:120052180~120056201:+
THYM	cis	rs11139399	0.676	rs56331531	ENSG00000233926.1	RP11-154D17.1	-4.13	7.86e-05	0.0374	-0.48	-0.39	Hippocampal atrophy;	chr9:81732934	chr9:81689713~81776900:+
THYM	cis	rs11139399	0.506	rs56351396	ENSG00000233926.1	RP11-154D17.1	-4.13	7.86e-05	0.0374	-0.48	-0.39	Hippocampal atrophy;	chr9:81733052	chr9:81689713~81776900:+
THYM	cis	rs11139399	0.689	rs11139387	ENSG00000233926.1	RP11-154D17.1	-4.13	7.86e-05	0.0374	-0.48	-0.39	Hippocampal atrophy;	chr9:81733693	chr9:81689713~81776900:+
THYM	cis	rs7246967	0.544	rs403717	ENSG00000198153.8	ZNF849P	-4.13	7.86e-05	0.0374	-0.49	-0.39	Bronchopulmonary dysplasia;	chr19:22826001	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.544	rs391308	ENSG00000198153.8	ZNF849P	-4.13	7.86e-05	0.0374	-0.49	-0.39	Bronchopulmonary dysplasia;	chr19:22826758	chr19:22685167~22686732:+
THYM	cis	rs792448	0.501	rs2307128	ENSG00000229983.1	RP11-15I11.2	4.13	7.87e-05	0.0375	0.31	0.39	White blood cell count (basophil);	chr1:212226474	chr1:212168207~212190259:+
THYM	cis	rs10838634	1	rs61882704	ENSG00000255520.1	RP11-390K5.3	4.13	7.87e-05	0.0375	0.89	0.39	Schizophrenia;	chr11:46433983	chr11:47123104~47130801:-
THYM	cis	rs10838634	1	rs79078082	ENSG00000255520.1	RP11-390K5.3	4.13	7.87e-05	0.0375	0.89	0.39	Schizophrenia;	chr11:46464509	chr11:47123104~47130801:-
THYM	cis	rs10838634	1	rs61884270	ENSG00000255520.1	RP11-390K5.3	4.13	7.87e-05	0.0375	0.89	0.39	Schizophrenia;	chr11:46631192	chr11:47123104~47130801:-
THYM	cis	rs10129255	0.957	rs8009073	ENSG00000253703.1	IGHV1-68	-4.13	7.87e-05	0.0375	-0.5	-0.39	Kawasaki disease;	chr14:106777278	chr14:106703852~106704146:-
THYM	cis	rs1387259	0.859	rs2054905	ENSG00000240399.1	RP1-228P16.1	4.13	7.88e-05	0.0375	0.4	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs2732461	ENSG00000240399.1	RP1-228P16.1	4.13	7.88e-05	0.0375	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48054813~48055591:-
THYM	cis	rs12736701	0.677	rs2647517	ENSG00000226084.5	RP4-706A16.3	4.13	7.88e-05	0.0375	0.81	0.39	Type 2 diabetes (age of onset);	chr1:77424969	chr1:77129114~77129668:+
THYM	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	4.13	7.88e-05	0.0375	0.5	0.39	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
THYM	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	4.13	7.88e-05	0.0375	0.26	0.39	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
THYM	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-4.13	7.88e-05	0.0375	-0.51	-0.39	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	4.13	7.88e-05	0.0375	0.51	0.39	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	4.13	7.88e-05	0.0375	0.51	0.39	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
THYM	cis	rs1595825	0.891	rs60129872	ENSG00000222017.1	AC011997.1	-4.13	7.88e-05	0.0375	-0.45	-0.39	Ulcerative colitis;	chr2:197788468	chr2:197693106~197774823:+
THYM	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	4.13	7.89e-05	0.0375	0.43	0.39	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
THYM	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	4.13	7.89e-05	0.0375	0.48	0.39	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
THYM	cis	rs11157436	0.958	rs12432733	ENSG00000211812.1	TRAV26-2	-4.13	7.89e-05	0.0375	-0.27	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22202583~22203368:+
THYM	cis	rs4835473	0.614	rs4487293	ENSG00000249741.2	RP11-673E1.3	-4.13	7.89e-05	0.0375	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143993880	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.742	rs6537238	ENSG00000249741.2	RP11-673E1.3	-4.13	7.89e-05	0.0375	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143996463	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1473055	ENSG00000249741.2	RP11-673E1.3	-4.13	7.89e-05	0.0375	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143997714	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4835126	ENSG00000249741.2	RP11-673E1.3	-4.13	7.89e-05	0.0375	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143997740	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.699	rs4835127	ENSG00000249741.2	RP11-673E1.3	-4.13	7.89e-05	0.0375	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143997972	chr4:143911514~143912053:-
THYM	cis	rs295140	0.565	rs295139	ENSG00000232732.8	AC073043.1	-4.13	7.89e-05	0.0375	-0.47	-0.39	QT interval;	chr2:200295265	chr2:199867396~199911159:-
THYM	cis	rs1559777	0.702	rs10518933	ENSG00000279683.1	RP11-31H5.2	4.13	7.9e-05	0.0375	0.47	0.39	Myopia (pathological);	chr15:57794266	chr15:56795382~56795522:+
THYM	cis	rs4835473	0.897	rs34425128	ENSG00000249741.2	RP11-673E1.3	4.13	7.9e-05	0.0375	0.35	0.39	Immature fraction of reticulocytes;	chr4:143725191	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs62337587	ENSG00000249741.2	RP11-673E1.3	4.13	7.9e-05	0.0375	0.35	0.39	Immature fraction of reticulocytes;	chr4:143725839	chr4:143911514~143912053:-
THYM	cis	rs3015497	0.616	rs34061700	ENSG00000270062.1	RP11-248J18.3	4.13	7.9e-05	0.0376	0.28	0.39	Mean platelet volume;	chr14:50618142	chr14:50723777~50724272:-
THYM	cis	rs3822625	1	rs3822625	ENSG00000271828.1	CTD-2310F14.1	4.13	7.91e-05	0.0376	0.88	0.39	Breast cancer (early onset);	chr5:56882284	chr5:56927874~56929573:+
THYM	cis	rs7223966	1	rs8067064	ENSG00000240280.5	TCAM1P	-4.13	7.91e-05	0.0376	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63748624	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9891018	ENSG00000240280.5	TCAM1P	-4.13	7.91e-05	0.0376	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63750496	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs7217982	ENSG00000240280.5	TCAM1P	-4.13	7.91e-05	0.0376	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63754790	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs55868506	ENSG00000240280.5	TCAM1P	-4.13	7.91e-05	0.0376	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63774326	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs8078862	ENSG00000240280.5	TCAM1P	-4.13	7.91e-05	0.0376	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63776708	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs11657120	ENSG00000240280.5	TCAM1P	-4.13	7.91e-05	0.0376	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63779858	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs8078462	ENSG00000240280.5	TCAM1P	-4.13	7.91e-05	0.0376	-0.58	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63780577	chr17:63849292~63864379:+
THYM	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-4.13	7.91e-05	0.0376	-0.46	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
THYM	cis	rs904251	0.714	rs2776910	ENSG00000279942.1	RP1-153P14.7	-4.13	7.92e-05	0.0376	-0.57	-0.39	Cognitive performance;	chr6:37468508	chr6:37567716~37571460:+
THYM	cis	rs9733	0.519	rs1336900	ENSG00000220323.3	HIST2H2BD	-4.13	7.92e-05	0.0376	-0.39	-0.39	Tonsillectomy;	chr1:150706557	chr1:149843041~149843533:+
THYM	cis	rs12902680	0.739	rs7179451	ENSG00000259520.4	CTD-2651B20.3	4.13	7.93e-05	0.0376	0.41	0.39	Neuroticism;	chr15:46141202	chr15:45251580~45279251:-
THYM	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	4.13	7.93e-05	0.0377	0.8	0.39	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
THYM	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-4.13	7.94e-05	0.0377	-0.47	-0.39	Height;	chr11:118786602	chr11:118704607~118750263:+
THYM	cis	rs2510897	0.618	rs7483509	ENSG00000278376.1	RP11-158I9.8	-4.13	7.94e-05	0.0377	-0.28	-0.39	Height;	chr11:118869471	chr11:118791254~118793137:+
THYM	cis	rs61160187	0.75	rs1807017	ENSG00000272308.1	RP11-231G3.1	-4.13	7.94e-05	0.0377	-0.34	-0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60866457~60866935:-
THYM	cis	rs7927592	0.913	rs6591346	ENSG00000222339.1	AP000807.2	4.13	7.94e-05	0.0377	0.45	0.39	Total body bone mineral density;	chr11:68617150	chr11:68505572~68505651:-
THYM	cis	rs7412746	0.658	rs11589458	ENSG00000220323.3	HIST2H2BD	-4.13	7.94e-05	0.0377	-0.37	-0.39	Melanoma;	chr1:150820140	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs17660092	ENSG00000220323.3	HIST2H2BD	-4.13	7.94e-05	0.0377	-0.37	-0.39	Melanoma;	chr1:150825272	chr1:149843041~149843533:+
THYM	cis	rs910316	0.967	rs119076	ENSG00000258646.1	RP11-950C14.3	4.13	7.95e-05	0.0377	0.36	0.39	Height;	chr14:75105716	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs175451	ENSG00000258646.1	RP11-950C14.3	4.13	7.95e-05	0.0377	0.36	0.39	Height;	chr14:75123026	chr14:75004719~75008481:-
THYM	cis	rs2283792	0.677	rs13340063	ENSG00000228050.1	TOP3BP1	-4.13	7.96e-05	0.0378	-0.46	-0.39	Multiple sclerosis;	chr22:21742717	chr22:22223187~22224566:-
THYM	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-4.13	7.96e-05	0.0378	-0.49	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-4.13	7.96e-05	0.0378	-0.49	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-4.13	7.96e-05	0.0378	-0.49	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
THYM	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-4.13	7.97e-05	0.0378	-0.52	-0.39	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
THYM	cis	rs8067545	0.75	rs9915758	ENSG00000231645.2	KRT17P6	-4.13	7.97e-05	0.0378	-0.46	-0.39	Schizophrenia;	chr17:20061462	chr17:20512560~20517479:-
THYM	cis	rs2430307	0.518	rs67763033	ENSG00000242435.1	UPK3BP1	4.13	7.97e-05	0.0378	0.56	0.39	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76888360	chr7:77004662~77005774:+
THYM	cis	rs1642645	0.831	rs348128	ENSG00000228452.1	RP5-994D16.9	-4.13	7.98e-05	0.0378	-0.53	-0.39	Left ventricular obstructive tract defect (maternal effect);	chr1:42022690	chr1:42775813~42776790:-
THYM	cis	rs295140	0.546	rs842830	ENSG00000232732.8	AC073043.1	4.13	7.98e-05	0.0379	0.49	0.39	QT interval;	chr2:200266401	chr2:199867396~199911159:-
THYM	cis	rs2292342	1	rs11880333	ENSG00000232871.7	SEC1P	-4.13	7.98e-05	0.0379	-0.76	-0.39	Elevated serum carcinoembryonic antigen levels;	chr19:48641533	chr19:48638071~48682245:+
THYM	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-4.13	7.98e-05	0.0379	-0.47	-0.39	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
THYM	cis	rs10129255	1	rs8010605	ENSG00000253703.1	IGHV1-68	-4.13	7.99e-05	0.0379	-0.48	-0.39	Kawasaki disease;	chr14:106678742	chr14:106703852~106704146:-
THYM	cis	rs7312933	0.558	rs11181507	ENSG00000257225.1	RP11-328C8.4	-4.13	7.99e-05	0.0379	-0.45	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42450961	chr12:42459366~42466128:+
THYM	cis	rs1387259	0.931	rs11168474	ENSG00000240399.1	RP1-228P16.1	4.13	7.99e-05	0.0379	0.4	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48054813~48055591:-
THYM	cis	rs7223966	0.921	rs67018565	ENSG00000240280.5	TCAM1P	-4.13	8e-05	0.0379	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63850695	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs9899491	ENSG00000240280.5	TCAM1P	-4.13	8e-05	0.0379	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63857024	chr17:63849292~63864379:+
THYM	cis	rs61270009	0.913	rs396676	ENSG00000247828.6	TMEM161B-AS1	-4.13	8e-05	0.0379	-0.33	-0.39	Depressive symptoms;	chr5:88220002	chr5:88268895~88436685:+
THYM	cis	rs12902680	0.844	rs28652697	ENSG00000259520.4	CTD-2651B20.3	4.12	8e-05	0.038	0.42	0.39	Neuroticism;	chr15:46041584	chr15:45251580~45279251:-
THYM	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	4.12	8.01e-05	0.038	0.51	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
THYM	cis	rs5742933	1	rs5742998	ENSG00000273240.1	RP11-455J20.3	-4.12	8.01e-05	0.038	-0.58	-0.39	Ferritin levels;	chr2:189799626	chr2:189763859~189764456:-
THYM	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	4.12	8.01e-05	0.038	0.45	0.39	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
THYM	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-4.12	8.02e-05	0.038	-0.51	-0.39	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
THYM	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-4.12	8.02e-05	0.038	-0.51	-0.39	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
THYM	cis	rs8177876	0.749	rs2549891	ENSG00000261838.4	RP11-303E16.6	-4.12	8.03e-05	0.038	-0.83	-0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81069854~81076598:+
THYM	cis	rs904251	0.605	rs4257849	ENSG00000227920.2	RP1-153P14.5	-4.12	8.03e-05	0.0381	-0.59	-0.39	Cognitive performance;	chr6:37443193	chr6:37545145~37550860:+
THYM	cis	rs904251	0.686	rs1224128	ENSG00000227920.2	RP1-153P14.5	-4.12	8.03e-05	0.0381	-0.59	-0.39	Cognitive performance;	chr6:37447900	chr6:37545145~37550860:+
THYM	cis	rs7617773	0.539	rs13069884	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48339658	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs2017859	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48340771	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.501	rs12185901	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48341429	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs13082217	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48341774	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs11706939	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48342502	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs11130165	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48343231	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs17593974	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48345844	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.514	rs11130166	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48346566	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.539	rs12486944	ENSG00000228638.1	FCF1P2	-4.12	8.03e-05	0.0381	-0.37	-0.39	Coronary artery disease;	chr3:48348526	chr3:48290793~48291375:-
THYM	cis	rs889398	0.741	rs6499270	ENSG00000226232.7	RP11-419C5.2	4.12	8.04e-05	0.0381	0.36	0.39	Body mass index;	chr16:69883837	chr16:69976388~69996188:-
THYM	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	4.12	8.04e-05	0.0381	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	4.12	8.04e-05	0.0381	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	4.12	8.04e-05	0.0381	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	4.12	8.04e-05	0.0381	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	4.12	8.04e-05	0.0381	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	4.12	8.04e-05	0.0381	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-4.12	8.04e-05	0.0381	-0.49	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
THYM	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-4.12	8.04e-05	0.0381	-0.45	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
THYM	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-4.12	8.04e-05	0.0381	-0.45	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
THYM	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-4.12	8.04e-05	0.0381	-0.45	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
THYM	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-4.12	8.04e-05	0.0381	-0.45	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
THYM	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-4.12	8.04e-05	0.0381	-0.45	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
THYM	cis	rs10129255	0.917	rs11625208	ENSG00000254329.1	IGHVII-60-1	4.12	8.06e-05	0.0381	0.38	0.39	Kawasaki disease;	chr14:106698757	chr14:106637718~106637973:-
THYM	cis	rs726288	1	rs12261336	ENSG00000225484.5	NUTM2B-AS1	-4.12	8.06e-05	0.0381	-0.89	-0.39	Rheumatoid arthritis;	chr10:79925801	chr10:79663088~79826594:-
THYM	cis	rs726288	1	rs12261337	ENSG00000225484.5	NUTM2B-AS1	-4.12	8.06e-05	0.0381	-0.89	-0.39	Rheumatoid arthritis;	chr10:79925802	chr10:79663088~79826594:-
THYM	cis	rs726288	1	rs75164680	ENSG00000225484.5	NUTM2B-AS1	-4.12	8.06e-05	0.0381	-0.89	-0.39	Rheumatoid arthritis;	chr10:79926377	chr10:79663088~79826594:-
THYM	cis	rs11098499	0.863	rs13134665	ENSG00000250412.1	KLHL2P1	4.12	8.06e-05	0.0382	0.37	0.39	Corneal astigmatism;	chr4:119505275	chr4:119334329~119378233:+
THYM	cis	rs9926296	0.712	rs258330	ENSG00000274627.1	RP11-104N10.2	4.12	8.06e-05	0.0382	0.45	0.39	Vitiligo;	chr16:89663166	chr16:89516797~89522217:+
THYM	cis	rs9926296	0.682	rs258328	ENSG00000274627.1	RP11-104N10.2	4.12	8.06e-05	0.0382	0.45	0.39	Vitiligo;	chr16:89663906	chr16:89516797~89522217:+
THYM	cis	rs9473147	1	rs9473147	ENSG00000270761.1	RP11-385F7.1	-4.12	8.06e-05	0.0382	-0.37	-0.39	Platelet distribution width;Mean platelet volume;	chr6:47641856	chr6:47477243~47477572:-
THYM	cis	rs8056742	1	rs11648527	ENSG00000261243.1	RP11-517C16.4	4.12	8.06e-05	0.0382	0.61	0.39	Amyotrophic lateral sclerosis;	chr16:85060307	chr16:84495599~84497495:+
THYM	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-4.12	8.06e-05	0.0382	-0.52	-0.39	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-4.12	8.06e-05	0.0382	-0.52	-0.39	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-4.12	8.06e-05	0.0382	-0.52	-0.39	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-4.12	8.06e-05	0.0382	-0.52	-0.39	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-4.12	8.06e-05	0.0382	-0.52	-0.39	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-4.12	8.06e-05	0.0382	-0.52	-0.39	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
THYM	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-4.12	8.06e-05	0.0382	-0.52	-0.39	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
THYM	cis	rs8177876	0.822	rs7203546	ENSG00000261838.4	RP11-303E16.6	-4.12	8.06e-05	0.0382	-0.77	-0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81069854~81076598:+
THYM	cis	rs3015497	0.616	rs11157759	ENSG00000270062.1	RP11-248J18.3	4.12	8.07e-05	0.0382	0.28	0.39	Mean platelet volume;	chr14:50620545	chr14:50723777~50724272:-
THYM	cis	rs11157436	0.602	rs17255447	ENSG00000211813.2	TRAV34	-4.12	8.07e-05	0.0382	-0.28	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.509	rs12589104	ENSG00000211813.2	TRAV34	4.12	8.07e-05	0.0382	0.28	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs11157437	ENSG00000211813.2	TRAV34	4.12	8.07e-05	0.0382	0.28	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs11157439	ENSG00000211813.2	TRAV34	4.12	8.07e-05	0.0382	0.28	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs10872984	ENSG00000211813.2	TRAV34	4.12	8.07e-05	0.0382	0.28	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171245	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs12588757	ENSG00000211813.2	TRAV34	4.12	8.07e-05	0.0382	0.28	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22207522~22208129:+
THYM	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	4.12	8.07e-05	0.0382	0.38	0.39	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
THYM	cis	rs2732480	0.5	rs7315820	ENSG00000240399.1	RP1-228P16.1	4.12	8.07e-05	0.0382	0.41	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48054813~48055591:-
THYM	cis	rs2235573	0.868	rs6001002	ENSG00000272669.1	RP3-508I15.21	-4.12	8.08e-05	0.0382	-0.26	-0.39	Glioma;Glioblastoma;	chr22:38103579	chr22:38742625~38743115:+
THYM	cis	rs9907295	1	rs9907295	ENSG00000270977.1	AC015849.16	-4.12	8.08e-05	0.0382	-0.72	-0.39	Fibroblast growth factor basic levels;	chr17:35930309	chr17:35893707~35911023:-
THYM	cis	rs7044106	0.5	rs56725168	ENSG00000238181.2	AHCYP2	-4.12	8.08e-05	0.0382	-0.4	-0.39	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120720673~120721972:+
THYM	cis	rs3015497	0.616	rs6572678	ENSG00000270062.1	RP11-248J18.3	4.12	8.08e-05	0.0382	0.28	0.39	Mean platelet volume;	chr14:50623397	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.616	rs4901044	ENSG00000270062.1	RP11-248J18.3	4.12	8.08e-05	0.0382	0.28	0.39	Mean platelet volume;	chr14:50623577	chr14:50723777~50724272:-
THYM	cis	rs7959452	0.535	rs10784771	ENSG00000274979.1	RP11-1143G9.5	-4.12	8.09e-05	0.0383	-0.38	-0.39	Blood protein levels;	chr12:69227484	chr12:69326574~69331882:-
THYM	cis	rs7927592	0.956	rs11228277	ENSG00000222339.1	AP000807.2	4.12	8.09e-05	0.0383	0.44	0.39	Total body bone mineral density;	chr11:68540856	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.956	rs11228278	ENSG00000222339.1	AP000807.2	4.12	8.09e-05	0.0383	0.44	0.39	Total body bone mineral density;	chr11:68541062	chr11:68505572~68505651:-
THYM	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	4.12	8.09e-05	0.0383	0.51	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	4.12	8.09e-05	0.0383	0.51	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
THYM	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	4.12	8.09e-05	0.0383	0.51	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
THYM	cis	rs34091987	0.56	rs35548382	ENSG00000256124.4	LINC01152	4.12	8.09e-05	0.0383	0.45	0.39	Nose size;	chr17:72028946	chr17:72030291~72041297:+
THYM	cis	rs7631605	0.905	rs11712979	ENSG00000272334.1	RP11-129K12.1	-4.12	8.1e-05	0.0383	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37154004	chr3:36973117~36973672:-
THYM	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	4.12	8.1e-05	0.0383	0.51	0.39	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
THYM	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	4.12	8.1e-05	0.0383	0.51	0.39	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
THYM	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	4.12	8.1e-05	0.0383	0.46	0.39	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
THYM	cis	rs7927592	0.956	rs60212556	ENSG00000222339.1	AP000807.2	4.12	8.11e-05	0.0383	0.44	0.39	Total body bone mineral density;	chr11:68538026	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.956	rs10896343	ENSG00000222339.1	AP000807.2	4.12	8.11e-05	0.0383	0.44	0.39	Total body bone mineral density;	chr11:68550392	chr11:68505572~68505651:-
THYM	cis	rs3096299	0.838	rs3096319	ENSG00000274627.1	RP11-104N10.2	4.12	8.11e-05	0.0383	0.44	0.39	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89516797~89522217:+
THYM	cis	rs4948275	0.773	rs2650726	ENSG00000237233.2	TMEM26-AS1	-4.12	8.11e-05	0.0383	-0.46	-0.39	Night sleep phenotypes;	chr10:61511113	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2650724	ENSG00000237233.2	TMEM26-AS1	-4.12	8.11e-05	0.0383	-0.46	-0.39	Night sleep phenotypes;	chr10:61513024	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs1902429	ENSG00000237233.2	TMEM26-AS1	-4.12	8.11e-05	0.0383	-0.46	-0.39	Night sleep phenotypes;	chr10:61517317	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2606097	ENSG00000237233.2	TMEM26-AS1	-4.12	8.11e-05	0.0383	-0.46	-0.39	Night sleep phenotypes;	chr10:61519195	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.742	rs2650694	ENSG00000237233.2	TMEM26-AS1	-4.12	8.11e-05	0.0383	-0.46	-0.39	Night sleep phenotypes;	chr10:61527069	chr10:61452639~61481956:+
THYM	cis	rs7178424	0.764	rs11634163	ENSG00000259251.2	RP11-643M14.1	-4.12	8.12e-05	0.0384	-0.45	-0.39	Height;	chr15:62038434	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.79	rs17271305	ENSG00000259251.2	RP11-643M14.1	-4.12	8.12e-05	0.0384	-0.45	-0.39	Height;	chr15:62040781	chr15:62060503~62062434:+
THYM	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	4.12	8.12e-05	0.0384	0.49	0.39	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
THYM	cis	rs9611565	0.729	rs137831	ENSG00000231993.1	EP300-AS1	4.12	8.12e-05	0.0384	0.36	0.39	Vitiligo;	chr22:41507809	chr22:41174591~41197456:-
THYM	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	4.12	8.13e-05	0.0384	0.32	0.39	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
THYM	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	-4.12	8.13e-05	0.0384	-0.48	-0.39	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
THYM	cis	rs11098499	0.82	rs28535956	ENSG00000250412.1	KLHL2P1	-4.12	8.13e-05	0.0384	-0.36	-0.39	Corneal astigmatism;	chr4:119615703	chr4:119334329~119378233:+
THYM	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-4.12	8.13e-05	0.0384	-0.49	-0.39	Pain;	chr19:21491155	chr19:21554640~21569237:-
THYM	cis	rs227275	0.554	rs223466	ENSG00000251288.2	RP11-10L12.2	-4.12	8.14e-05	0.0385	-0.39	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102751401~102752641:+
THYM	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-4.12	8.14e-05	0.0385	-0.52	-0.39	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
THYM	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	4.12	8.15e-05	0.0385	0.45	0.39	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
THYM	cis	rs3015497	0.616	rs10131107	ENSG00000270062.1	RP11-248J18.3	4.12	8.15e-05	0.0385	0.28	0.39	Mean platelet volume;	chr14:50595737	chr14:50723777~50724272:-
THYM	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-4.12	8.15e-05	0.0385	-0.52	-0.39	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
THYM	cis	rs12915845	1	rs12915845	ENSG00000271997.1	RP11-97O12.6	-4.12	8.16e-05	0.0385	-0.33	-0.39	Menarche (age at onset);	chr15:88499236	chr15:88501944~88505787:-
THYM	cis	rs7631605	0.875	rs4678937	ENSG00000272334.1	RP11-129K12.1	-4.12	8.16e-05	0.0385	-0.41	-0.39	Cerebrospinal P-tau181p levels;	chr3:37103683	chr3:36973117~36973672:-
THYM	cis	rs10829156	0.786	rs7077786	ENSG00000225527.1	RP11-383B4.4	-4.12	8.16e-05	0.0385	-0.52	-0.39	Sudden cardiac arrest;	chr10:18603453	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.741	rs9731044	ENSG00000225527.1	RP11-383B4.4	-4.12	8.16e-05	0.0385	-0.52	-0.39	Sudden cardiac arrest;	chr10:18605356	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.538	rs61840846	ENSG00000225527.1	RP11-383B4.4	-4.12	8.16e-05	0.0385	-0.52	-0.39	Sudden cardiac arrest;	chr10:18606393	chr10:18531849~18533336:-
THYM	cis	rs3015497	0.586	rs12587821	ENSG00000270062.1	RP11-248J18.3	4.12	8.17e-05	0.0386	0.28	0.39	Mean platelet volume;	chr14:50625836	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.586	rs12587842	ENSG00000270062.1	RP11-248J18.3	4.12	8.17e-05	0.0386	0.28	0.39	Mean platelet volume;	chr14:50625844	chr14:50723777~50724272:-
THYM	cis	rs9309473	0.519	rs1815027	ENSG00000273245.1	RP11-434P11.2	-4.12	8.17e-05	0.0386	-0.44	-0.39	Metabolite levels;	chr2:73604713	chr2:73750256~73750786:-
THYM	cis	rs1595825	1	rs1440091	ENSG00000222017.1	AC011997.1	-4.12	8.17e-05	0.0386	-0.45	-0.39	Ulcerative colitis;	chr2:198014733	chr2:197693106~197774823:+
THYM	cis	rs9309473	0.5	rs10865398	ENSG00000163016.8	ALMS1P	-4.12	8.18e-05	0.0386	-0.44	-0.39	Metabolite levels;	chr2:73514370	chr2:73644919~73685576:+
THYM	cis	rs728616	0.558	rs17616958	ENSG00000242600.5	MBL1P	4.12	8.18e-05	0.0386	0.56	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr10:79904898~79950336:+
THYM	cis	rs728616	0.558	rs17616964	ENSG00000242600.5	MBL1P	4.12	8.18e-05	0.0386	0.56	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr10:79904898~79950336:+
THYM	cis	rs4835473	0.897	rs13144504	ENSG00000249741.2	RP11-673E1.3	4.12	8.18e-05	0.0386	0.34	0.39	Immature fraction of reticulocytes;	chr4:143707402	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs11728121	ENSG00000249741.2	RP11-673E1.3	-4.12	8.18e-05	0.0386	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143707079	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs11723113	ENSG00000249741.2	RP11-673E1.3	-4.12	8.18e-05	0.0386	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143707283	chr4:143911514~143912053:-
THYM	cis	rs1850744	0.826	rs9291607	ENSG00000250268.3	ALG1L14P	4.12	8.18e-05	0.0386	0.86	0.39	Economic and political preferences;	chr4:9707174	chr4:9166297~9170270:-
THYM	cis	rs17253792	0.732	rs75796044	ENSG00000186615.9	KTN1-AS1	-4.12	8.19e-05	0.0386	-0.75	-0.39	Putamen volume;	chr14:55567410	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77761669	ENSG00000186615.9	KTN1-AS1	-4.12	8.19e-05	0.0386	-0.75	-0.39	Putamen volume;	chr14:55567498	chr14:55499278~55580110:-
THYM	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-4.12	8.19e-05	0.0387	-0.48	-0.39	Height;	chr11:118747911	chr11:118704607~118750263:+
THYM	cis	rs2013441	1	rs9915059	ENSG00000231645.2	KRT17P6	4.12	8.2e-05	0.0387	0.46	0.39	Obesity-related traits;	chr17:20273791	chr17:20512560~20517479:-
THYM	cis	rs1584120	0.57	rs7974302	ENSG00000256321.4	RP11-153K16.1	-4.12	8.21e-05	0.0387	-0.43	-0.39	Pelvic organ prolapse (moderate/severe);	chr12:23106584	chr12:23099368~23191587:+
THYM	cis	rs910316	1	rs2098297	ENSG00000258646.1	RP11-950C14.3	4.12	8.22e-05	0.0387	0.35	0.39	Height;	chr14:75152415	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4903289	ENSG00000258646.1	RP11-950C14.3	4.12	8.22e-05	0.0387	0.35	0.39	Height;	chr14:75157285	chr14:75004719~75008481:-
THYM	cis	rs910316	0.874	rs61980828	ENSG00000258646.1	RP11-950C14.3	4.12	8.22e-05	0.0387	0.35	0.39	Height;	chr14:75163675	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10149880	ENSG00000258646.1	RP11-950C14.3	4.12	8.22e-05	0.0387	0.35	0.39	Height;	chr14:75166305	chr14:75004719~75008481:-
THYM	cis	rs910316	0.935	rs11159119	ENSG00000258646.1	RP11-950C14.3	4.12	8.22e-05	0.0387	0.35	0.39	Height;	chr14:75170264	chr14:75004719~75008481:-
THYM	cis	rs910316	0.839	rs35977276	ENSG00000258646.1	RP11-950C14.3	4.12	8.22e-05	0.0387	0.35	0.39	Height;	chr14:75170656	chr14:75004719~75008481:-
THYM	cis	rs910316	0.935	rs2268620	ENSG00000258646.1	RP11-950C14.3	4.12	8.22e-05	0.0387	0.35	0.39	Height;	chr14:75173700	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs4322591	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75133994	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12435391	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75135034	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs876403	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75136131	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs1047418	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75139089	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs2268617	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75142025	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs4903285	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75142565	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs7147118	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75143467	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs12588240	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75145380	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs10138183	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75148524	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs910316	ENSG00000258646.1	RP11-950C14.3	-4.12	8.22e-05	0.0387	-0.35	-0.39	Height;	chr14:75159339	chr14:75004719~75008481:-
THYM	cis	rs4908760	0.827	rs6692693	ENSG00000232912.4	RP5-1115A15.1	4.12	8.22e-05	0.0387	0.38	0.39	Vitiligo;	chr1:8647057	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.827	rs11121210	ENSG00000232912.4	RP5-1115A15.1	4.12	8.22e-05	0.0387	0.38	0.39	Vitiligo;	chr1:8648470	chr1:8424645~8434838:+
THYM	cis	rs2267681	0.544	rs4726838	ENSG00000240889.1	NDUFB2-AS1	-4.12	8.23e-05	0.0388	-0.48	-0.39	Cervical cancer;	chr7:139817165	chr7:140695336~140697077:-
THYM	cis	rs3015497	0.616	rs4901043	ENSG00000270062.1	RP11-248J18.3	-4.12	8.23e-05	0.0388	-0.28	-0.39	Mean platelet volume;	chr14:50616876	chr14:50723777~50724272:-
THYM	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-4.12	8.23e-05	0.0388	-0.58	-0.39	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
THYM	cis	rs9652601	0.879	rs9926367	ENSG00000274038.1	RP11-66H6.4	-4.12	8.24e-05	0.0388	-0.42	-0.39	Systemic lupus erythematosus;	chr16:10999322	chr16:11056556~11057034:+
THYM	cis	rs7210990	0.661	rs6502482	ENSG00000275413.1	CTC-529I10.1	4.12	8.24e-05	0.0388	0.38	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15995927	chr17:16023323~16023653:-
THYM	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	4.12	8.25e-05	0.0388	0.47	0.39	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
THYM	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-4.12	8.25e-05	0.0388	-0.43	-0.39	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
THYM	cis	rs1900504	1	rs1900504	ENSG00000266200.5	PNLIPRP2	4.12	8.25e-05	0.0388	0.45	0.39	Tonsillectomy;	chr10:116625761	chr10:116620953~116645143:+
THYM	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-4.12	8.25e-05	0.0389	-0.36	-0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
THYM	cis	rs10859871	0.536	rs10859859	ENSG00000199172.2	MIR331	-4.12	8.26e-05	0.0389	-0.26	-0.39	Endometriosis;	chr12:95247746	chr12:95308410~95308520:+
THYM	cis	rs687432	0.847	rs12419176	ENSG00000213592.4	AP000662.9	4.12	8.26e-05	0.0389	0.53	0.39	Parkinson's disease;	chr11:57939239	chr11:57718044~57718530:-
THYM	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	4.12	8.26e-05	0.0389	0.43	0.39	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
THYM	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	4.12	8.26e-05	0.0389	0.46	0.39	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
THYM	cis	rs9926296	0.682	rs467357	ENSG00000274627.1	RP11-104N10.2	4.12	8.27e-05	0.0389	0.46	0.39	Vitiligo;	chr16:89650989	chr16:89516797~89522217:+
THYM	cis	rs9926296	0.712	rs258332	ENSG00000274627.1	RP11-104N10.2	4.12	8.27e-05	0.0389	0.46	0.39	Vitiligo;	chr16:89661275	chr16:89516797~89522217:+
THYM	cis	rs9926296	0.712	rs258319	ENSG00000274627.1	RP11-104N10.2	4.12	8.27e-05	0.0389	0.46	0.39	Vitiligo;	chr16:89665616	chr16:89516797~89522217:+
THYM	cis	rs6040076	0.781	rs2057054	ENSG00000230506.1	RP11-416N4.4	4.12	8.28e-05	0.0389	0.45	0.39	Pulse pressure;Birth weight;	chr20:10702805	chr20:10173520~10196990:+
THYM	cis	rs6040076	0.817	rs6040098	ENSG00000230506.1	RP11-416N4.4	4.12	8.28e-05	0.0389	0.45	0.39	Pulse pressure;Birth weight;	chr20:10703750	chr20:10173520~10196990:+
THYM	cis	rs12902680	0.706	rs1836302	ENSG00000259520.4	CTD-2651B20.3	4.12	8.28e-05	0.0389	0.4	0.39	Neuroticism;	chr15:46233827	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.644	rs12442481	ENSG00000259520.4	CTD-2651B20.3	4.12	8.28e-05	0.0389	0.4	0.39	Neuroticism;	chr15:46235903	chr15:45251580~45279251:-
THYM	cis	rs34792	0.812	rs153789	ENSG00000262380.1	CTB-193M12.3	-4.12	8.28e-05	0.0389	-0.49	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15500720	chr16:15683290~15684570:+
THYM	cis	rs12474201	0.569	rs13411633	ENSG00000260977.1	RP11-333I13.1	4.12	8.28e-05	0.039	0.43	0.39	Height;	chr2:46705527	chr2:46777783~46780245:+
THYM	cis	rs10129255	0.719	rs7156660	ENSG00000254329.1	IGHVII-60-1	4.12	8.29e-05	0.039	0.38	0.39	Kawasaki disease;	chr14:106673171	chr14:106637718~106637973:-
THYM	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	4.12	8.29e-05	0.039	0.52	0.39	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
THYM	cis	rs589448	0.535	rs12423794	ENSG00000274979.1	RP11-1143G9.5	-4.12	8.29e-05	0.039	-0.37	-0.39	Cerebrospinal fluid biomarker levels;	chr12:69319238	chr12:69326574~69331882:-
THYM	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-4.12	8.29e-05	0.039	-0.64	-0.39	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
THYM	cis	rs1023500	0.506	rs6002625	ENSG00000205702.9	CYP2D7	-4.12	8.3e-05	0.039	-0.36	-0.39	Schizophrenia;	chr22:42121685	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	4.12	8.3e-05	0.039	0.36	0.39	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
THYM	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-4.12	8.3e-05	0.039	-0.48	-0.39	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
THYM	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	4.12	8.3e-05	0.039	0.48	0.39	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
THYM	cis	rs397969	0.646	rs850622	ENSG00000231645.2	KRT17P6	-4.12	8.3e-05	0.039	-0.48	-0.39	Platelet count;	chr17:19934223	chr17:20512560~20517479:-
THYM	cis	rs7077446	0.625	rs10786652	ENSG00000269609.4	RPARP-AS1	4.11	8.3e-05	0.039	0.29	0.39	Intelligence (multi-trait analysis);	chr10:101908529	chr10:102449817~102461106:+
THYM	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-4.11	8.31e-05	0.039	-0.34	-0.39	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
THYM	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-4.11	8.31e-05	0.039	-0.34	-0.39	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
THYM	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-4.11	8.31e-05	0.0391	-0.47	-0.39	Height;	chr11:118781100	chr11:118704607~118750263:+
THYM	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-4.11	8.32e-05	0.0391	-0.52	-0.39	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
THYM	cis	rs397969	0.646	rs1638528	ENSG00000231645.2	KRT17P6	-4.11	8.32e-05	0.0391	-0.47	-0.39	Platelet count;	chr17:19934616	chr17:20512560~20517479:-
THYM	cis	rs7927592	0.956	rs2510384	ENSG00000222339.1	AP000807.2	4.11	8.32e-05	0.0391	0.45	0.39	Total body bone mineral density;	chr11:68624369	chr11:68505572~68505651:-
THYM	cis	rs12908161	1	rs12908161	ENSG00000275120.1	RP11-182J1.17	4.11	8.32e-05	0.0391	0.53	0.39	Schizophrenia;	chr15:84664594	chr15:84599434~84606463:-
THYM	cis	rs910316	0.967	rs10142770	ENSG00000258646.1	RP11-950C14.3	-4.11	8.32e-05	0.0391	-0.36	-0.39	Height;	chr14:75058746	chr14:75004719~75008481:-
THYM	cis	rs564343	0.545	rs576836	ENSG00000255320.1	RP11-755F10.1	-4.11	8.32e-05	0.0391	-0.44	-0.39	Obesity (early onset extreme);	chr11:66056098	chr11:66244840~66246239:-
THYM	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	4.11	8.33e-05	0.0391	0.31	0.39	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
THYM	cis	rs886716	0.507	rs740181	ENSG00000122548.5	KIAA0087	-4.11	8.33e-05	0.0392	-0.47	-0.39	Smoking behavior;	chr7:26535343	chr7:26533121~26538788:-
THYM	cis	rs863345	0.604	rs11265007	ENSG00000236656.1	RP11-144L1.4	-4.11	8.34e-05	0.0392	-0.24	-0.39	Pneumococcal bacteremia;	chr1:158528732	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs11265024	ENSG00000236656.1	RP11-144L1.4	4.11	8.35e-05	0.0392	0.25	0.39	Pneumococcal bacteremia;	chr1:158543465	chr1:158474454~158494886:-
THYM	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	4.11	8.35e-05	0.0392	0.3	0.39	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
THYM	cis	rs9907295	1	rs9904675	ENSG00000270871.1	AC015849.19	4.11	8.35e-05	0.0392	0.45	0.39	Fibroblast growth factor basic levels;	chr17:35921435	chr17:35816717~35830293:-
THYM	cis	rs2283792	0.905	rs5755694	ENSG00000228050.1	TOP3BP1	4.11	8.35e-05	0.0392	0.42	0.39	Multiple sclerosis;	chr22:21846241	chr22:22223187~22224566:-
THYM	cis	rs4273100	0.646	rs4924990	ENSG00000262319.1	CTC-457L16.2	4.11	8.35e-05	0.0392	0.56	0.39	Schizophrenia;	chr17:19391511	chr17:19141017~19143689:-
THYM	cis	rs1519814	0.696	rs7832657	ENSG00000254343.2	RP11-760H22.2	-4.11	8.35e-05	0.0392	-0.57	-0.39	Breast cancer;	chr8:120024393	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.696	rs2875927	ENSG00000254343.2	RP11-760H22.2	-4.11	8.35e-05	0.0392	-0.57	-0.39	Breast cancer;	chr8:120024602	chr8:120052180~120056201:+
THYM	cis	rs12681366	0.959	rs58826082	ENSG00000253704.1	RP11-267M23.4	4.11	8.35e-05	0.0392	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94351487	chr8:94553722~94569745:+
THYM	cis	rs12681366	1	rs7825731	ENSG00000253704.1	RP11-267M23.4	4.11	8.35e-05	0.0392	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94362147	chr8:94553722~94569745:+
THYM	cis	rs12681366	1	rs66787185	ENSG00000253704.1	RP11-267M23.4	4.11	8.35e-05	0.0392	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94365254	chr8:94553722~94569745:+
THYM	cis	rs12681366	1	rs10956911	ENSG00000253704.1	RP11-267M23.4	4.11	8.35e-05	0.0392	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94371647	chr8:94553722~94569745:+
THYM	cis	rs12681366	1	rs67808321	ENSG00000253704.1	RP11-267M23.4	4.11	8.35e-05	0.0392	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94373317	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs2197004	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94444748	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs2919667	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94452974	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs2919664	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94456485	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs2919659	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94459544	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs2919656	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94460806	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs2381886	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94464825	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs9297939	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94467961	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.564	rs10808669	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94468833	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.563	rs6999103	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94470309	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs10956913	ENSG00000253704.1	RP11-267M23.4	4.11	8.36e-05	0.0392	0.48	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94471459	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs10956914	ENSG00000253704.1	RP11-267M23.4	-4.11	8.36e-05	0.0392	-0.48	-0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94471495	chr8:94553722~94569745:+
THYM	cis	rs12549902	0.966	rs17659386	ENSG00000271938.1	RP11-589C21.6	-4.11	8.36e-05	0.0392	-0.45	-0.39	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41656012	chr8:42139461~42139752:-
THYM	cis	rs7429990	0.965	rs4392441	ENSG00000199476.1	Y_RNA	4.11	8.37e-05	0.0393	0.52	0.39	Educational attainment (years of education);	chr3:48036211	chr3:48288587~48288694:+
THYM	cis	rs61160187	0.788	rs12519587	ENSG00000272308.1	RP11-231G3.1	-4.11	8.37e-05	0.0393	-0.34	-0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60791073	chr5:60866457~60866935:-
THYM	cis	rs495337	0.76	rs492702	ENSG00000229222.1	KRT18P4	-4.11	8.37e-05	0.0393	-0.45	-0.39	Psoriasis;	chr20:49906048	chr20:49956745~49958032:+
THYM	cis	rs7631605	0.905	rs3774326	ENSG00000272334.1	RP11-129K12.1	-4.11	8.37e-05	0.0393	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37058075	chr3:36973117~36973672:-
THYM	cis	rs910316	0.763	rs175016	ENSG00000258646.1	RP11-950C14.3	4.11	8.38e-05	0.0393	0.35	0.39	Height;	chr14:74992930	chr14:75004719~75008481:-
THYM	cis	rs2303759	0.709	rs3760667	ENSG00000269352.1	PTOV1-AS2	4.11	8.38e-05	0.0393	0.36	0.39	Multiple sclerosis;	chr19:49311575	chr19:49856970~49859289:-
THYM	cis	rs904251	0.686	rs931649	ENSG00000227920.2	RP1-153P14.5	-4.11	8.38e-05	0.0393	-0.58	-0.39	Cognitive performance;	chr6:37498303	chr6:37545145~37550860:+
THYM	cis	rs7560272	0.723	rs7609249	ENSG00000163016.8	ALMS1P	4.11	8.38e-05	0.0393	0.47	0.39	Schizophrenia;	chr2:73586693	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.723	rs6743576	ENSG00000163016.8	ALMS1P	4.11	8.38e-05	0.0393	0.47	0.39	Schizophrenia;	chr2:73587206	chr2:73644919~73685576:+
THYM	cis	rs9402743	0.671	rs4896158	ENSG00000236703.1	MYB-AS1	-4.11	8.39e-05	0.0394	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135630087	chr6:135195083~135195995:-
THYM	cis	rs11096990	0.855	rs1597722	ENSG00000249685.1	RP11-360F5.3	4.11	8.39e-05	0.0394	0.38	0.39	Cognitive function;	chr4:39173255	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs1820939	ENSG00000249685.1	RP11-360F5.3	-4.11	8.39e-05	0.0394	-0.38	-0.39	Cognitive function;	chr4:39170115	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs6855008	ENSG00000249685.1	RP11-360F5.3	-4.11	8.39e-05	0.0394	-0.38	-0.39	Cognitive function;	chr4:39172006	chr4:39133913~39135608:+
THYM	cis	rs11096990	0.855	rs56275407	ENSG00000249685.1	RP11-360F5.3	-4.11	8.39e-05	0.0394	-0.38	-0.39	Cognitive function;	chr4:39177224	chr4:39133913~39135608:+
THYM	cis	rs1519814	0.696	rs2139439	ENSG00000254343.2	RP11-760H22.2	-4.11	8.39e-05	0.0394	-0.58	-0.39	Breast cancer;	chr8:120024852	chr8:120052180~120056201:+
THYM	cis	rs793108	1	rs793108	ENSG00000272381.1	RP11-192P3.4	4.11	8.4e-05	0.0394	0.34	0.39	Multiple sclerosis;Rheumatoid arthritis;	chr10:31126177	chr10:31187883~31261910:+
THYM	cis	rs7927592	0.913	rs10047412	ENSG00000222339.1	AP000807.2	4.11	8.4e-05	0.0394	0.51	0.39	Total body bone mineral density;	chr11:68465444	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs12363722	ENSG00000222339.1	AP000807.2	4.11	8.4e-05	0.0394	0.51	0.39	Total body bone mineral density;	chr11:68468823	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.871	rs12360903	ENSG00000222339.1	AP000807.2	4.11	8.4e-05	0.0394	0.51	0.39	Total body bone mineral density;	chr11:68468846	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7106339	ENSG00000222339.1	AP000807.2	4.11	8.4e-05	0.0394	0.51	0.39	Total body bone mineral density;	chr11:68472773	chr11:68505572~68505651:-
THYM	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	4.11	8.4e-05	0.0394	0.42	0.39	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-4.11	8.4e-05	0.0394	-0.42	-0.39	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-4.11	8.4e-05	0.0394	-0.42	-0.39	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
THYM	cis	rs73108077	0.736	rs6057603	ENSG00000277112.2	RP11-755J8.1	4.11	8.4e-05	0.0394	0.52	0.39	Red blood cell density in sickle cell anemia;	chr20:31354892	chr20:30681825~30723932:-
THYM	cis	rs4925386	0.765	rs6142737	ENSG00000273619.1	RP5-908M14.9	-4.11	8.4e-05	0.0394	-0.31	-0.39	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62386303~62386970:-
THYM	cis	rs7631605	0.905	rs1046512	ENSG00000272334.1	RP11-129K12.1	-4.11	8.41e-05	0.0394	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:36990805	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs3172297	ENSG00000272334.1	RP11-129K12.1	-4.11	8.41e-05	0.0394	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:36990879	chr3:36973117~36973672:-
THYM	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	4.11	8.41e-05	0.0394	0.33	0.39	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
THYM	cis	rs1550576	0.568	rs4646632	ENSG00000274719.1	RP11-86K22.2	4.11	8.41e-05	0.0394	0.8	0.39	Hypertension;	chr15:57961644	chr15:57990217~57990636:-
THYM	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-4.11	8.41e-05	0.0395	-0.31	-0.39	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
THYM	cis	rs889398	0.741	rs4146819	ENSG00000226232.7	RP11-419C5.2	-4.11	8.42e-05	0.0395	-0.37	-0.39	Body mass index;	chr16:69889660	chr16:69976388~69996188:-
THYM	cis	rs889398	0.741	rs7193038	ENSG00000226232.7	RP11-419C5.2	-4.11	8.42e-05	0.0395	-0.37	-0.39	Body mass index;	chr16:69892231	chr16:69976388~69996188:-
THYM	cis	rs889398	0.741	rs7192213	ENSG00000226232.7	RP11-419C5.2	-4.11	8.42e-05	0.0395	-0.37	-0.39	Body mass index;	chr16:69892377	chr16:69976388~69996188:-
THYM	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-4.11	8.42e-05	0.0395	-0.47	-0.39	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
THYM	cis	rs12902680	0.706	rs12102098	ENSG00000259520.4	CTD-2651B20.3	4.11	8.42e-05	0.0395	0.41	0.39	Neuroticism;	chr15:46161273	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12909615	ENSG00000259520.4	CTD-2651B20.3	4.11	8.42e-05	0.0395	0.41	0.39	Neuroticism;	chr15:46161683	chr15:45251580~45279251:-
THYM	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	4.11	8.43e-05	0.0395	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
THYM	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	4.11	8.43e-05	0.0395	0.42	0.39	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
THYM	cis	rs4835473	0.932	rs35164917	ENSG00000249741.2	RP11-673E1.3	-4.11	8.43e-05	0.0395	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143748891	chr4:143911514~143912053:-
THYM	cis	rs35888008	1	rs62029107	ENSG00000261267.1	RP11-44I10.3	4.11	8.43e-05	0.0395	0.51	0.39	Major depressive disorder;	chr16:49424942	chr16:48559661~48587403:+
THYM	cis	rs7560272	0.538	rs4852972	ENSG00000163016.8	ALMS1P	-4.11	8.43e-05	0.0395	-0.49	-0.39	Schizophrenia;	chr2:73689545	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs2421575	ENSG00000163016.8	ALMS1P	-4.11	8.43e-05	0.0395	-0.49	-0.39	Schizophrenia;	chr2:73692395	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs13014700	ENSG00000163016.8	ALMS1P	-4.11	8.43e-05	0.0395	-0.49	-0.39	Schizophrenia;	chr2:73692994	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.512	rs13015885	ENSG00000163016.8	ALMS1P	-4.11	8.43e-05	0.0395	-0.49	-0.39	Schizophrenia;	chr2:73693355	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs35767294	ENSG00000163016.8	ALMS1P	-4.11	8.43e-05	0.0395	-0.49	-0.39	Schizophrenia;	chr2:73695707	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs13006448	ENSG00000163016.8	ALMS1P	-4.11	8.43e-05	0.0395	-0.49	-0.39	Schizophrenia;	chr2:73697297	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.502	rs13013228	ENSG00000163016.8	ALMS1P	-4.11	8.43e-05	0.0395	-0.49	-0.39	Schizophrenia;	chr2:73698089	chr2:73644919~73685576:+
THYM	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-4.11	8.43e-05	0.0395	-0.46	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
THYM	cis	rs1949733	0.655	rs2631736	ENSG00000205959.3	RP11-689P11.2	4.11	8.44e-05	0.0396	0.4	0.39	Response to antineoplastic agents;	chr4:8476694	chr4:8482270~8512610:+
THYM	cis	rs756777	0.878	rs7855899	ENSG00000273473.1	LL09NC01-139C3.1	4.11	8.44e-05	0.0396	0.31	0.39	IgG glycosylation;	chr9:133800186	chr9:134168769~134169340:+
THYM	cis	rs4853012	0.838	rs60964317	ENSG00000272183.1	RP11-523H20.3	4.11	8.44e-05	0.0396	0.5	0.39	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74501717~74502365:+
THYM	cis	rs7927592	0.83	rs10896339	ENSG00000222339.1	AP000807.2	4.11	8.45e-05	0.0396	0.44	0.39	Total body bone mineral density;	chr11:68535378	chr11:68505572~68505651:-
THYM	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	4.11	8.45e-05	0.0396	0.49	0.39	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
THYM	cis	rs11157436	1	rs61972228	ENSG00000211812.1	TRAV26-2	-4.11	8.45e-05	0.0396	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22202583~22203368:+
THYM	cis	rs11157436	1	rs12587157	ENSG00000211812.1	TRAV26-2	-4.11	8.45e-05	0.0396	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22202583~22203368:+
THYM	cis	rs11157436	1	rs11157440	ENSG00000211812.1	TRAV26-2	-4.11	8.45e-05	0.0396	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.915	rs11622938	ENSG00000211812.1	TRAV26-2	-4.11	8.45e-05	0.0396	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22202583~22203368:+
THYM	cis	rs11157436	1	rs75648426	ENSG00000211812.1	TRAV26-2	-4.11	8.45e-05	0.0396	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs61972229	ENSG00000211812.1	TRAV26-2	-4.11	8.45e-05	0.0396	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22202583~22203368:+
THYM	cis	rs11157436	0.958	rs17183301	ENSG00000211812.1	TRAV26-2	-4.11	8.45e-05	0.0396	-0.25	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22202583~22203368:+
THYM	cis	rs11668609	0.81	rs9305015	ENSG00000268442.1	CTD-2027I19.2	-4.11	8.46e-05	0.0396	-0.38	-0.39	Response to taxane treatment (docetaxel);	chr19:24157700	chr19:24162370~24163425:-
THYM	cis	rs7260598	0.71	rs10423819	ENSG00000268442.1	CTD-2027I19.2	4.11	8.46e-05	0.0396	0.38	0.39	Response to taxane treatment (placlitaxel);	chr19:24153857	chr19:24162370~24163425:-
THYM	cis	rs1529093	0.666	rs6705298	ENSG00000222043.2	AC079305.10	4.11	8.46e-05	0.0396	0.34	0.39	Non-alcoholic fatty liver disease histology (other);	chr2:177064278	chr2:177264359~177265515:+
THYM	cis	rs1529093	0.666	rs1406572	ENSG00000222043.2	AC079305.10	4.11	8.46e-05	0.0396	0.34	0.39	Non-alcoholic fatty liver disease histology (other);	chr2:177065834	chr2:177264359~177265515:+
THYM	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-4.11	8.47e-05	0.0396	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-4.11	8.47e-05	0.0396	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-4.11	8.47e-05	0.0396	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
THYM	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-4.11	8.47e-05	0.0396	-0.44	-0.39	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-4.11	8.47e-05	0.0396	-0.44	-0.39	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-4.11	8.47e-05	0.0396	-0.44	-0.39	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-4.11	8.47e-05	0.0396	-0.44	-0.39	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
THYM	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	4.11	8.47e-05	0.0397	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
THYM	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	4.11	8.47e-05	0.0397	0.36	0.39	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
THYM	cis	rs3781264	0.761	rs11187869	ENSG00000273450.1	RP11-76P2.4	4.11	8.48e-05	0.0397	0.48	0.39	Esophageal cancer and gastric cancer;	chr10:94327740	chr10:94314907~94315327:-
THYM	cis	rs78547569	1	rs2166302	ENSG00000230731.2	RP11-478K15.6	-4.11	8.48e-05	0.0397	-0.99	-0.39	Response to paliperidone in schizophrenia (negative Marder score);Response to paliperidone in schizophrenia (Multivariate);	chr13:43899815	chr13:44234118~44243192:-
THYM	cis	rs7560272	0.538	rs12233115	ENSG00000163016.8	ALMS1P	-4.11	8.49e-05	0.0397	-0.5	-0.39	Schizophrenia;	chr2:73704764	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.538	rs11126414	ENSG00000163016.8	ALMS1P	-4.11	8.49e-05	0.0397	-0.5	-0.39	Schizophrenia;	chr2:73704917	chr2:73644919~73685576:+
THYM	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-4.11	8.49e-05	0.0398	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
THYM	cis	rs495337	1	rs615926	ENSG00000229222.1	KRT18P4	-4.11	8.5e-05	0.0398	-0.46	-0.39	Psoriasis;	chr20:49902721	chr20:49956745~49958032:+
THYM	cis	rs7160151	0.621	rs7154215	ENSG00000274012.1	RN7SL2	4.11	8.5e-05	0.0398	0.57	0.39	C-reactive protein (red blood cell fatty acid level interaction);	chr14:49342744	chr14:49862550~49862849:-
THYM	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	4.11	8.5e-05	0.0398	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
THYM	cis	rs4262	0.506	rs6975837	ENSG00000278388.1	GS1-345D13.1	4.11	8.51e-05	0.0398	0.41	0.39	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93943026	chr7:93914987~93915108:+
THYM	cis	rs877819	0.583	rs2170133	ENSG00000228403.1	RP11-563N6.6	-4.11	8.51e-05	0.0398	-0.5	-0.39	Systemic lupus erythematosus;	chr10:48848166	chr10:48878022~48878649:+
THYM	cis	rs17134212	0.874	rs1366143	ENSG00000270067.1	CTC-487M23.5	4.11	8.52e-05	0.0398	0.36	0.39	Common carotid intima-media thickness in HIV negative individuals;	chr5:112192566	chr5:112893333~112894001:+
THYM	cis	rs797680	0.856	rs6688230	ENSG00000223745.6	RP4-717I23.3	4.11	8.52e-05	0.0398	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93175567	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs7553465	ENSG00000223745.6	RP4-717I23.3	4.11	8.52e-05	0.0398	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93178853	chr1:93262186~93346025:-
THYM	cis	rs797680	0.856	rs1335679	ENSG00000223745.6	RP4-717I23.3	4.11	8.52e-05	0.0398	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93179625	chr1:93262186~93346025:-
THYM	cis	rs797680	0.822	rs2297707	ENSG00000223745.6	RP4-717I23.3	4.11	8.52e-05	0.0398	0.34	0.39	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93180650	chr1:93262186~93346025:-
THYM	cis	rs1642645	1	rs1642645	ENSG00000228452.1	RP5-994D16.9	-4.11	8.52e-05	0.0399	-0.53	-0.39	Left ventricular obstructive tract defect (maternal effect);	chr1:42036610	chr1:42775813~42776790:-
THYM	cis	rs11098499	0.818	rs55825515	ENSG00000250412.1	KLHL2P1	4.11	8.52e-05	0.0399	0.37	0.39	Corneal astigmatism;	chr4:119565247	chr4:119334329~119378233:+
THYM	cis	rs9535495	0.965	rs9316505	ENSG00000200711.1	RNA5SP28	-4.11	8.52e-05	0.0399	-0.44	-0.39	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50816462	chr13:50812988~50813106:-
THYM	cis	rs11098499	0.954	rs6847248	ENSG00000250412.1	KLHL2P1	4.11	8.52e-05	0.0399	0.39	0.39	Corneal astigmatism;	chr4:119304800	chr4:119334329~119378233:+
THYM	cis	rs3862435	0.572	rs2601165	ENSG00000259212.1	CTD-3065B20.2	4.11	8.53e-05	0.0399	0.58	0.39	Response to exercise (triglyceride level interaction);	chr15:90365702	chr15:90595840~90596447:-
THYM	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-4.11	8.53e-05	0.0399	-0.43	-0.39	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-4.11	8.53e-05	0.0399	-0.43	-0.39	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
THYM	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-4.11	8.53e-05	0.0399	-0.51	-0.39	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
THYM	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-4.11	8.53e-05	0.0399	-0.45	-0.39	QT interval;	chr12:29344573	chr12:29280418~29317848:-
THYM	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	4.11	8.53e-05	0.0399	0.52	0.39	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
THYM	cis	rs9535495	0.719	rs11617827	ENSG00000200711.1	RNA5SP28	-4.11	8.53e-05	0.0399	-0.44	-0.39	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50812888	chr13:50812988~50813106:-
THYM	cis	rs10129255	0.613	rs36005652	ENSG00000253209.1	IGHV3-65	4.11	8.54e-05	0.0399	0.38	0.39	Kawasaki disease;	chr14:106651223	chr14:106666092~106666532:-
THYM	cis	rs10129255	0.53	rs35069612	ENSG00000253209.1	IGHV3-65	4.11	8.54e-05	0.0399	0.38	0.39	Kawasaki disease;	chr14:106651364	chr14:106666092~106666532:-
THYM	cis	rs10129255	0.528	rs61997578	ENSG00000253209.1	IGHV3-65	4.11	8.54e-05	0.0399	0.38	0.39	Kawasaki disease;	chr14:106651717	chr14:106666092~106666532:-
THYM	cis	rs10129255	0.56	rs61997579	ENSG00000253209.1	IGHV3-65	4.11	8.54e-05	0.0399	0.38	0.39	Kawasaki disease;	chr14:106651755	chr14:106666092~106666532:-
THYM	cis	rs10129255	0.528	rs17113214	ENSG00000253209.1	IGHV3-65	4.11	8.54e-05	0.0399	0.38	0.39	Kawasaki disease;	chr14:106651954	chr14:106666092~106666532:-
THYM	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-4.11	8.54e-05	0.0399	-0.65	-0.39	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
THYM	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-4.11	8.54e-05	0.0399	-0.65	-0.39	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
THYM	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-4.11	8.54e-05	0.0399	-0.65	-0.39	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
THYM	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-4.11	8.54e-05	0.0399	-0.47	-0.39	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
THYM	cis	rs2235573	0.805	rs132934	ENSG00000273096.1	RP3-508I15.20	-4.11	8.54e-05	0.0399	-0.32	-0.39	Glioma;Glioblastoma;	chr22:38093551	chr22:38736610~38736792:-
THYM	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-4.11	8.56e-05	0.04	-0.51	-0.39	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
THYM	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-4.11	8.56e-05	0.04	-0.48	-0.39	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
THYM	cis	rs990871	1	rs11209948	ENSG00000227207.2	RPL31P12	4.11	8.57e-05	0.04	0.54	0.39	Subcutaneous adipose tissue;	chr1:72346221	chr1:72301472~72301829:+
THYM	cis	rs7178424	0.806	rs4587915	ENSG00000259251.2	RP11-643M14.1	4.11	8.57e-05	0.04	0.4	0.39	Height;	chr15:61949763	chr15:62060503~62062434:+
THYM	cis	rs11098499	0.82	rs28578366	ENSG00000250412.1	KLHL2P1	-4.11	8.57e-05	0.04	-0.37	-0.39	Corneal astigmatism;	chr4:119615750	chr4:119334329~119378233:+
THYM	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-4.11	8.57e-05	0.04	-0.5	-0.39	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
THYM	cis	rs2115630	1	rs4633690	ENSG00000275120.1	RP11-182J1.17	-4.11	8.57e-05	0.04	-0.45	-0.39	P wave terminal force;	chr15:84818729	chr15:84599434~84606463:-
THYM	cis	rs2253762	0.507	rs4752630	ENSG00000276742.1	RP11-500G22.4	4.11	8.57e-05	0.04	0.47	0.39	Breast cancer;	chr10:121991440	chr10:121956782~121957098:+
THYM	cis	rs853679	0.517	rs16893666	ENSG00000199851.2	U3	-4.11	8.57e-05	0.0401	-0.51	-0.39	Depression;	chr6:28086929	chr6:28015568~28015777:+
THYM	cis	rs7631605	0.809	rs1055095	ENSG00000272334.1	RP11-129K12.1	-4.11	8.57e-05	0.0401	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:36986442	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.845	rs1133661	ENSG00000272334.1	RP11-129K12.1	-4.11	8.57e-05	0.0401	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:36986575	chr3:36973117~36973672:-
THYM	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	4.11	8.58e-05	0.0401	0.46	0.39	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
THYM	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	4.11	8.58e-05	0.0401	0.46	0.39	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
THYM	cis	rs7851726	0.668	rs10217143	ENSG00000232063.1	RP11-307E17.8	4.11	8.58e-05	0.0401	0.38	0.39	Urinary albumin-to-creatinine ratio;	chr9:94876351	chr9:94332476~94360948:+
THYM	cis	rs2732480	0.538	rs1387260	ENSG00000240399.1	RP1-228P16.1	4.11	8.58e-05	0.0401	0.41	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48054813~48055591:-
THYM	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-4.11	8.59e-05	0.0401	-0.42	-0.39	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-4.11	8.59e-05	0.0401	-0.42	-0.39	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
THYM	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-4.11	8.59e-05	0.0401	-0.36	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
THYM	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-4.11	8.6e-05	0.0401	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
THYM	cis	rs9907295	0.901	rs9907121	ENSG00000270977.1	AC015849.16	-4.11	8.6e-05	0.0401	-0.64	-0.39	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs4796118	ENSG00000270977.1	AC015849.16	-4.11	8.6e-05	0.0401	-0.64	-0.39	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs9914401	ENSG00000270977.1	AC015849.16	-4.11	8.6e-05	0.0401	-0.64	-0.39	Fibroblast growth factor basic levels;	chr17:35861810	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs9898152	ENSG00000270977.1	AC015849.16	-4.11	8.6e-05	0.0401	-0.64	-0.39	Fibroblast growth factor basic levels;	chr17:35869211	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs78023535	ENSG00000270977.1	AC015849.16	-4.11	8.6e-05	0.0401	-0.64	-0.39	Fibroblast growth factor basic levels;	chr17:35869598	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs4795095	ENSG00000270977.1	AC015849.16	-4.11	8.6e-05	0.0401	-0.64	-0.39	Fibroblast growth factor basic levels;	chr17:35870296	chr17:35893707~35911023:-
THYM	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-4.11	8.6e-05	0.0402	-0.44	-0.39	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
THYM	cis	rs7927592	0.956	rs12277225	ENSG00000222339.1	AP000807.2	4.11	8.6e-05	0.0402	0.45	0.39	Total body bone mineral density;	chr11:68573499	chr11:68505572~68505651:-
THYM	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	4.11	8.61e-05	0.0402	0.46	0.39	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
THYM	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	4.11	8.61e-05	0.0402	0.41	0.39	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
THYM	cis	rs897984	0.762	rs4889599	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30957268	chr16:30956872~30957199:-
THYM	cis	rs897984	0.721	rs2305884	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30959420	chr16:30956872~30957199:-
THYM	cis	rs897984	0.762	rs11150601	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30966478	chr16:30956872~30957199:-
THYM	cis	rs897984	0.762	rs897986	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30969581	chr16:30956872~30957199:-
THYM	cis	rs897984	0.721	rs28360557	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30971939	chr16:30956872~30957199:-
THYM	cis	rs897984	0.762	rs7204459	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30972891	chr16:30956872~30957199:-
THYM	cis	rs897984	0.762	rs4889604	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30974673	chr16:30956872~30957199:-
THYM	cis	rs897984	0.762	rs12931046	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30975823	chr16:30956872~30957199:-
THYM	cis	rs897984	0.721	rs4889525	ENSG00000275263.1	RP11-1072A3.4	4.1	8.61e-05	0.0402	0.35	0.39	Dementia with Lewy bodies;	chr16:30978537	chr16:30956872~30957199:-
THYM	cis	rs4835473	0.897	rs55635947	ENSG00000249741.2	RP11-673E1.3	4.1	8.62e-05	0.0402	0.33	0.39	Immature fraction of reticulocytes;	chr4:143736218	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs56334914	ENSG00000249741.2	RP11-673E1.3	4.1	8.62e-05	0.0402	0.33	0.39	Immature fraction of reticulocytes;	chr4:143736291	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs56324738	ENSG00000249741.2	RP11-673E1.3	4.1	8.62e-05	0.0402	0.33	0.39	Immature fraction of reticulocytes;	chr4:143736297	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs55862664	ENSG00000249741.2	RP11-673E1.3	4.1	8.62e-05	0.0402	0.33	0.39	Immature fraction of reticulocytes;	chr4:143736311	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4615131	ENSG00000249741.2	RP11-673E1.3	4.1	8.62e-05	0.0402	0.33	0.39	Immature fraction of reticulocytes;	chr4:143740295	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4499657	ENSG00000249741.2	RP11-673E1.3	4.1	8.62e-05	0.0402	0.33	0.39	Immature fraction of reticulocytes;	chr4:143740316	chr4:143911514~143912053:-
THYM	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-4.1	8.62e-05	0.0402	-0.48	-0.39	Height;	chr11:118761813	chr11:118704607~118750263:+
THYM	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-4.1	8.62e-05	0.0402	-0.48	-0.39	Height;	chr11:118764443	chr11:118704607~118750263:+
THYM	cis	rs2732480	0.5	rs12828309	ENSG00000240399.1	RP1-228P16.1	4.1	8.62e-05	0.0402	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs1552550	ENSG00000240399.1	RP1-228P16.1	4.1	8.62e-05	0.0402	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48054813~48055591:-
THYM	cis	rs12666612	0.85	rs680416	ENSG00000279048.1	RP11-511H23.2	-4.1	8.62e-05	0.0402	-0.47	-0.39	Obesity-related traits;	chr7:18333719	chr7:17940503~17942922:+
THYM	cis	rs28785552	0.931	rs10406850	ENSG00000250731.1	TPM3P6	-4.1	8.62e-05	0.0402	-0.55	-0.39	Response to paliperidone in schizophrenia (PANSS score);	chr19:52737554	chr19:53479350~53480091:+
THYM	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-4.1	8.63e-05	0.0403	-0.48	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-4.1	8.63e-05	0.0403	-0.48	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
THYM	cis	rs703980	0.585	rs697238	ENSG00000244733.5	RP11-506M13.3	4.1	8.64e-05	0.0403	0.36	0.39	Type 2 diabetes;	chr10:79187911	chr10:79660891~79677996:+
THYM	cis	rs10160246	1	rs10160246	ENSG00000255418.4	RP11-266A24.1	-4.1	8.64e-05	0.0403	-0.44	-0.39	Cancer;	chr11:23153770	chr11:23164900~23203161:+
THYM	cis	rs10888838	1	rs33988698	ENSG00000198711.5	SSBP3-AS1	4.1	8.66e-05	0.0404	0.27	0.39	Mitochondrial DNA levels;	chr1:54220182	chr1:54236440~54239063:+
THYM	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-4.1	8.66e-05	0.0404	-0.49	-0.39	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
THYM	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	4.1	8.66e-05	0.0404	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
THYM	cis	rs35888008	1	rs4785168	ENSG00000261267.1	RP11-44I10.3	4.1	8.67e-05	0.0404	0.51	0.39	Major depressive disorder;	chr16:49418927	chr16:48559661~48587403:+
THYM	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-4.1	8.67e-05	0.0404	-0.41	-0.39	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-4.1	8.67e-05	0.0404	-0.41	-0.39	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-4.1	8.67e-05	0.0404	-0.41	-0.39	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-4.1	8.67e-05	0.0404	-0.41	-0.39	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
THYM	cis	rs7631605	0.845	rs9311149	ENSG00000272334.1	RP11-129K12.1	-4.1	8.68e-05	0.0405	-0.38	-0.39	Cerebrospinal P-tau181p levels;	chr3:36988684	chr3:36973117~36973672:-
THYM	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-4.1	8.68e-05	0.0405	-0.38	-0.39	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
THYM	cis	rs763121	0.886	rs1013339	ENSG00000273076.1	RP3-508I15.22	4.1	8.68e-05	0.0405	0.5	0.39	Menopause (age at onset);	chr22:38578675	chr22:38743495~38743910:+
THYM	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	4.1	8.69e-05	0.0405	0.58	0.39	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
THYM	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-4.1	8.69e-05	0.0405	-0.71	-0.39	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
THYM	cis	rs7631605	0.87	rs55755638	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37115654	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs67233917	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37116144	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs3821823	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37117336	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs11707406	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37119186	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6787539	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37123156	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs11927149	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37124570	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6764444	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37132224	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs9832423	ENSG00000272334.1	RP11-129K12.1	-4.1	8.69e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37134625	chr3:36973117~36973672:-
THYM	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	4.1	8.69e-05	0.0405	0.48	0.39	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
THYM	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	4.1	8.69e-05	0.0405	0.49	0.39	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	4.1	8.69e-05	0.0405	0.49	0.39	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	4.1	8.69e-05	0.0405	0.49	0.39	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
THYM	cis	rs7181230	1	rs7181230	ENSG00000259584.1	RP11-521C20.2	-4.1	8.7e-05	0.0405	-0.33	-0.39	Dehydroepiandrosterone sulphate levels;	chr15:40068540	chr15:40075204~40078704:-
THYM	cis	rs7631605	0.905	rs3774343	ENSG00000272334.1	RP11-129K12.1	-4.1	8.7e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:36994343	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs4647215	ENSG00000272334.1	RP11-129K12.1	-4.1	8.7e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:36999829	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs4647222	ENSG00000272334.1	RP11-129K12.1	-4.1	8.7e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37001469	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs4647250	ENSG00000272334.1	RP11-129K12.1	-4.1	8.7e-05	0.0405	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37007607	chr3:36973117~36973672:-
THYM	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	4.1	8.7e-05	0.0405	0.51	0.39	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
THYM	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-4.1	8.71e-05	0.0406	-0.53	-0.39	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
THYM	cis	rs393951	1	rs393951	ENSG00000226348.1	VN2R10P	4.1	8.71e-05	0.0406	0.45	0.39	Childhood ear infection;	chr16:77586162	chr16:77220406~77221258:+
THYM	cis	rs393951	1	rs400226	ENSG00000226348.1	VN2R10P	4.1	8.71e-05	0.0406	0.45	0.39	Childhood ear infection;	chr16:77586225	chr16:77220406~77221258:+
THYM	cis	rs10129255	0.957	rs8009464	ENSG00000253703.1	IGHV1-68	-4.1	8.72e-05	0.0406	-0.5	-0.39	Kawasaki disease;	chr14:106777611	chr14:106703852~106704146:-
THYM	cis	rs910316	0.692	rs7156586	ENSG00000258646.1	RP11-950C14.3	-4.1	8.72e-05	0.0406	-0.35	-0.39	Height;	chr14:75039527	chr14:75004719~75008481:-
THYM	cis	rs11157436	0.918	rs1983519	ENSG00000211812.1	TRAV26-2	-4.1	8.73e-05	0.0406	-0.26	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22202583~22203368:+
THYM	cis	rs7178424	0.875	rs12912208	ENSG00000259251.2	RP11-643M14.1	4.1	8.74e-05	0.0407	0.38	0.39	Height;	chr15:62062371	chr15:62060503~62062434:+
THYM	cis	rs910316	1	rs876402	ENSG00000258646.1	RP11-950C14.3	4.1	8.74e-05	0.0407	0.35	0.39	Height;	chr14:75135159	chr14:75004719~75008481:-
THYM	cis	rs2115630	1	rs58581703	ENSG00000275120.1	RP11-182J1.17	-4.1	8.75e-05	0.0407	-0.47	-0.39	P wave terminal force;	chr15:84733704	chr15:84599434~84606463:-
THYM	cis	rs2115630	0.967	rs8028490	ENSG00000275120.1	RP11-182J1.17	-4.1	8.75e-05	0.0407	-0.47	-0.39	P wave terminal force;	chr15:84734657	chr15:84599434~84606463:-
THYM	cis	rs60180747	0.544	rs11635253	ENSG00000261318.1	RP11-653J6.1	4.1	8.75e-05	0.0407	0.42	0.39	Testicular germ cell tumor;	chr15:66276869	chr15:66278498~66293357:-
THYM	cis	rs7044106	0.791	rs4836830	ENSG00000238181.2	AHCYP2	-4.1	8.75e-05	0.0407	-0.4	-0.39	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120720673~120721972:+
THYM	cis	rs4835473	0.897	rs4835333	ENSG00000249741.2	RP11-673E1.3	4.1	8.75e-05	0.0407	0.34	0.39	Immature fraction of reticulocytes;	chr4:143703174	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs1450246	ENSG00000249741.2	RP11-673E1.3	-4.1	8.75e-05	0.0407	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143702954	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs6835827	ENSG00000249741.2	RP11-673E1.3	-4.1	8.75e-05	0.0407	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143712803	chr4:143911514~143912053:-
THYM	cis	rs453301	0.652	rs2043129	ENSG00000253893.2	FAM85B	-4.1	8.75e-05	0.0407	-0.47	-0.39	Joint mobility (Beighton score);	chr8:8967994	chr8:8167819~8226614:-
THYM	cis	rs7829975	0.508	rs1594437	ENSG00000253893.2	FAM85B	-4.1	8.75e-05	0.0407	-0.47	-0.39	Mood instability;	chr8:8968365	chr8:8167819~8226614:-
THYM	cis	rs3811273	0.614	rs12589879	ENSG00000211816.2	TRAV38-1	-4.1	8.75e-05	0.0407	-0.31	-0.39	Periodontal disease-related phenotypes;	chr14:22266010	chr14:22271968~22272563:+
THYM	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	4.1	8.76e-05	0.0407	0.5	0.39	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
THYM	cis	rs7560272	0.723	rs6744697	ENSG00000273245.1	RP11-434P11.2	4.1	8.76e-05	0.0407	0.43	0.39	Schizophrenia;	chr2:73538311	chr2:73750256~73750786:-
THYM	cis	rs1595825	0.891	rs112898725	ENSG00000222017.1	AC011997.1	-4.1	8.76e-05	0.0408	-0.44	-0.39	Ulcerative colitis;	chr2:197785282	chr2:197693106~197774823:+
THYM	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	4.1	8.76e-05	0.0408	0.39	0.39	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
THYM	cis	rs11098499	0.954	rs11098525	ENSG00000250412.1	KLHL2P1	4.1	8.76e-05	0.0408	0.38	0.39	Corneal astigmatism;	chr4:119468997	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs11098526	ENSG00000250412.1	KLHL2P1	4.1	8.76e-05	0.0408	0.38	0.39	Corneal astigmatism;	chr4:119469204	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.821	rs10032151	ENSG00000250412.1	KLHL2P1	4.1	8.76e-05	0.0408	0.38	0.39	Corneal astigmatism;	chr4:119470473	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs10032158	ENSG00000250412.1	KLHL2P1	4.1	8.76e-05	0.0408	0.38	0.39	Corneal astigmatism;	chr4:119470477	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs6838814	ENSG00000250412.1	KLHL2P1	4.1	8.76e-05	0.0408	0.38	0.39	Corneal astigmatism;	chr4:119471288	chr4:119334329~119378233:+
THYM	cis	rs7631605	0.875	rs4678932	ENSG00000272334.1	RP11-129K12.1	-4.1	8.77e-05	0.0408	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37054812	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs58693636	ENSG00000272334.1	RP11-129K12.1	-4.1	8.77e-05	0.0408	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37061132	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs2058476	ENSG00000272334.1	RP11-129K12.1	-4.1	8.77e-05	0.0408	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37063405	chr3:36973117~36973672:-
THYM	cis	rs2738048	0.545	rs2738168	ENSG00000233531.1	DEFA10P	4.1	8.77e-05	0.0408	0.41	0.39	IgA nephropathy;	chr8:6967055	chr8:6968141~6969113:-
THYM	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	4.1	8.77e-05	0.0408	0.56	0.39	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
THYM	cis	rs9309473	0.5	rs4852308	ENSG00000273245.1	RP11-434P11.2	-4.1	8.77e-05	0.0408	-0.44	-0.39	Metabolite levels;	chr2:73606908	chr2:73750256~73750786:-
THYM	cis	rs3862435	0.764	rs16974212	ENSG00000259212.1	CTD-3065B20.2	-4.1	8.78e-05	0.0408	-0.61	-0.39	Response to exercise (triglyceride level interaction);	chr15:90472669	chr15:90595840~90596447:-
THYM	cis	rs6121246	0.909	rs6058460	ENSG00000230613.1	HM13-AS1	4.1	8.78e-05	0.0408	0.59	0.39	Mean corpuscular hemoglobin;	chr20:31775268	chr20:31567707~31573263:-
THYM	cis	rs926326	0.774	rs6932536	ENSG00000219682.4	RP3-425P12.4	4.1	8.78e-05	0.0409	0.58	0.39	Platelet count;	chr6:25677087	chr6:25140003~25141403:+
THYM	cis	rs7631605	0.905	rs17204675	ENSG00000272334.1	RP11-129K12.1	-4.1	8.78e-05	0.0409	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37094306	chr3:36973117~36973672:-
THYM	cis	rs42490	0.51	rs13278061	ENSG00000251136.7	RP11-37B2.1	-4.1	8.78e-05	0.0409	-0.35	-0.39	Leprosy;	chr8:89686032	chr8:89609409~89757727:-
THYM	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	4.1	8.79e-05	0.0409	0.5	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
THYM	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-4.1	8.79e-05	0.0409	-0.47	-0.39	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
THYM	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-4.1	8.79e-05	0.0409	-0.47	-0.39	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
THYM	cis	rs2929278	0.617	rs3087657	ENSG00000166763.7	STRCP1	4.1	8.8e-05	0.0409	0.44	0.39	Schizophrenia;	chr15:43771661	chr15:43699488~43718184:-
THYM	cis	rs7267979	0.789	rs6050472	ENSG00000276952.1	RP5-965G21.6	4.1	8.8e-05	0.0409	0.47	0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:25284915~25285588:-
THYM	cis	rs1532557	1	rs12089565	ENSG00000188460.4	ACTBP11	4.1	8.8e-05	0.0409	0.55	0.39	Cancer;	chr1:224588138	chr1:223863726~223864851:-
THYM	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	4.1	8.81e-05	0.0409	0.46	0.39	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
THYM	cis	rs972578	1	rs2267480	ENSG00000215347.3	SLC25A5P1	-4.1	8.81e-05	0.0409	-0.31	-0.39	Mean platelet volume;	chr22:42966970	chr22:42001069~42001966:-
THYM	cis	rs495337	0.76	rs2745078	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49908923	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs2254930	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49910570	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs2769978	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49910886	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs2769977	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49910927	chr20:49956745~49958032:+
THYM	cis	rs495337	0.646	rs6067267	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49911700	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs13040201	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49919812	chr20:49956745~49958032:+
THYM	cis	rs495337	0.72	rs2869937	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49920081	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6067270	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49920717	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6125813	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49924646	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6122844	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49925008	chr20:49956745~49958032:+
THYM	cis	rs495337	0.72	rs6067271	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49925126	chr20:49956745~49958032:+
THYM	cis	rs495337	0.72	rs6067274	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49927849	chr20:49956745~49958032:+
THYM	cis	rs495337	0.72	rs6125819	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49929173	chr20:49956745~49958032:+
THYM	cis	rs495337	0.786	rs6125820	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49929294	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6067275	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49929336	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6122845	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49929737	chr20:49956745~49958032:+
THYM	cis	rs495337	0.965	rs6122848	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49930020	chr20:49956745~49958032:+
THYM	cis	rs495337	0.721	rs11696404	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49931743	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs11696437	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49931781	chr20:49956745~49958032:+
THYM	cis	rs495337	0.721	rs6125822	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49932229	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6125825	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49937166	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs1056200	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49939711	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6067282	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49952741	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs6125830	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49955125	chr20:49956745~49958032:+
THYM	cis	rs495337	0.76	rs4810995	ENSG00000229222.1	KRT18P4	-4.1	8.82e-05	0.041	-0.45	-0.39	Psoriasis;	chr20:49955265	chr20:49956745~49958032:+
THYM	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-4.1	8.82e-05	0.041	-0.4	-0.39	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
THYM	cis	rs7631605	0.935	rs9831084	ENSG00000272334.1	RP11-129K12.1	-4.1	8.83e-05	0.041	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:36984170	chr3:36973117~36973672:-
THYM	cis	rs10129255	0.5	rs2027902	ENSG00000253703.1	IGHV1-68	-4.1	8.83e-05	0.041	-0.42	-0.39	Kawasaki disease;	chr14:106807157	chr14:106703852~106704146:-
THYM	cis	rs9907295	1	rs11650409	ENSG00000270871.1	AC015849.19	-4.1	8.83e-05	0.041	-0.4	-0.39	Fibroblast growth factor basic levels;	chr17:35907949	chr17:35816717~35830293:-
THYM	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-4.1	8.84e-05	0.041	-0.56	-0.39	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
THYM	cis	rs13248545	0.55	rs7388041	ENSG00000253944.1	RP11-156K13.1	4.1	8.84e-05	0.041	0.38	0.39	Yeast infection;	chr8:17757079	chr8:17801345~17861069:+
THYM	cis	rs7851726	0.714	rs1867102	ENSG00000232063.1	RP11-307E17.8	4.1	8.84e-05	0.041	0.4	0.39	Urinary albumin-to-creatinine ratio;	chr9:94865485	chr9:94332476~94360948:+
THYM	cis	rs3015497	0.789	rs3015502	ENSG00000270062.1	RP11-248J18.3	4.1	8.84e-05	0.041	0.28	0.39	Mean platelet volume;	chr14:50641709	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.789	rs3015500	ENSG00000270062.1	RP11-248J18.3	4.1	8.84e-05	0.041	0.28	0.39	Mean platelet volume;	chr14:50642159	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.789	rs3015498	ENSG00000270062.1	RP11-248J18.3	4.1	8.84e-05	0.041	0.28	0.39	Mean platelet volume;	chr14:50646106	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.789	rs3015496	ENSG00000270062.1	RP11-248J18.3	4.1	8.84e-05	0.041	0.28	0.39	Mean platelet volume;	chr14:50647333	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.763	rs2934689	ENSG00000270062.1	RP11-248J18.3	4.1	8.84e-05	0.041	0.28	0.39	Mean platelet volume;	chr14:50651609	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.753	rs4643225	ENSG00000270062.1	RP11-248J18.3	4.1	8.84e-05	0.041	0.28	0.39	Mean platelet volume;	chr14:50655487	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.789	rs923908	ENSG00000270062.1	RP11-248J18.3	4.1	8.84e-05	0.041	0.28	0.39	Mean platelet volume;	chr14:50656877	chr14:50723777~50724272:-
THYM	cis	rs7178424	0.87	rs8034914	ENSG00000259251.2	RP11-643M14.1	4.1	8.84e-05	0.041	0.43	0.39	Height;	chr15:61958231	chr15:62060503~62062434:+
THYM	cis	rs7631605	0.875	rs56180213	ENSG00000272334.1	RP11-129K12.1	-4.1	8.85e-05	0.0411	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37068142	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs9823428	ENSG00000272334.1	RP11-129K12.1	-4.1	8.85e-05	0.0411	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37069639	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs17810211	ENSG00000272334.1	RP11-129K12.1	-4.1	8.85e-05	0.0411	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37071914	chr3:36973117~36973672:-
THYM	cis	rs6782228	0.606	rs2712381	ENSG00000277250.1	Metazoa_SRP	-4.1	8.85e-05	0.0411	-0.54	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs1127030	ENSG00000277250.1	Metazoa_SRP	-4.1	8.85e-05	0.0411	-0.54	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs2712419	ENSG00000277250.1	Metazoa_SRP	-4.1	8.85e-05	0.0411	-0.54	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs2712417	ENSG00000277250.1	Metazoa_SRP	-4.1	8.85e-05	0.0411	-0.54	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128673681~128674021:-
THYM	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-4.1	8.85e-05	0.0411	-0.43	-0.39	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
THYM	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-4.1	8.85e-05	0.0411	-0.43	-0.39	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
THYM	cis	rs890448	0.774	rs6848852	ENSG00000254531.1	FLJ20021	4.1	8.87e-05	0.0411	0.34	0.39	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101526997	chr4:101347780~101348883:+
THYM	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-4.1	8.87e-05	0.0411	-0.48	-0.39	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
THYM	cis	rs397969	0.646	rs1638527	ENSG00000231645.2	KRT17P6	4.1	8.87e-05	0.0411	0.48	0.39	Platelet count;	chr17:19942080	chr17:20512560~20517479:-
THYM	cis	rs397969	0.607	rs169413	ENSG00000231645.2	KRT17P6	-4.1	8.87e-05	0.0411	-0.48	-0.39	Platelet count;	chr17:19946432	chr17:20512560~20517479:-
THYM	cis	rs11098499	0.863	rs13136462	ENSG00000250412.1	KLHL2P1	4.1	8.88e-05	0.0411	0.37	0.39	Corneal astigmatism;	chr4:119622018	chr4:119334329~119378233:+
THYM	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-4.1	8.88e-05	0.0412	-0.65	-0.39	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
THYM	cis	rs9907295	0.591	rs3817655	ENSG00000270871.1	AC015849.19	-4.1	8.9e-05	0.0412	-0.35	-0.39	Fibroblast growth factor basic levels;	chr17:35872637	chr17:35816717~35830293:-
THYM	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	4.1	8.9e-05	0.0412	0.37	0.39	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
THYM	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-4.1	8.9e-05	0.0412	-0.33	-0.39	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
THYM	cis	rs9402743	0.67	rs7769840	ENSG00000236703.1	MYB-AS1	4.1	8.9e-05	0.0412	0.26	0.39	Systemic lupus erythematosus;	chr6:135605412	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.702	rs9399150	ENSG00000236703.1	MYB-AS1	-4.1	8.9e-05	0.0412	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135599752	chr6:135195083~135195995:-
THYM	cis	rs7617773	0.925	rs7374376	ENSG00000228638.1	FCF1P2	4.1	8.9e-05	0.0412	0.4	0.39	Coronary artery disease;	chr3:48131197	chr3:48290793~48291375:-
THYM	cis	rs7631605	0.905	rs6796088	ENSG00000272334.1	RP11-129K12.1	-4.1	8.91e-05	0.0412	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37106081	chr3:36973117~36973672:-
THYM	cis	rs1529093	0.666	rs10193787	ENSG00000222043.2	AC079305.10	4.1	8.91e-05	0.0412	0.35	0.39	Non-alcoholic fatty liver disease histology (other);	chr2:177052878	chr2:177264359~177265515:+
THYM	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	4.1	8.92e-05	0.0413	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	4.1	8.92e-05	0.0413	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
THYM	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	4.1	8.92e-05	0.0413	0.49	0.39	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
THYM	cis	rs73198271	1	rs11774744	ENSG00000253893.2	FAM85B	4.1	8.92e-05	0.0413	0.59	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750254	chr8:8167819~8226614:-
THYM	cis	rs73198271	1	rs11784958	ENSG00000253893.2	FAM85B	4.1	8.92e-05	0.0413	0.59	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr8:8167819~8226614:-
THYM	cis	rs73198271	1	rs11775476	ENSG00000253893.2	FAM85B	4.1	8.92e-05	0.0413	0.59	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr8:8167819~8226614:-
THYM	cis	rs73198271	1	rs73198279	ENSG00000253893.2	FAM85B	4.1	8.92e-05	0.0413	0.59	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8167819~8226614:-
THYM	cis	rs73198271	1	rs11776513	ENSG00000253893.2	FAM85B	4.1	8.92e-05	0.0413	0.59	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8167819~8226614:-
THYM	cis	rs73198271	1	rs11775821	ENSG00000253893.2	FAM85B	4.1	8.92e-05	0.0413	0.59	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8167819~8226614:-
THYM	cis	rs9876781	1	rs7630741	ENSG00000244380.1	RP11-24C3.2	4.09	8.93e-05	0.0413	0.51	0.39	Longevity;	chr3:48378233	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs9311423	ENSG00000244380.1	RP11-24C3.2	4.09	8.93e-05	0.0413	0.51	0.39	Longevity;	chr3:48378818	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs7634377	ENSG00000244380.1	RP11-24C3.2	4.09	8.93e-05	0.0413	0.51	0.39	Longevity;	chr3:48379768	chr3:48440352~48446656:-
THYM	cis	rs9876781	1	rs6804774	ENSG00000244380.1	RP11-24C3.2	4.09	8.93e-05	0.0413	0.51	0.39	Longevity;	chr3:48389129	chr3:48440352~48446656:-
THYM	cis	rs4835473	0.9	rs3856989	ENSG00000249741.2	RP11-673E1.3	-4.09	8.94e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143921752	chr4:143911514~143912053:-
THYM	cis	rs863345	0.604	rs2054993	ENSG00000236656.1	RP11-144L1.4	4.09	8.95e-05	0.0414	0.25	0.39	Pneumococcal bacteremia;	chr1:158536178	chr1:158474454~158494886:-
THYM	cis	rs863345	0.604	rs2054992	ENSG00000236656.1	RP11-144L1.4	4.09	8.95e-05	0.0414	0.25	0.39	Pneumococcal bacteremia;	chr1:158536225	chr1:158474454~158494886:-
THYM	cis	rs2140773	0.835	rs4973548	ENSG00000251791.1	SCARNA6	4.09	8.95e-05	0.0414	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr2:232649926	chr2:233288676~233288940:+
THYM	cis	rs4835473	0.932	rs1450236	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143783069	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs62339580	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143785090	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs62339581	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143785172	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs7666368	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143785372	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs7690428	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143785400	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs34781605	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143785486	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs11100810	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143787518	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs4835278	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143788433	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs4835279	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143788917	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.801	rs35839125	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143792351	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.75	rs12498381	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143793928	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.838	rs6832094	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143795388	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.868	rs62337291	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143807903	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs13121861	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143814007	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs4835303	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143821533	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs4835034	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143821538	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs6827971	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143822126	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs4835305	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143823646	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs11721700	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143824264	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs17018500	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143824849	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.778	rs6856553	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143825973	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.868	rs11737787	ENSG00000246448.2	RP13-578N3.3	4.09	8.95e-05	0.0414	0.49	0.39	Immature fraction of reticulocytes;	chr4:143826498	chr4:143700257~143865072:+
THYM	cis	rs73108077	0.736	rs6060436	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31258500	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6060596	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31261457	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6060617	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31261849	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs77855283	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31262576	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs732860	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31269641	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6121224	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31272881	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6060993	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31278917	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs56047717	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31279756	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6058479	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31282419	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6061028	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31285774	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs6058492	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31286965	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs2376545	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31293314	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs13433373	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31296736	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.688	rs6061150	ENSG00000277112.2	RP11-755J8.1	-4.09	8.95e-05	0.0414	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31301527	chr20:30681825~30723932:-
THYM	cis	rs7631605	0.905	rs9836891	ENSG00000272334.1	RP11-129K12.1	-4.09	8.95e-05	0.0414	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37107391	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs7620643	ENSG00000272334.1	RP11-129K12.1	-4.09	8.95e-05	0.0414	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37110640	chr3:36973117~36973672:-
THYM	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
THYM	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
THYM	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	4.09	8.96e-05	0.0414	0.48	0.39	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
THYM	cis	rs4835473	0.831	rs4323050	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143992106	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs4423826	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143992165	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1849128	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143992582	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.715	rs4538428	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143992751	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.771	rs2175452	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143992887	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.8	rs2175451	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143992964	chr4:143911514~143912053:-
THYM	cis	rs4323050	0.51	rs4254715	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143911514~143912053:-
THYM	cis	rs4323050	0.51	rs4273414	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.831	rs1912743	ENSG00000249741.2	RP11-673E1.3	-4.09	8.96e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143993705	chr4:143911514~143912053:-
THYM	cis	rs910316	0.967	rs4903292	ENSG00000258646.1	RP11-950C14.3	-4.09	8.97e-05	0.0414	-0.35	-0.39	Height;	chr14:75189542	chr14:75004719~75008481:-
THYM	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	4.09	8.97e-05	0.0414	0.49	0.39	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	4.09	8.97e-05	0.0414	0.49	0.39	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	4.09	8.97e-05	0.0414	0.49	0.39	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	4.09	8.97e-05	0.0414	0.49	0.39	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	4.09	8.97e-05	0.0414	0.49	0.39	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	4.09	8.97e-05	0.0414	0.49	0.39	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
THYM	cis	rs9611565	0.918	rs9611566	ENSG00000273366.1	CTA-989H11.1	-4.09	8.98e-05	0.0414	-0.43	-0.39	Vitiligo;	chr22:41372621	chr22:42278188~42278846:+
THYM	cis	rs11098499	0.82	rs28394116	ENSG00000250412.1	KLHL2P1	4.09	8.98e-05	0.0414	0.37	0.39	Corneal astigmatism;	chr4:119603128	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.866	rs3756156	ENSG00000250412.1	KLHL2P1	4.09	8.98e-05	0.0414	0.37	0.39	Corneal astigmatism;	chr4:119603686	chr4:119334329~119378233:+
THYM	cis	rs4835473	0.808	rs1984810	ENSG00000249741.2	RP11-673E1.3	-4.09	8.98e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143824970	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.831	rs1984809	ENSG00000249741.2	RP11-673E1.3	-4.09	8.98e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143825018	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10857413	ENSG00000249741.2	RP11-673E1.3	-4.09	8.98e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143827752	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6828935	ENSG00000249741.2	RP11-673E1.3	-4.09	8.98e-05	0.0414	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143829113	chr4:143911514~143912053:-
THYM	cis	rs3796619	1	rs1466214	ENSG00000215367.9	TMED11P	4.09	8.98e-05	0.0414	0.38	0.39	Recombination rate (males);	chr4:1079972	chr4:1115197~1153726:-
THYM	cis	rs3796619	0.961	rs11732520	ENSG00000215367.9	TMED11P	4.09	8.98e-05	0.0414	0.38	0.39	Recombination rate (males);	chr4:1080221	chr4:1115197~1153726:-
THYM	cis	rs3796619	1	rs13146371	ENSG00000215367.9	TMED11P	4.09	8.98e-05	0.0414	0.38	0.39	Recombination rate (males);	chr4:1089099	chr4:1115197~1153726:-
THYM	cis	rs4948275	0.631	rs2814024	ENSG00000237233.2	TMEM26-AS1	-4.09	8.99e-05	0.0415	-0.44	-0.39	Night sleep phenotypes;	chr10:61590868	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.598	rs2650742	ENSG00000237233.2	TMEM26-AS1	-4.09	8.99e-05	0.0415	-0.44	-0.39	Night sleep phenotypes;	chr10:61591188	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2787739	ENSG00000237233.2	TMEM26-AS1	-4.09	8.99e-05	0.0415	-0.45	-0.39	Night sleep phenotypes;	chr10:61503040	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.806	rs2256377	ENSG00000237233.2	TMEM26-AS1	-4.09	8.99e-05	0.0415	-0.45	-0.39	Night sleep phenotypes;	chr10:61504725	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2256370	ENSG00000237233.2	TMEM26-AS1	-4.09	8.99e-05	0.0415	-0.45	-0.39	Night sleep phenotypes;	chr10:61504853	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.773	rs2256066	ENSG00000237233.2	TMEM26-AS1	-4.09	8.99e-05	0.0415	-0.45	-0.39	Night sleep phenotypes;	chr10:61507370	chr10:61452639~61481956:+
THYM	cis	rs11098499	0.73	rs12505735	ENSG00000250412.1	KLHL2P1	4.09	9e-05	0.0415	0.37	0.39	Corneal astigmatism;	chr4:119611801	chr4:119334329~119378233:+
THYM	cis	rs897984	0.683	rs729482	ENSG00000260911.2	RP11-196G11.2	4.09	9e-05	0.0415	0.34	0.39	Dementia with Lewy bodies;	chr16:31005649	chr16:31043150~31049868:+
THYM	cis	rs7202877	0.656	rs6564245	ENSG00000261783.1	RP11-252K23.2	4.09	9e-05	0.0415	0.62	0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75275001	chr16:75379818~75381260:-
THYM	cis	rs910316	0.763	rs175435	ENSG00000258646.1	RP11-950C14.3	-4.09	9.01e-05	0.0415	-0.35	-0.39	Height;	chr14:75145322	chr14:75004719~75008481:-
THYM	cis	rs910316	0.789	rs175444	ENSG00000258646.1	RP11-950C14.3	4.09	9.01e-05	0.0415	0.35	0.39	Height;	chr14:75135079	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs175424	ENSG00000258646.1	RP11-950C14.3	4.09	9.01e-05	0.0415	0.35	0.39	Height;	chr14:75159554	chr14:75004719~75008481:-
THYM	cis	rs910316	0.763	rs2080201	ENSG00000258646.1	RP11-950C14.3	4.09	9.01e-05	0.0415	0.35	0.39	Height;	chr14:75163269	chr14:75004719~75008481:-
THYM	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
THYM	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
THYM	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
THYM	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
THYM	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
THYM	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	4.09	9.01e-05	0.0415	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
THYM	cis	rs12959333	0.685	rs12327289	ENSG00000274849.1	RP11-49I11.4	-4.09	9.01e-05	0.0415	-0.64	-0.39	Post bronchodilator FEV1;	chr18:35640254	chr18:36189824~36190272:+
THYM	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-4.09	9.01e-05	0.0416	-0.39	-0.39	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
THYM	cis	rs7617773	1	rs12496784	ENSG00000228638.1	FCF1P2	4.09	9.02e-05	0.0416	0.4	0.39	Coronary artery disease;	chr3:48144777	chr3:48290793~48291375:-
THYM	cis	rs1519814	0.581	rs1879150	ENSG00000254343.2	RP11-760H22.2	-4.09	9.02e-05	0.0416	-0.6	-0.39	Breast cancer;	chr8:119998994	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.616	rs2326428	ENSG00000254343.2	RP11-760H22.2	-4.09	9.02e-05	0.0416	-0.6	-0.39	Breast cancer;	chr8:119999124	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.654	rs11986190	ENSG00000254343.2	RP11-760H22.2	-4.09	9.02e-05	0.0416	-0.6	-0.39	Breast cancer;	chr8:120001086	chr8:120052180~120056201:+
THYM	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	4.09	9.02e-05	0.0416	0.51	0.39	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
THYM	cis	rs4352210	0.547	rs7587009	ENSG00000236213.1	AC006369.2	4.09	9.02e-05	0.0416	0.41	0.39	RR interval (heart rate);	chr2:37579401	chr2:37600136~37646698:+
THYM	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-4.09	9.02e-05	0.0416	-0.48	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-4.09	9.02e-05	0.0416	-0.48	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	4.09	9.02e-05	0.0416	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
THYM	cis	rs1555322	0.53	rs2297789	ENSG00000269202.1	RP4-614O4.12	-4.09	9.03e-05	0.0416	-0.47	-0.39	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35201747~35203288:-
THYM	cis	rs12410462	0.591	rs903692	ENSG00000227711.2	RP11-275O4.5	-4.09	9.03e-05	0.0416	-0.41	-0.39	Major depressive disorder;	chr1:227545020	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs903693	ENSG00000227711.2	RP11-275O4.5	-4.09	9.03e-05	0.0416	-0.41	-0.39	Major depressive disorder;	chr1:227545086	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.551	rs903694	ENSG00000227711.2	RP11-275O4.5	-4.09	9.03e-05	0.0416	-0.41	-0.39	Major depressive disorder;	chr1:227545304	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2819496	ENSG00000227711.2	RP11-275O4.5	-4.09	9.03e-05	0.0416	-0.41	-0.39	Major depressive disorder;	chr1:227546201	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2644146	ENSG00000227711.2	RP11-275O4.5	-4.09	9.03e-05	0.0416	-0.41	-0.39	Major depressive disorder;	chr1:227546216	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2814061	ENSG00000227711.2	RP11-275O4.5	-4.09	9.03e-05	0.0416	-0.41	-0.39	Major depressive disorder;	chr1:227547413	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.636	rs1495849	ENSG00000227711.2	RP11-275O4.5	-4.09	9.03e-05	0.0416	-0.41	-0.39	Major depressive disorder;	chr1:227548662	chr1:227509028~227520477:-
THYM	cis	rs4842666	0.915	rs117742247	ENSG00000258302.2	RP11-981P6.1	4.09	9.03e-05	0.0416	0.45	0.39	Blood pressure;	chr12:89597536	chr12:89561129~89594878:+
THYM	cis	rs935334	0.932	rs8008819	ENSG00000258454.1	RP11-361H10.3	-4.09	9.04e-05	0.0416	-0.52	-0.39	Blood pressure;	chr14:76155693	chr14:76235817~76263474:+
THYM	cis	rs935334	1	rs12147952	ENSG00000258454.1	RP11-361H10.3	-4.09	9.04e-05	0.0416	-0.52	-0.39	Blood pressure;	chr14:76158541	chr14:76235817~76263474:+
THYM	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-4.09	9.04e-05	0.0416	-0.55	-0.39	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
THYM	cis	rs8067545	0.611	rs7216599	ENSG00000231645.2	KRT17P6	-4.09	9.04e-05	0.0416	-0.45	-0.39	Schizophrenia;	chr17:20112287	chr17:20512560~20517479:-
THYM	cis	rs4657175	0.611	rs10918859	ENSG00000227941.1	UQCRBP2	4.09	9.04e-05	0.0416	0.42	0.39	QT interval;	chr1:162199478	chr1:162541332~162541628:-
THYM	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-4.09	9.05e-05	0.0417	-0.5	-0.39	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
THYM	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-4.09	9.05e-05	0.0417	-0.5	-0.39	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
THYM	cis	rs1529093	0.666	rs10176401	ENSG00000222043.2	AC079305.10	4.09	9.05e-05	0.0417	0.34	0.39	Non-alcoholic fatty liver disease histology (other);	chr2:177060300	chr2:177264359~177265515:+
THYM	cis	rs11096990	0.855	rs75746161	ENSG00000249685.1	RP11-360F5.3	-4.09	9.05e-05	0.0417	-0.38	-0.39	Cognitive function;	chr4:39167481	chr4:39133913~39135608:+
THYM	cis	rs28829049	0.539	rs34441374	ENSG00000270728.1	RP4-657E11.10	-4.09	9.06e-05	0.0417	-0.25	-0.39	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19066195	chr1:19297080~19297903:+
THYM	cis	rs3015497	0.653	rs2356455	ENSG00000270062.1	RP11-248J18.3	4.09	9.06e-05	0.0417	0.27	0.39	Mean platelet volume;	chr14:50626424	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.653	rs2356456	ENSG00000270062.1	RP11-248J18.3	4.09	9.06e-05	0.0417	0.27	0.39	Mean platelet volume;	chr14:50626498	chr14:50723777~50724272:-
THYM	cis	rs1387259	0.929	rs11168460	ENSG00000240399.1	RP1-228P16.1	4.09	9.07e-05	0.0417	0.4	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs7297824	ENSG00000240399.1	RP1-228P16.1	4.09	9.07e-05	0.0417	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs11168464	ENSG00000240399.1	RP1-228P16.1	4.09	9.07e-05	0.0417	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48054813~48055591:-
THYM	cis	rs1387259	0.899	rs7307566	ENSG00000240399.1	RP1-228P16.1	4.09	9.07e-05	0.0417	0.4	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48054813~48055591:-
THYM	cis	rs12908161	1	rs35630683	ENSG00000275120.1	RP11-182J1.17	4.09	9.07e-05	0.0418	0.53	0.39	Schizophrenia;	chr15:84806000	chr15:84599434~84606463:-
THYM	cis	rs35828350	1	rs35828350	ENSG00000275120.1	RP11-182J1.17	4.09	9.07e-05	0.0418	0.53	0.39	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84599434~84606463:-
THYM	cis	rs12908161	1	rs56864281	ENSG00000275120.1	RP11-182J1.17	4.09	9.07e-05	0.0418	0.53	0.39	Schizophrenia;	chr15:84814418	chr15:84599434~84606463:-
THYM	cis	rs10129255	0.879	rs10144100	ENSG00000254329.1	IGHVII-60-1	4.09	9.08e-05	0.0418	0.38	0.39	Kawasaki disease;	chr14:106699411	chr14:106637718~106637973:-
THYM	cis	rs12900463	0.813	rs186266	ENSG00000235370.6	DNM1P51	4.09	9.08e-05	0.0418	0.49	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:84398316~84411701:-
THYM	cis	rs910316	1	rs11159117	ENSG00000258646.1	RP11-950C14.3	-4.09	9.08e-05	0.0418	-0.36	-0.39	Height;	chr14:75118164	chr14:75004719~75008481:-
THYM	cis	rs7394190	0.748	rs60212594	ENSG00000268584.1	RP11-464F9.20	4.09	9.09e-05	0.0418	0.59	0.39	Incident atrial fibrillation;	chr10:73654586	chr10:73625996~73626790:+
THYM	cis	rs7394190	0.748	rs60632610	ENSG00000268584.1	RP11-464F9.20	4.09	9.09e-05	0.0418	0.59	0.39	Incident atrial fibrillation;	chr10:73655919	chr10:73625996~73626790:+
THYM	cis	rs495337	0.76	rs4810994	ENSG00000229222.1	KRT18P4	-4.09	9.09e-05	0.0418	-0.45	-0.39	Psoriasis;	chr20:49955136	chr20:49956745~49958032:+
THYM	cis	rs9903692	0.865	rs7220520	ENSG00000266601.1	RP11-6N17.3	-4.09	9.09e-05	0.0418	-0.36	-0.39	Pulse pressure;	chr17:48090580	chr17:47929682~47933106:-
THYM	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	4.09	9.1e-05	0.0418	0.49	0.39	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
THYM	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	4.09	9.1e-05	0.0419	0.37	0.39	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
THYM	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-4.09	9.1e-05	0.0419	-0.47	-0.39	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-4.09	9.1e-05	0.0419	-0.47	-0.39	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs35569628	ENSG00000269125.1	RP11-98F14.11	-4.09	9.1e-05	0.0419	-0.47	-0.39	Platelet distribution width;	chr13:113218398	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-4.09	9.1e-05	0.0419	-0.47	-0.39	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
THYM	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-4.09	9.1e-05	0.0419	-0.48	-0.39	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
THYM	cis	rs2732480	0.5	rs2450989	ENSG00000240399.1	RP1-228P16.1	-4.09	9.11e-05	0.0419	-0.4	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs11168468	ENSG00000240399.1	RP1-228P16.1	4.09	9.11e-05	0.0419	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs1387257	ENSG00000240399.1	RP1-228P16.1	4.09	9.11e-05	0.0419	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs2450991	ENSG00000240399.1	RP1-228P16.1	4.09	9.11e-05	0.0419	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48054813~48055591:-
THYM	cis	rs2732480	0.5	rs2450986	ENSG00000240399.1	RP1-228P16.1	4.09	9.11e-05	0.0419	0.4	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48054813~48055591:-
THYM	cis	rs1387259	0.929	rs2634666	ENSG00000240399.1	RP1-228P16.1	4.09	9.11e-05	0.0419	0.4	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48054813~48055591:-
THYM	cis	rs1387259	0.929	rs2956703	ENSG00000240399.1	RP1-228P16.1	4.09	9.11e-05	0.0419	0.4	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48054813~48055591:-
THYM	cis	rs1387259	0.931	rs1107654	ENSG00000240399.1	RP1-228P16.1	4.09	9.11e-05	0.0419	0.4	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48054813~48055591:-
THYM	cis	rs9907295	0.818	rs11658222	ENSG00000270977.1	AC015849.16	-4.09	9.11e-05	0.0419	-0.64	-0.39	Fibroblast growth factor basic levels;	chr17:35825092	chr17:35893707~35911023:-
THYM	cis	rs7202877	0.706	rs4888375	ENSG00000261783.1	RP11-252K23.2	-4.09	9.11e-05	0.0419	-0.59	-0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75288458	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs11149812	ENSG00000261783.1	RP11-252K23.2	-4.09	9.11e-05	0.0419	-0.59	-0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75289747	chr16:75379818~75381260:-
THYM	cis	rs2288012	0.592	rs10852563	ENSG00000260186.4	RP11-481J2.2	4.09	9.11e-05	0.0419	0.47	0.39	Systemic lupus erythematosus;	chr16:58298172	chr16:58421326~58462470:+
THYM	cis	rs60180747	0.544	rs11633808	ENSG00000261318.1	RP11-653J6.1	4.09	9.12e-05	0.0419	0.43	0.39	Testicular germ cell tumor;	chr15:66275773	chr15:66278498~66293357:-
THYM	cis	rs7208859	0.673	rs216440	ENSG00000266490.1	CTD-2349P21.9	4.09	9.12e-05	0.0419	0.63	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30792372~30792833:+
THYM	cis	rs17826219	0.561	rs562840	ENSG00000266490.1	CTD-2349P21.9	4.09	9.12e-05	0.0419	0.63	0.39	Body mass index;	chr17:30622372	chr17:30792372~30792833:+
THYM	cis	rs495337	0.735	rs2281217	ENSG00000229222.1	KRT18P4	-4.09	9.12e-05	0.0419	-0.45	-0.39	Psoriasis;	chr20:49951518	chr20:49956745~49958032:+
THYM	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	4.09	9.13e-05	0.0419	0.3	0.39	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
THYM	cis	rs3753275	0.624	rs7518204	ENSG00000230679.1	ENO1-AS1	4.09	9.13e-05	0.042	0.47	0.39	Educational attainment;	chr1:8728577	chr1:8878835~8879894:+
THYM	cis	rs11633886	0.585	rs17636535	ENSG00000273972.1	CTD-2306A12.1	4.09	9.14e-05	0.042	0.48	0.39	Diisocyanate-induced asthma;	chr15:45786680	chr15:45702640~45703183:+
THYM	cis	rs2235573	0.805	rs4821738	ENSG00000273096.1	RP3-508I15.20	-4.09	9.14e-05	0.042	-0.31	-0.39	Glioma;Glioblastoma;	chr22:38104473	chr22:38736610~38736792:-
THYM	cis	rs7429990	0.965	rs9854454	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47971307	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs6770467	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47977742	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.932	rs6770477	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47977768	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs28637561	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47979528	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs7426976	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47981083	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs7427418	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47981217	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs13075795	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47983139	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs7431572	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47986361	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs13074973	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47986654	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs1013431	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47987628	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs7430913	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47990867	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.901	rs7433678	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47995588	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs7430879	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:47997224	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.932	rs4293721	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:48003647	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.932	rs2166772	ENSG00000199476.1	Y_RNA	4.09	9.14e-05	0.042	0.51	0.39	Educational attainment (years of education);	chr3:48006384	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs9811277	ENSG00000199476.1	Y_RNA	-4.09	9.14e-05	0.042	-0.51	-0.39	Educational attainment (years of education);	chr3:47970148	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.932	rs9862913	ENSG00000199476.1	Y_RNA	-4.09	9.14e-05	0.042	-0.51	-0.39	Educational attainment (years of education);	chr3:47974682	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs9814961	ENSG00000199476.1	Y_RNA	-4.09	9.14e-05	0.042	-0.51	-0.39	Educational attainment (years of education);	chr3:47976127	chr3:48288587~48288694:+
THYM	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.49	0.39	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.49	0.39	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
THYM	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.49	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
THYM	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
THYM	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
THYM	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.49	0.39	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
THYM	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
THYM	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	4.09	9.15e-05	0.042	0.51	0.39	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
THYM	cis	rs6540731	1	rs951623	ENSG00000229983.1	RP11-15I11.2	4.09	9.15e-05	0.042	0.31	0.39	Intelligence (childhood);	chr1:212225720	chr1:212168207~212190259:+
THYM	cis	rs7560272	0.501	rs11891140	ENSG00000163016.8	ALMS1P	-4.09	9.15e-05	0.042	-0.49	-0.39	Schizophrenia;	chr2:73716957	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.501	rs12713789	ENSG00000163016.8	ALMS1P	-4.09	9.15e-05	0.042	-0.49	-0.39	Schizophrenia;	chr2:73718473	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.501	rs12713790	ENSG00000163016.8	ALMS1P	-4.09	9.15e-05	0.042	-0.49	-0.39	Schizophrenia;	chr2:73718484	chr2:73644919~73685576:+
THYM	cis	rs61270009	0.955	rs10514299	ENSG00000247828.6	TMEM161B-AS1	4.09	9.16e-05	0.042	0.34	0.39	Depressive symptoms;	chr5:88367793	chr5:88268895~88436685:+
THYM	cis	rs11098499	0.954	rs2389803	ENSG00000250412.1	KLHL2P1	-4.09	9.16e-05	0.042	-0.37	-0.39	Corneal astigmatism;	chr4:119472356	chr4:119334329~119378233:+
THYM	cis	rs295140	0.605	rs3769471	ENSG00000232732.8	AC073043.1	4.09	9.16e-05	0.042	0.5	0.39	QT interval;	chr2:200330680	chr2:199867396~199911159:-
THYM	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	4.09	9.17e-05	0.042	0.5	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
THYM	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	4.09	9.17e-05	0.042	0.5	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
THYM	cis	rs6575793	0.512	rs7147982	ENSG00000258904.1	RP11-638I2.2	4.09	9.17e-05	0.042	0.38	0.39	Menarche (age at onset);	chr14:100580312	chr14:100263781~100265405:+
THYM	cis	rs4737732	0.614	rs13277017	ENSG00000254006.4	RP11-1D12.2	-4.09	9.17e-05	0.0421	-0.4	-0.39	Stem cell growth factor beta levels;	chr8:65440255	chr8:64801236~64817573:-
THYM	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	4.09	9.17e-05	0.0421	0.53	0.39	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
THYM	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
THYM	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	4.09	9.17e-05	0.0421	0.53	0.39	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
THYM	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	4.09	9.17e-05	0.0421	0.43	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
THYM	cis	rs910316	1	rs175442	ENSG00000258646.1	RP11-950C14.3	4.09	9.18e-05	0.0421	0.35	0.39	Height;	chr14:75136861	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs175426	ENSG00000258646.1	RP11-950C14.3	4.09	9.18e-05	0.0421	0.35	0.39	Height;	chr14:75157431	chr14:75004719~75008481:-
THYM	cis	rs910316	1	rs175425	ENSG00000258646.1	RP11-950C14.3	4.09	9.18e-05	0.0421	0.35	0.39	Height;	chr14:75159428	chr14:75004719~75008481:-
THYM	cis	rs910316	0.935	rs175422	ENSG00000258646.1	RP11-950C14.3	4.09	9.18e-05	0.0421	0.35	0.39	Height;	chr14:75160616	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs35446981	ENSG00000258646.1	RP11-950C14.3	4.09	9.18e-05	0.0421	0.35	0.39	Height;	chr14:75170648	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs2268619	ENSG00000258646.1	RP11-950C14.3	4.09	9.18e-05	0.0421	0.35	0.39	Height;	chr14:75173651	chr14:75004719~75008481:-
THYM	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	4.09	9.18e-05	0.0421	0.51	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
THYM	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	4.09	9.18e-05	0.0421	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
THYM	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	4.09	9.18e-05	0.0421	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
THYM	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	4.09	9.18e-05	0.0421	0.51	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
THYM	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	4.09	9.18e-05	0.0421	0.51	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
THYM	cis	rs17473412	0.963	rs7731697	ENSG00000250539.1	KRT8P33	4.09	9.18e-05	0.0421	0.49	0.39	Total body bone mineral density;	chr5:123399758	chr5:123400922~123402344:-
THYM	cis	rs17473412	1	rs111295980	ENSG00000250539.1	KRT8P33	4.09	9.18e-05	0.0421	0.49	0.39	Total body bone mineral density;	chr5:123401563	chr5:123400922~123402344:-
THYM	cis	rs1474476	1	rs6572277	ENSG00000211790.2	TRAV8-4	-4.09	9.18e-05	0.0421	-0.42	-0.39	Obesity-related traits;	chr14:22127586	chr14:21894433~21895030:+
THYM	cis	rs1474476	1	rs8016900	ENSG00000211790.2	TRAV8-4	-4.09	9.18e-05	0.0421	-0.42	-0.39	Obesity-related traits;	chr14:22127651	chr14:21894433~21895030:+
THYM	cis	rs7927592	0.956	rs12281742	ENSG00000222339.1	AP000807.2	-4.09	9.18e-05	0.0421	-0.44	-0.39	Total body bone mineral density;	chr11:68536161	chr11:68505572~68505651:-
THYM	cis	rs3781264	0.724	rs10882435	ENSG00000273450.1	RP11-76P2.4	4.09	9.19e-05	0.0421	0.49	0.39	Esophageal cancer and gastric cancer;	chr10:94348110	chr10:94314907~94315327:-
THYM	cis	rs3781264	0.761	rs11187899	ENSG00000273450.1	RP11-76P2.4	4.09	9.19e-05	0.0421	0.49	0.39	Esophageal cancer and gastric cancer;	chr10:94348345	chr10:94314907~94315327:-
THYM	cis	rs3781264	0.687	rs11187900	ENSG00000273450.1	RP11-76P2.4	4.09	9.19e-05	0.0421	0.49	0.39	Esophageal cancer and gastric cancer;	chr10:94348607	chr10:94314907~94315327:-
THYM	cis	rs3781264	0.687	rs10882436	ENSG00000273450.1	RP11-76P2.4	4.09	9.19e-05	0.0421	0.49	0.39	Esophageal cancer and gastric cancer;	chr10:94349043	chr10:94314907~94315327:-
THYM	cis	rs8177876	0.749	rs2549896	ENSG00000261838.4	RP11-303E16.6	-4.09	9.19e-05	0.0421	-0.8	-0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054334	chr16:81069854~81076598:+
THYM	cis	rs7959452	0.64	rs11177599	ENSG00000274979.1	RP11-1143G9.5	-4.09	9.19e-05	0.0421	-0.38	-0.39	Blood protein levels;	chr12:69328190	chr12:69326574~69331882:-
THYM	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-4.09	9.19e-05	0.0421	-0.5	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
THYM	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	4.09	9.19e-05	0.0421	0.5	0.39	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	4.09	9.19e-05	0.0421	0.5	0.39	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
THYM	cis	rs6782228	0.606	rs2811489	ENSG00000277250.1	Metazoa_SRP	4.09	9.2e-05	0.0421	0.53	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs58977394	ENSG00000277250.1	Metazoa_SRP	-4.09	9.2e-05	0.0421	-0.53	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.527	rs2712371	ENSG00000277250.1	Metazoa_SRP	-4.09	9.2e-05	0.0421	-0.53	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128673681~128674021:-
THYM	cis	rs1023500	0.505	rs134886	ENSG00000227370.1	RP4-669P10.19	-4.09	9.2e-05	0.0422	-0.46	-0.39	Schizophrenia;	chr22:42277850	chr22:42132543~42132998:+
THYM	cis	rs853679	0.55	rs1233704	ENSG00000272009.1	RP1-313I6.12	4.09	9.2e-05	0.0422	0.49	0.39	Depression;	chr6:28199145	chr6:28078792~28081130:-
THYM	cis	rs7605378	1	rs2346662	ENSG00000232732.8	AC073043.1	-4.09	9.21e-05	0.0422	-0.5	-0.39	Osteoporosis;	chr2:199814435	chr2:199867396~199911159:-
THYM	cis	rs8067545	0.578	rs4925087	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20121269	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs11868116	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20126280	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs12936443	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20130133	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs6587219	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20131218	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs9893832	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20134960	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs7219908	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20139723	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs8078716	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20140978	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.611	rs8066143	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20145042	chr17:20512560~20517479:-
THYM	cis	rs8067545	0.578	rs62066870	ENSG00000231645.2	KRT17P6	-4.09	9.21e-05	0.0422	-0.45	-0.39	Schizophrenia;	chr17:20160445	chr17:20512560~20517479:-
THYM	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-4.09	9.22e-05	0.0422	-0.52	-0.39	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-4.09	9.22e-05	0.0422	-0.52	-0.39	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
THYM	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-4.09	9.22e-05	0.0422	-0.42	-0.39	Migraine;	chr4:56852087	chr4:56960927~56961373:-
THYM	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-4.09	9.22e-05	0.0422	-0.42	-0.39	Migraine;	chr4:56853383	chr4:56960927~56961373:-
THYM	cis	rs5760092	0.618	rs4461358	ENSG00000099984.9	GSTT2	4.09	9.22e-05	0.0422	0.45	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23980123~23983911:+
THYM	cis	rs4691139	0.658	rs4690798	ENSG00000250227.1	TRIM60P14	4.09	9.23e-05	0.0422	0.46	0.39	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005434	chr4:164915565~164916983:+
THYM	cis	rs12410462	0.591	rs66491073	ENSG00000227711.2	RP11-275O4.5	-4.09	9.23e-05	0.0423	-0.39	-0.39	Major depressive disorder;	chr1:227595020	chr1:227509028~227520477:-
THYM	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-4.09	9.23e-05	0.0423	-0.36	-0.39	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
THYM	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-4.09	9.23e-05	0.0423	-0.28	-0.39	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
THYM	cis	rs10888838	0.941	rs11585887	ENSG00000198711.5	SSBP3-AS1	4.09	9.24e-05	0.0423	0.26	0.39	Mitochondrial DNA levels;	chr1:54221850	chr1:54236440~54239063:+
THYM	cis	rs12220777	1	rs72644211	ENSG00000230091.5	TMEM254-AS1	4.09	9.24e-05	0.0423	0.61	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021939	chr10:80046860~80078912:-
THYM	cis	rs889398	0.774	rs6499263	ENSG00000226232.7	RP11-419C5.2	-4.09	9.24e-05	0.0423	-0.35	-0.39	Body mass index;	chr16:69856246	chr16:69976388~69996188:-
THYM	cis	rs12744534	0.799	rs10489233	ENSG00000276381.1	Z98750.1	4.09	9.24e-05	0.0423	0.32	0.39	Hip circumference adjusted for BMI;	chr1:170777021	chr1:171591083~171591145:+
THYM	cis	rs8067545	0.611	rs16960697	ENSG00000231645.2	KRT17P6	-4.09	9.24e-05	0.0423	-0.45	-0.39	Schizophrenia;	chr17:20124405	chr17:20512560~20517479:-
THYM	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-4.09	9.25e-05	0.0423	-0.5	-0.39	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
THYM	cis	rs8067545	0.516	rs4925086	ENSG00000231645.2	KRT17P6	-4.09	9.25e-05	0.0423	-0.45	-0.39	Schizophrenia;	chr17:20110146	chr17:20512560~20517479:-
THYM	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	4.09	9.25e-05	0.0424	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
THYM	cis	rs1426063	0.748	rs10005117	ENSG00000248165.1	RP11-44F21.2	4.09	9.26e-05	0.0424	0.59	0.39	QT interval;	chr4:75108281	chr4:74993877~75034824:-
THYM	cis	rs11098499	0.954	rs10518328	ENSG00000250412.1	KLHL2P1	4.09	9.26e-05	0.0424	0.38	0.39	Corneal astigmatism;	chr4:119480624	chr4:119334329~119378233:+
THYM	cis	rs910316	0.737	rs2098251	ENSG00000258646.1	RP11-950C14.3	-4.09	9.26e-05	0.0424	-0.34	-0.39	Height;	chr14:75025993	chr14:75004719~75008481:-
THYM	cis	rs910316	0.664	rs2098252	ENSG00000258646.1	RP11-950C14.3	-4.09	9.26e-05	0.0424	-0.34	-0.39	Height;	chr14:75026029	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs28687415	ENSG00000258646.1	RP11-950C14.3	-4.09	9.26e-05	0.0424	-0.34	-0.39	Height;	chr14:75028779	chr14:75004719~75008481:-
THYM	cis	rs2243480	1	rs78803505	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65917585	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs34577383	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65920739	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs7795242	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65925107	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs2177703	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65926730	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs35432774	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65928032	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs56985706	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65929575	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs60683927	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65929781	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs58062456	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65929865	chr7:65751142~65763354:+
THYM	cis	rs2243480	1	rs34529418	ENSG00000228409.4	CCT6P1	4.09	9.26e-05	0.0424	0.48	0.39	Diabetic kidney disease;	chr7:65938222	chr7:65751142~65763354:+
THYM	cis	rs7429990	0.965	rs1550914	ENSG00000199476.1	Y_RNA	-4.09	9.27e-05	0.0424	-0.52	-0.39	Educational attainment (years of education);	chr3:47953678	chr3:48288587~48288694:+
THYM	cis	rs12410462	0.636	rs7413796	ENSG00000227711.2	RP11-275O4.5	-4.09	9.27e-05	0.0424	-0.41	-0.39	Major depressive disorder;	chr1:227553722	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.551	rs74997063	ENSG00000227711.2	RP11-275O4.5	-4.09	9.27e-05	0.0424	-0.41	-0.39	Major depressive disorder;	chr1:227556836	chr1:227509028~227520477:-
THYM	cis	rs2732480	0.538	rs1387259	ENSG00000240399.1	RP1-228P16.1	-4.09	9.27e-05	0.0424	-0.4	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48054813~48055591:-
THYM	cis	rs12902680	0.816	rs7162596	ENSG00000259520.4	CTD-2651B20.3	4.08	9.27e-05	0.0424	0.41	0.39	Neuroticism;	chr15:46050853	chr15:45251580~45279251:-
THYM	cis	rs2712431	0.554	rs2010054	ENSG00000277250.1	Metazoa_SRP	-4.08	9.28e-05	0.0424	-0.51	-0.39	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128673681~128674021:-
THYM	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-4.08	9.29e-05	0.0425	-0.48	-0.39	Height;	chr11:118760944	chr11:118704607~118750263:+
THYM	cis	rs2243480	1	rs313813	ENSG00000228409.4	CCT6P1	4.08	9.29e-05	0.0425	0.44	0.39	Diabetic kidney disease;	chr7:66038513	chr7:65751142~65763354:+
THYM	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	4.08	9.3e-05	0.0425	0.45	0.39	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
THYM	cis	rs7223966	1	rs7209758	ENSG00000240280.5	TCAM1P	-4.08	9.3e-05	0.0425	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63836261	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs11658175	ENSG00000240280.5	TCAM1P	-4.08	9.3e-05	0.0425	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63846478	chr17:63849292~63864379:+
THYM	cis	rs73001065	0.901	rs8107974	ENSG00000267220.1	CTC-260E6.9	4.08	9.3e-05	0.0425	0.94	0.39	LDL cholesterol;	chr19:19277691	chr19:20131894~20151908:-
THYM	cis	rs73001065	0.901	rs10401969	ENSG00000267220.1	CTC-260E6.9	4.08	9.3e-05	0.0425	0.94	0.39	LDL cholesterol;	chr19:19296909	chr19:20131894~20151908:-
THYM	cis	rs73001065	0.901	rs739846	ENSG00000267220.1	CTC-260E6.9	4.08	9.3e-05	0.0425	0.94	0.39	LDL cholesterol;	chr19:19308262	chr19:20131894~20151908:-
THYM	cis	rs3781913	0.642	rs341052	ENSG00000228915.3	OR7E128P	-4.08	9.31e-05	0.0425	-0.42	-0.39	Rheumatoid arthritis;	chr11:72633497	chr11:71893410~71894433:+
THYM	cis	rs739525	0.518	rs178268	ENSG00000272829.1	XXbac-B135H6.18	4.08	9.31e-05	0.0426	0.38	0.39	Testicular germ cell tumor;	chr22:20975977	chr22:20981361~20981755:-
THYM	cis	rs12902680	0.706	rs12440561	ENSG00000259520.4	CTD-2651B20.3	4.08	9.32e-05	0.0426	0.4	0.39	Neuroticism;	chr15:46239206	chr15:45251580~45279251:-
THYM	cis	rs8002861	0.691	rs9525851	ENSG00000230793.1	SMARCE1P5	-4.08	9.33e-05	0.0426	-0.43	-0.39	Leprosy;	chr13:43827996	chr13:44594858~44596082:+
THYM	cis	rs8002861	0.754	rs7330760	ENSG00000230793.1	SMARCE1P5	-4.08	9.33e-05	0.0426	-0.43	-0.39	Leprosy;	chr13:43828952	chr13:44594858~44596082:+
THYM	cis	rs12545912	0.525	rs12543209	ENSG00000233609.3	RP11-62H7.2	-4.08	9.34e-05	0.0427	-0.45	-0.39	Multiple myeloma (hyperdiploidy);	chr8:9868683	chr8:8961200~8979025:+
THYM	cis	rs12902680	0.844	rs12441828	ENSG00000259520.4	CTD-2651B20.3	4.08	9.34e-05	0.0427	0.42	0.39	Neuroticism;	chr15:46039520	chr15:45251580~45279251:-
THYM	cis	rs2282300	0.739	rs1933342	ENSG00000254532.1	RP11-624D11.2	-4.08	9.35e-05	0.0427	-0.59	-0.39	Morning vs. evening chronotype;	chr11:30291278	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs2225909	ENSG00000254532.1	RP11-624D11.2	-4.08	9.35e-05	0.0427	-0.59	-0.39	Morning vs. evening chronotype;	chr11:30308197	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.702	rs2211018	ENSG00000254532.1	RP11-624D11.2	-4.08	9.35e-05	0.0427	-0.59	-0.39	Morning vs. evening chronotype;	chr11:30308532	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs7926465	ENSG00000254532.1	RP11-624D11.2	-4.08	9.35e-05	0.0427	-0.59	-0.39	Morning vs. evening chronotype;	chr11:30311469	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1616223	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30317236	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1765133	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30317853	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1222219	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30322798	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1222216	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30324505	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1222215	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30326049	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.696	rs1222214	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30326148	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1631451	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30327586	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1717775	ENSG00000254532.1	RP11-624D11.2	4.08	9.35e-05	0.0427	0.59	0.39	Morning vs. evening chronotype;	chr11:30328707	chr11:30044058~30084343:-
THYM	cis	rs12902680	0.706	rs12910246	ENSG00000259520.4	CTD-2651B20.3	4.08	9.35e-05	0.0427	0.4	0.39	Neuroticism;	chr15:46241220	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12908762	ENSG00000259520.4	CTD-2651B20.3	4.08	9.35e-05	0.0427	0.4	0.39	Neuroticism;	chr15:46231893	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12908323	ENSG00000259520.4	CTD-2651B20.3	4.08	9.35e-05	0.0427	0.4	0.39	Neuroticism;	chr15:46231894	chr15:45251580~45279251:-
THYM	cis	rs1595825	0.786	rs75415672	ENSG00000222017.1	AC011997.1	-4.08	9.36e-05	0.0428	-0.43	-0.39	Ulcerative colitis;	chr2:197670955	chr2:197693106~197774823:+
THYM	cis	rs17023900	0.588	rs73846616	ENSG00000281392.1	LINC00506	-4.08	9.36e-05	0.0428	-0.48	-0.39	Prostate cancer;	chr3:87088064	chr3:87089129~87157069:+
THYM	cis	rs34792	0.513	rs255002	ENSG00000262380.1	CTB-193M12.3	4.08	9.37e-05	0.0428	0.49	0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15484406	chr16:15683290~15684570:+
THYM	cis	rs11722779	0.838	rs4533776	ENSG00000251288.2	RP11-10L12.2	-4.08	9.37e-05	0.0428	-0.39	-0.39	Schizophrenia;	chr4:102912732	chr4:102751401~102752641:+
THYM	cis	rs11722779	0.838	rs6821247	ENSG00000251288.2	RP11-10L12.2	-4.08	9.37e-05	0.0428	-0.39	-0.39	Schizophrenia;	chr4:102913483	chr4:102751401~102752641:+
THYM	cis	rs228614	0.514	rs59550147	ENSG00000251288.2	RP11-10L12.2	-4.08	9.37e-05	0.0428	-0.39	-0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102751401~102752641:+
THYM	cis	rs227275	0.525	rs3974608	ENSG00000251288.2	RP11-10L12.2	-4.08	9.37e-05	0.0428	-0.39	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102751401~102752641:+
THYM	cis	rs227275	0.525	rs10028116	ENSG00000251288.2	RP11-10L12.2	-4.08	9.37e-05	0.0428	-0.39	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102751401~102752641:+
THYM	cis	rs227275	0.554	rs9307281	ENSG00000251288.2	RP11-10L12.2	-4.08	9.37e-05	0.0428	-0.39	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102751401~102752641:+
THYM	cis	rs11722779	0.903	rs6533037	ENSG00000251288.2	RP11-10L12.2	-4.08	9.37e-05	0.0428	-0.39	-0.39	Schizophrenia;	chr4:102935865	chr4:102751401~102752641:+
THYM	cis	rs3121446	0.842	rs2254924	ENSG00000229654.1	RP1-60O19.2	-4.08	9.37e-05	0.0428	-0.48	-0.39	Daytime sleep phenotypes;	chr6:106696921	chr6:106695535~106699994:+
THYM	cis	rs17685	0.712	rs6976236	ENSG00000280388.1	RP11-229D13.3	-4.08	9.38e-05	0.0428	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76111769	chr7:76043977~76045963:-
THYM	cis	rs3096299	0.566	rs4129126	ENSG00000261118.1	RP11-104N10.1	4.08	9.38e-05	0.0428	0.47	0.39	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89492017~89504460:-
THYM	cis	rs6026584	0.823	rs6026574	ENSG00000270951.1	RP1-309F20.4	-4.08	9.39e-05	0.0428	-0.41	-0.39	Renal function-related traits (BUN);	chr20:58881440	chr20:58876592~58876981:-
THYM	cis	rs10129255	0.5	rs4600373	ENSG00000254329.1	IGHVII-60-1	4.08	9.39e-05	0.0428	0.35	0.39	Kawasaki disease;	chr14:106704809	chr14:106637718~106637973:-
THYM	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-4.08	9.39e-05	0.0428	-0.46	-0.39	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
THYM	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-4.08	9.39e-05	0.0428	-0.48	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-4.08	9.39e-05	0.0428	-0.48	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	4.08	9.39e-05	0.0428	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
THYM	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-4.08	9.39e-05	0.0428	-0.5	-0.39	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
THYM	cis	rs564343	0.563	rs493320	ENSG00000255320.1	RP11-755F10.1	-4.08	9.39e-05	0.0428	-0.43	-0.39	Obesity (early onset extreme);	chr11:66064896	chr11:66244840~66246239:-
THYM	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-4.08	9.4e-05	0.0428	-0.56	-0.39	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
THYM	cis	rs8002861	0.658	rs9533635	ENSG00000230793.1	SMARCE1P5	-4.08	9.4e-05	0.0428	-0.43	-0.39	Leprosy;	chr13:43823785	chr13:44594858~44596082:+
THYM	cis	rs6506900	0.538	rs2217075	ENSG00000265888.1	DSCAS	-4.08	9.4e-05	0.0429	-0.42	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr18:31246735	chr18:31101588~31162789:+
THYM	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-4.08	9.4e-05	0.0429	-0.35	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
THYM	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-4.08	9.4e-05	0.0429	-0.35	-0.39	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
THYM	cis	rs728616	0.681	rs117420340	ENSG00000242600.5	MBL1P	4.08	9.41e-05	0.0429	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406739	chr10:79904898~79950336:+
THYM	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-4.08	9.42e-05	0.0429	-0.3	-0.39	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
THYM	cis	rs10129255	0.642	rs11624918	ENSG00000253209.1	IGHV3-65	4.08	9.42e-05	0.0429	0.39	0.39	Kawasaki disease;	chr14:106664672	chr14:106666092~106666532:-
THYM	cis	rs7631605	0.905	rs11129748	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37025559	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6781146	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37026766	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs9852810	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37027478	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs2286940	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37028615	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs3774335	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37031136	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs3774334	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37031214	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6765395	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37032088	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs3821826	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37032877	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs4678925	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37037015	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs67401825	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37044479	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs1860968	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37049834	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs1558529	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37051573	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs4579	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37053188	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs7639327	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37058297	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.875	rs7372657	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37059658	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6808735	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37062755	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs1468712	ENSG00000272334.1	RP11-129K12.1	4.08	9.42e-05	0.0429	0.4	0.39	Cerebrospinal P-tau181p levels;	chr3:37064522	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs1468713	ENSG00000272334.1	RP11-129K12.1	-4.08	9.42e-05	0.0429	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37064624	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs17204801	ENSG00000272334.1	RP11-129K12.1	4.08	9.42e-05	0.0429	0.4	0.39	Cerebrospinal P-tau181p levels;	chr3:37101943	chr3:36973117~36973672:-
THYM	cis	rs7412746	0.658	rs57818453	ENSG00000220323.3	HIST2H2BD	-4.08	9.42e-05	0.0429	-0.37	-0.39	Melanoma;	chr1:150790663	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.566	rs2864871	ENSG00000220323.3	HIST2H2BD	-4.08	9.42e-05	0.0429	-0.37	-0.39	Melanoma;	chr1:150794488	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs2089082	ENSG00000220323.3	HIST2H2BD	-4.08	9.42e-05	0.0429	-0.37	-0.39	Melanoma;	chr1:150827614	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs10305704	ENSG00000220323.3	HIST2H2BD	-4.08	9.42e-05	0.0429	-0.37	-0.39	Melanoma;	chr1:150831953	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs3768016	ENSG00000220323.3	HIST2H2BD	-4.08	9.42e-05	0.0429	-0.37	-0.39	Melanoma;	chr1:150837443	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs1027699	ENSG00000220323.3	HIST2H2BD	-4.08	9.42e-05	0.0429	-0.37	-0.39	Melanoma;	chr1:150839236	chr1:149843041~149843533:+
THYM	cis	rs7412746	0.658	rs3768015	ENSG00000220323.3	HIST2H2BD	-4.08	9.42e-05	0.0429	-0.37	-0.39	Melanoma;	chr1:150840478	chr1:149843041~149843533:+
THYM	cis	rs7631605	0.905	rs9852378	ENSG00000272334.1	RP11-129K12.1	-4.08	9.43e-05	0.0429	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:36997280	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs4647218	ENSG00000272334.1	RP11-129K12.1	-4.08	9.43e-05	0.0429	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37000591	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs3774341	ENSG00000272334.1	RP11-129K12.1	-4.08	9.43e-05	0.0429	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37003742	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs4234259	ENSG00000272334.1	RP11-129K12.1	-4.08	9.43e-05	0.0429	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37007142	chr3:36973117~36973672:-
THYM	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	4.08	9.43e-05	0.0429	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
THYM	cis	rs4671400	0.543	rs2290324	ENSG00000273302.1	RP11-493E12.2	-4.08	9.44e-05	0.043	-0.43	-0.39	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61221641	chr2:61199979~61200769:+
THYM	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-4.08	9.45e-05	0.043	-0.48	-0.39	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
THYM	cis	rs904251	0.647	rs2776908	ENSG00000227920.2	RP1-153P14.5	-4.08	9.45e-05	0.043	-0.62	-0.39	Cognitive performance;	chr6:37467081	chr6:37545145~37550860:+
THYM	cis	rs7077446	0.733	rs7901209	ENSG00000269609.4	RPARP-AS1	4.08	9.46e-05	0.043	0.29	0.39	Intelligence (multi-trait analysis);	chr10:101994428	chr10:102449817~102461106:+
THYM	cis	rs7487075	0.554	rs7960819	ENSG00000257261.4	RP11-96H19.1	4.08	9.46e-05	0.043	0.36	0.39	Itch intensity from mosquito bite;	chr12:46234999	chr12:46383679~46876159:+
THYM	cis	rs7487075	0.554	rs7957777	ENSG00000257261.4	RP11-96H19.1	4.08	9.46e-05	0.043	0.36	0.39	Itch intensity from mosquito bite;	chr12:46235006	chr12:46383679~46876159:+
THYM	cis	rs9473147	0.843	rs6904933	ENSG00000270761.1	RP11-385F7.1	-4.08	9.47e-05	0.043	-0.34	-0.39	Platelet distribution width;Mean platelet volume;	chr6:47660822	chr6:47477243~47477572:-
THYM	cis	rs295137	0.836	rs1217429	ENSG00000232732.8	AC073043.1	-4.08	9.47e-05	0.043	-0.49	-0.39	Asthma (bronchodilator response);	chr2:200229428	chr2:199867396~199911159:-
THYM	cis	rs9811920	0.893	rs720688	ENSG00000273374.1	RP11-383I23.2	4.08	9.47e-05	0.043	0.33	0.39	Axial length;	chr3:100161725	chr3:99802699~99806058:-
THYM	cis	rs564343	0.583	rs2430978	ENSG00000255320.1	RP11-755F10.1	-4.08	9.48e-05	0.0431	-0.44	-0.39	Obesity (early onset extreme);	chr11:66049185	chr11:66244840~66246239:-
THYM	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	4.08	9.5e-05	0.0431	0.48	0.39	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
THYM	cis	rs12902680	0.706	rs12901725	ENSG00000259520.4	CTD-2651B20.3	4.08	9.5e-05	0.0431	0.41	0.39	Neuroticism;	chr15:46207764	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12913435	ENSG00000259520.4	CTD-2651B20.3	4.08	9.5e-05	0.0431	0.41	0.39	Neuroticism;	chr15:46213298	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs8037404	ENSG00000259520.4	CTD-2651B20.3	4.08	9.5e-05	0.0431	0.41	0.39	Neuroticism;	chr15:46213584	chr15:45251580~45279251:-
THYM	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	4.08	9.5e-05	0.0431	0.48	0.39	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
THYM	cis	rs3015497	0.789	rs8003372	ENSG00000270062.1	RP11-248J18.3	4.08	9.5e-05	0.0431	0.28	0.39	Mean platelet volume;	chr14:50635633	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.789	rs2934688	ENSG00000270062.1	RP11-248J18.3	4.08	9.5e-05	0.0431	0.28	0.39	Mean platelet volume;	chr14:50645642	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.789	rs10133849	ENSG00000270062.1	RP11-248J18.3	4.08	9.5e-05	0.0431	0.28	0.39	Mean platelet volume;	chr14:50654982	chr14:50723777~50724272:-
THYM	cis	rs3015497	0.789	rs1389652	ENSG00000270062.1	RP11-248J18.3	4.08	9.5e-05	0.0431	0.28	0.39	Mean platelet volume;	chr14:50658522	chr14:50723777~50724272:-
THYM	cis	rs7959452	0.64	rs4761233	ENSG00000274979.1	RP11-1143G9.5	-4.08	9.5e-05	0.0431	-0.38	-0.39	Blood protein levels;	chr12:69329100	chr12:69326574~69331882:-
THYM	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	4.08	9.5e-05	0.0431	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
THYM	cis	rs6506900	0.617	rs2912323	ENSG00000265888.1	DSCAS	-4.08	9.51e-05	0.0432	-0.41	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr18:31235875	chr18:31101588~31162789:+
THYM	cis	rs11085466	1	rs4399664	ENSG00000268705.1	BNIP3P26	4.08	9.51e-05	0.0432	0.33	0.39	Colorectal or endometrial cancer;	chr19:21595224	chr19:21521343~21521896:-
THYM	cis	rs495337	1	rs4810998	ENSG00000229222.1	KRT18P4	-4.08	9.52e-05	0.0432	-0.45	-0.39	Psoriasis;	chr20:49963473	chr20:49956745~49958032:+
THYM	cis	rs495337	0.965	rs4810999	ENSG00000229222.1	KRT18P4	-4.08	9.52e-05	0.0432	-0.45	-0.39	Psoriasis;	chr20:49964432	chr20:49956745~49958032:+
THYM	cis	rs495337	1	rs6067293	ENSG00000229222.1	KRT18P4	-4.08	9.52e-05	0.0432	-0.45	-0.39	Psoriasis;	chr20:49965204	chr20:49956745~49958032:+
THYM	cis	rs7631605	0.935	rs4647224	ENSG00000272334.1	RP11-129K12.1	-4.08	9.52e-05	0.0432	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37001739	chr3:36973117~36973672:-
THYM	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-4.08	9.52e-05	0.0432	-0.47	-0.39	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
THYM	cis	rs9535495	0.773	rs9563004	ENSG00000200711.1	RNA5SP28	-4.08	9.53e-05	0.0433	-0.44	-0.39	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50837346	chr13:50812988~50813106:-
THYM	cis	rs9535495	0.773	rs4264297	ENSG00000200711.1	RNA5SP28	-4.08	9.53e-05	0.0433	-0.44	-0.39	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50837628	chr13:50812988~50813106:-
THYM	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-4.08	9.53e-05	0.0433	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-4.08	9.53e-05	0.0433	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
THYM	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-4.08	9.53e-05	0.0433	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
THYM	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	4.08	9.54e-05	0.0433	0.36	0.39	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
THYM	cis	rs160451	0.966	rs218886	ENSG00000251136.7	RP11-37B2.1	-4.08	9.54e-05	0.0433	-0.36	-0.39	Leprosy;	chr8:89678365	chr8:89609409~89757727:-
THYM	cis	rs160451	0.933	rs218888	ENSG00000251136.7	RP11-37B2.1	-4.08	9.54e-05	0.0433	-0.36	-0.39	Leprosy;	chr8:89679693	chr8:89609409~89757727:-
THYM	cis	rs160451	0.933	rs218889	ENSG00000251136.7	RP11-37B2.1	-4.08	9.54e-05	0.0433	-0.36	-0.39	Leprosy;	chr8:89679935	chr8:89609409~89757727:-
THYM	cis	rs11971779	0.59	rs11762145	ENSG00000273391.1	RP11-634H22.1	4.08	9.55e-05	0.0433	0.4	0.39	Diisocyanate-induced asthma;	chr7:139237920	chr7:139359032~139359566:-
THYM	cis	rs7223966	0.921	rs6504186	ENSG00000240280.5	TCAM1P	-4.08	9.56e-05	0.0433	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63786572	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.921	rs7225092	ENSG00000240280.5	TCAM1P	-4.08	9.56e-05	0.0433	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63786645	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs7222060	ENSG00000240280.5	TCAM1P	-4.08	9.56e-05	0.0433	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63790919	chr17:63849292~63864379:+
THYM	cis	rs7223966	0.96	rs11659013	ENSG00000240280.5	TCAM1P	-4.08	9.56e-05	0.0433	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63792199	chr17:63849292~63864379:+
THYM	cis	rs7223966	1	rs7214312	ENSG00000240280.5	TCAM1P	-4.08	9.56e-05	0.0433	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63793503	chr17:63849292~63864379:+
THYM	cis	rs10829156	0.796	rs6482567	ENSG00000225527.1	RP11-383B4.4	-4.08	9.56e-05	0.0434	-0.51	-0.39	Sudden cardiac arrest;	chr10:18625860	chr10:18531849~18533336:-
THYM	cis	rs10829156	0.755	rs10732437	ENSG00000225527.1	RP11-383B4.4	-4.08	9.56e-05	0.0434	-0.51	-0.39	Sudden cardiac arrest;	chr10:18626973	chr10:18531849~18533336:-
THYM	cis	rs9473147	0.747	rs9395288	ENSG00000270761.1	RP11-385F7.1	-4.08	9.56e-05	0.0434	-0.39	-0.39	Platelet distribution width;Mean platelet volume;	chr6:47630389	chr6:47477243~47477572:-
THYM	cis	rs2288012	0.592	rs3815802	ENSG00000260186.4	RP11-481J2.2	4.08	9.56e-05	0.0434	0.48	0.39	Systemic lupus erythematosus;	chr16:58262641	chr16:58421326~58462470:+
THYM	cis	rs4834770	1	rs878375	ENSG00000249244.1	RP11-548H18.2	4.08	9.57e-05	0.0434	0.3	0.39	Blood protein levels;	chr4:119316419	chr4:119391831~119395335:-
THYM	cis	rs34792	0.853	rs170194	ENSG00000262380.1	CTB-193M12.3	4.08	9.58e-05	0.0434	0.48	0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464415	chr16:15683290~15684570:+
THYM	cis	rs2115630	0.967	rs12595786	ENSG00000275120.1	RP11-182J1.17	-4.08	9.58e-05	0.0434	-0.45	-0.39	P wave terminal force;	chr15:84793439	chr15:84599434~84606463:-
THYM	cis	rs863345	1	rs863351	ENSG00000236656.1	RP11-144L1.4	4.08	9.58e-05	0.0434	0.24	0.39	Pneumococcal bacteremia;	chr1:158568873	chr1:158474454~158494886:-
THYM	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-4.08	9.59e-05	0.0435	-0.46	-0.39	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-4.08	9.59e-05	0.0435	-0.46	-0.39	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
THYM	cis	rs3753275	0.624	rs7517436	ENSG00000230679.1	ENO1-AS1	-4.08	9.59e-05	0.0435	-0.45	-0.39	Educational attainment;	chr1:8810817	chr1:8878835~8879894:+
THYM	cis	rs17253792	0.822	rs79538158	ENSG00000186615.9	KTN1-AS1	-4.08	9.59e-05	0.0435	-0.78	-0.39	Putamen volume;	chr14:55584647	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs78432811	ENSG00000186615.9	KTN1-AS1	-4.08	9.59e-05	0.0435	-0.78	-0.39	Putamen volume;	chr14:55584827	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs74609892	ENSG00000186615.9	KTN1-AS1	-4.08	9.59e-05	0.0435	-0.78	-0.39	Putamen volume;	chr14:55586284	chr14:55499278~55580110:-
THYM	cis	rs2075230	0.705	rs1641525	ENSG00000244604.1	RP11-713H12.1	-4.08	9.6e-05	0.0435	-0.56	-0.39	Hormone measurements;	chr17:7645893	chr17:8561230~8561576:+
THYM	cis	rs6664467	1	rs6664467	ENSG00000203288.3	RP11-98D18.9	-4.08	9.6e-05	0.0435	-0.52	-0.39	Carotid plaque burden;	chr1:151765927	chr1:151790804~151794402:+
THYM	cis	rs150641967	1	rs150641967	ENSG00000267220.1	CTC-260E6.9	4.08	9.61e-05	0.0435	0.98	0.39	Very low density lipoprotein cholesterol levels;Low density lipoprotein cholesterol;Total cholesterol levels;Triglyceride levels;	chr19:19259535	chr19:20131894~20151908:-
THYM	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	4.08	9.61e-05	0.0435	0.52	0.39	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
THYM	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	4.08	9.61e-05	0.0435	0.45	0.39	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
THYM	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	4.08	9.61e-05	0.0435	0.45	0.39	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
THYM	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	4.08	9.61e-05	0.0435	0.45	0.39	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
THYM	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	4.08	9.61e-05	0.0435	0.45	0.39	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
THYM	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-4.08	9.61e-05	0.0435	-0.45	-0.39	QT interval;	chr12:29314736	chr12:29280418~29317848:-
THYM	cis	rs7077446	0.733	rs10748815	ENSG00000269609.4	RPARP-AS1	4.07	9.61e-05	0.0436	0.29	0.39	Intelligence (multi-trait analysis);	chr10:101930912	chr10:102449817~102461106:+
THYM	cis	rs7077446	0.733	rs3922860	ENSG00000269609.4	RPARP-AS1	4.07	9.61e-05	0.0436	0.29	0.39	Intelligence (multi-trait analysis);	chr10:101969833	chr10:102449817~102461106:+
THYM	cis	rs7077446	0.695	rs10786658	ENSG00000269609.4	RPARP-AS1	4.07	9.61e-05	0.0436	0.29	0.39	Intelligence (multi-trait analysis);	chr10:101977436	chr10:102449817~102461106:+
THYM	cis	rs7077446	0.733	rs11191174	ENSG00000269609.4	RPARP-AS1	4.07	9.61e-05	0.0436	0.29	0.39	Intelligence (multi-trait analysis);	chr10:101999764	chr10:102449817~102461106:+
THYM	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	4.07	9.61e-05	0.0436	0.48	0.39	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
THYM	cis	rs12902680	0.706	rs984639	ENSG00000259520.4	CTD-2651B20.3	4.07	9.61e-05	0.0436	0.41	0.39	Neuroticism;	chr15:46166318	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.677	rs17562424	ENSG00000259520.4	CTD-2651B20.3	4.07	9.61e-05	0.0436	0.41	0.39	Neuroticism;	chr15:46172857	chr15:45251580~45279251:-
THYM	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	4.07	9.62e-05	0.0436	0.51	0.39	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
THYM	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-4.07	9.62e-05	0.0436	-0.58	-0.39	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-4.07	9.62e-05	0.0436	-0.58	-0.39	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-4.07	9.62e-05	0.0436	-0.58	-0.39	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
THYM	cis	rs11157436	0.602	rs928954	ENSG00000211813.2	TRAV34	4.07	9.63e-05	0.0436	0.28	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22207522~22208129:+
THYM	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-4.07	9.63e-05	0.0436	-0.5	-0.39	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
THYM	cis	rs853679	0.517	rs17711344	ENSG00000199851.2	U3	-4.07	9.63e-05	0.0436	-0.53	-0.39	Depression;	chr6:28109824	chr6:28015568~28015777:+
THYM	cis	rs853679	0.517	rs9393884	ENSG00000199851.2	U3	4.07	9.63e-05	0.0436	0.53	0.39	Depression;	chr6:28079011	chr6:28015568~28015777:+
THYM	cis	rs853679	0.517	rs9393887	ENSG00000199851.2	U3	4.07	9.63e-05	0.0436	0.53	0.39	Depression;	chr6:28091242	chr6:28015568~28015777:+
THYM	cis	rs853679	0.517	rs9380052	ENSG00000199851.2	U3	4.07	9.63e-05	0.0436	0.53	0.39	Depression;	chr6:28096845	chr6:28015568~28015777:+
THYM	cis	rs11139399	0.675	rs11139388	ENSG00000233926.1	RP11-154D17.1	-4.07	9.64e-05	0.0437	-0.47	-0.39	Hippocampal atrophy;	chr9:81733987	chr9:81689713~81776900:+
THYM	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-4.07	9.64e-05	0.0437	-0.27	-0.39	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
THYM	cis	rs12736701	0.677	rs80008689	ENSG00000226084.5	RP4-706A16.3	4.07	9.64e-05	0.0437	0.84	0.39	Type 2 diabetes (age of onset);	chr1:77365420	chr1:77129114~77129668:+
THYM	cis	rs2115630	1	rs6496452	ENSG00000275120.1	RP11-182J1.17	-4.07	9.66e-05	0.0437	-0.47	-0.39	P wave terminal force;	chr15:84829414	chr15:84599434~84606463:-
THYM	cis	rs4713118	0.662	rs149970	ENSG00000199851.2	U3	4.07	9.66e-05	0.0437	0.51	0.39	Parkinson's disease;	chr6:28012442	chr6:28015568~28015777:+
THYM	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-4.07	9.67e-05	0.0437	-0.47	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
THYM	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	4.07	9.67e-05	0.0437	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
THYM	cis	rs7107174	0.579	rs1981405	ENSG00000251323.2	RP11-452H21.4	4.07	9.67e-05	0.0437	0.51	0.39	Testicular germ cell tumor;	chr11:78265162	chr11:78423982~78429836:-
THYM	cis	rs877819	0.583	rs2663021	ENSG00000228403.1	RP11-563N6.6	-4.07	9.67e-05	0.0437	-0.51	-0.39	Systemic lupus erythematosus;	chr10:48870072	chr10:48878022~48878649:+
THYM	cis	rs7082209	1	rs2146807	ENSG00000214089.3	RP11-256K7.1	4.07	9.67e-05	0.0438	0.56	0.39	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr10:44318290	chr10:44414649~44415153:-
THYM	cis	rs7202877	0.539	rs17764278	ENSG00000261783.1	RP11-252K23.2	-4.07	9.68e-05	0.0438	-0.71	-0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75340131	chr16:75379818~75381260:-
THYM	cis	rs4852324	0.536	rs6721042	ENSG00000272183.1	RP11-523H20.3	4.07	9.68e-05	0.0438	0.75	0.39	Systemic lupus erythematosus;	chr2:73990156	chr2:74501717~74502365:+
THYM	cis	rs7631605	0.935	rs9861967	ENSG00000272334.1	RP11-129K12.1	-4.07	9.68e-05	0.0438	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37117307	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs6780799	ENSG00000272334.1	RP11-129K12.1	-4.07	9.68e-05	0.0438	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37121267	chr3:36973117~36973672:-
THYM	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-4.07	9.68e-05	0.0438	-0.46	-0.39	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
THYM	cis	rs12736701	0.677	rs10518553	ENSG00000226084.5	RP4-706A16.3	-4.07	9.69e-05	0.0438	-0.84	-0.39	Type 2 diabetes (age of onset);	chr1:77404797	chr1:77129114~77129668:+
THYM	cis	rs12736701	0.677	rs111432790	ENSG00000226084.5	RP4-706A16.3	4.07	9.69e-05	0.0438	0.84	0.39	Type 2 diabetes (age of onset);	chr1:77418843	chr1:77129114~77129668:+
THYM	cis	rs12736701	0.677	rs3104461	ENSG00000226084.5	RP4-706A16.3	4.07	9.69e-05	0.0438	0.84	0.39	Type 2 diabetes (age of onset);	chr1:77420654	chr1:77129114~77129668:+
THYM	cis	rs12736701	0.677	rs7415865	ENSG00000226084.5	RP4-706A16.3	-4.07	9.69e-05	0.0438	-0.84	-0.39	Type 2 diabetes (age of onset);	chr1:77425614	chr1:77129114~77129668:+
THYM	cis	rs12736701	0.677	rs2647519	ENSG00000226084.5	RP4-706A16.3	-4.07	9.69e-05	0.0438	-0.84	-0.39	Type 2 diabetes (age of onset);	chr1:77426589	chr1:77129114~77129668:+
THYM	cis	rs42490	0.51	rs218885	ENSG00000251136.7	RP11-37B2.1	4.07	9.69e-05	0.0438	0.32	0.39	Leprosy;	chr8:89678313	chr8:89609409~89757727:-
THYM	cis	rs7959452	0.57	rs10878964	ENSG00000274979.1	RP11-1143G9.5	-4.07	9.69e-05	0.0438	-0.38	-0.39	Blood protein levels;	chr12:69326911	chr12:69326574~69331882:-
THYM	cis	rs910316	0.646	rs11546525	ENSG00000258646.1	RP11-950C14.3	-4.07	9.69e-05	0.0438	-0.36	-0.39	Height;	chr14:75070678	chr14:75004719~75008481:-
THYM	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	4.07	9.69e-05	0.0438	0.32	0.39	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
THYM	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-4.07	9.7e-05	0.0439	-0.33	-0.39	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
THYM	cis	rs7851726	0.69	rs11788697	ENSG00000232063.1	RP11-307E17.8	4.07	9.71e-05	0.0439	0.38	0.39	Urinary albumin-to-creatinine ratio;	chr9:94823083	chr9:94332476~94360948:+
THYM	cis	rs718433	0.717	rs12893255	ENSG00000258458.4	CTD-2555K7.2	-4.07	9.72e-05	0.0439	-0.47	-0.39	Intraocular pressure;	chr14:21773162	chr14:22702611~22766562:-
THYM	cis	rs910316	1	rs175436	ENSG00000258646.1	RP11-950C14.3	4.07	9.73e-05	0.044	0.35	0.39	Height;	chr14:75141980	chr14:75004719~75008481:-
THYM	cis	rs12410462	0.585	rs2644143	ENSG00000227711.2	RP11-275O4.5	-4.07	9.73e-05	0.044	-0.4	-0.39	Major depressive disorder;	chr1:227543456	chr1:227509028~227520477:-
THYM	cis	rs12410462	0.591	rs2644144	ENSG00000227711.2	RP11-275O4.5	-4.07	9.73e-05	0.044	-0.4	-0.39	Major depressive disorder;	chr1:227544166	chr1:227509028~227520477:-
THYM	cis	rs748404	0.666	rs12911569	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43305099	chr15:43642389~43643023:-
THYM	cis	rs748404	0.626	rs1814324	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43314951	chr15:43642389~43643023:-
THYM	cis	rs748404	0.629	rs34657657	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43315763	chr15:43642389~43643023:-
THYM	cis	rs748404	0.626	rs62019432	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43316482	chr15:43642389~43643023:-
THYM	cis	rs748404	0.666	rs7176923	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43317679	chr15:43642389~43643023:-
THYM	cis	rs748404	0.666	rs7177892	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43321171	chr15:43642389~43643023:-
THYM	cis	rs748404	0.666	rs7181545	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43321363	chr15:43642389~43643023:-
THYM	cis	rs748404	0.666	rs17723479	ENSG00000275601.1	AC011330.13	4.07	9.73e-05	0.044	0.53	0.39	Lung cancer;	chr15:43322114	chr15:43642389~43643023:-
THYM	cis	rs7631605	0.967	rs9847384	ENSG00000272334.1	RP11-129K12.1	-4.07	9.73e-05	0.044	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:36966371	chr3:36973117~36973672:-
THYM	cis	rs4262	0.505	rs6955457	ENSG00000278388.1	GS1-345D13.1	4.07	9.74e-05	0.044	0.42	0.39	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93936049	chr7:93914987~93915108:+
THYM	cis	rs4262	0.505	rs11981520	ENSG00000278388.1	GS1-345D13.1	4.07	9.74e-05	0.044	0.42	0.39	Heart rate variability traits (SDNN);Heart rate variability traits (pvRSA/HF);	chr7:93937596	chr7:93914987~93915108:+
THYM	cis	rs1062746	0.683	rs891094	ENSG00000269901.1	RP11-178L8.9	4.07	9.74e-05	0.044	0.34	0.39	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr16:87344395	chr16:87362536~87367476:+
THYM	cis	rs1062746	0.711	rs8056833	ENSG00000269901.1	RP11-178L8.9	-4.07	9.74e-05	0.044	-0.34	-0.39	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr16:87344782	chr16:87362536~87367476:+
THYM	cis	rs7246967	0.8	rs2169794	ENSG00000198153.8	ZNF849P	-4.07	9.75e-05	0.044	-0.48	-0.39	Bronchopulmonary dysplasia;	chr19:22842966	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.8	rs2061774	ENSG00000198153.8	ZNF849P	-4.07	9.75e-05	0.044	-0.48	-0.39	Bronchopulmonary dysplasia;	chr19:22842973	chr19:22685167~22686732:+
THYM	cis	rs11098499	0.954	rs10017371	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119372621	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs10020034	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119373176	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.618	rs28491261	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119373745	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs59394118	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119374396	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs9996417	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119374707	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs7436506	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119472614	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs12499324	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119472631	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10008459	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119473076	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs2127821	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119473380	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs4577559	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119482888	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs7656252	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119483113	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs28845498	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119484031	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs28753180	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119484212	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs56270433	ENSG00000250412.1	KLHL2P1	4.07	9.75e-05	0.044	0.38	0.39	Corneal astigmatism;	chr4:119484875	chr4:119334329~119378233:+
THYM	cis	rs1642645	0.915	rs10890177	ENSG00000228452.1	RP5-994D16.9	-4.07	9.75e-05	0.0441	-0.53	-0.39	Left ventricular obstructive tract defect (maternal effect);	chr1:42040710	chr1:42775813~42776790:-
THYM	cis	rs1550576	0.568	rs55848030	ENSG00000274719.1	RP11-86K22.2	4.07	9.76e-05	0.0441	0.71	0.39	Hypertension;	chr15:57929910	chr15:57990217~57990636:-
THYM	cis	rs1550576	0.568	rs55695119	ENSG00000274719.1	RP11-86K22.2	4.07	9.76e-05	0.0441	0.71	0.39	Hypertension;	chr15:57937205	chr15:57990217~57990636:-
THYM	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	4.07	9.77e-05	0.0441	0.49	0.39	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
THYM	cis	rs7005380	0.62	rs7462302	ENSG00000245330.4	KB-1471A8.1	4.07	9.77e-05	0.0441	0.54	0.39	Interstitial lung disease;	chr8:119905531	chr8:119867419~119874488:-
THYM	cis	rs2562456	0.917	rs2650804	ENSG00000268081.1	RP11-678G14.2	4.07	9.77e-05	0.0441	0.49	0.39	Pain;	chr19:21497382	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-4.07	9.77e-05	0.0441	-0.49	-0.39	Pain;	chr19:21499472	chr19:21554640~21569237:-
THYM	cis	rs9611565	0.605	rs202638	ENSG00000231993.1	EP300-AS1	-4.07	9.78e-05	0.0441	-0.38	-0.39	Vitiligo;	chr22:41459454	chr22:41174591~41197456:-
THYM	cis	rs17818399	0.817	rs17767994	ENSG00000279254.1	RP11-536C12.1	4.07	9.78e-05	0.0441	0.45	0.39	Height;	chr2:46632940	chr2:46668870~46670778:+
THYM	cis	rs42490	0.664	rs389848	ENSG00000251136.7	RP11-37B2.1	-4.07	9.8e-05	0.0441	-0.31	-0.39	Leprosy;	chr8:89784739	chr8:89609409~89757727:-
THYM	cis	rs7631605	0.935	rs1558528	ENSG00000272334.1	RP11-129K12.1	-4.07	9.8e-05	0.0441	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37015499	chr3:36973117~36973672:-
THYM	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	4.07	9.81e-05	0.0441	0.48	0.39	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	4.07	9.81e-05	0.0441	0.48	0.39	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	4.07	9.81e-05	0.0441	0.48	0.39	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	4.07	9.81e-05	0.0441	0.48	0.39	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
THYM	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	4.07	9.81e-05	0.0441	0.48	0.39	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
THYM	cis	rs6763848	0.669	rs10212168	ENSG00000214073.2	RPL21P17	-4.07	9.81e-05	0.0441	-0.46	-0.39	Prostate cancer (SNP x SNP interaction);	chr3:1475717	chr3:1905651~1906125:+
THYM	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	4.07	9.81e-05	0.0441	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
THYM	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	4.07	9.81e-05	0.0441	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
THYM	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-4.07	9.81e-05	0.0441	-0.52	-0.39	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
THYM	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-4.07	9.81e-05	0.0441	-0.52	-0.39	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
THYM	cis	rs2107732	1	rs2107732	ENSG00000230160.1	AC004854.5	4.07	9.81e-05	0.0441	0.89	0.39	Coronary artery disease;	chr7:45038379	chr7:44919669~44920329:+
THYM	cis	rs11098499	0.954	rs4309825	ENSG00000250412.1	KLHL2P1	-4.07	9.81e-05	0.0441	-0.38	-0.39	Corneal astigmatism;	chr4:119393726	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs9993199	ENSG00000250412.1	KLHL2P1	-4.07	9.81e-05	0.0441	-0.38	-0.39	Corneal astigmatism;	chr4:119471718	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs6849561	ENSG00000250412.1	KLHL2P1	-4.07	9.81e-05	0.0441	-0.38	-0.39	Corneal astigmatism;	chr4:119488539	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs59866101	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119375436	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.618	rs6858383	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119375617	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.697	rs6832410	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119375645	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs1112817	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119376645	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.779	rs10016060	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119377257	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10005644	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119377322	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.697	rs10016448	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119377690	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.657	rs9996569	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119377849	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs11723757	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119378514	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs11723839	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119378518	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs11729050	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119378911	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs28429722	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119378938	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10014845	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119379922	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs12506546	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119380463	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.779	rs7674500	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119382438	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs28884220	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119386056	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs28793658	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119386059	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.697	rs4373140	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119386543	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs13113483	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119387884	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.542	rs10440343	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119388632	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs28668716	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119388720	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.779	rs10011097	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119389204	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.779	rs7699346	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119389387	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.542	rs7677836	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119389483	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs10002083	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119389997	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10024844	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119390373	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs7437420	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119391748	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs4345162	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119391804	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.657	rs4463052	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119392103	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.697	rs4560394	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119392280	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs13151285	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119393586	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs11098513	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119394920	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs28572238	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119395531	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs28714195	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119395795	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.863	rs12508173	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119397371	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs12504149	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119397422	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10008392	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119397684	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.58	rs12509234	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119398279	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs10014719	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119399560	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10017543	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119400265	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs7695996	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119400878	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs7696649	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119401022	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10518331	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119402440	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs13133522	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119403269	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs35091806	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119404374	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs35165976	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119404475	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs2389802	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119404577	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs3890049	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119405128	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs6846442	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119405168	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.738	rs72918577	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119405546	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs67265404	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119438115	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs71614422	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119438185	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.738	rs34566984	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119440115	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.738	rs34965784	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119440431	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs17009122	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119441248	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs9685777	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119444810	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs9759478	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119446843	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs71614438	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119450097	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs66506550	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119450290	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs7659501	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119450397	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs71629403	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119451412	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.697	rs28655325	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119451844	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs73842633	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119454309	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.779	rs28495013	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119454676	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs28571712	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119454825	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.738	rs28408407	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119454875	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs1809406	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119455967	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs2389809	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119456244	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.657	rs71614442	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119458191	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs2892848	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119460186	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs9994730	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119460409	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs9994810	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119460435	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.697	rs10020027	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119460724	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.779	rs7356491	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119460819	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.697	rs11941899	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119461603	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs7681978	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119462620	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.821	rs28665282	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119463031	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.738	rs10026493	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119463039	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs7681214	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119464165	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs28559989	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119465472	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs28499576	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119465522	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs28632018	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119465575	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs71614449	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119465900	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs35063680	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119465947	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs34858317	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119465955	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs17046116	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119466104	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs17046118	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119466341	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs7654587	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119467251	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs13107475	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119471856	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10006525	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119487776	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10006706	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119487997	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs6849171	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119488394	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs7681544	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119490100	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs17005535	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119490407	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs11940028	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119490752	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs11935596	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119491302	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs12507964	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119491906	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs11098530	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119491999	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs6834796	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119493538	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs11729521	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119495633	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs11734241	ENSG00000250412.1	KLHL2P1	4.07	9.81e-05	0.0441	0.38	0.39	Corneal astigmatism;	chr4:119495717	chr4:119334329~119378233:+
THYM	cis	rs1865760	0.534	rs72834629	ENSG00000216331.1	HIST1H1PS1	4.07	9.81e-05	0.0441	0.59	0.39	Height;	chr6:26022804	chr6:26195566~26195771:+
THYM	cis	rs12902680	0.706	rs8038141	ENSG00000259520.4	CTD-2651B20.3	4.07	9.82e-05	0.0442	0.41	0.39	Neuroticism;	chr15:46153621	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.706	rs12915878	ENSG00000259520.4	CTD-2651B20.3	4.07	9.82e-05	0.0442	0.41	0.39	Neuroticism;	chr15:46153941	chr15:45251580~45279251:-
THYM	cis	rs3753275	0.508	rs2781068	ENSG00000230679.1	ENO1-AS1	4.07	9.82e-05	0.0442	0.45	0.39	Educational attainment;	chr1:8864862	chr1:8878835~8879894:+
THYM	cis	rs9733	0.596	rs12089989	ENSG00000220323.3	HIST2H2BD	-4.07	9.82e-05	0.0442	-0.37	-0.39	Tonsillectomy;	chr1:150743306	chr1:149843041~149843533:+
THYM	cis	rs10129255	1	rs4612959	ENSG00000254329.1	IGHVII-60-1	4.07	9.82e-05	0.0442	0.4	0.39	Kawasaki disease;	chr14:106767055	chr14:106637718~106637973:-
THYM	cis	rs10129255	1	rs10129407	ENSG00000254329.1	IGHVII-60-1	4.07	9.82e-05	0.0442	0.4	0.39	Kawasaki disease;	chr14:106767956	chr14:106637718~106637973:-
THYM	cis	rs10129255	1	rs10129255	ENSG00000254329.1	IGHVII-60-1	-4.07	9.82e-05	0.0442	-0.4	-0.39	Kawasaki disease;	chr14:106767970	chr14:106637718~106637973:-
THYM	cis	rs17507216	1	rs17507216	ENSG00000274376.3	ADAMTS7P1	-4.07	9.83e-05	0.0442	-0.43	-0.39	Excessive daytime sleepiness;	chr15:82558175	chr15:82298553~82334609:+
THYM	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	4.07	9.83e-05	0.0442	0.48	0.39	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
THYM	cis	rs4908760	0.792	rs6577515	ENSG00000232912.4	RP5-1115A15.1	4.07	9.83e-05	0.0442	0.37	0.39	Vitiligo;	chr1:8654143	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.827	rs7556169	ENSG00000232912.4	RP5-1115A15.1	-4.07	9.83e-05	0.0442	-0.37	-0.39	Vitiligo;	chr1:8681342	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.792	rs4908505	ENSG00000232912.4	RP5-1115A15.1	4.07	9.83e-05	0.0442	0.37	0.39	Vitiligo;	chr1:8668805	chr1:8424645~8434838:+
THYM	cis	rs4908760	0.827	rs10864362	ENSG00000232912.4	RP5-1115A15.1	4.07	9.83e-05	0.0442	0.37	0.39	Vitiligo;	chr1:8672395	chr1:8424645~8434838:+
THYM	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-4.07	9.84e-05	0.0442	-0.48	-0.39	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-4.07	9.84e-05	0.0442	-0.48	-0.39	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-4.07	9.84e-05	0.0442	-0.48	-0.39	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-4.07	9.84e-05	0.0442	-0.48	-0.39	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-4.07	9.84e-05	0.0442	-0.48	-0.39	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
THYM	cis	rs863345	0.604	rs1112915	ENSG00000236656.1	RP11-144L1.4	4.07	9.84e-05	0.0442	0.24	0.39	Pneumococcal bacteremia;	chr1:158474657	chr1:158474454~158494886:-
THYM	cis	rs863345	0.625	rs11264978	ENSG00000236656.1	RP11-144L1.4	4.07	9.84e-05	0.0442	0.24	0.39	Pneumococcal bacteremia;	chr1:158478131	chr1:158474454~158494886:-
THYM	cis	rs60180747	0.544	rs11635867	ENSG00000261318.1	RP11-653J6.1	4.07	9.84e-05	0.0442	0.42	0.39	Testicular germ cell tumor;	chr15:66278908	chr15:66278498~66293357:-
THYM	cis	rs4835473	0.643	rs34680080	ENSG00000246448.2	RP13-578N3.3	4.07	9.84e-05	0.0442	0.51	0.39	Immature fraction of reticulocytes;	chr4:143797290	chr4:143700257~143865072:+
THYM	cis	rs73108077	0.688	rs6119825	ENSG00000277112.2	RP11-755J8.1	-4.07	9.84e-05	0.0442	-0.5	-0.39	Red blood cell density in sickle cell anemia;	chr20:31326768	chr20:30681825~30723932:-
THYM	cis	rs12681366	0.62	rs2930968	ENSG00000253704.1	RP11-267M23.4	4.07	9.85e-05	0.0443	0.45	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94450467	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.663	rs2930970	ENSG00000253704.1	RP11-267M23.4	4.07	9.85e-05	0.0443	0.45	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94452109	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.663	rs2921389	ENSG00000253704.1	RP11-267M23.4	4.07	9.85e-05	0.0443	0.45	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94454138	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.663	rs2043987	ENSG00000253704.1	RP11-267M23.4	4.07	9.85e-05	0.0443	0.45	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94457465	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.663	rs2919662	ENSG00000253704.1	RP11-267M23.4	4.07	9.85e-05	0.0443	0.45	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94458044	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.663	rs2919660	ENSG00000253704.1	RP11-267M23.4	4.07	9.85e-05	0.0443	0.45	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94458469	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.663	rs1561648	ENSG00000253704.1	RP11-267M23.4	4.07	9.85e-05	0.0443	0.45	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94462209	chr8:94553722~94569745:+
THYM	cis	rs16970672	0.92	rs4789523	ENSG00000279886.1	RP11-219G17.8	4.07	9.86e-05	0.0443	0.4	0.39	Psychosis and Alzheimer's disease;	chr17:78016773	chr17:78250346~78250932:-
THYM	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-4.07	9.86e-05	0.0443	-0.52	-0.39	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
THYM	cis	rs6782228	0.606	rs6787559	ENSG00000277250.1	Metazoa_SRP	-4.07	9.86e-05	0.0443	-0.53	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128673681~128674021:-
THYM	cis	rs6782228	0.606	rs2001703	ENSG00000277250.1	Metazoa_SRP	-4.07	9.86e-05	0.0443	-0.53	-0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128673681~128674021:-
THYM	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-4.07	9.87e-05	0.0443	-0.4	-0.39	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
THYM	cis	rs2434422	0.614	rs16983718	ENSG00000182310.11	SPACA6P	4.07	9.87e-05	0.0443	0.55	0.39	Cannabis use (initiation);	chr19:52333321	chr19:51693340~51712387:+
THYM	cis	rs7178424	0.742	rs963024	ENSG00000259251.2	RP11-643M14.1	4.07	9.87e-05	0.0443	0.4	0.39	Height;	chr15:61919251	chr15:62060503~62062434:+
THYM	cis	rs888468	1	rs888466	ENSG00000255920.1	CCND2-AS2	4.07	9.88e-05	0.0444	0.33	0.39	Response to cytadine analogues (cytosine arabinoside);	chr12:4424439	chr12:4252735~4275065:-
THYM	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	4.07	9.88e-05	0.0444	0.48	0.39	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
THYM	cis	rs1005277	0.505	rs7099777	ENSG00000275858.1	RP11-291L22.8	-4.07	9.89e-05	0.0444	-0.35	-0.39	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38450738~38451069:-
THYM	cis	rs1005277	0.505	rs7917943	ENSG00000275858.1	RP11-291L22.8	-4.07	9.89e-05	0.0444	-0.35	-0.39	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38450738~38451069:-
THYM	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	4.07	9.89e-05	0.0444	0.5	0.39	Pain;	chr19:21568976	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	4.07	9.89e-05	0.0444	0.5	0.39	Pain;	chr19:21569041	chr19:21554640~21569237:-
THYM	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	4.07	9.89e-05	0.0444	0.51	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
THYM	cis	rs9811920	0.928	rs9865713	ENSG00000273374.1	RP11-383I23.2	4.07	9.89e-05	0.0444	0.33	0.39	Axial length;	chr3:100151455	chr3:99802699~99806058:-
THYM	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	4.07	9.9e-05	0.0444	0.36	0.39	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
THYM	cis	rs8177876	0.749	rs2278024	ENSG00000261838.4	RP11-303E16.6	4.07	9.9e-05	0.0444	0.86	0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81069854~81076598:+
THYM	cis	rs853679	0.517	rs6922063	ENSG00000199851.2	U3	4.07	9.91e-05	0.0445	0.52	0.39	Depression;	chr6:28126588	chr6:28015568~28015777:+
THYM	cis	rs853679	0.517	rs2275508	ENSG00000199851.2	U3	4.07	9.91e-05	0.0445	0.52	0.39	Depression;	chr6:28126953	chr6:28015568~28015777:+
THYM	cis	rs7202877	0.706	rs247423	ENSG00000261783.1	RP11-252K23.2	4.07	9.92e-05	0.0445	0.53	0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75422733	chr16:75379818~75381260:-
THYM	cis	rs7202877	0.706	rs247425	ENSG00000261783.1	RP11-252K23.2	4.07	9.92e-05	0.0445	0.53	0.39	Type 1 diabetes;Type 2 diabetes;	chr16:75426504	chr16:75379818~75381260:-
THYM	cis	rs9309473	0.5	rs10189578	ENSG00000273245.1	RP11-434P11.2	4.07	9.92e-05	0.0445	0.42	0.39	Metabolite levels;	chr2:73501482	chr2:73750256~73750786:-
THYM	cis	rs7223966	0.921	rs2854207	ENSG00000240280.5	TCAM1P	-4.07	9.93e-05	0.0445	-0.57	-0.39	Hip circumference adjusted for BMI;Body mass index;	chr17:63869747	chr17:63849292~63864379:+
THYM	cis	rs4273100	0.831	rs59571799	ENSG00000228157.4	AC007952.5	4.07	9.93e-05	0.0445	0.67	0.39	Schizophrenia;	chr17:19275579	chr17:19092974~19096837:+
THYM	cis	rs4948275	0.693	rs1378889	ENSG00000237233.2	TMEM26-AS1	-4.07	9.93e-05	0.0445	-0.44	-0.39	Night sleep phenotypes;	chr10:61575134	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.693	rs2814031	ENSG00000237233.2	TMEM26-AS1	-4.07	9.93e-05	0.0445	-0.44	-0.39	Night sleep phenotypes;	chr10:61577762	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.693	rs2814028	ENSG00000237233.2	TMEM26-AS1	-4.07	9.93e-05	0.0445	-0.44	-0.39	Night sleep phenotypes;	chr10:61578535	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.693	rs2606103	ENSG00000237233.2	TMEM26-AS1	-4.07	9.93e-05	0.0445	-0.44	-0.39	Night sleep phenotypes;	chr10:61578805	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.658	rs1933444	ENSG00000237233.2	TMEM26-AS1	-4.07	9.93e-05	0.0445	-0.44	-0.39	Night sleep phenotypes;	chr10:61579286	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.693	rs2246190	ENSG00000237233.2	TMEM26-AS1	-4.07	9.93e-05	0.0445	-0.44	-0.39	Night sleep phenotypes;	chr10:61580354	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.693	rs2814033	ENSG00000237233.2	TMEM26-AS1	4.07	9.93e-05	0.0445	0.44	0.39	Night sleep phenotypes;	chr10:61571836	chr10:61452639~61481956:+
THYM	cis	rs4948275	0.693	rs2814027	ENSG00000237233.2	TMEM26-AS1	4.07	9.93e-05	0.0445	0.44	0.39	Night sleep phenotypes;	chr10:61582354	chr10:61452639~61481956:+
THYM	cis	rs4591358	0.678	rs13015934	ENSG00000223466.1	AC064834.2	-4.07	9.93e-05	0.0445	-0.42	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195504897	chr2:195533035~195538681:+
THYM	cis	rs1499614	1	rs34250985	ENSG00000228409.4	CCT6P1	4.07	9.94e-05	0.0445	0.49	0.39	Gout;	chr7:66696075	chr7:65751142~65763354:+
THYM	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	4.07	9.95e-05	0.0445	0.49	0.39	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
THYM	cis	rs910316	1	rs175443	ENSG00000258646.1	RP11-950C14.3	4.07	9.95e-05	0.0446	0.35	0.39	Height;	chr14:75135260	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs175432	ENSG00000258646.1	RP11-950C14.3	4.07	9.95e-05	0.0446	0.35	0.39	Height;	chr14:75148543	chr14:75004719~75008481:-
THYM	cis	rs7937127	0.557	rs113179541	ENSG00000254907.1	RP11-484D2.2	4.07	9.95e-05	0.0446	0.54	0.39	Fibrinogen levels;	chr11:43510640	chr11:43328748~43359296:-
THYM	cis	rs7937127	0.696	rs56388058	ENSG00000254907.1	RP11-484D2.2	4.07	9.95e-05	0.0446	0.54	0.39	Fibrinogen levels;	chr11:43512927	chr11:43328748~43359296:-
THYM	cis	rs12304921	0.683	rs55987825	ENSG00000277201.1	AC087884.1	4.07	9.96e-05	0.0446	0.37	0.39	Type 2 diabetes;	chr12:51049604	chr12:51049921~51050025:+
THYM	cis	rs7077446	0.733	rs3802682	ENSG00000269609.4	RPARP-AS1	4.07	9.96e-05	0.0446	0.29	0.39	Intelligence (multi-trait analysis);	chr10:101961453	chr10:102449817~102461106:+
THYM	cis	rs12188164	0.515	rs11742006	ENSG00000277812.1	AC021087.1	-4.06	9.97e-05	0.0446	-0.59	-0.39	Cystic fibrosis severity;	chr5:408414	chr5:262769~262881:+
THYM	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	4.06	9.98e-05	0.0447	0.48	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
THYM	cis	rs1790761	0.559	rs10896190	ENSG00000231793.4	DOC2GP	-4.06	9.98e-05	0.0447	-0.37	-0.39	Mean corpuscular volume;	chr11:67638652	chr11:67612653~67616257:-
THYM	cis	rs10483853	0.806	rs10146612	ENSG00000258695.2	RP3-414A15.2	-4.06	9.98e-05	0.0447	-0.53	-0.39	Coronary artery calcification;	chr14:73291217	chr14:73522878~73530610:+
THYM	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-4.06	9.98e-05	0.0447	-0.26	-0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
THYM	cis	rs7763358	0.51	rs9369462	ENSG00000271754.1	RP3-337H4.9	-4.06	9.98e-05	0.0447	-0.79	-0.39	Vascular endothelial growth factor levels;	chr6:44173869	chr6:43519180~43519724:-
THYM	cis	rs910316	0.934	rs8016330	ENSG00000258646.1	RP11-950C14.3	4.06	9.99e-05	0.0447	0.34	0.39	Height;	chr14:75190804	chr14:75004719~75008481:-
THYM	cis	rs910316	0.967	rs11624893	ENSG00000258646.1	RP11-950C14.3	4.06	9.99e-05	0.0447	0.34	0.39	Height;	chr14:75193421	chr14:75004719~75008481:-
THYM	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-4.06	1e-04	0.0447	-0.36	-0.39	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-4.06	1e-04	0.0447	-0.36	-0.39	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
THYM	cis	rs9907295	0.688	rs4572457	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35813645	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.581	rs4251751	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35823733	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.748	rs4251752	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35823900	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.71	rs4796113	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35832562	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs4796114	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35832653	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs3785764	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35833760	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.748	rs78672421	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35837325	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.818	rs4796115	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35841315	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.71	rs9894083	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35842151	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs78905197	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs3760326	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35853493	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs9898132	ENSG00000270977.1	AC015849.16	-4.06	1e-04	0.0447	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35869187	chr17:35893707~35911023:-
THYM	cis	rs7210990	0.831	rs178809	ENSG00000275413.1	CTC-529I10.1	4.06	1e-04	0.0447	0.39	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16196459	chr17:16023323~16023653:-
THYM	cis	rs7210990	0.866	rs178805	ENSG00000275413.1	CTC-529I10.1	4.06	1e-04	0.0447	0.39	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16197814	chr17:16023323~16023653:-
THYM	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	4.06	1e-04	0.0447	0.44	0.39	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
THYM	cis	rs2712184	0.756	rs2541388	ENSG00000229352.1	AC007563.3	4.06	1e-04	0.0447	0.46	0.39	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216799561	chr2:216799608~216805335:+
THYM	cis	rs793108	0.742	rs2793109	ENSG00000272381.1	RP11-192P3.4	4.06	1e-04	0.0447	0.33	0.39	Multiple sclerosis;Rheumatoid arthritis;	chr10:31090917	chr10:31187883~31261910:+
THYM	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-4.06	1e-04	0.0447	-0.47	-0.39	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
THYM	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-4.06	1e-04	0.0448	-0.49	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
THYM	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-4.06	1e-04	0.0448	-0.49	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
THYM	cis	rs863345	0.534	rs10797009	ENSG00000236656.1	RP11-144L1.4	4.06	1e-04	0.0448	0.24	0.39	Pneumococcal bacteremia;	chr1:158476258	chr1:158474454~158494886:-
THYM	cis	rs10751647	0.804	rs3809112	ENSG00000255328.1	RP11-326C3.12	-4.06	1e-04	0.0448	-0.26	-0.39	Monocyte count;	chr11:307036	chr11:327171~330122:+
THYM	cis	rs73108077	0.92	rs10084487	ENSG00000277112.2	RP11-755J8.1	-4.06	1e-04	0.0448	-0.63	-0.39	Red blood cell density in sickle cell anemia;	chr20:31425330	chr20:30681825~30723932:-
THYM	cis	rs73108077	1	rs10084488	ENSG00000277112.2	RP11-755J8.1	-4.06	1e-04	0.0448	-0.63	-0.39	Red blood cell density in sickle cell anemia;	chr20:31425366	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.736	rs1997742	ENSG00000277112.2	RP11-755J8.1	-4.06	1e-04	0.0448	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31347432	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.688	rs6058752	ENSG00000277112.2	RP11-755J8.1	-4.06	1e-04	0.0448	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31353900	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.688	rs60840652	ENSG00000277112.2	RP11-755J8.1	-4.06	1e-04	0.0448	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31354399	chr20:30681825~30723932:-
THYM	cis	rs73108077	0.605	rs2143192	ENSG00000277112.2	RP11-755J8.1	-4.06	1e-04	0.0448	-0.51	-0.39	Red blood cell density in sickle cell anemia;	chr20:31364639	chr20:30681825~30723932:-
THYM	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	4.06	1e-04	0.0448	0.5	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
THYM	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-4.06	1e-04	0.0449	-0.54	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
THYM	cis	rs10129255	0.913	rs10140943	ENSG00000253703.1	IGHV1-68	-4.06	1e-04	0.0449	-0.5	-0.39	Kawasaki disease;	chr14:106767441	chr14:106703852~106704146:-
THYM	cis	rs10129255	1	rs10141557	ENSG00000253703.1	IGHV1-68	-4.06	1e-04	0.0449	-0.5	-0.39	Kawasaki disease;	chr14:106767990	chr14:106703852~106704146:-
THYM	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	4.06	1e-04	0.0449	0.48	0.39	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
THYM	cis	rs853679	0.723	rs9366718	ENSG00000216901.1	AL022393.7	4.06	1e-04	0.0449	0.64	0.39	Depression;	chr6:28237724	chr6:28176188~28176674:+
THYM	cis	rs7240205	0.724	rs6508447	ENSG00000275805.1	RP11-349H17.2	4.06	1e-04	0.0449	0.44	0.39	Breast cancer;	chr18:26552657	chr18:26565723~26575626:-
THYM	cis	rs8064024	0.901	rs930855	ENSG00000267077.1	RP11-127I20.5	4.06	1e-04	0.0449	0.42	0.39	Cancer;	chr16:4814178	chr16:4795265~4796532:-
THYM	cis	rs7927592	0.956	rs948315	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0449	0.44	0.39	Total body bone mineral density;	chr11:68541672	chr11:68505572~68505651:-
THYM	cis	rs526231	0.726	rs35800	ENSG00000175749.11	EIF3KP1	4.06	0.000101	0.0449	0.5	0.39	Primary biliary cholangitis;	chr5:103272980	chr5:103032376~103033031:+
THYM	cis	rs7927592	0.871	rs871212	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0449	0.45	0.39	Total body bone mineral density;	chr11:68581227	chr11:68505572~68505651:-
THYM	cis	rs7927592	1	rs7927592	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0449	0.45	0.39	Total body bone mineral density;	chr11:68602492	chr11:68505572~68505651:-
THYM	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	4.06	0.000101	0.045	0.53	0.39	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
THYM	cis	rs3738443	0.868	rs60698393	ENSG00000227671.4	RP11-488L18.4	-4.06	0.000101	0.045	-0.24	-0.39	Alcohol dependence;	chr1:247198135	chr1:247189851~247210856:-
THYM	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	4.06	0.000101	0.045	0.57	0.39	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
THYM	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	-4.06	0.000101	0.045	-0.47	-0.39	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
THYM	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-4.06	0.000101	0.045	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
THYM	cis	rs61160187	0.673	rs4353980	ENSG00000272308.1	RP11-231G3.1	4.06	0.000101	0.045	0.34	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60779501	chr5:60866457~60866935:-
THYM	cis	rs61160187	0.605	rs10068474	ENSG00000272308.1	RP11-231G3.1	4.06	0.000101	0.045	0.34	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782085	chr5:60866457~60866935:-
THYM	cis	rs9402743	0.671	rs4896157	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135620981	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.599	rs6919741	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135622057	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.671	rs9321516	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135622150	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.598	rs7761716	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135623243	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.671	rs7762139	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135623289	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.671	rs7767066	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135623970	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.598	rs9483856	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135624088	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.635	rs9376118	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135624521	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.671	rs742738	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135625301	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.671	rs9402728	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135626450	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.671	rs9373137	ENSG00000236703.1	MYB-AS1	-4.06	0.000101	0.045	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135629059	chr6:135195083~135195995:-
THYM	cis	rs9907295	1	rs11650409	ENSG00000270977.1	AC015849.16	4.06	0.000101	0.045	0.6	0.39	Fibroblast growth factor basic levels;	chr17:35907949	chr17:35893707~35911023:-
THYM	cis	rs972578	0.967	rs7291153	ENSG00000215347.3	SLC25A5P1	-4.06	0.000101	0.045	-0.3	-0.39	Mean platelet volume;	chr22:42960493	chr22:42001069~42001966:-
THYM	cis	rs12803066	0.545	rs12269943	ENSG00000248027.1	CTD-2383M3.1	-4.06	0.000101	0.045	-0.48	-0.39	Myopia (pathological);	chr11:100115832	chr11:100684162~100687955:-
THYM	cis	rs8113308	0.752	rs11879758	ENSG00000269235.1	ZNF350-AS1	4.06	0.000101	0.045	0.42	0.39	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51986911	chr19:51949134~51981367:+
THYM	cis	rs135150	0.588	rs73156461	ENSG00000128254.12	C22orf24	4.06	0.000101	0.0451	0.5	0.39	Blood protein levels;	chr22:32752116	chr22:31933521~31945518:-
THYM	cis	rs295137	0.836	rs1217456	ENSG00000232732.8	AC073043.1	-4.06	0.000101	0.0451	-0.48	-0.39	Asthma (bronchodilator response);	chr2:200227556	chr2:199867396~199911159:-
THYM	cis	rs7631605	0.935	rs6550448	ENSG00000272334.1	RP11-129K12.1	-4.06	0.000101	0.0451	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37067405	chr3:36973117~36973672:-
THYM	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	4.06	0.000101	0.0451	0.37	0.39	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
THYM	cis	rs972578	0.837	rs5758957	ENSG00000215347.3	SLC25A5P1	-4.06	0.000101	0.0451	-0.31	-0.39	Mean platelet volume;	chr22:42822457	chr22:42001069~42001966:-
THYM	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	4.06	0.000101	0.0451	0.52	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
THYM	cis	rs7429990	0.965	rs9846062	ENSG00000199476.1	Y_RNA	-4.06	0.000101	0.0451	-0.52	-0.39	Educational attainment (years of education);	chr3:47957476	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs7649981	ENSG00000199476.1	Y_RNA	-4.06	0.000101	0.0451	-0.52	-0.39	Educational attainment (years of education);	chr3:47957847	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.965	rs2053767	ENSG00000199476.1	Y_RNA	-4.06	0.000101	0.0451	-0.52	-0.39	Educational attainment (years of education);	chr3:47958184	chr3:48288587~48288694:+
THYM	cis	rs7429990	0.93	rs7374516	ENSG00000199476.1	Y_RNA	-4.06	0.000101	0.0451	-0.52	-0.39	Educational attainment (years of education);	chr3:47961150	chr3:48288587~48288694:+
THYM	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	4.06	0.000101	0.0452	0.49	0.39	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
THYM	cis	rs7927592	0.913	rs12272917	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68495902	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs59056571	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68505505	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs66752716	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68506158	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs11228262	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68507439	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs55883802	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68511361	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs11228268	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68519979	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs4084149	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68521099	chr11:68505572~68505651:-
THYM	cis	rs7927592	0.913	rs7925275	ENSG00000222339.1	AP000807.2	4.06	0.000101	0.0452	0.5	0.39	Total body bone mineral density;	chr11:68522965	chr11:68505572~68505651:-
THYM	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.06	0.000101	0.0452	0.52	0.39	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
THYM	cis	rs7182621	0.883	rs10468181	ENSG00000182397.13	DNM1P46	4.06	0.000101	0.0452	0.45	0.39	Colonoscopy-negative controls vs population controls;	chr15:99885244	chr15:99790156~99806927:-
THYM	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	4.06	0.000101	0.0452	0.53	0.39	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
THYM	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-4.06	0.000101	0.0452	-0.6	-0.39	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
THYM	cis	rs4809760	0.687	rs2869935	ENSG00000229222.1	KRT18P4	4.06	0.000101	0.0452	0.49	0.39	Gut microbiota (beta diversity);	chr20:49877390	chr20:49956745~49958032:+
THYM	cis	rs10888838	0.941	rs10888842	ENSG00000198711.5	SSBP3-AS1	4.06	0.000102	0.0453	0.26	0.39	Mitochondrial DNA levels;	chr1:54223229	chr1:54236440~54239063:+
THYM	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-4.06	0.000102	0.0453	-0.31	-0.39	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
THYM	cis	rs889398	0.9	rs4783722	ENSG00000226232.7	RP11-419C5.2	4.06	0.000102	0.0453	0.33	0.39	Body mass index;	chr16:69548009	chr16:69976388~69996188:-
THYM	cis	rs12902680	0.844	rs7169482	ENSG00000259520.4	CTD-2651B20.3	4.06	0.000102	0.0453	0.41	0.39	Neuroticism;	chr15:46055390	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.816	rs12050675	ENSG00000259520.4	CTD-2651B20.3	4.06	0.000102	0.0453	0.41	0.39	Neuroticism;	chr15:46057212	chr15:45251580~45279251:-
THYM	cis	rs10129255	0.957	rs10136560	ENSG00000253703.1	IGHV1-68	-4.06	0.000102	0.0453	-0.5	-0.39	Kawasaki disease;	chr14:106787630	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.957	rs10136817	ENSG00000253703.1	IGHV1-68	-4.06	0.000102	0.0453	-0.5	-0.39	Kawasaki disease;	chr14:106787730	chr14:106703852~106704146:-
THYM	cis	rs4478858	0.735	rs12563669	ENSG00000260386.4	LINC01225	4.06	0.000102	0.0453	0.2	0.39	Alcohol dependence;	chr1:31385220	chr1:31500085~31540885:+
THYM	cis	rs12736701	0.677	rs113097836	ENSG00000226084.5	RP4-706A16.3	4.06	0.000102	0.0453	0.84	0.39	Type 2 diabetes (age of onset);	chr1:77407720	chr1:77129114~77129668:+
THYM	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0453	-0.52	-0.39	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
THYM	cis	rs2834288	0.5	rs7280837	ENSG00000273102.1	AP000569.9	4.06	0.000102	0.0453	0.39	0.39	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33967101~33968573:-
THYM	cis	rs2834288	0.5	rs4817602	ENSG00000273102.1	AP000569.9	4.06	0.000102	0.0453	0.39	0.39	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33967101~33968573:-
THYM	cis	rs12902680	0.739	rs1402117	ENSG00000259520.4	CTD-2651B20.3	4.06	0.000102	0.0453	0.4	0.39	Neuroticism;	chr15:46099221	chr15:45251580~45279251:-
THYM	cis	rs12959333	0.772	rs12964866	ENSG00000274849.1	RP11-49I11.4	-4.06	0.000102	0.0453	-0.61	-0.39	Post bronchodilator FEV1;	chr18:35600051	chr18:36189824~36190272:+
THYM	cis	rs13256369	0.511	rs7012395	ENSG00000253893.2	FAM85B	4.06	0.000102	0.0453	0.55	0.39	Obesity-related traits;	chr8:8680499	chr8:8167819~8226614:-
THYM	cis	rs4835473	0.9	rs13134869	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143782301	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.897	rs12508285	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143792642	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs7667544	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143793802	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs6849896	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143794927	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs6826665	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143795140	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.838	rs35998817	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143795355	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs13134808	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143798339	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.808	rs6831401	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143801038	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.778	rs6853798	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143801153	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs12502940	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143812117	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs12503074	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143812560	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.778	rs2622380	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143814571	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs35792820	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143814806	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.864	rs62337300	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143815897	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs7697498	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143816854	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs7656455	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143817005	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs13133239	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143818894	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs13106488	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143818969	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs13105102	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143819046	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.868	rs13105118	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143819077	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs35271123	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143819629	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs1383443	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143819940	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs7669198	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143821229	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.9	rs6834494	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143822257	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs11734290	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143823636	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs11734383	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143824093	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.868	rs11735295	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143824150	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.868	rs62337303	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143824967	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.838	rs6838981	ENSG00000246448.2	RP13-578N3.3	4.06	0.000102	0.0453	0.49	0.39	Immature fraction of reticulocytes;	chr4:143826484	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.932	rs7670010	ENSG00000246448.2	RP13-578N3.3	-4.06	0.000102	0.0453	-0.49	-0.39	Immature fraction of reticulocytes;	chr4:143821679	chr4:143700257~143865072:+
THYM	cis	rs73198271	0.531	rs3827812	ENSG00000253893.2	FAM85B	4.06	0.000102	0.0454	0.71	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8797388	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs3827810	ENSG00000253893.2	FAM85B	4.06	0.000102	0.0454	0.71	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801530	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs75525911	ENSG00000253893.2	FAM85B	4.06	0.000102	0.0454	0.71	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801849	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs17698256	ENSG00000253893.2	FAM85B	4.06	0.000102	0.0454	0.71	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802103	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs79296712	ENSG00000253893.2	FAM85B	4.06	0.000102	0.0454	0.71	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802468	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs76702427	ENSG00000253893.2	FAM85B	4.06	0.000102	0.0454	0.71	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802631	chr8:8167819~8226614:-
THYM	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	4.06	0.000102	0.0454	0.33	0.39	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
THYM	cis	rs9611519	1	rs5751069	ENSG00000235513.1	RP4-756G23.5	4.06	0.000102	0.0454	0.32	0.39	Neuroticism;	chr22:41231771	chr22:41209122~41217627:-
THYM	cis	rs4835473	0.897	rs36083752	ENSG00000249741.2	RP11-673E1.3	4.06	0.000102	0.0454	0.34	0.39	Immature fraction of reticulocytes;	chr4:143693377	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs35162238	ENSG00000249741.2	RP11-673E1.3	4.06	0.000102	0.0454	0.34	0.39	Immature fraction of reticulocytes;	chr4:143693518	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs1545437	ENSG00000249741.2	RP11-673E1.3	4.06	0.000102	0.0454	0.34	0.39	Immature fraction of reticulocytes;	chr4:143696689	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.864	rs61427459	ENSG00000249741.2	RP11-673E1.3	4.06	0.000102	0.0454	0.34	0.39	Immature fraction of reticulocytes;	chr4:143699605	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs11100802	ENSG00000249741.2	RP11-673E1.3	4.06	0.000102	0.0454	0.34	0.39	Immature fraction of reticulocytes;	chr4:143700046	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs7657088	ENSG00000249741.2	RP11-673E1.3	4.06	0.000102	0.0454	0.34	0.39	Immature fraction of reticulocytes;	chr4:143701877	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.863	rs7696828	ENSG00000249741.2	RP11-673E1.3	-4.06	0.000102	0.0454	-0.34	-0.39	Immature fraction of reticulocytes;	chr4:143700846	chr4:143911514~143912053:-
THYM	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	4.06	0.000102	0.0454	0.44	0.39	Height;	chr6:109375003	chr6:109382795~109383666:+
THYM	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
THYM	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	4.06	0.000102	0.0454	0.51	0.39	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
THYM	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-4.06	0.000102	0.0454	-0.51	-0.39	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
THYM	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	4.06	0.000102	0.0454	0.54	0.39	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
THYM	cis	rs926326	0.774	rs1883259	ENSG00000219682.4	RP3-425P12.4	-4.06	0.000102	0.0455	-0.56	-0.39	Platelet count;	chr6:25683052	chr6:25140003~25141403:+
THYM	cis	rs17253792	0.822	rs74720318	ENSG00000186615.9	KTN1-AS1	-4.06	0.000102	0.0455	-0.71	-0.39	Putamen volume;	chr14:55633110	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75509578	ENSG00000186615.9	KTN1-AS1	-4.06	0.000102	0.0455	-0.71	-0.39	Putamen volume;	chr14:55666775	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs11546	ENSG00000186615.9	KTN1-AS1	-4.06	0.000102	0.0455	-0.71	-0.39	Putamen volume;	chr14:55679639	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10148122	ENSG00000186615.9	KTN1-AS1	-4.06	0.000102	0.0455	-0.71	-0.39	Putamen volume;	chr14:55679976	chr14:55499278~55580110:-
THYM	cis	rs61160187	0.673	rs6874699	ENSG00000272308.1	RP11-231G3.1	4.06	0.000102	0.0455	0.34	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60778173	chr5:60866457~60866935:-
THYM	cis	rs957448	0.561	rs4735302	ENSG00000253704.1	RP11-267M23.4	-4.06	0.000102	0.0455	-0.48	-0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94553722~94569745:+
THYM	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-4.06	0.000102	0.0455	-0.46	-0.39	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
THYM	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-4.06	0.000102	0.0455	-0.49	-0.39	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
THYM	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-4.06	0.000102	0.0455	-0.49	-0.39	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
THYM	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-4.06	0.000102	0.0455	-0.49	-0.39	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
THYM	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-4.06	0.000102	0.0455	-0.41	-0.39	Migraine;	chr4:56852029	chr4:56960927~56961373:-
THYM	cis	rs1910358	0.515	rs10068750	ENSG00000248874.4	C5orf17	4.06	0.000102	0.0455	0.53	0.39	Venous thromboembolism (SNP x SNP interaction);	chr5:23724183	chr5:23951348~24178263:+
THYM	cis	rs7631605	0.905	rs11717310	ENSG00000272334.1	RP11-129K12.1	-4.06	0.000103	0.0455	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37133659	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.87	rs6775008	ENSG00000272334.1	RP11-129K12.1	-4.06	0.000103	0.0455	-0.4	-0.39	Cerebrospinal P-tau181p levels;	chr3:37137540	chr3:36973117~36973672:-
THYM	cis	rs26949	0.554	rs11742421	ENSG00000272308.1	RP11-231G3.1	-4.06	0.000103	0.0455	-0.32	-0.39	Intelligence (multi-trait analysis);	chr5:60681590	chr5:60866457~60866935:-
THYM	cis	rs3796619	1	rs4974601	ENSG00000215367.9	TMED11P	4.06	0.000103	0.0455	0.37	0.39	Recombination rate (males);	chr4:1101622	chr4:1115197~1153726:-
THYM	cis	rs4239252	0.725	rs1994182	ENSG00000270977.1	AC015849.16	4.06	0.000103	0.0455	0.47	0.39	Blood protein levels;	chr17:35760685	chr17:35893707~35911023:-
THYM	cis	rs1023500	0.505	rs134901	ENSG00000227370.1	RP4-669P10.19	4.06	0.000103	0.0455	0.45	0.39	Schizophrenia;	chr22:42287514	chr22:42132543~42132998:+
THYM	cis	rs4591358	0.773	rs35261538	ENSG00000223466.1	AC064834.2	-4.06	0.000103	0.0456	-0.42	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509681	chr2:195533035~195538681:+
THYM	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	4.06	0.000103	0.0456	0.47	0.39	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
THYM	cis	rs910316	0.737	rs175510	ENSG00000258646.1	RP11-950C14.3	4.06	0.000103	0.0456	0.35	0.39	Height;	chr14:75058136	chr14:75004719~75008481:-
THYM	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-4.06	0.000103	0.0456	-0.58	-0.39	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
THYM	cis	rs4853012	0.941	rs2421752	ENSG00000272183.1	RP11-523H20.3	4.06	0.000103	0.0456	0.54	0.39	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74501717~74502365:+
THYM	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	4.06	0.000103	0.0456	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
THYM	cis	rs7560272	0.501	rs7210	ENSG00000163016.8	ALMS1P	-4.06	0.000103	0.0456	-0.46	-0.39	Schizophrenia;	chr2:73729997	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.501	rs2272178	ENSG00000163016.8	ALMS1P	-4.06	0.000103	0.0456	-0.46	-0.39	Schizophrenia;	chr2:73750482	chr2:73644919~73685576:+
THYM	cis	rs7560272	0.501	rs12713798	ENSG00000163016.8	ALMS1P	-4.06	0.000103	0.0456	-0.46	-0.39	Schizophrenia;	chr2:73759294	chr2:73644919~73685576:+
THYM	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	4.06	0.000103	0.0457	0.46	0.39	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
THYM	cis	rs60180747	0.544	rs11630157	ENSG00000261318.1	RP11-653J6.1	4.06	0.000103	0.0457	0.42	0.39	Testicular germ cell tumor;	chr15:66261087	chr15:66278498~66293357:-
THYM	cis	rs60180747	0.544	rs11637318	ENSG00000261318.1	RP11-653J6.1	4.06	0.000103	0.0457	0.42	0.39	Testicular germ cell tumor;	chr15:66266317	chr15:66278498~66293357:-
THYM	cis	rs60180747	0.544	rs11638535	ENSG00000261318.1	RP11-653J6.1	4.06	0.000103	0.0457	0.42	0.39	Testicular germ cell tumor;	chr15:66266923	chr15:66278498~66293357:-
THYM	cis	rs60180747	0.544	rs11632542	ENSG00000261318.1	RP11-653J6.1	-4.06	0.000103	0.0457	-0.42	-0.39	Testicular germ cell tumor;	chr15:66267733	chr15:66278498~66293357:-
THYM	cis	rs60180747	0.544	rs11633568	ENSG00000261318.1	RP11-653J6.1	4.06	0.000103	0.0457	0.42	0.39	Testicular germ cell tumor;	chr15:66272068	chr15:66278498~66293357:-
THYM	cis	rs8014252	1	rs1953802	ENSG00000259158.2	ADAM20P1	-4.06	0.000103	0.0457	-0.4	-0.39	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70497091	chr14:70468881~70483756:-
THYM	cis	rs2562456	0.833	rs2562507	ENSG00000268081.1	RP11-678G14.2	-4.06	0.000103	0.0457	-0.48	-0.39	Pain;	chr19:21543535	chr19:21554640~21569237:-
THYM	cis	rs9402743	0.671	rs9399151	ENSG00000236703.1	MYB-AS1	-4.06	0.000103	0.0457	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135617920	chr6:135195083~135195995:-
THYM	cis	rs9402743	0.671	rs9376116	ENSG00000236703.1	MYB-AS1	-4.06	0.000103	0.0457	-0.26	-0.39	Systemic lupus erythematosus;	chr6:135618763	chr6:135195083~135195995:-
THYM	cis	rs34773007	0.514	rs6583840	ENSG00000272817.1	RP11-402D21.2	4.06	0.000103	0.0457	0.46	0.39	Type 2 diabetes;	chr10:92782827	chr10:91908131~91909348:+
THYM	cis	rs1800932	0.512	rs78861659	ENSG00000233230.1	AC079807.2	4.06	0.000103	0.0457	0.33	0.39	Menopause (age at onset);	chr2:47768110	chr2:47905678~47907810:+
THYM	cis	rs1910358	0.554	rs10057796	ENSG00000248874.4	C5orf17	4.06	0.000103	0.0458	0.52	0.39	Venous thromboembolism (SNP x SNP interaction);	chr5:23759637	chr5:23951348~24178263:+
THYM	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	4.06	0.000103	0.0458	0.53	0.39	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
THYM	cis	rs3738443	0.83	rs6684181	ENSG00000227671.4	RP11-488L18.4	-4.05	0.000103	0.0458	-0.24	-0.39	Alcohol dependence;	chr1:247184669	chr1:247189851~247210856:-
THYM	cis	rs995758	0.967	rs6831503	ENSG00000236296.6	GUSBP5	4.05	0.000103	0.0458	0.44	0.39	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144550793	chr4:143559472~143649305:+
THYM	cis	rs17253792	0.822	rs10151664	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.72	-0.39	Putamen volume;	chr14:55562815	chr14:55499278~55580110:-
THYM	cis	rs61160187	0.673	rs10062240	ENSG00000272308.1	RP11-231G3.1	4.05	0.000104	0.0459	0.33	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782585	chr5:60866457~60866935:-
THYM	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	4.05	0.000104	0.0459	0.46	0.39	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
THYM	cis	rs2243480	1	rs55895244	ENSG00000228409.4	CCT6P1	4.05	0.000104	0.0459	0.48	0.39	Diabetic kidney disease;	chr7:65922691	chr7:65751142~65763354:+
THYM	cis	rs6121246	0.559	rs6058468	ENSG00000230613.1	HM13-AS1	4.05	0.000104	0.0459	0.55	0.39	Mean corpuscular hemoglobin;	chr20:31818645	chr20:31567707~31573263:-
THYM	cis	rs2115536	0.967	rs934137	ENSG00000278600.1	RP11-81A1.6	-4.05	0.000104	0.0459	-0.29	-0.39	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79919426	chr15:79920195~79922455:-
THYM	cis	rs17253792	0.822	rs75351812	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55615474	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28831725	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55620851	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs113350960	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55620995	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77544029	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55621199	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28754619	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55621676	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.732	rs28380739	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55621684	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28681420	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55621685	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10483643	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55623213	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79921041	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55624061	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75897560	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55624247	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28549152	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55624521	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs10147431	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55625123	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75663029	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55625667	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75991559	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55625701	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79262019	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55625986	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79024594	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55626279	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28392709	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55626967	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs79618862	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55627253	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs28513551	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55628275	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs74824071	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55628424	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs80085988	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55629455	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs77676035	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55629511	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs75555677	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55629711	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs2274075	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55630013	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.731	rs28587929	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55630774	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs9323289	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55640066	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs2296181	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55640333	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.822	rs17747083	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55643876	chr14:55499278~55580110:-
THYM	cis	rs17253792	0.731	rs74829671	ENSG00000186615.9	KTN1-AS1	-4.05	0.000104	0.0459	-0.71	-0.39	Putamen volume;	chr14:55646041	chr14:55499278~55580110:-
THYM	cis	rs889398	0.738	rs7196842	ENSG00000226232.7	RP11-419C5.2	-4.05	0.000104	0.0459	-0.36	-0.39	Body mass index;	chr16:69889430	chr16:69976388~69996188:-
THYM	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	4.05	0.000104	0.0459	0.3	0.39	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	4.05	0.000104	0.0459	0.3	0.39	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
THYM	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	4.05	0.000104	0.0459	0.3	0.39	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
THYM	cis	rs35888008	1	rs4785291	ENSG00000261267.1	RP11-44I10.3	4.05	0.000104	0.0459	0.49	0.39	Major depressive disorder;	chr16:49418706	chr16:48559661~48587403:+
THYM	cis	rs10975370	0.887	rs10815304	ENSG00000272866.1	RP11-12D24.10	-4.05	0.000104	0.046	-0.51	-0.39	Breast cancer;	chr9:5908217	chr9:5351796~5352410:-
THYM	cis	rs7789940	0.81	rs12533978	ENSG00000205583.12	STAG3L1	-4.05	0.000104	0.046	-0.32	-0.39	Multiple sclerosis;	chr7:76314035	chr7:75359194~75395383:+
THYM	cis	rs7789940	0.904	rs6953281	ENSG00000205583.12	STAG3L1	-4.05	0.000104	0.046	-0.32	-0.39	Multiple sclerosis;	chr7:76317626	chr7:75359194~75395383:+
THYM	cis	rs7789940	0.951	rs7787526	ENSG00000205583.12	STAG3L1	-4.05	0.000104	0.046	-0.32	-0.39	Multiple sclerosis;	chr7:76318236	chr7:75359194~75395383:+
THYM	cis	rs56804039	1	rs17616779	ENSG00000253893.2	FAM85B	-4.05	0.000104	0.046	-0.56	-0.39	Cervical cancer;	chr8:8524864	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs67180327	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8523244	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs67611618	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8523429	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs58361948	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8523485	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs56804039	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8523519	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs6986470	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8523920	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs7017341	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8524154	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs59620654	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8525122	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs34154295	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8525967	chr8:8167819~8226614:-
THYM	cis	rs56804039	1	rs11777086	ENSG00000253893.2	FAM85B	4.05	0.000104	0.046	0.56	0.39	Cervical cancer;	chr8:8526969	chr8:8167819~8226614:-
THYM	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	4.05	0.000104	0.046	0.49	0.39	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
THYM	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-4.05	0.000104	0.046	-0.49	-0.39	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
THYM	cis	rs756777	1	rs756777	ENSG00000273473.1	LL09NC01-139C3.1	-4.05	0.000104	0.046	-0.32	-0.39	IgG glycosylation;	chr9:133813958	chr9:134168769~134169340:+
THYM	cis	rs990871	1	rs11209943	ENSG00000227207.2	RPL31P12	-4.05	0.000104	0.046	-0.55	-0.39	Subcutaneous adipose tissue;	chr1:72284817	chr1:72301472~72301829:+
THYM	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
THYM	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-4.05	0.000104	0.046	-0.5	-0.39	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-4.05	0.000104	0.046	-0.5	-0.39	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
THYM	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	4.05	0.000104	0.046	0.5	0.39	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
THYM	cis	rs4842666	0.915	rs73437358	ENSG00000258302.2	RP11-981P6.1	4.05	0.000104	0.046	0.41	0.39	Blood pressure;	chr12:89678299	chr12:89561129~89594878:+
THYM	cis	rs11157436	0.602	rs2075492	ENSG00000211813.2	TRAV34	4.05	0.000104	0.046	0.27	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163321	chr14:22207522~22208129:+
THYM	cis	rs1800932	0.512	rs78294774	ENSG00000233230.1	AC079807.2	4.05	0.000104	0.046	0.34	0.39	Menopause (age at onset);	chr2:47765542	chr2:47905678~47907810:+
THYM	cis	rs7312933	0.533	rs3747557	ENSG00000257225.1	RP11-328C8.4	4.05	0.000104	0.046	0.44	0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42324159	chr12:42459366~42466128:+
THYM	cis	rs7312933	0.558	rs11181422	ENSG00000257225.1	RP11-328C8.4	4.05	0.000104	0.046	0.44	0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42324750	chr12:42459366~42466128:+
THYM	cis	rs7312933	0.558	rs3747560	ENSG00000257225.1	RP11-328C8.4	4.05	0.000104	0.046	0.44	0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42326088	chr12:42459366~42466128:+
THYM	cis	rs7312933	0.531	rs2406674	ENSG00000257225.1	RP11-328C8.4	4.05	0.000104	0.046	0.44	0.39	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42326348	chr12:42459366~42466128:+
THYM	cis	rs35888008	1	rs2356265	ENSG00000261267.1	RP11-44I10.3	4.05	0.000104	0.046	0.49	0.39	Major depressive disorder;	chr16:49416136	chr16:48559661~48587403:+
THYM	cis	rs11157436	0.602	rs12587826	ENSG00000211813.2	TRAV34	4.05	0.000104	0.046	0.27	0.39	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22207522~22208129:+
THYM	cis	rs9834970	0.787	rs11129735	ENSG00000234073.1	AC011816.1	-4.05	0.000104	0.0461	-0.39	-0.39	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36828739	chr3:36880184~36880729:-
THYM	cis	rs863345	0.604	rs11265009	ENSG00000236656.1	RP11-144L1.4	4.05	0.000104	0.0461	0.25	0.39	Pneumococcal bacteremia;	chr1:158528982	chr1:158474454~158494886:-
THYM	cis	rs1529093	0.666	rs6712636	ENSG00000222043.2	AC079305.10	4.05	0.000104	0.0461	0.34	0.39	Non-alcoholic fatty liver disease histology (other);	chr2:177041584	chr2:177264359~177265515:+
THYM	cis	rs17685	0.753	rs1637045	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76074577	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs4398845	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76087463	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs4732578	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76092214	chr7:76043977~76045963:-
THYM	cis	rs17685	0.587	rs1623759	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76095361	chr7:76043977~76045963:-
THYM	cis	rs17685	0.625	rs1639630	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76101181	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs1637051	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76101341	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs4573217	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76104628	chr7:76043977~76045963:-
THYM	cis	rs17685	0.784	rs1613890	ENSG00000280388.1	RP11-229D13.3	-4.05	0.000104	0.0461	-0.4	-0.39	Coffee consumption (cups per day);Coffee consumption;	chr7:76105719	chr7:76043977~76045963:-
THYM	cis	rs7210990	0.661	rs1079534	ENSG00000275413.1	CTC-529I10.1	4.05	0.000105	0.0461	0.39	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16045819	chr17:16023323~16023653:-
THYM	cis	rs2562456	0.876	rs62110202	ENSG00000268081.1	RP11-678G14.2	4.05	0.000105	0.0461	0.5	0.39	Pain;	chr19:21571799	chr19:21554640~21569237:-
THYM	cis	rs7631605	1	rs4647277	ENSG00000272334.1	RP11-129K12.1	-4.05	0.000105	0.0462	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37017018	chr3:36973117~36973672:-
THYM	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	4.05	0.000105	0.0462	0.31	0.39	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
THYM	cis	rs718433	0.617	rs2293708	ENSG00000211845.1	TRAJ44	-4.05	0.000105	0.0462	-0.44	-0.39	Intraocular pressure;	chr14:21862976	chr14:22494821~22494883:+
THYM	cis	rs728616	0.558	rs61859215	ENSG00000242600.5	MBL1P	4.05	0.000105	0.0462	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391392	chr10:79904898~79950336:+
THYM	cis	rs728616	0.558	rs72817596	ENSG00000242600.5	MBL1P	4.05	0.000105	0.0462	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391838	chr10:79904898~79950336:+
THYM	cis	rs728616	0.558	rs12772945	ENSG00000242600.5	MBL1P	4.05	0.000105	0.0462	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80394740	chr10:79904898~79950336:+
THYM	cis	rs728616	0.558	rs12414691	ENSG00000242600.5	MBL1P	4.05	0.000105	0.0462	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79904898~79950336:+
THYM	cis	rs728616	0.558	rs12767261	ENSG00000242600.5	MBL1P	4.05	0.000105	0.0462	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79904898~79950336:+
THYM	cis	rs728616	0.558	rs2343302	ENSG00000242600.5	MBL1P	4.05	0.000105	0.0462	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79904898~79950336:+
THYM	cis	rs728616	0.558	rs2880599	ENSG00000242600.5	MBL1P	4.05	0.000105	0.0462	0.5	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79904898~79950336:+
THYM	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-4.05	0.000105	0.0462	-0.43	-0.39	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
THYM	cis	rs7631605	0.905	rs3774339	ENSG00000272334.1	RP11-129K12.1	4.05	0.000105	0.0462	0.39	0.39	Cerebrospinal P-tau181p levels;	chr3:37021363	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs2286939	ENSG00000272334.1	RP11-129K12.1	-4.05	0.000105	0.0462	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37020549	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs3774338	ENSG00000272334.1	RP11-129K12.1	-4.05	0.000105	0.0462	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37021468	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.905	rs6550445	ENSG00000272334.1	RP11-129K12.1	-4.05	0.000105	0.0462	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37024878	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs6550447	ENSG00000272334.1	RP11-129K12.1	-4.05	0.000105	0.0462	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37036789	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs7639375	ENSG00000272334.1	RP11-129K12.1	-4.05	0.000105	0.0462	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37065531	chr3:36973117~36973672:-
THYM	cis	rs11633886	0.585	rs12915664	ENSG00000273972.1	CTD-2306A12.1	4.05	0.000105	0.0462	0.47	0.39	Diisocyanate-induced asthma;	chr15:45787855	chr15:45702640~45703183:+
THYM	cis	rs2282300	0.667	rs10734405	ENSG00000254532.1	RP11-624D11.2	-4.05	0.000105	0.0462	-0.58	-0.39	Morning vs. evening chronotype;	chr11:30252203	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs7925340	ENSG00000254532.1	RP11-624D11.2	-4.05	0.000105	0.0462	-0.58	-0.39	Morning vs. evening chronotype;	chr11:30258861	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.702	rs4379811	ENSG00000254532.1	RP11-624D11.2	-4.05	0.000105	0.0462	-0.58	-0.39	Morning vs. evening chronotype;	chr11:30273213	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs3858428	ENSG00000254532.1	RP11-624D11.2	-4.05	0.000105	0.0462	-0.58	-0.39	Morning vs. evening chronotype;	chr11:30275003	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs6484478	ENSG00000254532.1	RP11-624D11.2	-4.05	0.000105	0.0462	-0.58	-0.39	Morning vs. evening chronotype;	chr11:30284893	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs10742237	ENSG00000254532.1	RP11-624D11.2	-4.05	0.000105	0.0462	-0.58	-0.39	Morning vs. evening chronotype;	chr11:30289112	chr11:30044058~30084343:-
THYM	cis	rs2282300	0.739	rs1933343	ENSG00000254532.1	RP11-624D11.2	-4.05	0.000105	0.0462	-0.58	-0.39	Morning vs. evening chronotype;	chr11:30289445	chr11:30044058~30084343:-
THYM	cis	rs3781264	1	rs10509671	ENSG00000273450.1	RP11-76P2.4	4.05	0.000105	0.0463	0.47	0.39	Esophageal cancer and gastric cancer;	chr10:94309297	chr10:94314907~94315327:-
THYM	cis	rs897984	0.647	rs8060857	ENSG00000275263.1	RP11-1072A3.4	4.05	0.000105	0.0463	0.34	0.39	Dementia with Lewy bodies;	chr16:30991399	chr16:30956872~30957199:-
THYM	cis	rs11891401	1	rs12995799	ENSG00000277998.1	RP11-452N17.1	-4.05	0.000105	0.0463	-0.48	-0.39	Blood pressure;	chr2:164233880	chr2:164573741~164574054:+
THYM	cis	rs12681366	0.564	rs2165405	ENSG00000253704.1	RP11-267M23.4	4.05	0.000105	0.0463	0.47	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94442079	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs3019284	ENSG00000253704.1	RP11-267M23.4	4.05	0.000105	0.0463	0.47	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94460848	chr8:94553722~94569745:+
THYM	cis	rs12681366	0.537	rs10095298	ENSG00000253704.1	RP11-267M23.4	4.05	0.000105	0.0463	0.47	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94472353	chr8:94553722~94569745:+
THYM	cis	rs11098499	0.69	rs7674713	ENSG00000250412.1	KLHL2P1	4.05	0.000105	0.0463	0.36	0.39	Corneal astigmatism;	chr4:119401102	chr4:119334329~119378233:+
THYM	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	4.05	0.000105	0.0464	0.44	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
THYM	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	4.05	0.000105	0.0464	0.27	0.39	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
THYM	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-4.05	0.000105	0.0464	-0.53	-0.39	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
THYM	cis	rs4948275	0.773	rs2100559	ENSG00000237233.2	TMEM26-AS1	-4.05	0.000105	0.0464	-0.44	-0.39	Night sleep phenotypes;	chr10:61528566	chr10:61452639~61481956:+
THYM	cis	rs4342066	0.732	rs34463163	ENSG00000225548.4	AC098973.2	-4.05	0.000105	0.0464	-0.39	-0.39	Colonoscopy-negative controls vs population controls;	chr3:28303421	chr3:27802762~27891301:+
THYM	cis	rs4342066	0.696	rs13099977	ENSG00000225548.4	AC098973.2	-4.05	0.000105	0.0464	-0.39	-0.39	Colonoscopy-negative controls vs population controls;	chr3:28307167	chr3:27802762~27891301:+
THYM	cis	rs3781264	0.848	rs6583934	ENSG00000273450.1	RP11-76P2.4	4.05	0.000105	0.0464	0.46	0.39	Esophageal cancer and gastric cancer;	chr10:94309648	chr10:94314907~94315327:-
THYM	cis	rs2929278	0.617	rs11070410	ENSG00000166763.7	STRCP1	-4.05	0.000105	0.0464	-0.43	-0.39	Schizophrenia;	chr15:43764847	chr15:43699488~43718184:-
THYM	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	4.05	0.000106	0.0465	0.53	0.39	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
THYM	cis	rs2115536	0.692	rs6495451	ENSG00000278600.1	RP11-81A1.6	-4.05	0.000106	0.0465	-0.31	-0.39	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79871711	chr15:79920195~79922455:-
THYM	cis	rs7208859	0.673	rs11656462	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs11655623	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs11654331	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs73277960	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs73277964	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs11652409	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9896095	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs58920731	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs73277984	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs73277986	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs12103588	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.614	rs9914534	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs4131618	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs11658344	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs9900144	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.573	rs11656121	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs11650973	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.623	rs73263788	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs56085216	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs12949860	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs11650305	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs11654914	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs9914271	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30792372~30792833:+
THYM	cis	rs7208859	0.673	rs75142521	ENSG00000266490.1	CTD-2349P21.9	4.05	0.000106	0.0465	0.66	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30792372~30792833:+
THYM	cis	rs853679	0.666	rs200956	ENSG00000182477.5	OR2B8P	4.05	0.000106	0.0465	0.63	0.39	Depression;	chr6:27871968	chr6:28053228~28054165:-
THYM	cis	rs73198271	1	rs4840356	ENSG00000253893.2	FAM85B	4.05	0.000106	0.0465	0.59	0.39	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750017	chr8:8167819~8226614:-
THYM	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-4.05	0.000106	0.0465	-0.49	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
THYM	cis	rs10888838	1	rs10888838	ENSG00000198711.5	SSBP3-AS1	4.05	0.000106	0.0465	0.26	0.39	Mitochondrial DNA levels;	chr1:54207424	chr1:54236440~54239063:+
THYM	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	4.05	0.000106	0.0465	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
THYM	cis	rs910316	0.763	rs12588981	ENSG00000258646.1	RP11-950C14.3	-4.05	0.000106	0.0466	-0.34	-0.39	Height;	chr14:74993858	chr14:75004719~75008481:-
THYM	cis	rs1894633	0.519	rs17368942	ENSG00000225704.2	RP4-798A17.5	4.05	0.000106	0.0466	0.64	0.39	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:172338538	chr1:171345089~171345320:+
THYM	cis	rs1894633	0.574	rs61806074	ENSG00000225704.2	RP4-798A17.5	4.05	0.000106	0.0466	0.64	0.39	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:172342059	chr1:171345089~171345320:+
THYM	cis	rs7560272	0.723	rs1052161	ENSG00000273245.1	RP11-434P11.2	4.05	0.000106	0.0466	0.44	0.39	Schizophrenia;	chr2:73601411	chr2:73750256~73750786:-
THYM	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	4.05	0.000106	0.0466	0.53	0.39	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
THYM	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	4.05	0.000106	0.0466	0.5	0.39	Pain;	chr19:21567846	chr19:21554640~21569237:-
THYM	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	4.05	0.000106	0.0466	0.42	0.39	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
THYM	cis	rs758747	0.626	rs7200737	ENSG00000276754.1	RP11-461A8.5	4.05	0.000106	0.0466	0.47	0.39	Body mass index;	chr16:3661655	chr16:3686998~3687380:+
THYM	cis	rs9813712	0.571	rs9846596	ENSG00000228252.7	COL6A4P2	-4.05	0.000106	0.0466	-0.43	-0.39	Response to amphetamines;	chr3:130288318	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.595	rs1453239	ENSG00000228252.7	COL6A4P2	-4.05	0.000106	0.0466	-0.43	-0.39	Response to amphetamines;	chr3:130288915	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.523	rs9866942	ENSG00000228252.7	COL6A4P2	-4.05	0.000106	0.0466	-0.43	-0.39	Response to amphetamines;	chr3:130297796	chr3:130212823~130273806:+
THYM	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-4.05	0.000106	0.0466	-0.38	-0.39	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
THYM	cis	rs877819	0.552	rs2127586	ENSG00000228403.1	RP11-563N6.6	-4.05	0.000106	0.0466	-0.51	-0.39	Systemic lupus erythematosus;	chr10:48871605	chr10:48878022~48878649:+
THYM	cis	rs910316	0.591	rs7157158	ENSG00000258646.1	RP11-950C14.3	-4.05	0.000106	0.0467	-0.34	-0.39	Height;	chr14:74990535	chr14:75004719~75008481:-
THYM	cis	rs877819	0.583	rs2663049	ENSG00000228403.1	RP11-563N6.6	-4.05	0.000106	0.0467	-0.49	-0.39	Systemic lupus erythematosus;	chr10:48858716	chr10:48878022~48878649:+
THYM	cis	rs4591358	0.773	rs17781713	ENSG00000223466.1	AC064834.2	-4.05	0.000106	0.0467	-0.41	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506827	chr2:195533035~195538681:+
THYM	cis	rs4591358	0.773	rs17781737	ENSG00000223466.1	AC064834.2	-4.05	0.000106	0.0467	-0.41	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508251	chr2:195533035~195538681:+
THYM	cis	rs3738443	0.868	rs7546908	ENSG00000227671.4	RP11-488L18.4	4.05	0.000106	0.0467	0.24	0.39	Alcohol dependence;	chr1:247200531	chr1:247189851~247210856:-
THYM	cis	rs3738443	0.868	rs61840048	ENSG00000227671.4	RP11-488L18.4	-4.05	0.000106	0.0467	-0.24	-0.39	Alcohol dependence;	chr1:247199829	chr1:247189851~247210856:-
THYM	cis	rs889398	0.967	rs12599391	ENSG00000226232.7	RP11-419C5.2	-4.05	0.000106	0.0467	-0.34	-0.39	Body mass index;	chr16:69571446	chr16:69976388~69996188:-
THYM	cis	rs889398	0.933	rs244418	ENSG00000226232.7	RP11-419C5.2	4.05	0.000106	0.0467	0.34	0.39	Body mass index;	chr16:69588859	chr16:69976388~69996188:-
THYM	cis	rs889398	0.869	rs862320	ENSG00000226232.7	RP11-419C5.2	4.05	0.000106	0.0467	0.34	0.39	Body mass index;	chr16:69617963	chr16:69976388~69996188:-
THYM	cis	rs889398	0.935	rs244420	ENSG00000226232.7	RP11-419C5.2	4.05	0.000106	0.0467	0.34	0.39	Body mass index;	chr16:69624093	chr16:69976388~69996188:-
THYM	cis	rs889398	0.967	rs244417	ENSG00000226232.7	RP11-419C5.2	4.05	0.000106	0.0467	0.34	0.39	Body mass index;	chr16:69629616	chr16:69976388~69996188:-
THYM	cis	rs889398	0.967	rs244415	ENSG00000226232.7	RP11-419C5.2	4.05	0.000106	0.0467	0.34	0.39	Body mass index;	chr16:69632780	chr16:69976388~69996188:-
THYM	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	4.05	0.000106	0.0467	0.49	0.39	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
THYM	cis	rs6687758	1	rs12125383	ENSG00000229399.1	RP11-378J18.6	-4.05	0.000106	0.0467	-0.74	-0.39	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221995092	chr1:222641414~222641858:-
THYM	cis	rs9907295	0.748	rs4795091	ENSG00000270977.1	AC015849.16	-4.05	0.000106	0.0467	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35814874	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.71	rs4795092	ENSG00000270977.1	AC015849.16	-4.05	0.000106	0.0467	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35814967	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.901	rs4251729	ENSG00000270977.1	AC015849.16	-4.05	0.000106	0.0467	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35818348	chr17:35893707~35911023:-
THYM	cis	rs9907295	0.605	rs11652192	ENSG00000270977.1	AC015849.16	-4.05	0.000106	0.0467	-0.66	-0.39	Fibroblast growth factor basic levels;	chr17:35833174	chr17:35893707~35911023:-
THYM	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	4.05	0.000106	0.0467	0.29	0.39	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
THYM	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-4.05	0.000106	0.0467	-0.65	-0.39	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
THYM	cis	rs6545883	0.525	rs1729658	ENSG00000273302.1	RP11-493E12.2	4.05	0.000106	0.0468	0.37	0.39	Tuberculosis;	chr2:61146385	chr2:61199979~61200769:+
THYM	cis	rs1030877	0.515	rs17030766	ENSG00000235319.1	AC012360.4	4.05	0.000106	0.0468	0.57	0.39	Obesity-related traits;	chr2:105295448	chr2:105324210~105330529:+
THYM	cis	rs4737732	0.515	rs13282490	ENSG00000254006.4	RP11-1D12.2	4.05	0.000106	0.0468	0.39	0.39	Stem cell growth factor beta levels;	chr8:65407952	chr8:64801236~64817573:-
THYM	cis	rs4737732	0.515	rs11780426	ENSG00000254006.4	RP11-1D12.2	4.05	0.000106	0.0468	0.39	0.39	Stem cell growth factor beta levels;	chr8:65411125	chr8:64801236~64817573:-
THYM	cis	rs8177876	0.597	rs2317085	ENSG00000261838.4	RP11-303E16.6	-4.05	0.000106	0.0468	-0.9	-0.39	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104460	chr16:81069854~81076598:+
THYM	cis	rs9309473	0.519	rs13009035	ENSG00000273245.1	RP11-434P11.2	-4.05	0.000107	0.0468	-0.44	-0.39	Metabolite levels;	chr2:73618582	chr2:73750256~73750786:-
THYM	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	4.05	0.000107	0.0468	0.6	0.39	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
THYM	cis	rs12304921	0.683	rs17125286	ENSG00000277201.1	AC087884.1	4.05	0.000107	0.0469	0.36	0.39	Type 2 diabetes;	chr12:51060427	chr12:51049921~51050025:+
THYM	cis	rs495337	0.965	rs12151879	ENSG00000229222.1	KRT18P4	-4.05	0.000107	0.0469	-0.44	-0.39	Psoriasis;	chr20:49932705	chr20:49956745~49958032:+
THYM	cis	rs495337	1	rs4287819	ENSG00000229222.1	KRT18P4	-4.05	0.000107	0.0469	-0.44	-0.39	Psoriasis;	chr20:49935419	chr20:49956745~49958032:+
THYM	cis	rs79600951	1	rs16962014	ENSG00000205361.7	MT1DP	-4.05	0.000107	0.047	-0.76	-0.39	HDL cholesterol;	chr16:56786007	chr16:56643705~56644786:+
THYM	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-4.05	0.000107	0.047	-0.34	-0.39	Breast cancer;	chr11:825777	chr11:777578~784297:+
THYM	cis	rs4835473	0.932	rs2127788	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143741996	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6852195	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143742584	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1839448	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143752113	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10021860	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143754593	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10030428	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143762699	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13129702	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143785132	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs11100812	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143790400	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.545	rs10022856	ENSG00000249741.2	RP11-673E1.3	-4.05	0.000107	0.047	-0.33	-0.39	Immature fraction of reticulocytes;	chr4:143793157	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17018238	ENSG00000249741.2	RP11-673E1.3	4.05	0.000107	0.047	0.33	0.39	Immature fraction of reticulocytes;	chr4:143782737	chr4:143911514~143912053:-
THYM	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	4.05	0.000107	0.047	0.43	0.39	QT interval;	chr12:29379056	chr12:29280418~29317848:-
THYM	cis	rs9549367	0.713	rs3024743	ENSG00000269125.1	RP11-98F14.11	-4.04	0.000107	0.0471	-0.51	-0.39	Platelet distribution width;	chr13:113167116	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs3024746	ENSG00000269125.1	RP11-98F14.11	-4.04	0.000107	0.0471	-0.51	-0.39	Platelet distribution width;	chr13:113167463	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.713	rs3024747	ENSG00000269125.1	RP11-98F14.11	-4.04	0.000107	0.0471	-0.51	-0.39	Platelet distribution width;	chr13:113167473	chr13:113165002~113165183:-
THYM	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-4.04	0.000107	0.0471	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
THYM	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-4.04	0.000107	0.0471	-0.45	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
THYM	cis	rs2025009	0.663	rs12435046	ENSG00000259502.1	RP11-643G16.3	-4.04	0.000107	0.0471	-0.47	-0.39	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr14:68406810	chr14:67610986~67613864:+
THYM	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-4.04	0.000107	0.0471	-0.34	-0.39	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
THYM	cis	rs11603020	0.95	rs28362947	ENSG00000265566.2	RN7SL605P	-4.04	0.000107	0.0471	-0.53	-0.39	Blood protein levels;	chr11:57601535	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.95	rs28362948	ENSG00000265566.2	RN7SL605P	-4.04	0.000107	0.0471	-0.53	-0.39	Blood protein levels;	chr11:57601540	chr11:57528085~57528365:-
THYM	cis	rs11603020	0.95	rs11229063	ENSG00000265566.2	RN7SL605P	-4.04	0.000107	0.0471	-0.53	-0.39	Blood protein levels;	chr11:57602257	chr11:57528085~57528365:-
THYM	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-4.04	0.000107	0.0471	-0.31	-0.39	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
THYM	cis	rs7631605	0.967	rs9832138	ENSG00000272334.1	RP11-129K12.1	-4.04	0.000107	0.0471	-0.39	-0.39	Cerebrospinal P-tau181p levels;	chr3:37134469	chr3:36973117~36973672:-
THYM	cis	rs2235573	0.868	rs6001003	ENSG00000272669.1	RP3-508I15.21	-4.04	0.000107	0.0471	-0.25	-0.38	Glioma;Glioblastoma;	chr22:38103925	chr22:38742625~38743115:+
THYM	cis	rs9549367	0.804	rs9549704	ENSG00000269125.1	RP11-98F14.11	-4.04	0.000107	0.0471	-0.49	-0.38	Platelet distribution width;	chr13:113230873	chr13:113165002~113165183:-
THYM	cis	rs7246967	0.866	rs438972	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22837025	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.604	rs12981846	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22838557	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs12981220	ENSG00000198153.8	ZNF849P	4.04	0.000107	0.0471	0.47	0.38	Bronchopulmonary dysplasia;	chr19:22838598	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.8	rs2362131	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22839634	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs12983770	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22840812	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs12980225	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22843943	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs35968517	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22844238	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs35446354	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22844522	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs34897621	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22844725	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs35948178	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22845717	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs35687548	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22846345	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs11879853	ENSG00000198153.8	ZNF849P	4.04	0.000107	0.0471	0.47	0.38	Bronchopulmonary dysplasia;	chr19:22846632	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.799	rs12983185	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22847773	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs12984122	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22847872	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs35039856	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22848537	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs66737024	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22848884	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs4932792	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22849647	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs4932694	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22849905	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs34949383	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22851056	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs35332070	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22851464	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs12972095	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22851708	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs7250801	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22853155	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs4932695	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22853575	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs4932793	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22853647	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.8	rs4932794	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22853754	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs6511385	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22854134	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs62120772	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22854349	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs35007403	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22854645	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.8	rs12985313	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22854978	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs8105614	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22855221	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.8	rs7256135	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22856319	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs35735434	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22856675	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs58238799	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22857380	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs115497901	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22859959	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs7257731	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22860001	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs62120780	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22860912	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs34373479	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22861060	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.551	rs7351072	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22861727	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs34752785	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22861771	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs62120784	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22861933	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs7256599	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22863119	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs35105042	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22865550	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.866	rs34294248	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22867667	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs62120788	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22868210	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs4932798	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22868705	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs4932799	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22868779	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs4932800	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22868846	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.932	rs4932801	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22868851	chr19:22685167~22686732:+
THYM	cis	rs7246967	0.673	rs55638152	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22872492	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs936526	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22873185	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs936525	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22873387	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs7246967	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22873544	chr19:22685167~22686732:+
THYM	cis	rs7246967	1	rs7257127	ENSG00000198153.8	ZNF849P	-4.04	0.000107	0.0471	-0.47	-0.38	Bronchopulmonary dysplasia;	chr19:22873897	chr19:22685167~22686732:+
THYM	cis	rs1642645	0.872	rs4660210	ENSG00000228452.1	RP5-994D16.9	-4.04	0.000107	0.0471	-0.52	-0.38	Left ventricular obstructive tract defect (maternal effect);	chr1:42011005	chr1:42775813~42776790:-
THYM	cis	rs1642645	0.872	rs4660595	ENSG00000228452.1	RP5-994D16.9	-4.04	0.000107	0.0471	-0.52	-0.38	Left ventricular obstructive tract defect (maternal effect);	chr1:42016381	chr1:42775813~42776790:-
THYM	cis	rs910316	0.575	rs12889133	ENSG00000258646.1	RP11-950C14.3	-4.04	0.000107	0.0471	-0.35	-0.38	Height;	chr14:74998386	chr14:75004719~75008481:-
THYM	cis	rs1023500	0.505	rs134887	ENSG00000227370.1	RP4-669P10.19	4.04	0.000107	0.0471	0.44	0.38	Schizophrenia;	chr22:42278233	chr22:42132543~42132998:+
THYM	cis	rs11157436	0.602	rs1894371	ENSG00000211813.2	TRAV34	-4.04	0.000108	0.0471	-0.27	-0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166799	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.581	rs17255433	ENSG00000211813.2	TRAV34	4.04	0.000108	0.0471	0.27	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs17255440	ENSG00000211813.2	TRAV34	4.04	0.000108	0.0471	0.27	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs11157435	ENSG00000211813.2	TRAV34	4.04	0.000108	0.0471	0.27	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs11157438	ENSG00000211813.2	TRAV34	4.04	0.000108	0.0471	0.27	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs4982569	ENSG00000211813.2	TRAV34	4.04	0.000108	0.0471	0.27	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22207522~22208129:+
THYM	cis	rs11157436	0.602	rs2331594	ENSG00000211813.2	TRAV34	4.04	0.000108	0.0471	0.27	0.38	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22207522~22208129:+
THYM	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	4.04	0.000108	0.0471	0.34	0.38	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
THYM	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	4.04	0.000108	0.0471	0.54	0.38	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
THYM	cis	rs7005380	0.733	rs10107579	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000108	0.0472	-0.54	-0.38	Interstitial lung disease;	chr8:119922329	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.733	rs4871787	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000108	0.0472	-0.54	-0.38	Interstitial lung disease;	chr8:119924178	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.746	rs1464276	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000108	0.0472	-0.54	-0.38	Interstitial lung disease;	chr8:119924801	chr8:119867419~119874488:-
THYM	cis	rs9467773	0.62	rs2451738	ENSG00000261353.1	CTA-14H9.5	4.04	0.000108	0.0472	0.28	0.38	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26527063~26527404:+
THYM	cis	rs1426063	0.614	rs75345649	ENSG00000248165.1	RP11-44F21.2	4.04	0.000108	0.0472	0.9	0.38	QT interval;	chr4:75100963	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.614	rs77333523	ENSG00000248165.1	RP11-44F21.2	4.04	0.000108	0.0472	0.9	0.38	QT interval;	chr4:75101024	chr4:74993877~75034824:-
THYM	cis	rs1426063	0.614	rs17199632	ENSG00000248165.1	RP11-44F21.2	4.04	0.000108	0.0472	0.9	0.38	QT interval;	chr4:75103663	chr4:74993877~75034824:-
THYM	cis	rs34091987	0.562	rs2216167	ENSG00000256124.4	LINC01152	4.04	0.000108	0.0472	0.44	0.38	Nose size;	chr17:72025607	chr17:72030291~72041297:+
THYM	cis	rs4835473	0.9	rs13137885	ENSG00000249741.2	RP11-673E1.3	4.04	0.000108	0.0472	0.33	0.38	Immature fraction of reticulocytes;	chr4:143734212	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13105550	ENSG00000249741.2	RP11-673E1.3	4.04	0.000108	0.0472	0.33	0.38	Immature fraction of reticulocytes;	chr4:143734220	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs13105571	ENSG00000249741.2	RP11-673E1.3	4.04	0.000108	0.0472	0.33	0.38	Immature fraction of reticulocytes;	chr4:143734241	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.9	rs36083417	ENSG00000249741.2	RP11-673E1.3	4.04	0.000108	0.0472	0.33	0.38	Immature fraction of reticulocytes;	chr4:143734253	chr4:143911514~143912053:-
THYM	cis	rs9652601	0.879	rs8062322	ENSG00000274038.1	RP11-66H6.4	-4.04	0.000108	0.0472	-0.41	-0.38	Systemic lupus erythematosus;	chr16:10998462	chr16:11056556~11057034:+
THYM	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	4.04	0.000108	0.0472	0.27	0.38	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
THYM	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	4.04	0.000108	0.0472	0.27	0.38	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
THYM	cis	rs2235573	0.805	rs5995536	ENSG00000272669.1	RP3-508I15.21	-4.04	0.000108	0.0472	-0.25	-0.38	Glioma;Glioblastoma;	chr22:38104820	chr22:38742625~38743115:+
THYM	cis	rs7976269	0.559	rs10843313	ENSG00000275476.1	RP11-996F15.4	-4.04	0.000108	0.0473	-0.43	-0.38	Male-pattern baldness;	chr12:29078317	chr12:29277397~29277882:-
THYM	cis	rs783540	0.632	rs17356528	ENSG00000278603.1	RP13-608F4.5	-4.04	0.000108	0.0473	-0.5	-0.38	Schizophrenia;	chr15:82636799	chr15:82472203~82472426:+
THYM	cis	rs9890032	0.509	rs11656986	ENSG00000266490.1	CTD-2349P21.9	4.04	0.000108	0.0473	0.45	0.38	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30792372~30792833:+
THYM	cis	rs3015497	0.587	rs1353204	ENSG00000270062.1	RP11-248J18.3	4.04	0.000108	0.0473	0.28	0.38	Mean platelet volume;	chr14:50614797	chr14:50723777~50724272:-
THYM	cis	rs34773007	1	rs17377483	ENSG00000272817.1	RP11-402D21.2	-4.04	0.000108	0.0473	-0.49	-0.38	Type 2 diabetes;	chr10:92900376	chr10:91908131~91909348:+
THYM	cis	rs9326248	0.53	rs17120139	ENSG00000280143.1	AP000892.6	-4.04	0.000108	0.0473	-0.53	-0.38	Blood protein levels;	chr11:116903485	chr11:117204967~117210292:+
THYM	cis	rs7005380	0.785	rs7814294	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000108	0.0474	-0.53	-0.38	Interstitial lung disease;	chr8:119927196	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.733	rs10808505	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000108	0.0474	-0.53	-0.38	Interstitial lung disease;	chr8:119927966	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.733	rs56864850	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000108	0.0474	-0.53	-0.38	Interstitial lung disease;	chr8:119931204	chr8:119867419~119874488:-
THYM	cis	rs7005380	0.785	rs55892034	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000108	0.0474	-0.53	-0.38	Interstitial lung disease;	chr8:119931267	chr8:119867419~119874488:-
THYM	cis	rs7487075	0.558	rs7959095	ENSG00000257261.4	RP11-96H19.1	4.04	0.000108	0.0474	0.35	0.38	Itch intensity from mosquito bite;	chr12:46239545	chr12:46383679~46876159:+
THYM	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-4.04	0.000108	0.0474	-0.46	-0.38	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
THYM	cis	rs72799341	1	rs1458201	ENSG00000275263.1	RP11-1072A3.4	-4.04	0.000108	0.0474	-0.39	-0.38	Diastolic blood pressure;	chr16:30904808	chr16:30956872~30957199:-
THYM	cis	rs889398	0.933	rs6499240	ENSG00000226232.7	RP11-419C5.2	-4.04	0.000108	0.0474	-0.35	-0.38	Body mass index;	chr16:69653009	chr16:69976388~69996188:-
THYM	cis	rs7178424	0.764	rs35967150	ENSG00000259251.2	RP11-643M14.1	-4.04	0.000108	0.0474	-0.44	-0.38	Height;	chr15:62032272	chr15:62060503~62062434:+
THYM	cis	rs4835473	0.897	rs35598237	ENSG00000246448.2	RP13-578N3.3	4.04	0.000108	0.0474	0.48	0.38	Immature fraction of reticulocytes;	chr4:143735961	chr4:143700257~143865072:+
THYM	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-4.04	0.000108	0.0475	-0.46	-0.38	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
THYM	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-4.04	0.000108	0.0475	-0.46	-0.38	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
THYM	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-4.04	0.000108	0.0475	-0.46	-0.38	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
THYM	cis	rs57481061	1	rs57481061	ENSG00000258302.2	RP11-981P6.1	4.04	0.000109	0.0475	0.47	0.38	Coronary artery disease;	chr12:89625401	chr12:89561129~89594878:+
THYM	cis	rs728616	0.558	rs35547640	ENSG00000242600.5	MBL1P	4.04	0.000109	0.0475	0.54	0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80379394	chr10:79904898~79950336:+
THYM	cis	rs9326248	0.53	rs72645460	ENSG00000280143.1	AP000892.6	-4.04	0.000109	0.0475	-0.53	-0.38	Blood protein levels;	chr11:116900659	chr11:117204967~117210292:+
THYM	cis	rs3096299	0.606	rs8052103	ENSG00000261118.1	RP11-104N10.1	-4.04	0.000109	0.0475	-0.47	-0.38	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89492017~89504460:-
THYM	cis	rs495337	1	rs2281216	ENSG00000229222.1	KRT18P4	-4.04	0.000109	0.0475	-0.44	-0.38	Psoriasis;	chr20:49951966	chr20:49956745~49958032:+
THYM	cis	rs11098499	0.909	rs10017335	ENSG00000250412.1	KLHL2P1	-4.04	0.000109	0.0475	-0.37	-0.38	Corneal astigmatism;	chr4:119460368	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs1022145	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119309824	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs11722872	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119311875	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs1546502	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119314743	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs878373	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119316329	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs1546504	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119320024	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs1546505	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119320069	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10006877	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119321638	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs12505469	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119328430	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs2017057	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119336556	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs1002152	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119352232	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.865	rs11722183	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119359442	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs1480931	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119474654	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs9998585	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119475647	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10034623	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119476674	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.909	rs6842762	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119477081	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.908	rs11098527	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119478751	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs6848389	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119481467	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs6822679	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119481547	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs17006190	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119497683	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs28685688	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119499179	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs7687843	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119500056	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs2306455	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119500814	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10031483	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119501481	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs10031665	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119501697	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs3733519	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119502293	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs3733520	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119502325	chr4:119334329~119378233:+
THYM	cis	rs11098499	0.954	rs3733523	ENSG00000250412.1	KLHL2P1	4.04	0.000109	0.0475	0.37	0.38	Corneal astigmatism;	chr4:119502564	chr4:119334329~119378233:+
THYM	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	4.04	0.000109	0.0475	0.53	0.38	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
THYM	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	4.04	0.000109	0.0475	0.36	0.38	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
THYM	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	4.04	0.000109	0.0476	0.48	0.38	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
THYM	cis	rs10888838	0.756	rs11206306	ENSG00000198711.5	SSBP3-AS1	4.04	0.000109	0.0476	0.25	0.38	Mitochondrial DNA levels;	chr1:54224092	chr1:54236440~54239063:+
THYM	cis	rs10888838	0.756	rs11206307	ENSG00000198711.5	SSBP3-AS1	4.04	0.000109	0.0476	0.25	0.38	Mitochondrial DNA levels;	chr1:54224289	chr1:54236440~54239063:+
THYM	cis	rs28790308	1	rs17659026	ENSG00000259935.1	RP11-519C12.1	-4.04	0.000109	0.0476	-0.75	-0.38	Telomere length;	chr15:53041218	chr15:52648634~52649866:-
THYM	cis	rs863345	0.565	rs7549123	ENSG00000236656.1	RP11-144L1.4	4.04	0.000109	0.0476	0.24	0.38	Pneumococcal bacteremia;	chr1:158475130	chr1:158474454~158494886:-
THYM	cis	rs17685	0.712	rs10235086	ENSG00000280388.1	RP11-229D13.3	-4.04	0.000109	0.0477	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76203820	chr7:76043977~76045963:-
THYM	cis	rs1949733	0.701	rs2631735	ENSG00000205959.3	RP11-689P11.2	-4.04	0.000109	0.0477	-0.41	-0.38	Response to antineoplastic agents;	chr4:8474391	chr4:8482270~8512610:+
THYM	cis	rs7223966	1	rs8066719	ENSG00000240280.5	TCAM1P	-4.04	0.000109	0.0477	-0.55	-0.38	Hip circumference adjusted for BMI;Body mass index;	chr17:63748404	chr17:63849292~63864379:+
THYM	cis	rs7927592	0.956	rs7106259	ENSG00000222339.1	AP000807.2	4.04	0.000109	0.0477	0.44	0.38	Total body bone mineral density;	chr11:68531044	chr11:68505572~68505651:-
THYM	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-4.04	0.000109	0.0477	-0.48	-0.38	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
THYM	cis	rs6586163	0.527	rs3740286	ENSG00000275693.1	FAS-AS1	-4.04	0.000109	0.0477	-0.44	-0.38	Chronic lymphocytic leukemia;	chr10:88991583	chr10:88992370~88992539:+
THYM	cis	rs3015497	0.789	rs2356457	ENSG00000270062.1	RP11-248J18.3	4.04	0.000109	0.0477	0.27	0.38	Mean platelet volume;	chr14:50650145	chr14:50723777~50724272:-
THYM	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-4.04	0.000109	0.0477	-0.48	-0.38	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
THYM	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-4.04	0.000109	0.0477	-0.41	-0.38	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-4.04	0.000109	0.0477	-0.41	-0.38	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
THYM	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-4.04	0.000109	0.0477	-0.41	-0.38	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
THYM	cis	rs7551345	0.671	rs7545865	ENSG00000229447.2	RP11-490K7.4	4.04	0.000109	0.0478	0.45	0.38	Schizophrenia;	chr1:31470508	chr1:31263245~31263681:-
THYM	cis	rs8067545	1	rs56142708	ENSG00000231645.2	KRT17P6	-4.04	0.00011	0.0478	-0.46	-0.38	Schizophrenia;	chr17:20031650	chr17:20512560~20517479:-
THYM	cis	rs7044106	0.578	rs4837788	ENSG00000238181.2	AHCYP2	-4.04	0.00011	0.0478	-0.49	-0.38	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120720673~120721972:+
THYM	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-4.04	0.00011	0.0478	-0.43	-0.38	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
THYM	cis	rs4853012	0.887	rs77148265	ENSG00000272183.1	RP11-523H20.3	4.04	0.00011	0.0478	0.53	0.38	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74501717~74502365:+
THYM	cis	rs3796619	1	rs3796619	ENSG00000215367.9	TMED11P	4.04	0.00011	0.0478	0.37	0.38	Recombination rate (males);	chr4:1101493	chr4:1115197~1153726:-
THYM	cis	rs3121446	0.731	rs1986323	ENSG00000229654.1	RP1-60O19.2	-4.04	0.00011	0.0478	-0.47	-0.38	Daytime sleep phenotypes;	chr6:106696384	chr6:106695535~106699994:+
THYM	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	4.04	0.00011	0.0478	0.44	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
THYM	cis	rs8067545	0.611	rs2703807	ENSG00000231645.2	KRT17P6	4.04	0.00011	0.0478	0.46	0.38	Schizophrenia;	chr17:20205876	chr17:20512560~20517479:-
THYM	cis	rs12049671	0.627	rs11018406	ENSG00000227076.1	RP11-4C20.4	4.04	0.00011	0.0478	0.54	0.38	Response to amphetamines;	chr10:127931269	chr10:127934698~127936167:+
THYM	cis	rs9309473	0.519	rs6746971	ENSG00000273245.1	RP11-434P11.2	4.04	0.00011	0.0479	0.44	0.38	Metabolite levels;	chr2:73442334	chr2:73750256~73750786:-
THYM	cis	rs12902680	0.706	rs8025021	ENSG00000259520.4	CTD-2651B20.3	4.04	0.00011	0.0479	0.42	0.38	Neuroticism;	chr15:46172641	chr15:45251580~45279251:-
THYM	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	4.04	0.00011	0.0479	0.27	0.38	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
THYM	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	4.04	0.00011	0.0479	0.27	0.38	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
THYM	cis	rs3796619	1	rs11247973	ENSG00000215367.9	TMED11P	4.04	0.00011	0.0479	0.38	0.38	Recombination rate (males);	chr4:1100526	chr4:1115197~1153726:-
THYM	cis	rs875971	0.571	rs160641	ENSG00000164669.11	INTS4P1	4.04	0.00011	0.0479	0.55	0.38	Aortic root size;	chr7:66112359	chr7:65141225~65234216:+
THYM	cis	rs875971	0.545	rs4441996	ENSG00000164669.11	INTS4P1	4.04	0.00011	0.0479	0.55	0.38	Aortic root size;	chr7:66123233	chr7:65141225~65234216:+
THYM	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-4.04	0.00011	0.0479	-0.49	-0.38	Height;	chr6:109625358	chr6:109382795~109383666:+
THYM	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	4.04	0.00011	0.0479	0.49	0.38	Height;	chr6:109645257	chr6:109382795~109383666:+
THYM	cis	rs12549902	0.933	rs17659428	ENSG00000271938.1	RP11-589C21.6	-4.04	0.00011	0.0479	-0.44	-0.38	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41656290	chr8:42139461~42139752:-
THYM	cis	rs12549902	0.966	rs12544241	ENSG00000271938.1	RP11-589C21.6	-4.04	0.00011	0.0479	-0.44	-0.38	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41657369	chr8:42139461~42139752:-
THYM	cis	rs12549902	0.966	rs6990613	ENSG00000271938.1	RP11-589C21.6	-4.04	0.00011	0.0479	-0.44	-0.38	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41657611	chr8:42139461~42139752:-
THYM	cis	rs12549902	0.966	rs716199	ENSG00000271938.1	RP11-589C21.6	-4.04	0.00011	0.0479	-0.44	-0.38	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41658012	chr8:42139461~42139752:-
THYM	cis	rs12549902	0.966	rs10504042	ENSG00000271938.1	RP11-589C21.6	-4.04	0.00011	0.0479	-0.44	-0.38	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41658474	chr8:42139461~42139752:-
THYM	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-4.04	0.00011	0.048	-0.41	-0.38	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
THYM	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-4.04	0.00011	0.048	-0.48	-0.38	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
THYM	cis	rs7631605	0.967	rs6550446	ENSG00000272334.1	RP11-129K12.1	-4.04	0.00011	0.048	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37024882	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs997588	ENSG00000272334.1	RP11-129K12.1	-4.04	0.00011	0.048	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37033651	chr3:36973117~36973672:-
THYM	cis	rs7631605	1	rs6772548	ENSG00000272334.1	RP11-129K12.1	-4.04	0.00011	0.048	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37034443	chr3:36973117~36973672:-
THYM	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	4.04	0.00011	0.048	0.53	0.38	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
THYM	cis	rs2055375	0.63	rs171748	ENSG00000272308.1	RP11-231G3.1	-4.04	0.00011	0.048	-0.32	-0.38	Intelligence (multi-trait analysis);	chr5:61203304	chr5:60866457~60866935:-
THYM	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	4.04	0.00011	0.048	0.41	0.38	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
THYM	cis	rs7631605	0.935	rs3733029	ENSG00000272334.1	RP11-129K12.1	-4.04	0.00011	0.048	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37129259	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.647	rs59594366	ENSG00000272334.1	RP11-129K12.1	-4.04	0.00011	0.048	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37132283	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.544	rs61493618	ENSG00000272334.1	RP11-129K12.1	-4.04	0.00011	0.048	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37132284	chr3:36973117~36973672:-
THYM	cis	rs7631605	0.935	rs2885608	ENSG00000272334.1	RP11-129K12.1	-4.04	0.00011	0.048	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37134554	chr3:36973117~36973672:-
THYM	cis	rs11626933	1	rs2236402	ENSG00000242571.1	RPL21P11	4.04	0.00011	0.0481	0.41	0.38	Gut microbiota (bacterial taxa);	chr14:90268034	chr14:90366697~90367179:-
THYM	cis	rs972578	0.776	rs2267464	ENSG00000215347.3	SLC25A5P1	-4.04	0.00011	0.0481	-0.3	-0.38	Mean platelet volume;	chr22:42902640	chr22:42001069~42001966:-
THYM	cis	rs7208859	0.673	rs216424	ENSG00000266490.1	CTD-2349P21.9	4.04	0.00011	0.0481	0.63	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30792372~30792833:+
THYM	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-4.04	0.00011	0.0481	-0.64	-0.38	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
THYM	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-4.04	0.000111	0.0481	-0.34	-0.38	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-4.04	0.000111	0.0481	-0.34	-0.38	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-4.04	0.000111	0.0481	-0.34	-0.38	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-4.04	0.000111	0.0481	-0.34	-0.38	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-4.04	0.000111	0.0481	-0.34	-0.38	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-4.04	0.000111	0.0481	-0.34	-0.38	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
THYM	cis	rs1439840	0.611	rs4848788	ENSG00000213239.3	NPM1P32	4.04	0.000111	0.0481	0.82	0.38	QT interval (sulfonylurea treatment interaction);	chr2:122645196	chr2:121708512~121709115:-
THYM	cis	rs11976180	1	rs2951308	ENSG00000244479.5	OR2A1-AS1	-4.04	0.000111	0.0481	-0.34	-0.38	Obesity-related traits;	chr7:144070056	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2961118	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144058350	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2961119	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144058759	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2371244	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144060518	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs4726669	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144061098	chr7:144251264~144356181:-
THYM	cis	rs11976180	0.953	rs2951355	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144063469	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2951354	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144063908	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2951353	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144064023	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2961125	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144064677	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2961126	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144065643	chr7:144251264~144356181:-
THYM	cis	rs11976180	0.953	rs2961127	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144065644	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1919948	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144065750	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2961128	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144066390	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2371247	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144067086	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2371248	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144067096	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1533268	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144069265	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1533267	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144069347	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1533266	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144069621	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1919949	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144070630	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs1919950	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144070805	chr7:144251264~144356181:-
THYM	cis	rs11976180	1	rs2961132	ENSG00000244479.5	OR2A1-AS1	4.04	0.000111	0.0481	0.34	0.38	Obesity-related traits;	chr7:144071035	chr7:144251264~144356181:-
THYM	cis	rs4835473	0.9	rs10032963	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143733068	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs28796049	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143733990	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs6851999	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143742567	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs2323200	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143765448	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs13152209	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143776088	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs10016223	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143777429	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs17694797	ENSG00000249741.2	RP11-673E1.3	4.04	0.000111	0.0481	0.32	0.38	Immature fraction of reticulocytes;	chr4:143778812	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs35947975	ENSG00000249741.2	RP11-673E1.3	4.04	0.000111	0.0481	0.32	0.38	Immature fraction of reticulocytes;	chr4:143778969	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.778	rs75562808	ENSG00000249741.2	RP11-673E1.3	4.04	0.000111	0.0481	0.32	0.38	Immature fraction of reticulocytes;	chr4:143779065	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1375987	ENSG00000249741.2	RP11-673E1.3	4.04	0.000111	0.0481	0.32	0.38	Immature fraction of reticulocytes;	chr4:143779622	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs7687151	ENSG00000249741.2	RP11-673E1.3	4.04	0.000111	0.0481	0.32	0.38	Immature fraction of reticulocytes;	chr4:143781681	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs4383567	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143788873	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs1842484	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143793829	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.932	rs9997931	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143904601	chr4:143911514~143912053:-
THYM	cis	rs4835473	0.897	rs2036880	ENSG00000249741.2	RP11-673E1.3	-4.04	0.000111	0.0481	-0.32	-0.38	Immature fraction of reticulocytes;	chr4:143907834	chr4:143911514~143912053:-
THYM	cis	rs556990	0.574	rs473598	ENSG00000269125.1	RP11-98F14.11	-4.04	0.000111	0.0482	-0.57	-0.38	Blood protein levels;	chr13:113146875	chr13:113165002~113165183:-
THYM	cis	rs7560272	0.723	rs6729468	ENSG00000163016.8	ALMS1P	4.04	0.000111	0.0482	0.44	0.38	Schizophrenia;	chr2:73538126	chr2:73644919~73685576:+
THYM	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	4.04	0.000111	0.0482	0.47	0.38	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
THYM	cis	rs2288012	0.568	rs7200791	ENSG00000260186.4	RP11-481J2.2	-4.04	0.000111	0.0482	-0.47	-0.38	Systemic lupus erythematosus;	chr16:58279286	chr16:58421326~58462470:+
THYM	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	4.04	0.000111	0.0482	0.3	0.38	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
THYM	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	4.04	0.000111	0.0482	0.3	0.38	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
THYM	cis	rs73607972	0.518	rs7193898	ENSG00000275191.1	RP11-36I17.2	4.04	0.000111	0.0482	0.39	0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53551009	chr16:53628256~53628816:-
THYM	cis	rs889398	0.874	rs2917677	ENSG00000226232.7	RP11-419C5.2	4.04	0.000111	0.0483	0.35	0.38	Body mass index;	chr16:69716946	chr16:69976388~69996188:-
THYM	cis	rs10129255	0.5	rs2027903	ENSG00000253703.1	IGHV1-68	-4.04	0.000111	0.0483	-0.42	-0.38	Kawasaki disease;	chr14:106807047	chr14:106703852~106704146:-
THYM	cis	rs10129255	0.518	rs28378320	ENSG00000253703.1	IGHV1-68	-4.04	0.000111	0.0483	-0.42	-0.38	Kawasaki disease;	chr14:106808609	chr14:106703852~106704146:-
THYM	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	4.04	0.000111	0.0483	0.46	0.38	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
THYM	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	4.04	0.000111	0.0483	0.46	0.38	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
THYM	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	4.04	0.000111	0.0483	0.46	0.38	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
THYM	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	4.04	0.000111	0.0483	0.46	0.38	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
THYM	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	4.04	0.000111	0.0483	0.46	0.38	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
THYM	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.04	0.000111	0.0483	0.52	0.38	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
THYM	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	4.04	0.000111	0.0483	0.5	0.38	Pain;	chr19:21567257	chr19:21554640~21569237:-
THYM	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	4.04	0.000111	0.0483	0.5	0.38	Pain;	chr19:21567449	chr19:21554640~21569237:-
THYM	cis	rs10276381	0.892	rs7786444	ENSG00000253187.2	HOXA10-AS	4.04	0.000111	0.0483	0.33	0.38	Crohn's disease;	chr7:28114765	chr7:27168619~27171915:+
THYM	cis	rs1642645	0.831	rs784103	ENSG00000228452.1	RP5-994D16.9	-4.04	0.000111	0.0483	-0.52	-0.38	Left ventricular obstructive tract defect (maternal effect);	chr1:42021388	chr1:42775813~42776790:-
THYM	cis	rs853679	0.55	rs1233701	ENSG00000272009.1	RP1-313I6.12	4.04	0.000111	0.0483	0.5	0.38	Depression;	chr6:28200948	chr6:28078792~28081130:-
THYM	cis	rs7005380	0.733	rs6469878	ENSG00000245330.4	KB-1471A8.1	-4.04	0.000111	0.0483	-0.54	-0.38	Interstitial lung disease;	chr8:119926208	chr8:119867419~119874488:-
THYM	cis	rs910316	0.737	rs108621	ENSG00000258646.1	RP11-950C14.3	4.03	0.000111	0.0483	0.34	0.38	Height;	chr14:75013934	chr14:75004719~75008481:-
THYM	cis	rs60180747	0.544	rs1020927	ENSG00000261318.1	RP11-653J6.1	4.03	0.000111	0.0484	0.42	0.38	Testicular germ cell tumor;	chr15:66258920	chr15:66278498~66293357:-
THYM	cis	rs831571	0.55	rs153734	ENSG00000280620.1	SCAANT1	4.03	0.000111	0.0484	0.52	0.38	Type 2 diabetes;	chr3:64092333	chr3:63911518~63911772:-
THYM	cis	rs2108622	0.64	rs58858790	ENSG00000279717.1	LLNLF-158E9.1	-4.03	0.000111	0.0484	-0.38	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15863463	chr19:15904556~15907234:+
THYM	cis	rs4276643	0.602	rs4732791	ENSG00000253875.1	RP11-16P20.3	-4.03	0.000111	0.0484	-0.32	-0.38	Low vWF levels;	chr8:27923096	chr8:27733338~27756426:+
THYM	cis	rs61270009	0.955	rs13171573	ENSG00000247828.6	TMEM161B-AS1	4.03	0.000111	0.0484	0.32	0.38	Depressive symptoms;	chr5:88383625	chr5:88268895~88436685:+
THYM	cis	rs2411233	0.901	rs11630372	ENSG00000259345.4	RP11-624L4.1	4.03	0.000111	0.0484	0.27	0.38	Platelet count;	chr15:39015227	chr15:38865322~39427195:-
THYM	cis	rs2411233	0.839	rs1380939	ENSG00000259345.4	RP11-624L4.1	4.03	0.000111	0.0484	0.27	0.38	Platelet count;	chr15:39017614	chr15:38865322~39427195:-
THYM	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-4.03	0.000111	0.0484	-0.46	-0.38	Height;	chr3:53069965	chr3:53064283~53065091:-
THYM	cis	rs10483853	0.747	rs2333193	ENSG00000258695.2	RP3-414A15.2	-4.03	0.000112	0.0485	-0.53	-0.38	Coronary artery calcification;	chr14:73285359	chr14:73522878~73530610:+
THYM	cis	rs10483853	0.806	rs28653374	ENSG00000258695.2	RP3-414A15.2	-4.03	0.000112	0.0485	-0.53	-0.38	Coronary artery calcification;	chr14:73362103	chr14:73522878~73530610:+
THYM	cis	rs10483853	0.806	rs11159014	ENSG00000258695.2	RP3-414A15.2	-4.03	0.000112	0.0485	-0.53	-0.38	Coronary artery calcification;	chr14:73363814	chr14:73522878~73530610:+
THYM	cis	rs10483853	0.806	rs11159016	ENSG00000258695.2	RP3-414A15.2	-4.03	0.000112	0.0485	-0.53	-0.38	Coronary artery calcification;	chr14:73394553	chr14:73522878~73530610:+
THYM	cis	rs10483853	0.806	rs881035	ENSG00000258695.2	RP3-414A15.2	-4.03	0.000112	0.0485	-0.53	-0.38	Coronary artery calcification;	chr14:73402685	chr14:73522878~73530610:+
THYM	cis	rs807029	0.533	rs3740485	ENSG00000273030.1	RP11-285F16.1	-4.03	0.000112	0.0485	-0.44	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs3740486	ENSG00000273030.1	RP11-285F16.1	-4.03	0.000112	0.0485	-0.44	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs3740487	ENSG00000273030.1	RP11-285F16.1	-4.03	0.000112	0.0485	-0.44	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100412934~100413421:+
THYM	cis	rs807029	0.533	rs3824783	ENSG00000273030.1	RP11-285F16.1	-4.03	0.000112	0.0485	-0.44	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs3740488	ENSG00000273030.1	RP11-285F16.1	-4.03	0.000112	0.0485	-0.44	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100412934~100413421:+
THYM	cis	rs807029	0.577	rs11190787	ENSG00000273030.1	RP11-285F16.1	-4.03	0.000112	0.0485	-0.44	-0.38	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100412934~100413421:+
THYM	cis	rs4835473	0.932	rs2218791	ENSG00000246448.2	RP13-578N3.3	4.03	0.000112	0.0485	0.48	0.38	Immature fraction of reticulocytes;	chr4:143749300	chr4:143700257~143865072:+
THYM	cis	rs4273100	0.646	rs4924990	ENSG00000279825.1	CTC-457L16.1	-4.03	0.000112	0.0485	-0.46	-0.38	Schizophrenia;	chr17:19391511	chr17:19030857~19033529:+
THYM	cis	rs10129255	0.957	rs10136560	ENSG00000254329.1	IGHVII-60-1	4.03	0.000112	0.0485	0.4	0.38	Kawasaki disease;	chr14:106787630	chr14:106637718~106637973:-
THYM	cis	rs10129255	0.957	rs10136817	ENSG00000254329.1	IGHVII-60-1	4.03	0.000112	0.0485	0.4	0.38	Kawasaki disease;	chr14:106787730	chr14:106637718~106637973:-
THYM	cis	rs9611565	1	rs5751086	ENSG00000273366.1	CTA-989H11.1	4.03	0.000112	0.0485	0.38	0.38	Vitiligo;	chr22:41372858	chr22:42278188~42278846:+
THYM	cis	rs1910358	0.515	rs10073904	ENSG00000248874.4	C5orf17	-4.03	0.000112	0.0486	-0.53	-0.38	Venous thromboembolism (SNP x SNP interaction);	chr5:23724265	chr5:23951348~24178263:+
THYM	cis	rs1910358	0.515	rs10059485	ENSG00000248874.4	C5orf17	-4.03	0.000112	0.0486	-0.53	-0.38	Venous thromboembolism (SNP x SNP interaction);	chr5:23724421	chr5:23951348~24178263:+
THYM	cis	rs1910358	0.515	rs1521002	ENSG00000248874.4	C5orf17	-4.03	0.000112	0.0486	-0.53	-0.38	Venous thromboembolism (SNP x SNP interaction);	chr5:23726490	chr5:23951348~24178263:+
THYM	cis	rs12908161	0.96	rs11633450	ENSG00000235370.6	DNM1P51	4.03	0.000112	0.0486	0.52	0.38	Schizophrenia;	chr15:84764056	chr15:84398316~84411701:-
THYM	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	4.03	0.000112	0.0486	0.44	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
THYM	cis	rs6672530	0.518	rs12079123	ENSG00000227711.2	RP11-275O4.5	-4.03	0.000112	0.0486	-0.33	-0.38	Hip circumference adjusted for BMI;	chr1:227625240	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs2132367	ENSG00000227711.2	RP11-275O4.5	-4.03	0.000112	0.0486	-0.33	-0.38	Hip circumference adjusted for BMI;	chr1:227626689	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs12080321	ENSG00000227711.2	RP11-275O4.5	-4.03	0.000112	0.0486	-0.33	-0.38	Hip circumference adjusted for BMI;	chr1:227631668	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs12070002	ENSG00000227711.2	RP11-275O4.5	-4.03	0.000112	0.0486	-0.33	-0.38	Hip circumference adjusted for BMI;	chr1:227631789	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs12070036	ENSG00000227711.2	RP11-275O4.5	-4.03	0.000112	0.0486	-0.33	-0.38	Hip circumference adjusted for BMI;	chr1:227631813	chr1:227509028~227520477:-
THYM	cis	rs6672530	0.518	rs10799433	ENSG00000227711.2	RP11-275O4.5	-4.03	0.000112	0.0486	-0.33	-0.38	Hip circumference adjusted for BMI;	chr1:227632371	chr1:227509028~227520477:-
THYM	cis	rs7178424	0.905	rs7177173	ENSG00000259251.2	RP11-643M14.1	4.03	0.000112	0.0486	0.43	0.38	Height;	chr15:61944605	chr15:62060503~62062434:+
THYM	cis	rs7178424	0.875	rs28513564	ENSG00000259251.2	RP11-643M14.1	-4.03	0.000112	0.0486	-0.43	-0.38	Height;	chr15:61940161	chr15:62060503~62062434:+
THYM	cis	rs8177876	0.749	rs804885	ENSG00000261838.4	RP11-303E16.6	-4.03	0.000112	0.0486	-0.72	-0.38	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061758	chr16:81069854~81076598:+
THYM	cis	rs7989332	0.961	rs4770041	ENSG00000279065.1	RP11-264J4.10	-4.03	0.000112	0.0487	-0.45	-0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20474430	chr13:20194412~20196005:+
THYM	cis	rs3096299	0.606	rs4785674	ENSG00000261118.1	RP11-104N10.1	4.03	0.000112	0.0487	0.48	0.38	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89492017~89504460:-
THYM	cis	rs2732480	0.538	rs2732462	ENSG00000240399.1	RP1-228P16.1	4.03	0.000112	0.0487	0.4	0.38	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48054813~48055591:-
THYM	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	4.03	0.000112	0.0487	0.47	0.38	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
THYM	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	4.03	0.000112	0.0487	0.47	0.38	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
THYM	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-4.03	0.000112	0.0487	-0.32	-0.38	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
THYM	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-4.03	0.000112	0.0487	-0.32	-0.38	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
THYM	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-4.03	0.000112	0.0487	-0.32	-0.38	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
THYM	cis	rs12902680	0.739	rs28479523	ENSG00000259520.4	CTD-2651B20.3	4.03	0.000112	0.0487	0.4	0.38	Neuroticism;	chr15:46113822	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.71	rs1915158	ENSG00000259520.4	CTD-2651B20.3	4.03	0.000112	0.0487	0.4	0.38	Neuroticism;	chr15:46114750	chr15:45251580~45279251:-
THYM	cis	rs12902680	0.71	rs1402119	ENSG00000259520.4	CTD-2651B20.3	4.03	0.000112	0.0487	0.4	0.38	Neuroticism;	chr15:46115030	chr15:45251580~45279251:-
THYM	cis	rs2253762	0.54	rs10887051	ENSG00000276742.1	RP11-500G22.4	4.03	0.000112	0.0488	0.49	0.38	Breast cancer;	chr10:122026030	chr10:121956782~121957098:+
THYM	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	4.03	0.000112	0.0488	0.58	0.38	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
THYM	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-4.03	0.000112	0.0488	-0.44	-0.38	QT interval;	chr12:29297620	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-4.03	0.000112	0.0488	-0.44	-0.38	QT interval;	chr12:29298788	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-4.03	0.000112	0.0488	-0.44	-0.38	QT interval;	chr12:29300845	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-4.03	0.000112	0.0488	-0.44	-0.38	QT interval;	chr12:29302457	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-4.03	0.000112	0.0488	-0.44	-0.38	QT interval;	chr12:29302458	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-4.03	0.000112	0.0488	-0.44	-0.38	QT interval;	chr12:29303562	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	4.03	0.000112	0.0488	0.44	0.38	QT interval;	chr12:29292489	chr12:29280418~29317848:-
THYM	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	4.03	0.000112	0.0488	0.44	0.38	QT interval;	chr12:29304617	chr12:29280418~29317848:-
THYM	cis	rs1519814	0.659	rs7829279	ENSG00000254343.2	RP11-760H22.2	-4.03	0.000113	0.0488	-0.6	-0.38	Breast cancer;	chr8:120011275	chr8:120052180~120056201:+
THYM	cis	rs1519814	0.659	rs7387672	ENSG00000254343.2	RP11-760H22.2	-4.03	0.000113	0.0488	-0.6	-0.38	Breast cancer;	chr8:120012272	chr8:120052180~120056201:+
THYM	cis	rs12410462	0.591	rs3748806	ENSG00000227711.2	RP11-275O4.5	4.03	0.000113	0.0488	0.39	0.38	Major depressive disorder;	chr1:227563411	chr1:227509028~227520477:-
THYM	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-4.03	0.000113	0.0489	-0.38	-0.38	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
THYM	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
THYM	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
THYM	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
THYM	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
THYM	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
THYM	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
THYM	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
THYM	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
THYM	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	4.03	0.000113	0.0489	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
THYM	cis	rs935334	1	rs2121077	ENSG00000258454.1	RP11-361H10.3	-4.03	0.000113	0.0489	-0.51	-0.38	Blood pressure;	chr14:76210012	chr14:76235817~76263474:+
THYM	cis	rs10028773	0.7	rs7690338	ENSG00000250412.1	KLHL2P1	4.03	0.000113	0.0489	0.35	0.38	Educational attainment;	chr4:119335313	chr4:119334329~119378233:+
THYM	cis	rs4853012	0.838	rs4563249	ENSG00000272183.1	RP11-523H20.3	4.03	0.000113	0.0489	0.5	0.38	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74501717~74502365:+
THYM	cis	rs11098499	0.866	rs72676074	ENSG00000250412.1	KLHL2P1	4.03	0.000113	0.0489	0.37	0.38	Corneal astigmatism;	chr4:119438686	chr4:119334329~119378233:+
THYM	cis	rs1023500	0.505	rs134889	ENSG00000227370.1	RP4-669P10.19	4.03	0.000113	0.0489	0.44	0.38	Schizophrenia;	chr22:42278344	chr22:42132543~42132998:+
THYM	cis	rs756777	0.878	rs7865299	ENSG00000273473.1	LL09NC01-139C3.1	-4.03	0.000113	0.0489	-0.31	-0.38	IgG glycosylation;	chr9:133797806	chr9:134168769~134169340:+
THYM	cis	rs3796619	1	rs12647929	ENSG00000215367.9	TMED11P	4.03	0.000113	0.049	0.37	0.38	Recombination rate (males);	chr4:1098231	chr4:1115197~1153726:-
THYM	cis	rs34792	0.853	rs4781668	ENSG00000262380.1	CTB-193M12.3	4.03	0.000113	0.049	0.49	0.38	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15463766	chr16:15683290~15684570:+
THYM	cis	rs4591358	0.731	rs34634374	ENSG00000223466.1	AC064834.2	-4.03	0.000113	0.049	-0.41	-0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509437	chr2:195533035~195538681:+
THYM	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
THYM	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
THYM	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
THYM	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
THYM	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
THYM	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
THYM	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
THYM	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	4.03	0.000113	0.049	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
THYM	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	4.03	0.000113	0.049	0.56	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
THYM	cis	rs972578	1	rs972578	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42991689	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs4820502	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42991909	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs4822244	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42993022	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5759075	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42993084	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs738377	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42993564	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs733139	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42994077	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs6002997	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42996258	chr22:42001069~42001966:-
THYM	cis	rs972578	1	rs5759078	ENSG00000215347.3	SLC25A5P1	-4.03	0.000113	0.049	-0.31	-0.38	Mean platelet volume;	chr22:42997036	chr22:42001069~42001966:-
THYM	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	4.03	0.000113	0.049	0.35	0.38	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
THYM	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	4.03	0.000113	0.049	0.35	0.38	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
THYM	cis	rs910316	0.673	rs2012627	ENSG00000258646.1	RP11-950C14.3	-4.03	0.000113	0.0491	-0.34	-0.38	Height;	chr14:74976400	chr14:75004719~75008481:-
THYM	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	4.03	0.000113	0.0491	0.48	0.38	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
THYM	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	4.03	0.000113	0.0491	0.48	0.38	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
THYM	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	4.03	0.000113	0.0491	0.48	0.38	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
THYM	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	4.03	0.000113	0.0491	0.48	0.38	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
THYM	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	4.03	0.000113	0.0491	0.48	0.38	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
THYM	cis	rs8523	0.586	rs1225753	ENSG00000216368.2	RP3-486D24.1	-4.03	0.000113	0.0491	-0.44	-0.38	Red blood cell fatty acid levels;	chr6:10956456	chr6:10118452~10119253:+
THYM	cis	rs890448	0.796	rs13143896	ENSG00000254531.1	FLJ20021	4.03	0.000113	0.0492	0.33	0.38	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101440045	chr4:101347780~101348883:+
THYM	cis	rs9813712	0.595	rs1993217	ENSG00000228252.7	COL6A4P2	-4.03	0.000114	0.0492	-0.43	-0.38	Response to amphetamines;	chr3:130284832	chr3:130212823~130273806:+
THYM	cis	rs9813712	0.595	rs16825656	ENSG00000228252.7	COL6A4P2	-4.03	0.000114	0.0492	-0.43	-0.38	Response to amphetamines;	chr3:130286225	chr3:130212823~130273806:+
THYM	cis	rs1949733	1	rs3103072	ENSG00000205959.3	RP11-689P11.2	4.03	0.000114	0.0492	0.41	0.38	Response to antineoplastic agents;	chr4:8506704	chr4:8482270~8512610:+
THYM	cis	rs7631605	0.905	rs11714716	ENSG00000272334.1	RP11-129K12.1	-4.03	0.000114	0.0492	-0.42	-0.38	Cerebrospinal P-tau181p levels;	chr3:37228187	chr3:36973117~36973672:-
THYM	cis	rs1910358	0.554	rs1568457	ENSG00000248874.4	C5orf17	4.03	0.000114	0.0492	0.51	0.38	Venous thromboembolism (SNP x SNP interaction);	chr5:23756914	chr5:23951348~24178263:+
THYM	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0492	0.57	0.38	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0492	0.57	0.38	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0492	0.57	0.38	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
THYM	cis	rs910316	0.663	rs175034	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:74996984	chr14:75004719~75008481:-
THYM	cis	rs910316	0.763	rs175042	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:75004130	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs175045	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:75008572	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs175055	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:75022243	chr14:75004719~75008481:-
THYM	cis	rs910316	0.687	rs175059	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:75023964	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs175071	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:75031474	chr14:75004719~75008481:-
THYM	cis	rs910316	0.737	rs175072	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:75036124	chr14:75004719~75008481:-
THYM	cis	rs910316	0.712	rs175074	ENSG00000258646.1	RP11-950C14.3	4.03	0.000114	0.0492	0.33	0.38	Height;	chr14:75037751	chr14:75004719~75008481:-
THYM	cis	rs853679	0.55	rs1233707	ENSG00000272009.1	RP1-313I6.12	-4.03	0.000114	0.0492	-0.43	-0.38	Depression;	chr6:28205175	chr6:28078792~28081130:-
THYM	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-4.03	0.000114	0.0493	-0.49	-0.38	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
THYM	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	4.03	0.000114	0.0493	0.49	0.38	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
THYM	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	-4.03	0.000114	0.0493	-0.45	-0.38	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
THYM	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	-4.03	0.000114	0.0493	-0.45	-0.38	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
THYM	cis	rs7267979	0.966	rs2261784	ENSG00000276952.1	RP5-965G21.6	4.03	0.000114	0.0493	0.43	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25284915~25285588:-
THYM	cis	rs7267979	0.966	rs2261785	ENSG00000276952.1	RP5-965G21.6	4.03	0.000114	0.0493	0.43	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25284915~25285588:-
THYM	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-4.03	0.000114	0.0493	-0.41	-0.38	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-4.03	0.000114	0.0493	-0.41	-0.38	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
THYM	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-4.03	0.000114	0.0493	-0.41	-0.38	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
THYM	cis	rs7617480	0.519	rs6790914	ENSG00000270441.1	RP11-694I15.7	-4.03	0.000114	0.0493	-0.41	-0.38	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49140086~49160851:-
THYM	cis	rs56804039	1	rs11780966	ENSG00000253893.2	FAM85B	4.03	0.000114	0.0493	0.56	0.38	Cervical cancer;	chr8:8525886	chr8:8167819~8226614:-
THYM	cis	rs6782228	0.606	rs2811488	ENSG00000277250.1	Metazoa_SRP	-4.03	0.000114	0.0493	-0.52	-0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128673681~128674021:-
THYM	cis	rs17577085	0.704	rs77475235	ENSG00000271871.1	AC005740.6	4.03	0.000114	0.0493	0.64	0.38	Coronary heart disease;	chr5:142487685	chr5:141952419~141953375:+
THYM	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	4.03	0.000114	0.0493	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
THYM	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	4.03	0.000114	0.0493	0.52	0.38	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
THYM	cis	rs3753275	0.624	rs4908776	ENSG00000230679.1	ENO1-AS1	4.03	0.000114	0.0493	0.46	0.38	Educational attainment;	chr1:8743974	chr1:8878835~8879894:+
THYM	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-4.03	0.000114	0.0494	-0.43	-0.38	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
THYM	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	4.03	0.000114	0.0494	0.57	0.38	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
THYM	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-4.03	0.000114	0.0494	-0.57	-0.38	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
THYM	cis	rs295140	0.526	rs295114	ENSG00000232732.8	AC073043.1	-4.03	0.000114	0.0494	-0.46	-0.38	QT interval;	chr2:200330879	chr2:199867396~199911159:-
THYM	cis	rs17685	0.753	rs10233282	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76160763	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs10251863	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76160874	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs9691174	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76161087	chr7:76043977~76045963:-
THYM	cis	rs17685	0.664	rs9801113	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76162713	chr7:76043977~76045963:-
THYM	cis	rs17685	0.558	rs60787921	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76163526	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs56965035	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76166352	chr7:76043977~76045963:-
THYM	cis	rs17685	0.672	rs56343450	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76166917	chr7:76043977~76045963:-
THYM	cis	rs17685	0.712	rs60232511	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76170764	chr7:76043977~76045963:-
THYM	cis	rs17685	0.743	rs10277259	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76173356	chr7:76043977~76045963:-
THYM	cis	rs17685	0.753	rs4728586	ENSG00000280388.1	RP11-229D13.3	-4.03	0.000114	0.0494	-0.4	-0.38	Coffee consumption (cups per day);Coffee consumption;	chr7:76173551	chr7:76043977~76045963:-
THYM	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-4.03	0.000114	0.0494	-0.46	-0.38	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	4.03	0.000114	0.0494	0.46	0.38	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	4.03	0.000114	0.0494	0.46	0.38	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
THYM	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	4.03	0.000114	0.0494	0.46	0.38	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
THYM	cis	rs7631605	0.967	rs9859086	ENSG00000272334.1	RP11-129K12.1	-4.03	0.000114	0.0494	-0.39	-0.38	Cerebrospinal P-tau181p levels;	chr3:37104700	chr3:36973117~36973672:-
THYM	cis	rs73198271	0.562	rs17154743	ENSG00000253893.2	FAM85B	4.03	0.000114	0.0494	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793277	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs964772	ENSG00000253893.2	FAM85B	4.03	0.000114	0.0494	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793796	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs964773	ENSG00000253893.2	FAM85B	4.03	0.000114	0.0494	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793804	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.53	rs11778326	ENSG00000253893.2	FAM85B	4.03	0.000114	0.0494	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794056	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs113730597	ENSG00000253893.2	FAM85B	4.03	0.000114	0.0494	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794063	chr8:8167819~8226614:-
THYM	cis	rs73198271	0.562	rs73519953	ENSG00000253893.2	FAM85B	4.03	0.000114	0.0494	0.62	0.38	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802768	chr8:8167819~8226614:-
THYM	cis	rs138641402	1	rs138641402	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1/FVC ratio;Lung function (FEV1);Post bronchodilator FEV1;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;Lung function (FEV1/FVC);Chronic obstructive pulmonary disease;	chr4:144524627	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs13129662	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144533222	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs7435469	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144534398	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs11936476	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144537332	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs720485	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144541436	chr4:143559472~143649305:+
THYM	cis	rs995758	0.903	rs6835650	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144542415	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs11938745	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144544616	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs6537292	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144548816	chr4:143559472~143649305:+
THYM	cis	rs1828590	1	rs1828590	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144552044	chr4:143559472~143649305:+
THYM	cis	rs995758	1	rs1489760	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144553145	chr4:143559472~143649305:+
THYM	cis	rs995758	1	rs12509311	ENSG00000236296.6	GUSBP5	4.03	0.000114	0.0494	0.45	0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144557510	chr4:143559472~143649305:+
THYM	cis	rs995758	0.967	rs13147758	ENSG00000236296.6	GUSBP5	-4.03	0.000114	0.0494	-0.45	-0.38	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144539078	chr4:143559472~143649305:+
THYM	cis	rs397969	0.573	rs203475	ENSG00000231645.2	KRT17P6	-4.03	0.000114	0.0494	-0.47	-0.38	Platelet count;	chr17:19947662	chr17:20512560~20517479:-
THYM	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-4.03	0.000114	0.0494	-0.63	-0.38	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
THYM	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-4.03	0.000114	0.0494	-0.31	-0.38	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
THYM	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-4.03	0.000115	0.0495	-0.44	-0.38	QT interval;	chr12:29349303	chr12:29280418~29317848:-
THYM	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	4.03	0.000115	0.0495	0.44	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
THYM	cis	rs6121246	0.909	rs1994251	ENSG00000230613.1	HM13-AS1	4.03	0.000115	0.0495	0.58	0.38	Mean corpuscular hemoglobin;	chr20:31699525	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs1994250	ENSG00000230613.1	HM13-AS1	4.03	0.000115	0.0495	0.58	0.38	Mean corpuscular hemoglobin;	chr20:31699691	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs1994249	ENSG00000230613.1	HM13-AS1	4.03	0.000115	0.0495	0.58	0.38	Mean corpuscular hemoglobin;	chr20:31699790	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060793	ENSG00000230613.1	HM13-AS1	4.03	0.000115	0.0495	0.58	0.38	Mean corpuscular hemoglobin;	chr20:31701027	chr20:31567707~31573263:-
THYM	cis	rs6121246	0.909	rs6060812	ENSG00000230613.1	HM13-AS1	4.03	0.000115	0.0495	0.58	0.38	Mean corpuscular hemoglobin;	chr20:31705000	chr20:31567707~31573263:-
THYM	cis	rs4835473	0.808	rs4054643	ENSG00000246448.2	RP13-578N3.3	4.03	0.000115	0.0496	0.48	0.38	Immature fraction of reticulocytes;	chr4:143787329	chr4:143700257~143865072:+
THYM	cis	rs4835473	0.838	rs34819068	ENSG00000246448.2	RP13-578N3.3	4.03	0.000115	0.0496	0.48	0.38	Immature fraction of reticulocytes;	chr4:143787330	chr4:143700257~143865072:+
THYM	cis	rs1167832	0.645	rs1167829	ENSG00000205583.12	STAG3L1	-4.03	0.000115	0.0496	-0.35	-0.38	Ankle injury;	chr7:75535697	chr7:75359194~75395383:+
THYM	cis	rs7247513	0.93	rs35275129	ENSG00000213290.4	PGK1P2	-4.03	0.000115	0.0496	-0.43	-0.38	Bipolar disorder;	chr19:12605679	chr19:12559571~12561105:+
THYM	cis	rs7247513	0.897	rs12979146	ENSG00000213290.4	PGK1P2	-4.03	0.000115	0.0496	-0.43	-0.38	Bipolar disorder;	chr19:12607090	chr19:12559571~12561105:+
THYM	cis	rs7959452	0.535	rs1350166	ENSG00000274979.1	RP11-1143G9.5	-4.03	0.000115	0.0496	-0.37	-0.38	Blood protein levels;	chr12:69242534	chr12:69326574~69331882:-
THYM	cis	rs7631605	0.967	rs6769734	ENSG00000272334.1	RP11-129K12.1	-4.03	0.000115	0.0496	-0.38	-0.38	Cerebrospinal P-tau181p levels;	chr3:36982847	chr3:36973117~36973672:-
THYM	cis	rs12902680	0.614	rs35052509	ENSG00000259520.4	CTD-2651B20.3	4.03	0.000115	0.0496	0.39	0.38	Neuroticism;	chr15:46243829	chr15:45251580~45279251:-
THYM	cis	rs2841233	0.558	rs10145270	ENSG00000258811.1	CTD-3051D23.1	4.03	0.000115	0.0496	0.37	0.38	IgG glycosylation;	chr14:104883554	chr14:104842663~104845916:+
THYM	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-4.03	0.000115	0.0496	-0.44	-0.38	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
THYM	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-4.03	0.000115	0.0496	-0.44	-0.38	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
THYM	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	4.03	0.000115	0.0496	0.49	0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
THYM	cis	rs877819	0.583	rs1904600	ENSG00000228403.1	RP11-563N6.6	-4.03	0.000115	0.0496	-0.5	-0.38	Systemic lupus erythematosus;	chr10:48859171	chr10:48878022~48878649:+
THYM	cis	rs877819	0.583	rs2663050	ENSG00000228403.1	RP11-563N6.6	-4.03	0.000115	0.0496	-0.5	-0.38	Systemic lupus erythematosus;	chr10:48862280	chr10:48878022~48878649:+
THYM	cis	rs877819	0.583	rs2940729	ENSG00000228403.1	RP11-563N6.6	-4.03	0.000115	0.0496	-0.5	-0.38	Systemic lupus erythematosus;	chr10:48866159	chr10:48878022~48878649:+
THYM	cis	rs877819	0.583	rs2663019	ENSG00000228403.1	RP11-563N6.6	-4.03	0.000115	0.0496	-0.5	-0.38	Systemic lupus erythematosus;	chr10:48867416	chr10:48878022~48878649:+
THYM	cis	rs877819	0.583	rs2663020	ENSG00000228403.1	RP11-563N6.6	-4.03	0.000115	0.0496	-0.5	-0.38	Systemic lupus erythematosus;	chr10:48868229	chr10:48878022~48878649:+
THYM	cis	rs10129255	0.912	rs61997792	ENSG00000254329.1	IGHVII-60-1	4.03	0.000115	0.0497	0.39	0.38	Kawasaki disease;	chr14:106799304	chr14:106637718~106637973:-
THYM	cis	rs1598856	0.675	rs28871712	ENSG00000251288.2	RP11-10L12.2	-4.03	0.000115	0.0497	-0.41	-0.38	Primary biliary cholangitis;	chr4:102473257	chr4:102751401~102752641:+
THYM	cis	rs7210990	0.83	rs178806	ENSG00000275413.1	CTC-529I10.1	4.03	0.000115	0.0497	0.39	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16197297	chr17:16023323~16023653:-
THYM	cis	rs12902680	0.69	rs1343102	ENSG00000259520.4	CTD-2651B20.3	4.02	0.000115	0.0497	0.4	0.38	Neuroticism;	chr15:46036172	chr15:45251580~45279251:-
THYM	cis	rs4869139	0.967	rs13164745	ENSG00000272021.1	AC008592.8	4.02	0.000115	0.0497	0.41	0.38	Body mass index;	chr5:96501629	chr5:95849309~95849855:+
THYM	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-4.02	0.000115	0.0497	-0.34	-0.38	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-4.02	0.000115	0.0497	-0.34	-0.38	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-4.02	0.000115	0.0497	-0.34	-0.38	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
THYM	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-4.02	0.000115	0.0497	-0.34	-0.38	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
THYM	cis	rs12902680	0.706	rs12914435	ENSG00000259520.4	CTD-2651B20.3	4.02	0.000115	0.0497	0.41	0.38	Neuroticism;	chr15:46167415	chr15:45251580~45279251:-
THYM	cis	rs17818399	0.781	rs4952837	ENSG00000279254.1	RP11-536C12.1	-4.02	0.000116	0.0499	-0.44	-0.38	Height;	chr2:46638595	chr2:46668870~46670778:+
THYM	cis	rs17818399	0.781	rs6746598	ENSG00000279254.1	RP11-536C12.1	-4.02	0.000116	0.0499	-0.44	-0.38	Height;	chr2:46638634	chr2:46668870~46670778:+
THYM	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	4.02	0.000116	0.0499	0.4	0.38	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
THYM	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	4.02	0.000116	0.0499	0.4	0.38	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
THYM	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-4.02	0.000116	0.0499	-0.49	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
THYM	cis	rs7223966	1	rs8075273	ENSG00000240280.5	TCAM1P	-4.02	0.000116	0.0499	-0.59	-0.38	Hip circumference adjusted for BMI;Body mass index;	chr17:63651521	chr17:63849292~63864379:+
THYM	cis	rs17473412	1	rs17408604	ENSG00000250539.1	KRT8P33	4.02	0.000116	0.0499	0.48	0.38	Total body bone mineral density;	chr5:123391089	chr5:123400922~123402344:-
THYM	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	4.02	0.000116	0.0499	0.51	0.38	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
THYM	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	4.02	0.000116	0.0499	0.46	0.38	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
THYM	cis	rs4964805	1	rs34307072	ENSG00000257681.1	RP11-341G23.4	4.02	0.000116	0.0499	0.46	0.38	Attention deficit hyperactivity disorder;	chr12:103802526	chr12:103746315~103768858:-
THYM	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	4.02	0.000116	0.0499	0.61	0.38	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
THYM	cis	rs9733	0.596	rs3087960	ENSG00000220323.3	HIST2H2BD	-4.02	0.000116	0.05	-0.37	-0.38	Tonsillectomy;	chr1:150648093	chr1:149843041~149843533:+
THYM	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	19.17	3.02e-34	1.51e-24	1.22	0.89	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	18.93	7.79e-34	3.17e-24	1.19	0.89	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-18.87	1e-33	3.27e-24	-1.22	-0.89	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	18.87	1e-33	3.27e-24	1.22	0.89	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	18.87	1e-33	3.27e-24	1.22	0.89	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
THYM	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	18.35	7.86e-33	1.71e-23	1.1	0.88	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
THYM	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	18.35	7.86e-33	1.71e-23	1.1	0.88	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
THYM	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	18.35	7.86e-33	1.71e-23	1.1	0.88	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
THYM	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	18.35	7.86e-33	1.71e-23	1.1	0.88	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
THYM	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	18.35	7.86e-33	1.71e-23	1.1	0.88	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
THYM	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	18.08	2.35e-32	4.93e-23	1.09	0.88	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
THYM	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	17.94	4.09e-32	8.33e-23	1.09	0.88	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
THYM	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	17.71	1.08e-31	2.06e-22	1.22	0.88	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	17.6	1.66e-31	3.01e-22	1.19	0.88	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	17.6	1.66e-31	3.01e-22	1.19	0.88	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
THYM	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	17.48	2.77e-31	4.87e-22	1.13	0.87	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
THYM	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	17.24	7.26e-31	1.13e-21	1.14	0.87	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	17.18	9.44e-31	1.43e-21	1.14	0.87	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
THYM	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	17.01	1.94e-30	2.25e-21	1.19	0.87	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
THYM	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	16.91	2.88e-30	2.25e-21	1.13	0.87	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
THYM	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	16.72	6.4e-30	2.32e-21	1.2	0.87	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	16.12	8.2e-29	2.74e-20	1.18	0.86	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
THYM	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-15.97	1.58e-28	5.01e-20	-1.08	-0.85	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-15.97	1.58e-28	5.01e-20	-1.08	-0.85	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-15.97	1.58e-28	5.01e-20	-1.08	-0.85	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-15.97	1.58e-28	5.01e-20	-1.08	-0.85	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-15.91	2.05e-28	6.4e-20	-1.1	-0.85	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-15.85	2.71e-28	8.06e-20	-1.09	-0.85	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-15.85	2.71e-28	8.06e-20	-1.09	-0.85	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-15.85	2.71e-28	8.06e-20	-1.09	-0.85	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
THYM	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-15.85	2.71e-28	8.06e-20	-1.09	-0.85	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
THYM	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	15.85	2.71e-28	8.06e-20	1.09	0.85	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
THYM	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	15.8	3.3e-28	9.79e-20	1.19	0.85	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
THYM	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-15.69	5.28e-28	1.54e-19	-1.04	-0.85	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
THYM	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-15.63	6.91e-28	1.98e-19	-1.34	-0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
THYM	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	15.54	1.02e-27	2.91e-19	1.1	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
THYM	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	15.5	1.26e-27	3.53e-19	1.14	0.85	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
THYM	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	15.46	1.45e-27	4.04e-19	1.11	0.85	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
THYM	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	15.32	2.73e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	15.31	2.81e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	15.31	2.81e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	15.31	2.81e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	15.31	2.81e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	15.31	2.81e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	15.31	2.81e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	15.31	2.81e-27	7.49e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	15.3	2.92e-27	7.75e-19	1.1	0.84	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
THYM	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	15.14	5.87e-27	1.5e-18	1.36	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	15.14	5.87e-27	1.5e-18	1.36	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	15.12	6.59e-27	1.6e-18	1.36	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	15.12	6.59e-27	1.6e-18	1.36	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	15.12	6.59e-27	1.6e-18	1.36	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	15.12	6.59e-27	1.6e-18	1.36	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	15.12	6.59e-27	1.6e-18	1.36	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
THYM	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	15.09	7.39e-27	1.78e-18	1.41	0.84	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	15.09	7.39e-27	1.78e-18	1.41	0.84	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
THYM	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	15.08	7.75e-27	1.86e-18	1.34	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	15.06	8.52e-27	2.03e-18	1.37	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
THYM	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	14.95	1.39e-26	3.27e-18	1.39	0.84	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	14.95	1.39e-26	3.27e-18	1.39	0.84	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	14.95	1.39e-26	3.27e-18	1.39	0.84	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	14.93	1.52e-26	3.54e-18	1.41	0.84	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	14.93	1.52e-26	3.54e-18	1.41	0.84	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	14.93	1.52e-26	3.54e-18	1.41	0.84	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	14.93	1.52e-26	3.54e-18	1.41	0.84	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
THYM	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	14.72	3.83e-26	8.41e-18	1.34	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	14.72	3.83e-26	8.41e-18	1.34	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
THYM	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	14.68	4.6e-26	1e-17	1.38	0.83	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	14.68	4.6e-26	1e-17	1.38	0.83	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	14.68	4.6e-26	1e-17	1.38	0.83	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
THYM	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	14.53	9.07e-26	1.92e-17	1.35	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	14.53	9.07e-26	1.92e-17	1.35	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
THYM	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	14.53	9.19e-26	1.93e-17	1.4	0.83	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	14.53	9.19e-26	1.93e-17	1.4	0.83	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	14.53	9.19e-26	1.93e-17	1.4	0.83	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
THYM	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	14.47	1.19e-25	2.38e-17	1.34	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
THYM	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	14.45	1.28e-25	2.54e-17	1.39	0.83	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
THYM	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	14.44	1.34e-25	2.66e-17	1.05	0.83	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
THYM	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	14.42	1.52e-25	3e-17	1.07	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-14.38	1.76e-25	3.44e-17	-1.08	-0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	14.3	2.54e-25	4.69e-17	1.08	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	14.3	2.54e-25	4.69e-17	1.08	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	14.3	2.54e-25	4.69e-17	1.08	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	14.3	2.54e-25	4.69e-17	1.08	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	14.3	2.54e-25	4.69e-17	1.08	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	14.3	2.54e-25	4.69e-17	1.08	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-14.3	2.58e-25	4.74e-17	-1.07	-0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-14.3	2.58e-25	4.74e-17	-1.07	-0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
THYM	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	14.27	2.9e-25	5.3e-17	1.08	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
THYM	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	14.15	5.16e-25	9.31e-17	1.31	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	14.15	5.16e-25	9.31e-17	1.31	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	13.99	1.05e-24	1.73e-16	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	13.96	1.19e-24	1.95e-16	1.33	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	13.95	1.26e-24	2.07e-16	1.3	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	13.71	3.84e-24	5.77e-16	1.22	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	13.71	3.84e-24	5.77e-16	1.22	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	13.67	4.45e-24	6.59e-16	1.25	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	13.45	1.26e-23	1.8e-15	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	13.45	1.26e-23	1.8e-15	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	13.45	1.26e-23	1.8e-15	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	13.45	1.26e-23	1.8e-15	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	13.45	1.26e-23	1.8e-15	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	13.41	1.49e-23	2.11e-15	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	13.41	1.49e-23	2.11e-15	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
THYM	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	13.37	1.83e-23	2.48e-15	1.07	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
THYM	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-13.36	1.86e-23	2.48e-15	-1.09	-0.81	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	13.36	1.86e-23	2.48e-15	1.09	0.81	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	13.36	1.9e-23	2.5e-15	1.1	0.81	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
THYM	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	13.36	1.9e-23	2.5e-15	1.1	0.81	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	13.36	1.9e-23	2.5e-15	1.1	0.81	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
THYM	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	13.35	1.98e-23	2.57e-15	1.02	0.81	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	13.35	1.98e-23	2.57e-15	1.02	0.81	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	13.35	1.98e-23	2.57e-15	1.02	0.81	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	13.35	1.98e-23	2.57e-15	1.02	0.81	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	13.35	1.98e-23	2.57e-15	1.02	0.81	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
THYM	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	13.33	2.15e-23	2.76e-15	1.1	0.81	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	13.33	2.15e-23	2.76e-15	1.1	0.81	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	13.33	2.15e-23	2.76e-15	1.1	0.81	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	13.33	2.15e-23	2.76e-15	1.1	0.81	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	13.29	2.65e-23	3.34e-15	1.24	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	13.27	2.84e-23	3.55e-15	1.21	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
THYM	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	13.24	3.29e-23	4.07e-15	1.04	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
THYM	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-13.21	3.88e-23	4.75e-15	-1.1	-0.81	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-13.21	3.88e-23	4.75e-15	-1.1	-0.81	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-13.21	3.88e-23	4.75e-15	-1.1	-0.81	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	13.2	3.98e-23	4.85e-15	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-13.18	4.32e-23	5.2e-15	-1.1	-0.81	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-13.18	4.32e-23	5.2e-15	-1.1	-0.81	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-13.18	4.32e-23	5.2e-15	-1.1	-0.81	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-13.18	4.32e-23	5.2e-15	-1.1	-0.81	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-13.17	4.65e-23	5.59e-15	-1.19	-0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
THYM	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	13.09	6.74e-23	7.91e-15	1.31	0.8	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
THYM	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	13.06	7.62e-23	8.79e-15	1.01	0.8	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	13.06	7.62e-23	8.79e-15	1.01	0.8	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	13.06	7.62e-23	8.79e-15	1.01	0.8	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	13.06	7.62e-23	8.79e-15	1.01	0.8	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	13.06	7.62e-23	8.79e-15	1.01	0.8	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	13.06	7.62e-23	8.79e-15	1.01	0.8	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	13.03	8.69e-23	9.93e-15	1.01	0.8	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	13.03	8.69e-23	9.93e-15	1.01	0.8	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-13.03	8.69e-23	9.93e-15	-1.01	-0.8	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	12.99	1.08e-22	1.22e-14	1.01	0.8	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
THYM	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	12.98	1.14e-22	1.28e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	12.98	1.14e-22	1.28e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	12.97	1.17e-22	1.3e-14	1.23	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	12.97	1.17e-22	1.3e-14	1.23	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	12.95	1.26e-22	1.4e-14	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	12.92	1.45e-22	1.57e-14	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
THYM	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	12.91	1.55e-22	1.67e-14	1.01	0.8	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
THYM	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	12.89	1.71e-22	1.8e-14	1.36	0.8	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	12.89	1.71e-22	1.8e-14	1.36	0.8	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	12.89	1.71e-22	1.8e-14	1.36	0.8	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	12.89	1.71e-22	1.8e-14	1.36	0.8	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	12.89	1.71e-22	1.8e-14	1.36	0.8	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	12.89	1.71e-22	1.8e-14	1.36	0.8	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
THYM	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	12.87	1.85e-22	1.94e-14	1.03	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
THYM	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	12.85	2.04e-22	2.14e-14	1.08	0.8	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	12.83	2.25e-22	2.33e-14	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	12.83	2.25e-22	2.33e-14	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
THYM	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	12.82	2.39e-22	2.46e-14	1.37	0.8	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
THYM	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-12.81	2.49e-22	2.55e-14	-1.08	-0.8	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-12.81	2.49e-22	2.55e-14	-1.08	-0.8	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-12.81	2.49e-22	2.55e-14	-1.08	-0.8	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	12.79	2.78e-22	2.81e-14	1.06	0.8	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	12.79	2.78e-22	2.81e-14	1.06	0.8	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	12.77	3.05e-22	3.01e-14	1.02	0.8	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-12.77	3.05e-22	3.01e-14	-1.02	-0.8	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	12.76	3.18e-22	3.1e-14	1.02	0.8	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	12.76	3.18e-22	3.1e-14	1.02	0.8	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	12.76	3.18e-22	3.1e-14	1.02	0.8	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	12.76	3.18e-22	3.1e-14	1.02	0.8	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	12.76	3.18e-22	3.1e-14	1.02	0.8	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	12.76	3.18e-22	3.1e-14	1.02	0.8	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	12.75	3.24e-22	3.1e-14	1.07	0.8	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	12.75	3.35e-22	3.19e-14	1.05	0.8	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	12.72	3.84e-22	3.62e-14	1.02	0.8	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
THYM	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	12.68	4.45e-22	4.17e-14	1.37	0.79	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	12.68	4.45e-22	4.17e-14	1.37	0.79	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
THYM	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-12.66	4.94e-22	4.48e-14	-1.08	-0.79	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-12.66	4.94e-22	4.48e-14	-1.08	-0.79	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	12.66	4.94e-22	4.48e-14	1.08	0.79	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
THYM	trans	rs877636	0.562	rs10876864	ENSG00000212994.5	RPS26P6	-12.65	5.28e-22	4.78e-14	-0.94	-0.79	Cognitive function;	chr12:56007301	chr8:100895771~100896118:+
THYM	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	12.65	5.34e-22	4.82e-14	1.02	0.79	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	12.65	5.34e-22	4.82e-14	1.02	0.79	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	12.62	5.95e-22	5.35e-14	1.2	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
THYM	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	12.62	5.98e-22	5.37e-14	1.36	0.79	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
THYM	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	12.62	6.03e-22	5.41e-14	1.21	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
THYM	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-12.62	6.04e-22	5.41e-14	-1.07	-0.79	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	12.61	6.35e-22	5.6e-14	1.02	0.79	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	12.61	6.35e-22	5.6e-14	1.02	0.79	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	12.61	6.35e-22	5.6e-14	1.02	0.79	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	12.61	6.35e-22	5.6e-14	1.02	0.79	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	12.61	6.35e-22	5.6e-14	1.02	0.79	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	12.61	6.35e-22	5.6e-14	1.02	0.79	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
THYM	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	12.59	6.89e-22	6.04e-14	1.09	0.79	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	12.59	6.89e-22	6.04e-14	1.09	0.79	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
THYM	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	12.58	7.38e-22	6.45e-14	1.37	0.79	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
THYM	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	12.57	7.81e-22	6.8e-14	1.34	0.79	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
THYM	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-12.54	8.74e-22	7.59e-14	-1.21	-0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	12.54	8.84e-22	7.65e-14	1.08	0.79	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	12.54	8.84e-22	7.65e-14	1.08	0.79	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	12.52	9.53e-22	8.19e-14	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	12.52	9.53e-22	8.19e-14	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
THYM	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	12.51	1.02e-21	8.73e-14	1.08	0.79	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
THYM	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	12.51	1.03e-21	8.77e-14	1.22	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	12.5	1.07e-21	9.09e-14	1.06	0.79	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	12.49	1.1e-21	9.31e-14	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	12.49	1.1e-21	9.31e-14	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	12.49	1.1e-21	9.31e-14	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	12.49	1.1e-21	9.31e-14	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	12.49	1.1e-21	9.31e-14	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	12.47	1.2e-21	1.01e-13	1.2	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-12.47	1.2e-21	1.01e-13	-1.08	-0.79	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-12.45	1.33e-21	1.1e-13	-1.13	-0.79	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	12.45	1.36e-21	1.13e-13	1.24	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
THYM	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	12.42	1.58e-21	1.29e-13	1.09	0.79	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
THYM	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	12.42	1.58e-21	1.29e-13	1.23	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	12.42	1.58e-21	1.29e-13	1.23	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	12.4	1.75e-21	1.42e-13	1.13	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
THYM	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	12.38	1.84e-21	1.5e-13	1.01	0.79	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	12.35	2.12e-21	1.71e-13	1.2	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	12.34	2.29e-21	1.84e-13	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	12.34	2.29e-21	1.84e-13	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	12.33	2.33e-21	1.87e-13	1.11	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	12.33	2.33e-21	1.87e-13	1.11	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
THYM	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	12.31	2.58e-21	2.05e-13	1.08	0.79	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
THYM	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	12.31	2.59e-21	2.05e-13	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	12.29	2.86e-21	2.27e-13	1.1	0.79	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	12.28	2.96e-21	2.34e-13	1.2	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
THYM	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-12.26	3.36e-21	2.64e-13	-1.06	-0.78	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	12.22	3.94e-21	3.04e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	12.22	3.94e-21	3.04e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	12.22	4.08e-21	3.14e-13	1.04	0.78	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
THYM	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	12.21	4.11e-21	3.16e-13	1.1	0.78	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
THYM	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	12.21	4.15e-21	3.18e-13	1.2	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	12.21	4.15e-21	3.18e-13	1.2	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
THYM	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	12.21	4.18e-21	3.19e-13	0.91	0.78	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
THYM	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	12.21	4.25e-21	3.2e-13	1.23	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
THYM	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	12.18	4.82e-21	3.6e-13	1.09	0.78	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
THYM	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	12.12	6.38e-21	4.74e-13	1.12	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
THYM	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	12.12	6.46e-21	4.79e-13	1.05	0.78	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
THYM	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	12.1	6.95e-21	5.14e-13	1.04	0.78	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
THYM	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-12.05	8.9e-21	6.55e-13	-1.2	-0.78	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
THYM	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	11.99	1.21e-20	8.83e-13	0.96	0.78	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	11.94	1.49e-20	1.06e-12	1.04	0.78	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
THYM	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	11.94	1.49e-20	1.06e-12	1.04	0.78	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
THYM	trans	rs1816752	1	rs9511272	ENSG00000237917.1	PARP4P1	11.94	1.49e-20	1.06e-12	1.04	0.78	Obesity-related traits;	chr13:24446495	chrY:26594851~26634652:-
THYM	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	11.94	1.55e-20	1.09e-12	1.08	0.78	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
THYM	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	11.9	1.8e-20	1.27e-12	1.12	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	11.9	1.8e-20	1.27e-12	1.12	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-11.9	1.88e-20	1.31e-12	-1.02	-0.78	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	11.9	1.89e-20	1.31e-12	0.95	0.78	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	11.9	1.89e-20	1.31e-12	0.95	0.78	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	11.9	1.89e-20	1.31e-12	0.95	0.78	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	11.9	1.89e-20	1.31e-12	0.95	0.78	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	11.9	1.89e-20	1.31e-12	0.95	0.78	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	11.9	1.89e-20	1.31e-12	0.95	0.78	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-11.89	1.96e-20	1.36e-12	-1.05	-0.77	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-11.89	1.96e-20	1.36e-12	-1.05	-0.77	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-11.89	1.96e-20	1.36e-12	-1.05	-0.77	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
THYM	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	11.88	2.06e-20	1.41e-12	0.96	0.77	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	11.88	2.06e-20	1.41e-12	0.96	0.77	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	11.88	2.06e-20	1.41e-12	0.96	0.77	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	11.88	2.06e-20	1.41e-12	0.96	0.77	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
THYM	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	11.87	2.13e-20	1.46e-12	0.95	0.77	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
THYM	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	11.85	2.34e-20	1.59e-12	1.1	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	11.82	2.73e-20	1.83e-12	1.09	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
THYM	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-11.81	2.83e-20	1.85e-12	-1.01	-0.77	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-11.81	2.87e-20	1.85e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	11.81	2.87e-20	1.85e-12	1.19	0.77	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
THYM	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	11.8	3.01e-20	1.92e-12	0.95	0.77	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
THYM	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	11.8	3.01e-20	1.92e-12	0.96	0.77	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	11.8	3.01e-20	1.92e-12	0.96	0.77	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	11.8	3.01e-20	1.92e-12	0.96	0.77	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	11.8	3.01e-20	1.92e-12	0.96	0.77	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
THYM	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-11.79	3.07e-20	1.96e-12	-1.09	-0.77	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
THYM	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-11.78	3.22e-20	2.05e-12	-0.95	-0.77	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
THYM	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-11.78	3.29e-20	2.09e-12	-1.01	-0.77	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-11.78	3.29e-20	2.09e-12	-1.01	-0.77	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	11.77	3.45e-20	2.19e-12	1.14	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-11.77	3.51e-20	2.22e-12	-1.02	-0.77	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	11.77	3.52e-20	2.22e-12	1.21	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-11.76	3.55e-20	2.24e-12	-0.91	-0.77	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
THYM	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	11.75	3.78e-20	2.36e-12	1.1	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	11.72	4.33e-20	2.66e-12	1.01	0.77	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-11.72	4.36e-20	2.67e-12	-1.06	-0.77	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-11.72	4.36e-20	2.67e-12	-1.06	-0.77	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-11.72	4.36e-20	2.67e-12	-1.06	-0.77	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	11.71	4.52e-20	2.74e-12	1	0.77	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.581	rs2245384	ENSG00000213058.3	RP4-765C7.2	11.71	4.56e-20	2.76e-12	1.14	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:178411616~178411972:+
THYM	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	11.71	4.68e-20	2.83e-12	1	0.77	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	11.7	4.89e-20	2.95e-12	1.18	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
THYM	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-11.69	4.98e-20	3e-12	-1.19	-0.77	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
THYM	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	11.69	5.06e-20	3.04e-12	0.95	0.77	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
THYM	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	11.69	5.13e-20	3.08e-12	1	0.77	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	11.65	6.03e-20	3.59e-12	1.14	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
THYM	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-11.61	7.56e-20	4.39e-12	-0.89	-0.77	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
THYM	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-11.61	7.56e-20	4.39e-12	-0.89	-0.77	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
THYM	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	11.6	7.6e-20	4.39e-12	0.97	0.77	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	11.6	7.75e-20	4.47e-12	1.11	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	11.6	7.86e-20	4.51e-12	1.03	0.77	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	11.6	7.86e-20	4.51e-12	1.03	0.77	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	11.6	7.86e-20	4.51e-12	1.03	0.77	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	11.6	7.86e-20	4.51e-12	1.03	0.77	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-11.6	7.87e-20	4.51e-12	-1.01	-0.77	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-11.59	8.03e-20	4.59e-12	-1.1	-0.77	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	11.58	8.43e-20	4.82e-12	0.97	0.77	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
THYM	trans	rs2657294	0.603	rs11543	ENSG00000172974.11	AC007318.5	11.56	9.28e-20	5.28e-12	0.72	0.77	Pneumonia;	chr10:75210855	chr2:65205108~65205988:+
THYM	trans	rs13177918	0.581	rs2748244	ENSG00000213058.3	RP4-765C7.2	11.56	9.44e-20	5.37e-12	1.09	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr1:178411616~178411972:+
THYM	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-11.55	9.76e-20	5.51e-12	-1.06	-0.77	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-11.55	9.76e-20	5.51e-12	-1.06	-0.77	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-11.54	1.03e-19	5.8e-12	-1.07	-0.77	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	11.54	1.04e-19	5.84e-12	1.13	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
THYM	trans	rs12291225	0.546	rs11023199	ENSG00000236360.2	RP11-334A14.2	11.53	1.07e-19	6.04e-12	0.96	0.77	Sense of smell;	chr11:14372712	chr1:52993201~52993702:-
THYM	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-11.51	1.2e-19	6.74e-12	-1	-0.76	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	11.5	1.26e-19	7.05e-12	1.11	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	11.5	1.26e-19	7.05e-12	1.11	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
THYM	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	11.48	1.37e-19	7.62e-12	0.97	0.76	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	11.39	2.13e-19	1.16e-11	1.12	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
THYM	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	11.37	2.33e-19	1.27e-11	0.94	0.76	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	11.37	2.33e-19	1.27e-11	0.94	0.76	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
THYM	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	11.35	2.64e-19	1.42e-11	1.06	0.76	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
THYM	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	11.34	2.7e-19	1.46e-11	1.12	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-11.34	2.72e-19	1.47e-11	-1	-0.76	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	11.33	2.88e-19	1.54e-11	1.15	0.76	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000235459.5	RPS26P31	-11.29	3.41e-19	1.81e-11	-0.92	-0.76	Cognitive function;	chr12:56007301	chr7:122681315~122681662:+
THYM	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	11.26	3.91e-19	2.07e-11	0.93	0.76	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
THYM	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	11.25	4.1e-19	2.16e-11	1.12	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	11.25	4.1e-19	2.16e-11	1.12	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
THYM	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	11.25	4.28e-19	2.24e-11	1.16	0.76	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	11.25	4.28e-19	2.24e-11	1.16	0.76	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
THYM	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	11.24	4.43e-19	2.32e-11	0.99	0.76	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
THYM	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	11.22	4.78e-19	2.49e-11	1.02	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-11.22	4.81e-19	2.5e-11	-1.01	-0.76	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-11.22	4.81e-19	2.5e-11	-1.01	-0.76	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
THYM	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	11.21	5.09e-19	2.64e-11	1.03	0.76	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
THYM	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-11.21	5.19e-19	2.69e-11	-1.04	-0.76	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-11.21	5.19e-19	2.69e-11	-1.04	-0.76	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-11.2	5.3e-19	2.74e-11	-0.96	-0.76	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-11.19	5.5e-19	2.84e-11	-1.07	-0.76	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	11.19	5.68e-19	2.93e-11	0.96	0.76	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	11.19	5.68e-19	2.93e-11	0.96	0.76	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	11.18	5.81e-19	2.99e-11	0.98	0.76	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
THYM	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-11.17	6.23e-19	3.2e-11	-0.88	-0.76	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
THYM	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-11.17	6.29e-19	3.23e-11	-1.08	-0.76	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-11.16	6.45e-19	3.3e-11	-1.01	-0.75	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-11.16	6.45e-19	3.3e-11	-1.01	-0.75	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-11.16	6.45e-19	3.3e-11	-1.01	-0.75	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-11.16	6.45e-19	3.3e-11	-1.01	-0.75	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-11.16	6.45e-19	3.3e-11	-1.01	-0.75	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	11.15	6.64e-19	3.38e-11	1.12	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-11.09	9.12e-19	4.55e-11	-1.05	-0.75	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-11.09	9.12e-19	4.55e-11	-1.05	-0.75	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	11.07	1.01e-18	5.01e-11	0.97	0.75	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-11.06	1.04e-18	5.15e-11	-1.06	-0.75	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-11	1.41e-18	6.92e-11	-1.03	-0.75	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
THYM	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-10.99	1.49e-18	7.32e-11	-0.87	-0.75	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
THYM	trans	rs13177918	0.559	rs3901731	ENSG00000213058.3	RP4-765C7.2	10.99	1.49e-18	7.32e-11	1.07	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.581	rs2245384	ENSG00000224114.1	RP11-343H5.4	10.97	1.63e-18	7.81e-11	1.04	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:206695837~206696269:-
THYM	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-10.96	1.72e-18	8.18e-11	-0.96	-0.75	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-10.96	1.72e-18	8.18e-11	-0.96	-0.75	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-10.96	1.72e-18	8.18e-11	-0.96	-0.75	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
THYM	trans	rs877636	0.562	rs10876864	ENSG00000243403.1	RP11-330L19.1	-10.96	1.72e-18	8.18e-11	-0.9	-0.75	Cognitive function;	chr12:56007301	chr15:64592979~64593326:+
THYM	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	10.96	1.73e-18	8.23e-11	1.09	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
THYM	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	10.94	1.92e-18	9.09e-11	0.99	0.75	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-10.93	1.99e-18	9.21e-11	-1.15	-0.75	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	10.93	1.99e-18	9.21e-11	1.15	0.75	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
THYM	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	10.93	2.02e-18	9.25e-11	0.98	0.75	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
THYM	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	10.93	2.02e-18	9.25e-11	0.98	0.75	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
THYM	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-10.93	2.02e-18	9.25e-11	-0.98	-0.75	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	10.92	2.08e-18	9.53e-11	0.88	0.75	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
THYM	trans	rs7121616	0.545	rs116414356	ENSG00000234176.1	HSPA8P1	10.9	2.24e-18	1.02e-10	1.07	0.75	Breast cancer;	chr11:123082611	chrX:121203182~121205014:-
THYM	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-10.9	2.28e-18	1.04e-10	-0.94	-0.75	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	10.9	2.28e-18	1.04e-10	0.94	0.75	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	10.9	2.28e-18	1.04e-10	0.94	0.75	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	10.9	2.28e-18	1.04e-10	0.94	0.75	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	10.88	2.57e-18	1.16e-10	0.86	0.75	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
THYM	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-10.86	2.74e-18	1.24e-10	-0.97	-0.75	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-10.84	3.05e-18	1.37e-10	-0.95	-0.75	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-10.84	3.05e-18	1.37e-10	-0.95	-0.75	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
THYM	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	10.83	3.2e-18	1.43e-10	1	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	10.83	3.21e-18	1.44e-10	1.01	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
THYM	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	10.82	3.45e-18	1.53e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
THYM	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	10.8	3.75e-18	1.66e-10	1.02	0.74	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	10.79	3.86e-18	1.7e-10	0.84	0.74	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
THYM	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	10.77	4.39e-18	1.94e-10	1.02	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
THYM	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-10.76	4.47e-18	1.97e-10	-1.14	-0.74	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-10.76	4.47e-18	1.97e-10	-1.14	-0.74	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
THYM	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
THYM	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-10.76	4.6e-18	2.02e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
THYM	trans	rs13177918	0.501	rs2545345	ENSG00000213058.3	RP4-765C7.2	10.74	4.89e-18	2.14e-10	1.13	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464080	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	10.74	5.06e-18	2.21e-10	0.99	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
THYM	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	10.73	5.21e-18	2.26e-10	1.14	0.74	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
THYM	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-10.72	5.41e-18	2.34e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
THYM	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	10.72	5.52e-18	2.38e-10	1	0.74	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	10.7	5.9e-18	2.51e-10	1	0.74	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
THYM	trans	rs13177918	0.501	rs2545345	ENSG00000239528.1	RPS14P8	10.7	6.04e-18	2.56e-10	1.09	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464080	chr5:116562562~116562930:+
THYM	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	10.69	6.35e-18	2.69e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	10.69	6.35e-18	2.69e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
THYM	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	10.69	6.35e-18	2.69e-10	1	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
THYM	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-10.69	6.41e-18	2.71e-10	-0.85	-0.74	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
THYM	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-10.68	6.72e-18	2.82e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-10.68	6.72e-18	2.82e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-10.68	6.72e-18	2.82e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
THYM	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	10.66	7.45e-18	3.08e-10	1	0.74	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
THYM	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-10.63	8.54e-18	3.51e-10	-0.82	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-10.63	8.54e-18	3.51e-10	-0.82	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-10.63	8.54e-18	3.51e-10	-0.82	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
THYM	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-10.62	8.88e-18	3.64e-10	-0.83	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
THYM	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-10.61	9.27e-18	3.78e-10	-1.13	-0.74	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	10.61	9.27e-18	3.78e-10	1.13	0.74	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	10.61	9.27e-18	3.78e-10	1.13	0.74	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-10.61	9.5e-18	3.87e-10	-0.87	-0.74	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
THYM	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	10.6	9.66e-18	3.94e-10	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
THYM	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-10.56	1.18e-17	4.73e-10	-0.85	-0.74	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
THYM	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-10.56	1.18e-17	4.73e-10	-0.85	-0.74	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
THYM	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	10.56	1.22e-17	4.88e-10	0.99	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	10.56	1.22e-17	4.88e-10	0.99	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	10.56	1.22e-17	4.88e-10	0.99	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
THYM	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	10.54	1.34e-17	5.34e-10	1.4	0.74	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
THYM	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	10.53	1.35e-17	5.41e-10	1.02	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
THYM	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-10.52	1.44e-17	5.71e-10	-0.93	-0.74	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-10.51	1.51e-17	6e-10	-0.85	-0.74	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
THYM	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	10.51	1.52e-17	6.01e-10	0.93	0.74	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
THYM	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	10.51	1.52e-17	6.01e-10	0.93	0.74	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
THYM	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	10.51	1.52e-17	6.01e-10	0.93	0.74	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
THYM	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	10.51	1.52e-17	6.01e-10	0.93	0.74	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
THYM	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	10.51	1.52e-17	6.01e-10	0.93	0.74	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
THYM	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-10.46	1.91e-17	7.54e-10	-0.94	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-10.46	1.97e-17	7.74e-10	-1.01	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
THYM	trans	rs13177918	0.581	rs2748244	ENSG00000224114.1	RP11-343H5.4	10.45	2.03e-17	8e-10	0.98	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr1:206695837~206696269:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-10.44	2.09e-17	8.22e-10	-0.83	-0.73	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
THYM	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-10.44	2.09e-17	8.22e-10	-0.83	-0.73	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
THYM	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	10.44	2.18e-17	8.49e-10	1.12	0.73	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	10.44	2.18e-17	8.49e-10	1.12	0.73	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
THYM	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	10.43	2.3e-17	8.96e-10	0.81	0.73	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
THYM	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	10.42	2.32e-17	9e-10	1.39	0.73	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
THYM	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	10.42	2.32e-17	9e-10	1.39	0.73	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
THYM	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	10.4	2.65e-17	1.03e-09	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
THYM	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	10.39	2.74e-17	1.06e-09	0.91	0.73	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
THYM	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
THYM	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
THYM	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
THYM	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-10.38	2.85e-17	1.1e-09	-0.97	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
THYM	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-10.37	2.97e-17	1.13e-09	-1.14	-0.73	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
THYM	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	10.36	3.21e-17	1.22e-09	1.39	0.73	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
THYM	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	10.36	3.21e-17	1.22e-09	1.39	0.73	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
THYM	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-10.36	3.21e-17	1.22e-09	-1.39	-0.73	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
THYM	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	10.36	3.21e-17	1.22e-09	1.39	0.73	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
THYM	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-10.36	3.21e-17	1.22e-09	-1.39	-0.73	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
THYM	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	10.35	3.35e-17	1.27e-09	0.91	0.73	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
THYM	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-10.34	3.44e-17	1.3e-09	-0.83	-0.73	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
THYM	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-10.33	3.71e-17	1.39e-09	-0.84	-0.73	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
THYM	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	10.32	3.92e-17	1.42e-09	0.81	0.73	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	10.32	3.92e-17	1.42e-09	0.81	0.73	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	10.32	3.92e-17	1.42e-09	0.81	0.73	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	10.32	3.92e-17	1.42e-09	0.81	0.73	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	10.32	3.92e-17	1.42e-09	0.81	0.73	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	10.32	3.92e-17	1.42e-09	0.81	0.73	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	10.32	3.92e-17	1.42e-09	0.81	0.73	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
THYM	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-10.31	4.08e-17	1.48e-09	-0.83	-0.73	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
THYM	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-10.3	4.29e-17	1.55e-09	-0.85	-0.73	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
THYM	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	10.29	4.46e-17	1.61e-09	1.01	0.73	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
THYM	trans	rs13177918	0.501	rs2545345	ENSG00000224114.1	RP11-343H5.4	10.27	4.87e-17	1.75e-09	1.04	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464080	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.581	rs2245384	ENSG00000239528.1	RPS14P8	10.24	5.78e-17	2.06e-09	1.04	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-10.23	5.94e-17	2.11e-09	-0.98	-0.73	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
THYM	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	10.22	6.32e-17	2.24e-09	0.83	0.73	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
THYM	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	10.21	6.44e-17	2.28e-09	0.92	0.73	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
THYM	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-10.21	6.71e-17	2.37e-09	-0.91	-0.73	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
THYM	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	10.2	6.97e-17	2.46e-09	0.8	0.72	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
THYM	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-10.19	7.41e-17	2.61e-09	-0.92	-0.72	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
THYM	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-10.17	8.15e-17	2.85e-09	-0.94	-0.72	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	10.16	8.23e-17	2.87e-09	1.11	0.72	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
THYM	trans	rs13177918	0.581	rs2748244	ENSG00000239528.1	RPS14P8	10.15	8.62e-17	3e-09	1	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr5:116562562~116562930:+
THYM	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	10.15	8.89e-17	3.06e-09	1.1	0.72	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	10.15	8.89e-17	3.06e-09	1.1	0.72	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	10.15	8.89e-17	3.06e-09	1.1	0.72	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
THYM	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-10.14	9.4e-17	3.18e-09	-0.9	-0.72	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
THYM	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-10.12	1.04e-16	3.49e-09	-0.83	-0.72	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
THYM	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-10.12	1.04e-16	3.49e-09	-0.83	-0.72	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	10.12	1.04e-16	3.49e-09	0.83	0.72	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
THYM	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	10.12	1.04e-16	3.49e-09	0.83	0.72	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
THYM	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	10.12	1.04e-16	3.49e-09	0.83	0.72	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
THYM	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	10.12	1.04e-16	3.49e-09	0.83	0.72	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
THYM	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-10.12	1.05e-16	3.51e-09	-0.83	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
THYM	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	10.09	1.18e-16	3.93e-09	0.85	0.72	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
THYM	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	10.09	1.2e-16	4.01e-09	0.99	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
THYM	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	10.09	1.21e-16	4.02e-09	0.84	0.72	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
THYM	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-10.08	1.25e-16	4.17e-09	-0.97	-0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
THYM	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	10.07	1.31e-16	4.34e-09	0.96	0.72	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
THYM	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	10.06	1.4e-16	4.63e-09	0.96	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
THYM	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	10.05	1.42e-16	4.7e-09	0.83	0.72	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
THYM	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	10.05	1.42e-16	4.7e-09	0.97	0.72	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
THYM	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	10.04	1.49e-16	4.93e-09	0.97	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
THYM	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	10.03	1.61e-16	5.32e-09	0.88	0.72	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-10.01	1.74e-16	5.72e-09	-0.89	-0.72	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
THYM	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	10.01	1.75e-16	5.76e-09	0.96	0.72	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
THYM	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-10.01	1.76e-16	5.79e-09	-0.84	-0.72	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
THYM	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-10.01	1.76e-16	5.79e-09	-0.84	-0.72	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
THYM	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	10	1.8e-16	5.92e-09	0.97	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
THYM	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	10	1.8e-16	5.92e-09	0.97	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
THYM	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-10	1.81e-16	5.93e-09	-0.78	-0.72	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
THYM	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	10	1.85e-16	6.01e-09	0.96	0.72	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
THYM	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-9.99	1.88e-16	6.1e-09	-0.96	-0.72	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
THYM	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
THYM	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
THYM	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
THYM	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	9.99	1.96e-16	6.32e-09	0.79	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
THYM	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-9.98	1.98e-16	6.36e-09	-0.96	-0.72	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
THYM	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	9.96	2.24e-16	7.14e-09	0.96	0.72	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
THYM	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	9.96	2.24e-16	7.14e-09	1.02	0.72	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
THYM	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	9.96	2.24e-16	7.14e-09	1.02	0.72	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
THYM	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	9.96	2.24e-16	7.14e-09	1.02	0.72	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
THYM	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	9.96	2.24e-16	7.14e-09	1.02	0.72	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
THYM	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	9.96	2.24e-16	7.14e-09	1.02	0.72	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
THYM	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	9.96	2.27e-16	7.22e-09	1.03	0.72	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
THYM	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	9.95	2.31e-16	7.32e-09	0.88	0.72	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.559	rs3901731	ENSG00000224114.1	RP11-343H5.4	9.95	2.33e-16	7.4e-09	0.96	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr1:206695837~206696269:-
THYM	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	9.93	2.59e-16	8.11e-09	0.97	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
THYM	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	9.93	2.62e-16	8.19e-09	0.9	0.72	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
THYM	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-9.92	2.71e-16	8.46e-09	-1	-0.72	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	9.92	2.75e-16	8.57e-09	0.86	0.72	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
THYM	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-9.92	2.78e-16	8.66e-09	-0.91	-0.71	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-9.91	2.82e-16	8.76e-09	-1.09	-0.71	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
THYM	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	9.89	3.17e-16	9.81e-09	1.13	0.71	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
THYM	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-9.89	3.17e-16	9.82e-09	-0.85	-0.71	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	9.88	3.32e-16	1.03e-08	0.84	0.71	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
THYM	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	9.88	3.33e-16	1.03e-08	1.01	0.71	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
THYM	trans	rs61990749	0.571	rs2364841	ENSG00000235400.1	RP4-641G12.4	9.88	3.38e-16	1.04e-08	1.05	0.71	Fibroblast growth factor basic levels;	chr14:77817693	chr1:78749073~78750659:+
THYM	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	9.87	3.44e-16	1.06e-08	1.25	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
THYM	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	9.85	3.88e-16	1.19e-08	1.03	0.71	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
THYM	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-9.83	4.23e-16	1.29e-08	-0.84	-0.71	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	9.83	4.23e-16	1.29e-08	0.84	0.71	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	9.83	4.23e-16	1.29e-08	0.84	0.71	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	9.83	4.23e-16	1.29e-08	0.84	0.71	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	9.83	4.23e-16	1.29e-08	0.84	0.71	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	9.83	4.23e-16	1.29e-08	0.84	0.71	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	9.83	4.23e-16	1.29e-08	0.84	0.71	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
THYM	trans	rs13177918	0.559	rs3901731	ENSG00000239528.1	RPS14P8	9.82	4.39e-16	1.34e-08	0.99	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr5:116562562~116562930:+
THYM	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-9.82	4.4e-16	1.34e-08	-0.95	-0.71	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
THYM	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	9.81	4.59e-16	1.4e-08	1.41	0.71	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
THYM	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	9.8	4.78e-16	1.45e-08	0.83	0.71	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	9.8	4.78e-16	1.45e-08	0.83	0.71	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
THYM	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	9.8	4.96e-16	1.5e-08	0.96	0.71	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
THYM	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-9.78	5.32e-16	1.61e-08	-0.78	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
THYM	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-9.78	5.35e-16	1.61e-08	-0.95	-0.71	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
THYM	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	9.78	5.42e-16	1.63e-08	0.86	0.71	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	9.78	5.42e-16	1.63e-08	0.86	0.71	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	9.78	5.42e-16	1.63e-08	0.86	0.71	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	9.78	5.42e-16	1.63e-08	0.86	0.71	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
THYM	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	9.78	5.42e-16	1.63e-08	0.86	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	9.78	5.42e-16	1.63e-08	0.86	0.71	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
THYM	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	9.78	5.42e-16	1.63e-08	0.86	0.71	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-9.78	5.44e-16	1.63e-08	-1.09	-0.71	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
THYM	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	9.77	5.54e-16	1.66e-08	0.95	0.71	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
THYM	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	9.77	5.68e-16	1.7e-08	0.64	0.71	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
THYM	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	9.77	5.75e-16	1.72e-08	0.85	0.71	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	9.76	5.81e-16	1.73e-08	0.83	0.71	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	9.76	5.81e-16	1.73e-08	0.83	0.71	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	9.76	6.08e-16	1.81e-08	0.83	0.71	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
THYM	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-9.75	6.34e-16	1.88e-08	-0.78	-0.71	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
THYM	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	9.75	6.35e-16	1.89e-08	1.17	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
THYM	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	9.75	6.37e-16	1.89e-08	0.83	0.71	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
THYM	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	9.73	7.05e-16	2.07e-08	0.64	0.71	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	9.73	7.05e-16	2.07e-08	0.64	0.71	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	9.73	7.05e-16	2.07e-08	0.64	0.71	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
THYM	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	9.72	7.25e-16	2.12e-08	1.01	0.71	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
THYM	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	9.72	7.25e-16	2.12e-08	1.01	0.71	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
THYM	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-9.69	8.43e-16	2.45e-08	-0.82	-0.71	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
THYM	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	9.69	8.48e-16	2.46e-08	1.41	0.71	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
THYM	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	9.68	8.61e-16	2.5e-08	0.79	0.71	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	9.68	8.81e-16	2.55e-08	0.79	0.71	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
THYM	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	9.68	8.97e-16	2.6e-08	0.75	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
THYM	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	9.68	9e-16	2.61e-08	1.36	0.71	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
THYM	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-9.66	9.49e-16	2.74e-08	-0.91	-0.71	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
THYM	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-9.66	9.94e-16	2.86e-08	-0.82	-0.71	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
THYM	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-9.65	1.02e-15	2.92e-08	-0.87	-0.71	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
THYM	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	9.64	1.09e-15	3.12e-08	0.94	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
THYM	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	9.62	1.21e-15	3.45e-08	0.85	0.7	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
THYM	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	9.59	1.38e-15	3.83e-08	0.93	0.7	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
THYM	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-9.58	1.42e-15	3.86e-08	-0.94	-0.7	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
THYM	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	9.58	1.42e-15	3.86e-08	0.94	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
THYM	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	9.58	1.45e-15	3.93e-08	0.97	0.7	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
THYM	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	9.57	1.54e-15	4.09e-08	1.38	0.7	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
THYM	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	9.55	1.62e-15	4.29e-08	0.84	0.7	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
THYM	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	9.55	1.65e-15	4.36e-08	0.93	0.7	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
THYM	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-9.55	1.67e-15	4.39e-08	-1	-0.7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
THYM	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	9.53	1.81e-15	4.75e-08	1.38	0.7	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
THYM	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	9.53	1.81e-15	4.75e-08	0.77	0.7	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	9.53	1.81e-15	4.75e-08	0.77	0.7	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	9.53	1.81e-15	4.75e-08	0.77	0.7	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	9.53	1.81e-15	4.75e-08	0.77	0.7	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	9.53	1.81e-15	4.75e-08	0.77	0.7	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-9.53	1.81e-15	4.75e-08	-0.77	-0.7	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
THYM	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-9.53	1.83e-15	4.79e-08	-0.81	-0.7	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
THYM	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-9.53	1.85e-15	4.85e-08	-0.96	-0.7	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
THYM	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	9.52	1.9e-15	4.97e-08	0.77	0.7	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	9.49	2.28e-15	5.93e-08	0.77	0.7	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	9.48	2.36e-15	6.12e-08	0.76	0.7	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	9.48	2.36e-15	6.12e-08	0.76	0.7	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
THYM	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-9.47	2.46e-15	6.37e-08	-1	-0.7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	9.47	2.46e-15	6.37e-08	1	0.7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	9.47	2.46e-15	6.37e-08	1	0.7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
THYM	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	9.47	2.49e-15	6.41e-08	0.78	0.7	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	9.47	2.49e-15	6.41e-08	0.78	0.7	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	9.47	2.49e-15	6.41e-08	0.78	0.7	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	9.47	2.49e-15	6.41e-08	0.78	0.7	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
THYM	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	9.46	2.53e-15	6.48e-08	0.8	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
THYM	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	9.45	2.68e-15	6.86e-08	0.78	0.7	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
THYM	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-9.45	2.76e-15	7.05e-08	-0.98	-0.7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
THYM	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	9.44	2.82e-15	7.19e-08	0.94	0.7	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-9.44	2.82e-15	7.19e-08	-0.94	-0.7	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	9.44	2.82e-15	7.19e-08	0.94	0.7	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
THYM	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	9.44	2.82e-15	7.19e-08	0.94	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
THYM	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	9.44	2.82e-15	7.19e-08	0.94	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
THYM	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-9.44	2.82e-15	7.19e-08	-0.94	-0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
THYM	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	9.44	2.85e-15	7.24e-08	0.83	0.7	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-9.43	2.96e-15	7.49e-08	-0.79	-0.7	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	9.43	2.96e-15	7.49e-08	0.79	0.7	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	9.43	2.96e-15	7.49e-08	0.79	0.7	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	9.43	2.96e-15	7.49e-08	0.79	0.7	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
THYM	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	9.42	3.18e-15	8.05e-08	1.01	0.7	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
THYM	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-9.4	3.41e-15	8.59e-08	-0.85	-0.7	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
THYM	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	9.39	3.66e-15	9.19e-08	0.99	0.7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
THYM	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	9.39	3.69e-15	9.24e-08	0.79	0.7	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	9.39	3.69e-15	9.24e-08	0.79	0.7	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
THYM	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-9.38	3.88e-15	9.64e-08	-0.81	-0.7	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
THYM	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-9.36	4.2e-15	1.03e-07	-0.81	-0.69	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
THYM	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-9.36	4.3e-15	1.05e-07	-1.01	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-9.36	4.3e-15	1.05e-07	-1.01	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
THYM	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	9.35	4.49e-15	1.1e-07	0.79	0.69	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000223416.3	RPS26P15	-9.34	4.61e-15	1.12e-07	-0.81	-0.69	Cognitive function;	chr12:56007301	chr1:58056133~58056480:-
THYM	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	9.34	4.72e-15	1.15e-07	0.63	0.69	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	9.34	4.72e-15	1.15e-07	0.63	0.69	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.73	rs1259505	ENSG00000172974.11	AC007318.5	9.33	4.8e-15	1.17e-07	0.66	0.69	Pneumonia;	chr10:75237183	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.73	rs1259508	ENSG00000172974.11	AC007318.5	9.33	4.8e-15	1.17e-07	0.66	0.69	Pneumonia;	chr10:75238334	chr2:65205108~65205988:+
THYM	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	9.33	4.94e-15	1.18e-07	0.99	0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
THYM	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-9.32	5.08e-15	1.18e-07	-0.81	-0.69	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	9.32	5.22e-15	1.2e-07	0.81	0.69	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
THYM	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	9.31	5.46e-15	1.26e-07	0.81	0.69	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
THYM	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	9.3	5.55e-15	1.28e-07	1	0.69	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
THYM	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	9.3	5.59e-15	1.28e-07	0.77	0.69	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
THYM	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	9.3	5.62e-15	1.29e-07	0.84	0.69	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	9.3	5.62e-15	1.29e-07	0.84	0.69	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
THYM	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-9.3	5.63e-15	1.29e-07	-1.01	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	9.29	6.05e-15	1.38e-07	0.83	0.69	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
THYM	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-9.27	6.4e-15	1.45e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
THYM	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	9.27	6.53e-15	1.48e-07	0.77	0.69	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	9.27	6.53e-15	1.48e-07	0.77	0.69	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	9.25	7.16e-15	1.61e-07	0.74	0.69	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
THYM	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	9.25	7.26e-15	1.64e-07	0.84	0.69	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
THYM	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	9.25	7.26e-15	1.64e-07	0.84	0.69	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	9.25	7.26e-15	1.64e-07	0.84	0.69	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
THYM	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-9.23	8.04e-15	1.8e-07	-0.93	-0.69	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
THYM	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-9.21	8.88e-15	1.95e-07	-0.88	-0.69	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
THYM	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	9.2	9.17e-15	2.01e-07	0.99	0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
THYM	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-9.2	9.31e-15	2.04e-07	-0.84	-0.69	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
THYM	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	9.18	1.01e-14	2.21e-07	0.74	0.69	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	9.17	1.06e-14	2.3e-07	0.74	0.69	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
THYM	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	9.15	1.16e-14	2.51e-07	0.91	0.69	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
THYM	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	9.14	1.21e-14	2.62e-07	0.75	0.69	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	9.14	1.21e-14	2.62e-07	0.75	0.69	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
THYM	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	9.14	1.21e-14	2.62e-07	0.93	0.69	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
THYM	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	9.14	1.21e-14	2.63e-07	0.64	0.69	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
THYM	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-9.14	1.21e-14	2.63e-07	-0.79	-0.69	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
THYM	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-9.14	1.24e-14	2.68e-07	-0.82	-0.69	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-9.13	1.33e-14	2.87e-07	-0.85	-0.69	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
THYM	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	9.12	1.37e-14	2.95e-07	0.89	0.69	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
THYM	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-9.12	1.39e-14	2.99e-07	-1	-0.69	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
THYM	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	9.1	1.48e-14	3.18e-07	0.91	0.68	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-9.09	1.61e-14	3.45e-07	-0.81	-0.68	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
THYM	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	9.09	1.62e-14	3.47e-07	1.37	0.68	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
THYM	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-9.07	1.71e-14	3.63e-07	-0.84	-0.68	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	9.05	1.89e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	9.05	1.89e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	9.05	1.89e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
THYM	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
THYM	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
THYM	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
THYM	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
THYM	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	9.05	1.9e-14	3.98e-07	0.91	0.68	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-9.05	1.9e-14	3.98e-07	-0.91	-0.68	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	9.05	1.93e-14	4.03e-07	1.11	0.68	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-9.04	1.98e-14	4.13e-07	-0.78	-0.68	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
THYM	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	9.04	2.04e-14	4.22e-07	0.74	0.68	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
THYM	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-9.03	2.16e-14	4.42e-07	-0.83	-0.68	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
THYM	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	9.01	2.3e-14	4.69e-07	0.88	0.68	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
THYM	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	9.01	2.32e-14	4.72e-07	1.06	0.68	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
THYM	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	9.01	2.33e-14	4.73e-07	0.76	0.68	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	9.01	2.33e-14	4.73e-07	0.76	0.68	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
THYM	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-9.01	2.35e-14	4.77e-07	-0.81	-0.68	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
THYM	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	9.01	2.38e-14	4.81e-07	1.34	0.68	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
THYM	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	9.01	2.38e-14	4.81e-07	1.34	0.68	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
THYM	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	9	2.46e-14	4.98e-07	1.06	0.68	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
THYM	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	9	2.47e-14	4.99e-07	0.96	0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
THYM	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-9	2.5e-14	5.05e-07	-0.79	-0.68	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
THYM	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	8.99	2.52e-14	5.09e-07	1.06	0.68	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
THYM	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	8.99	2.53e-14	5.1e-07	0.97	0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
THYM	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	8.99	2.53e-14	5.1e-07	0.74	0.68	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	8.99	2.53e-14	5.1e-07	0.74	0.68	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	8.99	2.53e-14	5.1e-07	0.74	0.68	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	8.99	2.53e-14	5.1e-07	0.74	0.68	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	8.99	2.53e-14	5.1e-07	0.74	0.68	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
THYM	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-8.97	2.83e-14	5.68e-07	-0.85	-0.68	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
THYM	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	8.96	2.94e-14	5.9e-07	0.75	0.68	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
THYM	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-8.96	3.02e-14	6.06e-07	-0.64	-0.68	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
THYM	trans	rs2731664	0.792	rs2630767	ENSG00000215571.5	GRK6P1	8.95	3.19e-14	6.38e-07	0.81	0.68	Intelligence (multi-trait analysis);	chr5:177443699	chr13:21319156~21320866:+
THYM	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	8.95	3.2e-14	6.4e-07	0.83	0.68	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-8.95	3.2e-14	6.4e-07	-0.83	-0.68	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
THYM	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-8.93	3.46e-14	6.89e-07	-0.91	-0.68	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	8.93	3.5e-14	6.96e-07	0.91	0.68	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	8.93	3.5e-14	6.96e-07	0.91	0.68	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	8.93	3.5e-14	6.96e-07	0.91	0.68	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	8.93	3.5e-14	6.96e-07	0.91	0.68	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
THYM	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	8.92	3.72e-14	7.37e-07	0.74	0.68	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	8.88	4.47e-14	8.78e-07	0.75	0.68	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
THYM	trans	rs13190036	1	rs351864	ENSG00000217325.2	PRELID1P1	-8.88	4.49e-14	8.8e-07	-0.98	-0.68	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr6:126643488~126644390:+
THYM	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-8.84	5.43e-14	1.06e-06	-0.86	-0.67	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	8.83	5.55e-14	1.07e-06	0.79	0.67	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
THYM	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-8.83	5.64e-14	1.09e-06	-0.83	-0.67	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	8.81	6.32e-14	1.21e-06	0.76	0.67	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
THYM	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	8.8	6.5e-14	1.25e-06	1.15	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
THYM	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	8.78	7.36e-14	1.4e-06	0.79	0.67	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	8.78	7.36e-14	1.4e-06	0.79	0.67	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.792	rs2544809	ENSG00000215571.5	GRK6P1	8.78	7.36e-14	1.4e-06	0.79	0.67	Intelligence (multi-trait analysis);	chr5:177458498	chr13:21319156~21320866:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000225071.1	GS1-184P14.2	-8.77	7.42e-14	1.41e-06	-0.82	-0.67	Cognitive function;	chr12:56007301	chrX:24429573~24429920:-
THYM	trans	rs2731664	0.792	rs2545795	ENSG00000215571.5	GRK6P1	8.77	7.62e-14	1.45e-06	0.79	0.67	Intelligence (multi-trait analysis);	chr5:177460105	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	8.74	8.84e-14	1.66e-06	0.76	0.67	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
THYM	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	8.74	8.92e-14	1.67e-06	0.89	0.67	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
THYM	trans	rs2731664	0.792	rs466256	ENSG00000215571.5	GRK6P1	8.73	9.13e-14	1.7e-06	0.79	0.67	Intelligence (multi-trait analysis);	chr5:177448955	chr13:21319156~21320866:+
THYM	trans	rs13190036	0.786	rs10068127	ENSG00000217325.2	PRELID1P1	-8.73	9.29e-14	1.73e-06	-0.95	-0.67	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177204786	chr6:126643488~126644390:+
THYM	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	8.71	1.02e-13	1.9e-06	0.76	0.67	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
THYM	trans	rs2731664	0.792	rs335435	ENSG00000215571.5	GRK6P1	8.7	1.09e-13	2.01e-06	0.8	0.67	Intelligence (multi-trait analysis);	chr5:177440942	chr13:21319156~21320866:+
THYM	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-8.67	1.21e-13	2.22e-06	-0.92	-0.67	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
THYM	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-8.65	1.35e-13	2.47e-06	-0.94	-0.67	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-8.65	1.35e-13	2.47e-06	-0.94	-0.67	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
THYM	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	8.64	1.44e-13	2.63e-06	0.99	0.67	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	8.64	1.46e-13	2.67e-06	0.8	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
THYM	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	8.63	1.5e-13	2.73e-06	0.99	0.66	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
THYM	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-8.62	1.55e-13	2.82e-06	-0.79	-0.66	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
THYM	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-8.62	1.56e-13	2.83e-06	-0.77	-0.66	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-8.61	1.64e-13	2.97e-06	-0.78	-0.66	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
THYM	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-8.61	1.64e-13	2.97e-06	-0.78	-0.66	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
THYM	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-8.61	1.68e-13	3.04e-06	-0.89	-0.66	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-8.61	1.68e-13	3.04e-06	-0.89	-0.66	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-8.61	1.68e-13	3.04e-06	-0.89	-0.66	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
THYM	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	8.6	1.71e-13	3.09e-06	0.77	0.66	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	8.6	1.71e-13	3.09e-06	0.77	0.66	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	8.6	1.71e-13	3.09e-06	0.77	0.66	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-8.6	1.71e-13	3.09e-06	-0.77	-0.66	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
THYM	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	8.6	1.75e-13	3.16e-06	0.92	0.66	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.704	rs7995968	ENSG00000237917.1	PARP4P1	-8.6	1.76e-13	3.17e-06	-0.85	-0.66	Obesity-related traits;	chr13:24392754	chrY:26594851~26634652:-
THYM	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	8.59	1.79e-13	3.21e-06	0.77	0.66	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
THYM	trans	rs13190036	1	rs351862	ENSG00000226986.4	RP11-543B16.2	-8.58	1.88e-13	3.38e-06	-0.95	-0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr1:211207239~211207897:+
THYM	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	8.58	1.91e-13	3.43e-06	0.62	0.66	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	8.58	1.91e-13	3.43e-06	0.62	0.66	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	8.58	1.91e-13	3.43e-06	0.62	0.66	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
THYM	trans	rs13190036	0.901	rs10056655	ENSG00000217325.2	PRELID1P1	8.58	1.93e-13	3.46e-06	0.94	0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.901	rs6898107	ENSG00000217325.2	PRELID1P1	8.58	1.93e-13	3.46e-06	0.94	0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr6:126643488~126644390:+
THYM	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	8.58	1.94e-13	3.48e-06	0.72	0.66	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
THYM	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-8.57	1.99e-13	3.55e-06	-0.99	-0.66	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
THYM	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	8.57	2e-13	3.56e-06	0.74	0.66	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	8.57	2e-13	3.56e-06	0.74	0.66	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
THYM	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-8.57	2.05e-13	3.64e-06	-0.77	-0.66	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
THYM	trans	rs13190036	1	rs351864	ENSG00000226986.4	RP11-543B16.2	-8.56	2.15e-13	3.81e-06	-0.98	-0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr1:211207239~211207897:+
THYM	trans	rs2950393	0.804	rs7295862	ENSG00000121089.4	NACA3P	-8.56	2.15e-13	3.81e-06	-0.83	-0.66	Platelet distribution width;	chr12:56775374	chr4:164943290~164943937:+
THYM	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	8.55	2.16e-13	3.83e-06	0.86	0.66	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
THYM	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	8.54	2.31e-13	4.02e-06	0.93	0.66	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
THYM	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	8.54	2.35e-13	4.02e-06	0.77	0.66	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
THYM	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	8.54	2.36e-13	4.02e-06	0.95	0.66	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
THYM	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	8.53	2.4e-13	4.02e-06	1.03	0.66	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	8.53	2.4e-13	4.02e-06	1.03	0.66	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	8.53	2.4e-13	4.02e-06	1.03	0.66	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
THYM	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
THYM	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
THYM	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
THYM	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
THYM	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	8.53	2.42e-13	4.02e-06	0.92	0.66	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
THYM	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	8.53	2.48e-13	4.1e-06	0.76	0.66	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
THYM	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	8.51	2.65e-13	4.36e-06	0.73	0.66	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
THYM	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-8.51	2.69e-13	4.43e-06	-0.74	-0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
THYM	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-8.51	2.73e-13	4.5e-06	-1.07	-0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
THYM	trans	rs7121616	0.92	rs7109445	ENSG00000234176.1	HSPA8P1	8.5	2.81e-13	4.62e-06	0.95	0.66	Breast cancer;	chr11:123094779	chrX:121203182~121205014:-
THYM	trans	rs4822044	0.568	rs1883370	ENSG00000268568.1	AC007228.9	8.5	2.84e-13	4.66e-06	0.89	0.66	Cannabis dependence symptom count;	chr22:41747736	chr19:56672574~56673901:-
THYM	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-8.48	3.15e-13	5.12e-06	-0.61	-0.66	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
THYM	trans	rs2950393	0.646	rs7966413	ENSG00000121089.4	NACA3P	8.48	3.16e-13	5.15e-06	0.79	0.66	Platelet distribution width;	chr12:56745415	chr4:164943290~164943937:+
THYM	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	8.46	3.37e-13	5.47e-06	0.73	0.66	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	8.46	3.37e-13	5.47e-06	0.73	0.66	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	8.46	3.37e-13	5.47e-06	0.73	0.66	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	8.46	3.37e-13	5.47e-06	0.73	0.66	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	8.46	3.37e-13	5.47e-06	0.73	0.66	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
THYM	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-8.46	3.43e-13	5.56e-06	-0.9	-0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-8.45	3.53e-13	5.71e-06	-0.76	-0.66	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
THYM	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	8.44	3.7e-13	5.97e-06	1.06	0.66	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
THYM	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	8.43	3.97e-13	6.38e-06	0.94	0.66	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
THYM	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	8.42	4.15e-13	6.66e-06	0.84	0.66	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
THYM	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	8.42	4.16e-13	6.66e-06	0.94	0.66	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	8.42	4.16e-13	6.66e-06	0.94	0.66	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
THYM	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	8.42	4.17e-13	6.68e-06	0.91	0.66	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	8.42	4.17e-13	6.68e-06	0.91	0.66	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
THYM	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	8.41	4.33e-13	6.91e-06	0.73	0.66	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
THYM	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-8.4	4.54e-13	7.2e-06	-0.77	-0.65	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
THYM	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	8.4	4.56e-13	7.24e-06	0.86	0.65	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
THYM	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	8.4	4.68e-13	7.4e-06	0.9	0.65	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
THYM	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	8.39	4.77e-13	7.53e-06	0.78	0.65	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-8.39	4.81e-13	7.57e-06	-1.02	-0.65	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
THYM	trans	rs13190036	0.892	rs71601339	ENSG00000226986.4	RP11-543B16.2	-8.38	4.96e-13	7.8e-06	-0.95	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr1:211207239~211207897:+
THYM	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	8.37	5.23e-13	8.21e-06	0.78	0.65	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
THYM	trans	rs13190036	1	rs13157667	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs13167431	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs35535623	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs71601343	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs71601344	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs3733875	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs13185316	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs13177748	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs34832871	ENSG00000226986.4	RP11-543B16.2	-8.37	5.32e-13	8.33e-06	-0.96	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr1:211207239~211207897:+
THYM	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-8.35	5.73e-13	8.91e-06	-0.63	-0.65	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
THYM	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	8.35	5.85e-13	9.08e-06	0.83	0.65	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
THYM	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	8.35	5.85e-13	9.08e-06	0.83	0.65	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
THYM	trans	rs13190036	0.681	rs28461408	ENSG00000217325.2	PRELID1P1	8.33	6.39e-13	9.88e-06	0.95	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr6:126643488~126644390:+
THYM	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-8.33	6.43e-13	9.93e-06	-0.75	-0.65	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
THYM	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	8.33	6.57e-13	1.01e-05	0.91	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
THYM	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-8.33	6.6e-13	1.02e-05	-0.82	-0.65	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
THYM	trans	rs877636	0.562	rs10876864	ENSG00000234354.3	RPS26P47	-8.32	6.63e-13	1.02e-05	-0.91	-0.65	Cognitive function;	chr12:56007301	chr13:100539901~100540248:-
THYM	trans	rs13190036	0.901	rs55741473	ENSG00000226986.4	RP11-543B16.2	-8.31	6.95e-13	1.07e-05	-0.97	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs34446750	ENSG00000226986.4	RP11-543B16.2	-8.31	6.95e-13	1.07e-05	-0.97	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr1:211207239~211207897:+
THYM	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	8.3	7.51e-13	1.12e-05	0.83	0.65	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
THYM	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	8.3	7.51e-13	1.12e-05	0.83	0.65	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
THYM	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	8.3	7.54e-13	1.13e-05	0.79	0.65	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-8.29	7.89e-13	1.18e-05	-0.73	-0.65	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
THYM	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-8.29	7.89e-13	1.18e-05	-0.73	-0.65	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
THYM	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	8.29	8e-13	1.19e-05	1.05	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
THYM	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	8.25	9.53e-13	1.4e-05	0.86	0.65	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
THYM	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	8.24	9.82e-13	1.44e-05	0.9	0.65	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-8.24	1.01e-12	1.48e-05	-0.82	-0.65	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-8.24	1.01e-12	1.48e-05	-0.82	-0.65	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	8.24	1.01e-12	1.48e-05	0.9	0.65	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
THYM	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	8.24	1.01e-12	1.48e-05	0.9	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
THYM	trans	rs877636	0.809	rs1689510	ENSG00000212994.5	RPS26P6	8.23	1.03e-12	1.5e-05	0.84	0.65	Cognitive function;	chr12:56002984	chr8:100895771~100896118:+
THYM	trans	rs13190036	1	rs655623	ENSG00000226986.4	RP11-543B16.2	8.23	1.07e-12	1.57e-05	0.94	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.901	rs28715668	ENSG00000226986.4	RP11-543B16.2	8.22	1.08e-12	1.58e-05	0.94	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr1:211207239~211207897:+
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	8.22	1.12e-12	1.63e-05	0.75	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
THYM	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	8.21	1.14e-12	1.66e-05	0.83	0.65	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
THYM	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	8.21	1.17e-12	1.69e-05	1.02	0.65	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	8.21	1.17e-12	1.69e-05	1.02	0.65	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
THYM	trans	rs13190036	1	rs628506	ENSG00000226986.4	RP11-543B16.2	-8.21	1.17e-12	1.69e-05	-0.94	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs625882	ENSG00000226986.4	RP11-543B16.2	-8.21	1.17e-12	1.69e-05	-0.94	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr1:211207239~211207897:+
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	8.19	1.26e-12	1.82e-05	0.78	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
THYM	trans	rs13190036	0.579	rs13159114	ENSG00000217325.2	PRELID1P1	8.19	1.26e-12	1.83e-05	0.96	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177234807	chr6:126643488~126644390:+
THYM	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-8.19	1.27e-12	1.83e-05	-0.68	-0.65	Longevity;	chr3:48422209	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-8.19	1.27e-12	1.83e-05	-0.68	-0.65	Longevity;	chr3:48423094	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-8.19	1.27e-12	1.83e-05	-0.68	-0.65	Longevity;	chr3:48426493	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-8.19	1.27e-12	1.83e-05	-0.68	-0.65	Longevity;	chr3:48432839	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-8.19	1.27e-12	1.83e-05	-0.68	-0.65	Longevity;	chr3:48437797	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-8.19	1.27e-12	1.83e-05	-0.68	-0.65	Longevity;	chr3:48440024	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-8.19	1.27e-12	1.83e-05	-0.68	-0.65	Longevity;	chr3:48440237	chr1:27649419~27649610:+
THYM	trans	rs13190036	1	rs17078781	ENSG00000226986.4	RP11-543B16.2	-8.19	1.29e-12	1.85e-05	-0.94	-0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.901	rs28563911	ENSG00000226986.4	RP11-543B16.2	8.19	1.29e-12	1.85e-05	0.94	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr1:211207239~211207897:+
THYM	trans	rs13190036	1	rs28580074	ENSG00000226986.4	RP11-543B16.2	8.19	1.29e-12	1.85e-05	0.94	0.65	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr1:211207239~211207897:+
THYM	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	8.18	1.31e-12	1.88e-05	0.89	0.65	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	8.18	1.31e-12	1.88e-05	0.89	0.65	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	8.18	1.31e-12	1.88e-05	0.89	0.65	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	8.18	1.31e-12	1.88e-05	0.89	0.65	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
THYM	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	8.18	1.31e-12	1.88e-05	0.75	0.65	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
THYM	trans	rs13190036	0.901	rs28684504	ENSG00000226986.4	RP11-543B16.2	8.17	1.37e-12	1.96e-05	0.95	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr1:211207239~211207897:+
THYM	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-8.17	1.41e-12	2.02e-05	-0.67	-0.64	Longevity;	chr3:48445949	chr1:27649419~27649610:+
THYM	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	8.15	1.53e-12	2.17e-05	0.78	0.64	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
THYM	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	8.15	1.57e-12	2.23e-05	0.69	0.64	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
THYM	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	8.13	1.74e-12	2.44e-05	0.78	0.64	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
THYM	trans	rs13190036	1	rs4976682	ENSG00000226986.4	RP11-543B16.2	8.12	1.76e-12	2.46e-05	0.92	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr1:211207239~211207897:+
THYM	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-8.11	1.89e-12	2.61e-05	-0.68	-0.64	Longevity;	chr3:48446507	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-8.11	1.89e-12	2.61e-05	-0.68	-0.64	Longevity;	chr3:48452692	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-8.11	1.89e-12	2.61e-05	-0.68	-0.64	Longevity;	chr3:48455358	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-8.11	1.89e-12	2.61e-05	-0.68	-0.64	Longevity;	chr3:48457056	chr1:27649419~27649610:+
THYM	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	8.1	1.92e-12	2.66e-05	0.82	0.64	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
THYM	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	8.1	1.92e-12	2.66e-05	0.82	0.64	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
THYM	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-8.1	1.98e-12	2.73e-05	-0.65	-0.64	Longevity;	chr3:48413059	chr1:27649419~27649610:+
THYM	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	8.1	1.98e-12	2.74e-05	0.6	0.64	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	8.1	1.98e-12	2.74e-05	0.6	0.64	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
THYM	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-8.09	2.11e-12	2.9e-05	-0.72	-0.64	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
THYM	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	8.08	2.15e-12	2.95e-05	0.75	0.64	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-8.08	2.15e-12	2.95e-05	-0.75	-0.64	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
THYM	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	8.08	2.18e-12	2.99e-05	1.02	0.64	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	8.07	2.25e-12	3.08e-05	1.02	0.64	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
THYM	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	8.07	2.25e-12	3.09e-05	0.83	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-8.07	2.25e-12	3.09e-05	-0.83	-0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	8.06	2.34e-12	3.2e-05	0.89	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
THYM	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	8.06	2.43e-12	3.32e-05	0.65	0.64	Longevity;	chr3:48407742	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-8.06	2.43e-12	3.32e-05	-0.65	-0.64	Longevity;	chr3:48408490	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-8.06	2.43e-12	3.32e-05	-0.65	-0.64	Longevity;	chr3:48408549	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	8.05	2.56e-12	3.49e-05	0.64	0.64	Longevity;	chr3:48377081	chr1:27649419~27649610:+
THYM	trans	rs916888	0.779	rs199526	ENSG00000214425.5	LRRC37A4P	8.04	2.59e-12	3.52e-05	0.65	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45506741~45550335:-
THYM	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	8.04	2.69e-12	3.66e-05	0.82	0.64	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
THYM	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-8.02	2.92e-12	3.96e-05	-0.75	-0.64	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
THYM	trans	rs877636	0.702	rs773108	ENSG00000212994.5	RPS26P6	8.01	3.04e-12	4.05e-05	0.84	0.64	Cognitive function;	chr12:55976127	chr8:100895771~100896118:+
THYM	trans	rs13190036	0.681	rs28461408	ENSG00000226986.4	RP11-543B16.2	7.99	3.28e-12	4.33e-05	0.95	0.64	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr1:211207239~211207897:+
THYM	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-7.98	3.5e-12	4.58e-05	-0.74	-0.64	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	7.98	3.52e-12	4.59e-05	0.79	0.64	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-7.97	3.63e-12	4.73e-05	-0.99	-0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
THYM	trans	rs13190036	0.901	rs10056655	ENSG00000226986.4	RP11-543B16.2	7.97	3.74e-12	4.85e-05	0.91	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.901	rs6898107	ENSG00000226986.4	RP11-543B16.2	7.97	3.74e-12	4.85e-05	0.91	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr1:211207239~211207897:+
THYM	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-7.97	3.74e-12	4.85e-05	-0.79	-0.63	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
THYM	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	7.96	3.87e-12	4.92e-05	0.58	0.63	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
THYM	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	7.96	3.94e-12	4.98e-05	0.81	0.63	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
THYM	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	7.96	3.94e-12	4.98e-05	0.81	0.63	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
THYM	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	7.96	3.94e-12	4.98e-05	0.81	0.63	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
THYM	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	7.96	3.94e-12	4.98e-05	0.81	0.63	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
THYM	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	7.96	3.94e-12	4.98e-05	0.81	0.63	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
THYM	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-7.96	3.94e-12	4.98e-05	-0.79	-0.63	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-7.96	3.94e-12	4.98e-05	-0.79	-0.63	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-7.96	3.95e-12	4.99e-05	-0.86	-0.63	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
THYM	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-7.95	4.01e-12	5.06e-05	-0.8	-0.63	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	7.95	4.01e-12	5.06e-05	0.8	0.63	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	7.95	4.01e-12	5.06e-05	0.8	0.63	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	7.95	4.01e-12	5.06e-05	0.8	0.63	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
THYM	trans	rs1816752	0.679	rs7999480	ENSG00000237917.1	PARP4P1	-7.95	4.03e-12	5.07e-05	-0.81	-0.63	Obesity-related traits;	chr13:24397865	chrY:26594851~26634652:-
THYM	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-7.95	4.06e-12	5.09e-05	-0.79	-0.63	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-7.95	4.06e-12	5.09e-05	-0.79	-0.63	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-7.95	4.06e-12	5.09e-05	-0.79	-0.63	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-7.95	4.06e-12	5.09e-05	-0.79	-0.63	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-7.95	4.06e-12	5.09e-05	-0.79	-0.63	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-7.95	4.06e-12	5.09e-05	-0.79	-0.63	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-7.95	4.06e-12	5.09e-05	-0.79	-0.63	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
THYM	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-7.95	4.13e-12	5.18e-05	-0.83	-0.63	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
THYM	trans	rs13190036	0.792	rs6874206	ENSG00000226986.4	RP11-543B16.2	-7.93	4.44e-12	5.55e-05	-0.91	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.901	rs10072499	ENSG00000226986.4	RP11-543B16.2	-7.93	4.44e-12	5.55e-05	-0.91	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr1:211207239~211207897:+
THYM	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48372725	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48384185	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48384586	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48385276	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48385757	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48386489	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48387420	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48388977	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48392157	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48392588	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48392923	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48395329	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48396724	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48398582	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-7.93	4.46e-12	5.55e-05	-0.64	-0.63	Longevity;	chr3:48402409	chr1:27649419~27649610:+
THYM	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	7.92	4.63e-12	5.75e-05	0.99	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
THYM	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-7.92	4.66e-12	5.79e-05	-0.79	-0.63	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
THYM	trans	rs13190036	1	rs6889220	ENSG00000226986.4	RP11-543B16.2	7.92	4.67e-12	5.79e-05	0.92	0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr1:211207239~211207897:+
THYM	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	7.92	4.77e-12	5.88e-05	0.78	0.63	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
THYM	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-7.92	4.77e-12	5.88e-05	-0.78	-0.63	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
THYM	trans	rs2731664	0.756	rs4976695	ENSG00000215571.5	GRK6P1	7.92	4.81e-12	5.92e-05	0.75	0.63	Intelligence (multi-trait analysis);	chr5:177435962	chr13:21319156~21320866:+
THYM	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	7.91	4.82e-12	5.93e-05	0.95	0.63	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
THYM	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	7.91	4.84e-12	5.95e-05	1.04	0.63	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
THYM	trans	rs9876781	0.967	rs2885509	ENSG00000235912.1	RP1-159A19.3	7.91	4.93e-12	6.06e-05	0.64	0.63	Longevity;	chr3:48376729	chr1:27649419~27649610:+
THYM	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	7.91	4.94e-12	6.07e-05	0.78	0.63	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	7.91	4.94e-12	6.07e-05	0.78	0.63	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
THYM	trans	rs9876781	1	rs2885510	ENSG00000235912.1	RP1-159A19.3	7.9	5.26e-12	6.44e-05	0.63	0.63	Longevity;	chr3:48376736	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	7.9	5.26e-12	6.44e-05	0.63	0.63	Longevity;	chr3:48377218	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6442117	ENSG00000235912.1	RP1-159A19.3	7.9	5.26e-12	6.44e-05	0.63	0.63	Longevity;	chr3:48378407	chr1:27649419~27649610:+
THYM	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-7.9	5.29e-12	6.46e-05	-0.87	-0.63	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
THYM	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	7.89	5.45e-12	6.65e-05	0.79	0.63	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	7.89	5.45e-12	6.65e-05	0.79	0.63	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	7.89	5.45e-12	6.65e-05	0.79	0.63	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
THYM	trans	rs2731664	0.792	rs1130857	ENSG00000215571.5	GRK6P1	7.89	5.55e-12	6.77e-05	0.74	0.63	Intelligence (multi-trait analysis);	chr5:177436518	chr13:21319156~21320866:+
THYM	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-7.87	6.07e-12	7.36e-05	-0.79	-0.63	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
THYM	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-7.87	6.07e-12	7.36e-05	-0.79	-0.63	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
THYM	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	7.87	6.1e-12	7.38e-05	0.79	0.63	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	7.87	6.1e-12	7.38e-05	0.79	0.63	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
THYM	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	7.85	6.55e-12	7.86e-05	0.82	0.63	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
THYM	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	7.85	6.61e-12	7.92e-05	1.03	0.63	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	7.85	6.61e-12	7.92e-05	1.03	0.63	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	7.85	6.61e-12	7.92e-05	1.03	0.63	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	7.85	6.61e-12	7.92e-05	1.03	0.63	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
THYM	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	7.84	6.82e-12	8.15e-05	0.74	0.63	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
THYM	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-7.84	6.97e-12	8.32e-05	-0.86	-0.63	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000244604.1	RP11-713H12.1	7.84	7.05e-12	8.42e-05	0.7	0.63	Cognitive function;	chr12:56076841	chr17:8561230~8561576:+
THYM	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-7.83	7.21e-12	8.56e-05	-0.78	-0.63	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
THYM	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	7.83	7.28e-12	8.64e-05	0.8	0.63	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
THYM	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	7.8	8.26e-12	9.77e-05	0.77	0.63	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
THYM	trans	rs13190036	0.786	rs10068127	ENSG00000226986.4	RP11-543B16.2	-7.8	8.36e-12	9.88e-05	-0.9	-0.63	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177204786	chr1:211207239~211207897:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000244604.1	RP11-713H12.1	-7.79	8.77e-12	0.000104	-0.71	-0.63	Cognitive function;	chr12:56080024	chr17:8561230~8561576:+
THYM	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	7.79	8.98e-12	0.000106	0.82	0.63	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
THYM	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	7.79	8.98e-12	0.000106	0.82	0.63	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
THYM	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	7.79	8.98e-12	0.000106	0.82	0.63	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
THYM	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	7.78	9.23e-12	0.000108	0.87	0.63	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
THYM	trans	rs12709013	0.636	rs30835	ENSG00000230849.2	GOT2P2	7.78	9.32e-12	0.00011	0.68	0.63	Blood metabolite ratios;	chr16:58714117	chr1:173141100~173142350:-
THYM	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-7.77	9.82e-12	0.000115	-0.75	-0.63	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
THYM	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	7.76	9.92e-12	0.000116	0.84	0.63	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
THYM	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	7.76	1e-11	0.000117	1.32	0.62	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
THYM	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	7.76	1.01e-11	0.000118	0.75	0.62	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
THYM	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-7.76	1.03e-11	0.00012	-0.95	-0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
THYM	trans	rs13190036	1	rs59737888	ENSG00000226986.4	RP11-543B16.2	-7.75	1.06e-11	0.000123	-0.93	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr1:211207239~211207897:+
THYM	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	7.75	1.06e-11	0.000123	0.88	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
THYM	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	7.74	1.09e-11	0.000127	0.74	0.62	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
THYM	trans	rs916888	0.779	rs199526	ENSG00000264070.1	DND1P1	-7.73	1.18e-11	0.000136	-0.77	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45585871~45586929:+
THYM	trans	rs55665837	1	rs2305306	ENSG00000236360.2	RP11-334A14.2	7.73	1.19e-11	0.000137	0.75	0.62	Vitamin D levels;	chr11:14513453	chr1:52993201~52993702:-
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	7.72	1.23e-11	0.000142	0.86	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
THYM	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	7.72	1.23e-11	0.000142	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-7.72	1.23e-11	0.000142	-0.83	-0.62	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
THYM	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-7.72	1.24e-11	0.000142	-0.8	-0.62	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
THYM	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	7.72	1.25e-11	0.000144	0.73	0.62	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
THYM	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	7.72	1.25e-11	0.000144	0.73	0.62	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
THYM	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832276	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14461728	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	7.71	1.28e-11	0.000146	0.74	0.62	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
THYM	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-7.7	1.37e-11	0.000154	-0.8	-0.62	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
THYM	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	7.7	1.39e-11	0.000156	0.95	0.62	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	7.7	1.39e-11	0.000156	0.95	0.62	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	7.7	1.39e-11	0.000156	0.95	0.62	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
THYM	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	7.7	1.39e-11	0.000156	0.95	0.62	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
THYM	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	7.69	1.4e-11	0.000158	0.73	0.62	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
THYM	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10832278	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14475073	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10766182	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14477990	chr1:52993201~52993702:-
THYM	trans	rs55665837	0.961	rs11023237	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14478788	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs10466412	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14483643	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs12364959	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14485889	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs11023246	ENSG00000236360.2	RP11-334A14.2	7.69	1.42e-11	0.000158	0.74	0.62	Vitamin D levels;	chr11:14515410	chr1:52993201~52993702:-
THYM	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	7.68	1.47e-11	0.000164	0.84	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
THYM	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	7.68	1.49e-11	0.000166	0.81	0.62	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
THYM	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-7.68	1.5e-11	0.000167	-0.74	-0.62	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	7.68	1.51e-11	0.000168	0.77	0.62	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-7.68	1.51e-11	0.000168	-0.77	-0.62	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
THYM	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	7.67	1.53e-11	0.000171	0.79	0.62	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000234513.1	AC073072.7	-7.67	1.54e-11	0.000171	-0.76	-0.62	Cognitive function;	chr12:56007301	chr7:22773646~22773993:-
THYM	trans	rs55665837	1	rs34980103	ENSG00000236360.2	RP11-334A14.2	7.67	1.54e-11	0.000171	0.74	0.62	Vitamin D levels;	chr11:14491339	chr1:52993201~52993702:-
THYM	trans	rs877636	0.74	rs705698	ENSG00000212994.5	RPS26P6	7.66	1.61e-11	0.000178	0.79	0.62	Cognitive function;	chr12:55990903	chr8:100895771~100896118:+
THYM	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-7.66	1.61e-11	0.000178	-0.79	-0.62	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000212829.8	RPS26P3	-7.66	1.62e-11	0.000179	-0.74	-0.62	Cognitive function;	chr12:56007301	chr9:9090898~9091245:+
THYM	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-7.65	1.75e-11	0.000193	-0.8	-0.62	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-7.65	1.75e-11	0.000193	-0.8	-0.62	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-7.64	1.77e-11	0.000196	-0.84	-0.62	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
THYM	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	7.64	1.78e-11	0.000196	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
THYM	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	7.64	1.8e-11	0.000198	0.74	0.62	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	7.64	1.8e-11	0.000198	0.74	0.62	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
THYM	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	7.64	1.8e-11	0.000198	0.74	0.62	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
THYM	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-7.64	1.81e-11	0.000199	-0.64	-0.62	Longevity;	chr3:48393807	chr1:27649419~27649610:+
THYM	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	7.63	1.93e-11	0.000211	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
THYM	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	7.62	1.97e-11	0.000215	0.82	0.62	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	7.62	1.97e-11	0.000215	0.82	0.62	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-7.62	2e-11	0.000219	-0.76	-0.62	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	7.62	2.01e-11	0.00022	0.74	0.62	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
THYM	trans	rs9876781	1	rs6784322	ENSG00000235912.1	RP1-159A19.3	-7.62	2.02e-11	0.00022	-0.67	-0.62	Longevity;	chr3:48380745	chr1:27649419~27649610:+
THYM	trans	rs7312770	1	rs7312770	ENSG00000212829.8	RPS26P3	-7.61	2.04e-11	0.000222	-0.71	-0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:9090898~9091245:+
THYM	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-7.61	2.04e-11	0.000223	-0.77	-0.62	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
THYM	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	7.61	2.08e-11	0.000226	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
THYM	trans	rs13190036	0.515	rs2878686	ENSG00000217325.2	PRELID1P1	-7.61	2.08e-11	0.000227	-0.8	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr6:126643488~126644390:+
THYM	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	7.61	2.08e-11	0.000227	0.83	0.62	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
THYM	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	7.61	2.12e-11	0.000231	0.81	0.62	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
THYM	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	7.61	2.12e-11	0.000231	0.81	0.62	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
THYM	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-7.61	2.12e-11	0.000231	-0.82	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
THYM	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-7.6	2.14e-11	0.000233	-0.87	-0.62	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
THYM	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-7.6	2.15e-11	0.000234	-0.64	-0.62	Longevity;	chr3:48378233	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-7.6	2.15e-11	0.000234	-0.64	-0.62	Longevity;	chr3:48378818	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-7.6	2.15e-11	0.000234	-0.64	-0.62	Longevity;	chr3:48379768	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-7.6	2.15e-11	0.000234	-0.64	-0.62	Longevity;	chr3:48389129	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.872	rs11797	ENSG00000235912.1	RP1-159A19.3	-7.6	2.2e-11	0.000239	-0.65	-0.62	Longevity;	chr3:48467186	chr1:27649419~27649610:+
THYM	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-7.6	2.22e-11	0.000241	-0.86	-0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-7.6	2.22e-11	0.000241	-0.86	-0.62	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-7.6	2.23e-11	0.000242	-0.74	-0.62	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
THYM	trans	rs13190036	0.551	rs7732930	ENSG00000217325.2	PRELID1P1	-7.58	2.4e-11	0.000258	-0.79	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr6:126643488~126644390:+
THYM	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	7.58	2.4e-11	0.000259	0.59	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
THYM	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-7.58	2.4e-11	0.000259	-0.59	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
THYM	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-7.58	2.4e-11	0.000259	-0.59	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
THYM	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-7.58	2.43e-11	0.000261	-0.79	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
THYM	trans	rs9876781	1	rs7653691	ENSG00000235912.1	RP1-159A19.3	7.58	2.43e-11	0.000261	0.63	0.62	Longevity;	chr3:48378199	chr1:27649419~27649610:+
THYM	trans	rs13190036	1	rs7714695	ENSG00000226986.4	RP11-543B16.2	-7.58	2.45e-11	0.000263	-0.91	-0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr1:211207239~211207897:+
THYM	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-7.57	2.49e-11	0.000267	-0.76	-0.62	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
THYM	trans	rs13190036	0.748	rs28395268	ENSG00000217325.2	PRELID1P1	7.57	2.54e-11	0.000273	0.81	0.62	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr6:126643488~126644390:+
THYM	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-7.56	2.68e-11	0.000285	-0.6	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
THYM	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-7.56	2.71e-11	0.000288	-0.72	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
THYM	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-7.56	2.71e-11	0.000288	-0.72	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
THYM	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	7.55	2.72e-11	0.00029	0.93	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
THYM	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-7.55	2.75e-11	0.000293	-0.59	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
THYM	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-7.55	2.75e-11	0.000293	-0.59	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
THYM	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-7.55	2.75e-11	0.000293	-0.59	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
THYM	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	7.55	2.76e-11	0.000293	0.78	0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
THYM	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-7.54	2.97e-11	0.000316	-0.86	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
THYM	trans	rs9611565	0.765	rs727563	ENSG00000268568.1	AC007228.9	7.53	3.08e-11	0.000326	0.73	0.61	Vitiligo;	chr22:41471373	chr19:56672574~56673901:-
THYM	trans	rs9876781	1	rs1459242	ENSG00000235912.1	RP1-159A19.3	7.51	3.34e-11	0.000352	0.62	0.61	Longevity;	chr3:48372047	chr1:27649419~27649610:+
THYM	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	7.51	3.35e-11	0.000353	0.82	0.61	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
THYM	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	7.51	3.35e-11	0.000353	0.82	0.61	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
THYM	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	7.51	3.38e-11	0.000356	0.78	0.61	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
THYM	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	7.5	3.57e-11	0.000375	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	7.5	3.6e-11	0.000378	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	7.5	3.6e-11	0.000378	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
THYM	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	7.49	3.61e-11	0.000379	0.72	0.61	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
THYM	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	7.49	3.63e-11	0.000381	0.8	0.61	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
THYM	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	7.49	3.66e-11	0.000384	0.7	0.61	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
THYM	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-7.49	3.71e-11	0.00039	-0.77	-0.61	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
THYM	trans	rs9876781	1	rs898225	ENSG00000235912.1	RP1-159A19.3	7.48	3.81e-11	0.000399	0.62	0.61	Longevity;	chr3:48371689	chr1:27649419~27649610:+
THYM	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-7.48	3.83e-11	0.000401	-0.78	-0.61	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-7.48	3.83e-11	0.000401	-0.78	-0.61	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-7.48	3.91e-11	0.000409	-0.73	-0.61	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	7.48	3.92e-11	0.000411	0.76	0.61	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
THYM	trans	rs13190036	0.551	rs11955537	ENSG00000217325.2	PRELID1P1	-7.47	4.12e-11	0.00043	-0.8	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-7.46	4.19e-11	0.000437	-0.88	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
THYM	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-7.46	4.19e-11	0.000437	-0.88	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000196933.5	RPS26P11	-7.45	4.38e-11	0.000454	-0.75	-0.61	Cognitive function;	chr12:56007301	chrX:72044545~72044892:+
THYM	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-7.45	4.45e-11	0.000461	-0.71	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
THYM	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-7.45	4.45e-11	0.000461	-0.71	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
THYM	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	7.45	4.49e-11	0.000465	0.61	0.61	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
THYM	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	7.45	4.52e-11	0.000468	0.59	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
THYM	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-7.45	4.53e-11	0.000469	-0.79	-0.61	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	7.45	4.53e-11	0.000469	0.79	0.61	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
THYM	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	7.44	4.62e-11	0.000477	0.83	0.61	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
THYM	trans	rs10037055	0.685	rs10039241	ENSG00000217325.2	PRELID1P1	-7.44	4.64e-11	0.000479	-0.78	-0.61	Migraine without aura;	chr5:177151071	chr6:126643488~126644390:+
THYM	trans	rs10037055	0.636	rs13166688	ENSG00000217325.2	PRELID1P1	-7.44	4.64e-11	0.000479	-0.78	-0.61	Migraine without aura;	chr5:177156965	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-7.44	4.64e-11	0.000479	-0.78	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.551	rs9313751	ENSG00000217325.2	PRELID1P1	-7.44	4.64e-11	0.000479	-0.78	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr6:126643488~126644390:+
THYM	trans	rs13190036	0.551	rs11957608	ENSG00000217325.2	PRELID1P1	-7.44	4.64e-11	0.000479	-0.78	-0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr6:126643488~126644390:+
THYM	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-7.44	4.68e-11	0.000482	-1	-0.61	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	7.44	4.68e-11	0.000482	1	0.61	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	7.44	4.68e-11	0.000482	1	0.61	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
THYM	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-7.44	4.75e-11	0.000489	-0.72	-0.61	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-7.43	4.87e-11	5e-04	-0.79	-0.61	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-7.43	4.87e-11	5e-04	-0.79	-0.61	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-7.43	4.87e-11	5e-04	-0.79	-0.61	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-7.43	4.87e-11	5e-04	-0.79	-0.61	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
THYM	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	7.43	4.99e-11	0.000511	0.77	0.61	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
THYM	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-7.43	5.02e-11	0.000514	-0.79	-0.61	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-7.43	5.02e-11	0.000514	-0.79	-0.61	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-7.43	5.02e-11	0.000514	-0.79	-0.61	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-7.43	5.02e-11	0.000514	-0.79	-0.61	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
THYM	trans	rs877636	0.736	rs773107	ENSG00000212994.5	RPS26P6	7.42	5.09e-11	0.000521	0.81	0.61	Cognitive function;	chr12:55975722	chr8:100895771~100896118:+
THYM	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-7.42	5.2e-11	0.000533	-0.8	-0.61	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
THYM	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	7.42	5.22e-11	0.000534	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	7.42	5.22e-11	0.000534	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	7.42	5.22e-11	0.000534	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	7.42	5.22e-11	0.000534	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	7.42	5.22e-11	0.000534	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	7.42	5.22e-11	0.000534	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	7.42	5.22e-11	0.000534	0.82	0.61	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
THYM	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-7.42	5.22e-11	0.000534	-0.98	-0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
THYM	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	7.42	5.27e-11	0.000538	0.77	0.61	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	7.42	5.27e-11	0.000538	0.77	0.61	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	7.41	5.33e-11	0.000545	0.77	0.61	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
THYM	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-7.41	5.36e-11	0.000548	-0.82	-0.61	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
THYM	trans	rs616147	0.671	rs675595	ENSG00000183298.5	RP11-556K13.1	-7.41	5.38e-11	0.000549	-0.85	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr1:101786340~101787219:-
THYM	trans	rs616147	0.616	rs1768234	ENSG00000183298.5	RP11-556K13.1	-7.41	5.38e-11	0.000549	-0.85	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr1:101786340~101787219:-
THYM	trans	rs616147	0.655	rs1707981	ENSG00000183298.5	RP11-556K13.1	-7.41	5.38e-11	0.000549	-0.85	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr1:101786340~101787219:-
THYM	trans	rs616147	0.72	rs1768209	ENSG00000183298.5	RP11-556K13.1	-7.41	5.38e-11	0.000549	-0.85	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr1:101786340~101787219:-
THYM	trans	rs616147	0.72	rs2965067	ENSG00000183298.5	RP11-556K13.1	-7.41	5.38e-11	0.000549	-0.85	-0.61	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr1:101786340~101787219:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000244604.1	RP11-713H12.1	-7.41	5.51e-11	0.000562	-0.67	-0.61	Cognitive function;	chr12:56084218	chr17:8561230~8561576:+
THYM	trans	rs877636	0.692	rs7971751	ENSG00000244604.1	RP11-713H12.1	-7.41	5.51e-11	0.000562	-0.67	-0.61	Cognitive function;	chr12:56084874	chr17:8561230~8561576:+
THYM	trans	rs13190036	0.579	rs13159114	ENSG00000226986.4	RP11-543B16.2	7.4	5.55e-11	0.000566	0.92	0.61	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177234807	chr1:211207239~211207897:+
THYM	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	7.4	5.66e-11	0.000576	0.96	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
THYM	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	7.4	5.66e-11	0.000576	0.96	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000196656.7	AC004057.1	-7.4	5.73e-11	0.000582	-0.75	-0.61	Cognitive function;	chr12:56007301	chr4:113214046~113217170:-
THYM	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-7.39	6.07e-11	0.000616	-0.61	-0.61	Longevity;	chr3:48398713	chr1:27649419~27649610:+
THYM	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	7.38	6.22e-11	0.000629	0.96	0.61	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
THYM	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-7.38	6.22e-11	0.000629	-0.77	-0.61	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	7.38	6.22e-11	0.000629	0.77	0.61	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	7.38	6.22e-11	0.000629	0.77	0.61	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
THYM	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	7.38	6.39e-11	0.000645	0.81	0.61	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
THYM	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	7.37	6.54e-11	0.00066	0.7	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
THYM	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	7.37	6.54e-11	0.00066	0.7	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
THYM	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	7.37	6.54e-11	0.00066	0.7	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
THYM	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-7.37	6.56e-11	0.000661	-0.85	-0.61	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
THYM	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-7.37	6.56e-11	0.000661	-0.85	-0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
THYM	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-7.37	6.56e-11	0.000661	-0.85	-0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-7.37	6.56e-11	0.000661	-0.85	-0.61	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-7.37	6.56e-11	0.000661	-0.85	-0.61	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-7.37	6.56e-11	0.000661	-0.85	-0.61	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-7.37	6.56e-11	0.000661	-0.85	-0.61	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	7.37	6.56e-11	0.000661	0.85	0.61	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	7.37	6.56e-11	0.000661	0.85	0.61	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
THYM	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	7.37	6.56e-11	0.000661	0.85	0.61	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	7.37	6.56e-11	0.000661	0.85	0.61	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
THYM	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	7.37	6.63e-11	0.000667	0.59	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
THYM	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	7.37	6.63e-11	0.000667	0.59	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
THYM	trans	rs7824557	0.872	rs2572431	ENSG00000253893.2	FAM85B	7.36	6.72e-11	0.000675	0.75	0.6	Retinal vascular caliber;	chr8:11247568	chr8:8167819~8226614:-
THYM	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-7.36	6.79e-11	0.000682	-0.79	-0.6	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
THYM	trans	rs13190036	0.901	rs4631	ENSG00000226986.4	RP11-543B16.2	7.36	6.79e-11	0.000682	0.88	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr1:211207239~211207897:+
THYM	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-7.36	6.98e-11	7e-04	-0.76	-0.6	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
THYM	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-7.36	7.01e-11	0.000703	-0.71	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
THYM	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-7.35	7.13e-11	0.000715	-0.7	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
THYM	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	7.35	7.13e-11	0.000715	0.7	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
THYM	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	7.35	7.13e-11	0.000715	0.7	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
THYM	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	7.34	7.45e-11	0.000747	0.72	0.6	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
THYM	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-7.34	7.71e-11	0.000772	-0.77	-0.6	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
THYM	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	7.34	7.72e-11	0.000773	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-7.33	7.8e-11	0.000781	-0.8	-0.6	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
THYM	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-7.33	7.8e-11	0.000781	-0.8	-0.6	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
THYM	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-7.33	8.1e-11	0.000809	-0.76	-0.6	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
THYM	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	7.32	8.2e-11	0.000818	0.8	0.6	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
THYM	trans	rs13190036	1	rs13175695	ENSG00000226986.4	RP11-543B16.2	7.32	8.22e-11	0.000821	0.85	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr1:211207239~211207897:+
THYM	trans	rs941207	0.724	rs4788	ENSG00000257210.1	NACAP3	7.32	8.46e-11	0.000844	0.76	0.6	Platelet count;	chr12:56712876	chr12:93124063~93124543:-
THYM	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-7.31	8.52e-11	0.00085	-0.78	-0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
THYM	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	7.31	8.57e-11	0.000854	0.59	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
THYM	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	7.31	8.6e-11	0.000855	0.93	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
THYM	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	7.31	8.6e-11	0.000855	0.93	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
THYM	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-7.3	8.92e-11	0.000876	-0.96	-0.6	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	7.3	8.92e-11	0.000876	0.96	0.6	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
THYM	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-7.3	9.04e-11	0.000886	-0.77	-0.6	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
THYM	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-7.3	9.1e-11	0.000892	-0.64	-0.6	Longevity;	chr3:48436629	chr1:27649419~27649610:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-7.3	9.26e-11	0.000907	-0.82	-0.6	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
THYM	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	7.29	9.36e-11	0.000915	0.97	0.6	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
THYM	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-7.29	9.4e-11	0.000918	-0.74	-0.6	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
THYM	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-7.29	9.55e-11	0.000932	-0.78	-0.6	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-7.29	9.55e-11	0.000932	-0.78	-0.6	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-7.29	9.55e-11	0.000932	-0.78	-0.6	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	7.29	9.56e-11	0.000933	0.77	0.6	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
THYM	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	7.28	9.88e-11	0.000964	0.96	0.6	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
THYM	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-7.27	1.04e-10	0.00101	-0.7	-0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
THYM	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	7.27	1.05e-10	0.00102	0.96	0.6	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	7.27	1.05e-10	0.00102	0.96	0.6	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
THYM	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	7.27	1.07e-10	0.00104	0.98	0.6	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
THYM	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-7.27	1.08e-10	0.00105	-0.72	-0.6	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
THYM	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	7.26	1.09e-10	0.00106	0.98	0.6	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
THYM	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	7.26	1.09e-10	0.00106	0.81	0.6	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-7.26	1.11e-10	0.00107	-0.81	-0.6	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
THYM	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-7.26	1.11e-10	0.00107	-0.81	-0.6	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
THYM	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	7.26	1.12e-10	0.00109	0.97	0.6	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	7.26	1.12e-10	0.00109	0.97	0.6	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	7.26	1.12e-10	0.00109	0.97	0.6	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	7.26	1.12e-10	0.00109	0.97	0.6	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	7.26	1.12e-10	0.00109	0.97	0.6	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
THYM	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	7.25	1.14e-10	0.00111	0.7	0.6	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
THYM	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	7.25	1.15e-10	0.00111	0.6	0.6	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	7.25	1.15e-10	0.00111	0.6	0.6	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	7.25	1.15e-10	0.00111	0.6	0.6	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
THYM	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	7.24	1.21e-10	0.00116	0.96	0.6	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	7.24	1.21e-10	0.00116	0.96	0.6	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
THYM	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-7.22	1.3e-10	0.00125	-0.78	-0.6	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
THYM	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	7.22	1.31e-10	0.00126	0.89	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
THYM	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	7.22	1.31e-10	0.00126	0.89	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
THYM	trans	rs941207	0.756	rs2958149	ENSG00000257210.1	NACAP3	7.22	1.32e-10	0.00127	0.76	0.6	Platelet count;	chr12:56716008	chr12:93124063~93124543:-
THYM	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	7.22	1.34e-10	0.00129	0.78	0.6	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
THYM	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	7.22	1.34e-10	0.00129	0.98	0.6	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
THYM	trans	rs916888	0.558	rs199521	ENSG00000214425.5	LRRC37A4P	7.22	1.35e-10	0.0013	0.59	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776090	chr17:45506741~45550335:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-7.22	1.36e-10	0.00131	-0.77	-0.6	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
THYM	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-7.22	1.36e-10	0.00131	-0.77	-0.6	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
THYM	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	7.21	1.37e-10	0.00131	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	7.21	1.37e-10	0.00131	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
THYM	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	7.21	1.37e-10	0.00131	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
THYM	trans	rs7312770	1	rs7312770	ENSG00000242970.2	AC068522.4	-7.21	1.37e-10	0.00131	-0.77	-0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:58588420~58588764:-
THYM	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	7.21	1.4e-10	0.00134	0.7	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
THYM	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	7.21	1.4e-10	0.00134	0.78	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
THYM	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	7.21	1.43e-10	0.00136	0.73	0.6	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	7.21	1.43e-10	0.00136	0.73	0.6	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	7.21	1.43e-10	0.00136	0.73	0.6	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
THYM	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-7.21	1.43e-10	0.00136	-0.71	-0.6	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
THYM	trans	rs916888	0.558	rs199521	ENSG00000264070.1	DND1P1	-7.21	1.43e-10	0.00137	-0.71	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776090	chr17:45585871~45586929:+
THYM	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-7.2	1.44e-10	0.00138	-0.79	-0.6	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
THYM	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	7.2	1.46e-10	0.00139	0.85	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
THYM	trans	rs877636	1	rs705696	ENSG00000212994.5	RPS26P6	7.2	1.48e-10	0.00141	0.74	0.6	Cognitive function;	chr12:56086864	chr8:100895771~100896118:+
THYM	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-7.19	1.52e-10	0.00145	-0.8	-0.6	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
THYM	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	7.19	1.53e-10	0.00145	0.75	0.6	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
THYM	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	7.18	1.6e-10	0.00151	0.96	0.6	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
THYM	trans	rs17711722	0.583	rs10085415	ENSG00000226824.5	RP4-756H11.3	7.18	1.6e-10	0.00151	0.78	0.6	Calcium levels;	chr7:65628655	chr7:66654538~66669855:+
THYM	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	7.18	1.6e-10	0.00151	0.58	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
THYM	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	7.18	1.6e-10	0.00151	0.58	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
THYM	trans	rs4925166	1	rs4925166	ENSG00000263946.1	RP11-434D2.11	7.17	1.65e-10	0.00156	0.62	0.59	Multiple sclerosis;	chr17:18307496	chr17:20554971~20559410:-
THYM	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-7.17	1.67e-10	0.00157	-0.7	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
THYM	trans	rs7224296	0.709	rs199518	ENSG00000264070.1	DND1P1	-7.17	1.67e-10	0.00157	-0.71	-0.59	Intelligence (multi-trait analysis);	chr17:46777214	chr17:45585871~45586929:+
THYM	trans	rs916888	0.647	rs199517	ENSG00000264070.1	DND1P1	-7.17	1.67e-10	0.00157	-0.71	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46777221	chr17:45585871~45586929:+
THYM	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	7.16	1.74e-10	0.00164	0.86	0.59	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
THYM	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-7.16	1.76e-10	0.00165	-0.78	-0.59	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
THYM	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	7.16	1.77e-10	0.00167	1	0.59	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	7.16	1.78e-10	0.00167	0.71	0.59	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
THYM	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	7.16	1.78e-10	0.00167	0.73	0.59	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
THYM	trans	rs916888	0.61	rs142167	ENSG00000264070.1	DND1P1	-7.16	1.8e-10	0.00169	-0.69	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45585871~45586929:+
THYM	trans	rs7224296	0.709	rs199518	ENSG00000214425.5	LRRC37A4P	7.16	1.8e-10	0.00169	0.59	0.59	Intelligence (multi-trait analysis);	chr17:46777214	chr17:45506741~45550335:-
THYM	trans	rs916888	0.647	rs199517	ENSG00000214425.5	LRRC37A4P	7.16	1.8e-10	0.00169	0.59	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46777221	chr17:45506741~45550335:-
THYM	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	7.15	1.82e-10	0.0017	0.97	0.59	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	7.15	1.82e-10	0.0017	0.97	0.59	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
THYM	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-7.15	1.82e-10	0.00171	-0.76	-0.59	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
THYM	trans	rs877636	0.692	rs2271194	ENSG00000244604.1	RP11-713H12.1	-7.15	1.85e-10	0.00173	-0.66	-0.59	Cognitive function;	chr12:56083910	chr17:8561230~8561576:+
THYM	trans	rs7824557	0.872	rs1347410	ENSG00000253893.2	FAM85B	7.14	1.96e-10	0.00184	0.7	0.59	Retinal vascular caliber;	chr8:11253733	chr8:8167819~8226614:-
THYM	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-7.13	2.02e-10	0.00189	-0.72	-0.59	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
THYM	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	7.13	2.08e-10	0.00194	0.95	0.59	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	7.13	2.08e-10	0.00194	0.95	0.59	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	7.13	2.08e-10	0.00194	0.95	0.59	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
THYM	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	7.12	2.09e-10	0.00195	0.73	0.59	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
THYM	trans	rs13190036	1	rs6880798	ENSG00000226986.4	RP11-543B16.2	7.12	2.11e-10	0.00195	0.85	0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr1:211207239~211207897:+
THYM	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	7.12	2.11e-10	0.00195	0.97	0.59	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
THYM	trans	rs1816752	0.624	rs2862901	ENSG00000237917.1	PARP4P1	-7.12	2.16e-10	0.002	-0.74	-0.59	Obesity-related traits;	chr13:24461101	chrY:26594851~26634652:-
THYM	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-7.12	2.18e-10	0.00201	-0.72	-0.59	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
THYM	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	7.11	2.2e-10	0.00203	0.88	0.59	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
THYM	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-7.11	2.21e-10	0.00204	-0.78	-0.59	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
THYM	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-7.11	2.21e-10	0.00204	-0.78	-0.59	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000204652.6	RPS26P8	-7.11	2.25e-10	0.00207	-0.69	-0.59	Cognitive function;	chr12:56007301	chr17:45608571~45608918:+
THYM	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	7.11	2.29e-10	0.00211	0.97	0.59	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
THYM	trans	rs13190036	0.901	rs6556309	ENSG00000226986.4	RP11-543B16.2	7.1	2.3e-10	0.00212	0.84	0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr1:211207239~211207897:+
THYM	trans	rs916888	0.647	rs199520	ENSG00000264070.1	DND1P1	-7.1	2.31e-10	0.00212	-0.7	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776506	chr17:45585871~45586929:+
THYM	trans	rs916888	0.647	rs199519	ENSG00000264070.1	DND1P1	-7.1	2.31e-10	0.00212	-0.7	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776558	chr17:45585871~45586929:+
THYM	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-7.1	2.35e-10	0.00216	-0.78	-0.59	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000243538.1	CTB-55B8.1	-7.1	2.38e-10	0.00218	-0.83	-0.59	Cognitive function;	chr12:56007301	chr5:16902294~16902641:-
THYM	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	7.09	2.41e-10	0.00221	0.8	0.59	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
THYM	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-7.09	2.45e-10	0.00224	-0.75	-0.59	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
THYM	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-7.09	2.48e-10	0.00228	-0.8	-0.59	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
THYM	trans	rs2657294	1	rs2657294	ENSG00000172974.11	AC007318.5	7.09	2.5e-10	0.00229	0.55	0.59	Pneumonia;	chr10:75193267	chr2:65205108~65205988:+
THYM	trans	rs7824557	0.843	rs2736375	ENSG00000253893.2	FAM85B	7.08	2.57e-10	0.00234	0.71	0.59	Retinal vascular caliber;	chr8:11258240	chr8:8167819~8226614:-
THYM	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	7.07	2.67e-10	0.00243	0.71	0.59	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	7.07	2.67e-10	0.00243	0.71	0.59	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	7.07	2.67e-10	0.00243	0.71	0.59	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	7.07	2.67e-10	0.00243	0.71	0.59	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
THYM	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-7.07	2.68e-10	0.00243	-0.63	-0.59	Longevity;	chr3:48443151	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-7.07	2.68e-10	0.00243	-0.63	-0.59	Longevity;	chr3:48443275	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-7.07	2.68e-10	0.00243	-0.63	-0.59	Longevity;	chr3:48445934	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6442123	ENSG00000235912.1	RP1-159A19.3	-7.07	2.68e-10	0.00243	-0.63	-0.59	Longevity;	chr3:48458887	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs2242150	ENSG00000235912.1	RP1-159A19.3	7.07	2.68e-10	0.00243	0.63	0.59	Longevity;	chr3:48464565	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-7.07	2.71e-10	0.00245	-0.63	-0.59	Longevity;	chr3:48421052	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-7.07	2.71e-10	0.00245	-0.63	-0.59	Longevity;	chr3:48422302	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-7.07	2.71e-10	0.00245	-0.63	-0.59	Longevity;	chr3:48429347	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-7.07	2.71e-10	0.00245	-0.63	-0.59	Longevity;	chr3:48431794	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-7.07	2.71e-10	0.00245	-0.63	-0.59	Longevity;	chr3:48437629	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-7.06	2.79e-10	0.00252	-0.63	-0.59	Longevity;	chr3:48442021	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-7.06	2.79e-10	0.00252	-0.63	-0.59	Longevity;	chr3:48442035	chr1:27649419~27649610:+
THYM	trans	rs941207	0.724	rs1979325	ENSG00000257210.1	NACAP3	7.06	2.8e-10	0.00253	0.74	0.59	Platelet count;	chr12:56728152	chr12:93124063~93124543:-
THYM	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	7.06	2.86e-10	0.00257	0.93	0.59	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
THYM	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	7.06	2.88e-10	0.00258	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
THYM	trans	rs2731664	0.792	rs2630763	ENSG00000215571.5	GRK6P1	7.06	2.88e-10	0.00258	0.69	0.59	Intelligence (multi-trait analysis);	chr5:177474004	chr13:21319156~21320866:+
THYM	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-7.05	2.91e-10	0.00261	-0.78	-0.59	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
THYM	trans	rs877636	0.562	rs10876864	ENSG00000242970.2	AC068522.4	-7.05	3e-10	0.00268	-0.79	-0.59	Cognitive function;	chr12:56007301	chr8:58588420~58588764:-
THYM	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-7.04	3.06e-10	0.00274	-0.68	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
THYM	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	7.04	3.07e-10	0.00275	0.84	0.59	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
THYM	trans	rs17834760	1	rs17239464	ENSG00000252733.1	AC067718.1	7.04	3.07e-10	0.00275	1.07	0.59	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr6:61699646	chr3:190143656~190143743:+
THYM	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-7.04	3.1e-10	0.00278	-0.76	-0.59	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
THYM	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	7.04	3.12e-10	0.00278	0.71	0.59	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	7.04	3.12e-10	0.00278	0.71	0.59	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	7.04	3.12e-10	0.00278	0.71	0.59	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	7.04	3.12e-10	0.00278	0.71	0.59	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
THYM	trans	rs9899728	0.572	rs9915968	ENSG00000234925.2	ATP5HP4	7.04	3.14e-10	0.0028	0.82	0.59	Alzheimer's disease or small vessel stroke;	chr17:75063521	chr12:68642519~68642993:-
THYM	trans	rs9899728	0.572	rs4365317	ENSG00000234925.2	ATP5HP4	7.04	3.14e-10	0.0028	0.82	0.59	Alzheimer's disease or small vessel stroke;	chr17:75063725	chr12:68642519~68642993:-
THYM	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	7.04	3.15e-10	0.00281	0.75	0.59	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
THYM	trans	rs9611519	0.78	rs1983631	ENSG00000268568.1	AC007228.9	-7.04	3.15e-10	0.00281	-0.69	-0.59	Neuroticism;	chr22:41248070	chr19:56672574~56673901:-
THYM	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	7.04	3.15e-10	0.00282	0.83	0.59	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
THYM	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	7.04	3.17e-10	0.00282	0.95	0.59	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
THYM	trans	rs9611565	0.525	rs9611548	ENSG00000268568.1	AC007228.9	-7.03	3.3e-10	0.00295	-0.7	-0.59	Vitiligo;	chr22:41308139	chr19:56672574~56673901:-
THYM	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-7.03	3.32e-10	0.00296	-0.92	-0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
THYM	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-7.02	3.35e-10	0.00298	-0.74	-0.59	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
THYM	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-7.02	3.43e-10	0.00305	-0.68	-0.59	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
THYM	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	7.01	3.52e-10	0.00313	0.74	0.59	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
THYM	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	7.01	3.54e-10	0.00314	0.62	0.59	Longevity;	chr3:48407507	chr1:27649419~27649610:+
THYM	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	7.01	3.58e-10	0.00317	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
THYM	trans	rs7554547	0.63	rs4845889	ENSG00000261819.1	RP11-680G24.4	7	3.71e-10	0.00328	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11911288	chr16:14988259~14990160:-
THYM	trans	rs7554547	0.667	rs7525521	ENSG00000261819.1	RP11-680G24.4	7	3.71e-10	0.00328	0.75	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11915109	chr16:14988259~14990160:-
THYM	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-7	3.77e-10	0.00332	-0.76	-0.59	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-7	3.77e-10	0.00332	-0.76	-0.59	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-7	3.77e-10	0.00332	-0.76	-0.59	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-7	3.77e-10	0.00332	-0.76	-0.59	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-7	3.77e-10	0.00332	-0.76	-0.59	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-7	3.77e-10	0.00332	-0.76	-0.59	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	6.99	3.88e-10	0.00342	0.72	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
THYM	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-6.99	3.94e-10	0.00347	-0.77	-0.58	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-6.99	3.95e-10	0.00347	-0.76	-0.58	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-6.98	4.04e-10	0.00354	-0.77	-0.58	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-6.98	4.04e-10	0.00354	-0.77	-0.58	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-6.98	4.04e-10	0.00354	-0.77	-0.58	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
THYM	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-6.98	4.05e-10	0.00354	-0.63	-0.58	Longevity;	chr3:48414217	chr1:27649419~27649610:+
THYM	trans	rs9611519	0.964	rs5995992	ENSG00000268568.1	AC007228.9	-6.98	4.14e-10	0.00362	-0.73	-0.58	Neuroticism;	chr22:41091214	chr19:56672574~56673901:-
THYM	trans	rs9611519	0.929	rs11090039	ENSG00000268568.1	AC007228.9	-6.98	4.14e-10	0.00362	-0.73	-0.58	Neuroticism;	chr22:41100796	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-6.98	4.14e-10	0.00362	-0.68	-0.58	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-6.98	4.18e-10	0.00365	-0.77	-0.58	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-6.98	4.18e-10	0.00365	-0.77	-0.58	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-6.98	4.18e-10	0.00365	-0.77	-0.58	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
THYM	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	6.98	4.18e-10	0.00365	0.79	0.58	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
THYM	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-6.98	4.2e-10	0.00367	-0.8	-0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
THYM	trans	rs9876781	1	rs4858793	ENSG00000235912.1	RP1-159A19.3	6.98	4.21e-10	0.00368	0.62	0.58	Longevity;	chr3:48373517	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6810060	ENSG00000235912.1	RP1-159A19.3	-6.97	4.26e-10	0.00372	-0.59	-0.58	Longevity;	chr3:48393284	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs6770470	ENSG00000235912.1	RP1-159A19.3	-6.97	4.26e-10	0.00372	-0.59	-0.58	Longevity;	chr3:48393659	chr1:27649419~27649610:+
THYM	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-6.97	4.26e-10	0.00372	-0.73	-0.58	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
THYM	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	6.97	4.29e-10	0.00374	0.71	0.58	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-6.97	4.29e-10	0.00374	-0.77	-0.58	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-6.97	4.29e-10	0.00374	-0.77	-0.58	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-6.97	4.29e-10	0.00374	-0.77	-0.58	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-6.97	4.29e-10	0.00374	-0.77	-0.58	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
THYM	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-6.97	4.35e-10	0.00379	-0.82	-0.58	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
THYM	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-6.97	4.39e-10	0.00382	-0.77	-0.58	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-6.97	4.39e-10	0.00382	-0.77	-0.58	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
THYM	trans	rs11992162	0.591	rs35657308	ENSG00000253893.2	FAM85B	6.96	4.45e-10	0.00387	0.72	0.58	Monocyte count;	chr8:11946893	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.713	rs9286062	ENSG00000253893.2	FAM85B	6.96	4.47e-10	0.00389	0.68	0.58	Retinal vascular caliber;	chr8:11261018	chr8:8167819~8226614:-
THYM	trans	rs941207	0.756	rs2926743	ENSG00000257210.1	NACAP3	6.96	4.48e-10	0.0039	0.74	0.58	Platelet count;	chr12:56720316	chr12:93124063~93124543:-
THYM	trans	rs7312770	1	rs7312770	ENSG00000244604.1	RP11-713H12.1	-6.96	4.55e-10	0.00395	-0.65	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:8561230~8561576:+
THYM	trans	rs9876781	1	rs4858817	ENSG00000235912.1	RP1-159A19.3	6.96	4.63e-10	0.00403	0.59	0.58	Longevity;	chr3:48375266	chr1:27649419~27649610:+
THYM	trans	rs877636	0.562	rs10876864	ENSG00000244604.1	RP11-713H12.1	-6.95	4.68e-10	0.00406	-0.68	-0.58	Cognitive function;	chr12:56007301	chr17:8561230~8561576:+
THYM	trans	rs10435719	0.902	rs7006538	ENSG00000253893.2	FAM85B	-6.95	4.8e-10	0.00416	-0.73	-0.58	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:8167819~8226614:-
THYM	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-6.95	4.84e-10	0.0042	-0.67	-0.58	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
THYM	trans	rs877636	0.702	rs773108	ENSG00000234513.1	AC073072.7	6.94	4.88e-10	0.00423	0.79	0.58	Cognitive function;	chr12:55976127	chr7:22773646~22773993:-
THYM	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-6.94	4.9e-10	0.00425	-0.75	-0.58	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
THYM	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-6.94	4.95e-10	0.00429	-0.88	-0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
THYM	trans	rs7312770	1	rs7312770	ENSG00000243538.1	CTB-55B8.1	-6.94	4.96e-10	0.0043	-0.78	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr5:16902294~16902641:-
THYM	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-6.94	4.98e-10	0.00431	-0.73	-0.58	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
THYM	trans	rs9611565	0.506	rs2024566	ENSG00000268568.1	AC007228.9	-6.94	5.07e-10	0.00437	-0.69	-0.58	Vitiligo;	chr22:41301334	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.506	rs2024567	ENSG00000268568.1	AC007228.9	-6.94	5.07e-10	0.00437	-0.69	-0.58	Vitiligo;	chr22:41303202	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.506	rs4822020	ENSG00000268568.1	AC007228.9	-6.94	5.07e-10	0.00437	-0.69	-0.58	Vitiligo;	chr22:41304199	chr19:56672574~56673901:-
THYM	trans	rs9611519	0.732	rs1883826	ENSG00000268568.1	AC007228.9	-6.94	5.07e-10	0.00437	-0.69	-0.58	Neuroticism;	chr22:41307424	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.525	rs9611549	ENSG00000268568.1	AC007228.9	-6.94	5.07e-10	0.00437	-0.69	-0.58	Vitiligo;	chr22:41309905	chr19:56672574~56673901:-
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	6.93	5.11e-10	0.0044	0.71	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
THYM	trans	rs11790131	1	rs11790131	ENSG00000233613.4	DCUN1D2-AS	-6.93	5.17e-10	0.00445	-0.96	-0.58	Liver fibrosis severity in HIV/hepatitis C co-infection;	chr9:19469848	chr13:113468901~113476135:+
THYM	trans	rs9611519	0.857	rs4820434	ENSG00000268568.1	AC007228.9	-6.93	5.17e-10	0.00445	-0.7	-0.58	Neuroticism;	chr22:41241115	chr19:56672574~56673901:-
THYM	trans	rs35851103	0.6	rs4841662	ENSG00000253893.2	FAM85B	6.93	5.24e-10	0.00451	0.7	0.58	Neuroticism;	chr8:11986249	chr8:8167819~8226614:-
THYM	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	6.93	5.3e-10	0.00456	0.81	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
THYM	trans	rs7824557	0.806	rs10503418	ENSG00000253893.2	FAM85B	6.92	5.34e-10	0.00459	0.72	0.58	Retinal vascular caliber;	chr8:11261474	chr8:8167819~8226614:-
THYM	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-6.92	5.41e-10	0.00465	-0.76	-0.58	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
THYM	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-6.92	5.54e-10	0.00475	-0.72	-0.58	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
THYM	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	6.92	5.55e-10	0.00476	0.81	0.58	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
THYM	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-6.91	5.6e-10	0.0048	-0.73	-0.58	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
THYM	trans	rs13190036	0.591	rs78523677	ENSG00000226986.4	RP11-543B16.2	-6.91	5.7e-10	0.00489	-0.77	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.551	rs4976639	ENSG00000226986.4	RP11-543B16.2	6.91	5.7e-10	0.00489	0.77	0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr1:211207239~211207897:+
THYM	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-6.91	5.76e-10	0.00494	-0.82	-0.58	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
THYM	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	6.91	5.77e-10	0.00494	0.57	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
THYM	trans	rs9611519	0.78	rs9611527	ENSG00000268568.1	AC007228.9	-6.91	5.83e-10	0.005	-0.7	-0.58	Neuroticism;	chr22:41248424	chr19:56672574~56673901:-
THYM	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	6.9	5.91e-10	0.00506	0.88	0.58	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
THYM	trans	rs9611519	0.78	rs3171692	ENSG00000268568.1	AC007228.9	-6.9	5.93e-10	0.00507	-0.68	-0.58	Neuroticism;	chr22:41246208	chr19:56672574~56673901:-
THYM	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	6.9	5.95e-10	0.00509	0.86	0.58	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
THYM	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	6.9	5.98e-10	0.00512	0.91	0.58	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	6.9	5.98e-10	0.00512	0.91	0.58	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-6.9	6.06e-10	0.00518	-0.69	-0.58	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
THYM	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-6.9	6.06e-10	0.00518	-0.69	-0.58	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
THYM	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-6.9	6.06e-10	0.00518	-0.69	-0.58	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
THYM	trans	rs13190036	0.551	rs28932178	ENSG00000226986.4	RP11-543B16.2	-6.89	6.18e-10	0.00528	-0.78	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr1:211207239~211207897:+
THYM	trans	rs4711350	0.862	rs688209	ENSG00000184319.14	RPL23AP82	-6.89	6.27e-10	0.00535	-0.86	-0.58	Schizophrenia;	chr6:33732599	chr22:50756948~50801309:+
THYM	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	6.89	6.31e-10	0.00538	0.81	0.58	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
THYM	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	6.89	6.4e-10	0.00545	0.74	0.58	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
THYM	trans	rs7819412	0.645	rs4841508	ENSG00000253893.2	FAM85B	6.88	6.69e-10	0.00569	0.74	0.58	Triglycerides;	chr8:11207494	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.902	rs4840599	ENSG00000253893.2	FAM85B	6.87	6.79e-10	0.00577	0.72	0.58	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.509	rs13282439	ENSG00000253893.2	FAM85B	-6.87	6.94e-10	0.00589	-0.74	-0.58	Neuroticism;	chr8:11937392	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.746	rs58007588	ENSG00000253893.2	FAM85B	-6.87	6.94e-10	0.00589	-0.74	-0.58	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937460	chr8:8167819~8226614:-
THYM	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-6.86	7.11e-10	0.00603	-0.69	-0.58	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
THYM	trans	rs2069408	1	rs2069408	ENSG00000212994.5	RPS26P6	-6.85	7.42e-10	0.00627	-0.73	-0.58	Asthma;	chr12:55970537	chr8:100895771~100896118:+
THYM	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	6.85	7.43e-10	0.00627	0.95	0.58	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	6.85	7.43e-10	0.00627	0.95	0.58	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs11763511	ENSG00000228546.2	CTA-313A17.3	6.85	7.43e-10	0.00627	0.95	0.58	Platelet count;	chr7:100484321	chr7:102337316~102339115:+
THYM	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-6.85	7.64e-10	0.00644	-0.68	-0.58	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
THYM	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-6.85	7.64e-10	0.00644	-0.68	-0.58	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
THYM	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	6.85	7.69e-10	0.00648	0.71	0.58	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
THYM	trans	rs284491	0.965	rs284492	ENSG00000236526.1	RP4-742J24.2	6.84	8.01e-10	0.00673	0.43	0.58	Glaucoma (low intraocular pressure);	chr8:104947372	chr20:11909404~11918677:-
THYM	trans	rs916888	0.647	rs199520	ENSG00000214425.5	LRRC37A4P	6.84	8.06e-10	0.00675	0.57	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776506	chr17:45506741~45550335:-
THYM	trans	rs916888	0.647	rs199519	ENSG00000214425.5	LRRC37A4P	6.84	8.06e-10	0.00675	0.57	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46776558	chr17:45506741~45550335:-
THYM	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-6.83	8.27e-10	0.00692	-0.8	-0.58	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
THYM	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-6.83	8.27e-10	0.00692	-0.8	-0.58	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
THYM	trans	rs13190036	0.551	rs1052432	ENSG00000226986.4	RP11-543B16.2	-6.83	8.32e-10	0.00696	-0.75	-0.58	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr1:211207239~211207897:+
THYM	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-6.83	8.37e-10	0.007	-0.77	-0.58	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
THYM	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	6.83	8.45e-10	0.00706	0.79	0.58	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
THYM	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	6.83	8.46e-10	0.00707	0.93	0.58	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
THYM	trans	rs9876781	0.933	rs6442124	ENSG00000235912.1	RP1-159A19.3	-6.83	8.5e-10	0.0071	-0.62	-0.58	Longevity;	chr3:48463903	chr1:27649419~27649610:+
THYM	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	6.82	8.61e-10	0.00717	0.85	0.58	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
THYM	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	6.82	8.84e-10	0.00735	0.69	0.58	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	6.82	8.84e-10	0.00735	0.69	0.58	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
THYM	trans	rs1473500	0.59	rs60988894	ENSG00000254501.1	AP003068.9	-6.82	8.84e-10	0.00735	-0.97	-0.58	Immune reponse to smallpox (secreted IL-2);	chr6:168112912	chr11:65110714~65111695:-
THYM	trans	rs1473500	0.59	rs73790778	ENSG00000254501.1	AP003068.9	-6.82	8.84e-10	0.00735	-0.97	-0.58	Immune reponse to smallpox (secreted IL-2);	chr6:168119017	chr11:65110714~65111695:-
THYM	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	6.81	9e-10	0.00746	0.75	0.57	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
THYM	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	6.81	9e-10	0.00746	0.75	0.57	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
THYM	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	6.81	9e-10	0.00746	0.75	0.57	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
THYM	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	6.81	9e-10	0.00746	0.75	0.57	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
THYM	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	6.81	9e-10	0.00746	0.75	0.57	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
THYM	trans	rs7824557	0.815	rs2736372	ENSG00000253893.2	FAM85B	6.81	9.06e-10	0.00751	0.7	0.57	Retinal vascular caliber;	chr8:11248532	chr8:8167819~8226614:-
THYM	trans	rs13190036	0.551	rs7732930	ENSG00000226986.4	RP11-543B16.2	-6.8	9.44e-10	0.00782	-0.75	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr1:211207239~211207897:+
THYM	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-6.8	9.47e-10	0.00784	-0.73	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
THYM	trans	rs877636	0.692	rs10876870	ENSG00000212829.8	RPS26P3	-6.8	9.6e-10	0.00795	-0.66	-0.57	Cognitive function;	chr12:56084218	chr9:9090898~9091245:+
THYM	trans	rs877636	0.692	rs7971751	ENSG00000212829.8	RPS26P3	-6.8	9.6e-10	0.00795	-0.66	-0.57	Cognitive function;	chr12:56084874	chr9:9090898~9091245:+
THYM	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	6.8	9.61e-10	0.00796	0.94	0.57	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
THYM	trans	rs941207	0.756	rs7978685	ENSG00000257210.1	NACAP3	6.8	9.69e-10	0.00801	0.73	0.57	Platelet count;	chr12:56709370	chr12:93124063~93124543:-
THYM	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-6.8	9.7e-10	0.00802	-0.67	-0.57	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
THYM	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	6.79	1.01e-09	0.00836	0.75	0.57	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
THYM	trans	rs1816752	0.669	rs4770699	ENSG00000237917.1	PARP4P1	-6.79	1.02e-09	0.00845	-0.77	-0.57	Obesity-related traits;	chr13:24488234	chrY:26594851~26634652:-
THYM	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	6.78	1.04e-09	0.00861	0.68	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
THYM	trans	rs9876781	1	rs7635522	ENSG00000235912.1	RP1-159A19.3	-6.78	1.05e-09	0.00868	-0.58	-0.57	Longevity;	chr3:48382166	chr1:27649419~27649610:+
THYM	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-6.78	1.06e-09	0.00871	-0.68	-0.57	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
THYM	trans	rs13190036	0.515	rs2878686	ENSG00000226986.4	RP11-543B16.2	-6.77	1.08e-09	0.00885	-0.76	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr1:211207239~211207897:+
THYM	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	6.77	1.08e-09	0.00892	0.75	0.57	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
THYM	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-6.77	1.12e-09	0.00922	-0.76	-0.57	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
THYM	trans	rs9876781	1	rs2362452	ENSG00000235912.1	RP1-159A19.3	6.76	1.13e-09	0.00927	0.57	0.57	Longevity;	chr3:48376724	chr1:27649419~27649610:+
THYM	trans	rs877636	0.809	rs1689510	ENSG00000235459.5	RPS26P31	6.76	1.16e-09	0.00949	0.76	0.57	Cognitive function;	chr12:56002984	chr7:122681315~122681662:+
THYM	trans	rs941207	0.756	rs7313074	ENSG00000257210.1	NACAP3	-6.76	1.17e-09	0.00956	-0.72	-0.57	Platelet count;	chr12:56760705	chr12:93124063~93124543:-
THYM	trans	rs9876781	1	rs2362450	ENSG00000235912.1	RP1-159A19.3	-6.75	1.19e-09	0.0097	-0.6	-0.57	Longevity;	chr3:48419904	chr1:27649419~27649610:+
THYM	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-6.75	1.19e-09	0.0097	-0.6	-0.57	Longevity;	chr3:48438208	chr1:27649419~27649610:+
THYM	trans	rs941207	0.756	rs2950388	ENSG00000257210.1	NACAP3	-6.73	1.33e-09	0.0108	-0.7	-0.57	Platelet count;	chr12:56639569	chr12:93124063~93124543:-
THYM	trans	rs941207	0.756	rs7315472	ENSG00000257210.1	NACAP3	-6.73	1.33e-09	0.0108	-0.7	-0.57	Platelet count;	chr12:56648276	chr12:93124063~93124543:-
THYM	trans	rs941207	0.756	rs67046307	ENSG00000257210.1	NACAP3	-6.73	1.33e-09	0.0108	-0.7	-0.57	Platelet count;	chr12:56651152	chr12:93124063~93124543:-
THYM	trans	rs941207	0.756	rs10876915	ENSG00000257210.1	NACAP3	-6.73	1.33e-09	0.0108	-0.7	-0.57	Platelet count;	chr12:56655280	chr12:93124063~93124543:-
THYM	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	6.72	1.37e-09	0.0111	0.69	0.57	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	6.72	1.37e-09	0.0111	0.69	0.57	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	6.72	1.37e-09	0.0111	0.69	0.57	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	6.72	1.37e-09	0.0111	0.69	0.57	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
THYM	trans	rs284491	1	rs284491	ENSG00000236526.1	RP4-742J24.2	-6.72	1.4e-09	0.0114	-0.42	-0.57	Glaucoma (low intraocular pressure);	chr8:104946405	chr20:11909404~11918677:-
THYM	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-6.71	1.45e-09	0.0118	-0.82	-0.57	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
THYM	trans	rs7811142	1	rs11559117	ENSG00000228546.2	CTA-313A17.3	6.71	1.47e-09	0.0119	0.94	0.57	Platelet count;	chr7:100478991	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs2406253	ENSG00000228546.2	CTA-313A17.3	6.71	1.47e-09	0.0119	0.94	0.57	Platelet count;	chr7:100479650	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs4463351	ENSG00000228546.2	CTA-313A17.3	6.71	1.47e-09	0.0119	0.94	0.57	Platelet count;	chr7:100480603	chr7:102337316~102339115:+
THYM	trans	rs9611519	0.964	rs4820428	ENSG00000268568.1	AC007228.9	6.71	1.48e-09	0.012	0.7	0.57	Neuroticism;	chr22:41141585	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-6.7	1.53e-09	0.0123	-0.75	-0.57	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-6.7	1.53e-09	0.0123	-0.75	-0.57	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-6.7	1.53e-09	0.0123	-0.75	-0.57	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
THYM	trans	rs11992162	0.569	rs11786149	ENSG00000253893.2	FAM85B	6.7	1.53e-09	0.0123	0.69	0.57	Monocyte count;	chr8:11943309	chr8:8167819~8226614:-
THYM	trans	rs2950393	0.611	rs7138821	ENSG00000121089.4	NACA3P	-6.7	1.55e-09	0.0125	-0.69	-0.57	Platelet distribution width;	chr12:56796206	chr4:164943290~164943937:+
THYM	trans	rs9611519	0.929	rs2064560	ENSG00000268568.1	AC007228.9	-6.69	1.56e-09	0.0125	-0.7	-0.57	Neuroticism;	chr22:41134036	chr19:56672574~56673901:-
THYM	trans	rs9611519	0.828	rs4822008	ENSG00000268568.1	AC007228.9	-6.69	1.56e-09	0.0125	-0.7	-0.57	Neuroticism;	chr22:41143202	chr19:56672574~56673901:-
THYM	trans	rs9611519	1	rs9611505	ENSG00000268568.1	AC007228.9	-6.69	1.56e-09	0.0125	-0.7	-0.57	Neuroticism;	chr22:41144275	chr19:56672574~56673901:-
THYM	trans	rs9611519	0.964	rs20551	ENSG00000268568.1	AC007228.9	-6.69	1.56e-09	0.0125	-0.7	-0.57	Neuroticism;	chr22:41152004	chr19:56672574~56673901:-
THYM	trans	rs9611519	1	rs2057070	ENSG00000268568.1	AC007228.9	-6.69	1.56e-09	0.0125	-0.7	-0.57	Neuroticism;	chr22:41168283	chr19:56672574~56673901:-
THYM	trans	rs9611519	0.929	rs9611509	ENSG00000268568.1	AC007228.9	-6.69	1.56e-09	0.0125	-0.7	-0.57	Neuroticism;	chr22:41169823	chr19:56672574~56673901:-
THYM	trans	rs9611519	1	rs9611510	ENSG00000268568.1	AC007228.9	-6.69	1.56e-09	0.0125	-0.7	-0.57	Neuroticism;	chr22:41173120	chr19:56672574~56673901:-
THYM	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	6.69	1.58e-09	0.0127	0.59	0.57	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
THYM	trans	rs9611565	0.506	rs1883825	ENSG00000268568.1	AC007228.9	-6.69	1.6e-09	0.0128	-0.67	-0.57	Vitiligo;	chr22:41307404	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.525	rs1883827	ENSG00000268568.1	AC007228.9	-6.69	1.6e-09	0.0128	-0.67	-0.57	Vitiligo;	chr22:41307575	chr19:56672574~56673901:-
THYM	trans	rs10037055	0.685	rs10039241	ENSG00000226986.4	RP11-543B16.2	-6.69	1.6e-09	0.0128	-0.74	-0.57	Migraine without aura;	chr5:177151071	chr1:211207239~211207897:+
THYM	trans	rs10037055	0.636	rs13166688	ENSG00000226986.4	RP11-543B16.2	-6.69	1.6e-09	0.0128	-0.74	-0.57	Migraine without aura;	chr5:177156965	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.551	rs7710269	ENSG00000226986.4	RP11-543B16.2	-6.69	1.6e-09	0.0128	-0.74	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.551	rs9313751	ENSG00000226986.4	RP11-543B16.2	-6.69	1.6e-09	0.0128	-0.74	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr1:211207239~211207897:+
THYM	trans	rs13190036	0.551	rs11957608	ENSG00000226986.4	RP11-543B16.2	-6.69	1.6e-09	0.0128	-0.74	-0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr1:211207239~211207897:+
THYM	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	6.69	1.6e-09	0.0128	0.74	0.57	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
THYM	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-6.69	1.6e-09	0.0128	-0.74	-0.57	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
THYM	trans	rs616147	1	rs1768208	ENSG00000183298.5	RP11-556K13.1	-6.69	1.62e-09	0.013	-0.81	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr1:101786340~101787219:-
THYM	trans	rs877636	0.809	rs1689510	ENSG00000225071.1	GS1-184P14.2	6.68	1.64e-09	0.0131	0.76	0.57	Cognitive function;	chr12:56002984	chrX:24429573~24429920:-
THYM	trans	rs6683225	0.584	rs6668274	ENSG00000266938.1	AC119403.1	6.68	1.65e-09	0.0132	0.64	0.57	Obesity-related traits;	chr1:237177810	chr19:2896625~2897222:-
THYM	trans	rs11992162	0.636	rs4841645	ENSG00000253893.2	FAM85B	6.68	1.66e-09	0.0132	0.69	0.57	Monocyte count;	chr8:11941175	chr8:8167819~8226614:-
THYM	trans	rs11992162	0.636	rs4841642	ENSG00000253893.2	FAM85B	-6.68	1.66e-09	0.0132	-0.69	-0.57	Monocyte count;	chr8:11940825	chr8:8167819~8226614:-
THYM	trans	rs11992162	0.636	rs4841644	ENSG00000253893.2	FAM85B	-6.68	1.66e-09	0.0132	-0.69	-0.57	Monocyte count;	chr8:11940924	chr8:8167819~8226614:-
THYM	trans	rs11992162	0.636	rs4841646	ENSG00000253893.2	FAM85B	-6.68	1.66e-09	0.0132	-0.69	-0.57	Monocyte count;	chr8:11941198	chr8:8167819~8226614:-
THYM	trans	rs11992162	0.613	rs6998690	ENSG00000253893.2	FAM85B	-6.68	1.66e-09	0.0132	-0.69	-0.57	Monocyte count;	chr8:11941287	chr8:8167819~8226614:-
THYM	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-6.68	1.66e-09	0.0132	-0.71	-0.57	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
THYM	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-6.68	1.66e-09	0.0132	-0.71	-0.57	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
THYM	trans	rs1908814	0.516	rs4841641	ENSG00000253893.2	FAM85B	-6.68	1.71e-09	0.0136	-0.7	-0.57	Neuroticism;	chr8:11940718	chr8:8167819~8226614:-
THYM	trans	rs7811142	0.83	rs28495773	ENSG00000228546.2	CTA-313A17.3	6.67	1.74e-09	0.0138	0.95	0.57	Platelet count;	chr7:100345960	chr7:102337316~102339115:+
THYM	trans	rs2657294	0.895	rs2395137	ENSG00000172974.11	AC007318.5	6.67	1.78e-09	0.0141	0.53	0.57	Pneumonia;	chr10:75088235	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.895	rs2002023	ENSG00000172974.11	AC007318.5	6.67	1.78e-09	0.0141	0.53	0.57	Pneumonia;	chr10:75088766	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.796	rs7082123	ENSG00000172974.11	AC007318.5	6.67	1.78e-09	0.0141	0.53	0.57	Pneumonia;	chr10:75091101	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.861	rs6480769	ENSG00000172974.11	AC007318.5	6.67	1.78e-09	0.0141	0.53	0.57	Pneumonia;	chr10:75091745	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs10824285	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75153271	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.931	rs2804522	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75159132	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs2047951	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75161310	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs2804523	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75161584	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs2657285	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75164166	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs7899946	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75166013	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs10824286	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75172251	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs4746270	ENSG00000172974.11	AC007318.5	6.66	1.81e-09	0.0143	0.52	0.57	Pneumonia;	chr10:75185189	chr2:65205108~65205988:+
THYM	trans	rs7617400	0.515	rs61044605	ENSG00000250906.1	RP11-632F7.3	-6.66	1.81e-09	0.0143	-0.53	-0.57	Liver enzyme levels (aspartate transaminase);	chr3:79573481	chr4:40812779~40826151:+
THYM	trans	rs2657294	0.895	rs4746262	ENSG00000172974.11	AC007318.5	6.66	1.82e-09	0.0144	0.53	0.57	Pneumonia;	chr10:75093631	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.895	rs3088142	ENSG00000172974.11	AC007318.5	6.66	1.82e-09	0.0144	0.53	0.57	Pneumonia;	chr10:75094806	chr2:65205108~65205988:+
THYM	trans	rs7824557	0.751	rs2099456	ENSG00000253893.2	FAM85B	-6.66	1.85e-09	0.0146	-0.68	-0.57	Retinal vascular caliber;	chr8:11269492	chr8:8167819~8226614:-
THYM	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	6.65	1.88e-09	0.0149	0.65	0.57	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
THYM	trans	rs7824557	0.836	rs2736378	ENSG00000253893.2	FAM85B	6.64	1.97e-09	0.0156	0.7	0.57	Retinal vascular caliber;	chr8:11262251	chr8:8167819~8226614:-
THYM	trans	rs11992162	0.613	rs56094399	ENSG00000253893.2	FAM85B	6.64	1.99e-09	0.0157	0.69	0.57	Monocyte count;	chr8:11939961	chr8:8167819~8226614:-
THYM	trans	rs9611519	0.964	rs2092563	ENSG00000268568.1	AC007228.9	-6.64	2.02e-09	0.0158	-0.71	-0.56	Neuroticism;	chr22:41196673	chr19:56672574~56673901:-
THYM	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	6.64	2.04e-09	0.016	0.83	0.56	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
THYM	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	6.63	2.12e-09	0.0166	0.78	0.56	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
THYM	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-6.63	2.13e-09	0.0167	-0.69	-0.56	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
THYM	trans	rs12367822	0.597	rs2371559	ENSG00000121089.4	NACA3P	-6.63	2.13e-09	0.0167	-0.68	-0.56	Platelet aggregation;	chr12:56805073	chr4:164943290~164943937:+
THYM	trans	rs12709013	0.792	rs1646289	ENSG00000230849.2	GOT2P2	6.62	2.21e-09	0.0173	0.6	0.56	Blood metabolite ratios;	chr16:58755689	chr1:173141100~173142350:-
THYM	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	6.61	2.25e-09	0.0176	0.63	0.56	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
THYM	trans	rs7312770	1	rs7312770	ENSG00000234354.3	RPS26P47	-6.61	2.3e-09	0.0179	-0.75	-0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr13:100539901~100540248:-
THYM	trans	rs7824557	1	rs7824557	ENSG00000253893.2	FAM85B	6.61	2.31e-09	0.018	0.69	0.56	Retinal vascular caliber;	chr8:11246602	chr8:8167819~8226614:-
THYM	trans	rs13190036	0.551	rs11955537	ENSG00000226986.4	RP11-543B16.2	-6.61	2.35e-09	0.0183	-0.75	-0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr1:211207239~211207897:+
THYM	trans	rs7824557	0.836	rs765731	ENSG00000253893.2	FAM85B	6.6	2.36e-09	0.0184	0.68	0.56	Retinal vascular caliber;	chr8:11263989	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.836	rs1435278	ENSG00000253893.2	FAM85B	6.6	2.36e-09	0.0184	0.68	0.56	Retinal vascular caliber;	chr8:11265520	chr8:8167819~8226614:-
THYM	trans	rs9611519	1	rs6002271	ENSG00000268568.1	AC007228.9	-6.6	2.43e-09	0.0188	-0.7	-0.56	Neuroticism;	chr22:41170591	chr19:56672574~56673901:-
THYM	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-6.6	2.46e-09	0.019	-0.59	-0.56	Longevity;	chr3:48445369	chr1:27649419~27649610:+
THYM	trans	rs10435719	0.902	rs12681142	ENSG00000253893.2	FAM85B	-6.59	2.49e-09	0.0192	-0.71	-0.56	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.902	rs7459545	ENSG00000253893.2	FAM85B	-6.59	2.49e-09	0.0192	-0.71	-0.56	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:8167819~8226614:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	6.59	2.49e-09	0.0192	0.67	0.56	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
THYM	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	6.59	2.5e-09	0.0193	0.58	0.56	Longevity;	chr3:48447994	chr1:27649419~27649610:+
THYM	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	6.59	2.5e-09	0.0193	0.58	0.56	Longevity;	chr3:48453142	chr1:27649419~27649610:+
THYM	trans	rs4295623	0.556	rs10903343	ENSG00000253893.2	FAM85B	-6.59	2.53e-09	0.0195	-0.75	-0.56	Morning vs. evening chronotype;	chr8:11838363	chr8:8167819~8226614:-
THYM	trans	rs7459609	0.901	rs4458859	ENSG00000176912.3	TYMSOS	6.58	2.63e-09	0.0203	0.66	0.56	Ankle injury;	chr8:42663625	chr18:641320~658340:-
THYM	trans	rs12367822	0.597	rs11171985	ENSG00000121089.4	NACA3P	-6.58	2.65e-09	0.0204	-0.68	-0.56	Platelet aggregation;	chr12:56818365	chr4:164943290~164943937:+
THYM	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-6.58	2.66e-09	0.0205	-0.6	-0.56	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-6.58	2.66e-09	0.0205	-0.6	-0.56	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
THYM	trans	rs2657294	0.965	rs2657286	ENSG00000172974.11	AC007318.5	-6.58	2.66e-09	0.0205	-0.52	-0.56	Pneumonia;	chr10:75145940	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs4746264	ENSG00000172974.11	AC007318.5	6.58	2.7e-09	0.0207	0.52	0.56	Pneumonia;	chr10:75114194	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs9299525	ENSG00000172974.11	AC007318.5	6.58	2.7e-09	0.0207	0.52	0.56	Pneumonia;	chr10:75118267	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs10762658	ENSG00000172974.11	AC007318.5	6.58	2.7e-09	0.0207	0.52	0.56	Pneumonia;	chr10:75119804	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs2395140	ENSG00000172974.11	AC007318.5	6.58	2.7e-09	0.0207	0.52	0.56	Pneumonia;	chr10:75139253	chr2:65205108~65205988:+
THYM	trans	rs2657294	0.965	rs2997754	ENSG00000172974.11	AC007318.5	6.58	2.7e-09	0.0207	0.52	0.56	Pneumonia;	chr10:75144379	chr2:65205108~65205988:+
THYM	trans	rs284491	0.965	rs284489	ENSG00000236526.1	RP4-742J24.2	6.57	2.73e-09	0.021	0.42	0.56	Glaucoma (low intraocular pressure);	chr8:104945792	chr20:11909404~11918677:-
THYM	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	6.57	2.77e-09	0.0212	0.63	0.56	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
THYM	trans	rs2657294	0.929	rs6480771	ENSG00000172974.11	AC007318.5	6.57	2.78e-09	0.0213	0.52	0.56	Pneumonia;	chr10:75101922	chr2:65205108~65205988:+
THYM	trans	rs12709013	0.792	rs1657170	ENSG00000230849.2	GOT2P2	6.57	2.83e-09	0.0216	0.6	0.56	Blood metabolite ratios;	chr16:58752082	chr1:173141100~173142350:-
THYM	trans	rs7121616	0.5	rs12574868	ENSG00000234176.1	HSPA8P1	6.56	2.84e-09	0.0217	0.88	0.56	Breast cancer;	chr11:123040824	chrX:121203182~121205014:-
THYM	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-6.56	2.87e-09	0.0218	-0.59	-0.56	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	6.56	2.87e-09	0.0218	0.59	0.56	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
THYM	trans	rs877636	0.702	rs773108	ENSG00000235459.5	RPS26P31	6.56	2.9e-09	0.0221	0.76	0.56	Cognitive function;	chr12:55976127	chr7:122681315~122681662:+
THYM	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-6.56	2.93e-09	0.0222	-0.68	-0.56	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
THYM	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	6.56	2.94e-09	0.0223	0.58	0.56	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
THYM	trans	rs9329221	0.905	rs10283145	ENSG00000253893.2	FAM85B	6.56	2.94e-09	0.0223	0.68	0.56	Neuroticism;	chr8:10383901	chr8:8167819~8226614:-
THYM	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	6.55	3.03e-09	0.023	0.66	0.56	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
THYM	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	6.55	3.09e-09	0.0234	0.59	0.56	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
THYM	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	6.54	3.11e-09	0.0235	0.73	0.56	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
THYM	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	6.54	3.11e-09	0.0235	0.73	0.56	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
THYM	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	6.54	3.11e-09	0.0235	0.73	0.56	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
THYM	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	6.54	3.11e-09	0.0235	0.73	0.56	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
THYM	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	6.54	3.11e-09	0.0235	0.73	0.56	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
THYM	trans	rs4494548	1	rs73543347	ENSG00000255717.5	SNHG1	6.54	3.11e-09	0.0235	0.61	0.56	Urinary uromodulin levels;	chr16:20374452	chr11:62851988~62855914:-
THYM	trans	rs5022636	0.525	rs6587559	ENSG00000180764.13	PIPSL	6.54	3.15e-09	0.0237	0.63	0.56	Gut microbiota (functional units);	chr1:151245262	chr10:93958191~93961540:-
THYM	trans	rs5022636	0.525	rs4971021	ENSG00000180764.13	PIPSL	6.54	3.15e-09	0.0237	0.63	0.56	Gut microbiota (functional units);	chr1:151246152	chr10:93958191~93961540:-
THYM	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	6.54	3.15e-09	0.0237	0.63	0.56	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
THYM	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	6.54	3.15e-09	0.0237	0.63	0.56	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
THYM	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	6.54	3.15e-09	0.0237	0.63	0.56	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
THYM	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	6.54	3.15e-09	0.0237	0.63	0.56	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
THYM	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	6.54	3.15e-09	0.0237	0.66	0.56	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
THYM	trans	rs7824557	0.737	rs10481445	ENSG00000253893.2	FAM85B	6.54	3.16e-09	0.0238	0.74	0.56	Retinal vascular caliber;	chr8:11251760	chr8:8167819~8226614:-
THYM	trans	rs17592366	0.713	rs78656697	ENSG00000274767.1	AC131056.3	-6.54	3.22e-09	0.0242	-1.01	-0.56	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34885029	chr17:36183235~36196471:+
THYM	trans	rs17592366	0.838	rs17102817	ENSG00000274767.1	AC131056.3	-6.54	3.22e-09	0.0242	-1.01	-0.56	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;	chr14:34886170	chr17:36183235~36196471:+
THYM	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-6.54	3.24e-09	0.0244	-0.68	-0.56	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
THYM	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-6.54	3.24e-09	0.0244	-0.68	-0.56	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
THYM	trans	rs877636	0.702	rs773109	ENSG00000234513.1	AC073072.7	6.54	3.25e-09	0.0244	0.74	0.56	Cognitive function;	chr12:55980911	chr7:22773646~22773993:-
THYM	trans	rs877636	0.702	rs773110	ENSG00000234513.1	AC073072.7	6.54	3.25e-09	0.0244	0.74	0.56	Cognitive function;	chr12:55981353	chr7:22773646~22773993:-
THYM	trans	rs877636	0.702	rs773111	ENSG00000234513.1	AC073072.7	6.54	3.25e-09	0.0244	0.74	0.56	Cognitive function;	chr12:55981956	chr7:22773646~22773993:-
THYM	trans	rs877636	0.702	rs773112	ENSG00000234513.1	AC073072.7	6.54	3.25e-09	0.0244	0.74	0.56	Cognitive function;	chr12:55982097	chr7:22773646~22773993:-
THYM	trans	rs877636	0.702	rs61937249	ENSG00000234513.1	AC073072.7	6.54	3.25e-09	0.0244	0.74	0.56	Cognitive function;	chr12:55988132	chr7:22773646~22773993:-
THYM	trans	rs13190036	0.748	rs28395268	ENSG00000226986.4	RP11-543B16.2	6.53	3.29e-09	0.0247	0.75	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177283546	chr1:211207239~211207897:+
THYM	trans	rs6981523	0.553	rs11989369	ENSG00000253893.2	FAM85B	-6.53	3.34e-09	0.025	-0.75	-0.56	Neuroticism;	chr8:11197876	chr8:8167819~8226614:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	6.53	3.36e-09	0.0252	0.68	0.56	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
THYM	trans	rs877636	0.736	rs773107	ENSG00000234513.1	AC073072.7	6.53	3.37e-09	0.0253	0.77	0.56	Cognitive function;	chr12:55975722	chr7:22773646~22773993:-
THYM	trans	rs11992162	0.613	rs6601634	ENSG00000253893.2	FAM85B	6.53	3.38e-09	0.0253	0.7	0.56	Monocyte count;	chr8:11948947	chr8:8167819~8226614:-
THYM	trans	rs4711350	0.862	rs597723	ENSG00000184319.14	RPL23AP82	6.52	3.41e-09	0.0255	0.84	0.56	Schizophrenia;	chr6:33726302	chr22:50756948~50801309:+
THYM	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-6.52	3.47e-09	0.026	-0.75	-0.56	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
THYM	trans	rs877636	0.809	rs1689510	ENSG00000223416.3	RPS26P15	6.52	3.48e-09	0.026	0.72	0.56	Cognitive function;	chr12:56002984	chr1:58056133~58056480:-
THYM	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-6.52	3.49e-09	0.026	-0.72	-0.56	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	6.52	3.49e-09	0.026	0.72	0.56	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	6.52	3.49e-09	0.026	0.72	0.56	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	6.52	3.49e-09	0.026	0.72	0.56	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	6.52	3.49e-09	0.026	0.72	0.56	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	6.52	3.49e-09	0.026	0.72	0.56	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	6.52	3.49e-09	0.026	0.72	0.56	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
THYM	trans	rs5022636	0.525	rs4520422	ENSG00000180764.13	PIPSL	6.52	3.5e-09	0.0261	0.63	0.56	Gut microbiota (functional units);	chr1:151207467	chr10:93958191~93961540:-
THYM	trans	rs5022636	0.525	rs7539584	ENSG00000180764.13	PIPSL	6.52	3.5e-09	0.0261	0.63	0.56	Gut microbiota (functional units);	chr1:151210477	chr10:93958191~93961540:-
THYM	trans	rs17783634	0.509	rs11775489	ENSG00000253893.2	FAM85B	6.52	3.53e-09	0.0263	0.75	0.56	Subjective well-being;	chr8:11179334	chr8:8167819~8226614:-
THYM	trans	rs7819412	0.521	rs11777887	ENSG00000253893.2	FAM85B	-6.52	3.53e-09	0.0263	-0.75	-0.56	Triglycerides;	chr8:11179290	chr8:8167819~8226614:-
THYM	trans	rs7819412	0.502	rs11777918	ENSG00000253893.2	FAM85B	-6.52	3.53e-09	0.0263	-0.75	-0.56	Triglycerides;	chr8:11179410	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.902	rs6601633	ENSG00000253893.2	FAM85B	6.52	3.54e-09	0.0264	0.7	0.56	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:8167819~8226614:-
THYM	trans	rs284491	0.965	rs284490	ENSG00000236526.1	RP4-742J24.2	6.51	3.58e-09	0.0266	0.42	0.56	Glaucoma (low intraocular pressure);	chr8:104945968	chr20:11909404~11918677:-
THYM	trans	rs10435719	0.902	rs11250179	ENSG00000253893.2	FAM85B	-6.51	3.59e-09	0.0267	-0.71	-0.56	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs11250178	ENSG00000253893.2	FAM85B	-6.51	3.63e-09	0.027	-0.7	-0.56	Neuroticism;	chr8:11942725	chr8:8167819~8226614:-
THYM	trans	rs941207	0.756	rs9634246	ENSG00000257210.1	NACAP3	-6.51	3.66e-09	0.0271	-0.69	-0.56	Platelet count;	chr12:56640604	chr12:93124063~93124543:-
THYM	trans	rs941207	0.756	rs2950394	ENSG00000257210.1	NACAP3	-6.51	3.66e-09	0.0271	-0.69	-0.56	Platelet count;	chr12:56644548	chr12:93124063~93124543:-
THYM	trans	rs941207	0.756	rs1465081	ENSG00000257210.1	NACAP3	-6.51	3.66e-09	0.0271	-0.69	-0.56	Platelet count;	chr12:56656390	chr12:93124063~93124543:-
THYM	trans	rs941207	0.789	rs2958145	ENSG00000257210.1	NACAP3	-6.51	3.66e-09	0.0271	-0.69	-0.56	Platelet count;	chr12:56662290	chr12:93124063~93124543:-
THYM	trans	rs941207	0.756	rs2958153	ENSG00000257210.1	NACAP3	6.51	3.66e-09	0.0271	0.69	0.56	Platelet count;	chr12:56687733	chr12:93124063~93124543:-
THYM	trans	rs10770857	0.931	rs7958387	ENSG00000226649.1	AC019118.4	6.51	3.68e-09	0.0273	0.75	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8550310	chr2:3156756~3157797:+
THYM	trans	rs10770857	0.965	rs7307154	ENSG00000226649.1	AC019118.4	6.51	3.68e-09	0.0273	0.75	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8551080	chr2:3156756~3157797:+
THYM	trans	rs4494548	1	rs28510439	ENSG00000255717.5	SNHG1	6.51	3.7e-09	0.0274	0.63	0.56	Urinary uromodulin levels;	chr16:20370382	chr11:62851988~62855914:-
THYM	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	6.51	3.71e-09	0.0274	0.57	0.56	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	6.51	3.71e-09	0.0274	0.57	0.56	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	6.51	3.71e-09	0.0274	0.57	0.56	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
THYM	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	6.51	3.71e-09	0.0274	0.57	0.56	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-6.5	3.77e-09	0.0278	-0.57	-0.56	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	6.5	3.79e-09	0.028	0.59	0.56	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
THYM	trans	rs10770857	1	rs7971298	ENSG00000226649.1	AC019118.4	6.5	3.8e-09	0.028	0.75	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8550545	chr2:3156756~3157797:+
THYM	trans	rs10770857	0.965	rs10770853	ENSG00000226649.1	AC019118.4	6.5	3.8e-09	0.028	0.75	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8550737	chr2:3156756~3157797:+
THYM	trans	rs10770857	0.965	rs10770854	ENSG00000226649.1	AC019118.4	6.5	3.8e-09	0.028	0.75	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8550755	chr2:3156756~3157797:+
THYM	trans	rs10770857	1	rs10743422	ENSG00000226649.1	AC019118.4	6.5	3.8e-09	0.028	0.75	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8550883	chr2:3156756~3157797:+
THYM	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	6.5	3.81e-09	0.0281	0.73	0.56	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
THYM	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-6.5	3.86e-09	0.0284	-0.77	-0.56	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
THYM	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	6.5	3.89e-09	0.0286	0.73	0.56	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
THYM	trans	rs7811142	1	rs67471932	ENSG00000228546.2	CTA-313A17.3	6.5	3.89e-09	0.0287	0.9	0.56	Platelet count;	chr7:100412362	chr7:102337316~102339115:+
THYM	trans	rs711355	0.528	rs11637788	ENSG00000231829.2	RP11-310E22.5	-6.5	3.9e-09	0.0287	-0.6	-0.56	Response to antipsychotic treatment;	chr15:29892825	chr10:95141925~95168425:-
THYM	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-6.49	3.93e-09	0.0289	-0.75	-0.56	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-6.49	3.93e-09	0.0289	-0.75	-0.56	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
THYM	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-6.49	3.93e-09	0.0289	-0.75	-0.56	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
THYM	trans	rs9329221	0.905	rs6601451	ENSG00000253893.2	FAM85B	6.49	3.95e-09	0.029	0.66	0.56	Neuroticism;	chr8:10386171	chr8:8167819~8226614:-
THYM	trans	rs7824557	1	rs2736371	ENSG00000253893.2	FAM85B	6.49	3.98e-09	0.0292	0.69	0.56	Retinal vascular caliber;	chr8:11248020	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.679	rs7004362	ENSG00000253893.2	FAM85B	6.49	4.09e-09	0.0299	0.67	0.56	Retinal vascular caliber;	chr8:11278465	chr8:8167819~8226614:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	6.48	4.11e-09	0.0301	0.66	0.56	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
THYM	trans	rs10770857	0.541	rs7308405	ENSG00000226649.1	AC019118.4	6.48	4.23e-09	0.031	0.74	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8551359	chr2:3156756~3157797:+
THYM	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-6.48	4.26e-09	0.0311	-0.64	-0.56	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
THYM	trans	rs10770857	0.965	rs10770855	ENSG00000226649.1	AC019118.4	6.48	4.27e-09	0.0312	0.75	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8551925	chr2:3156756~3157797:+
THYM	trans	rs10770857	1	rs10743424	ENSG00000226649.1	AC019118.4	6.48	4.27e-09	0.0312	0.74	0.56	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8551762	chr2:3156756~3157797:+
THYM	trans	rs616147	0.962	rs1708104	ENSG00000183298.5	RP11-556K13.1	-6.47	4.29e-09	0.0313	-0.76	-0.56	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr1:101786340~101787219:-
THYM	trans	rs11992162	0.636	rs11250182	ENSG00000253893.2	FAM85B	6.47	4.31e-09	0.0315	0.69	0.56	Monocyte count;	chr8:11950067	chr8:8167819~8226614:-
THYM	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	6.47	4.34e-09	0.0317	0.56	0.56	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
THYM	trans	rs9611565	0.506	rs1984839	ENSG00000268568.1	AC007228.9	-6.47	4.38e-09	0.0319	-0.66	-0.56	Vitiligo;	chr22:41289933	chr19:56672574~56673901:-
THYM	trans	rs7824557	0.872	rs2572417	ENSG00000253893.2	FAM85B	6.47	4.42e-09	0.0322	0.65	0.55	Retinal vascular caliber;	chr8:11253953	chr8:8167819~8226614:-
THYM	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
THYM	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	6.46	4.52e-09	0.0328	0.92	0.55	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
THYM	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-6.46	4.52e-09	0.0328	-0.92	-0.55	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
THYM	trans	rs928391	0.689	rs2644600	ENSG00000227183.3	HDGFP1	6.46	4.57e-09	0.0331	0.8	0.55	Platelet count;	chr1:156820891	chrX:131646639~131646890:+
THYM	trans	rs7121616	0.531	rs12573932	ENSG00000234176.1	HSPA8P1	6.46	4.62e-09	0.0334	0.86	0.55	Breast cancer;	chr11:123040995	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.531	rs11826861	ENSG00000234176.1	HSPA8P1	6.46	4.62e-09	0.0334	0.86	0.55	Breast cancer;	chr11:123041207	chrX:121203182~121205014:-
THYM	trans	rs7121616	0.576	rs9665920	ENSG00000234176.1	HSPA8P1	6.46	4.62e-09	0.0334	0.86	0.55	Breast cancer;	chr11:123041700	chrX:121203182~121205014:-
THYM	trans	rs9876781	1	rs7636782	ENSG00000235912.1	RP1-159A19.3	-6.46	4.65e-09	0.0336	-0.57	-0.55	Longevity;	chr3:48379897	chr1:27649419~27649610:+
THYM	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-6.46	4.67e-09	0.0337	-0.75	-0.55	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
THYM	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	6.45	4.75e-09	0.0343	0.75	0.55	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
THYM	trans	rs4711350	0.871	rs1998949	ENSG00000184319.14	RPL23AP82	-6.45	4.77e-09	0.0344	-0.8	-0.55	Schizophrenia;	chr6:33753680	chr22:50756948~50801309:+
THYM	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	6.45	4.78e-09	0.0345	0.67	0.55	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
THYM	trans	rs6981523	0.553	rs11783045	ENSG00000253893.2	FAM85B	6.45	4.81e-09	0.0347	0.74	0.55	Neuroticism;	chr8:11198666	chr8:8167819~8226614:-
THYM	trans	rs73110464	0.505	rs2638503	ENSG00000254285.3	KRT8P3	-6.45	4.84e-09	0.0349	-0.72	-0.55	Cancer (pleiotropy);	chr12:52913585	chr8:61578220~61579668:+
THYM	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	6.45	4.86e-09	0.035	0.56	0.55	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
THYM	trans	rs7819412	0.691	rs73198970	ENSG00000253893.2	FAM85B	6.45	4.89e-09	0.0352	0.73	0.55	Triglycerides;	chr8:11182707	chr8:8167819~8226614:-
THYM	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	6.45	4.89e-09	0.0352	0.56	0.55	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
THYM	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	6.45	4.89e-09	0.0352	0.56	0.55	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
THYM	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	6.45	4.89e-09	0.0352	0.56	0.55	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	6.45	4.89e-09	0.0352	0.56	0.55	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
THYM	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	6.45	4.89e-09	0.0352	0.56	0.55	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
THYM	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	6.45	4.89e-09	0.0352	0.56	0.55	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
THYM	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	6.45	4.89e-09	0.0352	0.56	0.55	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
THYM	trans	rs12615966	1	rs55805894	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104763962	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs17030292	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104767138	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs9941641	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104767721	chr12:94272150~94277195:-
THYM	trans	rs12615966	0.929	rs9941698	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104768259	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs17030308	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104769414	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs12618379	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104770396	chr12:94272150~94277195:-
THYM	trans	rs12615966	0.79	rs72830459	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104771170	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs61424916	ENSG00000258172.1	RP11-1105G2.4	6.44	4.92e-09	0.0354	0.77	0.55	Pancreatic cancer;	chr2:104773730	chr12:94272150~94277195:-
THYM	trans	rs7824557	0.569	rs2409718	ENSG00000253893.2	FAM85B	6.44	4.98e-09	0.0358	0.71	0.55	Retinal vascular caliber;	chr8:11155467	chr8:8167819~8226614:-
THYM	trans	rs9329221	0.537	rs6601414	ENSG00000253893.2	FAM85B	-6.44	4.99e-09	0.0358	-0.65	-0.55	Neuroticism;	chr8:10119238	chr8:8167819~8226614:-
THYM	trans	rs9329221	0.537	rs6601415	ENSG00000253893.2	FAM85B	-6.44	4.99e-09	0.0358	-0.65	-0.55	Neuroticism;	chr8:10119295	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.767	rs7003241	ENSG00000253893.2	FAM85B	-6.44	5e-09	0.0358	-0.66	-0.55	Retinal vascular caliber;	chr8:11311566	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.767	rs1897950	ENSG00000253893.2	FAM85B	-6.44	5e-09	0.0358	-0.66	-0.55	Retinal vascular caliber;	chr8:11312042	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.767	rs7837036	ENSG00000253893.2	FAM85B	-6.44	5.01e-09	0.0359	-0.68	-0.55	Retinal vascular caliber;	chr8:11317980	chr8:8167819~8226614:-
THYM	trans	rs9329221	0.51	rs4841282	ENSG00000253893.2	FAM85B	-6.44	5.05e-09	0.0362	-0.65	-0.55	Neuroticism;	chr8:10118094	chr8:8167819~8226614:-
THYM	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	6.44	5.08e-09	0.0364	0.92	0.55	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
THYM	trans	rs1053338	0.529	rs17069316	ENSG00000228878.6	SEPT7-AS1	6.44	5.1e-09	0.0365	0.61	0.55	Breast cancer;	chr3:63728293	chr7:35751856~35800616:-
THYM	trans	rs10770857	1	rs10770856	ENSG00000226649.1	AC019118.4	-6.44	5.12e-09	0.0366	-0.73	-0.55	Response to radiotherapy in prostate cancer (overall toxicity);	chr12:8552810	chr2:3156756~3157797:+
THYM	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	6.44	5.14e-09	0.0367	0.59	0.55	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
THYM	trans	rs7824557	0.734	rs2293856	ENSG00000253893.2	FAM85B	-6.43	5.19e-09	0.037	-0.67	-0.55	Retinal vascular caliber;	chr8:11319938	chr8:8167819~8226614:-
THYM	trans	rs7614738	1	rs7614738	ENSG00000197582.5	GPX1P1	6.43	5.2e-09	0.0372	0.83	0.55	Red cell distribution width;	chr3:49273698	chrX:13378735~13379340:-
THYM	trans	rs5022636	0.525	rs4971013	ENSG00000180764.13	PIPSL	6.43	5.22e-09	0.0373	0.62	0.55	Gut microbiota (functional units);	chr1:151200637	chr10:93958191~93961540:-
THYM	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	6.43	5.23e-09	0.0373	0.72	0.55	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
THYM	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	6.43	5.23e-09	0.0373	0.72	0.55	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
THYM	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	6.43	5.23e-09	0.0373	0.72	0.55	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
THYM	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	6.43	5.23e-09	0.0373	0.72	0.55	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
THYM	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	6.43	5.23e-09	0.0373	0.72	0.55	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
THYM	trans	rs4295623	0.559	rs4841600	ENSG00000253893.2	FAM85B	-6.43	5.28e-09	0.0377	-0.71	-0.55	Morning vs. evening chronotype;	chr8:11830639	chr8:8167819~8226614:-
THYM	trans	rs4295623	0.559	rs2409836	ENSG00000253893.2	FAM85B	-6.43	5.28e-09	0.0377	-0.71	-0.55	Morning vs. evening chronotype;	chr8:11831719	chr8:8167819~8226614:-
THYM	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-6.43	5.36e-09	0.0381	-0.7	-0.55	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
THYM	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	6.43	5.37e-09	0.0382	0.93	0.55	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
THYM	trans	rs12615966	0.932	rs1947308	ENSG00000258172.1	RP11-1105G2.4	6.42	5.42e-09	0.0386	0.75	0.55	Pancreatic cancer;	chr2:104775472	chr12:94272150~94277195:-
THYM	trans	rs12615966	0.932	rs72830462	ENSG00000258172.1	RP11-1105G2.4	6.42	5.42e-09	0.0386	0.75	0.55	Pancreatic cancer;	chr2:104778142	chr12:94272150~94277195:-
THYM	trans	rs12615966	0.872	rs72830464	ENSG00000258172.1	RP11-1105G2.4	6.42	5.42e-09	0.0386	0.75	0.55	Pancreatic cancer;	chr2:104778825	chr12:94272150~94277195:-
THYM	trans	rs12615966	0.932	rs17030324	ENSG00000258172.1	RP11-1105G2.4	6.42	5.42e-09	0.0386	0.75	0.55	Pancreatic cancer;	chr2:104786793	chr12:94272150~94277195:-
THYM	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	6.42	5.47e-09	0.0389	0.62	0.55	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
THYM	trans	rs12567355	0.737	rs10494124	ENSG00000223023.1	Y_RNA	-6.42	5.48e-09	0.0389	-0.89	-0.55	Obesity-related traits;	chr1:110896922	chr18:23024596~23024703:+
THYM	trans	rs453301	0.682	rs2929451	ENSG00000253893.2	FAM85B	-6.42	5.49e-09	0.039	-0.7	-0.55	Joint mobility (Beighton score);	chr8:9227785	chr8:8167819~8226614:-
THYM	trans	rs877636	0.809	rs1689510	ENSG00000243403.1	RP11-330L19.1	6.42	5.51e-09	0.0391	0.73	0.55	Cognitive function;	chr12:56002984	chr15:64592979~64593326:+
THYM	trans	rs7819412	0.745	rs4841498	ENSG00000253893.2	FAM85B	6.42	5.54e-09	0.0393	0.7	0.55	Triglycerides;	chr8:11127922	chr8:8167819~8226614:-
THYM	trans	rs11829119	1	rs74514962	ENSG00000228427.1	RP5-1091N2.9	-6.42	5.54e-09	0.0393	-0.63	-0.55	Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio);	chr12:19031112	chrX:71183559~71198175:-
THYM	trans	rs877636	0.74	rs705698	ENSG00000235459.5	RPS26P31	6.42	5.59e-09	0.0396	0.72	0.55	Cognitive function;	chr12:55990903	chr7:122681315~122681662:+
THYM	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-6.42	5.59e-09	0.0396	-0.72	-0.55	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
THYM	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	6.42	5.61e-09	0.0397	0.72	0.55	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
THYM	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	6.42	5.61e-09	0.0397	0.72	0.55	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
THYM	trans	rs877636	0.736	rs773107	ENSG00000225071.1	GS1-184P14.2	6.41	5.66e-09	0.04	0.76	0.55	Cognitive function;	chr12:55975722	chrX:24429573~24429920:-
THYM	trans	rs11200392	0.906	rs1106992	ENSG00000266521.1	RP11-650P15.1	6.41	5.69e-09	0.0402	0.83	0.55	Obesity-related traits;	chr10:122086382	chr18:31496645~31497195:-
THYM	trans	rs11200392	0.814	rs4752642	ENSG00000266521.1	RP11-650P15.1	6.41	5.69e-09	0.0402	0.83	0.55	Obesity-related traits;	chr10:122086773	chr18:31496645~31497195:-
THYM	trans	rs11200392	0.859	rs4751871	ENSG00000266521.1	RP11-650P15.1	6.41	5.69e-09	0.0402	0.83	0.55	Obesity-related traits;	chr10:122086970	chr18:31496645~31497195:-
THYM	trans	rs11200392	0.859	rs11599291	ENSG00000266521.1	RP11-650P15.1	6.41	5.69e-09	0.0402	0.83	0.55	Obesity-related traits;	chr10:122087345	chr18:31496645~31497195:-
THYM	trans	rs11200392	0.906	rs10788237	ENSG00000266521.1	RP11-650P15.1	6.41	5.69e-09	0.0402	0.83	0.55	Obesity-related traits;	chr10:122087840	chr18:31496645~31497195:-
THYM	trans	rs1908814	0.516	rs10113042	ENSG00000253893.2	FAM85B	-6.41	5.73e-09	0.0404	-0.71	-0.55	Neuroticism;	chr8:11935669	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs10113062	ENSG00000253893.2	FAM85B	-6.41	5.73e-09	0.0404	-0.71	-0.55	Neuroticism;	chr8:11935740	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs10113145	ENSG00000253893.2	FAM85B	-6.41	5.73e-09	0.0404	-0.71	-0.55	Neuroticism;	chr8:11935786	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs7812563	ENSG00000253893.2	FAM85B	-6.41	5.73e-09	0.0404	-0.71	-0.55	Neuroticism;	chr8:11936979	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs13281315	ENSG00000253893.2	FAM85B	-6.41	5.73e-09	0.0404	-0.71	-0.55	Neuroticism;	chr8:11937346	chr8:8167819~8226614:-
THYM	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	6.41	5.75e-09	0.0405	0.82	0.55	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
THYM	trans	rs877636	0.736	rs773107	ENSG00000235459.5	RPS26P31	6.41	5.78e-09	0.0407	0.76	0.55	Cognitive function;	chr12:55975722	chr7:122681315~122681662:+
THYM	trans	rs7819412	0.521	rs10110684	ENSG00000253893.2	FAM85B	6.41	5.81e-09	0.0409	0.75	0.55	Triglycerides;	chr8:11181650	chr8:8167819~8226614:-
THYM	trans	rs7819412	0.54	rs2409725	ENSG00000253893.2	FAM85B	6.41	5.81e-09	0.0409	0.75	0.55	Triglycerides;	chr8:11184152	chr8:8167819~8226614:-
THYM	trans	rs7819412	0.54	rs2409726	ENSG00000253893.2	FAM85B	6.41	5.81e-09	0.0409	0.75	0.55	Triglycerides;	chr8:11185629	chr8:8167819~8226614:-
THYM	trans	rs7819412	0.54	rs11777355	ENSG00000253893.2	FAM85B	6.41	5.81e-09	0.0409	0.75	0.55	Triglycerides;	chr8:11187180	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.806	rs34171564	ENSG00000253893.2	FAM85B	6.41	5.82e-09	0.0409	0.67	0.55	Retinal vascular caliber;	chr8:11237837	chr8:8167819~8226614:-
THYM	trans	rs284491	0.965	rs1521772	ENSG00000236526.1	RP4-742J24.2	6.41	5.84e-09	0.041	0.41	0.55	Glaucoma (low intraocular pressure);	chr8:104954532	chr20:11909404~11918677:-
THYM	trans	rs11992162	0.56	rs13256329	ENSG00000253893.2	FAM85B	6.41	5.89e-09	0.0413	0.67	0.55	Monocyte count;	chr8:11924705	chr8:8167819~8226614:-
THYM	trans	rs804280	0.543	rs13261205	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Myopia (pathological);	chr8:11933707	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.867	rs34465618	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.867	rs34583868	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:8167819~8226614:-
THYM	trans	rs804280	0.518	rs34266352	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Myopia (pathological);	chr8:11933953	chr8:8167819~8226614:-
THYM	trans	rs804280	0.542	rs34117651	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Myopia (pathological);	chr8:11934108	chr8:8167819~8226614:-
THYM	trans	rs804280	0.542	rs36100659	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Myopia (pathological);	chr8:11934144	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.805	rs13269417	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:8167819~8226614:-
THYM	trans	rs804280	0.517	rs7815179	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Myopia (pathological);	chr8:11934539	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.871	rs7815186	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs7833079	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11934620	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.899	rs7815595	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.744	rs11250175	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.834	rs11250176	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs13252853	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11935465	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs13252854	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11935469	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs13279577	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11935587	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs10112958	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11935631	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs4367597	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11936020	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.899	rs9329251	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.773	rs7842810	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.541	rs7824267	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11936770	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs7825529	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11936935	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs13281077	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11937305	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.867	rs6999030	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.834	rs6985792	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.718	rs7813935	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.504	rs7830734	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11938130	chr8:8167819~8226614:-
THYM	trans	rs1908814	0.516	rs4840597	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Neuroticism;	chr8:11938559	chr8:8167819~8226614:-
THYM	trans	rs804280	0.509	rs4841639	ENSG00000253893.2	FAM85B	-6.4	5.93e-09	0.0413	-0.7	-0.55	Myopia (pathological);	chr8:11938584	chr8:8167819~8226614:-
THYM	trans	rs1404872	0.702	rs73046661	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3330072	chr17:53105734~53106358:+
THYM	trans	rs1404872	0.702	rs4509207	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3330804	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs59673826	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3331319	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs59296189	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3331329	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs11973436	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3331535	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs11974237	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3331899	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs73046689	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3333814	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs73046694	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3335039	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs73046699	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3336028	chr17:53105734~53106358:+
THYM	trans	rs17133277	0.571	rs73046702	ENSG00000262902.1	RP11-750B16.1	6.4	5.95e-09	0.0414	1.1	0.55	Facial morphology (factor 5, width of mouth relative to central midface);	chr7:3336365	chr17:53105734~53106358:+
THYM	trans	rs11992162	0.551	rs35010200	ENSG00000253893.2	FAM85B	6.4	5.95e-09	0.0414	0.67	0.55	Monocyte count;	chr8:11928146	chr8:8167819~8226614:-
THYM	trans	rs73110464	0.505	rs2682296	ENSG00000254285.3	KRT8P3	-6.4	5.96e-09	0.0414	-0.71	-0.55	Cancer (pleiotropy);	chr12:52914481	chr8:61578220~61579668:+
THYM	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-6.4	6.04e-09	0.0419	-0.65	-0.55	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
THYM	trans	rs7824557	0.767	rs6991606	ENSG00000253893.2	FAM85B	-6.4	6.07e-09	0.0421	-0.66	-0.55	Retinal vascular caliber;	chr8:11318650	chr8:8167819~8226614:-
THYM	trans	rs7554547	0.722	rs7554327	ENSG00000261819.1	RP11-680G24.4	6.4	6.07e-09	0.0421	0.68	0.55	Nonsyndromic cleft lip with cleft palate;	chr1:11877347	chr16:14988259~14990160:-
THYM	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	6.4	6.09e-09	0.0422	0.72	0.55	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
THYM	trans	rs12709013	0.792	rs1646270	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58745823	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1657165	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58747980	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.818	rs1646273	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58748318	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1646276	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58749654	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs12325510	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58749707	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs12325054	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58749804	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1646277	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58750037	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs62066815	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58751577	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.766	rs1657175	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58755527	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1646290	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58755807	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1364346	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58756420	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs257626	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58759574	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs257625	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58759978	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1646262	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58760593	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs257623	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58761247	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.693	rs1627257	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58763764	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.755	rs1628029	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58763846	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs12926512	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58768317	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs12595974	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58769132	chr1:173141100~173142350:-
THYM	trans	rs12709013	0.792	rs1836877	ENSG00000230849.2	GOT2P2	6.4	6.12e-09	0.0423	0.58	0.55	Blood metabolite ratios;	chr16:58769821	chr1:173141100~173142350:-
THYM	trans	rs11992162	0.55	rs61426048	ENSG00000253893.2	FAM85B	6.4	6.14e-09	0.0424	0.67	0.55	Monocyte count;	chr8:11927447	chr8:8167819~8226614:-
THYM	trans	rs7811142	0.943	rs66958101	ENSG00000228546.2	CTA-313A17.3	6.39	6.23e-09	0.0429	0.9	0.55	Platelet count;	chr7:100476397	chr7:102337316~102339115:+
THYM	trans	rs4711350	0.834	rs9461905	ENSG00000184319.14	RPL23AP82	-6.39	6.27e-09	0.0429	-0.79	-0.55	Schizophrenia;	chr6:33754156	chr22:50756948~50801309:+
THYM	trans	rs7819412	0.775	rs2001329	ENSG00000253893.2	FAM85B	6.39	6.39e-09	0.0435	0.7	0.55	Triglycerides;	chr8:11129349	chr8:8167819~8226614:-
THYM	trans	rs877636	0.702	rs773109	ENSG00000223416.3	RPS26P15	6.39	6.42e-09	0.0437	0.69	0.55	Cognitive function;	chr12:55980911	chr1:58056133~58056480:-
THYM	trans	rs877636	0.702	rs773110	ENSG00000223416.3	RPS26P15	6.39	6.42e-09	0.0437	0.69	0.55	Cognitive function;	chr12:55981353	chr1:58056133~58056480:-
THYM	trans	rs877636	0.702	rs773111	ENSG00000223416.3	RPS26P15	6.39	6.42e-09	0.0437	0.69	0.55	Cognitive function;	chr12:55981956	chr1:58056133~58056480:-
THYM	trans	rs877636	0.702	rs773112	ENSG00000223416.3	RPS26P15	6.39	6.42e-09	0.0437	0.69	0.55	Cognitive function;	chr12:55982097	chr1:58056133~58056480:-
THYM	trans	rs877636	0.702	rs61937249	ENSG00000223416.3	RPS26P15	6.39	6.42e-09	0.0437	0.69	0.55	Cognitive function;	chr12:55988132	chr1:58056133~58056480:-
THYM	trans	rs616147	0.962	rs545397	ENSG00000183298.5	RP11-556K13.1	6.38	6.49e-09	0.044	0.78	0.55	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr1:101786340~101787219:-
THYM	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	6.38	6.49e-09	0.044	0.58	0.55	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
THYM	trans	rs58530613	0.792	rs17492080	ENSG00000280032.1	RP11-832A4.7	6.38	6.52e-09	0.0442	0.69	0.55	Platelet count;	chr4:123885304	chr11:118264593~118266817:+
THYM	trans	rs908822	0.541	rs79336632	ENSG00000280032.1	RP11-832A4.7	-6.38	6.52e-09	0.0442	-0.69	-0.55	Nonsyndromic cleft lip with cleft palate;	chr4:123901916	chr11:118264593~118266817:+
THYM	trans	rs6732160	0.809	rs13416592	ENSG00000236165.1	PRADC1P1	6.38	6.56e-09	0.0445	0.73	0.55	Intelligence (multi-trait analysis);	chr2:73137928	chr3:36976316~36976840:+
THYM	trans	rs11992162	0.56	rs7846248	ENSG00000253893.2	FAM85B	-6.38	6.62e-09	0.0448	-0.69	-0.55	Monocyte count;	chr8:11936540	chr8:8167819~8226614:-
THYM	trans	rs7819412	0.521	rs2409720	ENSG00000253893.2	FAM85B	6.38	6.72e-09	0.0454	0.73	0.55	Triglycerides;	chr8:11180394	chr8:8167819~8226614:-
THYM	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	6.38	6.73e-09	0.0454	0.57	0.55	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	6.38	6.73e-09	0.0454	0.57	0.55	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
THYM	trans	rs7824557	0.806	rs7007394	ENSG00000253893.2	FAM85B	6.37	6.84e-09	0.0462	0.66	0.55	Retinal vascular caliber;	chr8:11237057	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.806	rs6601573	ENSG00000253893.2	FAM85B	6.37	6.84e-09	0.0462	0.66	0.55	Retinal vascular caliber;	chr8:11237242	chr8:8167819~8226614:-
THYM	trans	rs7824557	0.806	rs6601574	ENSG00000253893.2	FAM85B	6.37	6.84e-09	0.0462	0.66	0.55	Retinal vascular caliber;	chr8:11237376	chr8:8167819~8226614:-
THYM	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	6.37	6.87e-09	0.0464	0.57	0.55	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	6.37	6.87e-09	0.0464	0.57	0.55	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
THYM	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	6.37	6.93e-09	0.0467	0.56	0.55	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
THYM	trans	rs804280	0.509	rs13276433	ENSG00000253893.2	FAM85B	-6.37	6.95e-09	0.0468	-0.69	-0.55	Myopia (pathological);	chr8:11925527	chr8:8167819~8226614:-
THYM	trans	rs10435719	0.902	rs7459983	ENSG00000253893.2	FAM85B	-6.37	6.96e-09	0.0469	-0.69	-0.55	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:8167819~8226614:-
THYM	trans	rs10037055	0.947	rs10063803	ENSG00000217325.2	PRELID1P1	6.37	6.97e-09	0.0469	0.67	0.55	Migraine without aura;	chr5:177240326	chr6:126643488~126644390:+
THYM	trans	rs7811142	1	rs76913697	ENSG00000228546.2	CTA-313A17.3	6.37	7.02e-09	0.0472	0.89	0.55	Platelet count;	chr7:100405149	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.943	rs3900792	ENSG00000228546.2	CTA-313A17.3	6.37	7.02e-09	0.0472	0.89	0.55	Platelet count;	chr7:100406954	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs73161759	ENSG00000228546.2	CTA-313A17.3	6.37	7.02e-09	0.0472	0.89	0.55	Platelet count;	chr7:100412371	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	6.37	7.02e-09	0.0472	0.89	0.55	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
THYM	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	6.37	7.02e-09	0.0472	0.89	0.55	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	6.37	7.02e-09	0.0472	0.89	0.55	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
THYM	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	6.37	7.02e-09	0.0472	0.89	0.55	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
THYM	trans	rs14057	0.929	rs12079872	ENSG00000215869.3	RP11-364B6.1	6.37	7.06e-09	0.0474	0.69	0.55	Systolic blood pressure;	chr1:6629764	chr1:104073023~104077087:+
THYM	trans	rs12615966	0.872	rs11898434	ENSG00000258172.1	RP11-1105G2.4	6.37	7.07e-09	0.0475	0.77	0.55	Pancreatic cancer;	chr2:104760246	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs12615966	ENSG00000258172.1	RP11-1105G2.4	-6.37	7.07e-09	0.0475	-0.77	-0.55	Pancreatic cancer;	chr2:104762499	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs12620555	ENSG00000258172.1	RP11-1105G2.4	6.37	7.07e-09	0.0475	0.77	0.55	Pancreatic cancer;	chr2:104762657	chr12:94272150~94277195:-
THYM	trans	rs12615966	0.858	rs17030286	ENSG00000258172.1	RP11-1105G2.4	6.37	7.07e-09	0.0475	0.77	0.55	Pancreatic cancer;	chr2:104764762	chr12:94272150~94277195:-
THYM	trans	rs12615966	1	rs9941579	ENSG00000258172.1	RP11-1105G2.4	6.37	7.07e-09	0.0475	0.77	0.55	Pancreatic cancer;	chr2:104768048	chr12:94272150~94277195:-
THYM	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	6.36	7.12e-09	0.0477	0.59	0.55	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
THYM	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	6.36	7.21e-09	0.048	0.66	0.55	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
THYM	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-6.36	7.36e-09	0.0489	-0.57	-0.55	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
THYM	trans	rs12567355	0.737	rs79251827	ENSG00000223023.1	Y_RNA	-6.36	7.38e-09	0.049	-0.88	-0.55	Obesity-related traits;	chr1:110902066	chr18:23024596~23024703:+
THYM	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	6.35	7.45e-09	0.0493	0.66	0.55	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
THYM	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-6.35	7.53e-09	0.0497	-0.65	-0.55	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
THYM	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-6.35	7.53e-09	0.0497	-0.65	-0.55	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
THYM	trans	rs7824557	0.778	rs6601572	ENSG00000253893.2	FAM85B	6.35	7.55e-09	0.0499	0.66	0.55	Retinal vascular caliber;	chr8:11235828	chr8:8167819~8226614:-